"Name","MOA","Target","SMILES","SLC","SLC.count","SCN","SCN.count","PTGS","PTGS.count","MAO","MAO.count","HTR","HTR.count","HRH","HRH.count","GABR","GABR.count","DRD","DRD.count","CHR","CHR.count","ADR","ADR.count","Parkinson's Disease","depression","pain relief","schizophrenia","phase","disease_area","indication","first.SMILES","mass","num.atoms","xlogp","tpsa","glm_prob","rf_prob","avg_prob","glm_pred","rf_pred"
"tetrindole","monoamine oxidase inhibitor","MAOA","C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1",0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1",294.209598832,22,6.453,16.96,0.430833164640824,0.53,0.480416582320412,1,1
"tranylcypromine (2-pcpa) hcl","","","N[C@H]1C[C@@H]1c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","N[C@H]1C[C@@H]1c1ccccc1",133.089149352,10,1.357,26.02,0.342652038965163,0.544,0.443326019482582,1,1
"dizocilpine-(+)","glutamate receptor antagonist","GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D","C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@]12N[C@H](Cc3ccccc13)c1ccccc21",221.12044948,17,3.26,12.03,0.412878055467824,0.438,0.425439027733912,1,1
"dizocilpine-(-)","glutamate receptor antagonist","","C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21, C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21, C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21, C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21",221.12044948,17,3.26,12.03,0.412878055467824,0.438,0.425439027733912,1,1
"WAY-629","serotonin receptor agonist","HTR2C","C1CCc2c(C1)n1CCNCc3cccc2c13, C1CCc2c(C1)n1CCNCc3cccc2c13",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C1CCc2c(C1)n1CCNCc3cccc2c13",226.146998576,17,3.845,16.96,0.391014069832616,0.406,0.398507034916308,1,1
"triptan","serotonin receptor agonist","HTR1B, HTR1D","CC(C)C(C)(C)C",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)C(C)(C)C",100.125200512,7,4.238,0,0.680333185291475,0.106,0.393166592645738,1,0
"dasotraline","dopamine-norepinephrine-serotonin reuptake inhibitor","","N[C@@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","N[C@@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12",291.05815484,19,4.754,26.02,0.179277271967686,0.562,0.370638635983843,1,1
"indatraline","norepinephrine transporter inhibitor","MAOA, MAOB","CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1, CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1, CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1, CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1, CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1",0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1",291.05815484,19,4.575,12.03,0.224291136145894,0.514,0.369145568072947,1,1
"NH125","eukaryotic translation elongation factor 2 inhibitor","","CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C, CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C, CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C, CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C, CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C",397.357725860091,29,11.348,8.81,0.56416871126702,0.162,0.36308435563351,1,1
"CP-339818","potassium channel blocker","KCNA3","CCCCC\N=c1/ccn(Cc2ccccc2)c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCC\N=c1/ccn(Cc2ccccc2)c2ccccc12",304.193948768,23,7.159,17.29,0.469737545689632,0.252,0.360868772844816,1,1
"DHBP","ryanodine receptor blocker","","CCCCCCC[n+]1ccc(cc1)-c1cc[n+](CCCCCCC)cc1, CCCCCCC[n+]1ccc(cc1)-c1cc[n+](CCCCCCC)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCC[n+]1ccc(cc1)-c1cc[n+](CCCCCCC)cc1",354.302402056181,26,10.514,7.76,0.602521022417731,0.1,0.351260511208866,1,0
"norcyclobenzaprine","adrenergic receptor agonist, serotonin receptor antagonist","","CNCCC=C1c2ccccc2C=Cc2ccccc12 |c:13|, CNCCC=C1c2ccccc2C=Cc2ccccc12 |c:13|, CNCCC=C1c2ccccc2C=Cc2ccccc12 |c:13|, CNCCC=C1c2ccccc2C=Cc2ccccc12 |c:13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CNCCC=C1c2ccccc2C=Cc2ccccc12 |c:13|",261.151749608,20,4.975,12.03,0.450859759966149,0.25,0.350429879983075,1,1
"D-limonene","","","CC(=C)[C@@H]1CCC(C)=CC1 |c:7|, CC(=C)[C@@H]1CCC(C)=CC1 |c:7|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(=C)[C@@H]1CCC(C)=CC1 |c:7|",136.125200512,10,3.729,0,0.613252755532522,0.078,0.345626377766261,1,0
"elemene","VEGFR inhibitor","","CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C1)C(C)=C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C1)C(C)=C",204.187800768,15,6.071,0,0.636534053070087,0.048,0.342267026535044,1,0
"g-caryophyllene","acetylcholinesterase inhibitor","ACHE","C\C1=C/CCC(=C)[C@H]2CC(C)(C)[C@@H]2CC1 |c:1|, C\C1=C/CCC(=C)[C@H]2CC(C)(C)[C@@H]2CC1 |c:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C\C1=C/CCC(=C)[C@H]2CC(C)(C)[C@@H]2CC1 |c:1|",204.187800768,15,6.044,0,0.635000299187623,0.036,0.335500149593811,1,0
"bicifadine","dopamine reuptake inhibitor, serotonin receptor antagonist","","[H][C@@]12C[C@@]1(CNC2)c1ccc(C)cc1 |&1:1,3,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","[H][C@@]12C[C@@]1(CNC2)c1ccc(C)cc1 |&1:1",173.12044948,14,1.947,12.03,0.445760412665589,0.222,0.333880206332794,1,1
"talopram","adrenergic inhibitor","SLC6A2","CNCCC[C@]1(OC(C)(C)c2ccccc12)c1ccccc1 |&1:5|, CNCCC[C@]1(OC(C)(C)c2ccccc12)c1ccccc1 |&1:5|, CNCCC[C@]1(OC(C)(C)c2ccccc12)c1ccccc1 |&1:5|",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CNCCC[C@]1(OC(C)(C)c2ccccc12)c1ccccc1 |&1:5|",295.19361442,22,4.05,21.26,0.270685518710943,0.394,0.332342759355472,1,1
"1-(1,2-diphenylethyl)piperidine-(+/-)","glutamate receptor antagonist","","C([C@@H](N1CCCCC1)c1ccccc1)c1ccccc1 |&1:1|, C([C@@H](N1CCCCC1)c1ccccc1)c1ccccc1 |&1:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C([C@@H](N1CCCCC1)c1ccccc1)c1ccccc1 |&1:1|",265.183049736,20,4.608,3.24,0.455161537831325,0.194,0.324580768915663,1,1
"benzyldimethylhexadecylammonium","cationic surfactant","","CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1, CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1, CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1",360.362476892091,26,9.76,0,0.566115387444672,0.08,0.323057693722336,1,0
"L-693403","sigma receptor agonist, sigma receptor antagonist","DRD2, SIGMAR1","C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1, C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1, C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1, C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1, C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,"preclinical","","","C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1",277.183049736,21,4.421,3.24,0.429917390306023,0.212,0.320958695153011,1,1
"MPEP","glutamate receptor antagonist","GRM1, GRM4, GRM5","Cc1cccc(n1)C#Cc1ccccc1, Cc1cccc(n1)C#Cc1ccccc1, Cc1cccc(n1)C#Cc1ccccc1, Cc1cccc(n1)C#Cc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cccc(n1)C#Cc1ccccc1",193.089149352,15,3.774,12.89,0.490855348024875,0.148,0.319427674012437,1,1
"1-octacosanol","","","CCCCCCCCCCCCCCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCCCCCCCCCCCCCO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCCCCCCCCCCCCCCCCCCCCCCCCCCO",410.448766476,29,14.507,20.23,0.611892390098184,0.022,0.316946195049092,1,0
"4-phenyl-1,2,3,4-tetrahydroisoquinoline","dopamine release inhibitor","","C1NCc2ccccc2[C@@H]1c1ccccc1 |&1:9,r|, C1NCc2ccccc2[C@@H]1c1ccccc1 |&1:9,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C1NCc2ccccc2[C@@H]1c1ccccc1 |&1:9",209.12044948,16,2.87,12.03,0.403410919542009,0.23,0.316705459771004,1,1
"centanafadine","dopamine reuptake inhibitor","","C1[C@@H]2CNC[C@]12c1ccc2ccccc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C1[C@@H]2CNC[C@]12c1ccc2ccccc2c1",209.12044948,16,2.776,12.03,0.397873842018875,0.224,0.310936921009437,1,1
"terodiline","cholinergic receptor antagonist","","C[C@@H](CC(c1ccccc1)c1ccccc1)NC(C)(C)C |&1:1|, C[C@@H](CC(c1ccccc1)c1ccccc1)NC(C)(C)C |&1:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","C[C@@H](CC(c1ccccc1)c1ccccc1)NC(C)(C)C |&1:1|",281.214349864,21,5.3,12.03,0.409331849522464,0.206,0.307665924761232,1,1
"FPL-12495","glutamate receptor antagonist","","CC(N)(Cc1ccccc1)c1ccccc1 |&1:1|, CC(N)(Cc1ccccc1)c1ccccc1 |&1:1|, CC(N)(Cc1ccccc1)c1ccccc1 |&1:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(N)(Cc1ccccc1)c1ccccc1 |&1:1|",211.136099544,16,3.225,26.02,0.336995497713132,0.272,0.304497748856566,1,1
"benzyldimethyloctylammonium","","","CCCCCCCC[N+](C)(C)Cc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCC[N+](C)(C)Cc1ccccc1",248.237276380091,18,5.208,0,0.496687718013969,0.112,0.304343859006984,1,0
"xaliproden","serotonin receptor agonist","HTR1A","FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1 |t:11|, FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1 |t:11|, FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1 |t:11|, FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1 |t:11|",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1 |t:11|",381.170434364,28,6.235,3.24,0.329500408343126,0.278,0.303750204171563,1,1
"SDZ-SER-082","serotonin receptor antagonist","HTR2A, HTR2B, HTR2C","CN1CC[C@@H]2CN3CCc4cccc([C@@H]2C1)c34, CN1CC[C@@H]2CN3CCc4cccc([C@@H]2C1)c34",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CC[C@@H]2CN3CCc4cccc([C@@H]2C1)c34",228.16264864,17,2.146,6.48,0.339601582666923,0.266,0.302800791333462,1,1
"4-PPBP","sigma receptor ligand","SIGMAR1","C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1, C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1, C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1",293.214349864,22,5.102,3.24,0.4333982956842,0.168,0.3006991478421,1,1
"ORG-9768","adrenergic receptor antagonist","ADRA2A","CC1(CN)Cc2ccccc2C1, CC1(CN)Cc2ccccc2C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"phase 1","","","CC1(CN)Cc2ccccc2C1",161.12044948,12,1.775,26.02,0.319014586150407,0.282,0.300507293075204,1,1
"dicarbine","dopamine receptor ligand","","CN1CCC2Nc3ccc(C)cc3C2C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCC2Nc3ccc(C)cc3C2C1",202.146998576,15,1.859,15.27,0.314729209016827,0.284,0.299364604508414,1,1
"stobadine","adrenergic receptor antagonist","ADRA1A","CN1CC[C@H]2Nc3ccc(C)cc3[C@H]2C1, CN1CC[C@H]2Nc3ccc(C)cc3[C@H]2C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"phase 2","","","CN1CC[C@H]2Nc3ccc(C)cc3[C@H]2C1",202.146998576,15,1.859,15.27,0.314729209016827,0.284,0.299364604508414,1,1
"bakuchiol","DNA polymerase inhibitor","HIF1A","CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1, CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1, CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1, CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1, CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1",256.182715388,19,7.206,20.23,0.512086480464142,0.082,0.297043240232071,1,0
"1-hexadecanal","sphingosine 1-phosphate receptor substrate","DBI, RHO","CCCCCCCCCCCCCCCC=O, CCCCCCCCCCCCCCCC=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCCCCCCCCCC=O",240.245315644,17,7.984,17.07,0.557899879170627,0.034,0.295949939585313,1,0
"prenylamine","calcium channel blocker","","C[C@@H](Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1 |&2:1|, C[C@@H](Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1 |&2:1|, C[C@@H](Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1 |&2:1|, C[C@@H](Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1 |&2:1|, C[C@@H](Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1 |&2:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","C[C@@H](Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1 |&2:1|",329.214349864,25,5.868,12.03,0.388575217554928,0.198,0.293287608777464,1,1
"benethamine","","","C(Cc1ccccc1)NCc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C(Cc1ccccc1)NCc1ccccc1",211.136099544,16,3.402,12.03,0.423368002229066,0.162,0.292684001114533,1,1
"2,6-dimethylpiperidine","","","C[C@H]1CCC[C@@H](C)N1 |&1:1,&2:5,r|, C[C@H]1CCC[C@@H](C)N1 |&1:1,&2:5,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H]1CCC[C@@H](C)N1 |&1:1",113.12044948,8,1.608,12.03,0.43806278331342,0.146,0.29203139165671,1,1
"BTS-54505","dopamine reuptake inhibitor","SLC6A2, SLC6A3, SLC6A4","CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|, CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|, CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|, CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|, CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|",1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|",251.144077384,17,4.542,26.02,0.253545258048526,0.32,0.286772629024263,1,1
"fendiline","calcium channel blocker","HTR2B","C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|, C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|, C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|, C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|, C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|, C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|",315.1986998,24,5.776,12.03,0.408250873957618,0.16,0.284125436978809,1,1
"napamezole","adrenergic receptor antagonist, monoamine reuptake inhibitor","","C(C1=NCCN1)C1=Cc2ccccc2CC1 |t:1,7|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C(C1=NCCN1)C1=Cc2ccccc2CC1 |t:1",212.131348512,16,2.261,24.39,0.289215060108319,0.278,0.28360753005416,1,1
"diphencyprone","immunostimulant","","O=c1c(c1-c1ccccc1)-c1ccccc1, O=c1c(c1-c1ccccc1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O=c1c(c1-c1ccccc1)-c1ccccc1",206.07316494,16,3.602,17.07,0.436424209491501,0.128,0.28221210474575,1,0
"phenylethyl-alcohol","","","OCCc1ccccc1, OCCc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OCCc1ccccc1",122.07316494,9,1.369,20.23,0.381927591303089,0.18,0.280963795651545,1,1
"igmesine","sigma receptor agonist","SIGMAR1","CCC(C\C=C\c1ccccc1)(N(C)CC1CC1)c1ccccc1 |&1:2|, CCC(C\C=C\c1ccccc1)(N(C)CC1CC1)c1ccccc1 |&1:2|, CCC(C\C=C\c1ccccc1)(N(C)CC1CC1)c1ccccc1 |&1:2|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCC(C\C=C\c1ccccc1)(N(C)CC1CC1)c1ccccc1 |&1:2|",319.229999928,24,5.763,3.24,0.433643587049487,0.128,0.280821793524743,1,0
"norfluoxetine","selective serotonin reuptake inhibitor (SSRI)","HTR2B","NCC[C@@H](Oc1ccc(cc1)C(F)(F)F)c1ccccc1 |&1:3,r|, NCC[C@@H](Oc1ccc(cc1)C(F)(F)F)c1ccccc1 |&1:3,r|",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","NCC[C@@H](Oc1ccc(cc1)C(F)(F)F)c1ccccc1 |&1:3",295.118398792,21,4.257,35.25,0.183420444311816,0.376,0.279710222155908,1,1
"4,4-pentamethylenepiperidine","M2 channel blocker","","C1CCC2(CC1)CCNCC2, C1CCC2(CC1)CCNCC2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C1CCC2(CC1)CCNCC2",153.151749608,11,3.169,12.03,0.467067027317542,0.09,0.278533513658771,1,0
"amiflamine","monoamine oxidase inhibitor","MAOA, SLC6A2","C[C@@H](N)Cc1ccc(cc1C)N(C)C |&1:1,r|, C[C@@H](N)Cc1ccc(cc1C)N(C)C |&1:1,r|",1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@@H](N)Cc1ccc(cc1C)N(C)C |&1:1",192.16264864,14,2.408,29.26,0.276983844043204,0.28,0.278491922021602,1,1
"octadecan-1-ol","","","CCCCCCCCCCCCCCCCCCO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCCCCCCCCCCCCO",270.292265836,19,8.817,20.23,0.526522087745919,0.028,0.27726104387296,1,0
"SIB-1893","glutamate receptor antagonist","GRM4, GRM5","Cc1cccc(\C=C\c2ccccc2)n1, Cc1cccc(\C=C\c2ccccc2)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cccc(\C=C\c2ccccc2)n1",195.104799416,15,3.386,12.89,0.455131650373948,0.098,0.276565825186974,1,0
"octodrine","antitumor agent","","CC(C)CCC[C@@H](C)N |&1:6,r|, CC(C)CCC[C@@H](C)N |&1:6,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)CCC[C@@H](C)N |&1:6",129.151749608,9,2.89,26.02,0.398495532492807,0.152,0.275247766246403,1,1
"2-octyldodecan-1-ol","","","CCCCCCCCCC[C@@H](CO)CCCCCCCC |&1:10,r|, CCCCCCCCCC[C@@H](CO)CCCCCCCC |&1:10,r|, CCCCCCCCCC[C@@H](CO)CCCCCCCC |&1:10,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCCCC[C@@H](CO)CCCCCCCC |&1:10",298.323565964,21,9.683,20.23,0.527293058278762,0.022,0.274646529139381,1,0
"ML204","transient receptor potential channel antagonist","TRPC4, TRPC5","Cc1cc(nc2ccccc12)N1CCCCC1, Cc1cc(nc2ccccc12)N1CCCCC1, Cc1cc(nc2ccccc12)N1CCCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(nc2ccccc12)N1CCCCC1",226.146998576,17,4.483,16.13,0.433569573531876,0.114,0.273784786765938,1,0
"cinnamaldehyde","aldose reductase inhibitor, TRPV agonist","TRPA1","O=C\C=C\c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C\C=C\c1ccccc1",132.057514876,10,1.99,17.07,0.434365290201117,0.112,0.273182645100559,1,0
"ER-27319","mediator release inhibitor, SYK inhibitor","SYK","Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O",280.15756326,21,5.122,48.02,0.228027844025352,0.314,0.271013922012676,1,1
"trebenzomine","","","C[C@H]1Oc2ccccc2C[C@@H]1N(C)C |&1:1,&2:10,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@H]1Oc2ccccc2C[C@@H]1N(C)C |&1:1",191.131014164,14,2.133,12.47,0.351369715655319,0.19,0.270684857827659,1,1
"lylamine","cannabinoid receptor agonist","CNR1","CC(C)c1ccc2c(CC[C@H]3[C@](C)(CN)CCC[C@]23C)c1, CC(C)c1ccc2c(CC[C@H]3[C@](C)(CN)CCC[C@]23C)c1, CC(C)c1ccc2c(CC[C@H]3[C@](C)(CN)CCC[C@]23C)c1, CC(C)c1ccc2c(CC[C@H]3[C@](C)(CN)CCC[C@]23C)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)c1ccc2c(CC[C@H]3[C@](C)(CN)CCC[C@]23C)c1",285.245649992,21,5.971,26.02,0.349134888721026,0.192,0.270567444360513,1,1
"phenol","","CA1, CA12, CA14, CA2, CA4, CA9","Oc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","otolaryngology","pharyngitis","Oc1ccccc1",94.041864812,7,1.616,20.23,0.447336697000927,0.09,0.268668348500464,1,0
"amitifadine","serotonin transporter (SERT) inhibitor","SLC6A2, SLC6A3, SLC6A4","Clc1ccc(cc1Cl)[C@@]12C[C@@H]1CNC2 |&1:8,&2:10|, Clc1ccc(cc1Cl)[C@@]12C[C@@H]1CNC2 |&1:8,&2:10|",1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Clc1ccc(cc1Cl)[C@@]12C[C@@H]1CNC2 |&1:8",227.026854712,14,2.754,12.03,0.212694180023872,0.324,0.268347090011936,1,1
"McN-5652-(+/-)","selective serotonin reuptake inhibitor (SSRI)","","CSc1ccc(cc1)[C@H]1CN2CCC[C@H]2c2ccccc12, CSc1ccc(cc1)[C@H]1CN2CCC[C@H]2c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CSc1ccc(cc1)[C@H]1CN2CCC[C@H]2c2ccccc12",295.139470672,21,4.46,28.54,0.216108258751301,0.31,0.26305412937565,1,1
"SN-2","transient receptor potential channel agonist","MCOLN3","Cc1cc(C)c(C2=NO[C@@H]3[C@H]4CC[C@H](C4)[C@H]23)c(C)c1 |&1:9,10,13,15,t:6|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(C)c(C2=NO[C@@H]3[C@H]4CC[C@H](C4)[C@H]23)c(C)c1 |&1:9",255.162314292,19,4.904,21.59,0.372039060678856,0.15,0.261019530339428,1,1
"GTP-14564","FLT3 inhibitor, tyrosine kinase inhibitor","CSF1R, FLT3, KIT, PDGFRB","c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12, c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12, c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12, c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12, c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12",234.07931294,18,4.387,41.82,0.300347918114567,0.216,0.258173959057284,1,1
"4-tert-butylphenol","","","CC(C)(C)c1ccc(O)cc1, CC(C)(C)c1ccc(O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)c1ccc(O)cc1",150.104465068,11,3.433,20.23,0.454030091527877,0.062,0.258015045763939,1,0
"beta-naphthol","","","Oc1ccc2ccccc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc2ccccc2c1",144.057514876,11,2.882,20.23,0.456365630091399,0.058,0.2571828150457,1,0
"clofilium","potassium channel blocker","KCNA5, KCNH1","CCCCCCC[N+](CC)(CC)CCCCc1ccc(Cl)cc1, CCCCCCC[N+](CC)(CC)CCCCc1ccc(Cl)cc1, CCCCCCC[N+](CC)(CC)CCCCc1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCCCCC[N+](CC)(CC)CCCCc1ccc(Cl)cc1",338.260904284091,23,7.192,0,0.371259899464546,0.142,0.256629949732273,1,1
"desoxypeganine","acetylcholinesterase inhibitor, monoamine oxidase inhibitor","ACHE","C1CN2Cc3ccccc3N=C2C1 |c:11|, C1CN2Cc3ccccc3N=C2C1 |c:11|, C1CN2Cc3ccccc3N=C2C1 |c:11|, C1CN2Cc3ccccc3N=C2C1 |c:11|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C1CN2Cc3ccccc3N=C2C1 |c:11|",172.100048384,13,1.979,15.6,0.377828705135831,0.134,0.255914352567916,1,1
"vabicaserin hydrochloride","serotonin receptor agonist","HTR2A, HTR2B, HTR2C","[H][C@@]12C3=CC=CC4=C3N(CCNC4)C[C@]1([H])CCC2.Cl",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,1,"phase 2","neurology/psychiatry","schizophrenia","[H][C@@]12C3=CC=CC4=C3N(CCNC4)C[C@]1([H])CCC2.Cl",264.139326352,20,2.639,15.27,0.285612828050711,0.224,0.254806414025356,1,1
"1-octanol","","GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1","CCCCCCCCO, CCCCCCCCO, CCCCCCCCO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCCCCCCO",130.135765196,9,3.127,20.23,0.439572369947639,0.068,0.253786184973819,1,0
"abt 418","","","CN1CCC[C@H]1c2onc(C)c2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCC[C@H]1c2onc(C)c2",166.110613068,12,1.295,29.27,0.255267483285532,0.252,0.253633741642766,1,1
"dicyclohexylamine","","","C1CCC(CC1)NC1CCCCC1, C1CCC(CC1)NC1CCCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C1CCC(CC1)NC1CCCCC1",181.183049736,13,3.48,12.03,0.434140626621305,0.072,0.253070313310652,1,0
"JAK3-inhibitor-V","JAK inhibitor","JAK3","C=CC(=O)c1ccc2ccccc2c1, C=CC(=O)c1ccc2ccccc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C=CC(=O)c1ccc2ccccc2c1",182.07316494,14,3.417,17.07,0.453109966857049,0.05,0.251554983428524,1,0
"CY208-243","dopamine receptor agonist","CALY","CN1Cc2ccccc2[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CN1Cc2ccccc2[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CN1Cc2ccccc2[C@H]2[C@H]1Cc1c[nH]c3cccc2c13",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN1Cc2ccccc2[C@H]2[C@H]1Cc1c[nH]c3cccc2c13",274.146998576,21,3.346,19.03,0.301668928685086,0.2,0.250834464342543,1,1
"UH-232-(+)","dopamine receptor antagonist","DRD2, DRD3, DRD4, HTR1A","CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C, CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C",0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,3,0,0,0,0,0,0,0,0,"preclinical","","","CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C",275.224914548,20,3.942,12.47,0.310604453020062,0.186,0.248302226510031,1,1
"amylene-hydrate","local anesthetic","","CCC(C)(C)O, CCC(C)(C)O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCC(C)(C)O",88.088815004,6,1.159,20.23,0.398516695763633,0.098,0.248258347881816,1,0
"sitosterol","","","CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|, CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|, CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|",414.38616622,30,11.595,20.23,0.469346235346834,0.022,0.245673117673417,1,0
"17-PA","glucocorticoid receptor agonist","","C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CC=C2c1ccccc1 |c:21|, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CC=C2c1ccccc1 |c:21|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CC=C2c1ccccc1 |c:21|",350.260965708,26,8.265,20.23,0.418683051234983,0.07,0.244341525617492,1,0
"5-methylfurmethiodide","acetylcholine receptor agonist","CHRM1, CHRM2, CHRM3, CHRM4","Cc1ccc(C[N+](C)(C)C)o1, Cc1ccc(C[N+](C)(C)C)o1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,"preclinical","","","Cc1ccc(C[N+](C)(C)C)o1",154.122640552091,11,0.515,13.14,0.303238650316313,0.184,0.243619325158156,1,1
"pentylenetetrazol","GABA receptor antagonist","","C1CCc2nnnn2CC1, C1CCc2nnnn2CC1, C1CCc2nnnn2CC1, C1CCc2nnnn2CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","C1CCc2nnnn2CC1",138.09054632,10,1.839,43.6,0.25723309961158,0.23,0.24361654980579,1,1
"2-BFI","imidazoline receptor ligand","ADRA2A, ADRA2B, ADRA2C, MAOA, MAOB","C1CN=C(N1)c1cc2ccccc2o1 |c:2|",0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,"preclinical","","","C1CN=C(N1)c1cc2ccccc2o1 |c:2|",186.07931294,14,1.743,37.53,0.237058723459088,0.25,0.243529361729544,1,1
"buthionine-sulfoximine","glutathione transferase inhibitor","GCLM","CCCCS(=N)(=O)CC[C@H](N)C(O)=O |a:9,&1:4|, CCCCS(=N)(=O)CC[C@H](N)C(O)=O |a:9,&1:4|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCCCS(=N)(=O)CC[C@H](N)C(O)=O |a:9",222.103813436,14,-1.222,112.62,0.0110045728943576,0.472,0.241502286447179,0,1
"ethoxyquin","antioxidant","","CCOc1ccc2NC(C)(C)C=C(C)c2c1 |t:11|, CCOc1ccc2NC(C)(C)C=C(C)c2c1 |t:11|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOc1ccc2NC(C)(C)C=C(C)c2c1 |t:11|",217.146664228,16,3.324,21.26,0.334970450935124,0.146,0.240485225467562,1,1
"phenethyl-isothiocyanate","anticancer agent","CYP2E1","S=C=NCCc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","S=C=NCCc1ccccc1",163.045570288,11,3.32,44.45,0.252931894097662,0.228,0.240465947048831,1,1
"indeloxazine","norepinephrine reuptake inhibitor, serotonin reuptake inhibitor","","C(Oc1cccc2C=CCc12)[C@H]1CNCCO1 |&1:11,c:7|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","C(Oc1cccc2C=CCc12)[C@H]1CNCCO1 |&1:11",231.125928784,17,1.945,30.49,0.207205448123488,0.272,0.239602724061744,1,1
"fluroxene","local anesthetic","","FC(F)(F)COC=C, FC(F)(F)COC=C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)COC=C",126.02924944,8,2.249,9.23,0.416897302471812,0.062,0.239448651235906,1,0
"cholesterol","","RORA","CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|",386.354866092,28,10.518,20.23,0.455710813275305,0.022,0.238855406637653,1,0
"meparfylon","","","CCC(C)(O)C#C |&1:2|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCC(C)(O)C#C |&1:2|",98.07316494,7,0.763,20.23,0.373536244672302,0.104,0.238768122336151,1,0
"MN-64","tankyrase inhibitor","TNKS","CC(C)c1ccc(cc1)-c1cc(=O)c2ccccc2o1, CC(C)c1ccc(cc1)-c1cc(=O)c2ccccc2o1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)c1ccc(cc1)-c1cc(=O)c2ccccc2o1",264.115029752,20,6.291,30.21,0.4093414066159,0.066,0.23767070330795,1,0
"butylidenephthalide","cyclooxygenase inhibitor","","CCC\C=C1/OC(=O)c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","CCC\C=C1/OC(=O)c2ccccc12",188.083729624,14,3.688,26.3,0.382411205099696,0.092,0.237205602549848,1,0
"somantadine","antiviral","","CC(C)(N)CC12CC3CC(CC(C3)C1)C2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)(N)CC12CC3CC(CC(C3)C1)C2",207.1986998,15,4.986,26.02,0.405880624433431,0.068,0.236940312216715,1,0
"BRD7389","ribosomal protein inhibitor","RPS6KA1, RPS6KA2, RPS6KA3","O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23, O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23, O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23, O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23",366.136827816,28,5.586,61.96,0.133368248603172,0.34,0.236684124301586,1,1
"GSK-LSD-1","histone lysine demethylase inhibitor","KDM1A","C1[C@@H](NC2CCNCC2)[C@@H]1c1ccccc1, C1[C@@H](NC2CCNCC2)[C@@H]1c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C1[C@@H](NC2CCNCC2)[C@@H]1c1ccccc1",216.16264864,16,1.904,24.06,0.254355949502413,0.218,0.236177974751206,1,1
"stigmasterol","","","CC[C@H](\C=C\[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|, CC[C@H](\C=C\[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC[C@H](\C=C\[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|",412.370516156,30,11.071,20.23,0.449394632045863,0.022,0.235697316022932,1,0
"androstenone","steroid","","C[C@@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]34C)[C@@H]1CC=C2 |&1:1,&2:4,&3:5,&4:8,&5:14,&6:16,r,c:21|, C[C@@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]34C)[C@@H]1CC=C2 |&1:1,&2:4,&3:5,&4:8,&5:14,&6:16,r,c:21|, C[C@@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]34C)[C@@H]1CC=C2 |&1:1,&2:4,&3:5,&4:8,&5:14,&6:16,r,c:21|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]34C)[C@@H]1CC=C2 |&1:1",272.214015516,20,6.291,17.07,0.436417983738054,0.034,0.235208991869027,1,0
"tanshinone-I","AP inhibitor","IFNG","Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12, Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12, Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12, Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12",276.078644244,21,3.769,47.28,0.19205656646907,0.278,0.235028283234535,1,1
"domiphen","","","CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1, CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1, CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1, CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1, CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1, CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1",334.310441320091,24,7.501,9.23,0.415786699758317,0.054,0.234893349879158,1,0
"anthraquinone","CDC inhibitor","CDC25B","O=C1c2ccccc2C(=O)c2ccccc12, O=C1c2ccccc2C(=O)c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C1c2ccccc2C(=O)c2ccccc12",208.052429496,16,3.108,34.14,0.305778903698405,0.164,0.234889451849203,1,1
"4-P-PDOT","melatonin receptor antagonist","MTNR1A, MTNR1B","CCC(=O)N[C@H]1C[C@@H](c2ccccc2)c2ccccc2C1 |&1:5,7|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCC(=O)N[C@H]1C[C@@H](c2ccccc2)c2ccccc2C1 |&1:5",279.162314292,21,3.562,29.1,0.242367034063944,0.226,0.234183517031972,1,1
"NSC-405020","matrix metalloprotease inhibitor","MMP1","CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|, CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|, CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|, CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|, CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|, CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3",259.05306946,16,4.481,29.1,0.169988444172746,0.298,0.233994222086373,1,1
"butylated-hydroxytoluene","carbonic anhydrase inhibitor","CA2","Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C",220.182715388,16,5.265,20.23,0.435767757831164,0.032,0.233883878915582,1,0
"pentacosanoic-acid","","","CCCCCCCCCCCCCCCCCCCCCCCCC(O)=O, CCCCCCCCCCCCCCCCCCCCCCCCC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCCCCCCCCCCCCCCCCCCC(O)=O",382.38108084,27,12.691,37.3,0.45618096131954,0.01,0.23309048065977,1,0
"compound-401","DNA dependent protein kinase inhibitor","MTOR, PRKDC","O=c1cc(nc2c3ccccc3ccn12)N1CCOCC1, O=c1cc(nc2c3ccccc3ccn12)N1CCOCC1, O=c1cc(nc2c3ccccc3ccn12)N1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=c1cc(nc2c3ccccc3ccn12)N1CCOCC1",281.11642672,21,3.057,46.84,0.151663063744449,0.314,0.232831531872224,1,1
"chlorindanol","","","Oc1ccc(Cl)c2CCCc12, Oc1ccc(Cl)c2CCCc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(Cl)c2CCCc12",168.034192588,11,2.709,20.23,0.312016759765959,0.152,0.23200837988298,1,1
"PhiKan-083","p53 stabilizing agent","TP53","CCn1c2ccccc2c2cc(CNC)ccc12, CCn1c2ccccc2c2cc(CNC)ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCn1c2ccccc2c2cc(CNC)ccc12",238.146998576,18,3.77,16.96,0.373336831034979,0.09,0.23166841551749,1,0
"atiprimod","JAK inhibitor, STAT inhibitor","JAK2, STAT3","CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1, CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1",336.350449408,24,7.075,6.48,0.394217179734404,0.068,0.231108589867202,1,0
"safranal","benzodiazepine receptor agonist","GABBR1","CC1=C(C=O)C(C)(C)CC=C1 |c:1,9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC1=C(C=O)C(C)(C)CC=C1 |c:1",150.104465068,11,2.45,17.07,0.412829179480697,0.048,0.230414589740348,1,0
"6-aminochrysene","transferase inhibitor","","Nc1cc2c3ccccc3ccc2c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Nc1cc2c3ccccc3ccc2c2ccccc12",243.104799416,19,5.003,26.02,0.422237036850412,0.038,0.230118518425206,1,0
"dimethindene-(S)-(+)","acetylcholine receptor antagonist","HRH1","C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|, C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|, C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|, C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|, C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|",292.193948768,22,2.863,16.13,0.251302226077605,0.204,0.227651113038803,1,1
"olesoxime","apoptosis stimulant","","CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4=C\C(CC[C@]4(C)[C@H]3CC[C@]12C)=N\O |t:15|, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4=C\C(CC[C@]4(C)[C@H]3CC[C@]12C)=N\O |t:15|, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4=C\C(CC[C@]4(C)[C@H]3CC[C@]12C)=N\O |t:15|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4=C\C(CC[C@]4(C)[C@H]3CC[C@]12C)=N\O |t:15|",399.35011506,29,10.754,32.59,0.380707683686382,0.074,0.227353841843191,1,0
"tro 19622","","","CC(C)CCCC(C)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(CC[C@]4(C)[C@H]3CC[C@]12C)=NO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CC(C)CCCC(C)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(CC[C@]4(C)[C@H]3CC[C@]12C)=NO",399.35011506,29,10.754,32.59,0.380707683686382,0.074,0.227353841843191,1,0
"ZSET1446","nicotinic receptor agonist","","O=C1N=C2C=CC=CN2C11Cc2ccccc2C1 |c:4,6,t:2|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C1N=C2C=CC=CN2C11Cc2ccccc2C1 |c:4",236.094963004,18,2.116,32.67,0.224643033175266,0.23,0.227321516587633,1,1
"butaclamol","dopamine receptor antagonist","DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A","CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc([C@@H]2C1)c34",0,0,0,0,0,0,0,0,1,2,0,0,0,0,1,5,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc([C@@H]2C1)c34",361.240564612,27,4.837,23.47,0.218181096044581,0.236,0.227090548022291,1,1
"butaclamol (+)","dopamine receptor antagonist","","CC(C)(C)[C@@]1(O)CCN2C[C@@H]3c4ccccc4CCc4cccc([C@H]2C1)c34",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)(C)[C@@]1(O)CCN2C[C@@H]3c4ccccc4CCc4cccc([C@H]2C1)c34",361.240564612,27,4.837,23.47,0.218181096044581,0.236,0.227090548022291,1,1
"DFB","glutamate receptor agonist","GRM5","Fc1cccc(\C=N\N=C\c2cccc(F)c2)c1, Fc1cccc(\C=N\N=C\c2cccc(F)c2)c1, Fc1cccc(\C=N\N=C\c2cccc(F)c2)c1, Fc1cccc(\C=N\N=C\c2cccc(F)c2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1cccc(\C=N\N=C\c2cccc(F)c2)c1",244.08120476,18,5.058,24.72,0.37197422398191,0.082,0.226987111990955,1,0
"tremorine","acetylcholine receptor agonist","","C(C#CCN1CCCC1)N1CCCC1, C(C#CCN1CCCC1)N1CCCC1, C(C#CCN1CCCC1)N1CCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C(C#CCN1CCCC1)N1CCCC1",192.16264864,14,1.256,6.48,0.32872413724384,0.124,0.22636206862192,1,0
"ZD-7288","HCN channel blocker","HCN1, HCN2, HCN3, HCN4","CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1, CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1, CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1, CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1, CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1, CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1",256.16879664,19,4.895,33.42,0.3049138145215,0.146,0.22545690726075,1,1
"PACOCF3","phospholipase inhibitor","PLA2G4A","CCCCCCCCCCCCCCCC(=O)C(F)(F)F, CCCCCCCCCCCCCCCC(=O)C(F)(F)F, CCCCCCCCCCCCCCCC(=O)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCCCCCCCCCC(=O)C(F)(F)F",308.232700272,21,8.534,17.07,0.416720404911634,0.034,0.225360202455817,1,0
"tanshinone-IIA","anti-inflammatory agent, interleukin inhibitor","IL1B, NR1I2, TNF","Cc1coc-2c1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc-21, Cc1coc-2c1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc-21, Cc1coc-2c1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc-21, Cc1coc-2c1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc-21",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","Cc1coc-2c1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc-21",294.125594436,22,4.444,47.28,0.186611532697898,0.264,0.225305766348949,1,1
"AC1NDSS5","","","CCCCCCCCCCCCCCCCCC[S+](CCC)c1ccccc1C(=O)OCC, CCCCCCCCCCCCCCCCCC[S+](CCC)c1ccccc1C(=O)OCC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCCCCCCCCCCCCCCCCC[S+](CCC)c1ccccc1C(=O)OCC",477.376078356091,33,13.363,26.3,0.344218785342466,0.106,0.225109392671233,1,0
"oncrasin-1","apoptosis stimulant","","Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1, Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1, Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1, Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1, Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1, Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1, Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1",269.060741684,19,4.425,22,0.272336293413763,0.176,0.224168146706882,1,1
"CID-5458317","MAP kinase phosphatase inhibitor","MAPK3","OC1=c2ccccc2=C(NC2CCCCC2)\C1=C/c1ccccc1 |c:1,t:8|, OC1=c2ccccc2=C(NC2CCCCC2)\C1=C/c1ccccc1 |c:1,t:8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC1=c2ccccc2=C(NC2CCCCC2)\C1=C/c1ccccc1 |c:1",317.177964356,24,6.06,32.26,0.306220440439722,0.142,0.224110220219861,1,1
"N-methylpyrrolidone","","","CN1CCCC1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN1CCCC1=O",99.068413908,7,-0.17,20.31,0.316132815837003,0.132,0.224066407918501,1,1
"nisoxetine hydrochloride","norepinephrine reuptake inhibitor","","CNCCC(Oc1ccccc1OC)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CNCCC(Oc1ccccc1OC)c1ccccc1",271.157228912,20,3.369,30.49,0.221257066784254,0.226,0.223628533392127,1,1
"AVex-73","sigma receptor agonist","","CN(C)C[C@H]1CCOC1(c1ccccc1)c1ccccc1 |&1:4,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)C[C@H]1CCOC1(c1ccccc1)c1ccccc1 |&1:4",281.177964356,21,3.629,12.47,0.313034286289945,0.134,0.223517143144972,1,1
"5-(4chlorophenyl)-4-ethyl-2,4-dihydro-3H-1,2,4-triazol-3-one","","","CCn1c(n[nH]c1=O)-c1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCn1c(n[nH]c1=O)-c1ccc(Cl)cc1",223.05123962,15,2.973,50.68,0.138768144137426,0.306,0.222384072068713,1,1
"1-ethyl-2-pyrrolidone","transdermal absorption-enhancing compound","","CCN1CCCC1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN1CCCC1=O",113.084063972,8,0.253,20.31,0.315936830812224,0.128,0.221968415406112,1,0
"GW274150","nitric oxide synthase inhibitor","","CC(=N)NCCSCC[C@H](N)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(=N)NCCSCC[C@H](N)C(O)=O",219.104147784,14,-1.75,124.5,0.00791072444378792,0.436,0.221955362221894,0,1
"zometapine","","","Cc1nn(C)c2NCCN=C(c12)c1cccc(Cl)c1 |c:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1nn(C)c2NCCN=C(c12)c1cccc(Cl)c1 |c:9|",274.09852416,19,3.286,42.21,0.135733053467444,0.308,0.221866526733722,1,1
"sr-31747","immunosuppressant","SIGMAR1","CCN(C/C=C\C1=CC=C(C2CCCCC2)C(Cl)=C1)C3CCCCC3.Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","oncology","prostate cancer","CCN(C/C=C\C1=CC=C(C2CCCCC2)C(Cl)=C1)C3CCCCC3.Cl",395.21465548,26,7.154,3.24,0.217262219967342,0.226,0.221631109983671,1,1
"PNU-22394","serotonin receptor agonist","HTR2A, HTR2B, HTR2C, MAOA, MAOB","Cn1c2CCNCCc2c2ccccc12, Cn1c2CCNCCc2c2ccccc12",0,0,0,0,0,0,1,2,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cn1c2CCNCCc2c2ccccc12",200.131348512,15,2.236,16.96,0.33701960811858,0.106,0.22150980405929,1,0
"(5z,8z,11z,14z,17z)-methyl icosa-5,8,11,14,17-pentaenoate","","","CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC",316.240230264,23,8.34300000000001,26.3,0.418810538087252,0.024,0.221405269043626,1,0
"cedrol","","","C[C@H]1CC[C@H]2C(C)(C)[C@H]3C[C@@]12CC[C@@]3(C)O |&1:1,&2:4,&3:8,&4:10,&5:13,r|, C[C@H]1CC[C@H]2C(C)(C)[C@H]3C[C@@]12CC[C@@]3(C)O |&1:1,&2:4,&3:8,&4:10,&5:13,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@H]1CC[C@H]2C(C)(C)[C@H]3C[C@@]12CC[C@@]3(C)O |&1:1",222.198365452,16,5.176,20.23,0.418633964278807,0.022,0.220316982139403,1,0
"cedrol-(+)","sedative","","C[C@@H]1CC[C@H]2C(C)(C)[C@H]3C[C@@]12CC[C@@]3(C)O, C[C@@H]1CC[C@H]2C(C)(C)[C@H]3C[C@@]12CC[C@@]3(C)O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@@H]1CC[C@H]2C(C)(C)[C@H]3C[C@@]12CC[C@@]3(C)O",222.198365452,16,5.176,20.23,0.418633964278807,0.022,0.220316982139403,1,0
"2-pyridylethylamine","histamine receptor agonist","HRH1","NCCc1ccccn1, NCCc1ccccn1, NCCc1ccccn1",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NCCc1ccccn1",122.08439832,9,0.139,38.91,0.228564881681825,0.212,0.220282440840913,1,1
"SCH-23390","dopamine receptor antagonist","DRD1, DRD5, HTR2C, KCNJ4, KCNJ6","CN1CCc2cc(Cl)c(O)cc2[C@H](C1)c1ccccc1, CN1CCc2cc(Cl)c(O)cc2[C@H](C1)c1ccccc1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCc2cc(Cl)c(O)cc2[C@H](C1)c1ccccc1",287.107691876,20,3.483,23.47,0.1901517947613,0.25,0.22007589738065,1,1
"ZLN005","","","CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1, CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1, CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1, CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1, CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1",250.146998576,19,5.087,28.68,0.372142200882523,0.068,0.220071100441262,1,0
"AGN-192403","imidazoline receptor ligand","NISCH","CC(C)[C@@H]1[C@H]2CC[C@@H](C2)[C@H]1N |a:3,9,&1:4,&2:7|, CC(C)[C@@H]1[C@H]2CC[C@@H](C2)[C@H]1N |a:3,9,&1:4,&2:7|, CC(C)[C@@H]1[C@H]2CC[C@@H](C2)[C@H]1N |a:3,9,&1:4,&2:7|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)[C@@H]1[C@H]2CC[C@@H](C2)[C@H]1N |a:3",153.151749608,11,2.532,26.02,0.351485662385749,0.088,0.219742831192875,1,0
"dibenzothiophene","","","c1ccc2c(c1)sc1ccccc21, c1ccc2c(c1)sc1ccccc21, c1ccc2c(c1)sc1ccccc21",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","c1ccc2c(c1)sc1ccccc21",184.034671256,13,4.135,28.24,0.36626405265676,0.07,0.21813202632838,1,0
"AZD1446","acetylcholine receptor agonist","CHRNA4, CHRNB2","Clc1ccc(o1)C(=O)N1C[C@H]2CNC[C@@H]2C1 |&1:10,&2:14,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,"phase 2","","","Clc1ccc(o1)C(=O)N1C[C@H]2CNC[C@@H]2C1 |&1:10",240.066555336,16,0.559,45.48,0.0777311030891351,0.358,0.217865551544568,0,1
"pyrazolanthrone","JNK inhibitor","MAPK10, MAPK8, MAPK8IP1, MAPK9, TTK","O=C1c2ccccc2-c2[nH]nc3cccc1c23, O=C1c2ccccc2-c2[nH]nc3cccc1c23, O=C1c2ccccc2-c2[nH]nc3cccc1c23, O=C1c2ccccc2-c2[nH]nc3cccc1c23, O=C1c2ccccc2-c2[nH]nc3cccc1c23",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C1c2ccccc2-c2[nH]nc3cccc1c23",220.063662876,17,3.821,45.75,0.274696486720141,0.16,0.217348243360071,1,1
"NFKB-activation-inhibitor-II","NFkB pathway inhibitor","RELA","Cc1ccc(NCCCc2ccccc2)c(N)c1, Cc1ccc(NCCCc2ccccc2)c(N)c1, Cc1ccc(NCCCc2ccccc2)c(N)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(NCCCc2ccccc2)c(N)c1",240.16264864,18,3.514,38.05,0.246410116588823,0.188,0.217205058294411,1,1
"xanthone","antimalarial agent","","O=c1c2ccccc2oc2ccccc12, O=c1c2ccccc2oc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=c1c2ccccc2oc2ccccc12",196.052429496,15,4.212,30.21,0.400947534404188,0.032,0.216473767202094,1,0
"AZD6765","glutamate receptor antagonist","GRIN1","N[C@@H](Cc1ccccn1)c1ccccc1 |&1:1,r|, N[C@@H](Cc1ccccn1)c1ccccc1 |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","N[C@@H](Cc1ccccn1)c1ccccc1 |&1:1",198.115698448,15,1.952,38.91,0.230242194154716,0.196,0.213121097077358,1,1
"mofegiline","monoamine oxidase inhibitor","MAOA, MAOB","NC\C(CCc1ccc(F)cc1)=C\F, NC\C(CCc1ccc(F)cc1)=C\F, NC\C(CCc1ccc(F)cc1)=C\F, NC\C(CCc1ccc(F)cc1)=C\F",0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","NC\C(CCc1ccc(F)cc1)=C\F",197.101605856,14,2.218,26.02,0.259405700129627,0.166,0.212702850064814,1,1
"2-isopropyl-5-methylcyclohexanol","","","CC(C)C1CCC(C)CC1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CC(C)C1CCC(C)CC1O",156.15141526,11,3.211,20.23,0.405296808503065,0.02,0.212648404251533,1,0
"nisoxetine","norepinephrine reuptake inhibitor","SLC6A2, SLC6A3, SLC6A4","CNCC[C@@H](Oc1ccccc1OC)c1ccccc1 |&1:4,r|",1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CNCC[C@@H](Oc1ccccc1OC)c1ccccc1 |&1:4",271.157228912,20,3.369,30.49,0.221257066784253,0.204,0.212628533392127,1,1
"MG-624","acetylcholine receptor antagonist","CHRNA7","CC[N+](CC)(CC)CCOc1ccc(\C=C\c2ccccc2)cc1, CC[N+](CC)(CC)CCOc1ccc(\C=C\c2ccccc2)cc1, CC[N+](CC)(CC)CCOc1ccc(\C=C\c2ccccc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"preclinical","","","CC[N+](CC)(CC)CCOc1ccc(\C=C\c2ccccc2)cc1",324.232191000091,24,5.502,9.23,0.356750555730485,0.068,0.212375277865243,1,0
"napabucasin","STAT inhibitor","STAT3","CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O",240.042258736,18,1.926,64.35,0.107720740788247,0.316,0.211860370394123,0,1
"laurocapram","","","CCCCCCCCCCCCN1CCCCCC1=O, CCCCCCCCCCCCN1CCCCCC1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCCCCCCCCCCCN1CCCCCC1=O",281.27186474,20,6.448,20.31,0.375454646503084,0.048,0.211727323251542,1,0
"O-1918","cannabinoid receptor antagonist","","COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C |t:13|, COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C |t:13|, COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C |t:13|, COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C |t:13|, COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C |t:13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C |t:13|",286.193280072,21,5.275,18.46,0.345026285449697,0.076,0.210513142724848,1,0
"camphor-(+)","","","CC1(C)[C@@H]2CC[C@@]1(C)C(=O)C2, CC1(C)[C@@H]2CC[C@@]1(C)C(=O)C2, CC1(C)[C@@H]2CC[C@@]1(C)C(=O)C2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC1(C)[C@@H]2CC[C@@]1(C)C(=O)C2",152.120115132,11,2.127,17.07,0.382320244135797,0.038,0.210160122067899,1,0
"camphor-(1R)","TRPV activator","TRPV1","CC1(C)[C@@H]2CC[C@]1(C)C(=O)C2, CC1(C)[C@@H]2CC[C@]1(C)C(=O)C2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC1(C)[C@@H]2CC[C@]1(C)C(=O)C2",152.120115132,11,2.127,17.07,0.382320244135797,0.038,0.210160122067899,1,0
"CBS-1114","lipoxygenase inhibitor","ALOX5","NC(=NNc1ccccc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","NC(=NNc1ccccc1)c1ccccc1",211.110947416,16,3.849,50.41,0.251906458351766,0.168,0.209953229175883,1,1
"befuraline","","","O=C(N1CCN(Cc2ccccc2)CC1)c1cc2ccccc2o1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O=C(N1CCN(Cc2ccccc2)CC1)c1cc2ccccc2o1",320.15247788,24,2.978,36.69,0.148335497654907,0.27,0.209167748827454,1,1
"2-methylimidazole","cholesterol inhibitor","","Cc1ncc[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ncc[nH]1",82.053098192,6,0.198,28.68,0.332039869393628,0.086,0.209019934696814,1,0
"talsaclidine","acetylcholine receptor agonist","","C#CCO[C@H]1CN2CCC1CC2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","C#CCO[C@H]1CN2CCC1CC2",165.1153641,12,0.706,12.47,0.309612790424024,0.108,0.208806395212012,1,0
"abt-418 (hydrochloride)","nicotinic receptor agonist","CHRNA4, CHRNA7, HTR3A","CN1CCC[C@H]1c1cc(C)no1.Cl |a:5|",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,2,0,0,0,0,0,0,"preclinical","neurology/psychiatry","alzheimer's disease","CN1CCC[C@H]1c1cc(C)no1.Cl |a:5|",202.08729078,13,1.807,29.27,0.171521952293846,0.246,0.208760976146923,1,1
"TTNPB","retinoid receptor agonist","RARA, RARB, RARG","C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C, C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C, C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C, C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C",348.208930136,26,7.957,37.3,0.320732772485592,0.096,0.208366386242796,1,0
"FPS-ZM1","RAGE receptor antagonist","AGER","Clc1ccc(cc1)C(=O)N(Cc1ccccc1)C1CCCCC1, Clc1ccc(cc1)C(=O)N(Cc1ccccc1)C1CCCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1ccc(cc1)C(=O)N(Cc1ccccc1)C1CCCCC1",327.138992004,23,5.729,20.31,0.251500866372248,0.164,0.207750433186124,1,1
"gramine","norepinephrine reputake inhibitor","","CN(C)Cc1c[nH]c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)Cc1c[nH]c2ccccc12",174.115698448,13,1.881,19.03,0.342870781270667,0.072,0.207435390635333,1,0
"ergosterol","vitamin D precursor","","CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:13,15|, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:13,15|, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:13,15|, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:13,15|, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:13,15|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:13",396.339216028,29,9.499,20.23,0.3927238627886,0.022,0.2073619313943,1,0
"7,8,9,10-tetrahydroazepino[2,1-b]quinazolin-12(6H)-one","","","O=C1N2CCCCC=C2Nc2ccccc12 |c:7|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C1N2CCCCC=C2Nc2ccccc12 |c:7|",214.110613068,16,2.732,32.34,0.265946343044158,0.148,0.206973171522079,1,1
"EMD-386088","serotonin receptor agonist","HTR6","Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1 |t:13|, Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1 |t:13|, Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1 |t:13|, Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1 |t:13|",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1 |t:13|",246.09237616,17,2.866,27.82,0.195938564737248,0.218,0.206969282368624,1,1
"2-((2-ethoxyphenoxy)(phenyl)methyl)morpholine methanesulfonate","","","CCOc1ccccc1OC(C1CNCCO1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CCOc1ccccc1OC(C1CNCCO1)c1ccccc1",313.167793596,23,3.071,39.72,0.134868015505574,0.278,0.206434007752787,1,1
"HTHQ","antioxidant","","CCCCCCOc1cc(C)c(O)c(C)c1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCOc1cc(C)c(O)c(C)c1C",236.177630008,17,4.697,29.46,0.317850260888503,0.094,0.205925130444251,1,0
"5-fluoropyrimidine","kinase inhibitor","","Fc1cncnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Fc1cncnc1",98.028026316,7,-0.11,25.78,0.297586412660546,0.114,0.205793206330273,1,0
"dipraglurant","glutamate receptor negative allosteric modulator","GRM5","Fc1ccc2nc(CCC#Cc3ccccn3)cn2c1, Fc1ccc2nc(CCC#Cc3ccccn3)cn2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Fc1ccc2nc(CCC#Cc3ccccn3)cn2c1",265.101525604,20,3.979,30.19,0.277485477878958,0.134,0.205742738939479,1,1
"SIB-1757","glutamate receptor antagonist","GRM5","C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|, C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|, C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|, C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|, C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|, C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|",213.090211972,16,3.45,53.49,0.213311806294241,0.198,0.205655903147121,1,1
"AIM-100","tyrosine kinase inhibitor","TNK2","C(Nc1ncnc2oc(c(-c3ccccc3)c12)-c1ccccc1)[C@@H]1CCCO1, C(Nc1ncnc2oc(c(-c3ccccc3)c12)-c1ccccc1)[C@@H]1CCCO1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C(Nc1ncnc2oc(c(-c3ccccc3)c12)-c1ccccc1)[C@@H]1CCCO1",371.163376912,28,5.038,60.18,0.110578079403969,0.3,0.205289039701984,0,1
"BD-1047","adrenergic receptor antagonist","SIGMAR1","CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1, CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1, CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1",274.100354,17,3.028,6.48,0.175507687634534,0.234,0.204753843817267,1,1
"oxacyclohexadecan-2-one","protein kinase inhibitor","","O=C1CCCCCCCCCCCCCCO1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C1CCCCCCCCCCCCCCO1",240.208930136,17,6.056,26.3,0.388547133963371,0.02,0.204273566981686,1,0
"map4343","microtubule stimulant","MAP2","[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@H](CC[C@]12C)OC |t:19|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"phase 2","neurology/psychiatry","depression","[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@H](CC[C@]12C)OC |t:19|",330.255880328,27,5.352,26.3,0.383499235734225,0.024,0.203749617867112,1,0
"DPPE","histamine receptor antagonist","ABCB1, HRH1","CCN(CC)CCOc1ccc(Cc2ccccc2)cc1, CCN(CC)CCOc1ccc(Cc2ccccc2)cc1, CCN(CC)CCOc1ccc(Cc2ccccc2)cc1",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCN(CC)CCOc1ccc(Cc2ccccc2)cc1",283.19361442,21,4.602,12.47,0.355378574657942,0.052,0.203689287328971,1,0
"BD-1063","sigma receptor antagonist","SIGMAR1","CN1CCN(CCc2ccc(Cl)c(Cl)c2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCN(CCc2ccc(Cl)c(Cl)c2)CC1",272.084703936,17,2.818,6.48,0.175027703448404,0.232,0.203513851724202,1,1
"TRAM-34","potassium channel antagonist","KCNN4","Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1cccn1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1cccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1cccn1",344.108026224,25,6.471,17.82,0.310941157562374,0.096,0.203470578781187,1,0
"splitomycin","SIRT inhibitor","SIRT1","O=C1CCc2c(O1)ccc1ccccc21, O=C1CCc2c(O1)ccc1ccccc21",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C1CCc2c(O1)ccc1ccccc21",198.06807956,15,2.749,26.3,0.327843203412506,0.078,0.202921601706253,1,0
"AJ76-(+)","dopamine receptor antagonist","DRD2, DRD3, DRD4","CCCN[C@@H]1CCc2c(OC)cccc2[C@@H]1C, CCCN[C@@H]1CCc2c(OC)cccc2[C@@H]1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,"preclinical","","","CCCN[C@@H]1CCc2c(OC)cccc2[C@@H]1C",233.177964356,17,2.922,21.26,0.28145189872153,0.124,0.202725949360765,1,0
"RX-821002","adrenergic receptor antagonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C","CO[C@]1(COc2ccccc2O1)C1=NCCN1 |&1:2,t:14|, CO[C@]1(COc2ccccc2O1)C1=NCCN1 |&1:2,t:14|, CO[C@]1(COc2ccccc2O1)C1=NCCN1 |&1:2,t:14|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,6,0,0,0,0,"preclinical","","","CO[C@]1(COc2ccccc2O1)C1=NCCN1 |&1:2",234.100442308,17,0.543,52.08,0.0947113941041694,0.31,0.202355697052085,0,1
"golgicide-A","ARF inhibitor","GBF1","Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|, Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|, Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|, Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|, Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8",284.112504888,21,3.379,24.92,0.230393155884992,0.174,0.202196577942496,1,1
"ABT-239","histamine receptor antagonist","HRH1, HRH2, HRH3","C[C@@H]1CCCN1CCc1cc2cc(ccc2o1)-c1ccc(cc1)C#N",0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@@H]1CCCN1CCc1cc2cc(ccc2o1)-c1ccc(cc1)C#N",330.173213324,25,4.613,40.17,0.192093397298274,0.212,0.202046698649137,1,1
"NLG919","indoleamine 2,3-dioxygenase inhibitor","IDO1","O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|, O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|, O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|, O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|, O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|, O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1",282.173213324,21,4.141,38.05,0.218028915089848,0.186,0.202014457544924,1,1
"altinicline","nicotinic receptor agonist","CHRNA4, CHRNB2","CN1CCC[C@H]1c1cncc(c1)C#C, CN1CCC[C@H]1c1cncc(c1)C#C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,"phase 2","","","CN1CCC[C@H]1c1cncc(c1)C#C",186.115698448,14,1.628,16.13,0.331404824144248,0.072,0.201702412072124,1,0
"hordenine","","","CN(C)CCc1ccc(O)cc1, CN(C)CCc1ccc(O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)CCc1ccc(O)cc1",165.1153641,12,1.525,23.47,0.298168614570858,0.104,0.201084307285429,1,0
"trichloroethylene","","","ClC=C(Cl)Cl, ClC=C(Cl)Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","ClC=C(Cl)Cl",129.914383072,5,2.642,0,0.308026238508763,0.094,0.201013119254382,1,0
"cinflumide","muscle relaxant","","Fc1cccc(\C=C\C(=O)NC2CC2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Fc1cccc(\C=C\C(=O)NC2CC2)c1",205.090292224,15,2.403,29.1,0.261990578805704,0.14,0.200995289402852,1,1
"N-methyl-(-)ephedrine-[1R,2S]","","","C[C@@H]([C@H](O)c1ccccc1)N(C)C, C[C@@H]([C@H](O)c1ccccc1)N(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H]([C@H](O)c1ccccc1)N(C)C",179.131014164,13,1.627,23.47,0.281772731628841,0.12,0.20088636581442,1,0
"EC-23","retinoid receptor agonist","RARA, RARB, RARG","CC1(C)CCC(C)(C)c2cc(ccc12)C#Cc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C#Cc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C#Cc1ccc(cc1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC1(C)CCC(C)(C)c2cc(ccc12)C#Cc1ccc(cc1)C(O)=O",332.177630008,25,7.531,37.3,0.331359858308198,0.07,0.200679929154099,1,0
"BRD9876","kinesin inhibitor","KIF11","CC(C)(C)c1ccc2cc(C#N)c(cc2c1)C#N, CC(C)(C)c1ccc2cc(C#N)c(cc2c1)C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)c1ccc2cc(C#N)c(cc2c1)C#N",234.115698448,18,4.551,47.58,0.28093776351063,0.12,0.200468881755315,1,0
"N-methylformamide","","","CNC=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CNC=O",59.03711378,4,-0.526,29.1,0.310691996871832,0.088,0.199345998435916,1,0
"TRAM-39","calcium-activated potassium channel activator","KCNN4","Clc1ccccc1C(C#N)(c1ccccc1)c1ccccc1, Clc1ccccc1C(C#N)(c1ccccc1)c1ccccc1, Clc1ccccc1C(C#N)(c1ccccc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1ccccc1C(C#N)(c1ccccc1)c1ccccc1",303.081477128,22,6.012,23.79,0.319275742185619,0.078,0.198637871092809,1,0
"tryptanthrin","cyclooxygenase inhibitor","IDO1","O=C1c2ccccc2-n2c1nc1ccccc1c2=O, O=C1c2ccccc2-n2c1nc1ccccc1c2=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C1c2ccccc2-n2c1nc1ccccc1c2=O",248.058577496,19,2.784,51.96,0.171114124138448,0.224,0.197557062069224,1,1
"AC-55649","retinoid receptor agonist","RARA, RARB","CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O, CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O, CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O, CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O",310.193280072,23,7.892,37.3,0.366160937181553,0.028,0.197080468590777,1,0
"acetanilide","hydrogen peroxide decomposition inhibitor","","CC(=O)Nc1ccccc1, CC(=O)Nc1ccccc1, CC(=O)Nc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)Nc1ccccc1",135.068413908,10,1.276,29.1,0.312148002424931,0.082,0.197074001212466,1,0
"efaroxan","adrenergic receptor antagonist","ADORA2A","CCC1(Cc2ccccc2O1)C1=NCCN1, CCC1(Cc2ccccc2O1)C1=NCCN1, CCC1(Cc2ccccc2O1)C1=NCCN1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCC1(Cc2ccccc2O1)C1=NCCN1",216.126263132,16,1.786,33.62,0.209951209610994,0.184,0.196975604805497,1,1
"4-HQN","PARP inhibitor","PARP1","O=c1nc[nH]c2ccccc12, O=c1nc[nH]c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=c1nc[nH]c2ccccc12",146.048012812,11,2.342,45.75,0.279554461366094,0.114,0.196777230683047,1,0
"linalool","anticonvulsant","","CC(C)=CCC[C@@](C)(O)C=C |&1:6,r|, CC(C)=CCC[C@@](C)(O)C=C |&1:6,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)=CCC[C@@](C)(O)C=C |&1:6",154.135765196,11,2.468,20.23,0.373433827917999,0.02,0.196716913959,1,0
"8-hydroxy-DPAT","serotonin receptor agonist","HTR5A, HTR7","CCCN(CCC)[C@H]1CCc2cccc(O)c2C1 |&1:7|, CCCN(CCC)[C@H]1CCc2cccc(O)c2C1 |&1:7|",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCN(CCC)[C@H]1CCc2cccc(O)c2C1 |&1:7|",247.19361442,18,3.328,23.47,0.270205063456027,0.122,0.196102531728013,1,0
"tapentadol hydrochloride","","","CC[C@@H]([C@@H](C)CN(C)C)c1cccc(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CC[C@@H]([C@@H](C)CN(C)C)c1cccc(O)c1",221.177964356,16,3.253,23.47,0.299258859683089,0.092,0.195629429841544,1,0
"RLX","","","O=c1n2CCCCCc2nc2ccccc12, O=c1n2CCCCCc2nc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=c1n2CCCCCc2nc2ccccc12",214.110613068,16,2.776,34.89,0.256620086330037,0.134,0.195310043165018,1,1
"DCP-LA","protein kinase activator","","CCCCC[C@H]1C[C@H]1C[C@H]1C[C@H]1CCCCCCCC(O)=O |&1:11,&2:9,&3:7,&4:5,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCC[C@H]1C[C@H]1C[C@H]1C[C@H]1CCCCCCCC(O)=O |&1:11",308.271530392,22,8.922,37.3,0.382122917040023,0.008,0.195061458520011,1,0
"LY320135","cannabinoid receptor antagonist","CNR1","COc1ccc(cc1)-c1oc2cc(OC)ccc2c1C(=O)c1ccc(cc1)C#N, COc1ccc(cc1)-c1oc2cc(OC)ccc2c1C(=O)c1ccc(cc1)C#N, COc1ccc(cc1)-c1oc2cc(OC)ccc2c1C(=O)c1ccc(cc1)C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1)-c1oc2cc(OC)ccc2c1C(=O)c1ccc(cc1)C#N",383.115758024,29,5.043,72.46,0.0813869559846037,0.308,0.194693477992302,0,1
"NS-8593","calcium-activated potassium channel modulator","KCNN1, KCNN2, KCNN3","C1C[C@@H](Nc2nc3ccccc3[nH]2)c2ccccc2C1, C1C[C@@H](Nc2nc3ccccc3[nH]2)c2ccccc2C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C1C[C@@H](Nc2nc3ccccc3[nH]2)c2ccccc2C1",263.142247544,20,4.041,40.71,0.2425411260704,0.146,0.1942705630352,1,1
"linoleic-acid","oxidative stress inducer","FABP4, FFAR1, FFAR4, HNF4A, KCNB1, PPARG, TRPM8","CCCCC\C=C/C\C=C/CCCCCCCC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCCCC\C=C/C\C=C/CCCCCCCC(O)=O",280.240230264,20,7.865,37.3,0.370401617318976,0.018,0.194200808659488,1,0
"BD-1008","sigma receptor antagonist","","CN(CCN1CCCC1)CCc1ccc(Cl)c(Cl)c1, CN(CCN1CCCC1)CCc1ccc(Cl)c(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(CCN1CCCC1)CCc1ccc(Cl)c(Cl)c1",300.116004064,19,3.534,6.48,0.17021430670265,0.218,0.194107153351325,1,1
"methylbenzethonium-chloride","other antibiotic","","Cc1cc(ccc1OCCOCC[N+](C)(C)Cc1ccccc1)C(C)(C)CC(C)(C)C, Cc1cc(ccc1OCCOCC[N+](C)(C)Cc1ccccc1)C(C)(C)CC(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(ccc1OCCOCC[N+](C)(C)Cc1ccccc1)C(C)(C)CC(C)(C)C",426.336656068091,31,7.414,18.46,0.238182352922585,0.15,0.194091176461293,1,1
"(+)-sk&f 10047 hydrochloride","sigma receptor agonist","","C[C@H]1C2Cc3ccc(O)cc3[C@@]1(C)CCN2CC=C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@H]1C2Cc3ccc(O)cc3[C@@]1(C)CCN2CC=C",257.177964356,19,3.108,23.47,0.258106318349182,0.13,0.194053159174591,1,1
"SK&F-10047-(+)","sigma receptor agonist","SIGMAR1","C[C@@H]1[C@@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2CC=C, C[C@@H]1[C@@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2CC=C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@@H]1[C@@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2CC=C",257.177964356,19,3.108,23.47,0.258106318349182,0.13,0.194053159174591,1,1
"L-741742","dopamine receptor antagonist","DRD3, DRD4, SCN1A, SCN3A","Cc1c(noc1-c1ccc(Cl)cc1)C1CCN(CCc2ccccc2)CC1, Cc1c(noc1-c1ccc(Cl)cc1)C1CCN(CCc2ccccc2)CC1",0,0,1,2,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"preclinical","","","Cc1c(noc1-c1ccc(Cl)cc1)C1CCN(CCc2ccccc2)CC1",380.1655411,27,5.608,29.27,0.157875075927845,0.23,0.193937537963922,1,1
"aminomethyltransferase","nitric oxide synthase inhibitor","NOS2","C[C@H]1CCN=C(N)S1 |&1:1,t:4|, C[C@H]1CCN=C(N)S1 |&1:1,t:4|, C[C@H]1CCN=C(N)S1 |&1:1,t:4|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H]1CCN=C(N)S1 |&1:1",130.05646932,8,0.613,63.68,0.109539343678566,0.278,0.193769671839283,0,1
"dihomo-gamma-linolenic-acid","prostanoid receptor agonist","PTGS1, PTGS2","CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O",306.255880328,22,8.67600000000001,37.3,0.37925797279302,0.008,0.19362898639651,1,0
"diethylstilbestrol","estrogen receptor agonist","ESR1, ESR2, ESRRB, ESRRG","CC\C(=C(\CC)c1ccc(O)cc1)c1ccc(O)cc1, CC\C(=C(\CC)c1ccc(O)cc1)c1ccc(O)cc1, CC\C(=C(\CC)c1ccc(O)cc1)c1ccc(O)cc1, CC\C(=C(\CC)c1ccc(O)cc1)c1ccc(O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CC\C(=C(\CC)c1ccc(O)cc1)c1ccc(O)cc1",268.14632988,20,5.556,40.46,0.292969346856972,0.094,0.193484673428486,1,0
"meta-cresyl-acetate","","","CC(=O)Oc1cccc(C)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)Oc1cccc(C)c1",150.06807956,11,2.244,26.3,0.350708895960578,0.036,0.193354447980289,1,0
"ZM-39923","JAK inhibitor","JAK1, JAK3","CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1, CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1, CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1, CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1, CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1",331.19361442,25,5.441,20.31,0.310596489775468,0.076,0.193298244887734,1,0
"benzyl-isothiocyanate","methylazoxymethanol acetate inhibitor","","S=C=NCc1ccccc1, S=C=NCc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","S=C=NCc1ccccc1",149.029920224,10,2.816,44.45,0.249365431591543,0.136,0.192682715795772,1,1
"chuanxiongzine","","","Cc1nc(C)c(C)nc1C, Cc1nc(C)c(C)nc1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1nc(C)c(C)nc1C",136.100048384,10,0.778,25.78,0.297347767725091,0.088,0.192673883862546,1,0
"SU4312","PDGFR tyrosine kinase receptor inhibitor, tyrosine kinase inhibitor, VEGFR inhibitor","KDR, PDGFRB","CN(C)c1ccc(\C=C2/C(=O)Nc3ccccc23)cc1, CN(C)c1ccc(\C=C2/C(=O)Nc3ccccc23)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)c1ccc(\C=C2/C(=O)Nc3ccccc23)cc1",264.126263132,20,3.31,32.34,0.240926627155871,0.144,0.192463313577936,1,1
"CI-844","","","O(c1ccccc1)c1cccnc1, O(c1ccccc1)c1cccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O(c1ccccc1)c1cccnc1",171.068413908,13,2.251,22.12,0.363886115565075,0.02,0.191943057782537,1,0
"N-methylquipazine","serotonin receptor agonist","","CN1CCN(CC1)c1ccc2ccccc2n1, CN1CCN(CC1)c1ccc2ccccc2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCN(CC1)c1ccc2ccccc2n1",227.142247544,17,2.825,19.37,0.315844475426629,0.068,0.191922237713314,1,0
"fluorofenidone","nadph oxidase inhibitor","NOX1","CC1=CN(C(=O)C=C1)c2cccc(F)c2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","pulmonary","idiopathic pulmonary fibrosis (ipf)","CC1=CN(C(=O)C=C1)c2cccc(F)c2",203.07464216,15,1.937,20.31,0.289463810577456,0.094,0.191731905288728,1,0
"arachidonic-acid","cytochrome P450 inhibitor","CLCN2, KCNJ4, KCNK10, KCNK18, KCNK2, PRKCZ, PTGS1, TRPC6, TRPM2","CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O",304.240230264,22,8.34900000000001,37.3,0.371749022949417,0.01,0.190874511474708,1,0
"BCI-540","glutamate receptor agonist","","Cc1oc2nc3CCCCc3c(NC(=O)CN3CCCC3=O)c2c1C, Cc1oc2nc3CCCCc3c(NC(=O)CN3CCCC3=O)c2c1C, Cc1oc2nc3CCCCc3c(NC(=O)CN3CCCC3=O)c2c1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1oc2nc3CCCCc3c(NC(=O)CN3CCCC3=O)c2c1C",341.173941596,25,1.422,75.44,0.0355731878184897,0.346,0.190786593909245,0,1
"NQDI-1","caspase inhibitor","CASP3","CCOC(=O)c1c2-c3ccccc3C(=O)c3cccc([nH]c1=O)c23, CCOC(=O)c1c2-c3ccccc3C(=O)c3cccc([nH]c1=O)c23",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)c1c2-c3ccccc3C(=O)c3cccc([nH]c1=O)c23",319.084457896,24,4.431,76.23,0.0925911908169143,0.288,0.190295595408457,0,1
"atractylenolide-i","JAK inhibitor","","[H][C@@]12CC3=C(C)C(=O)OC3=C[C@@]1(C)CCCC2=C |c:3,10|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@@]12CC3=C(C)C(=O)OC3=C[C@@]1(C)CCCC2=C |c:3",230.130679816,18,3.177,26.3,0.334421491993253,0.046,0.190210745996626,1,0
"7-hydroxy-DPAT","dopamine receptor agonist","DRD2, DRD3","CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1 |&1:7|, CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1 |&1:7|, CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1 |&1:7|, CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1 |&1:7|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"preclinical","","","CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1 |&1:7|",247.19361442,18,3.328,23.47,0.270205063456027,0.11,0.190102531728013,1,0
"clobutinol","antitussive","","C[C@@H](CN(C)C)C(C)(O)Cc1ccc(Cl)cc1 |&1:1,&2:6|, C[C@@H](CN(C)C)C(C)(O)Cc1ccc(Cl)cc1 |&1:1,&2:6|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","C[C@@H](CN(C)C)C(C)(O)Cc1ccc(Cl)cc1 |&1:1",255.138992004,17,2.953,23.47,0.181533436723061,0.198,0.18976671836153,1,1
"nornicotine","acetylcholine receptor agonist","","C1CN[C@H](C1)c1cccnc1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C1CN[C@H](C1)c1cccnc1 |r|",148.100048384,11,0.891,24.92,0.295508102504125,0.084,0.189754051252063,1,0
"3,3'-dichlorobenzaldazine","glutamate receptor modulator","GRM5","Clc1cccc(\C=N\N=C\c2cccc(Cl)c2)c1, Clc1cccc(\C=N\N=C\c2cccc(Cl)c2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1cccc(\C=N\N=C\c2cccc(Cl)c2)c1",276.02210368,18,5.98,24.72,0.257062428311316,0.122,0.189531214155658,1,0
"alpha-linolenic-acid","omega 3 fatty acid stimulant","ELOVL4, FADS1, FADS2, FFAR1, FFAR4, PTGS2, SLC8A1, TRPV1","CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O, CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O, CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O, CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O, CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O",1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O",278.2245802,20,7.538,37.3,0.36296548430541,0.016,0.189482742152705,1,0
"harmane","monoamine oxidase inhibitor","MAOA, MAOB","Cc1nccc2c3ccccc3[nH]c12",0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1nccc2c3ccccc3[nH]c12",182.08439832,14,2.594,28.68,0.340868572351075,0.038,0.189434286175537,1,0
"cicloprofen","cyclooxygenase inhibitor","PTGS1, PTGS2","C[C@@H](C(O)=O)c1ccc-2c(Cc3ccccc-23)c1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc-2c(Cc3ccccc-23)c1 |&1:1,r|",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](C(O)=O)c1ccc-2c(Cc3ccccc-23)c1 |&1:1",238.099379688,18,3.547,37.3,0.26056472758382,0.118,0.18928236379191,1,0
"CYM-50358","sphingosine 1-phosphate receptor antagonist","S1PR4","Cc1cc(CN)cc(C)c1NC(=O)c1ccc(o1)-c1cc(Cl)ccc1Cl, Cc1cc(CN)cc(C)c1NC(=O)c1ccc(o1)-c1cc(Cl)ccc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(CN)cc(C)c1NC(=O)c1ccc(o1)-c1cc(Cl)ccc1Cl",388.074533176,26,4.464,68.26,0.0363262481476239,0.342,0.189163124073812,0,1
"CL-225385","","","O=C(CC#N)c1ccccc1, O=C(CC#N)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O=C(CC#N)c1ccccc1",145.052763844,11,1.211,40.86,0.252191736382295,0.126,0.189095868191147,1,0
"ISX-9","neural stem cell inducer","NEUROD1","O=C(NC1CC1)c1cc(on1)-c1cccs1, O=C(NC1CC1)c1cc(on1)-c1cccs1, O=C(NC1CC1)c1cc(on1)-c1cccs1, O=C(NC1CC1)c1cc(on1)-c1cccs1, O=C(NC1CC1)c1cc(on1)-c1cccs1, O=C(NC1CC1)c1cc(on1)-c1cccs1, O=C(NC1CC1)c1cc(on1)-c1cccs1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(NC1CC1)c1cc(on1)-c1cccs1",234.04629856,16,1.625,83.37,0.0499003632562006,0.328,0.1889501816281,0,1
"modaline","","","Cc1nccnc1N1CCCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1nccnc1N1CCCCC1",177.12659748,13,1.754,29.02,0.271847266118406,0.106,0.188923633059203,1,0
"palmitoleic-acid","","","CCCCCC\C=C/CCCCCCCC(O)=O, CCCCCC\C=C/CCCCCCCC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCC\C=C/CCCCCCCC(O)=O",254.2245802,18,7.054,37.3,0.361631589335826,0.016,0.188815794667913,1,0
"mCPP","serotonin receptor agonist","HTR1A, HTR1D, HTR1E, HTR2A, HTR2B, HTR2C, HTR6","Clc1cccc(c1)N1CCNCC1, Clc1cccc(c1)N1CCNCC1",0,0,0,0,0,0,0,0,1,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Clc1cccc(c1)N1CCNCC1",196.076726096,13,2.377,15.27,0.275523357849124,0.102,0.188761678924562,1,0
"sodium-butyrate","HDAC inhibitor","BCHE, FFAR2, FFAR3, HDAC1, HDAC2, HDAC3, HDAC8","CCCC(O)=O, CCCC(O)=O, CCCC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCC(O)=O",88.052429496,6,0.742,37.3,0.287244007535644,0.09,0.188622003767822,1,0
"gamma-linolenic-acid","cyclooxygenase inhibitor, prostanoid receptor agonist","PTGS1, PTGS2","CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O",278.2245802,20,7.538,37.3,0.36296548430541,0.014,0.188482742152705,1,0
"A-582941","nicotinic receptor agonist","CHRNA7","CN1C[C@H]2CN(C[C@H]2C1)c1ccc(nn1)-c1ccccc1, CN1C[C@H]2CN(C[C@H]2C1)c1ccc(nn1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"preclinical","","","CN1C[C@H]2CN(C[C@H]2C1)c1ccc(nn1)-c1ccccc1",280.16879664,21,2.923,32.26,0.1987982572401,0.178,0.18839912862005,1,1
"dihydrexidine","dopamine receptor agonist","DRD1, DRD2, DRD3, DRD4, DRD5","Oc1cc2CC[C@H]3NCc4ccccc4[C@@H]3c2cc1O, Oc1cc2CC[C@H]3NCc4ccccc4[C@@H]3c2cc1O, Oc1cc2CC[C@H]3NCc4ccccc4[C@@H]3c2cc1O, Oc1cc2CC[C@H]3NCc4ccccc4[C@@H]3c2cc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,5,0,0,0,0,0,0,0,0,"phase 2","","","Oc1cc2CC[C@H]3NCc4ccccc4[C@@H]3c2cc1O",267.125928784,20,2.46,52.49,0.130677810761687,0.246,0.188338905380843,1,1
"TRIM","","","FC(F)(F)c1ccccc1-n1ccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)c1ccccc1-n1ccnc1",212.056132884,15,2.757,17.82,0.298624025632701,0.078,0.18831201281635,1,0
"pipequaline","benzodiazepine receptor agonist","ALB, GABRA1","C(Cc1cc(nc2ccccc12)-c1ccccc1)C1CCNCC1",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"preclinical","neurology/psychiatry","drowsiness","C(Cc1cc(nc2ccccc12)-c1ccccc1)C1CCNCC1",316.193948768,24,5.342,24.92,0.309963366117209,0.066,0.187981683058605,1,0
"UPF-1069","PARP inhibitor","PARP2","O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1, O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1, O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1, O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1, O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1",279.089543276,21,3.358,59.16,0.131823701544466,0.244,0.187911850772233,1,1
"lofemizole","cyclooxygenase inhibitor","","Cc1[nH]cnc1-c1ccc(Cl)cc1, Cc1[nH]cnc1-c1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cc1[nH]cnc1-c1ccc(Cl)cc1",192.045425968,13,3.084,28.68,0.26740324414728,0.108,0.18770162207364,1,0
"ORY-1001","histone lysine demethylase inhibitor","KDM1A","NC1CCC(CC1)N[C@@H]1C[C@H]1c1ccccc1, NC1CCC(CC1)N[C@@H]1C[C@H]1c1ccccc1, NC1CCC(CC1)N[C@@H]1C[C@H]1c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","NC1CCC(CC1)N[C@@H]1C[C@H]1c1ccccc1",230.178298704,17,2.267,38.05,0.195372914453576,0.18,0.187686457226788,1,1
"seclazone","anti-inflammatory agent","","Clc1ccc2O[C@H]3CCON3C(=O)c2c1 |&1:6,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Clc1ccc2O[C@H]3CCON3C(=O)c2c1 |&1:6",225.019270796,15,2.127,38.77,0.141360210649838,0.234,0.187680105324919,1,1
"SCH-221510","nociceptin/orphanin FQ receptor agonist","OPRL1","Cc1ccccc1C(N1[C@H]2CC[C@@H]1C[C@](O)(C2)c1ccccc1)c1ccccc1C |&1:9,12,14,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccccc1C(N1[C@H]2CC[C@@H]1C[C@](O)(C2)c1ccccc1)c1ccccc1C |&1:9",397.240564612,30,6.099,23.47,0.243027683041688,0.132,0.187513841520844,1,1
"3-anilinopropan-1-ol","","","OCCCNc1ccccc1, OCCCNc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OCCCNc1ccccc1",151.099714036,11,1.746,32.26,0.288860220826338,0.086,0.187430110413169,1,0
"alpha-asarone","cytochrome P450 inhibitor, HMGCR inhibitor","HMGCR","COc1cc(OC)c(\C=C\C)cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(OC)c(\C=C\C)cc1OC",208.109944372,15,2.749,27.69,0.270856147749467,0.104,0.187428073874734,1,0
"ligustilide","tumor necrosis factor production inhibitor","TNF","CCC\C=C1/OC(=O)C2=C1CCC=C2 |c:8,13|, CCC\C=C1/OC(=O)C2=C1CCC=C2 |c:8,13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCC\C=C1/OC(=O)C2=C1CCC=C2 |c:8",190.099379688,14,2.819,26.3,0.322852125776206,0.052,0.187426062888103,1,0
"preclamol","dopamine receptor agonist","DRD2","CCCN1CCC[C@@H](C1)c1cccc(O)c1, CCCN1CCC[C@@H](C1)c1cccc(O)c1, CCCN1CCC[C@@H](C1)c1cccc(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,"phase 2","","","CCCN1CCC[C@@H](C1)c1cccc(O)c1",219.162314292,16,2.682,23.47,0.280353852412676,0.094,0.187176926206338,1,0
"ML133","potassium channel blocker","","COc1ccc(CNCc2cccc3ccccc23)cc1, COc1ccc(CNCc2cccc3ccccc23)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(CNCc2cccc3ccccc23)cc1",277.146664228,21,4.425,21.26,0.332234897224558,0.042,0.187117448612279,1,0
"LY2140023","glutamate receptor agonist","GRM3","N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O",235.015058008,15,-4.714,143.14,0.00214854835783542,0.372,0.187074274178918,0,1
"AX-024","cytokine production inhibitor","","COc1ccc2OCC(CN3CCCC3)=C(c3ccc(F)cc3)c2c1 |t:15|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc2OCC(CN3CCCC3)=C(c3ccc(F)cc3)c2c1 |t:15|",339.163457164,25,4.043,21.7,0.20374340789125,0.17,0.186871703945625,1,1
"AC-186","estrogen receptor agonist","ESR2","Oc1ccc(cc1)C1(CCC(F)(F)CC1)c1ccccc1F, Oc1ccc(cc1)C1(CCC(F)(F)CC1)c1ccccc1F, Oc1ccc(cc1)C1(CCC(F)(F)CC1)c1ccccc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(cc1)C1(CCC(F)(F)CC1)c1ccccc1F",306.123149824,22,5.713,20.23,0.305626681649864,0.068,0.186813340824932,1,0
"perillyl-alcohol","apoptosis stimulant, farnesyltransferase inhibitor","FNTA","CC(=C)[C@H]1CCC(CO)=CC1 |&1:3,r,c:8|, CC(=C)[C@H]1CCC(CO)=CC1 |&1:3,r,c:8|, CC(=C)[C@H]1CCC(CO)=CC1 |&1:3,r,c:8|, CC(=C)[C@H]1CCC(CO)=CC1 |&1:3,r,c:8|, CC(=C)[C@H]1CCC(CO)=CC1 |&1:3,r,c:8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(=C)[C@H]1CCC(CO)=CC1 |&1:3",152.120115132,11,1.848,20.23,0.349460557901067,0.024,0.186730278950533,1,0
"centhaquin","analgesic agent","","Cc1cccc(c1)N1CCN(CCc2ccc3ccccc3n2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1cccc(c1)N1CCN(CCc2ccc3ccccc3n2)CC1",331.2048478,25,4.491,19.37,0.267204339625186,0.106,0.186602169812593,1,0
"ML213","potassium channel activator","KCNQ4","Cc1cc(C)c(NC(=O)[C@@H]2C[C@H]3CC[C@@H]2C3)c(C)c1 |&1:11,14,&2:9,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(C)c(NC(=O)[C@@H]2C[C@H]3CC[C@@H]2C3)c(C)c1 |&1:11",257.177964356,19,4.185,29.1,0.284518864289703,0.088,0.186259432144851,1,0
"1S,2R-phenylpropanolamine","adrenergic receptor agonist","","C[C@@H](N)[C@@H](O)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","C[C@@H](N)[C@@H](O)c1ccccc1",151.099714036,11,0.998,46.25,0.19643163438498,0.176,0.18621581719249,1,1
"apoptosis-activator-II","carboxylesterase inhibitor","BCHE, CES1","Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl, Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl, Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl, Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl",305.001033888,20,3.681,37.38,0.104260153078625,0.268,0.186130076539313,0,1
"PNU-282987","cholinergic receptor agonist","CHRNA7","Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2, Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2, Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2, Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"preclinical","","","Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2",264.102940844,18,2.467,32.34,0.140067177760372,0.232,0.186033588880186,1,1
"hexamethonium","cholinergic receptor antagonist","CHRNA2, CHRNA3, CHRNA4, CHRNA6","C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,"preclinical","","","C[N+](C)(C)CCCCCC[N+](C)(C)C",202.239801800181,14,0.966,0,0.294044337026511,0.078,0.186022168513255,1,0
"SAR407899","rho associated kinase inhibitor","ROCK1","O=c1[nH]ccc2cc(OC3CCNCC3)ccc12, O=c1[nH]ccc2cc(OC3CCNCC3)ccc12, O=c1[nH]ccc2cc(OC3CCNCC3)ccc12, O=c1[nH]ccc2cc(OC3CCNCC3)ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O=c1[nH]ccc2cc(OC3CCNCC3)ccc12",244.121177752,18,2.154,54.12,0.128009716401739,0.244,0.186004858200869,1,1
"5-BDBD","purinergic receptor antagonist","P2RX4","Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|, Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|, Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|, Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|, Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|, Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|",354.000389692,22,3.236,54.6,0.0332517772058206,0.338,0.18562588860291,0,1
"butylated-hydroxyanisole","antioxidant","","COc1ccc(O)c(c1)C(C)(C)C, COc1ccc(O)c(c1)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(O)c(c1)C(C)(C)C",180.115029752,13,3.137,29.46,0.325708179022505,0.044,0.184854089511253,1,0
"aptiganel","glutamate receptor antagonist","GRIN1","CCc1cccc(c1)N(C)C(=N)Nc1cccc2ccccc12, CCc1cccc(c1)N(C)C(=N)Nc1cccc2ccccc12, CCc1cccc(c1)N(C)C(=N)Nc1cccc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCc1cccc(c1)N(C)C(=N)Nc1cccc2ccccc12",303.173547672,23,6.142,39.12,0.298937057236832,0.07,0.184468528618416,1,0
"propyphenazone","anti-inflammatory agent","","CC(C)c1c(C)n(C)n(-c2ccccc2)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)c1c(C)n(C)n(-c2ccccc2)c1=O",230.141913196,17,2.47,26.93,0.248429447737878,0.12,0.184214723868939,1,0
"indalpine","selective serotonin reuptake inhibitor (SSRI)","SLC6A4","C(Cc1c[nH]c2ccccc12)C1CCNCC1, C(Cc1c[nH]c2ccccc12)C1CCNCC1",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","C(Cc1c[nH]c2ccccc12)C1CCNCC1",228.16264864,17,3.107,27.82,0.284132982452388,0.084,0.184066491226194,1,0
"CYM-5541","sphingosine 1-phosphate receptor agonist","S1PR3","O=C(N(C1CCCCC1)C1CCCCC1)c1cc(on1)C1CC1, O=C(N(C1CCCCC1)C1CCCCC1)c1cc(on1)C1CC1, O=C(N(C1CCCCC1)C1CCCCC1)c1cc(on1)C1CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(N(C1CCCCC1)C1CCCCC1)c1cc(on1)C1CC1",316.215078136,23,4.307,46.34,0.144091532831615,0.224,0.184045766415808,1,1
"CID-2011756","protein kinase inhibitor","PKD1","Clc1cccc(c1)-c1ccc(o1)C(=O)Nc1ccc(CN2CCOCC2)cc1, Clc1cccc(c1)-c1ccc(o1)C(=O)Nc1ccc(CN2CCOCC2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1cccc(c1)-c1ccc(o1)C(=O)Nc1ccc(CN2CCOCC2)cc1",396.124070212,28,3.619,54.71,0.0520080177100311,0.316,0.184004008855016,0,1
"DWK-1339","beta amyloid aggregation inhibitor","","COCCCc1ccc2oc(cc2c1)-c1ccc(OC)c(OC)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COCCCc1ccc2oc(cc2c1)-c1ccc(OC)c(OC)c1",326.151809184,24,3.804,40.83,0.143746815682814,0.224,0.183873407841407,1,1
"lauric-acid","bacterial permeability inducer","GPR84, HNF4A, LTF, LY96, PLA2G2A, TLR4","CCCCCCCCCCCC(O)=O, CCCCCCCCCCCC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCCCCCCCCCCC(O)=O",200.177630008,14,5.294,37.3,0.34761519674056,0.02,0.18380759837028,1,0
"NDD-094","","","Cc1nccn1Cc1ccccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1nccn1Cc1ccccn1",173.095297352,13,1.049,30.71,0.249551794642161,0.118,0.18377589732108,1,0
"indole-3-carbinol","aryl hydrocarbon receptor agonist, indoleamine 2,3-dioxygenase inhibitor","AHR","OCc1c[nH]c2ccccc12, OCc1c[nH]c2ccccc12, OCc1c[nH]c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","OCc1c[nH]c2ccccc12",147.068413908,11,1.748,36.02,0.29085927793726,0.076,0.18342963896863,1,0
"DPO-1","potassium channel blocker","KCNA5","CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1P(=O)(c1ccccc1)c1ccccc1, CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1P(=O)(c1ccccc1)c1ccccc1, CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1P(=O)(c1ccccc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1P(=O)(c1ccccc1)c1ccccc1",340.195602178,24,7.126,26.88,0.27249913860659,0.094,0.183249569303295,1,0
"AP-18","transient receptor potential channel antagonist","TRPA1","C\C(=C/c1ccc(Cl)cc1)\C(\C)=N\O, C\C(=C/c1ccc(Cl)cc1)\C(\C)=N\O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C\C(=C/c1ccc(Cl)cc1)\C(\C)=N\O",209.060741684,14,3.217,32.59,0.22404421087719,0.142,0.183022105438595,1,1
"emoxipin","","","CCc1nc(C)ccc1O, CCc1nc(C)ccc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCc1nc(C)ccc1O",137.084063972,10,1.247,33.12,0.281183154418791,0.084,0.182591577209395,1,0
"YC-1","guanylyl cyclase activator","GUCY1A2, GUCY1A3, GUCY1B3, HIF1A","OCc1ccc(o1)-c1nn(Cc2ccccc2)c2ccccc12, OCc1ccc(o1)-c1nn(Cc2ccccc2)c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OCc1ccc(o1)-c1nn(Cc2ccccc2)c2ccccc12",304.121177752,23,3.42,51.19,0.139125190027539,0.226,0.182562595013769,1,1
"aloperine","","","C1CCN2C[C@H]3C[C@H](C=C4CCCN[C@@H]34)[C@H]2C1 |t:8|, C1CCN2C[C@H]3C[C@H](C=C4CCCN[C@@H]34)[C@H]2C1 |t:8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C1CCN2C[C@H]3C[C@H](C=C4CCCN[C@@H]34)[C@H]2C1 |t:8|",232.193948768,17,1.308,15.27,0.23670907634774,0.128,0.18235453817387,1,0
"isuzinaxib","nadph oxidase inhibitor","NOX1, NOX4","CCCc1c([nH]n(-c2ccccn2)c1=O)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","nephrology","diabetic nephropathy","CCCc1c([nH]n(-c2ccccn2)c1=O)-c1ccccc1",279.137162164,21,4.352,50.68,0.190673762276388,0.174,0.182336881138194,1,1
"WAY-170523","metalloproteinase inhibitor","MMP13","Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO",613.188271332,44,5.806,146.56,0.00247570019168438,0.362,0.182237850095842,0,1
"BTS-71321","","","CC(C)(NCCCn1ccnc1)c1ccc(Cl)cc1, CC(C)(NCCCn1ccnc1)c1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)(NCCCn1ccnc1)c1ccc(Cl)cc1",277.13457532,19,3.206,29.85,0.160182978170045,0.204,0.182091489085023,1,1
"benurestat","urease inhibitor","","ONC(=O)CNC(=O)c1ccc(Cl)cc1, ONC(=O)CNC(=O)c1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","ONC(=O)CNC(=O)c1ccc(Cl)cc1",228.030169828,15,0.783,78.43,0.0420811666702236,0.322,0.182040583335112,0,1
"4-propylbenzoic-acid","","","CCCc1ccc(cc1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCc1ccc(cc1)C(O)=O",164.083729624,12,3.107,37.3,0.317798469957044,0.046,0.181899234978522,1,0
"flumexadol","","","FC(F)(F)c1cccc(c1)[C@H]1CNCCO1 |&1:10,r|, FC(F)(F)c1cccc(c1)[C@H]1CNCCO1 |&1:10,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)c1cccc(c1)[C@H]1CNCCO1 |&1:10",231.087098664,16,2.162,21.26,0.213466156236852,0.15,0.181733078118426,1,1
"trigonelline","","","C[n+]1cccc(c1)C(O)=O, C[n+]1cccc(c1)C(O)=O, C[n+]1cccc(c1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[n+]1cccc(c1)C(O)=O",138.054954916091,10,2.026,41.18,0.277364418834925,0.086,0.181682209417463,1,0
"trans-2-undecenoic-acid","","","CCCCCCCC\C=C\C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCC\C=C\C(O)=O",184.14632988,13,4.614,37.3,0.344459870924068,0.018,0.181229935462034,1,0
"INCA-6","calcineurin inhibitor","NFATC1","O=C1C=CC(=O)C2=C1C1c3ccccc3C2c2ccccc12 |c:2,6|, O=C1C=CC(=O)C2=C1C1c3ccccc3C2c2ccccc12 |c:2,6|, O=C1C=CC(=O)C2=C1C1c3ccccc3C2c2ccccc12 |c:2,6|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C1C=CC(=O)C2=C1C1c3ccccc3C2c2ccccc12 |c:2",284.083729624,22,2.482,34.14,0.196431143172245,0.166,0.181215571586122,1,1
"BMS-863233","CDC inhibitor","CDC7, PIM1","Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1, Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1, Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1, Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1, Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1, Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1",289.061804304,20,2.095,70.92,0.0503894645740253,0.312,0.181194732287013,0,1
"hydrastinine","hemostatic agent","","C[N+]1=Cc2cc3OCOc3cc2CC1 |t:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[N+]1=Cc2cc3OCOc3cc2CC1 |t:1|",190.086255044091,14,1.381,21.47,0.272660995267519,0.088,0.180330497633759,1,0
"delpazolid","antibacterial","","CN1CCN(C=N1)c1ccc(cc1F)N1C[C@H](CO)OC1=O |c:5|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN1CCN(C=N1)c1ccc(cc1F)N1C[C@H](CO)OC1=O |c:5|",308.128468624,22,1.312,68.61,0.0443705393031348,0.316,0.180185269651567,0,1
"tapinarof","aryl hydrocarbon receptor agonist","","CC(C)c1c(O)cc(\C=C\c2ccccc2)cc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(C)c1c(O)cc(\C=C\c2ccccc2)cc1O",254.130679816,19,5.038,40.46,0.288351517111292,0.072,0.180175758555646,1,0
"quinpirol-(-)","dopamine receptor agonist","DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C","CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12, CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12, CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12, CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12, CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12",0,0,0,0,0,0,0,0,1,4,0,0,0,0,1,4,0,0,0,0,0,0,0,0,"phase 2","","","CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12",219.173547672,16,2.344,31.92,0.22762219738515,0.132,0.179811098692575,1,1
"HQK-1001","","","CCC(C)(C)C(O)=O, CCC(C)(C)C(O)=O, CCC(C)(C)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCC(C)(C)C(O)=O",116.083729624,8,1.236,37.3,0.269537660632611,0.09,0.179768830316306,1,0
"ADX-10059","glutamate receptor negative allosteric modulator","GRM5","Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1, Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1, Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1, Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1, Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1",240.106276636,18,3.344,38.91,0.235386217521475,0.124,0.179693108760738,1,0
"NAS-181","serotonin receptor antagonist","HTR1B","C(Oc1cccc2C=C(CN3CCOCC3)COc12)[C@H]1CNCCO1 |t:7|",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C(Oc1cccc2C=C(CN3CCOCC3)COc12)[C@H]1CNCCO1 |t:7|",346.189257312,25,0.101,52.19,0.0389814042697789,0.32,0.179490702134889,0,1
"zaprinast","phosphodiesterase inhibitor","GPR35, PDE1A, PDE4D, PDE5A, PDE9A","CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1, CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1, CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1, CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1, CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1, CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1",271.106924656,20,4.604,96.55,0.0768694148046823,0.282,0.179434707402341,0,1
"diclofensine","dopamine reuptake inhibitor","DRD1, MAOA, MAOB","COc1ccc2[C@@H](CN(C)Cc2c1)c1ccc(Cl)c(Cl)c1 |&1:6|, COc1ccc2[C@@H](CN(C)Cc2c1)c1ccc(Cl)c(Cl)c1 |&1:6|",0,0,0,0,0,0,1,2,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,"phase 3","","","COc1ccc2[C@@H](CN(C)Cc2c1)c1ccc(Cl)c(Cl)c1 |&1:6|",321.068719524,21,4.268,12.47,0.170369166919941,0.188,0.17918458345997,1,1
"isaxonine","nerve growth factor agonist","","CC(C)Nc1ncccn1, CC(C)Nc1ncccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CC(C)Nc1ncccn1",137.095297352,10,0.986,37.81,0.247568435600005,0.11,0.178784217800002,1,0
"chlormezanone","GABA receptor modulator","GABRA1","CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|, CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|, CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|, CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|, CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2",273.022641924,17,1.299,62.83,0.0372616003950969,0.32,0.178630800197548,0,1
"PSN-375963","glucose dependent insulinotropic receptor agonist","GPR119","CCCCC1CCC(CC1)c1nc(no1)-c1ccncc1, CCCCC1CCC(CC1)c1nc(no1)-c1ccncc1, CCCCC1CCC(CC1)c1nc(no1)-c1ccncc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCC1CCC(CC1)c1nc(no1)-c1ccncc1",285.184112356,21,5.263,51.81,0.198938635946737,0.158,0.178469317973369,1,1
"methoxyamine","DNA repair enzyme inhibitor","APEX1","CON, CON",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CON",47.03711378,3,-1.009,35.25,0.268652912888247,0.088,0.178326456444123,1,0
"oleamide","cannabinoid receptor agonist","HTR7, PLA2G2A","CCCCCCCC\C=C/CCCCCCCC(N)=O, CCCCCCCC\C=C/CCCCCCCC(N)=O, CCCCCCCC\C=C/CCCCCCCC(N)=O",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCC\C=C/CCCCCCCC(N)=O",281.27186474,20,7.464,43.09,0.312649939966363,0.044,0.178324969983181,1,0
"chlorindione","","","Clc1ccc(cc1)C1C(=O)c2ccccc2C1=O, Clc1ccc(cc1)C1C(=O)c2ccccc2C1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1ccc(cc1)C1C(=O)c2ccccc2C1=O",256.029107208,18,3.346,34.14,0.190342335061328,0.166,0.178171167530664,1,1
"medorinone","","","Cc1nccc2[nH]c(=O)ccc12, Cc1nccc2[nH]c(=O)ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1nccc2[nH]c(=O)ccc12",160.063662876,12,1.234,45.75,0.210294866786149,0.146,0.178147433393075,1,1
"BU-224","imidazoline receptor ligand","MAOA, MAOB","C1CN=C(N1)c1ccc2ccccc2n1 |c:2|, C1CN=C(N1)c1ccc2ccccc2n1 |c:2|, C1CN=C(N1)c1ccc2ccccc2n1 |c:2|",0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C1CN=C(N1)c1ccc2ccccc2n1 |c:2|",197.095297352,15,1.879,37.28,0.238183274564714,0.118,0.178091637282357,1,0
"3,3'-diindolylmethane","CHK inhibitor, cytochrome P450 activator, indoleamine 2,3-dioxygenase inhibitor","AR, HIF1A, IFNG, PI3","C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12, C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12, C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12, C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12",246.115698448,19,3.993,31.58,0.318158322643591,0.038,0.178079161321795,1,0
"anabasine","acetylcholine receptor agonist","","C1CC[C@@H](NC1)c1cccnc1 |&1:3,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C1CC[C@@H](NC1)c1cccnc1 |&1:3",162.115698448,12,1.249,24.92,0.292011967871422,0.064,0.178005983935711,1,0
"APC-100","androgen receptor antagonist, anti-inflammatory agent","AR","Cc1c(C)c2OC(C)(C)CCc2c(C)c1O, Cc1c(C)c2OC(C)(C)CCc2c(C)c1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","Cc1c(C)c2OC(C)(C)CCc2c(C)c1O",220.14632988,16,3.29,29.46,0.277689281474273,0.078,0.177844640737136,1,0
"rivanicline","acetylcholine receptor agonist","CHRNA4, CHRNB2, CXCL8","CNCC\C=C\c1cccnc1, CNCC\C=C\c1cccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,"phase 2","","","CNCC\C=C\c1cccnc1",162.115698448,12,1.042,24.92,0.281625758720701,0.074,0.177812879360351,1,0
"nepinalone","antitussive","SIGMAR1","CC1(CCN2CCCCC2)C(=O)CCc3ccccc13",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","pulmonary","cough suppressant","CC1(CCN2CCCCC2)C(=O)CCc3ccccc13",271.19361442,20,2.966,20.31,0.245625118517055,0.11,0.177812559258528,1,0
"isoxepac","anti-inflammatory agent","","OC(=O)Cc1ccc2OCc3ccccc3C(=O)c2c1, OC(=O)Cc1ccc2OCc3ccccc3C(=O)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)Cc1ccc2OCc3ccccc3C(=O)c2c1",268.073558864,20,2.606,63.6,0.105327367428801,0.25,0.177663683714401,0,1
"k-80003","retinoid receptor antagonist","RXRA","CC(C)c1ccc(\C=C/2\C(=C(CC(=O)O)c3cc(F)ccc23)C)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","cardiology","atherosclerosis","CC(C)c1ccc(\C=C/2\C(=C(CC(=O)O)c3cc(F)ccc23)C)cc1",336.152558132,25,6.315,37.3,0.250606700464457,0.104,0.177303350232228,1,0
"PBI-4050","free fatty acid receptor agonist","","CCCCCc1cccc(CC(O)=O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","CCCCCc1cccc(CC(O)=O)c1",206.130679816,15,4.057,37.3,0.300507660689316,0.054,0.177253830344658,1,0
"choline","acetylcholine precursor","ACHE, BCHE, CHRNA2, PCYT1A, PCYT1B, PHOSPHO1, PLD1, PLD2","C[N+](C)(C)CCO, C[N+](C)(C)CCO, C[N+](C)(C)CCO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"phase 3","","","C[N+](C)(C)CCO",104.106990488091,7,-0.837,20.23,0.258488087829574,0.096,0.177244043914787,1,0
"allylisothiocyanate","TRPV agonist","TRPA1","C=CCN=C=S, C=CCN=C=S",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C=CCN=C=S",99.01427016,6,1.721,44.45,0.250395074937171,0.104,0.177197537468586,1,0
"lusaperidone","adrenergic receptor antagonist","","Cc1nc2ccccn2c(=O)c1CCN1CCc2oc3ccccc3c2C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1nc2ccccn2c(=O)c1CCN1CCc2oc3ccccc3c2C1",359.163376912,27,3.198,50.75,0.0943940304953902,0.26,0.177197015247695,0,1
"cirazoline","adrenergic receptor agonist","ADRA1A","C(Oc1ccccc1C1CC1)C1=NCCN1 |t:13|, C(Oc1ccccc1C1CC1)C1=NCCN1 |t:13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"preclinical","","","C(Oc1ccccc1C1CC1)C1=NCCN1 |t:13|",216.126263132,16,2.223,33.62,0.228285244472252,0.126,0.177142622236126,1,0
"abametapir","metalloproteinase inhibitor","MMP9","Cc1ccc(nc1)-c1ccc(C)cn1, Cc1ccc(nc1)-c1ccc(C)cn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cc1ccc(nc1)-c1ccc(C)cn1",184.100048384,14,2.088,25.78,0.317666444260259,0.036,0.176833222130129,1,0
"delta-tocotrienol","HMGCR inhibitor","HMGCR","CC(C)=CCC\C(C)=C\CC\C(C)=C\CC[C@]1(C)CCc2cc(O)cc(C)c2O1, CC(C)=CCC\C(C)=C\CC\C(C)=C\CC[C@]1(C)CCc2cc(O)cc(C)c2O1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)=CCC\C(C)=C\CC\C(C)=C\CC[C@]1(C)CCc2cc(O)cc(C)c2O1",396.30283052,29,8.198,29.46,0.275252580030794,0.078,0.176626290015397,1,0
"butibufen","cyclooxygenase inhibitor","","CC[C@@H](C(O)=O)c1ccc(CC(C)C)cc1 |&1:2,r|, CC[C@@H](C(O)=O)c1ccc(CC(C)C)cc1 |&1:2,r|, CC[C@@H](C(O)=O)c1ccc(CC(C)C)cc1 |&1:2,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CC[C@@H](C(O)=O)c1ccc(CC(C)C)cc1 |&1:2",220.14632988,16,4.21,37.3,0.28658625803331,0.066,0.176293129016655,1,0
"CCT-031374","WNT signaling inhibitor","CTNNB1","O=C(CN1C2=NCCN2c2ccccc12)c1ccc(cc1)-c1ccccc1 |t:4|, O=C(CN1C2=NCCN2c2ccccc12)c1ccc(cc1)-c1ccccc1 |t:4|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(CN1C2=NCCN2c2ccccc12)c1ccc(cc1)-c1ccccc1 |t:4|",353.152812228,27,5.649,35.91,0.236471505432007,0.116,0.176235752716003,1,0
"BU226","imidazoline receptor ligand","","C1CN=C(N1)c1cc2ccccc2cn1 |c:2|, C1CN=C(N1)c1cc2ccccc2cn1 |c:2|, C1CN=C(N1)c1cc2ccccc2cn1 |c:2|, C1CN=C(N1)c1cc2ccccc2cn1 |c:2|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C1CN=C(N1)c1cc2ccccc2cn1 |c:2|",197.095297352,15,1.79,37.28,0.234244379478866,0.118,0.176122189739433,1,0
"IEM1460","glutamate receptor antagonist","GRIA2","C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2, C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2, C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2, C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2, C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2",293.295125604091,21,4.244,12.03,0.286053565643754,0.066,0.176026782821877,1,0
"A-967079","transient receptor potential channel antagonist","TRPA1","CC\C(=N/O)\C(\C)=C\c1ccc(F)cc1, CC\C(=N/O)\C(\C)=C\c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC\C(=N/O)\C(\C)=C\c1ccc(F)cc1",207.105942288,15,3.009,32.59,0.265789073093826,0.086,0.175894536546913,1,0
"isovaleramide","alcohol dehydrogenase inhibitor","","CC(C)CC(N)=O, CC(C)CC(N)=O, CC(C)CC(N)=O, CC(C)CC(N)=O, CC(C)CC(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)CC(N)=O",101.084063972,7,0.522,43.09,0.235385077564351,0.116,0.175692538782175,1,0
"KD-023","ACAT inhibitor","ACACA, ACACB","CCCCCCCCCCCCCCOc1ccc(o1)C(O)=O, CCCCCCCCCCCCCCOc1ccc(o1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCCCCCCCCCCCCOc1ccc(o1)C(O)=O",324.230059504,23,7.784,59.67,0.193185871600884,0.158,0.175592935800442,1,1
"nesbuvir","RNA polymerase inhibitor","","CNC(=O)c1c(oc2cc(N(CCO)S(C)(=O)=O)c(cc12)C1CC1)-c1ccc(F)cc1, CNC(=O)c1c(oc2cc(N(CCO)S(C)(=O)=O)c(cc12)C1CC1)-c1ccc(F)cc1, CNC(=O)c1c(oc2cc(N(CCO)S(C)(=O)=O)c(cc12)C1CC1)-c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CNC(=O)c1c(oc2cc(N(CCO)S(C)(=O)=O)c(cc12)C1CC1)-c1ccc(F)cc1",446.131171056,31,3.45,108.23,0.00910752170062477,0.342,0.175553760850312,0,1
"zindotrine","phosphodiesterase inhibitor","","Cc1cc(nn2cnnc12)N1CCCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1cc(nn2cnnc12)N1CCCCC1",217.13274548,16,4.477,46.32,0.272182139061613,0.078,0.175091069530806,1,0
"A-803467","sodium channel blocker","SCN10A","COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1, COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1",357.076785672,25,4.098,60.7,0.0640429996616611,0.286,0.175021499830831,0,1
"RAD140","androgen receptor modulator","","[H][C@@](C)(O)[C@@]([H])(Nc1ccc(C#N)c(Cl)c1C)c1nnc(o1)-c1ccc(cc1)C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","[H][C@@](C)(O)[C@@]([H])(Nc1ccc(C#N)c(Cl)c1C)c1nnc(o1)-c1ccc(cc1)C#N",393.099252432,30,4.406,118.76,0.0250491408172114,0.324,0.174524570408606,0,1
"magnolol","PPAR receptor agonist","GABRA1, PPARG","Oc1ccc(CC=C)cc1-c1cc(CC=C)ccc1O, Oc1ccc(CC=C)cc1-c1cc(CC=C)ccc1O, Oc1ccc(CC=C)cc1-c1cc(CC=C)ccc1O",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(CC=C)cc1-c1cc(CC=C)ccc1O",266.130679816,20,5.736,40.46,0.312457386923155,0.036,0.174228693461578,1,0
"NSC-632839","ubiquitin specific protease inhibitor","SENP2, USP1, USP2, USP7","Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1, Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1, Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1, Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1, Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1",303.162314292,23,4.104,29.1,0.246058708115954,0.102,0.174029354057977,1,0
"idramantone","","","[H][C@@]12C[C@@]3([H])C[C@@](O)(C1)C[C@@]([H])(C2)C3=O |&1:1,3,6,10|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@@]12C[C@@]3([H])C[C@@](O)(C1)C[C@@]([H])(C2)C3=O |&1:1",166.099379688,15,0.299,37.3,0.307975430636887,0.04,0.173987715318443,1,0
"salicyl-alcohol","","","OCc1ccccc1O, OCc1ccccc1O, OCc1ccccc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OCc1ccccc1O",124.052429496,9,1.234,40.46,0.262927564851716,0.084,0.173463782425858,1,0
"SR-11302","","","C\C(\C=C\C=C(\C=C\C1=C(C)CCCC1(C)C)/c1ccc(C)cc1)=C/C(O)=O |c:8|, C\C(\C=C\C=C(\C=C\C1=C(C)CCCC1(C)C)/c1ccc(C)cc1)=C/C(O)=O |c:8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C\C(\C=C\C=C(\C=C\C1=C(C)CCCC1(C)C)/c1ccc(C)cc1)=C/C(O)=O |c:8|",376.240230264,28,8.157,37.3,0.286858678251954,0.06,0.173429339125977,1,0
"rucinol","tyrosinase inhibitor","TYR","CCCCc1ccc(O)cc1O, CCCCc1ccc(O)cc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCCCc1ccc(O)cc1O",166.099379688,12,3.038,40.46,0.288580786615443,0.058,0.173290393307722,1,0
"myristyl-nicotinate","topical sunscreen agent","","CCCCCCCCCCCCCCOC(=O)c1cccnc1, CCCCCCCCCCCCCCOC(=O)c1cccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCCCCCCCCCCCCCOC(=O)c1cccnc1",319.251129296,23,7.746,39.19,0.3004979303456,0.046,0.1732489651728,1,0
"D-phenylalanine","enkephalinase inhibitor","CCBL1, CRH, HCAR3","N[C@H](Cc1ccccc1)C(O)=O, N[C@H](Cc1ccccc1)C(O)=O, N[C@H](Cc1ccccc1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@H](Cc1ccccc1)C(O)=O",165.078978592,12,-1.379,63.32,0.0764642736228256,0.27,0.173232136811413,0,1
"latrepirdine","glutamate receptor antagonist","HRH1, HTR6","CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1",0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1",319.2048478,24,3.685,21.06,0.233388803716755,0.112,0.172694401858378,1,0
"hymecromone","monoamine oxidase inhibitor","MAOA, MAOB","Cc1cc(=O)oc2cc(O)ccc12, Cc1cc(=O)oc2cc(O)ccc12, Cc1cc(=O)oc2cc(O)ccc12, Cc1cc(=O)oc2cc(O)ccc12",0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1cc(=O)oc2cc(O)ccc12",176.047344116,13,2.681,50.44,0.226419137845594,0.118,0.172209568922797,1,0
"BRL-44408","adrenergic receptor antagonist","ADRA2A, ADRA2B, ADRA2C","C[C@H]1N(CC2=NCCN2)Cc2ccccc12 |&1:1,t:4|, C[C@H]1N(CC2=NCCN2)Cc2ccccc12 |&1:1,t:4|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,"preclinical","","","C[C@H]1N(CC2=NCCN2)Cc2ccccc12 |&1:1",215.142247544,16,1.419,27.63,0.222206439055011,0.122,0.172103219527506,1,0
"AFN-1252","FABI inhibitor","","CN(Cc1oc2ccccc2c1C)C(=O)\C=C\c1cnc2NC(=O)CCc2c1, CN(Cc1oc2ccccc2c1C)C(=O)\C=C\c1cnc2NC(=O)CCc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN(Cc1oc2ccccc2c1C)C(=O)\C=C\c1cnc2NC(=O)CCc2c1",375.158291532,28,2.191,75.44,0.0379594301316764,0.306,0.171979715065838,0,1
"MK2-IN-1","MAP kinase inhibitor","MAPKAPK2","Clc1ccc(cc1)-c1ccc(o1)C(=O)N(Cc1ccccn1)c1ccc(cc1)N1CCNCC1, Clc1ccc(cc1)-c1ccc(o1)C(=O)N(Cc1ccccn1)c1ccc(cc1)N1CCNCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1ccc(cc1)-c1ccc(o1)C(=O)N(Cc1ccccn1)c1ccc(cc1)N1CCNCC1",472.16660372,34,4.69,61.61,0.0378437510831294,0.306,0.171921875541565,0,1
"5-HMF","","","OCc1ccc(C=O)o1, OCc1ccc(C=O)o1, OCc1ccc(C=O)o1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OCc1ccc(C=O)o1",126.031694052,9,-0.383,50.44,0.153661861710616,0.19,0.171830930855308,1,1
"9-anthracenecarboxylic-acid","","ANO1, CLCN1","OC(=O)c1c2ccccc2cc2ccccc12, OC(=O)c1c2ccccc2cc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1c2ccccc2cc2ccccc12",222.06807956,17,4.169,37.3,0.323532395432621,0.02,0.17176619771631,1,0
"CP-376395","corticotropin releasing factor receptor antagonist","CRHR1","CCC(CC)Nc1cc(C)nc(Oc2c(C)cc(C)cc2C)c1C, CCC(CC)Nc1cc(C)nc(Oc2c(C)cc(C)cc2C)c1C, CCC(CC)Nc1cc(C)nc(Oc2c(C)cc(C)cc2C)c1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCC(CC)Nc1cc(C)nc(Oc2c(C)cc(C)cc2C)c1C",326.23581358,24,5.654,34.15,0.235441621246999,0.108,0.1717208106235,1,0
"arundic-acid","astrocyte modulating agent","PTGS2, S100B","CCCCCC[C@@H](CCC)C(O)=O, CCCCCC[C@@H](CCC)C(O)=O",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","CCCCCC[C@@H](CCC)C(O)=O",186.161979944,13,4.449,37.3,0.324722532892909,0.018,0.171361266446454,1,0
"heclin","ubiquitin ligase inhibitor","NEDD4, SMURF2, WWP1","CCc1ccc(\C=C\C(=O)Nc2ccc(cc2)C(C)=O)o1, CCc1ccc(\C=C\C(=O)Nc2ccc(cc2)C(C)=O)o1, CCc1ccc(\C=C\C(=O)Nc2ccc(cc2)C(C)=O)o1, CCc1ccc(\C=C\C(=O)Nc2ccc(cc2)C(C)=O)o1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCc1ccc(\C=C\C(=O)Nc2ccc(cc2)C(C)=O)o1",283.120843404,21,2.331,59.31,0.0965003386992299,0.246,0.171250169349615,0,1
"UCL-2077","slow afterhyperpolarization channel blocker","","C(NC(c1ccccc1)(c1ccccc1)c1ccccc1)c1cccnc1, C(NC(c1ccccc1)(c1ccccc1)c1ccccc1)c1cccnc1, C(NC(c1ccccc1)(c1ccccc1)c1ccccc1)c1cccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C(NC(c1ccccc1)(c1ccccc1)c1ccccc1)c1cccnc1",350.178298704,27,5.534,24.92,0.294333068604104,0.048,0.171166534302052,1,0
"amineptine","dopamine receptor agonist","SLC6A2, SLC6A4","OC(=O)CCCCCCNC1c2ccccc2CCc2ccccc12, OC(=O)CCCCCCNC1c2ccccc2CCc2ccccc12, OC(=O)CCCCCCNC1c2ccccc2CCc2ccccc12",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","OC(=O)CCCCCCNC1c2ccccc2CCc2ccccc12",337.204179104,25,4.616,49.33,0.139890893347956,0.202,0.170945446673978,1,1
"benzenemethanol,-2,5-dimethyl-[[(1-methylethyl)amino]methyl]","","","CC(C)NC[C@@H](O)c1cc(C)ccc1C |&1:5,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)NC[C@@H](O)c1cc(C)ccc1C |&1:5",207.162314292,15,2.685,32.26,0.251755534993998,0.09,0.170877767496999,1,0
"siramesine","sigma receptor antagonist","ADRA1A, ADRA1B, ADRA1D","Fc1ccc(cc1)-n1cc(CCCCN2CCC3(CC2)OCc2ccccc32)c2ccccc12, Fc1ccc(cc1)-n1cc(CCCCN2CCC3(CC2)OCc2ccccc32)c2ccccc12, Fc1ccc(cc1)-n1cc(CCCCN2CCC3(CC2)OCc2ccccc32)c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,"phase 2","","","Fc1ccc(cc1)-n1cc(CCCCN2CCC3(CC2)OCc2ccccc32)c2ccccc12",454.242041832,34,6.29,17.4,0.199453043246953,0.142,0.170726521623477,1,1
"UB-165","acetylcholine receptor agonist","CHRNA3, CHRNA4, CHRNB2","Clc1ccc(cn1)C1=CCC[C@H]2CC[C@@H]1N2 |&1:11,&2:14,t:8,THB:4:7:12.13:15|, Clc1ccc(cn1)C1=CCC[C@H]2CC[C@@H]1N2 |&1:11,&2:14,t:8,THB:4:7:12.13:15|, Clc1ccc(cn1)C1=CCC[C@H]2CC[C@@H]1N2 |&1:11,&2:14,t:8,THB:4:7:12.13:15|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,"preclinical","","","Clc1ccc(cn1)C1=CCC[C@H]2CC[C@@H]1N2 |&1:11",234.09237616,16,2.4,24.92,0.197422858752399,0.144,0.170711429376199,1,1
"1E-1-(2-hydroxy-5-methylphenyl)-1-dodecanone-oxime","","","CCCCCCCCCCC[C@@H](N=O)c1cc(C)ccc1O |r|, CCCCCCCCCCC[C@@H](N=O)c1cc(C)ccc1O |r|, CCCCCCCCCCC[C@@H](N=O)c1cc(C)ccc1O |r|, CCCCCCCCCCC[C@@H](N=O)c1cc(C)ccc1O |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCCCCC[C@@H](N=O)c1cc(C)ccc1O |r|",305.235479232,22,7.338,49.66,0.25292599252445,0.088,0.170462996262225,1,0
"clorgiline","monoamine oxidase inhibitor","MAOA","CN(CCCOc1ccc(Cl)cc1Cl)CC#C, CN(CCCOc1ccc(Cl)cc1Cl)CC#C, CN(CCCOc1ccc(Cl)cc1Cl)CC#C, CN(CCCOc1ccc(Cl)cc1Cl)CC#C",0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN(CCCOc1ccc(Cl)cc1Cl)CC#C",271.05306946,17,3.66,12.47,0.188765138399602,0.152,0.170382569199801,1,1
"eseroline-(-)","acetylcholinesterase inhibitor","OPRD1, OPRM1","CN1CC[C@]2(C)[C@H]1N(C)c1ccc(O)cc21",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CC[C@]2(C)[C@H]1N(C)c1ccc(O)cc21",218.141913196,16,2.037,26.71,0.240188400980841,0.1,0.170094200490421,1,0
"2-CMDO","dopamine receptor antagonist","DRD2, DRD4","CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12 |t:8|, CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12 |t:8|, CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12 |t:8|, CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12 |t:8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12 |t:8|",326.118590908,23,4.612,15.71,0.22555280072684,0.114,0.16977640036342,1,0
"2-chloropyrazine","","","Clc1cnccn1, Clc1cnccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1cnccn1",113.998475776,7,0.229,25.78,0.239119341460892,0.1,0.169559670730446,1,0
"tramadol hydrochloride","","","COc1cccc(c1)[C@]1(O)CCCC[C@H]1CN(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","COc1cccc(c1)[C@]1(O)CCCC[C@H]1CN(C)C",263.18852904,19,2.434,32.7,0.170956177462695,0.168,0.169478088731347,1,1
"tetradecylthioacetic-acid","lipid peroxidase inhibitor","","CCCCCCCCCCCCCCSCC(O)=O, CCCCCCCCCCCCCCSCC(O)=O, CCCCCCCCCCCCCCSCC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCCCCCCCCCCCCSCC(O)=O",288.212301264,19,7.403,62.6,0.160917927663162,0.178,0.169458963831581,1,1
"quipazine","serotonin receptor agonist","HTR1A, HTR1D, HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR6, SLC6A4","C1CN(CCN1)c1ccc2ccccc2n1, C1CN(CCN1)c1ccc2ccccc2n1, C1CN(CCN1)c1ccc2ccccc2n1, C1CN(CCN1)c1ccc2ccccc2n1",1,1,0,0,0,0,0,0,1,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C1CN(CCN1)c1ccc2ccccc2n1",213.12659748,16,2.586,28.16,0.282788807079239,0.056,0.16939440353962,1,0
"cryptotanshinone","acetylcholinesterase inhibitor, STAT inhibitor","STAT3","C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|, C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|, C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|, C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|",296.1412445,22,4.152,43.37,0.182222872787591,0.156,0.169111436393796,1,1
"PCI-24781","HDAC inhibitor","HDAC1, HDAC2, HDAC3, HDAC6","CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO, CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO, CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO, CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO, CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO",397.163770836,29,1.883,104.04,0.0138320511902945,0.324,0.168916025595147,0,1
"honokiol","AKT inhibitor","ALOX5, PTGS1, PTGS2","Oc1ccc(cc1CC=C)-c1cc(CC=C)ccc1O, Oc1ccc(cc1CC=C)-c1cc(CC=C)ccc1O, Oc1ccc(cc1CC=C)-c1cc(CC=C)ccc1O",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Oc1ccc(cc1CC=C)-c1cc(CC=C)ccc1O",266.130679816,20,5.525,40.46,0.301447152080553,0.036,0.168723576040277,1,0
"LE-135","retinoid receptor agonist","RARB","CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C |t:9|, CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C |t:9|, CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C |t:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C |t:9|",438.2307282,33,8.016,52.9,0.162884925706296,0.174,0.168442462853148,1,1
"oxotremorine-sesquifumarate","cholinergic receptor agonist","CHRM1, CHRM2, CHRM3, CHRM4","O=C1CCCN1CC#CCN1CCCC1, O=C1CCCN1CC#CCN1CCCC1, O=C1CCCN1CC#CCN1CCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,"preclinical","","","O=C1CCCN1CC#CCN1CCCC1",206.141913196,15,0.517,23.55,0.198645502998762,0.138,0.168322751499381,1,1
"picolamine","","","NCc1cccnc1, NCc1cccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NCc1cccnc1",108.068748256,8,-0.108,38.91,0.236430253522135,0.1,0.168215126761068,1,0
"cetilistat","triacylglycerol lipase inhibitor","PNLIP","CCCCCCCCCCCCCCCCOc1nc2ccc(C)cc2c(=O)o1, CCCCCCCCCCCCCCCCOc1nc2ccc(C)cc2c(=O)o1, CCCCCCCCCCCCCCCCOc1nc2ccc(C)cc2c(=O)o1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCCCCCCCCCCCCCCCOc1nc2ccc(C)cc2c(=O)o1",401.292994108,29,10.745,52.33,0.270351514604527,0.066,0.168175757302263,1,0
"bergapten","","","COc1c2ccoc2cc2oc(=O)ccc12, COc1c2ccoc2cc2oc(=O)ccc12, COc1c2ccoc2cc2oc(=O)ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1c2ccoc2cc2oc(=O)ccc12",216.042258736,16,2.608,52.58,0.17348664976771,0.162,0.167743324883855,1,1
"GS-143","ubiquitin ligase inhibitor","BTRC, NFKBIA","OC(=O)c1ccc(cc1)N1N=C(Cc2ccccc2)\C(=C/c2ccc(o2)-c2ccccc2F)C1=O |t:11|, OC(=O)c1ccc(cc1)N1N=C(Cc2ccccc2)\C(=C/c2ccc(o2)-c2ccccc2F)C1=O |t:11|, OC(=O)c1ccc(cc1)N1N=C(Cc2ccccc2)\C(=C/c2ccc(o2)-c2ccccc2F)C1=O |t:11|, OC(=O)c1ccc(cc1)N1N=C(Cc2ccccc2)\C(=C/c2ccc(o2)-c2ccccc2F)C1=O |t:11|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1ccc(cc1)N1N=C(Cc2ccccc2)\C(=C/c2ccc(o2)-c2ccccc2F)C1=O |t:11|",466.132885308,35,5.761,83.11,0.0432432892944948,0.292,0.167621644647247,0,1
"SCH-202676","G protein-coupled receptor modulator","CHRM1, CHRM2, DRD1, DRD2","CN=c1nc(-c2ccccc2)n(s1)-c1ccccc1, CN=c1nc(-c2ccccc2)n(s1)-c1ccccc1, CN=c1nc(-c2ccccc2)n(s1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,1,2,0,0,0,0,0,0,"preclinical","","","CN=c1nc(-c2ccccc2)n(s1)-c1ccccc1",267.083018416,19,4.297,58.42,0.140488649079058,0.194,0.167244324539529,1,1
"ST-91","adrenergic receptor agonist","","CCc1cccc(CC)c1NC1=NCCN1 |t:12|, CCc1cccc(CC)c1NC1=NCCN1 |t:12|, CCc1cccc(CC)c1NC1=NCCN1 |t:12|, CCc1cccc(CC)c1NC1=NCCN1 |t:12|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCc1cccc(CC)c1NC1=NCCN1 |t:12|",217.157897608,16,2.818,36.42,0.238369683967556,0.096,0.167184841983778,1,0
"bornyl acetate","apoptosis stimulant","","CC(=O)O[C@@H]1C[C@@H]2CC[C@@]1(C)C2(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)O[C@@H]1C[C@@H]2CC[C@@]1(C)C2(C)C",196.14632988,14,3.474,26.3,0.326380656637557,0.006,0.166190328318779,1,0
"bornyl-acetate","","","CC(=O)O[C@H]1C[C@H]2CC[C@@]1(C)C2(C)C |&1:4,&2:6,&3:9,r,TLB:3:4:7.8:11|, CC(=O)O[C@H]1C[C@H]2CC[C@@]1(C)C2(C)C |&1:4,&2:6,&3:9,r,TLB:3:4:7.8:11|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)O[C@H]1C[C@H]2CC[C@@]1(C)C2(C)C |&1:4",196.14632988,14,3.474,26.3,0.326380656637557,0.006,0.166190328318779,1,0
"GBR-12783","dopamine reuptake inhibitor","","C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1, C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1, C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1, C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1, C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1, C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1",412.251463644,31,5.113,15.71,0.209722913113512,0.122,0.165861456556756,1,0
"JNJ-40411813","glutamate receptor positive allosteric modulator","GRM2","CCCCn1ccc(N2CCC(CC2)c2ccccc2)c(Cl)c1=O, CCCCn1ccc(N2CCC(CC2)c2ccccc2)c(Cl)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCCn1ccc(N2CCC(CC2)c2ccccc2)c(Cl)c1=O",344.1655411,24,5.998,25.24,0.211552737789069,0.12,0.165776368894534,1,0
"BYK-204165","PARP inhibitor","PARP1","Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12",252.089877624,19,2.236,51.1,0.143240364448247,0.188,0.165620182224124,1,1
"beta-lapachone","topoisomerase inhibitor","TOP1","CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|",242.094294308,18,2.716,43.37,0.18495545142352,0.146,0.16547772571176,1,1
"MY-5445","phosphodiesterase inhibitor, platelet aggregation inhibitor","PDE5A","Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1, Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1, Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1, Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1",331.087625128,24,5.797,37.81,0.206916466799491,0.124,0.165458233399746,1,0
"ML348","lysophospholipase inhibitor","LYPLA1","FC(F)(F)c1ccc(Cl)c(NC(=O)CN2CCN(CC2)C(=O)c2ccco2)c1, FC(F)(F)c1ccc(Cl)c(NC(=O)CN2CCN(CC2)C(=O)c2ccco2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)c1ccc(Cl)c(NC(=O)CN2CCN(CC2)C(=O)c2ccco2)c1",415.091053744,28,2.197,65.79,0.0186670831276945,0.312,0.165333541563847,0,1
"AN2718","leucyl-tRNA synthetase inhibitor","","OB1OCc2cc(Cl)ccc12, OB1OCc2cc(Cl)ccc12, OB1OCc2cc(Cl)ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OB1OCc2cc(Cl)ccc12",168.014937512,11,1.876,29.46,0.229954299738533,0.1,0.164977149869266,1,0
"FPL-62064","cyclooxygenase inhibitor, lipoxygenase inhibitor","","COc1ccc(Nc2ccn(n2)-c2ccccc2)cc1, COc1ccc(Nc2ccn(n2)-c2ccccc2)cc1, COc1ccc(Nc2ccn(n2)-c2ccccc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1ccc(Nc2ccn(n2)-c2ccccc2)cc1",265.1215121,20,3.615,39.08,0.222209548186707,0.106,0.164104774093354,1,0
"isobutyramide","gene expression stimulant","HBE1, HBG1","CC(C)C(N)=O, CC(C)C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)C(N)=O",87.068413908,6,-0.262,43.09,0.219977111914977,0.108,0.163988555957489,1,0
"lupanine","sodium channel blocker, sodium channel blocker, insulin secretagogue, insulin secretagogue","INS","[H][C@@]12CCCCN1C[C@@H]1C[C@H]2CN2C(=O)CCC[C@]12[H], [H][C@@]12CCCCN1C[C@@H]1C[C@H]2CN2C(=O)CCC[C@]12[H], O=C1CCCC2C3CC(CN12)[C@@H]1CCCCN1C3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","endocrinology","diabetes mellitus","[H][C@@]12CCCCN1C[C@@H]1C[C@H]2CN2C(=O)CCC[C@]12[H]",248.188863388,20,1.381,23.55,0.261929356241051,0.066,0.163964678120526,1,0
"bisphenol-A","synthetic estrogen","AR, ESR1, ESR2, ESRRG, PPARG","CC(C)(c1ccc(O)cc1)c1ccc(O)cc1, CC(C)(c1ccc(O)cc1)c1ccc(O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)(c1ccc(O)cc1)c1ccc(O)cc1",228.115029752,17,4.522,40.46,0.29549725503528,0.032,0.16374862751764,1,0
"citiolone","lipotropic, mucolytic agent","","CC(=O)N[C@H]1CCSC1=O |&1:4,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)N[C@H]1CCSC1=O |&1:4",159.035399528,10,0.488,71.47,0.0731880951357406,0.254,0.16359404756787,0,1
"HT-2157","galanin receptor 3 antagonist","","FC(F)(F)c1cccc(c1)\N=C1/C(=O)N(c2ccccc12)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","FC(F)(F)c1cccc(c1)\N=C1/C(=O)N(c2ccccc12)c1ccccc1",366.097997696,27,4.876,32.67,0.168519548302086,0.158,0.163259774151043,1,1
"5-fluoro-3-pyridyl-methanol","","","OCc1cncc(F)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OCc1cncc(F)c1",127.043342032,9,0.12,33.12,0.230510113086088,0.096,0.163255056543044,1,0
"piconol","","","OCc1ccccn1, OCc1ccccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OCc1ccccn1",109.052763844,8,0.0479999999999999,33.12,0.264369268227159,0.062,0.163184634113579,1,0
"lerisetron","serotonin receptor antagonist","HTR3A","C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1, C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1, C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1",292.16879664,22,3.556,33.09,0.2117746683362,0.114,0.1628873341681,1,0
"osthol","calcium channel blocker","","COc1ccc2ccc(=O)oc2c1CC=C(C)C, COc1ccc2ccc(=O)oc2c1CC=C(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc2ccc(=O)oc2c1CC=C(C)C",244.109944372,18,4.233,39.44,0.255768772586928,0.07,0.162884386293464,1,0
"tecalcet","calcium-sensing receptor agonist","CASR","COc1cccc(c1)[C@@H](C)NCCCc1ccccc1Cl, COc1cccc(c1)[C@@H](C)NCCCc1ccccc1Cl, COc1cccc(c1)[C@@H](C)NCCCc1ccccc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1cccc(c1)[C@@H](C)NCCCc1ccccc1Cl",303.138992004,21,4.823,21.26,0.227594921744235,0.098,0.162797460872117,1,0
"captamine","","","CN(C)CCS, CN(C)CCS",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)CCS",105.061220352,6,0.735,42.04,0.193551786300753,0.132,0.162775893150376,1,1
"funapide","sodium channel blocker","","FC(F)(F)c1ccc(CN2C(=O)[C@@]3(COc4cc5OCOc5cc34)c3ccccc23)o1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)c1ccc(CN2C(=O)[C@@]3(COc4cc5OCOc5cc34)c3ccccc23)o1",429.082407208,31,3.415,61.14,0.0392121838725934,0.286,0.162606091936297,0,1
"CL-218872","benzodiazepine receptor agonist","GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2","Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F, Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F, Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,1,6,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F",278.077930948,20,5.135,43.08,0.21712714977383,0.108,0.162563574886915,1,0
"jnj-5207852","histamine receptor antagonist","HRH3","C(COc1ccc(CN2CCCCC2)cc1)CN1CCCCC1",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","neurology/psychiatry","epilepsy","C(COc1ccc(CN2CCCCC2)cc1)CN1CCCCC1",316.251463644,23,3.627,15.71,0.224557701606832,0.1,0.162278850803416,1,0
"paquinimod","S100A9 inhibitor","","CCN(C(=O)c1c(O)c2c(CC)cccc2n(C)c1=O)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCN(C(=O)c1c(O)c2c(CC)cccc2n(C)c1=O)c1ccccc1",350.163042564,26,5.333,62.54,0.116503996172706,0.208,0.162251998086353,1,1
"DBPR-211","cannabinoid receptor antagonist","","FC(F)(F)c1ccc(cc1)C#Cc1ccc(s1)-c1c(CNS(=O)(=O)N2CCCC2)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)c1ccc(cc1)C#Cc1ccc(s1)-c1c(CNS(=O)(=O)N2CCCC2)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1",750.122820872,49,6.674,136.19,0.000467648458259438,0.324,0.16223382422913,0,1
"F-16915","","","CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)OCc1cccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)OCc1cccnc1",419.282429424,31,9.612,39.19,0.281831529157489,0.042,0.161915764578745,1,0
"pronethalol","adrenergic receptor antagonist","","CC(C)NC[C@@H](O)c1ccc2ccccc2c1 |&1:5,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CC(C)NC[C@@H](O)c1ccc2ccccc2c1 |&1:5",229.146664228,17,3.077,32.26,0.257716378496229,0.066,0.161858189248114,1,0
"pronethalol hydrochloride","adrenergic receptor antagonist","","CC(C)NCC(O)c1ccc2ccccc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CC(C)NCC(O)c1ccc2ccccc2c1",229.146664228,17,3.077,32.26,0.257716378496229,0.066,0.161858189248114,1,0
"EN460","endoplasmic reticulum oxidation inhibitor","ERO1A","OC(=O)c1cc(ccc1Cl)N1N=C(\C(=C\c2ccc(o2)-c2ccccc2)C1=O)C(F)(F)F |c:12|, OC(=O)c1cc(ccc1Cl)N1N=C(\C(=C\c2ccc(o2)-c2ccccc2)C1=O)C(F)(F)F |c:12|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1cc(ccc1Cl)N1N=C(\C(=C\c2ccc(o2)-c2ccccc2)C1=O)C(F)(F)F |c:12|",460.043769204,32,5.392,83.11,0.0233628999321709,0.3,0.161681449966085,0,1
"U-99194","dopamine receptor antagonist","DRD3","CCCN(CCC)C1Cc2cc(OC)c(OC)cc2C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,"preclinical","","","CCCN(CCC)C1Cc2cc(OC)c(OC)cc2C1",277.204179104,20,2.938,21.7,0.213343257469345,0.11,0.161671628734673,1,0
"uprosertib","AKT inhibitor","AKT1, AKT2, AKT3","Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1, Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1, Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1, Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1",428.061837552,28,3.233,86.08,0.0111123335516982,0.312,0.161556166775849,0,1
"sumanirole","dopamine receptor agonist","DRD2","CN[C@@H]1Cc2cccc3[nH]c(=O)n(C1)c23, CN[C@@H]1Cc2cccc3[nH]c(=O)n(C1)c23",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,"phase 3","","","CN[C@@H]1Cc2cccc3[nH]c(=O)n(C1)c23",203.105862036,15,0.884,49.82,0.136912134781493,0.186,0.161456067390747,1,1
"arecoline","acetylcholine receptor agonist","CHRM1, CHRM2, CHRM3, CHRM4","COC(=O)C1=CCCN(C)C1 |t:4|, COC(=O)C1=CCCN(C)C1 |t:4|, COC(=O)C1=CCCN(C)C1 |t:4|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,"phase 1","","","COC(=O)C1=CCCN(C)C1 |t:4|",155.094628656,11,0.172,29.54,0.21090059728042,0.112,0.16145029864021,1,0
"YM-750","ACAT inhibitor","SOAT1","Cc1cc(C)c(NC(=O)N(Cc2ccc-3c(Cc4ccccc-34)c2)C2CCCCCC2)c(C)c1, Cc1cc(C)c(NC(=O)N(Cc2ccc-3c(Cc4ccccc-34)c2)C2CCCCCC2)c(C)c1, Cc1cc(C)c(NC(=O)N(Cc2ccc-3c(Cc4ccccc-34)c2)C2CCCCCC2)c(C)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1cc(C)c(NC(=O)N(Cc2ccc-3c(Cc4ccccc-34)c2)C2CCCCCC2)c(C)c1",452.282763772,34,7.938,32.34,0.216708373718657,0.106,0.161354186859328,1,0
"YM-976","phosphodiesterase inhibitor","PDE4A","CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1, CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1, CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1, CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1",313.098189812,22,4.939,47.78,0.139916858427931,0.182,0.160958429213966,1,1
"DMAB-anabaseine","adrenergic receptor agonist","CHRNA7","CN(C)c1ccc(\C=C2/CCCN=C2c2cccnc2)cc1 |c:12|, CN(C)c1ccc(\C=C2/CCCN=C2c2cccnc2)cc1 |c:12|, CN(C)c1ccc(\C=C2/CCCN=C2c2cccnc2)cc1 |c:12|, CN(C)c1ccc(\C=C2/CCCN=C2c2cccnc2)cc1 |c:12|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"preclinical","","","CN(C)c1ccc(\C=C2/CCCN=C2c2cccnc2)cc1 |c:12|",291.173547672,22,3.172,28.49,0.217887120046598,0.104,0.160943560023299,1,0
"LXR-623","LXR agonist","AR, NR1H2, NR1H3, NR1I2, NR3C1","Fc1ccc(cc1)-c1n(Cc2ccc(F)cc2Cl)nc2c(cccc12)C(F)(F)F, Fc1ccc(cc1)-c1n(Cc2ccc(F)cc2Cl)nc2c(cccc12)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Fc1ccc(cc1)-c1n(Cc2ccc(F)cc2Cl)nc2c(cccc12)C(F)(F)F",422.060917164,29,7.797,17.82,0.195834742367947,0.126,0.160917371183973,1,0
"cyclocytidine","DNA synthesis inhibitor, RNA synthesis inhibitor","","OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O, OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O, OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O, OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O",225.074955832,16,0.455,100.59,0.0317297710419294,0.29,0.160864885520965,0,1
"ripazepam","benzodiazepine receptor agonist","GABRA1","CCn1nc(C)c2NC(=O)CN=C(c12)c1ccccc1 |c:11|, CCn1nc(C)c2NC(=O)CN=C(c12)c1ccccc1 |c:11|",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCn1nc(C)c2NC(=O)CN=C(c12)c1ccccc1 |c:11|",268.132411132,20,1.574,59.28,0.0916376461239913,0.23,0.160818823061996,0,1
"C646","histone acetyltransferase inhibitor","EP300","CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|",445.127385328,33,4.837,126.25,0.0136250092582278,0.308,0.160812504629114,0,1
"fenaclon","","","ClCCC(=O)NCCc1ccccc1, ClCCC(=O)NCCc1ccccc1, ClCCC(=O)NCCc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","ClCCC(=O)NCCc1ccccc1",211.076391748,14,2.173,29.1,0.187605958416792,0.134,0.160802979208396,1,1
"(e)-2-(2-(2,5-dimethyl-1-phenyl-1h-pyrrol-3-yl)vinyl)-6-(dimethylamino)-1-methylquinolin-1-ium 4,4'-methylenebis(3-hydroxy-2-naphthoate)","","","CN(C)c1ccc2[n+](C)c(\C=C\c3cc(C)n(c3C)-c3ccccc3)ccc2c1.CN(C)c1ccc2[n+](C)c(\C=C\c3cc(C)n(c3C)-c3ccccc3)ccc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CN(C)c1ccc2[n+](C)c(\C=C\c3cc(C)n(c3C)-c3ccccc3)ccc2c1.CN(C)c1ccc2[n+](C)c(\C=C\c3cc(C)n(c3C)-c3ccccc3)ccc2c1",764.455548632181,58,14.666,24.1,0.201502008577475,0.12,0.160751004288737,1,0
"imiloxan","adrenergic receptor antagonist","ADRA2A, ADRA2B","CCn1ccnc1C[C@H]1COc2ccccc2O1 |&1:8|, CCn1ccnc1C[C@H]1COc2ccccc2O1 |&1:8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,"phase 1","","","CCn1ccnc1C[C@H]1COc2ccccc2O1 |&1:8|",244.121177752,18,1.956,36.28,0.17455839779237,0.146,0.160279198896185,1,1
"SEW-2871","lysophospholipid receptor agonist","S1PR1","FC(F)(F)c1sc(cc1-c1ccccc1)-c1nc(no1)-c1cccc(c1)C(F)(F)F, FC(F)(F)c1sc(cc1-c1ccccc1)-c1nc(no1)-c1cccc(c1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)c1sc(cc1-c1ccccc1)-c1nc(no1)-c1cccc(c1)C(F)(F)F",440.04180326,30,6.499,67.16,0.0441808901532752,0.276,0.160090445076638,0,1
"evodiamine","ATPase inhibitor, TRPV agonist","TRPV1","CN1[C@H]2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12 |&1:2,r|, CN1[C@H]2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12 |&1:2,r|, CN1[C@H]2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12 |&1:2,r|, CN1[C@H]2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12 |&1:2,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1[C@H]2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12 |&1:2",303.137162164,23,3.878,39.34,0.195922467158139,0.124,0.15996123357907,1,0
"PHP-501","GABA receptor antagonist","GABRA1, GABRB2, GABRG2","On1ncc(C2CCNCC2)c1-c1cccc(c1)-c1ccccc1, On1ncc(C2CCNCC2)c1-c1cccc(c1)-c1ccccc1, On1ncc(C2CCNCC2)c1-c1cccc(c1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,"preclinical","","","On1ncc(C2CCNCC2)c1-c1cccc(c1)-c1ccccc1",319.168462292,24,4.001,50.08,0.143852270556773,0.176,0.159926135278386,1,1
"MDL-11939","serotonin receptor antagonist","HTR2A, HTR2B, HTR2C","O[C@@H](C1CCN(CCc2ccccc2)CC1)c1ccccc1 |&1:1,r|, O[C@@H](C1CCN(CCc2ccccc2)CC1)c1ccccc1 |&1:1,r|, O[C@@H](C1CCN(CCc2ccccc2)CC1)c1ccccc1 |&1:1,r|",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O[C@@H](C1CCN(CCc2ccccc2)CC1)c1ccccc1 |&1:1",295.19361442,22,3.773,23.47,0.247808892454143,0.072,0.159904446227072,1,0
"flurothyl","","","FC(F)(F)COCC(F)(F)F, FC(F)(F)COCC(F)(F)F, FC(F)(F)COCC(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)COCC(F)(F)F",182.016634068,11,2.87,9.23,0.303534618621419,0.016,0.159767309310709,1,0
"antalarmin","corticotropin releasing factor receptor antagonist","CRHR1","CCCCN(CC)c1nc(C)nc2n(c(C)c(C)c12)-c1c(C)cc(C)cc1C, CCCCN(CC)c1nc(C)nc2n(c(C)c(C)c12)-c1c(C)cc(C)cc1C, CCCCN(CC)c1nc(C)nc2n(c(C)c(C)c12)-c1c(C)cc(C)cc1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCN(CC)c1nc(C)nc2n(c(C)c(C)c12)-c1c(C)cc(C)cc1C",378.278347088,28,6.811,33.95,0.229356928833992,0.09,0.159678464416996,1,0
"rimcazole","sigma receptor antagonist","SIGMAR1","C[C@H]1CN(CCCn2c3ccccc3c3ccccc23)C[C@@H](C)N1, C[C@H]1CN(CCCn2c3ccccc3c3ccccc23)C[C@@H](C)N1, C[C@H]1CN(CCCn2c3ccccc3c3ccccc23)C[C@@H](C)N1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@H]1CN(CCCn2c3ccccc3c3ccccc23)C[C@@H](C)N1",321.220497864,24,4.37,20.2,0.259322308735573,0.06,0.159661154367786,1,0
"vesamicol","acetylcholinesterase inhibitor","SLC18A3","O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1, O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1, O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1, O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1, O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1",259.19361442,19,2.894,23.47,0.239299243417161,0.08,0.159649621708581,1,0
"galeterone","androgen receptor modulator","AR, CYP17A1","[H][C@@]12CC=C(n3cnc4ccccc34)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C |t:3,27|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","[H][C@@]12CC=C(n3cnc4ccccc34)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C |t:3",388.251463644,32,5.115,38.05,0.261202903485644,0.058,0.159601451742822,1,0
"etretinate","protein synthesis inhibitor","RARA, RXRG","CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C, CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C, CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C, CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C, CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C",354.21949482,26,6.534,35.53,0.231090805750796,0.088,0.159545402875398,1,0
"chlormethine (hydrochloride)","","","CN(CCCl)CCCl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CN(CCCl)CCCl",155.026854712,8,1.593,3.24,0.259048803934351,0.06,0.159524401967175,1,0
"pirquinozol","histamine release inhibitor","","OCc1cc2c3ccccc3[nH]c(=O)n2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OCc1cc2c3ccccc3[nH]c(=O)n2n1",215.069476528,16,0.976,70.39,0.0869791135797257,0.232,0.159489556789863,0,1
"SQ-109","bacterial cell wall synthesis inhibitor","FDFT1","CC(C)=CCC\C(C)=C\CNCCNC1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2 |r|, CC(C)=CCC\C(C)=C\CNCCNC1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(C)=CCC\C(C)=C\CNCCNC1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2 |r|",330.303499216,24,5.219,24.06,0.240875053364936,0.078,0.159437526682468,1,0
"sq109","bacterial cell wall synthesis inhibitor","","CC(C)=CCC\C(C)=C\CNCCNC1C2CC3CC(C2)CC1C3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","infectious disease","tuberculosis","CC(C)=CCC\C(C)=C\CNCCNC1C2CC3CC(C2)CC1C3",330.303499216,24,5.219,24.06,0.240875053364936,0.078,0.159437526682468,1,0
"4-pyrimidinecarbonitrile","","","N#Cc1ccncn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N#Cc1ccncn1",105.032697096,8,-0.459,49.57,0.192632757891178,0.126,0.159316378945589,1,0
"arecaidine-but-2-ynyl-ester","acetylcholine receptor agonist","CHRM2","CC#CCOC(=O)C1=CCCN(C)C1 |t:7|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"preclinical","","","CC#CCOC(=O)C1=CCCN(C)C1 |t:7|",193.11027872,14,1.039,29.54,0.210078720641485,0.108,0.159039360320742,1,0
"VU0360172","glutamate receptor positive allosteric modulator","GRM5","Fc1cccc(c1)C#Cc1ccc(cn1)C(=O)NC1CCC1, Fc1cccc(c1)C#Cc1ccc(cn1)C(=O)NC1CCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1cccc(c1)C#Cc1ccc(cn1)C(=O)NC1CCC1",294.11684132,22,3.926,41.99,0.185971331403148,0.132,0.158985665701574,1,1
"BRL-26314","cholesterol inhibitor","LPL","OC(=O)[C@@H](Cc1ccccc1)NCc1ccc(Cl)cc1 |&1:3,r|, OC(=O)[C@@H](Cc1ccccc1)NCc1ccc(Cl)cc1 |&1:3,r|, OC(=O)[C@@H](Cc1ccccc1)NCc1ccc(Cl)cc1 |&1:3,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC(=O)[C@@H](Cc1ccccc1)NCc1ccc(Cl)cc1 |&1:3",289.086956432,20,1.343,49.33,0.0678101984689656,0.25,0.158905099234483,0,1
"SIB-1553A","acetylcholine receptor agonist","CHRNB4","CN1CCC[C@@H]1CCSc1ccc(O)cc1 |&1:5|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"phase 2","","","CN1CCC[C@@H]1CCSc1ccc(O)cc1 |&1:5|",237.118735228,16,3.047,48.77,0.133652928038815,0.184,0.158826464019408,1,1
"methyl-nicotinate","","","COC(=O)c1cccnc1, COC(=O)c1cccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COC(=O)c1cccnc1",137.047678464,10,0.706,39.19,0.229495208265952,0.088,0.158747604132976,1,0
"LY231617","lipid peroxidase inhibitor","","CCNCc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CCNCc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCNCc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C",263.224914548,19,4.763,32.26,0.26929383674503,0.048,0.158646918372515,1,0
"AC-7954-(+/-)","urotensin receptor agonist","UTS2R","CN(C)CC[C@]1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1 |&1:5|, CN(C)CC[C@]1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1 |&1:5|, CN(C)CC[C@]1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1 |&1:5|, CN(C)CC[C@]1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1 |&1:5|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)CC[C@]1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1 |&1:5|",329.11825656,23,4.137,29.54,0.149000672456292,0.168,0.158500336228146,1,1
"SKF-77434","dopamine receptor agonist","DRD1","Oc1cc2CCN(CC=C)C[C@@H](c3ccccc3)c2cc1O |&1:11|, Oc1cc2CCN(CC=C)C[C@@H](c3ccccc3)c2cc1O |&1:11|, Oc1cc2CCN(CC=C)C[C@@H](c3ccccc3)c2cc1O |&1:11|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,"preclinical","","","Oc1cc2CCN(CC=C)C[C@@H](c3ccccc3)c2cc1O |&1:11|",295.157228912,22,3.231,43.7,0.152980633966175,0.164,0.158490316983088,1,1
"K-858","kinesin-like spindle protein inhibitor","KIF11","CC(=O)NC1=NN(C(C)=O)[C@@](C)(S1)c1ccccc1 |&1:10,r,t:4|, CC(=O)NC1=NN(C(C)=O)[C@@](C)(S1)c1ccccc1 |&1:10,r,t:4|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)NC1=NN(C(C)=O)[C@@](C)(S1)c1ccccc1 |&1:10",277.08849772,19,1.839,87.07,0.0349711612915832,0.282,0.158485580645792,0,1
"p-dimethylinamyl-benzoate","","","CCCCCOC(=O)c1ccc(cc1)N(C)C, CCCCCOC(=O)c1ccc(cc1)N(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCOC(=O)c1ccc(cc1)N(C)C",235.157228912,17,4.086,29.54,0.290901469070649,0.026,0.158450734535325,1,0
"procyclidine","antispasmodic, acetylcholine receptor antagonist","CHRM1","OC(CCN1CCCC1)(C2CCCCC2)c3ccccc3, COc1cc(N[C@@H](C)CCCN)c2ncccc2c1 |&1:6|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,"withdrawn","neurology/psychiatry","parkinsonism, Parkinson's Disease, akathisia, dystonia","OC(CCN1CCCC1)(C2CCCCC2)c3ccccc3",287.224914548,21,4.163,23.47,0.258348029627651,0.058,0.158174014813825,1,0
"procyclidine (hydrochloride)","","","OC(CCN1CCCC1)(C1CCCCC1)c1ccccc1 |&1:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","OC(CCN1CCCC1)(C1CCCCC1)c1ccccc1 |&1:1|",287.224914548,21,4.163,23.47,0.258348029627651,0.058,0.158174014813825,1,0
"mepiroxol","","","OCc1ccc[n+]([O-])c1, OCc1ccc[n+]([O-])c1, OCc1ccc[n+]([O-])c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OCc1ccc[n+]([O-])c1",125.047678464,9,0.524,47.17,0.200314158738456,0.116,0.158157079369228,1,0
"NE-100","sigma receptor antagonist","SIGMAR1","CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1, CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1, CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1",355.251129296,26,4.923,21.7,0.213929073076044,0.102,0.157964536538022,1,0
"XE-991","potassium channel blocker","KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5","O=C1c2ccccc2C(Cc2ccncc2)(Cc2ccncc2)c2ccccc12, O=C1c2ccccc2C(Cc2ccncc2)(Cc2ccncc2)c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C1c2ccccc2C(Cc2ccncc2)(Cc2ccncc2)c2ccccc12",376.15756326,29,5.252,42.85,0.179526228422021,0.136,0.15776311421101,1,1
"CAY10505","PI3K inhibitor","PIK3CG","Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1, Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1, Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1, Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1",289.020892336,20,2.285,84.61,0.0389383972708024,0.276,0.157469198635401,0,1
"OG-L002","histone lysine demethylase inhibitor","KDM1A","N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1, N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1, N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1, N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1, N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1, N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1",225.1153641,17,2.891,46.25,0.208921241280603,0.106,0.157460620640302,1,0
"alantolactone","apoptosis stimulant, STAT inhibitor","STAT3","C[C@H]1CCC[C@]2(C)C[C@H]3OC(=O)C(=C)[C@H]3C=C12 |t:16|, C[C@H]1CCC[C@]2(C)C[C@H]3OC(=O)C(=C)[C@H]3C=C12 |t:16|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H]1CCC[C@]2(C)C[C@H]3OC(=O)C(=C)[C@H]3C=C12 |t:16|",232.14632988,17,3.443,26.3,0.288713542897253,0.026,0.157356771448627,1,0
"GW-441756","growth factor receptor inhibitor","NTRK1","Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12, Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12",275.105862036,21,2.313,46.92,0.146506494599753,0.168,0.157253247299877,1,1
"TCID","","","Clc1c2C(=O)CC(=O)c2c(Cl)c(Cl)c1Cl, Clc1c2C(=O)CC(=O)c2c(Cl)c(Cl)c1Cl, Clc1c2C(=O)CC(=O)c2c(Cl)c(Cl)c1Cl, Clc1c2C(=O)CC(=O)c2c(Cl)c(Cl)c1Cl, Clc1c2C(=O)CC(=O)c2c(Cl)c(Cl)c1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1c2C(=O)CC(=O)c2c(Cl)c(Cl)c1Cl",281.880890024,15,3.545,34.14,0.062478205895225,0.252,0.157239102947613,0,1
"5-FP","thymidylate synthase inhibitor","TYMS","Fc1cnc(=O)[nH]c1, Fc1cnc(=O)[nH]c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Fc1cnc(=O)[nH]c1",114.022940936,8,0.507,45.75,0.210415471488083,0.104,0.157207735744042,1,0
"KT-433","uricosuric agent","","CCc1oc2ccccc2c1C(=O)c1ccc(OCC(O)=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCc1oc2ccccc2c1C(=O)c1ccc(OCC(O)=O)cc1",324.099773612,24,3.323,76.74,0.0638079482480933,0.25,0.156903974124047,0,1
"4E1RCat","protein synthesis inhibitor","EIF4E, EIF4G1","OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|, OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|, OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|, OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|, OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|",478.116486296,36,5.566,113.89,0.0195660237360319,0.294,0.156783011868016,0,1
"famprofazone","cyclooxygenase inhibitor","","CC(C)c1c(CN(C)[C@@H](C)Cc2ccccc2)n(C)n(-c2ccccc2)c1=O |&1:8,r|, CC(C)c1c(CN(C)[C@@H](C)Cc2ccccc2)n(C)n(-c2ccccc2)c1=O |&1:8,r|, CC(C)c1c(CN(C)[C@@H](C)Cc2ccccc2)n(C)n(-c2ccccc2)c1=O |&1:8,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)c1c(CN(C)[C@@H](C)Cc2ccccc2)n(C)n(-c2ccccc2)c1=O |&1:8",377.246712612,28,4.323,30.17,0.153166451100831,0.16,0.156583225550415,1,1
"levamisole","acetylcholine receptor agonist","ALPL","C1CN2C[C@@H](N=C2S1)c1ccccc1 |c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |c:5|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","C1CN2C[C@@H](N=C2S1)c1ccccc1 |c:5|",204.072119384,14,2.469,40.9,0.182557442434331,0.13,0.156278721217165,1,1
"putrescine","tissue transglutaminase inhibitor","AMD1, KCNJ4, ODC1","NCCCCN",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NCCCCN",88.100048384,6,-0.626,52.04,0.169771607333673,0.142,0.155885803666837,1,1
"peretinoin","retinoid receptor agonist","RXRA","CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O",302.2245802,22,6.222,37.3,0.269275681031641,0.042,0.155637840515821,1,0
"PNU-89843","benzodiazepine receptor agonist","GABBR1","Cc1cc2c(nc(nc2n1C)N1CCCC1)N1CCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc2c(nc(nc2n1C)N1CCCC1)N1CCCC1",285.195345736,21,4.276,37.19,0.214772264444696,0.096,0.155386132222348,1,0
"suritozole","GABA receptor inverse agonist","GABBR1","Cn1nc(-c2cccc(F)c2)n(C)c1=S, Cn1nc(-c2cccc(F)c2)n(C)c1=S",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cn1nc(-c2cccc(F)c2)n(C)c1=S",223.05794654,15,3.145,54.84,0.132392609545623,0.178,0.155196304772812,1,1
"indirubin","CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK5, GSK3A","O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O, O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O, O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O, O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O",262.07422756,20,3.038,58.2,0.146192988637017,0.164,0.155096494318509,1,1
"MK-2206","AKT inhibitor","AKT1, AKT2, AKT3","NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1",407.174610292,31,5.13,89.07,0.0520675687347779,0.258,0.155033784367389,0,1
"semaxanib","VEGFR inhibitor","FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET","Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1",238.110613068,18,2.328,44.89,0.179712624035705,0.13,0.154856312017852,1,1
"N-alpha-methylhistamine-dihydrochloride","histamine receptor agonist","HRH4","CNCCc1cnc[nH]1, CNCCc1cnc[nH]1, CNCCc1cnc[nH]1",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CNCCc1cnc[nH]1",125.095297352,9,-0.358,40.71,0.18968289293015,0.12,0.154841446465075,1,0
"isoguvacine","benzodiazepine receptor agonist","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRR1, GABRR2, GABRR3","OC(=O)C1=CCNCC1 |t:3|, OC(=O)C1=CCNCC1 |t:3|, OC(=O)C1=CCNCC1 |t:3|",0,0,0,0,0,0,0,0,0,0,0,0,1,9,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)C1=CCNCC1 |t:3|",127.063328528,9,-0.388,49.33,0.153641055254273,0.156,0.154820527627136,1,1
"F351","TGF beta receptor inhibitor","TGFB1","Cc1ccc(=O)n(c1)-c1ccc(O)cc1, Cc1ccc(=O)n(c1)-c1ccc(O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1ccc(=O)n(c1)-c1ccc(O)cc1",201.078978592,15,2.669,42.23,0.235254191713096,0.074,0.154627095856548,1,0
"CDPPB","glutamate receptor positive allosteric modulator","GRM5","O=C(Nc1cc(nn1-c1ccccc1)-c1ccccc1)c1cccc(c1)C#N, O=C(Nc1cc(nn1-c1ccccc1)-c1ccccc1)c1cccc(c1)C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(Nc1cc(nn1-c1ccccc1)-c1ccccc1)c1cccc(c1)C#N",364.132411132,28,5.207,70.71,0.10722571845251,0.202,0.154612859226255,0,1
"hypoxanthine","PARP inhibitor","PNP","O=c1nc[nH]c2nc[nH]c12, O=c1nc[nH]c2nc[nH]c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=c1nc[nH]c2nc[nH]c12",136.038510748,10,1.439,74.43,0.138931834877543,0.17,0.154465917438772,1,1
"chlorphenoxamine","histamine receptor antagonist","","CN(C)CCO[C@@](C)(c1ccccc1)c1ccc(Cl)cc1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)CCO[C@@](C)(c1ccccc1)c1ccc(Cl)cc1 |r|",303.138992004,21,4.294,12.47,0.240866951327267,0.068,0.154433475663633,1,0
"3-methyladenine","PI3K inhibitor","PI3","Cn1cnc(=N)c2[nH]cnc12, Cn1cnc(=N)c2[nH]cnc12, Cn1cnc(=N)c2[nH]cnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cn1cnc(=N)c2[nH]cnc12",149.070145224,11,1.709,70.35,0.148740373672,0.16,0.154370186836,1,1
"MK-0354","niacin receptor agonist","HCAR2, HCAR3","C1Cc2[nH]nc(-c3nn[nH]n3)c2C1, C1Cc2[nH]nc(-c3nn[nH]n3)c2C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C1Cc2[nH]nc(-c3nn[nH]n3)c2C1",176.081044256,13,1.386,83.14,0.0906925641895871,0.218,0.154346282094794,0,1
"Ro-60-0175","serotonin receptor agonist","HTR2A, HTR2B, HTR2C","C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12, C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12, C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12, C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12, C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12",226.067304284,15,2.946,30.95,0.190479567644738,0.118,0.154239783822369,1,0
"GP1a","cannabinoid receptor agonist","CNR2","Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1",440.117066684,30,5.453,50.16,0.0502800143376305,0.258,0.154140007168815,0,1
"FPL-64176","calcium channel activator","CACNA1C, CACNA1S","COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1, COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1, COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1, COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1, COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1",347.152143532,26,5.441,59.16,0.135976468631024,0.172,0.153988234315512,1,1
"SKF-38393","dopamine receptor agonist","CALY, DRD1, DRD5","Oc1cc2CCNC[C@@H](c3ccccc3)c2cc1O |&1:8|, Oc1cc2CCNC[C@@H](c3ccccc3)c2cc1O |&1:8|, Oc1cc2CCNC[C@@H](c3ccccc3)c2cc1O |&1:8|, Oc1cc2CCNC[C@@H](c3ccccc3)c2cc1O |&1:8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"preclinical","","","Oc1cc2CCNC[C@@H](c3ccccc3)c2cc1O |&1:8|",255.125928784,19,2.377,52.49,0.134835815928034,0.172,0.153417907964017,1,1
"2-APB","1,4,5-trisphosphate inhibitor","TRPC1, TRPC3, TRPC4, TRPC5, TRPC6, TRPC7, TRPM2, TRPM3, TRPM6, TRPV1, TRPV6","NCCOB(c1ccccc1)c1ccccc1, NCCOB(c1ccccc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NCCOB(c1ccccc1)c1ccccc1",225.132494532,17,3.238,35.25,0.270573571216996,0.036,0.153286785608498,1,0
"N-methyllidocaine-iodide","antiarrhythmic medication","","CC[N+](C)(CC)CC(=O)Nc1c(C)cccc1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC[N+](C)(CC)CC(=O)Nc1c(C)cccc1C",249.196139840091,18,1.908,29.1,0.17941389239448,0.126,0.15270694619724,1,0
"securinine","GABA receptor antagonist, TP53 activator","GABRA1","O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31 |c:6,9|, O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31 |c:6,9|, O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31 |c:6,9|, O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31 |c:6,9|",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31 |c:6",217.11027872,16,1.018,29.54,0.191149381266466,0.114,0.152574690633233,1,0
"geranyl-farnesylacetate","mucin production enhancer","","CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C, CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C, CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C",400.334130648,29,8.519,26.3,0.286484361486899,0.018,0.152242180743449,1,0
"lazabemide","monoamine oxidase inhibitor","MAOB","NCCNC(=O)c1ccc(Cl)cn1, NCCNC(=O)c1ccc(Cl)cn1, NCCNC(=O)c1ccc(Cl)cn1, NCCNC(=O)c1ccc(Cl)cn1",0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","NCCNC(=O)c1ccc(Cl)cn1",199.05123962,13,0.11,68.01,0.0564291196209553,0.248,0.152214559810478,0,1
"RS-504393","CC chemokine receptor antagonist","CCL2, CCR2","Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1, Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1",417.205241724,31,3.932,67.6,0.0503202209065924,0.254,0.152160110453296,0,1
"2,5-furandimethanol","hemoglobin modulator","HBB","OCc1ccc(CO)o1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OCc1ccc(CO)o1",128.047344116,9,-0.893,53.6,0.124256494871383,0.18,0.152128247435692,1,1
"CYM-50769","neuropeptide receptor antagonist","NPBWR1","COc1ccc(Oc2c(Cl)cnn(C3c4ccccc4-c4ccccc34)c2=O)cc1, COc1ccc(Oc2c(Cl)cnn(C3c4ccccc4-c4ccccc34)c2=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(Oc2c(Cl)cnn(C3c4ccccc4-c4ccccc34)c2=O)cc1",416.092770084,30,5.559,53.35,0.0822557520084805,0.222,0.15212787600424,0,1
"cetaben","ACAT inhibitor, cholesterol inhibitor","PPARA","CCCCCCCCCCCCCCCCNc1ccc(cc1)C(O)=O, CCCCCCCCCCCCCCCCNc1ccc(cc1)C(O)=O, CCCCCCCCCCCCCCCCNc1ccc(cc1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCCCCCCCCCCCCCCNc1ccc(cc1)C(O)=O",361.298079488,26,9.461,49.33,0.274220233076545,0.03,0.152110116538273,1,0
"dibenzepine","norepinephrine reputake inhibitor","","CN(C)CCN1c2ccccc2N(C)c2ccccc2C1=O, CN(C)CCN1c2ccccc2N(C)c2ccccc2C1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)CCN1c2ccccc2N(C)c2ccccc2C1=O",295.168462292,22,2.861,26.79,0.196167605063051,0.108,0.152083802531525,1,0
"IOWH032","CFTR channel antagonist","CFTR","Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1, Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1, Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1, Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1",542.94293016,31,5.95,97.48,0.00214643394529602,0.302,0.152073216972648,0,1
"BVT-948","tyrosine phosphatase inhibitor","PTPN1, PTPN11, PTPN2","CC1(C)C(=O)NC2=C1C(=O)C(=O)c1ccccc21 |c:6|, CC1(C)C(=O)NC2=C1C(=O)C(=O)c1ccccc21 |c:6|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC1(C)C(=O)NC2=C1C(=O)C(=O)c1ccccc21 |c:6|",241.073893212,18,1.405,63.24,0.0961306210487483,0.208,0.152065310524374,0,1
"C11-Acetate","","ABAT, ACE, AKR1C3, CA2, CELA1, ESR2, FFAR2, FFAR3, HPRT1, LTA4H, MMP12, NOS1, NOS3, PLA2G1B, PTPN1, SOD1, TXN","[Y+3]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","[Y+3]",88.9042025602722,1,0,0,0.198024597233723,0.106,0.152012298616862,1,0
"sodium-tanshinone-II-A-sulfonate","potassium channel activator","","Cc1c2c(oc1S(O)(=O)=O)-c1ccc3c(CCCC3(C)C)c1C(=O)C2=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1c2c(oc1S(O)(=O)=O)-c1ccc3c(CCCC3(C)C)c1C(=O)C2=O",374.082409296,26,3.048,110.03,0.013934292432837,0.29,0.151967146216418,0,1
"sameridine","opioid receptor modulator","","CCCCCCN1CCC(CC1)(C(=O)N(C)CC)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCN1CCC(CC1)(C(=O)N(C)CC)c1ccccc1",330.267113708,24,4.729,23.55,0.221767355748998,0.082,0.151883677874499,1,0
"9-aminoacridine","","","Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1c2ccccc2nc2ccccc12",194.08439832,15,2.663,38.91,0.281680763416404,0.022,0.151840381708202,1,0
"RU-24969","serotonin receptor agonist","HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR6","COc1ccc2[nH]cc(C3=CCNCC3)c2c1 |t:9|, COc1ccc2[nH]cc(C3=CCNCC3)c2c1 |t:9|, COc1ccc2[nH]cc(C3=CCNCC3)c2c1 |t:9|, COc1ccc2[nH]cc(C3=CCNCC3)c2c1 |t:9|",0,0,0,0,0,0,0,0,1,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1ccc2[nH]cc(C3=CCNCC3)c2c1 |t:9|",228.126263132,17,1.923,37.05,0.19347166669173,0.11,0.151735833345865,1,0
"QX-314","sodium channel blocker","MAPK14, TGFBR1","CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C, CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C, CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C, CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C",263.211789904091,19,2.331,29.1,0.179280445660332,0.124,0.151640222830166,1,0
"tasquinimod","angiogenesis inhibitor, S100A9 inhibitor","HDAC4","COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12, COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12, COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12, COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12",406.114041684,29,4.849,71.77,0.0471943563745101,0.256,0.151597178187255,0,1
"benzoxiquine","antiinfective drug","","O=C(Oc1cccc2cccnc12)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(Oc1cccc2cccnc12)c1ccccc1",249.078978592,19,3.627,39.19,0.249869804423213,0.052,0.150934902211607,1,0
"tropanyl-3,5-dimethylbenzoate","serotonin receptor antagonist","HTR3A, HTR3B","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1cc(C)cc(C)c1 |&1:2,&2:5,&3:7,r,TLB:0:1:3.4:6.7.8|",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1cc(C)cc(C)c1 |&1:2",273.172878976,20,3.808,29.54,0.235621678256143,0.066,0.150810839128072,1,0
"rutaecarpine","cyclooxygenase inhibitor","PTGS2","O=c1n2CCc3c([nH]c4ccccc34)-c2nc2ccccc12, O=c1n2CCc3c([nH]c4ccccc34)-c2nc2ccccc12, O=c1n2CCc3c([nH]c4ccccc34)-c2nc2ccccc12",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=c1n2CCc3c([nH]c4ccccc34)-c2nc2ccccc12",287.105862036,22,3.885,50.68,0.179419238254879,0.122,0.150709619127439,1,0
"eltoprazine","serotonin receptor agonist","HTR1A, HTR1B","C1CN(CCN1)c1cccc2OCCOc12, C1CN(CCN1)c1cccc2OCCOc12, C1CN(CCN1)c1cccc2OCCOc12, C1CN(CCN1)c1cccc2OCCOc12",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C1CN(CCN1)c1cccc2OCCOc12",220.121177752,16,1.107,33.73,0.169404409575338,0.132,0.150702204787669,1,1
"denatonium-benzoate","","","CC[N+](CC)(CC(=O)Nc1c(C)cccc1C)Cc1ccccc1, CC[N+](CC)(CC(=O)Nc1c(C)cccc1C)Cc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC[N+](CC)(CC(=O)Nc1c(C)cccc1C)Cc1ccccc1",325.227439968091,24,3.618,29.1,0.177102630258321,0.124,0.150551315129161,1,0
"alagebrium","glycosylation inhibitor","","Cc1sc[n+](CC(=O)c2ccccc2)c1C, Cc1sc[n+](CC(=O)c2ccccc2)c1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","Cc1sc[n+](CC(=O)c2ccccc2)c1C",232.079061488091,16,2.976,49.19,0.144835692836367,0.156,0.150417846418183,1,1
"methylphenidate hydrochloride","","","COC(=O)C(C1CCCCN1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","COC(=O)C(C1CCCCN1)c1ccccc1",233.141578848,17,2.505,38.33,0.192409565548047,0.108,0.150204782774023,1,0
"HLCL-61","protein arginine N-methyltransferase inhibitor","PRMT5","CCn1c2ccccc2c2cc(CNCc3ccccc3OC)ccc12, CCn1c2ccccc2c2cc(CNCc3ccccc3OC)ccc12, CCn1c2ccccc2c2cc(CNCc3ccccc3OC)ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCn1c2ccccc2c2cc(CNCc3ccccc3OC)ccc12",344.188863388,26,5.395,26.19,0.26401435431212,0.036,0.15000717715606,1,0
"deoxyarbutin","tyrosinase inhibitor","","Oc1ccc(O[C@H]2CCCCO2)cc1 |&1:6,r|, Oc1ccc(O[C@H]2CCCCO2)cc1 |&1:6,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(O[C@H]2CCCCO2)cc1 |&1:6",194.094294308,14,2.379,38.69,0.225938617043455,0.074,0.149969308521728,1,0
"menadiol sodium sulfate","vitamin k","F10, F2, F7, F9, GGCX, PROC, PROS1","Oc2c1ccccc1c(O)c(c2)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","hematology","hemorrhage","Oc2c1ccccc1c(O)c(c2)C",174.06807956,13,2.702,40.46,0.279931751990425,0.02,0.149965875995213,1,0
"NU-1025","PARP inhibitor","PARP1","Cc1nc(=O)c2cccc(O)c2[nH]1, Cc1nc(=O)c2cccc(O)c2[nH]1, Cc1nc(=O)c2cccc(O)c2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1nc(=O)c2cccc(O)c2[nH]1",176.058577496,13,2.68,65.98,0.169465557136507,0.13,0.149732778568253,1,1
"etidocaine","sodium channel blocker","A1BG","CCCN(CC)C(CC)C(=O)Nc1c(C)cccc1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","neurology/psychiatry","anesthetic","CCCN(CC)C(CC)C(=O)Nc1c(C)cccc1C",276.220163516,20,3.341,32.34,0.193228264203345,0.106,0.149614132101672,1,0
"1,4-butanediol","benzodiazepine receptor agonist, gamma hydroxybutyric acid agonist","MAN1B1, PLA2G2A, PLA2G2E","OCCCCO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OCCCCO",90.06807956,6,-0.492,40.46,0.208668132294964,0.09,0.149334066147482,1,0
"phenothiazine","dopamine receptor antagonist","","N1c2ccccc2Sc2ccccc12, N1c2ccccc2Sc2ccccc12, N1c2ccccc2Sc2ccccc12, N1c2ccccc2Sc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N1c2ccccc2Sc2ccccc12",199.045570288,14,3.786,37.33,0.274264298851229,0.024,0.149132149425615,1,0
"SP-141","ubiquitin ligase inhibitor","MDM2","COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12, COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12, COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12, COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12, COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12",324.126263132,25,5.489,37.91,0.264133101341404,0.034,0.149066550670702,1,0
"idronoxil","XIAP inhibitor","ENOX2, SPHK1","Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1 |t:8|, Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1 |t:8|, Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1 |t:8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1 |t:8|",240.078644244,18,2.98,49.69,0.179949770800641,0.118,0.14897488540032,1,0
"NS-9283","acetylcholine receptor allosteric modulator","CHRNA4","N#Cc1cccc(c1)-c1nc(no1)-c1cccnc1, N#Cc1cccc(c1)-c1nc(no1)-c1cccnc1, N#Cc1cccc(c1)-c1nc(no1)-c1cccnc1, N#Cc1cccc(c1)-c1nc(no1)-c1cccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"preclinical","","","N#Cc1cccc(c1)-c1nc(no1)-c1cccnc1",248.069810876,19,2.575,75.6,0.101804292720534,0.196,0.148902146360267,0,1
"QX-222","sodium channel blocker","","Cc1cccc(C)c1NC(=O)C[N+](C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cccc(C)c1NC(=O)C[N+](C)(C)C",221.164839712091,16,1.062,29.1,0.179681018676151,0.118,0.148840509338076,1,0
"AS-77","potassium channel blocker","KCNA3, KCNA5, KCNN4","O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1, O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1, O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1",350.115423676,26,5.051,61.81,0.111344914440541,0.186,0.14867245722027,0,1
"ST-1859","antiamyloidogenic agent","","Oc1ccc2ccccc2c1Cc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1Cc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1Cc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1Cc1c(O)ccc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Oc1ccc2ccccc2c1Cc1c(O)ccc2ccccc12",300.115029752,23,5.497,40.46,0.275174581532176,0.022,0.148587290766088,1,0
"naxagolide","dopamine receptor agonist","","CCCN1CCO[C@H]2[C@H]1CCc1ccc(O)cc21",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCCN1CCO[C@H]2[C@H]1CCc1ccc(O)cc21",247.157228912,18,2.092,32.7,0.180954436475645,0.116,0.148477218237823,1,0
"AMN-082","glutamate receptor modulator","GRM7","C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1, C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1, C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1, C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1",392.225248896,30,6.008,24.06,0.25879606291458,0.038,0.14839803145729,1,0
"10-DEBC","AKT inhibitor","PIM1","CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12, CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12, CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12, CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12",344.1655411,24,5.413,15.71,0.224755770380919,0.072,0.14837788519046,1,0
"MS-424","glutamate transporter modulator","","C[C@@H]1C=CNN1C(=O)c1cccnc1 |c:2|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@@H]1C=CNN1C(=O)c1cccnc1 |c:2|",189.090211972,14,1.028,45.23,0.168713873230197,0.128,0.148356936615098,1,0
"PNU-74654","beta-catenin inhibitor","CTNNB1, TCF4","Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1, Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1, Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1, Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1, Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1, Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1",320.116092372,24,4.411,63.83,0.116654183020364,0.18,0.148327091510182,1,1
"SB-366791","TRPV antagonist","TRPV1","COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1",287.071306368,20,3.802,38.33,0.152593972807012,0.144,0.148296986403506,1,1
"acrylate","mucus protecting agent","","[Na].OC(=O)C=C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","[Na].OC(=O)C=C",95.010898648,6,0.212,37.3,0.230551542075386,0.066,0.148275771037693,1,0
"darglitazone","PPAR receptor antagonist","PPARG","Cc1oc(nc1CCC(=O)c1ccc(CC2SC(=O)NC2=O)cc1)-c1ccccc1, Cc1oc(nc1CCC(=O)c1ccc(CC2SC(=O)NC2=O)cc1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1oc(nc1CCC(=O)c1ccc(CC2SC(=O)NC2=O)cc1)-c1ccccc1",420.11437812,30,2.949,114.57,0.0102744886594069,0.286,0.148137244329703,0,1
"costunolide","telomerase inhibitor","","C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1",232.14632988,17,3.308,26.3,0.281960600799412,0.014,0.147980300399706,1,0
"radafaxine","dopamine-norepinephrine reuptake inhibitor","SLC6A3","C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(Cl)c1, C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(Cl)c1",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(Cl)c1",255.102606496,17,2.74,41.49,0.121838836790215,0.174,0.147919418395107,1,1
"benzoin","","CES1","O[C@@H](C(=O)c1ccccc1)c1ccccc1 |&1:1,r|, O[C@@H](C(=O)c1ccccc1)c1ccccc1 |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O[C@@H](C(=O)c1ccccc1)c1ccccc1 |&1:1",212.083729624,16,2.437,37.3,0.239726700412086,0.056,0.147863350206043,1,0
"rimonabant","cannabinoid receptor antagonist","CNR1, GPR55","Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1",462.078094332,30,6.131,50.16,0.0356628591557892,0.26,0.147831429577895,0,1
"amyl-nitrite","atrial natriuretic peptide receptor agonist","","CCCCCO[NH2+][O-]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCO[NH2+][O-]",119.094628656,8,1.47,48.9,0.21746841777494,0.078,0.14773420888747,1,0
"RS-45041-190","imidazoline receptor agonist","","Clc1cccc2CN(Cc12)C1=NCCN1 |t:12|, Clc1cccc2CN(Cc12)C1=NCCN1 |t:12|, Clc1cccc2CN(Cc12)C1=NCCN1 |t:12|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1cccc2CN(Cc12)C1=NCCN1 |t:12|",221.071975064,15,2.575,27.63,0.207263418909934,0.088,0.147631709454967,1,0
"amyleine","local anesthetic","","CC[C@@](C)(CN(C)C)OC(=O)c1ccccc1 |&1:2|, CC[C@@](C)(CN(C)C)OC(=O)c1ccccc1 |&1:2|, CC[C@@](C)(CN(C)C)OC(=O)c1ccccc1 |&1:2|, CC[C@@](C)(CN(C)C)OC(=O)c1ccccc1 |&1:2|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC[C@@](C)(CN(C)C)OC(=O)c1ccccc1 |&1:2|",235.157228912,17,3.046,29.54,0.24119625237613,0.054,0.147598126188065,1,0
"arecaidine-propargyl-ester","acetylcholine receptor agonist","CHRM1, CHRM2, CHRM3, CHRM4","CN1CCC=C(C1)C(=O)OCC#C |c:4|, CN1CCC=C(C1)C(=O)OCC#C |c:4|, CN1CCC=C(C1)C(=O)OCC#C |c:4|, CN1CCC=C(C1)C(=O)OCC#C |c:4|, CN1CCC=C(C1)C(=O)OCC#C |c:4|, CN1CCC=C(C1)C(=O)OCC#C |c:4|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,"preclinical","","","CN1CCC=C(C1)C(=O)OCC#C |c:4|",179.094628656,13,0.44,29.54,0.203150482928519,0.092,0.14757524146426,1,0
"xanomeline","acetylcholine receptor agonist","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7","CCCCCCOc1nsnc1C1=CCCN(C)C1 |t:13|, CCCCCCOc1nsnc1C1=CCCN(C)C1 |t:13|, CCCCCCOc1nsnc1C1=CCCN(C)C1 |t:13|",0,0,0,0,0,0,0,0,1,10,0,0,0,0,0,0,1,5,0,0,0,0,0,0,"phase 3","","","CCCCCCOc1nsnc1C1=CCCN(C)C1 |t:13|",281.156183356,19,3.341,66.49,0.0711384306009995,0.224,0.1475692153005,0,1
"alpha-methylhistamine-dihydrobromide-(R)-(-)","histamine receptor agonist","HRH3","C[C@@H](N)Cc1cnc[nH]1, C[C@@H](N)Cc1cnc[nH]1",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](N)Cc1cnc[nH]1",125.095297352,9,-0.288,54.7,0.146886788175743,0.148,0.147443394087871,1,1
"alpha-methylhistamine-dihydrobromide-(S)-(+)","histamine receptor agonist","HRH3","C[C@H](N)Cc1cnc[nH]1, C[C@H](N)Cc1cnc[nH]1",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H](N)Cc1cnc[nH]1",125.095297352,9,-0.288,54.7,0.146886788175743,0.148,0.147443394087871,1,1
"sulforaphane","anticancer agent, aryl hydrocarbon receptor antagonist","NFE2L2","C[S@@](=O)CCCCN=C=S |r|, C[S@@](=O)CCCCN=C=S |r|, C[S@@](=O)CCCCN=C=S |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[S@@](=O)CCCCN=C=S |r|",177.028205972,10,1.175,80.73,0.0467494506174268,0.248,0.147374725308713,0,1
"navarixin","CC chemokine receptor antagonist","CXCR1, CXCR2","CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1, CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1, CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1",397.163770836,29,3.392,111.88,0.0166522085795901,0.278,0.147326104289795,0,1
"palovarotene","retinoid receptor agonist","RARG","CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12, CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12, CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12, CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12, CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12",414.2307282,31,7.85,55.12,0.165736697722773,0.128,0.146868348861387,1,0
"SC-560","cyclooxygenase inhibitor","PTGS1","COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F, COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F, COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F, COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F",352.059025344,24,5.533,27.05,0.159714207217873,0.134,0.146857103608936,1,1
"xenalipin","","","OC(=O)c1ccccc1-c1ccc(cc1)C(F)(F)F, OC(=O)c1ccccc1-c1ccc(cc1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)c1ccccc1-c1ccc(cc1)C(F)(F)F",266.055464188,19,4.502,37.3,0.223262313579298,0.07,0.146631156789649,1,0
"chlorpropham","antiviral","","CC(C)OC(=O)Nc1cccc(Cl)c1, CC(C)OC(=O)Nc1cccc(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)OC(=O)Nc1cccc(Cl)c1",213.055656304,14,2.952,38.33,0.177139569696853,0.116,0.146569784848426,1,0
"RBC8","Ral GTPase inhibitor","RALA, RALB","COc1ccc(OC)c(c1)[C@@H]1C(C#N)C(=N)Oc2[nH]nc(c12)-c1ccc2ccccc2c1 |&1:10,r|, COc1ccc(OC)c(c1)[C@@H]1C(C#N)C(=N)Oc2[nH]nc(c12)-c1ccc2ccccc2c1 |&1:10,r|, COc1ccc(OC)c(c1)[C@@H]1C(C#N)C(=N)Oc2[nH]nc(c12)-c1ccc2ccccc2c1 |&1:10,r|, COc1ccc(OC)c(c1)[C@@H]1C(C#N)C(=N)Oc2[nH]nc(c12)-c1ccc2ccccc2c1 |&1:10,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(OC)c(c1)[C@@H]1C(C#N)C(=N)Oc2[nH]nc(c12)-c1ccc2ccccc2c1 |&1:10",424.1535405,32,5.064,104.01,0.0310741919921265,0.262,0.146537095996063,0,1
"A-769662","AMPK activator","","Oc1ccccc1-c1ccc(cc1)-c1csc2[nH]c(=O)c(C#N)c(O)c12, Oc1ccccc1-c1ccc(cc1)-c1csc2[nH]c(=O)c(C#N)c(O)c12, Oc1ccccc1-c1ccc(cc1)-c1csc2[nH]c(=O)c(C#N)c(O)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccccc1-c1ccc(cc1)-c1csc2[nH]c(=O)c(C#N)c(O)c12",360.056863244,26,4.389,125.35,0.0188868941119911,0.274,0.146443447055996,0,1
"brofaromine","monoamine oxidase inhibitor","MAOA","COc1cc(Br)c2oc(cc2c1)C3CCNCC3",0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"phase 1","neurology/psychiatry","depression","COc1cc(Br)c2oc(cc2c1)C3CCNCC3",309.036440852,18,2.834,34.4,0.0548455267201386,0.238,0.146422763360069,0,1
"TCN238","glutamate receptor positive allosteric modulator","GRM4","Nc1nccc(\C=C\c2ccccc2)n1, Nc1nccc(\C=C\c2ccccc2)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1nccc(\C=C\c2ccccc2)n1",197.095297352,15,1.941,51.8,0.184812977787058,0.108,0.146406488893529,1,0
"filanesib","kinesin inhibitor, kinesin-like spindle protein inhibitor","KIF11","CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|",420.143153384,29,3.688,96.46,0.0148065611194335,0.278,0.146403280559717,0,1
"KU14R","imidazoline receptor antagonist","","CC[C@]1(Cc2ccccc2O1)c1ncc[nH]1 |&1:2,r|, CC[C@]1(Cc2ccccc2O1)c1ncc[nH]1 |&1:2,r|, CC[C@]1(Cc2ccccc2O1)c1ncc[nH]1 |&1:2,r|, CC[C@]1(Cc2ccccc2O1)c1ncc[nH]1 |&1:2,r|, CC[C@]1(Cc2ccccc2O1)c1ncc[nH]1 |&1:2,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC[C@]1(Cc2ccccc2O1)c1ncc[nH]1 |&1:2",214.110613068,16,2.014,37.91,0.210726918165009,0.082,0.146363459082504,1,0
"BHQ","ATPase inhibitor","ATP2A1","CC(C)(C)c1cc(O)c(cc1O)C(C)(C)C, CC(C)(C)c1cc(O)c(cc1O)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)c1cc(O)c(cc1O)C(C)(C)C",222.161979944,16,4.422,40.46,0.272600401229978,0.02,0.146300200614989,1,0
"centazolone","monoamine oxidase inhibitor","","Nn1cnc2cc3ccccc3cc2c1=O, Nn1cnc2cc3ccccc3cc2c1=O, Nn1cnc2cc3ccccc3cc2c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Nn1cnc2cc3ccccc3cc2c1=O",211.074561908,16,2.269,60.91,0.152050130612634,0.14,0.146025065306317,1,1
"sophocarpine","","","O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34 |c:2|, O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34 |c:2|, O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34 |c:2|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34 |c:2|",246.173213324,18,1.27,23.55,0.186049462610844,0.106,0.146024731305422,1,0
"hexylene-glycol","","AKR1C3, CTPS1, DLG4, HSP90AA1, NOS3, PGF, PLA2G1B, PTPN1, SELP","C[C@@H](O)CC(C)(C)O |&1:1,r|, C[C@@H](O)CC(C)(C)O |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](O)CC(C)(C)O |&1:1",118.099379688,8,0.487,40.46,0.213801807552157,0.078,0.145900903776078,1,0
"PD-168568","dopamine receptor antagonist","DRD2, DRD4","Cc1ccc(cc1C)N1CCN(CC[C@H]2NC(=O)c3ccccc23)CC1 |&1:14|, Cc1ccc(cc1C)N1CCN(CC[C@H]2NC(=O)c3ccccc23)CC1 |&1:14|, Cc1ccc(cc1C)N1CCN(CC[C@H]2NC(=O)c3ccccc23)CC1 |&1:14|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(cc1C)N1CCN(CC[C@H]2NC(=O)c3ccccc23)CC1 |&1:14|",349.215412484,26,4.234,35.58,0.161394893898467,0.13,0.145697446949234,1,1
"A-33903","","","CC(=O)N[C@@H]1N=C(c2ccccc2)c2ccccc2NC1=O |&1:4,r,t:5|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(=O)N[C@@H]1N=C(c2ccccc2)c2ccccc2NC1=O |&1:4",293.11642672,22,2.431,70.56,0.0771611133910416,0.214,0.145580556695521,0,1
"SEP-227900","D-amino acid oxidase Inhibitor","DAO","OC(=O)c1cc2occc2[nH]1, OC(=O)c1cc2occc2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC(=O)c1cc2occc2[nH]1",151.02694302,11,0.828,66.23,0.128766826843475,0.162,0.145383413421737,1,1
"Y16","rho associated kinase inhibitor","RHOA","Cc1cccc(COc2cccc(\C=C3/C(=O)NN(C3=O)c3ccccc3)c2)c1, Cc1cccc(COc2cccc(\C=C3/C(=O)NN(C3=O)c3ccccc3)c2)c1, Cc1cccc(COc2cccc(\C=C3/C(=O)NN(C3=O)c3ccccc3)c2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cccc(COc2cccc(\C=C3/C(=O)NN(C3=O)c3ccccc3)c2)c1",384.1473925,29,5.141,58.64,0.108719561418957,0.182,0.145359780709479,0,1
"nefazodone","adrenergic inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotonin reuptake inhibitor","ADRA1A, ADRA1B, ADRA2A, CYP3A4, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A3, SLC6A4","CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1, CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1, CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1, CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1",1,3,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,1,3,0,0,0,0,"withdrawn","","","CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1",469.224452944,33,4.849,55.53,0.0385735740453091,0.252,0.145286787022655,0,1
"CIM-0216","transient receptor potential channel agonist","TRPM3","Cc1cc(NC(=O)[C@@H](N2CCCc3ccccc23)c2ccccc2)no1 |&1:7,r|, Cc1cc(NC(=O)[C@@H](N2CCCc3ccccc23)c2ccccc2)no1 |&1:7,r|, Cc1cc(NC(=O)[C@@H](N2CCCc3ccccc23)c2ccccc2)no1 |&1:7,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(NC(=O)[C@@H](N2CCCc3ccccc23)c2ccccc2)no1 |&1:7",347.163376912,26,4.151,58.37,0.104563003539227,0.186,0.145281501769614,0,1
"SKF-91488","histamine N-methyltransferase inhibitor","HNMT","CN(C)CCCCSC(N)=N, CN(C)CCCCSC(N)=N, CN(C)CCCCSC(N)=N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)CCCCSC(N)=N",175.114318544,11,0.935,78.41,0.0604286704829774,0.23,0.145214335241489,0,1
"4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine","serotonin receptor antagonist","HTR2A","Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1",339.199842672,25,4.914,20.31,0.246374886415367,0.044,0.145187443207684,1,0
"REV-5901","leukotriene receptor antagonist, lipoxygenase inhibitor","ALOX5","CCCCC[C@@H](O)c1cccc(OCc2ccc3ccccc3n2)c1 |&1:5,r|, CCCCC[C@@H](O)c1cccc(OCc2ccc3ccccc3n2)c1 |&1:5,r|, CCCCC[C@@H](O)c1cccc(OCc2ccc3ccccc3n2)c1 |&1:5,r|, CCCCC[C@@H](O)c1cccc(OCc2ccc3ccccc3n2)c1 |&1:5,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCCC[C@@H](O)c1cccc(OCc2ccc3ccccc3n2)c1 |&1:5",335.18852904,25,5.619,42.35,0.204217736734324,0.086,0.145108868367162,1,0
"S15535","serotonin receptor agonist","","C1C(Cc2ccccc12)N1CCN(CC1)c1cccc2OCCOc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C1C(Cc2ccccc12)N1CCN(CC1)c1cccc2OCCOc12",336.183778008,25,3.097,24.94,0.168122607042067,0.122,0.145061303521034,1,0
"guvacine","GABA uptake inhibitor","SLC6A1, SLC6A11, SLC6A12, SLC6A13","OC(=O)C1=CCCNC1 |t:3|, OC(=O)C1=CCCNC1 |t:3|, OC(=O)C1=CCCNC1 |t:3|, OC(=O)C1=CCCNC1 |t:3|",1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)C1=CCCNC1 |t:3|",127.063328528,9,0.041,49.33,0.167829815997581,0.122,0.14491490799879,1,0
"VU0364770","glutamate receptor positive allosteric modulator","GRM4","Clc1cccc(NC(=O)c2ccccn2)c1, Clc1cccc(NC(=O)c2ccccn2)c1, Clc1cccc(NC(=O)c2ccccn2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1cccc(NC(=O)c2ccccn2)c1",232.040340588,16,2.452,41.99,0.149771689994579,0.14,0.144885844997289,1,1
"BQU57","Ras GTPase inhibitor","RALA, RALB","Cc1nn(C)c2OC(=N)C(C#N)[C@@H](c12)c1ccc(cc1)C(F)(F)F |&1:12,r|, Cc1nn(C)c2OC(=N)C(C#N)[C@@H](c12)c1ccc(cc1)C(F)(F)F |&1:12,r|, Cc1nn(C)c2OC(=N)C(C#N)[C@@H](c12)c1ccc(cc1)C(F)(F)F |&1:12,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1nn(C)c2OC(=N)C(C#N)[C@@H](c12)c1ccc(cc1)C(F)(F)F |&1:12",334.104145696,24,3.021,74.69,0.0496558683319163,0.24,0.144827934165958,0,1
"CS-110266","dopamine receptor agonist","SLC6A3","C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1",299.1707708,21,4.618,31.48,0.19555994768625,0.094,0.144779973843125,1,0
"pterostilbene","cyclooxygenase inhibitor, PPAR receptor agonist, cyclooxygenase inhibitor, ppar receptor agonist","PTGS2","COc1cc(OC)cc(C=Cc2ccc(O)cc2)c1, COc1cc(OC)cc(\C=C\c2ccc(O)cc2)c1",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","COc1cc(OC)cc(C=Cc2ccc(O)cc2)c1",256.109944372,19,4.08,38.69,0.24145821739291,0.048,0.144729108696455,1,0
"AS-252424","PI3K inhibitor","PIK3CG","Oc1cc(F)ccc1-c1ccc(\C=C2/SC(=O)NC2=O)o1, Oc1cc(F)ccc1-c1ccc(\C=C2/SC(=O)NC2=O)o1, Oc1cc(F)ccc1-c1ccc(\C=C2/SC(=O)NC2=O)o1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1cc(F)ccc1-c1ccc(\C=C2/SC(=O)NC2=O)o1",305.015806956,21,1.879,104.84,0.0193287721697874,0.27,0.144664386084894,0,1
"Ro-5263397","trace amine associated receptor agonist","","Cc1c(F)cccc1[C@H]1COC(N)=N1 |c:13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1c(F)cccc1[C@H]1COC(N)=N1 |c:13|",194.085541192,14,1.64,47.61,0.165307673432265,0.124,0.144653836716132,1,0
"GYKI-52466","glutamate receptor antagonist","GRIA1, GRIA2, GRIA3, GRIA4","CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1 |t:1,3|, CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1 |t:1,3|, CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1 |t:1,3|, CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1 |t:1,3|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1 |t:1",293.11642672,22,3.24,69.2,0.0952137445581127,0.194,0.144606872279056,0,1
"kevetrin","p53 activator","","NC(=N)SCCCC#N, NC(=N)SCCCC#N, NC(=N)SCCCC#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","NC(=N)SCCCC#N",143.051718288,9,0.375,98.96,0.0451308106938128,0.244,0.144565405346906,0,1
"TC-S-7003","SRC inhibitor","LCK","CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n2c(nc4ccccc24)n(-c2c(C)cccc2C)c3=O)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n2c(nc4ccccc24)n(-c2c(C)cccc2C)c3=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n2c(nc4ccccc24)n(-c2c(C)cccc2C)c3=O)cc1",530.25425758,40,5.963,83.59,0.0310920832659175,0.258,0.144546041632959,0,1
"CP-94253","serotonin receptor agonist","HTR1B","CCCOc1ccc2[nH]cc(C3=CCNCC3)c2n1 |t:11|, CCCOc1ccc2[nH]cc(C3=CCNCC3)c2n1 |t:11|",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCOc1ccc2[nH]cc(C3=CCNCC3)c2n1 |t:11|",257.152812228,19,2.269,49.94,0.13299866301837,0.156,0.144499331509185,1,1
"ZAMI-633","urease inhibitor","","CCC(=O)NO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCC(=O)NO",89.047678464,6,-0.475,49.33,0.180933294176319,0.108,0.14446664708816,1,0
"casin","GTPase inhibitor","CDC42","OCCN[C@H]1CCCc2c1[nH]c1ccc(cc21)-c1ccccc1 |&1:4,r|, OCCN[C@H]1CCCc2c1[nH]c1ccc(cc21)-c1ccccc1 |&1:4,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OCCN[C@H]1CCCc2c1[nH]c1ccc(cc21)-c1ccccc1 |&1:4",306.173213324,23,3.824,48.05,0.154499271308106,0.134,0.144249635654053,1,1
"zimelidine","selective serotonin reuptake inhibitor (SSRI)","MAOA, MAOB, SLC6A4","CN(C)C\C=C(\c1ccc(Br)cc1)c1cccnc1, CN(C)C\C=C(\c1ccc(Br)cc1)c1cccnc1",1,1,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CN(C)C\C=C(\c1ccc(Br)cc1)c1cccnc1",316.057510644,19,3.779,16.13,0.106320598827804,0.182,0.144160299413902,0,1
"hydroxyfasudil","rho associated kinase inhibitor","PKIA, PRKACA, ROCK1","O=c1[nH]ccc2c(cccc12)S(=O)(=O)N1CCCNCC1, O=c1[nH]ccc2c(cccc12)S(=O)(=O)N1CCCNCC1, O=c1[nH]ccc2c(cccc12)S(=O)(=O)N1CCCNCC1, O=c1[nH]ccc2c(cccc12)S(=O)(=O)N1CCCNCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=c1[nH]ccc2c(cccc12)S(=O)(=O)N1CCCNCC1",307.099062404,21,0.932,90.65,0.0202370498452131,0.268,0.144118524922607,0,1
"afimoxifene","estrogen receptor antagonist","ESR1, ESR2, ESRRG, PLD1, PRKCD, PRKCE, PRKCQ, PRKCZ","CC\C(=C(/c1ccc(O)cc1)c1ccc(OCCN(C)C)cc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC\C(=C(/c1ccc(O)cc1)c1ccc(OCCN(C)C)cc1)c1ccccc1",387.219829168,29,6.732,32.7,0.234029719035747,0.054,0.144014859517874,1,0
"STF-118804","NAMPT inhibitor","NAMPT","Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1",461.140927216,33,3.631,110.54,0.00998481058952204,0.278,0.143992405294761,0,1
"1-acetyl-4-methylpiperazine","acetylcholine receptor agonist","","CN1CCN(CC1)C(C)=O, CN1CCN(CC1)C(C)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCN(CC1)C(C)=O",142.110613068,10,-0.505,23.55,0.21982131713335,0.068,0.143910658566675,1,0
"GSK356278","phosphodiesterase inhibitor","","CCn1ncc2c(NC3CCOCC3)c(cnc12)-c1nnc(Cc2sc(C)nc2C)o1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCn1ncc2c(NC3CCOCC3)c(cnc12)-c1nnc(Cc2sc(C)nc2C)o1",439.17904404,31,3.092,132.02,0.00569405172190363,0.282,0.143847025860952,0,1
"TCS-2002","glycogen synthase kinase inhibitor","GSK3B","Cc1nnc(o1)-c1ccc2occ(-c3ccc(cc3)[S@](C)=O)c2c1 |&1:19,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1nnc(o1)-c1ccc2occ(-c3ccc(cc3)[S@](C)=O)c2c1 |&1:19",338.072513308,24,3.742,88.34,0.0396894596939236,0.248,0.143844729846962,0,1
"JHW-007","dopamine reuptake inhibitor","SLC6A3","CCCCN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccc(F)cc1)c1ccc(F)cc1, CCCCN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccc(F)cc1)c1ccc(F)cc1",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccc(F)cc1)c1ccc(F)cc1",385.221720988,28,5.953,12.47,0.251530023886713,0.036,0.143765011943356,1,0
"NVP-AUY922","HSP inhibitor","HSP90AA1, HSP90AB1","CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O",465.226371092,34,4.034,108.06,0.0132876765052216,0.274,0.143643838252611,0,1
"1-(2-chloro-5-methylphenoxy)-3-(isopropylamino)-2-propanol","","","CC(C)NC[C@@H](O)COc1cc(C)ccc1Cl |&1:5,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)NC[C@@H](O)COc1cc(C)ccc1Cl |&1:5",257.11825656,17,2.821,41.49,0.118840605086344,0.168,0.143420302543172,1,1
"oxypurinol","xanthine oxidase inhibitor","XDH","O=c1nc2[nH][nH]cc2c(=O)[nH]1, O=c1nc2[nH][nH]cc2c(=O)[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","O=c1nc2[nH][nH]cc2c(=O)[nH]1",152.033425368,11,0.501,94.4,0.0648122664602252,0.222,0.143406133230113,0,1
"NSC-625987","CDK inhibitor","CDK2, CDK4","COc1ccc(OC)c2c1[nH]c1ccccc1c2=S",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(OC)c2c1[nH]c1ccccc1c2=S",271.066699656,19,4.159,66.34,0.106790730200998,0.18,0.143395365100499,0,1
"UF-010","HDAC inhibitor","HDAC1, HDAC2, HDAC3, HDAC8","CCCCNNC(=O)c1ccc(Br)cc1, CCCCNNC(=O)c1ccc(Br)cc1, CCCCNNC(=O)c1ccc(Br)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCNNC(=O)c1ccc(Br)cc1",270.0367752,15,3.951,41.13,0.0767263397068344,0.21,0.143363169853417,0,1
"ESI-09","EPAC inhibitor","RAPGEF3, RAPGEF4","CC(C)(C)c1cc(no1)C(=O)C(=N\Nc1cccc(Cl)c1)\C#N, CC(C)(C)c1cc(no1)C(=O)C(=N\Nc1cccc(Cl)c1)\C#N, CC(C)(C)c1cc(no1)C(=O)C(=N\Nc1cccc(Cl)c1)\C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)c1cc(no1)C(=O)C(=N\Nc1cccc(Cl)c1)\C#N",330.0883534,23,4.27,91.28,0.0405296940958721,0.246,0.143264847047936,0,1
"tolimidone","SRC activator","LYN, SRC","Cc1cccc(Oc2cnc(=O)[nH]c2)c1, Cc1cccc(Oc2cnc(=O)[nH]c2)c1, Cc1cccc(Oc2cnc(=O)[nH]c2)c1, Cc1cccc(Oc2cnc(=O)[nH]c2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1cccc(Oc2cnc(=O)[nH]c2)c1",202.07422756,15,2.264,54.98,0.168316339255371,0.118,0.143158169627686,1,0
"SKF-81297","dopamine receptor agonist","DRD1, DRD5","Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1, Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1, Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1, Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1, Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"preclinical","","","Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1",289.086956432,20,2.999,52.49,0.0921343368039716,0.194,0.143067168401986,0,1
"CINPA-1","CAR antagonist","NR1H4, NR1I3, PPARG","CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(CC)CC)c2c1, CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(CC)CC)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(CC)CC)c2c1",395.220891788,29,3.105,61.88,0.050057906807905,0.236,0.143028953403952,0,1
"DMeOB","glutamate receptor modulator","GRM5","COc1cccc(\C=N\N=C\c2cccc(OC)c2)c1, COc1cccc(\C=N\N=C\c2cccc(OC)c2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cccc(\C=N\N=C\c2cccc(OC)c2)c1",268.121177752,20,4.566,43.18,0.233917886543921,0.052,0.14295894327196,1,0
"ODQ","guanylyl cyclase inhibitor","GUCY1A2, GUCY1A3, GUCY1B3","O=c1onc2cnc3ccccc3n12, O=c1onc2cnc3ccccc3n12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=c1onc2cnc3ccccc3n12",187.0381764,14,1.623,60.4,0.147866716889157,0.138,0.142933358444578,1,1
"AMG-9810","TRPV antagonist","TRPV1","CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1, CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1, CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1, CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1, CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1",337.167793596,25,4.434,47.56,0.13956123004177,0.146,0.142780615020885,1,1
"oxotremorine-M","acetylcholine receptor agonist","CHRM1, CHRM2, CHRM3, CHRM4","C[N+](C)(C)CC#CCN1CCCC1=O, C[N+](C)(C)CC#CCN1CCCC1=O, C[N+](C)(C)CC#CCN1CCCC1=O, C[N+](C)(C)CC#CCN1CCCC1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,"preclinical","","","C[N+](C)(C)CC#CCN1CCCC1=O",195.149189648091,14,-0.18,20.31,0.188734262961825,0.096,0.142367131480912,1,0
"etifoxine (hydrochloride)","","","CCNC1=Nc2ccc(Cl)cc2C(C)(O1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CCNC1=Nc2ccc(Cl)cc2C(C)(O1)c1ccccc1",300.102940844,21,4.623,33.62,0.184680487375251,0.1,0.142340243687625,1,0
"CGP-13501","GABA receptor modulator","GABBR1","CC(C)(C)c1cc(CC(C)(C)C=O)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(CC(C)(C)C=O)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(CC(C)(C)C=O)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(CC(C)(C)C=O)cc(c1O)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)c1cc(CC(C)(C)C=O)cc(c1O)C(C)(C)C",290.2245802,21,5.332,37.3,0.238640361784527,0.046,0.142320180892263,1,0
"3-alpha-bis(4-fluorophenyl)methoxytropane hydrochloride","dopamine reuptake inhibitor","","CN1C2CCC1CC(C2)OC(c1ccc(F)cc1)c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1C2CCC1CC(C2)OC(c1ccc(F)cc1)c1ccc(F)cc1",343.174770796,25,4.603,12.47,0.248315084710426,0.036,0.142157542355213,1,0
"3-alpha-bis-(4-fluorophenyl)-methoxytropane","dopamine uptake inhibitor","CHRM1, SLC6A2, SLC6A3, SLC6A4","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccc(F)cc1)c1ccc(F)cc1 |&1:2,5,7|",1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"preclinical","","","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccc(F)cc1)c1ccc(F)cc1 |&1:2",343.174770796,25,4.603,12.47,0.248315084710426,0.036,0.142157542355213,1,0
"GTS21","cholinergic receptor agonist","CHRNA7","COc1ccc(\C=C2/CCCN=C2c2cccnc2)c(OC)c1 |c:11|, COc1ccc(\C=C2/CCCN=C2c2cccnc2)c(OC)c1 |c:11|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"phase 1/phase 2","","","COc1ccc(\C=C2/CCCN=C2c2cccnc2)c(OC)c1 |c:11|",308.15247788,23,2.793,43.71,0.130180399083665,0.154,0.142090199541833,1,1
"tiracizine","sodium channel blocker","SCN5A","CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(C)C)c2c1, CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(C)C)c2c1",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(C)C)c2c1",367.18959166,27,2.259,61.88,0.0501442062824305,0.234,0.142072103141215,0,1
"IU1","ubiquitin C-terminal hydrolase inhibitor","USP14","Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1, Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1, Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1",300.163791512,22,3.148,25.24,0.194109892430937,0.09,0.142054946215468,1,0
"droloxifene","selective estrogen receptor modulator (SERM)","ESR1","CC\C(=C(\c1ccc(OCCN(C)C)cc1)c1cccc(O)c1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC\C(=C(\c1ccc(OCCN(C)C)cc1)c1cccc(O)c1)c1ccccc1",387.219829168,29,6.732,32.7,0.234029719035747,0.05,0.142014859517874,1,0
"JIB04","histone lysine demethylase inhibitor","KDM4E","Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1",308.082874096,22,5.134,50.17,0.153991041498142,0.13,0.141995520749071,1,1
"roquinimex","angiogenesis inhibitor, tumor necrosis factor production inhibitor","","CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1, CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1, CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1",308.116092372,23,4.009,62.54,0.115399796637856,0.168,0.141699898318928,1,1
"MK-8245","stearoyl-CoA desaturase inhibitor","SCD","OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br, OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br, OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br, OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br, OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br",466.040043312,29,4.278,119.4,0.00339431072594295,0.28,0.141697155362971,0,1
"np-g2-044","","PDCD1","Cc1occc1C(=O)Nc2nn(Cc3ccc(cc3)C(F)(F)F)c4ccccc24",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","breast cancer","Cc1occc1C(=O)Nc2nn(Cc3ccc(cc3)C(F)(F)F)c4ccccc24",399.119461412,29,4.725,60.06,0.0693420165858746,0.214,0.141671008292937,0,1
"J147","BDNF inducer","","COc1cccc(\C=N\N(C(=O)C(F)(F)F)c2ccc(C)cc2C)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1cccc(\C=N\N(C(=O)C(F)(F)F)c2ccc(C)cc2C)c1",350.124212444,25,5.014,41.9,0.135259568833699,0.148,0.14162978441685,1,1
"ditolylguanidine","sigma receptor agonist","GRIN1, GRIN2A, GRIN2B, SIGMAR1","Cc1ccccc1NC(=N)Nc1ccccc1C, Cc1ccccc1NC(=N)Nc1ccccc1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccccc1NC(=N)Nc1ccccc1C",239.142247544,18,3.864,47.91,0.225101836455201,0.058,0.141550918227601,1,0
"TC-G-1000","adrenergic receptor agonist","ADRA2A, ADRA2B, ADRA2C","Cc1sc(C)c2c1CCC=C2c1cnc[nH]1 |c:10|, Cc1sc(C)c2c1CCC=C2c1cnc[nH]1 |c:10|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,"preclinical","","","Cc1sc(C)c2c1CCC=C2c1cnc[nH]1 |c:10|",230.087769448,16,2.089,56.92,0.106702420799123,0.176,0.141351210399561,0,1
"nikethamide","immunostimulant","","CCN(CC)C(=O)c1cccnc1, CCN(CC)C(=O)c1cccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CCN(CC)C(=O)c1cccnc1",178.110613068,13,1.163,33.2,0.222582197865163,0.06,0.141291098932582,1,0
"furegrelate","thromboxane synthase inhibitor","TBXAS1","OC(=O)c1cc2cc(Cc3cccnc3)ccc2o1, OC(=O)c1cc2cc(Cc3cccnc3)ccc2o1, OC(=O)c1cc2cc(Cc3cccnc3)ccc2o1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC(=O)c1cc2cc(Cc3cccnc3)ccc2o1",253.073893212,19,2.196,63.33,0.108563253043378,0.174,0.141281626521689,0,1
"spautin-1","deubiquitinase inhibitor","USP10, USP13","Fc1ccc(CNc2ncnc3ccc(F)cc23)cc1, Fc1ccc(CNc2ncnc3ccc(F)cc23)cc1, Fc1ccc(CNc2ncnc3ccc(F)cc23)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1ccc(CNc2ncnc3ccc(F)cc23)cc1",271.092103792,20,3.49,37.81,0.198321929112272,0.084,0.141160964556136,1,0
"gaboxadol","benzodiazepine receptor agonist","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRD, GABRR1, GABRR2, GABRR3","O=c1[nH]oc2CNCCc12, O=c1[nH]oc2CNCCc12, O=c1[nH]oc2CNCCc12, O=c1[nH]oc2CNCCc12, O=c1[nH]oc2CNCCc12",0,0,0,0,0,0,0,0,0,0,0,0,1,10,0,0,0,0,0,0,0,0,0,0,"phase 3","","","O=c1[nH]oc2CNCCc12",140.058577496,10,-0.629,58.03,0.114314254111301,0.168,0.141157127055651,0,1
"ansofaxine","","","CN(C)CC(c1ccc(OC(=O)c2ccc(C)cc2)cc1)C3(O)CCCCC3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CN(C)CC(c1ccc(OC(=O)c2ccc(C)cc2)cc1)C3(O)CCCCC3",381.230393852,28,4.853,49.77,0.10625283286102,0.176,0.14112641643051,0,1
"GDC-0927","estrogen receptor antagonist","","CC1=C([C@@H](Oc2ccc(O)cc12)c1ccc(OCCN2CC(CF)C2)cc1)c1cccc(O)c1 |t:1|, CC1=C([C@@H](Oc2ccc(O)cc12)c1ccc(OCCN2CC(CF)C2)cc1)c1cccc(O)c1 |t:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC1=C([C@@H](Oc2ccc(O)cc12)c1ccc(OCCN2CC(CF)C2)cc1)c1cccc(O)c1 |t:1|",461.200236596,34,5.365,62.16,0.0562173891104255,0.226,0.141108694555213,0,1
"ITX3","GEF inhibitor","TRIO","Cc1cc(\C=c2\sc3nc4ccccc4n3c2=O)c(C)n1-c1ccccc1, Cc1cc(\C=c2\sc3nc4ccccc4n3c2=O)c(C)n1-c1ccccc1, Cc1cc(\C=c2\sc3nc4ccccc4n3c2=O)c(C)n1-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(\C=c2\sc3nc4ccccc4n3c2=O)c(C)n1-c1ccccc1",371.109233164,27,3.872,39.3,0.107554297564178,0.174,0.140777148782089,0,1
"GBR-13069","dopamine reuptake inhibitor","SLC6A3","Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1",448.23262002,33,5.435,15.71,0.161510134585418,0.12,0.140755067292709,1,0
"CaCCinh-A01","calcium-activated chloride channel inhibitor","CLCA1","CC(C)(C)[C@H]1CCc2c(C1)sc(NC(=O)c1ccco1)c2C(O)=O |&1:4,r|, CC(C)(C)[C@H]1CCc2c(C1)sc(NC(=O)c1ccco1)c2C(O)=O |&1:4,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)[C@H]1CCc2c(C1)sc(NC(=O)c1ccco1)c2C(O)=O |&1:4",347.119129152,24,3.88,107.78,0.0214719621052519,0.26,0.140735981052626,0,1
"benzoclidine","","","O=C(O[C@H]1CN2CCC1CC2)c1ccccc1 |&1:3,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(O[C@H]1CN2CCC1CC2)c1ccccc1 |&1:3",231.125928784,17,2.376,29.54,0.228976252203529,0.052,0.140488126101764,1,0
"bavisant","histamine receptor antagonist","HRH3","O=C(N1CCN(CC1)C1CC1)c1ccc(CN2CCOCC2)cc1, O=C(N1CCN(CC1)C1CC1)c1ccc(CN2CCOCC2)cc1, O=C(N1CCN(CC1)C1CC1)c1ccc(CN2CCOCC2)cc1",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O=C(N1CCN(CC1)C1CC1)c1ccc(CN2CCOCC2)cc1",329.210327104,24,1.106,36.02,0.0825663194319365,0.198,0.140283159715968,0,1
"vatinoxan","adrenergic receptor antagonist","","[H][C@@]12C[C@@]3(CNC(=O)N3CCNS(C)(=O)=O)CCN1CCc1c2oc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@@]12C[C@@]3(CNC(=O)N3CCNS(C)(=O)=O)CCN1CCc1c2oc2ccccc12",418.167476312,30,0.823,103.27,0.00831970252143322,0.272,0.140159851260717,0,1
"nerbacadol","cyclooxygenase inhibitor","","Cc1oncc1C(=O)N1CCCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cc1oncc1C(=O)N1CCCCC1",194.105527688,14,1.309,46.34,0.15822590890248,0.122,0.14011295445124,1,0
"homoveratrylamine","monoamine oxidase inhibitor","","COc1ccc(CCN)cc1OC, COc1ccc(CCN)cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(CCN)cc1OC",181.11027872,13,0.864,44.48,0.160130740718227,0.12,0.140065370359114,1,0
"metaphit","phencyclidine receptor acylator","","S=C=Nc1cccc(c1)C1(CCCCC1)N1CCCCC1, S=C=Nc1cccc(c1)C1(CCCCC1)N1CCCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","S=C=Nc1cccc(c1)C1(CCCCC1)N1CCCCC1",300.166019768,21,5.655,47.69,0.173720464109616,0.106,0.139860232054808,1,0
"salicylanilide","other antibiotic","","Oc1ccccc1C(=O)Nc1ccccc1, Oc1ccccc1C(=O)Nc1ccccc1, Oc1ccccc1C(=O)Nc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccccc1C(=O)Nc1ccccc1",213.078978592,16,3.016,49.33,0.211679440246627,0.068,0.139839720123314,1,0
"flurizan","gamma secretase inhibitor","APH1B, BACE1, IKBKG, PSEN1, PSEN2, PTGS1, PTGS2","C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1, C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1, C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1, C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1",244.089957876,18,3.764,37.3,0.243600718806338,0.036,0.139800359403169,1,0
"TUG-891","free fatty acid receptor agonist","FFAR4","Cc1ccc(cc1)-c1ccc(F)cc1COc1ccc(CCC(O)=O)cc1, Cc1ccc(cc1)-c1ccc(F)cc1COc1ccc(CCC(O)=O)cc1, Cc1ccc(cc1)-c1ccc(F)cc1COc1ccc(CCC(O)=O)cc1, Cc1ccc(cc1)-c1ccc(F)cc1COc1ccc(CCC(O)=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(cc1)-c1ccc(F)cc1COc1ccc(CCC(O)=O)cc1",364.147472752,27,5.781,46.53,0.161267250805117,0.118,0.139633625402558,1,0
"pipofezine","selective serotonin reuptake inhibitor (SSRI)","","CN1CCN(CC1)c1cc2N(C)c3ccccc3Oc2nn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCN(CC1)c1cc2N(C)c3ccccc3Oc2nn1",297.158960228,22,2.722,44.73,0.12920399900112,0.15,0.13960199950056,1,1
"ICI-118,551","adrenergic receptor antagonist","ADRB2, ADRB3","CC(C)N[C@@H](C)[C@H](O)COc1ccc(C)c2CCCc12, CC(C)N[C@@H](C)[C@H](O)COc1ccc(C)c2CCCc12, CC(C)N[C@@H](C)[C@H](O)COc1ccc(C)c2CCCc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,"phase 2","","","CC(C)N[C@@H](C)[C@H](O)COc1ccc(C)c2CCCc12",277.204179104,20,3.341,41.49,0.159115925066216,0.12,0.139557962533108,1,0
"AQW-051","nicotinic receptor agonist","","Cc1ccc(cc1)-c1ccc(O[C@H]2CN3CCC2CC3)cn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(cc1)-c1ccc(O[C@H]2CN3CCC2CC3)cn1",294.173213324,22,3.569,25.36,0.235089296558082,0.044,0.139544648279041,1,0
"KPT-9274","NAMPT inhibitor","","Nc1ccc(\C=C\C(=O)NCc2cc3cc(cc(-c4ccc(F)cc4)c3o2)-c2ccc(cc2)C(=O)N2CCC(F)(F)CC2)cn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Nc1ccc(\C=C\C(=O)NCc2cc3cc(cc(-c4ccc(F)cc4)c3o2)-c2ccc(cc2)C(=O)N2CCC(F)(F)CC2)cn1",610.219175448,45,7.096,101.46,0.0129284041711399,0.266,0.13946420208557,0,1
"ICA-110381","voltage-gated potassium channel activator","KCNQ2","Clc1ccc(cc1)C(=O)Nc1ccc(Cl)nc1, Clc1ccc(cc1)C(=O)Nc1ccc(Cl)nc1, Clc1ccc(cc1)C(=O)Nc1ccc(Cl)nc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1ccc(cc1)C(=O)Nc1ccc(Cl)nc1",266.001368236,17,3.074,41.99,0.102902728977247,0.176,0.139451364488624,0,1
"erteberel","estrogen receptor agonist","ESR1, ESR2","Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12, Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12, Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12",282.125594436,21,4.172,49.69,0.176783015015896,0.102,0.139391507507948,1,0
"PK-11195","benzodiazepine receptor antagonist","TSPO","CC[C@@H](C)N(C)C(=O)c1cc2ccccc2c(n1)-c1ccccc1Cl |&1:2,r|, CC[C@@H](C)N(C)C(=O)c1cc2ccccc2c(n1)-c1ccccc1Cl |&1:2,r|, CC[C@@H](C)N(C)C(=O)c1cc2ccccc2c(n1)-c1ccccc1Cl |&1:2,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC[C@@H](C)N(C)C(=O)c1cc2ccccc2c(n1)-c1ccccc1Cl |&1:2",352.134240972,25,5.564,33.2,0.172689992607568,0.106,0.139344996303784,1,0
"AM-251","cannabinoid receptor antagonist","CNR1, GPR18, GPR55","Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1",554.013714652,30,6.577,50.16,0.00455883509543133,0.274,0.139279417547716,0,1
"CP-93129","serotonin receptor agonist","HTR1A","O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1 |t:8|, O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1 |t:8|, O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1 |t:8|",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1 |t:8|",215.105862036,16,0.891,60.68,0.104545842837869,0.174,0.139272921418935,0,1
"xibenolol","adrenergic receptor antagonist","","Cc1cccc(OC[C@@H](O)CNC(C)(C)C)c1C |&1:8,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cc1cccc(OC[C@@H](O)CNC(C)(C)C)c1C |&1:8",251.18852904,18,2.842,41.49,0.164368153645616,0.114,0.139184076822808,1,0
"DMP-543","acetylcholine release enhancer","","Fc1cc(CC2(Cc3ccnc(F)c3)c3ccccc3C(=O)c3ccccc23)ccn1, Fc1cc(CC2(Cc3ccnc(F)c3)c3ccccc3C(=O)c3ccccc23)ccn1, Fc1cc(CC2(Cc3ccnc(F)c3)c3ccccc3C(=O)c3ccccc23)ccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Fc1cc(CC2(Cc3ccnc(F)c3)c3ccccc3C(=O)c3ccccc23)ccn1",412.138719636,31,5.752,42.85,0.142297956828097,0.136,0.139148978414049,1,1
"AG-14361","PARP inhibitor","PARP1","CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23",320.16371126,24,3.417,50.16,0.124273580976405,0.154,0.139136790488203,1,1
"COR-170","cannabinoid receptor inverse agonist","CNR2","CCCCCn1cc(C(=O)NC23CC4CC(CC(C4)C2)C3)c(=O)c2cc(ccc12)-c1ccccc1, CCCCCn1cc(C(=O)NC23CC4CC(CC(C4)C2)C3)c(=O)c2cc(ccc12)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCn1cc(C(=O)NC23CC4CC(CC(C4)C2)C3)c(=O)c2cc(ccc12)-c1ccccc1",468.277678392,35,9.664,51.1,0.190239072075477,0.088,0.139119536037739,1,0
"pifithrin-cyclic","TP53 inhibitor","TP53","Cc1ccc(cc1)-c1cn2c3CCCCc3sc2n1, Cc1ccc(cc1)-c1cn2c3CCCCc3sc2n1, Cc1ccc(cc1)-c1cn2c3CCCCc3sc2n1, Cc1ccc(cc1)-c1cn2c3CCCCc3sc2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(cc1)-c1cn2c3CCCCc3sc2n1",268.103419512,19,3.923,45.54,0.163996943101336,0.114,0.138998471550668,1,0
"ASP-2535","glycine transporter inhibitor","SLC6A9","CC(C)c1nnc(-c2ccc(nc2)-c2ccccc2)n1-c1cccc2nonc12, CC(C)c1nnc(-c2ccc(nc2)-c2ccccc2)n1-c1cccc2nonc12, CC(C)c1nnc(-c2ccc(nc2)-c2ccccc2)n1-c1cccc2nonc12",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)c1nnc(-c2ccc(nc2)-c2ccccc2)n1-c1cccc2nonc12",382.154209196,29,7.081,82.52,0.105841706319428,0.172,0.138920853159714,0,1
"furagin","antibacterial","","[O-][N+](=O)c1ccc(\C=C\C=N\N2CC(=O)NC2=O)o1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[O-][N+](=O)c1ccc(\C=C\C=N\N2CC(=O)NC2=O)o1",264.049469356,19,0.179,118.05,0.0158081987542147,0.262,0.138904099377107,0,1
"BMS-207940","endothelin receptor antagonist","","CN(Cc1cc(ccc1-c1ccccc1S(=O)(=O)Nc1noc(C)c1C)-c1ncco1)C(=O)CC(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(Cc1cc(ccc1-c1ccccc1S(=O)(=O)Nc1noc(C)c1C)-c1ncco1)C(=O)CC(C)(C)C",536.209341124,38,5.378,126.92,0.00553829133085401,0.272,0.138769145665427,0,1
"ezutromid","utrophin enhancer","UTRN","CCN(CC)c1ccc(cc1)-n1nc2cc(C)c(N)cc2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCN(CC)c1ccc(cc1)-n1nc2cc(C)c(N)cc2n1",295.179695672,22,4.66,59.97,0.149492312054927,0.128,0.138746156027464,1,0
"8-M-PDOT","melatonin receptor agonist","MTNR1A, MTNR1B","CCC(=O)N[C@H]1CCc2cccc(OC)c2C1 |&1:5,r|, CCC(=O)N[C@H]1CCc2cccc(OC)c2C1 |&1:5,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCC(=O)N[C@H]1CCc2cccc(OC)c2C1 |&1:5",233.141578848,17,1.987,38.33,0.173431604413078,0.104,0.138715802206539,1,0
"JTE-907","cannabinoid receptor inverse agonist","CNR2","CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12, CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12, CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12",438.179086552,32,5.382,98.88,0.0271665541848012,0.25,0.138583277092401,0,1
"U-54494A","opioid receptor agonist","OPRK1","CN([C@@H]1CCCC[C@@H]1N1CCCC1)C(=O)c1ccc(Cl)c(Cl)c1, CN([C@@H]1CCCC[C@@H]1N1CCCC1)C(=O)c1ccc(Cl)c(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN([C@@H]1CCCC[C@@H]1N1CCCC1)C(=O)c1ccc(Cl)c(Cl)c1",354.126568748,23,4.468,23.55,0.107134606533672,0.17,0.138567303266836,0,1
"IPI549","PI3K inhibitor","","C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cnn(C)c3)c2c(=O)n1-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cnn(C)c3)c2c(=O)n1-c1ccccc1",528.202222008,40,5.31,125.13,0.0108427129267261,0.266,0.138421356463363,0,1
"TC-I-2000","transient receptor potential channel antagonist","TRPM8","Fc1ccc(NC(=O)N2CCc3ccccc3[C@@H]2c2ccc(cc2)C(F)(F)F)cc1 |&1:17,r|, Fc1ccc(NC(=O)N2CCc3ccccc3[C@@H]2c2ccc(cc2)C(F)(F)F)cc1 |&1:17,r|, Fc1ccc(NC(=O)N2CCc3ccccc3[C@@H]2c2ccc(cc2)C(F)(F)F)cc1 |&1:17,r|, Fc1ccc(NC(=O)N2CCc3ccccc3[C@@H]2c2ccc(cc2)C(F)(F)F)cc1 |&1:17,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1ccc(NC(=O)N2CCc3ccccc3[C@@H]2c2ccc(cc2)C(F)(F)F)cc1 |&1:17",414.135526076,30,5.275,32.34,0.124784587637136,0.152,0.138392293818568,1,1
"neticonazole","other antifungal","","CCCCCOc1ccccc1\C(=C/SC)\n2ccnc2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","infectious disease","fungal infection","CCCCCOc1ccccc1\C(=C/SC)\n2ccnc2",302.145284324,21,5.335,52.35,0.142663464668189,0.134,0.138331732334095,1,1
"basimglurant","glutamate receptor antagonist","GRM5","Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(F)cc1, Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(F)cc1",325.078203316,23,4.848,30.71,0.182638771139178,0.094,0.138319385569589,1,0
"3-CPMT","dopamine reuptake inhibitor","","CN1[C@H]2CC[C@@H]1C[C@@H](C2)O[C@H](c1ccccc1)c1ccc(Cl)cc1 |&1:2,5,7,&2:10,r,THB:0:1:3.4:6.7.8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1[C@H]2CC[C@@H]1C[C@@H](C2)O[C@H](c1ccccc1)c1ccc(Cl)cc1 |&1:2",341.154642068,24,4.903,12.47,0.228611529620794,0.048,0.138305764810397,1,0
"3-cpmt","dopamine reuptake inhibitor","","CN1C2CCC1CC(C2)OC(c1ccccc1)c1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1C2CCC1CC(C2)OC(c1ccccc1)c1ccc(Cl)cc1",341.154642068,24,4.903,12.47,0.228611529620794,0.048,0.138305764810397,1,0
"acolbifene","estrogen receptor antagonist","","CC1=C([C@@H](Oc2cc(O)ccc12)c1ccc(OCCN2CCCCC2)cc1)c1ccc(O)cc1 |t:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC1=C([C@@H](Oc2cc(O)ccc12)c1ccc(OCCN2CCCCC2)cc1)c1ccc(O)cc1 |t:1|",457.225308472,34,5.579,62.16,0.0645775025746988,0.212,0.138288751287349,0,1
"GBR-12935","dopamine reuptake inhibitor","AGTR1, SLC6A3","C(CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1)Cc1ccccc1, C(CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1)Cc1ccccc1",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C(CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1)Cc1ccccc1",414.267113708,31,5.027,15.71,0.198469495884619,0.078,0.138234747942309,1,0
"OAC2","Oct activator","POU5F1","O=C(Nc1ccc2[nH]ccc2c1)c1ccccc1, O=C(Nc1ccc2[nH]ccc2c1)c1ccccc1, O=C(Nc1ccc2[nH]ccc2c1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(Nc1ccc2[nH]ccc2c1)c1ccccc1",236.094963004,18,3.146,44.89,0.219353539914836,0.056,0.137676769957418,1,0
"SKF-83566","dopamine receptor antagonist","DRD1, DRD5","CN1CCc2cc(Br)c(O)cc2[C@@H](C1)c1ccccc1 |&1:12|, CN1CCc2cc(Br)c(O)cc2[C@@H](C1)c1ccccc1 |&1:12|, CN1CCc2cc(Br)c(O)cc2[C@@H](C1)c1ccccc1 |&1:12|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCc2cc(Br)c(O)cc2[C@@H](C1)c1ccccc1 |&1:12|",331.057176296,20,3.659,23.47,0.0789507638683842,0.196,0.137475381934192,0,1
"khellin","vasodilator","","COc1c2ccoc2c(OC)c2oc(C)cc(=O)c12, COc1c2ccoc2c(OC)c2oc(C)cc(=O)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1c2ccoc2c(OC)c2oc(C)cc(=O)c12",260.068473484,19,2.749,61.81,0.108917282942354,0.166,0.137458641471177,0,1
"ameltolide","anticonvulsant","","Cc1cccc(C)c1NC(=O)c1ccc(N)cc1, Cc1cccc(C)c1NC(=O)c1ccc(N)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cccc(C)c1NC(=O)c1ccc(N)cc1",240.126263132,18,2.628,55.12,0.150580022171366,0.124,0.137290011085683,1,0
"mubritinib","protein tyrosine kinase inhibitor","EGFR, ERBB2","FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1",468.177310636,34,5.373,65.97,0.0441985849102596,0.23,0.13709929245513,0,1
"ethyl pyruvate","tnf production inhibitor","HMGB1, TNF","CC(C(OCC)=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","gastroenterology","pancreatitis","CC(C(OCC)=O)=O",116.047344116,8,0.318,43.37,0.203913039810728,0.07,0.136956519905364,1,0
"AZD9272","glutamate receptor antagonist","GRM5","Fc1ccc(nc1)-c1noc(n1)-c1cc(F)cc(c1)C#N, Fc1ccc(nc1)-c1noc(n1)-c1cc(F)cc(c1)C#N, Fc1ccc(nc1)-c1noc(n1)-c1cc(F)cc(c1)C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1ccc(nc1)-c1noc(n1)-c1cc(F)cc(c1)C#N",284.050967252,21,2.986,75.6,0.0775620897293961,0.196,0.136781044864698,0,1
"cloxyquin","potassium channel activator","KCNK18","Oc1ccc(Cl)c2cccnc12, Oc1ccc(Cl)c2cccnc12, Oc1ccc(Cl)c2cccnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(Cl)c2cccnc12",179.013791492,12,2.341,33.12,0.229366713907675,0.044,0.136683356953837,1,0
"EPPTB","trace amine associated receptor antagonist","TAAR1","CCOc1cccc(NC(=O)c2ccc(N3CCCC3)c(c2)C(F)(F)F)c1, CCOc1cccc(NC(=O)c2ccc(N3CCCC3)c(c2)C(F)(F)F)c1, CCOc1cccc(NC(=O)c2ccc(N3CCCC3)c(c2)C(F)(F)F)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOc1cccc(NC(=O)c2ccc(N3CCCC3)c(c2)C(F)(F)F)c1",378.155512572,27,5.091,41.57,0.115266455455193,0.158,0.136633227727597,1,1
"CGP-7930","GABA receptor modulator","GABBR1","CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C",292.240230264,21,5.225,40.46,0.212846993515159,0.06,0.13642349675758,1,0
"MK-2048","HIV integrase inhibitor","","CCN1C[C@H](C)n2c(c(O)c3c2c(nn(Cc2ccc(F)c(Cl)c2)c3=O)C(=O)NC)C1=O, CCN1C[C@H](C)n2c(c(O)c3c2c(nn(Cc2ccc(F)c(Cl)c2)c3=O)C(=O)NC)C1=O, CCN1C[C@H](C)n2c(c(O)c3c2c(nn(Cc2ccc(F)c(Cl)c2)c3=O)C(=O)NC)C1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN1C[C@H](C)n2c(c(O)c3c2c(nn(Cc2ccc(F)c(Cl)c2)c3=O)C(=O)NC)C1=O",461.126610052,32,3.877,109.46,0.00865116213396517,0.264,0.136325581066983,0,1
"rolziracetam","","","O=C1CCC2CCC(=O)N12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O=C1CCC2CCC(=O)N12",139.063328528,10,-0.285,37.38,0.188390977990335,0.084,0.136195488995168,1,0
"pincainide","antiarrhythmic","","Cc1cccc(C)c1NC(=O)CN1CCCCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1cccc(C)c1NC(=O)CN1CCCCCC1",260.188863388,19,2.475,32.34,0.184110970070517,0.088,0.136055485035259,1,0
"ABT-202","acetylcholine receptor agonist","","N[C@H]1CCN(C1)c1cccnc1 |&1:1|, N[C@H]1CCN(C1)c1cccnc1 |&1:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","N[C@H]1CCN(C1)c1cccnc1 |&1:1|",163.110947416,12,0.508,42.15,0.183824732240765,0.088,0.135912366120382,1,0
"LY364947","p38 MAPK inhibitor, TGF beta receptor inhibitor","TGFBR1","c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1",272.106196384,21,3.448,54.46,0.169817885315202,0.102,0.135908942657601,1,0
"fenebrutinib","Bruton's tyrosine kinase (BTK) inhibitor","","C[C@H]1CN(CCN1c1ccc(Nc2cc(cn(C)c2=O)-c2ccnc(N3CCn4c5CC(C)(C)Cc5cc4C3=O)c2CO)nc1)C1COC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@H]1CN(CCN1c1ccc(Nc2cc(cn(C)c2=O)-c2ccnc(N3CCn4c5CC(C)(C)Cc5cc4C3=O)c2CO)nc1)C1COC1",664.348551888,49,5.441,120.99,0.00380914212045244,0.268,0.135904571060226,0,1
"NIDA-41020","cannabinoid receptor antagonist","CNR1","COc1ccc(cc1)-c1c(C)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, COc1ccc(cc1)-c1c(C)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, COc1ccc(cc1)-c1c(C)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1)-c1c(C)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1",458.127631368,31,5.424,59.39,0.0335742761782685,0.238,0.135787138089134,0,1
"CI-923","acetylcholine receptor antagonist","","CCN[C@@H](C)CN1CCc2c(C1)c(=O)oc1ccccc21 |&1:3,r|, CCN[C@@H](C)CN1CCc2c(C1)c(=O)oc1ccccc21 |&1:3,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCN[C@@H](C)CN1CCc2c(C1)c(=O)oc1ccccc21 |&1:3",286.168127944,21,2.744,45.48,0.131511881606821,0.14,0.13575594080341,1,1
"dimaprit","histamine receptor agonist","HRH2, HRH3, HRH4","CN(C)CCCSC(N)=N, CN(C)CCCSC(N)=N, CN(C)CCCSC(N)=N, CN(C)CCCSC(N)=N",0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)CCCSC(N)=N",161.09866848,10,0.577,78.41,0.0613925849867415,0.21,0.135696292493371,0,1
"meprylcaine","local anesthetic","","CCCNC(C)(C)COC(=O)c1ccccc1, CCCNC(C)(C)COC(=O)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCNC(C)(C)COC(=O)c1ccccc1",235.157228912,17,3.23,38.33,0.2133627270764,0.058,0.1356813635382,1,0
"neurodazine","neurogenesis of non-pluripotent C2C12 myoblast inducer","","COc1ccc(cc1)-c1nc([nH]c1-c1ccc(OC)cc1)-c1ccc(o1)-c1cccc(Cl)c1, COc1ccc(cc1)-c1nc([nH]c1-c1ccc(OC)cc1)-c1ccc(o1)-c1cccc(Cl)c1, COc1ccc(cc1)-c1nc([nH]c1-c1ccc(OC)cc1)-c1ccc(o1)-c1cccc(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1)-c1nc([nH]c1-c1ccc(OC)cc1)-c1ccc(o1)-c1cccc(Cl)c1",456.124070212,33,7.237,60.28,0.081141529695858,0.19,0.135570764847929,0,1
"zoxazolamine","myorelaxant","","Nc1nc2cc(Cl)ccc2o1, Nc1nc2cc(Cl)ccc2o1, Nc1nc2cc(Cl)ccc2o1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Nc1nc2cc(Cl)ccc2o1",168.00904046,11,1.504,52.05,0.13902795159481,0.132,0.135513975797405,1,1
"AT7867","AKT inhibitor","AKT2, GSK3B, PKIA, PRKACA","Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1",337.13457532,24,5.225,40.71,0.155021821815811,0.116,0.135510910907906,1,0
"azacyclonol","histamine receptor antagonist","HRH1","OC(C1CCNCC1)(c1ccccc1)c1ccccc1, OC(C1CCNCC1)(c1ccccc1)c1ccccc1, OC(C1CCNCC1)(c1ccccc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(C1CCNCC1)(c1ccccc1)c1ccccc1",267.162314292,20,3.229,32.26,0.224747023876078,0.046,0.135373511938039,1,0
"4-hydroxy-phenazone","","","Cc1c(O)c(=O)n(-c2ccccc2)n1C, Cc1c(O)c(=O)n(-c2ccccc2)n1C, Cc1c(O)c(=O)n(-c2ccccc2)n1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1c(O)c(=O)n(-c2ccccc2)n1C",204.089877624,15,1.669,47.16,0.166523362660875,0.104,0.135261681330438,1,0
"GP2a","cannabinoid receptor agonist","CNR2","Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NC2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NC2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NC2CCCCC2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NC2CCCCC2)c1",439.121817716,30,6.636,46.92,0.0724635508864259,0.198,0.135231775443213,0,1
"nebracetam","acetylcholine receptor agonist","CHRM1","NC[C@H]1CN(Cc2ccccc2)C(=O)C1 |&1:2|, NC[C@H]1CN(Cc2ccccc2)C(=O)C1 |&1:2|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"phase 3","","","NC[C@H]1CN(Cc2ccccc2)C(=O)C1 |&1:2|",204.126263132,15,0.638,46.33,0.136459520691395,0.134,0.135229760345697,1,1
"PIT","purinergic receptor antagonist","P2RY1","[O-][N+]1=C(C(=O)c2ccccc12)c1ccccn1 |t:1|, [O-][N+]1=C(C(=O)c2ccccc12)c1ccccn1 |t:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[O-][N+]1=C(C(=O)c2ccccc12)c1ccccn1 |t:1|",224.058577496,17,1.406,56.03,0.130427173268243,0.14,0.135213586634121,1,1
"IEM1754","glutamate receptor antagonist","GRIA1","NCCCCCNCC12CC3CC(CC(C3)C1)C2, NCCCCCNCC12CC3CC(CC(C3)C1)C2, NCCCCCNCC12CC3CC(CC(C3)C1)C2, NCCCCCNCC12CC3CC(CC(C3)C1)C2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NCCCCCNCC12CC3CC(CC(C3)C1)C2",250.24089896,18,3.806,38.05,0.216328280338132,0.054,0.135164140169066,1,0
"phenolphthalein","indicator dye","UGT1A9","Oc1ccc(cc1)C1(OC(=O)c2ccccc12)c1ccc(O)cc1, Oc1ccc(cc1)C1(OC(=O)c2ccccc12)c1ccc(O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","Oc1ccc(cc1)C1(OC(=O)c2ccccc12)c1ccc(O)cc1",318.089208928,24,4.376,66.76,0.113794794231895,0.156,0.134897397115947,0,1
"CPI-0610","bromodomain inhibitor","BRD4","Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|, Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|, Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|, Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|, Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|, Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|",365.093104432,26,3.855,81.48,0.0397495663123954,0.23,0.134874783156198,0,1
"TMPH","","","CCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1, CCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1, CCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1",269.235479232,19,4.681,38.33,0.213701217686942,0.056,0.134850608843471,1,0
"4-methylhistamine","histamine receptor agonist","HRH4","Cc1nc[nH]c1CCN",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1nc[nH]c1CCN",125.095297352,9,-0.198,54.7,0.149675016733051,0.12,0.134837508366525,1,0
"SB-612111","nociceptin/orphanin FQ receptor antagonist","OPRL1","Cc1cccc2[C@@H](O)C[C@@H](CN3CCC(CC3)c3c(Cl)cccc3Cl)CCc12, Cc1cccc2[C@@H](O)C[C@@H](CN3CCC(CC3)c3c(Cl)cccc3Cl)CCc12, Cc1cccc2[C@@H](O)C[C@@H](CN3CCC(CC3)c3c(Cl)cccc3Cl)CCc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cccc2[C@@H](O)C[C@@H](CN3CCC(CC3)c3c(Cl)cccc3Cl)CCc12",417.162619908,28,6.097,23.47,0.111662675192328,0.158,0.134831337596164,0,1
"LY294002","DNA dependent protein kinase inhibitor, mTOR inhibitor, phosphodiesterase inhibitor, PI3K inhibitor, PLK inhibitor","AKT1, CHEK1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIM1, PLK1, PRKCA, PRKDC, ROCK1, RPS6KB1, SGK1","O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1",307.120843404,23,4.966,42.68,0.211191035636796,0.058,0.134595517818398,1,0
"SB-222200","tachykinin antagonist","TACR3","CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1, CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1, CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1, CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1",380.188863388,29,6.379,41.99,0.210893507948122,0.058,0.134446753974061,1,0
"pifithrin-alpha","TP53 inhibitor","TP53","Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N, Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N, Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N, Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N",286.113984196,20,3.579,74.09,0.0707492301287124,0.198,0.134374615064356,0,1
"TMS","","","COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1, COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1, COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1, COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1, COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1",300.13615912,22,4.105,36.92,0.188639028210279,0.08,0.134319514105139,1,0
"desidustat","hypoxia inducible factor prolyl hydroxylase inhibitor","","OC(=O)CNC(=O)c1c(O)c2ccccc2n(OCC2CC2)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)CNC(=O)c1c(O)c2ccccc2n(OCC2CC2)c1=O",332.100836232,24,0.441,117.86,0.0105866650029881,0.258,0.134293332501494,0,1
"furprofen","prostagladin inhibitor","PTGS2","C[C@@H](C(O)=O)c1ccc(cc1)C(=O)c1ccco1 |&1:1,r|",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"","neurology/psychiatry","pain relief","C[C@@H](C(O)=O)c1ccc(cc1)C(=O)c1ccco1 |&1:1",244.073558864,18,1.917,67.51,0.0922813791542201,0.176,0.13414068957711,0,1
"ML167","CLK inhibitor, DYRK inhibitor","CLK4, DYRK1B","Cc1ccc(CNc2ncnc3ccc(cc23)-c2ccc(CO)o2)o1, Cc1ccc(CNc2ncnc3ccc(cc23)-c2ccc(CO)o2)o1, Cc1ccc(CNc2ncnc3ccc(cc23)-c2ccc(CO)o2)o1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(CNc2ncnc3ccc(cc23)-c2ccc(CO)o2)o1",335.126991404,25,1.94,84.32,0.0379005416494385,0.23,0.133950270824719,0,1
"TIC10","AKT inhibitor, TRAIL modulator","AKT1, MAPK1","Cc1ccccc1CN1C2=NCCN2C(=O)C2=C1CCN(Cc1ccccc1)C2 |c:18,t:10|, Cc1ccccc1CN1C2=NCCN2C(=O)C2=C1CCN(Cc1ccccc1)C2 |c:18,t:10|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1ccccc1CN1C2=NCCN2C(=O)C2=C1CCN(Cc1ccccc1)C2 |c:18",386.210661452,29,3.629,39.15,0.111819109668287,0.156,0.133909554834144,0,1
"pti-428","cftr channel potentiator","CFTR","C[C@@H](O)c1oc(nn1)[C@@H]2C[C@H](C2)NC(=O)c3onc(c3)c4ccccc4",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","pulmonary","cystic fibrosis","C[C@@H](O)c1oc(nn1)[C@@H]2C[C@H](C2)NC(=O)c3onc(c3)c4ccccc4",354.132805056,26,2.953,114.28,0.0197587195368936,0.248,0.133879359768447,0,1
"S-07662","CAR antagonist","NR1I3","Cc1oc2ccccc2c1CNC(=O)NCc1cccs1, Cc1oc2ccccc2c1CNC(=O)NCc1cccs1, Cc1oc2ccccc2c1CNC(=O)NCc1cccs1, Cc1oc2ccccc2c1CNC(=O)NCc1cccs1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1oc2ccccc2c1CNC(=O)NCc1cccs1",300.093248752,21,2.066,82.51,0.0374927339411037,0.23,0.133746366970552,0,1
"minaprine","serotonin reuptake inhibitor","ACHE, CHRM1, DRD1, DRD2, HTR2A, HTR2B, HTR2C, MAOA, SLC6A4","Cc1cc(nnc1NCCN1CCOCC1)-c1ccccc1, Cc1cc(nnc1NCCN1CCOCC1)-c1ccccc1",1,1,0,0,0,0,1,1,1,3,0,0,0,0,1,2,1,1,0,0,0,0,0,0,"withdrawn","","","Cc1cc(nnc1NCCN1CCOCC1)-c1ccccc1",298.179361324,22,2.022,50.28,0.096843842426857,0.17,0.133421921213428,0,1
"BNC105","tubulin polymerization inhibitor","","COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O, COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O, COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O, COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O, COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O",372.12090298,27,2.759,87.36,0.0285436196330475,0.238,0.133271809816524,0,1
"propranolol-(R)","adrenergic receptor antagonist","ADRB2, ADRB3","CC(C)NC[C@@H](O)COc1cccc2ccccc12, CC(C)NC[C@@H](O)COc1cccc2ccccc12, CC(C)NC[C@@H](O)COc1cccc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,"preclinical","","","CC(C)NC[C@@H](O)COc1cccc2ccccc12",259.157228912,19,3.028,41.49,0.176456650335959,0.09,0.133228325167979,1,0
"propranolol-(S)","adrenergic receptor antagonist","ADRB1, HTR1A, HTR5A, SLC10A1","CC(C)NC[C@H](O)COc1cccc2ccccc12, CC(C)NC[C@H](O)COc1cccc2ccccc12, CC(C)NC[C@H](O)COc1cccc2ccccc12, CC(C)NC[C@H](O)COc1cccc2ccccc12",1,1,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"preclinical","","","CC(C)NC[C@H](O)COc1cccc2ccccc12",259.157228912,19,3.028,41.49,0.176456650335959,0.09,0.133228325167979,1,0
"ethyl-pyruvate","tumor necrosis factor production inhibitor","","CCOC(=O)C(O)=C, CCOC(=O)C(O)=C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCOC(=O)C(O)=C",116.047344116,8,0.875,46.53,0.214394775080359,0.052,0.133197387540179,1,0
"homosalate","HSP inducer","","C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)c1ccccc1O |&1:1,&2:3,r|, C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)c1ccccc1O |&1:1,&2:3,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)c1ccccc1O |&1:1",262.156894564,19,5.431,46.53,0.242389074337914,0.024,0.133194537168957,1,0
"L-365260","CCK receptor antagonist","CCKAR, CCKBR, KCNQ1","CN1c2ccccc2C(=N[C@@H](NC(=O)Nc2cccc(C)c2)C1=O)c1ccccc1 |c:9|, CN1c2ccccc2C(=N[C@@H](NC(=O)Nc2cccc(C)c2)C1=O)c1ccccc1 |c:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN1c2ccccc2C(=N[C@@H](NC(=O)Nc2cccc(C)c2)C1=O)c1ccccc1 |c:9|",398.174275944,30,4.216,73.8,0.0580200995784535,0.208,0.133010049789227,0,1
"1-((Z)-3-chloroallyl)-1,3,5,7-tetraazaadamantan-1-ium","","","Cl\C=C/C[N+]12CN3CN(CN(C3)C1)C2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cl\C=C/C[N+]12CN3CN(CN(C3)C1)C2",215.105800612091,14,0.947,9.72,0.195690554401804,0.07,0.132845277200902,1,0
"N-MPPP","opioid receptor agonist","","CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccccc1, CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccccc1, CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccccc1, CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccccc1",322.204513452,24,3.553,23.55,0.205690096117096,0.06,0.132845048058548,1,0
"BI-78D3","JNK inhibitor","MAPK8","[O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1",379.004510388,25,1.19,178.71,0.00128527703076658,0.264,0.132642638515383,0,1
"e1210","other antifungal","","Nc1ncccc1c2onc(Cc3ccc(COc4ccccn4)cc3)c2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","infectious disease","cutaneous candidiasis","Nc1ncccc1c2onc(Cc3ccc(COc4ccccn4)cc3)c2",358.142975816,27,4.167,87.06,0.055158984432911,0.21,0.132579492216456,0,1
"N-(p-amylcinnamoyl)-anthranilic-acid","phospholipase inhibitor","","CCCCCc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1",337.167793596,25,5.917,66.4,0.131026661529675,0.134,0.132513330764838,1,1
"nemiralisib","","","CC(C)N1CCN(Cc2cnc(o2)-c2cc(cc3[nH]ncc23)-c2cccc3[nH]ccc23)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)N1CCN(Cc2cnc(o2)-c2cc(cc3[nH]ncc23)-c2cccc3[nH]ccc23)CC1",440.232459516,33,4.311,76.98,0.0410165232064874,0.224,0.132508261603244,0,1
"litronesib","kinesin-like spindle protein inhibitor","KIF11","CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 |c:19|, CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 |c:19|, CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 |c:19|, CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 |c:19|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 |c:19|",511.228696664,34,2.09,153.65,0.000966116760371546,0.264,0.132483058380186,0,1
"ilepcimide","anticonvulsant","","O=C(\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(C=Cc1ccc2OCOc2c1)N1CCCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","O=C(\C=C\c1ccc2OCOc2c1)N1CCCCC1",259.120843404,19,2.194,38.77,0.156936397657354,0.108,0.132468198828677,1,0
"DR-4485","serotonin receptor antagonist","HTR7","Clc1ccc(cc1)C1=CCN(CCCC[C@@]23CCCc4c2c(NC3=O)ccc4Cl)CC1 |&1:15,t:8|, Clc1ccc(cc1)C1=CCN(CCCC[C@@]23CCCc4c2c(NC3=O)ccc4Cl)CC1 |&1:15,t:8|, Clc1ccc(cc1)C1=CCN(CCCC[C@@]23CCCc4c2c(NC3=O)ccc4Cl)CC1 |&1:15,t:8|",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1ccc(cc1)C1=CCN(CCCC[C@@]23CCCc4c2c(NC3=O)ccc4Cl)CC1 |&1:15",454.157868876,31,5.918,32.34,0.0746995850151114,0.19,0.132349792507556,0,1
"TC1","beta-secretase inhibitor","BACE1","O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|, O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|, O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|, O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|, O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|, O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1",297.15289248,22,2.753,23.47,0.196645193471063,0.068,0.132322596735532,1,0
"amcenestrant","","ESR1","OC(=O)c1ccc2c(CCCC(c3ccc(Cl)cc3Cl)=C2c2ccc(O[C@H]3CCN(CCCF)C3)cc2)c1 |c:20|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","oncology","breast cancer","OC(=O)c1ccc2c(CCCC(c3ccc(Cl)cc3Cl)=C2c2ccc(O[C@H]3CCN(CCCF)C3)cc2)c1 |c:20|",553.1586774,38,8.949,49.77,0.0506322072523543,0.214,0.132316103626177,0,1
"2-ethyl-1,3-hexanediol","","","CCC[C@@H](O)[C@@H](CC)CO |&1:3,&2:5,r|, CCC[C@@H](O)[C@@H](CC)CO |&1:3,&2:5,r|, CCC[C@@H](O)[C@@H](CC)CO |&1:3,&2:5,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCC[C@@H](O)[C@@H](CC)CO |&1:3",146.130679816,10,1.403,40.46,0.216394746206661,0.048,0.132197373103331,1,0
"YM-022","CCK receptor antagonist","CCKBR","Cc1cccc(NC(=O)N[C@@H]2N=C(c3ccccc3)c3ccccc3N(CC(=O)c3ccccc3C)C2=O)c1 |t:11|, Cc1cccc(NC(=O)N[C@@H]2N=C(c3ccccc3)c3ccccc3N(CC(=O)c3ccccc3C)C2=O)c1 |t:11|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1cccc(NC(=O)N[C@@H]2N=C(c3ccccc3)c3ccccc3N(CC(=O)c3ccccc3C)C2=O)c1 |t:11|",516.216140756,39,6.014,90.87,0.0295904182964228,0.234,0.131795209148211,0,1
"quazinone","phosphodiesterase inhibitor","PDE3A, PDE3B","CC1N2Cc3c(Cl)cccc3NC2=NC1=O |c:14|, CC1N2Cc3c(Cl)cccc3NC2=NC1=O |c:14|, CC1N2Cc3c(Cl)cccc3NC2=NC1=O |c:14|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC1N2Cc3c(Cl)cccc3NC2=NC1=O |c:14|",235.05123962,16,3.118,44.7,0.15344494952944,0.11,0.13172247476472,1,0
"TGX-221","PI3K inhibitor","PIK3CB, PIK3CD","C[C@@H](Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1 |&1:1,r|, C[C@@H](Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1 |&1:1,r|, C[C@@H](Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1 |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1 |&1:1",364.189926008,27,3.899,58.87,0.0833562302721447,0.18,0.131678115136072,0,1
"ipidacrine","acetylcholinesterase inhibitor","ACHE","Nc1c2CCCc2nc2CCCCc12, Nc1c2CCCc2nc2CCCCc12, Nc1c2CCCc2nc2CCCCc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Nc1c2CCCc2nc2CCCCc12",188.131348512,14,1.22,38.91,0.201293851803655,0.062,0.131646925901828,1,0
"(R)-baclofen","benzodiazepine receptor agonist","GABBR1, GABBR2","NC[C@H](CC(O)=O)c1ccc(Cl)cc1, NC[C@H](CC(O)=O)c1ccc(Cl)cc1, NC[C@H](CC(O)=O)c1ccc(Cl)cc1, NC[C@H](CC(O)=O)c1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","NC[C@H](CC(O)=O)c1ccc(Cl)cc1",213.055656304,14,1.334,63.32,0.0750140728437548,0.188,0.131507036421877,0,1
"ORG-26576","glutamate receptor modulator","","O=C1N2CCC[C@H]2COc2ncccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O=C1N2CCC[C@H]2COc2ncccc12",204.089877624,15,1.293,42.43,0.168955057774049,0.094,0.131477528887025,1,0
"meisoindigo","STAT inhibitor","STAT3","CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12, CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12, CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12, CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12, CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12",276.089877624,21,2.11,49.41,0.130866423841946,0.132,0.131433211920973,1,1
"GKT137831","NADPH oxidase inhibitor","NOX1, NOX4","CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12, CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12, CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12, CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12",394.119653528,28,5.421,63.03,0.0687624874175102,0.194,0.131381243708755,0,1
"diphenylguanidine","","","N=C(Nc1ccccc1)Nc1ccccc1, N=C(Nc1ccccc1)Nc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N=C(Nc1ccccc1)Nc1ccccc1",211.110947416,16,3.412,47.91,0.242740463608887,0.02,0.131370231804443,1,0
"methoprene-(s)","","","COC(C)(C)CCC[C@H](C)C\C=C\C(\C)=C\C(=O)OC(C)C, COC(C)(C)CCC[C@H](C)C\C=C\C(\C)=C\C(=O)OC(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(C)(C)CCC[C@H](C)C\C=C\C(\C)=C\C(=O)OC(C)C",310.250794948,22,5.905,35.53,0.226717780709345,0.036,0.131358890354672,1,0
"menaquinone-7","osteoclast inhibitor","TNFRSF11B","CC(=CCC\C(=C\CC\C(=C\CC\C(=C\CC\C(=C\CC\C(=C\CC\C(=C\CC1=C(C)C(=O)c2ccccc2C1=O)\C)\C)\C)\C)\C)\C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","cardiology","arteriosclerosis","CC(=CCC\C(=C\CC\C(=C\CC\C(=C\CC\C(=C\CC\C(=C\CC\C(=C\CC1=C(C)C(=O)c2ccccc2C1=O)\C)\C)\C)\C)\C)\C)C",648.490631288,48,14.176,34.14,0.220700500745199,0.042,0.1313502503726,1,0
"NU-7026","DNA dependent protein kinase inhibitor, mTOR inhibitor, PI3K inhibitor","PRKDC","O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1, O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1, O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1, O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1, O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1",281.10519334,21,4.292,42.68,0.210494227720524,0.052,0.131247113860262,1,0
"Ro-10-5824","dopamine receptor agonist","DRD4","Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1 |c:9|, Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1 |c:9|, Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1 |c:9|, Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1 |c:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1 |c:9|",280.16879664,21,1.819,55.04,0.10040319089747,0.162,0.131201595448735,0,1
"NMS-E973","HSP inhibitor","","CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O, CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O, CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O, CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O, CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O",454.148849044,33,2.977,151.2,0.00394039506691023,0.258,0.130970197533455,0,1
"A-381393","dopamine receptor antagonist","","Cc1ccc(cc1C)N1CCN(Cc2nc3ccccc3[nH]2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(cc1C)N1CCN(Cc2nc3ccccc3[nH]2)CC1",320.200096768,24,3.883,35.16,0.183714810391816,0.078,0.130857405195908,1,0
"phenylbutazone","cyclooxygenase inhibitor, prostanoid receptor antagonist","PTGIS, PTGS1, PTGS2","CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1",308.15247788,23,3.71,40.62,0.167593428326805,0.094,0.130796714163402,1,0
"OXF-BD-02","bromodomain inhibitor","BRD4","Cc1noc(C)c1-c1cc(O)cc(c1)[C@@H](O)c1ccccc1 |&1:14,r|, Cc1noc(C)c1-c1cc(O)cc(c1)[C@@H](O)c1ccccc1 |&1:14,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1noc(C)c1-c1cc(O)cc(c1)[C@@H](O)c1ccccc1 |&1:14",295.120843404,22,3.377,66.49,0.099475406872989,0.162,0.130737703436495,0,1
"xilobam","","","CN1CCC\C1=N\C(=O)Nc1c(C)cccc1C, CN1CCC\C1=N\C(=O)Nc1c(C)cccc1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN1CCC\C1=N\C(=O)Nc1c(C)cccc1C",245.152812228,18,2.286,44.7,0.155437620627769,0.106,0.130718810313885,1,0
"AM-404","cyclooxygenase inhibitor, FAAH inhibitor, TRPV antagonist","CNR1, CNR2, FAAH, TRPV1","CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1",395.282429424,29,9.29900000000001,49.33,0.243369240383043,0.018,0.130684620191521,1,0
"GW-4064","FXR agonist","NR1H4","CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl, CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl, CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl, CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl, CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl, CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl",541.061441224,36,8.868,72.56,0.0253065668149493,0.236,0.130653283407475,0,1
"TC2559","acetylcholine receptor agonist","CHRNA4","CCOc1cncc(\C=C\CCNC)c1, CCOc1cncc(\C=C\CCNC)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"preclinical","","","CCOc1cncc(\C=C\CCNC)c1",206.141913196,15,1.38,34.15,0.19328282373074,0.068,0.13064141186537,1,0
"desmethylclozapine","acetylcholine receptor agonist","HTR2C","Clc1ccc2Nc3ccccc3C(=Nc2c1)N1CCNCC1 |c:13|, Clc1ccc2Nc3ccccc3C(=Nc2c1)N1CCNCC1 |c:13|",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Clc1ccc2Nc3ccccc3C(=Nc2c1)N1CCNCC1 |c:13|",312.114174224,22,3.625,39.66,0.127133573741885,0.134,0.130566786870942,1,1
"CGS-9896","GABA receptor antagonist","GABRA1, GABRB2, GABRG2","Clc1ccc(cc1)-n1[nH]c2c(cnc3ccccc23)c1=O, Clc1ccc(cc1)-n1[nH]c2c(cnc3ccccc23)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1ccc(cc1)-n1[nH]c2c(cnc3ccccc23)c1=O",295.05123962,21,3.79,50.68,0.123033661092467,0.138,0.130516830546234,1,1
"endoxifen","estrogen receptor antagonist","ESR1","CC\C(=C(/c1ccc(O)cc1)c1ccc(OCCNC)cc1)c1ccccc1, CC\C(=C(/c1ccc(O)cc1)c1ccc(OCCNC)cc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC\C(=C(/c1ccc(O)cc1)c1ccc(OCCNC)cc1)c1ccccc1",373.204179104,28,6.493,41.49,0.206946576556015,0.054,0.130473288278008,1,0
"azimilide","potassium channel blocker","KCNA5","CN1CCN(CCCCN2C(=O)CN(\N=C\c3ccc(o3)-c3ccc(Cl)cc3)C2=O)CC1, CN1CCN(CCCCN2C(=O)CN(\N=C\c3ccc(o3)-c3ccc(Cl)cc3)C2=O)CC1, CN1CCN(CCCCN2C(=O)CN(\N=C\c3ccc(o3)-c3ccc(Cl)cc3)C2=O)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CN1CCN(CCCCN2C(=O)CN(\N=C\c3ccc(o3)-c3ccc(Cl)cc3)C2=O)CC1",457.188067436,32,2.772,72.6,0.0168942295578747,0.244,0.130447114778937,0,1
"JNJ-54175446","purinergic receptor antagonist","","C[C@H]1N(CCc2c1nnn2-c1ncc(F)cn1)C(=O)c1cccc(c1Cl)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@H]1N(CCc2c1nnn2-c1ncc(F)cn1)C(=O)c1cccc(c1Cl)C(F)(F)F",440.077549596,30,3.378,76.8,0.0168862130816062,0.244,0.130443106540803,0,1
"riamilovir","antiviral","","CSc1nc2[nH]nc([N+]([O-])=O)c(=O)n2n1.O.O.[NaH]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","infectious disease","influenza a virus infection","CSc1nc2[nH]nc([N+]([O-])=O)c(=O)n2n1.O.O.[NaH]",288.025282668,18,1.041,144.38,0.00480179517942297,0.256,0.130400897589711,0,1
"farampator","ionotropic glutamate receptor agonist","","O=C(N1CCCCC1)c1ccc2nonc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(N1CCCCC1)c1ccc2nonc2c1",231.100776656,17,3.083,59.23,0.150796459420082,0.11,0.130398229710041,1,0
"S-isopropylisothiourea","nitric oxide synthase inhibitor","NOS3","CC(C)SC(N)=N, CC(C)SC(N)=N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)SC(N)=N",118.05646932,7,1.086,75.17,0.100713877789886,0.16,0.130356938894943,0,1
"gamma-aminobutyric-acid","benzodiazepine receptor agonist","GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2, GATM, KCTD12, KCTD16, KCTD8, SLC6A1","NCCCC(O)=O, NCCCC(O)=O, NCCCC(O)=O, NCCCC(O)=O",1,1,0,0,0,0,0,0,0,0,0,0,1,6,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NCCCC(O)=O",103.063328528,7,-0.668,63.32,0.120639881698677,0.14,0.130319940849339,1,1
"Isoquinoline,-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro,","","","COc1cc2CCN[C@@H](C)c2cc1OC |&1:8|, COc1cc2CCN[C@@H](C)c2cc1OC |&1:8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2CCN[C@@H](C)c2cc1OC |&1:8|",207.125928784,15,1.468,30.49,0.206539903179643,0.054,0.130269951589821,1,0
"piperine","monoamine oxidase inhibitor","MAOA, MAOB, TRPV1","O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1",0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1",285.136493468,21,2.888,38.77,0.158143364908417,0.102,0.130071682454208,1,0
"R-121919","CRF receptor antagonist","","CCCN(CCC)c1cc(C)nc2c(c(C)nn12)-c1cnc(cc1C)N(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCN(CCC)c1cc(C)nc2c(c(C)nn12)-c1cnc(cc1C)N(C)C",380.268845024,28,5.514,49.56,0.12569264884485,0.134,0.129846324422425,1,1
"RGB-286638","CDK inhibitor","CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK9, FLT3, GSK3B, JAK2, MAP3K7, MAPK9","COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1, COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1, COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1, COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1, COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1",545.2750526,40,1.532,115.06,0.00362993913765779,0.256,0.129814969568829,0,1
"DR-2313","PARP inhibitor","PARP1, PARP3","Cc1nc(=O)c2CSCCc2[nH]1, Cc1nc(=O)c2CSCCc2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1nc(=O)c2CSCCc2[nH]1",182.05138394,12,1.906,71.05,0.0935906928821803,0.166,0.12979534644109,0,1
"zuranolone","GABA receptor agonist","","[H][C@@]12CC[C@H](C(=O)Cn3cc(cn3)C#N)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@]2([H])C[C@](C)(O)CC[C@]12[H]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","[H][C@@]12CC[C@H](C(=O)Cn3cc(cn3)C#N)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@]2([H])C[C@](C)(O)CC[C@]12[H]",409.27292736,35,5.609,78.91,0.157480569247017,0.102,0.129740284623508,1,0
"SB-216641","serotonin receptor antagonist","HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C","COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1OCCN(C)C, COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1OCCN(C)C",0,0,0,0,0,0,0,0,1,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1OCCN(C)C",486.22670544,36,5.15,89.72,0.0253368069484902,0.234,0.129668403474245,0,1
"VU0357121","glutamate receptor positive allosteric modulator","GRM5","CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F, CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F, CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F, CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F, CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F, CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F, CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F",305.122735224,22,4.58,38.33,0.183281181677758,0.076,0.129640590838879,1,0
"cardionogen-1","WNT signaling inhibitor","CTNNB1","C1CCC(CC1)c1nn2c(nnc2s1)-c1ccco1, C1CCC(CC1)c1nn2c(nnc2s1)-c1ccco1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C1CCC(CC1)c1nn2c(nnc2s1)-c1ccco1",274.088832068,19,3.967,84.46,0.0651688384630356,0.194,0.129584419231518,0,1
"T-5601640","LIM kinase inhibitor","LIMK2","Cc1cc(on1)C(=O)Nc1cccc(c1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1cc(on1)C(=O)Nc1cccc(c1)C(=O)Nc1cccc(c1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(on1)C(=O)Nc1cccc(c1)C(=O)Nc1cccc(c1)C(F)(F)F",389.098725968,28,3.805,84.23,0.0331274376073265,0.226,0.129563718803663,0,1
"vipadenant","adenosine receptor antagonist","ADORA1, ADORA2A, ADORA2B, ADORA3","Cc1cc(Cn2nnc3c(nc(N)nc23)-c2ccco2)ccc1N, Cc1cc(Cn2nnc3c(nc(N)nc23)-c2ccco2)ccc1N, Cc1cc(Cn2nnc3c(nc(N)nc23)-c2ccco2)ccc1N, Cc1cc(Cn2nnc3c(nc(N)nc23)-c2ccco2)ccc1N, Cc1cc(Cn2nnc3c(nc(N)nc23)-c2ccco2)ccc1N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1cc(Cn2nnc3c(nc(N)nc23)-c2ccco2)ccc1N",321.1338081,24,1.198,121.67,0.01509887511336,0.244,0.12954943755668,0,1
"methanesulfonyl-fluoride","acetylcholinesterase inhibitor","ACHE","CS(F)(=O)=O, CS(F)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CS(F)(=O)=O",97.983778556,5,-0.0630000000000001,42.52,0.155093123595191,0.104,0.129546561797595,1,0
"KL-001","proteasome inhibitor","CRY1, CRY2","CS(=O)(=O)N(C[C@@H](O)Cn1c2ccccc2c2ccccc12)Cc1ccco1 |&1:6,r|, CS(=O)(=O)N(C[C@@H](O)Cn1c2ccccc2c2ccccc12)Cc1ccco1 |&1:6,r|, CS(=O)(=O)N(C[C@@H](O)Cn1c2ccccc2c2ccccc12)Cc1ccco1 |&1:6,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CS(=O)(=O)N(C[C@@H](O)Cn1c2ccccc2c2ccccc12)Cc1ccco1 |&1:6",398.130028184,28,3.017,84.06,0.0223350916439589,0.236,0.129167545821979,0,1
"aldoxorubicin","topoisomerase inhibitor","TOP2A","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(\CO)=N\NC(=O)CCCCCN1C(=O)C=CC1=O |c:55|, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(\CO)=N\NC(=O)CCCCCN1C(=O)C=CC1=O |c:55|, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(\CO)=N\NC(=O)CCCCCN1C(=O)C=CC1=O |c:55|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(\CO)=N\NC(=O)CCCCCN1C(=O)C=CC1=O |c:55|",750.274837404,54,1.104,267.84,1.77846405154568e-05,0.258,0.129008892320258,0,1
"CPI-444","adenosine receptor antagonist","","Cc1ccc(o1)-c1nc(N)nc2n(Cc3cccc(CO[C@H]4CCOC4)n3)nnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","Cc1ccc(o1)-c1nc(N)nc2n(Cc3cccc(CO[C@H]4CCOC4)n3)nnc12",407.170587532,30,0.654,127,0.00600328985494777,0.252,0.129001644927474,0,1
"homidium","","","CC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12, CC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12",314.165174060091,24,5.68,55.92,0.199800812394184,0.058,0.128900406197092,1,0
"EIT-hydrobromide","nitric oxide synthase inhibitor","NOS2, NOS3","CCSC(N)=N, CCSC(N)=N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCSC(N)=N",104.040819256,6,0.789,75.17,0.103632275884269,0.154,0.128816137942135,0,1
"EMD-66684","angiotensin receptor antagonist","AGTR1","CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1",510.2491722,38,5.894,114.59,0.0154074376665136,0.242,0.128703718833257,0,1
"bupicomide","adrenergic receptor antagonist","ADRB1","CCCCc1ccc(nc1)C(N)=O, CCCCc1ccc(nc1)C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"phase 1","","","CCCCc1ccc(nc1)C(N)=O",178.110613068,13,1.574,55.98,0.157364823090313,0.1,0.128682411545156,1,0
"blebbistatin-(+/-)","ATPase inhibitor","MYH14, MYH2","Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1 |&1:10,r,t:5|, Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1 |&1:10,r,t:5|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1 |&1:10",292.121177752,22,3.151,52.9,0.133341914344926,0.124,0.128670957172463,1,0
"blebbistatin-(-)","ATPase inhibitor","","Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1 |t:5|, Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1 |t:5|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1 |t:5|",292.121177752,22,3.151,52.9,0.133341914344926,0.124,0.128670957172463,1,0
"3-methyl-GABA","GABA aminotransferase activator","ABAT","C[C@@H](CN)CC(O)=O |&1:1|, C[C@@H](CN)CC(O)=O |&1:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](CN)CC(O)=O |&1:1|",117.078978592,8,-0.371,63.32,0.117305210092817,0.14,0.128652605046408,1,1
"linopirdine","potassium channel blocker","KCNQ2, KCNQ3, KCNQ4, KCNQ5","O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1, O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1, O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1, O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1",391.168462292,30,3.801,46.09,0.111146071269179,0.146,0.128573035634589,0,1
"2-iminobiotin","nitric oxide synthase inhibitor","NOS1, NOS2","NC1=N[C@H]2CS[C@@H](CCCCC(O)=O)[C@H]2N1 |t:1|, NC1=N[C@H]2CS[C@@H](CCCCC(O)=O)[C@H]2N1 |t:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NC1=N[C@H]2CS[C@@H](CCCCC(O)=O)[C@H]2N1 |t:1|",243.104147784,16,0.798,113.01,0.0170714651673904,0.24,0.128535732583695,0,1
"LY393558","serotonin receptor antagonist","HTR1B, HTR1D, HTR2A, HTR2B","CC(C)N1Cc2cc(ccc2N(CCN2CCC(=CC2)c2c[nH]c3cc(F)ccc23)S1(=O)=O)S(C)(=O)=O |c:18|, CC(C)N1Cc2cc(ccc2N(CCN2CCC(=CC2)c2c[nH]c3cc(F)ccc23)S1(=O)=O)S(C)(=O)=O |c:18|",0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)N1Cc2cc(ccc2N(CCN2CCC(=CC2)c2c[nH]c3cc(F)ccc23)S1(=O)=O)S(C)(=O)=O |c:18|",546.177075692,37,3.301,110.55,0.00305080911817462,0.254,0.128525404559087,0,1
"picolinic-acid","chelating agent","","OC(=O)c1ccccn1, OC(=O)c1ccccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)c1ccccn1",123.0320284,9,0.474,50.19,0.194910089910452,0.062,0.128455044955226,1,0
"ozanimod","sphingosine 1-phosphate receptor agonist","S1PR1","CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@H](CCc12)NCCO, CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@H](CCc12)NCCO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@H](CCc12)NCCO",404.184840628,30,3.735,104.2,0.0228952444326733,0.234,0.128447622216337,0,1
"1-EBIO","potassium channel activator","KCNN1, KCNN2, KCNN3, KCNN4","CCn1c2ccccc2[nH]c1=O, CCn1c2ccccc2[nH]c1=O, CCn1c2ccccc2[nH]c1=O, CCn1c2ccccc2[nH]c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCn1c2ccccc2[nH]c1=O",162.07931294,12,1.025,37.79,0.224770929323517,0.032,0.128385464661759,1,0
"ADX-47273","glutamate receptor modulator","GRM5","Fc1ccc(cc1)C(=O)N1CCC[C@@H](C1)c1nc(no1)-c1ccc(F)cc1, Fc1ccc(cc1)C(=O)N1CCC[C@@H](C1)c1nc(no1)-c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1ccc(cc1)C(=O)N1CCC[C@@H](C1)c1nc(no1)-c1ccc(F)cc1",369.128883224,27,4.274,59.23,0.0807617788712271,0.176,0.128380889435614,0,1
"obatoclax","BCL inhibitor","BCL2","COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4",317.152812228,24,3.714,53.17,0.132676188779934,0.124,0.128338094389967,1,0
"naltriben","opioid receptor antagonist","OPRD1, OPRK1, OPRM1","Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1oc2ccccc2c1C[C@@]35O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1oc2ccccc2c1C[C@@]35O",415.17835828,31,2.644,66.07,0.0403203190378331,0.216,0.128160159518917,0,1
"BMS-309403","fatty acid binding protein inhibitor","FABP4","CCc1c(c(nn1-c1ccccc1-c1cccc(OCC(O)=O)c1)-c1ccccc1)-c1ccccc1, CCc1c(c(nn1-c1ccccc1-c1cccc(OCC(O)=O)c1)-c1ccccc1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCc1c(c(nn1-c1ccccc1-c1cccc(OCC(O)=O)c1)-c1ccccc1)-c1ccccc1",474.194342692,36,7.605,64.35,0.10231619812478,0.154,0.12815809906239,0,1
"JNJ-7777120","histamine receptor antagonist","HRH4","CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1, CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1, CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1, CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1",277.098189812,19,2,39.34,0.102307227645554,0.154,0.128153613822777,0,1
"CP-99994","tachykinin antagonist","TACR1","COc1ccccc1CN[C@H]1CCCN[C@H]1c1ccccc1, COc1ccccc1CN[C@H]1CCCN[C@H]1c1ccccc1, COc1ccccc1CN[C@H]1CCCN[C@H]1c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1ccccc1CN[C@H]1CCCN[C@H]1c1ccccc1",296.188863388,22,3.419,33.29,0.190213161432314,0.066,0.128106580716157,1,0
"TAS-103","topoisomerase inhibitor","TOP1","CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12, CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12, CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12",333.147726848,25,3.418,65.46,0.0841671791078289,0.172,0.128083589553914,0,1
"D-64131","microtubule inhibitor","TUBB","COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1, COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1, COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1, COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1, COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1, COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1",251.094628656,19,3.657,42.09,0.230166260730777,0.026,0.128083130365388,1,0
"lithium-acetoacetate","","FAH","CC(=O)CC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)CC(O)=O",102.031694052,7,-0.0340000000000001,54.37,0.168162846478031,0.088,0.128081423239015,1,0
"walrycin-B","transcriptional regulatory protein WalR","","Cn1nc(nc2c1nc(=O)n(C)c2=O)-c1ccc(cc1)C(F)(F)F, Cn1nc(nc2c1nc(=O)n(C)c2=O)-c1ccc(cc1)C(F)(F)F, Cn1nc(nc2c1nc(=O)n(C)c2=O)-c1ccc(cc1)C(F)(F)F, Cn1nc(nc2c1nc(=O)n(C)c2=O)-c1ccc(cc1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cn1nc(nc2c1nc(=O)n(C)c2=O)-c1ccc(cc1)C(F)(F)F",337.07865922,24,4.085,82.67,0.0498870681521222,0.206,0.127943534076061,0,1
"compound-58112","","","COc1cccc(CN2C[Si](C)(C)O[Si](C)(C)C2)c1, COc1cccc(CN2C[Si](C)(C)O[Si](C)(C)C2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cccc(CN2C[Si](C)(C)O[Si](C)(C)C2)c1",295.1423821,19,3.674,21.7,0.143848019901746,0.112,0.127924009950873,1,0
"CX-516","glutamate receptor modulator","","O=C(N1CCCCC1)c1ccc2OCOc2c1, O=C(N1CCCCC1)c1ccc2OCOc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","O=C(N1CCCCC1)c1ccc2OCOc2c1",233.10519334,17,1.922,38.77,0.169838111340768,0.086,0.127919055670384,1,0
"iproniazid","monoamine oxidase inhibitor","MAOA, MAOB","CC(C)NNC(=O)c1ccncc1, CC(C)NNC(=O)c1ccncc1, CC(C)NNC(=O)c1ccncc1",0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CC(C)NNC(=O)c1ccncc1",179.105862036,13,1.434,54.02,0.155687932547658,0.1,0.127843966273829,1,0
"SR-59230A","adrenergic receptor antagonist","ADRB1, ADRB2, ADRB3","CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12, CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12, CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12, CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,"preclinical","","","CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12",325.204179104,24,4.155,41.49,0.155637601008273,0.1,0.127818800504136,1,0
"PD-168077","dopamine receptor agonist","DRD2","Cc1cccc(c1)C(=O)NCN1CCN(CC1)c1ccccc1C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cccc(c1)C(=O)NCN1CCN(CC1)c1ccccc1C#N",334.179361324,25,3.508,59.37,0.0954847070729276,0.16,0.127742353536464,0,1
"SB-271046","serotonin receptor antagonist","HTR6","COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1",451.079111244,29,3.566,107.29,0.00538653984383812,0.25,0.127693269921919,0,1
"nidufexor","fxr agonist","NR1H4","Cn1nc(C(=O)N(Cc2ccccc2)Cc3ccc(cc3)C(=O)O)c4COc5ccc(Cl)cc5c14",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","gastroenterology","non-alcoholic steatohepatitis (nash)","Cn1nc(C(=O)N(Cc2ccccc2)Cc3ccc(cc3)C(=O)O)c4COc5ccc(Cl)cc5c14",487.129883864,35,5.352,84.66,0.023316208175765,0.232,0.127658104087883,0,1
"pozanicline","acetylcholine receptor antagonist","CHRNA4, CHRNB2","Cc1ncccc1OC[C@@H]1CCCN1, Cc1ncccc1OC[C@@H]1CCCN1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,"phase 2","","","Cc1ncccc1OC[C@@H]1CCCN1",192.126263132,14,1.157,34.15,0.201193767265151,0.054,0.127596883632575,1,0
"firsocostat","acetyl-CoA carboxylase inhibitor","","COc1ccccc1[C@H](Cn1c2sc(c(C)c2c(=O)n(c1=O)C(C)(C)C(O)=O)-c1ncco1)OC1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1ccccc1[C@H](Cn1c2sc(c(C)c2c(=O)n(c1=O)C(C)(C)C(O)=O)-c1ncco1)OC1CCOCC1",569.183185952,40,3.115,163.26,0.000991158845605509,0.254,0.127495579422803,0,1
"BAM7","BAX activator","BAX","CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|, CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|, CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|, CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|, CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|, CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|",405.125945848,29,5.084,107.42,0.0229698196576394,0.232,0.12748490982882,0,1
"sulopenem","antibacterial","","C[C@@H](O)[C@@H]1[C@H]2SC(S[C@H]3CC[S@@](=O)C3)=C(N2C1=O)C(O)=O |&1:11,c:14|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C[C@@H](O)[C@@H]1[C@H]2SC(S[C@H]3CC[S@@](=O)C3)=C(N2C1=O)C(O)=O |&1:11",349.01123558,21,-0.898,164.72,0.000868388168483095,0.254,0.127434194084242,0,1
"L-701324","glutamate receptor antagonist","GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D","Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12, Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12, Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12, Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12",363.066220988,26,5.808,62.32,0.0986019560127571,0.156,0.127300978006379,0,1
"edaglitazone","PPAR receptor agonist","PPARG","Cc1oc(nc1CCOc1ccc(C[C@@H]2SC(=O)NC2=O)c2sccc12)-c1ccccc1 |&1:14,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1oc(nc1CCOc1ccc(C[C@@H]2SC(=O)NC2=O)c2sccc12)-c1ccccc1 |&1:14",464.08644912,32,3.932,134.97,0.00454103584068898,0.25,0.127270517920344,0,1
"WB-4101","adrenergic receptor antagonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1A","COc1cccc(OC)c1OCCNC[C@H]1COc2ccccc2O1 |&1:15|, COc1cccc(OC)c1OCCNC[C@H]1COc2ccccc2O1 |&1:15|, COc1cccc(OC)c1OCCNC[C@H]1COc2ccccc2O1 |&1:15|",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,6,0,0,0,0,"preclinical","","","COc1cccc(OC)c1OCCNC[C@H]1COc2ccccc2O1 |&1:15|",345.157622836,25,2.582,58.18,0.0623569343507102,0.192,0.127178467175355,0,1
"GW-438014A","neuropeptide receptor antagonist","NPY5R","O=C(Nc1nc2ccccc2n1CCc1ccccc1)c1ccccc1, O=C(Nc1nc2ccccc2n1CCc1ccccc1)c1ccccc1, O=C(Nc1nc2ccccc2n1CCc1ccccc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(Nc1nc2ccccc2n1CCc1ccccc1)c1ccccc1",341.152812228,26,4.952,46.92,0.176263583369538,0.078,0.127131791684769,1,0
"TD139","anti-inflammatory agent","","OC[C@H]1O[C@@H](S[C@@H]2O[C@H](CO)[C@H](O)[C@@H]([C@H]2O)n2cc(nn2)-c2cccc(F)c2)[C@H](O)[C@H]([C@H]1O)n1cc(nn1)-c1cccc(F)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC[C@H]1O[C@@H](S[C@@H]2O[C@H](CO)[C@H](O)[C@@H]([C@H]2O)n2cc(nn2)-c2cccc(F)c2)[C@H](O)[C@H]([C@H]1O)n1cc(nn1)-c1cccc(F)c1",648.18138936,45,0.366999999999999,226.56,5.57888951988785e-05,0.254,0.127027894447599,0,1
"ARQ-621","kinesin-like spindle protein inhibitor","KIF11","NCCCN([C@H](CC#C)c1nc2cc(Cl)ccc2c(=O)n1Nc1ccccc1)C(=O)c1cccc(Cl)c1F, NCCCN([C@H](CC#C)c1nc2cc(Cl)ccc2c(=O)n1Nc1ccccc1)C(=O)c1cccc(Cl)c1F, NCCCN([C@H](CC#C)c1nc2cc(Cl)ccc2c(=O)n1Nc1ccccc1)C(=O)c1cccc(Cl)c1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","NCCCN([C@H](CC#C)c1nc2cc(Cl)ccc2c(=O)n1Nc1ccccc1)C(=O)c1cccc(Cl)c1F",551.129108588,38,6.099,93.25,0.0100527010068983,0.244,0.127026350503449,0,1
"proadifen","nitric oxide synthase inhibitor","NOS1","CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1, CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1, CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1",353.235479232,26,5.984,29.54,0.236008538886652,0.018,0.127004269443326,1,0
"alaproclate","serotonin receptor antagonist","SLC6A4","C[C@@H](N)C(=O)OC(C)(C)Cc1ccc(Cl)cc1 |&1:1|, C[C@@H](N)C(=O)OC(C)(C)Cc1ccc(Cl)cc1 |&1:1|",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@@H](N)C(=O)OC(C)(C)Cc1ccc(Cl)cc1 |&1:1|",255.102606496,17,3.03,52.32,0.103859077788384,0.15,0.126929538894192,0,1
"sb-218078","chk inhibitor","CHEK1","[H][C@]12CC[C@]([H])(O1)n1c3ccccc3c3c4C(=O)NC(=O)c4c4c5ccccc5n2c4c13 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@]12CC[C@]([H])(O1)n1c3ccccc3c3c4C(=O)NC(=O)c4c4c5ccccc5n2c4c13 |r|",393.11134134,32,6.372,65.26,0.185672166868558,0.068,0.126836083434279,1,0
"NK-252","nuclear factor erythroid derived, like (NRF2) activator","NFE2L2","O=C(NCc1ccccn1)Nc1nnc(o1)-c1ccco1, O=C(NCc1ccccn1)Nc1nnc(o1)-c1ccco1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(NCc1ccccn1)Nc1nnc(o1)-c1ccco1",285.086189212,21,1.525,106.08,0.0274993428745127,0.226,0.126749671437256,0,1
"GR-127935","serotonin receptor antagonist","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6","COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1, COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1, COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1, COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1, COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1",0,0,0,0,0,0,0,0,1,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1",497.242689852,37,5.622,83.73,0.0314277517001483,0.222,0.126713875850074,0,1
"prisotinol","","","CC(C)N[C@H](C)Cc1ccc(O)cn1 |&1:4,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)N[C@H](C)Cc1ccc(O)cn1 |&1:4",194.141913196,14,1.466,45.15,0.167109006950647,0.086,0.126554503475323,1,0
"cot-inhibitor-1","MAPK-interacting kinase inhibitor","MAP3K8","Fc1ccc(Nc2c(cnc3c(Cl)cc(NCc4cn(CCN5CCCCCC5)nn4)cc23)C#N)cc1Cl, Fc1ccc(Nc2c(cnc3c(Cl)cc(NCc4cn(CCN5CCCCCC5)nn4)cc23)C#N)cc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1ccc(Nc2c(cnc3c(Cl)cc(NCc4cn(CCN5CCCCCC5)nn4)cc23)C#N)cc1Cl",552.171976444,38,4.847,94.69,0.00699696611936143,0.246,0.126498483059681,0,1
"prinaberel","estrogen receptor agonist","ESR2, NCOA1","Oc1cc(C=C)c2oc(nc2c1)-c1ccc(O)c(F)c1, Oc1cc(C=C)c2oc(nc2c1)-c1ccc(O)c(F)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Oc1cc(C=C)c2oc(nc2c1)-c1ccc(O)c(F)c1",271.0644714,20,3.235,66.49,0.106824419146919,0.146,0.126412209573459,0,1
"isamoltane","adrenergic receptor antagonist","HTR1A, HTR1B","CC(C)NC[C@@H](O)COc1ccccc1-n1cccc1 |&1:5|, CC(C)NC[C@@H](O)COc1ccccc1-n1cccc1 |&1:5|",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)NC[C@@H](O)COc1ccccc1-n1cccc1 |&1:5|",274.168127944,20,2.429,46.42,0.126723678154554,0.126,0.126361839077277,1,0
"TC-F-2","FAAH inhibitor","FAAH","CCn1c2ccccc2n([C@H]2CCCN(C2)c2nccc(n2)-c2cc3ccccc3o2)c1=O, CCn1c2ccccc2n([C@H]2CCCN(C2)c2nccc(n2)-c2cc3ccccc3o2)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCn1c2ccccc2n([C@H]2CCCN(C2)c2nccc(n2)-c2cc3ccccc3o2)c1=O",439.20082504,33,4.371,69.09,0.0507095760017264,0.202,0.126354788000863,0,1
"O4I1","Oct inducer","POU5F1","COc1ccc(COc2ccc(CC#N)cc2)cc1, COc1ccc(COc2ccc(CC#N)cc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(COc2ccc(CC#N)cc2)cc1",253.11027872,19,3.1,42.25,0.198465281115432,0.054,0.126232640557716,1,0
"OXA-06","rho associated kinase inhibitor","ROCK1, ROCK2","Fc1ccccc1CNCc1ccc(cc1)-c1ccnc2[nH]ccc12, Fc1ccccc1CNCc1ccc(cc1)-c1ccnc2[nH]ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1ccccc1CNCc1ccc(cc1)-c1ccnc2[nH]ccc12",331.148475796,25,4.974,40.71,0.20040815260491,0.052,0.126204076302455,1,0
"AMG-837","free fatty acid receptor agonist","FFAR1","CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1, CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1, CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1, CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1, CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1",438.144279192,32,6.755,46.53,0.11640178296498,0.136,0.12620089148249,1,1
"laquinimod","immunosuppressant","CXCL2","CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1, CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1, CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1, CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1, CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1",356.092770084,25,5.054,62.54,0.0782311074620606,0.174,0.12611555373103,0,1
"tecastemizole","histamine receptor antagonist","KCNH2","Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1, Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1, Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1, Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1",324.175024892,24,3.787,41.88,0.146070440184144,0.106,0.126035220092072,1,0
"S-sulfo-L-cysteine","glutamate receptor agonist","","N[C@@H](CSS(O)(=O)=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@@H](CSS(O)(=O)=O)C(O)=O",200.976564324,11,-4.104,151.37,0.00185155228465423,0.25,0.125925776142327,0,1
"fanetizole","neutrophil superoxide production","","C(Cc1ccccc1)Nc1nc(cs1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C(Cc1ccccc1)Nc1nc(cs1)-c1ccccc1",280.103419512,20,4.372,53.16,0.147823728143914,0.104,0.125911864071957,1,0
"ebselen","cyclooxygenase inhibitor, glutathione peroxidase agonist, H+/K+-ATPase inhibitor, nitric oxide synthase inhibitor","ALB","O=c1n([se]c2ccccc12)-c1ccccc1, O=c1n([se]c2ccccc12)-c1ccccc1, O=c1n([se]c2ccccc12)-c1ccccc1, O=c1n([se]c2ccccc12)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","O=c1n([se]c2ccccc12)-c1ccccc1",274.984935208,16,3.126,22,0.105794355890785,0.146,0.125897177945392,0,1
"MK-1903","niacin receptor agonist","","OC(=O)c1n[nH]c2[C@@H]3C[C@@H]3Cc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)c1n[nH]c2[C@@H]3C[C@@H]3Cc12",164.058577496,12,0.871,65.98,0.121670292938916,0.13,0.125835146469458,1,1
"AQ-13","antimalarial agent","","CCN(CC)CCCNc1ccnc2cc(Cl)ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCN(CC)CCCNc1ccnc2cc(Cl)ccc12",291.150225384,20,3.45,28.16,0.159425990745509,0.092,0.125712995372754,1,0
"resmetirom","thyroid hormone receptor agonist","","CC(C)c1cc(Oc2c(Cl)cc(cc2Cl)-n2nc(C#N)c(=O)[nH]c2=O)nnc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(C)c1cc(Oc2c(Cl)cc(cc2Cl)-n2nc(C#N)c(=O)[nH]c2=O)nnc1O",434.029708224,29,3.723,146.78,0.00337567362606399,0.248,0.125687836813032,0,1
"VGX-1027","tumor necrosis factor receptor antagonist","TLR4","OC(=O)C[C@H]1CC(=NO1)c1ccccc1 |&1:4,r,c:6|, OC(=O)C[C@H]1CC(=NO1)c1ccccc1 |&1:4,r,c:6|, OC(=O)C[C@H]1CC(=NO1)c1ccccc1 |&1:4,r,c:6|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC(=O)C[C@H]1CC(=NO1)c1ccccc1 |&1:4",205.073893212,15,1.934,58.89,0.136941670001968,0.114,0.125470835000984,1,0
"AS-2444697","interleukin inhibitor","IRAK4","Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1, Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1, Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1, Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1, Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1",396.15460312,29,0.65,138.16,0.00479116388240125,0.246,0.125395581941201,0,1
"TAK-779","CC chemokine receptor antagonist","","Cc1ccc(cc1)-c1ccc2CCCC(=Cc2c1)C(=O)Nc1ccc(C[N+](C)(C)C2CCOCC2)cc1 |c:15|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(cc1)-c1ccc2CCCC(=Cc2c1)C(=O)Nc1ccc(C[N+](C)(C)C2CCOCC2)cc1 |c:15|",495.300604908091,37,6.192,38.33,0.100709829804868,0.15,0.125354914902434,0,1
"4-iodo-L-phenylalanine","","DPP4","N[C@H](Cc1ccc(I)cc1)C(O)=O, N[C@H](Cc1ccc(I)cc1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@H](Cc1ccc(I)cc1)C(O)=O",290.97562656,13,-0.311,63.32,0.00663222337209704,0.244,0.125316111686049,0,1
"thiamet-g","GLCNAC phosphotransferase inhibitor","MGEA5","CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1 |t:3|, CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1 |t:3|, CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1 |t:3|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1 |t:3|",248.083077992,16,-0.932,119.61,0.00858115129785952,0.242,0.12529057564893,0,1
"aleglitazar","ppar receptor agonist","PPARA, PPARG","CC1=C(CCOC2=CC=C(C[C@@H](C(O)=O)OC)C3=C2C=CS3)N=C(C4=CC=CC=C4)O1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","endocrinology","diabetes mellitus","CC1=C(CCOC2=CC=C(C[C@@H](C(O)=O)OC)C3=C2C=CS3)N=C(C4=CC=CC=C4)O1",437.129693836,31,2.566,102.65,0.0103356006155352,0.24,0.125167800307768,0,1
"lirimilast","phosphodiesterase inhibitor","","CS(=O)(=O)Oc1ccc2c(NC(N)=O)c(oc2c1)C(=O)c1ccc(Cl)cc1Cl, CS(=O)(=O)Oc1ccc2c(NC(N)=O)c(oc2c1)C(=O)c1ccc(Cl)cc1Cl, CS(=O)(=O)Oc1ccc2c(NC(N)=O)c(oc2c1)C(=O)c1ccc(Cl)cc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CS(=O)(=O)Oc1ccc2c(NC(N)=O)c(oc2c1)C(=O)c1ccc(Cl)cc1Cl",441.979312464,28,2.681,137.08,0.00215235675062209,0.248,0.125076178375311,0,1
"verubulin","tubulin polymerization inhibitor","TUBB","COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12, COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12, COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12, COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12, COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12",279.137162164,21,3.817,38.25,0.216070455498325,0.034,0.125035227749162,1,0
"flavin-adenine-dinucleotide","","ACAD8, ACADM, ACADS, ACOX1, AIFM1, CYB5R1, CYB5R3, DAO, DLD, DPYD, ERO1LB, FDXR, GCDH, GFER, GSR, IL4I1, IVD, MAOA, MAOB, NOS1, NQO1, NQO2, POR, TXNRD1, XDH","Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO[P@@](O)(=O)O[P@@](O)(=O)OC[C@H]3O[C@H]([C@H](O)[C@@H]3O)n3cnc4c(N)ncnc34)c2cc1C |a:15,17,19,32,34,35,37,&1:23,&2:27|",0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO[P@@](O)(=O)O[P@@](O)(=O)OC[C@H]3O[C@H]([C@H](O)[C@@H]3O)n3cnc4c(N)ncnc34)c2cc1C |a:15",785.157134616,53,-2.71,382.55,1.68458812606228e-07,0.25,0.125000084229406,0,1
"Calhex-231","calcium sensing receptor negative allosteric modulator","CASR","C[C@@H](N[C@H]1CCCC[C@@H]1NC(=O)c1ccc(Cl)cc1)c1cccc2ccccc12, C[C@@H](N[C@H]1CCCC[C@@H]1NC(=O)c1ccc(Cl)cc1)c1cccc2ccccc12, C[C@@H](N[C@H]1CCCC[C@@H]1NC(=O)c1ccc(Cl)cc1)c1cccc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](N[C@H]1CCCC[C@@H]1NC(=O)c1ccc(Cl)cc1)c1cccc2ccccc12",406.181191164,29,6.461,41.13,0.129998041529584,0.12,0.124999020764792,1,0
"voxtalisib","mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA","CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O, CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O, CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O",270.122909068,20,2.003,102.48,0.0377728133791781,0.212,0.124886406689589,0,1
"S-methylcysteine","","CTSD, MGMT","CSC[C@H](N)C(O)=O, CSC[C@H](N)C(O)=O, CSC[C@H](N)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CSC[C@H](N)C(O)=O",135.035399528,8,-2.211,88.62,0.0297293290398619,0.22,0.124864664519931,0,1
"osemozotan","serotonin receptor agonist","HTR1A","C(CNC[C@H]1COc2ccccc2O1)COc1ccc2OCOc2c1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","C(CNC[C@H]1COc2ccccc2O1)COc1ccc2OCOc2c1",343.141972772,25,2.867,58.18,0.0696300163331962,0.18,0.124815008166598,0,1
"XAV-939","tankyrase inhibitor","TNKS, TNKS2","FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1, FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1, FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1, FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1, FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1",312.054418632,21,4.545,71.05,0.0655228847290467,0.184,0.124761442364523,0,1
"4-DAMP","cholinergic receptor antagonist","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","C[N+]1(C)CCC(CC1)OC(=O)C(c1ccccc1)c1ccccc1, C[N+]1(C)CCC(CC1)OC(=O)C(c1ccccc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,5,0,0,0,0,0,0,"preclinical","","","C[N+]1(C)CCC(CC1)OC(=O)C(c1ccccc1)c1ccccc1",324.195805492091,24,3.642,26.3,0.191446915759514,0.058,0.124723457879757,1,0
"L-733060","tachykinin antagonist","TACR1","FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F",403.137083548,28,5.55,21.26,0.139258019714636,0.11,0.124629009857318,1,0
"PYR-41","ubiquitin activating enzyme inhibitor","","CCOC(=O)c1ccc(cc1)N1NC(=O)\C(=C\c2ccc(o2)[N+]([O-])=O)C1=O, CCOC(=O)c1ccc(cc1)N1NC(=O)\C(=C\c2ccc(o2)[N+]([O-])=O)C1=O, CCOC(=O)c1ccc(cc1)N1NC(=O)\C(=C\c2ccc(o2)[N+]([O-])=O)C1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)c1ccc(cc1)N1NC(=O)\C(=C\c2ccc(o2)[N+]([O-])=O)C1=O",371.075349756,27,2.202,131.99,0.00925166046045343,0.24,0.124625830230227,0,1
"veledimex","cytochrome P450 inhibitor","","CCC[C@@H](N(NC(=O)c1cccc(OC)c1CC)C(=O)c1cc(C)cc(C)c1)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCC[C@@H](N(NC(=O)c1cccc(OC)c1CC)C(=O)c1cc(C)cc(C)c1)C(C)(C)C",438.288243076,32,7.255,58.64,0.100789074708778,0.148,0.124394537354389,0,1
"ML228","hypoxia inducible factor activator","HIF1A","C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1, C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1, C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1, C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1, C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1, C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1, C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1",415.179695672,32,5.818,63.59,0.108783799104479,0.14,0.12439189955224,0,1
"cb-103","notch signaling inhibitor","NOTCH1","CC(C)(C)c1ccc(Oc2ccc(N)cn2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","oncology","breast cancer","CC(C)(C)c1ccc(Oc2ccc(N)cn2)cc1",242.141913196,18,3.979,48.14,0.216696469674209,0.032,0.124348234837104,1,0
"LY303511","casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor","BRD2, BRD3, BRD4","O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1",306.136827816,23,4.77,45.48,0.196671929751568,0.052,0.124335964875784,1,0
"GS-967","voltage-gated sodium channel blocker","","FC(F)(F)Oc1ccc(cc1)-c1ccc2nnc(n2c1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)Oc1ccc(cc1)-c1ccc2nnc(n2c1)C(F)(F)F",347.049331164,24,6.817,39.42,0.180587995726038,0.068,0.124293997863019,1,0
"proxyfan","histamine receptor modulator","HRH3","C(COCc1ccccc1)Cc1cnc[nH]1, C(COCc1ccccc1)Cc1cnc[nH]1, C(COCc1ccccc1)Cc1cnc[nH]1",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C(COCc1ccccc1)Cc1cnc[nH]1",216.126263132,16,1.906,37.91,0.198572966350372,0.05,0.124286483175186,1,0
"T-62","adenosine receptor modulator","ADORA2A","Nc1sc2CCCCc2c1C(=O)c1ccc(Cl)cc1, Nc1sc2CCCCc2c1C(=O)c1ccc(Cl)cc1, Nc1sc2CCCCc2c1C(=O)c1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Nc1sc2CCCCc2c1C(=O)c1ccc(Cl)cc1",291.048462748,19,3.762,71.33,0.0565302630504096,0.192,0.124265131525205,0,1
"MR-16728","acetylcholine release enhancer","","O=C(NCCCN1CCCCCC1)[C@@H](C1CCCCC1)c1ccccc1 |&1:13|, O=C(NCCCN1CCCCCC1)[C@@H](C1CCCCC1)c1ccccc1 |&1:13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(NCCCN1CCCCCC1)[C@@H](C1CCCCC1)c1ccccc1 |&1:13|",356.282763772,26,5.33,32.34,0.186503022247976,0.062,0.124251511123988,1,0
"mavacamten","myosin inhibitor ","","CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O",273.147726848,20,3.788,66.89,0.114353395191279,0.134,0.124176697595639,0,1
"1400W","nitric oxide synthase inhibitor","NOS1, NOS2, NOS3","CC(=N)NCc1cccc(CN)c1, CC(=N)NCc1cccc(CN)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=N)NCc1cccc(CN)c1",177.12659748,13,1.21,61.9,0.132276882653151,0.116,0.124138441326576,1,0
"luzindole","melatonin receptor antagonist","MTNR1A, MTNR1B","CC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12, CC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12, CC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12",292.15756326,22,3.451,44.89,0.166129672587692,0.082,0.124064836293846,1,0
"pleconaril","","","Cc1cc(CCCOc2c(C)cc(cc2C)-c2noc(n2)C(F)(F)F)on1, Cc1cc(CCCOc2c(C)cc(cc2C)-c2noc(n2)C(F)(F)F)on1, Cc1cc(CCCOc2c(C)cc(cc2C)-c2noc(n2)C(F)(F)F)on1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cc1cc(CCCOc2c(C)cc(cc2C)-c2noc(n2)C(F)(F)F)on1",381.130026096,27,4.592,74.18,0.0479906917393996,0.2,0.1239953458697,0,1
"tasisulam","apoptosis stimulant","","Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1, Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1, Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1, Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1, Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1, Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1, Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1",412.834952512,20,3.203,99.86,0.001842443840979,0.246,0.12392122192049,0,1
"GSK650394","serum/glucocorticoid regulated kinase inhibitor","SGK1, SGK2","OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1",382.168127944,29,7.267,65.98,0.153787740439566,0.094,0.123893870219783,1,0
"5,7-dichlorokynurenic-acid","glutamate receptor antagonist","GLRA2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D","OC(=O)c1cc(=O)c2c(Cl)cc(Cl)cc2[nH]1, OC(=O)c1cc(=O)c2c(Cl)cc(Cl)cc2[nH]1, OC(=O)c1cc(=O)c2c(Cl)cc(Cl)cc2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1cc(=O)c2c(Cl)cc(Cl)cc2[nH]1",256.96464838,16,3.671,70.16,0.0637825103449283,0.184,0.123891255172464,0,1
"2-ethoxybenzoic-acid","analgesic agent","","CCOc1ccccc1C(O)=O, CCOc1ccccc1C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCOc1ccccc1C(O)=O",166.06299418,12,1.975,46.53,0.213677021786217,0.034,0.123838510893109,1,0
"CYM-5442","sphingosine 1-phosphate receptor agonist","S1PR1","CCOc1ccc(cc1OCC)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCO |&1:22|, CCOc1ccc(cc1OCC)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCO |&1:22|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOc1ccc(cc1OCC)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCO |&1:22|",409.200156344,30,3.622,89.64,0.0275515690723903,0.22,0.123775784536195,0,1
"ampyrone","cyclooxygenase inhibitor","","Cc1c(N)c(=O)n(-c2ccccc2)n1C, Cc1c(N)c(=O)n(-c2ccccc2)n1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1c(N)c(=O)n(-c2ccccc2)n1C",203.105862036,15,1.258,52.95,0.13919479056091,0.108,0.123597395280455,1,0
"4,4'-DDT","","","Clc1ccc(cc1)C(c1ccc(Cl)cc1)C(Cl)(Cl)Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1ccc(cc1)C(c1ccc(Cl)cc1)C(Cl)(Cl)Cl",351.914688688,19,6.648,0,0.129149081412245,0.118,0.123574540706123,1,0
"phenacetin","cyclooxygenase inhibitor","PTGS1","CCOc1ccc(NC(C)=O)cc1, CCOc1ccc(NC(C)=O)cc1, CCOc1ccc(NC(C)=O)cc1",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CCOc1ccc(NC(C)=O)cc1",179.094628656,13,1.614,38.33,0.217124407045167,0.03,0.123562203522584,1,0
"4-acetyl-1,1-dimethylpiperazinium","acetylcholine receptor agonist","","CC(=O)N1CC[N+](C)(C)CC1, CC(=O)N1CC[N+](C)(C)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)N1CC[N+](C)(C)CC1",157.133539584091,11,-0.696,20.31,0.203071592135864,0.044,0.123535796067932,1,0
"verucerfont","corticotropin releasing factor receptor antagonist","","CC[C@H](Nc1cc(C)nc2c(c(C)nn12)-c1ccc(OC)cc1C)c1nc(C)no1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC[C@H](Nc1cc(C)nc2c(c(C)nn12)-c1ccc(OC)cc1C)c1nc(C)no1",406.211724072,30,4.638,90.37,0.0369694840459361,0.21,0.123484742022968,0,1
"(+)-matrine","opioid receptor agonist","","O=C1CCC[C@@H]2[C@@H]3CCCN4CCC[C@H](CN12)[C@@H]34",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O=C1CCC[C@@H]2[C@@H]3CCCN4CCC[C@H](CN12)[C@@H]34",248.188863388,18,1.381,23.55,0.18289548336473,0.064,0.123447741682365,1,0
"matrine","opioid receptor agonist","OPRK1","O=C1CCC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O=C1CCC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34",248.188863388,18,1.381,23.55,0.18289548336473,0.064,0.123447741682365,1,0
"BET-BAY-002","bromodomain inhibitor","","Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1 |t:7|, Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1 |t:7|, Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1 |t:7|, Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1 |t:7|, Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1 |t:7|, Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1 |t:7|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1 |t:7|",403.119987876,29,7.411,69.63,0.0948801743188531,0.152,0.123440087159427,0,1
"PJ-34","PARP inhibitor","EEF2, PARP1, PARP15, PARP3","CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1",295.132076784,22,2.216,65.2,0.0788384603358845,0.168,0.123419230167942,0,1
"lazertinib","tyrosine kinase inhibitor","","COc1cc(N2CCOCC2)c(NC(=O)C=C)cc1Nc1nccc(n1)-n1cc(CN(C)C)c(n1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","COc1cc(N2CCOCC2)c(NC(=O)C=C)cc1Nc1nccc(n1)-n1cc(CN(C)C)c(n1)-c1ccccc1",554.275386948,41,3.492,109.67,0.0067335609919877,0.24,0.123366780495994,0,1
"SCH-58261","adenosine receptor antagonist","ADORA1, ADORA2A, ADORA2B, ADORA3","Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1",345.1338081,26,3.084,100.06,0.0346484681231595,0.212,0.12332423406158,0,1
"3-AQC","serotonin receptor agonist","HTR3A","C=CCN1CCN(CC1)c1nc2ccccc2nc1C#N, C=CCN1CCN(CC1)c1nc2ccccc2nc1C#N, C=CCN1CCN(CC1)c1nc2ccccc2nc1C#N",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C=CCN1CCN(CC1)c1nc2ccccc2nc1C#N",279.148395544,21,2.089,56.05,0.10663953525554,0.14,0.12331976762777,0,1
"trequinsin","phosphodiesterase inhibitor","PDE5A","COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC, COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC, COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC, COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC",405.205241724,30,5.144,57.75,0.0866239327593532,0.16,0.123311966379677,0,1
"PI-103","mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC","Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1",348.122240372,26,2.973,84.51,0.0445561064557183,0.202,0.123278053227859,0,1
"oxiniacic-acid","","","OC(=O)c1ccc[n+]([O-])c1, OC(=O)c1ccc[n+]([O-])c1, OC(=O)c1ccc[n+]([O-])c1, OC(=O)c1ccc[n+]([O-])c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1ccc[n+]([O-])c1",139.02694302,10,0.95,64.24,0.144381412010965,0.102,0.123190706005482,1,0
"TCS-PIM-1-1","Pim kinase inhibitor","PIM1","Oc1ccc(Br)cc1-c1cc(-c2ccccc2)c(C#N)c(=O)[nH]1, Oc1ccc(Br)cc1-c1cc(-c2ccccc2)c(C#N)c(=O)[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(Br)cc1-c1cc(-c2ccccc2)c(C#N)c(=O)[nH]1",366.000389692,23,4.9,76.88,0.0283428264873732,0.218,0.123171413243687,0,1
"S63845","MCL1 inhibitor","","CN1CCN(CCOc2ccc(-c3c(sc4ncnc(O[C@H](Cc5ccccc5OCc5ccnn5CC(F)(F)F)C(O)=O)c34)-c3ccc(F)o3)c(C)c2Cl)CC1, CN1CCN(CCOc2ccc(-c3c(sc4ncnc(O[C@H](Cc5ccccc5OCc5ccnn5CC(F)(F)F)C(O)=O)c34)-c3ccc(F)o3)c(C)c2Cl)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCN(CCOc2ccc(-c3c(sc4ncnc(O[C@H](Cc5ccccc5OCc5ccnn5CC(F)(F)F)C(O)=O)c34)-c3ccc(F)o3)c(C)c2Cl)CC1",828.211994464,57,6.777,156.45,0.00029291900064443,0.246,0.123146459500322,0,1
"mexeneone","","","COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1, COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1, COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1",242.094294308,18,3.951,46.53,0.22210727123509,0.024,0.123053635617545,1,0
"GLPG1837","CFTR channel potentiator","","CC1(C)Cc2c(sc(NC(=O)c3cc[nH]n3)c2C(N)=O)C(C)(C)O1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC1(C)Cc2c(sc(NC(=O)c3cc[nH]n3)c2C(N)=O)C(C)(C)O1",348.1256115,24,1.616,138.34,0.00601646853409981,0.24,0.12300823426705,0,1
"3-amino-benzamide","PARP inhibitor","PARP1","NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NC(=O)c1cccc(N)c1",136.063662876,10,0.0920000000000001,69.11,0.1158950488954,0.13,0.1229475244477,1,1
"BRL-15572","serotonin receptor antagonist","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6","O[C@@H](CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1 |&1:1|, O[C@@H](CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1 |&1:1|, O[C@@H](CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1 |&1:1|, O[C@@H](CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1 |&1:1|",0,0,0,0,0,0,0,0,1,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O[C@@H](CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1 |&1:1|",406.181191164,29,5.302,26.71,0.135756488983231,0.11,0.122878244491615,1,0
"remacemide","glutamate receptor antagonist","GRIN1","C[C@@](Cc1ccccc1)(NC(=O)CN)c1ccccc1 |&1:1|, C[C@@](Cc1ccccc1)(NC(=O)CN)c1ccccc1 |&1:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C[C@@](Cc1ccccc1)(NC(=O)CN)c1ccccc1 |&1:1|",268.15756326,20,2.397,55.12,0.119616028719532,0.126,0.122808014359766,1,0
"sanguinarium-chloride","apoptosis stimulant","CASP3","C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12",332.091734348091,25,5.544,40.8,0.21950409478116,0.026,0.12275204739058,1,0
"licochalcone a","topoisomerase inhibitor","","COc1cc(O)c(cc1C=CC(=O)c1ccc(O)cc1)C(C)(C)C=C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1cc(O)c(cc1C=CC(=O)c1ccc(O)cc1)C(C)(C)C=C",338.151809184,25,5.379,66.76,0.11347143314601,0.132,0.122735716573005,0,1
"licochalcone-A","topoisomerase inhibitor","PTPN1","COc1cc(O)c(cc1\C=C\C(=O)c1ccc(O)cc1)C(C)(C)C=C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1cc(O)c(cc1\C=C\C(=O)c1ccc(O)cc1)C(C)(C)C=C",338.151809184,25,5.379,66.76,0.11347143314601,0.132,0.122735716573005,0,1
"preladenant","adenosine receptor antagonist","ADORA1, ADORA2A, ADORA2B, ADORA3","COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1, COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1, COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1, COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1, COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1",503.239335788,37,2.725,125,0.00527788990069508,0.24,0.122638944950348,0,1
"O-304","AMPK activator","","Clc1ccc(Cn2sc(NC(=O)c3ccc(Cl)cc3)nc2=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1ccc(Cn2sc(NC(=O)c3ccc(Cl)cc3)nc2=O)cc1",378.994902952,24,4.048,92.23,0.0150717134904327,0.23,0.122535856745216,0,1
"furamidine","protein arginine N-methyltransferase inhibitor","PRMT1","NC(=N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=N, NC(=N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC(=N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=N",304.132411132,23,3.835,112.88,0.0410441104075066,0.204,0.122522055203753,0,1
"loreclezole","benzodiazepine receptor agonist","GABRB2, GABRB3","Cl\C(=C/n1cncn1)c1ccc(Cl)cc1Cl, Cl\C(=C/n1cncn1)c1ccc(Cl)cc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cl\C(=C/n1cncn1)c1ccc(Cl)cc1Cl",272.962730232,16,3.711,30.71,0.10484585194644,0.14,0.12242292597322,0,1
"Z160","N-type calcium channel blocker","CACNA2D1","O=C(CC(c1ccccc1)c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, O=C(CC(c1ccccc1)c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, O=C(CC(c1ccccc1)c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O=C(CC(c1ccccc1)c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1",460.251463644,35,5.968,23.55,0.178796299165168,0.066,0.122398149582584,1,0
"telatinib","KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","KDR","CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1, CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1, CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1",409.094167052,29,3.14,102.17,0.0147683680667549,0.23,0.122384184033377,0,1
"cadazolid","antibacterial ","","OC[C@H]1CN(C(=O)O1)c1ccc(OCC2(O)CCN(CC2)c2cc3n(cc(C(O)=O)c(=O)c3cc2F)C2CC2)c(F)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","OC[C@H]1CN(C(=O)O1)c1ccc(OCC2(O)CCN(CC2)c2cc3n(cc(C(O)=O)c(=O)c3cc2F)C2CC2)c(F)c1",585.192271328,42,4.837,141.77,0.00268627319795143,0.242,0.122343136598976,0,1
"AM-281","cannabinoid receptor antagonist","CNR1, CNR2, GPR55","Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCOCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCOCC1",555.992979208,30,5.313,59.39,0.00257971288253509,0.242,0.122289856441268,0,1
"DBeQ","ATPase inhibitor","CASP3","C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1, C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1, C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1, C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1",340.16879664,26,5.252,49.84,0.180576961875443,0.064,0.122288480937722,1,0
"eniluracil","dihydropyrimidine dehydrogenase inhibitor","AOX1, DPYD, XDH","O=c1[nH]cc(C#C)c(=O)[nH]1, O=c1[nH]cc(C#C)c(=O)[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","O=c1[nH]cc(C#C)c(=O)[nH]1",136.027277368,10,0.319,65.72,0.130477307717492,0.114,0.122238653858746,1,0
"PPT","estrogen receptor agonist","ESR1","CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1, CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1, CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1, CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1",386.163042564,29,5.97,78.51,0.0824612975015111,0.162,0.122230648750756,0,1
"IC261","casein kinase inhibitor","CSNK1A1, CSNK1D, CSNK1E, CSNK1G2","COc1cc(OC)c(\C=C2\C(=O)Nc3ccccc23)c(OC)c1, COc1cc(OC)c(\C=C2\C(=O)Nc3ccccc23)c(OC)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(OC)c(\C=C2\C(=O)Nc3ccccc23)c(OC)c1",311.115758024,23,2.846,56.79,0.0944519506407624,0.15,0.122225975320381,0,1
"JNJ-63533054","G protein-coupled receptor agonist","GPR139","C[C@H](NC(=O)CNC(=O)c1cccc(Cl)c1)c1ccccc1, C[C@H](NC(=O)CNC(=O)c1cccc(Cl)c1)c1ccccc1, C[C@H](NC(=O)CNC(=O)c1cccc(Cl)c1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H](NC(=O)CNC(=O)c1cccc(Cl)c1)c1ccccc1",316.097855464,22,3.457,58.2,0.0763631168235755,0.168,0.122181558411788,0,1
"indirubin-3-monoxime","CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK2, CDK5, CDK5R1, GSK3B","O\N=C1\C(\Nc2ccccc\12)=C1\C(=O)Nc2ccccc12, O\N=C1\C(\Nc2ccccc\12)=C1\C(=O)Nc2ccccc12, O\N=C1\C(\Nc2ccccc\12)=C1\C(=O)Nc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O\N=C1\C(\Nc2ccccc\12)=C1\C(=O)Nc2ccccc12",277.085126592,21,3.281,73.72,0.100341448800983,0.144,0.122170724400492,0,1
"urethane","local anesthetic","","CCOC(N)=O, CCOC(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(N)=O",89.047678464,6,-0.214,52.32,0.180150480985003,0.064,0.122075240492501,1,0
"CGP-25454A","dopamine receptor antagonist","","CCN(CC)CCNC(=O)c1cc(C#N)c(Cl)cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN(CC)CCNC(=O)c1cc(C#N)c(Cl)cc1OC",309.12440456,21,2.386,65.36,0.0480969855492288,0.196,0.122048492774614,0,1
"DH-97","melatonin receptor antagonist","MTNR1B","CCCCC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12, CCCCC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12, CCCCC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12",334.204513452,25,4.842,44.89,0.169933097668561,0.074,0.121966548834281,1,0
"dexbrompheniramine","histamine receptor antagonist","HRH1","Brc1ccc(cc1)[C@@H](c2ncccc2)CCN(C)C",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","allergy","allergic rhinitis","Brc1ccc(cc1)[C@@H](c2ncccc2)CCN(C)C",318.073160708,19,3.414,16.13,0.0939254059632631,0.15,0.121962702981632,0,1
"NKY-80","adenylyl cyclase inhibitor","ADCY5","Nc1ncc2C(=O)C[C@@H](Cc2n1)c1ccco1 |&1:8,r|, Nc1ncc2C(=O)C[C@@H](Cc2n1)c1ccco1 |&1:8,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1ncc2C(=O)C[C@@H](Cc2n1)c1ccco1 |&1:8",229.085126592,17,-0.283,82.01,0.0459135065671764,0.198,0.121956753283588,0,1
"curcumol","JAK inhibitor","JAK1, JAK2, JAK3","CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C, CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C, CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C, CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C, CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C",236.177630008,17,2.876,29.46,0.229634127730413,0.014,0.121817063865206,1,0
"cebranopadol","opioid receptor agonist","OPRL1, OPRM1","CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1 |r|, CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1 |r|, CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1 |r|",378.210741704,28,4.496,28.26,0.161608166253945,0.082,0.121804083126973,1,0
"SPP86","receptor tyrosine protein kinase inhibitor","RET","CC(C)n1nc(C#Cc2ccccc2)c2c(N)ncnc12, CC(C)n1nc(C#Cc2ccccc2)c2c(N)ncnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)n1nc(C#Cc2ccccc2)c2c(N)ncnc12",277.13274548,21,3.7,69.62,0.119545633102677,0.124,0.121772816551339,1,0
"FGIN-1-27","inositol monophosphatase inhibitor","TSPO","CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1",436.288992024,32,8.579,36.1,0.215286239409655,0.028,0.121643119704828,1,0
"ASP-6537","cyclooxygenase inhibitor","","COc1nc(-c2ccc(OC)cc2)n(n1)-c1ccc(OC)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1nc(-c2ccc(OC)cc2)n(n1)-c1ccc(OC)cc1",311.126991404,23,3.487,58.4,0.105194196501156,0.138,0.121597098250578,0,1
"ORG-12962","serotonin receptor agonist","HTR2A, HTR2B, HTR2C","FC(F)(F)c1ccc(nc1Cl)N1CCNCC1, FC(F)(F)c1ccc(nc1Cl)N1CCNCC1",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","FC(F)(F)c1ccc(nc1Cl)N1CCNCC1",265.059359692,17,2.867,28.16,0.133193230490763,0.11,0.121596615245382,1,0
"cotinine","nicotine metabolite","","CN1[C@@H](CCC1=O)c1cccnc1, CN1[C@@H](CCC1=O)c1cccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN1[C@@H](CCC1=O)c1cccnc1",176.094963004,13,0.391,33.2,0.199109990937608,0.044,0.121554995468804,1,0
"PNU-37883","ATP-sensitive potassium channel antagonist","","C1CCC(CC1)N=C(NC12CC3CC(CC(C3)C1)C2)N1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C1CCC(CC1)N=C(NC12CC3CC(CC(C3)C1)C2)N1CCOCC1",345.27801274,25,5.137,36.86,0.169054235250007,0.074,0.121527117625003,1,0
"ansofaxine hydrochloride","dopamine-norepinephrine reuptake inhibitor","ADRA1A, DRD2, HTR2A","CN(C)C[C@H](c1ccc(OC(=O)c2ccc(C)cc2)cc1)C1(O)CCCCC1.Cl |&1:4,r|",0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,"phase 3","neurology/psychiatry","depression","CN(C)C[C@H](c1ccc(OC(=O)c2ccc(C)cc2)cc1)C1(O)CCCCC1.Cl |&1:4",417.207071564,29,5.365,49.77,0.0669965753094612,0.176,0.121498287654731,0,1
"picartamide","H+/K+-ATPase inhibitor","ATP4A","CNC(=S)[C@]1(CCCS1)c1ccccn1 |&1:4,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CNC(=S)[C@]1(CCCS1)c1ccccn1 |&1:4",238.059840448,15,1.786,82.31,0.0388329954847277,0.204,0.121416497742364,0,1
"letrazuril","antiinfective drug","","Fc1ccc(cc1)[C@@H](C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O |&1:7,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Fc1ccc(cc1)[C@@H](C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O |&1:7",390.008659108,26,3.634,91.54,0.0168275932828575,0.226,0.121413796641429,0,1
"LSN-2463359","glutamate receptor positive allosteric modulator","GRM5","CC(C)NC(=O)c1ccc(cn1)C#Cc1ccncc1, CC(C)NC(=O)c1ccc(cn1)C#Cc1ccncc1, CC(C)NC(=O)c1ccc(cn1)C#Cc1ccncc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)NC(=O)c1ccc(cn1)C#Cc1ccncc1",265.1215121,20,2.495,54.88,0.130803330987419,0.112,0.12140166549371,1,0
"chrysophanic-acid","EGFR inhibitor","EGFR, MTOR","Cc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1, Cc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1",254.0579088,19,2.733,74.6,0.094612778656706,0.148,0.121306389328353,0,1
"SY-640","","","CN(Cc1ccc2OCOc2c1)C(C)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN(Cc1ccc2OCOc2c1)C(C)=O",207.089543276,15,1.051,38.77,0.162561838624211,0.08,0.121280919312106,1,0
"cinromide","","","CCNC(=O)\C=C\c1cccc(Br)c1, CCNC(=O)\C=C\c1cccc(Br)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCNC(=O)\C=C\c1cccc(Br)c1",253.010226104,14,2.92,29.1,0.0923695356358183,0.15,0.121184767817909,0,1
"CCMI","acetylcholine receptor allosteric modulator","CHRNA7","Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"preclinical","","","Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1",387.05413208,26,5.296,67.16,0.0463438269868885,0.196,0.121171913493444,0,1
"navoximod","indoleamine 2,3-dioxygenase inhibitor","IDO1","O[C@H](CC1)CC[C@]1([H])[C@H](O)C[C@@H]2N3C(C4=C2C(F)=CC=C4)=CN=C3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","melanoma","O[C@H](CC1)CC[C@]1([H])[C@H](O)C[C@@H]2N3C(C4=C2C(F)=CC=C4)=CN=C3",316.158706132,24,1.261,56.06,0.074297483860524,0.168,0.121148741930262,0,1
"ICI-169369","serotonin receptor antagonist","","CN(C)CCSc1nc2ccccc2cc1-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN(C)CCSc1nc2ccccc2cc1-c1ccccc1",308.13471964,22,4.684,41.43,0.166221654865579,0.076,0.121110827432789,1,0
"tempol","free radical scavenger","","CC1(C)CC(O)CC(C)(C)N1O, CC1(C)CC(O)CC(C)(C)N1O, CC1(C)CC(O)CC(C)(C)N1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC1(C)CC(O)CC(C)(C)N1O",173.141578848,12,0.763,43.7,0.153961799750451,0.088,0.120980899875226,1,0
"alizarin","","","Oc1ccc2C(=O)c3ccccc3C(=O)c2c1O, Oc1ccc2C(=O)c3ccccc3C(=O)c2c1O, Oc1ccc2C(=O)c3ccccc3C(=O)c2c1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc2C(=O)c3ccccc3C(=O)c2c1O",240.042258736,18,2.457,74.6,0.0978272434543647,0.144,0.120913621727182,0,1
"sardomozide","S-adenosylmethionine decarboxylase inhibitor","","NC(=N)N\N=C1/CCc2c1cccc2C(N)=N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC(=N)N\N=C1/CCc2c1cccc2C(N)=N",230.127994448,17,1.957,124.13,0.0297160116746675,0.212,0.120858005837334,0,1
"immethridine","histamine receptor agonist","HRH3","C(c1cnc[nH]1)c1ccncc1, C(c1cnc[nH]1)c1ccncc1, C(c1cnc[nH]1)c1ccncc1",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C(c1cnc[nH]1)c1ccncc1",159.079647288,12,0.475,41.57,0.199582400339898,0.042,0.120791200169949,1,0
"BU-239","imidazoline receptor agonist, imidazoline receptor ligand","","C1CN=C(N1)c1cnc2ccccc2n1 |c:2|, C1CN=C(N1)c1cnc2ccccc2n1 |c:2|, C1CN=C(N1)c1cnc2ccccc2n1 |c:2|, C1CN=C(N1)c1cnc2ccccc2n1 |c:2|, C1CN=C(N1)c1cnc2ccccc2n1 |c:2|, C1CN=C(N1)c1cnc2ccccc2n1 |c:2|, C1CN=C(N1)c1cnc2ccccc2n1 |c:2|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C1CN=C(N1)c1cnc2ccccc2n1 |c:2|",198.09054632,15,0.716,50.17,0.145469442250476,0.096,0.120734721125238,1,0
"cipargamin","antimalarial agent","","C[C@H]1Cc2c([nH]c3cc(Cl)c(F)cc23)[C@@]2(N1)C(=O)Nc1ccc(Cl)cc21",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@H]1Cc2c([nH]c3cc(Cl)c(F)cc23)[C@@]2(N1)C(=O)Nc1ccc(Cl)cc21",389.049795648,26,4.616,56.92,0.0473649739494421,0.194,0.120682486974721,0,1
"BIBR-1532","telomerase inhibitor","TERT","C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1",331.120843404,25,4.967,66.4,0.12127913340796,0.12,0.12063956670398,1,0
"SCH-28080","ATPase inhibitor","ATP4A","Cc1nc2c(OCc3ccccc3)cccn2c1CC#N, Cc1nc2c(OCc3ccccc3)cccn2c1CC#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1nc2c(OCc3ccccc3)cccn2c1CC#N",277.1215121,21,3.411,50.32,0.165213907984358,0.076,0.120606953992179,1,0
"SR-95639A","acetylcholine receptor agonist","CHRM1","C(CN1CCOCC1)Nc1cc2CCCc3ccccc3-c2nn1, C(CN1CCOCC1)Nc1cc2CCCc3ccccc3-c2nn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"preclinical","","","C(CN1CCOCC1)Nc1cc2CCCc3ccccc3-c2nn1",324.195011388,24,2.478,50.28,0.0926175494631157,0.148,0.120308774731558,0,1
"BMY-45778","IP1 prostacyclin receptor agonist","PTGIR","OC(=O)COc1cccc(c1)-c1ocnc1-c1nc(c(o1)-c1ccccc1)-c1ccccc1, OC(=O)COc1cccc(c1)-c1ocnc1-c1nc(c(o1)-c1ccccc1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)COc1cccc(c1)-c1ocnc1-c1nc(c(o1)-c1ccccc1)-c1ccccc1",438.121571676,33,5.426,98.59,0.0345932584633136,0.206,0.120296629231657,0,1
"BAZ2-ICR","bromodomain inhibitor","ZNF215","Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(cc2)C#N)cn1, Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(cc2)C#N)cn1, Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(cc2)C#N)cn1, Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(cc2)C#N)cn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(cc2)C#N)cn1",357.170193608,27,3.097,77.25,0.0545473683038122,0.186,0.120273684151906,0,1
"creatinine","","","CN1CC(=O)NC1=N, CN1CC(=O)NC1=N, CN1CC(=O)NC1=N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CC(=O)NC1=N",113.058911844,8,0.033,56.19,0.160073675718723,0.08,0.120036837859361,1,0
"JW-55","tankyrase inhibitor","TNKS, TNKS2","COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1",434.184171932,32,2.845,89.8,0.0199464269631603,0.22,0.11997321348158,0,1
"teijin-compound-1","CC chemokine receptor antagonist","CCR2","FC(F)(F)c1cccc(c1)C(=O)NCC(=O)N[C@@H]1CCN(Cc2ccc(Cl)cc2)C1, FC(F)(F)c1cccc(c1)C(=O)NCC(=O)N[C@@H]1CCN(Cc2ccc(Cl)cc2)C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)c1cccc(c1)C(=O)NCC(=O)N[C@@H]1CCN(Cc2ccc(Cl)cc2)C1",439.127439252,30,3.894,61.44,0.027683639981539,0.212,0.119841819990769,0,1
"tramiprosate","beta amyloid protein neurotoxicity inhibitor","APP","NCCCS(O)(=O)=O, NCCCS(O)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","NCCCS(O)(=O)=O",139.030314148,8,-1.32,88.77,0.0333794255552874,0.206,0.119689712777644,0,1
"esonarimod","antirheumatic drug","","CC(=O)SC[C@H](CC(=O)c1ccc(C)cc1)C(O)=O |&1:5,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)SC[C@H](CC(=O)c1ccc(C)cc1)C(O)=O |&1:5",280.076929992,19,2.002,96.74,0.0272975306895797,0.212,0.11964876534479,0,1
"asapiprant","prostaglandin inhibitor","","CC(C)Oc1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(-c2ncco2)c(OCC(O)=O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)Oc1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(-c2ncco2)c(OCC(O)=O)c1",501.156971204,35,2.919,130.79,0.00321510782198029,0.236,0.11960755391099,0,1
"hydroxytacrine-maleate-(R,S)","cholinesterase inhibitor","ACHE","Nc1c2[C@@H](O)CCCc2nc2ccccc12 |&1:3|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1c2[C@@H](O)CCCc2nc2ccccc12 |&1:3|",214.110613068,16,1.251,59.14,0.119213902667455,0.12,0.119606951333728,1,0
"flindokalner","potassium channel agonist","KCNMA1, KCNN4, KCNQ2, KCNQ4, KCNQ5","COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F, COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F, COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F, COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F",359.03361912,24,4.469,38.33,0.087094904682453,0.152,0.119547452341226,0,1
"tipifarnib","farnesyltransferase inhibitor","FNTA, FNTB","Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1, Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1, Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1, Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1, Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1, Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1, Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1",488.117066684,34,6.975,65.84,0.0409096265475464,0.198,0.119454813273773,0,1
"5-methylhydantoin-(D)","","","C[C@H]1NC(=O)NC1=O, C[C@H]1NC(=O)NC1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H]1NC(=O)NC1=O",114.042927432,8,-0.363,58.2,0.138841150080283,0.1,0.119420575040142,1,0
"5-methylhydantoin-(L)","","","C[C@@H]1NC(=O)NC1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H]1NC(=O)NC1=O",114.042927432,8,-0.363,58.2,0.138841150080283,0.1,0.119420575040142,1,0
"declopramide","cell cycle inhibitor","","CCN(CC)CCNC(=O)c1ccc(N)c(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN(CC)CCNC(=O)c1ccc(N)c(Cl)c1",269.12948994,18,1.931,58.36,0.0647896893100851,0.174,0.119394844655043,0,1
"TC-S-7004","DYRK inhibitor","DYRK1A, DYRK1B","COc1ncc2cc(C(=O)Nc3cc(ccc3Cl)C(=O)NCc3cccc(Cl)c3)c(=O)[nH]c2n1, COc1ncc2cc(C(=O)Nc3cc(ccc3Cl)C(=O)NCc3cccc(Cl)c3)c(=O)[nH]c2n1, COc1ncc2cc(C(=O)Nc3cc(ccc3Cl)C(=O)NCc3cccc(Cl)c3)c(=O)[nH]c2n1, COc1ncc2cc(C(=O)Nc3cc(ccc3Cl)C(=O)NCc3cccc(Cl)c3)c(=O)[nH]c2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ncc2cc(C(=O)Nc3cc(ccc3Cl)C(=O)NCc3cccc(Cl)c3)c(=O)[nH]c2n1",497.065759384,34,4.491,126.07,0.00461303615128984,0.234,0.119306518075645,0,1
"N-benzylnaltrindole","opioid receptor antagonist","","Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1c(C[C@@]35O)c2ccccc2n1Cc1ccccc1 |TLB:21:22:7.12.13:4.5.18,23:22:7.12.13:4.5.18|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1c(C[C@@]35O)c2ccccc2n1Cc1ccccc1 |TLB:21:22:7.12.13:4.5.18",504.241292884,38,4.768,57.86,0.0485784643848096,0.19,0.119289232192405,0,1
"SID-7969543","steroidogenic factor antagonist","NR5A1","CCOC(=O)[C@@H](C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O |&1:5,r|, CCOC(=O)[C@@H](C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O |&1:5,r|, CCOC(=O)[C@@H](C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O |&1:5,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)[C@@H](C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O |&1:5",452.158351108,33,3.176,105.09,0.012528405619713,0.226,0.119264202809857,0,1
"acumapimod","p38 MAPK inhibitor","","Cc1ccc(cc1-n1ncc(C(=O)c2cccc(c2)C#N)c1N)C(=O)NC1CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1ccc(cc1-n1ncc(C(=O)c2cccc(c2)C#N)c1N)C(=O)NC1CC1",385.153874848,29,3.636,113.8,0.0224026837616599,0.216,0.11920134188083,0,1
"vanillin","","ABAT, ALDH5A1","COc1cc(C=O)ccc1O, COc1cc(C=O)ccc1O, COc1cc(C=O)ccc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(C=O)ccc1O",152.047344116,11,0.959,46.53,0.190392146069108,0.048,0.119196073034554,1,0
"NS-3861","acetylcholine receptor agonist","CHRNA3, CHRNB4","CN1[C@@H]2CC[C@H]1C=C(C2)c1sccc1Br |&1:2,5,c:7|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,"preclinical","","","CN1[C@@H]2CC[C@H]1C=C(C2)c1sccc1Br |&1:2",283.003032548,15,2.637,31.48,0.0523354033062594,0.186,0.11916770165313,0,1
"3-hydroxy-3-phenylpentanamide","GABA receptor modulator","","CC[C@@](O)(CC(N)=O)c1ccccc1 |&1:2,r|, CC[C@@](O)(CC(N)=O)c1ccccc1 |&1:2,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC[C@@](O)(CC(N)=O)c1ccccc1 |&1:2",193.11027872,14,0.594,63.32,0.0982577249956077,0.14,0.119128862497804,0,1
"R-428","AXL kinase inhibitor","AXL","Nc1nc(Nc2ccc3CC[C@@H](CCc3c2)N2CCCC2)nn1-c1cc2CCCc3ccccc3-c2nn1, Nc1nc(Nc2ccc3CC[C@@H](CCc3c2)N2CCCC2)nn1-c1cc2CCCc3ccccc3-c2nn1, Nc1nc(Nc2ccc3CC[C@@H](CCc3c2)N2CCCC2)nn1-c1cc2CCCc3ccccc3-c2nn1, Nc1nc(Nc2ccc3CC[C@@H](CCc3c2)N2CCCC2)nn1-c1cc2CCCc3ccccc3-c2nn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Nc1nc(Nc2ccc3CC[C@@H](CCc3c2)N2CCCC2)nn1-c1cc2CCCc3ccccc3-c2nn1",506.290643088,38,5.047,97.78,0.020217140873517,0.218,0.119108570436758,0,1
"senicapoc","intermediate conductance potassium channel blocker","KCNN4","NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1, NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1, NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1",323.11217054,24,4.873,43.09,0.182128689783382,0.056,0.119064344891691,1,0
"devazepide","CCK receptor antagonist","","CN1c2ccccc2C(=N[C@H](NC(=O)c2cc3ccccc3[nH]2)C1=O)c1ccccc1 |c:9|, CN1c2ccccc2C(=N[C@H](NC(=O)c2cc3ccccc3[nH]2)C1=O)c1ccccc1 |c:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1c2ccccc2C(=N[C@H](NC(=O)c2cc3ccccc3[nH]2)C1=O)c1ccccc1 |c:9|",408.15862588,31,4.456,77.56,0.0560530297944929,0.182,0.119026514897246,0,1
"AAI101","lactamase inhibitor","","[H][C@@]12CC(=O)N1[C@@H](C(O)=O)[C@](C)(Cn1cc[n+](C)n1)S2(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","[H][C@@]12CC(=O)N1[C@@H](C(O)=O)[C@](C)(Cn1cc[n+](C)n1)S2(=O)=O",315.075767000091,22,-1.267,121.83,0.00604561525945385,0.232,0.119022807629727,0,1
"argireline","neurotransmitter release inhibitor","","CSCC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(C)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CSCC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(C)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O",888.42358436,61,-4.152,484.48,5.95568011413342e-09,0.238,0.11900000297784,0,1
"avridine","immunostimulant","","CCCCCCCCCCCCCCCCCCN(CCCCCCCCCCCCCCCCCC)CCCN(CCO)CCO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCCCCCCCCCCCCN(CCCCCCCCCCCCCCCCCC)CCCN(CCO)CCO",666.70023012,47,17.488,46.94,0.19596565449784,0.042,0.11898282724892,1,0
"TY-52156","sphingosine 1-phosphate receptor antagonist","S1PR3","CC(C)(C)C(=O)C(Nc1ccc(Cl)cc1)=NNc1ccc(Cl)cc1, CC(C)(C)C(=O)C(Nc1ccc(Cl)cc1)=NNc1ccc(Cl)cc1, CC(C)(C)C(=O)C(Nc1ccc(Cl)cc1)=NNc1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)C(=O)C(Nc1ccc(Cl)cc1)=NNc1ccc(Cl)cc1",363.090517588,24,6.235,53.49,0.0858909682993069,0.152,0.118945484149653,0,1
"mivebresib","bromodomain inhibitor","","CCS(=O)(=O)Nc1ccc(Oc2ccc(F)cc2F)c(c1)-c1cn(C)c(=O)c2[nH]ccc12, CCS(=O)(=O)Nc1ccc(Oc2ccc(F)cc2F)c(c1)-c1cn(C)c(=O)c2[nH]ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCS(=O)(=O)Nc1ccc(Oc2ccc(F)cc2F)c(c1)-c1cn(C)c(=O)c2[nH]ccc12",459.106433528,32,5.441,101.57,0.0158830605300943,0.222,0.118941530265047,0,1
"PF-02545920","phosphodiesterase inhibitor","PDE10A","Cn1cc(c(n1)-c1ccc(OCc2ccc3ccccc3n2)cc1)-c1ccncc1, Cn1cc(c(n1)-c1ccc(OCc2ccc3ccccc3n2)cc1)-c1ccncc1, Cn1cc(c(n1)-c1ccc(OCc2ccc3ccccc3n2)cc1)-c1ccncc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cn1cc(c(n1)-c1ccc(OCc2ccc3ccccc3n2)cc1)-c1ccncc1",392.16371126,30,4.878,52.83,0.119735360902662,0.118,0.118867680451331,1,0
"merimepodib","inosine monophosphate dehydrogenase inhibitor","IMPDH1","COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1, COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1, COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1, COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1, COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1, COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1, COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1",452.169584488,33,1.744,123.95,0.00573205491132019,0.232,0.11886602745566,0,1
"AZ960","JAK inhibitor","JAK2","C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1",354.140450952,26,4.808,89.42,0.0535041253227475,0.184,0.118752062661374,0,1
"AC260584","cholinergic receptor agonist","","CCCCC1CCN(CCCN2C(=O)COc3cc(F)ccc23)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCC1CCN(CCCN2C(=O)COc3cc(F)ccc23)CC1",348.221306388,25,4.246,32.78,0.143477270095349,0.094,0.118738635047674,1,0
"AZD3965","monocarboxylate transporter inhibitor","SLC16A1","CC(C)n1c2sc(Cc3c(C)[nH]nc3C(F)(F)F)c(C(=O)N3C[C@](C)(O)CO3)c2c(=O)n(C)c1=O, CC(C)n1c2sc(Cc3c(C)[nH]nc3C(F)(F)F)c(C(=O)N3C[C@](C)(O)CO3)c2c(=O)n(C)c1=O",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)n1c2sc(Cc3c(C)[nH]nc3C(F)(F)F)c(C(=O)N3C[C@](C)(O)CO3)c2c(=O)n(C)c1=O",515.145024528,35,2.874,150.69,0.00143735686646267,0.236,0.118718678433231,0,1
"carsalam","analgesic agent","","O=c1[nH]c(=O)c2ccccc2o1, O=c1[nH]c(=O)c2ccccc2o1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=c1[nH]c(=O)c2ccccc2o1",163.02694302,12,1.829,63.07,0.161166911452861,0.076,0.11858345572643,1,0
"PRT4165","polycomb repressive complex inhibitor","PRC1","O=C1C(=Cc2cccnc2)C(=O)c2ccccc12, O=C1C(=Cc2cccnc2)C(=O)c2ccccc12, O=C1C(=Cc2cccnc2)C(=O)c2ccccc12, O=C1C(=Cc2cccnc2)C(=O)c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C1C(=Cc2cccnc2)C(=O)c2ccccc12",235.063328528,18,2.046,47.03,0.17304142302906,0.064,0.11852071151453,1,0
"dapansutrile","anti-inflammatory agent","","CS(=O)(=O)CCC#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CS(=O)(=O)CCC#N",133.019749464,8,-0.324,66.31,0.0789183921822364,0.158,0.118459196091118,0,1
"eltanolone","GABA receptor positive allosteric modulator","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB2, GABRG2","CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C",0,0,0,0,0,0,0,0,0,0,0,0,1,8,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C",318.255880328,23,6.098,37.3,0.234767089001881,0.002,0.11838354450094,1,0
"butyl-paraben","DNA synthesis inhibitor","","CCCCOC(=O)c1ccc(O)cc1, CCCCOC(=O)c1ccc(O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCOC(=O)c1ccc(O)cc1",194.094294308,14,2.902,46.53,0.216726584925807,0.02,0.118363292462903,1,0
"7-chlorokynurenic-acid","glutamate receptor antagonist","GRIN1, GRIN2A, GRIN2B, GRIN2C","OC(=O)c1cc(=O)c2ccc(Cl)cc2[nH]1, OC(=O)c1cc(=O)c2ccc(Cl)cc2[nH]1, OC(=O)c1cc(=O)c2ccc(Cl)cc2[nH]1, OC(=O)c1cc(=O)c2ccc(Cl)cc2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1cc(=O)c2ccc(Cl)cc2[nH]1",223.003620732,15,3.049,70.16,0.0947146507252362,0.142,0.118357325362618,0,1
"metarrestin","rna polymerase inhibitor","EEF1A2","O[C@H]1CC[C@@H](CC1)n1cnc2n(Cc3ccccc3)c(c(-c3ccccc3)c2c1=N)-c1ccccc1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","pancreatic cancer","O[C@H]1CC[C@@H](CC1)n1cnc2n(Cc3ccccc3)c(c(-c3ccccc3)c2c1=N)-c1ccccc1 |r|",474.24196158,36,8.751,66.83,0.124634395501495,0.112,0.118317197750747,1,0
"2-oxopropanoate","pyruvate dehydrogenase kinase inhibitor","ABAT","OC(=C)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=C)C(O)=O",88.016043988,6,0.131,57.53,0.178460443023687,0.058,0.118230221511844,1,0
"dantron","laxative","","Oc1cccc2C(=O)c3cccc(O)c3C(=O)c12, Oc1cccc2C(=O)c3cccc(O)c3C(=O)c12, Oc1cccc2C(=O)c3cccc(O)c3C(=O)c12, Oc1cccc2C(=O)c3cccc(O)c3C(=O)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","Oc1cccc2C(=O)c3cccc(O)c3C(=O)c12",240.042258736,18,2.296,74.6,0.0943964780351719,0.142,0.118198239017586,0,1
"ganaxolone","GABA receptor modulator","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6","CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C",0,0,0,0,0,0,0,0,0,0,0,0,1,6,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C",332.271530392,24,6.515,37.3,0.23434005037154,0.002,0.11817002518577,1,0
"kb-0742","","","CCC(CC)c1cc(N[C@H]2CC[C@H](N)C2)n3nccc3n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCC(CC)c1cc(N[C@H]2CC[C@H](N)C2)n3nccc3n1",287.2109958,21,3.074,68.24,0.0863306452885672,0.15,0.118165322644284,0,1
"T-807","PET radiotracer","","Fc1ccc(cn1)-c1ccc2c(c1)[nH]c1ccncc21",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Fc1ccc(cn1)-c1ccc2c(c1)[nH]c1ccncc21",263.08587554,20,3.217,41.57,0.204317858733794,0.032,0.118158929366897,1,0
"TMN-355","cyclophilin inhibitor","PPIA","Fc1cccc(Cl)c1C(=O)NC(=O)NC1c2ccccc2-c2ccccc12, Fc1cccc(Cl)c1C(=O)NC(=O)NC1c2ccccc2-c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1cccc(Cl)c1C(=O)NC(=O)NC1c2ccccc2-c2ccccc12",380.072783588,27,5.932,58.2,0.0942246447215908,0.142,0.118112322360795,0,1
"RU-42173","adrenergic receptor agonist","ADRB2","CC(C)N[C@@H]1CCn2c3c(cccc3[nH]c2=O)[C@H]1O, CC(C)N[C@@H]1CCn2c3c(cccc3[nH]c2=O)[C@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"phase 2","","","CC(C)N[C@@H]1CCn2c3c(cccc3[nH]c2=O)[C@H]1O",261.147726848,19,1.79,70.05,0.0721626623664166,0.164,0.118081331183208,0,1
"PRX-08066","serotonin receptor antagonist","HTR2B","Fc1ccc(CN2CCC(CC2)Nc2ncnc3sc(Cl)cc23)cc1C#N, Fc1ccc(CN2CCC(CC2)Nc2ncnc3sc(Cl)cc23)cc1C#N, Fc1ccc(CN2CCC(CC2)Nc2ncnc3sc(Cl)cc23)cc1C#N",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Fc1ccc(CN2CCC(CC2)Nc2ncnc3sc(Cl)cc23)cc1C#N",401.087722444,27,3.204,93.08,0.0141553227402667,0.222,0.118077661370133,0,1
"nitrosodimethylurea","DNA synthesis inhibitor","","CNC(=O)N(C)[NH2+][O-]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CNC(=O)N(C)[NH2+][O-]",119.069476528,8,-1.194,72.01,0.0780498350859276,0.158,0.118024917542964,0,1
"inarigivir-soproxil","antiviral","","[H][C@]1(O)C[C@@]([H])(O[C@]1([H])CO[P@](=O)(O[C@]1([H])[C@@]([H])(CO)O[C@@]([H])(n2ccc(=O)[nH]c2=O)[C@]1([H])OC)SCOC(=O)OC(C)C)n1cnc2c(N)ncnc12 |&1:11,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","[H][C@]1(O)C[C@@]([H])(O[C@]1([H])CO[P@](=O)(O[C@]1([H])[C@@]([H])(CO)O[C@@]([H])(n2ccc(=O)[nH]c2=O)[C@]1([H])OC)SCOC(=O)OC(C)C)n1cnc2c(N)ncnc12 |&1:11",703.167291778,54,-1.304,298.8,1.48238297362336e-05,0.236,0.118007411914868,0,1
"pafuramidine","DNA synthesis inhibitor","","CON=C(N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=NOC, CON=C(N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=NOC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CON=C(N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=NOC",364.1535405,27,4.699,108.36,0.0339671768966919,0.202,0.117983588448346,0,1
"zibotentan","endothelin receptor antagonist","EDNRA","COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(cc1)-c1nnco1, COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(cc1)-c1nnco1, COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(cc1)-c1nnco1, COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(cc1)-c1nnco1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(cc1)-c1nnco1",424.095373992,30,3.544,141.37,0.00583346092436469,0.23,0.117916730462182,0,1
"SR-57227A","serotonin receptor agonist","HTR3A","NC1CCN(CC1)c1cccc(Cl)n1, NC1CCN(CC1)c1cccc(Cl)n1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NC1CCN(CC1)c1cccc(Cl)n1",211.087625128,14,2.305,42.15,0.149813159420394,0.086,0.117906579710197,1,0
"difamilast","phosphodiesterase inhibitor","PDE4A","CCOc1ccccc1C(=O)NCc2coc(n2)c3ccc(OC(F)F)c(OC(C)C)c3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","dermatology","dermatitis","CCOc1ccccc1C(=O)NCc2coc(n2)c3ccc(OC(F)F)c(OC(C)C)c3",446.165328308,32,4.741,82.82,0.0278114015695526,0.208,0.117905700784776,0,1
"GW-6471","PPAR receptor antagonist","PPARA","CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F, CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F, CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F, CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F",619.265791292,45,6.811,93.46,0.0117037704858022,0.224,0.117851885242901,0,1
"impentamine","histamine receptor antagonist","HRH3","NCCCCCc1cnc[nH]1, NCCCCCc1cnc[nH]1, NCCCCCc1cnc[nH]1",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NCCCCCc1cnc[nH]1",153.12659748,11,0.326,54.7,0.139679390432788,0.096,0.117839695216394,1,0
"SANT-1","smoothened receptor antagonist","SHH, SMO","Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1",373.226645864,28,4.238,36.66,0.143666247222092,0.092,0.117833123611046,1,0
"aminothiadiazole","inosine monophosphate dehydrogenase inhibitor","ADORA3, IMPDH1","Nc1nncs1, Nc1nncs1, Nc1nncs1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Nc1nncs1",101.004768096,6,0.864,80.04,0.101614568396075,0.134,0.117807284198037,0,1
"sari-59-801","","","CCc1noc(C)c1-c1[nH]c2ccccc2c1[C@@H](O)CN(C)C |&1:17,r|, CCc1noc(C)c1-c1[nH]c2ccccc2c1[C@@H](O)CN(C)C |&1:17,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCc1noc(C)c1-c1[nH]c2ccccc2c1[C@@H](O)CN(C)C |&1:17",313.179026976,23,2.967,65.29,0.0774752985488918,0.158,0.117737649274446,0,1
"cilostamide","phosphodiesterase inhibitor","PDE3A, PDE3B","CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1, CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1, CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1",342.194342692,25,3.744,62.4,0.0792614735148117,0.156,0.117630736757406,0,1
"rp-54745","interleukin inhibitor","IL6","C[C@@H]1N(CCc2ccccc12)c1ssc(=O)c1Cl |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","rheumatology","rheumatoid arthritis","C[C@@H]1N(CCc2ccccc12)c1ssc(=O)c1Cl |&1:1",297.004883684,18,3.743,76.79,0.0349287774323667,0.2,0.117464388716183,0,1
"L-valine","","","CC(C)[C@@H](N)C(O)=O, CC(C)[C@@H](N)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)[C@@H](N)C(O)=O",117.078978592,8,-2.169,63.32,0.0787634593783275,0.156,0.117381729689164,0,1
"oglemilast","phosphodiesterase inhibitor","","CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1, CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1, CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1, CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1, CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1, CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1",514.992103316,33,4.253,118.91,0.00266281634239696,0.232,0.117331408171198,0,1
"lucanthone","endonuclease inhibitor","APEX1, TOP1, TOP2A","CCN(CC)CCNc1ccc(C)c2sc3ccccc3c(=O)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCN(CC)CCNc1ccc(C)c2sc3ccccc3c(=O)c12",340.160934388,24,4.603,60.58,0.0846071748113445,0.15,0.117303587405672,0,1
"kynurenic-acid","glutamate receptor antagonist","GPR35, GRIN1, GRIN2A, GRIN2B","OC(=O)c1cc(=O)c2ccccc2[nH]1, OC(=O)c1cc(=O)c2ccccc2[nH]1, OC(=O)c1cc(=O)c2ccccc2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC(=O)c1cc(=O)c2ccccc2[nH]1",189.042593084,14,2.427,70.16,0.138429679089408,0.096,0.117214839544704,1,0
"TA-01","casein kinase inhibitor, MAP kinase inhibitor","CSNK1D, CSNK1E, MAPK14","Fc1ccc(cc1)-c1[nH]c(nc1-c1ccncc1)-c1c(F)cccc1F, Fc1ccc(cc1)-c1[nH]c(nc1-c1ccncc1)-c1c(F)cccc1F, Fc1ccc(cc1)-c1[nH]c(nc1-c1ccncc1)-c1c(F)cccc1F, Fc1ccc(cc1)-c1[nH]c(nc1-c1ccncc1)-c1c(F)cccc1F, Fc1ccc(cc1)-c1[nH]c(nc1-c1ccncc1)-c1c(F)cccc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1ccc(cc1)-c1[nH]c(nc1-c1ccncc1)-c1c(F)cccc1F",351.098332044,26,5.363,41.57,0.174391518156221,0.06,0.11719575907811,1,0
"ochromycinone","STAT inhibitor","STAT3","C[C@@H]1CC(=O)c2c(C1)ccc1C(=O)c3c(O)cccc3C(=O)c21",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@@H]1CC(=O)c2c(C1)ccc1C(=O)c3c(O)cccc3C(=O)c21",306.089208928,23,3.332,71.44,0.0862211218145449,0.148,0.117110560907272,0,1
"PFK-015","phosphofructokinase inhibitor","PFKFB3","O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1",260.094963004,20,2.788,42.85,0.194203938473995,0.04,0.117101969236998,1,0
"milnacipran (hydrochloride)","","","CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)c1ccccc1",246.173213324,18,1.909,46.33,0.136197022488063,0.098,0.117098511244032,1,0
"BAY-87-2243","hypoxia inducible factor inhibitor","HIF1A","Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1, Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1, Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1, Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1, Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1, Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1, Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1",525.210007732,38,5.701,85.34,0.0201472132263493,0.214,0.117073606613175,0,1
"olutasidenib","isocitrate dehydrogenase inhibitor","IDH1","C[C@H](Nc1ccc(C#N)n(C)c1=O)c1cc2cc(Cl)ccc2[nH]c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","oncology","glioma","C[C@H](Nc1ccc(C#N)n(C)c1=O)c1cc2cc(Cl)ccc2[nH]c1=O",354.0883534,25,4.412,90.68,0.0381050210400318,0.196,0.117052510520016,0,1
"paeonol","anti-inflammatory agent","","COc1ccc(C(C)=O)c(O)c1, COc1ccc(C(C)=O)c(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(C(C)=O)c(O)c1",166.06299418,12,1.837,46.53,0.208044242400355,0.026,0.117022121200177,1,0
"foxy-5","WNT5a peptide mimetic","WNT5A","CSCC[C@H](NC=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O, CSCC[C@H](NC=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O, CSCC[C@H](NC=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CSCC[C@H](NC=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O",694.230212784,46,-3.573,350.6,5.01025159034879e-07,0.234,0.11700025051258,0,1
"L-161982","prostanoid receptor antagonist","PTGER4","CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C, CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C, CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C, CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C",654.158232068,45,7.332,139.68,0.00199708777304523,0.232,0.116998543886523,0,1
"plurisin-1","stearoyl-CoA desaturase inhibitor","SCD","O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(NNc1ccccc1)c1ccncc1",213.090211972,16,2.117,54.02,0.16187237401873,0.072,0.116936187009365,1,0
"ONC201","AKT inhibitor, MAP kinase inhibitor","TNFSF10","Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O |t:10,16|, Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O |t:10,16|, Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O |t:10,16|, Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O |t:10,16|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O |t:10",386.210661452,29,3.629,39.15,0.111819109668287,0.122,0.116909554834144,0,0
"RSV604","RSV replication inhibitor","","Fc1ccccc1NC(=O)N[C@H]1N=C(c2ccccc2)c2ccccc2NC1=O |t:13|, Fc1ccccc1NC(=O)N[C@H]1N=C(c2ccccc2)c2ccccc2NC1=O |t:13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Fc1ccccc1NC(=O)N[C@H]1N=C(c2ccccc2)c2ccccc2NC1=O |t:13|",388.133554004,29,3.798,82.59,0.0437770758028121,0.19,0.116888537901406,0,1
"o-3M3FBS","phospholipase activator","","Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1ccccc1C(F)(F)F, Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1ccccc1C(F)(F)F, Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1ccccc1C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1ccccc1C(F)(F)F",343.085384412,23,4.529,54.55,0.07175343837589,0.162,0.116876719187945,0,1
"NSC-319726","p53 activator","","C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C\C(=N/NC(=S)N1CCC1)c1ccccn1",234.093917448,16,2.647,72.61,0.079619984477836,0.154,0.116809992238918,0,1
"palmatine-chloride","dopamine synthesis inhibitor","CYP3A4","COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC, COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC, COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC",352.154334604091,26,4.774,40.8,0.153591753429382,0.08,0.116795876714691,1,0
"valnivudine","antiviral","","O=C1N=C2C(C=C(C3=CC=C(C=C3)CCCCC)O2)=CN1[C@]4([H])O[C@@H]([C@H](C4)O)COC([C@@H](N)C(C)C)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","infectious disease","varicella-zoster virus (vzv)","O=C1N=C2C(C=C(C3=CC=C(C=C3)CCCCC)O2)=CN1[C@]4([H])O[C@@H]([C@H](C4)O)COC([C@@H](N)C(C)C)=O",497.25258584,37,3.435,123.68,0.0074577099323853,0.226,0.116728854966193,0,1
"VU0361737","glutamate receptor positive allosteric modulator","GRM4","COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(NC(=O)c2ccccn2)ccc1Cl",262.050905272,18,2.367,51.22,0.0972734835162068,0.136,0.116636741758103,0,1
"terameprocol","lipoxygenase inhibitor","BIRC5, CDK1","COc1ccc(C[C@H](C)[C@H](C)Cc2ccc(OC)c(OC)c2)cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","COc1ccc(C[C@H](C)[C@H](C)Cc2ccc(OC)c(OC)c2)cc1OC",358.21440944,26,5.914,36.92,0.18512586136801,0.048,0.116562930684005,1,0
"wortmannin","PI3K inhibitor","PI4KA, PI4KB, PIK3CA, PIK3CD, PIK3CG, PIK3R1, PLK1, PRKDC","COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C([C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O)C3=O |t:16|, COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C([C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O)C3=O |t:16|, COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C([C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O)C3=O |t:16|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C([C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O)C3=O |t:16|",428.147117728,31,0.714,109.11,0.00702609847681869,0.226,0.116513049238409,0,1
"bay 2416964","antitumor agent","AHR","C[C@@H](CO)NC(=O)c1cc(nn(-c2cnn(C)c2)c1=O)-c1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","non-small cell lung cancer (nsclc)","C[C@@H](CO)NC(=O)c1cc(nn(-c2cnn(C)c2)c1=O)-c1ccc(Cl)cc1",387.109817116,27,2.907,102.04,0.0149236699123008,0.218,0.11646183495615,0,1
"SUN-B-8155","calcitonin agonist","CALCR","C\C(=N/c1ccccc1N)c1c(C)cc(=O)n(O)c1O, C\C(=N/c1ccccc1N)c1c(C)cc(=O)n(O)c1O, C\C(=N/c1ccccc1N)c1c(C)cc(=O)n(O)c1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C\C(=N/c1ccccc1N)c1c(C)cc(=O)n(O)c1O",273.11134134,20,2.662,100.84,0.0427197226424041,0.19,0.116359861321202,0,1
"sclareol","","","CC(O)(CC[C@H]1[C@](C)(O)CC[C@H]2C(C)(C)CCC[C@]12C)C=C |a:5,6,18,&1:1,&2:11|, CC(O)(CC[C@H]1[C@](C)(O)CC[C@H]2C(C)(C)CCC[C@]12C)C=C |a:5,6,18,&1:1,&2:11|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(O)(CC[C@H]1[C@](C)(O)CC[C@H]2C(C)(C)CCC[C@]12C)C=C |a:5",308.271530392,22,5.989,40.46,0.218692940758384,0.014,0.116346470379192,1,0
"atglistatin","adipose triglyceride lipase inhibitor","","CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C, CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C, CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C, CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C",283.168462292,21,3.207,35.58,0.186510693560665,0.046,0.116255346780333,1,0
"VU1545","glutamate receptor positive allosteric modulator","GRM5","[O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1F)-c1ccccc1, [O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1F)-c1ccccc1, [O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1F)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1F)-c1ccccc1",402.11281856,30,5.537,90.06,0.0504854164431835,0.182,0.116242708221592,0,1
"urolithin-A","antioxidant","","Oc1ccc2c(c1)oc(=O)c1cc(O)ccc21",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Oc1ccc2c(c1)oc(=O)c1cc(O)ccc21",228.042258736,17,3.104,70.67,0.128386594803683,0.104,0.116193297401842,1,0
"trans-4-methoxycinnamic-acid","","","COc1ccc(\C=C\C(O)=O)cc1, COc1ccc(\C=C\C(O)=O)cc1, COc1ccc(\C=C\C(O)=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(\C=C\C(O)=O)cc1",178.06299418,13,1.824,46.53,0.198384488867407,0.034,0.116192244433704,1,0
"spizofurone","","","CC(=O)c1ccc2OC3(CC3)C(=O)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CC(=O)c1ccc2OC3(CC3)C(=O)c2c1",202.06299418,15,1.449,43.37,0.178270142214459,0.054,0.116135071107229,1,0
"AM095","lysophosphatidic acid receptor antagonist","","C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1",456.168521868,34,6.231,101.66,0.032181595516726,0.2,0.116090797758363,0,1
"tanaproget","progesterone receptor agonist","PGR","Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N",297.0935831,21,3.453,82.07,0.0560818879323093,0.176,0.116040943966155,0,1
"mw-150","p38 mapk inhibitor","MAPK14","CN1CCN(C2=NN=C(C3=CC=C4C=CC=CC4=C3)C(C5=CC=NC=C5)=C2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","neurology/psychiatry","alzheimer's disease","CN1CCN(C2=NN=C(C3=CC=C4C=CC=CC4=C3)C(C5=CC=NC=C5)=C2)CC1",381.195345736,29,3.401,43.56,0.108076262026141,0.124,0.11603813101307,0,0
"WAY-200070","estrogen receptor agonist","ERBB2, ERBB3, ERBB4, ESR2","Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1, Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1, Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1",304.968755216,18,3.146,66.49,0.031769184319786,0.2,0.115884592159893,0,1
"pinanediol","","","CC1(C)[C@H]2C[C@@H]1[C@](C)(O)[C@H](O)C2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC1(C)[C@H]2C[C@@H]1[C@](C)(O)[C@H](O)C2",170.130679816,12,1.944,40.46,0.219763524318777,0.012,0.115881762159388,1,0
"2,3-cis/exo-pinanediol","","","CC1(C)C2CC1[C@](C)(O)[C@H](O)C2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC1(C)C2CC1[C@](C)(O)[C@H](O)C2",170.130679816,12,1.944,40.46,0.219763524318777,0.012,0.115881762159388,1,0
"RS-127445","serotonin receptor antagonist","HTR2A, HTR2B, HTR2C","CC(C)c1cc(nc(N)n1)-c1ccc(F)c2ccccc12, CC(C)c1cc(nc(N)n1)-c1ccc(F)c2ccccc12, CC(C)c1cc(nc(N)n1)-c1ccc(F)c2ccccc12",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)c1cc(nc(N)n1)-c1ccc(F)c2ccccc12",281.132825732,21,3.957,51.8,0.165727225102308,0.066,0.115863612551154,1,0
"FRAX486","serine/threonine kinase inhibitor","PAK1, PAK2, PAK3, PAK4","CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O, CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O, CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O, CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O, CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O",512.129442936,35,6.167,75.08,0.0196325747820499,0.212,0.115816287391025,0,1
"ITI214","phosphodiesterase inhibitor","PDE1A","CN1C2=N[C@@H]3CCC[C@@H]3N2c2nn(Cc3ccc(cc3)-c3cccc(F)n3)c(Nc3ccccc3)c2C1=O |t:2|, CN1C2=N[C@@H]3CCC[C@@H]3N2c2nn(Cc3ccc(cc3)-c3cccc(F)n3)c(Nc3ccccc3)c2C1=O |t:2|, CN1C2=N[C@@H]3CCC[C@@H]3N2c2nn(Cc3ccc(cc3)-c3cccc(F)n3)c(Nc3ccccc3)c2C1=O |t:2|, CN1C2=N[C@@H]3CCC[C@@H]3N2c2nn(Cc3ccc(cc3)-c3cccc(F)n3)c(Nc3ccccc3)c2C1=O |t:2|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","CN1C2=N[C@@H]3CCC[C@@H]3N2c2nn(Cc3ccc(cc3)-c3cccc(F)n3)c(Nc3ccccc3)c2C1=O |t:2|",507.218286672,38,6.139,78.65,0.0394826224447946,0.192,0.115741311222397,0,1
"UAMC-00039","dipeptidyl peptidase inhibitor","DPP4, DPP7","N[C@@H](CCNCc1ccc(Cl)cc1)C(=O)N1CCCCC1, N[C@@H](CCNCc1ccc(Cl)cc1)C(=O)N1CCCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@@H](CCNCc1ccc(Cl)cc1)C(=O)N1CCCCC1",309.160790068,21,2.019,58.36,0.0514725753141354,0.18,0.115736287657068,0,1
"BI-847325","Aurora kinase inhibitor, MEK inhibitor","AURKA, AURKB, AURKC, MAP2K1, MAP2K2","CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1, CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1, CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1, CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1, CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1",464.221226136,35,4.877,73.47,0.0454611985569495,0.186,0.115730599278475,0,1
"GW-9662","PPAR receptor antagonist","NCOA2, PPARG, RXRA","[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1",276.030169828,19,3.507,72.24,0.0731453067100228,0.158,0.115572653355011,0,1
"gemcadiol","antilipemic","","CC(C)(CO)CCCCCCC(C)(C)CO, CC(C)(CO)CCCCCCC(C)(C)CO, CC(C)(CO)CCCCCCC(C)(C)CO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)(CO)CCCCCCC(C)(C)CO",230.2245802,16,3.884,40.46,0.213119413316953,0.018,0.115559706658476,1,0
"BAY1217389","kinase inhibitor","","COc1ccc(Oc2cc(NCCC(F)(F)F)c3ncc(-c4ccc(C(=O)NC5CC5)c(C)c4)n3n2)c(F)c1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1ccc(Oc2cc(NCCC(F)(F)F)c3ncc(-c4ccc(C(=O)NC5CC5)c(C)c4)n3n2)c(F)c1F",561.179930728,40,7.068,89.78,0.0171057068528737,0.214,0.115552853426437,0,1
"proacipimox","cholesterol inhibitor","","COCc1c[n+]([O-])c(C)cn1, COCc1c[n+]([O-])c(C)cn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COCc1c[n+]([O-])c(C)cn1",154.07422756,11,0.195,49.06,0.149059455699858,0.082,0.115529727849929,1,0
"azomycin-(2-nitroimidazole)","protein synthesis inhibitor","","[O-][N+](=O)c1ncc[nH]1, [O-][N+](=O)c1ncc[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[O-][N+](=O)c1ncc[nH]1",113.022526336,8,0.0259999999999999,71.82,0.117028325818388,0.114,0.115514162909194,1,0
"immepip","histamine receptor agonist","HRH3, HRH4","C(C1CCNCC1)c1cnc[nH]1, C(C1CCNCC1)c1cnc[nH]1",0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C(C1CCNCC1)c1cnc[nH]1",165.12659748,12,0.38,40.71,0.176992627793204,0.054,0.115496313896602,1,0
"adarotene","retinoid receptor agonist","RARB, RARG","OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2",374.188194692,28,7.26,57.53,0.174990951324771,0.056,0.115495475662385,1,0
"cis-exo-camphanediol-2,3","nitric oxide stimulant","NOS3","CC1(C)[C@H]2CC[C@]1(C)[C@@H](O)[C@H]2O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC1(C)[C@H]2CC[C@]1(C)[C@@H](O)[C@H]2O",170.130679816,12,1.922,40.46,0.218839544730842,0.012,0.115419772365421,1,0
"2,3-cis/exo-camphanediol","","","CC1(C)[C@@H]2CC[C@@]1(C)[C@H](O)[C@@H]2O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC1(C)[C@@H]2CC[C@@]1(C)[C@H](O)[C@@H]2O",170.130679816,12,1.922,40.46,0.218839544730842,0.012,0.115419772365421,1,0
"CD-437","retinoid receptor agonist","RARG","OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2",398.188194692,30,8.254,57.53,0.194696307743081,0.036,0.115348153871541,1,0
"piperazinedione","DNA synthesis inhibitor","","O=C1CNC(=O)CN1, O=C1CNC(=O)CN1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O=C1CNC(=O)CN1",114.042927432,8,-0.798,58.2,0.126567139691593,0.104,0.115283569845796,1,0
"PP-1","SRC inhibitor","HCK, RET","Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C",281.164045608,21,3.894,69.62,0.114503931841418,0.116,0.115251965920709,0,0
"benzofenac","","","OC(=O)Cc1ccc(OCc2ccccc2)c(Cl)c1, OC(=O)Cc1ccc(OCc2ccccc2)c(Cl)c1, OC(=O)Cc1ccc(OCc2ccccc2)c(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC(=O)Cc1ccc(OCc2ccccc2)c(Cl)c1",276.055321956,19,3.696,46.53,0.130385756239075,0.1,0.115192878119538,1,0
"MKT-077","HSP inhibitor","","CCn1\c(=C/c2cccc[n+]2CC)s\c(=C2\Sc3ccccc3N2C)c1=O, CCn1\c(=C/c2cccc[n+]2CC)s\c(=C2\Sc3ccccc3N2C)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCn1\c(=C/c2cccc[n+]2CC)s\c(=C2\Sc3ccccc3N2C)c1=O",396.119880744091,27,5.733,49.49,0.0763016305524278,0.154,0.115150815276214,0,1
"IBMX","phosphodiesterase inhibitor","ADORA1, PDE2A, PDE3B, PDE4D, PDE5A, PDE6G, PDE7A, PDE8A, PDE9A","CC(C)Cn1c2nc[nH]c2c(=O)n(C)c1=O, CC(C)Cn1c2nc[nH]c2c(=O)n(C)c1=O, CC(C)Cn1c2nc[nH]c2c(=O)n(C)c1=O, CC(C)Cn1c2nc[nH]c2c(=O)n(C)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)Cn1c2nc[nH]c2c(=O)n(C)c1=O",222.111675688,16,2.69,72.68,0.104135278763373,0.126,0.115067639381687,0,0
"solithromycin","protein synthesis inhibitor","","CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cc(nn3)-c3cccc(N)c3)C(=O)O[C@]12C)OC, CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cc(nn3)-c3cccc(N)c3)C(=O)O[C@]12C)OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cc(nn3)-c3cccc(N)c3)C(=O)O[C@]12C)OC",844.4746205,60,3.405,197.87,6.63661831198648e-05,0.23,0.11503318309156,0,1
"GDC-0994","MAP kinase inhibitor","MAPK1, MAPK3","Cn1nccc1Nc1nccc(n1)-c1ccn([C@@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1 |&1:17,r|, Cn1nccc1Nc1nccc(n1)-c1ccn([C@@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1 |&1:17,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cn1nccc1Nc1nccc(n1)-c1ccn([C@@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1 |&1:17",440.116379716,31,3.65,97.86,0.0139776241904807,0.216,0.11498881209524,0,1
"ravoxertinib","ERK1 and ERK2 phosphorylation inhibitor","MAPK1, MAPK3","Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1, Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1, Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1, Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1, Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1",440.116379716,31,3.65,97.86,0.0139776241904807,0.216,0.11498881209524,0,1
"pamiparib","PARP inhibitor","","C[C@]12CCCN1Cc1n[nH]c(=O)c3cc(F)cc4[nH]c2c1c34",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C[C@]12CCCN1Cc1n[nH]c(=O)c3cc(F)cc4[nH]c2c1c34",298.12298932,22,2.054,64.78,0.0717741264862449,0.158,0.114887063243122,0,1
"RWJ-67657","MAP kinase inhibitor","MAPK14, PTGS2","OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1, OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1, OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1, OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1, OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1",425.190340608,32,5.638,50.94,0.109732934089352,0.12,0.114866467044676,0,0
"SKF-86002","p38 MAPK inhibitor","ALOX5, MAPK14","Fc1ccc(cc1)-c1nc2SCCn2c1-c1ccncc1, Fc1ccc(cc1)-c1nc2SCCn2c1-c1ccncc1, Fc1ccc(cc1)-c1nc2SCCn2c1-c1ccncc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1ccc(cc1)-c1nc2SCCn2c1-c1ccncc1",297.073596604,21,3.869,56.01,0.107498500463045,0.122,0.114749250231523,0,0
"eliprodil","glutamate receptor antagonist","GRIN1, GRIN2B","O[C@@H](CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1 |&1:1,r|, O[C@@H](CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1 |&1:1,r|, O[C@@H](CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1 |&1:1,r|, O[C@@H](CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1 |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","O[C@@H](CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1 |&1:1",347.145220256,24,4.767,23.47,0.161409412500168,0.068,0.114704706250084,1,0
"estradiol-benzoate","contraceptive agent","ESR1","C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)c5ccccc5)ccc34)[C@@H]1CC[C@@H]2O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)c5ccccc5)ccc34)[C@@H]1CC[C@@H]2O",376.203844756,28,6.14,46.53,0.165399550276854,0.064,0.114699775138427,1,0
"sep-363856","trace amine associated receptor agonist","HTR1A, TAAR1","CNC[C@@H]1OCCc2ccsc12",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,"phase 2","neurology/psychiatry","schizophrenia","CNC[C@@H]1OCCc2ccsc12",183.071785036,12,0.506,49.5,0.105382580890764,0.124,0.114691290445382,0,0
"SGC-CBP30","bromodomain inhibitor","CREBBP, EP300","COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl, COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl, COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl, COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl, COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl, COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl, COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl",508.224118596,36,5.002,65.55,0.0252890631756196,0.204,0.11464453158781,0,1
"pardoprunox","dopamine receptor agonist, serotonin receptor agonist","DRD2, DRD3, DRD4, HTR1A, HTR7","CN1CCN(CC1)c1cccc2[nH]c(=O)oc12, CN1CCN(CC1)c1cccc2[nH]c(=O)oc12, CN1CCN(CC1)c1cccc2[nH]c(=O)oc12, CN1CCN(CC1)c1cccc2[nH]c(=O)oc12",0,0,0,0,0,0,0,0,1,2,0,0,0,0,1,3,0,0,0,0,0,0,0,0,"phase 3","","","CN1CCN(CC1)c1cccc2[nH]c(=O)oc12",233.11642672,17,0.963,52.48,0.105256721231612,0.124,0.114628360615806,0,0
"CH55","retinoid receptor binder","RARA, RARB","CC(C)(C)c1cc(cc(c1)C(C)(C)C)C(=O)\C=C\c1ccc(cc1)C(O)=O, CC(C)(C)c1cc(cc(c1)C(C)(C)C)C(=O)\C=C\c1ccc(cc1)C(O)=O, CC(C)(C)c1cc(cc(c1)C(C)(C)C)C(=O)\C=C\c1ccc(cc1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)c1cc(cc(c1)C(C)(C)C)C(=O)\C=C\c1ccc(cc1)C(O)=O",364.203844756,27,7.097,54.37,0.181071668230832,0.048,0.114535834115416,1,0
"GK921","transglutaminase inhibitor","TGM2","C(CN1CCCC1)Oc1nc2cccnc2nc1C#Cc1ccccc1, C(CN1CCCC1)Oc1nc2cccnc2nc1C#Cc1ccccc1, C(CN1CCCC1)Oc1nc2cccnc2nc1C#Cc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C(CN1CCCC1)Oc1nc2cccnc2nc1C#Cc1ccccc1",344.16371126,26,3.612,51.14,0.11502512031245,0.114,0.114512560156225,1,0
"PF-04447943","phosphodiesterase inhibitor","PDE9A","C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc(=O)c2cnn(C3CCOCC3)c2[nH]1, C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc(=O)c2cnn(C3CCOCC3)c2[nH]1, C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc(=O)c2cnn(C3CCOCC3)c2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc(=O)c2cnn(C3CCOCC3)c2[nH]1",395.20697304,29,1.818,101.82,0.0150009107124856,0.214,0.114500455356243,0,1
"ICI-199441","opioid receptor agonist","CYP2D6, OPRD1, OPRK1, OPRM1, UTS2R","CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1",390.126568748,26,4.797,23.55,0.0989382725007215,0.13,0.114469136250361,0,1
"mtep","glutamate metabotropic receptor antagonist","GRM5","Cc1nc(cs1)C#Cc1cccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","neurology","parkinson's disease","Cc1nc(cs1)C#Cc1cccnc1",200.040819256,14,2.125,54.02,0.142916599201122,0.086,0.114458299600561,1,0
"WZ811","CC chemokine receptor antagonist","CXCR4","C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1, C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1, C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1, C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1, C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1",290.153146576,22,3.686,49.84,0.164861587034867,0.064,0.114430793517434,1,0
"equilin","estrogen receptor agonist","HSD17B1","C[C@@]12CC[C@H]3C(=CCc4cc(O)ccc34)[C@@H]1CCC2=O |&1:1,&2:4,&3:15,r,c:5|, C[C@@]12CC[C@H]3C(=CCc4cc(O)ccc34)[C@@H]1CCC2=O |&1:1,&2:4,&3:15,r,c:5|, C[C@@]12CC[C@H]3C(=CCc4cc(O)ccc34)[C@@H]1CCC2=O |&1:1,&2:4,&3:15,r,c:5|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@]12CC[C@H]3C(=CCc4cc(O)ccc34)[C@@H]1CCC2=O |&1:1",268.14632988,20,2.853,37.3,0.186817903976278,0.042,0.114408951988139,1,0
"VU29","glutamate receptor potentiator","GRM5","[O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1)-c1ccccc1, [O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1)-c1ccccc1, [O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1)-c1ccccc1",384.122240372,29,5.376,90.06,0.0587428300935603,0.17,0.11437141504678,0,1
"GSK3179106","RET tyrosine kinase inhibitor","","CCOc1cc(=O)[nH]cc1-c1ccc(CC(=O)Nc2cc(on2)C(C)(C)C(F)(F)F)c(F)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCOc1cc(=O)[nH]cc1-c1ccc(CC(=O)Nc2cc(on2)C(C)(C)C(F)(F)F)c(F)c1",467.146819032,33,5.07,97.22,0.0166515726028366,0.212,0.114325786301418,0,1
"cilofexor","FXR agonist","","OC(=O)c1ccnc(c1)N1CC(O)(C1)c1ccc(OCc2c(onc2-c2c(Cl)cccc2Cl)C2CC2)cc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","OC(=O)c1ccnc(c1)N1CC(O)(C1)c1ccc(OCc2c(onc2-c2c(Cl)cccc2Cl)C2CC2)cc1Cl",585.062503844,39,6.491,108.92,0.00433005537285427,0.224,0.114165027686427,0,1
"ACPC","glutamate receptor antagonist","","NC1(CC1)C(O)=O, NC1(CC1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","NC1(CC1)C(O)=O",101.047678464,7,-3.054,63.32,0.0742270989191945,0.154,0.114113549459597,0,1
"HER2-Inhibitor-1","EGFR inhibitor","","Cc1cc(Nc2ncnc3ccc(cc23)-c2ccc(CNCCS(C)(=O)=O)o2)ccc1Oc1ccn2ncnc2c1, Cc1cc(Nc2ncnc3ccc(cc23)-c2ccc(CNCCS(C)(=O)=O)o2)ccc1Oc1ccn2ncnc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(Nc2ncnc3ccc(cc23)-c2ccc(CNCCS(C)(=O)=O)o2)ccc1Oc1ccn2ncnc2c1",569.184523344,41,3.409,144.92,0.00204985263055537,0.226,0.114024926315278,0,1
"YL0919","selective serotonin reuptake inhibitor (SSRI)","","OC1(Cn2ccccc2=O)CCN(Cc2ccccc2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC1(Cn2ccccc2=O)CCN(Cc2ccccc2)CC1",298.168127944,22,2.844,45.47,0.127931596357384,0.1,0.113965798178692,1,0
"oxolinic-acid","bacterial DNA gyrase inhibitor","","CCn1cc(C(O)=O)c(=O)c2cc3OCOc3cc12, CCn1cc(C(O)=O)c(=O)c2cc3OCOc3cc12, CCn1cc(C(O)=O)c(=O)c2cc3OCOc3cc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCn1cc(C(O)=O)c(=O)c2cc3OCOc3cc12",261.063722452,19,3.478,77.76,0.089758875990917,0.138,0.113879437995458,0,1
"CYM-50260","sphingosine 1-phosphate receptor agonist","S1PR4","FCc1ccc(OCCOc2ccc(Cl)cc2Cl)c(Cl)n1, FCc1ccc(OCCOc2ccc(Cl)cc2Cl)c(Cl)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FCc1ccc(OCCOc2ccc(Cl)cc2Cl)c(Cl)n1",348.983939852,21,4.782,31.35,0.0716193856372275,0.156,0.113809692818614,0,1
"MRS-1220","adenosine receptor antagonist","ADORA2B, ADORA3","Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1",403.083602368,29,4.134,85.32,0.0316086862919573,0.196,0.113804343145979,0,1
"PD-102807","acetylcholine receptor antagonist","CHRM4","CCOC(=O)c1c(C)[nH]c2ccc3O[C@H]4N(CCc5cc(OC)ccc45)Cc3c12 |&1:14,r|, CCOC(=O)c1c(C)[nH]c2ccc3O[C@H]4N(CCc5cc(OC)ccc45)Cc3c12 |&1:14,r|, CCOC(=O)c1c(C)[nH]c2ccc3O[C@H]4N(CCc5cc(OC)ccc45)Cc3c12 |&1:14,r|, CCOC(=O)c1c(C)[nH]c2ccc3O[C@H]4N(CCc5cc(OC)ccc45)Cc3c12 |&1:14,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"preclinical","","","CCOC(=O)c1c(C)[nH]c2ccc3O[C@H]4N(CCc5cc(OC)ccc45)Cc3c12 |&1:14",392.173607248,29,4.284,63.79,0.0675203370747907,0.16,0.113760168537395,0,1
"VX-745","p38 MAPK inhibitor","MAPK11, MAPK12, MAPK14","Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1",434.981144708,28,7.468,72.56,0.0355147889456502,0.192,0.113757394472825,0,1
"HA-966-(R)-(+)","glutamate receptor agonist","GRIA1","N[C@@H]1CCN(O)C1=O, N[C@@H]1CCN(O)C1=O, N[C@@H]1CCN(O)C1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@@H]1CCN(O)C1=O",116.058577496,8,-0.829,66.56,0.101445361341388,0.126,0.113722680670694,0,0
"HA-966-(S)-(-)","glutamate receptor antagonist","GRIA1","N[C@H]1CCN(O)C1=O, N[C@H]1CCN(O)C1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@H]1CCN(O)C1=O",116.058577496,8,-0.829,66.56,0.101445361341388,0.126,0.113722680670694,0,0
"E-2001","antioxidant","","Fc1ccc(cc1)C(=O)C1CCN(CC(=O)c2ccc3ccccc3c2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1ccc(cc1)C(=O)C1CCN(CC(=O)c2ccc3ccccc3c2)CC1",375.163457164,28,4.746,37.38,0.151414328468129,0.076,0.113707164234064,1,0
"MRK-409","benzodiazepine receptor agonist","","Cn1ncnc1COc1nn2c(nnc2cc1C1CCC1)-c1c(F)cccc1F, Cn1ncnc1COc1nn2c(nnc2cc1C1CCC1)-c1c(F)cccc1F, Cn1ncnc1COc1nn2c(nnc2cc1C1CCC1)-c1c(F)cccc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cn1ncnc1COc1nn2c(nnc2cc1C1CCC1)-c1c(F)cccc1F",397.146264604,29,5.721,83.02,0.0553251197772937,0.172,0.113662559888647,0,1
"YM-201636","PI3K inhibitor","","Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1",467.170587532,35,3.009,132.29,0.00712672962473285,0.22,0.113563364812366,0,1
"cyacetacide","","","NNC(=O)CC#N, NNC(=O)CC#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NNC(=O)CC#N",99.04326178,7,-1.976,78.91,0.0709259427320601,0.156,0.11346297136603,0,1
"RP-001","sphingosine 1-phosphate receptor agonist","S1PR1","CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCC(O)=O |&1:22|, CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCC(O)=O |&1:22|, CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCC(O)=O |&1:22|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCC(O)=O |&1:22|",432.179755248,32,4.413,121.27,0.0148974818912879,0.212,0.113448740945644,0,1
"pyrithyldione","psychoactive drug","","CCC1(CC)C(=O)NC=CC1=O |c:8|, CCC1(CC)C(=O)NC=CC1=O |c:8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CCC1(CC)C(=O)NC=CC1=O |c:8|",167.094628656,12,1.14,46.17,0.17886495536654,0.048,0.11343247768327,1,0
"phenylmethylsulfonyl-fluoride","serine protease inhibitor","","FS(=O)(=O)Cc1ccccc1, FS(=O)(=O)Cc1ccccc1, FS(=O)(=O)Cc1ccccc1, FS(=O)(=O)Cc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FS(=O)(=O)Cc1ccccc1",174.015078684,11,1.382,42.52,0.144799433537241,0.082,0.113399716768621,1,0
"CD-1530","retinoid receptor agonist","RARG","OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2",398.188194692,30,8.254,57.53,0.194696307743081,0.032,0.113348153871541,1,0
"IDF-11774","hypoxia inducible factor inhibitor","","CN1CCN(CC1)C(=O)COc1ccc(cc1)C12CC3CC(CC(C3)C1)C2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCN(CC1)C(=O)COc1ccc(cc1)C12CC3CC(CC(C3)C1)C2",368.246378264,27,4.922,32.78,0.162629769699057,0.064,0.113314884849529,1,0
"BW-A4C","lipoxygenase inhibitor","ALOX5","CC(=O)N(O)C\C=C\c1cccc(Oc2ccccc2)c1, CC(=O)N(O)C\C=C\c1cccc(Oc2ccccc2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(=O)N(O)C\C=C\c1cccc(Oc2ccccc2)c1",283.120843404,21,2.959,49.77,0.134527268513254,0.092,0.113263634256627,1,0
"LY2979165","glutamate receptor agonist","GRM2","C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O",355.095039644,24,-2.65,196.59,0.000466045498315471,0.226,0.113233022749158,0,1
"BAY-60-7550","phosphodiesterase inhibitor","PDE2A","COc1ccc(Cc2nc(=O)c3c(C)nc([C@@H](CCCc4ccccc4)[C@@H](C)O)n3[nH]2)cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(Cc2nc(=O)c3c(C)nc([C@@H](CCCc4ccccc4)[C@@H](C)O)n3[nH]2)cc1OC",476.242355504,35,5.724,101.74,0.0223264985360081,0.204,0.113163249268004,0,1
"AZD6482","PI3K inhibitor","PIK3CA, PIK3CB, PIK3CD, PIK3CG","C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1",408.179755248,30,3.943,96.17,0.0262880786798589,0.2,0.113144039339929,0,1
"ethyl-vanillin","","","CCOc1cc(C=O)ccc1O, CCOc1cc(C=O)ccc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOc1cc(C=O)ccc1O",166.06299418,12,1.382,46.53,0.190252426967451,0.036,0.113126213483726,1,0
"CGS-20625","benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6","COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O, COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O, COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O, COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O, COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O",0,0,0,0,0,0,0,0,0,0,0,0,1,6,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O",309.147726848,23,3.215,59.91,0.100181940607954,0.126,0.113090970303977,0,0
"PIK-294","PI3K inhibitor","PIK3CB, PIK3CD, PIK3CG","Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc23)nc2cccc(C)c2c1=O, Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc23)nc2cccc(C)c2c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc23)nc2cccc(C)c2c1=O",489.191322976,37,5.354,124.74,0.0140345494364446,0.212,0.113017274718222,0,1
"YM-90709","IL5 inhibitor","CSF2RB, IL5RA","COc1cc2CC(C)(C)n3c(cc4nc5ccccc5nc34)-c2cc1OC, COc1cc2CC(C)(C)n3c(cc4nc5ccccc5nc34)-c2cc1OC, COc1cc2CC(C)(C)n3c(cc4nc5ccccc5nc34)-c2cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2CC(C)(C)n3c(cc4nc5ccccc5nc34)-c2cc1OC",359.163376912,27,4.793,49.17,0.137854181769479,0.088,0.11292709088474,1,0
"beta-hydroxybutyrate","","HCAR2","CC(O)CC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(O)CC(O)=O",104.047344116,7,-0.499,57.53,0.137735637177218,0.088,0.112867818588609,1,0
"d,l-3-hydroxybutyric acid","hydroxycarboxylic acid receptor agonist","HCAR2, HDAC2, HDAC3","C[C@@H](O)CC(O)=O |&1:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@@H](O)CC(O)=O |&1:1|",104.047344116,7,-0.499,57.53,0.137735637177218,0.088,0.112867818588609,1,0
"ADL5859","opioid receptor agonist","OPRD1","CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|",392.209992756,29,3.982,61.8,0.0657282843278586,0.16,0.112864142163929,0,1
"SMI-4a","Pim kinase inhibitor","PIM1","FC(F)(F)c1cccc(\C=C2/SC(=O)NC2=O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)c1cccc(\C=C2/SC(=O)NC2=O)c1",273.007134092,18,2.396,71.47,0.0496326473737418,0.176,0.112816323686871,0,1
"RS-102895","CCR antagonist","CCR2","FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1, FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1, FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1",390.155512572,28,4.077,41.57,0.0876027842821574,0.138,0.112801392141079,0,1
"XL228","Abl kinase inhibitor, insulin growth factor receptor inhibitor, SRC inhibitor","IGF1R, SRC","CC(C)c1cc(CNc2nc(Nc3cc(n[nH]3)C3CC3)cc(n2)N2CCN(C)CC2)on1, CC(C)c1cc(CNc2nc(Nc3cc(n[nH]3)C3CC3)cc(n2)N2CCN(C)CC2)on1, CC(C)c1cc(CNc2nc(Nc3cc(n[nH]3)C3CC3)cc(n2)N2CCN(C)CC2)on1, CC(C)c1cc(CNc2nc(Nc3cc(n[nH]3)C3CC3)cc(n2)N2CCN(C)CC2)on1, CC(C)c1cc(CNc2nc(Nc3cc(n[nH]3)C3CC3)cc(n2)N2CCN(C)CC2)on1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)c1cc(CNc2nc(Nc3cc(n[nH]3)C3CC3)cc(n2)N2CCN(C)CC2)on1",437.265156612,32,3.561,111.03,0.0135897471397633,0.212,0.112794873569882,0,1
"anpirtoline","serotonin receptor agonist","HTR1B","Clc1cccc(SC2CCNCC2)n1, Clc1cccc(SC2CCNCC2)n1, Clc1cccc(SC2CCNCC2)n1, Clc1cccc(SC2CCNCC2)n1, Clc1cccc(SC2CCNCC2)n1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Clc1cccc(SC2CCNCC2)n1",228.048797096,14,2.241,50.22,0.0875120701966395,0.138,0.11275603509832,0,1
"C-751","","","CCOC(=O)c1cnc[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)c1cnc[nH]1",140.058577496,10,0.334,54.98,0.149253329480226,0.076,0.112626664740113,1,0
"cbl0137","histone chaperone inhibitor","","CC(C)NCCn1c2ccc(cc2c2cc(ccc12)C(C)=O)C(C)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)NCCn1c2ccc(cc2c2cc(ccc12)C(C)=O)C(C)=O",336.183778008,25,4.086,51.1,0.123159303560399,0.102,0.112579651780199,1,0
"fenclonine-(+/-)","tryptophan hydroxylase inhibitor","PAH, TPH1, TPH2","N[C@@H](Cc1ccc(Cl)cc1)C(O)=O |&1:1|, N[C@@H](Cc1ccc(Cl)cc1)C(O)=O |&1:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@@H](Cc1ccc(Cl)cc1)C(O)=O |&1:1|",199.04000624,13,-0.757,63.32,0.0511555855586786,0.174,0.112577792779339,0,1
"PIM-1-Inhibitor-2","Pim kinase inhibitor","PIM1","Nc1nccc(n1)-c1ccc2noc(-c3ccc(Cl)cc3)c2c1, Nc1nccc(n1)-c1ccc2noc(-c3ccc(Cl)cc3)c2c1, Nc1nccc(n1)-c1ccc2noc(-c3ccc(Cl)cc3)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1nccc(n1)-c1ccc2noc(-c3ccc(Cl)cc3)c2c1",322.062138652,23,4.634,77.83,0.0710062261062184,0.154,0.112503113053109,0,1
"riboflavin-tetrabutyrate","antioxidant","","CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@H](Cn1c2cc(C)c(C)cc2nc2c1nc(=O)[nH]c2=O)OC(=O)CCC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@H](Cn1c2cc(C)c(C)cc2nc2c1nc(=O)[nH]c2=O)OC(=O)CCC",656.305743608,47,6.824,185.84,0.000911716087097331,0.224,0.112455858043549,0,1
"JPH203","solute carrier family member inhibitor","","N[C@@H](Cc1cc(Cl)c(OCc2cc(N)cc3nc(oc23)-c2ccccc2)c(Cl)c1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@@H](Cc1cc(Cl)c(OCc2cc(N)cc3nc(oc23)-c2ccccc2)c(Cl)c1)C(O)=O",471.075261448,32,1.811,124.6,0.00290895721493215,0.222,0.112454478607466,0,1
"zosuquidar","P glycoprotein inhibitor","ABCB1, ABCB4","O[C@@H](COc1cccc2ncccc12)CN1CCN(CC1)[C@@H]1c2ccccc2[C@@H]2[C@H](c3ccccc13)C2(F)F, O[C@@H](COc1cccc2ncccc12)CN1CCN(CC1)[C@@H]1c2ccccc2[C@@H]2[C@H](c3ccccc13)C2(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","O[C@@H](COc1cccc2ncccc12)CN1CCN(CC1)[C@@H]1c2ccccc2[C@@H]2[C@H](c3ccccc13)C2(F)F",527.238433672,39,4.462,48.83,0.040702129737259,0.184,0.11235106486863,0,1
"NSC-4644","ACAT inhibitor, sterol regulatory element binding protein (SREBP) inhibitor","PYGM","CC(=C)[C@@H]1CC[C@]2(CO)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12, CC(=C)[C@@H]1CC[C@]2(CO)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(=C)[C@@H]1CC[C@]2(CO)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12",442.38108084,32,9.714,40.46,0.220687518719527,0.004,0.112343759359764,1,0
"PHTPP","estrogen receptor antagonist","ESR2","Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1, Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1, Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1",423.080631292,30,5.877,50.42,0.0806734651674051,0.144,0.112336732583703,0,1
"clobenpropit","histamine receptor antagonist","HRH1, HRH2, HRH3, HRH4","Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1, Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1, Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1, Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1, Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1",0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1",308.086245224,20,3.337,89.86,0.0285937122748266,0.196,0.112296856137413,0,1
"sparsentan","angiotensin receptor antagonist","","CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(c(COCC)c1)-c1ccccc1S(=O)(=O)Nc1noc(C)c1C |t:4|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(c(COCC)c1)-c1ccccc1S(=O)(=O)Nc1noc(C)c1C |t:4|",592.27194138,42,5.899,122.48,0.00459368786349292,0.22,0.112296843931746,0,1
"HM-30181","P glycoprotein inhibitor","","COc1cc2CCN(CCc3ccc(cc3)-n3nnc(n3)-c3cc(OC)c(OC)cc3NC(=O)c3cc(=O)c4ccccc4o3)Cc2cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1cc2CCN(CCc3ccc(cc3)-n3nnc(n3)-c3cc(OC)c(OC)cc3NC(=O)c3cc(=O)c4ccccc4o3)Cc2cc1OC",688.264547492,51,6.3,143.07,0.00252586733389822,0.222,0.112262933666949,0,1
"A-438079","purinergic receptor antagonist","P2RX7","Clc1cccc(-c2nnnn2Cc2cccnc2)c1Cl, Clc1cccc(-c2nnnn2Cc2cccnc2)c1Cl, Clc1cccc(-c2nnnn2Cc2cccnc2)c1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1cccc(-c2nnnn2Cc2cccnc2)c1Cl",305.023500648,20,3.865,56.49,0.0724810811304071,0.152,0.112240540565204,0,1
"RITA","MDM inhibitor","MDM2","OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1, OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1, OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1",292.022786244,19,0.367,110.08,0.0102593633683818,0.214,0.112129681684191,0,1
"FK-962","somatostatin receptor agonist","","CC(=O)N1CCC(CC1)NC(=O)c1ccc(F)cc1, CC(=O)N1CCC(CC1)NC(=O)c1ccc(F)cc1, CC(=O)N1CCC(CC1)NC(=O)c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(=O)N1CCC(CC1)NC(=O)c1ccc(F)cc1",264.127406004,19,1.773,49.41,0.10425164211194,0.12,0.11212582105597,0,0
"PHA-543613","nicotinic receptor agonist","","O=C(N[C@H]1CN2CCC1CC2)c1cc2ccoc2cn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(N[C@H]1CN2CCC1CC2)c1cc2ccoc2cn1",271.132076784,20,0.725,58.37,0.0722456170894901,0.152,0.112122808544745,0,1
"molidustat","hypoxia inducible factor inhibitor","EGLN2","O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1, O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1, O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1, O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1",314.123971688,23,0.319,106.75,0.0161350323247486,0.208,0.112067516162374,0,1
"MCOPPB","nociceptin/orphanin FQ receptor agonist","OPRL1","CC1(CCCCCCC1)N1CCC(CC1)n1c(nc2ccccc12)[C@@H]1CCCNC1, CC1(CCCCCCC1)N1CCC(CC1)n1c(nc2ccccc12)[C@@H]1CCCNC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC1(CCCCCCC1)N1CCC(CC1)n1c(nc2ccccc12)[C@@H]1CCCNC1",408.32529728,30,5.456,33.09,0.144063294837482,0.08,0.112031647418741,1,0
"ispinesib","kinesin inhibitor","KIF11","CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1",516.229203976,37,6.445,81.22,0.0260327304707371,0.198,0.112016365235369,0,1
"PF-4981517","cytochrome P450 inhibitor","CYP3A4","Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12, Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12",456.274993024,34,5.088,67.9,0.0519597543488813,0.172,0.111979877174441,0,1
"NS-8","potassium channel agonist","KCNMA1","Cc1c([nH]c(N)c1C#N)-c1ccccc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1c([nH]c(N)c1C#N)-c1ccccc1F",215.08587554,16,2.43,65.6,0.131958084067559,0.092,0.11197904203378,1,0
"ME-0328","PPAR receptor antagonist","PARP3","C[C@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1, C[C@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1, C[C@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1",321.147726848,24,4.053,74.85,0.083748944578395,0.14,0.111874472289198,0,1
"ME0328","PARP inhibitor","PARP3","C[C@@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1 |&1:1,r|, C[C@@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1 |&1:1,r|, C[C@@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1 |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1 |&1:1",321.147726848,24,4.053,74.85,0.0837489445783949,0.14,0.111874472289197,0,1
"YM-155","survivin inhibitor","BIRC5","COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O, COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O, COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O, COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O, COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O",363.145166888091,27,1.696,77.96,0.0337123893445815,0.19,0.111856194672291,0,1
"4-mu-8C","IRE1 inhibitor","ERN1","Cc1cc(=O)oc2c(C=O)c(O)ccc12, Cc1cc(=O)oc2c(C=O)c(O)ccc12, Cc1cc(=O)oc2c(C=O)c(O)ccc12, Cc1cc(=O)oc2c(C=O)c(O)ccc12, Cc1cc(=O)oc2c(C=O)c(O)ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(=O)oc2c(C=O)c(O)ccc12",204.042258736,15,2.806,67.51,0.141584975928121,0.082,0.111792487964061,1,0
"BRL-54443","serotonin receptor agonist","HTR1E, HTR1F","CN1CCC(CC1)c1c[nH]c2ccc(O)cc12, CN1CCC(CC1)c1c[nH]c2ccc(O)cc12, CN1CCC(CC1)c1c[nH]c2ccc(O)cc12, CN1CCC(CC1)c1c[nH]c2ccc(O)cc12",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCC(CC1)c1c[nH]c2ccc(O)cc12",230.141913196,17,2.009,39.26,0.181541234653613,0.042,0.111770617326806,1,0
"BMS-770767","11-beta-HSD1 inhibitor","","O[C@@]12CC[C@@](CC1)(C2)c1nnc2c(Oc3ccccc3Cl)cccn12 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O[C@@]12CC[C@@](CC1)(C2)c1nnc2c(Oc3ccccc3Cl)cccn12 |r|",355.108754496,25,5.284,59.65,0.0895062078864674,0.134,0.111753103943234,0,1
"cgp 55845","gaba receptor antagonist","","C[C@H](NC[C@H](O)CP(O)(=O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"preclinical","neurology","depression","C[C@H](NC[C@H](O)CP(O)(=O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1",401.071435554,25,3.545,79.37,0.0133550349523548,0.21,0.111677517476177,0,1
"CGP-55845","GABA receptor antagonist","GABBR1, GABBR2, KCTD12, KCTD16, KCTD8","C[C@H](NC[C@H](O)CP(O)(=O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1, C[C@H](NC[C@H](O)CP(O)(=O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H](NC[C@H](O)CP(O)(=O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1",401.071435554,25,3.545,79.37,0.0133550349523548,0.21,0.111677517476177,0,1
"dehydrocorydaline","acetylcholinesterase inhibitor","ACHE","COc1ccc2c(C)c3-c4cc(OC)c(OC)cc4CC[n+]3cc2c1OC, COc1ccc2c(C)c3-c4cc(OC)c(OC)cc4CC[n+]3cc2c1OC, COc1ccc2c(C)c3-c4cc(OC)c(OC)cc4CC[n+]3cc2c1OC, COc1ccc2c(C)c3-c4cc(OC)c(OC)cc4CC[n+]3cc2c1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1ccc2c(C)c3-c4cc(OC)c(OC)cc4CC[n+]3cc2c1OC",366.169984668091,27,5,40.8,0.14730000544376,0.076,0.11165000272188,1,0
"sograzepide","gastrin inhibitor","","CNc1cccc(NC(=O)N[C@@H]2N=C(c3ccccn3)c3ccccc3N(CC(=O)C(C)(C)C)C2=O)c1 |t:12|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CNc1cccc(NC(=O)N[C@@H]2N=C(c3ccccn3)c3ccccc3N(CC(=O)C(C)(C)C)C2=O)c1 |t:12|",498.23793882,37,2.656,115.79,0.00722638338926103,0.216,0.111613191694631,0,1
"chlorisondamine-diiodide","acetylcholine receptor antagonist","CHRNA1","C[N+](C)(C)CC[N+]1(C)Cc2c(C1)c(Cl)c(Cl)c(Cl)c2Cl, C[N+](C)(C)CC[N+]1(C)Cc2c(C1)c(Cl)c(Cl)c(Cl)c2Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"preclinical","","","C[N+](C)(C)CC[N+]1(C)Cc2c(C1)c(Cl)c(Cl)c(Cl)c2Cl",356.036962200181,20,3.42,0,0.0711944510556761,0.152,0.111597225527838,0,1
"cysteamine hcl","","","Cl.NCCS",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","Cl.NCCS",113.006597936,5,0.618,64.82,0.0828436331344998,0.14,0.11142181656725,0,1
"alinidine","bradycardic effect ","","Clc1cccc(Cl)c1N(CC=C)C1=NCCN1 |t:13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Clc1cccc(Cl)c1N(CC=C)C1=NCCN1 |t:13|",269.048652776,17,3.86,27.63,0.152837143212071,0.07,0.111418571606035,1,0
"PD-128907","dopamine receptor agonist","DRD2, DRD3","CCCN1CCO[C@H]2[C@H]1COc1ccc(O)cc21, CCCN1CCO[C@H]2[C@H]1COc1ccc(O)cc21, CCCN1CCO[C@H]2[C@H]1COc1ccc(O)cc21",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"preclinical","","","CCCN1CCO[C@H]2[C@H]1COc1ccc(O)cc21",249.136493468,18,1.593,41.93,0.130833685826805,0.092,0.111416842913402,1,0
"sodium oxybate","","","OCCCC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","OCCCC(O)=O",104.047344116,7,-0.601,57.53,0.134790803385573,0.088,0.111395401692786,1,0
"carmoterol","adrenergic receptor agonist","ADRB2","COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"phase 2","","","COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1",368.173607248,27,3.343,94.58,0.030557751827943,0.192,0.111278875913972,0,1
"caroxazone","monoamine oxidase inhibitor","MAOA, MAOB","NC(=O)CN1Cc2ccccc2OC1=O, NC(=O)CN1Cc2ccccc2OC1=O, NC(=O)CN1Cc2ccccc2OC1=O",0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","NC(=O)CN1Cc2ccccc2OC1=O",206.06914218,15,-0.069,72.63,0.0644880630280194,0.158,0.11124403151401,0,1
"DC-260126","free fatty acid receptor antagonist","FFAR1","CCCCc1ccc(NS(=O)(=O)c2ccc(F)cc2)cc1, CCCCc1ccc(NS(=O)(=O)c2ccc(F)cc2)cc1, CCCCc1ccc(NS(=O)(=O)c2ccc(F)cc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCc1ccc(NS(=O)(=O)c2ccc(F)cc2)cc1",307.104228036,21,4.915,54.55,0.1124512178255,0.11,0.11122560891275,0,0
"vanoxerine","dopamine reuptake inhibitor","SLC6A3","Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1",450.248270084,33,5.349,15.71,0.152345031047719,0.07,0.111172515523859,1,0
"SJ-172550","MDM inhibitor","MDM4","CCOc1cc(\C=C2/C(C)=NN(C2=O)c2ccccc2)cc(Cl)c1OCC(=O)OC |c:9|, CCOc1cc(\C=C2/C(C)=NN(C2=O)c2ccccc2)cc(Cl)c1OCC(=O)OC |c:9|, CCOc1cc(\C=C2/C(C)=NN(C2=O)c2ccccc2)cc(Cl)c1OCC(=O)OC |c:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOc1cc(\C=C2/C(C)=NN(C2=O)c2ccccc2)cc(Cl)c1OCC(=O)OC |c:9|",428.113899452,30,4.113,77.43,0.0262758712857186,0.196,0.111137935642859,0,1
"ABX464","antiviral","","FC(F)(F)Oc1ccc(Nc2ccc3cccc(Cl)c3n2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","FC(F)(F)Oc1ccc(Nc2ccc3cccc(Cl)c3n2)cc1",338.04337528,23,5.854,34.15,0.16225591099181,0.06,0.111127955495905,1,0
"hydroxytoluic-acid","","","Cc1cccc(C(O)=O)c1O, Cc1cccc(C(O)=O)c1O, Cc1cccc(C(O)=O)c1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cccc(C(O)=O)c1O",152.047344116,11,1.886,57.53,0.186172535963587,0.036,0.111086267981794,1,0
"AR-C155858","monocarboxylate transporter inhibitor","SLC16A1, SLC16A7","CC(C)Cn1c2sc(Cc3c(C)n[nH]c3C)c(C(=O)N3C[C@H](O)CO3)c2c(=O)n(C)c1=O, CC(C)Cn1c2sc(Cc3c(C)n[nH]c3C)c(C(=O)N3C[C@H](O)CO3)c2c(=O)n(C)c1=O",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)Cn1c2sc(Cc3c(C)n[nH]c3C)c(C(=O)N3C[C@H](O)CO3)c2c(=O)n(C)c1=O",461.173289964,32,2.116,150.69,0.00217117346616668,0.22,0.111085586733083,0,1
"2,3-DCPE","BCL-XL downregulator","BCL2L1","OCCNCCCOc1cccc(Cl)c1Cl, OCCNCCCOc1cccc(Cl)c1Cl, OCCNCCCOc1cccc(Cl)c1Cl, OCCNCCCOc1cccc(Cl)c1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OCCNCCCOc1cccc(Cl)c1Cl",263.04798408,16,2.444,41.49,0.0781205192583681,0.144,0.111060259629184,0,1
"1,3-dipropyl-8-phenylxanthine","adenosine receptor antagonist","","CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)-c1ccccc1, CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)-c1ccccc1",312.15862588,23,5.062,72.68,0.108113736059333,0.114,0.111056868029666,0,0
"ethyl-paraben","","","CCOC(=O)c1ccc(O)cc1, CCOC(=O)c1ccc(O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)c1ccc(O)cc1",166.06299418,12,1.975,46.53,0.213677021786217,0.008,0.110838510893109,1,0
"Ro-5028442","vasopressin receptor antagonist","","CN(C)CCn1cc(C(=O)N2CCC3(CC2)OCc2ccccc32)c2ccc(Cl)cc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN(C)CCn1cc(C(=O)N2CCC3(CC2)OCc2ccccc32)c2ccc(Cl)cc12",437.187004816,31,3.923,37.71,0.0615284003057183,0.16,0.110764200152859,0,1
"ML323","ubiquitin specific protease inhibitor","USP1","CC(C)c1ccccc1-c1ncc(C)c(NCc2ccc(cc2)-n2ccnn2)n1, CC(C)c1ccccc1-c1ncc(C)c(NCc2ccc(cc2)-n2ccnn2)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)c1ccccc1-c1ncc(C)c(NCc2ccc(cc2)-n2ccnn2)n1",384.206244768,29,4.666,68.52,0.0793753450219639,0.142,0.110687672510982,0,1
"acebilustat","leukotriene inhibitor","","[H][C@]12CN(Cc3ccc(cc3)C(O)=O)[C@]([H])(CN1Cc1ccc(Oc3ccc(cc3)-c3ncco3)cc1)C2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","[H][C@]12CN(Cc3ccc(cc3)C(O)=O)[C@]([H])(CN1Cc1ccc(Oc3ccc(cc3)-c3ncco3)cc1)C2",481.200156344,38,4.227,79.04,0.0453217356684727,0.176,0.110660867834236,0,1
"itacitinib","JAK inhibitor","JAK1","Fc1c(ccnc1C(F)(F)F)C(=O)N1CCC(CC1)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12, Fc1c(ccnc1C(F)(F)F)C(=O)N1CCC(CC1)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12, Fc1c(ccnc1C(F)(F)F)C(=O)N1CCC(CC1)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Fc1c(ccnc1C(F)(F)F)C(=O)N1CCC(CC1)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12",553.196169236,40,2.282,119.62,0.00324940085006578,0.218,0.110624700425033,0,1
"VUF10460","histamine receptor agonist","HRH4","CN1CCN(CC1)c1cc(nc(N)n1)-c1ccccc1, CN1CCN(CC1)c1cc(nc(N)n1)-c1ccccc1, CN1CCN(CC1)c1cc(nc(N)n1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCN(CC1)c1cc(nc(N)n1)-c1ccccc1",269.164045608,20,2.369,58.28,0.109071228713171,0.112,0.110535614356586,0,0
"CHR-6494","serine/threonine kinase inhibitor","GSG2","CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1, CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1, CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1, CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1, CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1",292.143644512,22,4.401,70.9,0.1210077784883,0.1,0.11050388924415,1,0
"KME-4","prostaglandin inhibitor","","CC(C)(C)c1cc(\C=C2/CCOC2=O)cc(c1O)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)c1cc(\C=C2/CCOC2=O)cc(c1O)C(C)(C)C",302.188194692,22,4.837,46.53,0.174918245373277,0.046,0.110459122686638,1,0
"mavoglurant","glutamate receptor antagonist","GRM5","COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc1cccc(C)c1, COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc1cccc(C)c1, COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc1cccc(C)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc1cccc(C)c1",313.167793596,23,3.192,49.77,0.11285627939865,0.108,0.110428139699325,0,0
"U-0124","MEK inhibitor","","CSC(=N)C(C#N)C(C#N)C(=N)SC, CSC(=N)C(C#N)C(C#N)C(=N)SC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CSC(=N)C(C#N)C(C#N)C(=N)SC",226.03468832,14,0.21,145.88,0.00661256842406343,0.214,0.110306284212032,0,1
"N-hydroxynicotinamide","","","ONC(=O)c1cccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","ONC(=O)c1cccnc1",138.042927432,10,-0.263,62.22,0.118514877571913,0.102,0.110257438785957,1,0
"hematoxylin","","","Oc1ccc2[C@H]3c4cc(O)c(O)cc4C[C@@]3(O)COc2c1O, Oc1ccc2[C@H]3c4cc(O)c(O)cc4C[C@@]3(O)COc2c1O, Oc1ccc2[C@H]3c4cc(O)c(O)cc4C[C@@]3(O)COc2c1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc2[C@H]3c4cc(O)c(O)cc4C[C@@]3(O)COc2c1O",302.079038168,22,1.407,110.38,0.020428181916474,0.2,0.110214090958237,0,1
"Imazodan","phosphodiesterase inhibitor","","O=C1CCC(=NN1)c1ccc(cc1)-n1ccnc1 |c:4|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","O=C1CCC(=NN1)c1ccc(cc1)-n1ccnc1 |c:4|",240.101111004,18,1.718,59.28,0.11414022254023,0.106,0.110070111270115,0,0
"1-naphthyl-PP1","SRC inhibitor","SRC","CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12",317.164045608,24,4.723,69.62,0.117989148509619,0.102,0.10999457425481,1,0
"verdiperstat","myeloperoxidase inhibitor","","CC(C)OCCn1c2cc[nH]c2c(=O)[nH]c1=S",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(C)OCCn1c2cc[nH]c2c(=O)[nH]c1=S",253.08849772,17,2.876,94.9,0.0418138700160183,0.178,0.109906935008009,0,1
"OAC1","Oct activator","","O=C(Nc1cc2cc[nH]c2cn1)c1ccccc1, O=C(Nc1cc2cc[nH]c2cn1)c1ccccc1, O=C(Nc1cc2cc[nH]c2cn1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(Nc1cc2cc[nH]c2cn1)c1ccccc1",237.090211972,18,2.622,57.78,0.151793229475314,0.068,0.109896614737657,1,0
"JNJ-38877605","tyrosine kinase inhibitor","MET","Cn1cc(cn1)-c1ccc2nnc(n2n1)C(F)(F)c1ccc2ncccc2c1, Cn1cc(cn1)-c1ccc2nnc(n2n1)C(F)(F)c1ccc2ncccc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cn1cc(cn1)-c1ccc2nnc(n2n1)C(F)(F)c1ccc2ncccc2c1",377.120049856,28,5.09,73.79,0.0737789752148605,0.146,0.10988948760743,0,1
"PD-118057","potassium channel activator","KCNH2","OC(=O)c1ccccc1Nc1ccc(CCc2ccc(Cl)c(Cl)c2)cc1, OC(=O)c1ccccc1Nc1ccc(CCc2ccc(Cl)c(Cl)c2)cc1, OC(=O)c1ccccc1Nc1ccc(CCc2ccc(Cl)c(Cl)c2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1ccccc1Nc1ccc(CCc2ccc(Cl)c(Cl)c2)cc1",385.063634144,26,6.868,49.33,0.101776270858269,0.118,0.109888135429135,0,0
"tirasemtiv","troponin activator","","CCC(CC)n1c2nc(cnc2[nH]c1=O)C#C, CCC(CC)n1c2nc(cnc2[nH]c1=O)C#C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCC(CC)n1c2nc(cnc2[nH]c1=O)C#C",230.116761068,17,1.74,63.57,0.105750207445751,0.114,0.109875103722875,0,0
"CGS-15943","adenosine receptor antagonist","ADORA1, ADORA2A, ADORA2B, ADORA3","Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1",285.041737556,20,2.534,82.24,0.0476572797153369,0.172,0.109828639857668,0,1
"U-50488-(-)","opioid receptor agonist","OPRK1","CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1",368.142218812,24,4.28,23.55,0.093541432079428,0.126,0.109770716039714,0,0
"efonidipine hydrochloride monoethanolate","","","CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1",677.286601998,48,6.652,150.28,0.00151883979719718,0.218,0.109759419898599,0,1
"licogliflozin","sodium/glucose cotransporter inhibitor","","CCc1ccc(cc1Cc1ccc2OCCOc2c1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCc1ccc(cc1Cc1ccc2OCCOc2c1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O",416.183503236,30,2.441,108.61,0.0114276869557016,0.208,0.109713843477851,0,1
"AZD3264","IKK inhibitor","IKBKB","Cc1noc(C)c1-c1ccc(-c2cc(C(N)=O)c(NC(N)=O)s2)c(O[C@H]2CCNC2)c1, Cc1noc(C)c1-c1ccc(-c2cc(C(N)=O)c(NC(N)=O)s2)c(O[C@H]2CCNC2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1noc(C)c1-c1ccc(-c2cc(C(N)=O)c(NC(N)=O)s2)c(O[C@H]2CCNC2)c1",441.147075216,31,1.337,173.74,0.00134852876020627,0.218,0.109674264380103,0,1
"FG-7142","GABA benzodiazepine site receptor inverse agonist","","CNC(=O)c1cc2c(cn1)[nH]c1ccccc21, CNC(=O)c1cc2c(cn1)[nH]c1ccccc21, CNC(=O)c1cc2c(cn1)[nH]c1ccccc21, CNC(=O)c1cc2c(cn1)[nH]c1ccccc21",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CNC(=O)c1cc2c(cn1)[nH]c1ccccc21",225.090211972,17,1.773,57.78,0.133264835495876,0.086,0.109632417747938,1,0
"VP-20629","beta amyloid antagonist","PLA2G2E, SLC36A1","OC(=O)CCc1c[nH]c2ccccc12, OC(=O)CCc1c[nH]c2ccccc12",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC(=O)CCc1c[nH]c2ccccc12",189.078978592,14,1.726,53.09,0.16721528169834,0.052,0.10960764084917,1,0
"TUG-770","free fatty acid receptor agonist","FFAR1","OC(=O)CCc1ccc(cc1F)C#Cc1ccccc1CC#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)CCc1ccc(cc1F)C#Cc1ccccc1CC#N",307.100856908,23,3.917,61.09,0.119054755394936,0.1,0.109527377697468,1,0
"remodelin","transferase inhibitor","NAT10","N#Cc1ccc(cc1)-c1csc(NN=C2CCCC2)n1, N#Cc1ccc(cc1)-c1csc(NN=C2CCCC2)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N#Cc1ccc(cc1)-c1csc(NN=C2CCCC2)n1",282.093917448,20,3.533,89.31,0.0550315081230561,0.164,0.109515754061528,0,1
"kenpaullone","CDK inhibitor, glycogen synthase kinase inhibitor","CCNB1, CDK1, CDK5, GSK3B","Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1",326.005475072,20,3.764,44.89,0.0569619095420537,0.162,0.109480954771027,0,1
"hexafluronium bromide","acetylcholinesterase inhibitor","BCHE","[Br-].[Br-].c1cccc3c1c2c(cccc2)C3[N+](CCCCCC[N+](C6c4ccccc4c5ccccc56)(C)C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","neurology/psychiatry","muscle relaxant","[Br-].[Br-].c1cccc3c1c2c(cccc2)C3[N+](CCCCCC[N+](C6c4ccccc4c5ccccc56)(C)C)(C)C",660.171473544,40,9.072,0,0.0209380917800803,0.198,0.10946904589004,0,1
"nevanimibe","","","CC(C)c1cccc(C(C)C)c1NC(=O)NCC2(CCCC2)c3ccc(cc3)N(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)c1cccc(C(C)C)c1NC(=O)NCC2(CCCC2)c3ccc(cc3)N(C)C",421.309312868,31,6.673,44.37,0.138845554865179,0.08,0.10942277743259,1,0
"SB-939","HDAC inhibitor","HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC9","CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC",358.2368762,26,3.186,70.39,0.050802332877059,0.168,0.10940116643853,0,1
"buramate","antiepileptic","","OCCOC(=O)NCc1ccccc1, OCCOC(=O)NCc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OCCOC(=O)NCc1ccccc1",195.089543276,14,0.882,58.56,0.110754315890309,0.108,0.109377157945154,0,0
"PSB-06126","NTPDase inhibitor","ENTPD3","Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O",444.077992612,32,4.65,134.94,0.00870758408701666,0.21,0.109353792043508,0,1
"pravadoline","cyclooxygenase inhibitor","CNR1, CNR2","COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2ccccc12",378.194342692,28,3.555,43.7,0.0966773505629734,0.122,0.109338675281487,0,0
"AVN-944","inosine monophosphate dehydrogenase inhibitor","IMPDH1, IMPDH2","CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1, CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1, CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1, CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1, CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1, CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1",477.201218964,35,2.744,138.51,0.00456032828090561,0.214,0.109280164140453,0,1
"torin-2","mTOR inhibitor","MTOR","Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1",432.11979576,32,5.831,73.8,0.0605528853497776,0.158,0.109276442674889,0,1
"plinabulin","tubulin polymerization inhibitor","","CC(C)(C)c1nc[nH]c1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1nc[nH]c1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1nc[nH]c1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(C)(C)c1nc[nH]c1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O",336.15862588,25,4.048,78.61,0.0685403180826077,0.15,0.109270159041304,0,1
"I-BRD9","bromodomain inhibitor","BRD9","CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1, CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1, CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1, CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1, CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1, CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1, CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1",497.105468224,33,5.507,128.64,0.00442529240285557,0.214,0.109212646201428,0,1
"A-839977","purinergic receptor antagonist","P2RX7","Clc1cccc(c1Cl)-n1nnnc1NCc1ccccc1Oc1ccccn1, Clc1cccc(c1Cl)-n1nnnc1NCc1ccccc1Oc1ccccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1cccc(c1Cl)-n1nnnc1NCc1ccccc1Oc1ccccn1",412.060614428,28,5.825,77.75,0.0363695650728531,0.182,0.109184782536427,0,1
"trabectedin","antitumor agent","","[H][C@@]12Cc3cc(C)c(OC)c(O)c3[C@@]([H])(N1C)[C@@]1([H])N([C@H]2O)[C@@]2([H])COC(=O)[C@]3(CS[C@]1([H])c1c(OC(C)=O)c(C)c4OCOc4c21)NCCc1cc(O)c(OC)cc31 |THB:16:15:2.3.12:17.19.20|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","[H][C@@]12Cc3cc(C)c(OC)c(O)c3[C@@]([H])(N1C)[C@@]1([H])N([C@H]2O)[C@@]2([H])COC(=O)[C@]3(CS[C@]1([H])c1c(OC(C)=O)c(C)c4OCOc4c21)NCCc1cc(O)c(OC)cc31 |THB:16:15:2.3.12:17.19.20|",761.261830196,59,2.838,194.02,0.000366588138686566,0.218,0.109183294069343,0,1
"D,L-mevalonic-acid-lactone","","","C[C@@]1(O)CCOC(=O)C1 |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@]1(O)CCOC(=O)C1 |&1:1",130.06299418,9,-0.036,46.53,0.164271186155269,0.054,0.109135593077634,1,0
"BRL-52537","opioid receptor agonist","OPRK1","Clc1ccc(CC(=O)N2CCCC[C@@H]2CN2CCCC2)cc1Cl |&1:13|, Clc1ccc(CC(=O)N2CCCC[C@@H]2CN2CCCC2)cc1Cl |&1:13|, Clc1ccc(CC(=O)N2CCCC[C@@H]2CN2CCCC2)cc1Cl |&1:13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1ccc(CC(=O)N2CCCC[C@@H]2CN2CCCC2)cc1Cl |&1:13|",354.126568748,23,3.885,23.55,0.0942028027656043,0.124,0.109101401382802,0,0
"azaguanine-8","purine antagonist","PNP","Nc1nc2nn[nH]c2c(=O)[nH]1, Nc1nc2nn[nH]c2c(=O)[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1nc2nn[nH]c2c(=O)[nH]1",152.044658748,11,0.02,113.34,0.0381768719877609,0.18,0.10908843599388,0,1
"NGB-2904","dopamine receptor antagonist","DRD3","Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,"preclinical","","","Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl",493.168767908,34,7.055,35.58,0.0721404650997725,0.146,0.109070232549886,0,1
"3PO","phosphofructokinase inhibitor","PFKFB3","O=C(\C=C\c1cccnc1)c1ccncc1, O=C(\C=C\c1cccnc1)c1ccncc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(\C=C\c1cccnc1)c1ccncc1",210.07931294,16,1.344,42.85,0.1819722824473,0.036,0.10898614122365,1,0
"lapirium chloride","cationic surfactant","","CCCCCCCCCCCC(=O)OCCNC(=O)C[n+]1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","infectious disease","antiseptic","CCCCCCCCCCCC(=O)OCCNC(=O)C[n+]1ccccc1",363.264219400091,26,6.807,59.28,0.129876732640898,0.088,0.108938366320449,1,0
"Y-26763","potassium channel activator","KCNJ8","CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N, CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N, CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N",276.111006992,20,1.041,93.79,0.0318186904258502,0.186,0.108909345212925,0,1
"NI-57","bromodomain inhibitor","BRD1, BRPF1, BRPF3","COc1cc(ccc1S(=O)(=O)Nc1ccc2n(C)c(=O)c(C)cc2c1)C#N, COc1cc(ccc1S(=O)(=O)Nc1ccc2n(C)c(=O)c(C)cc2c1)C#N, COc1cc(ccc1S(=O)(=O)Nc1ccc2n(C)c(=O)c(C)cc2c1)C#N, COc1cc(ccc1S(=O)(=O)Nc1ccc2n(C)c(=O)c(C)cc2c1)C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(ccc1S(=O)(=O)Nc1ccc2n(C)c(=O)c(C)cc2c1)C#N",383.093977024,27,3.43,109.57,0.0156729503812866,0.202,0.108836475190643,0,1
"nefiracetam","acetylcholine receptor agonist, benzodiazepine receptor agonist","CHRM1","Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"phase 3","","","Cc1cccc(C)c1NC(=O)CN1CCCC1=O",246.136827816,18,1.02,49.41,0.10566031118261,0.112,0.108830155591305,0,0
"nepicastat","dopamine beta hydroxylase inhibitor","DBH","NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1, NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1, NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1, NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1",295.09547492,20,2.816,78.83,0.0436448210036301,0.174,0.108822410501815,0,1
"BMS-986020","lysophosphatidic acid receptor antagonist","LPAR1","C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(cc1)C1(CC1)C(O)=O)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(cc1)C1(CC1)C(O)=O)c1ccccc1",482.184171932,36,6.815,101.66,0.0316290325167254,0.186,0.108814516258363,0,1
"kuromanin","ribosyl cyclase inhibitor","CD38","OC[C@H]1O[C@@H](Oc2cc3c(O)cc(O)cc3[o+]c2-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2cc3c(O)cc(O)cc3[o+]c2-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC[C@H]1O[C@@H](Oc2cc3c(O)cc(O)cc3[o+]c2-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O",449.107837912091,32,2.151,180.3,0.00147195749319739,0.216,0.108735978746599,0,1
"simurosertib","kinase inhibitor","","Cc1n[nH]cc1-c1cc2[nH]c(nc(=O)c2s1)[C@H]1CC2CCN1CC2 |&1:16,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1n[nH]cc1-c1cc2[nH]c(nc(=O)c2s1)[C@H]1CC2CCN1CC2 |&1:16",341.131031228,24,3.114,105.91,0.0214430101238191,0.196,0.10872150506191,0,1
"cinanserin","serotonin receptor antagonist","HTR2A","CN(C)CCCSc1ccccc1NC(=O)\C=C\c1ccccc1, CN(C)CCCSc1ccccc1NC(=O)\C=C\c1ccccc1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)CCCSc1ccccc1NC(=O)\C=C\c1ccccc1",340.160934388,24,4.153,57.64,0.0813932513752906,0.136,0.108696625687645,0,1
"CS-917","fructose biphosphate inhibitor","FBP1","CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O, CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O, CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O, CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O, CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O",302.04901459,19,0.111,147.63,0.0031971249866223,0.214,0.108598562493311,0,1
"LY2811376","beta-secretase inhibitor","BACE1","C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|, C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|, C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|, C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|, C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|, C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|",320.090723888,22,2.374,89.46,0.0271550968038537,0.19,0.108577548401927,0,1
"cutamesine","sigma receptor agonist","SIGMAR1","COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC, COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC, COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC, COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC, COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC",368.246378264,27,3.362,24.94,0.13708452206263,0.08,0.108542261031315,1,0
"zoliflodacin","antibacterial ","","[H][C@]12[C@H](C)O[C@H](C)CN1c1c(CC22C(=O)NC(=O)NC2=O)cc2c(noc2c1F)N1[C@@H](C)COC1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","[H][C@]12[C@H](C)O[C@H](C)CN1c1c(CC22C(=O)NC(=O)NC2=O)cc2c(noc2c1F)N1[C@@H](C)COC1=O",487.150326264,36,1.374,143.31,0.00289871749950977,0.214,0.108449358749755,0,1
"80841-78-7","","","Cc1oc(=O)oc1CCl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1oc(=O)oc1CCl",147.9927217,9,1.187,43.35,0.156863570305723,0.06,0.108431785152861,1,0
"Ro-48-6791","GABA receptor modulator","","CCCN(CCC)Cc1nc(no1)-c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCN(CCC)Cc1nc(no1)-c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21",412.20230226,30,4.008,80.29,0.0347539811431858,0.182,0.108376990571593,0,1
"ozenoxacin","antiinfective drug","","CNc1ncc(cc1C)-c1ccc2c(c1C)n(cc(C(O)=O)c2=O)C1CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CNc1ncc(cc1C)-c1ccc2c(c1C)n(cc(C(O)=O)c2=O)C1CC1",363.158291532,27,5.46,84.22,0.0705882203532575,0.146,0.108294110176629,0,1
"triciribine-phosphate","AKT inhibitor","","Cn1nc(N)c2cn([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]3O)c3ncnc1c23",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","Cn1nc(N)c2cn([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]3O)c3ncnc1c23",400.089633514,27,-0.967,200.81,0.000434780811062321,0.216,0.108217390405531,0,1
"rac-BHFF","GABA receptor positive allosteric modulator","GABBR1","CC(C)(C)c1cc2c(OC(=O)[C@@]2(O)C(F)(F)F)c(c1)C(C)(C)C |&1:11,r|, CC(C)(C)c1cc2c(OC(=O)[C@@]2(O)C(F)(F)F)c(c1)C(C)(C)C |&1:11,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)c1cc2c(OC(=O)[C@@]2(O)C(F)(F)F)c(c1)C(C)(C)C |&1:11",330.144279192,23,5.691,46.53,0.144345126395125,0.072,0.108172563197562,1,0
"2-(chloromethyl)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one","","","ClC=C1Nc2sc3CCCCc3c2C(=O)N1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","ClC=C1Nc2sc3CCCCc3c2C(=O)N1",254.028061652,16,2.915,69.37,0.0582336246127891,0.158,0.108116812306395,0,1
"K-247","","","OC[C@H]1O[C@@H](Nc2ccc(cc2)C(O)=O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:15,&4:17,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC[C@H]1O[C@@H](Nc2ccc(cc2)C(O)=O)[C@@H](O)[C@@H]1O |&1:2",269.0899372,19,0.328,119.25,0.0141599174634433,0.202,0.108079958731722,0,1
"n-(4-carboxyphenyl)pentopyranosylamine","","","O[C@H]1CO[C@@H](Nc2ccc(cc2)C(O)=O)[C@@H](O)[C@@H]1O |&1:1,&2:4,&3:15,&4:17,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","O[C@H]1CO[C@@H](Nc2ccc(cc2)C(O)=O)[C@@H](O)[C@@H]1O |&1:1",269.0899372,19,0.328,119.25,0.0141599174634433,0.202,0.108079958731722,0,1
"tianeptine (sodium salt)","","","CN1c2ccccc2C(NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CN1c2ccccc2C(NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O",436.12235596,29,4.268,95.09,0.0120592285153876,0.204,0.108029614257694,0,1
"PIK-293","PI3K inhibitor","PIK3CA, PIK3CB, PIK3CD, PIK3CG","Cc1ccccc1-n1c(Cn2ncc3c(N)ncnc23)nc2cccc(C)c2c1=O, Cc1ccccc1-n1c(Cn2ncc3c(N)ncnc23)nc2cccc(C)c2c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccccc1-n1c(Cn2ncc3c(N)ncnc23)nc2cccc(C)c2c1=O",397.165108228,30,3.902,104.51,0.0278672112939312,0.188,0.107933605646966,0,1
"PF-04937319","glucokinase activator","GCK","CN(C)C(=O)c1ncc(Oc2cc(cc3oc(C)cc23)C(=O)Nc2cnc(C)cn2)cn1, CN(C)C(=O)c1ncc(Oc2cc(cc3oc(C)cc23)C(=O)Nc2cnc(C)cn2)cn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN(C)C(=O)c1ncc(Oc2cc(cc3oc(C)cc23)C(=O)Nc2cnc(C)cn2)cn1",432.15460312,32,0.635,123.34,0.00567653261133565,0.21,0.107838266305668,0,1
"emixustat","retinoid isomerohydrolase inhibitor","","NCC[C@@H](O)c1cccc(OCC2CCCCC2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","NCC[C@@H](O)c1cccc(OCC2CCCCC2)c1",263.18852904,19,3.256,55.48,0.129506504346383,0.086,0.107753252173192,1,0
"boronophenylalanine","","","N[C@@H](Cc1ccc(cc1)B(O)O)C(O)=O, N[C@@H](Cc1ccc(cc1)B(O)O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","N[C@@H](Cc1ccc(cc1)B(O)O)C(O)=O",209.085938264,15,-2.354,103.78,0.0174737226517041,0.198,0.107736861325852,0,1
"PD-166285","SRC inhibitor","EGFR, FGFR1, PDGFRB, PKMYT1, SRC, WEE1","CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1, CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1, CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1, CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1, CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1, CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1",511.154180464,35,6.529,72.28,0.0233460628519029,0.192,0.107673031425951,0,1
"nialamide","monoamine oxidase inhibitor","COMT, MAOA, MAOB","O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1, O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1, O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1",0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1",298.142975816,22,1.591,83.12,0.0431492145586542,0.172,0.107574607279327,0,1
"isbufylline","phosphodiesterase inhibitor","","CC(C)Cn1cnc2n(C)c(=O)n(C)c(=O)c12, CC(C)Cn1cnc2n(C)c(=O)n(C)c(=O)c12, CC(C)Cn1cnc2n(C)c(=O)n(C)c(=O)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)Cn1cnc2n(C)c(=O)n(C)c(=O)c12",236.127325752,17,2.63,61.82,0.11714764898457,0.098,0.107573824492285,1,0
"deoxyepinephrine","adrenergic receptor agonist, dopamine receptor agonist","ADRA1A, DRD1, DRD2","CNCCc1ccc(O)c(O)c1, CNCCc1ccc(O)c(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,1,1,0,0,0,0,"preclinical","","","CNCCc1ccc(O)c(O)c1",167.094628656,12,1.041,52.49,0.155137954380015,0.06,0.107568977190007,1,0
"KN-93","calcium/calmodulin dependent protein kinase inhibitor","CAMK2A","COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1, COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1, COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1, COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1",500.153656088,34,5.169,78.46,0.0150974663385089,0.2,0.107548733169254,0,1
"terpene","","","CC(C)(O)[C@H]1CC[C@](C)(O)CC1 |&1:7,&2:4|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(O)[C@H]1CC[C@](C)(O)CC1 |&1:7",172.14632988,12,1.577,40.46,0.196981449042175,0.018,0.107490724521088,1,0
"fenretinide","apoptosis stimulant, retinoid receptor agonist","RARA","C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|",391.251129296,29,7.204,49.33,0.174821984400096,0.04,0.107410992200048,1,0
"ADD-233089","benzodiazepine receptor agonist","","Clc1ccc(cc1)-n1cc([nH]c1=O)N1CCOCC1, Clc1ccc(cc1)-n1cc([nH]c1=O)N1CCOCC1, Clc1ccc(cc1)-n1cc([nH]c1=O)N1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Clc1ccc(cc1)-n1cc([nH]c1=O)N1CCOCC1",279.077454368,19,2.167,50.26,0.0808121300410902,0.134,0.107406065020545,0,1
"BP-554","serotonin receptor agonist","HTR1A","C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1, C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1, C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1, C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1, C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1",340.178692628,25,3.568,34.17,0.142711609018002,0.072,0.107355804509001,1,0
"ZD-7155","angiotensin receptor antagonist","AGTR1","CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1, CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1, CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1, CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1, CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1",438.216809452,33,5.079,87.66,0.0405859627283196,0.174,0.10729298136416,0,1
"elacestrant","estrogen receptor degrader","","CCNCCc1ccc(CN(CC)c2cc(OC)ccc2[C@@H]2CCc3cc(O)ccc3C2)cc1, CCNCCc1ccc(CN(CC)c2cc(OC)ccc2[C@@H]2CCc3cc(O)ccc3C2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCNCCc1ccc(CN(CC)c2cc(OC)ccc2[C@@H]2CCc3cc(O)ccc3C2)cc1",458.293328456,34,6.597,44.73,0.114572386168389,0.1,0.107286193084195,0,0
"minerval","FAAH inhibitor","","CCCCCCCC\C=C/CCCCCC[C@@H](O)C(O)=O |&1:16,r|, CCCCCCCC\C=C/CCCCCC[C@@H](O)C(O)=O |&1:16,r|, CCCCCCCC\C=C/CCCCCC[C@@H](O)C(O)=O |&1:16,r|, CCCCCCCC\C=C/CCCCCC[C@@H](O)C(O)=O |&1:16,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","CCCCCCCC\C=C/CCCCCC[C@@H](O)C(O)=O |&1:16",298.250794948,21,7.217,57.53,0.204461650635609,0.01,0.107230825317805,1,0
"INX-08189","antiviral","","[H][C@@](C)(N[P@](=O)(OC[C@@]1([H])O[C@@]([H])(n2cnc3c(OC)nc(N)nc23)[C@](C)(O)[C@]1([H])O)Oc1cccc2ccccc12)C(=O)OCC(C)(C)C |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","[H][C@@](C)(N[P@](=O)(OC[C@@]1([H])O[C@@]([H])(n2cnc3c(OC)nc(N)nc23)[C@](C)(O)[C@]1([H])O)Oc1cccc2ccccc12)C(=O)OCC(C)(C)C |r|",658.251613458,50,3.712,212.21,0.000439600521290126,0.214,0.107219800260645,0,1
"CPI-1189","tumor necrosis factor release inhibitor","TNF","CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C, CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C, CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C, CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C",234.136827816,17,1.981,58.2,0.11431398975153,0.1,0.107156994875765,0,0
"TCS-5861528","transient receptor potential channel antagonist","TRPA1","CC[C@@H](C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1 |&1:2,r|, CC[C@@H](C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1 |&1:2,r|, CC[C@@H](C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1 |&1:2,r|, CC[C@@H](C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1 |&1:2,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC[C@@H](C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1 |&1:2",369.180089596,27,4.264,90.92,0.0402954281131903,0.174,0.107147714056595,0,1
"GANT-61","GLI antagonist","GLI1, GLI2","CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1",429.28924612,32,4.6,25.85,0.134185405636252,0.08,0.107092702818126,1,0
"tropifexor","FXR agonist","","OC(=O)c1cc(F)c2nc(sc2c1)N1[C@H]2CC[C@@H]1C[C@@H](C2)OCc1c(onc1-c1ccccc1OC(F)(F)F)C1CC1 |TLB:9:13:16.15:19.20.18|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)c1cc(F)c2nc(sc2c1)N1[C@H]2CC[C@@H]1C[C@@H](C2)OCc1c(onc1-c1ccccc1OC(F)(F)F)C1CC1 |TLB:9:13:16.15:19.20.18|",603.14510478,42,6.823,126.16,0.00408193466881235,0.21,0.107040967334406,0,1
"metenkephalin","immunostimulant","OPRD1","CSCC[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O |&1:4,&2:8,&3:27,r|, CSCC[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O |&1:4,&2:8,&3:27,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CSCC[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O |&1:4",573.22571946,40,-1.629,225.25,6.68384616528731e-05,0.214,0.107033419230826,0,1
"lhf-535","antiviral","","CC(C)Oc1ccc(cc1)n2cnc3cc(\C=C/c4ccc(cc4)C(C)(C)O)ccc23",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","endocrinology","fever","CC(C)Oc1ccc(cc1)n2cnc3cc(\C=C/c4ccc(cc4)C(C)(C)O)ccc23",412.215078136,31,6.444,46.76,0.151993530976004,0.062,0.106996765488002,1,0
"chromanol-293B-(-)-[3R,4S]","potassium channel blocker","","CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N, CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N",324.11437812,22,1.461,99.01,0.0159812059199964,0.198,0.106990602959998,0,1
"macelignan","anti-inflammatory agent, antioxidant","","COc1cc(C[C@H](C)[C@H](C)Cc2ccc3OCOc3c2)ccc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(C[C@H](C)[C@H](C)Cc2ccc3OCOc3c2)ccc1O",328.167459248,24,5.52,47.92,0.171345332468826,0.042,0.106672666234413,1,0
"BIX-02189","MEK inhibitor","MAP2K5, MAPK7","CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c2ccccc2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c2ccccc2)c1",440.221226136,33,3.936,64.68,0.0493376774369227,0.164,0.106668838718461,0,1
"sevelamer hcl","","","NCC=C.ClCC1CO1, null",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","NCC=C.ClCC1CO1",149.060741684,9,0.661,38.55,0.15122265256783,0.062,0.106611326283915,1,0
"imidazoacridinone","anticancer agent","","CCN(CC)CCNc1ccc2ncn3c2c1c(=O)c1cc(O)ccc31",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN(CC)CCNc1ccc2ncn3c2c1c(=O)c1cc(O)ccc31",350.174275944,26,4.056,69.87,0.0752003072029074,0.138,0.106600153601454,0,1
"genz-644282","topoisomerase inhibitor","TOP1","CNCCn1c2c3cc4OCOc4cc3ncc2c2cc(OC)c(OC)cc2c1=O, CNCCn1c2c3cc4OCOc4cc3ncc2c2cc(OC)c(OC)cc2c1=O, CNCCn1c2c3cc4OCOc4cc3ncc2c2cc(OC)c(OC)cc2c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CNCCn1c2c3cc4OCOc4cc3ncc2c2cc(OC)c(OC)cc2c1=O",407.148120772,30,3.11,83.84,0.0291467902052021,0.184,0.106573395102601,0,1
"opicapone","catechol O methyltransferase inhibitor","COMT","Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(n1)-c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(n1)-c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(n1)-c1cc(O)c(O)c(c1)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(n1)-c1cc(O)c(O)c(c1)[N+]([O-])=O",411.9977394,27,5.39,149.46,0.00509150627519358,0.208,0.106545753137597,0,1
"ripretinib","receptor tyrosine protein kinase inhibitor","","CCn1c2cc(NC)ncc2cc(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)c1=O, CCn1c2cc(NC)ncc2cc(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCn1c2cc(NC)ncc2cc(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)c1=O",509.086265232,33,5.712,88.05,0.00891415164201343,0.204,0.106457075821007,0,1
"GSK2194069","fatty acid synthase inhibitor","FASN","O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(cc2)-c2ccc3occc3c2)C1, O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(cc2)-c2ccc3occc3c2)C1, O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(cc2)-c2ccc3occc3c2)C1, O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(cc2)-c2ccc3occc3c2)C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(cc2)-c2ccc3occc3c2)C1",428.184840628,32,3.818,84.13,0.0328952637426895,0.18,0.106447631871345,0,1
"aminothiazole","cyclin D inhibitor","NOS2","Nc1nccs1, Nc1nccs1, Nc1nccs1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1nccs1",100.009519128,6,-0.223,67.15,0.106839453456137,0.106,0.106419726728068,0,0
"PSB-11","adenosine receptor antagonist","ADORA1, ADORA2A, ADORA3","CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|, CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|, CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|, CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|, CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|",295.143310164,22,2.378,64.59,0.0828209832300849,0.13,0.106410491615042,0,1
"milacemide","monoamine oxidase inhibitor","MAOB","CCCCCNCC(N)=O, CCCCCNCC(N)=O, CCCCCNCC(N)=O, CCCCCNCC(N)=O",0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCCCCNCC(N)=O",144.126263132,10,0.397,55.12,0.138772897734024,0.074,0.106386448867012,1,0
"JNJ-38877618","c-Met inhibitor","","FC(F)(c1nnc2ccc(nn12)-c1ccncc1)c1ccc2ncccc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","FC(F)(c1nnc2ccc(nn12)-c1ccncc1)c1ccc2ncccc2c1",374.109150824,28,5.345,68.86,0.0926918259726088,0.12,0.106345912986304,0,0
"LY2452473","androgen receptor modulator","AR","CC(C)OC(=O)N[C@@H]1Cc2c(C1)c1cc(ccc1n2Cc1ccccn1)C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)OC(=O)N[C@@H]1Cc2c(C1)c1cc(ccc1n2Cc1ccccn1)C#N",374.174275944,28,3.207,79.94,0.0446126612896805,0.168,0.10630633064484,0,1
"CGP-54626","GABA receptor antagonist","GABBR1, GABBR2, KCTD12, KCTD16, KCTD8","C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1 |a:1,4,&1:7|, C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1 |a:1,4,&1:7|, C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1 |a:1,4,&1:7|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1 |a:1",407.118385746,25,4.48,79.37,0.0145195173259539,0.198,0.106259758662977,0,1
"EXO-1","ARF inhibitor","","COC(=O)c1ccccc1NC(=O)c1ccc(F)cc1, COC(=O)c1ccccc1NC(=O)c1ccc(F)cc1, COC(=O)c1ccccc1NC(=O)c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)c1ccccc1NC(=O)c1ccc(F)cc1",273.080121464,20,3.519,55.4,0.136458205694523,0.076,0.106229102847261,1,0
"ZM-241385","adenosine receptor antagonist","ADORA1, ADORA2A, ADORA2B, ADORA3","Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1, Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1, Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1, Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1, Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1, Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1",337.12872272,25,1.563,127.39,0.012456390879016,0.2,0.106228195439508,0,1
"liarozole","cytochrome P450 inhibitor","CYP19A1, CYP26A1","Clc1cccc(c1)[C@H](c1ccc2nc[nH]c2c1)n1ccnc1 |&1:7,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","Clc1cccc(c1)[C@H](c1ccc2nc[nH]c2c1)n1ccnc1 |&1:7",308.082874096,22,3.468,46.5,0.116372389340503,0.096,0.106186194670251,1,0
"epacadostat","indoleamine 2,3-dioxygenase inhibitor","IDO1","NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1, NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1, NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1, NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1, NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1",436.991713216,25,0.991,176.14,0.000325047222818722,0.212,0.106162523611409,0,1
"risdiplam","RNA splicing inhibitor","","Cc1cn2nc(cc(C)c2n1)-c1cc(=O)n2cc(ccc2n1)N1CCNC2(CC2)C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","Cc1cn2nc(cc(C)c2n1)-c1cc(=O)n2cc(ccc2n1)N1CCNC2(CC2)C1",401.196408356,30,3.519,79.83,0.0403015752959032,0.172,0.106150787647952,0,1
"asivatrep","transient receptor potential channel antagonist","","CCCc1nc(ccc1\C=C\C(=O)N[C@H](C)c1cc(F)c(NS(C)(=O)=O)c(F)c1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCCc1nc(ccc1\C=C\C(=O)N[C@H](C)c1cc(F)c(NS(C)(=O)=O)c(F)c1)C(F)(F)F",491.130203664,33,4.396,96.54,0.00815059737685946,0.204,0.10607529868843,0,1
"DPCPX","adenosine receptor antagonist","ADORA1, ADORA2A, ADORA2B, ADORA3","CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C1CCCC1, CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C1CCCC1, CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C1CCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C1CCCC1",304.189926008,22,4.689,72.68,0.0960794306735267,0.116,0.106039715336763,0,0
"ARV-825","bromodomain inhibitor","BRD4","Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(OCCOCCOCCOCCNc3cccc4C(=O)N([C@H]5CCC(=O)NC5=O)C(=O)c34)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |a:9,&1:39,c:8|, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(OCCOCCOCCOCCNc3cccc4C(=O)N([C@H]5CCC(=O)NC5=O)C(=O)c34)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |a:9,&1:39,c:8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(OCCOCCOCCOCCNc3cccc4C(=O)N([C@H]5CCC(=O)NC5=O)C(=O)c34)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |a:9",922.287523764,65,5.186,232.91,2.24546172974123e-05,0.212,0.106011227308649,0,1
"IOX2","hypoxia inducible factor inhibitor","EGLN1, KDM2A, KDM5C","OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O, OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O, OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O, OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O, OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O",352.105921612,26,1.82,108.63,0.0179387038656855,0.194,0.105969351932843,0,1
"SB-203186","serotonin receptor antagonist","HTR4","O=C(OCCN1CCCCC1)c1c[nH]c2ccccc12, O=C(OCCN1CCCCC1)c1c[nH]c2ccccc12",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(OCCN1CCCCC1)c1c[nH]c2ccccc12",272.15247788,20,3.175,45.33,0.157921142328935,0.054,0.105960571164467,1,0
"octamethyltrisiloxane","","","C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C",236.108409598,13,4.392,18.46,0.181889893037638,0.03,0.105944946518819,1,0
"A-366","histone lysine methyltransferase inhibitor","EHMT1, EHMT2","COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|",329.210327104,24,2.106,60.08,0.0617773263320206,0.15,0.10588866316601,0,1
"dimethadione","oxazolidine antiepileptic","","CC1(C)OC(=O)NC1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC1(C)OC(=O)NC1=O",129.042593084,9,-0.151,55.4,0.137497627977902,0.074,0.105748813988951,1,0
"oleoylethanolamide","cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist","CNR1, GPR119, GPR55, PPARA","CCCCCCCC\C=C/CCCCCCCC(=O)NCCO, CCCCCCCC\C=C/CCCCCCCC(=O)NCCO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCC\C=C/CCCCCCCC(=O)NCCO",325.298079488,23,7.273,49.33,0.207408368544196,0.004,0.105704184272098,1,0
"VUF10166","serotonin receptor antagonist","HTR3A, HTR3B","CN1CCN(CC1)c1nc2ccccc2nc1Cl, CN1CCN(CC1)c1nc2ccccc2nc1Cl",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCN(CC1)c1nc2ccccc2nc1Cl",262.09852416,18,2.373,32.26,0.143316792221846,0.068,0.105658396110923,1,0
"asaraldehyde","cyclooxygenase inhibitor","PTGS2","COc1cc(OC)c(C=O)cc1OC, COc1cc(OC)c(C=O)cc1OC",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(OC)c(C=O)cc1OC",196.073558864,14,1.195,44.76,0.153179274598949,0.058,0.105589637299475,1,0
"cenerimod","sphingosine 1-phosphate receptor modulator","","CCc1cc(cc(C)c1OC[C@@H](O)CO)-c1noc(n1)-c1cc(OC)nc(c1)C1CCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCc1cc(cc(C)c1OC[C@@H](O)CO)-c1noc(n1)-c1cc(OC)nc(c1)C1CCCC1",453.226371092,33,4.604,110.73,0.0151702114072828,0.196,0.105585105703641,0,1
"titanocene-dichloride","apoptosis stimulant","","Cl[Ti](Cl)(C1C=CC=C1)C1C=CC=C1 |c:4,6,10,12|, Cl[Ti](Cl)(C1C=CC=C1)C1C=CC=C1 |c:4,6,10,12|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cl[Ti](Cl)(C1C=CC=C1)C1C=CC=C1 |c:4",247.96390198,13,2.571,0,0.141144813138634,0.07,0.105572406569317,1,0
"muscimol","benzodiazepine receptor agonist","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRR1, GABRR2, GABRR3","NCc1cc(=O)[nH]o1, NCc1cc(=O)[nH]o1",0,0,0,0,0,0,0,0,0,0,0,0,1,9,0,0,0,0,0,0,0,0,0,0,"phase 1","","","NCc1cc(=O)[nH]o1",114.042927432,8,-1.096,72.02,0.0890614010129212,0.122,0.105530700506461,0,0
"banoxantrone","topoisomerase inhibitor","TOP2A","C[N+](C)([O-])CCNc1ccc(NCC[N+](C)(C)[O-])c2C(=O)c3c(O)ccc(O)c3C(=O)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","C[N+](C)([O-])CCNc1ccc(NCC[N+](C)(C)[O-])c2C(=O)c3c(O)ccc(O)c3C(=O)c12",444.200884616,32,0.79,144.78,0.00269738743720022,0.208,0.1053486937186,0,1
"benfluorex","gluconeogenesis inhibitor","HMGCR","C[C@@H](Cc1cccc(c1)C(F)(F)F)NCCOC(=O)c1ccccc1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","C[C@@H](Cc1cccc(c1)C(F)(F)F)NCCOC(=O)c1ccccc1 |r|",351.14461354,25,4.825,38.33,0.136669493676929,0.074,0.105334746838464,1,0
"benfluorex hydrochloride","gluconeogenesis inhibitor","","CC(Cc1cccc(c1)C(F)(F)F)NCCOC(=O)c1ccccc1, CC(Cc1cccc(c1)C(F)(F)F)NCCOC(=O)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CC(Cc1cccc(c1)C(F)(F)F)NCCOC(=O)c1ccccc1",351.14461354,25,4.825,38.33,0.136669493676929,0.074,0.105334746838464,1,0
"Ro-08-2750","NGF binding inhibitor","NGF, NGFR","Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C)c2cc1C=O, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C)c2cc1C=O, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C)c2cc1C=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C)c2cc1C=O",270.07529018,20,2.625,97.71,0.0486441427212474,0.162,0.105322071360624,0,1
"2-hydroxysaclofen","GABA receptor antagonist","GABBR1, GABBR2","NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2",265.017556544,16,-0.265,109,0.00862111753051,0.202,0.105310558765255,0,1
"caroverin","cytochrome P450 inhibitor","","CCN(CC)CCn1c2ccccc2nc(Cc2ccc(OC)cc2)c1=O, CCN(CC)CCn1c2ccccc2nc(Cc2ccc(OC)cc2)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCN(CC)CCn1c2ccccc2nc(Cc2ccc(OC)cc2)c1=O",365.210327104,27,4.103,47.36,0.10860073828523,0.102,0.105300369142615,0,0
"indotecan","topoisomerase inhibitor","CHEK1, PDLIM7, TOP1","COc1cc2c3C(=O)c4cc5OCOc5cc4-c3n(CCCN3CCOCC3)c(=O)c2cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","soft tissue sarcoma (sts)","COc1cc2c3C(=O)c4cc5OCOc5cc4-c3n(CCCN3CCOCC3)c(=O)c2cc1OC",478.174001172,35,3.41,88.46,0.0165388684160352,0.194,0.105269434208018,0,1
"triciribine","AKT inhibitor","AKT1, AKT2, AKT3","Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23",320.123302992,23,0.691,144.47,0.00645036422107703,0.204,0.105225182110539,0,1
"CC-115","DNA protein kinase inhibitor, mTOR inhibitor","MTOR","CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1 |c:9,t:6,11|, CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1 |c:9,t:6,11|, CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1 |c:9,t:6,11|, CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1 |c:9,t:6,11|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1 |c:9",336.144707132,25,1.535,111.52,0.0181920023948279,0.192,0.105096001197414,0,1
"mecarbinate","","","CCOC(=O)c1c(C)n(C)c2ccc(O)cc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)c1c(C)n(C)c2ccc(O)cc12",233.10519334,17,2.586,51.46,0.15211848422023,0.058,0.105059242110115,1,0
"alpidem","benzodiazepine receptor agonist","GABRA1","CCCN(CCC)C(=O)Cc1c(nc2ccc(Cl)cn12)-c1ccc(Cl)cc1, CCCN(CCC)C(=O)Cc1c(nc2ccc(Cl)cn12)-c1ccc(Cl)cc1, CCCN(CCC)C(=O)Cc1c(nc2ccc(Cl)cn12)-c1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CCCN(CCC)C(=O)Cc1c(nc2ccc(Cl)cn12)-c1ccc(Cl)cc1",403.121817716,27,6.127,37.61,0.0920345023030736,0.118,0.105017251151537,0,0
"guadecitabine","DNA methyltransferase inhibitor","","Nc1ncn([C@H]2C[C@H](OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3O)n3cnc4c3[nH]c(N)nc4=O)[C@@H](CO)O2)c(=O)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Nc1ncn([C@H]2C[C@H](OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3O)n3cnc4c3[nH]c(N)nc4=O)[C@@H](CO)O2)c(=O)n1",557.138374598,38,-1.841,287.88,1.37651472793695e-05,0.21,0.10500688257364,0,1
"visomitin","antioxidant","","CC1=C(C)C(=O)C(CCCCCCCCCC[P+](c2ccccc2)(c2ccccc2)c2ccccc2)=CC1=O |c:1,38|, CC1=C(C)C(=O)C(CCCCCCCCCC[P+](c2ccccc2)(c2ccccc2)c2ccccc2)=CC1=O |c:1,38|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC1=C(C)C(=O)C(CCCCCCCCCC[P+](c2ccccc2)(c2ccccc2)c2ccccc2)=CC1=O |c:1",537.291693634091,39,10.471,34.14,0.169993865386165,0.04,0.104996932693082,1,0
"VE-822","ATR kinase inhibitor","ATM, ATR, MTOR, PIK3CG","CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C",463.16781066,33,3.768,132.38,0.00595336709908047,0.204,0.10497668354954,0,1
"spermidine","glutamate receptor modulator","KCNJ4, TXNRD1","NCCCCNCCCN, NCCCCNCCCN",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NCCCCNCCCN",145.157897608,10,-0.654,64.07,0.0898478212490841,0.12,0.104923910624542,0,0
"SCS","","","Oc1ccccc1\C=N\NC(=O)c1ccccc1O, Oc1ccccc1\C=N\NC(=O)c1ccccc1O, Oc1ccccc1\C=N\NC(=O)c1ccccc1O, Oc1ccccc1\C=N\NC(=O)c1ccccc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccccc1\C=N\NC(=O)c1ccccc1O",256.084792244,19,4.04,81.92,0.103761408799549,0.106,0.104880704399775,0,0
"CH-170","","","Cc1nc(Cn2cnc3n(C)c(=O)n(C)c(=O)c23)no1, Cc1nc(Cn2cnc3n(C)c(=O)n(C)c(=O)c23)no1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1nc(Cn2cnc3n(C)c(=O)n(C)c(=O)c23)no1",276.097088244,20,1.687,100.74,0.031747339107123,0.178,0.104873669553561,0,1
"PF-514273","cannabinoid receptor antagonist","","CC(F)(F)CN1CCOc2c(nn(c2-c2ccc(Cl)cc2)-c2ccccc2Cl)C1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(F)(F)CN1CCOc2c(nn(c2-c2ccc(Cl)cc2)-c2ccccc2Cl)C1=O",451.066588584,30,6.022,47.36,0.0476127703490775,0.162,0.104806385174539,0,1
"formononetin","alcohol dehydrogenase inhibitor","ADH1C, SLC5A2","COc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, COc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, COc1ccc(cc1)-c1coc2cc(O)ccc2c1=O",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1)-c1coc2cc(O)ccc2c1=O",268.073558864,20,4.058,59.67,0.155501785855425,0.054,0.104750892927713,1,0
"tyrphostin-A9","protein tyrosine kinase inhibitor, tyrosine kinase inhibitor","","CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C",282.173213324,21,4.464,67.81,0.131486339825615,0.078,0.104743169912808,1,0
"anisomycin","DNA synthesis inhibitor","NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1","COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1, COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1, COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1, COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1, COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1",265.131408088,19,1.259,67.79,0.0613959287605391,0.148,0.10469796438027,0,1
"apocynin","NADPH oxidase inhibitor","NOX4","COc1cc(ccc1O)C(C)=O, COc1cc(ccc1O)C(C)=O, COc1cc(ccc1O)C(C)=O, COc1cc(ccc1O)C(C)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1cc(ccc1O)C(C)=O",166.06299418,12,1.14,46.53,0.18127458664219,0.028,0.104637293321095,1,0
"sarcosine","glycine transporter inhibitor","SLC6A9","CNCC(O)=O",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CNCC(O)=O",89.047678464,6,-2.96,49.33,0.107203248694432,0.102,0.104601624347216,0,0
"anandamide","cannabinoid receptor agonist","CACNA1G, CACNA1H, CACNA1I, CNR1, CNR2, GLRA1, GPR18, GPR55, KCNA2, KCNK3, KCNK9, TRPM8, TRPV1","CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO",347.282429424,25,7.43000000000001,49.33,0.203126529258881,0.006,0.104563264629441,1,0
"GDC-0834","Bruton's tyrosine kinase (BTK) inhibitor","BTK","CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8",596.256960012,43,4.248,127.81,0.00310423587047503,0.206,0.104552117935238,0,1
"cenicriviroc","CC chemokine receptor antagonist","","CCCCOCCOc1ccc(cc1)-c1ccc2N(CC(C)C)CCC\C(=C/c2c1)C(=O)Nc1ccc(cc1)[S@@](=O)Cc1cncn1CCC |c:27|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCCCOCCOc1ccc(cc1)-c1ccc2N(CC(C)C)CCC\C(=C/c2c1)C(=O)Nc1ccc(cc1)[S@@](=O)Cc1cncn1CCC |c:27|",696.370927144,50,7.039,104.9,0.00478852885501571,0.204,0.104394264427508,0,1
"plovamer-acetate","","TAT, TH, YARS, YARS2","N[C@@H](Cc1ccc(O)cc1)C(O)=O |&1:1,r|, N[C@@H](Cc1ccc(O)cc1)C(O)=O |&1:1,r|, N[C@@H](Cc1ccc(O)cc1)C(O)=O |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","N[C@@H](Cc1ccc(O)cc1)C(O)=O |&1:1",181.073893212,13,-1.785,83.55,0.0387177214300109,0.17,0.104358860715005,0,1
"SU9516","CDK inhibitor","CDK1, CDK2, CDK4, CDK5","COc1ccc2NC(=O)\C(=C/c3cnc[nH]3)c2c1, COc1ccc2NC(=O)\C(=C/c3cnc[nH]3)c2c1, COc1ccc2NC(=O)\C(=C/c3cnc[nH]3)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc2NC(=O)\C(=C/c3cnc[nH]3)c2c1",241.085126592,18,0.969,67.01,0.0804979525439923,0.128,0.104248976271996,0,0
"KB-SRC-4","SRC inhibitor","SRC","Nc1ncnc2n(nc(-c3ccc(Cl)cc3)c12)-c1cccc(c1)-c1cnnn1Cc1cccc(c1)-c1ccccc1, Nc1ncnc2n(nc(-c3ccc(Cl)cc3)c12)-c1cccc(c1)-c1cnnn1Cc1cccc(c1)-c1ccccc1, Nc1ncnc2n(nc(-c3ccc(Cl)cc3)c12)-c1cccc(c1)-c1cnnn1Cc1cccc(c1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1ncnc2n(nc(-c3ccc(Cl)cc3)c12)-c1cccc(c1)-c1cnnn1Cc1cccc(c1)-c1ccccc1",554.173420416,41,7.575,100.33,0.0224594757943135,0.186,0.104229737897157,0,1
"SM-108","","","NC(=O)C1N=CNC1=O |c:4|, NC(=O)C1N=CNC1=O |c:4|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NC(=O)C1N=CNC1=O |c:4|",127.0381764,9,-1.443,84.55,0.0583579525584792,0.15,0.10417897627924,0,1
"BADGE","PPAR receptor antagonist","PPARG","CC(C)(c1ccc(OC[C@H]2CO2)cc1)c1ccc(OC[C@H]2CO2)cc1 |&1:9,&2:20,r|, CC(C)(c1ccc(OC[C@H]2CO2)cc1)c1ccc(OC[C@H]2CO2)cc1 |&1:9,&2:20,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(c1ccc(OC[C@H]2CO2)cc1)c1ccc(OC[C@H]2CO2)cc1 |&1:9",340.167459248,25,4.438,43.52,0.142336108752764,0.066,0.104168054376382,1,0
"presatovir","RSV fusion inhibitor","","Cc1cn2nc(cc2nc1N1CC[C@H](N)C1)[C@@H]1CCCCN1C(=O)c1cc(Cl)ccc1NS(C)(=O)=O, Cc1cn2nc(cc2nc1N1CC[C@H](N)C1)[C@@H]1CCCCN1C(=O)c1cc(Cl)ccc1NS(C)(=O)=O, Cc1cn2nc(cc2nc1N1CC[C@H](N)C1)[C@@H]1CCCCN1C(=O)c1cc(Cl)ccc1NS(C)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1cn2nc(cc2nc1N1CC[C@H](N)C1)[C@@H]1CCCCN1C(=O)c1cc(Cl)ccc1NS(C)(=O)=O",531.1819365,36,3.701,134.31,0.00220701706592561,0.206,0.104103508532963,0,1
"or-1896","phosphodiesterase inhibitor","PDE3A, SMPD1","C[C@@H]1CC(=O)NN=C1c1ccc(NC(C)=O)cc1 |c:6|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","cardiology","congestive heart failure","C[C@@H]1CC(=O)NN=C1c1ccc(NC(C)=O)cc1 |c:6|",245.11642672,18,1.455,70.56,0.0762046206669884,0.132,0.104102310333494,0,1
"methapyrilene","histamine receptor antagonist","HRH1","CN(C)CCN(Cc1cccs1)c1ccccn1, CN(C)CCN(Cc1cccs1)c1ccccn1, CN(C)CCN(Cc1cccs1)c1ccccn1",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CN(C)CCN(Cc1cccs1)c1ccccn1",261.129968608,18,2.332,47.61,0.106142031782826,0.102,0.104071015891413,0,0
"saclofen","GABA receptor antagonist","GABBR1, GABBR2, KCTD12, KCTD16, KCTD8","NC[C@@H](CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@H](CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@H](CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC[C@@H](CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2",249.022641924,15,0.682,88.77,0.020004621296767,0.188,0.104002310648383,0,1
"methylcobalamin","vitamin B","","[H][C@]1(CO)O[C@]([H])(n2cnc3cc(C)c(C)cc23)[C@]([H])(O)[C@]1([H])OP(O)(=O)O[C@H](C)CNC(=O)CC[C@@]1(C)\C2=C(C)\C3=N\C(=C\C4=N\C(=C(C)/C5=N[C@@](C)([C@@]([H])(N2[Co+]C)[C@]1([H])CC(N)=O)[C@@](C)(CC(N)=O)[C@]5([H])CCC(N)=O)\[C@@](C)(CC(N)=O)[C@]4([H])CCC(N)=O)\C(C)(C)[C@]3([H])CCC(N)=O |c:41,t:44,46,48,50,53|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","[H][C@]1(CO)O[C@]([H])(n2cnc3cc(C)c(C)cc23)[C@]([H])(O)[C@]1([H])OP(O)(=O)O[C@H](C)CNC(=O)CC[C@@]1(C)\C2=C(C)\C3=N\C(=C\C4=N\C(=C(C)/C5=N[C@@](C)([C@@]([H])(N2[Co+]C)[C@]1([H])CC(N)=O)[C@@](C)(CC(N)=O)[C@]5([H])CCC(N)=O)\[C@@](C)(CC(N)=O)[C@]4([H])CCC(N)=O)\C(C)(C)[C@]3([H])CCC(N)=O |c:41",1344.59507767409,101,-4.214,461.04,1.86480751568128e-09,0.208,0.104000000932404,0,1
"pirenperone","serotonin receptor antagonist","HTR2A, HTR7","Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1, Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1, Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1",393.185255228,29,3.414,54.68,0.0658763122732902,0.142,0.103938156136645,0,1
"GPP-78","NAMPT inhibitor","NAMPT","O=C(CCCCCCCn1cc(nn1)-c1cccnc1)Nc1ccccc1-c1ccccc1, O=C(CCCCCCCn1cc(nn1)-c1cccnc1)Nc1ccccc1-c1ccccc1, O=C(CCCCCCCn1cc(nn1)-c1cccnc1)Nc1ccccc1-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(CCCCCCCn1cc(nn1)-c1cccnc1)Nc1ccccc1-c1ccccc1",439.237210548,33,5.709,72.7,0.0638083711754927,0.144,0.103904185587746,0,1
"W-54011","anaphylatoxin chemotactic receptor antagonist","C5AR1","COc1ccc2CCC[C@@H](C(=O)N(Cc3ccc(cc3)N(C)C)c3ccc(cc3)C(C)C)c2c1 |&1:9|, COc1ccc2CCC[C@@H](C(=O)N(Cc3ccc(cc3)N(C)C)c3ccc(cc3)C(C)C)c2c1 |&1:9|, COc1ccc2CCC[C@@H](C(=O)N(Cc3ccc(cc3)N(C)C)c3ccc(cc3)C(C)C)c2c1 |&1:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc2CCC[C@@H](C(=O)N(Cc3ccc(cc3)N(C)C)c3ccc(cc3)C(C)C)c2c1 |&1:9|",456.277678392,34,6.961,32.78,0.163783796144685,0.044,0.103891898072343,1,0
"M-25","smoothened receptor antagonist","DHH, IHH, SMO","CCCC(CCC)C(=O)NCc1ccc2n(ncc2c1)-c1ccccc1OC, CCCC(CCC)C(=O)NCc1ccc2n(ncc2c1)-c1ccccc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCC(CCC)C(=O)NCc1ccc2n(ncc2c1)-c1ccccc1OC",379.225977168,28,5.654,56.15,0.115772264910781,0.092,0.103886132455391,1,0
"m-3M3FBS","phospholipase activator","PLCB2, PLCB3, PLCD1, PLCG1, PLCG2","Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1cccc(c1)C(F)(F)F, Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1cccc(c1)C(F)(F)F, Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1cccc(c1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1cccc(c1)C(F)(F)F",343.085384412,23,4.529,54.55,0.07175343837589,0.136,0.103876719187945,0,1
"AA-29504","GABA receptor positive allosteric modulator","GABRA1, GABRA4, GABRB3","CCOC(=O)Nc1ccc(NCc2c(C)cc(C)cc2C)cc1N, CCOC(=O)Nc1ccc(NCc2c(C)cc(C)cc2C)cc1N, CCOC(=O)Nc1ccc(NCc2c(C)cc(C)cc2C)cc1N",0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)Nc1ccc(NCc2c(C)cc(C)cc2C)cc1N",327.19467704,24,3.72,76.38,0.0657300881330414,0.142,0.103865044066521,0,1
"tarafenacin","acetylcholine receptor antagonist","CHRM3","Fc1cccc(c1)N(Cc1cc(F)c(F)c(F)c1)C(=O)O[C@H]1C[N@@]2CC[C@H]1CC2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"phase 2","","","Fc1cccc(c1)N(Cc1cc(F)c(F)c(F)c1)C(=O)O[C@H]1C[N@@]2CC[C@H]1CC2",408.14609076,29,4.361,32.78,0.0936780877779196,0.114,0.10383904388896,0,0
"tarafenacin (d-tartrate)","acetylcholine receptor antagonist","","Fc1cccc(c1)N(Cc1cc(F)c(F)c(F)c1)C(=O)O[C@H]1CN2CCC1CC2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Fc1cccc(c1)N(Cc1cc(F)c(F)c(F)c1)C(=O)O[C@H]1CN2CCC1CC2",408.14609076,29,4.361,32.78,0.0936780877779196,0.114,0.10383904388896,0,0
"7-methoxytacrine","acetylcholinesterase inhibitor","ACHE","COc1ccc2nc3CCCCc3c(N)c2c1, COc1ccc2nc3CCCCc3c(N)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1ccc2nc3CCCCc3c(N)c2c1",228.126263132,17,2.141,48.14,0.16366198898616,0.044,0.10383099449308,1,0
"SKF-89976A","GABA uptake inhibitor","SLC6A1","OC(=O)[C@H]1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1 |&1:3|, OC(=O)[C@H]1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1 |&1:3|, OC(=O)[C@H]1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1 |&1:3|, OC(=O)[C@H]1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1 |&1:3|",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)[C@H]1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1 |&1:3|",335.18852904,25,4.518,40.54,0.169628287924611,0.038,0.103814143962306,1,0
"RG1530","FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FGFR1, FGFR2","COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|, COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|, COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|, COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|, COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5",356.084016968,25,4.014,58.34,0.0675988760866423,0.14,0.103799438043321,0,1
"APY0201","phosphoinositide dependent kinase inhibitor","IL12A, IL12B, PIKFYVE","Cc1cccc(\C=N\Nc2cc(N3CCOCC3)n3nc(cc3n2)-c2ccncc2)c1, Cc1cccc(\C=N\Nc2cc(N3CCOCC3)n3nc(cc3n2)-c2ccncc2)c1, Cc1cccc(\C=N\Nc2cc(N3CCOCC3)n3nc(cc3n2)-c2ccncc2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cccc(\C=N\Nc2cc(N3CCOCC3)n3nc(cc3n2)-c2ccncc2)c1",413.196408356,31,5.286,79.94,0.0575518726564479,0.15,0.103775936328224,0,1
"LY2183240","FAAH inhibitor, FAAH reuptake inhibitor","FAAH","CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1, CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1, CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1, CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1, CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1",307.143310164,23,3.459,63.91,0.101546786921982,0.106,0.103773393460991,0,0
"IWP-L6","porcupine inhibitor","PORCN","O=C(CSc1nc2CCSc2c(=O)n1-c1ccccc1)Nc1ccc(cn1)-c1ccccc1, O=C(CSc1nc2CCSc2c(=O)n1-c1ccccc1)Nc1ccc(cn1)-c1ccccc1, O=C(CSc1nc2CCSc2c(=O)n1-c1ccccc1)Nc1ccc(cn1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(CSc1nc2CCSc2c(=O)n1-c1ccccc1)Nc1ccc(cn1)-c1ccccc1",472.10276788,33,5.14,127.48,0.00753000109612553,0.2,0.103765000548063,0,1
"AMG-PERK-44","PERK inhibitor","EIF2AK4","Cc1ccc2cc(ccc2n1)-c1c(C)ccc(C(=O)c2c(-c3ccccc3)n(C)n(-c3ccccc3)c2=O)c1N, Cc1ccc2cc(ccc2n1)-c1c(C)ccc(C(=O)c2c(-c3ccccc3)n(C)n(-c3ccccc3)c2=O)c1N, Cc1ccc2cc(ccc2n1)-c1c(C)ccc(C(=O)c2c(-c3ccccc3)n(C)n(-c3ccccc3)c2=O)c1N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc2cc(ccc2n1)-c1c(C)ccc(C(=O)c2c(-c3ccccc3)n(C)n(-c3ccccc3)c2=O)c1N",524.221226136,40,6.917,82.91,0.0454262219375221,0.162,0.103713110968761,0,1
"SLV-319-(+/-)","cannabinoid receptor antagonist","CNR1, DRD2, HTR1A","C\N=C(\NS(=O)(=O)c1ccc(Cl)cc1)N1C[C@@H](C(=N1)c1ccc(Cl)cc1)c1ccccc1 |&1:16,r,c:18|",0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,"phase 2","","","C\N=C(\NS(=O)(=O)c1ccc(Cl)cc1)N1C[C@@H](C(=N1)c1ccc(Cl)cc1)c1ccccc1 |&1:16",486.06840224,32,6.137,82.51,0.015389609730834,0.192,0.103694804865417,0,1
"NSI-189","neurotrophic agent","","CC(C)CCNc1ncccc1C(=O)N1CCN(Cc2ccccc2)CC1, CC(C)CCNc1ncccc1C(=O)N1CCN(Cc2ccccc2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)CCNc1ncccc1C(=O)N1CCN(Cc2ccccc2)CC1",366.24196158,27,4.331,48.47,0.109137337761865,0.098,0.103568668880933,0,0
"azeliragon","RAGE receptor antagonist","AGER","CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1, CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1, CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1, CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1, CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1",531.265255136,38,8.798,39.52,0.0991103118258305,0.108,0.103555155912915,0,0
"L-701252","glutamate receptor antagonist","GRIN1","Oc1c(C(=O)C2CC2)c(=O)[nH]c2cc(Cl)ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1c(C(=O)C2CC2)c(=O)[nH]c2cc(Cl)ccc12",263.03492086,18,3.328,70.16,0.079090872252613,0.128,0.103545436126307,0,0
"BMS-626531","p38 MAPK inhibitor","","Cc1c(cnn1-c1ncccc1C(F)(F)F)C(=O)Nc1cc(ccc1C)C(=O)NC1CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1c(cnn1-c1ncccc1C(F)(F)F)C(=O)Nc1cc(ccc1C)C(=O)NC1CC1",443.15690954,32,3.863,88.91,0.0210673489063945,0.186,0.103533674453197,0,1
"CH223191","aryl hydrocarbon receptor antagonist","AHR","Cc1ccccc1\N=N\c1ccc(NC(=O)c2ccnn2C)c(C)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccccc1\N=N\c1ccc(NC(=O)c2ccnn2C)c(C)c1",333.158960228,25,4.151,71.64,0.087005702952085,0.12,0.103502851476042,0,0
"imirestat","aldose reductase inhibitor","","Fc1ccc2-c3ccc(F)cc3C3(NC(=O)NC3=O)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1ccc2-c3ccc(F)cc3C3(NC(=O)NC3=O)c2c1",286.055383936,21,2.893,58.2,0.10495923228263,0.102,0.103479616141315,0,0
"metacetamol","analgesic agent","","CC(=O)Nc1cccc(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)Nc1cccc(O)c1",151.063328528,11,0.87,49.33,0.180837879778886,0.026,0.103418939889443,1,0
"rhodamine-123","","","COC(=O)c1ccccc1-c1c2ccc(N)cc2[o+]c2cc(N)ccc12, COC(=O)c1ccccc1-c1c2ccc(N)cc2[o+]c2cc(N)ccc12, COC(=O)c1ccccc1-c1c2ccc(N)cc2[o+]c2cc(N)ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COC(=O)c1ccccc1-c1c2ccc(N)cc2[o+]c2cc(N)ccc12",345.123368824091,26,4.894,78.34,0.0847536946220004,0.122,0.103376847311,0,0
"ZK-200775","kainate receptor antagonist","","OP(O)(=O)Cn1c2cc(N3CCOCC3)c(cc2[nH]c(=O)c1=O)C(F)(F)F, OP(O)(=O)Cn1c2cc(N3CCOCC3)c(cc2[nH]c(=O)c1=O)C(F)(F)F, OP(O)(=O)Cn1c2cc(N3CCOCC3)c(cc2[nH]c(=O)c1=O)C(F)(F)F, OP(O)(=O)Cn1c2cc(N3CCOCC3)c(cc2[nH]c(=O)c1=O)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OP(O)(=O)Cn1c2cc(N3CCOCC3)c(cc2[nH]c(=O)c1=O)C(F)(F)F",409.06505649,27,1.089,134.67,0.00268561018219535,0.204,0.103342805091098,0,1
"EX-527","SIRT inhibitor","SIRT1","NC(=O)[C@H]1CCCc2c1[nH]c1ccc(Cl)cc21 |&1:3,r|, NC(=O)[C@H]1CCCc2c1[nH]c1ccc(Cl)cc21 |&1:3,r|, NC(=O)[C@H]1CCCc2c1[nH]c1ccc(Cl)cc21 |&1:3,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NC(=O)[C@H]1CCCc2c1[nH]c1ccc(Cl)cc21 |&1:3",248.071640716,17,2.73,58.88,0.0986225209081519,0.108,0.103311260454076,0,0
"SD-169","p38 MAPK inhibitor","MAPK14","NC(=O)c1ccc2[nH]ccc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC(=O)c1ccc2[nH]ccc2c1",160.063662876,12,1.062,58.88,0.158459545613128,0.048,0.103229772806564,1,0
"alminoprofen","cyclooxygenase inhibitor","PTGS1, PTGS2","CC(C(=O)O)c1ccc(NCC(=C)C)cc1",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","cardiology","edema","CC(C(=O)O)c1ccc(NCC(=C)C)cc1",219.125928784,16,1.775,49.33,0.146309432021224,0.06,0.103154716010612,1,0
"aminoguanidine","nitric oxide synthase inhibitor","AKR1B1, NOS2, TIMP3","NN=C(N)N, NN=C(N)N, NN=C(N)N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","NN=C(N)N",74.059246192,5,-1.369,90.42,0.0721581828498012,0.134,0.103079091424901,0,1
"nemorubicin","topoisomerase inhibitor","TOP1, TOP2A","CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O, CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O, CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O, CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O",643.226490244,46,-0.26,201.75,0.00012051649061774,0.206,0.103060258245309,0,1
"amenamevir","helicase primase inhibitor","","Cc1cccc(C)c1N(CC(=O)Nc1ccc(cc1)-c1ncon1)C(=O)C1CCS(=O)(=O)CC1, Cc1cccc(C)c1N(CC(=O)Nc1ccc(cc1)-c1ncon1)C(=O)C1CCS(=O)(=O)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1cccc(C)c1N(CC(=O)Nc1ccc(cc1)-c1ncon1)C(=O)C1CCS(=O)(=O)CC1",482.162390932,34,2.693,130.85,0.00379682785566864,0.202,0.102898413927834,0,1
"parthenolide","NFkB pathway inhibitor","","C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|, C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|, C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|",248.1412445,18,2.449,38.83,0.169671327985448,0.036,0.102835663992724,1,0
"parthenolide-(-)","NFkB pathway inhibitor","HDAC1","C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |t:1|, C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |t:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |t:1|",248.1412445,18,2.449,38.83,0.169671327985447,0.036,0.102835663992724,1,0
"parthenolide-(alternate-stereo)","NFkB pathway inhibitor","IKBKB, RELA","C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|, C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|, C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|, C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|, C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|",248.1412445,18,2.449,38.83,0.169671327985447,0.036,0.102835663992724,1,0
"N-acetyltryptamine","melatonin receptor agonist","","CC(=O)NCCc1c[nH]c2ccccc12, CC(=O)NCCc1c[nH]c2ccccc12, CC(=O)NCCc1c[nH]c2ccccc12, CC(=O)NCCc1c[nH]c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)NCCc1c[nH]c2ccccc12",202.110613068,15,1.686,44.89,0.181480370242805,0.024,0.102740185121403,1,0
"AY-9944","hedgehog pathway modulator","","Clc1ccccc1CNC[C@H]1CC[C@H](CNCc2ccccc2Cl)CC1 |r|, Clc1ccccc1CNC[C@H]1CC[C@H](CNCc2ccccc2Cl)CC1 |r|, Clc1ccccc1CNC[C@H]1CC[C@H](CNCc2ccccc2Cl)CC1 |r|, Clc1ccccc1CNC[C@H]1CC[C@H](CNCc2ccccc2Cl)CC1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1ccccc1CNC[C@H]1CC[C@H](CNCc2ccccc2Cl)CC1 |r|",390.162954256,26,5.788,24.06,0.121460823193669,0.084,0.102730411596835,1,0
"TAK-063","phosphodiesterase inhibitor","PDE10A","COc1cn(nc(-c2ccnn2-c2ccccc2)c1=O)-c1ccc(cc1F)-n1cccn1, COc1cn(nc(-c2ccnn2-c2ccccc2)c1=O)-c1ccc(cc1F)-n1cccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1cn(nc(-c2ccnn2-c2ccccc2)c1=O)-c1ccc(cc1F)-n1cccn1",428.139702004,32,5.133,79.76,0.0494533889991118,0.156,0.102726694499556,0,1
"(-)-huperzine a","acetylcholinesterase inhibitor","","C\C=C1\[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C\C=C1\[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|",242.141913196,18,1.25,58.88,0.0994403213127406,0.106,0.10272016065637,0,0
"huperzine-A","acetylcholinesterase inhibitor","ACHE","C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|, C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|, C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|, C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|, C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|, C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|",242.141913196,18,1.25,58.88,0.0994403213127406,0.106,0.10272016065637,0,0
"ftaxilide","","","Cc1cccc(C)c1NC(=O)c1ccccc1C(O)=O, Cc1cccc(C)c1NC(=O)c1ccccc1C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cccc(C)c1NC(=O)c1ccccc1C(O)=O",269.10519334,20,3.06,66.4,0.107398621421278,0.098,0.102699310710639,0,0
"MRK-016","GABA receptor inverse agonist","GABRA1, GABRA2, GABRA3, GABRA5","Cc1cc(no1)-c1nncc2c(c(OCc3ncnn3C)nn12)C(C)(C)C, Cc1cc(no1)-c1nncc2c(c(OCc3ncnn3C)nn12)C(C)(C)C, Cc1cc(no1)-c1nncc2c(c(OCc3ncnn3C)nn12)C(C)(C)C, Cc1cc(no1)-c1nncc2c(c(OCc3ncnn3C)nn12)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1cc(no1)-c1nncc2c(c(OCc3ncnn3C)nn12)C(C)(C)C",368.17092188,27,1.853,109.05,0.0153978790449373,0.19,0.102698939522469,0,1
"tradipitant","neurokinin receptor antagonist","","FC(F)(F)c1cc(Cn2nnc(c2-c2ccncc2)-c2ncccc2C(=O)c2ccccc2Cl)cc(c1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","FC(F)(F)c1cc(Cn2nnc(c2-c2ccncc2)-c2ncccc2C(=O)c2ccccc2Cl)cc(c1)C(F)(F)F",587.094757132,41,7.187,73.56,0.017377414716607,0.188,0.102688707358303,0,1
"brequinar","dihydroorotate dehydrogenase inhibitor","DHODH","Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F, Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F, Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F",375.10708516,28,6.257,50.19,0.161309919268672,0.044,0.102654959634336,1,0
"L-leucine","","BCAT1, BCAT2, LARS, LARS2, LCMT1, LCMT2","CC(C)C[C@H](N)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(C)C[C@H](N)C(O)=O",131.094628656,9,-1.389,63.32,0.0852861917671887,0.12,0.102643095883594,0,0
"pyrrolidine-dithiocarbamate","NFkB pathway inhibitor","HSD11B1, RELA","SC(=S)N1CCCC1, SC(=S)N1CCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","SC(=S)N1CCCC1",147.017641288,8,1.564,74.13,0.07516206307155,0.13,0.102581031535775,0,1
"L-838417","GABA receptor partial agonist","GABRA1, GABRA2, GABRA3, GABRA5","Cn1ncnc1COc1nn2c(nnc2cc1C(C)(C)C)-c1cc(F)ccc1F, Cn1ncnc1COc1nn2c(nnc2cc1C(C)(C)C)-c1cc(F)ccc1F, Cn1ncnc1COc1nn2c(nnc2cc1C(C)(C)C)-c1cc(F)ccc1F",0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cn1ncnc1COc1nn2c(nnc2cc1C(C)(C)C)-c1cc(F)ccc1F",399.161914668,29,5.904,83.02,0.0551527545991367,0.15,0.102576377299568,0,1
"DS2-(806622)","","","Clc1ccc(cc1)C(=O)Nc1c(nc2ccccn12)-c1cccs1, Clc1ccc(cc1)C(=O)Nc1c(nc2ccccn12)-c1cccs1, Clc1ccc(cc1)C(=O)Nc1c(nc2ccccn12)-c1cccs1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1ccc(cc1)C(=O)Nc1c(nc2ccccn12)-c1cccs1",353.038960684,24,4.984,74.64,0.0510893042999553,0.154,0.102544652149978,0,1
"HC-030031","TRPA1 channel blocker","TRPA1","CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1, CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1, CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1, CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1, CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1, CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1",355.164439532,26,3.695,90.92,0.0389669083773109,0.166,0.102483454188655,0,1
"PHA-767491","CDC inhibitor","CDK1, RPS6KB1","O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C1NCCc2[nH]c(cc12)-c1ccncc1",213.090211972,16,1.012,57.78,0.118930450269219,0.086,0.102465225134609,1,0
"afalanine","dopamine receptor agonist","DRD2","CC(=O)N[C@@H](Cc1ccccc1)C(O)=O, CC(=O)N[C@@H](Cc1ccccc1)C(O)=O, CC(=O)N[C@@H](Cc1ccccc1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,"phase 3","","","CC(=O)N[C@@H](Cc1ccccc1)C(O)=O",207.089543276,15,-1.103,66.4,0.0568809358326316,0.148,0.102440467916316,0,1
"procysteine","glutathione synthase stimulant","","OC(=O)[C@@H]1CSC(=O)N1, OC(=O)[C@@H]1CSC(=O)N1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","OC(=O)[C@@H]1CSC(=O)N1",146.99901402,9,-0.564,91.7,0.0388498161240537,0.166,0.102424908062027,0,1
"torin-1","mTOR inhibitor","MTOR","CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1",607.219509796,45,7.289,71.33,0.0288115163644563,0.176,0.102405758182228,0,1
"BAY-K-8644-(s)-(-)","L-type calcium channel activator","CACNA1C","COC(=O)C1=C(C)NC(C)=C([C@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O |c:4,9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)C1=C(C)NC(C)=C([C@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O |c:4",356.09839162,25,5.093,81.47,0.0523492582551159,0.152,0.102174629127558,0,1
"JNJ-39758979","histamine receptor antagonist","","CC(C)c1cc(nc(N)n1)N1CC[C@@H](N)C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)c1cc(nc(N)n1)N1CC[C@@H](N)C1",221.164045608,16,0.967,81.06,0.0602912469008205,0.144,0.10214562345041,0,1
"pergolide","dopamine receptor agonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C","CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13",0,0,0,0,0,0,0,0,1,6,0,0,0,0,1,5,0,0,1,6,0,0,0,0,"withdrawn","","","CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13",314.181669832,22,4.235,44.33,0.126241881536894,0.078,0.102120940768447,1,0
"enprofylline","phosphodiesterase inhibitor","ADORA1, ADORA2A, ADORA2B, ADORA3, PDE4A, PDE4B","CCCn1c2nc[nH]c2c(=O)[nH]c1=O, CCCn1c2nc[nH]c2c(=O)[nH]c1=O, CCCn1c2nc[nH]c2c(=O)[nH]c1=O, CCCn1c2nc[nH]c2c(=O)[nH]c1=O, CCCn1c2nc[nH]c2c(=O)[nH]c1=O, CCCn1c2nc[nH]c2c(=O)[nH]c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCCn1c2nc[nH]c2c(=O)[nH]c1=O",194.08037556,14,1.691,83.54,0.0802035359627415,0.124,0.102101767981371,0,0
"GSK269962","rho associated kinase inhibitor","ROCK1, ROCK2","CCn1c(nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc12)-c1nonc1N, CCn1c(nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc12)-c1nonc1N, CCn1c(nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc12)-c1nonc1N, CCn1c(nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc12)-c1nonc1N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCn1c(nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc12)-c1nonc1N",570.23391606,42,3.701,155.68,0.00210695742351743,0.202,0.102053478711759,0,1
"motolimod","toll-like receptor agonist","TLR8","CCCN(CCC)C(=O)C1=Cc2ccc(cc2N=C(N)C1)-c1ccc(cc1)C(=O)N1CCCC1 |t:9,18|, CCCN(CCC)C(=O)C1=Cc2ccc(cc2N=C(N)C1)-c1ccc(cc1)C(=O)N1CCCC1 |t:9,18|, CCCN(CCC)C(=O)C1=Cc2ccc(cc2N=C(N)C1)-c1ccc(cc1)C(=O)N1CCCC1 |t:9,18|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCN(CCC)C(=O)C1=Cc2ccc(cc2N=C(N)C1)-c1ccc(cc1)C(=O)N1CCCC1 |t:9",458.268176328,34,4.003,79,0.0300297394578677,0.174,0.102014869728934,0,1
"PBT-1033","chelating agent","","CN(C)Cc1ccc2c(Cl)cc(Cl)c(O)c2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)Cc1ccc2c(Cl)cc(Cl)c(O)c2n1",270.032668364,17,2.803,36.36,0.0999546981616919,0.104,0.101977349080846,0,0
"mepazine","MALT1 inhibitor (JH)","MALT1","CN1CCC[C@@H](CN2c3ccccc3Sc3ccccc23)C1 |&1:5,r|, CN1CCC[C@@H](CN2c3ccccc3Sc3ccccc23)C1 |&1:5,r|, CN1CCC[C@@H](CN2c3ccccc3Sc3ccccc23)C1 |&1:5,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN1CCC[C@@H](CN2c3ccccc3Sc3ccccc23)C1 |&1:5",310.150369704,22,4.681,31.78,0.191876934555873,0.012,0.101938467277937,1,0
"5-hydroxymethyl-tolterodine","acetylcholine receptor antagonist","CHRM3","CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"phase 1","","","CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C",341.235479232,25,4.328,43.7,0.135554482996304,0.068,0.101777241498152,1,0
"onc206","dopamine receptor antagonist","DRD2","Fc1ccc(CN2C3=NCCN3C3=C(CN(Cc4ccccc4)CC3)C2=O)c(F)c1 |t:7,13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,"phase 1","oncology","glioblastoma","Fc1ccc(CN2C3=NCCN3C3=C(CN(Cc4ccccc4)CC3)C2=O)c(F)c1 |t:7",408.176167764,30,3.514,39.15,0.0835349529741649,0.12,0.101767476487082,0,0
"ETC-159","beta catenin inhibitor, porcupine inhibitor","PORCN","Cn1c2ncn(CC(=O)Nc3ccc(nn3)-c3ccccc3)c2c(=O)n(C)c1=O, Cn1c2ncn(CC(=O)Nc3ccc(nn3)-c3ccccc3)c2c(=O)n(C)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cn1c2ncn(CC(=O)Nc3ccc(nn3)-c3ccccc3)c2c(=O)n(C)c1=O",391.139287404,29,2.965,116.7,0.0155065776516334,0.188,0.101753288825817,0,1
"ly2940094","nociceptin/orphanin fq (nop) receptor antagonist","OPRL1","Cc1nn(cc1CN1CCC2(CC1)OCC(F)(F)c1cc(Cl)sc21)-c1ncccc1CO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"phase 2","neurology/psychiatry","depression","Cc1nn(cc1CN1CCC2(CC1)OCC(F)(F)c1cc(Cl)sc21)-c1ncccc1CO",480.119831096,32,2.162,91.65,0.00546820490269594,0.198,0.101734102451348,0,1
"elesclomol","oxidative stress inducer","HSPA1A","CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1, CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1, CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1, CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1",400.10276788,27,2.519,128.86,0.00539227026209642,0.198,0.101696135131048,0,1
"cot-inhibitor-2","MAPK-interacting kinase inhibitor","MAP3K8","CCN1CCC(CC1)n1cc(CNc2cc(Cl)c3ncc(C#N)c(Nc4ccc(F)c(Cl)c4)c3c2)nn1, CCN1CCC(CC1)n1cc(CNc2cc(Cl)c3ncc(C#N)c(Nc4ccc(F)c(Cl)c4)c3c2)nn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN1CCC(CC1)n1cc(CNc2cc(Cl)c3ncc(C#N)c(Nc4ccc(F)c(Cl)c4)c3c2)nn1",538.15632638,37,4.591,94.69,0.00729399149710403,0.196,0.101646995748552,0,1
"EBPC","aldose reductase inhibitor","AKR1B1","CCOC(=O)[C@@H]1CN(Cc2ccccc2)C(=O)C1=O |&1:5,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)[C@@H]1CN(Cc2ccccc2)C(=O)C1=O |&1:5",261.10010796,19,0.742,63.68,0.0652407716276322,0.138,0.101620385813816,0,1
"CUDC-427","apoptosis inhibitor","XIAP","CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1-c1ccccc1)-c1ncco1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1-c1ccccc1)-c1ncco1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1-c1ccccc1)-c1ncco1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1-c1ccccc1)-c1ncco1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1-c1ccccc1)-c1ncco1",564.251874632,40,2.975,157.7,0.00122549808406762,0.202,0.101612749042034,0,1
"icomucret","mucin production enhancer","LTB4R2","CCCCC[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCCCC[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O",320.235144884,23,6.413,57.53,0.165118022783753,0.038,0.101559011391877,1,0
"rogaratinib","FGFR inhibitor","","COCc1c(CN2CCNC(=O)C2)n2ncnc(N)c2c1-c1cc2cc(C)cc(OC)c2s1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","COCc1c(CN2CCNC(=O)C2)n2ncnc(N)c2c1-c1cc2cc(C)cc(OC)c2s1",466.178709692,33,1.581,135.25,0.00304002064106837,0.2,0.101520010320534,0,1
"serdemetan","MDM inhibitor","MDM2","C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1",328.16879664,25,3.604,52.74,0.127031252614816,0.076,0.101515626307408,1,0
"AT-7519","CDK inhibitor","CDK1, CDK2, CDK4, CDK5, CDK6, CDK9","Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1, Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1, Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1, Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1, Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1, Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1, Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1",381.075930144,25,3.336,98.91,0.0130145658776528,0.19,0.101507282938826,0,1
"camptothecin","topoisomerase inhibitor","TOP1","CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O",348.111006992,26,2.908,81.42,0.0469999693784879,0.156,0.101499984689244,0,1
"GW-803430","melanin inhibitor","KCNH2, MCHR1","COc1cc(ccc1OCCN1CCCC1)-n1cnc2cc(sc2c1=O)-c1ccc(Cl)cc1, COc1cc(ccc1OCCN1CCCC1)-n1cnc2cc(sc2c1=O)-c1ccc(Cl)cc1, COc1cc(ccc1OCCN1CCCC1)-n1cnc2cc(sc2c1=O)-c1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1cc(ccc1OCCN1CCCC1)-n1cnc2cc(sc2c1=O)-c1ccc(Cl)cc1",481.122690308,33,4.78,84.83,0.0148246682444564,0.188,0.101412334122228,0,1
"gabazine","GABA receptor antagonist","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRG2","COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1, COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1, COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1, COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1, COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1",0,0,0,0,0,0,0,0,0,0,0,0,1,7,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1",287.126991404,21,3.674,88.2,0.0645962563325395,0.138,0.10129812816627,0,1
"N20C","glutamate receptor antagonist","","NC(=O)CNCCC(c1ccccc1)c1ccccc1, NC(=O)CNCCC(c1ccccc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC(=O)CNCCC(c1ccccc1)c1ccccc1",268.15756326,20,2.194,55.12,0.114470439837525,0.088,0.101235219918762,0,0
"4-(aminomethyl)benzoic-acid","hemostatic agent","","NCc1ccc(cc1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NCc1ccc(cc1)C(O)=O",151.063328528,11,0.759,63.32,0.134442136640803,0.068,0.101221068320402,1,0
"TG-003","CLK inhibitor","CLK1, CLK4, DYRK1A, DYRK1B","CCN1\C(Sc2ccc(OC)cc12)=C\C(C)=O, CCN1\C(Sc2ccc(OC)cc12)=C\C(C)=O, CCN1\C(Sc2ccc(OC)cc12)=C\C(C)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN1\C(Sc2ccc(OC)cc12)=C\C(C)=O",249.08234972,17,2.959,54.84,0.110371158323704,0.092,0.101185579161852,0,0
"6-thio-2'-deoxyguanosine","telomerase inhibitor","TERT","OC[C@@H]1[C@H](C[C@H](N2C=NC3=C2NC(N)=NC3=S)O1)O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","oncology","non-small cell lung cancer (nsclc)","OC[C@@H]1[C@H](C[C@H](N2C=NC3=C2NC(N)=NC3=S)O1)O",283.073910276,19,-0.459,147.79,0.00435468358884081,0.198,0.10117734179442,0,1
"GS-6201","adenosine receptor antagonist","ADORA1, ADORA2A, ADORA2B, ADORA3","CCCn1c(=O)n(CC)c2nc([nH]c2c1=O)-c1cnn(Cc2cccc(c2)C(F)(F)F)c1, CCCn1c(=O)n(CC)c2nc([nH]c2c1=O)-c1cnn(Cc2cccc(c2)C(F)(F)F)c1, CCCn1c(=O)n(CC)c2nc([nH]c2c1=O)-c1cnn(Cc2cccc(c2)C(F)(F)F)c1, CCCn1c(=O)n(CC)c2nc([nH]c2c1=O)-c1cnn(Cc2cccc(c2)C(F)(F)F)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCCn1c(=O)n(CC)c2nc([nH]c2c1=O)-c1cnn(Cc2cccc(c2)C(F)(F)F)c1",446.167808572,32,5.832,90.5,0.0303371578138644,0.172,0.101168578906932,0,1
"G007-LK","tankyrase inhibitor","TNKS, TNKS2","CS(=O)(=O)c1ccc(nc1)-c1nnc(\C=C\c2nnc(o2)-c2ccc(cc2)C#N)n1-c1ccccc1Cl, CS(=O)(=O)c1ccc(nc1)-c1nnc(\C=C\c2nnc(o2)-c2ccc(cc2)C#N)n1-c1ccccc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CS(=O)(=O)c1ccc(nc1)-c1nnc(\C=C\c2nnc(o2)-c2ccc(cc2)C#N)n1-c1ccccc1Cl",529.072386052,37,6.683,148.83,0.00432881595695793,0.198,0.101164407978479,0,1
"BMS-649","retinoid receptor agonist","RXRA","CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O",380.198759376,28,6.042,55.76,0.124321575103379,0.078,0.10116078755169,1,0
"JNJ-37822681","dopamine receptor antagonist","DRD2","Fc1ccc(CN2CCC(CC2)Nc2ccc(nn2)C(F)(F)F)cc1F, Fc1ccc(CN2CCC(CC2)Nc2ccc(nn2)C(F)(F)F)cc1F, Fc1ccc(CN2CCC(CC2)Nc2ccc(nn2)C(F)(F)F)cc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,"phase 2","","","Fc1ccc(CN2CCC(CC2)Nc2ccc(nn2)C(F)(F)F)cc1F",372.137337644,26,3.756,41.05,0.0801712972178883,0.122,0.101085648608944,0,0
"furvina","quorum sensing signaling inhibitor","","[O-][N+](=O)C(\Br)=C/c1ccc(Br)o1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[O-][N+](=O)C(\Br)=C/c1ccc(Br)o1",294.847967156,12,2.817,56.28,0.0121086203453604,0.19,0.10105431017268,0,1
"hesperadin","Aurora kinase inhibitor","AURKB","CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1",516.219511884,37,4.851,98.92,0.0118541282552349,0.19,0.100927064127617,0,1
"NAB-2","ubiquitin ligase transport promoter","NEDD4","Cc1ccc(C)c(c1)-n1cnc2cc(ccc12)C(=O)NCc1ccccc1Cl, Cc1ccc(C)c(c1)-n1cnc2cc(ccc12)C(=O)NCc1ccccc1Cl, Cc1ccc(C)c(c1)-n1cnc2cc(ccc12)C(=O)NCc1ccccc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(C)c(c1)-n1cnc2cc(ccc12)C(=O)NCc1ccccc1Cl",389.12948994,28,5.587,46.92,0.111814323459571,0.09,0.100907161729786,0,0
"MR-948","thromboxane synthase inhibitor","TBXAS1","OCCc1ccc(OCCn2ccnc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OCCc1ccc(OCCn2ccnc2)cc1",232.121177752,17,1.34,47.28,0.129734916184353,0.072,0.100867458092176,1,0
"androsterone","androgen receptor agonist","","C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O",290.2245802,21,4.3,37.3,0.195712810652947,0.006,0.100856405326473,1,0
"epiandrosterone","steroid","G6PD","C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O",290.2245802,21,4.3,37.3,0.195712810652947,0.006,0.100856405326473,1,0
"3-alpha-hydroxy-5-beta-androstan-17-one","","HSD17B11, IGHG2, SULT2A1","C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O |a:1,5,8,10,14,16,&1:4|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O |a:1",290.2245802,21,4.3,37.3,0.195712810652947,0.006,0.100856405326473,1,0
"PF-670462","casein kinase inhibitor","CSNK1D, CSNK1E","Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1, Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1, Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1, Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1, Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1, Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1",337.17027386,25,4.179,69.62,0.0837104306580464,0.118,0.100855215329023,0,0
"tecarfarin","vitamin k antagonist","VKORC1","CC(OC(=O)c1ccc(CC2=C(O)c3ccccc3OC2=O)cc1)(C(F)(F)F)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","hematology","thrombosis","CC(OC(=O)c1ccc(CC2=C(O)c3ccccc3OC2=O)cc1)(C(F)(F)F)C(F)(F)F",460.074542868,32,6.643,72.83,0.0396008701885992,0.162,0.1008004350943,0,1
"sulbentine","other antifungal","","S=C1SCN(Cc2ccccc2)CN1Cc1ccccc1, S=C1SCN(Cc2ccccc2)CN1Cc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","S=C1SCN(Cc2ccccc2)CN1Cc1ccccc1",314.091140576,21,4.199,63.87,0.067564989824493,0.134,0.100782494912247,0,1
"A-412997","dopamine receptor agonist","DRD4","Cc1cccc(NC(=O)CN2CCC(CC2)c2ccccn2)c1, Cc1cccc(NC(=O)CN2CCC(CC2)c2ccccn2)c1, Cc1cccc(NC(=O)CN2CCC(CC2)c2ccccn2)c1, Cc1cccc(NC(=O)CN2CCC(CC2)c2ccccn2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cccc(NC(=O)CN2CCC(CC2)c2ccccn2)c1",309.184112356,23,2.319,45.23,0.111496412733686,0.09,0.100748206366843,0,0
"PP-2","SRC inhibitor","ABL1, LCK, RIPK2, SRC","CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12",301.109423192,21,4.079,69.62,0.0774825313440784,0.124,0.100741265672039,0,0
"JNJ-27141491","CC chemokine receptor antagonist","CCR2","CC[C@@H](c1ccc(F)c(F)c1)n1c(C(=O)OC)c([nH]c1=S)-c1ccno1, CC[C@@H](c1ccc(F)c(F)c1)n1c(C(=O)OC)c([nH]c1=S)-c1ccno1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC[C@@H](c1ccc(F)c(F)c1)n1c(C(=O)OC)c([nH]c1=S)-c1ccno1",379.08021878,26,5.235,105.14,0.0234533109208503,0.178,0.100726655460425,0,1
"PLX51107","bromodomain inhibitor","","C[C@@H](c1ccccn1)n1cc(-c2ccc(cc2)C(O)=O)c2ncc(cc12)-c1c(C)noc1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@@H](c1ccccn1)n1cc(-c2ccc(cc2)C(O)=O)c2ncc(cc12)-c1c(C)noc1C",438.169190564,33,4.859,94.04,0.0334514152060107,0.168,0.100725707603005,0,1
"astemizole","histamine receptor antagonist","HRH1, KCNH1, KCNH2","COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1",458.248189832,34,5.809,42.32,0.101449852349711,0.1,0.100724926174855,0,0
"omapatrilat","metalloproteinase inhibitor","ACE, MME","[H][C@]12CCC[C@H](N1C(=O)[C@H](CCS2)NC(=O)[C@@H](S)Cc1ccccc1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@]12CCC[C@H](N1C(=O)[C@H](CCS2)NC(=O)[C@@H](S)Cc1ccccc1)C(O)=O",408.117749248,28,2.585,150.81,0.00343172833838418,0.198,0.100715864169192,0,1
"TH-588","MTH1 inhibitor","NUDT1","Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl, Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl, Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl, Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl, Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl, Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl",294.043901744,19,3.83,63.83,0.0632183153147819,0.138,0.100609157657391,0,1
"flufenamic-acid","chloride channel blocker","AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5","OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F",281.06636322,20,4.203,49.33,0.150912302320066,0.05,0.100456151160033,1,0
"mivobulin","microtubule inhibitor","","CCOC(=O)Nc1cc2N=C(C)C(Nc2c(N)n1)c1ccccc1 |t:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCOC(=O)Nc1cc2N=C(C)C(Nc2c(N)n1)c1ccccc1 |t:9|",325.153874848,24,1.761,101.63,0.024810978202276,0.176,0.100405489101138,0,1
"BAY-2402234","dihydroorotate dehydrogenase inhibitor","","CCn1c(CO)nn(-c2cc(O[C@@H](C)C(F)(F)F)c(cc2F)C(=O)Nc2c(F)cccc2Cl)c1=O, CCn1c(CO)nn(-c2cc(O[C@@H](C)C(F)(F)F)c(cc2F)C(=O)Nc2c(F)cccc2Cl)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCn1c(CO)nn(-c2cc(O[C@@H](C)C(F)(F)F)c(cc2F)C(=O)Nc2c(F)cccc2Cl)c1=O",520.093673836,35,4.772,98.38,0.00680321089719469,0.194,0.100401605448597,0,1
"ML218","T-type calcium channel blocker","CACNA1G, CACNA1H, CACNA1I","CC(C)(C)CCN1C[C@H]2[C@H](CNC(=O)c3cc(Cl)cc(Cl)c3)[C@H]2C1, CC(C)(C)CCN1C[C@H]2[C@H](CNC(=O)c3cc(Cl)cc(Cl)c3)[C@H]2C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)CCN1C[C@H]2[C@H](CNC(=O)c3cc(Cl)cc(Cl)c3)[C@H]2C1",368.142218812,24,5.264,32.34,0.0967792641865702,0.104,0.100389632093285,0,0
"NS-309","calcium-activated potassium channel activator","KCNN1, KCNN2, KCNN3, KCNN4","O\N=C1/C(=O)Nc2c1ccc(Cl)c2Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O\N=C1/C(=O)Nc2c1ccc(Cl)c2Cl",229.964982728,14,2.93,61.69,0.0767671531973765,0.124,0.100383576598688,0,0
"ENMD-2076","Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor","AURKA, FLT3, KDR, PDGFRA, PTK2, SRC","CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(\C=C\c2ccccc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(\C=C\c2ccccc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(\C=C\c2ccccc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(\C=C\c2ccccc2)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(\C=C\c2ccccc2)n1",375.2171438,28,4.113,72.97,0.0626673240762926,0.138,0.100333662038146,0,1
"etosalamide","anti-inflammatory agent","","CCOCCOc1ccccc1C(N)=O, CCOCCOc1ccccc1C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOCCOc1ccccc1C(N)=O",209.10519334,15,1.057,61.55,0.0984896696726792,0.102,0.10024483483634,0,0
"pimitespib","hsp90 inhibitor","HSP90AB1","CCc1cc(ccc1n2nc(C(C)C)c3c(ccnc23)n4cnc(c4)c5cnn(C)c5)C(=O)N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","gastrointestinal stromal tumors (gist)","CCc1cc(ccc1n2nc(C(C)C)c3c(ccnc23)n4cnc(c4)c5cnn(C)c5)C(=O)N",454.222957452,34,3.866,108.4,0.0164063831772919,0.184,0.100203191588646,0,1
"mirogabalin-besylate","calcium channel antagonist","","[H][C@@]12C[C@](CN)(CC(O)=O)[C@]1([H])C=C(CC)C2 |t:13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@@]12C[C@](CN)(CC(O)=O)[C@]1([H])C=C(CC)C2 |t:13|",209.141578848,17,1.504,63.32,0.156370835380854,0.044,0.100185417690427,1,0
"ki16198","lipoprotein antagonist","LPA","COC(=O)CCSCc1ccc(cc1)-c1onc(C)c1NC(=O)O[C@@H](C)c1ccccc1Cl |&1:24,r|, COC(=O)CCSCc1ccc(cc1)-c1onc(C)c1NC(=O)O[C@@H](C)c1ccccc1Cl |&1:24,r|, COC(=O)CCSCc1ccc(cc1)-c1onc(C)c1NC(=O)O[C@@H](C)c1ccccc1Cl |&1:24,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)CCSCc1ccc(cc1)-c1onc(C)c1NC(=O)O[C@@H](C)c1ccccc1Cl |&1:24",488.11727058,33,6.016,115.96,0.00830752286990844,0.192,0.100153761434954,0,1
"AZD5991","MCL1 inhibitor","","Cc1c-2c(CSCc3cc(CSc4cc(OCCCc5c(C(O)=O)n(C)c6c-2c(Cl)ccc56)c2ccccc2c4)n(C)n3)nn1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1c-2c(CSCc3cc(CSc4cc(OCCCc5c(C(O)=O)n(C)c6c-2c(Cl)ccc56)c2ccccc2c4)n(C)n3)nn1C",671.179159628,46,8.259,137.7,0.00219957081241134,0.198,0.100099785406206,0,1
"dalfopristin","antibacterial ","","[H][C@]12[C@@H](CCN1C(=O)c1coc(CC(=O)C[C@H](O)\C=C(/C)\C=C/CNC(=O)\C=C\[C@@H](C)[C@@H](OC2=O)C(C)C)n1)S(=O)(=O)CCN(CC)CC |c:19,22,t:28|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@]12[C@@H](CCN1C(=O)c1coc(CC(=O)C[C@H](O)\C=C(/C)\C=C/CNC(=O)\C=C\[C@@H](C)[C@@H](OC2=O)C(C)C)n1)S(=O)(=O)CCN(CC)CC |c:19",690.32985018,49,1.702,184.8,0.000186989366401659,0.2,0.100093494683201,0,1
"ly2562175","fxr agonist","NR1H4","Cn1cc(C(O)=O)c2ccc(cc12)N1CCC(CC1)OCc1c(onc1-c1c(Cl)cccc1Cl)C1CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","gastroenterology","non-alcoholic steatohepatitis (nash)","Cn1cc(C(O)=O)c2ccc(cc12)N1CCC(CC1)OCc1c(onc1-c1c(Cl)cccc1Cl)C1CC1",539.137861704,37,6.625,80.73,0.0160754263667835,0.184,0.100037713183392,0,1
"PRN1371","protein tyrosine kinase inhibitor","","CNc1ncc2cc(-c3c(Cl)c(OC)cc(OC)c3Cl)c(=O)n(CCCN3CCN(CC3)C(=O)C=C)c2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CNc1ncc2cc(-c3c(Cl)c(OC)cc(OC)c3Cl)c(=O)n(CCCN3CCN(CC3)C(=O)C=C)c2n1",560.1705588,38,4.049,101.82,0.00403962141372627,0.196,0.100019810706863,0,1
"CMPD-1","p38 MAPK inhibitor","GNRHR, MAPK14","Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1, Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1, Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1",349.1478071,26,5.238,49.33,0.152033006610694,0.048,0.100016503305347,1,0
"tracazolate","GABA receptor modulator","GABRA1","CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12, CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12, CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12, CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12",304.189926008,22,3.951,69.04,0.0880067586128863,0.112,0.100003379306443,0,0
"cathepsin-inhibitor-1","cathepsin inhibitor","CTSB, CTSL, CTSV","Cn1nc(cc1C(=O)N[C@@H](Cc1cccc(Cl)c1)C(=O)NCC#N)C(C)(C)C, Cn1nc(cc1C(=O)N[C@@H](Cc1cccc(Cl)c1)C(=O)NCC#N)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cn1nc(cc1C(=O)N[C@@H](Cc1cccc(Cl)c1)C(=O)NCC#N)C(C)(C)C",401.161852688,28,2.201,99.81,0.0119287402788682,0.188,0.0999643701394341,0,1
"clinafloxacin (pd127391)","bacterial dna gyrase inhibitor","","NC1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","NC1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1",365.094247304,25,4.467,88.56,0.0313991432041543,0.168,0.0996995716020772,0,1
"clinafloxacin","bacterial DNA gyrase inhibitor","","N[C@H]1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1 |&1:1|, N[C@H]1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1 |&1:1|, N[C@H]1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1 |&1:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","N[C@H]1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1 |&1:1|",365.094247304,25,4.467,88.56,0.0313991432041543,0.168,0.0996995716020771,0,1
"hippuric-acid","","","OC(=O)CNC(=O)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)CNC(=O)c1ccccc1",179.058243148,13,-1.357,66.4,0.0653023288466202,0.134,0.0996511644233101,0,1
"ametantrone","anticancer agent","","OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3ccccc3C(=O)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3ccccc3C(=O)c12",412.211055376,30,0.21,122.72,0.00527420488587803,0.194,0.099637102442939,0,1
"veliflapon","leukotriene synthesis inhibitor","ALOX5AP","OC(=O)[C@H](C1CCCC1)c1ccc(OCc2ccc3ccccc3n2)cc1, OC(=O)[C@H](C1CCCC1)c1ccc(OCc2ccc3ccccc3n2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","OC(=O)[C@H](C1CCCC1)c1ccc(OCc2ccc3ccccc3n2)cc1",361.167793596,27,5.355,59.42,0.121221311885357,0.078,0.0996106559426786,1,0
"act-709478","calcium channel blocker","CACNA1G","FC(F)(F)C1(CC1)c1ccc(CC(=O)Nc2ccn(Cc3ccc(cn3)C#N)n2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","neurology/psychiatry","epilepsy","FC(F)(F)C1(CC1)c1ccc(CC(=O)Nc2ccn(Cc3ccc(cn3)C#N)n2)cc1",425.146344856,31,3.61,83.6,0.0271855338721219,0.172,0.099592766936061,0,1
"elenbecestat","beta secretase inhibitor","BACE1","FC1=CC=C(NC(C2=NC=C(C(F)F)N=C2)=O)C=C1[C@@]3(N=C(N)SC4)[C@@]4([H])[C@@H](C)OC3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","neurology/psychiatry","alzheimer's disease","FC1=CC=C(NC(C2=NC=C(C(F)F)N=C2)=O)C=C1[C@@]3(N=C(N)SC4)[C@@]4([H])[C@@H](C)OC3",437.113330476,31,0.00200000000000006,126.73,0.00317710975841274,0.196,0.0995885548792064,0,1
"trans-4-hydroxycrotonic-acid","gamma hydroxybutyric acid ligand","","OC\C=C\C(O)=O, OC\C=C\C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC\C=C\C(O)=O",102.031694052,7,-0.512,57.53,0.143168351507453,0.056,0.0995841757537266,1,0
"GSK3787","PPAR receptor antagonist","PPARD","FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1, FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1, FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1",392.020925584,25,3.079,84.51,0.013131892935454,0.186,0.099565946467727,0,1
"L-745870","dopamine receptor antagonist","DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR6, HTR7","Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1, Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1, Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1",0,0,0,0,0,0,0,0,1,4,0,0,0,0,1,4,0,0,0,0,0,0,0,0,"preclinical","","","Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1",326.129824288,23,3.91,35.16,0.135055410623514,0.064,0.0995277053117572,1,0
"butamben","sodium channel blocker","","CCCCOC(=O)c1ccc(N)cc1, CCCCOC(=O)c1ccc(N)cc1, CCCCOC(=O)c1ccc(N)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CCCCOC(=O)c1ccc(N)cc1",193.11027872,14,2.491,52.32,0.182967683594448,0.016,0.099483841797224,1,0
"UC-112","XIAP inhibitor","XIAP","Oc1c(CN2CCCC2)cc(COCc2ccccc2)c2cccnc12, Oc1c(CN2CCCC2)cc(COCc2ccccc2)c2cccnc12, Oc1c(CN2CCCC2)cc(COCc2ccccc2)c2cccnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1c(CN2CCCC2)cc(COCc2ccccc2)c2cccnc12",348.183778008,26,3.394,45.59,0.11291141900083,0.086,0.0994557095004152,0,0
"futibatinib","FGFR inhibitor","","COc1cc(OC)cc(c1)C#Cc1nn([C@H]2CCN(C2)C(=O)C=C)c2ncnc(N)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1cc(OC)cc(c1)C#Cc1nn([C@H]2CCN(C2)C(=O)C=C)c2ncnc(N)c12",418.175338564,31,2.766,108.39,0.0148824530948569,0.184,0.0994412265474285,0,1
"WEHI-345-analog","SRC inhibitor","","Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)CNC(=O)c1ncccc1C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)CNC(=O)c1ncccc1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)CNC(=O)c1ncccc1C",415.21205842,31,3.751,111.61,0.0188032285735817,0.18,0.0994016142867909,0,1
"HTH-01-015","protein kinase inhibitor","NUAK1","CN1c2cc3ccccc3cc2C(=O)N(C)c2c(C)nc(Nc3cnn(c3)C3CCNCC3)nc12, CN1c2cc3ccccc3cc2C(=O)N(C)c2c(C)nc(Nc3cnn(c3)C3CCNCC3)nc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1c2cc3ccccc3cc2C(=O)N(C)c2c(C)nc(Nc3cnn(c3)C3CCNCC3)nc12",468.238607516,35,4.021,91.21,0.0227166893730852,0.176,0.0993583446865426,0,1
"KI-16425","lysophosphatidic acid receptor antagonist","LPAR1, LPAR3","C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(CSCCC(O)=O)cc1)c1ccccc1Cl |&1:1,r|, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(CSCCC(O)=O)cc1)c1ccccc1Cl |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(CSCCC(O)=O)cc1)c1ccccc1Cl |&1:1",474.101620516,32,5.695,126.96,0.00661790823030196,0.192,0.099308954115151,0,1
"naringeninic-acid","","HCAR2, PTGR1","OC(=O)\C=C\c1ccc(O)cc1, OC(=O)\C=C\c1ccc(O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC(=O)\C=C\c1ccc(O)cc1",164.047344116,12,1.503,57.53,0.16444685313704,0.034,0.0992234265685202,1,0
"SU16f","PDGFR tyrosine kinase receptor inhibitor","PDGFRB","Cc1[nH]c(\C=C2/C(=O)Nc3cc(ccc23)-c2ccccc2)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3cc(ccc23)-c2ccccc2)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3cc(ccc23)-c2ccccc2)c(C)c1CCC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1[nH]c(\C=C2/C(=O)Nc3cc(ccc23)-c2ccccc2)c(C)c1CCC(O)=O",386.163042564,29,3.819,82.19,0.0464267334307384,0.152,0.0992133667153692,0,1
"IACS-10759","mitochondrial complex I inhibitor","","Cc1nc(nn1Cc1cccc(c1)N1CCC(CC1)S(C)(=O)=O)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1nc(nn1Cc1cccc(c1)N1CCC(CC1)S(C)(=O)=O)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1",562.16100894,39,5.783,124.62,0.00437306213468726,0.194,0.0991865310673436,0,1
"olumacostat-glasaretil","acetyl-CoA carboxylase inhibitor","","CCCCCCCCCCCCCCOc1ccc(o1)C(=O)OCC(=O)N(C)CC(=O)OCC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCCCCCCCCCCCCCOc1ccc(o1)C(=O)OCC(=O)N(C)CC(=O)OCC",481.303952716,34,7.545,95.28,0.0283492081095251,0.17,0.0991746040547626,0,1
"ethamivan","respiratory stimulant","","CCN(CC)C(=O)c1ccc(O)c(OC)c1, CCN(CC)C(=O)c1ccc(O)c(OC)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN(CC)C(=O)c1ccc(O)c(OC)c1",223.120843404,16,1.656,49.77,0.130249280000028,0.068,0.0991246400000139,1,0
"DY131","estrogen-related receptor agonist","ESRRB, ESRRG","CCN(CC)c1ccc(\C=N\NC(=O)c2ccc(O)cc2)cc1, CCN(CC)c1ccc(\C=N\NC(=O)c2ccc(O)cc2)cc1, CCN(CC)c1ccc(\C=N\NC(=O)c2ccc(O)cc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN(CC)c1ccc(\C=N\NC(=O)c2ccc(O)cc2)cc1",311.163376912,23,4.643,64.93,0.118211684030147,0.08,0.0991058420150737,1,0
"subasumstat","","SAE1","Cc1sc(cc1[C@@H]2NCCc3ccc(Cl)cc23)C(=O)c4cncnc4N[C@H]5C[C@H](O)[C@@H](COS(=O)(=O)N)C5",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","hematologic malignancy","myeloproliferative neoplasms","Cc1sc(cc1[C@@H]2NCCc3ccc(Cl)cc23)C(=O)c4cncnc4N[C@H]5C[C@H](O)[C@@H](COS(=O)(=O)N)C5",577.122038676,38,0.9,193.15,0.000150311321328085,0.198,0.099075155660664,0,1
"DQP-1105","glutamate receptor antagonist","GRIN2C, GRIN2D","Cc1ccc2[nH]c(=O)c(C3=NN([C@@H](C3)c3ccc(Br)cc3)C(=O)CCC(O)=O)c(-c3ccccc3)c2c1 |&1:12,r,t:9|, Cc1ccc2[nH]c(=O)c(C3=NN([C@@H](C3)c3ccc(Br)cc3)C(=O)CCC(O)=O)c(-c3ccccc3)c2c1 |&1:12,r,t:9|, Cc1ccc2[nH]c(=O)c(C3=NN([C@@H](C3)c3ccc(Br)cc3)C(=O)CCC(O)=O)c(-c3ccccc3)c2c1 |&1:12,r,t:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc2[nH]c(=O)c(C3=NN([C@@H](C3)c3ccc(Br)cc3)C(=O)CCC(O)=O)c(-c3ccccc3)c2c1 |&1:12",557.095018348,37,6.479,102.83,0.00610954253076222,0.192,0.0990547712653811,0,1
"ceftobiprole","antiinfective drug","","[H][C@]12SCC(\C=C3/CCN([C@@H]4CCNC4)C3=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\c1nsc(N)n1)C(O)=O |c:18|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","[H][C@]12SCC(\C=C3/CCN([C@@H]4CCNC4)C3=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\c1nsc(N)n1)C(O)=O |c:18|",534.110372424,37,-1.681,256.98,4.03615043014356e-05,0.198,0.0990201807521507,0,1
"brl-15572","5-ht1d receptor antagonist","HTR1D","OC(CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1",406.181191164,29,5.302,26.71,0.135756488983231,0.062,0.0988782444916154,1,0
"ic-87114","pi3k inhibitor","PIK3C2B, PIK3CD, PIK3CG","Cc1ccccc1-n1c(Cn2cnc3c(N)ncnc23)nc2cccc(C)c2c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","hematologic malignancy","acute myeloid leukemia (aml)","Cc1ccccc1-n1c(Cn2cnc3c(N)ncnc23)nc2cccc(C)c2c1=O",397.165108228,30,3.57,104.51,0.0257436981801358,0.172,0.0988718490900679,0,1
"HMN-214","PLK inhibitor","PLK1","COc1ccc(cc1)S(=O)(=O)N(C(C)=O)c1ccccc1\C=C\c1cc[n+]([O-])cc1, COc1ccc(cc1)S(=O)(=O)N(C(C)=O)c1ccccc1\C=C\c1cc[n+]([O-])cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1ccc(cc1)S(=O)(=O)N(C(C)=O)c1ccccc1\C=C\c1cc[n+]([O-])cc1",424.10929274,30,4.116,99,0.0177049575585075,0.18,0.0988524787792538,0,1
"L-694247","serotonin receptor agonist","HTR1A, HTR1B, HTR1D","CS(=O)(=O)Nc1ccc(Cc2noc(n2)-c2ccc3[nH]cc(CCN)c3c2)cc1, CS(=O)(=O)Nc1ccc(Cc2noc(n2)-c2ccc3[nH]cc(CCN)c3c2)cc1",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CS(=O)(=O)Nc1ccc(Cc2noc(n2)-c2ccc3[nH]cc(CCN)c3c2)cc1",411.136510532,29,2.547,135.28,0.00569599823564409,0.192,0.098847999117822,0,1
"TC-FPR-43","formyl peptide receptor agonist","FPR2","CC(C)c1c(NC(=O)Nc2ccc(Cl)cc2)c(=O)n(-c2ccccc2)n1C, CC(C)c1c(NC(=O)Nc2ccc(Cl)cc2)c(=O)n(-c2ccccc2)n1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)c1c(NC(=O)Nc2ccc(Cl)cc2)c(=O)n(-c2ccccc2)n1C",384.135303592,27,3.703,68.06,0.0416614376305743,0.156,0.0988307188152872,0,1
"delphinidin","membrane permeability inhibitor","GLO1","Oc1cc(O)c2cc(O)c([o+]c2c1)-c1cc(O)c(O)c(O)c1, Oc1cc(O)c2cc(O)c([o+]c2c1)-c1cc(O)c(O)c(O)c1, Oc1cc(O)c2cc(O)c([o+]c2c1)-c1cc(O)c(O)c(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Oc1cc(O)c2cc(O)c([o+]c2c1)-c1cc(O)c(O)c(O)c1",303.049929112091,22,3.48,121.38,0.0255832942758645,0.172,0.0987916471379322,0,1
"CGP-37157","mitochondrial Na+/Ca2+ exchanger antagonist, sodium/calcium exchange inhibitor","SLC8A1","Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|, Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|, Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|, Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|, Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10",322.993840332,20,3.941,54.4,0.0515750103878176,0.146,0.0987875051939088,0,1
"clonixin","cyclooxygenase inhibitor","PTGS1, PTGS2","Cc1c(Cl)cccc1Nc1ncccc1C(O)=O",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","rheumatology, infectious disease","rheumatoid arthritis, soft tissue infection","Cc1c(Cl)cccc1Nc1ncccc1C(O)=O",262.050905272,18,3.602,62.22,0.101565659740482,0.096,0.098782829870241,0,0
"Y-29794","prolyl endopeptidase inhibitor","PREP","CC(C)c1ccc(C(=O)c2cccs2)c(SCCCCCCCCN(C)C)n1, CC(C)c1ccc(C(=O)c2cccs2)c(SCCCCCCCCN(C)C)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)c1ccc(C(=O)c2cccs2)c(SCCCCCCCCN(C)C)n1",418.211255708,28,5.436,86.74,0.0234792498178157,0.174,0.0987396249089078,0,1
"diphenyleneiodonium","nitric oxide synthase inhibitor","NOS2, NOS3","[I]1c2ccccc2-c2ccccc12 |^1:0|, [I]1c2ccccc2-c2ccccc12 |^1:0|, [I]1c2ccccc2-c2ccccc12 |^1:0|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[I]1c2ccccc2-c2ccccc12 |^1:0|",278.967073256,13,3.88,0,0.0974403720349538,0.1,0.0987201860174769,0,0
"panipenem","antibacterial ","","C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(N)=C)=C(N2C1=O)C(O)=O |c:16|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(N)=C)=C(N2C1=O)C(O)=O |c:16|",339.125277152,23,0.6,132.4,0.00530391269021377,0.192,0.0986519563451069,0,1
"AC-264613","PAR agonist","F2RL1","C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1, C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1, C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1, C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1",399.058238916,25,4.424,70.56,0.0211567723391106,0.176,0.0985783861695553,0,1
"6-benzylaminopurine","purinergic receptor activator","","C(Nc1ncnc2nc[nH]c12)c1ccccc1, C(Nc1ncnc2nc[nH]c12)c1ccccc1, C(Nc1ncnc2nc[nH]c12)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C(Nc1ncnc2nc[nH]c12)c1ccccc1",225.101445352,17,1.836,66.49,0.113132803376496,0.084,0.098566401688248,0,0
"BINA","glutamate receptor positive allosteric modulator","GRM2","Cc1c2C(=O)[C@H](Cc2cc(OCc2cccc(c2)-c2ccc(cc2)C(O)=O)c1C)C1CCCC1 |&1:5,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1c2C(=O)[C@H](Cc2cc(OCc2cccc(c2)-c2ccc(cc2)C(O)=O)c1C)C1CCCC1 |&1:5",454.21440944,34,7.586,63.6,0.105063534567157,0.092,0.0985317672835787,0,0
"ALX-5407","glycine transporter inhibitor","SLC6A9","CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O, CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O, CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O",393.174021848,29,3.278,49.77,0.071022019225308,0.126,0.098511009612654,0,0
"cinchonidine","P glycoprotein inhibitor","","O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12, O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12, O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12, O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12",294.173213324,22,2.689,36.36,0.161017174835727,0.036,0.0985085874178634,1,0
"cinchonine","P glycoprotein inhibitor","CYP2D6","O[C@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O[C@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12",294.173213324,22,2.689,36.36,0.161017174835727,0.036,0.0985085874178634,1,0
"PF-06751979","beta secretase inhibitor","","C[C@H]1C[C@H]2CSC(N)=N[C@]2(CO1)c1nc(NC(=O)c2ccc(OC(F)F)cn2)cs1 |c:7|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@H]1C[C@H]2CSC(N)=N[C@]2(CO1)c1nc(NC(=O)c2ccc(OC(F)F)cn2)cs1 |c:7|",455.089737908,30,1.399,165.26,0.000948759610212289,0.196,0.0984743798051061,0,1
"L-655240","thromboxane receptor antagonist","PTGES","Cc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(F)cc12, Cc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(F)cc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(F)cc12",373.124484812,26,5.253,42.23,0.106809631777684,0.09,0.098404815888842,0,0
"dibutyl-phthalate","","TRPA1","CCCCOC(=O)c1ccccc1C(=O)OCCCC, CCCCOC(=O)c1ccccc1C(=O)OCCCC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCOC(=O)c1ccccc1C(=O)OCCCC",278.151809184,20,4.594,52.6,0.162782593976085,0.034,0.0983912969880426,1,0
"Ro-1138452","prostanoid receptor antagonist","PTGIR","CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1 |t:14|, CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1 |t:14|, CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1 |t:14|, CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1 |t:14|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1 |t:14|",309.184112356,23,4.202,45.65,0.164741396647903,0.032,0.0983706983239513,1,0
"2-PMDQ","adrenergic receptor antagonist","ADRA1A","O=C1Nc2ccccc2C2=N[C@@H](CN3CCN(CC3)c3ccccc3)CN12 |&1:11,r,t:10|, O=C1Nc2ccccc2C2=N[C@@H](CN3CCN(CC3)c3ccccc3)CN12 |&1:11,r,t:10|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"preclinical","","","O=C1Nc2ccccc2C2=N[C@@H](CN3CCN(CC3)c3ccccc3)CN12 |&1:11",361.190260356,27,2.508,51.18,0.0766455134628335,0.12,0.0983227567314168,0,0
"MLN9708","proteasome inhibitor","","CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(O)=O)(CC(O)=O)O1, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(O)=O)(CC(O)=O)O1, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(O)=O)(CC(O)=O)O1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(O)=O)(CC(O)=O)O1",516.087366076,34,2.29,168.33,0.000643017766546706,0.196,0.0983215088832734,0,1
"AZD9496","estrogen receptor agonist","ESR1","C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CC(C)(C)F)c1c(F)cc(\C=C\C(O)=O)cc1F, C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CC(C)(C)F)c1c(F)cc(\C=C\C(O)=O)cc1F, C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CC(C)(C)F)c1c(F)cc(\C=C\C(O)=O)cc1F, C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CC(C)(C)F)c1c(F)cc(\C=C\C(O)=O)cc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CC(C)(C)F)c1c(F)cc(\C=C\C(O)=O)cc1F",442.1868127,32,5.577,56.33,0.0666216786400919,0.13,0.0983108393200459,0,1
"EVP-6124","acetylcholine receptor agonist","CHRNA7","Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2, Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2, Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2, Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"phase 3","","","Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2",320.075011844,21,2.867,60.58,0.0466074752767472,0.15,0.0983037376383736,0,1
"NVP-BVU972","MET inhibitor","MET","Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1, Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1",340.143644512,26,3.248,60.9,0.0945034656957697,0.102,0.0982517328478849,0,0
"KW-3902","adenosine receptor antagonist","ADORA1, ADORA2A, ADORA2B, ADORA3","CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C12C[C@@H]3C[C@H]1C[C@H](C2)C3 |&1:23,&2:21,&3:19,r|, CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C12C[C@@H]3C[C@H]1C[C@H](C2)C3 |&1:23,&2:21,&3:19,r|, CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C12C[C@@H]3C[C@H]1C[C@H](C2)C3 |&1:23,&2:21,&3:19,r|, CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C12C[C@@H]3C[C@H]1C[C@H](C2)C3 |&1:23,&2:21,&3:19,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C12C[C@@H]3C[C@H]1C[C@H](C2)C3 |&1:23",356.221226136,26,5.734,72.68,0.0905021145598835,0.106,0.0982510572799417,0,0
"lurbinectedin","DNA binding agent","","[H][C@@]12Cc3cc(C)c(OC)c(O)c3[C@@]([H])(N1C)[C@@]1([H])N([C@H]2O)[C@@]2([H])COC(=O)[C@]3(CS[C@]1([H])c1c(OC(C)=O)c(C)c4OCOc4c21)NCCc1c3[nH]c2ccc(OC)cc12 |THB:16:15:2.3.12:20.19.17|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","[H][C@@]12Cc3cc(C)c(OC)c(O)c3[C@@]([H])(N1C)[C@@]1([H])N([C@H]2O)[C@@]2([H])COC(=O)[C@]3(CS[C@]1([H])c1c(OC(C)=O)c(C)c4OCOc4c21)NCCc1c3[nH]c2ccc(OC)cc12 |THB:16:15:2.3.12:20.19.17|",784.277814608,61,3.638,189.58,0.000452100845420678,0.196,0.0982260504227103,0,1
"TC-LPA5-4","lysophosphatidic acid receptor antagonist","LPAR5","COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O, COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O, COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O, COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O, COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O",410.139720276,29,6.747,64.35,0.0784370105290106,0.118,0.0982185052645053,0,0
"emodin","11-beta hydroxysteroid dehydrogenase inhibitor","CSNK2A1","Cc1cc(O)c2C(=O)c3c(O)cc(O)cc3C(=O)c2c1, Cc1cc(O)c2C(=O)c3c(O)cc(O)cc3C(=O)c2c1, Cc1cc(O)c2C(=O)c3c(O)cc(O)cc3C(=O)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(O)c2C(=O)c3c(O)cc(O)cc3C(=O)c2c1",270.05282342,20,2.327,94.83,0.0483765146979626,0.148,0.0981882573489813,0,1
"evenamide","voltage-gated sodium channel blocker","","CCCCOc1cccc(CCNCC(=O)N(C)C)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCCOc1cccc(CCNCC(=O)N(C)C)c1",278.199428072,20,2.271,41.57,0.124231647986213,0.072,0.0981158239931063,1,0
"tyrphostin-AG-1296","FLT3 inhibitor","FLT3","COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2ncc(nc2cc1OC)-c1ccccc1",266.105527688,20,2.553,44.24,0.160231362963446,0.036,0.0981156814817229,1,0
"NCS-382","GABA receptor antagonist","GABBR1, GABBR2, SLC52A2","O[C@@H]1c2ccccc2CCC\C1=C/C(O)=O |&1:1|, O[C@@H]1c2ccccc2CCC\C1=C/C(O)=O |&1:1|",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O[C@@H]1c2ccccc2CCC\C1=C/C(O)=O |&1:1|",218.094294308,16,1.37,57.53,0.116229634389427,0.08,0.0981148171947135,1,0
"ncs-382","gaba receptor antagonist","","OC1c2ccccc2CCC\C1=C/C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","neurology","epilepsy","OC1c2ccccc2CCC\C1=C/C(O)=O",218.094294308,16,1.37,57.53,0.116229634389427,0.08,0.0981148171947135,1,0
"BMS-986158","bromodomain inhibitor","","Cc1nnn(C)c1-c1cnc2c(c1)n([C@@H](C1CCOCC1)c1ccccc1)c1cc(ccc21)C(C)(C)O, Cc1nnn(C)c1-c1cnc2c(c1)n([C@@H](C1CCOCC1)c1ccccc1)c1cc(ccc21)C(C)(C)O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","Cc1nnn(C)c1-c1cnc2c(c1)n([C@@H](C1CCOCC1)c1ccccc1)c1cc(ccc21)C(C)(C)O",495.263425296,37,4.988,77.99,0.0321936291635404,0.164,0.0980968145817702,0,1
"basmisanil","GABA receptor inverse agonist","","Cc1onc(c1COc1ccc(cn1)C(=O)N1CCS(=O)(=O)CC1)-c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1onc(c1COc1ccc(cn1)C(=O)N1CCS(=O)(=O)CC1)-c1ccc(F)cc1",445.11076996,31,3.142,110.98,0.00812689621781238,0.188,0.0980634481089062,0,1
"fenoxaprop-p-ethyl","","NOS3","CCOC(=O)[C@@H](C)Oc1ccc(Oc2nc3ccc(Cl)cc3o2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)[C@@H](C)Oc1ccc(Oc2nc3ccc(Cl)cc3o2)cc1",361.071700292,25,4.369,70.79,0.0499747295667333,0.146,0.0979873647833667,0,1
"parethoxycaine","local anesthetic","","CCOc1ccc(cc1)C(=O)OCCN(CC)CC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOc1ccc(cc1)C(=O)OCCN(CC)CC",265.167793596,19,2.995,38.77,0.163927361939114,0.032,0.0979636809695569,1,0
"lorglumide","CCK receptor antagonist","CCKAR, CCKBR","CCCCCN(CCCCC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:13,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCCCCN(CCCCC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:13",458.173912864,30,5.824,86.71,0.0158809042515623,0.18,0.0979404521257812,0,1
"lorglumide sodium","cck receptor antagonist","","CCCCCN(CCCCC)C(=O)C(CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCCCCN(CCCCC)C(=O)C(CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1",458.173912864,30,5.824,86.71,0.0158809042515623,0.18,0.0979404521257812,0,1
"pirmenol","acetylcholine receptor inhibitor","","C[C@H]1CCC[C@@H](C)N1CCC[C@@](O)(c1ccccc1)c1ccccn1 |a:1,5,&1:11|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H]1CCC[C@@H](C)N1CCC[C@@](O)(c1ccccc1)c1ccccn1 |a:1",338.23581358,25,4.067,36.36,0.157777956847371,0.038,0.0978889784236857,1,0
"TC-ASK-10","MAP kinase inhibitor","MAP3K5, MAP3K6","CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1, CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1, CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1, CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1, CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1",359.174610292,27,5.154,64.22,0.109696647724216,0.086,0.0978483238621078,0,0
"CTS-1027","metalloproteinase inhibitor","MMP1, MMP13, MMP2, MMP3, MMP9","ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1, ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1, ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1, ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1, ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1",425.06998604,28,2.437,110.31,0.00563011307955756,0.19,0.0978150565397788,0,1
"IBC-293","hydroxycarboxylic acid receptor agonist","HCAR3","CC(C)n1nnc2cc(ccc12)C(O)=O, CC(C)n1nnc2cc(ccc12)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)n1nnc2cc(ccc12)C(O)=O",205.085126592,15,1.502,68.01,0.103530458496316,0.092,0.0977652292481581,0,0
"MMPX","phosphodiesterase inhibitor","","COCc1nc2n(CC(C)C)c(=O)n(C)c(=O)c2[nH]1, COCc1nc2n(CC(C)C)c(=O)n(C)c(=O)c2[nH]1, COCc1nc2n(CC(C)C)c(=O)n(C)c(=O)c2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COCc1nc2n(CC(C)C)c(=O)n(C)c(=O)c2[nH]1",266.137890436,19,2.408,81.91,0.0575082989341754,0.138,0.0977541494670877,0,1
"PF-05180999","phosphodiesterase inhibitor","","Cc1nc(-c2cnn(C)c2-c2ccc(cn2)C(F)(F)F)c2c(ncnn12)N1CCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1nc(-c2cnn(C)c2-c2ccc(cn2)C(F)(F)F)c2c(ncnn12)N1CCC1",414.152827204,30,3.73,77.03,0.0334608429521728,0.162,0.0977304214760864,0,1
"ML281","serine/threonine kinase inhibitor","STK33","CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O",389.119797848,28,4.475,103.09,0.0254048531627967,0.17,0.0977024265813984,0,1
"iodophenpropit","histamine receptor antagonist","HRH3, HRH4","Ic1ccc(CCNC(=N)SCCCc2cnc[nH]2)cc1",0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Ic1ccc(CCNC(=N)SCCCc2cnc[nH]2)cc1",414.037515608,21,3.941,89.86,0.00340106602249083,0.192,0.0977005330112454,0,1
"ML297","inward rectifier potassium channel activator","KCNJ3","Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1, Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1, Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1, Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1, Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1, Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1",328.113567508,24,3.618,58.95,0.0913616172044434,0.104,0.0976808086022217,0,0
"TCN201","glutamate receptor antagonist","GRIN2A","Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1, Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1, Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1, Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1",461.061232924,31,4.364,112.75,0.00719563244725964,0.188,0.0975978162236298,0,1
"basic-fuchsin","","","CC1=CC(C=CC1=N)=C(c1ccc(N)cc1)c1ccc(N)cc1 |c:4,t:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC1=CC(C=CC1=N)=C(c1ccc(N)cc1)c1ccc(N)cc1 |c:4",301.157897608,23,3.521,75.89,0.0911589423029501,0.104,0.097579471151475,0,0
"AGN-194310","retinoid receptor antagonist","RXRA, RXRB, RXRG","CCc1ccc(cc1)C1=CC(C)(C)Sc2ccc(cc12)C#Cc1ccc(cc1)C(O)=O |t:9|, CCc1ccc(cc1)C1=CC(C)(C)Sc2ccc(cc12)C#Cc1ccc(cc1)C(O)=O |t:9|, CCc1ccc(cc1)C1=CC(C)(C)Sc2ccc(cc12)C#Cc1ccc(cc1)C(O)=O |t:9|, CCc1ccc(cc1)C1=CC(C)(C)Sc2ccc(cc12)C#Cc1ccc(cc1)C(O)=O |t:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCc1ccc(cc1)C1=CC(C)(C)Sc2ccc(cc12)C#Cc1ccc(cc1)C(O)=O |t:9|",424.149701008,31,8.257,62.6,0.127096265085757,0.068,0.0975481325428787,1,0
"mdl 72222","serotonin receptor antagonist","","CN1C2CCC1CC(C2)OC(=O)c1cc(Cl)cc(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CN1C2CCC1CC(C2)OC(=O)c1cc(Cl)cc(Cl)c1",313.063634144,20,4.178,29.54,0.115080450097412,0.08,0.0975402250487058,1,0
"CE3F4","rap guanine nucleotide exchange factor inhibitor","RAPGEF3","C[C@H]1CCc2c(Br)c(F)c(Br)cc2N1C=O |&1:1,r|, C[C@H]1CCc2c(Br)c(F)c(Br)cc2N1C=O |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H]1CCc2c(Br)c(F)c(Br)cc2N1C=O |&1:1",348.91131636,16,3.603,20.31,0.0230709771071532,0.172,0.0975354885535766,0,1
"isotiquimide","","","Cc1ccnc2[C@@H](CCCc12)C(N)=S |&1:6,r|, Cc1ccnc2[C@@H](CCCc12)C(N)=S |&1:6,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1ccnc2[C@@H](CCCc12)C(N)=S |&1:6",206.087769448,14,1.127,71,0.0708092840884433,0.124,0.0974046420442217,0,0
"2-methoxyestradiol","hypoxia inducible factor inhibitor","COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB","COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O",302.188194692,22,3.879,49.69,0.1347696265342,0.06,0.0973848132671001,1,0
"TG-02","CDK inhibitor, FLT3 inhibitor, JAK inhibitor","CDK1, CDK2, CDK7, CDK9, FLT3, JAK2","CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|",372.195011388,28,4.291,50.28,0.11272022522978,0.082,0.0973601126148901,0,0
"polyinosine","immunostimulant","HPRT1, IMPDH2, PYGM","O[C@H]1[C@@H](COP(O)(O)=O)O[C@@H]([C@@H]1O)n1cnc2c1[nH]cnc2=O |&1:1,&2:2,&3:10,&4:11,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O[C@H]1[C@@H](COP(O)(O)=O)O[C@@H]([C@@H]1O)n1cnc2c1[nH]cnc2=O |&1:1",348.047100006,23,-1.728,189.83,0.000642311450708798,0.194,0.0973211557253544,0,1
"RG4733","gamma secretase inhibitor","PSEN1","CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O, CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O, CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O, CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O",469.1424826,33,5.6,87.3,0.022616794000245,0.172,0.0973083970001225,0,1
"ASTX660","apoptosis inhibitor","","C[C@@H]1CN(CC(=O)N2CC(C)(C)c3nc(CO)c(Cc4ccc(F)cc4)cc23)[C@@H](CN2CCOC[C@H]2C)CN1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","C[C@@H]1CN(CC(=O)N2CC(C)(C)c3nc(CO)c(Cc4ccc(F)cc4)cc23)[C@@H](CN2CCOC[C@H]2C)CN1",539.327168424,39,1.128,81.17,0.00658361562364942,0.188,0.0972918078118247,0,1
"JW-74","tankyrase inhibitor, WNT signaling inhibitor","TNKS, TNKS2","COc1ccc(cc1)-n1c(SCc2nc(no2)-c2ccc(C)cc2)nnc1-c1ccncc1, COc1ccc(cc1)-n1c(SCc2nc(no2)-c2ccc(C)cc2)nnc1-c1ccncc1, COc1ccc(cc1)-n1c(SCc2nc(no2)-c2ccc(C)cc2)nnc1-c1ccncc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1)-n1c(SCc2nc(no2)-c2ccc(C)cc2)nnc1-c1ccncc1",456.13684488,33,6.308,117.05,0.0185014174909837,0.176,0.0972507087454919,0,1
"epristeride","5 alpha reductase inhibitor","","[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C=C(CC[C@]12C)C(O)=O |c:25,t:23|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C=C(CC[C@]12C)C(O)=O |c:25",399.277344044,32,6.236,66.4,0.156355181135393,0.038,0.0971775905676966,1,0
"E-2012","gamma secretase modulator","APH1A, APH1B, PSENEN","COc1cc(\C=C2/CCCN([C@@H](C)c3ccc(F)cc3)C2=O)ccc1-n1cnc(C)c1, COc1cc(\C=C2/CCCN([C@@H](C)c3ccc(F)cc3)C2=O)ccc1-n1cnc(C)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1cc(\C=C2/CCCN([C@@H](C)c3ccc(F)cc3)C2=O)ccc1-n1cnc(C)c1",419.200905292,31,4.672,47.36,0.0882910824546587,0.106,0.0971455412273294,0,0
"PCI-29732","Bruton's tyrosine kinase (BTK) inhibitor","BTK","Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)C1CCCC1, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)C1CCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)C1CCCC1",371.174610292,28,4.897,78.85,0.0722564780398269,0.122,0.0971282390199135,0,0
"adoprazine","dopamine receptor antagonist, serotonin receptor agonist","DRD2, HTR1A","Fc1ccc(cc1)-c1cncc(CN2CCN(CC2)c2cccc3OCCOc23)c1, Fc1ccc(cc1)-c1cncc(CN2CCN(CC2)c2cccc3OCCOc23)c1, Fc1ccc(cc1)-c1cncc(CN2CCN(CC2)c2cccc3OCCOc23)c1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,"phase 2","","","Fc1ccc(cc1)-c1cncc(CN2CCN(CC2)c2cccc3OCCOc23)c1",405.185255228,30,3.905,37.83,0.0999997064090417,0.094,0.0969998532045208,0,0
"dovitinib","EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB","CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O",392.176087512,29,2.735,94.04,0.0239686491836484,0.17,0.0969843245918242,0,1
"LY2157299","TGF beta receptor inhibitor","TGFBR1","Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O, Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O, Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O, Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O",369.158960228,28,2.669,86.69,0.0379555843986833,0.156,0.0969777921993416,0,1
"AMG-337","MET inhibitor","MET","COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(cn34)-c3cnn(C)c3)c(=O)c2c1, COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(cn34)-c3cnn(C)c3)c(=O)c2c1, COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(cn34)-c3cnn(C)c3)c(=O)c2c1, COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(cn34)-c3cnn(C)c3)c(=O)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(cn34)-c3cnn(C)c3)c(=O)c2c1",463.176815784,34,4.441,101.36,0.0179267975118419,0.176,0.0969633987559209,0,1
"macozinone","DPRE1 inhibitor","","[O-][N+](=O)c1cc(cc2c1sc(nc2=O)N1CCN(CC2CCCCC2)CC1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[O-][N+](=O)c1cc(cc2c1sc(nc2=O)N1CCN(CC2CCCCC2)CC1)C(F)(F)F",456.144296256,31,6.136,107.82,0.0139185940492517,0.18,0.0969592970246259,0,1
"licofelone","cyclooxygenase inhibitor, lipoxygenase inhibitor","ALOX5, PLA2G2E, PTGS2","CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1, CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1, CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1, CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1",379.133906624,27,5.804,42.23,0.129901677395205,0.064,0.0969508386976026,1,0
"(R)-(-)-rolipram","phosphodiesterase inhibitor","PDE4A, PDE4B, PDE4C, PDE4D, PDE5A","COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1",275.152143532,20,1.889,47.56,0.10787173543205,0.086,0.096935867716025,0,0
"(S)-(+)-rolipram","phosphodiesterase inhibitor","PDE4B, PDE4D","COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1",275.152143532,20,1.889,47.56,0.10787173543205,0.086,0.096935867716025,0,0
"rolipram","phosphodiesterase inhibitor","","COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14,r|, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14,r|, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14,r|, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14,r|, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14,r|, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14",275.152143532,20,1.889,47.56,0.10787173543205,0.086,0.096935867716025,0,0
"thiodiglycol","","","OCCSCCO, OCCSCCO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OCCSCCO",122.04015056,7,-0.237,65.76,0.0838645356680076,0.11,0.0969322678340038,0,0
"2-thiouracil","","","O=c1cc[nH]c(=S)[nH]1, O=c1cc[nH]c(=S)[nH]1, O=c1cc[nH]c(=S)[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=c1cc[nH]c(=S)[nH]1",128.004433748,8,0.713,80.74,0.0818583616363327,0.112,0.0969291808181664,0,0
"lumiracoxib","cyclooxygenase inhibitor","PTGS1, PTGS2","Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1, Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1, Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1, Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1",293.061884556,20,3.881,49.33,0.109752829647379,0.084,0.0968764148236894,0,0
"BTZ043-racemate","DPRE1 inhibitor","","C[C@H]1COC2(CCN(CC2)c2nc(=O)c3cc(cc([N+]([O-])=O)c3s2)C(F)(F)F)O1 |&1:1,r|, C[C@H]1COC2(CCN(CC2)c2nc(=O)c3cc(cc([N+]([O-])=O)c3s2)C(F)(F)F)O1 |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","C[C@H]1COC2(CCN(CC2)c2nc(=O)c3cc(cc([N+]([O-])=O)c3s2)C(F)(F)F)O1 |&1:1",431.076276272,29,4.592,123.04,0.00773969111274006,0.186,0.09686984555637,0,1
"aloe-emodin","anticancer agent","CASP8","OCc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OCc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1",270.05282342,20,1.485,94.83,0.0397071889403856,0.154,0.0968535944701928,0,1
"ampalex","glutamate receptor agonist","GRIA1, GRIA2, GRIA3, GRIA4","O=C(N1CCCCC1)c1ccc2nccnc2c1, O=C(N1CCCCC1)c1ccc2nccnc2c1, O=C(N1CCCCC1)c1ccc2nccnc2c1, O=C(N1CCCCC1)c1ccc2nccnc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O=C(N1CCCCC1)c1ccc2nccnc2c1",241.1215121,18,1.373,46.09,0.135594005426067,0.058,0.0967970027130335,1,0
"L-threonine","","TARS, TARS2, THNSL1","C[C@@H](O)[C@H](N)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@@H](O)[C@H](N)C(O)=O",119.058243148,8,-3.496,83.55,0.035533123583255,0.158,0.0967665617916275,0,1
"octopamine","trace amine associated receptor agonist, neurotransmitter","ADRA2A, ADRA2B, ADRA2C, F10, TAAR1","NC[C@@H](O)c1ccc(O)cc1 |&1:2,r|, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,"preclinical","","","NC[C@@H](O)c1ccc(O)cc1 |&1:2",153.078978592,11,0.132,66.48,0.105504862620131,0.088,0.0967524313100657,0,0
"SDM25N","opioid receptor antagonist","OPRD1","CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|, CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|, CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|, CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|, CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7",414.194342692,31,2.482,68.72,0.0374207457108844,0.156,0.0967103728554422,0,1
"PRLX-93936","voltage-dependent anion selective channel protein inhibitor","","CCOc1ccccc1-n1c(CN2CCNCC2)nc2ccccc2c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","CCOc1ccccc1-n1c(CN2CCNCC2)nc2ccccc2c1=O",364.189926008,27,2.745,59.39,0.0634032068973202,0.13,0.0967016034486601,0,1
"4-cpa","pesticide","DPP9","OC(=O)COc1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)COc1ccc(Cl)cc1",186.008371764,12,1.941,46.53,0.143300937998582,0.05,0.0966504689992913,1,0
"mavatrep","transient receptor potential channel antagonist","","CC(C)(O)c1ccccc1-c1ccc2nc(\C=C\c3ccc(cc3)C(F)(F)F)[nH]c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(O)c1ccccc1-c1ccc2nc(\C=C\c3ccc(cc3)C(F)(F)F)[nH]c2c1",422.160597952,31,6.232,48.91,0.1131763974608,0.08,0.0965881987303999,0,0
"RG7800","RNA splicing modifier","","CCc1nc(C)cn2nc(cc12)-c1cc(=O)n2cc(cc(C)c2n1)C1CCN(C)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCc1nc(C)cn2nc(cc12)-c1cc(=O)n2cc(cc(C)c2n1)C1CCN(C)CC1",416.232459516,31,2.781,67.8,0.0391113117122921,0.154,0.0965556558561461,0,1
"CGP-78608","glutamate receptor antagonist","","C[C@@H](NCc1cc(Br)cc2[nH]c(=O)c(=O)[nH]c12)P(O)(O)=O, C[C@@H](NCc1cc(Br)cc2[nH]c(=O)c(=O)[nH]c12)P(O)(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](NCc1cc(Br)cc2[nH]c(=O)c(=O)[nH]c12)P(O)(O)=O",376.977619246,21,0.797,145.09,0.00106278234423524,0.192,0.0965313911721176,0,1
"erastin","ion channel antagonist","VDAC2","CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20,r|, CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20,r|, CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20,r|, CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20,r|, CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20",546.203383152,39,5.32,76.9,0.0170627675155029,0.176,0.0965313837577515,0,1
"ABX-1431","monoacylglycerol lipase inhibitor","","FC(F)(F)C(OC(=O)N1CCN(Cc2ccc(cc2N2CCCC2)C(F)(F)F)CC1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","FC(F)(F)C(OC(=O)N1CCN(Cc2ccc(cc2N2CCCC2)C(F)(F)F)CC1)C(F)(F)F",507.156830924,34,6.023,36.02,0.0410092981478785,0.152,0.0965046490739392,0,1
"5-hydroxyectoine","","","CC1=NC[C@H](O)[C@H](N1)C(O)=O |t:1|, CC1=NC[C@H](O)[C@H](N1)C(O)=O |t:1|, CC1=NC[C@H](O)[C@H](N1)C(O)=O |t:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC1=NC[C@H](O)[C@H](N1)C(O)=O |t:1|",158.06914218,11,-0.359,81.92,0.0609273640235166,0.132,0.0964636820117583,0,1
"iclaprim","dihydrofolate reductase inhibitor","","COc1cc(Cc2cnc(N)nc2N)c2C=C[C@H](Oc2c1OC)C1CC1 |&1:17,r,c:16|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1cc(Cc2cnc(N)nc2N)c2C=C[C@H](Oc2c1OC)C1CC1 |&1:17",354.169190564,26,1.914,105.51,0.018768357922769,0.174,0.0963841789613845,0,1
"smn-c3","cell splicing inhibitor","SMN2","CCN1CCC(CC1)c1cc(C)c2nc(cc(=O)n2c1)-c1cc2c(C)nc(C)cn2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN1CCC(CC1)c1cc(C)c2nc(cc(=O)n2c1)-c1cc2c(C)nc(C)cn2n1",416.232459516,31,2.951,67.8,0.040709043813493,0.152,0.0963545219067465,0,1
"palomid-529","AKT inhibitor, mTOR inhibitor","MTOR","COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)[C@@H](C)O)cc1 |&1:25,r|, COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)[C@@H](C)O)cc1 |&1:25,r|, COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)[C@@H](C)O)cc1 |&1:25,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)[C@@H](C)O)cc1 |&1:25",406.141638424,30,4.818,78.13,0.0506710277334224,0.142,0.0963355138667112,0,1
"acecainide","polarization inhibitor","SCN5A","CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1, CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1, CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1, CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1",277.179026976,20,1.38,61.44,0.0686398579225167,0.124,0.0963199289612584,0,0
"zardaverine","phosphodiesterase inhibitor","PDE4D","COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1",268.06594862,19,2.291,64.21,0.0786334612318772,0.114,0.0963167306159386,0,0
"acelarin","anticancer agent","","C[C@H](N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O)Oc1ccccc1)C(=O)OCc1ccccc1 |a:1,7,9,21,&1:3|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","C[C@H](N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O)Oc1ccccc1)C(=O)OCc1ccccc1 |a:1",580.153456894,40,3.179,174.04,0.00060350185831584,0.192,0.0963017509291579,0,1
"API-001","sigma receptor antagonist","SIGMAR1","Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1, Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1, Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1",337.179026976,25,3.358,39.52,0.130474481441972,0.062,0.0962372407209861,1,0
"PX-12","thioredoxin inhibitor","CNR1, TXN","CC[C@@H](C)SSc1ncc[nH]1 |&1:2,r|, CC[C@@H](C)SSc1ncc[nH]1 |&1:2,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC[C@@H](C)SSc1ncc[nH]1 |&1:2",188.044190384,11,1.982,79.28,0.0564419561007388,0.136,0.0962209780503694,0,1
"WP921","","","OC(=O)Cn1nnnc1-c1ccsc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)Cn1nnnc1-c1ccsc1",210.021146432,14,0.9,109.14,0.0263840902907203,0.166,0.0961920451453602,0,1
"diarylpropionitrile","estrogen receptor agonist","ESR2","Oc1ccc(C[C@@H](C#N)c2ccc(O)cc2)cc1 |&1:6,r|, Oc1ccc(C[C@@H](C#N)c2ccc(O)cc2)cc1 |&1:6,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(C[C@@H](C#N)c2ccc(O)cc2)cc1 |&1:6",239.094628656,18,2.407,64.25,0.12225290442832,0.07,0.0961264522141599,1,0
"8-bromo-cGMP","PKA activator","PRKG1","Nc1nc(=O)c2nc(Br)n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c2[nH]1 |a:10,12,19,20,&1:15|, Nc1nc(=O)c2nc(Br)n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c2[nH]1 |a:10,12,19,20,&1:15|, Nc1nc(=O)c2nc(Br)n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c2[nH]1 |a:10,12,19,20,&1:15|, Nc1nc(=O)c2nc(Br)n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c2[nH]1 |a:10,12,19,20,&1:15|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1nc(=O)c2nc(Br)n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c2[nH]1 |a:10",422.957946422,24,-0.42,184.62,0.00020986566499085,0.192,0.0961049328324954,0,1
"retagliptin","dipeptidyl peptidase inhibitor","","COC(=O)c1nc(n2CCN(Cc12)C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COC(=O)c1nc(n2CCN(Cc12)C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F)C(F)(F)F",464.128309756,32,3.022,90.45,0.0101289643467389,0.182,0.0960644821733694,0,1
"AC-55541","PARP inhibitor","PARP2","C\C(=N/NC(=O)[C@@H](NC(=O)c1ccccc1)c1n[nH]c(=O)c2ccccc12)c1cccc(Br)c1 |&1:6,r|, C\C(=N/NC(=O)[C@@H](NC(=O)c1ccccc1)c1n[nH]c(=O)c2ccccc12)c1cccc(Br)c1 |&1:6,r|, C\C(=N/NC(=O)[C@@H](NC(=O)c1ccccc1)c1n[nH]c(=O)c2ccccc12)c1cccc(Br)c1 |&1:6,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C\C(=N/NC(=O)[C@@H](NC(=O)c1ccccc1)c1n[nH]c(=O)c2ccccc12)c1cccc(Br)c1 |&1:6",517.0749516,34,5.039,116.31,0.00410280676424042,0.188,0.0960514033821202,0,1
"moxisylyte","adrenergic receptor antagonist","","CC(C)c1cc(OC(C)=O)c(C)cc1OCCN(C)C, CC(C)c1cc(OC(C)=O)c(C)cc1OCCN(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CC(C)c1cc(OC(C)=O)c(C)cc1OCCN(C)C",279.18344366,20,2.995,38.77,0.150081130093538,0.042,0.0960405650467688,1,0
"carboxyamidotriazole","calcium channel blocker","CXCL8","NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N, NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N, NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N, NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N",423.005657664,27,4.094,116.89,0.00605299695635587,0.186,0.0960264984781779,0,1
"LY310762","serotonin receptor antagonist","HTR1D","CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)c2ccc(F)cc2)c2ccccc12, CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)c2ccc(F)cc2)c2ccccc12, CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)c2ccc(F)cc2)c2ccccc12, CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)c2ccc(F)cc2)c2ccccc12",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)c2ccc(F)cc2)c2ccccc12",394.205656324,29,3.758,40.62,0.0939877306270301,0.098,0.095993865313515,0,0
"OF-1","bromodomain inhibitor","BRD1","COc1cc2n(C)c(=O)n(C)c2cc1NS(=O)(=O)c1ccc(Br)cc1C, COc1cc2n(C)c(=O)n(C)c2cc1NS(=O)(=O)c1ccc(Br)cc1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2n(C)c(=O)n(C)c2cc1NS(=O)(=O)c1ccc(Br)cc1C",439.020139156,26,2.376,90.71,0.0039542776803259,0.188,0.095977138840163,0,1
"naltrindole","opioid receptor antagonist","OPRD1, OPRK1, OPRM1","Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2ccccc2c1C[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2ccccc2c1C[C@@]35O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2ccccc2c1C[C@@]35O",414.194342692,31,2.754,68.72,0.039899780863038,0.152,0.095949890431519,0,1
"alpha-methylserotonin","serotonin receptor agonist","HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4","C[C@@H](N)Cc1c[nH]c2ccc(O)cc12 |&1:1|",0,0,0,0,0,0,0,0,1,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](N)Cc1c[nH]c2ccc(O)cc12 |&1:1|",190.110613068,14,1.464,62.04,0.129891493886348,0.062,0.0959457469431741,1,0
"methyl-5-hydroxytryptamine","","","C[C@@H](N)Cc1c[nH]c2ccc(O)cc12 |&1:1|, C[C@@H](N)Cc1c[nH]c2ccc(O)cc12 |&1:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](N)Cc1c[nH]c2ccc(O)cc12 |&1:1|",190.110613068,14,1.464,62.04,0.129891493886348,0.062,0.0959457469431741,1,0
"PDP-EA","FAAH activator","FAAH","CCCCCCCCCCCCCCCc1cccc(OCC(=O)NCCO)c1, CCCCCCCCCCCCCCCc1cccc(OCC(=O)NCCO)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCCCCCCCCCc1cccc(OCC(=O)NCCO)c1",405.324294236,29,8.698,58.56,0.149846128533248,0.042,0.0959230642666238,1,0
"GW-1929","PPAR receptor agonist","PPARG","CN(CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(O)=O)cc1)c1ccccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(O)=O)cc1)c1ccccn1",495.215806408,37,4.25,91.76,0.0197938186592336,0.172,0.0958969093296168,0,1
"vanillylacetone","","","COc1cc(CCC(C)=O)ccc1O, COc1cc(CCC(C)=O)ccc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(CCC(C)=O)ccc1O",194.094294308,14,1.124,46.53,0.151741580663339,0.04,0.0958707903316697,1,0
"allylthiourea","nitrification inhibitor","","NC(=S)NCC=C, NC(=S)NCC=C, NC(=S)NCC=C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC(=S)NCC=C",116.040819256,7,0.277,70.14,0.0977067866584648,0.094,0.0958533933292324,0,0
"RGFP966","HDAC inhibitor","HDAC3","Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1, Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1, Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1",362.154289448,27,3.414,72.94,0.0576447589167357,0.134,0.0958223794583679,0,1
"gw7604","selective estrogen receptor destabilizer","ESR1","O=C(O)/C=C/C1=CC=C(/C(C2=CC=C(O)C=C2)=C(C3=CC=CC=C3)/CC)C=C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","oncology","breast cancer","O=C(O)/C=C/C1=CC=C(/C(C2=CC=C(O)C=C2)=C(C3=CC=CC=C3)/CC)C=C1",370.156894564,28,5.973,57.53,0.145544197653104,0.046,0.0957720988265521,1,0
"TC-E-5006","gamma secretase modulator","APP","C[C@@H](C(O)=O)c1ccc([C@@H](N2CCC(C)CC2)c2ccc(F)cc2)c(c1)-c1ccc(cc1)C(F)(F)F |&1:1,&2:9,r|, C[C@@H](C(O)=O)c1ccc([C@@H](N2CCC(C)CC2)c2ccc(F)cc2)c(c1)-c1ccc(cc1)C(F)(F)F |&1:1,&2:9,r|, C[C@@H](C(O)=O)c1ccc([C@@H](N2CCC(C)CC2)c2ccc(F)cc2)c(c1)-c1ccc(cc1)C(F)(F)F |&1:1,&2:9,r|, C[C@@H](C(O)=O)c1ccc([C@@H](N2CCC(C)CC2)c2ccc(F)cc2)c(c1)-c1ccc(cc1)C(F)(F)F |&1:1,&2:9,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](C(O)=O)c1ccc([C@@H](N2CCC(C)CC2)c2ccc(F)cc2)c(c1)-c1ccc(cc1)C(F)(F)F |&1:1",499.213442048,36,7.387,40.54,0.0935150867933656,0.098,0.0957575433966828,0,0
"Y-320","interleukin inhibitor","IL17A","Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N, Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N",504.204051848,36,3.958,86.42,0.0134454107649158,0.178,0.0957227053824579,0,1
"NSP-805","phosphodiesterase inhibitor","","CC1=C(CCC1=O)Nc1ccc(cc1)C1=C(C)CC(=O)NN1 |c:16,t:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC1=C(CCC1=O)Nc1ccc(cc1)C1=C(C)CC(=O)NN1 |c:16",297.147726848,22,1.795,70.23,0.0614383179223691,0.13,0.0957191589611845,0,1
"GSK690693","AKT inhibitor","AKT1, AKT2, AKT3, PAK4, PAK6, PAK7, PRKCQ, PRKG1, PRKX","CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N, CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N, CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N, CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N, CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N, CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N, CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N",425.217537724,31,1.994,137.14,0.00539513378171414,0.186,0.0956975668908571,0,1
"camptothecin-20(s)-o-propionate","anticancer agent","TOP1","CCC(=O)O[C@]1(CC)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","breast cancer","CCC(=O)O[C@]1(CC)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O",404.13722174,30,3.472,87.49,0.0313814159576764,0.16,0.0956907079788382,0,1
"CaMKII-IN-1","calcium/calmodulin dependent protein kinase inhibitor","AKT1, CAMK2A, CAMK4, MYLK","Cc1c(Cl)cccc1S(=O)(=O)Nc1nc(NCCc2ccccc2)nc2CCN(Cc3ccccc3)Cc12, Cc1c(Cl)cccc1S(=O)(=O)Nc1nc(NCCc2ccccc2)nc2CCN(Cc3ccccc3)Cc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1c(Cl)cccc1S(=O)(=O)Nc1nc(NCCc2ccccc2)nc2CCN(Cc3ccccc3)Cc12",547.18087388,38,5.636,95.6,0.00934554602367116,0.182,0.0956727730118356,0,1
"guancydine","antihypertensive agent","","CCC(C)(C)NC(=N)NC#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCC(C)(C)NC(=N)NC#N",154.121846448,11,1.734,71.7,0.131191331416699,0.06,0.0955956657083493,1,0
"IDO5L","indoleamine 2,3-dioxygenase inhibitor","IDO1","Nc1nonc1\C(NO)=N/c1ccc(F)c(Cl)c1, Nc1nonc1\C(NO)=N/c1ccc(F)c(Cl)c1, Nc1nonc1\C(NO)=N/c1ccc(F)c(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1nonc1\C(NO)=N/c1ccc(F)c(Cl)c1",271.027230364,18,2.206,109.56,0.0211547637034349,0.17,0.0955773818517174,0,1
"cevipabulin","microtubule stimulant, tubulin polymerization inhibitor, microtubule stimulant, tubulin polymerization inhibitor","TUBB","CNCCCOc1cc(F)c(c(F)c1)-c1c(Cl)nc2ncnn2c1NC(C)C(F)(F)F, [H][C@@](C)(Nc1c(c(Cl)nc2ncnn12)-c1c(F)cc(OCCCNC)cc1F)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CNCCCOc1cc(F)c(c(F)c1)-c1c(Cl)nc2ncnn2c1NC(C)C(F)(F)F",464.115077976,31,4.801,76.37,0.0171327846363836,0.174,0.0955663923181918,0,1
"BIX-02188","MEK inhibitor","MAP2K5","CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1",412.189926008,31,3.276,87.46,0.0310944409722767,0.16,0.0955472204861383,0,1
"LTA","","","N=C(Nc1ccccc1)c1cccs1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","N=C(Nc1ccccc1)c1cccs1",202.05646932,14,2.723,64.12,0.127091745893706,0.064,0.095545872946853,1,0
"zoniporide","sodium/hydrogen exchanger inhibitor","SLC9A1","NC(N)=NC(=O)c1cnn(c1C1CC1)-c1cccc2ncccc12, NC(N)=NC(=O)c1cnn(c1C1CC1)-c1cccc2ncccc12",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","NC(N)=NC(=O)c1cnn(c1C1CC1)-c1cccc2ncccc12",320.138559132,24,1.584,112.18,0.0210531256890059,0.17,0.095526562844503,0,1
"leucomethylene-blue","nitric oxide production inhibitor, tau aggregation inhibitor","MAPT","CN(C)c1ccc2Nc3ccc(cc3Sc2c1)N(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CN(C)c1ccc2Nc3ccc(cc3Sc2c1)N(C)C",285.129968608,20,4.204,43.81,0.154934757656837,0.036,0.0954673788284186,1,0
"sodium-orthovanadate","","","O[V](O)(O)=O, O[V](O)(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O[V](O)(O)=O",117.947093076,5,-0.153,77.76,0.0469057798000519,0.144,0.095452889900026,0,1
"lixivaptan","vasopressin receptor antagonist","AVPR2","Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc23)c(Cl)c1, Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc23)c(Cl)c1, Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc23)c(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc23)c(Cl)c1",473.130632812,34,6.799,54.34,0.0709055232231331,0.12,0.0954527616115666,0,0
"3-indolebutyric-acid","","B2M, HLA-A, TRAC, TRBC1","OC(=O)CCCc1c[nH]c2ccccc12, OC(=O)CCCc1c[nH]c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)CCCc1c[nH]c2ccccc12",203.094628656,15,2.084,53.09,0.164881733439041,0.026,0.0954408667195203,1,0
"cis-urocanic acid","serotonin receptor agonist","","OC(=O)\C=C/c1cnc[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)\C=C/c1cnc[nH]1",138.042927432,10,-0.138,65.98,0.112737990480855,0.078,0.0953689952404274,0,0
"cis-urocanic-acid","serotonin receptor agonist","HTR2A","OC(=O)\C=C\c1cnc[nH]1, OC(=O)\C=C\c1cnc[nH]1, OC(=O)\C=C\c1cnc[nH]1, OC(=O)\C=C/c1cnc[nH]1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)\C=C\c1cnc[nH]1",138.042927432,10,-0.138,65.98,0.112737990480855,0.078,0.0953689952404274,0,0
"bromosporine","bromodomain inhibitor","","CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1",404.12667412,28,3.524,135.96,0.00668479114147324,0.184,0.0953423955707366,0,1
"relcovaptan","vasopressin receptor antagonist","AVPR1A, AVPR1B, AVPR2, OXTR","COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl, COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl, COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl",619.094676564,41,3.958,147.85,0.000665340255096798,0.19,0.0953326701275484,0,1
"AZD4282","glutamate receptor antagonist","AGXT, AGXT2, ALAS1, ALAS2, BAAT, GARS, GATM, GCAT, GCSH, GLDC, GLRA1, GLRA2, GLRA3, GLRB, GLYAT, GLYATL1, GLYATL2, GNMT, GPR18, GPRC6A, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3B, GSS, PIPOX, SHMT1, SHMT2, SLC32A1, SLC36A1, SLC6A5, SLC6A9","NCC(O)=O, NCC(O)=O",1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","NCC(O)=O",75.0320284,5,-3.35,63.32,0.0805453501971229,0.11,0.0952726750985615,0,0
"guanosine","","PNP","Nc1nc(=O)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1nc(=O)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1",283.091668516,20,-0.159,159.51,0.00449523702171489,0.186,0.0952476185108574,0,1
"SB-206553","serotonin receptor antagonist","HTR2A, HTR2B, HTR2C","Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1, Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1, Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1",292.132411132,22,1.675,50.16,0.102426211436193,0.088,0.0952131057180965,0,0
"butabindide","tripeptidyl peptidase inhibitor","TPP2","CCCCNC(=O)[C@@H]1Cc2ccccc2N1C(=O)[C@@H](N)CC, CCCCNC(=O)[C@@H]1Cc2ccccc2N1C(=O)[C@@H](N)CC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCNC(=O)[C@@H]1Cc2ccccc2N1C(=O)[C@@H](N)CC",303.19467704,22,1.669,75.43,0.0464259289165023,0.144,0.0952129644582511,0,1
"SM-21","sigma receptor antagonist","PGRMC1","CC[C@H](Oc1ccc(Cl)cc1)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C |&1:14,16,19,&2:2,r,TLB:22:21:17.18:14.15.20|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC[C@H](Oc1ccc(Cl)cc1)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C |&1:14",337.144471308,23,4.122,38.77,0.104141943041614,0.086,0.0950709715208069,0,0
"sm-21 maleate","cholinergic receptor antagonist","","CCC(Oc1ccc(Cl)cc1)C(=O)OC1CC2CCC(C1)N2C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCC(Oc1ccc(Cl)cc1)C(=O)OC1CC2CCC(C1)N2C",337.144471308,23,4.122,38.77,0.104141943041614,0.086,0.0950709715208069,0,0
"Ro-106-9920","NFkB pathway inhibitor","","O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1",245.037130844,17,0.977,92.25,0.0341016383676778,0.156,0.0950508191838389,0,1
"levomequitazine","histamine receptor antagonist","HRH1","C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1,r|, C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1,r|, C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1,r|, C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1,r|, C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1,r|",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1",322.150369704,23,4.703,31.78,0.184080639451775,0.006,0.0950403197258874,1,0
"MRK-560","gamma secretase inhibitor","APP","Fc1ccc(F)c(c1)[C@]1(CC[C@@H](CC1)NS(=O)(=O)C(F)(F)F)S(=O)(=O)c1ccc(Cl)cc1 |r|, Fc1ccc(F)c(c1)[C@]1(CC[C@@H](CC1)NS(=O)(=O)C(F)(F)F)S(=O)(=O)c1ccc(Cl)cc1 |r|, Fc1ccc(F)c(c1)[C@]1(CC[C@@H](CC1)NS(=O)(=O)C(F)(F)F)S(=O)(=O)c1ccc(Cl)cc1 |r|, Fc1ccc(F)c(c1)[C@]1(CC[C@@H](CC1)NS(=O)(=O)C(F)(F)F)S(=O)(=O)c1ccc(Cl)cc1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1ccc(F)c(c1)[C@]1(CC[C@@H](CC1)NS(=O)(=O)C(F)(F)F)S(=O)(=O)c1ccc(Cl)cc1 |r|",517.020768804,32,5.049,97.07,0.00405770788346125,0.186,0.0950288539417306,0,1
"dexloxiglumide","CCK receptor antagonist","CCKAR","CCCCCN(CCCOC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1, CCCCCN(CCCOC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCCCCN(CCCOC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1",460.15317742,30,4.073,95.94,0.00802233775793283,0.182,0.0950111688789664,0,1
"alafosfalin","bacterial cell wall synthesis inhibitor","","C[C@H](N)C(=O)N[C@@H](C)P(O)(O)=O, C[C@H](N)C(=O)N[C@@H](C)P(O)(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@H](N)C(=O)N[C@@H](C)P(O)(O)=O",196.061293526,12,-2.293,122.46,0.00794344742190896,0.182,0.0949717237109545,0,1
"10058-F4","c-Myc inhibitor","","CCc1ccc(\C=C2\SC(=S)NC2=O)cc1, CCc1ccc(\C=C2\SC(=S)NC2=O)cc1, CCc1ccc(\C=C2\SC(=S)NC2=O)cc1, CCc1ccc(\C=C2\SC(=S)NC2=O)cc1, CCc1ccc(\C=C2\SC(=S)NC2=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCc1ccc(\C=C2\SC(=S)NC2=O)cc1",249.028205972,16,2.623,86.49,0.0417956016218209,0.148,0.0948978008109104,0,1
"mcb-3681","other antibiotic","","CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(OCC2(O)CCN(CC2)c2cc3n(cc(C(O)=O)c(=O)c3cc2F)C2CC2)c(F)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","infectious disease","gram-positive bacterial infections","CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(OCC2(O)CCN(CC2)c2cc3n(cc(C(O)=O)c(=O)c3cc2F)C2CC2)c(F)c1",626.218820424,45,5.046,150.64,0.0017248407024231,0.188,0.0948624203512115,0,1
"repsox","TGF beta receptor inhibitor","TGFBR1","Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1",287.117095416,22,2.689,67.35,0.0997139725300792,0.09,0.0948569862650396,0,0
"vanitiolide","","","COc1cc(ccc1O)C(=S)N1CCOCC1, COc1cc(ccc1O)C(=S)N1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(ccc1O)C(=S)N1CCOCC1",253.07726434,17,1.464,74.02,0.0477039172363117,0.142,0.0948519586181559,0,1
"AZD8835","PI3K inhibitor","PIK3CA, PIK3CD","CCn1nc(nc1-c1cnc(N)c(n1)-c1nnc(o1)C(C)(C)C)C1CCN(CC1)C(=O)CCO, CCn1nc(nc1-c1cnc(N)c(n1)-c1nnc(o1)C(C)(C)C)C1CCN(CC1)C(=O)CCO, CCn1nc(nc1-c1cnc(N)c(n1)-c1nnc(o1)C(C)(C)C)C1CCN(CC1)C(=O)CCO, CCn1nc(nc1-c1cnc(N)c(n1)-c1nnc(o1)C(C)(C)C)C1CCN(CC1)C(=O)CCO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCn1nc(nc1-c1cnc(N)c(n1)-c1nnc(o1)C(C)(C)C)C1CCN(CC1)C(=O)CCO",469.254985852,34,1.073,161.97,0.00169221469212233,0.188,0.0948461073460612,0,1
"LY2090314","glycogen synthase kinase inhibitor","GSK3B","Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|, Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|, Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|, Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|, Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|",512.19721688,38,4.513,91.95,0.0176733487916748,0.172,0.0948366743958374,0,1
"L-asparagine","","ASNS, ASRGL1, NARS, NARS2, SLC1A5, SLC38A3","N[C@@H](CC(N)=O)C(O)=O",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","N[C@@H](CC(N)=O)C(O)=O",132.053492116,9,-4.435,106.41,0.0156471760893273,0.174,0.0948235880446636,0,1
"APcK-110","KIT inhibitor","KIT, STAT3","COc1cc(OC)cc(c1)-c1ccc2c([nH]nc2n1)-c1ccc(F)cc1, COc1cc(OC)cc(c1)-c1ccc2c([nH]nc2n1)-c1ccc(F)cc1, COc1cc(OC)cc(c1)-c1ccc2c([nH]nc2n1)-c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(OC)cc(c1)-c1ccc2c([nH]nc2n1)-c1ccc(F)cc1",349.122654972,26,5.27,60.03,0.123645660266158,0.066,0.0948228301330792,1,0
"SB-649868","orexin receptor antagonist","","Cc1nc(C(=O)N2CCCC[C@H]2CNC(=O)c2cccc3occc23)c(s1)-c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1nc(C(=O)N2CCCC[C@H]2CNC(=O)c2cccc3occc23)c(s1)-c1ccc(F)cc1",477.152240848,34,4.211,103.68,0.0115696861699509,0.178,0.0947848430849755,0,1
"FG-2216","hypoxia inducible factor prolyl hydroxylase inhibitor","EGLN1, EGLN2, HIF1A","OC(=O)CNC(=O)c1nc(Cl)c2ccccc2c1O, OC(=O)CNC(=O)c1nc(Cl)c2ccccc2c1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)CNC(=O)c1nc(Cl)c2ccccc2c1O",280.025084448,19,-0.0909999999999997,99.52,0.0155209052111215,0.174,0.0947604526055607,0,1
"AS-2034178","free fatty acid receptor agonist","FFAR1","OC(=O)CCc1ccc(NCc2cccc3N(CCOc4ccccc4)CCCc23)cc1F, OC(=O)CCc1ccc(NCc2cccc3N(CCOc4ccccc4)CCCc23)cc1F, OC(=O)CCc1ccc(NCc2cccc3N(CCOc4ccccc4)CCCc23)cc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)CCc1ccc(NCc2cccc3N(CCOc4ccccc4)CCCc23)cc1F",448.216221008,33,5.395,61.8,0.0615165884457835,0.128,0.0947582942228917,0,0
"MK-2461","FGFR inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB","CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1, CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1",495.1576399,35,1.975,124.03,0.00344258270056163,0.186,0.0947212913502808,0,1
"motapizone","phosphodiesterase inhibitor","","CC1=C(NNC(=O)C1)c1cc(cs1)-n1ccnc1 |t:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC1=C(NNC(=O)C1)c1cc(cs1)-n1ccnc1 |t:1|",260.073182004,18,1.392,87.19,0.0371950757822251,0.152,0.0945975378911125,0,1
"napirimus","immunosuppressant","","Cn1cc(cc1C(O)=O)C(=O)c1cccc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cn1cc(cc1C(O)=O)C(=O)c1cccc2ccccc12",279.089543276,21,3.489,59.3,0.135165363062127,0.054,0.0945826815310636,1,0
"BMS-707035","HIV integrase inhibitor","","Cn1c(nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O)N1CCCCS1(=O)=O, Cn1c(nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O)N1CCCCS1(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cn1c(nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O)N1CCCCS1(=O)=O",410.106018928,28,3.815,129.98,0.00714507818040745,0.182,0.0945725390902037,0,1
"1h,1'h-2,2'-bibenzo[d]imidazole","dna inhibitor","","c1ccc2[nH]c(nc2c1)-c1nc2ccccc2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","c1ccc2[nH]c(nc2c1)-c1nc2ccccc2[nH]1",234.09054632,18,2.578,57.36,0.16111713174351,0.028,0.0945585658717551,1,0
"IKK-2-inhibitor-V","IKK inhibitor, NFkB pathway inhibitor","IKBKB","Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F",383.014775496,25,5.488,49.33,0.0631136367473205,0.126,0.0945568183736603,0,0
"imeglimin","gluconeogenesis inhibitor","","C[C@H]1NC(=NC(N)=N1)N(C)C |c:3,6|, C[C@H]1NC(=NC(N)=N1)N(C)C |c:3,6|, C[C@H]1NC(=NC(N)=N1)N(C)C |c:3,6|, C[C@H]1NC(=NC(N)=N1)N(C)C |c:3,6|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@H]1NC(=NC(N)=N1)N(C)C |c:3",155.117095416,11,0.179,66.01,0.103047896681557,0.086,0.0945239483407786,0,0
"SU11274","hepatocyte growth factor receptor inhibitor, tyrosine kinase inhibitor","MET","CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1, CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1, CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1, CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1",567.17070312,39,3.743,114.2,0.00299874697759957,0.186,0.0944993734887998,0,1
"daphnetin","protein kinase inhibitor","","Oc1ccc2ccc(=O)oc2c1O, Oc1ccc2ccc(=O)oc2c1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc2ccc(=O)oc2c1O",178.026608672,13,1.999,70.67,0.128727176172249,0.06,0.0943635880861247,1,0
"agmatine","nitric oxide synthase inhibitor","ADRA2C, ASIC3, CACNA1B, CHRNA1, GRIN1, KCNJ1, NISCH","NCCCCNC(N)=N, NCCCCNC(N)=N, NCCCCNC(N)=N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,"phase 3","","","NCCCCNC(N)=N",130.121846448,9,-0.243,87.92,0.0667004012880092,0.122,0.0943502006440046,0,0
"gatifloxacin","bacterial DNA gyrase inhibitor","","COc1c(N2CCNC(C)C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1, COc1c(N2CCN[C@@H](C)C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1 |&1:8|, COc1c(N2CCN[C@@H](C)C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1 |&1:8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","COc1c(N2CCNC(C)C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1",375.159434404,27,4.215,83.8,0.0406868738722508,0.148,0.0943434369361254,0,1
"SR-3677","rho associated kinase inhibitor","ROCK2","CN(C)CCOc1cc(ccc1NC(=O)[C@H]1COc2ccccc2O1)-c1cn[nH]c1 |&1:15|, CN(C)CCOc1cc(ccc1NC(=O)[C@H]1COc2ccccc2O1)-c1cn[nH]c1 |&1:15|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)CCOc1cc(ccc1NC(=O)[C@H]1COc2ccccc2O1)-c1cn[nH]c1 |&1:15|",408.179755248,30,2.611,88.71,0.0226251569802774,0.166,0.0943125784901387,0,1
"JD-5037","cannabinoid receptor antagonist","","CC(C)[C@H](\N=C(\NS(=O)(=O)c1ccc(Cl)cc1)N1C[C@@H](C(=N1)c1ccc(Cl)cc1)c1ccccc1)C(N)=O |c:21|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)[C@H](\N=C(\NS(=O)(=O)c1ccc(Cl)cc1)N1C[C@@H](C(=N1)c1ccc(Cl)cc1)c1ccccc1)C(N)=O |c:21|",571.121166084,38,5.568,125.6,0.00260412072256194,0.186,0.094302060361281,0,1
"MJ-15","cannabinoid receptor antagonist","CNR1","Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NCc1cccnc1, Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NCc1cccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NCc1cccnc1",470.046794204,31,5.944,59.81,0.028553433132043,0.16,0.0942767165660215,0,1
"2'-C-methylguanosine","HCV inhibitor","","C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c1[nH]c(N)nc2=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c1[nH]c(N)nc2=O",297.10731858,21,0.258,159.51,0.00448460552047423,0.184,0.0942423027602371,0,1
"PHA-568487","nicotinic receptor agonist","CHRNA7","O=C(N[C@H]1CN2CCC1CC2)c1ccc2OCCOc2c1, O=C(N[C@H]1CN2CCC1CC2)c1ccc2OCCOc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"preclinical","","","O=C(N[C@H]1CN2CCC1CC2)c1ccc2OCCOc2c1",288.1473925,21,1.197,50.8,0.080334620317642,0.108,0.094167310158821,0,0
"freselestat","elastase inhibitor","CELA1, ELANE","CC(C)[C@@H](NC(=O)Cn1c(ncc(N)c1=O)-c1ccccc1)[C@@H](O)c1nnc(o1)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)[C@@H](NC(=O)Cn1c(ncc(N)c1=O)-c1ccccc1)[C@@H](O)c1nnc(o1)C(C)(C)C",454.23285344,33,3.154,149.16,0.0043043241502301,0.184,0.0941521620751151,0,1
"licarbazepine","voltage-gated sodium channel blocker","SCN5A","NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|, NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|, NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|, NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|, NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11",254.105527688,19,1.244,66.56,0.0802773849837606,0.108,0.0941386924918803,0,0
"isoxicam","cyclooxygenase inhibitor","PTGS1, PTGS2","CN1C(C(=O)Nc2cc(C)on2)=C(O)c2ccccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2cc(C)on2)=C(O)c2ccccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2cc(C)on2)=C(O)c2ccccc2S1(=O)=O |t:12|",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CN1C(C(=O)Nc2cc(C)on2)=C(O)c2ccccc2S1(=O)=O |t:12|",335.057591516,23,2.575,121.12,0.0122398578695363,0.176,0.0941199289347681,0,1
"hydroxytyrosol","lipoxygenase inhibitor","ALOX5","OC1=CC=C(CCO)C=C1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","oncology","breast cancer","OC1=CC=C(CCO)C=C1O",154.06299418,11,0.117,60.69,0.116039614435834,0.072,0.0940198072179169,1,0
"echinomycin","DNA intercalating agent","","[H][C@]1(COC(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@]2([H])N(C)C(=O)[C@H](C)NC(=O)[C@@]([H])(COC(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@]([H])(CS[C@]2([H])SC)N(C)C(=O)[C@H](C)NC1=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1 |&1:45,@:8,34|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","[H][C@]1(COC(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@]2([H])N(C)C(=O)[C@H](C)NC(=O)[C@@]([H])(COC(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@]([H])(CS[C@]2([H])SC)N(C)C(=O)[C@H](C)NC1=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1 |&1:45",1100.420807488,84,2.353,352.4,7.91088946659964e-07,0.188,0.0940003955444733,0,1
"paraxanthine","adenosine receptor antagonist","","Cn1cnc2[nH]c(=O)n(C)c(=O)c12, Cn1cnc2[nH]c(=O)n(C)c(=O)c12, Cn1cnc2[nH]c(=O)n(C)c(=O)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cn1cnc2[nH]c(=O)n(C)c(=O)c12",180.064725496,13,0.85,72.68,0.092000437260356,0.096,0.094000218630178,0,0
"ICI-63197","phosphodiesterase inhibitor","","CCCn1c2nc(N)nn2cc(C)c1=O, CCCn1c2nc(N)nn2cc(C)c1=O, CCCn1c2nc(N)nn2cc(C)c1=O, CCCn1c2nc(N)nn2cc(C)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCn1c2nc(N)nn2cc(C)c1=O",207.112010036,15,1.038,78.21,0.0719341361811883,0.116,0.0939670680905941,0,0
"hPGDS-IN-1","prostaglandin inhibitor","","CC(C)(O)c1nc(no1)-c1cccc(CNC(=O)c2cnc(nc2)-c2ccccn2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(O)c1nc(no1)-c1cccc(CNC(=O)c2cnc(nc2)-c2ccccn2)c1",416.1596885,31,1.674,126.92,0.00783069396165384,0.18,0.0939153469808269,0,1
"CHF5074","gamma secretase modulator","PSEN1","OC(=O)C1(CC1)c1ccc(c(F)c1)-c1ccc(Cl)c(Cl)c1, OC(=O)C1(CC1)c1ccc(c(F)c1)-c1ccc(Cl)c(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)C1(CC1)c1ccc(c(F)c1)-c1ccc(Cl)c(Cl)c1",324.012013172,21,5.378,37.3,0.123821691892203,0.064,0.0939108459461014,1,0
"BMS-986205","indoleamine 2,3-dioxygenase inhibitor","","[H][C@]1(CC[C@@H](CC1)c1ccnc2ccc(F)cc12)[C@@H](C)C(=O)Nc1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","[H][C@]1(CC[C@@H](CC1)c1ccnc2ccc(F)cc12)[C@@H](C)C(=O)Nc1ccc(Cl)cc1",410.156119288,30,6.532,41.99,0.145779531365732,0.042,0.0938897656828662,1,0
"carboxylosartan","angiotensin antagonist","AGTR1","CCCCc1nc(Cl)c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCCCc1nc(Cl)c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1",436.141451592,31,6.568,109.58,0.0237283566706974,0.164,0.0938641783353487,0,1
"tegaserod","serotonin receptor partial agonist","HTR2A, HTR2B, HTR2C, HTR4","CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12, CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12, CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12, CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12, CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12",0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12",301.190260356,22,4.858,85.29,0.0816060011020843,0.106,0.0938030005510421,0,0
"Ro-67-7476","glutamate receptor positive allosteric modulator","GRM1","Cc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1c1ccc(F)cc1, Cc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1c1ccc(F)cc1",319.104228036,22,4.027,45.76,0.105601472468039,0.082,0.0938007362340193,0,0
"daminozide","KDM2A inhibitor","KDM2A, KDM7A, PHF8","CN(C)NC(=O)CCC(O)=O, CN(C)NC(=O)CCC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)NC(=O)CCC(O)=O",160.084792244,11,-1.139,69.64,0.0635624598951964,0.124,0.0937812299475982,0,0
"valdecoxib","cyclooxygenase inhibitor","CA12, PTGS2","Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1, Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1, Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1, Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1",314.072513308,22,3.155,94.57,0.0335160126184434,0.154,0.0937580063092217,0,1
"YO-01027","gamma secretase inhibitor","","C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O",463.170748036,34,4.061,78.51,0.0274725527804096,0.16,0.0937362763902048,0,1
"STA-5326","interleukin synthesis inhibitor","IL12A","Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1",418.211724072,31,5.218,84.76,0.0454713905567415,0.142,0.0937356952783708,0,1
"BMS-566419","inosine monophosphate dehydrogenase inhibitor","IMPDH1, IMPDH2","CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F, CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F, CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F, CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F, CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F",487.23835342,36,5.861,81.33,0.035396577902748,0.152,0.093698288951374,0,1
"BE-2254","adrenergic receptor antagonist","ADRA1A","Oc1ccc(CCNC[C@H]2CCc3ccccc3C2=O)cc1 |r|, Oc1ccc(CCNC[C@H]2CCc3ccccc3C2=O)cc1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"phase 2","","","Oc1ccc(CCNC[C@H]2CCc3ccccc3C2=O)cc1 |r|",295.157228912,22,3.519,49.33,0.145382834477657,0.042,0.0936914172388287,1,0
"ritanserin","serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7","Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1",0,0,0,0,0,0,0,0,1,9,0,0,0,0,0,0,0,0,1,3,0,0,0,0,"phase 3","","","Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1",477.16863986,34,5.74,65.85,0.0393153624048157,0.148,0.0936576812024079,0,1
"CTEP","glutamate receptor antagonist","GRM5","Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1, Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1, Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1, Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1",391.069924376,27,5.854,39.94,0.10698965332645,0.08,0.0934948266632248,0,0
"skepinone-L","p38 MAPK inhibitor","MAPK14","OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1, OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1, OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1, OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1",425.143864592,31,3.968,78.79,0.0329863746923112,0.154,0.0934931873461556,0,1
"rilapladib","phospholipase inhibitor","","COCCN1CCC(CC1)N(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c(SCc2cccc(F)c2F)cc(=O)c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COCCN1CCC(CC1)N(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c(SCc2cccc(F)c2F)cc(=O)c2ccccc12",735.255404176,52,10.015,80.08,0.0109854769526421,0.176,0.093492738476321,0,1
"CCT245737","kinase inhibitor","","FC(F)(F)c1cnc(Nc2cnc(cn2)C#N)cc1NC[C@H]1CNCCO1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)c1cnc(Nc2cnc(cn2)C#N)cc1NC[C@H]1CNCCO1",379.136842792,27,0.568,107.78,0.00895999016011107,0.178,0.0934799950800555,0,1
"FT011","TGF beta receptor inhibitor","","COc1cc(\C=C\C(=O)Nc2ccccc2C(O)=O)ccc1OCC#C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(\C=C\C(=O)Nc2ccccc2C(O)=O)ccc1OCC#C",351.110672644,26,3.139,84.86,0.042931328175532,0.144,0.093465664087766,0,1
"F-11440","serotonin receptor agonist","HTR1A","Cn1c(=O)cnn(CCCCN2CCN(CC2)c2ncccn2)c1=O, Cn1c(=O)cnn(CCCCN2CCN(CC2)c2ncccn2)c1=O",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cn1c(=O)cnn(CCCCN2CCN(CC2)c2ncccn2)c1=O",345.191322976,25,1.265,89.15,0.0229246665347518,0.164,0.0934623332673759,0,1
"CKD-712","NFkB pathway inhibitor","JAK2, STAT1","Oc1cc2CCN[C@@H](Cc3cccc4ccccc34)c2cc1O |&1:7|, Oc1cc2CCN[C@@H](Cc3cccc4ccccc34)c2cc1O |&1:7|, Oc1cc2CCN[C@@H](Cc3cccc4ccccc34)c2cc1O |&1:7|, Oc1cc2CCN[C@@H](Cc3cccc4ccccc34)c2cc1O |&1:7|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Oc1cc2CCN[C@@H](Cc3cccc4ccccc34)c2cc1O |&1:7|",305.141578848,23,3.966,52.49,0.148910542980087,0.038,0.0934552714900435,1,0
"EPZ011989","histone lysine methyltransferase inhibitor","EZH2","CCN([C@H]1CC[C@@H](CC1)N(C)CCOC)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C#CCN1CCOCC1 |r|, CCN([C@H]1CC[C@@H](CC1)N(C)CCOC)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C#CCN1CCOCC1 |r|, CCN([C@H]1CC[C@@H](CC1)N(C)CCOC)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C#CCN1CCOCC1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN([C@H]1CC[C@@H](CC1)N(C)CCOC)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C#CCN1CCOCC1 |r|",605.394105112,44,4.94,90.14,0.00886404673294469,0.178,0.0934320233664723,0,1
"MDL-27531","glycine receptor agonist","","Cn1c(nnc1S(C)(=O)=O)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cn1c(nnc1S(C)(=O)=O)-c1ccccc1",237.057197592,16,2.837,73.23,0.0768356472185682,0.11,0.0934178236092841,0,0
"PZ-2891","pantothenate kinase activator","","CC(C)c1ccc(CC(=O)N2CCN(CC2)c2ccc(nn2)C#N)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)c1ccc(CC(=O)N2CCN(CC2)c2ccc(nn2)C#N)cc1",349.190260356,26,3.175,73.12,0.0585601162831586,0.128,0.0932800581415793,0,0
"sofosbuvir-impurity-m","antiviral","","CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@@](C)(O)[C@@H]1O)Oc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@@](C)(O)[C@@H]1O)Oc1ccccc1",527.16688079,36,1.209,188.22,0.000378464376000218,0.186,0.0931892321880001,0,1
"LMI070","survival motor neuron protein modulator","SMN1","CC1(C)CC(CC(C)(C)N1)Oc1ccc(nn1)-c1ccc(cc1O)-c1cn[nH]c1, CC1(C)CC(CC(C)(C)N1)Oc1ccc(nn1)-c1ccc(cc1O)-c1cn[nH]c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","CC1(C)CC(CC(C)(C)N1)Oc1ccc(nn1)-c1ccc(cc1O)-c1cn[nH]c1",393.216475104,29,4.745,95.95,0.0361649313631415,0.15,0.0930824656815708,0,1
"saredutant","neurokinin receptor antagonist","TACR2","CC(NC1(C2=CC=CC=C2)CCN(CC[C@@H](C3=CC(Cl)=C(Cl)C=C3)CN(C)C(C4=CC=CC=C4)=O)CC1)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"phase 3","neurology/psychiatry","depression","CC(NC1(C2=CC=CC=C2)CCN(CC[C@@H](C3=CC(Cl)=C(Cl)C=C3)CN(C)C(C4=CC=CC=C4)=O)CC1)=O",551.21063272,38,3.654,52.65,0.0140592789089665,0.172,0.0930296394544832,0,1
"sobetirome","thyroid hormone receptor agonist","THRA, THRB","CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O",328.167459248,24,4.947,66.76,0.104009049754621,0.082,0.0930045248773104,0,0
"YM-511","aromatase inhibitor","CYP19A1","Brc1ccc(CN(c2ccc(cc2)C#N)n2cnnc2)cc1, Brc1ccc(CN(c2ccc(cc2)C#N)n2cnnc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Brc1ccc(CN(c2ccc(cc2)C#N)n2cnnc2)cc1",353.027607484,22,3.988,57.74,0.0378735853574369,0.148,0.0929367926787185,0,1
"ruxolitinib-(S)","JAK inhibitor","JAK1, JAK2","N#CC[C@@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N#CC[C@@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12",306.159294576,23,2.696,83.18,0.0578378226095279,0.128,0.0929189113047639,0,0
"bonaphthone","","","Brc1ccc2C(=O)C(=O)C=Cc2c1 |c:9|, Brc1ccc2C(=O)C(=O)C=Cc2c1 |c:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Brc1ccc2C(=O)C(=O)C=Cc2c1 |c:9|",235.9472915,13,2.238,34.14,0.0838116594243564,0.102,0.0929058297121782,0,0
"azvudine (hydrochloride)","nucleoside reverse transcriptase inhibitor","","Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2F)c(=O)n1.Cl |a:5,7,13,15|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","infectious disease","human immunodeficiency virus (hiv-1)","Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2F)c(=O)n1.Cl |a:5",322.059258764,21,0.29,122.96,0.00580030631345564,0.18,0.0929001531567278,0,1
"BL-5583","hypercalcaemic agent","","OC(=O)c1cc2ccccc2s1, OC(=O)c1cc2ccccc2s1, OC(=O)c1cc2ccccc2s1, OC(=O)c1cc2ccccc2s1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1cc2ccccc2s1",178.008850432,12,2.037,65.54,0.117737862030724,0.068,0.092868931015362,1,0
"CPCCOEt","glutamate receptor antagonist","GRM1","CCOC(=O)[C@]12C[C@H]1\C(=N/O)c1ccccc1O2 |&1:5,7,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)[C@]12C[C@H]1\C(=N/O)c1ccccc1O2 |&1:5",247.084457896,18,1.611,68.12,0.0796369794660929,0.106,0.0928184897330465,0,0
"cimlanod","nitric oxide donor","","Cc1oc(cc1)S(=O)(=O)NO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","cardiology","congestive heart failure","Cc1oc(cc1)S(=O)(=O)NO",177.009578704,11,-0.25,87.92,0.0355561495305199,0.15,0.0927780747652599,0,1
"AZD1208","Pim kinase inhibitor","PIM1, PIM2, PIM3","N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1, N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1, N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1, N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1, N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1",379.135447912,27,3.507,100.73,0.0214248438802896,0.164,0.0927124219401448,0,1
"TS-011","delayed vasospasm antagonist","","[O-][N+]CNc1ccc(N2CCOCC2)c(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[O-][N+]CNc1ccc(N2CCOCC2)c(Cl)c1",255.077454368,17,1.592,47.56,0.0834119839596982,0.102,0.0927059919798491,0,0
"RS-67333","serotonin receptor partial agonist","HTR4","CCCCN1CCC(CCC(=O)c2cc(Cl)c(N)cc2OC)CC1, CCCCN1CCC(CCC(=O)c2cc(Cl)c(N)cc2OC)CC1, CCCCN1CCC(CCC(=O)c2cc(Cl)c(N)cc2OC)CC1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCN1CCC(CCC(=O)c2cc(Cl)c(N)cc2OC)CC1",352.191755848,24,3.748,55.56,0.0593926866984816,0.126,0.0926963433492408,0,0
"GSK2256098","kinase inhibitor","","CONC(=O)c1ccccc1Nc1cc(Nc2cc(C)nn2C(C)C)ncc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CONC(=O)c1ccccc1Nc1cc(Nc2cc(C)nn2C(C)C)ncc1Cl",414.157101656,29,4.666,93.1,0.0232748445760796,0.162,0.0926374222880398,0,1
"MDL-73005EF","serotonin receptor antagonist","HTR1A","O=C1CC2(CCCC2)CC(=O)N1CCNC[C@H]1COc2ccccc2O1 |&1:16|, O=C1CC2(CCCC2)CC(=O)N1CCNC[C@H]1COc2ccccc2O1 |&1:16|",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","O=C1CC2(CCCC2)CC(=O)N1CCNC[C@H]1COc2ccccc2O1 |&1:16|",358.189257312,26,2.257,67.87,0.0432722183050233,0.142,0.0926361091525116,0,1
"Ro-04-5595","glutamate receptor antagonist","GRIN2B","COc1cc2CCN(C)[C@@H](CCc3ccc(Cl)cc3)c2cc1O |&1:9|, COc1cc2CCN(C)[C@@H](CCc3ccc(Cl)cc3)c2cc1O |&1:9|, COc1cc2CCN(C)[C@@H](CCc3ccc(Cl)cc3)c2cc1O |&1:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2CCN(C)[C@@H](CCc3ccc(Cl)cc3)c2cc1O |&1:9|",331.133906624,23,3.811,32.7,0.125221744782698,0.06,0.0926108723913489,1,0
"SB-268262","calcitonin antagonist","CALCA","CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13,r|, CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13,r|, CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13,r|, CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13,r|, CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13",401.05039796,27,1.624,140.86,0.00321153976806803,0.182,0.092605769884034,0,1
"H-151","STING antagonist","","CCc1ccc(NC(=O)Nc2c[nH]c3ccccc23)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCc1ccc(NC(=O)Nc2c[nH]c3ccccc23)cc1",279.137162164,21,3.861,56.92,0.153066831378687,0.032,0.0925334156893435,1,0
"omaciclovir","dna polymerase inhibitor","","Nc1nc(=O)c2ncn(C[C@H](CO)CCO)c2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","infectious disease","virus herpes simplex (hsv)","Nc1nc(=O)c2ncn(C[C@H](CO)CCO)c2[nH]1",253.11748934,18,0.397,130.05,0.0130598276219374,0.172,0.0925299138109687,0,1
"9-aminocamptothecin","topoisomerase inhibitor","TOP1","CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc(N)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc(N)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc(N)c4cc3Cn1c2=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc(N)c4cc3Cn1c2=O",363.121906024,27,2.091,107.44,0.019047715049791,0.166,0.0925238575248955,0,1
"3,4-methylenedioxy-beta-nitrostyrene","SRC inhibitor, SYK inhibitor","SRC, SYK","[O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[O-][N+](=O)\C=C\c1ccc2OCOc2c1",193.037507704,14,1.676,61.6,0.129015144092071,0.056,0.0925075720460356,1,0
"WAY-255348","progesterone receptor antagonist","","Cn1c(ccc1-c1cc2c(NC(=O)C2(C)C)c(F)c1)C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cn1c(ccc1-c1cc2c(NC(=O)C2(C)C)c(F)c1)C#N",283.112090288,21,2.658,57.82,0.106999695804442,0.078,0.0924998479022211,0,0
"grepafloxacin","bacterial dna gyrase inhibitor","","O=C(O)\C2=C\N(c1cc(c(F)c(c1C2=O)C)N3CC(NCC3)C)C4CC4",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","infectious disease","gonorrhea","O=C(O)\C2=C\N(c1cc(c(F)c(c1C2=O)C)N3CC(NCC3)C)C4CC4",359.164519784,26,3.178,72.88,0.0469966097222487,0.138,0.0924983048611244,0,1
"eticlopride","dopamine receptor antagonist","DRD2, DRD3, DRD4","CCN1CCC[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,"preclinical","","","CCN1CCC[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC",340.15537034,23,3.925,61.8,0.0569874619507061,0.128,0.092493730975353,0,0
"tegobuvir","HCV inhibitor, protease inhibitor","","Fc1ccccc1-c1nc2ccn(Cc3ccc(nn3)-c3ccc(cc3C(F)(F)F)C(F)(F)F)cc2n1, Fc1ccccc1-c1nc2ccn(Cc3ccc(nn3)-c3ccc(cc3C(F)(F)F)C(F)(F)F)cc2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Fc1ccccc1-c1nc2ccn(Cc3ccc(nn3)-c3ccc(cc3C(F)(F)F)C(F)(F)F)cc2n1",517.113742988,37,7.039,56.49,0.0509728914161562,0.134,0.0924864457080781,0,1
"BTS","","","Cc1ccc(cc1)S(=O)(=O)NCc1ccccc1, Cc1ccc(cc1)S(=O)(=O)NCc1ccccc1, Cc1ccc(cc1)S(=O)(=O)NCc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(cc1)S(=O)(=O)NCc1ccccc1",261.08234972,18,3.018,54.55,0.106954176159714,0.078,0.0924770880798569,0,0
"AMG-208","tyrosine kinase inhibitor","MET","COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1, COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1",383.138224784,29,5.627,74.43,0.0889440671529515,0.096,0.0924720335764758,0,0
"ABT-724","dopamine receptor agonist","DRD4","C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1, C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1, C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1, C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,"phase 2","","","C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1",293.164045608,22,2.485,48.05,0.124815063515974,0.06,0.092407531757987,1,0
"petesicatib","cathepsin inhibitor","CTSS, CTSV","O=C(N1[C@@H](C[C@@H](S(=O)(C2=C(C=C(C3=CN(C)N=C3)C=C2)C(F)(F)F)=O)C1)C(NC4(CC4)C#N)=O)C5(CC5)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","rheumatology","sjogren's syndrome","O=C(N1[C@@H](C[C@@H](S(=O)(C2=C(C=C(C3=CN(C)N=C3)C=C2)C(F)(F)F)=O)C1)C(NC4(CC4)C#N)=O)C5(CC5)C(F)(F)F",603.137494536,41,1.595,131.32,0.000800510229875435,0.184,0.0924002551149377,0,1
"NMS-873","ATPase inhibitor","VCP","Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O, Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O",520.160282756,36,6.983,120.65,0.00876150409571418,0.176,0.0923807520478571,0,1
"evacetrapib","cholesteryl ester transfer protein inhibitor","CETP","Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1, Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1, Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1, Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1",638.280393712,45,8.441,87.38,0.0127435324494063,0.172,0.0923717662247032,0,1
"G-15","estrogen receptor antagonist","GPER1","Brc1cc2OCOc2cc1[C@H]1Nc2ccccc2[C@H]2C=CC[C@@H]12 |&1:10,18,22,c:22|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Brc1cc2OCOc2cc1[C@H]1Nc2ccccc2[C@H]2C=CC[C@@H]12 |&1:10",369.036440852,23,4.596,30.49,0.0687316623249919,0.116,0.0923658311624959,0,0
"NNC-711","GABA uptake inhibitor","SIGMAR1, SLC6A1","OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1 |t:3|, OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1 |t:3|, OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1 |t:3|",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1 |t:3|",350.163042564,26,4.055,62.13,0.0886717076906343,0.096,0.0923358538453171,0,0
"HSR6071","antiallergic agent","","O=C(Nc1nnn[nH]1)c1cncc(n1)N1CCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(Nc1nnn[nH]1)c1cncc(n1)N1CCCC1",260.113407004,19,1.445,112.58,0.0266019942790919,0.158,0.092300997139546,0,1
"lmp744 hydrochloride","topoisomerase inhibitor","TOP1","COc1cc2c3C(=O)c4cc5OCOc5cc4-c3n(CCCNCCO)c(=O)c2cc1OC.Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","ovarian cancer","COc1cc2c3C(=O)c4cc5OCOc5cc4-c3n(CCCNCCO)c(=O)c2cc1OC.Cl",488.13502882,34,3.374,108.25,0.00655076797687101,0.178,0.0922753839884355,0,1
"amuvatinib","FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAD51 inhibitor, RET tyrosine kinase inhibitor","KIT, MET","S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12",447.136510532,32,3.861,107.98,0.012413477120073,0.172,0.0922067385600365,0,1
"zamifenacin","acetylcholine receptor antagonist","CHRM3","C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1, C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1, C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"phase 3","","","C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1",415.214743788,31,5.058,30.93,0.146316815134387,0.038,0.0921584075671937,1,0
"NNC-05-2090","GABA uptake inhibitor, GAT inhibitor","SLC6A12","COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1",414.2307282,31,5.258,37.63,0.136281785054591,0.048,0.0921408925272955,1,0
"cintirorgon","ROR agonist","","CC(C)(C[C@H]1CN(c2cc(ccc2O1)-c1cc(F)cc(OC(F)F)c1)S(=O)(=O)c1cccc(c1)C(F)(F)F)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","CC(C)(C[C@H]1CN(c2cc(ccc2O1)-c1cc(F)cc(OC(F)F)c1)S(=O)(=O)c1cccc(c1)C(F)(F)F)C(O)=O",603.115027776,41,7.187,101.52,0.00626621328644349,0.178,0.0921331066432217,0,1
"talnetant","tachykinin antagonist","TACR2, TACR3","CC[C@H](NC(=O)c1c(O)c(nc2ccccc12)-c1ccccc1)c1ccccc1, CC[C@H](NC(=O)c1c(O)c(nc2ccccc12)-c1ccccc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC[C@H](NC(=O)c1c(O)c(nc2ccccc12)-c1ccccc1)c1ccccc1",382.168127944,29,6.605,62.22,0.14425077492526,0.04,0.0921253874626298,1,0
"MEK1-2-inhibitor","MEK inhibitor","MAP2K2","Nc1ccc(SC(=N)C(C#N)c2ccccc2C(F)(F)F)cc1, Nc1ccc(SC(=N)C(C#N)c2ccccc2C(F)(F)F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1ccc(SC(=N)C(C#N)c2ccccc2C(F)(F)F)cc1",335.070403044,23,3.647,98.96,0.0262282083550032,0.158,0.0921141041775016,0,1
"rs0481","immunostimulant","","C[C@@H](NC(=O)[C@@H]1CSCN1C(=O)c1ccccc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@@H](NC(=O)[C@@H]1CSCN1C(=O)c1ccccc1)c1ccccc1",340.12454888,24,3.483,74.71,0.0482095905915701,0.136,0.0921047952957851,0,1
"3-benzoyl-n-(1-phenylethyl)thiazolidine-4-carboxamide","","","C[C@@H](NC(=O)[C@H]1CSCN1C(=O)c1ccccc1)c1ccccc1 |&1:1,&2:5,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","C[C@@H](NC(=O)[C@H]1CSCN1C(=O)c1ccccc1)c1ccccc1 |&1:1",340.12454888,24,3.483,74.71,0.0482095905915701,0.136,0.0921047952957851,0,1
"micafungin (sodium)","","","CCCCCOc1ccc(cc1)-c1cc(no1)-c1ccc(cc1)C(=O)NC1C[C@@H](O)[C@@H](O)NC(=O)C2[C@@H](O)[C@@H](C)CN2C(=O)C(NC(=O)C(NC(=O)C2C[C@@H](O)CN2C(=O)C(NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)c(OS(O)(=O)=O)c1)[C@H](O)CC(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CCCCCOc1ccc(cc1)-c1cc(no1)-c1ccc(cc1)C(=O)NC1C[C@@H](O)[C@@H](O)NC(=O)C2[C@@H](O)[C@@H](C)CN2C(=O)C(NC(=O)C(NC(=O)C2C[C@@H](O)CN2C(=O)C(NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)c(OS(O)(=O)=O)c1)[C@H](O)CC(N)=O",1269.438350532,89,0.462999999999999,518.52,5.88369722741145e-10,0.184,0.0920000002941849,0,1
"NMS-1286937","PLK inhibitor","FLT3, PLK1, PLK2, PLK3","CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1",532.215821384,38,1.5,134.66,0.00197388023532095,0.182,0.0919869401176605,0,1
"SPP301","endothelin receptor antagonist","EDNRA","COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(nc1OC)-c1ccncc1, COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(nc1OC)-c1ccncc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(nc1OC)-c1ccncc1",479.126339772,34,2.761,133.8,0.00387664312266326,0.18,0.0919383215613316,0,1
"1-azakenpaullone","glycogen synthase kinase inhibitor","CCNB1, CDK1, CDK5, GSK3B","Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1",327.00072404,20,2.601,57.78,0.0318409084992633,0.152,0.0919204542496317,0,1
"KAF-156","antimalarial agent","","CC1(C)N(CCn2c(Nc3ccc(F)cc3)c(nc12)-c1ccc(F)cc1)C(=O)CN",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC1(C)N(CCn2c(Nc3ccc(F)cc3)c(nc12)-c1ccc(F)cc1)C(=O)CN",411.187066796,30,4.092,76.18,0.0397751031395048,0.144,0.0918875515697524,0,1
"ccr2 antagonist 3","potassium channel blocker","KCNJ3","CC1=C(F)C=CC(C(N(C)[C@@H](C(C)C)CN2CC(O)C2)=O)=C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","cardiology","cardiac arrythmia","CC1=C(F)C=CC(C(N(C)[C@@H](C(C)C)CN2CC(O)C2)=O)=C1",308.19000626,22,0.664,43.78,0.0657064588461529,0.118,0.0918532294230764,0,0
"Ro-20-1724","phosphodiesterase inhibitor","PDE3A, PDE4A, PDE4B, PDE4C, PDE4D","CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|, CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|, CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|, CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|, CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9",278.163042564,20,1.957,59.59,0.0796678689432581,0.104,0.091833934471629,0,0
"U-0521","catechol O methyltransferase inhibitor","COMT","CC(C)C(=O)c1ccc(O)c(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)C(=O)c1ccc(O)c(O)c1",180.078644244,13,1.794,57.53,0.153554710405253,0.03,0.0917773552026263,1,0
"TC-I-2014","transient receptor potential channel antagonist","TRPM8","FC(F)(F)c1ccccc1-c1cc(c2[nH]c(nc2c1)C1=NOC2(C1)CCCCC2)C(F)(F)F |t:22|, FC(F)(F)c1ccccc1-c1cc(c2[nH]c(nc2c1)C1=NOC2(C1)CCCCC2)C(F)(F)F |t:22|, FC(F)(F)c1ccccc1-c1cc(c2[nH]c(nc2c1)C1=NOC2(C1)CCCCC2)C(F)(F)F |t:22|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)c1ccccc1-c1cc(c2[nH]c(nc2c1)C1=NOC2(C1)CCCCC2)C(F)(F)F |t:22|",467.143231548,33,7.277,50.27,0.0795458813939162,0.104,0.0917729406969581,0,0
"tenalisib","PI3K inhibitor","","CC[C@H](Nc1ncnc2nc[nH]c12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC[C@H](Nc1ncnc2nc[nH]c12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1",415.144453036,31,5.449,96.7,0.0395083423645425,0.144,0.0917541711822713,0,1
"asciminib","Bcr-Abl kinase inhibitor","","O[C@@H]1CCN(C1)c1ncc(cc1-c1cc[nH]n1)C(=O)Nc1ccc(OC(F)(F)Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O[C@@H]1CCN(C1)c1ncc(cc1-c1cc[nH]n1)C(=O)Nc1ccc(OC(F)(F)Cl)cc1",449.106623556,31,4.206,103.37,0.0114017029792817,0.172,0.0917008514896408,0,1
"TCS-359","FLT3 inhibitor","FLT3","COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O",360.11437812,25,1.823,118.89,0.00936152194656809,0.174,0.091680760973284,0,1
"metamizole","cyclooxygenase inhibitor, opioid receptor agonist","PTGS1","CN(CS(O)(=O)=O)c1c(C)n(C)n(-c2ccccc2)c1=O, CN(CS(O)(=O)=O)c1c(C)n(C)n(-c2ccccc2)c1=O",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CN(CS(O)(=O)=O)c1c(C)n(C)n(-c2ccccc2)c1=O",311.093977024,21,0.385,92.92,0.0153355906603894,0.168,0.0916677953301947,0,1
"WY-16922","histamine release inhibitor","","CCOC(=O)C(=O)Nc1cccc(OC)c1C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCOC(=O)C(=O)Nc1cccc(OC)c1C(N)=O",266.090271548,19,0.643,107.72,0.0213153079643259,0.162,0.0916576539821629,0,1
"isobutamben","local anesthetic","","CC(C)COC(=O)c1ccc(N)cc1, CC(C)COC(=O)c1ccc(N)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)COC(=O)c1ccc(N)cc1",193.11027872,14,2.219,52.32,0.173203209693282,0.01,0.0916016048466408,1,0
"AL-8697","p38 MAPK inhibitor","MAPK14","Cc1c(F)cc(cc1-c1c(F)cn2c(nnc2c1F)C(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1c(F)cn2c(nnc2c1F)C(C)(C)C)C(=O)NC1CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1c(F)cc(cc1-c1c(F)cn2c(nnc2c1F)C(C)(C)C)C(=O)NC1CC1",402.166745952,29,6.355,59.29,0.0951774548515654,0.088,0.0915887274257827,0,0
"GDC-0077","PI3K inhibitor","","C[C@H](Nc1ccc2-c3nc(cn3CCOc2c1)N1[C@@H](COC1=O)C(F)F)C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@H](Nc1ccc2-c3nc(cn3CCOc2c1)N1[C@@H](COC1=O)C(F)F)C(N)=O",407.140510528,29,2.697,111.71,0.0111675258255363,0.172,0.0915837629127681,0,1
"etrasimod","sphingosine 1-phosphate receptor antagonist","","OC(=O)C[C@H]1CCc2c1[nH]c1ccc(OCc3ccc(C4CCCC4)c(c3)C(F)(F)F)cc21",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","OC(=O)C[C@H]1CCc2c1[nH]c1ccc(OCc3ccc(C4CCCC4)c(c3)C(F)(F)F)cc21",457.186478352,33,6.563,62.32,0.0650722081956975,0.118,0.0915361040978487,0,0
"PDD-00017273","PARG inhibitor","","Cc1cc(Cn2c3ccc(cc3c(=O)n(Cc3cnc(C)s3)c2=O)S(=O)(=O)NC2(C)CC2)n(C)n1, Cc1cc(Cn2c3ccc(cc3c(=O)n(Cc3cnc(C)s3)c2=O)S(=O)(=O)NC2(C)CC2)n(C)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(Cn2c3ccc(cc3c(=O)n(Cc3cnc(C)s3)c2=O)S(=O)(=O)NC2(C)CC2)n(C)n1",514.145695312,35,2.101,157.5,0.00104039122125244,0.182,0.0915201956106262,0,1
"20-HETE","ion channel antagonist","","OCCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OCCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O",320.235144884,23,6.584,57.53,0.170982244336803,0.012,0.0914911221684017,1,0
"relugolix","gonadotropin releasing factor hormone receptor antagonist","","CONC(=O)Nc1ccc(cc1)-c1sc2n(Cc3c(F)cccc3F)c(=O)n(-c3ccc(OC)nn3)c(=O)c2c1CN(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CONC(=O)Nc1ccc(cc1)-c1sc2n(Cc3c(F)cccc3F)c(=O)n(-c3ccc(OC)nn3)c(=O)c2c1CN(C)C",623.176244404,44,4.281,160.85,0.000964486469648521,0.182,0.0914822432348243,0,1
"cytochlor","","","Nc1nc(=O)n(cc1Cl)[C@H]1C[C@@H](O)[C@@H](CO)O1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Nc1nc(=O)n(cc1Cl)[C@H]1C[C@@H](O)[C@@H](CO)O1",261.051633544,17,0.238,110.6,0.0129539707836634,0.17,0.0914769853918317,0,1
"acifran","cholesterol inhibitor","HCAR2, HCAR3","C[C@]1(OC(=CC1=O)C(O)=O)c1ccccc1 |&1:1,r,c:3|, C[C@]1(OC(=CC1=O)C(O)=O)c1ccccc1 |&1:1,r,c:3|, C[C@]1(OC(=CC1=O)C(O)=O)c1ccccc1 |&1:1,r,c:3|, C[C@]1(OC(=CC1=O)C(O)=O)c1ccccc1 |&1:1,r,c:3|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C[C@]1(OC(=CC1=O)C(O)=O)c1ccccc1 |&1:1",218.0579088,16,1.637,63.6,0.108807290921582,0.074,0.091403645460791,0,0
"CCG-63802","G protein signaling inhibitor","RGS4","Cc1cccc(Oc2nc3c(C)cccn3c(=O)c2\C=C(/C#N)c2nc3ccccc3s2)c1, Cc1cccc(Oc2nc3c(C)cccn3c(=O)c2\C=C(/C#N)c2nc3ccccc3s2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cccc(Oc2nc3c(C)cccn3c(=O)c2\C=C(/C#N)c2nc3ccccc3s2)c1",450.115046816,33,5.401,108.52,0.0207956528991012,0.162,0.0913978264495506,0,1
"strychnine","acetylcholine receptor antagonist","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA10, CHRNA9, GLRA1, GLRA2, GLRA3, GLRB","O=C1CC2OCC=C3CN4CC[C@@]56C4C[C@@H]3[C@@H]2C5N1c1ccccc61, O=C1C[C@@H]2OCC=C3CN4CC[C@@]56[C@@H]4C[C@@H]3[C@@H]2[C@@H]5N1c1ccccc61 |t:6|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,7,0,0,0,0,0,0,"preclinical","","","O=C1CC2OCC=C3CN4CC[C@@]56C4C[C@@H]3[C@@H]2C5N1c1ccccc61",334.168127944,25,0.565,32.78,0.0867739939683919,0.096,0.0913869969841959,0,0
"GPi-688","glycogen phosphorylase inhibitor","","OC[C@H](O)CN1C(=O)[C@@H](Cc2ccccc12)NC(=O)c1cc2cc(Cl)sc2[nH]1 |a:2,&1:8|, OC[C@H](O)CN1C(=O)[C@@H](Cc2ccccc12)NC(=O)c1cc2cc(Cl)sc2[nH]1 |a:2,&1:8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC[C@H](O)CN1C(=O)[C@@H](Cc2ccccc12)NC(=O)c1cc2cc(Cl)sc2[nH]1 |a:2",419.070654736,28,1.064,133.9,0.00269345952388191,0.18,0.091346729761941,0,1
"PSI-6130","RNA polymerase inhibitor","","C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O, C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O",259.096834148,18,0.155,110.6,0.0166838133284737,0.166,0.0913419066642368,0,1
"orantinib","FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","AURKA, AURKB, EGFR, FGFR1, FGFR2, KDR, PDGFRA, PDGFRB","Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O",310.131742436,23,1.879,82.19,0.0446602375686923,0.138,0.0913301187843462,0,1
"SGS-742","GABA receptor antagonist","GABBR1, GABBR2","CCCCP(O)(=O)CCCN",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCP(O)(=O)CCCN",179.107515446,11,0.545,73.13,0.0566415857299278,0.126,0.0913207928649639,0,0
"sudan-IV","","","Cc1ccccc1\N=N\c1ccc(\N=N\c2c(O)ccc3ccccc23)c(C)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccccc1\N=N\c1ccc(\N=N\c2c(O)ccc3ccccc23)c(C)c1",380.16371126,29,7.57,69.67,0.158625977353686,0.024,0.0913129886768428,1,0
"NVS-PAK1-1","p21 activated kinase inhibitor","PAK1","CC(C)NC(=O)N1CC[C@@H](C1)NC1=Nc2cc(F)ccc2N(CC(F)F)c2ccc(Cl)cc12 |t:13|, CC(C)NC(=O)N1CC[C@@H](C1)NC1=Nc2cc(F)ccc2N(CC(F)F)c2ccc(Cl)cc12 |t:13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)NC(=O)N1CC[C@@H](C1)NC1=Nc2cc(F)ccc2N(CC(F)F)c2ccc(Cl)cc12 |t:13|",479.16997276,33,5.262,59.97,0.0306121132328105,0.152,0.0913060566164053,0,1
"GSK0660","PPAR receptor antagonist","PPARD","COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC, COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC, COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC",418.065713676,28,2.795,130.35,0.00457177130015898,0.178,0.0912858856500795,0,1
"tk216","binding of rna helicase a to the transcription factor ews-fli1 inhibitor","EWSR1, FLI1","OC1(CC(=O)c2ccc(cc2)C3CC3)C(=O)Nc4c(Cl)ccc(Cl)c14",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","ewing's sarcoma","OC1(CC(=O)c2ccc(cc2)C3CC3)C(=O)Nc4c(Cl)ccc(Cl)c14",375.0428987,25,4.998,66.4,0.0463997031175049,0.136,0.0911998515587524,0,1
"tipepidine","g protein signaling inhibitor","KCNJ3","CN1CCCC(=C(c2cccs2)c3cccs3)C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","neurology/psychiatry","attention-deficit/hyperactivity disorder (adhd)","CN1CCCC(=C(c2cccs2)c3cccs3)C1",275.080241544,18,2.186,59.72,0.0583659950988149,0.124,0.0911829975494074,0,0
"T-0070907","PPAR receptor antagonist","PPARG","[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1",277.025418796,19,2.255,85.13,0.0403451665044987,0.142,0.0911725832522493,0,1
"UK-383367","procollagen C-endopeptidase inhibitor","BMP1","NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO",324.179755248,23,2.5,131.34,0.0122975718631576,0.17,0.0911487859315788,0,1
"PFI-3","bromodomain inhibitor","PBRM1, SMARCA4","Oc1ccccc1C(=O)\C=C\N1C[C@H]2C[C@@H]1CN2c1ccccn1, Oc1ccccc1C(=O)\C=C\N1C[C@H]2C[C@@H]1CN2c1ccccn1, Oc1ccccc1C(=O)\C=C\N1C[C@H]2C[C@@H]1CN2c1ccccn1, Oc1ccccc1C(=O)\C=C\N1C[C@H]2C[C@@H]1CN2c1ccccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccccc1C(=O)\C=C\N1C[C@H]2C[C@@H]1CN2c1ccccn1",321.147726848,24,4.201,56.67,0.126231886845588,0.056,0.0911159434227939,1,0
"2-methyl-5-nitrophenol","","","Cc1ccc(cc1O)[N+]([O-])=O, Cc1ccc(cc1O)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(cc1O)[N+]([O-])=O",153.042593084,11,1.734,63.37,0.158218059531749,0.024,0.0911090297658743,1,0
"PNU-120596","acetylcholine receptor agonist","CHRNA7","COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"preclinical","","","COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl",311.067283608,21,2.217,85.62,0.0281175011391924,0.154,0.0910587505695962,0,1
"bucetin","analgesic agent","","CCOc1ccc(NC(=O)C[C@@H](C)O)cc1 |&1:11,r|, CCOc1ccc(NC(=O)C[C@@H](C)O)cc1 |&1:11,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CCOc1ccc(NC(=O)C[C@@H](C)O)cc1 |&1:11",223.120843404,16,1.624,58.56,0.108091565675328,0.074,0.091045782837664,0,0
"APD597","glucose dependent insulinotropic receptor agonist","GPR119","COc1c(Nc2ccc(nc2C)S(C)(=O)=O)ncnc1OC1CCN(CC1)C(=O)OC(C)C, COc1c(Nc2ccc(nc2C)S(C)(=O)=O)ncnc1OC1CCN(CC1)C(=O)OC(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1c(Nc2ccc(nc2C)S(C)(=O)=O)ncnc1OC1CCN(CC1)C(=O)OC(C)C",479.183854648,33,1.871,141.22,0.00208465727544057,0.18,0.0910423286377203,0,1
"rheochrysidin","protein tyrosine kinase inhibitor","PTPN1","COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1, COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1, COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1",284.068473484,21,2.648,83.83,0.060082666177054,0.122,0.091041333088527,0,0
"broxaterol","adrenergic receptor agonist","ADRB2","CC(C)(C)NC[C@@H](O)c1cc(Br)no1 |&1:6,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"phase 3","","","CC(C)(C)NC[C@@H](O)c1cc(Br)no1 |&1:6",262.03168982,14,1.713,58.29,0.0300744005834927,0.152,0.0910372002917463,0,1
"erythrosine","coloring agent","","Oc1c(I)cc2c(Oc3c(I)c(O)c(I)cc3C22OC(=O)c3ccccc23)c1I",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1c(I)cc2c(Oc3c(I)c(O)c(I)cc3C22OC(=O)c3ccccc23)c1I",835.655065356,29,8.107,75.99,3.46031954607287e-06,0.182,0.091001730159773,0,1
"AH11110","adrenergic receptor ligand","ADRA1B","O[C@@H](COc1ccccc1-c1ccccc1)CC(=N)N1CCCCC1 |&1:1|, O[C@@H](COc1ccccc1-c1ccccc1)CC(=N)N1CCCCC1 |&1:1|, O[C@@H](COc1ccccc1-c1ccccc1)CC(=N)N1CCCCC1 |&1:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"preclinical","","","O[C@@H](COc1ccccc1-c1ccccc1)CC(=N)N1CCCCC1 |&1:1|",338.199428072,25,4.75,56.55,0.121906086036533,0.06,0.0909530430182663,1,0
"KF-38789","P selectin inhibitor","SELP","COc1ccc([C@H]2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1 |&1:6,r,c:8|, COc1ccc([C@H]2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1 |&1:6,r,c:8|, COc1ccc([C@H]2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1 |&1:6,r,c:8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc([C@H]2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1 |&1:6",375.114043772,26,2.794,106.56,0.0138448487399216,0.168,0.0909224243699608,0,1
"ORG-27569","cannabinoid receptor modulator","CNR1","CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1, CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1, CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1, CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1, CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1",409.192090196,29,5.921,48.13,0.0938322864314982,0.088,0.0909161432157491,0,0
"GW-843682X","PLK inhibitor","PLK1, PLK3","COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC",477.097011716,33,3.565,116.84,0.00582119715329127,0.176,0.0909105985766456,0,1
"mitoflaxone","antitumor agent","VWF","OC(=O)Cc1cccc2c1oc(cc2=O)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)Cc1cccc2c1oc(cc2=O)-c1ccccc1",280.073558864,21,4.313,67.51,0.133800638285251,0.048,0.0909003191426256,1,0
"tetrahydrouridine","cytidine deaminase inhibitor","CDA","OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CC[C@@H](O)NC1=O |a:2,4,5,7,&1:12|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CC[C@@H](O)NC1=O |a:2",248.100836232,17,-2.279,122.49,0.0072696610131056,0.174,0.0906348305065528,0,1
"R-1479","HCV inhibitor","","Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@H]2O)c(=O)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@H]2O)c(=O)n1",284.086917484,20,-0.967,143.19,0.00525193797043946,0.176,0.0906259689852197,0,1
"Ro-9187","HCV inhibitor","","Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1",284.086917484,20,-0.967,143.19,0.00525193797043946,0.176,0.0906259689852197,0,1
"AMG-487","CC chemokine receptor antagonist","","CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1, CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1, CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1, CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1",603.209339036,44,5.769,99.44,0.00922244455193379,0.172,0.0906112222759669,0,1
"AMG-487-(+/-)","CC chemokine receptor antagonist","CXCR3","CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1 |&1:20,r|, CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1 |&1:20,r|, CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1 |&1:20,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1 |&1:20",603.209339036,44,5.769,99.44,0.00922244455193379,0.172,0.0906112222759669,0,1
"KW-2449","Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor","ABL1, AURKA, AURKB, FLT3","O=C(N1CCNCC1)c1ccc(\C=C\c2[nH]nc3ccccc23)cc1, O=C(N1CCNCC1)c1ccc(\C=C\c2[nH]nc3ccccc23)cc1, O=C(N1CCNCC1)c1ccc(\C=C\c2[nH]nc3ccccc23)cc1, O=C(N1CCNCC1)c1ccc(\C=C\c2[nH]nc3ccccc23)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","O=C(N1CCNCC1)c1ccc(\C=C\c2[nH]nc3ccccc23)cc1",332.16371126,25,3.636,61.02,0.0991155358717538,0.082,0.0905577679358769,0,0
"propidium-iodide","","ACHE","CC[N+](C)(CC)CCC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12, CC[N+](C)(CC)CCC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC[N+](C)(CC)CCC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12",414.277249928181,31,6.123,55.92,0.113100211273907,0.068,0.0905501056369536,0,0
"NU-7441","DNA dependent protein kinase inhibitor","PRKDC","O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1",413.108564468,30,7.079,70.92,0.0850845394871814,0.096,0.0905422697435907,0,0
"crenigacestat","notch signaling inhibitor","","C[C@H](NC(=O)CCC(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2cccnc2N(CCO)C1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H](NC(=O)CCC(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2cccnc2N(CCO)C1=O",464.167139876,33,2.59,111.63,0.00703603433664925,0.174,0.0905180171683246,0,1
"T-0156","phosphodiesterase inhibitor","PDE5A","COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1, COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1, COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1, COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1, COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1",583.206698268,43,3.631,136.78,0.00296132647016258,0.178,0.0904806632350813,0,1
"ponesimod","sphingosine 1-phosphate receptor agonist","S1PR1","CCC\N=C1/S\C(=C/c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C, CCC\N=C1/S\C(=C/c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C, CCC\N=C1/S\C(=C/c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCC\N=C1/S\C(=C/c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C",460.12235596,31,3.55,107.66,0.00678460378198253,0.174,0.0903923018909913,0,1
"dehydroacetic-acid","","","CC(=O)c1c(O)cc(C)oc1=O, CC(=O)c1c(O)cc(C)oc1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)c1c(O)cc(C)oc1=O",168.042258736,12,1.214,67.51,0.116779609066501,0.064,0.0903898045332507,1,0
"ligandrol","androgen receptor modulator","AR, SARM1","O[C@H]([C@H]1CCCN1c2ccc(C#N)c(c2)C(F)(F)F)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","endocrinology","cachexia","O[C@H]([C@H]1CCCN1c2ccc(C#N)c(c2)C(F)(F)F)C(F)(F)F",338.085382324,23,4.295,47.26,0.0887568332727879,0.092,0.090378416636394,0,0
"PF-03049423","phosphodiesterase inhibitor","PDE5A","CCCOCCn1c2cc(ncc2nc(N2CCN(CCO)CC2)c1=O)-c1ccc(OC)nc1, CCCOCCn1c2cc(ncc2nc(N2CCN(CCO)CC2)c1=O)-c1ccc(OC)nc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCOCCn1c2cc(ncc2nc(N2CCN(CCO)CC2)c1=O)-c1ccc(OC)nc1",468.248503504,34,2.395,105.84,0.00874579469675922,0.172,0.0903728973483796,0,1
"RV1729","PI3K inhibitor","","COCCN(CCOC)C(=O)CCCC#Cc1cccc2nc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc34)n(Cc3ccccc3Cl)c(=O)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COCCN(CCOC)C(=O)CCCC#Cc1cccc2nc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc34)n(Cc3ccccc3Cl)c(=O)c12",734.273194028,53,5.804,163.51,0.000736133653800481,0.18,0.0903680668269002,0,1
"sultiame","carbonic anhydrase inhibitor","CA2","NS(=O)(=O)c1ccc(cc1)N1CCCCS1(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","NS(=O)(=O)c1ccc(cc1)N1CCCCS1(=O)=O",290.039498928,18,0.845,114.3,0.00872457103006153,0.172,0.0903622855150308,0,1
"PSI-7976","HCV inhibitor","","CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1, CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1, CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1",529.162544358,36,1.932,167.99,0.000688452199601547,0.18,0.0903442260998008,0,1
"AGI-5198","isocitrate dehydrogenase inhibitor","IDH1","Cc1nccn1CC(=O)N([C@@H](C(=O)NC1CCCCC1)c1ccccc1C)c1cccc(F)c1 |&1:10,r|, Cc1nccn1CC(=O)N([C@@H](C(=O)NC1CCCCC1)c1ccccc1C)c1cccc(F)c1 |&1:10,r|, Cc1nccn1CC(=O)N([C@@H](C(=O)NC1CCCCC1)c1ccccc1C)c1cccc(F)c1 |&1:10,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1nccn1CC(=O)N([C@@H](C(=O)NC1CCCCC1)c1ccccc1C)c1cccc(F)c1 |&1:10",462.243104452,34,4.555,67.23,0.0406271335225404,0.14,0.0903135667612702,0,1
"TAK-285","EGFR inhibitor","ERBB2","CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12, CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12, CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12, CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12",547.159802,38,4.741,101.3,0.00659610835791872,0.174,0.0902980541789593,0,1
"gambogic-acid","caspase activator","BCL2","CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22",628.303618368,46,5.323,119.36,0.00455400410380094,0.176,0.0902770020519005,0,1
"UNC926","MBT inhibitor","L3MBTL1","Brc1cccc(c1)C(=O)N1CCC(CC1)N1CCCC1, Brc1cccc(c1)C(=O)N1CCC(CC1)N1CCCC1, Brc1cccc(c1)C(=O)N1CCC(CC1)N1CCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Brc1cccc(c1)C(=O)N1CCC(CC1)N1CCCC1",336.083725392,20,3.269,23.55,0.06450094672626,0.116,0.09025047336313,0,0
"ALS-8112","","","Nc1ccn([C@@H]2O[C@@](CO)(CCl)[C@@H](O)[C@H]2F)c(=O)n1, Nc1ccn([C@@H]2O[C@@](CO)(CCl)[C@@H](O)[C@H]2F)c(=O)n1, Nc1ccn([C@@H]2O[C@@](CO)(CCl)[C@@H](O)[C@H]2F)c(=O)n1, Nc1ccn([C@@H]2O[C@@](CO)(CCl)[C@@H](O)[C@H]2F)c(=O)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Nc1ccn([C@@H]2O[C@@](CO)(CCl)[C@@H](O)[C@H]2F)c(=O)n1",293.057861796,19,0.519,110.6,0.0102642703853863,0.17,0.0901321351926932,0,1
"FGIN-1-43","benzodiazepine receptor agonist","TSPO","CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1",486.220469132,33,9.662,36.1,0.120139900489416,0.06,0.090069950244708,1,0
"chicago-sky-blue-6b","glutamate inhibitor, macrophage migration inhibiting factor inhibitor","MIF","COc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1 |c:12,40|, COc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1 |c:12,40|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1 |c:12",904.044462816,60,3.19,404.42,1.26153417151098e-07,0.18,0.0900000630767086,0,1
"BTS-72664","GABA receptor antagonist","GABBR1","C[C@@H](Oc1ccc(Cl)cc1)c1ccnc2ncnn12 |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@@H](Oc1ccc(Cl)cc1)c1ccnc2ncnn12 |&1:1",274.062138652,19,2.544,52.31,0.0939365603566341,0.086,0.089968280178317,0,0
"NS-11394","GABA receptor agonist","","CC(C)(O)c1ccc2n(cnc2c1)-c1cccc(c1)-c1ccccc1C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(O)c1ccc2n(cnc2c1)-c1cccc(c1)-c1ccccc1C#N",353.152812228,27,4.675,61.84,0.117929058298981,0.062,0.0899645291494907,1,0
"rubitecan","topoisomerase inhibitor","TOP1","CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O",393.0960852,29,2.8,124.56,0.0118870830726117,0.168,0.0899435415363059,0,1
"nor-binaltorphimine","opioid receptor antagonist","OPRD1, OPRK1, OPRM1","Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O",661.315186096,49,2.245,121.65,0.00184520490661563,0.178,0.0899226024533078,0,1
"BMS-214662","farnesyltransferase inhibitor","","O=S(=O)(N1Cc2cc(ccc2N(Cc2cnc[nH]2)C[C@H]1Cc1ccccc1)C#N)c1cccs1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","O=S(=O)(N1Cc2cc(ccc2N(Cc2cnc[nH]2)C[C@H]1Cc1ccccc1)C#N)c1cccs1",489.129316976,34,3.289,129.71,0.00381979162387084,0.176,0.0899098958119354,0,1
"PH-797804","p38 MAPK inhibitor","MAPK11, MAPK14","CNC(=O)c1ccc(C)c(c1)-n1c(C)cc(OCc2ccc(F)cc2F)c(Br)c1=O, CNC(=O)c1ccc(C)c(c1)-n1c(C)cc(OCc2ccc(F)cc2F)c(Br)c1=O, CNC(=O)c1ccc(C)c(c1)-n1c(C)cc(OCc2ccc(F)cc2F)c(Br)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CNC(=O)c1ccc(C)c(c1)-n1c(C)cc(OCc2ccc(F)cc2F)c(Br)c1=O",476.054711008,30,5.54,60.33,0.0177708792907671,0.162,0.0898854396453835,0,1
"AMG-548","MAP kinase inhibitor","MAPK11, MAPK12, MAPK13, MAPK14","Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O, Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O, Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O, Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O",461.221560484,35,5.963,85.83,0.0477530452741441,0.132,0.089876522637072,0,1
"daidzein","estrogen receptor agonist","ESRRA, ESRRB, ESRRG, TRPC5","Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O",254.0579088,19,3.737,70.67,0.127731168986795,0.052,0.0898655844933977,1,0
"Y-27152","potassium channel activator","KCNJ8","CC(=O)N(OCc1ccccc1)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N, CC(=O)N(OCc1ccccc1)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(=O)N(OCc1ccccc1)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N",366.157957184,27,2.917,82.79,0.0376848901779691,0.142,0.0898424450889845,0,1
"N-cyclohexyl-2-benzothiazolesulfenamide","","","C1CCC(CC1)NSc1nc2ccccc2s1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C1CCC(CC1)NSc1nc2ccccc2s1",264.075490512,17,3.462,78.46,0.0536751898701283,0.126,0.0898375949350641,0,0
"pulrodemstat","histone lysine demethylase inhibitor","KDM1A, MBD2","COc1ccc(cc1F)-c1c(nc(N2CCC(N)CC2)n(C)c1=O)-c1ccc(C#N)c(F)c1.OS(=O)(=O)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","hematologic malignancy","acute myeloid leukemia (aml)","COc1ccc(cc1F)-c1c(nc(N2CCC(N)CC2)n(C)c1=O)-c1ccc(C#N)c(F)c1.OS(=O)(=O)c1ccccc1",609.185746468,43,5.846,159.92,0.00160438658596441,0.178,0.0898021932929822,0,1
"phenformin","AMPK activator","KCNJ8, PRKAA1","NC(N)=NC(=N)NCCc1ccccc1, NC(N)=NC(=N)NCCc1ccccc1, NC(N)=NC(=N)NCCc1ccccc1, NC(N)=NC(=N)NCCc1ccccc1, NC(N)=NC(=N)NCCc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","NC(N)=NC(=N)NCCc1ccccc1",205.13274548,15,0.766,100.28,0.0435882937613017,0.136,0.0897941468806508,0,1
"SB-399885","serotonin receptor antagonist","HTR6","COc1ccc(cc1N1CCNCC1)S(=O)(=O)Nc1cc(Cl)cc(Cl)c1OC, COc1ccc(cc1N1CCNCC1)S(=O)(=O)Nc1cc(Cl)cc(Cl)c1OC",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1N1CCNCC1)S(=O)(=O)Nc1cc(Cl)cc(Cl)c1OC",445.062982512,28,3.522,88.28,0.00757623903015979,0.172,0.0897881195150799,0,1
"NSC-697923","ubiquitin-conjugating enzyme inhibitor","UBE2N","Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O",267.020143388,18,2.194,98.8,0.0295351758319739,0.15,0.089767587915987,0,1
"N-salicoylaminophenol","ribonucleotide reductase inhibitor","","Oc1ccc(NC(=O)c2ccccc2O)cc1, Oc1ccc(NC(=O)c2ccccc2O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","Oc1ccc(NC(=O)c2ccccc2O)cc1",229.073893212,17,2.61,69.56,0.115534269670943,0.064,0.0897671348354713,1,0
"zebularine","DNA methyltransferase inhibitor","CDA, DNMT1","OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O",228.074621484,16,-0.896,104.81,0.0194698884021995,0.16,0.0897349442010998,0,1
"CFM-1571","guanylate cyclase activator","","COc1ccc(NC(=O)c2cc(OCCCN(C)C)nn2Cc2ccccc2)cc1, COc1ccc(NC(=O)c2cc(OCCCN(C)C)nn2Cc2ccccc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(NC(=O)c2cc(OCCCN(C)C)nn2Cc2ccccc2)cc1",408.216140756,30,3.657,68.62,0.0454625678887665,0.134,0.0897312839443833,0,1
"BAY-60-6583","adenosine receptor agonist","ADORA1, ADORA2A, ADORA2B, ADORA3","NC(=O)CSc1nc(N)c(C#N)c(-c2ccc(OCC3CC3)cc2)c1C#N, NC(=O)CSc1nc(N)c(C#N)c(-c2ccc(OCC3CC3)cc2)c1C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC(=O)CSc1nc(N)c(C#N)c(-c2ccc(OCC3CC3)cc2)c1C#N",379.110295784,27,1.94,164.11,0.00342002052319702,0.176,0.0897100102615985,0,1
"kb-0742 (dihydrochloride)","cdk9 inhibitor","CDK9","N[C@@H]1C[C@@H](NC2=CC(C(CC)CC)=NC3=CC=NN23)CC1.[H]Cl.[H]Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","oncology","prostate cancer","N[C@@H]1C[C@@H](NC2=CC(C(CC)CC)=NC3=CC=NN23)CC1.[H]Cl.[H]Cl",359.164351224,25,3.5,66.01,0.047347967154926,0.132,0.089673983577463,0,1
"PD-98059","MEK inhibitor","AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1","COc1cccc(c1N)-c1cc(=O)c2ccccc2o1, COc1cccc(c1N)-c1cc(=O)c2ccccc2o1, COc1cccc(c1N)-c1cc(=O)c2ccccc2o1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cccc(c1N)-c1cc(=O)c2ccccc2o1",267.089543276,20,3.984,65.46,0.139321142048168,0.04,0.0896605710240839,1,0
"reversan","MRP inhibitor","ABCC1","O=C(NCCCN1CCOCC1)c1cnn2c(cc(nc12)-c1ccccc1)-c1ccccc1, O=C(NCCCN1CCOCC1)c1cnn2c(cc(nc12)-c1ccccc1)-c1ccccc1, O=C(NCCCN1CCOCC1)c1cnn2c(cc(nc12)-c1ccccc1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(NCCCN1CCOCC1)c1cnn2c(cc(nc12)-c1ccccc1)-c1ccccc1",441.216475104,33,3.731,71.76,0.0392904183622174,0.14,0.0896452091811087,0,1
"CFM-2","glutamate receptor antagonist","","COc1cc2CC(=O)NN=C(c3ccc(N)cc3)c2cc1OC |t:9|, COc1cc2CC(=O)NN=C(c3ccc(N)cc3)c2cc1OC |t:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2CC(=O)NN=C(c3ccc(N)cc3)c2cc1OC |t:9|",311.126991404,23,2.387,85.94,0.0452563990877292,0.134,0.0896281995438646,0,1
"7-aminocephalosporanic-acid","beta lactamase inhibitor","","CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O |t:5|, CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O |t:5|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O |t:5|",272.046692484,18,-1.07,135.23,0.0051806715565691,0.174,0.0895903357782845,0,1
"rentiapril","angiotensin converting enzyme inhibitor","ACE","OC(=O)[C@@H]1CS[C@@H](N1C(=O)CCS)c2ccccc2O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","cardiology","hypertension","OC(=O)[C@@H]1CS[C@@H](N1C(=O)CCS)c2ccccc2O",313.04424996,20,1.649,141.94,0.00513995693569873,0.174,0.0895699784678494,0,1
"phenserine","acetylcholinesterase inhibitor, beta amyloid synthesis inhibitor","ACHE, BCHE","CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21, CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21, CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21, CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21",337.179026976,25,3.434,44.81,0.119122687309998,0.06,0.0895613436549991,1,0
"vapendavir","antiviral","","CCOc1noc2cc(OCCC3CCN(CC3)c3ccc(C)nn3)ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCOc1noc2cc(OCCC3CCN(CC3)c3ccc(C)nn3)ccc12",382.200490692,28,4.876,73.51,0.0631199498045446,0.116,0.0895599749022723,0,0
"PD1-PDL-inhibitor-1","programmed death ligand inhibitor","CD274","COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN1CCCC[C@H]1C(O)=O, COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN1CCCC[C@H]1C(O)=O, COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN1CCCC[C@H]1C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN1CCCC[C@H]1C(O)=O",475.235873156,35,5.954,68.23,0.0510740848917701,0.128,0.0895370424458851,0,0
"oteseconazole","other antifungal","","O[C@@](Cn1cnnn1)(c2ccc(F)cc2F)C(F)(F)c3ccc(cn3)c4ccc(OCC(F)(F)F)cc4",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","infectious disease","vulvovaginal candidiasis","O[C@@](Cn1cnnn1)(c2ccc(F)cc2F)C(F)(F)c3ccc(cn3)c4ccc(OCC(F)(F)F)cc4",527.119222292,37,5.633,85.95,0.0149019013014903,0.164,0.0894509506507451,0,1
"BMS-387032","CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor","CDK2, CDK7, CDK9","CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1, CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1, CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1, CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1, CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1",380.134068008,25,0.303,133.59,0.00285997926808474,0.176,0.0894299896340424,0,1
"AR-12","phosphoinositide dependent kinase inhibitor","PDPK1","NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F",460.151095888,34,5.678,72.94,0.0488594017731367,0.13,0.0894297008865684,0,1
"TC-G-1005","G protein-coupled receptor agonist","GPBAR1","Cc1ccc(C)c(Oc2ccncc2C(=O)N2CCN(C3CC3)c3ccccc23)c1, Cc1ccc(C)c(Oc2ccncc2C(=O)N2CCN(C3CC3)c3ccccc23)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(C)c(Oc2ccncc2C(=O)N2CCN(C3CC3)c3ccccc23)c1",399.19467704,30,4.689,45.67,0.114718574633805,0.064,0.0893592873169025,0,0
"NPS-2407","glutamate receptor antagonist","","CC(C)(Cc1ccccc1)NC(=O)c1cnc2ccccc2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(Cc1ccccc1)NC(=O)c1cnc2ccccc2n1",305.152812228,23,3.201,54.88,0.120626625943358,0.058,0.089313312971679,1,0
"trifloxystrobin","mitochondrial electron transport inhibitor","","CO\N=C(\C(=O)OC)c1ccccc1CO\N=C(/C)c1cccc(c1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CO\N=C(\C(=O)OC)c1ccccc1CO\N=C(/C)c1cccc(c1)C(F)(F)F",408.129691748,29,5.76,69.48,0.0585927564144273,0.12,0.0892963782072137,0,0
"sorbinil","aldose reductase inhibitor","AKR1B1","Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8,r|, Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8,r|, Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8,r|, Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8,r|, Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8",236.059720368,17,1.001,67.43,0.0725762480655184,0.106,0.0892881240327592,0,0
"moguisteine","ATP-sensitive potassium channel inhibitor","","CCOC(=O)CC(=O)N1CCS[C@@H]1COc1ccccc1OC |&1:12,r|, CCOC(=O)CC(=O)N1CCS[C@@H]1COc1ccccc1OC |&1:12,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCOC(=O)CC(=O)N1CCS[C@@H]1COc1ccccc1OC |&1:12",339.114043772,23,2.191,90.37,0.0204511064722273,0.158,0.0892255532361137,0,1
"R-96544","serotonin receptor antagonist","HTR2A","COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1, COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1, COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1",355.214743788,26,3.711,41.93,0.112361836848562,0.066,0.0891809184242808,0,0
"quinelorane","dopamine receptor agonist","DRD2, DRD3","CCCN1CCC[C@@H]2Cc3nc(N)ncc3C[C@@H]12, CCCN1CCC[C@@H]2Cc3nc(N)ncc3C[C@@H]12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"phase 3","","","CCCN1CCC[C@@H]2Cc3nc(N)ncc3C[C@@H]12",246.184446704,18,1.04,55.04,0.0942673851494706,0.084,0.0891336925747353,0,0
"VLX600","antitumor agent, ubiquitin C-terminal hydrolase inhibitor","TP53, USP14","CC(=NNc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1, CC(=NNc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1, C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1, C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1, C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1, C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(=NNc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1",317.13889348,24,3.516,91.74,0.05625787604079,0.122,0.089128938020395,0,0
"torcetrapib","cholesteryl ester transfer protein inhibitor","CETP","CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F, CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F, CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F, CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F",600.16706126,41,7.277,59.08,0.0181664143589184,0.16,0.0890832071794592,0,1
"PFK-158","phosphofructokinase inhibitor","PFKFB3","FC(F)(F)c1ccc2ccc(\C=C\C(=O)c3ccncc3)nc2c1, FC(F)(F)c1ccc2ccc(\C=C\C(=O)c3ccncc3)nc2c1, FC(F)(F)c1ccc2ccc(\C=C\C(=O)c3ccncc3)nc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","FC(F)(F)c1ccc2ccc(\C=C\C(=O)c3ccncc3)nc2c1",328.082347632,24,3.713,42.85,0.130128293770858,0.048,0.0890641468854289,1,0
"SIS3","serine/threonine kinase inhibitor","SMAD3, TGFBR1","COc1cc2CCN(Cc2cc1OC)C(=O)\C=C\c1c(-c2ccccc2)n(C)c2ncccc12, COc1cc2CCN(Cc2cc1OC)C(=O)\C=C\c1c(-c2ccccc2)n(C)c2ncccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2CCN(Cc2cc1OC)C(=O)\C=C\c1c(-c2ccccc2)n(C)c2ncccc12",453.205241724,34,4.763,56.59,0.0661089589873756,0.112,0.0890544794936878,0,0
"NGD-98-2","corticotropin releasing factor receptor antagonist","CRHR1","CCC(CC)Nc1nc(C)c(nc1OC)-c1ccc(OC(F)(F)F)cc1OC, CCC(CC)Nc1nc(C)c(nc1OC)-c1ccc(OC(F)(F)F)cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCC(CC)Nc1nc(C)c(nc1OC)-c1ccc(OC(F)(F)F)cc1OC",399.176976288,28,5.56,65.5,0.0600899654447954,0.118,0.0890449827223977,0,0
"LDN-57444","ubiquitin C-terminal hydrolase inhibitor","","CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12",395.983525252,25,5.011,58.97,0.0339539319600731,0.144,0.0889769659800366,0,1
"fagomine","glucosidase inhibitor","GLB1","OC[C@H]1NCC[C@@H](O)[C@@H]1O, OC[C@H]1NCC[C@@H](O)[C@@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC[C@H]1NCC[C@@H](O)[C@@H]1O",147.089543276,10,-0.757,72.72,0.0699485393388947,0.108,0.0889742696694474,0,0
"bropirimine","interferon inducer","","Nc1nc(=O)c(Br)c([nH]1)-c1ccccc1, Nc1nc(=O)c(Br)c([nH]1)-c1ccccc1, Nc1nc(=O)c(Br)c([nH]1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Nc1nc(=O)c(Br)c([nH]1)-c1ccccc1",264.985073976,15,3.725,71.77,0.0417799825675833,0.136,0.0888899912837917,0,1
"CPI-613","pyruvate dehydrogenase inhibitor","PDHA1","OC(=O)CCCC[C@@H](CCSCc1ccccc1)SCc1ccccc1 |&1:7,r|, OC(=O)CCCC[C@@H](CCSCc1ccccc1)SCc1ccccc1 |&1:7,r|, OC(=O)CCCC[C@@H](CCSCc1ccccc1)SCc1ccccc1 |&1:7,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","OC(=O)CCCC[C@@H](CCSCc1ccccc1)SCc1ccccc1 |&1:7",388.153072136,26,6.018,87.9,0.0337581570059906,0.144,0.0888790785029953,0,1
"PRN1008","Bruton's tyrosine kinase (BTK) inhibitor","","CC(C)(\C=C(/C#N)C(=O)N1CCC[C@H](C1)n1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc12)N1CCN(CC1)C1COC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(\C=C(/C#N)C(=O)N1CCC[C@H](C1)n1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc12)N1CCN(CC1)C1COC1",665.32381436,49,3.671,138.66,0.00160392643773024,0.176,0.0888019632188651,0,1
"A77636","dopamine receptor agonist","CALY","NC[C@@H]1O[C@@H](Cc2c(O)c(O)ccc12)[C@@]12CC3CC(CC(C3)C1)C2, NC[C@@H]1O[C@@H](Cc2c(O)c(O)ccc12)[C@@]12CC3CC(CC(C3)C1)C2, NC[C@@H]1O[C@@H](Cc2c(O)c(O)ccc12)[C@@]12CC3CC(CC(C3)C1)C2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC[C@@H]1O[C@@H](Cc2c(O)c(O)ccc12)[C@@]12CC3CC(CC(C3)C1)C2",329.199093724,24,3.973,75.71,0.0675757631507491,0.11,0.0887878815753746,0,0
"PF-06282999","myeloperoxidase inhibitor","","COc1ccc(Cl)cc1-c1cc(=O)[nH]c(=S)n1CC(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1ccc(Cl)cc1-c1cc(=O)[nH]c(=S)n1CC(N)=O",325.028789924,21,2.532,122.2,0.00949522817938969,0.168,0.0887476140896949,0,1
"seletalisib","PI3K inhibitor","","[O-][n+]1cccc(c1)-c1nc2c(Cl)cccc2cc1[C@@H](Nc1ncnc2cccnc12)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[O-][n+]1cccc(c1)-c1nc2c(Cl)cccc2cc1[C@@H](Nc1ncnc2cccnc12)C(F)(F)F",482.086971408,34,5.6,90.53,0.0194526381975253,0.158,0.0887263190987627,0,1
"pruvanserin","serotonin receptor antagonist","HTR2A, HTR2C","Fc1ccc(CCN2CCN(CC2)C(=O)c2cccc3c(c[nH]c23)C#N)cc1, Fc1ccc(CCN2CCN(CC2)C(=O)c2cccc3c(c[nH]c23)C#N)cc1, Fc1ccc(CCN2CCN(CC2)C(=O)c2cccc3c(c[nH]c23)C#N)cc1",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Fc1ccc(CCN2CCN(CC2)C(=O)c2cccc3c(c[nH]c23)C#N)cc1",376.169939512,28,3.464,63.13,0.0654324691541406,0.112,0.0887162345770703,0,0
"10-hydroxycamptothecin","topoisomerase inhibitor","TOP1","CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O",364.105921612,27,2.502,101.65,0.0234294593716076,0.154,0.0887147296858038,0,1
"carmoxirole","dopamine receptor agonist","DRD2","OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1 |c:17|, OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1 |c:17|, OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1 |c:17|, OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1 |c:17|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1 |c:17|",374.199428072,28,4.483,56.33,0.0993618871293655,0.078,0.0886809435646828,0,0
"practolol","adrenergic receptor antagonist","ADRB1","CC(C)NC[C@@H](O)COc1ccc(NC(C)=O)cc1 |&1:5,r|, CC(C)NC[C@@H](O)COc1ccc(NC(C)=O)cc1 |&1:5,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"withdrawn","","","CC(C)NC[C@@H](O)COc1ccc(NC(C)=O)cc1 |&1:5",266.163042564,19,1.016,70.59,0.0533407096825654,0.124,0.0886703548412827,0,0
"SB-205384","GABA receptor modulator","GABRA3, GABRA5, GABRA6","CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|",0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15",330.103813436,23,1.728,113.68,0.0132870042901609,0.164,0.0886435021450805,0,1
"selitrectinib","protein tyrosine kinase inhibitor","","[H][C@]12CCCN1c1ccn3ncc(C(=O)N[C@H](C)CCc4ncc(F)cc24)c3n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","[H][C@]12CCCN1c1ccn3ncc(C(=O)N[C@H](C)CCc4ncc(F)cc24)c3n1",380.176087512,29,3.183,75.42,0.0532387660101936,0.124,0.0886193830050968,0,0
"GSK9027","glucocorticoid receptor agonist","NR3C1","Fc1ccc(cc1)-n1ncc2cc(ccc12)-c1ccc(NS(=O)(=O)Cc2ccccc2)cc1C(F)(F)F, Fc1ccc(cc1)-n1ncc2cc(ccc12)-c1ccc(NS(=O)(=O)Cc2ccccc2)cc1C(F)(F)F, Fc1ccc(cc1)-n1ncc2cc(ccc12)-c1ccc(NS(=O)(=O)Cc2ccccc2)cc1C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1ccc(cc1)-n1ncc2cc(ccc12)-c1ccc(NS(=O)(=O)Cc2ccccc2)cc1C(F)(F)F",525.113410728,37,7.23,72.37,0.0311677290114758,0.146,0.0885838645057379,0,1
"OTS514","TOPK inhibitor","","C[C@@H](CN)c1ccc(cc1)-c1c(O)cc(C)c2[nH]c(=O)c3sccc3c12, C[C@@H](CN)c1ccc(cc1)-c1c(O)cc(C)c2[nH]c(=O)c3sccc3c12, C[C@@H](CN)c1ccc(cc1)-c1c(O)cc(C)c2[nH]c(=O)c3sccc3c12, C[C@@H](CN)c1ccc(cc1)-c1c(O)cc(C)c2[nH]c(=O)c3sccc3c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](CN)c1ccc(cc1)-c1c(O)cc(C)c2[nH]c(=O)c3sccc3c12",364.12454888,26,4.279,107.35,0.025156293562033,0.152,0.0885781467810165,0,1
"EED226","polycomb protein inhibitor","EED","CS(=O)(=O)c1ccc(cc1)-c1cnc(NCc2ccco2)n2cnnc12, CS(=O)(=O)c1ccc(cc1)-c1cnc(NCc2ccco2)n2cnnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CS(=O)(=O)c1ccc(cc1)-c1cnc(NCc2ccco2)n2cnnc12",369.08956034,26,4.361,110.77,0.0211434764141155,0.156,0.0885717382070578,0,1
"l-368,899 hydrochloride","oxytocin receptor antagonist","","Cc1ccccc1N1CCN(CC1)S(=O)(=O)CC12CCC(C[C@@H]1NC(=O)[C@@H](N)CCS(C)(=O)=O)C2(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1ccccc1N1CCN(CC1)S(=O)(=O)CC12CCC(C[C@@H]1NC(=O)[C@@H](N)CCS(C)(=O)=O)C2(C)C",554.259662444,37,3.231,146.64,0.00107281666341014,0.176,0.0885364083317051,0,1
"L-368899","oxytocin receptor antagonist","AVPR1A, AVPR2, OXTR","Cc1ccccc1N1CCN(CC1)S(=O)(=O)C[C@]12CC[C@H](C[C@@H]1NC(=O)[C@@H](N)CCS(C)(=O)=O)C2(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1ccccc1N1CCN(CC1)S(=O)(=O)C[C@]12CC[C@H](C[C@@H]1NC(=O)[C@@H](N)CCS(C)(=O)=O)C2(C)C",554.259662444,37,3.231,146.64,0.00107281666341014,0.176,0.0885364083317051,0,1
"NS-11021","calcium-activated potassium channel activator","KCNMA1","FC(F)(F)c1cc(NC(=S)Nc2ccc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(NC(=S)Nc2ccc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)c1cc(NC(=S)Nc2ccc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F",509.969696708,30,6.356,110.61,0.0030527848933971,0.174,0.0885263924466985,0,1
"DpC","","","CN(C1CCCCC1)C(=S)NN=C(c1ccccn1)c1ccccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN(C1CCCCC1)C(=S)NN=C(c1ccccn1)c1ccccn1",353.167416736,25,4.721,85.5,0.0469470155373436,0.13,0.0884735077686718,0,1
"flosequinan","phosphodiesterase inhibitor","","Cn1cc([S@@](C)=O)c(=O)c2ccc(F)cc12 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","Cn1cc([S@@](C)=O)c(=O)c2ccc(F)cc12 |r|",239.04162778,16,2.461,58.28,0.0928571458803679,0.084,0.088428572940184,0,0
"savolitinib","c-Met inhibitor","MET","C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(nc12)-c1cnn(C)c1, C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(nc12)-c1cnn(C)c1, C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(nc12)-c1cnn(C)c1, C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(nc12)-c1cnn(C)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(nc12)-c1cnn(C)c1",345.14504148,26,2.765,91.61,0.0387961639416345,0.138,0.0883980819708173,0,1
"CID-16020046","G protein-coupled receptor antagonist","GPR55","Cc1ccc(cc1)-c1n[nH]c2C(=O)N([C@H](c12)c1cccc(O)c1)c1ccc(cc1)C(O)=O |&1:14,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(cc1)-c1n[nH]c2C(=O)N([C@H](c12)c1cccc(O)c1)c1ccc(cc1)C(O)=O |&1:14",425.137556088,32,5.069,106.52,0.0287400896002704,0.148,0.0883700448001352,0,1
"ab928","adenosine receptor antagonist","ADORA2A, ADORA2B","Cc1c(cccc1c2cc(nc(N)n2)c3cn(Cc4cccc(n4)C(C)(C)O)nn3)C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","oncology","non-small cell lung cancer (nsclc)","Cc1c(cccc1c2cc(nc(N)n2)c3cn(Cc4cccc(n4)C(C)(C)O)nn3)C#N",426.191657324,32,2.27,139.42,0.00672719280778421,0.17,0.0883635964038921,0,1
"cyclovirobuxin-D","calcium channel modulator","","CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C, CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C, CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C",402.361014092,29,7.024,44.29,0.148706334641193,0.028,0.0883531673205966,1,0
"ranirestat","aldose reductase inhibitor","AKR1B1","Fc1cc(Br)ccc1CN1C(=O)c2cccn2[C@@]2(CC(=O)NC2=O)C1=O, Fc1cc(Br)ccc1CN1C(=O)c2cccn2[C@@]2(CC(=O)NC2=O)C1=O, Fc1cc(Br)ccc1CN1C(=O)c2cccn2[C@@]2(CC(=O)NC2=O)C1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Fc1cc(Br)ccc1CN1C(=O)c2cccn2[C@@]2(CC(=O)NC2=O)C1=O",418.991696152,26,2.374,88.48,0.00670013852622303,0.17,0.0883500692631115,0,1
"BMS-191011","potassium channel activator","KCNMA1","Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F, Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F, Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F, Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F, Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F",370.03320452,25,5.062,68.26,0.0506619688305238,0.126,0.0883309844152619,0,0
"NBI-74330-(+/-)","CC chemokine receptor antagonist","CXCR3","CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(F)c(c1)C(F)(F)F |&1:20,r|, CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(F)c(c1)C(F)(F)F |&1:20,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(F)c(c1)C(F)(F)F |&1:20",605.205002604,44,5.688,90.21,0.01066086327477,0.166,0.088330431637385,0,1
"pindolol-(-)","adrenergic receptor antagonist, serotonin receptor antagonist","HTR1A","CC(C)NC[C@H](O)COc1cccc2[nH]ccc12, CC(C)NC[C@H](O)COc1cccc2[nH]ccc12",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)NC[C@H](O)COc1cccc2[nH]ccc12",248.15247788,18,1.915,57.28,0.104616722562793,0.072,0.0883083612813966,0,0
"cresopirine","","","CC(=O)Oc1c(C)cccc1C(O)=O, CC(=O)Oc1c(C)cccc1C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)Oc1c(C)cccc1C(O)=O",194.0579088,14,1.648,63.6,0.120539898779275,0.056,0.0882699493896377,1,0
"ISO-1","macrophage migration inhibiting factor inhibitor","MIF","COC(=O)C[C@H]1CC(=NO1)c1ccc(O)cc1 |&1:5,r,c:7|, COC(=O)C[C@H]1CC(=NO1)c1ccc(O)cc1 |&1:5,r,c:7|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)C[C@H]1CC(=NO1)c1ccc(O)cc1 |&1:5",235.084457896,17,1.849,68.12,0.0884726945759444,0.088,0.0882363472879722,0,0
"ONO-AE3-208","prostanoid receptor antagonist","PTGER4","C[C@@H](C(=O)Nc1cc(ccc1CCCC(O)=O)C#N)c1ccc(F)c2ccccc12 |&1:1,r|, C[C@@H](C(=O)Nc1cc(ccc1CCCC(O)=O)C#N)c1ccc(F)c2ccccc12 |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](C(=O)Nc1cc(ccc1CCCC(O)=O)C#N)c1ccc(F)c2ccccc12 |&1:1",404.153620752,30,4.123,90.19,0.0344581336699927,0.142,0.0882290668349963,0,1
"dapivirine","non-nucleoside reverse transcriptase inhibitor","CYP3A4, CYP3A5","Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1, Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1, Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1, Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1, Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1",329.164045608,25,4.221,73.63,0.0924400481885475,0.084,0.0882200240942738,0,0
"acivicin","gamma glutamyltransferase inhibitor","CTPS1","N[C@H]([C@@H]1CC(Cl)=NO1)C(O)=O |c:5|, N[C@H]([C@@H]1CC(Cl)=NO1)C(O)=O |c:5|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","N[C@H]([C@@H]1CC(Cl)=NO1)C(O)=O |c:5|",178.014519764,11,-2.381,84.91,0.0223693198750865,0.154,0.0881846599375432,0,1
"tulrampator","antidepressant ","","Fc1cccc(CCn2nnc3cc4C(=O)N(COc4cc3c2=O)C2CC2)c1, Fc1cccc(CCn2nnc3cc4C(=O)N(COc4cc3c2=O)C2CC2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Fc1cccc(CCn2nnc3cc4C(=O)N(COc4cc3c2=O)C2CC2)c1",380.128468624,28,3.109,77.32,0.0403194742589962,0.136,0.0881597371294981,0,1
"ziritaxestat","autotaxin inhibitor","","CCc1nc2c(C)cc(cn2c1N(C)c1nc(c(s1)C#N)-c1ccc(F)cc1)N1CCN(CC(=O)N2CC(O)C2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCc1nc2c(C)cc(cn2c1N(C)c1nc(c(s1)C#N)-c1ccc(F)cc1)N1CCN(CC(=O)N2CC(O)C2)CC1",588.243121516,42,3.618,132.48,0.00229776048750257,0.174,0.0881488802437513,0,1
"sar-260301","pi3k inhibitor","PIK3C2G, PIK3C3, PIK3CA, PIK3CB, PIK3CD","O=C1N=C(CC(N2[C@@H](C)CC3=C2C=CC=C3)=O)NC(N4CCOCC4)=C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","melanoma","O=C1N=C(CC(N2[C@@H](C)CC3=C2C=CC=C3)=O)NC(N4CCOCC4)=C1",354.169190564,26,1.711,74.24,0.0362112450485572,0.14,0.0881056225242786,0,1
"trilaciclib","CDK inhibitor","","CN1CCN(CC1)c1ccc(Nc2ncc3cc4C(=O)NCC5(CCCCC5)n4c3n2)nc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN1CCN(CC1)c1ccc(Nc2ncc3cc4C(=O)NCC5(CCCCC5)n4c3n2)nc1",446.25425758,33,3.651,91.21,0.0221465215791761,0.154,0.088073260789588,0,1
"FK-33-824","opioid receptor agonist","OPRM1","C[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N[C@H](CO)CC[S@@](C)=O |a:1,5,23,34,&1:39|, C[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N[C@H](CO)CC[S@@](C)=O |a:1,5,23,34,&1:39|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N[C@H](CO)CC[S@@](C)=O |a:1",603.272669652,42,-0.981,210.37,8.55108655222183e-05,0.176,0.0880427554327611,0,1
"CID-2745687","G protein-coupled receptor antagonist","GPR35","COC(=O)c1cnn(c1\C=N\NC(=S)NC(C)(C)C)-c1ccc(F)cc1F, COC(=O)c1cnn(c1\C=N\NC(=S)NC(C)(C)C)-c1ccc(F)cc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)c1cnn(c1\C=N\NC(=S)NC(C)(C)C)-c1ccc(F)cc1F",395.122752288,27,4.428,112.63,0.014011690834525,0.162,0.0880058454172625,0,1
"MIW-815","interferon inducer","","[H][C@]12CO[P@](S)(=O)O[C@@]3([H])[C@@H](O)[C@@H](O[C@]3([H])CO[P@](S)(=O)O[C@@]([H])([C@@H](O1)n1cnc3c(N)ncnc13)[C@]2([H])O)n1cnc2c(N)ncnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@]12CO[P@](S)(=O)O[C@@]3([H])[C@@H](O)[C@@H](O[C@]3([H])CO[P@](S)(=O)O[C@@]([H])([C@@H](O1)n1cnc3c(N)ncnc13)[C@]2([H])O)n1cnc2c(N)ncnc12",690.059352228,49,-3.2,366.44,8.38819361233122e-07,0.176,0.0880004194096806,0,1
"sufugolix","gonadotropin releasing factor hormone receptor antagonist","","CONC(=O)Nc1ccc(cc1)-c1sc2n(Cc3c(F)cccc3F)c(=O)n(-c3ccccc3)c(=O)c2c1CN(C)Cc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CONC(=O)Nc1ccc(cc1)-c1sc2n(Cc3c(F)cccc3F)c(=O)n(-c3ccccc3)c(=O)c2c1CN(C)Cc1ccccc1",667.206481912,48,7.219,125.84,0.00390498593057883,0.172,0.0879524929652894,0,1
"plumbagin","anticancer agent","","CC1=CC(=O)c2c(O)cccc2C1=O |t:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC1=CC(=O)c2c(O)cccc2C1=O |t:1|",188.047344116,14,1.215,54.37,0.149840302978688,0.026,0.0879201514893439,1,0
"R-59022","diacylglycerol kinase inhibitor, protein kinase inhibitor","DGKA","Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccccc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccccc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccccc1)c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccccc1)c1ccc(F)cc1",459.178061672,33,5.579,65.85,0.045833987833951,0.13,0.0879169939169755,0,1
"torcitabine","DNA polymerase inhibitor","DCK, TK2","Nc1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Nc1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1",227.090605896,16,-0.384,110.6,0.0197563341962868,0.156,0.0878781670981434,0,1
"delafloxacin","antiinfective drug","","Nc1nc(c(F)cc1F)-n1cc(C(O)=O)c(=O)c2cc(F)c(N3CC(O)C3)c(Cl)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Nc1nc(c(F)cc1F)-n1cc(C(O)=O)c(=O)c2cc(F)c(N3CC(O)C3)c(Cl)c12",440.049917204,30,4.384,121.68,0.00771199217862941,0.168,0.0878559960893147,0,1
"etanidazole","bacterial cell wall synthesis inhibitor","","OCCNC(=O)Cn1ccnc1[N+]([O-])=O, OCCNC(=O)Cn1ccnc1[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","OCCNC(=O)Cn1ccnc1[N+]([O-])=O",214.0702048,15,-1.207,110.29,0.0176683482639705,0.158,0.0878341741319852,0,1
"PF-3274167","oxytocin receptor antagonist","AVPR1A, OXTR","COCc1nnc(N2CC(C2)Oc2ccc(F)cc2Cl)n1-c1ccc(OC)nc1, COCc1nnc(N2CC(C2)Oc2ccc(F)cc2Cl)n1-c1ccc(OC)nc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COCc1nnc(N2CC(C2)Oc2ccc(F)cc2Cl)n1-c1ccc(OC)nc1",419.116045368,29,5.186,74.53,0.0356628223346394,0.14,0.0878314111673197,0,1
"SB-772077B","rho associated kinase inhibitor","ROCK1, ROCK2","CCn1c(nc2cncc(C(=O)N3CC[C@H](N)C3)c12)-c1nonc1N, CCn1c(nc2cncc(C(=O)N3CC[C@H](N)C3)c12)-c1nonc1N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCn1c(nc2cncc(C(=O)N3CC[C@H](N)C3)c12)-c1nonc1N",342.155271816,25,0.109,141.98,0.00555165094313261,0.17,0.0877758254715663,0,1
"ly2886721","beta-secretase inhibitor","","NC1=N[C@]2(COC[C@@H]2CS1)c1cc(NC(=O)c2ccc(F)cn2)ccc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","NC1=N[C@]2(COC[C@@H]2CS1)c1cc(NC(=O)c2ccc(F)cn2)ccc1F",390.096203192,27,1.586,114.9,0.00751461014760842,0.168,0.0877573050738042,0,1
"LY2886721","beta-secretase inhibitor","BACE1","NC1=N[C@]2(COC[C@H]2CS1)c1cc(NC(=O)c2ccc(F)cn2)ccc1F |t:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","NC1=N[C@]2(COC[C@H]2CS1)c1cc(NC(=O)c2ccc(F)cn2)ccc1F |t:1|",390.096203192,27,1.586,114.9,0.00751461014760842,0.168,0.0877573050738042,0,1
"CCT137690","Aurora kinase inhibitor","AURKA, AURKB, AURKC","CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1",550.180419712,36,4.111,80.56,0.00537023584335652,0.17,0.0876851179216783,0,1
"DMH1","ALK tyrosine kinase receptor inhibitor","ACVR1","CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12",380.16371126,29,5.238,52.31,0.137276915825786,0.038,0.087638457912893,1,0
"SB-239063","p38 MAPK inhibitor","MAPK11, MAPK14, PTGS2","COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|, COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|, COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|, COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|, COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|, COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|, COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|",368.164854132,27,3.67,73.06,0.0532630120434491,0.122,0.0876315060217245,0,0
"INH1","Hec1 inhibitor","NDC80","Cc1ccc(-c2csc(NC(=O)c3ccccc3)n2)c(C)c1, Cc1ccc(-c2csc(NC(=O)c3ccccc3)n2)c(C)c1, Cc1ccc(-c2csc(NC(=O)c3ccccc3)n2)c(C)c1, Cc1ccc(-c2csc(NC(=O)c3ccccc3)n2)c(C)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(-c2csc(NC(=O)c3ccccc3)n2)c(C)c1",308.098334132,22,4.703,70.23,0.0932329574825768,0.082,0.0876164787412884,0,0
"irosustat","steroid sulfatase inhibitor","CA2, STS","NS(=O)(=O)Oc1ccc2c3CCCCCc3c(=O)oc2c1, NS(=O)(=O)Oc1ccc2c3CCCCCc3c(=O)oc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NS(=O)(=O)Oc1ccc2c3CCCCCc3c(=O)oc2c1",309.06709358,21,2.083,107.98,0.0171870818052227,0.158,0.0875935409026113,0,1
"CP-532623","cholesteryl ester transfer protein inhibitor","CETP","CC[C@@H]1C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(C)=O)c2cc(ccc2N1C(=O)OC(C)C)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC[C@@H]1C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(C)=O)c2cc(ccc2N1C(=O)OC(C)C)C(F)(F)F",598.187796704,41,7.566,49.85,0.0251445189196109,0.15,0.0875722594598055,0,1
"indibulin","tubulin polymerization inhibitor","","Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1, Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1, Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1, Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1",389.093104432,28,4.062,63.99,0.0551326577893553,0.12,0.0875663288946777,0,0
"PD-81723","adenosine receptor agonist","ADORA1","Cc1sc(N)c(C(=O)c2cccc(c2)C(F)(F)F)c1C, Cc1sc(N)c(C(=O)c2cccc(c2)C(F)(F)F)c1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1sc(N)c(C(=O)c2cccc(c2)C(F)(F)F)c1C",299.059169664,20,3.492,71.33,0.0550903124841061,0.12,0.0875451562420531,0,0
"derazantinib","tyrosine kinase inhibitor","","COCCNCCc1cccc(Nc2ncc3C[C@@H](c4ccccc4F)c4ccccc4-c3n2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COCCNCCc1cccc(Nc2ncc3C[C@@H](c4ccccc4F)c4ccccc4-c3n2)c1",468.232539768,35,4.731,59.07,0.0550827544199959,0.12,0.0875413772099979,0,0
"quizartinib","FLT3 inhibitor","CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET","CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1, CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1, CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1, CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1, CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1",560.220574504,40,4.137,134.4,0.00307436116888966,0.172,0.0875371805844448,0,1
"pyrintegrin","integrin signaling activator","","Oc1ccc2N(CCCc2c1)c1ccnc(Nc2ccc(cc2)S(=O)(=O)NCC2CC2)n1, Oc1ccc2N(CCCc2c1)c1ccnc(Nc2ccc(cc2)S(=O)(=O)NCC2CC2)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc2N(CCCc2c1)c1ccnc(Nc2ccc(cc2)S(=O)(=O)NCC2CC2)n1",451.16781066,32,3.677,115.83,0.00901335379678926,0.166,0.0875066768983946,0,1
"ganetespib","HSP inhibitor","HSP90AA1","CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O, CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O, CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O, CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O, CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O, CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O, CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O",364.1535405,27,4.333,96.07,0.0409862879550407,0.134,0.0874931439775204,0,1
"PF-06447475","serine/threonine kinase inhibitor","LRRK2","N#Cc1cccc(c1)-c1c[nH]c2ncnc(N3CCOCC3)c12, N#Cc1cccc(c1)-c1c[nH]c2ncnc(N3CCOCC3)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N#Cc1cccc(c1)-c1c[nH]c2ncnc(N3CCOCC3)c12",305.1276601,23,2.848,77.83,0.0688460420704007,0.106,0.0874230210352003,0,0
"nemazoline","adrenergic receptor agonist, adrenergic receptor antagonist","","Nc1c(Cl)cc(C=C2NCCN2)cc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Nc1c(Cl)cc(C=C2NCCN2)cc1Cl",243.033002712,15,2.607,50.08,0.0847725997496862,0.09,0.0873862998748431,0,0
"avagacestat","gamma secretase inhibitor","PSEN1","NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1, NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1, NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1, NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1",520.059516584,34,4.63,127.77,0.00265317151352377,0.172,0.0873265857567619,0,1
"AZ-10417808","caspase inhibitor","CASP3","[O-][N+](=O)c1cc(C(=O)NCC=C)c2[nH]c(Nc3ccc(Cl)c(Cl)c3)nc(=O)c2c1, [O-][N+](=O)c1cc(C(=O)NCC=C)c2[nH]c(Nc3ccc(Cl)c(Cl)c3)nc(=O)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[O-][N+](=O)c1cc(C(=O)NCC=C)c2[nH]c(Nc3ccc(Cl)c(Cl)c3)nc(=O)c2c1",433.034459256,29,5.867,130.02,0.008581813783789,0.166,0.0872909068918945,0,1
"zandelisib","pi3k inhibitor","PIK3CD","CN1CCC(CC1)c1ccccc1CC(C)(C)Nc1nc(nc(n1)-n1c(nc2ccccc12)C(F)F)N1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","oncology","non-hodgkin lymphoma (nhl)","CN1CCC(CC1)c1ccccc1CC(C)(C)Nc1nc(nc(n1)-n1c(nc2ccccc12)C(F)F)N1CCOCC1",576.313664276,42,5.466,84.23,0.0145375919427212,0.16,0.0872687959713606,0,1
"apricitabine","nucleoside reverse transcriptase inhibitor","","Nc1ccn([C@H]2CO[C@@H](CO)S2)c(=O)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Nc1ccn([C@H]2CO[C@@H](CO)S2)c(=O)n1",229.052112212,15,-0.0490000000000001,115.67,0.0145281912157835,0.16,0.0872640956078917,0,1
"benaxibine","","","OC[C@H]1O[C@@H](Nc2ccc(cc2)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC[C@H]1O[C@@H](Nc2ccc(cc2)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O",299.100501884,21,0.0849999999999999,139.48,0.00650698387333103,0.168,0.0872534919366655,0,1
"K-MAP","","","OC[C@H]1O[C@@H](Nc2ccc(cc2)C(O)=O)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:15,&4:17,&5:19,r|, OC[C@H]1O[C@@H](Nc2ccc(cc2)C(O)=O)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:15,&4:17,&5:19,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC[C@H]1O[C@@H](Nc2ccc(cc2)C(O)=O)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2",299.100501884,21,0.0849999999999999,139.48,0.00650698387333103,0.168,0.0872534919366655,0,1
"Ro-25-6981","glutamate receptor antagonist, monamine transporter modulator","GRIN2B","C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1, C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1, C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1, C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1",339.219829168,25,4.233,43.7,0.138497634902475,0.036,0.0872488174512377,1,0
"uprifosbuvir","antiviral","","CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(Cl)[C@@H]1O)Oc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(Cl)[C@@H]1O)Oc1ccccc1",545.132993818,36,2.069,167.99,0.000486092887755384,0.174,0.0872430464438777,0,1
"elacridar","P glycoprotein inhibitor","ABCB1","COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC",563.242021156,42,6.42,92.89,0.020420845224847,0.154,0.0872104226124235,0,1
"TH-302","DNA alkylating agent","","Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O, Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O, Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O",446.930664822,21,1.152,121.13,0.000379665057645036,0.174,0.0871898325288225,0,1
"metaflumizone","sodium channel blocker","SCN8A","FC(F)(F)OC1=CC=C(NC(=O)NN=C(CC2=CC=C(C=C2)C#N)C3=CC=CC(=C3)C(F)(F)F)C=C1",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","infectious disease","flea control","FC(F)(F)OC1=CC=C(NC(=O)NN=C(CC2=CC=C(C=C2)C#N)C3=CC=CC(=C3)C(F)(F)F)C=C1",506.117745072,36,4.419,86.51,0.0143389049322557,0.16,0.0871694524661279,0,1
"pemafibrate","PPAR receptor agonist","","CC[C@@H](Oc1cccc(CN(CCCOc2ccc(OC)cc2)c2nc3ccccc3o2)c1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC[C@@H](Oc1cccc(CN(CCCOc2ccc(OC)cc2)c2nc3ccccc3o2)c1)C(O)=O",490.21038668,36,5.799,94.26,0.0243367763954325,0.15,0.0871683881977163,0,1
"siremadlin","MDM inhibitor","","COc1ncc(-c2nc3C(=O)N([C@H](c3n2C(C)C)c2ccc(Cl)cc2)c2cc(Cl)cn(C)c2=O)c(OC)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ncc(-c2nc3C(=O)N([C@H](c3n2C(C)C)c2ccc(Cl)cc2)c2cc(Cl)cn(C)c2=O)c(OC)n1",554.123608608,38,5.545,104.37,0.00633628764985817,0.168,0.0871681438249291,0,1
"entasobulin","tubulin polymerization inhibitor","","Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccc4ncccc4c3)c3ccccc23)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccc4ncccc4c3)c3ccccc23)cc1",439.108754496,32,5.417,63.99,0.058248949961256,0.116,0.087124474980628,0,0
"E7046","prostanoid receptor antagonist","","C[C@H](NC(=O)c1c(nn(C)c1Oc1cccc(c1)C(F)(F)F)C(F)F)c1ccc(cc1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@H](NC(=O)c1c(nn(C)c1Oc1cccc(c1)C(F)(F)F)C(F)F)c1ccc(cc1)C(O)=O",483.121747156,34,5.227,93.45,0.0162374409276037,0.158,0.0871187204638019,0,1
"radezolid","bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor","","CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cn[nH]n2)cc1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cn[nH]n2)cc1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cn[nH]n2)cc1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cn[nH]n2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cn[nH]n2)cc1",438.181566816,32,3.329,112.24,0.0122291104979077,0.162,0.0871145552489538,0,1
"HKI-357","EGFR inhibitor","EGFR","CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C",573.194295688,41,5.19,99.51,0.0082098761085738,0.166,0.0871049380542869,0,1
"taladegib","smoothened receptor antagonist","DHH, IHH, SMO","CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F, CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F, CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F, CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F, CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F, CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F",512.194772268,37,5.868,67.15,0.0341938107973748,0.14,0.0870969053986874,0,1
"roluperidone","","","Fc1ccc(cc1)C(=O)CN1CCC(CN2Cc3ccccc3C2=O)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Fc1ccc(cc1)C(=O)CN1CCC(CN2Cc3ccccc3C2=O)CC1",366.174356196,27,3.37,40.62,0.104170299782448,0.07,0.087085149891224,0,0
"pelanserin","serotonin receptor antagonist","HTR2A","O=c1[nH]c2ccccc2c(=O)n1CCCN1CCN(CC1)c1ccccc1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O=c1[nH]c2ccccc2c(=O)n1CCCN1CCN(CC1)c1ccccc1",364.189926008,27,3.955,61.34,0.0800903443370908,0.094,0.0870451721685454,0,0
"WAY-161503","serotonin receptor agonist","HTR2C","Clc1cc2NC(=O)[C@H]3CNCCN3c2cc1Cl |&1:7|, Clc1cc2NC(=O)[C@H]3CNCCN3c2cc1Cl |&1:7|, Clc1cc2NC(=O)[C@H]3CNCCN3c2cc1Cl |&1:7|, Clc1cc2NC(=O)[C@H]3CNCCN3c2cc1Cl |&1:7|",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1cc2NC(=O)[C@H]3CNCCN3c2cc1Cl |&1:7|",271.027917332,17,1.818,44.37,0.0660598890272788,0.108,0.0870299445136394,0,0
"AZD8797","CC chemokine receptor antagonist","","CC(C)C[C@H](CO)Nc1nc(S[C@@H](C)c2ccccc2)nc2nc(N)sc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)C[C@H](CO)Nc1nc(S[C@@H](C)c2ccccc2)nc2nc(N)sc12",403.15005242,27,3.678,150.49,0.00404034553185939,0.17,0.0870201727659297,0,1
"PF-04691502","mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA","COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O |r|, COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O |r|, COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O |r|, COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O |r|",425.206304344,31,2.517,125.38,0.00803683502557905,0.166,0.0870184175127895,0,1
"2-(((((((2r,3s,4r,5r)-5-(4-amino-2-oxopyrimidin-1(2h)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)oxidophosphoryl)oxy)-n,n,n-trimethylethan-1-aminium","","","C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O",489.114607364091,31,-3.691,232.51,3.19858342371304e-05,0.174,0.0870159929171186,0,1
"lincomycin hydrochloride (lincocin)","","","CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@@H]1O",406.213757808,27,0.69,147.79,0.00192476954118286,0.172,0.0869623847705914,0,1
"karenitecin","topoisomerase inhibitor","TOP1","CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4c(CC[Si](C)(C)C)c3Cn1c2=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4c(CC[Si](C)(C)C)c3Cn1c2=O",448.181833906,32,4.801,81.42,0.0277832900552562,0.146,0.0868916450276281,0,1
"LY411575","gamma secretase inhibitor","","C[C@H](NC(=O)[C@@H](O)c1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O, C[C@H](NC(=O)[C@@H](O)c1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H](NC(=O)[C@@H](O)c1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O",479.165662656,35,3.07,98.74,0.0117648775668705,0.162,0.0868824387834353,0,1
"COTI-2","anticancer agent","","S=C(N\N=C1/CCCc2cccnc12)N1CCN(CC1)c1ccccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","S=C(N\N=C1/CCCc2cccnc12)N1CCN(CC1)c1ccccn1",366.162665704,26,3.94,88.74,0.0336463383685964,0.14,0.0868231691842982,0,1
"SAR405","PI3K inhibitor","PIK3C3","C[C@@H]1COCCN1c1cc(=O)n2CC[C@H](N(Cc3cncc(Cl)c3)c2n1)C(F)(F)F, C[C@@H]1COCCN1c1cc(=O)n2CC[C@H](N(Cc3cncc(Cl)c3)c2n1)C(F)(F)F, C[C@@H]1COCCN1c1cc(=O)n2CC[C@H](N(Cc3cncc(Cl)c3)c2n1)C(F)(F)F, C[C@@H]1COCCN1c1cc(=O)n2CC[C@H](N(Cc3cncc(Cl)c3)c2n1)C(F)(F)F, C[C@@H]1COCCN1c1cc(=O)n2CC[C@H](N(Cc3cncc(Cl)c3)c2n1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H]1COCCN1c1cc(=O)n2CC[C@H](N(Cc3cncc(Cl)c3)c2n1)C(F)(F)F",443.133587252,30,5.276,63.49,0.0334676981844407,0.14,0.0867338490922204,0,1
"chrysin","breast cancer resistance protein inhibitor","AKR1B1, CDK6, CYP19A1, CYP1B1","Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1, Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1, Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1, Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1",254.0579088,19,4.074,70.67,0.13722874495393,0.036,0.086614372476965,1,0
"cipamfylline","phosphodiesterase inhibitor","","Nc1nc2n(CC3CC3)c(=O)n(CC3CC3)c(=O)c2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Nc1nc2n(CC3CC3)c(=O)n(CC3CC3)c(=O)c2[nH]1",275.138224784,20,2.698,98.7,0.0431297038194358,0.13,0.0865648519097179,0,1
"atamparib","parp inhibitor","TIPARP","C[C@@H](COCCC(=O)N1CCN(CC1)c2ncc(cn2)C(F)(F)F)NC3=C(C(=O)NN=C3)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","carcinoid tumors","C[C@@H](COCCC(=O)N1CCN(CC1)c2ncc(cn2)C(F)(F)F)NC3=C(C(=O)NN=C3)C(F)(F)F",523.176656916,36,2.188,112.05,0.00308658898628878,0.17,0.0865432944931444,0,1
"CGP-52411","EGFR inhibitor","EGFR","O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12, O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12, O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12, O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12",329.11642672,25,3.416,70.23,0.0830421531789194,0.09,0.0865210765894597,0,0
"A-887826","sodium channel blocker","SCN10A","CCCCOc1ccc(cc1Cl)-c1cncc(c1)C(=O)NCc1cccnc1N1CCOCC1, CCCCOc1ccc(cc1Cl)-c1cncc(c1)C(=O)NCc1cccnc1N1CCOCC1",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCOc1ccc(cc1Cl)-c1cncc(c1)C(=O)NCc1cccnc1N1CCOCC1",480.192818468,34,5.117,76.58,0.0248454599244668,0.148,0.0864227299622334,0,1
"GSK37647","free fatty acid receptor agonist","FFAR4","COc1ccc(cc1)S(=O)(=O)Nc1c(C)cc(C)cc1C, COc1ccc(cc1)S(=O)(=O)Nc1c(C)cc(C)cc1C, COc1ccc(cc1)S(=O)(=O)Nc1c(C)cc(C)cc1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1)S(=O)(=O)Nc1c(C)cc(C)cc1C",305.108564468,21,3.519,63.78,0.0707872424784663,0.102,0.0863936212392331,0,0
"dynole-34-2","dynamin inhibitor","DNM1","CCCCCCCCNC(=O)C(=C\c1cn(CCCN(C)C)c2ccccc12)\C#N, CCCCCCCCNC(=O)C(=C\c1cn(CCCN(C)C)c2ccccc12)\C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCCNC(=O)C(=C\c1cn(CCCN(C)C)c2ccccc12)\C#N",408.288911772,30,5.552,61.06,0.0827199658740724,0.09,0.0863599829370362,0,0
"diperodon","local anesthetic","","O=C(Nc1ccccc1)OC[C@@H](CN1CCCCC1)OC(=O)Nc1ccccc1 |&1:11|, O=C(Nc1ccccc1)OC[C@@H](CN1CCCCC1)OC(=O)Nc1ccccc1 |&1:11|, O=C(Nc1ccccc1)OC[C@@H](CN1CCCCC1)OC(=O)Nc1ccccc1 |&1:11|, O=C(Nc1ccccc1)OC[C@@H](CN1CCCCC1)OC(=O)Nc1ccccc1 |&1:11|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(Nc1ccccc1)OC[C@@H](CN1CCCCC1)OC(=O)Nc1ccccc1 |&1:11|",397.200156344,29,3.438,79.9,0.034669368336784,0.138,0.086334684168392,0,1
"ZD-0947","potassium channel activator","","FC(F)(F)C1=C[C@H](C2=C(CCCC2=O)N1)c1cccc(c1)C#N |t:4,7|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)C1=C[C@H](C2=C(CCCC2=O)N1)c1cccc(c1)C#N |t:4",318.097997696,23,3.165,52.89,0.0945992503665896,0.078,0.0862996251832948,0,0
"NPPB","chloride channel blocker","ANO1, CLCN2, CLCN7, TRPA1","OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O, OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O, OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O, OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O",300.111006992,22,3.83,92.47,0.0565962832701251,0.116,0.0862981416350625,0,0
"PTC-028","BMI-1 inhibitor","","Cc1nc2cc(F)c(F)cc2n1-c1cncc(Nc2ccc(cc2)C(F)(F)F)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1nc2cc(F)c(F)cc2n1-c1cncc(Nc2ccc(cc2)C(F)(F)F)n1",405.101286484,29,4.834,55.63,0.0684703076924273,0.104,0.0862351538462137,0,0
"pocapavir","Enterovirus capsid inhibitor","","COc1ccc(OCc2ccc(COc3c(Cl)cccc3Cl)cc2)c(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(OCc2ccc(COc3c(Cl)cccc3Cl)cc2)c(Cl)c1",422.024327444,27,7.053,27.69,0.0924674430161819,0.08,0.0862337215080909,0,0
"talampanel","glutamate receptor antagonist","GRIA1, GRIA2, GRIA3, GRIA4","C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1 |c:14|, C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1 |c:14|, C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1 |c:14|, C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1 |c:14|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1 |c:14|",337.142641468,25,3.007,77.15,0.0544553883931739,0.118,0.0862276941965869,0,0
"TMC-353121","RSV fusion inhibitor","","Cc1ccc(CCCO)c(NCc2ccc3nc(NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1, Cc1ccc(CCCO)c(NCc2ccc3nc(NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1ccc(CCCO)c(NCc2ccc3nc(NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1",558.331839204,41,3.524,107.7,0.00644897072652518,0.166,0.0862244853632626,0,1
"DCPIB","chloride channel blocker, gap junction modulator, glutamate inhibitor","SLC1A2","CCCC[C@]1(Cc2cc(OCCCC(O)=O)c(Cl)c(Cl)c2C1=O)C1CCCC1 |&1:4,r|",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCC[C@]1(Cc2cc(OCCCC(O)=O)c(Cl)c(Cl)c2C1=O)C1CCCC1 |&1:4",426.136464736,28,6.708,63.6,0.0444091785155575,0.128,0.0862045892577787,0,0
"ethynylcytidine","antimetabolite","","Nc1ccn([C@@H]2O[C@H](CO)[C@](O)(C#C)[C@H]2O)c(=O)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1ccn([C@@H]2O[C@H](CO)[C@](O)(C#C)[C@H]2O)c(=O)n1",267.085520516,19,-0.964,130.83,0.00832153392896943,0.164,0.0861607669644847,0,1
"ST-1535","adenosine receptor antagonist","","CCCCc1nc(N)c2nc(-n3nccn3)n(C)c2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCc1nc(N)c2nc(-n3nccn3)n(C)c2n1",272.149792512,20,2.671,100.33,0.0442596175213729,0.128,0.0861298087606865,0,0
"WH-4-023","SRC inhibitor","LCK, SRC","COc1ccc(N(C(=O)Oc2c(C)cccc2C)c2ccnc(Nc3ccc(cc3)N3CCN(C)CC3)n2)c(OC)c1, COc1ccc(N(C(=O)Oc2c(C)cccc2C)c2ccnc(Nc3ccc(cc3)N3CCN(C)CC3)n2)c(OC)c1, COc1ccc(N(C(=O)Oc2c(C)cccc2C)c2ccnc(Nc3ccc(cc3)N3CCN(C)CC3)n2)c(OC)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(N(C(=O)Oc2c(C)cccc2C)c2ccnc(Nc3ccc(cc3)N3CCN(C)CC3)n2)c(OC)c1",568.279803632,42,5.35,92.29,0.0142086617349245,0.158,0.0861043308674622,0,1
"ZSTK-474","PI3K inhibitor","PIK3CB, PIK3CD, PIK3CG","FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1, FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1",417.172479352,30,2.719,81.43,0.0221924702955853,0.15,0.0860962351477927,0,1
"PF-429242","SREBP inhibitor","MBTPS1","CCN(CC)Cc1ccc(cc1)C(=O)N(CCc1ccccc1OC)[C@@H]1CCNC1, CCN(CC)Cc1ccc(cc1)C(=O)N(CCc1ccccc1OC)[C@@H]1CCNC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN(CC)Cc1ccc(cc1)C(=O)N(CCc1ccccc1OC)[C@@H]1CCNC1",409.27292736,30,3.748,44.81,0.0761886342682114,0.096,0.0860943171341057,0,0
"4-chlorophenylguanidine","urokinase inhibitor","PLAUR","NC(=N)Nc1ccc(Cl)cc1, NC(=N)Nc1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC(=N)Nc1ccc(Cl)cc1",169.040674936,11,2.005,61.9,0.12417160954432,0.048,0.0860858047721602,1,0
"piromidic-acid","bacterial DNA gyrase inhibitor","","CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1, CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1, CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1, CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1",288.122240372,21,3.47,88.32,0.0601180840278275,0.112,0.0860590420139137,0,0
"IDH-305","isocitrate dehydrogenase inhibitor","","C[C@H](F)[C@H]1COC(=O)N1c1ccnc(N[C@@H](C)c2cc(C)c(cn2)-c2ccnc(c2)C(F)(F)F)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@H](F)[C@H]1COC(=O)N1c1ccnc(N[C@@H](C)c2cc(C)c(cn2)-c2ccnc(c2)C(F)(F)F)n1",490.174036824,35,4.362,93.13,0.0141050475272597,0.158,0.0860525237636299,0,1
"1,12-Besm","polyamine biosynthesis inhibitor","","CCNCCCNCCCCNCCCNCC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCNCCCNCCCCNCCCNCC",258.278347088,18,0.944,48.12,0.082043561477721,0.09,0.0860217807388605,0,0
"lithocholic-acid","FXR antagonist, vitamin D receptor agonist","GPBAR1, NR1H4, NR1I2, VDR","C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C",376.29774514,27,8.263,57.53,0.170018295574982,0.002,0.0860091477874912,1,0
"YIL-781","ghrelin receptor antagonist","GHSR","CC(C)N1CCC[C@H](Cn2c(C)nc3ccc(Oc4ccc(F)cc4)cc3c2=O)C1, CC(C)N1CCC[C@H](Cn2c(C)nc3ccc(Oc4ccc(F)cc4)cc3c2=O)C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)N1CCC[C@H](Cn2c(C)nc3ccc(Oc4ccc(F)cc4)cc3c2=O)C1",409.216555356,30,5.198,47.36,0.0999873746958485,0.072,0.0859936873479242,0,0
"LY288513","CCK receptor antagonist","CCKBR","Brc1ccc(NC(=O)N2NC(=O)[C@H]([C@@H]2c2ccccc2)c2ccccc2)cc1, Brc1ccc(NC(=O)N2NC(=O)[C@H]([C@@H]2c2ccccc2)c2ccccc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Brc1ccc(NC(=O)N2NC(=O)[C@H]([C@@H]2c2ccccc2)c2ccccc2)cc1",435.058238916,28,4.409,61.44,0.0219649576527825,0.15,0.0859824788263912,0,1
"mkc8866","ire1 inhibitor","ERN1","COc1cc2c(C)c(CC(=O)N3CCOCC3)c(=O)oc2c(C=O)c1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","oncology","prostate cancer","COc1cc2c(C)c(CC(=O)N3CCOCC3)c(=O)oc2c(C=O)c1O",361.116151948,26,1.412,106.28,0.0138744357684084,0.158,0.0859372178842042,0,1
"pridopidine","dopamine receptor antagonist","","CCCN1CCC(CC1)c1cccc(c1)S(C)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCN1CCC(CC1)c1cccc(c1)S(C)(=O)=O",281.144949976,19,2.609,45.76,0.0938040774263906,0.078,0.0859020387131953,0,0
"L-cysteinesulfinic-acid","glutamate receptor agonist","GRM1, GRM5, GSR, HMGCS2, PAPOLA, PRDX2","N[C@@H](C[S@@](O)=O)C(O)=O |a:1,&1:3|, N[C@@H](C[S@@](O)=O)C(O)=O |a:1,&1:3|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@@H](C[S@@](O)=O)C(O)=O |a:1",153.009578704,9,-5.235,119.83,0.00576527203938615,0.166,0.0858826360196931,0,1
"PP-121","protein tyrosine kinase inhibitor","ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC","Nc1ncnc2n(nc(-c3cnc4[nH]ccc4c3)c12)C1CCCC1, Nc1ncnc2n(nc(-c3cnc4[nH]ccc4c3)c12)C1CCCC1, Nc1ncnc2n(nc(-c3cnc4[nH]ccc4c3)c12)C1CCCC1, Nc1ncnc2n(nc(-c3cnc4[nH]ccc4c3)c12)C1CCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1ncnc2n(nc(-c3cnc4[nH]ccc4c3)c12)C1CCCC1",319.154543544,24,3.045,98.3,0.0416575416320991,0.13,0.0858287708160495,0,1
"terciprazine","","","O[C@@H](COC1(CCCCC1)C#C)CN1CCN(CC1)c1cccc(c1)C(F)(F)F |&1:1,r|, O[C@@H](COC1(CCCCC1)C#C)CN1CCN(CC1)c1cccc(c1)C(F)(F)F |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","O[C@@H](COC1(CCCCC1)C#C)CN1CCN(CC1)c1cccc(c1)C(F)(F)F |&1:1",410.218112828,29,3.906,35.94,0.075581951344515,0.096,0.0857909756722575,0,0
"E7449","PARP inhibitor","PARP1, PARP2, TNKS, TNKS2","O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23",317.1276601,24,2.982,77.67,0.0675813813847207,0.104,0.0857906906923604,0,0
"balovaptan","vasopressin receptor antagonist","AVPR1A, AVPR2, HTR2B, OXTR","CN1CC2=NN=C([C@H]3CC[C@H](OC4=NC=CC=C4)CC3)[N@]2[C@]5=CC=C(Cl)C=C5C1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CN1CC2=NN=C([C@H]3CC[C@H](OC4=NC=CC=C4)CC3)[N@]2[C@]5=CC=C(Cl)C=C5C1",409.166938068,29,3.203,52.79,0.0455684993452417,0.126,0.0857842496726208,0,0
"ditiocarb-sodium-trihydrate","immunostimulant","CA1, CA2, CA4","CCN(CC)C(S)=S, CCN(CC)C(S)=S",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCN(CC)C(S)=S",149.033291352,8,1.784,74.13,0.0755643921535595,0.096,0.0857821960767797,0,0
"LY344864","serotonin receptor agonist","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR7","CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1, CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1, CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1",0,0,0,0,0,0,0,0,1,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1",351.174690544,26,3.698,48.13,0.107439636265514,0.064,0.0857198181327571,0,0
"2-(1-adamantylamino)benzoic-acid","","","OC(=O)c1ccccc1NC(=O)C12CC3CC(CC(C3)C1)C2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1ccccc1NC(=O)C12CC3CC(CC(C3)C1)C2",299.152143532,22,4.278,66.4,0.111417278522824,0.06,0.0857086392614118,0,0
"AVE-0991","angiotensin receptor agonist","MRGPRX1","CCNC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2c(C=O)c(OC)nc2-c2ccccc2)cc1, CCNC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2c(C=O)c(OC)nc2-c2ccccc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCNC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2c(C=O)c(OC)nc2-c2ccccc2)cc1",580.181412124,40,4.935,156.01,0.00140814519026489,0.17,0.0857040725951324,0,1
"safingol","PKC inhibitor","TRPM3","CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO",301.298079488,21,6.268,66.48,0.133335142868083,0.038,0.0856675714340414,1,0
"NM107","RNA polymerase inhibitor","","C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O",257.10117058,18,-0.568,130.83,0.00923821146359844,0.162,0.0856191057317992,0,1
"nm107","rna polymerase inhibitor","","CC1(O)C(O)C(CO)OC1n1ccc(N)nc1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC1(O)C(O)C(CO)OC1n1ccc(N)nc1=O",257.10117058,18,-0.568,130.83,0.00923821146359844,0.162,0.0856191057317992,0,1
"LY2606368","CHK inhibitor","CHEK1","COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1",365.160022848,27,1.802,134.76,0.00906200200903846,0.162,0.0855310010045192,0,1
"capadenoson","adenosine receptor agonist","ADORA1","Nc1nc(SCc2csc(n2)-c2ccc(Cl)cc2)c(C#N)c(-c2ccc(OCCO)cc2)c1C#N, Nc1nc(SCc2csc(n2)-c2ccc(Cl)cc2)c(C#N)c(-c2ccc(OCCO)cc2)c1C#N, Nc1nc(SCc2csc(n2)-c2ccc(Cl)cc2)c(C#N)c(-c2ccc(OCCO)cc2)c1C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Nc1nc(SCc2csc(n2)-c2ccc(Cl)cc2)c(C#N)c(-c2ccc(OCCO)cc2)c1C#N",519.059044496,35,4.64,182.38,0.000968738188408821,0.17,0.0854843690942044,0,1
"EPZ005687","histone lysine methyltransferase inhibitor","EZH2","Cc1cc(C)c(CNC(=O)c2cc(cc3n(ncc23)C2CCCC2)-c2ccc(CN3CCOCC3)cc2)c(=O)[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(C)c(CNC(=O)c2cc(cc3n(ncc23)C2CCCC2)-c2ccc(CN3CCOCC3)cc2)c(=O)[nH]1",539.289640044,40,5.593,92.25,0.0189506762822043,0.152,0.0854753381411021,0,1
"TBA-354","","","[O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(nc1)-c1ccc(OC(F)(F)F)cc1, [O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(nc1)-c1ccc(OC(F)(F)F)cc1, [O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(nc1)-c1ccc(OC(F)(F)F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","[O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(nc1)-c1ccc(OC(F)(F)F)cc1",436.09945424,31,5.66,101.54,0.0229231898046771,0.148,0.0854615949023386,0,1
"MLN0128","mTOR inhibitor","MTOR, PIK3CA, PIK3CD, PIK3CG","CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12, CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12, CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12, CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12, CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12",309.1338081,23,1.9,121.67,0.0189051432604784,0.152,0.0854525716302392,0,1
"etoxybamide","","","OCCCC(=O)NCCO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OCCCC(=O)NCCO",147.089543276,10,-1.52,69.56,0.0628911844960731,0.108,0.0854455922480366,0,0
"tasuldine","mucolytic agent","","C(Sc1ncccn1)c1cccnc1, C(Sc1ncccn1)c1cccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C(Sc1ncccn1)c1cccnc1",203.051718288,14,0.753,63.97,0.0808762173717256,0.09,0.0854381086858628,0,0
"vatalanib","KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","EGFR, FLT1, FLT4, KDR, PDGFRB","Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1",346.09852416,25,4.36,50.7,0.106841105260302,0.064,0.0854205526301511,0,0
"LY404187","glutamate receptor positive allosteric modulator","GRIA1, GRIA2, GRIA3, GRIA4","CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(cc1)C#N |&1:8,r|, CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(cc1)C#N |&1:8,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(cc1)C#N |&1:8",342.140198944,24,3.897,78.34,0.0468162523185783,0.124,0.0854081261592892,0,0
"JQ1-(+)","bromodomain inhibitor","BRD4, BRDT","Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|, Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|, Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|, Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|, Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|, Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|, Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|",456.13867472,31,6.413,97.61,0.0187850576362865,0.152,0.0853925288181432,0,1
"TC-Mps1-12","monopolar spindle 1 kinase inhibitor","TTK","CC(C)(C)Nc1nc(Nc2ccc(cc2)C(N)=O)cc(N)c1C#N, CC(C)(C)Nc1nc(Nc2ccc(cc2)C(N)=O)cc(N)c1C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)Nc1nc(Nc2ccc(cc2)C(N)=O)cc(N)c1C#N",324.16985926,24,2.177,129.85,0.0147741513045895,0.156,0.0853870756522947,0,1
"EF5","cytochrome P450 activator","","[O-][N+](=O)c1nccn1CC(=O)NCC(F)(F)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","[O-][N+](=O)c1nccn1CC(=O)NCC(F)(F)C(F)(F)F",302.043831184,20,1.808,90.06,0.0227361971415067,0.148,0.0853680985707533,0,1
"exatecan-mesylate","topoisomerase inhibitor","TOP1","CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45",435.159434404,32,2.724,107.44,0.0126607615287205,0.158,0.0853303807643602,0,1
"alosetron","serotonin receptor antagonist","HTR3A","Cc1nc[nH]c1CN1CCc2c(C1=O)c1ccccc1n2C, Cc1nc[nH]c1CN1CCc2c(C1=O)c1ccccc1n2C, Cc1nc[nH]c1CN1CCc2c(C1=O)c1ccccc1n2C",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","Cc1nc[nH]c1CN1CCc2c(C1=O)c1ccccc1n2C",294.148061196,22,2.323,53.92,0.104616171857099,0.066,0.0853080859285496,0,0
"piboserod","serotonin receptor antagonist","HTR2B, HTR4","CCCCN1CCC(CNC(=O)c2c3OCCCn3c3ccccc23)CC1, CCCCN1CCC(CNC(=O)c2c3OCCCn3c3ccccc23)CC1, CCCCN1CCC(CNC(=O)c2c3OCCCn3c3ccccc23)CC1",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCCN1CCC(CNC(=O)c2c3OCCCn3c3ccccc23)CC1",369.241627232,27,5.479,46.5,0.136576619116474,0.034,0.0852883095582368,1,0
"SGC-0946","histone lysine methyltransferase inhibitor","","CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12",617.23251486,40,4.091,150.79,0.000533244420674132,0.17,0.0852666222103371,0,1
"PD-123319","angiotensin antagonist","AGTR2","CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C, CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C, CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C, CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C",508.247440884,38,4.869,78.67,0.0285196971633726,0.142,0.0852598485816863,0,1
"KR-33494","cell death inhibitor ","","OC(=O)c1nn(CCc2ccccc2)cc1NC(=O)CSc1ccc(Br)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1nn(CCc2ccccc2)cc1NC(=O)CSc1ccc(Br)cc1",459.025224536,28,4.765,109.52,0.0045121509569574,0.166,0.0852560754784787,0,1
"4-CMTB","free fatty acid receptor agonist","FFAR2","CC(C)[C@@H](C(=O)Nc1nccs1)c1ccc(Cl)cc1 |&1:3,r|, CC(C)[C@@H](C(=O)Nc1nccs1)c1ccc(Cl)cc1 |&1:3,r|, CC(C)[C@@H](C(=O)Nc1nccs1)c1ccc(Cl)cc1 |&1:3,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)[C@@H](C(=O)Nc1nccs1)c1ccc(Cl)cc1 |&1:3",294.05936178,19,3.29,70.23,0.0484728535455382,0.122,0.0852364267727691,0,0
"lmp7-in-1","","PSMB8","OB(O)[C@H](Cc1coc2ccccc12)NC(=O)[C@@H]1C[C@H]2CC[C@@H]1O2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OB(O)[C@H](Cc1coc2ccccc12)NC(=O)[C@@H]1C[C@H]2CC[C@@H]1O2",329.14345314,24,0.812,91.93,0.0224302123612926,0.148,0.0852151061806463,0,1
"AZ-12080282","hedgehog pathway inhibitor","DHH","Cc1ccc(cc1NC(=O)c1ccc(OCc2ccccn2)cc1)-c1ncc[nH]1, Cc1ccc(cc1NC(=O)c1ccc(OCc2ccccn2)cc1)-c1ncc[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(cc1NC(=O)c1ccc(OCc2ccccn2)cc1)-c1ncc[nH]1",384.15862588,29,3.574,79.9,0.0482720362737039,0.122,0.0851360181368519,0,0
"SC-236","cyclooxygenase inhibitor","PTGS2","NS(=O)(=O)c1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F, NS(=O)(=O)c1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F, NS(=O)(=O)c1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NS(=O)(=O)c1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F",401.021259932,26,4.077,86.36,0.01626537633882,0.154,0.08513268816941,0,1
"VX-222","HCV inhibitor","","C[C@H]1CC[C@@H](CC1)C(=O)N([C@@H]1CC[C@H](O)CC1)c1cc(sc1C(O)=O)C#CC(C)(C)C |r|, C[C@H]1CC[C@@H](CC1)C(=O)N([C@@H]1CC[C@H](O)CC1)c1cc(sc1C(O)=O)C#CC(C)(C)C |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@H]1CC[C@@H](CC1)C(=O)N([C@@H]1CC[C@H](O)CC1)c1cc(sc1C(O)=O)C#CC(C)(C)C |r|",445.2286796,31,5.53,106.08,0.0161772705552049,0.154,0.0850886352776025,0,1
"PF-06260414","androgen receptor modulator","","C[C@@H]1CNS(=O)(=O)N(C1)c1ccc2c(nccc2c1)C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@@H]1CNS(=O)(=O)N(C1)c1ccc2c(nccc2c1)C#N",302.083746688,21,1.544,94.47,0.0241668958952273,0.146,0.0850834479476137,0,1
"AZ-628","RAF inhibitor","BRAF, RAF1","Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1",451.20082504,34,4.703,99.81,0.0261650717065377,0.144,0.0850825358532689,0,1
"CO-101244","glutamate receptor antagonist","GRIN2B","Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1, Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1, Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1, Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1",341.199093724,25,3.517,52.93,0.0940830340641725,0.076,0.0850415170320862,0,0
"bisoctrizole","","","CC(C)(C)CC(C)(C)c1cc(Cc2cc(cc(c2O)-n2nc3ccccc3n2)C(C)(C)CC(C)(C)C)c(O)c(c1)-n1nc2ccccc2n1, CC(C)(C)CC(C)(C)c1cc(Cc2cc(cc(c2O)-n2nc3ccccc3n2)C(C)(C)CC(C)(C)C)c(O)c(c1)-n1nc2ccccc2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)(C)CC(C)(C)c1cc(Cc2cc(cc(c2O)-n2nc3ccccc3n2)C(C)(C)CC(C)(C)C)c(O)c(c1)-n1nc2ccccc2n1",658.39952484,49,15.451,101.88,0.0740751421197607,0.096,0.0850375710598804,0,0
"cinoctramide","","","COc1cc(\C=C\C(=O)N2CCCCCCC2)cc(OC)c1OC, COc1cc(\C=C\C(=O)N2CCCCCCC2)cc(OC)c1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(\C=C\C(=O)N2CCCCCCC2)cc(OC)c1OC",333.194008344,24,3.109,48,0.091987527841011,0.078,0.0849937639205055,0,0
"spiroxatrine","serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2B","O=C1NCN(c2ccccc2)C11CCN(C[C@H]2COc3ccccc3O2)CC1 |&1:16,r|, O=C1NCN(c2ccccc2)C11CCN(C[C@H]2COc3ccccc3O2)CC1 |&1:16,r|",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,1,6,0,0,0,0,"preclinical","","","O=C1NCN(c2ccccc2)C11CCN(C[C@H]2COc3ccccc3O2)CC1 |&1:16",379.18959166,28,2.8,54.04,0.0639589278468365,0.106,0.0849794639234182,0,0
"lanabecestat","beta secretase inhibitor","","CO[C@H]1CC[C@@]2(Cc3ccc(cc3[C@@]22N=C(C)C(N)=N2)-c2cncc(c2)C#CC)CC1 |c:20,t:16|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CO[C@H]1CC[C@@]2(Cc3ccc(cc3[C@@]22N=C(C)C(N)=N2)-c2cncc(c2)C#CC)CC1 |c:20",412.226311516,31,4.242,72.86,0.0539331881439461,0.116,0.0849665940719731,0,0
"pinocembrin","cytochrome P450 inhibitor","CYP1B1","Oc1cc(O)c2C(=O)C[C@H](Oc2c1)c1ccccc1, Oc1cc(O)c2C(=O)C[C@H](Oc2c1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Oc1cc(O)c2C(=O)C[C@H](Oc2c1)c1ccccc1",256.073558864,19,2.435,66.76,0.0999201122609249,0.07,0.0849600561304624,0,0
"ETP-46464","ATR kinase inhibitor","","CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1",470.174275944,36,5.451,79.11,0.0499160449188795,0.12,0.0849580224594397,0,0
"WAY-208466","serotonin receptor agonist","DRD2, HTR2A, HTR2C, HTR6, HTR7","CN(C)CCn1cc(c2cccnc12)S(=O)(=O)c1cccc(F)c1, CN(C)CCn1cc(c2cccnc12)S(=O)(=O)c1cccc(F)c1, CN(C)CCn1cc(c2cccnc12)S(=O)(=O)c1cccc(F)c1",0,0,0,0,0,0,0,0,1,4,0,0,0,0,1,1,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)CCn1cc(c2cccnc12)S(=O)(=O)c1cccc(F)c1",347.110376036,24,2.898,63.58,0.0458564193871953,0.124,0.0849282096935976,0,0
"AZD9668","elastase inhibitor","ELANE","Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C, Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C, Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C",545.134459844,38,4.519,124.33,0.00385472284701867,0.166,0.0849273614235093,0,1
"apabetalone","apolipoprotein expression enhancer","BRD3","COc1cc(OC)c2c(c1)[nH]c(nc2=O)-c1cc(C)c(OCCO)c(C)c1, COc1cc(OC)c2c(c1)[nH]c(nc2=O)-c1cc(C)c(OCCO)c(C)c1, COc1cc(OC)c2c(c1)[nH]c(nc2=O)-c1cc(C)c(OCCO)c(C)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1cc(OC)c2c(c1)[nH]c(nc2=O)-c1cc(C)c(OCCO)c(C)c1",370.152871804,27,3.859,93.67,0.0336748014608205,0.136,0.0848374007304103,0,1
"ilorasertib","aurora kinase inhibitor","AURKC, KDR, VEGFA","Nc1ncc(c2cnn(CCO)c2)c3scc(c4ccc(NC(=O)Nc5cccc(F)c5)cc4)c13",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","hematologic malignancy","chronic myelomonocytic leukemia (cmmol)","Nc1ncc(c2cnn(CCO)c2)c3scc(c4ccc(NC(=O)Nc5cccc(F)c5)cc4)c13",488.143073132,35,3.659,146.33,0.00366869541336016,0.166,0.0848343477066801,0,1
"indoprofen","cyclooxygenase inhibitor, prostanoid receptor antagonist","CXCR1, CXCR2, PTGS1, PTGS2","C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1,r|",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1",281.10519334,21,2.464,57.61,0.107503671367039,0.062,0.0847518356835193,0,0
"roblitinib","FGFR inhibitor","","COCCNc1cc(NC(=O)N2CCCc3cc(CN4CCN(C)CC4=O)c(C=O)nc23)ncc1C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COCCNc1cc(NC(=O)N2CCCc3cc(CN4CCN(C)CC4=O)c(C=O)nc23)ncc1C#N",506.23900144,37,-0.401,143.79,0.00148166410077799,0.168,0.084740832050389,0,1
"GSK461364","PLK inhibitor","PLK1","C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F, C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F, C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F, C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F",543.191580796,38,3.923,104.86,0.00547010895558032,0.164,0.0847350544777902,0,1
"bisantrene","topoisomerase inhibitor","","C1CN=C(N\N=C\c2c3ccccc3c(\C=N\NC3=NCCN3)c3ccccc23)N1 |t:2,19|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C1CN=C(N\N=C\c2c3ccccc3c(\C=N\NC3=NCCN3)c3ccccc23)N1 |t:2",398.196742704,30,5.6,97.56,0.0474688025449833,0.122,0.0847344012724917,0,0
"TC-A-2317","Aurora kinase inhibitor","AURKA","C[C@@H](CCCC(C)(C)O)Nc1nc(Nc2cc(C)n[nH]2)cc(C)c1C#N |&1:1|, C[C@@H](CCCC(C)(C)O)Nc1nc(Nc2cc(C)n[nH]2)cc(C)c1C#N |&1:1|, C[C@@H](CCCC(C)(C)O)Nc1nc(Nc2cc(C)n[nH]2)cc(C)c1C#N |&1:1|, C[C@@H](CCCC(C)(C)O)Nc1nc(Nc2cc(C)n[nH]2)cc(C)c1C#N |&1:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](CCCC(C)(C)O)Nc1nc(Nc2cc(C)n[nH]2)cc(C)c1C#N |&1:1|",356.232459516,26,4.389,109.65,0.0294604167217658,0.14,0.0847302083608829,0,1
"WAY-362450","FXR agonist","NR1H4","CC(C)OC(=O)C1=CN(CC(C)(C)c2c1[nH]c1ccccc21)C(=O)c1ccc(F)c(F)c1 |t:6|, CC(C)OC(=O)C1=CN(CC(C)(C)c2c1[nH]c1ccccc21)C(=O)c1ccc(F)c(F)c1 |t:6|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)OC(=O)C1=CN(CC(C)(C)c2c1[nH]c1ccccc21)C(=O)c1ccc(F)c(F)c1 |t:6|",438.175499068,32,5.941,62.4,0.0694416958323212,0.1,0.0847208479161606,0,0
"HJC-0350","GTPase inhibitor","RAPGEF4","Cc1cc(C)n(c1)S(=O)(=O)c1c(C)cc(C)cc1C, Cc1cc(C)n(c1)S(=O)(=O)c1c(C)cc(C)cc1C, Cc1cc(C)n(c1)S(=O)(=O)c1c(C)cc(C)cc1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(C)n(c1)S(=O)(=O)c1c(C)cc(C)cc1C",277.113649848,19,3.476,47.45,0.119396915062609,0.05,0.0846984575313044,1,0
"YZ9","phosphofructokinase inhibitor","MIF, PFKFB3","CCOC(=O)c1cc2ccc(O)cc2oc1=O, CCOC(=O)c1cc2ccc(O)cc2oc1=O, CCOC(=O)c1cc2ccc(O)cc2oc1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)c1cc2ccc(O)cc2oc1=O",234.05282342,17,2.603,76.74,0.08926564409071,0.08,0.084632822045355,0,0
"VU0238429","acetylcholine receptor allosteric modulator","CHRM5","COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"preclinical","","","COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1",351.071842524,25,3.519,55.84,0.0712396742775822,0.098,0.0846198371387911,0,0
"sr 146131","cck receptor agonist","CCKAR","O=C(O)CN1C(C(NC2=NC(C3=CC(OC)=C(Cl)C=C3OC)=C(CCC4CCCCC4)S2)=O)=CC5=C1C(C)=CC(C)=C5",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","oncology","neuroblastoma","O=C(O)CN1C(C(NC2=NC(C3=CC(OC)=C(Cl)C=C3OC)=C(CCC4CCCCC4)S2)=O)=CC5=C1C(C)=CC(C)=C5",609.206419932,42,6.388,125.76,0.00320619955157493,0.166,0.0846030997757875,0,1
"PYM50028","neurotrophic agent","","C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC[C@@H]5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@H](C)CO1, C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC[C@@H]5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@H](C)CO1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC[C@@H]5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@H](C)CO1",416.329045268,30,7.306,38.69,0.161201437399488,0.008,0.084600718699744,1,0
"pyrotinib","kinase inhibitor","","CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\[C@H]1CCCN1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\[C@H]1CCCN1C",582.214616532,42,4.475,112.4,0.00520129622616554,0.164,0.0846006481130828,0,1
"anacetrapib","cholesteryl ester transfer protein inhibitor","CETP","COc1cc(F)c(cc1-c1ccc(cc1CN1[C@@H](C)[C@H](OC1=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(F)(F)F)C(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1cc(F)c(cc1-c1ccc(cc1CN1[C@@H](C)[C@H](OC1=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(F)(F)F)C(C)C",637.16747586,44,9.781,38.77,0.0431857063698952,0.126,0.0845928531849476,0,0
"anacetrapib (mk-0859)","cholesteryl ester transfer protein inhibitor","","COc1cc(F)c(cc1-c1ccc(cc1CN1[C@H](C)[C@H](OC1=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(F)(F)F)C(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1cc(F)c(cc1-c1ccc(cc1CN1[C@H](C)[C@H](OC1=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(F)(F)F)C(C)C",637.16747586,44,9.781,38.77,0.0431857063698952,0.126,0.0845928531849476,0,0
"rhein","","HSP90AA1","OC(=O)c1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1, OC(=O)c1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1, OC(=O)c1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC(=O)c1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1",284.032087976,21,1.911,111.9,0.0271001949016702,0.142,0.0845500974508351,0,1
"bufexamac","cyclooxygenase inhibitor","HDAC10, HDAC6","CCCCOc1ccc(CC(=O)NO)cc1, CCCCOc1ccc(CC(=O)NO)cc1, CCCCOc1ccc(CC(=O)NO)cc1, CCCCOc1ccc(CC(=O)NO)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CCCCOc1ccc(CC(=O)NO)cc1",223.120843404,16,2.066,58.56,0.118997522249588,0.05,0.0844987611247938,1,0
"BW-616U","monoamine oxidase inhibitor","MAOA","CNC(=O)c1ccc2C(=O)c3ccccc3S(=O)(=O)c2c1, CNC(=O)c1ccc2C(=O)c3ccccc3S(=O)(=O)c2c1",0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CNC(=O)c1ccc2C(=O)c3ccccc3S(=O)(=O)c2c1",301.040878832,21,1.933,88.69,0.0309498119562781,0.138,0.084474905978139,0,1
"AZD5069","CC chemokine receptor antagonist","CXCR2","C[C@@H](Oc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@@H](Oc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO",476.099968244,31,1.732,158.56,0.000916248660219081,0.168,0.0844581243301095,0,1
"SRT3190","CC chemokine receptor antagonist","","C[C@H](Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO, C[C@H](Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO, C[C@H](Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H](Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO",475.115952656,31,1.892,161.36,0.00091429655904641,0.168,0.0844571482795232,0,1
"tenilsetam","AGE inhibitor","","O=C1NCCN[C@@H]1c1cccs1 |&1:6,r|, O=C1NCCN[C@@H]1c1cccs1 |&1:6,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","O=C1NCCN[C@@H]1c1cccs1 |&1:6",182.05138394,12,-0.148,69.37,0.0609119808499251,0.108,0.0844559904249625,0,0
"TCS-3035","G protein-coupled receptor agonist","GPR35","OC(=O)COc1ccc(\C=C2/SC(=O)NC2=O)cc1, OC(=O)COc1ccc(\C=C2/SC(=O)NC2=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)COc1ccc(\C=C2/SC(=O)NC2=O)cc1",279.020143388,19,0.768,118,0.0128231551704997,0.156,0.0844115775852499,0,1
"CX-5461","RNA polymerase inhibitor","","CN1CCCN(CC1)c1ccc2c(n1)n1c3ccccc3sc1c(C(=O)NCc1cnc(C)cn1)c2=O, CN1CCCN(CC1)c1ccc2c(n1)n1c3ccccc3sc1c(C(=O)NCc1cnc(C)cn1)c2=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN1CCCN(CC1)c1ccc2c(n1)n1c3ccccc3sc1c(C(=O)NCc1cnc(C)cn1)c2=O",513.194694104,37,4.641,123.97,0.00680628738423155,0.162,0.0844031436921158,0,1
"nevanimibe hydrochloride","acat inhibitor","ACAT1","CC(C)c1cccc(C(C)C)c1NC(=O)NCC1(CCCC1)c1ccc(cc1)N(C)C.Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","endocrinology","congenital adrenal hyperplasia","CC(C)c1cccc(C(C)C)c1NC(=O)NCC1(CCCC1)c1ccc(cc1)N(C)C.Cl",457.28599058,32,7.185,44.37,0.0887432289979445,0.08,0.0843716144989723,0,0
"carnitine-(D/L)","","","C[N+](C)(C)C[C@@H](O)CC(O)=O |&1:5|, C[N+](C)(C)C[C@@H](O)CC(O)=O |&1:5|, C[N+](C)(C)C[C@@H](O)CC(O)=O |&1:5|, C[N+](C)(C)C[C@@H](O)CC(O)=O |&1:5|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C[N+](C)(C)C[C@@H](O)CC(O)=O |&1:5|",162.112469792091,11,-1.26,57.53,0.0767406558291151,0.092,0.0843703279145576,0,0
"LY2109761","TGF beta receptor inhibitor","TGFBR1, TGFBR2","C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1, C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1, C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1, C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1, C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1, C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1",441.216475104,33,2.835,65.3,0.0367304493842377,0.132,0.0843652246921189,0,1
"avasimibe","ACAT inhibitor","CES1","CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C",501.291279856,35,8.043,80.85,0.0347180926062313,0.134,0.0843590463031156,0,1
"procodazole","immunostimulant","","OC(=O)CCc1nc2ccccc2[nH]1, OC(=O)CCc1nc2ccccc2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)CCc1nc2ccccc2[nH]1",190.07422756,14,0.923,65.98,0.106680860746074,0.062,0.0843404303730371,0,0
"ST-2825","myeloid differentiation primary response inhibitor","MYD88","NC(=O)[C@H]1CCS[C@@H]2C[C@]3(CCCN3C(=O)Cc3ccc(NC(=O)COc4ccc(Cl)cc4Cl)cc3)C(=O)N12, NC(=O)[C@H]1CCS[C@@H]2C[C@]3(CCCN3C(=O)Cc3ccc(NC(=O)COc4ccc(Cl)cc4Cl)cc3)C(=O)N12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC(=O)[C@H]1CCS[C@@H]2C[C@]3(CCCN3C(=O)Cc3ccc(NC(=O)COc4ccc(Cl)cc4Cl)cc3)C(=O)N12",590.115746356,39,2.591,147.34,0.000607191926329244,0.168,0.0843035959631646,0,1
"SRPIN340","serine arginine protein kinase inhibitor","SRPK1, SRPK2","FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1, FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1, FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1, FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1",349.140196856,25,3.859,45.23,0.100449680822083,0.068,0.0842248404110417,0,0
"ML347","ALK tyrosine kinase receptor inhibitor","ACVR1, ACVRL1, BMPR1A","COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12",352.132411132,27,4.355,52.31,0.136418995467894,0.032,0.0842094977339472,1,0
"cndac","","","NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N",252.085854864,18,-2.429,132.17,0.0064142655396193,0.162,0.0842071327698097,0,1
"HC-070","transient receptor potential channel antagonist","","Cn1c2nc(Oc3cccc(Cl)c3)n(Cc3ccc(Cl)cc3)c2c(=O)n(CCCO)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cn1c2nc(Oc3cccc(Cl)c3)n(Cc3ccc(Cl)cc3)c2c(=O)n(CCCO)c1=O",474.08616048,32,6.063,91.28,0.0164066842552343,0.152,0.0842033421276172,0,1
"methiopril","angiotensin converting enzyme inhibitor","ACE","C[C@@H]1CCC[C@@H](N1C(=O)CCSC(C)=O)C(O)=O |&1:1,5,r|, CC1CCCC(N1C(=O)CCSC(C)=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@@H]1CCC[C@@H](N1C(=O)CCSC(C)=O)C(O)=O |&1:1",273.103479088,18,0.917,99.98,0.0183741845798367,0.15,0.0841870922899184,0,1
"SAR131675","VEGFR inhibitor","FLT4","CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC, CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC",358.164105184,26,3.039,119.47,0.0163054519051523,0.152,0.0841527259525762,0,1
"AZD3839","beta-secretase inhibitor","BACE1","NC1=N[C@@](c2cccc(F)c12)(c1cccc(c1)-c1cncnc1)c1ccnc(c1)C(F)F |t:1|, NC1=N[C@@](c2cccc(F)c12)(c1cccc(c1)-c1cncnc1)c1ccnc(c1)C(F)F |t:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","NC1=N[C@@](c2cccc(F)c12)(c1cccc(c1)-c1cncnc1)c1ccnc(c1)C(F)F |t:1|",431.135780172,32,4.078,77.05,0.038286490451506,0.13,0.084143245225753,0,1
"TEPP-46","pyruvate kinase isozyme activator","PKM","Cn1c2cc(sc2c2cnn(Cc3cccc(N)c3)c(=O)c12)[S@@](C)=O |r|, Cn1c2cc(sc2c2cnn(Cc3cccc(N)c3)c(=O)c12)[S@@](C)=O |r|, Cn1c2cc(sc2c2cnn(Cc3cccc(N)c3)c(=O)c12)[S@@](C)=O |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cn1c2cc(sc2c2cnn(Cc3cccc(N)c3)c(=O)c12)[S@@](C)=O |r|",372.071467752,25,0.854000000000001,130.36,0.00427259610216262,0.164,0.0841362980510813,0,1
"cimaterol","adrenergic receptor agonist","ADRB1, ADRB2, ADRB3","CC(C)NC[C@@H](O)c1ccc(N)c(c1)C#N |&1:5,r|, CC(C)NC[C@@H](O)c1ccc(N)c(c1)C#N |&1:5,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,"preclinical","","","CC(C)NC[C@@H](O)c1ccc(N)c(c1)C#N |&1:5",219.137162164,16,0.717,82.07,0.0582682984080813,0.11,0.0841341492040407,0,0
"ER-50891","retinoid receptor antagonist","RARA","CC(C)c1cccc2c(cc(nc12)-c1ccc([nH]1)-c1ccc(cc1)C(O)=O)-c1ccccc1, CC(C)c1cccc2c(cc(nc12)-c1ccc([nH]1)-c1ccc(cc1)C(O)=O)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)c1cccc2c(cc(nc12)-c1ccc([nH]1)-c1ccc(cc1)C(O)=O)-c1ccccc1",432.183778008,33,7.666,65.98,0.132225186832293,0.036,0.0841125934161463,1,0
"spirapril","angiotensin converting enzyme inhibitor","ACE","O=C(OCC)[C@@H](N[C@H](C(=O)N2[C@H](C(=O)O)CC1(SCCS1)C2)C)CCc3ccccc3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","cardiology","hypertension","O=C(OCC)[C@@H](N[C@H](C(=O)N2[C@H](C(=O)O)CC1(SCCS1)C2)C)CCc3ccccc3",466.15961406,31,2.972,146.54,0.00207900059188565,0.166,0.0840395002959428,0,1
"telenzepine","acetylcholine receptor antagonist","CHRM1","CN1CCN(CC(=O)N2c3c(C)scc3C(=O)Nc3ccccc23)CC1, CN1CCN(CC(=O)N2c3c(C)scc3C(=O)Nc3ccccc23)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"phase 3","","","CN1CCN(CC(=O)N2c3c(C)scc3C(=O)Nc3ccccc23)CC1",370.146346944,26,0.791,84.13,0.0160087159733795,0.152,0.0840043579866897,0,1
"PF-05175157","acetyl-CoA carboxylase inhibitor","","[H]n1c(C)nc2ccc(cc12)C(=O)N1CCC2(CC1)Cc1cnn(C(C)C)c1C(=O)C2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","[H]n1c(C)nc2ccc(cc12)C(=O)N1CCC2(CC1)Cc1cnn(C(C)C)c1C(=O)C2",405.216475104,31,2.874,83.88,0.0359844240973936,0.132,0.0839922120486968,0,1
"ANR-94","adenosine receptor antagonist","ADORA2A","CCOc1nc2c(N)ncnc2n1CC, CCOc1nc2c(N)ncnc2n1CC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOc1nc2c(N)ncnc2n1CC",207.112010036,15,1.22,78.85,0.0739497651889704,0.094,0.0839748825944852,0,0
"MF-101","estrogen receptor agonist","CYP19A1, XDH","Oc1ccc(cc1)[C@@H]1CC(=O)c2ccc(O)cc2O1, Oc1ccc(cc1)[C@@H]1CC(=O)c2ccc(O)cc2O1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Oc1ccc(cc1)[C@@H]1CC(=O)c2ccc(O)cc2O1",256.073558864,19,2.435,66.76,0.0999201122609249,0.068,0.0839600561304624,0,0
"SB-334867","orexin receptor antagonist","HCRTR1, HCRTR2","Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1, Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1, Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1, Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1",319.106924656,24,0.843,92.94,0.0279091140491202,0.14,0.0839545570245601,0,1
"8-hydroxy-PIPAT","dopamine receptor ligand","DRD2, DRD3","CCCN(C\C=C\I)[C@H]1CCc2cccc(O)c2C1 |&1:8|, CCCN(C\C=C\I)[C@H]1CCc2cccc(O)c2C1 |&1:8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"preclinical","","","CCCN(C\C=C\I)[C@H]1CCc2cccc(O)c2C1 |&1:8|",371.074612324,19,4.317,23.47,0.0298130553450355,0.138,0.0839065276725178,0,1
"dilmapimod","p38 MAPK inhibitor","","Cc1cc(F)ccc1-c1nc(NC(CO)CO)nc2n(-c3c(F)cccc3F)c(=O)ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1cc(F)ccc1-c1nc(NC(CO)CO)nc2n(-c3c(F)cccc3F)c(=O)ccc12",456.140925128,33,4.064,100.27,0.0157848172139151,0.152,0.0838924086069576,0,1
"SKA-31","potassium channel activator","KCNN4","Nc1nc2c(ccc3ccccc23)s1, Nc1nc2c(ccc3ccccc23)s1, Nc1nc2c(ccc3ccccc23)s1, Nc1nc2c(ccc3ccccc23)s1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1nc2c(ccc3ccccc23)s1",200.040819256,14,2.38,67.15,0.115769929100119,0.052,0.0838849645500593,1,0
"metoprine","histamine n-methyltransferase inhibitor","DHFR, HNMT","CC1=C(C(N)=NC(N)=N1)C2=CC=C(C(Cl)=C2)Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","oncology","renal cell carcinoma (rcc)","CC1=C(C(N)=NC(N)=N1)C2=CC=C(C(Cl)=C2)Cl",268.02825168,17,0.55,76.76,0.0256037867531158,0.142,0.0838018933765579,0,1
"BAY-11-7082","NFkB pathway inhibitor","RELA","Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(cc1)S(=O)(=O)\C=C\C#N",207.035399528,14,1.818,66.31,0.0895824001178169,0.078,0.0837912000589084,0,0
"I-BET151","bromodomain inhibitor","BRD2, BRD3, BRD4","COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C",415.164439532,31,2.69,98.83,0.019500896400524,0.148,0.083750448200262,0,1
"voreloxin","topoisomerase inhibitor","TOP2A","CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1, CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1, CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1",401.115775088,28,2.593,137.82,0.00548233962508418,0.162,0.0837411698125421,0,1
"pagoclone","GABA receptor agonist","","CC(C)CCC(=O)C[C@@H]1N(C(=O)c2ccccc12)c1ccc2ccc(Cl)nc2n1 |&1:8,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","CC(C)CCC(=O)C[C@@H]1N(C(=O)c2ccccc12)c1ccc2ccc(Cl)nc2n1 |&1:8",407.140054624,29,5.131,63.16,0.0594747905771191,0.108,0.0837373952885596,0,0
"ML179","liver receptor homolog inverse agonist","NR5A2","FC(F)(F)c1cccc(c1)N1CCN(CC1)c1cc(=O)n(C2CCCCC2)c(=O)[nH]1, FC(F)(F)c1cccc(c1)N1CCN(CC1)c1cc(=O)n(C2CCCCC2)c(=O)[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)c1cccc(c1)N1CCN(CC1)c1cc(=O)n(C2CCCCC2)c(=O)[nH]1",422.1929607,30,6.036,61.34,0.0674735948478077,0.1,0.0837367974239039,0,0
"BAN-ORL-24","nociceptin/orphanin FQ receptor antagonist","OPRL1","O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1",433.27292736,32,3.269,44.81,0.0614705734881659,0.106,0.083735286744083,0,0
"GNTI","opioid receptor antagonist","OPRK1, OPRM1","NC(=N)Nc1ccc2[nH]c3[C@@H]4Oc5c6c(C[C@H]7N(CC8CC8)CC[C@@]46[C@@]7(O)Cc3c2c1)ccc5O, NC(=N)Nc1ccc2[nH]c3[C@@H]4Oc5c6c(C[C@H]7N(CC8CC8)CC[C@@]46[C@@]7(O)Cc3c2c1)ccc5O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC(=N)Nc1ccc2[nH]c3[C@@H]4Oc5c6c(C[C@H]7N(CC8CC8)CC[C@@]46[C@@]7(O)Cc3c2c1)ccc5O",471.227039788,35,2.115,130.62,0.00540864918061606,0.162,0.083704324590308,0,1
"efloxate","vasodilator","","CCOC(=O)COc1ccc2c(c1)oc(cc2=O)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)COc1ccc2c(c1)oc(cc2=O)-c1ccccc1",324.099773612,24,4.927,65.74,0.115326345999693,0.052,0.0836631729998464,1,0
"7-nitroindazole","nitric oxide synthase inhibitor","NOS1, NOS2, NOS3","[O-][N+](=O)c1cccc2c[nH]nc12, [O-][N+](=O)c1cccc2c[nH]nc12, [O-][N+](=O)c1cccc2c[nH]nc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[O-][N+](=O)c1cccc2c[nH]nc12",163.0381764,12,2.352,71.82,0.151306089510767,0.016,0.0836530447553834,1,0
"VT-464","cytochrome P450 inhibitor","CYP17A1","CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1, CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1, CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1, CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1, CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1",399.120604284,28,5.73,80.26,0.0452575772236875,0.122,0.0836287886118437,0,0
"oltipraz","nuclear factor erythroid derived, like (NRF2) activator","ANG","Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cc1c(ssc1=S)-c1cnccn1",225.969311192,13,0.345,114.35,0.0112402195258579,0.156,0.0836201097629289,0,1
"TAK-715","p38 MAPK inhibitor","MAPK14","CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1",399.140533292,29,5.419,83.12,0.0491864886030515,0.118,0.0835932443015257,0,0
"mefexamide","psychoactive drug","","CCN(CC)CCNC(=O)COc1ccc(OC)cc1, CCN(CC)CCNC(=O)COc1ccc(OC)cc1, CCN(CC)CCNC(=O)COc1ccc(OC)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN(CC)CCNC(=O)COc1ccc(OC)cc1",280.178692628,20,1.723,50.8,0.0871701967207856,0.08,0.0835850983603928,0,0
"OSI-930","KIT inhibitor, VEGFR inhibitor","FLT1, KDR, KIT","FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1, FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1, FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1, FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1, FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1",443.091532412,31,5.435,91.49,0.0231620911645819,0.144,0.0835810455822909,0,1
"zomepirac","prostaglandin synthesis inhibitor","PTGDR2","Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1, Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1, Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1",291.066220988,20,2.93,59.3,0.0751617963988226,0.092,0.0835808981994113,0,0
"Ro-5126766","MEK inhibitor, RAF inhibitor","BRAF, MAP2K1, MAP2K2, RAF1","CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F, CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F, CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F",471.101267896,33,2.963,144.69,0.00304752163499977,0.164,0.0835237608174999,0,1
"BP-897","dopamine receptor agonist","ADRA1A, ADRA1D, ADRA2A, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2B","COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1, COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1",0,0,0,0,0,0,0,0,1,2,0,0,0,0,1,4,0,0,1,3,0,0,0,0,"phase 2","","","COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1",417.241627232,31,5.108,44.81,0.106999473856955,0.06,0.0834997369284777,0,0
"VER-155008","HSP inhibitor","HSPA1A","Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12",555.118857576,38,3.198,164.36,0.000870656793389717,0.166,0.0834353283966949,0,1
"SKF-96365","calcium channel blocker","CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2","COc1ccc(CCCO[C@@H](Cn2ccnc2)c2ccc(OC)cc2)cc1 |&1:10|, COc1ccc(CCCO[C@@H](Cn2ccnc2)c2ccc(OC)cc2)cc1 |&1:10|, COc1ccc(CCCO[C@@H](Cn2ccnc2)c2ccc(OC)cc2)cc1 |&1:10|, COc1ccc(CCCO[C@@H](Cn2ccnc2)c2ccc(OC)cc2)cc1 |&1:10|, COc1ccc(CCCO[C@@H](Cn2ccnc2)c2ccc(OC)cc2)cc1 |&1:10|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(CCCO[C@@H](Cn2ccnc2)c2ccc(OC)cc2)cc1 |&1:10|",366.194342692,27,3.945,45.51,0.106737048992593,0.06,0.0833685244962963,0,0
"retaspimycin","HSP inhibitor","HSP90AA1","CO[C@H]1C[C@H](C)Cc2c(O)c(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)cc(O)c2NCC=C |c:17,t:15,28|, CO[C@H]1C[C@H](C)Cc2c(O)c(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)cc(O)c2NCC=C |c:17,t:15,28|, CO[C@H]1C[C@H](C)Cc2c(O)c(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)cc(O)c2NCC=C |c:17,t:15,28|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CO[C@H]1C[C@H](C)Cc2c(O)c(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)cc(O)c2NCC=C |c:17",587.3206654,42,2.629,172.6,0.000728221757903775,0.166,0.0833641108789519,0,1
"CP-673451","PDGFR tyrosine kinase receptor inhibitor","KIT, PDGFRA, PDGFRB","COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1",417.216475104,31,3.839,78.43,0.0387213978426366,0.128,0.0833606989213183,0,0
"GSK2239633A","CC chemokine receptor antagonist","","COc1cccc2n(Cc3cccc(CNC(=O)C(C)(C)O)c3)nc(NS(=O)(=O)c3ccc(Cl)s3)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cccc2n(Cc3cccc(CNC(=O)C(C)(C)O)c3)nc(NS(=O)(=O)c3ccc(Cl)s3)c12",548.09548958,36,2.902,159.17,0.000681425950524183,0.166,0.0833407129752621,0,1
"zidebactam","beta lactamase inhibitor","","OS(=O)(=O)ON1[C@H]2CN([C@@H](CC2)C(=O)NNC(=O)[C@@H]2CCCNC2)C1=O |a:6,9,18|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","infectious disease","gram-negative bacterial infections","OS(=O)(=O)ON1[C@H]2CN([C@@H](CC2)C(=O)NNC(=O)[C@@H]2CCCNC2)C1=O |a:6",391.116169012,26,-2.559,165.76,0.000652471448146689,0.166,0.0833262357240734,0,1
"leteprinim","nerve growth factor agonist","","OC(=O)c1ccc(NC(=O)CCn2cnc3c2[nH]cnc3=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)c1ccc(NC(=O)CCn2cnc3c2[nH]cnc3=O)cc1",327.096753896,24,1.825,129.97,0.0126283105728982,0.154,0.0833141552864491,0,1
"4EGI-1","protein synthesis inhibitor","EIF4E","OC(=O)C(Cc1ccccc1[N+]([O-])=O)=NNc1nc(cs1)-c1ccc(Cl)c(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)C(Cc1ccccc1[N+]([O-])=O)=NNc1nc(cs1)-c1ccc(Cl)c(Cl)c1",449.995631224,29,3.961,145.96,0.00249210319523828,0.164,0.0832460515976192,0,1
"BAY-41-2272","guanylyl cyclase activator","GUCY1A3, GUCY1B3","Nc1nc(ncc1C1CC1)-c1nn(Cc2ccccc2F)c2ncccc12, Nc1nc(ncc1C1CC1)-c1nn(Cc2ccccc2F)c2ncccc12, Nc1nc(ncc1C1CC1)-c1nn(Cc2ccccc2F)c2ncccc12, Nc1nc(ncc1C1CC1)-c1nn(Cc2ccccc2F)c2ncccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1nc(ncc1C1CC1)-c1nn(Cc2ccccc2F)c2ncccc12",360.149872764,27,3.719,82.51,0.0524908065818868,0.114,0.0832454032909434,0,0
"balaglitazone","insulin sensitizer, PPAR receptor partial agonist","PPARG","Cn1c(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc2ccccc2c1=O |r|, Cn1c(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc2ccccc2c1=O |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cn1c(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc2ccccc2c1=O |r|",395.093977024,28,2.555,115.59,0.0104493837346254,0.156,0.0832246918673127,0,1
"edonerpic-maleate","beta amyloid inhibitor","","OC1CN(CCCOCCc2ccc3sccc3c2)C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC1CN(CCCOCCc2ccc3sccc3c2)C1",291.129299912,20,1.992,60.94,0.0584362961976397,0.108,0.0832181480988199,0,0
"AM-1241","cannabinoid receptor agonist","CNR1, CNR2","CN1CCCC[C@@H]1Cn1cc(C(=O)c2cc(ccc2I)[N+]([O-])=O)c2ccccc12 |&1:6,r|, CN1CCCC[C@@H]1Cn1cc(C(=O)c2cc(ccc2I)[N+]([O-])=O)c2ccccc12 |&1:6,r|, CN1CCCC[C@@H]1Cn1cc(C(=O)c2cc(ccc2I)[N+]([O-])=O)c2ccccc12 |&1:6,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCCC[C@@H]1Cn1cc(C(=O)c2cc(ccc2I)[N+]([O-])=O)c2ccccc12 |&1:6",503.070589564,29,5.665,68.38,0.00640264688338555,0.16,0.0832013234416928,0,1
"refametinib","MEK inhibitor","MAP2K1, MAP2K2","COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1, COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1, COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1, COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1, COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1, COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1",572.0089754,31,3.204,116.27,0.0003539496004912,0.166,0.0831769748002456,0,1
"MK-0557","neuropeptide receptor antagonist","","Fc1ccccc1-n1ccc(NC(=O)[C@H]2CC[C@]3(CC2)OC(=O)c2ccncc32)n1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Fc1ccccc1-n1ccc(NC(=O)[C@H]2CC[C@]3(CC2)OC(=O)c2ccncc32)n1 |r|",406.144118688,30,2.799,86.11,0.0263203128575834,0.14,0.0831601564287917,0,1
"VU10010","acetylcholine receptor allosteric modulator","CHRM4","Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc(Cl)cc1, Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc(Cl)cc1, Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc(Cl)cc1, Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"preclinical","","","Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc(Cl)cc1",345.070260812,23,3.685,96.25,0.0222852681298411,0.144,0.0831426340649205,0,1
"NPY-5RA972","neuropeptide receptor antagonist","NPY5R","CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12, CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12, CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12",351.19467704,26,3.58,46.5,0.108244331115038,0.058,0.0831221655575191,0,0
"suloctidil","adrenergic receptor antagonist","","CCCCCCCCN[C@H](C)[C@@H](O)c1ccc(SC(C)C)cc1 |&1:9,11|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CCCCCCCCN[C@H](C)[C@@H](O)c1ccc(SC(C)C)cc1 |&1:9",337.24393574,23,6.411,57.56,0.116243033078059,0.05,0.0831215165390296,1,0
"TAK-593","VEGFR inhibitor","PDGFRA","Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1, Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1, Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1",445.186237596,33,3.361,115.44,0.0121884123066021,0.154,0.0830942061533011,0,1
"DG-172","PPAR receptor inverse agonist","PPARD","CN1CCN(CC1)c1ccc(\C=C(/C#N)c2ccccc2Br)cc1, CN1CCN(CC1)c1ccc(\C=C(/C#N)c2ccccc2Br)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCN(CC1)c1ccc(\C=C(/C#N)c2ccccc2Br)cc1",381.08405974,24,4.645,30.27,0.066184419094904,0.1,0.083092209547452,0,0
"ciproxifan","histamine receptor antagonist","ADRA2A, ADRA2C, HRH3, HRH4, HTR3A","O=C(C1CC1)c1ccc(OCCCc2cnc[nH]2)cc1, O=C(C1CC1)c1ccc(OCCCc2cnc[nH]2)cc1",0,0,0,0,0,0,0,0,1,1,1,2,0,0,0,0,0,0,1,2,0,0,0,0,"preclinical","","","O=C(C1CC1)c1ccc(OCCCc2cnc[nH]2)cc1",270.136827816,20,2.196,54.98,0.110125724650191,0.056,0.0830628623250956,0,0
"ab-680","cd antagonist","NT5E","C[C@H](Nc1cc(Cl)nc2c1cnn2[C@@H]3O[C@H](COP(=O)(O)CP(=O)(O)O)[C@@H](O)[C@H]3O)c4ccccc4F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","pancreatic cancer","C[C@H](Nc1cc(Cl)nc2c1cnn2[C@@H]3O[C@H](COP(=O)(O)CP(=O)(O)O)[C@@H](O)[C@H]3O)c4ccccc4F",580.069107508,37,0.186,216.11,5.48423656731061e-05,0.166,0.0830274211828366,0,1
"BMS-911543","JAK inhibitor","","CCn1c(cc2c1nc(Nc1cc(C)n(C)n1)c1ncn(C)c21)C(=O)N(C1CC1)C1CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","CCn1c(cc2c1nc(Nc1cc(C)n(C)n1)c1ncn(C)c21)C(=O)N(C1CC1)C1CC1",432.238607516,32,3.699,85.8,0.0280364784324851,0.138,0.0830182392162426,0,1
"AZD4635","adenosine receptor antagonist","","Cc1cc(cc(Cl)n1)-c1nnc(N)nc1-c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","Cc1cc(cc(Cl)n1)-c1nnc(N)nc1-c1ccc(F)cc1",315.068701252,22,2.803,77.58,0.044026824052073,0.122,0.0830134120260365,0,0
"ASA-404","angiogenesis inhibitor","","Cc1ccc2c(oc3c(CC(O)=O)cccc3c2=O)c1C, Cc1ccc2c(oc3c(CC(O)=O)cccc3c2=O)c1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cc1ccc2c(oc3c(CC(O)=O)cccc3c2=O)c1C",282.089208928,21,4.302,67.51,0.128011390663689,0.038,0.0830056953318443,1,0
"PLX647","receptor tyrosine protein kinase inhibitor","CSF1R, KIT","FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)cc1, FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)cc1",382.140531204,28,5.118,53.6,0.102004635467802,0.064,0.0830023177339009,0,0
"etrabamine","dopamine receptor agonist","","CN[C@H]1CCc2ncsc2C1 |&1:2,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN[C@H]1CCc2ncsc2C1 |&1:2",168.072119384,11,0.439,53.16,0.10794716249402,0.058,0.0829735812470101,0,0
"BW-723C86","serotonin receptor agonist","HTR2A, HTR2B, HTR2C","C[C@@H](N)Cc1c[nH]c2ccc(OCc3cccs3)cc12 |&1:1|, C[C@@H](N)Cc1c[nH]c2ccc(OCc3cccs3)cc12 |&1:1|, C[C@@H](N)Cc1c[nH]c2ccc(OCc3cccs3)cc12 |&1:1|",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](N)Cc1c[nH]c2ccc(OCc3cccs3)cc12 |&1:1|",286.113984196,20,2.557,79.28,0.0499134096581407,0.116,0.0829567048290703,0,0
"AH-7614","free fatty acid receptor antagonist","FFAR4","Cc1ccc(cc1)S(=O)(=O)NC1c2ccccc2Oc2ccccc12, Cc1ccc(cc1)S(=O)(=O)NC1c2ccccc2Oc2ccccc12, Cc1ccc(cc1)S(=O)(=O)NC1c2ccccc2Oc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(cc1)S(=O)(=O)NC1c2ccccc2Oc2ccccc12",351.092914404,25,4.052,63.78,0.0677594290898485,0.098,0.0828797145449242,0,0
"azd-0364","erk1 and erk2 phosphorylation inhibitor","MAPK1","COC[C@H]1Cn2cc(nc2C(=O)N1Cc1ccc(F)c(F)c1)-c1nc(Nc2ccnn2C)ncc1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","oncology","non-small cell lung cancer (nsclc)","COC[C@H]1Cn2cc(nc2C(=O)N1Cc1ccc(F)c(F)c1)-c1nc(Nc2ccnn2C)ncc1C",494.199028448,36,3.949,102.99,0.0116272460442718,0.154,0.0828136230221359,0,1
"vercirnon","CC chemokine receptor antagonist","CCR9","CC(C)(C)c1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)cc1C(=O)c1cc[n+]([O-])cc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)cc1C(=O)c1cc[n+]([O-])cc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)cc1C(=O)c1cc[n+]([O-])cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(C)(C)c1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)cc1C(=O)c1cc[n+]([O-])cc1",444.091055832,30,6.45,98.56,0.0196263580508387,0.146,0.0828131790254193,0,1
"BAY-11-7085","NFkB pathway inhibitor","NFKBIA","CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N, CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N",249.08234972,17,3.198,66.31,0.0916015297912876,0.074,0.0828007648956438,0,0
"R-1485","serotonin receptor antagonist","HTR6","Fc1ccccc1S(=O)(=O)N1CCOc2c(cccc12)N1CCNCC1, Fc1ccccc1S(=O)(=O)N1CCOc2c(cccc12)N1CCNCC1, Fc1ccccc1S(=O)(=O)N1CCOc2c(cccc12)N1CCNCC1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Fc1ccccc1S(=O)(=O)N1CCOc2c(cccc12)N1CCNCC1",377.12094072,26,2.997,70.26,0.0315982372052085,0.134,0.0827991186026042,0,1
"volinanserin","serotonin receptor antagonist","HTR2A, HTR2B, HTR2C, KCNH2","COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC, COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC",373.205321976,27,3.496,41.93,0.0895374760718625,0.076,0.0827687380359312,0,0
"rostafuroxine","ATPase inhibitor","ATP1A1","C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1",374.245709568,27,3.469,73.83,0.0435078311782318,0.122,0.0827539155891159,0,0
"benzotript","CCK receptor antagonist","CCKAR, CCKBR","OC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1 |&1:3,r|, OC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1 |&1:3",342.07712002,24,1.344,82.19,0.0234856491277625,0.142,0.0827428245638813,0,1
"centpropazine","inositol monophosphatase inhibitor","","CCC(=O)c1ccc(OC[C@@H](O)CN2CCN(CC2)c2ccccc2)cc1 |&1:10,r|, CCC(=O)c1ccc(OC[C@@H](O)CN2CCN(CC2)c2ccccc2)cc1 |&1:10,r|, CCC(=O)c1ccc(OC[C@@H](O)CN2CCN(CC2)c2ccccc2)cc1 |&1:10,r|, CCC(=O)c1ccc(OC[C@@H](O)CN2CCN(CC2)c2ccccc2)cc1 |&1:10,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCC(=O)c1ccc(OC[C@@H](O)CN2CCN(CC2)c2ccccc2)cc1 |&1:10",368.209992756,27,3.179,53.01,0.0734756021777363,0.092,0.0827378010888682,0,0
"JTC-801","opioid receptor antagonist","OPRL1","CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1",411.19467704,31,5.12,77.24,0.0614530221388601,0.104,0.08272651106943,0,0
"GW-9508","free fatty acid receptor agonist, G protein-coupled receptor agonist","FFAR1, FFAR4","OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1, OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1, OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1, OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1",347.152143532,26,4.455,58.56,0.111344167367637,0.054,0.0826720836838186,0,0
"NS-5806","voltage-gated potassium channel activator","KCND3","FC(F)(F)c1cc(NC(=O)Nc2c(Br)cc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(NC(=O)Nc2c(Br)cc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(NC(=O)Nc2c(Br)cc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)c1cc(NC(=O)Nc2c(Br)cc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F",571.903052396,31,6.379,95.59,0.00124772331652329,0.164,0.0826238616582616,0,1
"TC-S-7005","PLK inhibitor","PLK2","C[C@H](Nc1cc2c(noc2cn1)-c1ccc2OCOc2c1)c1ccccc1, C[C@H](Nc1cc2c(noc2cn1)-c1ccc2OCOc2c1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H](Nc1cc2c(noc2cn1)-c1ccc2OCOc2c1)c1ccccc1",359.126991404,27,4.805,69.41,0.0912358490245079,0.074,0.0826179245122539,0,0
"HC-067047","transient receptor potential channel antagonist","TRPV4","Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F",471.213361796,34,4.937,46.5,0.0572144439319922,0.108,0.0826072219659961,0,0
"L-655,708","GABA receptor inverse agonist","GABRA1, GABRA2, GABRA3, GABRA5, GABRG2","CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21, CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21, CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21, CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21, CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21",0,0,0,0,0,0,0,0,0,0,0,0,1,5,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21",341.137556088,25,3.278,73.66,0.0571886507329161,0.108,0.082594325366458,0,0
"DAA-1106","benzodiazepine receptor agonist","TSPO","COc1ccc(OC)c(CN(C(C)=O)c2cc(F)ccc2Oc2ccccc2)c1, COc1ccc(OC)c(CN(C(C)=O)c2cc(F)ccc2Oc2ccccc2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(OC)c(CN(C(C)=O)c2cc(F)ccc2Oc2ccccc2)c1",395.153286404,29,4.6,48,0.0950836083232038,0.07,0.0825418041616019,0,0
"SB-242235","p38 MAPK inhibitor","HSPB1, MAPK14","COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1, COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1, COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1, COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1",353.16518848,26,3.24,64.86,0.0650728444205323,0.1,0.0825364222102662,0,0
"AT-1015","serotonin receptor antagonist","HTR2A","O=CN1CCC(CC1)C(=O)NCCN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:29|, O=CN1CCC(CC1)C(=O)NCCN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:29|",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=CN1CCC(CC1)C(=O)NCCN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:29|",455.257277296,34,3.797,52.65,0.0550573682071688,0.11,0.0825286841035844,0,0
"GW-5074","leucine rich repeat kinase inhibitor, RAF inhibitor","NTRK1, RAF1","Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br, Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br, Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br, Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br, Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br, Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br",518.796650696,21,5.359,49.33,0.00100917520872286,0.164,0.0825045876043614,0,1
"parbendazole","tubulin polymerization inhibitor","TUBB","CCCCc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCCc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCCc1ccc2nc(NC(=O)OC)[nH]c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCc1ccc2nc(NC(=O)OC)[nH]c2c1",247.132076784,18,3.702,67.01,0.129008723343667,0.036,0.0825043616718333,1,0
"JLK-6","gamma secretase inhibitor","PSEN1","COc1oc(=O)c2cc(N)ccc2c1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1oc(=O)c2cc(N)ccc2c1Cl",225.019270796,15,2.521,65.46,0.0889810959317279,0.076,0.082490547965864,0,0
"droxinostat","HDAC inhibitor","HDAC6, HDAC8","Cc1cc(Cl)ccc1OCCCC(=O)NO, Cc1cc(Cl)ccc1OCCCC(=O)NO, Cc1cc(Cl)ccc1OCCCC(=O)NO, Cc1cc(Cl)ccc1OCCCC(=O)NO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(Cl)ccc1OCCCC(=O)NO",243.066220988,16,2.035,58.56,0.076812875748041,0.088,0.0824064378740205,0,0
"LDN-27219","tissue transglutaminase inhibitor","TGM2","NNC(=O)CSc1nc2scc(-c3ccccc3)c2c(=O)n1-c1ccccc1, NNC(=O)CSc1nc2scc(-c3ccccc3)c2c(=O)n1-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NNC(=O)CSc1nc2scc(-c3ccccc3)c2c(=O)n1-c1ccccc1",408.071467752,28,3.27,143.55,0.00480251584407519,0.16,0.0824012579220376,0,1
"CCT128930","AKT inhibitor","","NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12, NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12, NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12, NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12, NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12",341.14072332,24,3.918,70.83,0.0567634758187236,0.108,0.0823817379093618,0,0
"AZD3988","diacylglycerol kinase inhibitor","DGAT1","OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(NC(=O)c2nnc(Nc3ccc(F)c(F)c3)o2)cc1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(NC(=O)c2nnc(Nc3ccc(F)c(F)c3)o2)cc1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(NC(=O)c2nnc(Nc3ccc(F)c(F)c3)o2)cc1 |r|",456.160911624,33,5.924,117.35,0.0167418095680526,0.148,0.0823709047840263,0,1
"PF-03084014","gamma secretase inhibitor","","CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(cn1)C(C)(C)CNCC(C)(C)C, CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(cn1)C(C)(C)CNCC(C)(C)C, CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(cn1)C(C)(C)CNCC(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(cn1)C(C)(C)CNCC(C)(C)C",489.327917372,35,5.137,70.98,0.0286601691215887,0.136,0.0823300845607944,0,1
"ABT-737","BCL inhibitor","BCL2, BCL2L1, BCL2L2","CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1",812.25813822,56,9.851,161.81,0.000639308623925539,0.164,0.0823196543119628,0,1
"7-methylxanthine","adenosine receptor antagonist","","Cn1cnc2[nH]c(=O)[nH]c(=O)c12, Cn1cnc2[nH]c(=O)[nH]c(=O)c12, Cn1cnc2[nH]c(=O)[nH]c(=O)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cn1cnc2[nH]c(=O)[nH]c(=O)c12",166.049075432,12,0.148,83.54,0.0685772440305521,0.096,0.0822886220152761,0,0
"PF-04995274","serotonin receptor agonist","","OC1(CN2CCC(COc3noc4cccc(O[C@@H]5CCOC5)c34)CC2)CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC1(CN2CCC(COc3noc4cccc(O[C@@H]5CCOC5)c34)CC2)CCOCC1",432.226036744,31,2.479,86.42,0.0164700164223658,0.148,0.0822350082111829,0,1
"MCC950","NOD like receptor inhibitor","NLRP3","CC(C)(O)c1coc(c1)S(=O)(=O)NC(=O)Nc1c2CCCc2cc2CCCc12, CC(C)(O)c1coc(c1)S(=O)(=O)NC(=O)Nc1c2CCCc2cc2CCCc12, CC(C)(O)c1coc(c1)S(=O)(=O)NC(=O)Nc1c2CCCc2cc2CCCc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(O)c1coc(c1)S(=O)(=O)NC(=O)Nc1c2CCCc2cc2CCCc12",404.140592868,28,2.662,117.02,0.00837646545672237,0.156,0.0821882327283612,0,1
"ONO-8130","prostanoid receptor antagonist","PTGER1","CC(C)CN(c1cc2CCCc2cc1OCc1ccc(cc1)C(O)=O)S(=O)(=O)c1nc(C)cs1, CC(C)CN(c1cc2CCCc2cc1OCc1ccc(cc1)C(O)=O)S(=O)(=O)c1nc(C)cs1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)CN(c1cc2CCCc2cc1OCc1ccc(cc1)C(O)=O)S(=O)(=O)c1nc(C)cs1",500.143963996,34,5.244,133.42,0.00434869118872165,0.16,0.0821743455943608,0,1
"KPT-185","exportin antagonist","XPO1","COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1, COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1, COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1",355.114376032,25,3.873,66.24,0.0563208348724444,0.108,0.0821604174362222,0,0
"evocalcet","calcium sensitizer","","C[C@@H](N[C@H]1CCN(C1)c1ccc(CC(O)=O)cc1)c1cccc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C[C@@H](N[C@H]1CCN(C1)c1ccc(CC(O)=O)cc1)c1cccc2ccccc12",374.199428072,28,5.079,52.57,0.122285577287488,0.042,0.0821427886437442,1,0
"levcromakalim","potassium channel activator","KCNJ5","CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N, CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N, CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N, CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N, CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N",286.131742436,21,1.276,73.56,0.0522584735310423,0.112,0.0821292367655212,0,0
"CP-640186","acetyl-CoA carboxylase inhibitor","ACACA, ACACB","O=C([C@@H]1CCCN(C1)C1CCN(CC1)C(=O)c1c2ccccc2cc2ccccc12)N1CCOCC1, O=C([C@@H]1CCCN(C1)C1CCN(CC1)C(=O)c1c2ccccc2cc2ccccc12)N1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C([C@@H]1CCCN(C1)C1CCN(CC1)C(=O)c1c2ccccc2cc2ccccc12)N1CCOCC1",485.26784198,36,3.945,53.09,0.044221576010458,0.12,0.082110788005229,0,0
"OTX015","bromodomain inhibitor","BRD2, BRD3, BRD4","Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|",491.118273624,34,5.742,120.64,0.00816845408381863,0.156,0.0820842270419093,0,1
"meglitinide","potassium channel blocker","CCR2","COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)C(O)=O, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)C(O)=O",333.076785672,23,3.447,75.63,0.0441555355115566,0.12,0.0820777677557783,0,0
"CYM-5520","sphingosine 1-phosphate receptor agonist","S1PR2","Cc1cc(C(=O)Cn2cc(ccc2=O)C#N)c(C)n1Cc1ccccc1, Cc1cc(C(=O)Cn2cc(ccc2=O)C#N)c(C)n1Cc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(C(=O)Cn2cc(ccc2=O)C#N)c(C)n1Cc1ccccc1",345.147726848,26,3.538,67.79,0.078125960070438,0.086,0.082062980035219,0,0
"ABC-294640","sphingosine kinase inhibitor","SPHK2","Clc1ccc(cc1)[C@]12C[C@H]3C[C@H](C[C@](C3)(C1)C(=O)NCc1ccncc1)C2 |&1:7,9,11,13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Clc1ccc(cc1)[C@]12C[C@H]3C[C@H](C[C@](C3)(C1)C(=O)NCc1ccncc1)C2 |&1:7",380.1655411,27,5.032,41.99,0.108098743812827,0.056,0.0820493719064137,0,0
"abc294640 hcl","sphingosine kinase inhibitor","","Clc1ccc(cc1)C12CC3CC(CC(C3)(C1)C(=O)NCc1ccncc1)C2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Clc1ccc(cc1)C12CC3CC(CC(C3)(C1)C(=O)NCc1ccncc1)C2",380.1655411,27,5.032,41.99,0.108098743812827,0.056,0.0820493719064137,0,0
"opaganib","angiogenesis inhibitor","DEGS1, DEGS2, SPHK2","Clc1ccc(cc1)[C@]12C[C@H]3C[C@H](C[C@](C3)(C1)C(=O)NCc1ccncc1)C2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","cardiology","atherosclerosis","Clc1ccc(cc1)[C@]12C[C@H]3C[C@H](C[C@](C3)(C1)C(=O)NCc1ccncc1)C2",380.1655411,27,5.032,41.99,0.108098743812827,0.056,0.0820493719064137,0,0
"TAK-659","spleen associated tyrosine kinase inhibitor","","Cn1cc(cn1)-c1nc(N[C@@H]2CCCC[C@@H]2N)c(F)c2CNC(=O)c12, Cn1cc(cn1)-c1nc(N[C@@H]2CCCC[C@@H]2N)c(F)c2CNC(=O)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cn1cc(cn1)-c1nc(N[C@@H]2CCCC[C@@H]2N)c(F)c2CNC(=O)c12",344.176087512,25,1.44,97.86,0.0200933121550024,0.144,0.0820466560775012,0,1
"LY266097","serotonin receptor antagonist","HTR2B","COc1ccc(C[C@H]2NCCc3c2[nH]c2ccc(C)cc32)c(Cl)c1OC |&1:7|, COc1ccc(C[C@H]2NCCc3c2[nH]c2ccc(C)cc32)c(Cl)c1OC |&1:7|, COc1ccc(C[C@H]2NCCc3c2[nH]c2ccc(C)cc32)c(Cl)c1OC |&1:7|",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(C[C@H]2NCCc3c2[nH]c2ccc(C)cc32)c(Cl)c1OC |&1:7|",370.144805656,26,4.366,46.28,0.0859603339457614,0.078,0.0819801669728807,0,0
"NDT-9513727","complement antagonist","C5AR1","CCCCn1c(CN(Cc2ccc3OCOc3c2)Cc2ccc3OCOc3c2)c(nc1-c1ccccc1)-c1ccccc1, CCCCn1c(CN(Cc2ccc3OCOc3c2)Cc2ccc3OCOc3c2)c(nc1-c1ccccc1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCn1c(CN(Cc2ccc3OCOc3c2)Cc2ccc3OCOc3c2)c(nc1-c1ccccc1)-c1ccccc1",573.2627566,43,8.26,57.98,0.0679235215527196,0.096,0.0819617607763598,0,0
"CORT-108297","glucocorticoid receptor antagonist","","CCOC[C@@]12CN(CCC1=Cc1c(C2)cnn1-c1ccc(F)cc1)S(=O)(=O)c1ccc(cc1)C(F)(F)F |c:10|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC[C@@]12CN(CCC1=Cc1c(C2)cnn1-c1ccc(F)cc1)S(=O)(=O)c1ccc(cc1)C(F)(F)F |c:10|",535.15527554,37,4.246,72.81,0.0119026941292973,0.152,0.0819513470646487,0,1
"tiprenolol","adrenergic receptor antagonist","ADRB1, ADRB2, ADRB3","CSc1ccccc1OC[C@@H](O)CNC(C)C |&1:10,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,"phase 2","","","CSc1ccccc1OC[C@@H](O)CNC(C)C |&1:10",255.129299912,17,2.504,66.79,0.0678501687500699,0.096,0.081925084375035,0,0
"farnesyl-thiosalicylic-acid-amide","Ras GTPase inhibitor","HRAS","CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(N)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(N)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(N)=O",357.212635612,25,6.231,68.39,0.0878403622389785,0.076,0.0819201811194892,0,0
"squaric-acid-dibutyl-ester","oxidative stress inducer","","CCCCOc1c(OCCCC)c(=O)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCOc1c(OCCCC)c(=O)c1=O",226.120509056,16,2.412,52.6,0.13579865423133,0.028,0.0818993271156652,1,0
"mobocertinib","egfr inhibitor","EGFR","COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2ncc(C(=O)OC(C)C)c(n2)c3cn(C)c4ccccc34",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","oncology","non-small cell lung cancer (nsclc)","COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2ncc(C(=O)OC(C)C)c(n2)c3cn(C)c4ccccc34",585.306352728,43,4.415,113.85,0.00579212741142556,0.158,0.0818960637057128,0,1
"namitecan","topoisomerase inhibitor","TOP1","CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4c(\C=N\OCCN)c3Cn1c2=O |a:2|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","soft tissue sarcoma (sts)","CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4c(\C=N\OCCN)c3Cn1c2=O |a:2|",434.159019804,32,2.666,129.03,0.00778814073301662,0.156,0.0818940703665083,0,1
"5-octanoylsalicylic-acid","protein kinase activator","","CCCCCCCC(=O)c1ccc(O)c(c1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCC(=O)c1ccc(O)c(c1)C(O)=O",264.13615912,19,4.635,74.6,0.115785203351336,0.048,0.0818926016756682,1,0
"ETP-45658","PI3K inhibitor","PIK3CA, PIK3CB, PIK3CD, PIK3CG","Cn1ncc2c(nc(nc12)-c1cccc(O)c1)N1CCOCC1, Cn1ncc2c(nc(nc12)-c1cccc(O)c1)N1CCOCC1, Cn1ncc2c(nc(nc12)-c1cccc(O)c1)N1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cn1ncc2c(nc(nc12)-c1cccc(O)c1)N1CCOCC1",311.138224784,23,2.668,76.3,0.0596952632292407,0.104,0.0818476316146203,0,0
"imrecoxib","cyclooxygenase inhibitor","PTGS2","CCCN1CC(=C(C1=O)c1ccc(C)cc1)c1ccc(cc1)S(C)(=O)=O |c:5|",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","rheumatology","osteoarthritis","CCCN1CC(=C(C1=O)c1ccc(C)cc1)c1ccc(cc1)S(C)(=O)=O |c:5|",369.139864596,26,4.081,62.83,0.0576736468897359,0.106,0.081836823444868,0,0
"HOKU-81","bronchodilator","","CC(C)(C)NC[C@H](O)c1ccc(O)cc1Cl |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)NC[C@H](O)c1ccc(O)cc1Cl |r|",243.102606496,16,2.444,52.49,0.095671069947804,0.068,0.081835534973902,0,0
"meluadrine","","","CC(C)(C)NC[C@@H](O)c1ccc(O)cc1Cl |&1:6,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)NC[C@@H](O)c1ccc(O)cc1Cl |&1:6",243.102606496,16,2.444,52.49,0.095671069947804,0.068,0.081835534973902,0,0
"ABT-072","RNA polymerase inhibitor","","COc1c(\C=C\c2ccc(NS(C)(=O)=O)cc2)cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1c(\C=C\c2ccc(NS(C)(=O)=O)cc2)cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O",469.167141964,33,5.038,118.64,0.00964910271863736,0.154,0.0818245513593187,0,1
"thiorphan","membrane metalloendopeptidase inhibitor","MME","OC(=O)CNC(=O)[C@@H](CS)Cc1ccccc1 |&1:7,r|, OC(=O)CNC(=O)[C@@H](CS)Cc1ccccc1 |&1:7,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC(=O)CNC(=O)[C@@H](CS)Cc1ccccc1 |&1:7",253.07726434,17,-0.834,105.2,0.0136478689274095,0.15,0.0818239344637048,0,1
"UK-5099","monocarboxylate transporter inhibitor","SLC16A1","OC(=O)C(=C\c1cn(-c2ccccc2)c2ccccc12)\C#N, OC(=O)C(=C\c1cn(-c2ccccc2)c2ccccc12)\C#N, OC(=O)C(=C\c1cn(-c2ccccc2)c2ccccc12)\C#N",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)C(=C\c1cn(-c2ccccc2)c2ccccc12)\C#N",288.089877624,22,3.491,66.02,0.119613623539805,0.044,0.0818068117699023,1,0
"xamoterol","adrenergic receptor agonist","ADRB1","OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1, OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1, OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1, OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"phase 3","","","OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1",339.1794209,24,-0.645,103.29,0.00960901783315417,0.154,0.0818045089165771,0,1
"SP-100030","NFkB pathway inhibitor","JUN, NFKB1","FC(F)(F)c1cc(NC(=O)c2cnc(Cl)nc2C(F)(F)F)cc(c1)C(F)(F)F, FC(F)(F)c1cc(NC(=O)c2cnc(Cl)nc2C(F)(F)F)cc(c1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)c1cc(NC(=O)c2cnc(Cl)nc2C(F)(F)F)cc(c1)C(F)(F)F",436.99774344,28,4.275,54.88,0.0235853350899539,0.14,0.0817926675449769,0,1
"sel120-34a (monohydrochloride)","cdk inhibitor","CDK19, CDK8","Cc1c(Br)c(Br)c2CCCn3c(nc1c23)N1CCNCC1.Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","hematologic malignancy","acute myeloid leukemia (aml)","Cc1c(Br)c(Br)c2CCCn3c(nc1c23)N1CCNCC1.Cl",447.966498488,22,5.169,33.09,0.00953009180782917,0.154,0.0817650459039146,0,1
"DCEBIO","potassium channel activator","KCNN2, KCNN3, KCNN4","CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O",230.001368236,14,2.269,37.79,0.109481202386671,0.054,0.0817406011933353,0,0
"clanfenur","anticancer agent","","CN(C)c1cccc(F)c1C(=O)NC(=O)Nc1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)c1cccc(F)c1C(=O)NC(=O)Nc1ccc(Cl)cc1",335.08368262,23,4.504,61.44,0.0734676998797355,0.09,0.0817338499398677,0,0
"AMD11070","CC chemokine receptor antagonist","CCR5, CXCR4","NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc12, NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc12, NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc12",349.226645864,26,2.23,70.83,0.0494088012673301,0.114,0.081704400633665,0,0
"MNITMT","lymphocyte inhibitor","","Cn1cnnc1Sc1c(ncn1C)[N+]([O-])=O, Cn1cnnc1Sc1c(ncn1C)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cn1cnnc1Sc1c(ncn1C)[N+]([O-])=O",240.042944496,16,2.187,116.97,0.0234077237193582,0.14,0.0817038618596791,0,1
"NBI-98782","vesicular monoamine transporter inhibitor","","COc1cc2CCN3C[C@@H](CC(C)C)[C@H](O)C[C@@H]3c2cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2CCN3C[C@@H](CC(C)C)[C@H](O)C[C@@H]3c2cc1OC",319.214743788,23,3.061,41.93,0.113361400853699,0.05,0.0816807004268494,0,0
"alrestatin","aldose reductase inhibitor","AKR1B1","OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23, OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23, OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23",255.053157768,19,-0.384,74.68,0.0452670367558844,0.118,0.0816335183779422,0,0
"AZD7762","CHK inhibitor","CHEK1, CHEK2","NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1",362.121275068,25,1.502,124.49,0.00725850658388137,0.156,0.0816292532919407,0,1
"PF-02413873","progesterone receptor antagonist","","Cc1c(Oc2cc(C)c(C#N)c(C)c2)c(nn1CS(C)(=O)=O)C1CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1c(Oc2cc(C)c(C#N)c(C)c2)c(nn1CS(C)(=O)=O)C1CC1",359.130362532,25,3.08,93.36,0.023248361362198,0.14,0.081624180681099,0,1
"oxyphenbutazone","cyclooxygenase inhibitor","","CCCC[C@H]1C(=O)N(N(C1=O)c1ccc(O)cc1)c1ccccc1 |r|, CCCC[C@H]1C(=O)N(N(C1=O)c1ccc(O)cc1)c1ccccc1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CCCC[C@H]1C(=O)N(N(C1=O)c1ccc(O)cc1)c1ccccc1 |r|",324.1473925,24,3.304,60.85,0.089206293295109,0.074,0.0816031466475545,0,0
"6-aminopenicillanic-acid","","","CC1(C)S[C@@H]2[C@H](N)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](N)C(=O)N2[C@H]1C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC1(C)S[C@@H]2[C@H](N)C(=O)N2[C@H]1C(O)=O",216.056863244,14,-0.313,108.93,0.0172039389828535,0.146,0.0816019694914268,0,1
"INCB-057643","bromodomain inhibitor","","CN1C(=O)C(C)(C)Oc2c1cc(cc2-c1cn(C)c(O)c2nccc12)S(C)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","CN1C(=O)C(C)(C)Oc2c1cc(cc2-c1cn(C)c(O)c2nccc12)S(C)(=O)=O",415.120191772,29,3.332,110.11,0.0111903975680641,0.152,0.0815951987840321,0,1
"AM-580","retinoid receptor agonist","RARA","CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O",351.18344366,26,5.902,66.4,0.119175199312919,0.044,0.0815875996564593,1,0
"rupintrivir","antiviral","","CCOC(=O)\C=C\[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@@H](CC(=O)[C@@H](NC(=O)c2cc(C)on2)C(C)C)Cc3ccc(F)cc3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","otolaryngology","common cold","CCOC(=O)\C=C\[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@@H](CC(=O)[C@@H](NC(=O)c2cc(C)on2)C(C)C)Cc3ccc(F)cc3",598.280277808,43,2.73,156.7,0.00104531280369171,0.162,0.0815226564018459,0,1
"tebanicline (dihydrochloride)","acetylcholine receptor agonist","CHRNA4, CHRNB2","[H]Cl.ClC(C=C1)=NC=C1OC[C@@H]2NCC2.[H]Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,"preclinical","neurology/psychiatry","chronic pain","[H]Cl.ClC(C=C1)=NC=C1OC[C@@H]2NCC2.[H]Cl",270.009346076,17,1.599,33.62,0.0809876975208978,0.082,0.0814938487604489,0,0
"RAF709","RAF inhibitor","","Cc1ncc(NC(=O)c2cccc(c2)C(F)(F)F)cc1-c1cnc(OC2CCOCC2)c(c1)N1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ncc(NC(=O)c2cccc(c2)C(F)(F)F)cc1-c1cnc(OC2CCOCC2)c(c1)N1CCOCC1",542.214090068,39,4.594,85.81,0.0128317588682024,0.15,0.0814158794341012,0,1
"SCP-1","analgesic agent","","Oc1ccc(NC(=O)CN2C(=O)c3ccccc3S2(=O)=O)cc1, Oc1ccc(NC(=O)CN2C(=O)c3ccccc3S2(=O)=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Oc1ccc(NC(=O)CN2C(=O)c3ccccc3S2(=O)=O)cc1",332.046692484,23,0.926,112.16,0.0108192746835072,0.152,0.0814096373417536,0,1
"dexfosfoserine","membrane integrity inhibitor","CFTR, GRM4, GRM6, GRM7, GRM8, KCNC4, PDPK1, PIM1, PRKACA, PRKCQ, PYGL, PYGM, REG1A, RHO, SERPINB3, SMAD2, TAOK2","N[C@@H](COP(O)(O)=O)C(O)=O, N[C@@H](COP(O)(O)=O)C(O)=O, N[C@@H](COP(O)(O)=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@@H](COP(O)(O)=O)C(O)=O",185.008923606,11,-5.185,139.89,0.00271260863890274,0.16,0.0813563043194514,0,1
"tubastatin-A","HDAC inhibitor","HDAC6","CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO",335.163376912,25,2.994,57.5,0.0866930542578654,0.076,0.0813465271289327,0,0
"MLN8054","Aurora kinase inhibitor","AURKA","OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1 |c:13|, OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1 |c:13|, OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1 |c:13|, OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1 |c:13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1 |c:13|",476.08515984,34,5.361,87.47,0.0226582334428035,0.14,0.0813291167214018,0,1
"LXH254","RAF inhibitor","","Cc1ccc(NC(=O)c2ccnc(c2)C(F)(F)F)cc1-c1cc(OCCO)nc(c1)N1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1ccc(NC(=O)c2ccnc(c2)C(F)(F)F)cc1-c1cc(OCCO)nc(c1)N1CCOCC1",502.18278994,36,4.471,96.81,0.0125887976901775,0.15,0.0812943988450888,0,1
"BCTC","TRPV antagonist","TRPV1","CC(C)(C)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2Cl)cc1, CC(C)(C)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2Cl)cc1",372.1716891,26,4.904,48.47,0.0885681038370857,0.074,0.0812840519185429,0,0
"kojic acid","nfkb pathway inhibitor","NFKB1","OCc1cc(=O)c(O)co1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OCc1cc(=O)c(O)co1",142.026608672,10,0.259,70.67,0.102507899836412,0.06,0.0812539499182062,0,0
"almonertinib","egfr inhibitor","EGFR","COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2nccc(n2)c3cn(C4CC4)c5ccccc35",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","oncology","non-small cell lung cancer (nsclc)","COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2nccc(n2)c3cn(C4CC4)c5ccccc35",525.28522336,39,4.139,87.55,0.0164620316487578,0.146,0.0812310158243789,0,1
"nolatrexed","thymidylate synthase inhibitor","TYMS","Cc1ccc2[nH]c(N)nc(=O)c2c1Sc1ccncc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cc1ccc2[nH]c(N)nc(=O)c2c1Sc1ccncc1",284.073182004,20,3.422,109.96,0.032404145954337,0.13,0.0812020729771685,0,1
"catharanthine","tubulin polymerization inhibitor","","CCC1=C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@](C2)([C@@H]13)C(=O)OC |t:2|, CCC1=C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@](C2)([C@@H]13)C(=O)OC |t:2|, CCC1=C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@](C2)([C@@H]13)C(=O)OC |t:2|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCC1=C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@](C2)([C@@H]13)C(=O)OC |t:2|",336.183778008,25,3.354,45.33,0.118297945601451,0.044,0.0811489728007257,1,0
"LY3200882","TGF beta receptor inhibitor","","CC(C)(O)c1cc(Nc2cc(Oc3cn(nc3C3CCOCC3)C3CC3)ccn2)ccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)(O)c1cc(Nc2cc(Oc3cn(nc3C3CCOCC3)C3CC3)ccn2)ccn1",435.227039788,32,2.493,94.32,0.0161329260408984,0.146,0.0810664630204492,0,1
"alisertib","Aurora kinase inhibitor","AURKA","COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|",518.11571102,37,5.03,105.93,0.010079761536575,0.152,0.0810398807682875,0,1
"msc2360844","pi3k inhibitor","PIK3CD","Fc1cccc2-c3c(CS(=O)(=O)c12)c(nn3-c1ccc(CN2CCOCC2)cc1)C(=O)N1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","rheumatology","lupus","Fc1cccc2-c3c(CS(=O)(=O)c12)c(nn3-c1ccc(CN2CCOCC2)cc1)C(=O)N1CCOCC1",526.168619184,37,1.714,102.35,0.00402942524242217,0.158,0.0810147126212111,0,1
"SB-202190","p38 MAPK inhibitor","AKT1, ALOX5, CHEK1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SGK1","Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1, Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1, Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1",331.112090288,25,4.635,61.8,0.124013044486054,0.038,0.0810065222430271,1,0
"tricaine","sodium channel blocker","SCN1A","CCOC(=O)C1=CC=CC(N)=C1",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","neurology/psychiatry","anesthetic","CCOC(=O)C1=CC=CC(N)=C1",165.078978592,12,0.601,52.32,0.147964052639522,0.014,0.0809820263197608,1,0
"salirasib","mTOR inhibitor","TRPA1","CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O",358.1966512,25,6.959,62.6,0.113950690289197,0.048,0.0809753451445984,0,0
"L-asparagine-N-hydroxy","","","N[C@@H](CC(=O)NO)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@@H](CC(=O)NO)C(O)=O",148.048406736,10,-4.355,112.65,0.0119060835490587,0.15,0.0809530417745294,0,1
"SNX-2112","HSP inhibitor","","CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1 |r|, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1 |r|, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1 |r|",464.203525384,33,3.858,110.24,0.0098806982345391,0.152,0.0809403491172695,0,1
"dxd","topoisomerase inhibitor","TOP1","CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](NC(=O)CO)c(c3Cn1c2=O)c45",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","oncology","breast cancer","CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](NC(=O)CO)c(c3Cn1c2=O)c45",493.164913708,36,1.963,130.75,0.00387731327322652,0.158,0.0809386566366133,0,1
"ibotenic-acid","glutamate receptor agonist","GRIN1","N[C@@H](C(O)=O)c1cc(=O)[nH]o1 |&1:1,r|, N[C@@H](C(O)=O)c1cc(=O)[nH]o1 |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@@H](C(O)=O)c1cc(=O)[nH]o1 |&1:1",158.032756672,11,-4.015,109.32,0.0138379305920209,0.148,0.0809189652960104,0,1
"GSK-3-inhibitor-IX","glycogen synthase kinase inhibitor, lipoxygenase inhibitor","GSK3A, GSK3B","O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12",354.99563866,22,4.079,73.72,0.0258290076841218,0.136,0.0809145038420609,0,1
"azd2098","ccr antagonist","CCR4","O=S(C1=CC=CC(Cl)=C1Cl)(NC2=NC=CN=C2OC)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","pulmonary","asthma","O=S(C1=CC=CC(Cl)=C1Cl)(NC2=NC=CN=C2OC)=O",332.974167508,20,0.263,88.5,0.00782026106883448,0.154,0.0809101305344172,0,1
"sutezolid","protein synthesis inhibitor","","CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCSCC2)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCSCC2)c(F)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCSCC2)c(F)c1",353.12094072,24,2.167,87.18,0.0197345514596784,0.142,0.0808672757298392,0,1
"CCG-63808","G protein signaling inhibitor","RGS4","Cc1cccn2c1nc(Oc1ccc(F)cc1)c(\C=C(/C#N)c1nc3ccccc3s1)c2=O, Cc1cccn2c1nc(Oc1ccc(F)cc1)c(\C=C(/C#N)c1nc3ccccc3s1)c2=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cccn2c1nc(Oc1ccc(F)cc1)c(\C=C(/C#N)c1nc3ccccc3s1)c2=O",454.08997494,33,5.125,108.52,0.0177276485533961,0.144,0.080863824276698,0,1
"AZD2461","PARP inhibitor","","COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F, COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F, COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F, COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F",395.164519784,29,3.157,75.29,0.037687879748545,0.124,0.0808439398742725,0,0
"ZM-336372","RAF inhibitor","BRAF, LCK, MAPK14, RAF1","CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1, CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1, CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1, CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1",389.173941596,29,3.993,81.67,0.0456689133417021,0.116,0.0808344566708511,0,0
"terfenadine","histamine receptor antagonist","HRH1, KCNH1, KCNH2","CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|, CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|, CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|, CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|, CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|, CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10",471.313729552,35,7.105,43.7,0.121612915744417,0.04,0.0808064578722086,1,0
"SC-19220","prostanoid receptor antagonist","PTGER1","CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12, CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12, CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12, CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12",331.072368988,23,2.727,70.67,0.0435805097309052,0.118,0.0807902548654526,0,0
"etazolate","phosphodiesterase inhibitor","GABRB3, PDE4A","CCOC(=O)c1cnc2n(CC)ncc2c1NN=C(C)C, CCOC(=O)c1cnc2n(CC)ncc2c1NN=C(C)C, CCOC(=O)c1cnc2n(CC)ncc2c1NN=C(C)C",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCOC(=O)c1cnc2n(CC)ncc2c1NN=C(C)C",289.153874848,21,3.426,81.4,0.0675796052554552,0.094,0.0807898026277276,0,0
"A-987306","histamine receptor antagonist","ADORA1, AVPR1A, CCR1, CHRM1, CHRM2, CHRM3, CHRM4, DRD3, HTR1A, HTR1B, HTR2A, HTR2B, HTR3A, TACR2","Nc1nc(N2CCNCC2)c2CCC3=C([C@@H]4CCCC[C@@H]4O3)c2n1 |t:14|, Nc1nc(N2CCNCC2)c2CCC3=C([C@@H]4CCCC[C@@H]4O3)c2n1 |t:14|",0,0,0,0,0,0,0,0,1,5,0,0,0,0,1,1,1,4,0,0,0,0,0,0,"preclinical","","","Nc1nc(N2CCNCC2)c2CCC3=C([C@@H]4CCCC[C@@H]4O3)c2n1 |t:14|",327.20591042,24,1.742,76.3,0.0415728722278591,0.12,0.0807864361139295,0,0
"LY2603618","CHK inhibitor","CHEK1","Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1",435.090601664,27,1.211,97.4,0.00352102522547451,0.158,0.0807605126127373,0,1
"A-61603","adrenergic receptor agonist","ADRA1A, ADRA1B, ADRA1D","CS(=O)(=O)Nc1c(O)ccc2[C@H](CCCc12)C1=NCCN1 |&1:11,r,t:18|, CS(=O)(=O)Nc1c(O)ccc2[C@H](CCCc12)C1=NCCN1 |&1:11,r,t:18|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,"preclinical","","","CS(=O)(=O)Nc1c(O)ccc2[C@H](CCCc12)C1=NCCN1 |&1:11",309.114712468,21,1.326,99.17,0.0174835449558957,0.144,0.0807417724779478,0,1
"9-ing-41","gsk3b inhibitor","GSK3B, MARK2","Cn1cc(C2=C(C(=O)NC2=O)c2coc3ccc(F)cc23)c2cc3OCOc3cc12 |t:4|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","hematologic malignancy","myelofibrosis","Cn1cc(C2=C(C(=O)NC2=O)c2coc3ccc(F)cc23)c2cc3OCOc3cc12 |t:4|",404.080849736,30,3.026,82.7,0.0314723096533046,0.13,0.0807361548266523,0,1
"talarozole","cytochrome P450 inhibitor","CYP26A1","CCC(CC)[C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1 |&1:5,r|, CCC(CC)[C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1 |&1:5,r|, CCC(CC)[C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1 |&1:5,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCC(CC)[C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1 |&1:5",377.167416736,27,4.89,83.87,0.0454615171481453,0.116,0.0807307585740726,0,0
"GDC-0879","RAF inhibitor","BRAF","OCCn1cc(c(n1)-c1ccncc1)-c1ccc2\C(CCc2c1)=N\O, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2\C(CCc2c1)=N\O, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2\C(CCc2c1)=N\O, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2\C(CCc2c1)=N\O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OCCn1cc(c(n1)-c1ccncc1)-c1ccc2\C(CCc2c1)=N\O",334.142975816,25,2.148,83.53,0.0414360332730371,0.12,0.0807180166365185,0,0
"aloin","angiogenesis inhibitor","","OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc12, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc12, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc12, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc12",418.126382284,30,-0.287,167.91,0.00142717028944612,0.16,0.0807135851447231,0,1
"selonsertib","MAP kinase activator","","CC(C)n1cnnc1-c1cccc(NC(=O)c2cc(c(C)cc2F)-n2cnc(c2)C2CC2)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)n1cnnc1-c1cccc(NC(=O)c2cc(c(C)cc2F)-n2cnc(c2)C2CC2)n1",445.202636608,33,5.678,90.52,0.0373522149281008,0.124,0.0806761074640504,0,0
"dabuzalgron","adrenergic receptor agonist","ADRB3","Cc1c(OCC2=NCCN2)ccc(Cl)c1NS(C)(=O)=O |t:5|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"phase 1","urology","urinary incontinence","Cc1c(OCC2=NCCN2)ccc(Cl)c1NS(C)(=O)=O |t:5|",317.060090052,20,1.457,88.17,0.0153355447606803,0.146,0.0806677723803401,0,1
"asimadoline","opioid receptor agonist","OPRK1","CN([C@H](CN1CC[C@H](O)C1)c1ccccc1)C(=O)C(c1ccccc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CN([C@H](CN1CC[C@H](O)C1)c1ccccc1)C(=O)C(c1ccccc1)c1ccccc1",414.2307282,31,4.19,43.78,0.0952556360666171,0.066,0.0806278180333086,0,0
"ciaftalan-zinc","reactive oxygen species stimulant","","[Zn]1n2c3\N=C4/N=C(/N=c5\n1\c(=N/C1=N/C(=N\c2c2ccccc32)/c2ccccc12)c1ccccc51)c1ccccc41 |c:3,7,11,15,t:5,13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","[Zn]1n2c3\N=C4/N=C(/N=c5\n1\c(=N/C1=N/C(=N\c2c2ccccc32)/c2ccccc12)c1ccccc51)c1ccccc41 |c:3",576.078934712,41,8.496,82.33,0.0252373848262491,0.136,0.0806186924131245,0,1
"CGM097","MDM inhibitor","MDM2","COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1",658.328583664,47,5.934,65.56,0.0112339908557609,0.15,0.0806169954278804,0,1
"N-oxydiethylenebenzothiazole-2-sulfenamide","","","C1CN(CCO1)Sc1nc2ccccc2s1, C1CN(CCO1)Sc1nc2ccccc2s1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C1CN(CCO1)Sc1nc2ccccc2s1",252.039105004,16,1.473,78.9,0.0352158280099335,0.126,0.0806079140049667,0,0
"MK-7622","cholinergic receptor agonist","","Cc1ccc(Cc2cc3c(ncn([C@H]4CCCC[C@@H]4O)c3=O)c3ccccc23)cn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1ccc(Cc2cc3c(ncn([C@H]4CCCC[C@@H]4O)c3=O)c3ccccc23)cn1",399.19467704,30,4.275,68.01,0.0651989917700621,0.096,0.0805994958850311,0,0
"EI1","histone lysine methyltransferase inhibitor","EZH2","CCC(CC)n1ccc2c(cc(cc12)C#N)C(=O)NCc1c(C)cc(C)[nH]c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCC(CC)n1ccc2c(cc(cc12)C#N)C(=O)NCc1c(C)cc(C)[nH]c1=O",390.205576072,29,4.891,90.68,0.0450946055104092,0.116,0.0805473027552046,0,0
"seltorexant","orexin receptor antagonist","HCRTR2","Cc1cc(C)nc(n1)N2CC3CN(CC3C2)C(=O)c4c(F)cccc4n5nccn5",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"phase 3","neurology/psychiatry","depression","Cc1cc(C)nc(n1)N2CC3CN(CC3C2)C(=O)c4c(F)cccc4n5nccn5",407.186986544,30,3.486,79.52,0.0350813968371515,0.126,0.0805406984185758,0,0
"pifithrin-mu","HSP inhibitor","HSPA1A, TP53","NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NS(=O)(=O)C#Cc1ccccc1",181.019749464,12,1.141,68.54,0.085070526913176,0.076,0.080535263456588,0,0
"RG7834","antiviral","","COCCCOc1cc2C[C@@H](C(C)C)n3cc(C(O)=O)c(=O)cc3-c2cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COCCCOc1cc2C[C@@H](C(C)C)n3cc(C(O)=O)c(=O)cc3-c2cc1OC",401.183837584,29,4.768,86.99,0.0369702900601128,0.124,0.0804851450300564,0,0
"BMS-906024","gamma secretase inhibitor","","CN1c2ccccc2C(=N[C@H](NC(=O)[C@H](CCC(F)(F)F)[C@H](CCC(F)(F)F)C(N)=O)C1=O)c1ccccc1 |c:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN1c2ccccc2C(=N[C@H](NC(=O)[C@H](CCC(F)(F)F)[C@H](CCC(F)(F)F)C(N)=O)C1=O)c1ccccc1 |c:9|",556.190910012,39,5.237,104.86,0.00695713064703864,0.154,0.0804785653235193,0,1
"LUF-5834","adenosine receptor agonist","ADORA2A, ADORA2B","Nc1nc(SCc2ncc[nH]2)c(C#N)c(-c2ccc(O)cc2)c1C#N, Nc1nc(SCc2ncc[nH]2)c(C#N)c(-c2ccc(O)cc2)c1C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1nc(SCc2ncc[nH]2)c(C#N)c(-c2ccc(O)cc2)c1C#N",348.079330004,25,1.887,160.7,0.0048324274589024,0.156,0.0804162137294512,0,1
"Y-11","focal adhesion kinase inhibitor","PTK2","OCC[N+]12CN3CN(CN(C3)C1)C2, OCC[N+]12CN3CN(CN(C3)C1)C2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OCC[N+]12CN3CN(CN(C3)C1)C2",185.139687584091,13,-1.086,29.95,0.130663466049996,0.03,0.080331733024998,1,0
"NMS-P715","protein kinase inhibitor","","CCc1cccc(CC)c1NC(=O)c1nn(C)c-2c1CCc1cnc(Nc3ccc(cc3OC(F)(F)F)C(=O)NC3CCN(C)CC3)nc-21",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCc1cccc(CC)c1NC(=O)c1nn(C)c-2c1CCc1cnc(Nc3ccc(cc3OC(F)(F)F)C(=O)NC3CCN(C)CC3)nc-21",676.309721768,49,5.502,126.3,0.00257156400981993,0.158,0.08028578200491,0,1
"GSK2606414","protein kinase inhibitor","EIF2AK3, MYLK2","Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12, Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12, Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12, Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12, Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12",451.16199492,33,4.379,77.04,0.0323600395189892,0.128,0.0801800197594946,0,0
"AZ20","ATR kinase inhibitor","ATR, MTOR","C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O, C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O",412.156911628,29,2.784,96.56,0.0143310257196783,0.146,0.0801655128598391,0,1
"M-14157","ATP-sensitive potassium channel antagonist","KCNQ1","CCCCCC(O)CCCC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCCCC(O)CCCC(O)=O",188.1412445,13,2.282,57.53,0.14429628253348,0.016,0.08014814126674,1,0
"5-hydroxydecanoic-acid","","","CCCCC[C@@H](O)CCCC(O)=O |&1:5|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCC[C@@H](O)CCCC(O)=O |&1:5|",188.1412445,13,2.282,57.53,0.14429628253348,0.016,0.08014814126674,1,0
"NMDA","glutamate receptor agonist","GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D","CN[C@H](CC(O)=O)C(O)=O, CN[C@H](CC(O)=O)C(O)=O, CN[C@H](CC(O)=O)C(O)=O, CN[C@H](CC(O)=O)C(O)=O, CN[C@H](CC(O)=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN[C@H](CC(O)=O)C(O)=O",147.053157768,10,-3.317,86.63,0.0282754382690936,0.132,0.0801377191345468,0,1
"arofylline","phosphodiesterase inhibitor","PDE4A","CCCn1c(=O)n(-c2ccc(Cl)cc2)c2nc[nH]c2c1=O, CCCn1c(=O)n(-c2ccc(Cl)cc2)c2nc[nH]c2c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCCn1c(=O)n(-c2ccc(Cl)cc2)c2nc[nH]c2c1=O",304.072703336,21,4.346,72.68,0.0722018540050083,0.088,0.0801009270025042,0,0
"cbp/p300-in-4","bromodomain inhibitor","CREBBP, EP300","CO[C@H]1CC[C@@H](CC1)n1c(nc2cc(ccc12)-c1c(C)noc1C)[C@@H]1CCCC(=O)N1c1ccc(F)c(F)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","genetics","duchenne muscular dystrophy (dmd)","CO[C@H]1CC[C@@H](CC1)n1c(nc2cc(ccc12)-c1c(C)noc1C)[C@@H]1CCCC(=O)N1c1ccc(F)c(F)c1",534.244247324,39,5.601,73.39,0.0261502766231335,0.134,0.0800751383115668,0,1
"baicalein","lipoxygenase inhibitor","ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH","Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1, Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1, Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1, Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1, Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1, Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1, Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1",270.05282342,20,4.258,90.9,0.0820847866972742,0.078,0.0800423933486371,0,0
"decloxizine","histamine receptor antagonist","","OCCOCCN1CCN(CC1)C(c1ccccc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OCCOCCN1CCN(CC1)C(c1ccccc1)c1ccccc1",340.215078136,25,2.092,35.94,0.100026525864987,0.06,0.0800132629324936,0,0
"((2r,3s,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyltriphosphoric acid","","","O[C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","O[C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O",483.96852767,29,-5.537,293.8,3.50345946619747e-06,0.16,0.0800017517297331,0,1
"INS316","purinergic receptor antagonist","","O[C@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O |a:2,18,&1:1,&2:5,&3:9,&4:19|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O[C@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O |a:2",483.96852767,29,-5.537,293.8,3.50345946619747e-06,0.16,0.0800017517297331,0,1
"olvanil","TRPV agonist","CNR1, GPR119, TRPV1","CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1",417.324294236,30,8.933,58.56,0.149995184044667,0.01,0.0799975920223338,1,0
"STF-62247","autophagy inducer","","Cc1cccc(Nc2nc(cs2)-c2ccncc2)c1, Cc1cccc(Nc2nc(cs2)-c2ccncc2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cccc(Nc2nc(cs2)-c2ccncc2)c1",267.083018416,19,3.255,66.05,0.0958911171896331,0.064,0.0799455585948166,0,0
"lipoamide","","","NC(=O)CCCC[C@H]1CCSS1 |&1:7,r|, NC(=O)CCCC[C@H]1CCSS1 |&1:7,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC(=O)CCCC[C@H]1CCSS1 |&1:7",205.0595061,12,1.344,93.69,0.0297878297176878,0.13,0.0798939148588439,0,1
"belotecan","topoisomerase inhibitor","","CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4c(CCNC(C)C)c3Cn1c2=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4c(CCNC(C)C)c3Cn1c2=O",433.200156344,32,3.461,93.45,0.0217843962827139,0.138,0.079892198141357,0,1
"CG-400549","FABI inhibitor","","Cc1c(N)cccc1Cn1ccc(OCCc2cccs2)cc1=O, Cc1c(N)cccc1Cn1ccc(OCCc2cccs2)cc1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1c(N)cccc1Cn1ccc(OCCc2cccs2)cc1=O",340.12454888,24,3.217,85.49,0.0356415206560031,0.124,0.0798207603280015,0,0
"rg-7112","mdm inhibitor","","CCOc1cc(ccc1C1=NC(C)(c2ccc(Cl)cc2)C(C)(N1C(=O)N1CCN(CCCS(C)(=O)=O)CC1)c1ccc(Cl)cc1)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCOc1cc(ccc1C1=NC(C)(c2ccc(Cl)cc2)C(C)(N1C(=O)N1CCN(CCCS(C)(=O)=O)CC1)c1ccc(Cl)cc1)C(C)(C)C",726.277332376,49,8.446,90.9,0.0036385311663701,0.156,0.079819265583185,0,1
"RG7112","MDM inhibitor","MDM2","CCOc1cc(ccc1C1=N[C@@](C)(c2ccc(Cl)cc2)[C@](C)(N1C(=O)N1CCN(CCCS(C)(=O)=O)CC1)c1ccc(Cl)cc1)C(C)(C)C |t:10|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCOc1cc(ccc1C1=N[C@@](C)(c2ccc(Cl)cc2)[C@](C)(N1C(=O)N1CCN(CCCS(C)(=O)=O)CC1)c1ccc(Cl)cc1)C(C)(C)C |t:10|",726.277332376,49,8.446,90.9,0.0036385311663701,0.156,0.079819265583185,0,1
"lodenosine","antiretroviral ","","Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@@H]1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@@H]1F",253.097502844,18,-0.0710000000000001,99.08,0.0236278229673388,0.136,0.0798139114836694,0,1
"epetraborole","leucyl-tRNA synthetase inhibitor","","NC[C@H]1OB(O)c2c1cccc2OCCCO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC[C@H]1OB(O)c2c1cccc2OCCCO",237.117238392,17,0.145,84.94,0.0395826295105361,0.12,0.079791314755268,0,0
"kartogenin","chondrocyte differentiation stimulator","FLNA","OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)-c1ccccc1, OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)-c1ccccc1",317.10519334,24,4.548,66.4,0.121480473869117,0.038,0.0797402369345587,1,0
"KPT-276","exportin antagonist","XPO1","FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)N2CC(F)(F)C2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)N2CC(F)(F)C2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)N2CC(F)(F)C2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)N2CC(F)(F)C2)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)N2CC(F)(F)C2)n1",426.0726867,29,4.282,51.02,0.0414714095603986,0.118,0.0797357047801993,0,0
"SGI-1776","Pim kinase inhibitor","FLT3, PIM1, PIM2, PIM3","CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1",405.177644984,29,4.94,54.69,0.0714611174520343,0.088,0.0797305587260172,0,0
"amonafide","topoisomerase inhibitor","TOP2A, TOP2B","CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23, CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23, CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23",283.132076784,21,1.436,66.64,0.0674534423629088,0.092,0.0797267211814544,0,0
"seladelpar","PPAR receptor agonist","","CCO[C@H](COc1ccc(cc1)C(F)(F)F)CSc1ccc(OCC(O)=O)c(C)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCO[C@H](COc1ccc(cc1)C(F)(F)F)CSc1ccc(OCC(O)=O)c(C)c1",444.121829496,30,5.144,90.29,0.0172855496393554,0.142,0.0796427748196777,0,1
"AH6809","prostanoid receptor antagonist","PTGDR, PTGER1, PTGER2, PTGER3","CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O, CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O, CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O",298.084123548,22,4.625,76.74,0.0992667741832154,0.06,0.0796333870916077,0,0
"Y-134","estrogen receptor antagonist","ESR1, ESR2","CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1, CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1, CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1, CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1, CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1",472.182063756,34,5.877,92.25,0.025204034163296,0.134,0.079602017081648,0,1
"lta4h-in-1","leukotriene inhibitor","LTA4H","N[C@@H](CC(=O)O)Cn1nnc(n1)c2ccc(Oc3ncc(Cl)cc3F)cc2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","gastroenterology","inflammatory bowel disease","N[C@@H](CC(=O)O)Cn1nnc(n1)c2ccc(Oc3ncc(Cl)cc3F)cc2",392.079994208,27,2.819,129.04,0.00699086189884489,0.152,0.0794954309494224,0,1
"adenine","protein synthesis stimulant","ACACB, ACP1, APRT, MTAP, PECR, SRPK2","Nc1ncnc2nc[nH]c12, Nc1ncnc2nc[nH]c12, Nc1ncnc2nc[nH]c12, Nc1ncnc2nc[nH]c12, Nc1ncnc2nc[nH]c12, Nc1ncnc2nc[nH]c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1ncnc2nc[nH]c12",135.05449516,10,-0.337,80.48,0.0849753484810609,0.074,0.0794876742405304,0,0
"CBiPES","glutamate receptor positive allosteric modulator","GRM2","CCS(=O)(=O)N(Cc1cccnc1)c1cccc(c1)-c1ccc(cc1)C#N, CCS(=O)(=O)N(Cc1cccnc1)c1cccc(c1)-c1ccc(cc1)C#N, CCS(=O)(=O)N(Cc1cccnc1)c1cccc(c1)-c1ccc(cc1)C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCS(=O)(=O)N(Cc1cccnc1)c1cccc(c1)-c1ccc(cc1)C#N",377.119797848,27,4.304,82.44,0.040940898182698,0.118,0.079470449091349,0,0
"amiselimod","sphingosine 1-phosphate receptor modulator","","CCCCCCCOc1ccc(CCC(N)(CO)CO)cc1C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCCCCCOc1ccc(CCC(N)(CO)CO)cc1C(F)(F)F",377.21777848,26,4.17,75.71,0.0368462310985405,0.122,0.0794231155492702,0,0
"SB-415286","glycogen synthase kinase inhibitor","GSK3A, GSK3B, RPS6KB1","Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|",359.0308981,25,3.256,121.57,0.0127872526513543,0.146,0.0793936263256771,0,1
"3-deazauridine","cytidine deaminase inhibitor","","OC[C@H]1O[C@@H]([C@@H](O)[C@@H]1O)n1ccc(O)cc1=O |&1:2,&2:4,&3:5,&4:7,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC[C@H]1O[C@@H]([C@@H](O)[C@@H]1O)n1ccc(O)cc1=O |&1:2",243.074287136,17,-0.832,112.15,0.0147465718323299,0.144,0.079373285916165,0,1
"tyrphostin-AG-494","EGFR inhibitor","EGFR","Oc1ccc(\C=C(/C#N)C(=O)Nc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)Nc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)Nc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)Nc2ccccc2)cc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(\C=C(/C#N)C(=O)Nc2ccccc2)cc1O",280.084792244,21,2.255,93.35,0.0487102679664283,0.11,0.0793551339832142,0,0
"CycLuc1","","","OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 |c:6|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 |c:6|",305.029268592,20,0.629,128.12,0.00666799815151483,0.152,0.0793339990757574,0,1
"ciglitazone","PPAR receptor agonist","PPARG","CC1(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)CCCCC1 |r|, CC1(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)CCCCC1 |r|, CC1(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)CCCCC1 |r|, CC1(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)CCCCC1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC1(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)CCCCC1 |r|",333.139864596,23,3.786,80.7,0.042665478886677,0.116,0.0793327394433385,0,0
"pivanex","HDAC inhibitor","HDAC1, HDAC2, HDAC3, HDAC8","CCCC(=O)OCOC(=O)C(C)(C)C, CCCC(=O)OCOC(=O)C(C)(C)C, CCCC(=O)OCOC(=O)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCC(=O)OCOC(=O)C(C)(C)C",202.120509056,14,1.978,52.6,0.13656234300028,0.022,0.0792811715001401,1,0
"tecadenoson","adenosine receptor agonist","ADORA1","OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@@H]3CCOC3)ncnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@@H]3CCOC3)ncnc12",337.138618708,24,-0.959,134.78,0.00452473554584766,0.154,0.0792623677729238,0,1
"SR-2640","leukotriene receptor antagonist","CYSLTR1","OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1, OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1, OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1",370.131742436,28,5.095,71.45,0.0905059564463784,0.068,0.0792529782231892,0,0
"DIM-C-pPhCO2Me","nuclear receptor antagonist","","COC(=O)c1ccc(cc1)C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)c1ccc(cc1)C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12",380.15247788,29,5.596,57.88,0.132488466204723,0.026,0.0792442331023613,1,0
"pelrinone","phosphodiesterase inhibitor","","Cc1nc(=O)c(C#N)c(NCc2cccnc2)[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1nc(=O)c(C#N)c(NCc2cccnc2)[nH]1",241.096359972,18,1.857,94.46,0.0544539822839812,0.104,0.0792269911419906,0,0
"TCS-2210","neural stem cell inducer","","ONC(=O)c1ccc2[nH]c(=O)c(CCCc3ccccc3)nc2c1, ONC(=O)c1ccc2[nH]c(=O)c(CCCc3ccccc3)nc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","ONC(=O)c1ccc2[nH]c(=O)c(CCCc3ccccc3)nc2c1",323.126991404,24,2.557,95.08,0.0364119541346816,0.122,0.0792059770673408,0,0
"GNF-5837","growth factor receptor inhibitor","NTRK1, NTRK2, NTRK3","Cc1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)cc1Nc1ccc2\C(=C\c3ccc[nH]3)C(=O)Nc2c1, Cc1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)cc1Nc1ccc2\C(=C\c3ccc[nH]3)C(=O)Nc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)cc1Nc1ccc2\C(=C\c3ccc[nH]3)C(=O)Nc2c1",535.163137792,39,4.895,98.05,0.0123186090399106,0.146,0.0791593045199553,0,1
"TGR-1202","PI3K inhibitor","","CC(C)Oc1ccc(cc1F)-c1nn([C@@H](C)c2oc3ccc(F)cc3c(=O)c2-c2cccc(F)c2)c2ncnc(N)c12, CC(C)Oc1ccc(cc1F)-c1nn([C@@H](C)c2oc3ccc(F)cc3c(=O)c2-c2cccc(F)c2)c2ncnc(N)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(C)Oc1ccc(cc1F)-c1nn([C@@H](C)c2oc3ccc(F)cc3c(=O)c2-c2cccc(F)c2)c2ncnc(N)c12",571.183124288,42,8.242,109.06,0.0181930705299862,0.14,0.0790965352649931,0,1
"chromanol-(+/-)","potassium channel blocker","","CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N.CCS(=O)(=O)N(C)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N.CCS(=O)(=O)N(C)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N",648.22875624,44,2.922,198.02,0.000160501453910004,0.158,0.079080250726955,0,1
"bicuculline-(+)","GABA receptor antagonist","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, KCNN1","CN1CCc2cc3OCOc3cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1OCOc21",0,0,0,0,0,0,0,0,0,0,0,0,1,6,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCc2cc3OCOc3cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1OCOc21",367.105587264,27,2.507,66.46,0.0481200589379626,0.11,0.0790600294689813,0,0
"gepotidacin","topoisomerase inhibitor","","O=c1ccc2ncc(=O)n3[C@H](CN4CCC(CC4)NCc4cc5CCCOc5cn4)Cn1c23",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O=c1ccc2ncc(=O)n3[C@H](CN4CCC(CC4)NCc4cc5CCCOc5cn4)Cn1c23",448.222288756,33,1.627,94.28,0.0120995403013437,0.146,0.0790497701506718,0,1
"FCE-22250","DNA directed DNA polymerase inhibitor","","CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N=C\N4CCCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:34,t:3,36|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N=C\N4CCCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:34",834.405123296,60,6.245,229.27,8.18321646167565e-05,0.158,0.0790409160823084,0,1
"fce-22250","dna directed dna polymerase inhibitor","","COC1\C=C\OC2(C)Oc3c(C2=O)c2c(O)c(\C=N\N=C\N4CCCCC4)c(NC(=O)\C(C)=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C)c(O)c2c(O)c3C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COC1\C=C\OC2(C)Oc3c(C2=O)c2c(O)c(\C=N\N=C\N4CCCCC4)c(NC(=O)\C(C)=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C)c(O)c2c(O)c3C",834.405123296,60,6.245,229.27,8.18321646167568e-05,0.158,0.0790409160823084,0,1
"cyanopindolol","adrenergic receptor antagonist","ADRB1, HTR1A, HTR1D","CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(cc12)C#N |&1:6|, CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(cc12)C#N |&1:6|, CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(cc12)C#N |&1:6|",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"phase 2","","","CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(cc12)C#N |&1:6|",287.163376912,21,2.068,81.07,0.0520367778836267,0.106,0.0790183889418133,0,0
"inarigivir","antiviral","","CO[C@@H]1[C@H](O[P@](S)(=O)OC[C@H]2O[C@H](C[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](CO)O[C@H]1n1ccc(=O)[nH]c1=O |a:2,3,10,12,14,26,30,&1:5|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CO[C@@H]1[C@H](O[P@](S)(=O)OC[C@H]2O[C@H](C[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](CO)O[C@H]1n1ccc(=O)[nH]c1=O |a:2",587.119947662,39,-2.33,276.77,9.71168223317653e-06,0.158,0.0790048558411166,0,1
"BS-181","CDK inhibitor","CDK7","CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12",380.268845024,28,4.802,80.27,0.0559245687688426,0.102,0.0789622843844213,0,0
"NHI-2","lactate dehydrogenase inhibitor","LDHA","COC(=O)c1cc2c(cc(cc2n1O)-c1ccccc1)C(F)(F)F, COC(=O)c1cc2c(cc(cc2n1O)-c1ccccc1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)c1cc2c(cc(cc2n1O)-c1ccccc1)C(F)(F)F",335.076927904,24,4.341,51.46,0.107876526953816,0.05,0.0789382634769081,0,0
"AC-710","PDGFR tyrosine kinase receptor inhibitor","CSF1R, FLT3, KIT, PDGFRA, PDGFRB","CCN1C(C)(C)CC(CC1(C)C)Oc1ccc(nc1)C(=O)Nc1ccc(NC(=O)Nc2cc(on2)C(C)(C)C)cc1, CCN1C(C)(C)CC(CC1(C)C)Oc1ccc(nc1)C(=O)Nc1ccc(NC(=O)Nc2cc(on2)C(C)(C)C)cc1, CCN1C(C)(C)CC(CC1(C)C)Oc1ccc(nc1)C(=O)Nc1ccc(NC(=O)Nc2cc(on2)C(C)(C)C)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN1C(C)(C)CC(CC1(C)C)Oc1ccc(nc1)C(=O)Nc1ccc(NC(=O)Nc2cc(on2)C(C)(C)C)cc1",562.326753824,41,4.808,121.62,0.00582002910108132,0.152,0.0789100145505407,0,1
"NSC-9965","acetylcholine receptor antagonist","CHRNA4, CHRNB2","CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1 |t:4,11|, CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1 |t:4,11|, CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1 |t:4,11|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,"preclinical","","","CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1 |t:4",275.152143532,20,-0.523,38.77,0.0758177872087575,0.082,0.0789088936043787,0,0
"OC000459","CRTH receptor antagonist","PTGDR2","Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O, Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O, Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O, Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O",348.127406004,26,4.16,55.12,0.109777122975429,0.048,0.0788885614877145,0,0
"adomeglivant","glucagon receptor antagonist","","Cc1cc(O[C@@H](CCC(F)(F)F)c2ccc(cc2)C(=O)NCCC(O)=O)cc(C)c1-c1ccc(cc1)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(O[C@@H](CCC(F)(F)F)c2ccc(cc2)C(=O)NCCC(O)=O)cc(C)c1-c1ccc(cc1)C(C)(C)C",555.259643292,40,9.467,75.63,0.0477432672408917,0.11,0.0788716336204459,0,0
"PKI-166","EGFR inhibitor","EGFR","C[C@@H](Nc1ncnc2[nH]c(cc12)-c1ccc(O)cc1)c1ccccc1, C[C@@H](Nc1ncnc2[nH]c(cc12)-c1ccc(O)cc1)c1ccccc1, C[C@@H](Nc1ncnc2[nH]c(cc12)-c1ccc(O)cc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@@H](Nc1ncnc2[nH]c(cc12)-c1ccc(O)cc1)c1ccccc1",330.148061196,25,4.767,73.83,0.101704763581999,0.056,0.0788523817909996,0,0
"ozolinone","diuretic","","CN1C(=O)[C@@H](S\C1=C/C(O)=O)N1CCCCC1 |&1:4,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CN1C(=O)[C@@H](S\C1=C/C(O)=O)N1CCCCC1 |&1:4",256.088163372,17,0.288,86.15,0.0256920048350246,0.132,0.0788460024175123,0,1
"GSK2636771","PI3K inhibitor","PIK3CB","Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O, Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O, Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O, Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O, Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O",433.161326224,31,4.473,67.59,0.0396850806885283,0.118,0.0788425403442641,0,0
"WP1066","STAT inhibitor","STAT3","C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1",355.032024168,22,3.3,65.78,0.0256311311595982,0.132,0.0788155655797991,0,1
"bindarit","NFkB pathway inhibitor","CCL2, CCL7, CCL8","CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O, CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O",324.1473925,24,3.344,64.35,0.0835782890768342,0.074,0.0787891445384171,0,0
"vincamine","adrenergic receptor antagonist","CHRM1, CHRM2, CHRM3, CHRM4","CC[C@@]12CCCN3CCc4c([C@H]13)n(c1ccccc41)[C@](O)(C2)C(=O)OC, CC[C@@]12CCCN3CCc4c([C@H]13)n(c1ccccc41)[C@@](O)(C2)C(=O)OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,"withdrawn","","","CC[C@@]12CCCN3CCc4c([C@H]13)n(c1ccccc41)[C@](O)(C2)C(=O)OC",354.194342692,26,3.69,54.7,0.0875726282743486,0.07,0.0787863141371743,0,0
"CPSI-1306-(+/-)","macrophage migration inhibiting factor inhibitor","MIF","Fc1ccc(C2=NO[C@@H](CC(=O)N3CCOCC3)C2)c(F)c1 |&1:8,r,t:5|, Fc1ccc(C2=NO[C@@H](CC(=O)N3CCOCC3)C2)c(F)c1 |&1:8,r,t:5|, Fc1ccc(C2=NO[C@@H](CC(=O)N3CCOCC3)C2)c(F)c1 |&1:8,r,t:5|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1ccc(C2=NO[C@@H](CC(=O)N3CCOCC3)C2)c(F)c1 |&1:8",310.112898812,22,1.788,51.13,0.0694456151184728,0.088,0.0787228075592364,0,0
"AZD6738","ATR kinase inhibitor","ATR","C[C@@H]1COCCN1c1cc(nc(n1)-c1ccnc2[nH]ccc12)C1(CC1)[S@@](C)(=N)=O |a:1,&1:25|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@@H]1COCCN1c1cc(nc(n1)-c1ccnc2[nH]ccc12)C1(CC1)[S@@](C)(=N)=O |a:1",412.168145008,29,2.827,116.23,0.00922451649681944,0.148,0.0786122582484097,0,1
"ceralasertib","atr kinase inhibitor","ATR","C[C@@H]1COCCN1c1cc(nc(n1)-c1ccnc2[nH]ccc12)C1(CC1)[S@](C)(=N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","oncology","breast cancer","C[C@@H]1COCCN1c1cc(nc(n1)-c1ccnc2[nH]ccc12)C1(CC1)[S@](C)(=N)=O",412.168145008,29,2.827,116.23,0.00922451649681944,0.148,0.0786122582484097,0,1
"selfotel","glutamate receptor antagonist","GRIN2A, GRIN2B, GRIN2C, GRIN2D","OC(=O)[C@H]1C[C@@H](CP(O)(O)=O)CCN1, OC(=O)[C@H]1C[C@@H](CP(O)(O)=O)CCN1, OC(=O)[C@H]1C[C@@H](CP(O)(O)=O)CCN1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","OC(=O)[C@H]1C[C@@H](CP(O)(O)=O)CCN1",223.060959178,14,-1.48,116.67,0.00920787777618614,0.148,0.0786039388880931,0,1
"CGP-12177","adrenergic receptor agonist","ADRB1, ADRB2, ADRB3","CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(=O)[nH]c12 |&1:6|, CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(=O)[nH]c12 |&1:6|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,"phase 1","","","CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(=O)[nH]c12 |&1:6|",279.158291532,20,0.617,90.14,0.0290961903434165,0.128,0.0785480951717083,0,0
"TC-S-7009","hypoxia inducible factor inhibitor","EPAS1","[O-][N+](=O)c1c(Nc2cc(F)cc(Cl)c2)ccc2nonc12, [O-][N+](=O)c1c(Nc2cc(F)cc(Cl)c2)ccc2nonc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[O-][N+](=O)c1c(Nc2cc(F)cc(Cl)c2)ccc2nonc12",308.011245952,21,5.417,94.09,0.0530937822088106,0.104,0.0785468911044053,0,0
"bromindione","anticoagulant","","Brc1ccc(cc1)C1C(=O)c2ccccc2C1=O, Brc1ccc(cc1)C1C(=O)c2ccccc2C1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Brc1ccc(cc1)C1C(=O)c2ccccc2C1=O",299.978591628,18,3.522,34.14,0.0790407512746318,0.078,0.0785203756373159,0,0
"YK-4-279","apoptosis inhibitor","EWSR1, FLI1","COc1ccc(cc1)C(=O)C[C@@]1(O)C(=O)Nc2c1c(Cl)ccc2Cl |&1:11,r|, COc1ccc(cc1)C(=O)C[C@@]1(O)C(=O)Nc2c1c(Cl)ccc2Cl |&1:11,r|, COc1ccc(cc1)C(=O)C[C@@]1(O)C(=O)Nc2c1c(Cl)ccc2Cl |&1:11,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1)C(=O)C[C@@]1(O)C(=O)Nc2c1c(Cl)ccc2Cl |&1:11",365.022163256,24,3.848,75.63,0.0290323289804948,0.128,0.0785161644902474,0,0
"danegaptide","gap junction modulator","","NCC(=O)N1C[C@@H](C[C@H]1C(O)=O)NC(=O)c1ccccc1, NCC(=O)N1C[C@@H](C[C@H]1C(O)=O)NC(=O)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NCC(=O)N1C[C@@H](C[C@H]1C(O)=O)NC(=O)c1ccccc1",291.121906024,21,-0.365,112.73,0.0130243293852595,0.144,0.0785121646926297,0,1
"AR-42","HDAC inhibitor","HDAC1","CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1, CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1, CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1",312.1473925,23,3.063,78.43,0.0610216900465542,0.096,0.0785108450232771,0,0
"fdcyd","DNA methyltransferase inhibitor","","Nc1nc(=O)n(cc1F)[C@H]1C[C@H](O)[C@@H](CO)O1, Nc1nc(=O)n(cc1F)[C@H]1C[C@H](O)[C@@H](CO)O1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Nc1nc(=O)n(cc1F)[C@H]1C[C@H](O)[C@@H](CO)O1",245.081184084,17,-0.223,110.6,0.0168809225783682,0.14,0.0784404612891841,0,1
"A-804598","purinergic receptor antagonist","P2RX7","C[C@H](N\C(NC#N)=N/c1cccc2ncccc12)c1ccccc1, C[C@H](\N=C(\NC#N)Nc1cccc2ncccc12)c1ccccc1, C[C@H](\N=C(\NC#N)Nc1cccc2ncccc12)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H](N\C(NC#N)=N/c1cccc2ncccc12)c1ccccc1",315.148395544,24,3.667,73.1,0.0908631363907769,0.066,0.0784315681953885,0,0
"SNX-5422","HSP inhibitor","HSP90AA1, HSP90AB1","CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|",521.2249891,37,3.494,142.33,0.002781180864171,0.154,0.0783905904320855,0,1
"baloxavir","endonuclease inhibitor","","[H][C@@]12COCCN1C(=O)c1c(O)c(=O)ccn1N2[C@@H]1c2ccccc2SCc2c(F)c(F)ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","[H][C@@]12COCCN1C(=O)c1c(O)c(=O)ccn1N2[C@@H]1c2ccccc2SCc2c(F)c(F)ccc12",483.106433528,35,3.903,100.31,0.0126535825003281,0.144,0.078326791250164,0,1
"allicin","cytokine production inhibitor","TRPA1, TRPV1","C=CCS[S@@](=O)CC=C |&1:4,r|, C=CCS[S@@](=O)CC=C |&1:4,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C=CCS[S@@](=O)CC=C |&1:4",162.01730694,9,0.237,61.58,0.0646004341418287,0.092,0.0783002170709143,0,0
"GSK1070916","Aurora kinase inhibitor","AURKA, AURKB, AURKC, CYP2D6, CYP3A4","CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1, CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1, CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1, CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1",507.274658676,38,5.105,82.08,0.0285778988639484,0.128,0.0782889494319742,0,0
"nicainoprol","angiotensin converting enzyme inhibitor","","CC(C)NC[C@H](O)COc1cccc2CCCN(C(=O)c3cccnc3)c12 |&1:5,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)NC[C@H](O)COc1cccc2CCCN(C(=O)c3cccnc3)c12 |&1:5",369.205241724,27,1.827,74.69,0.0325291220829147,0.124,0.0782645610414573,0,0
"zotatifin","eukaryotic translation initiation factor inhibitor","EIF4A1","COc1cc2O[C@]3([C@@H]([C@@H](CN(C)C)[C@@H](O)[C@@]3(O)c2c(OC)n1)c4ccccc4)c5ccc(cc5)C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1cc2O[C@]3([C@@H]([C@@H](CN(C)C)[C@@H](O)[C@@]3(O)c2c(OC)n1)c4ccccc4)c5ccc(cc5)C#N",487.210721028,36,3.333,108.07,0.0105137947343121,0.146,0.078256897367156,0,1
"iodoantipyrine","","","Cc1c(I)c(=O)n(-c2ccccc2)n1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1c(I)c(=O)n(-c2ccccc2)n1C",313.991610972,15,2.344,26.93,0.0265023266357744,0.13,0.0782511633178872,0,1
"PF-03882845","mineralocorticoid receptor antagonist","","OC(=O)c1ccc2C3=NN([C@@H](C4CCCC4)C3CCc2c1)c1ccc(C#N)c(Cl)c1 |t:7|, OC(=O)c1ccc2C3=NN([C@@H](C4CCCC4)C3CCc2c1)c1ccc(C#N)c(Cl)c1 |t:7|, OC(=O)c1ccc2C3=NN([C@@H](C4CCCC4)C3CCc2c1)c1ccc(C#N)c(Cl)c1 |t:7|, OC(=O)c1ccc2C3=NN([C@@H](C4CCCC4)C3CCc2c1)c1ccc(C#N)c(Cl)c1 |t:7|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC(=O)c1ccc2C3=NN([C@@H](C4CCCC4)C3CCc2c1)c1ccc(C#N)c(Cl)c1 |t:7|",419.140054624,30,5.934,76.69,0.0504959836870696,0.106,0.0782479918435348,0,0
"pavinetant","neurokinin receptor antagonist","","CC[C@H](NC(=O)c1c(NS(C)(=O)=O)c(nc2ccccc12)-c1ccccc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC[C@H](NC(=O)c1c(NS(C)(=O)=O)c(nc2ccccc12)-c1ccccc1)c1ccccc1",459.16166266,33,5.822,96.54,0.0244279772686123,0.132,0.0782139886343062,0,1
"S18986","glutamate receptor modulator","GRIA1, GRIA2, GRIA3, GRIA4","O=S1(=O)N[C@H]2CCCN2c2ccccc12, O=S1(=O)N[C@H]2CCCN2c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O=S1(=O)N[C@H]2CCCN2c2ccccc12",224.061948624,15,1.67,57.79,0.0883302376676032,0.068,0.0781651188338016,0,0
"MK-7246","CRTH receptor antagonist","","CN([C@@H]1CCc2c(CC(O)=O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN([C@@H]1CCc2c(CC(O)=O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1",416.120606372,29,4.197,87.99,0.0223054721144443,0.134,0.0781527360572222,0,1
"SGX523","hepatocyte growth factor receptor inhibitor","MET","Cn1cc(cn1)-c1ccc2nnc(Sc3ccc4ncccc4c3)n2n1, Cn1cc(cn1)-c1ccc2nnc(Sc3ccc4ncccc4c3)n2n1, Cn1cc(cn1)-c1ccc2nnc(Sc3ccc4ncccc4c3)n2n1, Cn1cc(cn1)-c1ccc2nnc(Sc3ccc4ncccc4c3)n2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cn1cc(cn1)-c1ccc2nnc(Sc3ccc4ncccc4c3)n2n1",359.095314416,26,4.775,99.09,0.0382815352840634,0.118,0.0781407676420317,0,0
"MK-886","lipoxygenase inhibitor","","CC(C)c1ccc2n(Cc3ccc(Cl)cc3)c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)c1ccc2n(Cc3ccc(Cl)cc3)c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c2c1",471.199878008,32,8.063,67.53,0.0481862102151688,0.108,0.0780931051075844,0,0
"LEQ506","G protein signaling inhibitor","","C[C@@H]1CN(CCN1c1cnc(cn1)C(C)(C)O)c1nnc(Cc2ccccc2)c(C)c1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@@H]1CN(CCN1c1cnc(cn1)C(C)(C)O)c1nnc(Cc2ccccc2)c(C)c1C",432.263759644,32,3.822,78.27,0.0341689278087321,0.122,0.078084463904366,0,0
"moxalactam (sodium salt)","","","CO[C@]1(NC(=O)[C@H](C(O)=O)c2ccc(O)cc2)[C@H]2OCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |c:30|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CO[C@]1(NC(=O)[C@H](C(O)=O)c2ccc(O)cc2)[C@H]2OCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |c:30|",520.10124722,36,0.301,231.6,0.000131222023227598,0.156,0.0780656110116138,0,1
"L-778123","farnesyltransferase inhibitor","FNTA, FNTB, PGGT1B","Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O, Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O, Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O, Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O, Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O",405.13563794,29,2.752,65.16,0.0341278281387535,0.122,0.0780639140693767,0,0
"APY-29","serine/threonine kinase inhibitor","ERN1","C1CC1c1cc(Nc2ccnc(Nc3ccc4nc[nH]c4c3)n2)[nH]n1, C1CC1c1cc(Nc2ccnc(Nc3ccc4nc[nH]c4c3)n2)[nH]n1, C1CC1c1cc(Nc2ccnc(Nc3ccc4nc[nH]c4c3)n2)[nH]n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C1CC1c1cc(Nc2ccnc(Nc3ccc4nc[nH]c4c3)n2)[nH]n1",332.149792512,25,2.553,107.2,0.0281126948544531,0.128,0.0780563474272265,0,0
"BMS-983970","notch signaling inhibitor","","NC(=O)[C@@H](CC1CC1)[C@@H](CCC(F)(F)F)C(=O)N[C@H]1N=C(c2ccccc2)c2cccc(F)c2NC1=O |t:20|, NC(=O)[C@@H](CC1CC1)[C@@H](CCC(F)(F)F)C(=O)N[C@H]1N=C(c2ccccc2)c2cccc(F)c2NC1=O |t:20|, NC(=O)[C@@H](CC1CC1)[C@@H](CCC(F)(F)F)C(=O)N[C@H]1N=C(c2ccccc2)c2cccc(F)c2NC1=O |t:20|, NC(=O)[C@@H](CC1CC1)[C@@H](CCC(F)(F)F)C(=O)N[C@H]1N=C(c2ccccc2)c2cccc(F)c2NC1=O |t:20|, NC(=O)[C@@H](CC1CC1)[C@@H](CCC(F)(F)F)C(=O)N[C@H]1N=C(c2ccccc2)c2cccc(F)c2NC1=O |t:20|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","NC(=O)[C@@H](CC1CC1)[C@@H](CCC(F)(F)F)C(=O)N[C@H]1N=C(c2ccccc2)c2cccc(F)c2NC1=O |t:20|",518.194103572,37,4.844,113.65,0.00805344415589841,0.148,0.0780267220779492,0,1
"7-hydroxy-PIPAT","dopamine receptor ligand","DRD3","CCCN(C\C=C\I)[C@H]1CCc2ccc(O)cc2C1 |&1:8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,"preclinical","","","CCCN(C\C=C\I)[C@H]1CCc2ccc(O)cc2C1 |&1:8|",371.074612324,19,4.317,23.47,0.0298130553450355,0.126,0.0779065276725178,0,0
"PETCM","caspase activator","CASP3","O[C@@H](Cc1ccncc1)C(Cl)(Cl)Cl |&1:1,r|, O[C@@H](Cc1ccncc1)C(Cl)(Cl)Cl |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O[C@@H](Cc1ccncc1)C(Cl)(Cl)Cl |&1:1",238.967146916,13,1.99,33.12,0.0757849326290647,0.08,0.0778924663145323,0,0
"CP-105,696","leukotriene receptor antagonist","","O[C@@H]1[C@@H](Cc2ccc(cc2)-c2ccccc2)COc2cc(ccc12)C1(CCCC1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O[C@@H]1[C@@H](Cc2ccc(cc2)-c2ccccc2)COc2cc(ccc12)C1(CCCC1)C(O)=O",428.198759376,32,6.208,66.76,0.0837593107918154,0.072,0.0778796553959077,0,0
"ningetinib-tosylate","protein tyrosine kinase inhibitor","","Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C",556.212198248,41,4.038,107.61,0.0077022698751439,0.148,0.0778511349375719,0,1
"TP-3654","1,4,5-trisphosphate inhibitor","","CC(C)(O)[C@H]1CC[C@@H](CC1)Nc1ccc2ncc(-c3cccc(c3)C(F)(F)F)n2n1 |r|, CC(C)(O)[C@H]1CC[C@@H](CC1)Nc1ccc2ncc(-c3cccc(c3)C(F)(F)F)n2n1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)(O)[C@H]1CC[C@@H](CC1)Nc1ccc2ncc(-c3cccc(c3)C(F)(F)F)n2n1 |r|",418.19804608,30,5.766,62.45,0.0676974508734121,0.088,0.077848725436706,0,0
"PCO-400","potassium channel activator","KCNJ8","CC1(C)Oc2ccc(cc2[C@@H](OC2=CC(=O)CC2)[C@@H]1O)C#N |t:13|, CC1(C)Oc2ccc(cc2[C@@H](OC2=CC(=O)CC2)[C@@H]1O)C#N |t:13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC1(C)Oc2ccc(cc2[C@@H](OC2=CC(=O)CC2)[C@@H]1O)C#N |t:13|",299.115758024,22,1.59,79.55,0.0456631658176573,0.11,0.0778315829088287,0,0
"statil","aldose reductase inhibitor","","OC(=O)Cc1nn(Cc2ccc(Br)cc2F)c(=O)c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)Cc1nn(Cc2ccc(Br)cc2F)c(=O)c2ccccc12",390.001532564,24,3.874,72.19,0.017618737051202,0.138,0.077809368525601,0,1
"ptc596","polycomb protein inhibitor","BMI1","Cc1nc2ccc(F)cc2n1c3nc(N)c(F)c(Nc4ccc(cc4)C(F)(F)F)n3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","glioma","Cc1nc2ccc(F)cc2n1c3nc(N)c(F)c(Nc4ccc(cc4)C(F)(F)F)n3",420.112185516,30,4.956,81.13,0.0355665464176832,0.12,0.0777832732088416,0,0
"VER-49009","HSP inhibitor","HSP90AA1","CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O, CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O, CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O, CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O, CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O",387.098583736,27,4.074,107.47,0.017479218687132,0.138,0.077739609343566,0,1
"AM-92016","potassium channel blocker","GRIN1","CN(CCc1ccc(Cl)c(Cl)c1)C[C@@H](O)COc1ccc(NS(C)(=O)=O)cc1 |&1:13|, CN(CCc1ccc(Cl)c(Cl)c1)C[C@@H](O)COc1ccc(NS(C)(=O)=O)cc1 |&1:13|, CN(CCc1ccc(Cl)c(Cl)c1)C[C@@H](O)COc1ccc(NS(C)(=O)=O)cc1 |&1:13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(CCc1ccc(Cl)c(Cl)c1)C[C@@H](O)COc1ccc(NS(C)(=O)=O)cc1 |&1:13|",446.083383608,28,3.47,87.25,0.00747707156726007,0.148,0.07773853578363,0,1
"icilin","TRPV agonist","TRPA1, TRPM8","Oc1ccccc1N1CC=C(NC1=O)c1cccc(c1)[N+]([O-])=O |c:10|, Oc1ccccc1N1CC=C(NC1=O)c1cccc(c1)[N+]([O-])=O |c:10|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Oc1ccccc1N1CC=C(NC1=O)c1cccc(c1)[N+]([O-])=O |c:10|",311.090605896,23,2.725,95.71,0.0394750292854347,0.116,0.0777375146427173,0,0
"erbstatin-analog","EGFR inhibitor, tyrosine kinase inhibitor","EGFR","COC(=O)\C=C\c1cc(O)ccc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)\C=C\c1cc(O)ccc1O",194.0579088,14,1.418,66.76,0.107454797184456,0.048,0.0777273985922281,0,0
"pexacerfont","crf receptor antagonist","CRHR1, PLXNA2","CC[C@@H](C)Nc1nc(C)nc2c(c(C)nn12)-c1ccc(OC)nc1C |a:2|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","neurology/psychiatry","generalized anxiety disorder (gad)","CC[C@@H](C)Nc1nc(C)nc2c(c(C)nn12)-c1ccc(OC)nc1C |a:2|",340.201159388,25,3.384,77.23,0.0553633928844002,0.1,0.0776816964422001,0,0
"MK-1775","WEE1 kinase inhibitor","WEE1","CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1",500.264822264,37,2.793,104.34,0.00926526340992964,0.146,0.0776326317049648,0,1
"LY2228820","p38 MAPK inhibitor","MAPK14","CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C, CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C, CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C, CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C, CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C",420.243773148,31,5.635,85.41,0.047178218152885,0.108,0.0775891090764425,0,0
"KU-60019","ATM kinase inhibitor","ATM","C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1, C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1, C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1, C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1, C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1",547.214092156,39,4.927,109.55,0.00716651301193916,0.148,0.0775832565059696,0,1
"ocinaplon","GABA receptor modulator","GABRA1, GABRA2, GABRA3, GABRA5","O=C(c1cnn2c(ccnc12)-c1ccncc1)c1ccccn1, O=C(c1cnn2c(ccnc12)-c1ccncc1)c1ccccn1",0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,0,0,"phase 3","","","O=C(c1cnn2c(ccnc12)-c1ccncc1)c1ccccn1",301.096359972,23,1.625,73.04,0.0631428923143923,0.092,0.0775714461571961,0,0
"SB-216763","glycogen synthase kinase inhibitor","CCNA2, CDK2, GSK3A, GSK3B","Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12 |t:4|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12 |t:4|",370.027582984,25,4.659,51.1,0.0671387534560185,0.088,0.0775693767280092,0,0
"LY225910","CCK receptor antagonist","CCKBR","CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O, CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O, CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O, CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O, CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O, CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O",501.105189108,33,6.88,59.91,0.0270817184915336,0.128,0.0775408592457668,0,0
"RP67580","","","COc1ccccc1CC(=N)N1C[C@H]2[C@@H](C1)C(CCC2=O)(c1ccccc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccccc1CC(=N)N1C[C@H]2[C@@H](C1)C(CCC2=O)(c1ccccc1)c1ccccc1",438.2307282,33,5.825,53.39,0.101037336051561,0.054,0.0775186680257803,0,0
"SNAP-94847","","ADRA1A, DRD2","CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1, CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1, CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1, CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1, CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,"preclinical","","","CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1",478.243184704,35,6.057,41.57,0.0870154135585301,0.068,0.0775077067792651,0,0
"SB-747651A","kinase inhibitor","AKT1, AKT3, ROCK1, RPS6KA5, RPS6KB1","CCn1c(nc2cncc(CNC3CCNCC3)c12)-c1nonc1N, CCn1c(nc2cncc(CNC3CCNCC3)c12)-c1nonc1N, CCn1c(nc2cncc(CNC3CCNCC3)c12)-c1nonc1N, CCn1c(nc2cncc(CNC3CCNCC3)c12)-c1nonc1N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCn1c(nc2cncc(CNC3CCNCC3)c12)-c1nonc1N",342.191657324,25,0.822,119.71,0.0110111802997871,0.144,0.0775055901498935,0,1
"SQ-22536","adenylyl cyclase inhibitor","ADCY1","Nc1ncnc2n(cnc12)[C@H]1CCCO1 |&1:10,r|, Nc1ncnc2n(cnc12)[C@H]1CCCO1 |&1:10,r|, Nc1ncnc2n(cnc12)[C@H]1CCCO1 |&1:10,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1ncnc2n(cnc12)[C@H]1CCCO1 |&1:10",205.096359972,15,0.457,78.85,0.0649781126446284,0.09,0.0774890563223142,0,0
"menadione-bisulfite","vitamin K","GGCX, VKORC1, VKORC1L1","C[C@]1(CC(=O)c2ccccc2C1=O)S(O)(=O)=O |&1:1|, C[C@]1(CC(=O)c2ccccc2C1=O)S(O)(=O)=O |&1:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@]1(CC(=O)c2ccccc2C1=O)S(O)(=O)=O |&1:1|",254.02489442,17,-0.173,96.89,0.0189227260128721,0.136,0.0774613630064361,0,1
"PRE-084","sigma receptor agonist","SIGMAR1","O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1, O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1, O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1, O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1",317.199093724,23,3.514,38.77,0.138921296498249,0.016,0.0774606482491245,1,0
"merbarone","topoisomerase inhibitor","TOP2A","Oc1[nH]c(=S)[nH]c(=O)c1C(=O)Nc1ccccc1, Oc1[nH]c(=S)[nH]c(=O)c1C(=O)Nc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Oc1[nH]c(=S)[nH]c(=O)c1C(=O)Nc1ccccc1",263.036462148,18,3.293,130.07,0.0207899037448349,0.134,0.0773949518724174,0,1
"iCRT-14","beta catenin inhibitor, WNT signaling inhibitor","CTNNB1, TCF4","Cc1cc(\C=C2/SC(=O)N(C2=O)c2ccccc2)c(C)n1-c1cccnc1, Cc1cc(\C=C2/SC(=O)N(C2=O)c2ccccc2)c(C)n1-c1cccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(\C=C2/SC(=O)N(C2=O)c2ccccc2)c(C)n1-c1cccnc1",375.104147784,27,2.984,80.5,0.032784583486176,0.122,0.077392291743088,0,0
"NSC-3852","HDAC inhibitor","HDAC1","Oc1ccc(N=O)c2cccnc12, Oc1ccc(N=O)c2cccnc12, Oc1ccc(N=O)c2cccnc12, Oc1ccc(N=O)c2cccnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(N=O)c2cccnc12",174.042927432,13,1.259,62.55,0.140602713443242,0.014,0.077301356721621,1,0
"AM679","cannabinoid receptor agonist, lipoxygenase inhibitor","ALOX5AP, CNR1, CNR2","COc1cnc(nc1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OC[C@@H]4Cc5ccccc5N4C(C)=O)ccc23)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cnc(nc1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OC[C@@H]4Cc5ccccc5N4C(C)=O)ccc23)cc1",692.303241508,50,6.693,132.08,0.00258752251687998,0.152,0.07729376125844,0,1
"demeclocycline hcl","","","CN(C)[C@H]1[C@@H]2C[C@@H]3[C@H](O)c4c(Cl)ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CN(C)[C@H]1[C@@H]2C[C@@H]3[C@H](O)c4c(Cl)ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O",464.098643312,32,-1.157,175.3,0.000513528040614323,0.154,0.0772567640203072,0,1
"SB-706375","urotensin receptor antagonist","UTS2R","COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(c(O[C@@H]2CCN(C)C2)c1)C(F)(F)F, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(c(O[C@@H]2CCN(C)C2)c1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(c(O[C@@H]2CCN(C)C2)c1)C(F)(F)F",538.038489564,32,3.953,85.48,0.0024584142960928,0.152,0.0772292071480464,0,1
"WIKI4","tankyrase inhibitor, WNT pathway inhibitor","TNKS2","COc1ccc(cc1)-n1c(SCCCN2C(=O)c3cccc4cccc(C2=O)c34)nnc1-c1ccncc1, COc1ccc(cc1)-n1c(SCCCN2C(=O)c3cccc4cccc(C2=O)c34)nnc1-c1ccncc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1)-n1c(SCCCN2C(=O)c3cccc4cccc(C2=O)c34)nnc1-c1ccncc1",521.152160596,38,6.77,115.51,0.0144215285851554,0.14,0.0772107642925777,0,1
"AMG-232","MDM inhibitor","MDM2","CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1",567.16129958,37,5.821,100.13,0.00435840369998519,0.15,0.0771792018499926,0,1
"brincidofovir","antiviral","","CCCCCCCCCCCCCCCCOCCCOP(O)(=O)CO[C@H](CO)Cn1ccc(N)nc1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCCCCCCCCCCCCCCCOCCCOP(O)(=O)CO[C@H](CO)Cn1ccc(N)nc1=O",561.354287634,38,7.012,155.94,0.0023204548435059,0.152,0.0771602274217529,0,1
"ibrolipim","lipoprotein lipase activator","LPL","CCOP(=O)(Cc1ccc(cc1)C(=O)Nc1ccc(Br)cc1C#N)OCC, CCOP(=O)(Cc1ccc(cc1)C(=O)Nc1ccc(Br)cc1C#N)OCC, CCOP(=O)(Cc1ccc(cc1)C(=O)Nc1ccc(Br)cc1C#N)OCC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCOP(=O)(Cc1ccc(cc1)C(=O)Nc1ccc(Br)cc1C#N)OCC",450.03440585,27,3.569,98.23,0.00430533532543151,0.15,0.0771526676627158,0,1
"GSK2110183","AKT inhibitor","AKT1, AKT2, AKT3","Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1, Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1, Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1, Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1, Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1",426.048415744,27,3.049,101.18,0.00626789190711135,0.148,0.0771339459535557,0,1
"S-38093","histamine receptor antagonist","","NC(=O)c1ccc(OCCCN2C[C@@H]3CCC[C@@H]3C2)cc1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC(=O)c1ccc(OCCCN2C[C@@H]3CCC[C@@H]3C2)cc1 |r|",288.183778008,21,2.364,55.56,0.0942550429015189,0.06,0.0771275214507595,0,0
"AS-1949490","SHIP2 phosphatase inhibitor","INPP5D","C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1, C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1, C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1, C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1, C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1",371.074677496,25,5.297,66.57,0.0542351808797035,0.1,0.0771175904398518,0,0
"verdinexor","exportin antagonist","","FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2ccccn2)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2ccccn2)n1",442.097678324,31,4.887,84.73,0.0242272067812331,0.13,0.0771136033906165,0,1
"indiplon","benzodiazepine receptor agonist","GABRA1","CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1",376.099396752,27,2.498,95.81,0.0201852487675423,0.134,0.0770926243837711,0,1
"FK-866","niacinamide phosphoribosyltransferase inhibitor","NAMPT","O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1, O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1, O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1",391.225977168,29,3.829,62.3,0.0641738502666573,0.09,0.0770869251333286,0,0
"diacetamate","","","CC(=O)Nc1ccc(OC(C)=O)cc1, CC(=O)Nc1ccc(OC(C)=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)Nc1ccc(OC(C)=O)cc1",193.073893212,14,1.061,55.4,0.128118717305422,0.026,0.0770593586527111,1,0
"2-phenylmelatonin","melatonin receptor agonist","MTNR1A, MTNR1B","COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1, COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1, COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1, COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1, COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1",308.15247788,23,3.554,54.12,0.124115835865442,0.03,0.0770579179327212,1,0
"MK-571","leukotriene receptor antagonist","ABCC2, CYSLTR1","CN(C)C(=O)CCS[C@@H](SCCC(O)=O)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1 |&1:8|, CN(C)C(=O)CCS[C@@H](SCCC(O)=O)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1 |&1:8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN(C)C(=O)CCS[C@@H](SCCC(O)=O)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1 |&1:8|",514.115162404,34,5.212,121.1,0.00411164691323384,0.15,0.0770558234566169,0,1
"WP1130","deubiquitinase inhibitor","JAK2, UCHL5, USP14, USP9X","CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1",383.063324296,24,4.227,65.78,0.0260859671451681,0.128,0.077042983572584,0,0
"MI-14","PI4K inhibitor","PI4KB","CN(C)S(=O)(=O)c1cccc(c1)-c1c(C)nc2c(NCCNC(C)=O)cc(Cl)nn12, CN(C)S(=O)(=O)c1cccc(c1)-c1c(C)nc2c(NCCNC(C)=O)cc(Cl)nn12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)S(=O)(=O)c1cccc(c1)-c1c(C)nc2c(NCCNC(C)=O)cc(Cl)nn12",450.124087276,30,2.303,117.08,0.00406219921082619,0.15,0.0770310996054131,0,1
"idalopirdine","serotonin receptor antagonist","HTR6","FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1, FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1, FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1, FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1, FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1",398.141754328,28,5.376,37.05,0.108054403098971,0.046,0.0770272015494857,0,0
"midafotel","glutamate receptor antagonist","GRIN2A, GRIN2B, GRIN2C, GRIN2D","OC(=O)[C@H]1CN(C\C=C\P(O)(O)=O)CCN1, OC(=O)[C@H]1CN(C\C=C\P(O)(O)=O)CCN1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","OC(=O)[C@H]1CN(C\C=C\P(O)(O)=O)CCN1",250.07185821,16,-2.167,119.91,0.00601758326019414,0.148,0.0770087916300971,0,1
"diquafosol","purinergic receptor activator","","O[C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2ccc(=O)[nH]c2=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","O[C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2ccc(=O)[nH]c2=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O",789.993829612,49,-7.598,443.69,4.36137767453243e-09,0.154,0.0770000021806888,0,1
"norvancomycin","","","[H][C@@]1(C[C@](C)(N)[C@H](O)[C@H](C)O1)O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(cc3Cl)[C@@H](O)[C@@H](NC(=O)[C@H](N)CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@]3([H])c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O)[C@]1([H])NC(=O)[C@]([H])(NC3=O)c2ccc(O)c(c2)-c2c(O)cc(O)cc2[C@]([H])(NC1=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@@]1(C[C@](C)(N)[C@H](O)[C@H](C)O1)O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(cc3Cl)[C@@H](O)[C@@H](NC(=O)[C@H](N)CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@]3([H])c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O)[C@]1([H])NC(=O)[C@]([H])(NC3=O)c2ccc(O)c(c2)-c2c(O)cc(O)cc2[C@]([H])(NC1=O)C(O)=O",1433.414549576,105,2.294,544.48,3.99849968211596e-10,0.154,0.077000000199925,0,1
"CCT018159","HSP inhibitor","HSP90AA1, HSP90AB1","CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O, CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O, CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O",352.14230712,26,3.974,87.6,0.0479879660080659,0.106,0.076993983004033,0,0
"PF-477736","CHK inhibitor","CHEK1, CHEK2","Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O",419.20697304,31,2.75,134.48,0.00795463956964562,0.146,0.0769773197848228,0,1
"adiporon","adiponectin receptor agonist","ADIPOR1, ADIPOR2","O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1, O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1, O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1, O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1, O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1",428.209992756,32,4.769,58.64,0.0719338791774812,0.082,0.0769669395887406,0,0
"TMC647055","RNA polymerase inhibitor","","COc1ccc2-c3c(C4CCCCC4)c4ccc5cc4n3CC(=Cc2c1)C(=O)N(C)CCOCCN(C)S(=O)(=O)NC5=O |c:25|, COc1ccc2-c3c(C4CCCCC4)c4ccc5cc4n3CC(=Cc2c1)C(=O)N(C)CCOCCN(C)S(=O)(=O)NC5=O |c:25|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1ccc2-c3c(C4CCCCC4)c4ccc5cc4n3CC(=Cc2c1)C(=O)N(C)CCOCCN(C)S(=O)(=O)NC5=O |c:25|",606.251205936,43,5.312,118.56,0.00392916924977419,0.15,0.0769645846248871,0,1
"uric-acid","","PYGL","O=c1[nH]c2[nH]c(=O)[nH]c(=O)c2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","O=c1[nH]c2[nH]c(=O)[nH]c(=O)c2[nH]1",168.028339988,12,-0.584,114.37,0.0279123933618666,0.126,0.0769561966809333,0,0
"2-methyl-5-hydroxytryptamine","serotonin receptor agonist","HTR1B, HTR1D, HTR1E, HTR1F, HTR3A, HTR3B, HTR6","Cc1[nH]c2ccc(O)cc2c1CCN, Cc1[nH]c2ccc(O)cc2c1CCN, Cc1[nH]c2ccc(O)cc2c1CCN",0,0,0,0,0,0,0,0,1,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1[nH]c2ccc(O)cc2c1CCN",190.110613068,14,1.24,62.04,0.123806410511282,0.03,0.076903205255641,1,0
"fipexide","psychoactive drug","","Clc1ccc(OCC(=O)N2CCN(Cc3ccc4OCOc4c3)CC2)cc1, Clc1ccc(OCC(=O)N2CCN(Cc3ccc4OCOc4c3)CC2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","Clc1ccc(OCC(=O)N2CCN(Cc3ccc4OCOc4c3)CC2)cc1",388.118984832,27,2.715,51.24,0.0438012161716036,0.11,0.0769006080858018,0,0
"AMG458","MET inhibitor","MET","COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1, COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1, COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1",539.216869028,40,3.353,120.5,0.00576908153217695,0.148,0.0768845407660885,0,1
"proflavine-hemisulfate","topical anesthetic","F2","Nc1ccc2cc3ccc(N)cc3nc2c1, Nc1ccc2cc3ccc(N)cc3nc2c1, Nc1ccc2cc3ccc(N)cc3nc2c1, Nc1ccc2cc3ccc(N)cc3nc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Nc1ccc2cc3ccc(N)cc3nc2c1",209.095297352,16,1.846,64.93,0.13374452870794,0.02,0.0768722643539698,1,0
"bicuculline methochloride","gaba receptor antagonist","","C[N+]1(C)CCc2cc3OCOc3cc2C1[C@@H]1OC(=O)c2c1ccc1OCOc21",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","null","epilepsy","C[N+]1(C)CCc2cc3OCOc3cc2C1[C@@H]1OC(=O)c2c1ccc1OCOc21",382.128513780091,28,2.316,63.22,0.0437202921426121,0.11,0.076860146071306,0,0
"bicuculline-methochloride-(-)","GABA receptor antagonist","","C[N+]1(C)CCc2cc3OCOc3cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1OCOc21",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[N+]1(C)CCc2cc3OCOc3cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1OCOc21",382.128513780091,28,2.316,63.22,0.0437202921426121,0.11,0.076860146071306,0,0
"LSZ-102","selective estrogen receptor modulator (SERM)","","CC(F)(F)c1cc(F)ccc1-c1sc2cc(O)ccc2c1Oc1ccc(\C=C\C(O)=O)cc1, CC(F)(F)c1cc(F)ccc1-c1sc2cc(O)ccc2c1Oc1ccc(\C=C\C(O)=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(F)(F)c1cc(F)ccc1-c1sc2cc(O)ccc2c1Oc1ccc(\C=C\C(O)=O)cc1",470.079964684,33,6.614,95,0.0236983534075802,0.13,0.0768491767037901,0,1
"tifenazoxide","ATP-sensitive potassium channel agonist","ABCC8, KCNJ11","CC1(CC1)NC1=NS(=O)(=O)c2sc(Cl)cc2N1 |t:6|, CC1(CC1)NC1=NS(=O)(=O)c2sc(Cl)cc2N1 |t:6|, CC1(CC1)NC1=NS(=O)(=O)c2sc(Cl)cc2N1 |t:6|, CC1(CC1)NC1=NS(=O)(=O)c2sc(Cl)cc2N1 |t:6|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC1(CC1)NC1=NS(=O)(=O)c2sc(Cl)cc2N1 |t:6|",290.99029624,17,1.638,107.18,0.00969470936071158,0.144,0.0768473546803558,0,1
"dichloroacetate","pyruvate dehydrogenase kinase inhibitor","","[Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","[Na].OC(=O)C(Cl)Cl",150.932953944,7,0.571,37.3,0.0976339342151617,0.056,0.0768169671075808,0,0
"PK-44","dipeptidyl peptidase inhibitor","DPP4","N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1[nH]nc2c(F)c(F)ccc12, N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1[nH]nc2c(F)c(F)ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1[nH]nc2c(F)c(F)ccc12",429.133649232,30,4.136,105.72,0.0135588575824585,0.14,0.0767794287912292,0,1
"tetrazol-5-yl-glycine-(RS)","glutamate receptor agonist","GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D","N[C@@H](C(O)=O)c1nn[nH]n1 |&1:1,r|, N[C@@H](C(O)=O)c1nn[nH]n1 |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@@H](C(O)=O)c1nn[nH]n1 |&1:1",143.0443244,10,-3.264,117.78,0.0155140233789229,0.138,0.0767570116894615,0,1
"GSK2578215A","leucine rich repeat kinase inhibitor","LRRK2","Fc1cc(ccn1)-c1ccc(OCc2ccccc2)c(c1)C(=O)Nc1cccnc1, Fc1cc(ccn1)-c1ccc(OCc2ccccc2)c(c1)C(=O)Nc1cccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1cc(ccn1)-c1ccc(OCc2ccccc2)c(c1)C(=O)Nc1cccnc1",399.138305036,30,4.304,64.11,0.0714906212415943,0.082,0.0767453106207971,0,0
"dioxybenzone","topical sunscreen agent","","COc1ccc(C(=O)c2ccccc2O)c(O)c1, COc1ccc(C(=O)c2ccccc2O)c(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(C(=O)c2ccccc2O)c(O)c1",244.073558864,18,3.537,66.76,0.133391065081609,0.02,0.0766955325408047,1,0
"SJ-733","ATPase inhibitor","","Fc1ccc(NC(=O)[C@@H]2[C@H](N(CC(F)(F)F)C(=O)c3ccccc23)c2cccnc2)cc1C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Fc1ccc(NC(=O)[C@@H]2[C@H](N(CC(F)(F)F)C(=O)c3ccccc23)c2cccnc2)cc1C#N",468.120938632,34,3.803,86.09,0.0193772583236016,0.134,0.0766886291618008,0,1
"I-BZA","","","CCN(CC)CCNC(=O)c1ccc(I)cc1, CCN(CC)CCNC(=O)c1ccc(I)cc1, CCN(CC)CCNC(=O)c1ccc(I)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCN(CC)CCNC(=O)c1ccc(I)cc1",346.054211228,17,3.194,32.34,0.0213253241690061,0.132,0.076662662084503,0,1
"AMG-510","K-Ras inhibitor","","CC(C)c1nccc(C)c1-n1c2nc(c(F)cc2c(nc1=O)N1CCN(C[C@@H]1C)C(=O)C=C)-c1c(O)cccc1F, CC(C)c1nccc(C)c1-n1c2nc(c(F)cc2c(nc1=O)N1CCN(C[C@@H]1C)C(=O)C=C)-c1c(O)cccc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","CC(C)c1nccc(C)c1-n1c2nc(c(F)cc2c(nc1=O)N1CCN(C[C@@H]1C)C(=O)C=C)-c1c(O)cccc1F",560.23474526,41,5.714,104.45,0.0113145116033828,0.142,0.0766572558016914,0,1
"PF-750","FAAH inhibitor","FAAH","O=C(Nc1ccccc1)N1CCC(Cc2cnc3ccccc3c2)CC1, O=C(Nc1ccccc1)N1CCC(Cc2cnc3ccccc3c2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(Nc1ccccc1)N1CCC(Cc2cnc3ccccc3c2)CC1",345.184112356,26,3.767,45.23,0.131270441036572,0.022,0.0766352205182862,1,0
"SU014813","PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","KDR","Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1",442.201633564,32,1.022,106.69,0.00721024043307374,0.146,0.0766051202165369,0,1
"su14813","pdgfr tyrosine kinase receptor inhibitor, vegfr inhibitor","","Cc1[nH]c(\C=C2\C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1[nH]c(\C=C2\C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1",442.201633564,32,1.022,106.69,0.00721024043307373,0.146,0.0766051202165369,0,1
"alflutinib","protein tyrosine kinase inhibitor","EGFR","CN(C)CCN(C)c1nc(OCC(F)(F)F)c(Nc2nccc(n2)c3cn(C)c4ccccc34)cc1NC(=O)C=C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","oncology","non-small cell lung cancer (nsclc)","CN(C)CCN(C)c1nc(OCC(F)(F)F)c(Nc2nccc(n2)c3cn(C)c4ccccc34)cc1NC(=O)C=C",568.252206892,41,5.225,100.44,0.00911224781781815,0.144,0.0765561239089091,0,1
"L-798106","prostanoid receptor antagonist","PTGER3","COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1, COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1, COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1",535.045291284,34,6.691,80.85,0.00906411992845378,0.144,0.0765320599642269,0,1
"PHA-848125","CDK inhibitor, growth factor receptor inhibitor","CDK2, CDK4, CDK7, NTRK1","CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21",460.269907644,34,2.476,91.21,0.0150592150904651,0.138,0.0765296075452325,0,1
"buparlisib","PI3K inhibitor","PIK3CA, PIK3CG","Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F",410.167808572,29,2.656,89.63,0.0170555722658319,0.136,0.0765277861329159,0,1
"L-760735","tachykinin antagonist","TACR1","C[C@@H](O[C@H]1OCCN(Cc2n[nH]nc2CN(C)C)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2n[nH]nc2CN(C)C)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](O[C@H]1OCCN(Cc2n[nH]nc2CN(C)C)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F",575.213122676,40,6.213,66.51,0.0170083279670307,0.136,0.0765041639835154,0,1
"schisandrin-B","antioxidant","ATR","COc1cc2C[C@H](C)[C@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2C[C@H](C)[C@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC |r|",400.188588616,29,5.589,55.38,0.0909607912890049,0.062,0.0764803956445024,0,0
"CI-976","ACAT inhibitor","ACAT1, CES1","CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC",393.287908728,28,6.889,56.79,0.110938341563113,0.042,0.0764691707815567,0,0
"GPBAR-A","G protein-coupled receptor agonist","GPBAR1","Fc1ccccc1-c1ccnc2OCC(=O)N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)Cc12, Fc1ccccc1-c1ccnc2OCC(=O)N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)Cc12, Fc1ccccc1-c1ccnc2OCC(=O)N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)Cc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1ccccc1-c1ccnc2OCC(=O)N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)Cc12",484.10217526,34,6.076,42.43,0.0608568598792033,0.092,0.0764284299396017,0,0
"lintopride","serotonin receptor antagonist","","CCN1CCN=C1CNC(=O)c1cc(Cl)c(N)cc1OC |c:5|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN1CCN=C1CNC(=O)c1cc(Cl)c(N)cc1OC |c:5|",310.119653528,21,1.685,79.95,0.0287696642552206,0.124,0.0763848321276103,0,0
"FR-180204","MAP kinase inhibitor","MAPK1, MAPK3","Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1, Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1, Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1, Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1",327.123243416,25,3.505,97.78,0.0487573029867179,0.104,0.076378651493359,0,0
"fosifloxuridine nafalbenamide","thymidylate synthase inhibitor","TYMS","C[C@H](N[P@@](=O)(OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O)Oc1cccc2ccccc12)C(=O)OCc1ccccc1 |&1:3|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","colorectal cancer","C[C@H](N[P@@](=O)(OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O)Oc1cccc2ccccc12)C(=O)OCc1ccccc1 |&1:3|",613.162544358,43,3.647,167.99,0.000706121213425359,0.152,0.0763530606067127,0,1
"canrenone","mineralocorticoid receptor antagonist","NR3C2","C[C@]12CCC3C(C=CC4=CC(=O)CC[C@]34C)C1CC[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]21CCC(=O)O1 |c:6,t:8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","C[C@]12CCC3C(C=CC4=CC(=O)CC[C@]34C)C1CC[C@@]21CCC(=O)O1",340.203844756,25,4.229,43.37,0.136498337706301,0.016,0.0762491688531506,1,0
"MTPG","glutamate receptor antagonist","GRM2, GRM3","C[C@@](N)(C(O)=O)c1ccc(cc1)-c1nn[nH]n1 |&1:1|, C[C@@](N)(C(O)=O)c1ccc(cc1)-c1nn[nH]n1 |&1:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@](N)(C(O)=O)c1ccc(cc1)-c1nn[nH]n1 |&1:1|",233.091274592,17,-0.81,117.78,0.0164909335211205,0.136,0.0762454667605602,0,1
"piceatannol","SYK inhibitor","ATP5A1, ATP5B, ATP5C1, IRF3","Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1",244.073558864,18,3.193,80.92,0.0924601064973117,0.06,0.0762300532486558,0,0
"ogerin","G protein-coupled receptor modulator","","Nc1nc(NCc2ccccc2)nc(n1)-c1ccccc1CO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1nc(NCc2ccccc2)nc(n1)-c1ccccc1CO",307.143310164,23,2.112,96.95,0.0363843740680161,0.116,0.0761921870340081,0,0
"atenolol-(+)","adrenergic receptor antagonist","","CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1, CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1",266.163042564,19,0.461,84.58,0.0343328590788738,0.118,0.0761664295394369,0,0
"EMD-1214063","hepatocyte growth factor receptor inhibitor","MET","CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1, CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1, CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1, CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1",492.227374136,37,4.127,96.93,0.0183254605928339,0.134,0.076162730296417,0,1
"PF-562271","focal adhesion kinase inhibitor","PTK2, PTK2B","CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O",507.13004316,35,2.718,137.59,0.00226832480406158,0.15,0.0761341624020308,0,1
"LY456236","glutamate receptor antagonist","GRM1","COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1, COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1, COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1, COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1",281.11642672,21,2.854,56.27,0.120253697929126,0.032,0.0761268489645628,1,0
"AS-604850","PI3K inhibitor","PIK3CA, PIK3CG","FC1(F)Oc2ccc(\C=C3/SC(=O)NC3=O)cc2O1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC1(F)Oc2ccc(\C=C3/SC(=O)NC3=O)cc2O1",284.99073508,19,1.668,89.93,0.0262157509796937,0.126,0.0761078754898468,0,0
"o-mercapto-benzoic-acid","","","OC(=O)c1ccccc1S",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1ccccc1S",154.008850432,10,2.015,76.1,0.104211570915265,0.048,0.0761057854576324,0,0
"SC-9","protein tyrosine kinase activator","PRKCA","Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1, Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1, Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1, Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1, Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1",401.121627688,27,6.692,54.55,0.0761856880262924,0.076,0.0760928440131462,0,0
"otenzepad","acetylcholine receptor antagonist","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","CCN(CC)C[C@H]1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12 |&1:6,r|, CCN(CC)C[C@H]1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12 |&1:6,r|, CCN(CC)C[C@H]1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12 |&1:6,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,5,0,0,0,0,0,0,"phase 3","","","CCN(CC)C[C@H]1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12 |&1:6",421.247775232,31,2.534,68.78,0.0321496858971172,0.12,0.0760748429485586,0,0
"SB-221284","serotonin receptor antagonist","HTR2A, HTR2B, HTR2C","CSc1cc2CCN(C(=O)Nc3cccnc3)c2cc1C(F)(F)F, CSc1cc2CCN(C(=O)Nc3cccnc3)c2cc1C(F)(F)F, CSc1cc2CCN(C(=O)Nc3cccnc3)c2cc1C(F)(F)F",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CSc1cc2CCN(C(=O)Nc3cccnc3)c2cc1C(F)(F)F",353.080967728,24,2.885,70.53,0.0341459903812948,0.118,0.0760729951906474,0,0
"ds-1971a","voltage-gated sodium channel blocker","SCN9A","O=S(C1=CC(Cl)=C(O[C@@H]2[C@@H](C3=CC=NN3C)CCCC2)C=C1F)(NC4=NC=NC=C4)=O",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","neurology/psychiatry","peripheral neuropathy","O=S(C1=CC(Cl)=C(O[C@@H]2[C@@H](C3=CC=NN3C)CCCC2)C=C1F)(NC4=NC=NC=C4)=O",465.103766432,31,1.595,104.1,0.0040602281472913,0.148,0.0760301140736456,0,1
"sanazole","","","COCCNC(=O)Cn1cnc(n1)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COCCNC(=O)Cn1cnc(n1)[N+]([O-])=O",229.081103832,16,-0.903,112.18,0.0160500172754758,0.136,0.0760250086377379,0,1
"pesampator","","","CC(C)S(=O)(=O)N[C@H]1COC[C@H]1OC1=CC=C(C=C1)C1=CC=C(S1)C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,"phase 2","neurology/psychiatry","schizophrenia","CC(C)S(=O)(=O)N[C@H]1COC[C@H]1OC1=CC=C(C=C1)C1=CC=C(S1)C#N",392.08644912,26,0.861000000000001,122.1,0.00404523921359204,0.148,0.076022619606796,0,1
"[sar9,met(o2)11]-substance-p","tachykinin antagonist","TACR1","CC(C)C[C@H](NC(=O)CN(C)C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCS(C)(=O)=O)C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)C[C@H](NC(=O)CN(C)C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCS(C)(=O)=O)C(N)=O",1392.7336255,98,-2.996,550.36,5.02326548837314e-11,0.152,0.0760000000251163,0,1
"2-amino-4-(methylselanyl)butanoic acid","","","C[Se]CC[C@@H](N)C(O)=O |&1:4,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","C[Se]CC[C@@H](N)C(O)=O |&1:4",196.995499892,9,-2.108,63.32,0.0159114432950711,0.136,0.0759557216475355,0,1
"PF-06459988","receptor tyrosine protein kinase inhibitor","","CO[C@H]1CN(C[C@@H]1COc1nc(Nc2cnn(C)c2)nc2[nH]cc(Cl)c12)C(=O)C=C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CO[C@H]1CN(C[C@@H]1COc1nc(Nc2cnn(C)c2)nc2[nH]cc(Cl)c12)C(=O)C=C",431.147265244,30,2.473,110.19,0.007792365480626,0.144,0.075896182740313,0,1
"seclidemstat","histone demethylase inhibitor","","CN1CCN(CC1)S(=O)(=O)c1cccc(c1)C(=O)N\N=C(/C)c1cc(Cl)ccc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN1CCN(CC1)S(=O)(=O)c1cccc(c1)C(=O)N\N=C(/C)c1cc(Cl)ccc1O",450.112853896,30,3.122,110.69,0.00575083024080068,0.146,0.0758754151204003,0,1
"fenobam","glutamate receptor antagonist","GRM5","CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1 |c:5|, CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1 |c:5|, CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1 |c:5|, CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1 |c:5|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1 |c:5|",266.057053272,18,1.773,73.8,0.0477491773229592,0.104,0.0758745886614796,0,0
"metitepine","serotonin receptor antagonist, anti-HCVE2","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7","CSc1ccc2Sc3ccccc3C[C@@H](N3CCN(C)CC3)c2c1 |&1:14,r|, CSc1ccc2Sc3ccccc3C[C@@H](N3CCN(C)CC3)c2c1 |&1:14,r|, CSc1ccc2Sc3ccccc3C[C@@H](N3CCN(C)CC3)c2c1 |&1:14,r|, CSc1ccc2Sc3ccccc3CC(N3CCN(C)CC3)c2c1",0,0,0,0,0,0,0,0,1,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","infectious disease","antiviral","CSc1ccc2Sc3ccccc3C[C@@H](N3CCN(C)CC3)c2c1 |&1:14",356.138090768,24,4.302,57.08,0.0597459573966487,0.092,0.0758729786983244,0,0
"IDRA-21","glutamate receptor positive allosteric modulator","GRIA1, GRIA2, GRIA3, GRIA4","C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|, C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|, C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|, C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|, C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1",232.007326208,14,1.526,66.58,0.0477105103932201,0.104,0.07585525519661,0,0
"dimethyl-isosorbide","cosmetic moisturizer","","CO[C@@H]1CO[C@H]2[C@H](CO[C@@H]12)OC |&1:6,&2:9,&3:2,&4:5,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CO[C@@H]1CO[C@H]2[C@H](CO[C@@H]12)OC |&1:6",174.089208928,12,-0.822,36.92,0.12366699668653,0.028,0.0758334983432652,1,0
"GSK2981278","ROR modulator","","CCc1ccc(cc1)N(CC(C)C)S(=O)(=O)c1ccc(OCC2CCOCC2)c(CO)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","CCc1ccc(cc1)N(CC(C)C)S(=O)(=O)c1ccc(OCC2CCOCC2)c(CO)c1",461.22359422,32,4.909,84.45,0.0196327997883605,0.132,0.0758163998941802,0,1
"NPC-15199","ICAM1 antagonist","PPARG","CC(C)C[C@@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O, CC(C)C[C@@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)C[C@@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O",353.162708216,26,2.334,75.63,0.0416132214696435,0.11,0.0758066107348218,0,0
"fmoc-L-leucine","PPAR receptor agonist","","CC(C)C[C@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O, CC(C)C[C@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)C[C@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O",353.162708216,26,2.334,75.63,0.0416132214696435,0.11,0.0758066107348217,0,0
"EO-1428","p38 MAPK inhibitor","MAPK11, MAPK14","Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl, Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl, Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl, Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl",414.013452912,25,5.828,55.12,0.029608655238086,0.122,0.075804327619043,0,0
"nrc-2694","anticancer agent","EGFR","COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCN1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","non-small cell lung cancer (nsclc)","COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCN1CCOCC1",418.200490692,31,2.895,68.74,0.0376034977271206,0.114,0.0758017488635603,0,0
"edasalonexent","NFkB pathway inhibitor","","CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)NCCNC(=O)c1ccccc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)NCCNC(=O)c1ccccc1O",490.319543204,36,10.292,78.43,0.0975652921084675,0.054,0.0757826460542338,0,0
"polaprezinc","chelating agent","","O=C1CCN[Zn]OC(=O)[C@H](Cc2cnc[nH]2)N1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C1CCN[Zn]OC(=O)[C@H](Cc2cnc[nH]2)N1",288.020082444,17,-0.729,96.11,0.007544017362157,0.144,0.0757720086810785,0,1
"ethimizol","","","CCn1cnc(C(=O)NC)c1C(=O)NC, CCn1cnc(C(=O)NC)c1C(=O)NC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCn1cnc(C(=O)NC)c1C(=O)NC",210.111675688,15,-0.164,76.02,0.0534961091343066,0.098,0.0757480545671533,0,0
"EUK-134","catalase stimulant","APP, SOD2","COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12 |t:7,11|, COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12 |t:7,11|, COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12 |t:7,11|, COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12 |t:7,11|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12 |t:7",416.032457676181,26,3.914,42.94,0.0294657429947449,0.122,0.0757328714973725,0,0
"wnt-c59","porcupine inhibitor","PORCN","Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1",379.168462292,29,4.496,54.88,0.113457848776354,0.038,0.075728924388177,0,0
"ruboxistaurin","PKC inhibitor","","CN(C)C[C@@H]1CCn2cc(C3=C(C(=O)NC3=O)c3cn(CCO1)c1ccccc31)c1ccccc21 |t:10|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CN(C)C[C@@H]1CCn2cc(C3=C(C(=O)NC3=O)c3cn(CCO1)c1ccccc31)c1ccccc21 |t:10|",468.216140756,35,6.094,68.5,0.0614491782098874,0.09,0.0757245891049437,0,0
"ZK-811752","CC chemokine receptor antagonist","CCR1","C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O",434.152096528,30,2.223,87.9,0.0113939560010556,0.14,0.0756969780005278,0,1
"sonepiprazole","dopamine receptor antagonist","","NS(=O)(=O)c1ccc(cc1)N1CCN(CC[C@@H]2OCCc3ccccc23)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NS(=O)(=O)c1ccc(cc1)N1CCN(CC[C@@H]2OCCc3ccccc23)CC1",401.177312724,28,2.28,84.25,0.0173430671088404,0.134,0.0756715335544202,0,1
"SMER-28","autophagy inducer","SNCA","Brc1ccc2ncnc(NCC=C)c2c1, Brc1ccc2ncnc(NCC=C)c2c1, Brc1ccc2ncnc(NCC=C)c2c1, Brc1ccc2ncnc(NCC=C)c2c1, Brc1ccc2ncnc(NCC=C)c2c1, Brc1ccc2ncnc(NCC=C)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Brc1ccc2ncnc(NCC=C)c2c1",263.00580942,15,2.871,37.81,0.0753315397431205,0.076,0.0756657698715603,0,0
"soraprazan","proton pump inhibitor","","COCCO[C@H]1[C@H](O)[C@H](Nc2c1ccn1c(C)c(C)nc21)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COCCO[C@H]1[C@H](O)[C@H](Nc2c1ccn1c(C)c(C)nc21)c1ccccc1",367.18959166,27,3.101,68.02,0.0532922422774997,0.098,0.0756461211387499,0,0
"RI-1","","RAD51","ClC1=C(N2CCOCC2)C(=O)N(C1=O)c1ccc(Cl)c(Cl)c1 |c:1|, ClC1=C(N2CCOCC2)C(=O)N(C1=O)c1ccc(Cl)c(Cl)c1 |c:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","ClC1=C(N2CCOCC2)C(=O)N(C1=O)c1ccc(Cl)c(Cl)c1 |c:1|",359.983525252,22,3.107,49.85,0.0312370974984879,0.12,0.075618548749244,0,0
"lersivirine","non-nucleoside reverse transcriptase inhibitor","","CCc1nn(CCO)c(CC)c1Oc1cc(cc(c1)C#N)C#N, CCc1nn(CCO)c(CC)c1Oc1cc(cc(c1)C#N)C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCc1nn(CCO)c(CC)c1Oc1cc(cc(c1)C#N)C#N",310.142975816,23,2.063,94.86,0.0351671196776969,0.116,0.0755835598388484,0,0
"3-deazaneplanocin-A","histone lysine methyltransferase inhibitor","EZH2","Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O |t:13|, Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O |t:13|, Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O |t:13|, Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O |t:13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O |t:13|",262.106590308,19,-0.833,117.42,0.0131449444254287,0.138,0.0755724722127143,0,1
"isodibut","aldehyde reductase inhibitor","","OC(=O)CCCN1C(=O)c2cccc3cccc(C1=O)c23, OC(=O)CCCN1C(=O)c2cccc3cccc(C1=O)c23, OC(=O)CCCN1C(=O)c2cccc3cccc(C1=O)c23",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)CCCN1C(=O)c2cccc3cccc(C1=O)c23",283.084457896,21,2.298,74.68,0.0691206067679882,0.082,0.0755603033839941,0,0
"PF-04217903","c-Met inhibitor","MET","OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1, OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1, OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1, OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1, OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1",372.144707132,28,1.582,107.43,0.017098795806681,0.134,0.0755493979033405,0,1
"alda-1","aldehyde dehydrogenase activator","ALDH2","Clc1cccc(Cl)c1C(=O)NCc1ccc2OCOc2c1, Clc1cccc(Cl)c1C(=O)NCc1ccc2OCOc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1cccc(Cl)c1C(=O)NCc1ccc2OCOc2c1",323.011598572,21,3.87,47.56,0.0730610869065763,0.078,0.0755305434532881,0,0
"JNJ-16259685","glutamate receptor antagonist","GRM1","CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1 |r|, CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1 |r|, CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1 |r|",325.167793596,24,3.618,48.42,0.121045028522486,0.03,0.075522514261243,1,0
"FPH1-(BRD-6125)","hepatocyte function enhancer","","Cc1ccc(Cl)cc1N(CC(=O)Nc1c(F)cccc1F)S(C)(=O)=O, Cc1ccc(Cl)cc1N(CC(=O)Nc1c(F)cccc1F)S(C)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(Cl)cc1N(CC(=O)Nc1c(F)cccc1F)S(C)(=O)=O",388.04599746,25,3.733,74.86,0.0210351084561453,0.13,0.0755175542280726,0,1
"cndac (hydrochloride)","antineoplastic agent","ATP8A2, BRCA2, RAD51D","Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N)c(=O)n1.Cl |a:5,7,10,12|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","hematologic malignancy","acute myeloid leukemia (aml)","Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N)c(=O)n1.Cl |a:5",288.062532576,19,-0.709,134.39,0.00495646589734584,0.146,0.0754782329486729,0,1
"TAK-733","MEK inhibitor","MAP2K1","Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O, Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O, Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O, Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O",504.0106094,28,2.695,109.38,0.000932588935493235,0.15,0.0754662944677466,0,1
"sparfloxacin","bacterial DNA gyrase inhibitor","TOP2A","C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1",392.165997004,28,4.104,100.59,0.0229107982084686,0.128,0.0754553991042343,0,0
"toyocamycin","serine/threonine kinase inhibitor","ERN1","Nc1ncnc2n(cc(C#N)c12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1ncnc2n(cc(C#N)c12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1ncnc2n(cc(C#N)c12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Nc1ncnc2n(cc(C#N)c12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",291.096753896,21,-0.918,150.44,0.00478672127308222,0.146,0.0753933606365411,0,1
"n-acetylcysteine amide","antioxidant","PSEN2","CC(=O)N[C@@H](CS)C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","neurology/psychiatry","parkinson's disease","CC(=O)N[C@@H](CS)C(N)=O",162.04629856,10,-0.861,110.99,0.0206773274361319,0.13,0.0753386637180659,0,1
"SB-657510","urotensin receptor antagonist","UTS2R","COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1",504.012132584,29,3.65,85.48,0.00257876770378732,0.148,0.0752893838518937,0,1
"AM-630","cannabinoid receptor antagonist","CNR1, CNR2","COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12, COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12, COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12, COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12, COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12, COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12",504.09099066,29,4.623,43.7,0.00855645830683841,0.142,0.0752782291534192,0,1
"CB-10-277","DNA synthesis inhibitor","","CN(C)\N=N\c1ccc(cc1)C(O)=O, CN(C)\N=N\c1ccc(cc1)C(O)=O, CN(C)\N=N\c1ccc(cc1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN(C)\N=N\c1ccc(cc1)C(O)=O",193.085126592,14,0.785,65.26,0.0984777350224877,0.052,0.0752388675112439,0,0
"metatinib","Bcr-Abl kinase inhibitor","ABL1, BCR","Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl, Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl, Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl, Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl",468.08007446,33,5.792,110.1,0.0144535516862635,0.136,0.0752267758431317,0,1
"NS-3623","voltage-gated potassium channel activator","KCNH2","FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1, FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1, FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1, FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1, FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1, FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1, FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1",426.0051557,26,4.656,95.59,0.00839547932234355,0.142,0.0751977396611718,0,1
"acalisib","PI3K inhibitor","PIK3CB, PIK3CD","C[C@H](Nc1ncnc2nc[nH]c12)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1, C[C@H](Nc1ncnc2nc[nH]c12)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1, C[C@H](Nc1ncnc2nc[nH]c12)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@H](Nc1ncnc2nc[nH]c12)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1",401.140036352,30,3.753,101.38,0.0263118596197397,0.124,0.0751559298098698,0,0
"ITD-1","TGF beta receptor inhibitor","TGFBR2","CCOC(=O)C1=C(C)NC2=C([C@@H]1c1ccc(cc1)-c1ccccc1)C(=O)CC(C)(C)C2 |&1:11,r,c:5,9|, CCOC(=O)C1=C(C)NC2=C([C@@H]1c1ccc(cc1)-c1ccccc1)C(=O)CC(C)(C)C2 |&1:11,r,c:5,9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)C1=C(C)NC2=C([C@@H]1c1ccc(cc1)-c1ccccc1)C(=O)CC(C)(C)C2 |&1:11",415.214743788,31,6.21,55.4,0.114206436799019,0.036,0.0751032183995096,0,0
"R-268712","serine/threonine kinase inhibitor","TGFBR1","Cc1cccc(n1)-c1n[nH]cc1-c1ccc(F)c(c1)-c1cnn(CCO)c1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc(F)c(c1)-c1cnn(CCO)c1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc(F)c(c1)-c1cnn(CCO)c1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc(F)c(c1)-c1cnn(CCO)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cccc(n1)-c1n[nH]cc1-c1ccc(F)c(c1)-c1cnn(CCO)c1",363.149538416,27,3.545,79.62,0.0501823696708039,0.1,0.0750911848354019,0,0
"oritavancin (diphosphate)","","","CNC(CC(C)C)C(=O)NC1C(O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)C(OC5CC(C)(N)C(O)C(C)O5)C5NC(=O)C(NC(=O)C4NC(=O)C(CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1C(NC5=O)C(O)=O)c3OC1OC(CO)C(O)C(O)C1OC1CC(C)(NCc3ccc(cc3)-c3ccc(Cl)cc3)C(O)C(C)O1)c(Cl)c2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CNC(CC(C)C)C(=O)NC1C(O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)C(OC5CC(C)(N)C(O)C(C)O5)C5NC(=O)C(NC(=O)C4NC(=O)C(CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1C(NC5=O)C(O)=O)c3OC1OC(CO)C(O)C(O)C1OC1CC(C)(NCc3ccc(cc3)-c3ccc(Cl)cc3)C(O)C(C)O1)c(Cl)c2",1790.564106264,125,7.463,560.98,1.90286688785844e-11,0.15,0.0750000000095143,0,1
"VBY-825","cathepsin inhibitor","CTSB, CTSL, CTSS","CC[C@H](NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1, CC[C@H](NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1, CC[C@H](NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1, CC[C@H](NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC[C@H](NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1",535.176404908,36,3.239,129.82,0.00198796465044591,0.148,0.0749939823252229,0,1
"S49076","tyrosine kinase inhibitor","","O=C1CSC(=O)N1Cc1ccc2NC(=O)\C(=C/c3cc(CN4CCOCC4)c[nH]3)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C1CSC(=O)N1Cc1ccc2NC(=O)\C(=C/c3cc(CN4CCOCC4)c[nH]3)c2c1",438.136176184,31,0.34,120.04,0.00393050649605562,0.146,0.0749652532480278,0,1
"MK-2295","TRPV antagonist","TRPV1","FC(F)(F)c1ccc(Nc2ncnc3cc(ccc23)-c2ncccc2C(F)(F)F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","FC(F)(F)c1ccc(Nc2ncnc3cc(ccc23)-c2ncccc2C(F)(F)F)cc1",434.096615704,31,5.651,50.7,0.0739106871532424,0.076,0.0749553435766212,0,0
"SNC-80","","OPRD1","CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(OC)c1, CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(OC)c1, CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(OC)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(OC)c1",449.304227488,33,4.834,36.02,0.0918765520384161,0.058,0.074938276019208,0,0
"foliglurax (monohydrochloride)","glutamate receptor modulator","GRM4","O/N=C1C=C(C2=CC3=C(C=CS3)C=N2)OC4=CC=C(CCCN5CCOCC5)C=C\14.Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","neurology/psychiatry","parkinson's disease","O/N=C1C=C(C2=CC3=C(C=CS3)C=N2)OC4=CC=C(CCCN5CCOCC5)C=C\14.Cl",457.122690308,31,2.366,91.95,0.00783870849207068,0.142,0.0749193542460353,0,1
"esaprazole","","","O=C(CN1CCNCC1)NC1CCCCC1, O=C(CN1CCNCC1)NC1CCCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O=C(CN1CCNCC1)NC1CCCCC1",225.184112356,16,0.467,44.37,0.107688250817077,0.042,0.0748441254085383,0,0
"MK-8998","T-type calcium channel blocker","","CC(C)c1ccc(CC(=O)N[C@H](C)c2ccc(OCC(F)(F)F)cn2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)c1ccc(CC(=O)N[C@H](C)c2ccc(OCC(F)(F)F)cn2)cc1",380.171162636,27,5.057,51.22,0.0896194061466901,0.06,0.0748097030733451,0,0
"VUF11207","CC chemokine receptor agonist","ACKR3","COc1cc(cc(OC)c1OC)C(=O)N(CC[C@H]1CCCN1C)C\C(C)=C\c1ccccc1F |&1:17|, COc1cc(cc(OC)c1OC)C(=O)N(CC[C@H]1CCCN1C)C\C(C)=C\c1ccccc1F |&1:17|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(cc(OC)c1OC)C(=O)N(CC[C@H]1CCCN1C)C\C(C)=C\c1ccccc1F |&1:17|",470.25808582,34,4.124,51.24,0.043583452715078,0.106,0.074791726357539,0,0
"pelitinib","EGFR inhibitor","EGFR","CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C",467.152430876,33,3.565,90.28,0.0135611174451345,0.136,0.0747805587225672,0,1
"PA-452","retinoid receptor antagonist","RXRA","CCCCCCOc1cc2c(cc1N(C)c1ncc(cn1)C(O)=O)C(C)(C)CCC2(C)C, CCCCCCOc1cc2c(cc1N(C)c1ncc(cn1)C(O)=O)C(C)(C)CCC2(C)C, CCCCCCOc1cc2c(cc1N(C)c1ncc(cn1)C(O)=O)C(C)(C)CCC2(C)C, CCCCCCOc1cc2c(cc1N(C)c1ncc(cn1)C(O)=O)C(C)(C)CCC2(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCOc1cc2c(cc1N(C)c1ncc(cn1)C(O)=O)C(C)(C)CCC2(C)C",439.283492044,32,7.544,75.55,0.073548694318218,0.076,0.074774347159109,0,0
"PF-4708671","ribosomal protein inhibitor","RPS6KB1","CCc1cncnc1N1CCN(Cc2nc3ccc(cc3[nH]2)C(F)(F)F)CC1, CCc1cncnc1N1CCN(Cc2nc3ccc(cc3[nH]2)C(F)(F)F)CC1, CCc1cncnc1N1CCN(Cc2nc3ccc(cc3[nH]2)C(F)(F)F)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCc1cncnc1N1CCN(Cc2nc3ccc(cc3[nH]2)C(F)(F)F)CC1",390.177979332,28,3.059,60.94,0.0455389138062557,0.104,0.0747694569031278,0,0
"BMS-299897","gamma secretase inhibitor","","C[C@@H](N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1)c1ccc(F)cc1CCCC(O)=O, C[C@@H](N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1)c1ccc(F)cc1CCCC(O)=O, C[C@@H](N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1)c1ccc(F)cc1CCCC(O)=O, C[C@@H](N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1)c1ccc(F)cc1CCCC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@@H](N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1)c1ccc(F)cc1CCCC(O)=O",511.083191492,34,6.784,83.06,0.0155226776033376,0.134,0.0747613388016688,0,1
"CPI-203","bromodomain inhibitor","BRD4","Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|, Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|, Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|, Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|, Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|",399.092058876,27,4.064,114.4,0.0112176485285891,0.138,0.0746088242642945,0,1
"TEN-010","bromodomain inhibitor","","CN1CCN(CCCNC(=O)C[C@@H]2N=C(c3c(C)c(C)sc3-n3c(C)nnc23)c2ccc(Cl)cc2)CC1 |c:13|, CN1CCN(CCCNC(=O)C[C@@H]2N=C(c3c(C)c(C)sc3-n3c(C)nnc23)c2ccc(Cl)cc2)CC1 |c:13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCN(CCCNC(=O)C[C@@H]2N=C(c3c(C)c(C)sc3-n3c(C)nnc23)c2ccc(Cl)cc2)CC1 |c:13|",539.223407388,37,4.436,106.89,0.00516972277926711,0.144,0.0745848613896335,0,1
"AVE-3085","nitric oxide synthase stimulant","","FC1(F)Oc2ccc(cc2O1)C(=O)NC1Cc2ccccc2C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC1(F)Oc2ccc(cc2O1)C(=O)NC1Cc2ccccc2C1",317.086349716,23,3.375,47.56,0.113100077900903,0.036,0.0745500389504517,0,0
"aldose reductase-in-1","aldose reductase inhibitor","AKR1B1","OC(=O)CC1=NN(Cc2nc3cc(ccc3s2)C(F)(F)F)C(=O)c4nccnc14",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","cardiology","cardiomyopathy","OC(=O)CC1=NN(Cc2nc3cc(ccc3s2)C(F)(F)F)C(=O)c4nccnc14",421.04564484,29,1.099,136.88,0.00304407406356325,0.146,0.0745220370317816,0,1
"CO-102862","sodium channel blocker","SCN4A, SCN9A","NC(=O)N\N=C\c1ccc(Oc2ccc(F)cc2)cc1, NC(=O)N\N=C\c1ccc(Oc2ccc(F)cc2)cc1, NC(=O)N\N=C\c1ccc(Oc2ccc(F)cc2)cc1",0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","NC(=O)N\N=C\c1ccc(Oc2ccc(F)cc2)cc1",273.091354844,20,3.041,76.71,0.0789587020899195,0.07,0.0744793510449597,0,0
"CIQ","glutamate receptor potentiator","GRIN2C, GRIN2D","COc1ccc(OC[C@H]2N(CCc3cc(OC)c(OC)cc23)C(=O)c2cccc(Cl)c2)cc1 |&1:8,r|, COc1ccc(OC[C@H]2N(CCc3cc(OC)c(OC)cc23)C(=O)c2cccc(Cl)c2)cc1 |&1:8,r|, COc1ccc(OC[C@H]2N(CCc3cc(OC)c(OC)cc23)C(=O)c2cccc(Cl)c2)cc1 |&1:8,r|, COc1ccc(OC[C@H]2N(CCc3cc(OC)c(OC)cc23)C(=O)c2cccc(Cl)c2)cc1 |&1:8,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(OC[C@H]2N(CCc3cc(OC)c(OC)cc23)C(=O)c2cccc(Cl)c2)cc1 |&1:8",467.149950612,33,5.054,57.23,0.0408801498251258,0.108,0.0744400749125629,0,0
"PIK-75","DNA protein kinase inhibitor, PI3K inhibitor","PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC","CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O, CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O, CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O",450.994987028,27,3.819,118.56,0.00279664088380271,0.146,0.0743983204419014,0,1
"MLN1117","PI3K inhibitor","PIK3CA","Nc1nc2cc(ccc2o1)-c1ccc2ncc(C(=O)N3CCOCC3)n2c1, Nc1nc2cc(ccc2o1)-c1ccc2ncc(C(=O)N3CCOCC3)n2c1, Nc1nc2cc(ccc2o1)-c1ccc2ncc(C(=O)N3CCOCC3)n2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Nc1nc2cc(ccc2o1)-c1ccc2ncc(C(=O)N3CCOCC3)n2c1",363.133139404,27,1.645,98.89,0.0207744312914061,0.128,0.074387215645703,0,0
"CHIR-124","CHK inhibitor","CHEK1","Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1, Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1, Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1",419.151288004,30,4.105,76.81,0.0327432082581717,0.116,0.0743716041290858,0,0
"TW-37","BCL inhibitor","BCL2, BCL2L1, MCL1","CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O, CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O, CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O, CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O",573.21850884,41,8.534,132.31,0.00870738965796269,0.14,0.0743536948289814,0,1
"nutlin-3","MDM inhibitor","MDM2, TP53","COc1ccc(C2=N[C@H]([C@H](N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1 |&1:8,9,r,t:6|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(C2=N[C@H]([C@H](N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1 |&1:8",580.1644108,40,5.526,83.47,0.00868878931613863,0.14,0.0743443946580693,0,1
"BVT-2733","11-beta hydroxysteroid dehydrogenase inhibitor","HSD17B1","CN1CCN(CC1)C(=O)Cc1csc(NS(=O)(=O)c2cccc(Cl)c2C)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCN(CC1)C(=O)Cc1csc(NS(=O)(=O)c2cccc(Cl)c2C)n1",428.074360212,27,1.461,119.23,0.00267141170382971,0.146,0.0743357058519148,0,1
"benzamil","sodium channel blocker","ASIC1, PKD2L1, SCNN1A, SCNN1B, SCNN1D, SCNN1G, SLC8A1","NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N, NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N, NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N",1,1,1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N",319.094835748,22,1.7,145.3,0.00659566974616487,0.142,0.0742978348730824,0,1
"GSK656","leucyl-tRNA synthetase inhibitor","","NC[C@H]1OB(O)c2c1c(Cl)ccc2OCCO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC[C@H]1OB(O)c2c1c(Cl)ccc2OCCO",257.062615976,17,0.409,84.94,0.0265681926785138,0.122,0.0742840963392569,0,0
"EIPA","sodium/hydrogen exchanger inhibitor, transient receptor potential polycystic inhibitor","ADRA2A, ASIC1, PKD2L1","CCN(C(C)C)c1nc(N)c(nc1Cl)C(=O)N=C(N)N, CCN(C(C)C)c1nc(N)c(nc1Cl)C(=O)N=C(N)N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"preclinical","","","CCN(C(C)C)c1nc(N)c(nc1Cl)C(=O)N=C(N)N",299.126135876,20,1.859,136.51,0.00853190347117076,0.14,0.0742659517355854,0,1
"R-1487","p38 MAPK inhibitor","","Cn1c2nc(NC3CCOCC3)ncc2cc(Oc2ccc(F)cc2F)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cn1c2nc(NC3CCOCC3)ncc2cc(Oc2ccc(F)cc2F)c1=O",388.134696876,28,3.321,78.27,0.0345157442366256,0.114,0.0742578721183128,0,0
"guanidinopropionic-acid","creatine kinase inhibitor","CKM","NC(=N)NCCC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NC(=N)NCCC(O)=O",131.069476528,9,-0.643,99.2,0.0464949392740605,0.102,0.0742474696370302,0,0
"SB-505124","ALK tyrosine kinase receptor inhibitor","TGFBR1","Cc1cccc(n1)-c1nc([nH]c1-c1ccc2OCOc2c1)C(C)(C)C, Cc1cccc(n1)-c1nc([nH]c1-c1ccc2OCOc2c1)C(C)(C)C, Cc1cccc(n1)-c1nc([nH]c1-c1ccc2OCOc2c1)C(C)(C)C, Cc1cccc(n1)-c1nc([nH]c1-c1ccc2OCOc2c1)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cccc(n1)-c1nc([nH]c1-c1ccc2OCOc2c1)C(C)(C)C",335.163376912,25,3.803,60.03,0.0984208281946553,0.05,0.0742104140973276,0,0
"GSK1838705A","insulin growth factor receptor inhibitor","ALK, IGF1R, INSR, RPS6KA1","CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12",532.234665008,39,3.167,127.51,0.00440283096009206,0.144,0.074201415480046,0,1
"perzinfotel","glutamate receptor antagonist","GRIN1, GRIN2A, GRIN2B","OP(O)(=O)CCN1CCCNc2c1c(=O)c2=O, OP(O)(=O)CCN1CCCNc2c1c(=O)c2=O, OP(O)(=O)CCN1CCCNc2c1c(=O)c2=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OP(O)(=O)CCN1CCCNc2c1c(=O)c2=O",260.056208146,17,-1.073,116.75,0.00837835352467647,0.14,0.0741891767623382,0,1
"motesanib","KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","FLT1, FLT4, KDR, KIT","CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12",373.190260356,28,2.988,78.94,0.044314748628744,0.104,0.074157374314372,0,0
"ryuvidine","histone lysine methyltransferase inhibitor","CDK2, CDK4","Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|",284.061948624,20,2.2,87.3,0.0402832647512111,0.108,0.0741416323756055,0,0
"P5091","ubiquitin specific protease inhibitor","USP7","CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O",346.924440444,20,4.242,113.75,0.00827652223177227,0.14,0.0741382611158861,0,1
"WWL-123","monoacylglycerol lipase inhibitor","ABHD6","CN(Cc1cccc(c1)-c1ccccc1)C(=O)Oc1ccc(cc1)-c1ccc(cc1)C(N)=O, CN(Cc1cccc(c1)-c1ccccc1)C(=O)Oc1ccc(cc1)-c1ccc(cc1)C(N)=O, CN(Cc1cccc(c1)-c1ccccc1)C(=O)Oc1ccc(cc1)-c1ccc(cc1)C(N)=O, CN(Cc1cccc(c1)-c1ccccc1)C(=O)Oc1ccc(cc1)-c1ccc(cc1)C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(Cc1cccc(c1)-c1ccccc1)C(=O)Oc1ccc(cc1)-c1ccc(cc1)C(N)=O",436.178692628,33,6.066,72.63,0.0742196781743773,0.074,0.0741098390871886,0,0
"U-18666A","oxidosqualene cyclase inhibitor","","CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:27|, CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:27|, CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:27|, CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:27|, CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:27|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:27|",387.313729552,28,4.253,29.54,0.124199478141024,0.024,0.0740997390705121,1,0
"BETP","GLP receptor positive allosteric modulator","GLP1R","CC[S@](=O)c1nc(cc(n1)C(F)(F)F)-c1cccc(OCc2ccccc2)c1 |&1:2,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC[S@](=O)c1nc(cc(n1)C(F)(F)F)-c1cccc(OCc2ccccc2)c1 |&1:2",406.096283444,28,3.557,71.29,0.0281687654600594,0.12,0.0740843827300297,0,0
"P22077","ubiquitin specific protease inhibitor","USP7","CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O",314.983541524,20,3.32,113.75,0.014084648530163,0.134,0.0740423242650815,0,1
"Debio-0932","HSP inhibitor","","CN(C)c1cc2OCOc2cc1Sc1nc2c(N)nccc2n1CCNCC(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN(C)c1cc2OCOc2cc1Sc1nc2c(N)nccc2n1CCNCC(C)(C)C",442.2150952,31,3.27,115.76,0.00804525518546539,0.14,0.0740226275927327,0,1
"lobendazole","anthelmintic agent","","CCOC(=O)Nc1nc2ccccc2[nH]1, CCOC(=O)Nc1nc2ccccc2[nH]1, CCOC(=O)Nc1nc2ccccc2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)Nc1nc2ccccc2[nH]1",205.085126592,15,2.086,67.01,0.120029117549219,0.028,0.0740145587746095,1,0
"BAY1125976","AKT inhibitor","","NC(=O)c1ccc2nc(c(-c3ccccc3)n2n1)-c1ccc(cc1)C1(N)CCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","NC(=O)c1ccc2nc(c(-c3ccccc3)n2n1)-c1ccc(cc1)C1(N)CCC1",383.174610292,29,3.824,99.3,0.0340158414952849,0.114,0.0740079207476425,0,0
"flesinoxan","serotonin receptor agonist","HTR1A","O=C(NCCN1CCN(C2=C3OC[C@@H](CO)OC3=CC=C2)CC1)C4=CC=C(F)C=C4",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","cardiology","hypertension","O=C(NCCN1CCN(C2=C3OC[C@@H](CO)OC3=CC=C2)CC1)C4=CC=C(F)C=C4",415.190734532,30,0.488,74.27,0.0159931493975772,0.132,0.0739965746987886,0,1
"swainsonine","alpha mannosidase inhibitor","MAN2A1","O[C@@H]1CN2CCC[C@@H](O)[C@@H]2[C@@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O[C@@H]1CN2CCC[C@@H](O)[C@@H]2[C@@H]1O",173.10519334,12,-1.191,63.93,0.0659078627578087,0.082,0.0739539313789044,0,0
"PDE10-IN-1","phosphodiesterase inhibitor","PDE10A","Cc1c(nc2c3cccnc3ccn12)[C@@H]1C[C@H]1c1nc2c(C)ncc(C)n2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1c(nc2c3cccnc3ccn12)[C@@H]1C[C@H]1c1nc2c(C)ncc(C)n2n1",369.170193608,28,2.566,73.27,0.0498754614318339,0.098,0.0739377307159169,0,0
"ZM-323881","VEGFR inhibitor","KDR","Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O, Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O, Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O, Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O, Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O",375.138305036,28,4.63,67.27,0.0798530861887839,0.068,0.073926543094392,0,0
"TC-O-9311","G protein-coupled receptor agonist","GPR139","COc1cc(OC)cc(c1)C(=O)NNC(=O)Nc1cccc2ccccc12, COc1cc(OC)cc(c1)C(=O)NNC(=O)Nc1cccc2ccccc12, COc1cc(OC)cc(c1)C(=O)NNC(=O)Nc1cccc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(OC)cc(c1)C(=O)NNC(=O)Nc1cccc2ccccc12",365.137556088,27,3.607,88.69,0.0398028369576486,0.108,0.0739014184788243,0,0
"ON123300","CDK inhibitor","CDK4, NUAK1, PDGFRB","CN1CCN(CC1)c1ccc(Nc2ncc3cc(C#N)c(=O)n(C4CCCC4)c3n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3cc(C#N)c(=O)n(C4CCCC4)c3n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3cc(C#N)c(=O)n(C4CCCC4)c3n2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCN(CC1)c1ccc(Nc2ncc3cc(C#N)c(=O)n(C4CCCC4)c3n2)cc1",429.227708484,32,3.457,90.08,0.0257706909111283,0.122,0.0738853454555641,0,0
"SR-27897","CCK receptor antagonist","CCKAR","OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl, OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl, OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl, OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl, OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl",411.044439988,28,4.303,112.46,0.0117658130334646,0.136,0.0738829065167323,0,1
"2-iodohippuric-acid","","","OC(=O)CNC(=O)c1ccccc1I, OC(=O)CNC(=O)c1ccccc1I",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)CNC(=O)c1ccccc1I",304.954891116,14,-0.289,66.4,0.00560224187524023,0.142,0.0738011209376201,0,1
"eperezolid","bacterial 30S ribosomal subunit inhibitor","","CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCN(CC2)C(=O)CO)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCN(CC2)C(=O)CO)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCN(CC2)C(=O)CO)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCN(CC2)C(=O)CO)c(F)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCN(CC2)C(=O)CO)c(F)c1",394.165248056,28,-0.199,102.42,0.00740060265667159,0.14,0.0737003013283358,0,1
"sotagliflozin","sodium/glucose cotransporter inhibitor","SLC5A1, SLC5A2","CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1, CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1, CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1",424.11112258,28,3.895,104.45,0.00940057900253852,0.138,0.0737002895012693,0,1
"ML365","potassium channel blocker","KCNK3, KCNK9","COc1ccccc1C(=O)Nc1cccc(NC(=O)c2cccc(C)c2)c1, COc1ccccc1C(=O)Nc1cccc(NC(=O)c2cccc(C)c2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccccc1C(=O)Nc1cccc(NC(=O)c2cccc(C)c2)c1",360.1473925,27,4.316,67.43,0.0833948721837205,0.064,0.0736974360918603,0,0
"fiacitabine","DNA synthesis inhibitor","","Nc1nc(=O)n(cc1I)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(=O)n(cc1I)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Nc1nc(=O)n(cc1I)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F",370.977832052,18,0.828,110.6,0.00137697075446678,0.146,0.0736884853772334,0,1
"GDC-0349","Pim kinase inhibitor","PIK3CA","CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1",452.253588884,33,1.515,91.85,0.0113183887643916,0.136,0.0736591943821958,0,1
"FH-535","PPAR receptor antagonist, WNT signaling inhibitor","PPARD, PPARG","Cc1cc(ccc1NS(=O)(=O)c1cc(Cl)ccc1Cl)[N+]([O-])=O, Cc1cc(ccc1NS(=O)(=O)c1cc(Cl)ccc1Cl)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(ccc1NS(=O)(=O)c1cc(Cl)ccc1Cl)[N+]([O-])=O",359.97383316,22,4.077,97.69,0.0133170355219745,0.134,0.0736585177609873,0,1
"SB-525334","TGF beta receptor inhibitor","TGFBR1","Cc1cccc(n1)-c1nc([nH]c1-c1ccc2nccnc2c1)C(C)(C)C, Cc1cccc(n1)-c1nc([nH]c1-c1ccc2nccnc2c1)C(C)(C)C, Cc1cccc(n1)-c1nc([nH]c1-c1ccc2nccnc2c1)C(C)(C)C, Cc1cccc(n1)-c1nc([nH]c1-c1ccc2nccnc2c1)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cccc(n1)-c1nc([nH]c1-c1ccc2nccnc2c1)C(C)(C)C",343.179695672,26,3.254,67.35,0.0772367178338691,0.07,0.0736183589169346,0,0
"PF-05089771","sodium channel blocker","","Nc1[nH]ncc1-c1cc(Cl)ccc1Oc1cc(F)c(cc1Cl)S(=O)(=O)Nc1cscn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1[nH]ncc1-c1cc(Cl)ccc1Oc1cc(F)c(cc1Cl)S(=O)(=O)Nc1cscn1",498.974264824,31,4.967,159.61,0.00114409261952489,0.146,0.0735720463097624,0,1
"eucatropine","acetylcholine receptor antagonist","","C[C@H]1C[C@@H](CC(C)(C)N1C)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:13|, C[C@H]1C[C@@H](CC(C)(C)N1C)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H]1C[C@@H](CC(C)(C)N1C)OC(=O)[C@@H](O)c1ccccc1 |&1:1",291.18344366,21,2.512,49.77,0.103035691667816,0.044,0.0735178458339081,0,0
"BMS-986142","Bruton's tyrosine kinase (BTK) inhibitor","","Cc1c(cccc1-n1c(=O)n(C)c2c(F)cccc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3C[C@H](CCc3c12)C(C)(C)O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1c(cccc1-n1c(=O)n(C)c2c(F)cccc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3C[C@H](CCc3c12)C(C)(C)O",572.22351188,42,6.769,123.11,0.00901068940725426,0.138,0.0735053447036271,0,1
"PK-THPP","potassium channel blocker","KCNK9","CCCC(=O)C1CCN(CC1)c1ncnc2CCN(Cc12)C(=O)c1ccc(cc1)-c1ccccc1, CCCC(=O)C1CCN(CC1)c1ncnc2CCN(Cc12)C(=O)c1ccc(cc1)-c1ccccc1, CCCC(=O)C1CCN(CC1)c1ncnc2CCN(Cc12)C(=O)c1ccc(cc1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCC(=O)C1CCN(CC1)c1ncnc2CCN(Cc12)C(=O)c1ccc(cc1)-c1ccccc1",468.252526264,35,4.921,66.4,0.0489828956425579,0.098,0.0734914478212789,0,0
"CPA-inhibitor","carboxypeptidase inhibitor","CPA1, CPA2","ON(C[C@@H](Cc1ccccc1)C(O)=O)C(=O)Cc1ccccc1 |&1:3,r|, ON(C[C@@H](Cc1ccccc1)C(O)=O)C(=O)Cc1ccccc1 |&1:3,r|, ON(C[C@@H](Cc1ccccc1)C(O)=O)C(=O)Cc1ccccc1 |&1:3,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","ON(C[C@@H](Cc1ccccc1)C(O)=O)C(=O)Cc1ccccc1 |&1:3",313.131408088,23,1.973,77.84,0.0469403028987378,0.1,0.0734701514493689,0,0
"tenidap","cyclooxygenase inhibitor","KCNJ4, PTGS1","NC(=O)N1C(=O)[C@@H](C(=O)c2cccs2)c2cc(Cl)ccc12 |&1:6,r|, NC(=O)N1C(=O)C(C(=O)c2cccs2)c2cc(Cl)ccc12",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","NC(=O)N1C(=O)[C@@H](C(=O)c2cccs2)c2cc(Cl)ccc12 |&1:6",320.002240828,21,1.348,108.71,0.0109333027797151,0.136,0.0734666513898575,0,1
"ICA-069673","voltage-gated potassium channel activator","KCNQ2, KCNQ3","Fc1ccc(cc1F)C(=O)Nc1cnc(Cl)nc1, Fc1ccc(cc1F)C(=O)Nc1cnc(Cl)nc1, Fc1ccc(cc1F)C(=O)Nc1cnc(Cl)nc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1ccc(cc1F)C(=O)Nc1cnc(Cl)nc1",269.016745932,18,1.733,54.88,0.0669305670708632,0.08,0.0734652835354316,0,0
"PF-06840003","indoleamine 2,3-dioxygenase inhibitor","","Fc1ccc2[nH]cc([C@H]3CC(=O)NC3=O)c2c1 |&1:8,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Fc1ccc2[nH]cc([C@H]3CC(=O)NC3=O)c2c1 |&1:8",232.064805748,17,0.789,61.96,0.084908594791605,0.062,0.0734542973958025,0,0
"WWL-113","carboxylesterase inhibitor","CES3","CCOC(=O)c1ccc(cc1)-c1ccc(OC(=O)N(C)Cc2cccc(c2)-c2ccncc2)cc1, CCOC(=O)c1ccc(cc1)-c1ccc(OC(=O)N(C)Cc2cccc(c2)-c2ccncc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)c1ccc(cc1)-c1ccc(OC(=O)N(C)Cc2cccc(c2)-c2ccncc2)cc1",466.189257312,35,6.286,68.73,0.0668636417259914,0.08,0.0734318208629957,0,0
"NPS-2143","calcium receptor antagonist","CASR","CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N",408.16045572,29,5.235,65.28,0.0568440789953645,0.09,0.0734220394976823,0,0
"tideglusib","glycogen synthase kinase inhibitor","GSK3B","O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1",334.077598688,24,4.066,72.24,0.0667371185963359,0.08,0.0733685592981679,0,0
"temanogrel","serotonin receptor antagonist","","COc1cccc(c1)C(=O)Nc1ccc(OCCN2CCOCC2)c(c1)-c1ccnn1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cccc(c1)C(=O)Nc1ccc(OCCN2CCOCC2)c(c1)-c1ccnn1C",436.211055376,32,2.804,77.85,0.0246976010133838,0.122,0.0733488005066919,0,0
"ACTB-1003","FGFR inhibitor, VEGFR inhibitor","KDR, TEK","COCc1c(CN2CCOCC2)n2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)c(F)c1, COCc1c(CN2CCOCC2)n2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)c(F)c1, COCc1c(CN2CCOCC2)n2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)c(F)c1, COCc1c(CN2CCOCC2)n2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)c(F)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COCc1c(CN2CCOCC2)n2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)c(F)c1",591.201728792,42,3.174,119.04,0.00262093667867114,0.144,0.0733104683393356,0,1
"PSI-697","P selectin inhibitor","","OC(=O)c1c(O)c(Cc2ccc(Cl)cc2)nc2c3CCCCc3ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC(=O)c1c(O)c(Cc2ccc(Cl)cc2)nc2c3CCCCc3ccc12",367.097521116,26,5.48,70.42,0.0706013377778007,0.076,0.0733006688889003,0,0
"andarine","androgen receptor modulator","AR","CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1, CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1, CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1, CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1",441.114769956,31,2.25,130.8,0.0045540486462114,0.142,0.0732770243231057,0,1
"mdivi-1","dynamin inhibitor","DNM1","COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O, COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O, COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O, COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O",351.98400392,22,5.26,79.11,0.0325047233061063,0.114,0.0732523616530531,0,0
"tyrphostin-AG-18","EGFR inhibitor, tyrosine kinase inhibitor","EGFR","Oc1ccc(C=C(C#N)C#N)cc1O, Oc1ccc(C=C(C#N)C#N)cc1O, Oc1ccc(C=C(C#N)C#N)cc1O, Oc1ccc(C=C(C#N)C#N)cc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(C=C(C#N)C#N)cc1O",186.042927432,14,1.007,88.04,0.0745007928074974,0.072,0.0732503964037487,0,0
"GF109203X","PKC inhibitor","PDPK1, PIM1, PRKCI, PRKCZ","CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|",412.189926008,31,3.697,70.13,0.0504933161737739,0.096,0.073246658086887,0,0
"rimacalib","calcium/calmodulin dependent protein kinase inhibitor","CAMK2A","N=C(N1CCOCC1)NC2=CC([C@H](C3=CC=C(C4=CC=CC=C4)C(F)=C3)C)=NO2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","rheumatology","rheumatoid arthritis","N=C(N1CCOCC1)NC2=CC([C@H](C3=CC=C(C4=CC=CC=C4)C(F)=C3)C)=NO2",394.180504196,29,3.968,69.94,0.0524759673335201,0.094,0.0732379836667601,0,0
"vinblastine (sulfate)","","","CC[C@]1(O)C[C@@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CC[C@]1(O)C[C@@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|",810.420379436,59,4.73,154.1,0.000454116264700762,0.146,0.0732270581323504,0,1
"NS-018","JAK inhibitor","JAK1, JAK2, JAK3, TYK2","C[C@H](Nc1cc(cc(Nc2cnccn2)n1)-c1cnn(C)c1)c1ccc(F)cc1, C[C@H](Nc1cc(cc(Nc2cnccn2)n1)-c1cnn(C)c1)c1ccc(F)cc1, C[C@H](Nc1cc(cc(Nc2cnccn2)n1)-c1cnn(C)c1)c1ccc(F)cc1, C[C@H](Nc1cc(cc(Nc2cnccn2)n1)-c1cnn(C)c1)c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","C[C@H](Nc1cc(cc(Nc2cnccn2)n1)-c1cnn(C)c1)c1ccc(F)cc1",389.17642186,29,4.138,80.55,0.0484243109135543,0.098,0.0732121554567771,0,0
"CH-5183284","fibroblast growth factor inhibitor","FGFR1, FGFR2, FGFR3","Cc1nc2ccc(cc2[nH]1)-n1ncc(C(=O)c2cc3ccccc3[nH]2)c1N, Cc1nc2ccc(cc2[nH]1)-n1ncc(C(=O)c2cc3ccccc3[nH]2)c1N, Cc1nc2ccc(cc2[nH]1)-n1ncc(C(=O)c2cc3ccccc3[nH]2)c1N, Cc1nc2ccc(cc2[nH]1)-n1ncc(C(=O)c2cc3ccccc3[nH]2)c1N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1nc2ccc(cc2[nH]1)-n1ncc(C(=O)c2cc3ccccc3[nH]2)c1N",356.138559132,27,3.436,105.38,0.0323923364891362,0.114,0.0731961682445681,0,0
"MK-0752","gamma secretase inhibitor","","OC(=O)CC[C@H]1CC[C@@](CC1)(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1 |r|, OC(=O)CC[C@H]1CC[C@@](CC1)(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1 |r|, OC(=O)CC[C@H]1CC[C@@](CC1)(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","OC(=O)CC[C@H]1CC[C@@](CC1)(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1 |r|",442.081714272,29,5.143,79.82,0.0183495274840375,0.128,0.0731747637420188,0,0
"combretastatin-A-4","tubulin polymerization inhibitor","","COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1O, COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1O",316.13107374,23,3.642,57.15,0.100340653530681,0.046,0.0731703267653407,0,0
"Q-203","ATP synthase inhibitor","","CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(cc1)N1CCC(CC1)c1ccc(OC(F)(F)F)cc1, CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(cc1)N1CCC(CC1)c1ccc(OC(F)(F)F)cc1, CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(cc1)N1CCC(CC1)c1ccc(OC(F)(F)F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(cc1)N1CCC(CC1)c1ccc(OC(F)(F)F)cc1",556.185288476,39,7.978,58.87,0.0383353800123176,0.108,0.0731676900061588,0,0
"necrostatin-2","necroptosis inhibitor, RIPK inhibitor","RIPK2","CN1C(=O)N[C@H](Cc2c[nH]c3c(Cl)cccc23)C1=O, CN1C(=O)N[C@H](Cc2c[nH]c3c(Cl)cccc23)C1=O, CN1C(=O)N[C@H](Cc2c[nH]c3c(Cl)cccc23)C1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1C(=O)N[C@H](Cc2c[nH]c3c(Cl)cccc23)C1=O",277.061804304,19,1.954,65.2,0.0583170783871729,0.088,0.0731585391935864,0,0
"BMS-833923","smoothened receptor antagonist","SMO","CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1",473.221560484,36,5.762,78.94,0.0502667928827466,0.096,0.0731333964413733,0,0
"tyrphostin-AG-825","protein tyrosine kinase inhibitor","ERBB2","COc1cc(\C=C(/C#N)C(N)=O)cc(CSc2nc3ccccc3s2)c1O, COc1cc(\C=C(/C#N)C(N)=O)cc(CSc2nc3ccccc3s2)c1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(\C=C(/C#N)C(N)=O)cc(CSc2nc3ccccc3s2)c1O",397.05548334,27,1.792,162.77,0.00221785167762789,0.144,0.0731089258388139,0,1
"navitoclax","BCL inhibitor","BCL2, BCL2L1, BCL2L2","CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|",973.29550982,65,10.689,170.42,0.000108901677034877,0.146,0.0730544508385174,0,1
"BRL-37344","adrenergic receptor agonist","ADRB1, ADRB2, ADRB3","C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1, C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1, C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1, C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,"phase 2","","","C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1",363.123735864,25,3.175,78.79,0.0301078321128426,0.116,0.0730539160564213,0,0
"LY2874455","FGFR antagonist","FGFR1, FGFR2, FGFR3, FGFR4, KDR","C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl",443.091580208,30,4.612,88.85,0.0160963457170597,0.13,0.0730481728585299,0,1
"diadenosine-tetraphosphate","adenosine kinase inhibitor","P2RY13, P2RY2","Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:10,12,32,34,35,37,49,51,&1:15,&2:19,&3:23,&4:27|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:10",836.048265196,53,-7.59,473.21,1.84226292416193e-09,0.146,0.0730000009211315,0,1
"p1,p4-di(adenosine-5')tetraphosphate ammonium","adenosine kinase inhibitor","","Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H](C(O)C2O)n2cnc3c(N)ncnc23)C(O)C1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H](C(O)C2O)n2cnc3c(N)ncnc23)C(O)C1O",836.048265196,53,-7.59,473.21,1.84226292416193e-09,0.146,0.0730000009211315,0,1
"ELN-441958","bradykinin receptor antagonist","BDKRB1","Clc1cccc2CN(C(=O)c12)c1cccc(c1)C(=O)N1CCC2(CC1)CCN(CC2)c1ccncc1, Clc1cccc2CN(C(=O)c12)c1cccc(c1)C(=O)N1CCC2(CC1)CCN(CC2)c1ccncc1, Clc1cccc2CN(C(=O)c12)c1cccc(c1)C(=O)N1CCC2(CC1)CCN(CC2)c1ccncc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1cccc2CN(C(=O)c12)c1cccc(c1)C(=O)N1CCC2(CC1)CCN(CC2)c1ccncc1",500.197903848,36,5.097,56.75,0.0379591562691608,0.108,0.0729795781345804,0,0
"SC-144","P glycoprotein inhibitor","","Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21",322.097837192,24,2.943,84.21,0.0519329938565522,0.094,0.0729664969282761,0,0
"MDL-72832","serotonin receptor agonist","HTR1A","O=C1CC2(CCCC2)CC(=O)N1CCCCNC[C@H]1COc2ccccc2O1 |&1:18|, O=C1CC2(CCCC2)CC(=O)N1CCCCNC[C@H]1COc2ccccc2O1 |&1:18|",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C1CC2(CCCC2)CC(=O)N1CCCCNC[C@H]1COc2ccccc2O1 |&1:18|",386.22055744,28,2.973,67.87,0.0418981771248421,0.104,0.072949088562421,0,0
"PHA-665752","c-Met inhibitor","MET","Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1",640.167781928,43,4.833,110.96,0.00185566609457179,0.144,0.0729278330472859,0,1
"OMDM-2","FAAH inhibitor","GPR119","CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](CO)Cc1ccc(O)cc1, CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](CO)Cc1ccc(O)cc1, CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](CO)Cc1ccc(O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](CO)Cc1ccc(O)cc1",431.3399443,31,8.772,69.56,0.105852959227233,0.04,0.0729264796136164,0,0
"CI-953","voltage-gated sodium channel blocker","","Cc1cccc(Cl)c1NC(=O)Nc1ccncc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1cccc(Cl)c1NC(=O)Nc1ccncc1",261.066889684,18,2.078,54.02,0.0878501182044104,0.058,0.0729250591022052,0,0
"zamicastat","dopamine beta hydroxylase inhibitor","DBH","Fc1cc(F)c2OC[C@@H](Cc2c1)n1c(CCNCc2ccccc2)c[nH]c1=S",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","pulmonary","pulmonary arterial hypertension (pah)","Fc1cc(F)c2OC[C@@H](Cc2c1)n1c(CCNCc2ccccc2)c[nH]c1=S",401.137339732,28,4.575,74.07,0.0377923944287074,0.108,0.0728961972143537,0,0
"AZD4573","CDK9 inhibitor","","CC(=O)N[C@@H]1CCC[C@@H](C1)C(=O)Nc1cc(-c2cnn3CC(C)(C)Cc23)c(Cl)cn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(=O)N[C@@H]1CCC[C@@H](C1)C(=O)Nc1cc(-c2cnn3CC(C)(C)Cc23)c(Cl)cn1",429.193152816,30,3.172,88.91,0.0157465933427244,0.13,0.0728732966713622,0,1
"favipiravir","RNA polymerase inhibitor","","NC(=O)c1nc(F)c[nH]c1=O, NC(=O)c1nc(F)c[nH]c1=O, NC(=O)c1nc(F)c[nH]c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","NC(=O)c1nc(F)c[nH]c1=O",157.028754588,11,-0.352,88.84,0.0537052353764818,0.092,0.0728526176882409,0,0
"GDC-0068","AKT inhibitor","AKT1, AKT2, AKT3, PRKG1","CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1",457.224452944,32,2.746,81.59,0.0136616393382647,0.132,0.0728308196691324,0,1
"givinostat","HDAC inhibitor","HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9","CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1",421.200156344,31,3.987,90.9,0.0276548896307319,0.118,0.0728274448153659,0,0
"AG-490","EGFR inhibitor, JAK inhibitor","EGFR, JAK2, JAK3","Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O",294.100442308,22,2.399,93.35,0.0455955682024628,0.1,0.0727977841012314,0,0
"PF-431396","focal adhesion kinase inhibitor","PTK2, PTK2B","CN(c1ccccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ccccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ccccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ccccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(c1ccccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O",506.134794192,35,3.242,124.7,0.0035569972554647,0.142,0.0727784986277323,0,1
"para-toluenesulfonamide","","CA12, CA2, CA6, CA9","Cc1ccc(cc1)S(N)(=O)=O, Cc1ccc(cc1)S(N)(=O)=O, Cc1ccc(cc1)S(N)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cc1ccc(cc1)S(N)(=O)=O",171.035399528,11,0.918,68.54,0.0815263658454371,0.064,0.0727631829227186,0,0
"TP-003","GABA receptor inverse agonist","GABRA1, GABRA2, GABRA3, GABRA5","CC(C)(O)c1ccn2c(cnc2c1F)-c1ccc(F)c(c1)-c1ccc(F)cc1C#N, CC(C)(O)c1ccn2c(cnc2c1F)-c1ccc(F)c(c1)-c1ccc(F)cc1C#N",0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(O)c1ccn2c(cnc2c1F)-c1ccc(F)c(c1)-c1ccc(F)cc1C#N",407.124546792,30,5.609,61.32,0.0854769007788137,0.06,0.0727384503894068,0,0
"PIM-447","Pim kinase inhibitor","","C[C@@H]1C[C@H](N)C[C@@H](C1)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cccc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@@H]1C[C@H](N)C[C@@H](C1)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cccc1F",440.182396016,32,4.218,80.9,0.0294595013024751,0.116,0.0727297506512375,0,0
"OLDA","TRPV agonist","GPR119","CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1",417.324294236,30,9.199,69.56,0.127371809644981,0.018,0.0726859048224906,1,0
"ferrostatin-1","ferroptosis inhibitor","","CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1, CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1, CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1, CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1",262.168127944,19,3.038,64.35,0.105265452278092,0.04,0.0726327261390459,0,0
"trichostatin-a","HDAC inhibitor","HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9","C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C",302.163042564,22,2.355,69.64,0.0632583519845394,0.082,0.0726291759922697,0,0
"lorediplon","GABA receptor modulator","GABRA1","CN(C(C)=O)c1cc(ccc1F)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cc(ccc1F)-c1ccnc2c(cnn12)C(=O)c1cccs1",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN(C(C)=O)c1cc(ccc1F)-c1ccnc2c(cnn12)C(=O)c1cccs1",394.08997494,28,2.659,95.81,0.0172485097546233,0.128,0.0726242548773116,0,0
"fasoracetam","GABA receptor antagonist","","O=C([C@H]1CCC(=O)N1)N1CCCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C([C@H]1CCC(=O)N1)N1CCCCC1",196.121177752,14,-0.0310000000000001,49.41,0.107209268969252,0.038,0.0726046344846258,0,0
"monostearin","","","CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)CO |&1:21,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)CO |&1:21",358.308309824,25,7.648,66.76,0.121201713826647,0.024,0.0726008569133234,1,0
"bretazenil","GABA benzodiazepine site receptor partial agonist","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6","CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21, CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21, CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21",0,0,0,0,0,0,0,0,0,0,0,0,1,6,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21",417.0688036,26,5.038,64.43,0.0231605630390492,0.122,0.0725802815195246,0,0
"veliparib","PARP inhibitor","PARP1, PARP2","C[C@@]1(CCCN1)c1nc2cccc(C(N)=O)c2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C[C@@]1(CCCN1)c1nc2cccc(C(N)=O)c2[nH]1",244.132411132,18,0.874,83.8,0.0511247683110807,0.094,0.0725623841555404,0,0
"SBI-115","G protein-coupled receptor antagonist","","CCS(=O)(=O)c1ncc(Cl)c(n1)C(=O)Oc1cccc(C)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCS(=O)(=O)c1ncc(Cl)c(n1)C(=O)Oc1cccc(C)c1",340.028455576,22,2.347,94.6,0.0150508097438556,0.13,0.0725254048719278,0,1
"EPZ020411","protein arginine N-methyltransferase inhibitor","PRMT6","CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1 |r|, CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1 |r|, CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1 |r|, CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1 |r|, CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1 |r|",442.294391076,32,3.181,71.64,0.0269868764252045,0.118,0.0724934382126022,0,0
"verubecestat","beta secretase inhibitor","","CN1C(N)=N[C@@](C)(CS1(=O)=O)c1cc(NC(=O)c2ccc(F)cn2)ccc1F |c:3|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CN1C(N)=N[C@@](C)(CS1(=O)=O)c1cc(NC(=O)c2ccc(F)cn2)ccc1F |c:3|",409.102016844,28,1.84,126.13,0.00494024588114929,0.14,0.0724701229405747,0,1
"butofilolol","adrenergic receptor antagonist","","CCCC(=O)c1cc(F)ccc1OC[C@@H](O)CNC(C)(C)C |&1:14,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCC(=O)c1cc(F)ccc1OC[C@@H](O)CNC(C)(C)C |&1:14",311.189671912,22,3.039,58.56,0.0768207131444622,0.068,0.0724103565722311,0,0
"RMC-4550","SHIP2 phosphatase inhibitor","","C[C@@H]1OCC2(CCN(CC2)c2nc(C)c(nc2CO)-c2cccc(Cl)c2Cl)[C@@H]1N, C[C@@H]1OCC2(CCN(CC2)c2nc(C)c(nc2CO)-c2cccc(Cl)c2Cl)[C@@H]1N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H]1OCC2(CCN(CC2)c2nc(C)c(nc2CO)-c2cccc(Cl)c2Cl)[C@@H]1N",436.143281432,29,3.472,84.5,0.012666441050354,0.132,0.072333220525177,0,1
"vixotrigine","sodium channel blocker","","NC(=O)[C@@H]1CC[C@@H](N1)c1ccc(OCc2ccccc2F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NC(=O)[C@@H]1CC[C@@H](N1)c1ccc(OCc2ccccc2F)cc1",314.143056068,23,2.686,64.35,0.0726050400258808,0.072,0.0723025200129404,0,0
"purmorphamine","smoothened receptor agonist","SMO","C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12",520.258674264,39,7.228,77.33,0.0485579221185255,0.096,0.0722789610592628,0,0
"GSK1904529A","IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand","IGF1R, INSR","CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O, CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O, CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O",851.338893044,61,7.413,154.91,0.000512962027360604,0.144,0.0722564810136803,0,1
"CC-401","JNK inhibitor","MAPK8","C(CN1CCCCC1)Oc1cccc(c1)-c1n[nH]c2ccc(cc12)-c1nnc[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C(CN1CCCCC1)Oc1cccc(c1)-c1n[nH]c2ccc(cc12)-c1nnc[nH]1",388.201159388,29,5.618,82.72,0.0664808924181821,0.078,0.072240446209091,0,0
"4-IBP","sigma receptor agonist","SIGMAR1","Ic1ccc(cc1)C(=O)NC1CCN(Cc2ccccc2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Ic1ccc(cc1)C(=O)NC1CCN(Cc2ccccc2)CC1",420.069861292,23,4.601,32.34,0.020467903808565,0.124,0.0722339519042825,0,0
"stemregenin-1","aryl hydrocarbon receptor antagonist","AHR","CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12, CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12, CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12",429.162331356,31,5.497,104.1,0.0244616616226023,0.12,0.0722308308113011,0,0
"I-BET-762","bromodomain inhibitor","BRD2, BRD3, BRD4","CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|",423.146202624,30,5.379,81.4,0.0364328098687742,0.108,0.0722164049343871,0,0
"GNF-7","glucokinase inhibitor, protein kinase inhibitor","GCK, TNK2","CN1C(=O)N(Cc2cnc(Nc3ccc(C)nc3)nc12)c1cc(NC(=O)c2cccc(c2)C(F)(F)F)ccc1C, CN1C(=O)N(Cc2cnc(Nc3ccc(C)nc3)nc12)c1cc(NC(=O)c2cccc(c2)C(F)(F)F)ccc1C, CN1C(=O)N(Cc2cnc(Nc3ccc(C)nc3)nc12)c1cc(NC(=O)c2cccc(c2)C(F)(F)F)ccc1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1C(=O)N(Cc2cnc(Nc3ccc(C)nc3)nc12)c1cc(NC(=O)c2cccc(c2)C(F)(F)F)ccc1C",547.194357668,40,4.014,103.35,0.00832228155514812,0.136,0.0721611407775741,0,1
"MDL-29951","glutamate receptor antagonist","FBP1","OC(=O)CCc1c([nH]c2cc(Cl)cc(Cl)c12)C(O)=O, OC(=O)CCc1c([nH]c2cc(Cl)cc(Cl)c12)C(O)=O, OC(=O)CCc1c([nH]c2cc(Cl)cc(Cl)c12)C(O)=O, OC(=O)CCc1c([nH]c2cc(Cl)cc(Cl)c12)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)CCc1c([nH]c2cc(Cl)cc(Cl)c12)C(O)=O",300.990863128,19,2.598,90.39,0.0223151628913314,0.122,0.0721575814456657,0,0
"8-bromo-cAMP","PKA activator","","Nc1ncnc2n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c(Br)nc12 |a:7,9,16,17,&1:12|, Nc1ncnc2n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c(Br)nc12 |a:7,9,16,17,&1:12|, Nc1ncnc2n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c(Br)nc12 |a:7,9,16,17,&1:12|, Nc1ncnc2n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c(Br)nc12 |a:7,9,16,17,&1:12|, Nc1ncnc2n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c(Br)nc12 |a:7,9,16,17,&1:12|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1ncnc2n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c(Br)nc12 |a:7",406.963031802,23,-1.678,164.65,0.000285075441642973,0.144,0.0721425377208215,0,1
"acoziborole","antitrypanosomal","","CC1(C)OB(O)c2cc(NC(=O)c3ccc(F)cc3C(F)(F)F)ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC1(C)OB(O)c2cc(NC(=O)c3ccc(F)cc3C(F)(F)F)ccc12",367.100286588,26,3.947,58.56,0.0642440919871005,0.08,0.0721220459935503,0,0
"alovudine","DNA synthesis marker","","Cc1cn([C@H]2C[C@H](F)[C@@H](CO)O2)c(=O)[nH]c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1cn([C@H]2C[C@H](F)[C@@H](CO)O2)c(=O)[nH]c1=O",244.085935116,17,0.151,84.32,0.0342322575929893,0.11,0.0721161287964946,0,0
"crisdesalazine","free radical scavenger","","OC(=O)c1cc(NCCc2ccc(cc2)C(F)(F)F)ccc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1cc(NCCc2ccc(cc2)C(F)(F)F)ccc1O",325.092577968,23,4.099,69.56,0.0702202892989797,0.074,0.0721101446494898,0,0
"SRT2104","SIRT activator","SIRT1","Cc1nc(sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1)-c1cccnc1, Cc1nc(sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1)-c1cccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1nc(sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1)-c1cccnc1",516.140216008,36,2.653,141.13,0.00208802446249444,0.142,0.0720440122312472,0,1
"tivantinib","tyrosine kinase inhibitor","MET","O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23, O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23, O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23, O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23, O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23",369.147726848,28,4.019,66.89,0.0800120026415202,0.064,0.0720060013207601,0,0
"adenosine-triphosphate","adenosine receptor agonist","ABCA1, ABCB1, ABCB11, ABCC2, ABCC8, ABCC9, ABCG1, ABL1, ABL2, ACSL1, ACSS1, ACSS2, ACVR1, ACVR1B, ACVRL1, ADCY1, ADRBK1, ADRBK2, AFG3L2, AKT1, ALK, AMHR2, APAF1, ARAF, ASNA1, ASNS, ASS1, CDK15, GPR17, ITPR1, NAE1, NT5C2, P2RY1, P2RY11, P2RY13, P2RY2, P2RY4, PRKAA1, RYR1, RYR2, RYR3, SLC25A4, TNK2, TRPM4, TRPM7","Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,"phase 2","","","Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O",506.995745462,31,-5.533,308.56,2.27699243236188e-06,0.144,0.0720011384962162,0,1
"atp","purinergic receptor activator","","Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","cardiology","cardiac arrythmia","Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O",506.995745462,31,-5.533,308.56,2.27699243236188e-06,0.144,0.0720011384962162,0,1
"oxamniquine","dna inhibitor","","[O-][N+](=O)c1c(cc2c(c1)NC(CC2)CNC(C)C)CO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","infectious disease","schistosomiasis","[O-][N+](=O)c1c(cc2c(c1)NC(CC2)CNC(C)C)CO",279.158291532,20,1.487,87.43,0.0380019626912203,0.106,0.0720009813456101,0,0
"coenzyme-I","","AASS, ACADS, ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH7, AKR1B1, AKR1C1, AKR1C2, AKR1C3, AKR1C4, ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, ALDH2, ALDH3A1, ALDH3A2, ALDH3B1, ALDH3B2, ALDH4A1, ALDH5A1, ALDH6A1, ALDH7A1, ALDH9A1, AMT, BDH1, BLVRA, BLVRB, CDO1, CYB5R3, CYP17A1, CYP4A11, DHCR7, DHFR, DLAT, DLD, EHHADH, GAPDH, GAPDHS, GLUD1, GLUD2, GPD1, GSR, H6PD, HADH, HADHA, HIBADH, HMGCR, HMOX1, HMOX2, HPGD, HSD11B1, HSD11B2, HSD17B1, HSD17B10, HSD17B2, HSD17B3, HSD17B4, HSD17B7, HSD17B8, HSD3B1, HSD3B2, IDH3A, IDH3B, IDH3G, IMPDH1, IMPDH2, LDHA, LDHAL6A, LDHAL6B, LDHB, LDHC, MDH1, MDH2, ME1, ME2, ME3, MSMO1, MT-ND1, MT-ND2, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-ND6, MTHFD1, MTHFD2, NDUFA1, NDUFA10, NDUFA11, NDUFA12, NDUFA13, NDUFA2, NDUFA3, NDUFA4, NDUFA4L2, NDUFA5, NDUFA6, NDUFA7, NDUFA8, NDUFA9, NDUFAB1, NDUFB1, NDUFB10, NDUFB2, NDUFB3, NDUFB4, NDUFB5, NDUFB6, NDUFB7, NDUFB8, NDUFB9, NDUFC1, NDUFC2, NDUFS1, NDUFS2, NDUFS3, NDUFS4, NDUFS5, NDUFS6, NDUFS7, NDUFS8, NDUFV1, NDUFV2, NDUFV3, NNT, NQO2, NSDHL, OGDH, PDHA1, PDHA2, PDHB, PHGDH, PYCR1, PYCR2, QDPR, RDH5, SORD, TSTA3, TYR, UGDH","NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18,c:6,t:3|, NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18,c:6,t:3|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9",665.124771868,44,-4.989,337.24,6.10360849826874e-07,0.144,0.0720003051804249,0,1
"substance-P","neurokinin receptor antagonist","TACR1, TACR2, TACR3","CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(N)=O, CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(N)=O, CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(N)=O, CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(N)=O",1346.728146196,95,-1.917,541.93,1.19755811283787e-10,0.144,0.0720000000598779,0,1
"K-Ras(G12C)-inhibitor-6","K-Ras inhibitor","","SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl, SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl, SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl, SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl",404.072818924,25,3.398,97.44,0.00792986858789588,0.136,0.0719649342939479,0,1
"sitaxentan","endothelin receptor antagonist","EDNRA, EDNRB","Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl",454.00600588,29,3.036,144.35,0.00187436556941521,0.142,0.0719371827847076,0,1
"IT1t","CC chemokine receptor antagonist","CXCR4","CC1(C)CN2C(CS\C(NC3CCCCC3)=N\C3CCCCC3)=CSC2=N1 |c:24,28|, CC1(C)CN2C(CS\C(NC3CCCCC3)=N\C3CCCCC3)=CSC2=N1 |c:24,28|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC1(C)CN2C(CS\C(NC3CCCCC3)=N\C3CCCCC3)=CSC2=N1 |c:24",406.222489088,27,5.627,90.59,0.0237979641732053,0.12,0.0718989820866027,0,0
"AGN-195183","retinoid receptor agonist","RARA","CC1(C)CCC(C)(C)c2c(Cl)c(O)c(cc12)C(=O)Nc1cc(F)c(C(O)=O)c(F)c1, CC1(C)CCC(C)(C)c2c(Cl)c(O)c(cc12)C(=O)Nc1cc(F)c(C(O)=O)c(F)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","CC1(C)CCC(C)(C)c2c(Cl)c(O)c(cc12)C(=O)Nc1cc(F)c(C(O)=O)c(F)c1",437.120542304,30,6.658,86.63,0.0317746279067799,0.112,0.0718873139533899,0,0
"CGP-53353","EGFR inhibitor, PKC inhibitor","EGFR, PRKCB","Fc1ccc(Nc2cc3C(=O)NC(=O)c3cc2Nc2ccc(F)cc2)cc1, Fc1ccc(Nc2cc3C(=O)NC(=O)c3cc2Nc2ccc(F)cc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1ccc(Nc2cc3C(=O)NC(=O)c3cc2Nc2ccc(F)cc2)cc1",365.097583096,27,3.738,70.23,0.061678841717906,0.082,0.071839420858953,0,0
"indole-3-pyrubate","melatonin receptor agonist","","OC(=O)C(O)=Cc1c[nH]c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)C(O)=Cc1c[nH]c2ccccc12",203.058243148,15,1.899,73.32,0.105661014321093,0.038,0.0718305071605463,0,0
"CCG-50014","G protein signaling inhibitor","RGS4, RGS8","Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O",316.068176876,22,3.398,72.24,0.055615478508381,0.088,0.0718077392541905,0,0
"BMS-182874","endothelin receptor antagonist","EDNRA","CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1onc(C)c1C, CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1onc(C)c1C, CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1onc(C)c1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1onc(C)c1C",345.114712468,24,3.766,83.82,0.0375475434188212,0.106,0.0717737717094106,0,0
"amcasertib","kinase inhibitor","","CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2\C(=O)Nc3ccc(cc23)-c2csc(n2)-c2ccccc2)c1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2\C(=O)Nc3ccc(cc23)-c2csc(n2)-c2ccccc2)c1C",539.235496296,39,5.188,118.36,0.00753531848561761,0.136,0.0717676592428088,0,1
"balapiravir","RNA polymerase inhibitor","","CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-], CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-], CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-], CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-]",494.21251192,35,2.033,161.4,0.00150477424133462,0.142,0.0717523871206673,0,1
"S-14506","serotonin receptor agonist","HTR1A","COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1, COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1, COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1, COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1, COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1, COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1",407.200905292,30,4.553,44.81,0.0954980456888795,0.048,0.0717490228444398,0,0
"defactinib","focal adhesion kinase inhibitor","PTK2","CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1",510.140942192,35,2.199,150.48,0.00137960383642492,0.142,0.0716898019182125,0,1
"WYE-354","mTOR inhibitor","MTOR","COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1, COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1",495.223017028,36,2.855,123.94,0.00537159142355595,0.138,0.071685795711778,0,1
"PI-828","PI3K inhibitor","","Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1",322.131742436,24,4.149,68.7,0.0953607009460003,0.048,0.0716803504730002,0,0
"NVP-TAE226","protein tyrosine kinase inhibitor","PTK2","CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl",468.16766634,33,3.909,100.64,0.0113518459199809,0.132,0.0716759229599904,0,1
"BMS-265246","CDK inhibitor","CDK1, CDK2","CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F",345.128883224,25,4.875,67.87,0.0853364536236375,0.058,0.0716682268118187,0,0
"KY02111","WNT pathway inhibitor","DKK1","COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC",376.064841084,25,3.067,88.69,0.0173300982291031,0.126,0.0716650491145515,0,0
"I-BZA2","","","CCN(CC)CCNC(=O)c1ccccc1I, CCN(CC)CCNC(=O)c1ccccc1I",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCN(CC)CCNC(=O)c1ccccc1I",346.054211228,17,3.194,32.34,0.0213253241690061,0.122,0.071662662084503,0,0
"mapracorat","glucocorticoid receptor agonist","CXCL8, MYOC, NR3C1","Cc1ccc2c(NC[C@](O)(CC(C)(C)c3cc(F)cc4CCOc34)C(F)(F)F)cccc2n1 |a:8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","ophthalmology","cataracts","Cc1ccc2c(NC[C@](O)(CC(C)(C)c3cc(F)cc4CCOc34)C(F)(F)F)cccc2n1 |a:8|",462.193040952,33,5.897,54.38,0.0593017779778399,0.084,0.0716508889889199,0,0
"API-1","AKT inhibitor","AKT1, AKT2, AKT3","NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c2c1=O, NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c2c1=O, NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c2c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c2c1=O",337.1022332,24,-1.212,186.81,0.00127814707611535,0.142,0.0716390735380577,0,1
"vadadustat","hypoxia inducible factor prolyl hydroxylase inhibitor","","OC(=O)CNC(=O)c1ncc(cc1O)-c1cccc(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","OC(=O)CNC(=O)c1ncc(cc1O)-c1cccc(Cl)c1",306.040734512,21,0.494,99.52,0.0152535856484985,0.128,0.0716267928242493,0,0
"JNJ-42041935","hypoxia inducible factor prolyl hydroxylase inhibitor","PDK2","OC(=O)c1cnn(c1)-c1nc2cc(Cl)c(OC(F)(F)F)cc2[nH]1, OC(=O)c1cnn(c1)-c1nc2cc(Cl)c(OC(F)(F)F)cc2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1cnn(c1)-c1nc2cc(Cl)c(OC(F)(F)F)cc2[nH]1",346.008052392,23,3.272,93.03,0.0212404485625127,0.122,0.0716202242812563,0,0
"fexaramine","FXR agonist","NR1H4","COC(=O)\C=C\c1cccc(c1)N(Cc1ccc(cc1)-c1ccc(cc1)N(C)C)C(=O)C1CCCCC1, COC(=O)\C=C\c1cccc(c1)N(Cc1ccc(cc1)-c1ccc(cc1)N(C)C)C(=O)C1CCCCC1, COC(=O)\C=C\c1cccc(c1)N(Cc1ccc(cc1)-c1ccc(cc1)N(C)C)C(=O)C1CCCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)\C=C\c1cccc(c1)N(Cc1ccc(cc1)-c1ccc(cc1)N(C)C)C(=O)C1CCCCC1",496.272593012,37,7.398,49.85,0.101212278292361,0.042,0.0716061391461803,0,0
"JTE-607","cytokine production inhibitor","IL10, IL1B, IL6, TNF","CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O",523.164076452,35,4.631,91.34,0.00718657171552945,0.136,0.0715932858577647,0,1
"SLV-320","adenosine receptor antagonist","ADORA1, ADORA2A, ADORA2B, ADORA3","O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1 |r|, O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1 |r|, O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1 |r|, O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1 |r|",308.16371126,23,3.6,73.83,0.0831773198629558,0.06,0.0715886599314779,0,0
"LDN-212854","bone morphogenic protein inhibitor","ABL1, ACVR1, RIPK2","C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12",406.190594704,31,4.173,58.35,0.0831122030664585,0.06,0.0715561015332293,0,0
"LDN193189","bone morphogenic protein inhibitor","ACVR1, BMPR1A","C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12",406.190594704,31,4.173,58.35,0.0831122030664585,0.06,0.0715561015332293,0,0
"bipenamol","dipeptidyl peptidase inhibitor","CTSC","NCc1ccccc1Sc1ccccc1CO, NCc1ccccc1Sc1ccccc1CO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NCc1ccccc1Sc1ccccc1CO",245.0874351,17,2.528,71.55,0.0769482227258004,0.066,0.0714741113629002,0,0
"PS178990","androgen receptor modulator","AR","Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N, Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N, Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N, Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N, Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N",305.056718924,21,0.682,84.64,0.0229109997512514,0.12,0.0714554998756257,0,0
"sirtinol","SIRT inhibitor","SIRT1, SIRT2","C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1,r|, C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1,r|, C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1,r|, C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1",394.168127944,30,5.877,61.69,0.118867241515871,0.024,0.0714336207579353,1,0
"pf-03463275","glycine transporter inhibitor","SLC6A9","O=C(C(N=C1)=CN1C)N(CC(C=C2)=CC(Cl)=C2F)C[C@@H]3[C@](C4)([H])[C@@]3([H])CN4C",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,"phase 2","neurology/psychiatry","schizophrenia","O=C(C(N=C1)=CN1C)N(CC(C=C2)=CC(Cl)=C2F)C[C@@H]3[C@](C4)([H])[C@@]3([H])CN4C",376.146617224,28,1.418,39.15,0.0688503904069307,0.074,0.0714251952034654,0,0
"crizotinib-(S)","MTH1 inhibitor","NUDT1","C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl",449.118543904,30,4.827,77.99,0.0188440789886695,0.124,0.0714220394943347,0,0
"EGF816","EGFR inhibitor","EGFR","CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12, CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12, CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12",494.219701912,35,3.442,83.36,0.0128315069053462,0.13,0.0714157534526731,0,1
"diosgenin","steroid","","C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@@H](C)CO1 |t:8|, C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@@H](C)CO1 |t:8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@@H](C)CO1 |t:8|",414.313395204,30,6.041,38.69,0.128819338032786,0.014,0.071409669016393,1,0
"BMS-345541","IKK inhibitor","CHUK, IKBKB","Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cnc2c(NCCN)nc3ccc(C)cc3n12",255.148395544,19,2.151,68.24,0.0927954310435698,0.05,0.0713977155217849,0,0
"ML324","histone lysine demethylase inhibitor","KDM4A","CN(C)CCCNC(=O)c1ccc(cc1)-c1cc(O)c2ncccc2c1, CN(C)CCCNC(=O)c1ccc(cc1)-c1cc(O)c2ncccc2c1, CN(C)CCCNC(=O)c1ccc(cc1)-c1cc(O)c2ncccc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)CCCNC(=O)c1ccc(cc1)-c1cc(O)c2ncccc2c1",349.179026976,26,3.275,65.46,0.0707664265493677,0.072,0.0713832132746839,0,0
"dorzagliatin","glucokinase activator","GCK","CC(C)C[C@H](N1CC(=CC1=O)Oc2ccccc2Cl)C(=O)Nc3ccn(C[C@@H](O)CO)n3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","endocrinology","diabetes mellitus","CC(C)C[C@H](N1CC(=CC1=O)Oc2ccccc2Cl)C(=O)Nc3ccn(C[C@@H](O)CO)n3",462.166997644,32,2.232,116.92,0.00476003632535743,0.138,0.0713800181626787,0,1
"chlorophyllin-copper","cytochrome P450 inhibitor","","CCC1=C(C)\C2=C\c3c(C=C)c(C)c4\C=C5/N=C([C@@H](CCC(O)=O)[C@@H]5C)/C(/CC(O)=O)=c5/c(C(O)=O)c(C)\c(=C\C1=N2)n5[Cu]n34 |&1:18,&2:24,r,c:2,14,16,42,t:5,31,39|, CCC1=C(C)\C2=C\c3c(C=C)c(C)c4\C=C5/N=C([C@@H](CCC(O)=O)[C@@H]5C)/C(/CC(O)=O)=c5/c(C(O)=O)c(C)\c(=C\C1=N2)n5[Cu]n34 |&1:18,&2:24,r,c:2,14,16,42,t:5,31,39|, CCC1=C(C)\C2=C\c3c(C=C)c(C)c4\C=C5/N=C([C@@H](CCC(O)=O)[C@@H]5C)/C(/CC(O)=O)=c5/c(C(O)=O)c(C)\c(=C\C1=N2)n5[Cu]n34 |&1:18,&2:24,r,c:2,14,16,42,t:5,31,39|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCC1=C(C)\C2=C\c3c(C=C)c(C)c4\C=C5/N=C([C@@H](CCC(O)=O)[C@@H]5C)/C(/CC(O)=O)=c5/c(C(O)=O)c(C)\c(=C\C1=N2)n5[Cu]n34 |&1:18",657.177432308,45,4.069,146.48,0.000713691034013972,0.142,0.071356845517007,0,1
"O6-benzylguanine","O6-alkylguanine-DNA alkyltransferase inhibitor","MGMT","Nc1nc(OCc2ccccc2)c2[nH]cnc2n1, Nc1nc(OCc2ccccc2)c2[nH]cnc2n1, Nc1nc(OCc2ccccc2)c2[nH]cnc2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Nc1nc(OCc2ccccc2)c2[nH]cnc2n1",241.096359972,18,2.016,89.71,0.062662328524904,0.08,0.071331164262452,0,0
"SP-420","","","COCCOCCOc1ccc(C2=N[C@](C)(CS2)C(O)=O)c(O)c1 |t:12|, COCCOCCOc1ccc(C2=N[C@](C)(CS2)C(O)=O)c(O)c1 |t:12|, COCCOCCOc1ccc(C2=N[C@](C)(CS2)C(O)=O)c(O)c1 |t:12|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COCCOCCOc1ccc(C2=N[C@](C)(CS2)C(O)=O)c(O)c1 |t:12|",355.108958392,24,1.238,122.88,0.00663650289450568,0.136,0.0713182514472528,0,1
"GSK2982772","RIPK inhibitor","","CN1c2ccccc2OC[C@H](NC(=O)c2nc(Cc3ccccc3)n[nH]2)C1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN1c2ccccc2OC[C@H](NC(=O)c2nc(Cc3ccccc3)n[nH]2)C1=O",377.148789468,28,2.549,100.21,0.0226086807242964,0.12,0.0713043403621482,0,0
"avoralstat","kallikrein inhibitor","","COc1cc(c(cc1C=C)C(=O)Nc1ccc(cc1)C(N)=N)-c1ccc(nc1C(O)=O)C(=O)NCC1CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1cc(c(cc1C=C)C(=O)Nc1ccc(cc1)C(N)=N)-c1ccc(nc1C(O)=O)C(=O)NCC1CC1",513.201218964,38,3.868,167.49,0.0025955990017081,0.14,0.0712977995008541,0,1
"FK-409","guanylyl cyclase activator","","CC\C(=C/C(=N/O)/C(N)=O)[C@@H](C)[N+]([O-])=O |&1:10,r|, CC\C(=C/C(=N/O)/C(N)=O)[C@@H](C)[N+]([O-])=O |&1:10,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC\C(=C/C(=N/O)/C(N)=O)[C@@H](C)[N+]([O-])=O |&1:10",215.090605896,15,-0.0990000000000002,118.82,0.0185511252399713,0.124,0.0712755626199856,0,0
"lasofoxifene","selective estrogen receptor modulator (SERM)","ESR1, ESR2","O[C@@H]([C@H](O)C(O)=O)C(O)=O.Oc1ccc2[C@H]([C@H](CCc2c1)c1ccccc1)c1ccc(OCCN2CCCC2)cc1, O[C@@H]([C@H](O)C(O)=O)C(O)=O.Oc1ccc2[C@H]([C@H](CCc2c1)c1ccccc1)c1ccc(OCCN2CCCC2)cc1, Oc1ccc2[C@H]([C@H](CCc2c1)c3ccccc3)c4ccc(OCCN5CCCC5)cc4",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","orthopedics, oncology","osteoporosis, breast cancer","O[C@@H]([C@H](O)C(O)=O)C(O)=O.Oc1ccc2[C@H]([C@H](CCc2c1)c1ccccc1)c1ccc(OCCN2CCCC2)cc1",563.251917144,41,3.984,147.76,0.00254551828705735,0.14,0.0712727591435287,0,1
"GLPG0187","integrin antagonist","","COc1ccc(cc1)S(=O)(=O)N[C@@H](CNc1nc(C)nc(N2CCC(CC2)c2ccc3CCCNc3n2)c1C)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1ccc(cc1)S(=O)(=O)N[C@@H](CNc1nc(C)nc(N2CCC(CC2)c2ccc3CCCNc3n2)c1C)C(O)=O",595.257688284,42,1.684,167.05,0.000543409186284348,0.142,0.0712717045931422,0,1
"GNE-7915","leucine rich repeat kinase inhibitor","","CCNc1nc(Nc2cc(F)c(cc2OC)C(=O)N2CCOCC2)ncc1C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCNc1nc(Nc2cc(F)c(cc2OC)C(=O)N2CCOCC2)ncc1C(F)(F)F",443.158052412,31,2.614,88.61,0.0125098922569157,0.13,0.0712549461284579,0,1
"macitentan-n-butyl-analogue","endothelin receptor antagonist","","CCCCS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1",584.968099352,32,5.323,124.57,0.000453518911143703,0.142,0.0712267594555718,0,1
"satraplatin","DNA alkylating agent","","CC(=O)O[Pt](N)(Cl)(Cl)(NC1CCCCC1)OC(C)=O, CC(=O)O[Pt](N)(Cl)(Cl)(NC1CCCCC1)OC(C)=O, NC1CCCCC1.CC(=O)O[Pt+4](C)(C)(Cl)(Cl)OC(C)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(=O)O[Pt](N)(Cl)(Cl)(NC1CCCCC1)OC(C)=O",497.04480358,19,3.715,90.65,0.000274682595978556,0.142,0.0711373412979893,0,1
"PLX4720","RAF inhibitor","BRAF, KDR","CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F",413.041246428,27,4.452,100.3,0.0122433541827832,0.13,0.0711216770913916,0,1
"CEP-32496","RAF inhibitor","BRAF, RAF1","COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC, COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC, COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC, COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC, COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC, COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC, COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC",517.157303464,37,4.347,120.63,0.00622761002272259,0.136,0.0711138050113613,0,1
"AG-555","tyrosine kinase inhibitor","CDK2","Oc1ccc(\C=C(/C#N)C(=O)NCCCc2ccccc2)cc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(\C=C(/C#N)C(=O)NCCCc2ccccc2)cc1O",322.131742436,24,2.915,93.35,0.0421263419668616,0.1,0.0710631709834308,0,0
"tak-071","mitotic inhibitor","FOS, SNCA","Cc1c(Cc2ccc(cc2)n3cccn3)cc4C(=O)N(Cc4c1F)[C@H]5COCC[C@@H]5O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","neurology/psychiatry","parkinson's disease","Cc1c(Cc2ccc(cc2)n3cccn3)cc4C(=O)N(Cc4c1F)[C@H]5COCC[C@@H]5O",421.180169848,31,3.074,67.07,0.0380175604699532,0.104,0.0710087802349766,0,0
"begacestat","gamma secretase inhibitor","PSEN1","OC[C@@H](NS(=O)(=O)c1ccc(Cl)s1)C(C(F)(F)F)C(F)(F)F, OC[C@@H](NS(=O)(=O)c1ccc(Cl)s1)C(C(F)(F)F)C(F)(F)F, OC[C@@H](NS(=O)(=O)c1ccc(Cl)s1)C(C(F)(F)F)C(F)(F)F, OC[C@@H](NS(=O)(=O)c1ccc(Cl)s1)C(C(F)(F)F)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC[C@@H](NS(=O)(=O)c1ccc(Cl)s1)C(C(F)(F)F)C(F)(F)F",390.953832116,22,2.59,103.02,0.00393311442129292,0.138,0.0709665572106465,0,1
"sulfisomidin","antibacterial","","Cc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(C)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(C)n1",278.083746688,19,0.963,106.35,0.0179281893643862,0.124,0.0709640946821931,0,0
"NVP-BSK805","JAK inhibitor","JAK2","Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1, Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1, Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1, Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1, Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1, Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1",490.229265956,36,3.254,68.1,0.0239060459718645,0.118,0.0709530229859323,0,0
"ID-1101","insulin sensitizer","INS","C[C@H](O)[C@H](C)[C@H](N)C(O)=O, C[C@H](O)[C@H](C)[C@H](N)C(O)=O, C[C@H](O)[C@H](C)[C@H](N)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@H](O)[C@H](C)[C@H](N)C(O)=O",147.089543276,10,-2.841,83.55,0.0339024432887514,0.108,0.0709512216443757,0,0
"levobunolol-(+)","adrenergic receptor antagonist","","CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12",291.18344366,21,2.09,58.56,0.0778991325351851,0.064,0.0709495662675926,0,0
"levobunolol-(+/-)","adrenergic receptor antagonist","","CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12 |&1:6|, CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12 |&1:6|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12 |&1:6|",291.18344366,21,2.09,58.56,0.077899132535185,0.064,0.0709495662675925,0,0
"BAG-956","phosphoinositide dependent kinase inhibitor","PIK3CG","Cc1nc2cnc3ccc(cc3c2n1-c1ccc(cc1)C(C)(C)C#N)C#Cc1cccnc1, Cc1nc2cnc3ccc(cc3c2n1-c1ccc(cc1)C(C)(C)C#N)C#Cc1cccnc1, Cc1nc2cnc3ccc(cc3c2n1-c1ccc(cc1)C(C)(C)C#N)C#Cc1cccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1nc2cnc3ccc(cc3c2n1-c1ccc(cc1)C(C)(C)C#N)C#Cc1cccnc1",427.179695672,33,5.336,67.39,0.0857994301731819,0.056,0.0708997150865909,0,0
"amibegron","adrenergic receptor agonist","ADRB3","CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1, CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1, CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1, CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"phase 3","","","CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1",403.155035992,28,3.7,67.79,0.0337506273944253,0.108,0.0708753136972126,0,0
"acadesine","AMPK activator","","NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N, NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N, NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N",258.096419548,18,-1.803,156.85,0.00366556212326711,0.138,0.0708327810616336,0,1
"AV-412","protein tyrosine kinase inhibitor","EGFR, ERBB2","CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C, CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C, CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C",506.199715416,36,4.043,73.39,0.0176298977395032,0.124,0.0708149488697516,0,0
"RS-17053","adrenergic receptor antagonist","ADRA1A, ADRA1D","CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,"preclinical","","","CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1",412.191755848,29,5.411,46.28,0.0815360436101712,0.06,0.0707680218050856,0,0
"NB-001","antiviral","","Nc1ncnc2n(CCNCCCCCO)cnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1ncnc2n(CCNCCCCCO)cnc12",264.16985926,19,-0.0540000000000001,101.88,0.0215317634151537,0.12,0.0707658817075768,0,0
"V-51","adrenergic receptor antagonist","","COc1cc(CN2CCN(CC2)c2ccc(F)cc2)cc(OC)c1OC, COc1cc(CN2CCN(CC2)c2ccc(F)cc2)cc(OC)c1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1cc(CN2CCN(CC2)c2ccc(F)cc2)cc(OC)c1OC",360.18492088,26,3.342,34.17,0.109457247101788,0.032,0.0707286235508939,0,0
"YS-035","calcium channel blocker","","COc1ccc(CCN(C)CCc2ccc(OC)c(OC)c2)cc1OC, COc1ccc(CCN(C)CCc2ccc(OC)c(OC)c2)cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(CCN(C)CCc2ccc(OC)c(OC)c2)cc1OC",359.209658408,26,3.191,40.16,0.0954455799311583,0.046,0.0707227899655791,0,0
"hmn-176","plk inhibitor","NFYA, PLK1","O=S(C1=CC=C(OC)C=C1)(NC2=CC=CC=C2/C=C/C3=CC=N(C=C3)=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","breast cancer","O=S(C1=CC=C(OC)C=C1)(NC2=CC=CC=C2/C=C/C3=CC=N(C=C3)=O)=O",382.098728056,27,2.161,92.53,0.0174213187383009,0.124,0.0707106593691504,0,0
"medica-16","ATP citrase lyase inhibitor","FFAR1","CC(C)(CCCCCCCCCCC(C)(C)CC(O)=O)CC(O)=O, CC(C)(CCCCCCCCCCC(C)(C)CC(O)=O)CC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)(CCCCCCCCCCC(C)(C)CC(O)=O)CC(O)=O",342.277009696,24,7.92400000000001,74.6,0.125397496839539,0.016,0.0706987484197695,1,0
"NBI-27914","corticotropin releasing factor receptor antagonist","CRHR1","CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl, CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl, CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl, CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl",432.04420736,26,6.928,41.05,0.0433437396447937,0.098,0.0706718698223969,0,0
"Gln-1062","cholinesterase inhibitor","","COc1ccc2CN(C)CC[C@@]34C=C[C@@H](C[C@@H]3Oc1c24)OC(=O)c1ccccc1 |c:12|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc2CN(C)CC[C@@]34C=C[C@@H](C[C@@H]3Oc1c24)OC(=O)c1ccccc1 |c:12|",391.17835828,29,4.032,48,0.091340111350919,0.05,0.0706700556754595,0,0
"gavorestat","aldose reductase inhibitor","AKR1B1","OC(=O)Cc1nn(Cc2nc3cc(ccc3s2)C(F)(F)F)c(=O)c2cscc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","OC(=O)Cc1nn(Cc2nc3cc(ccc3s2)C(F)(F)F)c(=O)c2cscc12",425.01156784,28,3.221,141.56,0.00331912991836349,0.138,0.0706595649591817,0,1
"alanosine","antimetabolite","","N[C@@H](CN(O)[N+][O-])C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","N[C@@H](CN(O)[N+][O-])C(O)=O",149.043655704,10,-4.772,109.85,0.0112074396411686,0.13,0.0706037198205843,0,1
"antimycin-A","ATP synthase inhibitor","CYCS","CCCCCC[C@@H]1[C@@H](OC(=O)CC(C)C)[C@H](C)OC(=O)[C@@H](NC(=O)c2cccc(NC=O)c2O)[C@@H](C)OC1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCC[C@@H]1[C@@H](OC(=O)CC(C)C)[C@H](C)OC(=O)[C@@H](NC(=O)c2cccc(NC=O)c2O)[C@@H](C)OC1=O",548.27338086,39,6.239,157.33,0.00319710454925081,0.138,0.0705985522746254,0,1
"nemorexant","orexin receptor antagonist","","COc1ccc(c(c1)C(=O)N1CCC[C@@]1(C)c1nc2ccc(Cl)c(C)c2[nH]1)-n1nccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(c(c1)C(=O)N1CCC[C@@]1(C)c1nc2ccc(Cl)c(C)c2[nH]1)-n1nccn1",450.157101656,32,4.572,88.93,0.0211932168209404,0.12,0.0705966084104702,0,0
"ML3403","MAP kinase inhibitor","CYP3A4, MAPK11, MAPK12, MAPK14","CSc1nc(c([nH]1)-c1ccc(F)cc1)-c1ccnc(N[C@@H](C)c2ccccc2)c1 |&1:20,r|, CSc1nc(c([nH]1)-c1ccc(F)cc1)-c1ccnc(N[C@@H](C)c2ccccc2)c1 |&1:20,r|, CSc1nc(c([nH]1)-c1ccc(F)cc1)-c1ccnc(N[C@@H](C)c2ccccc2)c1 |&1:20,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CSc1nc(c([nH]1)-c1ccc(F)cc1)-c1ccnc(N[C@@H](C)c2ccccc2)c1 |&1:20",404.147095892,29,6.45,78.9,0.0611882400246803,0.08,0.0705941200123401,0,0
"BMS-777607","AXL kinase inhibitor, c-Met inhibitor, FLT3 inhibitor, hepatocyte growth factor receptor inhibitor, macrophage migration inhibiting factor inhibitor, tyrosine kinase inhibitor","AXL, MERTK, MET, MST1R, TYRO3","CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1, CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1",512.106289208,36,5.242,108.47,0.00918704655959557,0.132,0.0705935232797978,0,1
"sotrastaurin","PKC inhibitor","PRKCA, PRKCB, PRKCD, PRKCE, PRKCH, PRKCQ","CN1CCN(CC1)c1nc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc2n1 |t:11|, CN1CCN(CC1)c1nc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc2n1 |t:11|, CN1CCN(CC1)c1nc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc2n1 |t:11|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN1CCN(CC1)c1nc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc2n1 |t:11|",438.180423944,33,2.962,94.22,0.021177064564451,0.12,0.0705885322822255,0,0
"WAY-600","mTOR inhibitor","MTOR","C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1, C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1, C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1",494.25425758,37,4.081,87.99,0.0211764845596951,0.12,0.0705882422798475,0,0
"6-chloromelatonin","melatonin receptor agonist","MTNR1A, MTNR1B","COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl, COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl, COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl, COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl",266.0822054,18,2.223,54.12,0.0811489598488272,0.06,0.0705744799244136,0,0
"A0001","","","CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O |c:21,t:27|, CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O |c:21,t:27|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O |c:21",446.37599546,32,8.993,54.37,0.135108358634215,0.006,0.0705541793171077,1,0
"VU0422288","glutamate receptor positive allosteric modulator","GRM3","Clc1ccc(Oc2ccc(NC(=O)c3ccccn3)cc2Cl)nc1, Clc1ccc(Oc2ccc(NC(=O)c3ccccn3)cc2Cl)nc1, Clc1ccc(Oc2ccc(NC(=O)c3ccccn3)cc2Cl)nc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1ccc(Oc2ccc(NC(=O)c3ccccn3)cc2Cl)nc1",359.022831952,24,4.031,64.11,0.0450245154194221,0.096,0.070512257709711,0,0
"rovazolac","LXR agonist","","CCOC(=O)Cn1nc(cc1-c1ccc(cc1)-c1cccc(c1)S(C)(=O)=O)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)Cn1nc(cc1-c1ccc(cc1)-c1cccc(c1)S(C)(=O)=O)C(F)(F)F",452.101762748,31,5.017,86.64,0.0189402880986154,0.122,0.0704701440493077,0,0
"ostarine","androgen receptor modulator","AR","C[C@](O)(COc1ccc(cc1)C#N)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F, C[C@](O)(COc1ccc(cc1)C#N)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C[C@](O)(COc1ccc(cc1)C#N)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F",389.098725968,28,2.55,106.14,0.0149275325387747,0.126,0.0704637662693873,0,0
"NGP555","gamma secretase modulator","","CCc1cc(Nc2nc(cs2)-c2ccc(c(F)c2)-n2cnc(C)c2)c(C)cc1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCc1cc(Nc2nc(cs2)-c2ccc(c(F)c2)-n2cnc(C)c2)c(C)cc1C",406.162745956,29,6.155,70.98,0.0649117794966089,0.076,0.0704558897483044,0,0
"tucatinib","EGFR inhibitor","ERBB2","Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 |t:14|, Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 |t:14|, Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 |t:14|, Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 |t:14|, Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 |t:14|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 |t:14|",480.202222008,36,3.753,110.85,0.012889846185238,0.128,0.070444923092619,0,0
"dazoxiben","thromboxane synthase inhibitor","TBXAS1","OC(=O)c1ccc(OCCn2ccnc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)c1ccc(OCCn2ccnc2)cc1",232.084792244,17,1.608,64.35,0.0968762708319378,0.044,0.0704381354159689,0,0
"PLX8394","serine/threonine kinase inhibitor","BRAF","F[C@@H]1CCN(C1)S(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2cnc(nc2)C2CC2)c1F, F[C@@H]1CCN(C1)S(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2cnc(nc2)C2CC2)c1F, F[C@@H]1CCN(C1)S(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2cnc(nc2)C2CC2)c1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","F[C@@H]1CCN(C1)S(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2cnc(nc2)C2CC2)c1F",542.134794192,38,3.499,129.32,0.00287515119001842,0.138,0.0704375755950092,0,1
"SB-218795","tachykinin antagonist","TACR3","COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1, COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1, COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1",396.1473925,30,4.837,68.29,0.0788078799717117,0.062,0.0704039399858559,0,0
"cyclocreatine","creatine kinase substrate","","NC1=NCCN1CC(O)=O |t:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","NC1=NCCN1CC(O)=O |t:1|",143.069476528,10,-2.692,78.92,0.0427060911343226,0.098,0.0703530455671613,0,0
"ensartinib","alk inihibitor","ALK","C[C@@H](Oc1cc(nnc1N)C(=O)Nc2ccc(cc2)C(=O)N3C[C@@H](C)N[C@@H](C)C3)c4c(Cl)ccc(F)c4Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","oncology","non-small cell lung cancer (nsclc)","C[C@@H](Oc1cc(nnc1N)C(=O)Nc2ccc(cc2)C(=O)N3C[C@@H](C)N[C@@H](C)C3)c4c(Cl)ccc(F)c4Cl",560.150572304,38,4.338,122.47,0.00269163147877814,0.138,0.0703458157393891,0,1
"testosterone propionate","","","CCC(=O)O[C@H]1CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@]12C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CCC(=O)O[C@H]1CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@]12C",344.235144884,25,4.628,43.37,0.136674009726588,0.004,0.0703370048632941,1,0
"pyridoxamine","AGE inhibitor","","Cc1ncc(CO)c(CN)c1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cc1ncc(CO)c(CN)c1O",168.089877624,12,-0.581,79.37,0.0606706344171356,0.08,0.0703353172085678,0,0
"belvarafenib","raf inhibitor","ARAF, BRAF, NRAS","Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","melanoma","Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12",478.077886032,33,4.356,134.06,0.0046370240585747,0.136,0.0703185120292874,0,1
"RX-3117","CDK inhibitor, DNA synthesis inhibitor","CDK2, DNMT1","Nc1ccn([C@H]2[C@H](O)[C@H](O)C(CO)=C2F)c(=O)n1 |c:12|, Nc1ccn([C@H]2[C@H](O)[C@H](O)C(CO)=C2F)c(=O)n1 |c:12|, Nc1ccn([C@H]2[C@H](O)[C@H](O)C(CO)=C2F)c(=O)n1 |c:12|, Nc1ccn([C@H]2[C@H](O)[C@H](O)C(CO)=C2F)c(=O)n1 |c:12|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","Nc1ccn([C@H]2[C@H](O)[C@H](O)C(CO)=C2F)c(=O)n1 |c:12|",257.081184084,18,-0.866,121.6,0.010625970030531,0.13,0.0703129850152655,0,1
"FH1","hepatocyte function enhancer","","CC(=O)Nc1ccc(Cc2ccc(NC(C)=O)cc2)cc1, CC(=O)Nc1ccc(Cc2ccc(NC(C)=O)cc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)Nc1ccc(Cc2ccc(NC(C)=O)cc2)cc1",282.136827816,21,2.496,58.2,0.10461264502425,0.036,0.0703063225121251,0,0
"solcitinib","JAK inhibitor","JAK1","CC1(C)CN(C1)C(=O)c1ccc(cc1)-c1cccc2nc(NC(=O)C3CC3)nn12, CC1(C)CN(C1)C(=O)c1ccc(cc1)-c1cccc2nc(NC(=O)C3CC3)nn12, CC1(C)CN(C1)C(=O)c1ccc(cc1)-c1cccc2nc(NC(=O)C3CC3)nn12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC1(C)CN(C1)C(=O)c1ccc(cc1)-c1cccc2nc(NC(=O)C3CC3)nn12",389.185174976,29,3.082,79.6,0.0385921420128773,0.102,0.0702960710064387,0,0
"crenolanib","PDGFR tyrosine kinase receptor inhibitor","CSF1R, FLT3, KIT, PDGFRA, PDGFRB","CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1",443.232125168,33,4.256,78.43,0.0365891317928126,0.104,0.0702945658964063,0,0
"BMS-817378","c-Met inhibitor, VEGFR inhibitor","KDR, MET","Nc1nccc(Oc2ccc(NC(=O)c3cn(COP(O)(O)=O)cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl, Nc1nccc(Oc2ccc(NC(=O)c3cn(COP(O)(O)=O)cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Nc1nccc(Oc2ccc(NC(=O)c3cn(COP(O)(O)=O)cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl",578.056969666,39,3.866,175.81,0.000572468603012732,0.14,0.0702862343015064,0,1
"bamaquimast","proton pump inhibitor","","CCCn1c2ccccc2nc(CCCOC(=O)NC)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCn1c2ccccc2nc(CCCOC(=O)NC)c1=O",303.158291532,22,2.6,73.22,0.0605473885362993,0.08,0.0702736942681497,0,0
"elinogrel","purinergic receptor antagonist","P2RY12","CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F, CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F",523.01871648,34,3.124,178.78,0.000524731855091528,0.14,0.0702623659275458,0,1
"SDZ-220-581","glutamate receptor antagonist","GRIN1","N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O, N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O, N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O, N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O",369.053286954,24,-0.646,130.66,0.00251127493872041,0.138,0.0702556374693602,0,1
"PF-03758309","p21 activated kinase inhibitor","PAK4","CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1",490.22632858,35,3.19,130.31,0.00450651800227591,0.136,0.070253259001138,0,1
"SBE-13","PLK inhibitor","PLK1","COc1ccc(CCNCc2ccc(OCc3ccc(Cl)nc3)c(OC)c2)cc1OC, COc1ccc(CCNCc2ccc(OCc3ccc(Cl)nc3)c(OC)c2)cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(CCNCc2ccc(OCc3ccc(Cl)nc3)c(OC)c2)cc1OC",442.165935024,31,3.963,61.84,0.0325025695624515,0.108,0.0702512847812257,0,0
"AZ7550","insulin growth factor receptor inhibitor","","CNCCN(C)c1cc(OC)c(Nc2nccc(n2)-c2cn(C)c3ccccc23)cc1NC(=O)C=C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CNCCN(C)c1cc(OC)c(Nc2nccc(n2)-c2cn(C)c3ccccc23)cc1NC(=O)C=C",485.253923232,36,3.357,96.34,0.0144873440657574,0.126,0.0702436720328787,0,0
"TAK-243","ubiquitin activating enzyme inhibitor","","NS(=O)(=O)OC[C@H]1C[C@@H](Nc2ccnc3cc(nn23)-c2cccc(SC(F)(F)F)c2)[C@H](O)[C@@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","NS(=O)(=O)OC[C@H]1C[C@@H](Nc2ccnc3cc(nn23)-c2cccc(SC(F)(F)F)c2)[C@H](O)[C@@H]1O",519.0857954,34,2.734,185.75,0.000445744964676623,0.14,0.0702228724823383,0,1
"ido1-in-5","indoleamine 2,3-dioxygenase inhibitor","IDO1","FC1=CC=C(C(N[C@H](C)C2=CC=C(N(C(C3CCOCC3)=O)CC4)C4=C2)=O)C=C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","renal cell carcinoma (rcc)","FC1=CC=C(C(N[C@H](C)C2=CC=C(N(C(C3CCOCC3)=O)CC4)C4=C2)=O)C=C1",396.18492088,29,0.778,58.64,0.0304131749990109,0.11,0.0702065874995054,0,0
"sibofimloc","","","CC(=O)N1CCC2(CC1)c3cc(ccc3c4ccc(cc24)C#C[C@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]5O)C#C[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]6O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","gastroenterology","crohn's disease","CC(=O)N1CCC2(CC1)c3cc(ccc3c4ccc(cc24)C#C[C@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]5O)C#C[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]6O",649.252311068,47,1.641,200.61,0.000215039183996781,0.14,0.0701075195919984,0,1
"EB-47","PARP inhibitor","PARP1","Nc1ncnc2n(cnc12)[C@H]1O[C@H]([C@H](O)[C@@H]1O)C(=O)N1CCN(CC(=O)Nc2cccc3C(=O)NCc23)CC1, Nc1ncnc2n(cnc12)[C@H]1O[C@H]([C@H](O)[C@@H]1O)C(=O)N1CCN(CC(=O)Nc2cccc3C(=O)NCc23)CC1, Nc1ncnc2n(cnc12)[C@H]1O[C@H]([C@H](O)[C@@H]1O)C(=O)N1CCN(CC(=O)Nc2cccc3C(=O)NCc23)CC1, Nc1ncnc2n(cnc12)[C@H]1O[C@H]([C@H](O)[C@@H]1O)C(=O)N1CCN(CC(=O)Nc2cccc3C(=O)NCc23)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1ncnc2n(cnc12)[C@H]1O[C@H]([C@H](O)[C@@H]1O)C(=O)N1CCN(CC(=O)Nc2cccc3C(=O)NCc23)CC1",537.208429584,39,-1.854,201.06,0.000208194855955476,0.14,0.0701040974279777,0,1
"gsk2983559 (free acid)","ripk inhibitor","RIPK2","CC(C)(C)S(C(C(OCCOP(O)(O)=O)=CC1=NC=N2)=CC1=C2NC3=CC(N=CS4)=C4C=C3)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","gastroenterology","inflammatory bowel disease","CC(C)(C)S(C(C(OCCOP(O)(O)=O)=CC1=NC=N2)=CC1=C2NC3=CC(N=CS4)=C4C=C3)(=O)=O",538.074577706,35,-0.761,202.73,0.000102054216253413,0.14,0.0700510271081267,0,1
"OPC-21268","vasopressin receptor antagonist","AVPR1A, AVPR2, OXTR","CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12, CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12, CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12, CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12, CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12",449.231456472,33,2.769,78.95,0.0220746203970884,0.118,0.0700373101985442,0,0
"danusertib","Aurora kinase inhibitor, growth factor receptor inhibitor","AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK","CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1",474.23793882,35,2.851,93.8,0.014033454833154,0.126,0.070016727416577,0,0
"CCG-1423","apoptosis stimulant","RHOC, SRF","C[C@@H](ONC(=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(=O)Nc1ccc(Cl)cc1 |&1:1,r|, C[C@@H](ONC(=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(=O)Nc1ccc(Cl)cc1 |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](ONC(=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(=O)Nc1ccc(Cl)cc1 |&1:1",454.051889276,30,5.32,67.43,0.024015677284613,0.116,0.0700078386423065,0,0
"lifirafenib","RAF inhibitor","","FC(F)(F)c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2Oc3ccc(Oc4ccnc5NC(=O)CCc45)cc3[C@@H]12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","FC(F)(F)c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2Oc3ccc(Oc4ccnc5NC(=O)CCc45)cc3[C@@H]12",478.125275064,35,3.335,89.13,0.016014278781151,0.124,0.0700071393905755,0,0
"enzastaurin","PKC inhibitor","AKT1, GSK3B, PRKCA, PRKCB, PRKCD, PRKCG","Cn1cc(C2=C(C(=O)NC2=O)c2cn(C3CCN(Cc4ccccn4)CC3)c3ccccc23)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2cn(C3CCN(Cc4ccccn4)CC3)c3ccccc23)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2cn(C3CCN(Cc4ccccn4)CC3)c3ccccc23)c2ccccc12 |t:4|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cn1cc(C2=C(C(=O)NC2=O)c2cn(C3CCN(Cc4ccccn4)CC3)c3ccccc23)c2ccccc12 |t:4|",515.232125168,39,4.733,72.16,0.0339860465981402,0.106,0.0699930232990701,0,0
"(r)-ketorolac","cyclooxygenase inhibitor","CDC42, RAC1","OC(=O)[C@@H]1CCn2c1ccc2C(=O)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","OC(=O)[C@@H]1CCn2c1ccc2C(=O)c1ccccc1",255.089543276,19,2.066,59.3,0.109861270822798,0.03,0.0699306354113989,0,0
"ansamitocin-p-3","apoptosis stimulant","","[H][C@@]12O[C@@]1(C)[C@H](CC(=O)N(C)c1cc(C\C(C)=C\C=C\[C@@H](OC)[C@@]3(O)C[C@]([H])(OC(=O)N3)[C@H]2C)cc(OC)c1Cl)OC(=O)C(C)C |t:17,19|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@@]12O[C@@]1(C)[C@H](CC(=O)N(C)c1cc(C\C(C)=C\C=C\[C@@H](OC)[C@@]3(O)C[C@]([H])(OC(=O)N3)[C@H]2C)cc(OC)c1Cl)OC(=O)C(C)C |t:17",634.265708636,46,3.775,136.16,0.00183485654680803,0.138,0.069917428273404,0,1
"olinciguat","guanylyl cyclase activator","GUCY1A1, GUCY1A2","FC1=C(C=CC=C1)CN2C(C3=NOC=C3)=CC(C4=NC=C(F)C(NC[C@](C(N)=O)(O)C(F)(F)F)=N4)=N2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","hematology","anemia","FC1=C(C=CC=C1)CN2C(C3=NOC=C3)=CC(C4=NC=C(F)C(NC[C@](C(N)=O)(O)C(F)(F)F)=N4)=N2",509.123478472,36,0.914,137.26,0.00176374382545274,0.138,0.0698818719127264,0,1
"zolantidine","histamine receptor antagonist","","C(CNc1nc2ccccc2s1)COc1cccc(CN2CCCCC2)c1, C(CNc1nc2ccccc2s1)COc1cccc(CN2CCCCC2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C(CNc1nc2ccccc2s1)COc1cccc(CN2CCCCC2)c1",381.187483484,27,4.277,65.63,0.0537583108212056,0.086,0.0698791554106028,0,0
"gavestinel","glutamate receptor antagonist","GLRB, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B","OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1, OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1, OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1, OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1",374.022497604,25,4.208,82.19,0.02769526853668,0.112,0.06984763426834,0,0
"RS-16566","serotonin receptor antagonist","","CC(C)n1cnc2c(cc(Cl)cc12)C(=O)N[C@H]1C[N@@]2CC[C@H]1CC2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)n1cnc2c(cc(Cl)cc12)C(=O)N[C@H]1C[N@@]2CC[C@H]1CC2",346.156039036,24,2.949,50.16,0.0636342537195248,0.076,0.0698171268597624,0,0
"decoglurant","glutamate receptor modulator","GRM2, GRM3","NC1=NC=C(C#CC2=C3N=C(C4=CC=C(C(F)(F)F)C=C4)C=C(C(F)(F)F)N3N=C2)C=C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"phase 2","neurology/psychiatry","depression","NC1=NC=C(C#CC2=C3N=C(C4=CC=C(C(F)(F)F)C=C4)C=C(C(F)(F)F)N3N=C2)C=C1",447.091864672,32,2.577,66.34,0.0235441370224947,0.116,0.0697720685112473,0,0
"AZD1480","JAK inhibitor","JAK1, JAK2, JAK3","C[C@H](Nc1ncc(Cl)c(Nc2cc(C)n[nH]2)n1)c1ncc(F)cn1, C[C@H](Nc1ncc(Cl)c(Nc2cc(C)n[nH]2)n1)c1ncc(F)cn1, C[C@H](Nc1ncc(Cl)c(Nc2cc(C)n[nH]2)n1)c1ncc(F)cn1, C[C@H](Nc1ncc(Cl)c(Nc2cc(C)n[nH]2)n1)c1ncc(F)cn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@H](Nc1ncc(Cl)c(Nc2cc(C)n[nH]2)n1)c1ncc(F)cn1",348.101398348,24,2.301,104.3,0.0155280802952885,0.124,0.0697640401476443,0,0
"NVP-TNKS656","tankyrase inhibitor","TNKS2","COc1ccc(cc1)C(=O)C1CCN(CC(=O)N(CC2CC2)Cc2nc(=O)c3COCCc3[nH]2)CC1, COc1ccc(cc1)C(=O)C1CCN(CC(=O)N(CC2CC2)Cc2nc(=O)c3COCCc3[nH]2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1)C(=O)C1CCN(CC(=O)N(CC2CC2)Cc2nc(=O)c3COCCc3[nH]2)CC1",494.252920188,36,2.332,104.83,0.00751493016564891,0.132,0.0697574650828245,0,1
"caffeic-acid-phenethyl-ester","HIV integrase inhibitor","RELA","Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O, Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O, Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O",284.104858992,21,3.447,66.76,0.103474230360914,0.036,0.069737115180457,0,0
"avacopan","complement inhibitor","","Cc1ccc(NC(=O)[C@H]2CCCN([C@H]2c2ccc(NC3CCCC3)cc2)C(=O)c2c(C)cccc2F)cc1C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1ccc(NC(=O)[C@H]2CCCN([C@H]2c2ccc(NC3CCCC3)cc2)C(=O)c2c(C)cccc2F)cc1C(F)(F)F",581.26654024,42,7.519,61.44,0.0354740328742942,0.104,0.0697370164371471,0,0
"betulinic-acid","apoptosis stimulant, NFkB pathway inhibitor","GPBAR1","CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O",456.360345396,33,9.407,57.53,0.137464484406707,0.002,0.0697322422033537,1,0
"PHCCC","glutamate receptor agonist","GRM1, GRM4","O\N=C1/[C@@H]2C[C@@]2(Oc2ccccc12)C(=O)Nc1ccccc1 |&1:3,5|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O\N=C1/[C@@H]2C[C@@]2(Oc2ccccc12)C(=O)Nc1ccccc1 |&1:3",294.100442308,22,2.223,70.92,0.0714612100651905,0.068,0.0697306050325952,0,0
"pradefovir","cytochrome P450 activator","","Nc1ncnc2n(CCOC[P@@]3(=O)OCC[C@H](O3)c3cccc(Cl)c3)cnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Nc1ncnc2n(CCOC[P@@]3(=O)OCC[C@H](O3)c3cccc(Cl)c3)cnc12",423.086318398,28,1.513,124.19,0.0034189531909569,0.136,0.0697094765954785,0,1
"tioxolone","carbonic anhydrase inhibitor","CA2","Oc1ccc2sc(=O)oc2c1, Oc1ccc2sc(=O)oc2c1, Oc1ccc2sc(=O)oc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc2sc(=O)oc2c1",167.988114988,11,1.348,78.68,0.0773779552305216,0.062,0.0696889776152608,0,0
"TC-S-7006","MAP kinase inhibitor","MAP3K8","Fc1ccc(Nc2c(cnc3cnc(NCc4cccnc4)cc23)C#N)cc1Cl, Fc1ccc(Nc2c(cnc3cnc(NCc4cccnc4)cc23)C#N)cc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1ccc(Nc2c(cnc3cnc(NCc4cccnc4)cc23)C#N)cc1Cl",404.095250348,29,3.423,86.52,0.0253666030784352,0.114,0.0696833015392176,0,0
"danirixin","CC chemokine receptor antagonist","CXCR2","Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(c1O)S(=O)(=O)[C@H]1CCCNC1, Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(c1O)S(=O)(=O)[C@H]1CCCNC1, Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(c1O)S(=O)(=O)[C@H]1CCCNC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(c1O)S(=O)(=O)[C@H]1CCCNC1",441.092533052,29,4.68,115.91,0.00734595664754902,0.132,0.0696729783237745,0,1
"PAC-1","caspase activator","CASP3","Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1",392.221226136,29,3.831,68.17,0.0552410262372349,0.084,0.0696205131186174,0,0
"ETC-206","MAPK-interacting kinase inhibitor","","O=C(N1CCOCC1)c1ccc(cc1)-c1ccc2ncc(-c3ccc(cc3)C#N)n2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","O=C(N1CCOCC1)c1ccc(cc1)-c1ccc2ncc(-c3ccc(cc3)C#N)n2c1",408.15862588,31,4.448,70.63,0.0650658518696642,0.074,0.0695329259348321,0,0
"SB-743921","kinesin-like spindle protein inhibitor","KIF11","CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1",516.217970596,37,7.484,76.54,0.0370268894968698,0.102,0.0695134447484349,0,0
"GSK1562590","urotensin receptor antagonist","UTS2R","CN([C@@H](CN1CCCC1)c1ccc(cc1)-c1cccc(c1)C(N)=O)C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc12, CN([C@@H](CN1CCCC1)c1ccc(cc1)-c1cccc(c1)C(N)=O)C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN([C@@H](CN1CCCC1)c1ccc(cc1)-c1cccc(c1)C(N)=O)C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc12",580.1644108,40,4.352,96.18,0.00487065419844821,0.134,0.0694353270992241,0,1
"CNX-2006","EGFR inhibitor","EGFR","COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F, COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F",545.216235984,39,3.949,103.44,0.00681602235633082,0.132,0.0694080111781654,0,1
"sparfosate","aspartate carbamoyltransferase inhibitor","CA2, CA4","OC(=O)C[C@@H](NC(=O)CP(O)(O)=O)C(O)=O |&1:4|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","OC(=O)C[C@@H](NC(=O)CP(O)(O)=O)C(O)=O |&1:4|",255.01440291,16,-5.486,171.04,0.000727811577007758,0.138,0.0693639057885039,0,1
"ZK-164015","estrogen receptor antagonist","ESR1, ESR2","CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1, CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1, CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1",513.291279856,36,9.178,87.91,0.0367249543653513,0.102,0.0693624771826756,0,0
"CA-4948","kinase inhibitor","","Nc1ccc(cn1)-c1cccc(n1)C(=O)Nc1cnc2nc(oc2c1)N1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Nc1ccc(cn1)-c1cccc(n1)C(=O)Nc1cnc2nc(oc2c1)N1CCOCC1",417.154937468,31,1.6,132.29,0.00663799810831009,0.132,0.069318999054155,0,1
"mirin","MRE11A exonuclease inhibitor","MRE11A","NC1=NC(=O)\C(S1)=C\c1ccc(O)cc1 |t:1|, NC1=NC(=O)\C(S1)=C\c1ccc(O)cc1 |t:1|, NC1=NC(=O)\C(S1)=C\c1ccc(O)cc1 |t:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC1=NC(=O)\C(S1)=C\c1ccc(O)cc1 |t:1|",220.030648496,15,1.309,100.98,0.034635186574902,0.104,0.069317593287451,0,0
"reparixin","CC chemokine receptor antagonist","CXCR1, CXCR2","CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O",283.124214532,19,3.025,71.62,0.0566345465052264,0.082,0.0693172732526132,0,0
"trap-101","nociceptin/orphanin FQ receptor antagonist, opioid receptor antagonist","OPRL1","CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O |c:11|, CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O |c:11|, CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O |c:11|, CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O |c:11|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O |c:11|",397.27292736,29,3.711,50.4,0.0706014715853319,0.068,0.0693007357926659,0,0
"ICI-162846","histamine receptor antagonist","HRH2","NC(=O)CCCCn1ccc(NC(=N)NCC(F)(F)F)n1, NC(=O)CCCCn1ccc(NC(=N)NCC(F)(F)F)n1",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","NC(=O)CCCCn1ccc(NC(=N)NCC(F)(F)F)n1",306.141593824,21,1.699,108.82,0.016463899188561,0.122,0.0692319495942805,0,0
"brivanib","FGFR inhibitor, VEGFR inhibitor","CYP3A4, FGFR1, FLT1, KCNH2, KDR","C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C, C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C, C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C, C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C, C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C",370.144118688,27,3.99,84.67,0.0424618756840968,0.096,0.0692309378420484,0,0
"GW-542573X","calcium channel activator","KCNN1","COc1ccccc1NC(=O)OCC1CCN(CC1)C(=O)OC(C)(C)C, COc1ccccc1NC(=O)OCC1CCN(CC1)C(=O)OC(C)(C)C, COc1ccccc1NC(=O)OCC1CCN(CC1)C(=O)OC(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccccc1NC(=O)OCC1CCN(CC1)C(=O)OC(C)(C)C",364.199821996,26,3.213,77.1,0.0384501348436474,0.1,0.0692250674218237,0,0
"CDK1-5-inhibitor","CDK inhibitor, glycogen synthase kinase inhibitor","CDK1, CDK5, GSK3B","Nc1[nH]nc2nc3ccccc3nc12, Nc1[nH]nc2nc3ccccc3nc12, Nc1[nH]nc2nc3ccccc3nc12, Nc1[nH]nc2nc3ccccc3nc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1[nH]nc2nc3ccccc3nc12",185.070145224,14,1.253,80.48,0.0944343781525933,0.044,0.0692171890762967,0,0
"BML-190","cannabinoid receptor inverse agonist","CNR2","COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1",426.134634896,30,2.95,60.77,0.0303476208092019,0.108,0.069173810404601,0,0
"zaldaride","calmodulin antagonist","CALM1","C[C@@]1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12 |&1:1|, C[C@@]1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12 |&1:1|, C[C@@]1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12 |&1:1|, C[C@@]1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12 |&1:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C[C@@]1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12 |&1:1|",428.221226136,32,4.09,55.19,0.0663468686329723,0.072,0.0691734343164862,0,0
"LY3000328","cathepsin inhibitor","CTSS","CNC(=O)O[C@H]1COc2ccc(cc2[C@@H]1NC(=O)c1ccc(F)cc1)N1CCN(CC1)C1COC1, CNC(=O)O[C@H]1COc2ccc(cc2[C@@H]1NC(=O)c1ccc(F)cc1)N1CCN(CC1)C1COC1, CNC(=O)O[C@H]1COc2ccc(cc2[C@@H]1NC(=O)c1ccc(F)cc1)N1CCN(CC1)C1COC1, CNC(=O)O[C@H]1COc2ccc(cc2[C@@H]1NC(=O)c1ccc(F)cc1)N1CCN(CC1)C1COC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CNC(=O)O[C@H]1COc2ccc(cc2[C@@H]1NC(=O)c1ccc(F)cc1)N1CCN(CC1)C1COC1",484.212198248,35,2.423,92.37,0.0103280960118839,0.128,0.0691640480059419,0,0
"pirinixic-acid","PPAR receptor agonist","PPARA","Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C, Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C, Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C, Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C, Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C",323.049525368,21,2.991,100.41,0.0183006878902716,0.12,0.0691503439451358,0,0
"exisulind","phosphodiesterase inhibitor","PDE5A","CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)S(C)(=O)=O |c:1|, CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)S(C)(=O)=O |c:1|, CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)S(C)(=O)=O |c:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)S(C)(=O)=O |c:1|",372.083158244,26,4.431,79.82,0.0402351912065613,0.098,0.0691175956032807,0,0
"fosfluconazole","other antifungal","","OP(O)(=O)OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OP(O)(=O)OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F",386.070395966,26,-0.845999999999999,137.99,0.00213013406176658,0.136,0.0690650670308833,0,1
"iothalamic-acid-d3","radiopaque medium","","CNC(=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CNC(=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I",613.769650768,20,3.5,95.5,1.79973962851094e-05,0.138,0.0690089986981426,0,1
"TAK-875","insulin secretagogue","FFAR1","Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1, Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1, Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1, Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1, Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1, Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1",524.186874364,37,5.72,107.51,0.00995552186029704,0.128,0.0689777609301485,0,0
"AD-5467","aldose reductase inhibitor","AKR1B1","CC(C)[C@H]1Oc2c(cccc2N(CC(O)=O)C1=S)C(C)C |&1:3,r|, CC(C)[C@H]1Oc2c(cccc2N(CC(O)=O)C1=S)C(C)C |&1:3,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)[C@H]1Oc2c(cccc2N(CC(O)=O)C1=S)C(C)C |&1:3",307.124214532,21,1.44,81.86,0.0278683084782589,0.11,0.0689341542391294,0,0
"PF-04885614","voltage-gated sodium channel blocker","SCN10A","CC(C)(N)c1nc(c[nH]1)-c1ccc(OC(F)(F)F)cc1, CC(C)(N)c1nc(c[nH]1)-c1ccc(OC(F)(F)F)cc1",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(N)c1nc(c[nH]1)-c1ccc(OC(F)(F)F)cc1",285.108896728,20,3.161,63.93,0.0817949145666694,0.056,0.0688974572833347,0,0
"PF-06747775","EGFR inhibitor","","COc1nn(C)cc1Nc1nc(nc2n(C)cnc12)N1C[C@@H](F)[C@@H](C1)NC(=O)C=C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1nn(C)cc1Nc1nc(nc2n(C)cnc12)N1C[C@@H](F)[C@@H](C1)NC(=O)C=C",415.188049164,30,2.314,115.02,0.00979365638419122,0.128,0.0688968281920956,0,0
"A-939572","stearoyl-CoA desaturase inhibitor","SCD","CNC(=O)c1cccc(NC(=O)N2CCC(CC2)Oc2ccccc2Cl)c1, CNC(=O)c1cccc(NC(=O)N2CCC(CC2)Oc2ccccc2Cl)c1, CNC(=O)c1cccc(NC(=O)N2CCC(CC2)Oc2ccccc2Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CNC(=O)c1cccc(NC(=O)N2CCC(CC2)Oc2ccccc2Cl)c1",387.134969244,27,3.355,70.67,0.0337897772540707,0.104,0.0688948886270354,0,0
"A-867744","acetylcholine receptor allosteric modulator","CHRNA3, CHRNA4, CHRNA7","CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O, CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O, CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O, CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O, CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,"preclinical","","","CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O",402.080491148,27,4.007,90.54,0.0177881120291279,0.12,0.068894056014564,0,0
"BMY-14802","sigma receptor antagonist","HTR1A","O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|, O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|, O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|, O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|, O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|, O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|",348.176167764,25,2.571,52.49,0.0657763416486809,0.072,0.0688881708243404,0,0
"JX-401","p38 MAPK inhibitor","MAPK14","COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1, COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1, COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1",355.16060004,25,5.043,54.84,0.0937631888641062,0.044,0.0688815944320531,0,0
"PSNCBAM-1","cannabinoid receptor modulator","CNR1","Clc1ccc(NC(=O)Nc2cccc(c2)-c2cccc(n2)N2CCCC2)cc1, Clc1ccc(NC(=O)Nc2cccc(c2)-c2cccc(n2)N2CCCC2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1ccc(NC(=O)Nc2cccc(c2)-c2cccc(n2)N2CCCC2)cc1",392.140388972,28,5.444,57.26,0.081726005935367,0.056,0.0688630029676835,0,0
"4BP-TQS","nicotinic receptor agonist","CHRNA7","NS(=O)(=O)c1ccc2N[C@@H]([C@H]3CC=C[C@@H]3c2c1)c1ccc(Br)cc1 |&1:9,&2:10,&3:14,r,c:12|, NS(=O)(=O)c1ccc2N[C@@H]([C@H]3CC=C[C@@H]3c2c1)c1ccc(Br)cc1 |&1:9,&2:10,&3:14,r,c:12|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"preclinical","","","NS(=O)(=O)c1ccc2N[C@@H]([C@H]3CC=C[C@@H]3c2c1)c1ccc(Br)cc1 |&1:9",404.019410884,24,3.566,80.57,0.00969872131201108,0.128,0.0688493606560055,0,0
"CT7001","CDK inhibitor","","CC(C)c1cnn2c(NCc3ccccc3)cc(NC[C@H]3CCNC[C@@H]3O)nc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","CC(C)c1cnn2c(NCc3ccccc3)cc(NC[C@H]3CCNC[C@@H]3O)nc12",394.24810958,29,3.897,86.51,0.0356855222457478,0.102,0.0688427611228739,0,0
"taminadenant","adenosine receptor antagonist","","Nc1nc(nc(c1Br)-n1cccn1)-n1cccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","Nc1nc(nc(c1Br)-n1cccn1)-n1cccn1",305.002455356,18,2.176,87.44,0.015651495168893,0.122,0.0688257475844465,0,0
"PF-4191834","lipoxygenase inhibitor","","Cn1nccc1-c1ccc(Sc2cccc(c2)C2(CCOCC2)C(N)=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cn1nccc1-c1ccc(Sc2cccc(c2)C2(CCOCC2)C(N)=O)cc1",393.151097976,28,3.838,95.44,0.0236055762239707,0.114,0.0688027881119853,0,0
"zopolrestat","","AKR1B1, AKR1B10","OC(=O)Cc1nn(Cc2nc3cc(ccc3s2)C(F)(F)F)c(=O)c2ccccc12, OC(=O)Cc1nn(Cc2nc3cc(ccc3s2)C(F)(F)F)c(=O)c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)Cc1nn(Cc2nc3cc(ccc3s2)C(F)(F)F)c(=O)c2ccccc12",419.055146904,29,3.382,113.32,0.00958729413938398,0.128,0.068793647069692,0,0
"AZD7986","dipeptidyl peptidase inhibitor","","Cn1c2cc(ccc2oc1=O)-c1ccc(C[C@H](NC(=O)[C@@H]2CNCCCO2)C#N)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cn1c2cc(ccc2oc1=O)-c1ccc(C[C@H](NC(=O)[C@@H]2CNCCCO2)C#N)cc1",420.179755248,31,2.001,109.29,0.0115548162586053,0.126,0.0687774081293027,0,0
"EMD534085","kinesin inhibitor","","[H][C@@]12CC[C@H](CNC(=O)NCCN(C)C)O[C@]1([H])c1cc(ccc1N[C@H]2c1ccccc1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@@]12CC[C@H](CNC(=O)NCCN(C)C)O[C@]1([H])c1cc(ccc1N[C@H]2c1ccccc1)C(F)(F)F",476.239910892,36,3.775,65.63,0.0395486719409713,0.098,0.0687743359704857,0,0
"orteronel","androgen biosynthesis inhibitor, androgen receptor antagonist, cytochrome P450 inhibitor","CYP17A1","CNC(=O)c1ccc2cc(ccc2c1)[C@]1(O)CCn2cncc12, CNC(=O)c1ccc2cc(ccc2c1)[C@]1(O)CCn2cncc12, CNC(=O)c1ccc2cc(ccc2c1)[C@]1(O)CCn2cncc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CNC(=O)c1ccc2cc(ccc2c1)[C@]1(O)CCn2cncc12",307.132076784,23,1.95,67.15,0.0675358589699104,0.07,0.0687679294849552,0,0
"AEE788","EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR","CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1",440.268845024,33,4.99,60.08,0.0694989829424936,0.068,0.0687494914712468,0,0
"WYE-687","mTOR inhibitor","MTOR","COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(Cc4cccnc4)CC3)c2n1, COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(Cc4cccnc4)CC3)c2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(Cc4cccnc4)CC3)c2n1",528.259736884,39,3.353,110.53,0.00748917559998535,0.13,0.0687445877999927,0,1
"fezolinetant","neurokinin receptor antagonist","","C[C@H]1N(CCn2c1nnc2-c1nc(C)ns1)C(=O)c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@H]1N(CCn2c1nnc2-c1nc(C)ns1)C(=O)c1ccc(F)cc1",358.10120832,25,4.122,105.04,0.023463761603011,0.114,0.0687318808015055,0,0
"CJ-033466","serotonin receptor agonist","HTR4","CC(C)CN1CCC(CNC(=O)c2cc(Cl)c(N)n3cc(C)nc23)CC1, CC(C)CN1CCC(CNC(=O)c2cc(Cl)c(N)n3cc(C)nc23)CC1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)CN1CCC(CNC(=O)c2cc(Cl)c(N)n3cc(C)nc23)CC1",377.198238196,26,4.23,75.66,0.0374307021532789,0.1,0.0687153510766395,0,0
"copper-histidine","","SLC15A3, SLC15A4, SLC38A5","N[C@H](Cc1cnc[nH]1)C(O)=O, N[C@H](Cc1cnc[nH]1)C(O)=O",1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","N[C@H](Cc1cnc[nH]1)C(O)=O",155.069476528,11,-3.429,92,0.0253259396348296,0.112,0.0686629698174148,0,0
"losmapimod","p38 MAPK inhibitor","MAPK14","Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1",383.200905292,28,4.012,71.09,0.0532880146369803,0.084,0.0686440073184901,0,0
"TAK-632","RAF inhibitor","BRAF","Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F, Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F, Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F, Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F",554.103574316,39,4.464,132.35,0.00321078837587263,0.134,0.0686053941879363,0,1
"foropafant","platelet activating factor receptor antagonist","PTAFR","CC(C)c1cc(C(C)C)c(-c2csc(n2)N(CCN(C)C)Cc2cccnc2)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(-c2csc(n2)N(CCN(C)C)Cc2cccnc2)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(-c2csc(n2)N(CCN(C)C)Cc2cccnc2)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(-c2csc(n2)N(CCN(C)C)Cc2cccnc2)c(c1)C(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(C)c1cc(C(C)C)c(-c2csc(n2)N(CCN(C)C)Cc2cccnc2)c(c1)C(C)C",464.29736828,33,7.593,60.5,0.073092228953012,0.064,0.068546114476506,0,0
"PF-06873600","CDK inhibitor","","C[C@@]1(O)CCC[C@H]1n1c2nc(NC3CCN(CC3)S(C)(=O)=O)ncc2cc(C(F)F)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@@]1(O)CCC[C@H]1n1c2nc(NC3CCN(CC3)S(C)(=O)=O)ncc2cc(C(F)F)c1=O",471.175181784,32,2.176,125.8,0.00308621782226322,0.134,0.0685431089111316,0,1
"ARQ-092","AKT inhibitor","AKT2","Nc1ncccc1-c1nc2ccc(nc2n1-c1ccc(cc1)C1(N)CCC1)-c1ccccc1, Nc1ncccc1-c1nc2ccc(nc2n1-c1ccc(cc1)C1(N)CCC1)-c1ccccc1, Nc1ncccc1-c1nc2ccc(nc2n1-c1ccc(cc1)C1(N)CCC1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Nc1ncccc1-c1nc2ccc(nc2n1-c1ccc(cc1)C1(N)CCC1)-c1ccccc1",432.206244768,33,5.08,95.64,0.0390176585916248,0.098,0.0685088292958124,0,0
"PHA-793887","CDK inhibitor","CDK1, CDK2, CDK4, CDK5, CDK7, CDK9","CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C",361.247775232,26,2.13,81.33,0.0289632932465848,0.108,0.0684816466232924,0,0
"remogliflozin etabonate","sodium/glucose cotransporter inhibitor","SLC5A2","CCOC(=O)OC[C@H]1O[C@@H](Oc2nn(C(C)C)c(C)c2Cc3ccc(OC(C)C)cc3)[C@H](O)[C@@H](O)[C@@H]1O",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","endocrinology","diabetes mellitus","CCOC(=O)OC[C@H]1O[C@@H](Oc2nn(C(C)C)c(C)c2Cc3ccc(OC(C)C)cc3)[C@H](O)[C@@H](O)[C@@H]1O",522.257730796,37,3.742,141.73,0.00292351454267858,0.134,0.0684617572713393,0,1
"CZC-54252","leucine rich repeat kinase inhibitor","LRRK2","COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCOCC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCOCC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCOCC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCOCC1",504.13465196,34,3.315,126.09,0.00292301630447514,0.134,0.0684615081522376,0,1
"PCI-34051","HDAC inhibitor","HDAC1, HDAC10, HDAC6, HDAC8","COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1, COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1, COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1, COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1, COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1",296.116092372,22,3.071,63.49,0.0968802465007286,0.04,0.0684401232503643,0,0
"Ro-4987655","MEK inhibitor","MAP2K1","OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F, OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F, OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F",565.032153368,32,3.494,100.13,0.000821605572581335,0.136,0.0684108027862907,0,1
"lisofylline","interleukin receptor antagonist, STAT inhibitor","","C[C@@H](O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O |&1:1,r|, C[C@@H](O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@@H](O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O |&1:1",280.1535405,20,2.312,82.05,0.0507834704237147,0.086,0.0683917352118573,0,0
"AZD2014","mTOR inhibitor","MTOR","CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C",462.23793882,34,3.711,92.71,0.0187163513187266,0.118,0.0683581756593633,0,0
"SCH-900776","CHK inhibitor","CDK2, CHEK1","Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1",375.080705676,23,1.734,86.06,0.00865254094335531,0.128,0.0683262704716776,0,0
"UNC1999","histone lysine methyltransferase inhibitor","EZH2","CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C",569.347823616,42,7.23,99.15,0.0186518500821941,0.118,0.0683259250410971,0,0
"isofloxythepin","dopamine receptor antagonist","","CC(C)c1ccc2Sc3cc(F)ccc3C[C@@H](N3CCN(CCO)CC3)c2c1 |&1:16,r|, CC(C)c1ccc2Sc3cc(F)ccc3C[C@@H](N3CCN(CCO)CC3)c2c1 |&1:16,r|, CC(C)c1ccc2Sc3cc(F)ccc3C[C@@H](N3CCN(CCO)CC3)c2c1 |&1:16,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)c1ccc2Sc3cc(F)ccc3C[C@@H](N3CCN(CCO)CC3)c2c1 |&1:16",400.198462768,28,4.417,52.01,0.0605391346046499,0.076,0.068269567302325,0,0
"ombrabulin","tubulin polymerization inhibitor","","COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO",402.179086552,29,2.021,112.27,0.0105221129286268,0.126,0.0682610564643134,0,0
"GABA-linoleamide","benzodiazepine receptor agonist","","CCCCC\C=C/C\C=C/CCCCCCCC(=O)NCCCC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCCC\C=C/C\C=C/CCCCCCCC(=O)NCCCC(O)=O",365.292994108,26,7.553,66.4,0.126460980567438,0.01,0.0682304902837189,1,0
"leniolisib","PI3K inhibitor","","CCC(=O)N1CC[C@@H](C1)Nc1ncnc2CCN(Cc12)c1cnc(OC)c(c1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","CCC(=O)N1CC[C@@H](C1)Nc1ncnc2CCN(Cc12)c1cnc(OC)c(c1)C(F)(F)F",450.1991087,32,2.473,83.48,0.0144541239888169,0.122,0.0682270619944085,0,0
"BAY-1895344","ATR kinase inhibitor","","C[C@@H]1COCCN1c1cc(-c2ccnn2C)c2ccnc(-c3ccn[nH]3)c2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@@H]1COCCN1c1cc(-c2ccnn2C)c2ccnc(-c3ccn[nH]3)c2n1",375.180758292,28,3.33,84.75,0.0403297124071085,0.096,0.0681648562035543,0,0
"zd-4190","antitumor agent","EGFR, KDR","COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCn1ccnn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","gastric adenocarcinoma","COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCn1ccnn1",458.050214072,29,2.984,86.98,0.00632402481982686,0.13,0.0681620124099134,0,1
"atizoram","phosphodiesterase inhibitor","PDE4A, PDE4B, PDE4C, PDE4D","COc1ccc(cc1O[C@H]1C[C@@H]2CC[C@H]1C2)C1CNC(=O)NC1, COc1ccc(cc1O[C@H]1C[C@@H]2CC[C@H]1C2)C1CNC(=O)NC1, COc1ccc(cc1O[C@H]1C[C@@H]2CC[C@H]1C2)C1CNC(=O)NC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1ccc(cc1O[C@H]1C[C@@H]2CC[C@H]1C2)C1CNC(=O)NC1",316.178692628,23,2.164,59.59,0.0682607263462268,0.068,0.0681303631731134,0,0
"RWJ-21757","toll-like receptor agonist","TLR7","Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1",339.117883264,24,-0.421,168.62,0.00225236215417275,0.134,0.0681261810770864,0,1
"nuvenzepine","acetylcholine receptor antagonist","","CN1CCC(CC1)C(=O)N1c2ccccc2NC(=O)c2cccnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCC(CC1)C(=O)N1c2ccccc2NC(=O)c2cccnc12",336.15862588,25,1.468,65.54,0.0502480559513669,0.086,0.0681240279756834,0,0
"linaprazan","ATP-sensitive potassium channel inhibitor","","Cc1nc2c(NCc3c(C)cccc3C)cc(cn2c1C)C(=O)NCCO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1nc2c(NCc3c(C)cccc3C)cc(cn2c1C)C(=O)NCCO",366.205576072,27,3.4,78.66,0.0462213022545149,0.09,0.0681106511272574,0,0
"cis-ACPD","glutamate receptor agonist","GRM2, GRM3, GRM6, GRM7, GRM8","[H][C@]1(CC[C@@](N)(C1)C(O)=O)C(O)=O |&1:1,4,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@]1(CC[C@@](N)(C1)C(O)=O)C(O)=O |&1:1",173.068807832,13,-3.286,100.62,0.022215230537607,0.114,0.0681076152688035,0,0
"cephalosporin-c-zn","bacterial cell wall synthesis inhibitor","","CC(=O)OCC1=C2N3[C@H](SC1)[C@H](NC(=O)CCC[C@H](N)C(=O)O[Zn]OC2=O)C3=O |t:5|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)OCC1=C2N3[C@H](SC1)[C@H](NC(=O)CCC[C@H](N)C(=O)O[Zn]OC2=O)C3=O |t:5|",477.018427768,29,-0.404,179.63,0.000205552912284189,0.136,0.0681027764561421,0,1
"ceftazidime pentahydrate","","","CC(C)(O\N=C(\C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CC(C)(O\N=C(\C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O",547.106415496091,37,1.461,241.93,9.06273824652343e-05,0.136,0.0680453136912326,0,1
"CYT-997","tubulin polymerization inhibitor","TUBB","CCC[C@H](Nc1nc(ncc1C)-c1ccc(NC(=O)NCC)c(OC)c1)c1cccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCC[C@H](Nc1nc(ncc1C)-c1ccc(NC(=O)NCC)c(OC)c1)c1cccnc1",434.2430242,32,3.501,101.06,0.0180555547634571,0.118,0.0680277773817285,0,0
"RN-1","histone demethylase inhibitor","KDM1A","CN1CCN(CC1)C(=O)CN[C@@H]1C[C@H]1c1ccc(OCc2ccccc2)cc1, CN1CCN(CC1)C(=O)CN[C@@H]1C[C@H]1c1ccc(OCc2ccccc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCN(CC1)C(=O)CN[C@@H]1C[C@H]1c1ccc(OCc2ccccc2)cc1",379.225977168,28,2.329,44.81,0.0700546391696425,0.066,0.0680273195848213,0,0
"MIRA-1","apoptosis stimulant","","CCC(=O)OCN1C(=O)C=CC1=O |c:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCC(=O)OCN1C(=O)C=CC1=O |c:9|",183.053157768,13,-0.113,63.68,0.0840545210183564,0.052,0.0680272605091782,0,0
"LY334370","serotonin receptor agonist","","CN1CCC(CC1)c1c[nH]c2ccc(NC(=O)c3ccc(F)cc3)cc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCC(CC1)c1c[nH]c2ccc(NC(=O)c3ccc(F)cc3)cc12",351.174690544,26,3.547,48.13,0.103938768721087,0.032,0.0679693843605434,0,0
"purvalanol-A","CDK inhibitor","CDK1, CDK2, CDK4, CDK5, CSNK1G3, RPS6KA1, SRC","CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1",388.1778371,27,4.281,87.89,0.0279168175169154,0.108,0.0679584087584577,0,0
"tirapazamine","DNA inhibitor","","Nc1n[n+]([O-])c2ccccc2[n+]1[O-], Nc1n[n+]([O-])c2ccccc2[n+]1[O-], Nc1n[n+]([O-])c2ccccc2[n+]1[O-], Nc1n[n+]([O-])c2ccccc2[n+]1[O-], Nc1n[n+]([O-])c2ccccc2[n+]1[O-], Nc1n[n+]([O-])c2ccccc2[n+]1[O-]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Nc1n[n+]([O-])c2ccccc2[n+]1[O-]",178.049075432,13,1.813,92.79,0.0778996785309504,0.058,0.0679498392654752,0,0
"cyclamic-acid","","","OS(=O)(=O)NC1CCCCC1, OS(=O)(=O)NC1CCCCC1, OS(=O)(=O)NC1CCCCC1, OS(=O)(=O)NC1CCCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OS(=O)(=O)NC1CCCCC1",179.061614276,11,0.319,74.78,0.0518923187160881,0.084,0.067946159358044,0,0
"PHA-680632","Aurora kinase inhibitor","AURKA, AURKB, AURKC","CCc1cccc(CC)c1NC(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1, CCc1cccc(CC)c1NC(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1, CCc1cccc(CC)c1NC(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1, CCc1cccc(CC)c1NC(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCc1cccc(CC)c1NC(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1",501.28522336,37,4.38,96.6,0.0158621639188825,0.12,0.0679310819594412,0,0
"higenamine","adrenergic receptor agonist","ADRB2","Oc1ccc(C[C@H]2NCCc3cc(O)c(O)cc23)cc1 |&1:6|, Oc1ccc(C[C@H]2NCCc3cc(O)c(O)cc23)cc1 |&1:6|, Oc1ccc(C[C@H]2NCCc3cc(O)c(O)cc23)cc1 |&1:6|, Oc1ccc(C[C@H]2NCCc3cc(O)c(O)cc23)cc1 |&1:6|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"phase 1","","","Oc1ccc(C[C@H]2NCCc3cc(O)c(O)cc23)cc1 |&1:6|",271.120843404,20,2.294,72.72,0.0758433798825619,0.06,0.0679216899412809,0,0
"BIA-10-2474","Fatty acid hydrolase inhibitor","","CN(C1CCCCC1)C(=O)n1cnc(c1)-c1ccc[n+]([O-])c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C1CCCCC1)C(=O)n1cnc(c1)-c1ccc[n+]([O-])c1",300.15862588,22,2.52,65.07,0.075799869547627,0.06,0.0678999347738135,0,0
"sal003","eukaryotic translation initiation factor inhibitor","EIF2A","Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|, Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|, Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|, Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|, Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9",460.96899382,27,5.812,85.25,0.0077376607352931,0.128,0.0678688303676466,0,0
"PD-407824","PKC inhibitor","WEE1","Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1",328.084792244,25,4.035,82.19,0.0756853358071067,0.06,0.0678426679035533,0,0
"gusacitinib","jak inhibitor","CLDN23, IL13, IL36G, JAK1, SYK","OC1CCN(CC1)c2ccc(Nc3nc(nc4C=NNC(=O)c34)N5CCC(CC#N)CC5)cc2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","dermatology","dermatitis","OC1CCN(CC1)c2ccc(Nc3nc(nc4C=NNC(=O)c34)N5CCC(CC#N)CC5)cc2",460.233522136,34,3.317,129.77,0.0076349750138378,0.128,0.0678174875069189,0,0
"AP26113","ALK tyrosine kinase receptor inhibitor","ALK, EGFR","COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C",528.216938638,36,5.469,92.43,0.00958049580190994,0.126,0.067790247900955,0,0
"5-carboxamidotryptamine","serotonin receptor agonist","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7","NCCc1c[nH]c2ccc(cc12)C(N)=O, NCCc1c[nH]c2ccc(cc12)C(N)=O",0,0,0,0,0,0,0,0,1,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NCCc1c[nH]c2ccc(cc12)C(N)=O",203.105862036,15,0.297,84.9,0.057408916468475,0.078,0.0677044582342375,0,0
"ABT-491","platelet activating factor receptor antagonist","PTAFR","CN(C)C(=O)n1cc(C(=O)c2ccc(Cn3c(C)nc4cnccc34)c(F)c2)c2c(cccc12)C#C, CN(C)C(=O)n1cc(C(=O)c2ccc(Cn3c(C)nc4cnccc34)c(F)c2)c2c(cccc12)C#C, CN(C)C(=O)n1cc(C(=O)c2ccc(Cn3c(C)nc4cnccc34)c(F)c2)c2c(cccc12)C#C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN(C)C(=O)n1cc(C(=O)c2ccc(Cn3c(C)nc4cnccc34)c(F)c2)c2c(cccc12)C#C",479.175753164,36,3.752,73.02,0.0311579550188589,0.104,0.0675789775094294,0,0
"5-amino-3-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione","","TLR7","Nc1nc(=O)c2sc(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1nc(=O)c2sc(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1",316.047755104,21,-0.415,191.93,0.00114390283219894,0.134,0.0675719514160995,0,1
"BGP-15","PARP inhibitor","","O[C@H](CONC(=N)c1cccnc1)CN1CCCCC1 |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O[C@H](CONC(=N)c1cccnc1)CN1CCCCC1 |&1:1",278.174275944,20,1.151,81.47,0.041008602806558,0.094,0.067504301403279,0,0
"ferroquine","antimalarial agent","","CN(C)CC1=CC=C[C@@]1(CNc1ccnc2cc(Cl)ccc12)[Fe]C1C=CC=C1 |&1:8,r,c:6,27,29,t:4|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN(C)CC1=CC=C[C@@]1(CNc1ccnc2cc(Cl)ccc12)[Fe]C1C=CC=C1 |&1:8",433.100812948,28,3.256,28.16,0.0369475798658591,0.098,0.0674737899329296,0,0
"PHT-427","AKT inhibitor, pyruvate dehydrogenase inhibitor","AKT2, PDPK1","CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1, CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1, CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1, CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1, CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1",409.185769232,27,8.965,108.57,0.0328339462381901,0.102,0.067416973119095,0,0
"bis(maltolato)oxovanadium(IV)","tyrosine phosphatase inhibitor","PTPN1","Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O, Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O, Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O, Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O",316.98661216,20,2.041,95.95,0.0148108552387086,0.12,0.0674054276193543,0,0
"GDC-0152","XIAP inhibitor","BIRC2, BIRC3, BIRC7, XIAP","CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1",498.241309948,35,3.376,144.56,0.00280348914855699,0.132,0.0674017445742785,0,1
"bitoscanate","anthelmintic agent","","S=C=Nc1ccc(cc1)N=C=S, S=C=Nc1ccc(cc1)N=C=S",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","S=C=Nc1ccc(cc1)N=C=S",191.981590128,12,4.896,88.9,0.100803163379804,0.034,0.0674015816899018,0,0
"prasterone-acetate","","","CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:23|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:23|",330.21949482,24,3.775,43.37,0.124796680040101,0.01,0.0673983400200503,1,0
"idasanutlin","MDM inhibitor","MDM2, TP53","COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O",615.150318208,42,7.218,111.45,0.00474351740893208,0.13,0.067371758704466,0,1
"tyrphostin-AG-835","protein tyrosine kinase inhibitor","EGFR","C[C@H](NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H](NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N)c1ccccc1",308.116092372,23,2.925,93.35,0.0466674558155192,0.088,0.0673337279077596,0,0
"indoximod","indoleamine 2,3-dioxygenase inhibitor","IDO1","Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12, Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12, Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12, Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12",218.105527688,16,-0.967,68.25,0.0546446825540374,0.08,0.0673223412770187,0,0
"NNC-63-0532","opioid receptor agonist","OPRL1","COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O, COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O, COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O, COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O, COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O, COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O",443.220891788,33,4.42,53.09,0.066435862611277,0.068,0.0672179313056385,0,0
"GLPG0492","androgen receptor modulator","AR","CN1C(=O)N(C(=O)[C@@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F, CN1C(=O)N(C(=O)[C@@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F, CN1C(=O)N(C(=O)[C@@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN1C(=O)N(C(=O)[C@@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F",389.098725968,28,2.566,84.64,0.0244314566563927,0.11,0.0672157283281964,0,0
"GLPG0492-R-enantiomer","androgen receptor modulator","AR","CN1C(=O)N(C(=O)[C@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F, CN1C(=O)N(C(=O)[C@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F, CN1C(=O)N(C(=O)[C@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN1C(=O)N(C(=O)[C@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F",389.098725968,28,2.566,84.64,0.0244314566563927,0.11,0.0672157283281964,0,0
"KH-CB19","CDC inhibitor","CLK1, CLK3, DYRK1A","CCOC(=O)c1c(C(C=N)C#N)c2ccc(Cl)c(Cl)c2n1C, CCOC(=O)c1c(C(C=N)C#N)c2ccc(Cl)c(Cl)c2n1C, CCOC(=O)c1c(C(C=N)C#N)c2ccc(Cl)c(Cl)c2n1C, CCOC(=O)c1c(C(C=N)C#N)c2ccc(Cl)c(Cl)c2n1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)c1c(C(C=N)C#N)c2ccc(Cl)c(Cl)c2n1C",337.038482016,22,3.747,78.87,0.0322465810070785,0.102,0.0671232905035392,0,0
"telratolimod","toll-like receptor agonist","","CCCCCCCCCCCCCCCCCC(=O)NCCCCOn1c(CCCC)nc2c(N)nc3ccccc3c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCCCCCCCCCCCC(=O)NCCCCOn1c(CCCC)nc2c(N)nc3ccccc3c12",593.466876128,43,11.48,95.06,0.0402391784526326,0.094,0.0671195892263163,0,0
"GSK1292263","glucose dependent insulinotropic receptor agonist","GRPR","CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1, CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1",456.183126376,32,4.567,106.8,0.0122217304697085,0.122,0.0671108652348543,0,0
"XMD17-109","MAP kinase inhibitor","MAPK7","CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1",638.369287332,47,4.566,97.38,0.00622121184103664,0.128,0.0671106059205183,0,0
"BW-348U87","antiviral","","C\C(=N/NC(=S)NNC(=S)Nc1ccccc1Cl)c1ccccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C\C(=N/NC(=S)NNC(=S)Nc1ccccc1Cl)c1ccccn1",378.04881416,24,4.509,137.55,0.00609185229620192,0.128,0.067045926148101,0,0
"N-(2-chlorophenyl)-2-({(2E)-2-[1-(2-pyridinyl)ethylidene]hydrazino}carbothioyl)hydrazinecarbothioamide","","","CC(=NNC(=S)NNC(=S)Nc1ccccc1Cl)c1ccccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=NNC(=S)NNC(=S)Nc1ccccc1Cl)c1ccccn1",378.04881416,24,4.509,137.55,0.00609185229620192,0.128,0.067045926148101,0,0
"dm4","tubulin inhibitor","CD19, MSLN, SDC1, TUBB","CO[C@@H]1\C=C\C=C(/C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)S)[C@]3(C)O[C@H]3[C@H](C)[C@@H]4C[C@@]1(O)NC(=O)O4",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","hematologic malignancy","multiple myeloma","CO[C@@H]1\C=C\C=C(/C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)S)[C@]3(C)O[C@H]3[C@H](C)[C@@H]4C[C@@]1(O)NC(=O)O4",779.321843608,53,4.621,195.27,8.98772153518759e-05,0.134,0.0670449386076759,0,1
"VS-4718","focal adhesion kinase inhibitor","","CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F, CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F, CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F, CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F, CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F, CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F, CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F, CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F",501.198774352,36,4.525,87.75,0.0160563102185972,0.118,0.0670281551092986,0,0
"GSK503","histone lysine methyltransferase inhibitor","EZH2","CC(C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCN(C)CC1)C(=O)NCc1c(C)cc(C)[nH]c1=O, CC(C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCN(C)CC1)C(=O)NCc1c(C)cc(C)[nH]c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCN(C)CC1)C(=O)NCc1c(C)cc(C)[nH]c1=O",526.305624456,39,6.021,86.26,0.0260100453509922,0.108,0.0670050226754961,0,0
"morin","cytochrome P450 inhibitor","ADORA2A, ESR2, FASN, MCL1, SLC22A12","Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O",302.04265266,22,3.285,131.36,0.0199374430356052,0.114,0.0669687215178026,0,0
"WZ-4002","EGFR inhibitor","EGFR, ERBB2","COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1",494.183316404,35,3.933,91.85,0.0119094351017375,0.122,0.0669547175508687,0,0
"XMD8-92","MAP kinase inhibitor","DCLK2, MAPK7, PLK4, TNK1","CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCC(O)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCC(O)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCC(O)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCC(O)CC1",474.23793882,35,3.884,94.06,0.0179016128545987,0.116,0.0669508064272993,0,0
"rucaparib","PARP inhibitor","PARP1, PARP2","CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23",323.143390416,24,3.253,56.92,0.0979016022469427,0.036,0.0669508011234713,0,0
"spiradoline","opioid receptor agonist","OPRK1","CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1",424.16843356,28,4.269,32.78,0.0518754920288768,0.082,0.0669377460144384,0,0
"SD-0006","p38 MAPK inhibitor","","OCC(=O)N1CCC(CC1)c1[nH]nc(c1-c1ccncn1)-c1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OCC(=O)N1CCC(CC1)c1[nH]nc(c1-c1ccncn1)-c1ccc(Cl)cc1",397.13055256,28,1.973,95,0.0138593939392259,0.12,0.066929696969613,0,0
"LY2784544","JAK inhibitor","JAK2, JAK3","Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1",469.17931432,33,4.69,83.37,0.0198560693687679,0.114,0.066928034684384,0,0
"chlorophyllin","cytochrome p450 inhibitor","","CCc1c(C)c2cc3nc(cc4[nH]c([C@@H](CCC(O)=O)[C@@H]4C)c(CC(O)=O)c4[nH]c(cc1n2)c(C)c4C(O)=O)c(C)c3C=C, CCc1c(C)c2=Cc3c(C=C)c(C)c4C=c5c(C)c(CCC(O)=O)c6=C7C(C(O)=O)C(=O)c8c(C)c9C=c1n2[Cu](n34)(n9c78)n56",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","urology, infectious disease","urinary incontinence, hepatitis b","CCc1c(C)c2cc3nc(cc4[nH]c([C@@H](CCC(O)=O)[C@@H]4C)c(CC(O)=O)c4[nH]c(cc1n2)c(C)c4C(O)=O)c(C)c3C=C",596.263484872,44,4.926,169.26,0.00176787928684206,0.132,0.066883939643421,0,1
"valrocemide","","","CCCC(CCC)C(=O)NCC(N)=O, CCCC(CCC)C(=O)NCC(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCC(CCC)C(=O)NCC(N)=O",200.15247788,14,1.186,72.19,0.0797664481216624,0.054,0.0668832240608312,0,0
"URMC-099","mixed lineage kinase inhibitor","CDKL2, DAPK3, FLT3, LRRK2, MAP3K10, MAP3K11, MAP3K2, MAP3K9, SRPK2","CN1CCN(Cc2ccc(cc2)-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)CC1, CN1CCN(Cc2ccc(cc2)-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)CC1, CN1CCN(Cc2ccc(cc2)-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCN(Cc2ccc(cc2)-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)CC1",421.226645864,32,4.996,50.95,0.103732803299118,0.03,0.0668664016495591,0,0
"Ro-48-8071","oxidosqualene cyclase inhibitor","LSS","CN(CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1)CC=C, CN(CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1)CC=C, CN(CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1)CC=C, CN(CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1)CC=C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1)CC=C",447.120919424,28,6.35,29.54,0.0537158787981326,0.08,0.0668579393990663,0,0
"semustine","DNA alkylating agent","","CC1CCC(CC1)NC(=O)N(CCCl)[NH2+][O-], CC1CCC(CC1)NC(=O)N(CCCl)[NH2+][O-]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC1CCC(CC1)NC(=O)N(CCCl)[NH2+][O-]",249.12440456,16,2.336,72.01,0.0536929906985487,0.08,0.0668464953492744,0,0
"CPP","glutamate receptor antagonist","GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D","OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1",252.087508274,16,-2.217,119.91,0.00566654058537787,0.128,0.0668332702926889,0,0
"4-(3-phosphonopropyl)-2-piperazinecarboxylic acid","","","OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1 |&1:3,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1 |&1:3",252.087508274,16,-2.217,119.91,0.00566654058537787,0.128,0.0668332702926889,0,0
"pirodavir","","","CCOC(=O)c1ccc(OCCC2CCN(CC2)c2ccc(C)nn2)cc1, CCOC(=O)c1ccc(OCCC2CCN(CC2)c2ccc(C)nn2)cc1, CCOC(=O)c1ccc(OCCC2CCN(CC2)c2ccc(C)nn2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCOC(=O)c1ccc(OCCC2CCN(CC2)c2ccc(C)nn2)cc1",369.205241724,27,4.494,64.55,0.0756318820253326,0.058,0.0668159410126663,0,0
"cisapride","serotonin receptor agonist","HTR2A, HTR3A, HTR4, KCNH2","COC1CN(CCCOc2ccc(F)cc2)CCC1NC(=O)c1cc(Cl)c(N)cc1OC, CO[C@H]1CN(CCCOc2ccc(F)cc2)CC[C@H]1NC(=O)c1cc(Cl)c(N)cc1OC, CO[C@H]1CN(CCCOc2ccc(F)cc2)CC[C@H]1NC(=O)c1cc(Cl)c(N)cc1OC, CO[C@H]1CN(CCCOc2ccc(F)cc2)CC[C@H]1NC(=O)c1cc(Cl)c(N)cc1OC",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","COC1CN(CCCOc2ccc(F)cc2)CCC1NC(=O)c1cc(Cl)c(N)cc1OC",465.183062308,32,3.278,86.05,0.011628605871182,0.122,0.066814302935591,0,0
"dazmegrel","thromboxane synthase inhibitor","TBXAS1","Cc1c(Cn2ccnc2)c2ccccc2n1CCC(O)=O, Cc1c(Cn2ccnc2)c2ccccc2n1CCC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1c(Cn2ccnc2)c2ccccc2n1CCC(O)=O",283.132076784,21,2.164,60.05,0.0915279295442308,0.042,0.0667639647721154,0,0
"SNAP","nitric oxide donor","PTPN1","CC(=O)N[C@@H](C(O)=O)C(C)(C)S[NH2+][O-] |&1:4,r|, CC(=O)N[C@@H](C(O)=O)C(C)(C)S[NH2+][O-] |&1:4,r|, CC(=O)N[C@@H](C(O)=O)C(C)(C)S[NH2+][O-] |&1:4,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(=O)N[C@@H](C(O)=O)C(C)(C)S[NH2+][O-] |&1:4",222.067427928,14,-2.293,131.37,0.00551410463673004,0.128,0.066757052318365,0,0
"odm-203","fgfr inhibitor","FGFR1, FLT1","Cn1cc(cn1)c2ccc3c(c2)ncn3c4cc(NS(=O)(=O)C5CC5)cc(c4)c6ccc(F)cc6F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","breast cancer","Cn1cc(cn1)c2ccc3c(c2)ncn3c4cc(NS(=O)(=O)C5CC5)cc(c4)c6ccc(F)cc6F",505.138402352,36,5.437,89.67,0.017456157505387,0.116,0.0667280787526935,0,0
"batimastat","matrix metalloprotease inhibitor","ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8","CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO",477.175598472,32,2.935,161.07,0.00142428187439634,0.132,0.0667121409371982,0,1
"uridine","dopamine receptor agonist","LSM6, TYMP","OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O",244.069536104,17,-1.421,124.78,0.00935010695048106,0.124,0.0666750534752405,0,0
"robalzotan","serotonin receptor antagonist","HTR1A","NC(=O)c1ccc(F)c2OC[C@@H](Cc12)N(C1CCC1)C1CCC1, NC(=O)c1ccc(F)c2OC[C@@H](Cc12)N(C1CCC1)C1CCC1, NC(=O)c1ccc(F)c2OC[C@@H](Cc12)N(C1CCC1)C1CCC1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NC(=O)c1ccc(F)c2OC[C@@H](Cc12)N(C1CCC1)C1CCC1",318.174356196,23,2.523,55.56,0.0772763797779959,0.056,0.066638189888998,0,0
"GSK2838232","HIV gag inhibitor","","CC(C)C1=C2[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@]2(CC1=O)[C@@H](O)CN(CCN(C)C)Cc1ccc(Cl)cc1 |c:3|, CC(C)C1=C2[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@]2(CC1=O)[C@@H](O)CN(CCN(C)C)Cc1ccc(Cl)cc1 |c:3|, CC(C)C1=C2[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@]2(CC1=O)[C@@H](O)CN(CCN(C)C)Cc1ccc(Cl)cc1 |c:3|, CC(C)C1=C2[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@]2(CC1=O)[C@@H](O)CN(CCN(C)C)Cc1ccc(Cl)cc1 |c:3|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)C1=C2[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@]2(CC1=O)[C@@H](O)CN(CCN(C)C)Cc1ccc(Cl)cc1 |c:3|",808.515715736,57,10.045,107.38,0.00325235432392065,0.13,0.0666261771619603,0,1
"LY2334737","antitumor agent, ribonucleotide reductase inhibitor","","CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1",389.17622734,27,3.032,113.68,0.0112245389354435,0.122,0.0666122694677218,0,0
"unbs-5162","CC chemokine receptor antagonist","","CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23, CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23, CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23",326.137890436,24,0.629,95.74,0.0211235638683336,0.112,0.0665617819341668,0,0
"2-oleoylglycerol","glucose dependent insulinotropic receptor ligand","GPR119","CCCCCCCC\C=C/CCCCCCCC(=O)OC(CO)CO, CCCCCCCC\C=C/CCCCCCCC(=O)OC(CO)CO, CCCCCCCC\C=C/CCCCCCCC(=O)OC(CO)CO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCCCCCCC\C=C/CCCCCCCC(=O)OC(CO)CO",356.29265976,25,7.132,66.76,0.113097518058041,0.02,0.0665487590290207,0,0
"U-0126","MEK inhibitor","AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1","Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N, Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N, Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N, Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N, Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N, Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N",380.087786512,26,1.482,197.92,0.00108545827705652,0.132,0.0665427291385283,0,1
"pikamilone","","","OC(=O)CCCNC(=O)c1cccnc1, OC(=O)CCCNC(=O)c1cccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC(=O)CCCNC(=O)c1cccnc1",208.084792244,15,0.0729999999999999,79.29,0.0550769130649791,0.078,0.0665384565324896,0,0
"EW-7197","TGF beta receptor inhibitor","ACVR1B, TGFBR1","Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1, Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1, Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1, Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1, Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1, Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1",399.160771796,30,3.559,83.79,0.0390324114273592,0.094,0.0665162057136796,0,0
"cintriamide","","","COc1cc(\C=C\C(N)=O)cc(OC)c1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(\C=C\C(N)=O)cc(OC)c1OC",237.10010796,17,0.658,70.78,0.0609707142640651,0.072,0.0664853571320325,0,0
"MPI-0479605","mitotic kinase inhibitor","TTK","Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1",407.243358548,30,4.049,90.99,0.0309626997890163,0.102,0.0664813498945082,0,0
"CM-4620","calcium release activated channel modulator","","Cc1cccc(F)c1C(=O)Nc1cnc(cn1)-c1cc2OC(F)(F)Oc2cc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1cccc(F)c1C(=O)Nc1cnc(cn1)-c1cc2OC(F)(F)Oc2cc1Cl",421.044103552,29,4.663,73.34,0.0309440440040043,0.102,0.0664720220020022,0,0
"fidarestat","aldose reductase inhibitor","AKR1B1","NC(=O)[C@H]1C[C@]2(NC(=O)NC2=O)c2cc(F)ccc2O1 |&1:3,&2:5,r|, NC(=O)[C@H]1C[C@]2(NC(=O)NC2=O)c2cc(F)ccc2O1 |&1:3,&2:5,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","NC(=O)[C@H]1C[C@]2(NC(=O)NC2=O)c2cc(F)ccc2O1 |&1:3",279.06553402,20,-0.242,110.52,0.0149409967490998,0.118,0.0664704983745499,0,0
"A12B4C3","polynucleotide kinase/phosphatase inhibitor","PNKP","CCCCCCCCCC[C@@H](O)[C@H]1C=C[C@H]2[C@@H](N1Nc1ccc(cc1)[N+]([O-])=O)C(=O)N(C2=O)c1ccccc1 |&1:10,&2:12,r,c:13|, CCCCCCCCCC[C@@H](O)[C@H]1C=C[C@H]2[C@@H](N1Nc1ccc(cc1)[N+]([O-])=O)C(=O)N(C2=O)c1ccccc1 |&1:10,&2:12,r,c:13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCCCC[C@@H](O)[C@H]1C=C[C@H]2[C@@H](N1Nc1ccc(cc1)[N+]([O-])=O)C(=O)N(C2=O)c1ccccc1 |&1:10",534.284220316,39,7.283,116.02,0.014861153566271,0.118,0.0664305767831355,0,0
"SRT1720","SIRT activator","SIRT1","O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1, O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1, O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1, O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1, O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1, O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1",469.168479356,34,2.418,115.69,0.00686040328523572,0.126,0.0664302016426179,0,0
"oxonic-acid","uricase inhibitor","","OC(=O)c1nc(=O)[nH]c(=O)[nH]1, OC(=O)c1nc(=O)[nH]c(=O)[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1nc(=O)[nH]c(=O)[nH]1",157.012355576,11,-0.734,115.91,0.0268591281967065,0.106,0.0664295640983532,0,0
"APR-246","p53 activator","TP53","COC[C@@]1(CO)N2CCC(CC2)C1=O |&1:3,r,TLB:2:3:7.8:10.11|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COC[C@@]1(CO)N2CCC(CC2)C1=O |&1:3",199.120843404,14,-0.974,49.77,0.0808417188027107,0.052,0.0664208594013554,0,0
"eltanexor","exportin inhibitor","","NC(=O)C(=C/n1cnc(n1)-c1cc(cc(c1)C(F)(F)F)C(F)(F)F)\c1cncnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC(=O)C(=C/n1cnc(n1)-c1cc(cc(c1)C(F)(F)F)C(F)(F)F)\c1cncnc1",428.08202826,30,2.516,99.58,0.0108039804772094,0.122,0.0664019902386047,0,0
"LM11A-31","neurotrophic agent","NGFR","CC[C@@H](C)[C@@H](N)C(=O)NCCN1CCOCC1 |&1:2,&2:4,r|, CC[C@@H](C)[C@@H](N)C(=O)NCCN1CCOCC1 |&1:2,&2:4,r|, CC[C@@H](C)[C@@H](N)C(=O)NCCN1CCOCC1 |&1:2,&2:4,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC[C@@H](C)[C@@H](N)C(=O)NCCN1CCOCC1 |&1:2",243.19467704,17,-0.191,67.59,0.046775555304003,0.086,0.0663877776520015,0,0
"JNJ-10191584","histamine receptor antagonist","HRH4","CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1, CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1, CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1, CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1",278.09343878,19,1.142,52.23,0.0626819772875553,0.07,0.0663409886437776,0,0
"TC-NTR1-17","neurotensin agonist","NTSR1","COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)N[C@@H](CC(C)C)C(O)=O, COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)N[C@@H](CC(C)C)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)N[C@@H](CC(C)C)C(O)=O",522.166997644,37,3.171,115.57,0.00466274707735933,0.128,0.0663313735386797,0,0
"OICR-9429","WDR5/MLL interaction inhibitor","WDR5","CN1CCN(CC1)c1ccc(cc1NC(=O)c1c[nH]c(=O)cc1C(F)(F)F)-c1cccc(CN2CCOCC2)c1, CN1CCN(CC1)c1ccc(cc1NC(=O)c1c[nH]c(=O)cc1C(F)(F)F)-c1cccc(CN2CCOCC2)c1, CN1CCN(CC1)c1ccc(cc1NC(=O)c1c[nH]c(=O)cc1C(F)(F)F)-c1cccc(CN2CCOCC2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCN(CC1)c1ccc(cc1NC(=O)c1c[nH]c(=O)cc1C(F)(F)F)-c1cccc(CN2CCOCC2)c1",555.245724544,40,4.404,80.91,0.0126536602958059,0.12,0.0663268301479029,0,0
"tacedinaline","HDAC inhibitor","HDAC1","CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N",269.11642672,20,1.43,84.22,0.050650050563122,0.082,0.066325025281561,0,0
"ZK-93426","benzodiazepine receptor antagonist","GABRA1, GABRA2, GABRA3, GABRA5","CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C, CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C, CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C, CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C",0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C",312.1473925,23,3.751,64.21,0.0966400528408331,0.036,0.0663200264204165,0,0
"metipranolol","adrenergic receptor antagonist","","CC(C)NC[C@@H](O)COc1cc(C)c(OC(C)=O)c(C)c1C |&1:5,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CC(C)NC[C@@H](O)COc1cc(C)c(OC(C)=O)c(C)c1C |&1:5",309.194008344,22,2.225,67.79,0.0545628736899381,0.078,0.0662814368449691,0,0
"AZD1080","glycogen synthase kinase inhibitor","GSK3A, GSK3B","O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N, O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N, O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N, O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N, O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N, O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N",334.142975816,25,0.361,78.25,0.0305534350906121,0.102,0.066276717545306,0,0
"BMS-754807","IGF-1 inhibitor","AKT1, IGF1R","C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1",461.208784608,34,4.16,116.13,0.0125221138740023,0.12,0.0662610569370012,0,0
"ocaperidone","serotonin receptor antagonist","","Cc1cccn2c1nc(C)c(CCN1CCC(CC1)c1noc3cc(F)ccc13)c2=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cccn2c1nc(C)c(CCN1CCC(CC1)c1noc3cc(F)ccc13)c2=O",420.19615426,31,4.022,63.64,0.0523839789695267,0.08,0.0661919894847634,0,0
"brucine","glycine receptor antagonist","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","COc1cc2N3[C@H]4[C@@H]5[C@H](CC3=O)OCC=C3CN6CC[C@]4([C@@H]6C[C@H]53)c2cc1OC |t:15|, COc1cc2N3C4[C@@H]5C(CC3=O)OCC=C3CN6CC[C@]4([C@@H]6C[C@H]53)c2cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,5,0,0,0,0,0,0,"preclinical","","","COc1cc2N3[C@H]4[C@@H]5[C@H](CC3=O)OCC=C3CN6CC[C@]4([C@@H]6C[C@H]53)c2cc1OC |t:15|",394.189257312,29,0.127,51.24,0.0322199117310032,0.1,0.0661099558655016,0,0
"mertansine","microtubule inhibitor","","[H][C@@]12C[C@@](O)(NC(=O)O1)[C@]([H])(OC)\C=C\C=C(C)\Cc1cc(OC)c(Cl)c(c1)N(C)C(=O)C[C@]([H])(OC(=O)[C@H](C)N(C)C(=O)CCS)[C@]1(C)O[C@H]1[C@@H]2C |c:16,t:14|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","[H][C@@]12C[C@@](O)(NC(=O)O1)[C@]([H])(OC)\C=C\C=C(C)\Cc1cc(OC)c(Cl)c(c1)N(C)C(=O)C[C@]([H])(OC(=O)[C@H](C)N(C)C(=O)CCS)[C@]1(C)O[C@H]1[C@@H]2C |c:16",737.274893416,53,3.571,195.27,0.000189828036687892,0.132,0.066094914018344,0,1
"PF-06409577","protein kinase activator","","OC(=O)c1c[nH]c2cc(Cl)c(cc12)-c1ccc(cc1)C1(O)CCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC(=O)c1c[nH]c2cc(Cl)c(cc12)-c1ccc(cc1)C1(O)CCC1",341.081871052,24,4.542,73.32,0.0621715814532221,0.07,0.0660857907266111,0,0
"TTP-22","casein kinase inhibitor","CSNK2A1","Cc1ccc(cc1)-c1csc2ncnc(SCCC(O)=O)c12, Cc1ccc(cc1)-c1csc2ncnc(SCCC(O)=O)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(cc1)-c1csc2ncnc(SCCC(O)=O)c12",330.049669688,22,3.194,116.62,0.0141292876916348,0.118,0.0660646438458174,0,0
"ritodrine","adrenergic receptor agonist","","C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1 |&1:1,12|, C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1 |&1:1,12|, C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1 |&1:1,12|, C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1 |&1:1,12|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","obstetrics/gynecology","premature labor","C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1 |&1:1",287.152143532,21,2.444,72.72,0.0680978633268164,0.064,0.0660489316634082,0,0
"ritodrine hydrochloride","adrenergic receptor agonist","","CC(NCCc1ccc(O)cc1)C(O)c1ccc(O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","obstetrics/gynecology","premature labor","CC(NCCc1ccc(O)cc1)C(O)c1ccc(O)cc1",287.152143532,21,2.444,72.72,0.0680978633268164,0.064,0.0660489316634082,0,0
"KU-0063794","mTOR inhibitor","MTOR","COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1",465.237604472,34,3.41,93.07,0.0160894581543927,0.116,0.0660447290771963,0,0
"trovirdine","non-nucleoside reverse transcriptase inhibitor","","Brc1ccc(NC(=S)NCCc2ccccn2)nc1, Brc1ccc(NC(=S)NCCc2ccccn2)nc1, Brc1ccc(NC(=S)NCCc2ccccn2)nc1, Brc1ccc(NC(=S)NCCc2ccccn2)nc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Brc1ccc(NC(=S)NCCc2ccccn2)nc1",336.004429516,19,2.67,81.93,0.0120888305142577,0.12,0.0660444152571289,0,0
"mb-07344","thyroid hormone receptor agonist","THRB","CC(C)c1cc(Cc2c(C)cc(OCP(O)(O)=O)cc2C)ccc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","endocrinology","hypercholesterolemia","CC(C)c1cc(Cc2c(C)cc(OCP(O)(O)=O)cc2C)ccc1O",364.14396053,25,3.68,96.8,0.0220868775674218,0.11,0.0660434387837109,0,0
"GGsTop","gamma glutamyltransferase Inhibitor","GGT1","COP(=O)(CC[C@@H](N)C(O)=O)Oc1cccc(CC(O)=O)c1 |&1:2,&2:6,r|, COP(=O)(CC[C@@H](N)C(O)=O)Oc1cccc(CC(O)=O)c1 |&1:2,&2:6,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COP(=O)(CC[C@@H](N)C(O)=O)Oc1cccc(CC(O)=O)c1 |&1:2",331.082088546,22,-2.034,145.96,0.00196042849907927,0.13,0.0659802142495396,0,1
"fananserin","dopamine receptor antagonist, serotonin receptor antagonist","HTR2A","Fc1ccc(cc1)N1CCN(CCCN2c3cccc4cccc(c34)S2(=O)=O)CC1, Fc1ccc(cc1)N1CCN(CCCN2c3cccc4cccc(c34)S2(=O)=O)CC1, Fc1ccc(cc1)N1CCN(CCCN2c3cccc4cccc(c34)S2(=O)=O)CC1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Fc1ccc(cc1)N1CCN(CCCN2c3cccc4cccc(c34)S2(=O)=O)CC1",425.157326228,30,4.945,52.24,0.0598775944123366,0.072,0.0659387972061683,0,0
"HEMADO","adenosine receptor agonist","ADORA1, ADORA2A, ADORA2B, ADORA3","CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1, CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1, CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1",361.175004216,26,1.834,125.55,0.0098697886072832,0.122,0.0659348943036416,0,0
"nafadotride","dopamine receptor antagonist","DRD2, DRD3, HTR1A","CCCCN1CCC[C@@H]1CNC(=O)c1cc(C#N)c2ccccc2c1OC |&1:8,r|",0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"preclinical","","","CCCCN1CCC[C@@H]1CNC(=O)c1cc(C#N)c2ccccc2c1OC |&1:8",365.210327104,27,4.077,65.36,0.0738646604163245,0.058,0.0659323302081622,0,0
"antineoplaston a10","p53 activator","DPM1, LGALS1","O=C(Cc1ccccc1)N[C@H]2CCC(=O)NC2=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","oncology","brainstem glioma","O=C(Cc1ccccc1)N[C@H]2CCC(=O)NC2=O",246.100442308,18,0.791,75.27,0.0578302142992439,0.074,0.065915107149622,0,0
"AZD3514","androgen receptor modulator","AR","CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|",519.256957924,37,3.904,79.09,0.0138111708469279,0.118,0.0659055854234639,0,0
"imisopasem-manganese","superoxide dismutase mimetic","","[H][C@@]12CCCC[C@@]1([H])N1Cc3cccc(CN4[C@]5([H])CCCC[C@@]5([H])N5CCN2[Mn]145(Cl)Cl)n3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@@]12CCCC[C@@]1([H])N1Cc3cccc(CN4[C@]5([H])CCCC[C@@]5([H])N5CCN2[Mn]145(Cl)Cl)n3",478.133696452,33,3.827,25.85,0.0478109847696012,0.084,0.0659054923848006,0,0
"azodicarbonamide","DNA synthesis inhibitor","","NC(=O)\N=N\C(N)=O, NC(=O)\N=N\C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NC(=O)\N=N\C(N)=O",116.033425368,8,-2.564,110.9,0.0257254643167252,0.106,0.0658627321583626,0,0
"way-181187","serotonin receptor agonist","HTR2A","NCCc1cn(c2ccccc12)S(=O)(=O)c1c(Cl)nc2sccn12",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"preclinical","neurology/psychiatry","depression","NCCc1cn(c2ccccc12)S(=O)(=O)c1c(Cl)nc2sccn12",380.016845336,24,2.684,119.01,0.00571103916075257,0.126,0.0658555195803763,0,0
"L-lysine","serotonin receptor agonist","GPRC6A, KARS, SLC7A1, SLC7A2, SLC7A3, SLC7A4","NCCCC[C@H](N)C(O)=O",1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NCCCC[C@H](N)C(O)=O",146.105527688,10,-2.949,89.34,0.0296851791715063,0.102,0.0658425895857531,0,0
"LY2801653","MET inhibitor","MET","Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1, Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1, Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1, Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1",552.172145004,41,6.497,106.83,0.0156638828009647,0.116,0.0658319414004823,0,0
"enarodustat","hypoxia inducible factor prolyl hydroxylase inhibitor","EGLN1","OC(=O)CNC(=O)c1c(O)cc(CCc2ccccc2)n3ncnc13",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","hematology","anemia","OC(=O)CNC(=O)c1c(O)cc(CCc2ccccc2)n3ncnc13",340.117154992,25,-0.191,116.82,0.00966367700749057,0.122,0.0658318385037453,0,0
"AZD1283","purinergic receptor antagonist","P2RY12","CCOC(=O)c1cc(C#N)c(nc1C)N1CCC(CC1)C(=O)NS(=O)(=O)Cc1ccccc1, CCOC(=O)c1cc(C#N)c(nc1C)N1CCC(CC1)C(=O)NS(=O)(=O)Cc1ccccc1, CCOC(=O)c1cc(C#N)c(nc1C)N1CCC(CC1)C(=O)NS(=O)(=O)Cc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)c1cc(C#N)c(nc1C)N1CCC(CC1)C(=O)NS(=O)(=O)Cc1ccccc1",470.162390932,33,2.969,137.84,0.00365626395656288,0.128,0.0658281319782814,0,0
"CI-966","GAT inhibitor","SLC6A1","OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1 |t:3|, OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1 |t:3|, OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1 |t:3|, OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1 |t:3|",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1 |t:3|",473.142562852,33,4.796,49.77,0.039581748593567,0.092,0.0657908742967835,0,0
"hemin","heme oxygenase activators, enzyme inducer, enzyme inducer, heme oxygenase activators","HMOX1, HMOX2","CC1=C(CCC(O)=O)\C2=C\c3c(CCC(O)=O)c(C)c4\C=C5/N=C(/C=c6/c(C=C)c(C)\c(=C\C1=N2)n6[Fe](O)n34)C(C)=C5C=C |c:1,20,34,45,t:8,22,24,31|, CC1=C(CCC(O)=O)\C2=C\c3c(CCC(O)=O)c(C)c4\C=C5/N=C(/C=c6/c(C=C)c(C)\c(=C\C1=N2)n6[Fe](O)n34)C(C)=C5C=C |c:1,20,34,45,t:8,22,24,31|, CC1=C(CCC(O)=O)\C2=C\c3c(CCC(O)=O)c(C)c4\C=C5/N=C(/C=c6/c(C=C)c(C)\c(=C\C1=N2)n6[Fe](O)n34)C(C)=C5C=C |c:1,20,34,45,t:8,22,24,31|, [Fe+3].Cc1c(C=C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C=C)c5C)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C, [Fe+3].Cc1c(C=C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C=C)c5C)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","neurology, hematology, cardiology, hematology, cardiology, neurology","multiple sclerosis, acute intermittent porphyria (aip), hypertension, ventricular tachycardia (vt), acute intermittent porphyria (AIP), hypertension, ventricular tachycardia (VT), multiple sclerosis","CC1=C(CCC(O)=O)\C2=C\c3c(CCC(O)=O)c(C)c4\C=C5/N=C(/C=c6/c(C=C)c(C)\c(=C\C1=N2)n6[Fe](O)n34)C(C)=C5C=C |c:1",633.180032656,44,4.159,129.41,0.00152658081319181,0.13,0.0657632904065959,0,1
"CGP-37849","glutamate receptor antagonist","GRIN2A, GRIN2B, GRIN2C, GRIN2D","C\C(CP(O)(O)=O)=C/[C@@H](N)C(O)=O |&1:8,r|, C\C(CP(O)(O)=O)=C/[C@@H](N)C(O)=O |&1:8,r|, C\C(CP(O)(O)=O)=C/[C@@H](N)C(O)=O |&1:8,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C\C(CP(O)(O)=O)=C/[C@@H](N)C(O)=O |&1:8",209.045309114,13,-4.761,130.66,0.00332496894990945,0.128,0.0656624844749547,0,0
"WZ-3146","EGFR inhibitor","EGFR","CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Oc3cccc(NC(=O)C=C)c3)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Oc3cccc(NC(=O)C=C)c3)n2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Oc3cccc(NC(=O)C=C)c3)n2)cc1",464.17275172,33,4.018,82.62,0.0193230761464176,0.112,0.0656615380732088,0,0
"GZD824","Bcr-Abl kinase inhibitor","ABL1, BCR","CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1",532.219844144,39,5.624,77.15,0.0253198848003878,0.106,0.0656599424001939,0,0
"cardiogenol-C","cardiomyogenesis inducer","","COc1ccc(Nc2nccc(NCCO)n2)cc1, COc1ccc(Nc2nccc(NCCO)n2)cc1, COc1ccc(Nc2nccc(NCCO)n2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(Nc2nccc(NCCO)n2)cc1",260.127325752,19,1.249,79.3,0.0533179148947401,0.078,0.0656589574473701,0,0
"ferulic-acid","antioxidant","CA1, CA12, CA14, CA2, CA4, CA6, CA9","COc1cc(\C=C\C(O)=O)ccc1O, COc1cc(\C=C\C(O)=O)ccc1O, COc1cc(\C=C\C(O)=O)ccc1O, COc1cc(\C=C\C(O)=O)ccc1O, COc1cc(\C=C\C(O)=O)ccc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1cc(\C=C\C(O)=O)ccc1O",194.0579088,14,1.15,66.76,0.101310278458437,0.03,0.0656551392292185,0,0
"integrin-antagonist-1","integrin antagonist","ITGAV, ITGB6","Cc1cc(C)n(n1)-c1cccc(c1)[C@@H](CN1CC[C@@H](CCc2ccc3CCCNc3n2)C1)CC(O)=O, Cc1cc(C)n(n1)-c1cccc(c1)[C@@H](CN1CC[C@@H](CCc2ccc3CCCNc3n2)C1)CC(O)=O, Cc1cc(C)n(n1)-c1cccc(c1)[C@@H](CN1CC[C@@H](CCc2ccc3CCCNc3n2)C1)CC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1cc(C)n(n1)-c1cccc(c1)[C@@H](CN1CC[C@@H](CCc2ccc3CCCNc3n2)C1)CC(O)=O",487.294725424,36,3.92,83.28,0.0212940563356053,0.11,0.0656470281678026,0,0
"dynasore","dynamin inhibitor","DNM1, DNM1L, DNM2","Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O, Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O, Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O, Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O, Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O, Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O",322.095356928,24,5.061,102.15,0.0572837878633621,0.074,0.0656418939316811,0,0
"cyclic-AMP","","CNGA3, TRPM7","Nc1ncnc2n(cnc12)[C@H]1O[C@H]2CO[P@](O)(=O)O[C@@H]2[C@@H]1O |&1:10,&2:12,&3:15,&4:19,&5:20,r|, Nc1ncnc2n(cnc12)[C@H]1O[C@H]2CO[P@](O)(=O)O[C@@H]2[C@@H]1O |&1:10,&2:12,&3:15,&4:19,&5:20,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1ncnc2n(cnc12)[C@H]1O[C@H]2CO[P@](O)(=O)O[C@@H]2[C@@H]1O |&1:10",329.052519734,22,-2.486,164.65,0.00119516818616947,0.13,0.0655975840930847,0,1
"maytansinol-isobutyrate","","","CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 |c:5,t:3|, CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 |c:5,t:3|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 |c:5",634.265708636,44,3.775,136.16,0.00115807211898523,0.13,0.0655790360594926,0,1
"WIN-64338","bradykinin receptor antagonist","BDKRB2","CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1, CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1, CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1, CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1, CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1",711.512525846091,51,13.169,65.52,0.0451471266293758,0.086,0.0655735633146879,0,0
"CGP-39551","NMDA receptor antagonist","","CCOC(=O)[C@H](N)\C=C(/C)CP(O)(O)=O |&1:5,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)[C@H](N)\C=C(/C)CP(O)(O)=O |&1:5",237.076609242,15,-1.851,119.66,0.00707951450996676,0.124,0.0655397572549834,0,0
"tiotidine","histamine receptor antagonist","HRH2","CN\C(NCCSCc1csc(N=C(N)N)n1)=N/C#N, CN=C(NCCSCc1csc(NC(N)=N)n1)NC#N",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN\C(NCCSCc1csc(N=C(N)N)n1)=N/C#N",312.093934512,20,-0.274,191.04,0.00105532520345901,0.13,0.0655276626017295,0,1
"LGD-6972","glucagon receptor antagonist","","Cc1cc(C)c(c(C)c1)-c1ccc(NC(=O)[C@H](Cc2ccc(cc2)C(=O)NCCS(O)(=O)=O)c2ccc(cc2)-c2ccc(cc2)C(C)(C)C)cc1, Cc1cc(C)c(c(C)c1)-c1ccc(NC(=O)[C@H](Cc2ccc(cc2)C(=O)NCCS(O)(=O)=O)c2ccc(cc2)-c2ccc(cc2)C(C)(C)C)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1cc(C)c(c(C)c1)-c1ccc(NC(=O)[C@H](Cc2ccc(cc2)C(=O)NCCS(O)(=O)=O)c2ccc(cc2)-c2ccc(cc2)C(C)(C)C)cc1",702.312743572,51,9.765,120.95,0.00702151568547343,0.124,0.0655107578427367,0,0
"tyrphostin-AG-1478","EGFR inhibitor","EGFR, MAPK14","COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC, COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC",315.077454368,22,3.208,56.27,0.0769334711061225,0.054,0.0654667355530612,0,0
"parcetasal","anti-inflammatory agent","","CC(=O)Nc1ccc(O[C@]2(C)OC(=O)c3ccccc3O2)cc1 |&1:9,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)Nc1ccc(O[C@]2(C)OC(=O)c3ccccc3O2)cc1 |&1:9",313.09502258,23,3.372,73.86,0.0707994073546561,0.06,0.0653997036773281,0,0
"SDZ-220-040","glutamate receptor antagonist","GRIN1","N[C@@H](Cc1cc(cc(CP(O)(O)=O)c1O)-c1ccc(Cl)cc1Cl)C(O)=O, N[C@@H](Cc1cc(cc(CP(O)(O)=O)c1O)-c1ccc(Cl)cc1Cl)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@@H](Cc1cc(cc(CP(O)(O)=O)c1O)-c1ccc(Cl)cc1Cl)C(O)=O",419.009229222,26,-0.43,150.89,0.000796869545145561,0.13,0.0653984347725728,0,1
"SR-140333","neurokinin receptor antagonist","TACR1","CC(C)Oc1cccc(CC(=O)N2CCC[C@@](CC[N+]34CCC(CC3)(CC4)c3ccccc3)(C2)c2ccc(Cl)c(Cl)c2)c1, CC(C)Oc1cccc(CC(=O)N2CCC[C@@](CC[N+]34CCC(CC3)(CC4)c3ccccc3)(C2)c2ccc(Cl)c(Cl)c2)c1, CC(C)Oc1cccc(CC(=O)N2CCC[C@@](CC[N+]34CCC(CC3)(CC4)c3ccccc3)(C2)c2ccc(Cl)c(Cl)c2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)Oc1cccc(CC(=O)N2CCC[C@@](CC[N+]34CCC(CC3)(CC4)c3ccccc3)(C2)c2ccc(Cl)c(Cl)c2)c1",619.285260460091,43,7.635,29.54,0.0386633303489037,0.092,0.0653316651744519,0,0
"ALS-8176","RNA polymerase inhibitor","","CC(C)C(=O)OC[C@@]1(CCl)O[C@H]([C@H](F)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)C(=O)OC[C@@]1(CCl)O[C@H]([C@H](F)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O",433.14159142,29,2.662,122.74,0.00463488102323131,0.126,0.0653174405116157,0,0
"PAT-1251","lysyl oxidase inhibitor","","NCc1cc(Oc2cccc(c2)C(=O)N2C[C@@H](O)[C@H](F)C2)nc(c1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","NCc1cc(Oc2cccc(c2)C(=O)N2C[C@@H](O)[C@H](F)C2)nc(c1)C(F)(F)F",399.120604284,28,2.282,88.68,0.0164620101894852,0.114,0.0652310050947426,0,0
"GSK369796","potassium channel antagonist","","CC(C)(C)NCc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)(C)NCc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O",355.145140004,25,4.794,57.18,0.0844404376927794,0.046,0.0652202188463897,0,0
"GR46611","serotonin receptor agonist","HTR1D","COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1, COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1, COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1, COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1",377.210327104,28,3.341,57.36,0.0704139179245234,0.06,0.0652069589622617,0,0
"L-ergothioneine","free radical scavenger","","C[N+](C)(C)[C@@H](Cc1c[nH]c(=S)[nH]1)C(O)=O, C[N+](C)(C)[C@@H](Cc1c[nH]c(=S)[nH]1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C[N+](C)(C)[C@@H](Cc1c[nH]c(=S)[nH]1)C(O)=O",230.095774172091,15,-2.004,100.97,0.0123609509369955,0.118,0.0651804754684977,0,0
"N6022","alcohol dehydrogenase inhibitor","ADH5","Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O, Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O, Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O, Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O, Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O, Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O",414.169190564,31,3.171,103.14,0.0203178323015289,0.11,0.0651589161507644,0,0
"L-689560","glutamate receptor antagonist","GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D","OC(=O)[C@H]1C[C@H](NC(=O)Nc2ccccc2)c2c(Cl)cc(Cl)cc2N1, OC(=O)[C@H]1C[C@H](NC(=O)Nc2ccccc2)c2c(Cl)cc(Cl)cc2N1, OC(=O)[C@H]1C[C@H](NC(=O)Nc2ccccc2)c2c(Cl)cc(Cl)cc2N1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)[C@H]1C[C@H](NC(=O)Nc2ccccc2)c2c(Cl)cc(Cl)cc2N1",379.0490467,25,3.252,90.46,0.0162251769991262,0.114,0.0651125884995631,0,0
"DSM265","dihydroorotate dehydrogenase inhibitor","","Cc1cc(Nc2ccc(cc2)S(F)(F)(F)(F)F)n2nc(nc2n1)C(C)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1cc(Nc2ccc(cc2)S(F)(F)(F)(F)F)n2nc(nc2n1)C(C)(F)F",415.070163924,27,4.899,55.11,0.0362053085408797,0.094,0.0651026542704398,0,0
"acedoben","","","CC(=O)Nc1ccc(cc1)C(O)=O, CC(=O)Nc1ccc(cc1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(=O)Nc1ccc(cc1)C(O)=O",179.058243148,13,0.891,66.4,0.108153877772717,0.022,0.0650769388863583,0,0
"G-1","G protein-coupled receptor agonist","GPER1","CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br |c:11|, CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br |c:11|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br |c:11|",411.047005536,26,4.473,47.56,0.0340463686365976,0.096,0.0650231843182988,0,0
"ABBV-744","bromodomain inhibitor","","CCNC(=O)c1cc2c(cn(C)c(O)c2n1)-c1cc(ccc1Oc1c(C)cc(F)cc1C)C(C)(C)O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCNC(=O)c1cc2c(cn(C)c(O)c2n1)-c1cc(ccc1Oc1c(C)cc(F)cc1C)C(C)(C)O",491.22203466,36,6.067,96.61,0.0240317443229768,0.106,0.0650158721614884,0,0
"tonabersat","gap junction modulator, nitric oxide production inhibitor","","CC(=O)c1ccc2OC(C)(C)[C@@H](O)[C@@H](NC(=O)c3ccc(F)c(Cl)c3)c2c1, CC(=O)c1ccc2OC(C)(C)[C@@H](O)[C@@H](NC(=O)c3ccc(F)c(Cl)c3)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(=O)c1ccc2OC(C)(C)[C@@H](O)[C@@H](NC(=O)c3ccc(F)c(Cl)c3)c2c1",391.098663988,27,4.239,75.63,0.0340221451039193,0.096,0.0650110725519597,0,0
"RWJ-50271","integrin inhibitor","ICAM1","Cc1c(cnn1-c1nc(cs1)-c1cccc(c1)C(F)(F)F)C(=O)NCCCO, Cc1c(cnn1-c1nc(cs1)-c1cccc(c1)C(F)(F)F)C(=O)NCCCO, Cc1c(cnn1-c1nc(cs1)-c1cccc(c1)C(F)(F)F)C(=O)NCCCO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1c(cnn1-c1nc(cs1)-c1cccc(c1)C(F)(F)F)C(=O)NCCCO",410.102431444,28,3.132,108.28,0.0099660873446879,0.12,0.0649830436723439,0,0
"amflutizole","xanthine oxidase inhibitor","XDH","Nc1c(snc1-c1cccc(c1)C(F)(F)F)C(O)=O, Nc1c(snc1-c1cccc(c1)C(F)(F)F)C(O)=O, Nc1c(snc1-c1cccc(c1)C(F)(F)F)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Nc1c(snc1-c1cccc(c1)C(F)(F)F)C(O)=O",288.018033124,19,2.96,104.45,0.0239653537089386,0.106,0.0649826768544693,0,0
"BRL-50481","phosphodiesterase inhibitor","PDE7A, PDE7B","CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O, CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O, CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O, CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O",244.051777864,16,1.228,88.9,0.0319422804428684,0.098,0.0649711402214342,0,0
"GSK2816126","histone lysine methyltransferase inhibitor","EZH2","CC[C@H](C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O, CC[C@H](C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O, CC[C@H](C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC[C@H](C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O",526.305624456,39,6.14,95.05,0.0219347414193962,0.108,0.0649673707096981,0,0
"3,4-DCPG-(+/-)","glutamate receptor agonist","GRM8","N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O |&1:1,r|, N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O |&1:1",239.042987008,17,-2.545,137.92,0.00592200548597139,0.124,0.0649610027429857,0,0
"3,4-DCPG-(R)","glutamate receptor antagonist","","N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O, N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O",239.042987008,17,-2.545,137.92,0.00592200548597139,0.124,0.0649610027429857,0,0
"3,4-DCPG-(S)","glutamate receptor agonist","GRM8","N[C@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O, N[C@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O, N[C@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O",239.042987008,17,-2.545,137.92,0.00592200548597139,0.124,0.0649610027429857,0,0
"L-phenylisopropyladenosine","","","C[C@H](Cc1ccccc1)Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H](Cc1ccccc1)Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",385.175004216,28,1.374,125.55,0.00789063167400134,0.122,0.0649453158370007,0,0
"mi-773","","","CC(C)(C)C[C@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CC(C)(C)C[C@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1",561.196125528,38,5.771,90.46,0.00779617312844264,0.122,0.0648980865642213,0,0
"SAR405838","MDM inhibitor","MDM2","CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1",561.196125528,38,5.771,90.46,0.00779617312844264,0.122,0.0648980865642213,0,0
"ERK5-IN-1","MAP kinase inhibitor","MAPK7","COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCN(C)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCN(C)CC1",459.238273168,34,3.27,77.07,0.0257472874075633,0.104,0.0648736437037817,0,0
"GSK2656157","PERK inhibitor","","Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1",416.176087512,31,2.767,89.93,0.0237398829722942,0.106,0.0648699414861471,0,0
"LY3023414","mTOR inhibitor, PI3K inhibitor","MTOR","CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O, CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O, CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O, CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O",406.200490692,30,1.63,82.17,0.0217209931949433,0.108,0.0648604965974716,0,0
"NVP-AEW541","IGF-1 inhibitor","IGF1R, INSR","Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|",439.237210548,33,5.084,69.2,0.0596300280250144,0.07,0.0648150140125072,0,0
"AZ5104","EGFR inhibitor","EGFR","COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1c[nH]c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1c[nH]c2ccccc12",485.253923232,36,3.292,98.41,0.0136023038845774,0.116,0.0648011519422887,0,0
"s55746","bcl inhibitor","BCL2","Oc1ccc(cc1)N(C(=O)c1cc(-c2cc3OCOc3cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2CCCCc12)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","hematologic malignancy","chronic lymphocytic leukemia (cll)","Oc1ccc(cc1)N(C(=O)c1cc(-c2cc3OCOc3cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2CCCCc12)c1ccccc1",710.310435064,53,6.697,96.71,0.0075943738818401,0.122,0.06479718694092,0,0
"tolamolol","adrenergic receptor antagonist","ADRB1, ADRB2, ADRB3","Cc1ccccc1OC[C@@H](O)CNCCOc1ccc(cc1)C(N)=O |&1:9,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,"phase 3","","","Cc1ccccc1OC[C@@H](O)CNCCOc1ccc(cc1)C(N)=O |&1:9",344.173607248,25,1.719,93.81,0.0235527423609784,0.106,0.0647763711804892,0,0
"e-7386","","CREBBP, CTNNB1","[H][C@]12CN(Cc3cccc(n3)N3CC(C3)N3CCN(CC)CC3)C(=O)[C@H](Cc3ccc(O)cc3F)N1C(=O)CN(CC=C)N2C(=O)NCc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","colorectal cancer","[H][C@]12CN(Cc3cccc(n3)N3CC(C3)N3CCN(CC)CC3)C(=O)[C@H](Cc3ccc(O)cc3F)N1C(=O)CN(CC=C)N2C(=O)NCc1ccccc1",725.381329236,54,2.808,119.04,0.0015401802292252,0.128,0.0647700901146126,0,0
"pt2399","hif modulator","EPAS1","O[C@H]1c2c(CC1(F)F)c(Oc3cc(F)cc(c3)C#N)ccc2S(=O)(=O)C(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","oncology","renal cell carcinoma (rcc)","O[C@H]1c2c(CC1(F)F)c(Oc3cc(F)cc(c3)C#N)ccc2S(=O)(=O)C(F)F",419.0250699,28,3.413,95.77,0.0115102337901021,0.118,0.064755116895051,0,0
"go-6983","protein kinase inhibitor","PRKCA, PRKCB, PRKCD, PRKCG, PRKCZ","COc1ccc2n(CCCN(C)C)cc(C3=C(C(=O)NC3=O)c3c[nH]c4ccccc34)c2c1 |t:15|, COc1ccc2n(CCCN(C)C)cc(C3=C(C(=O)NC3=O)c3c[nH]c4ccccc34)c2c1 |t:15|, COc1ccc2n(CCCN(C)C)cc(C3=C(C(=O)NC3=O)c3c[nH]c4ccccc34)c2c1 |t:15|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc2n(CCCN(C)C)cc(C3=C(C(=O)NC3=O)c3c[nH]c4ccccc34)c2c1 |t:15|",442.200490692,33,3.612,79.36,0.0315048501824854,0.098,0.0647524250912427,0,0
"spermine","","CA14, CA4, CA6, CA9, CASR, GRIN1, GRIN2A, KCNJ4, ODC1, SMOX, SMS, TRPM4, TRPM5","NCCCNCCCCNCCCN",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NCCCNCCCCNCCCN",202.215746832,14,-0.682,76.1,0.0454884144798785,0.084,0.0647442072399393,0,0
"S1P1-agonist-III","sphingosine kinase inhibitor","S1PR1","COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F, COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F, COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F, COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F",415.114376032,30,5.04,80.32,0.0414373354801582,0.088,0.0647186677400791,0,0
"A-784168","transient receptor potential channel antagonist","TRPV1","FC(F)(F)c1cccnc1N1CCC(=CC1)C(=O)Nc1ccc(cc1)S(=O)(=O)C(F)(F)F |c:14|, FC(F)(F)c1cccnc1N1CCC(=CC1)C(=O)Nc1ccc(cc1)S(=O)(=O)C(F)(F)F |c:14|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)c1cccnc1N1CCC(=CC1)C(=O)Nc1ccc(cc1)S(=O)(=O)C(F)(F)F |c:14|",479.07383166,32,3.918,87.75,0.00940435330468748,0.12,0.0647021766523437,0,0
"glycitein","tumor necrosis factor release inhibitor","TNF","COc1cc2c(cc1O)occ(-c1ccc(O)cc1)c2=O, COc1cc2c(cc1O)occ(-c1ccc(O)cc1)c2=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1cc2c(cc1O)occ(-c1ccc(O)cc1)c2=O",284.068473484,21,3.384,79.9,0.0773854115573226,0.052,0.0646927057786613,0,0
"bethanechol chloride","","","CC(C[N+](C)(C)C)OC(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CC(C[N+](C)(C)C)OC(N)=O",161.128454204091,11,-0.515,52.32,0.103362324364766,0.026,0.0646811621823829,0,0
"R406","SYK inhibitor","RET, SYK","COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC",470.171396056,34,2.718,128.75,0.00533423332779691,0.124,0.0646671166638985,0,0
"rociletinib","EGFR inhibitor","EGFR","COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O",555.220572416,40,3.756,111.72,0.0053265997541529,0.124,0.0646632998770764,0,0
"GDC-0810","selective estrogen receptor destabilizer","ESR1","CC\C(=C(\c1ccc(\C=C\C(O)=O)cc1)c1ccc2n[nH]cc2c1)c1ccc(F)cc1Cl, CC\C(=C(\c1ccc(\C=C\C(O)=O)cc1)c1ccc2n[nH]cc2c1)c1ccc(F)cc1Cl, CC\C(=C(\c1ccc(\C=C\C(O)=O)cc1)c1ccc2n[nH]cc2c1)c1ccc(F)cc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC\C(=C(\c1ccc(\C=C\C(O)=O)cc1)c1ccc2n[nH]cc2c1)c1ccc(F)cc1Cl",446.11973378,32,8.267,65.98,0.0913178351457709,0.038,0.0646589175728855,0,0
"TC-OT-39","oxytocin receptor agonist, vasopressin receptor agonist","AVPR1A, OXT","CN1CCCN(CC1)C(=S)[C@@H]1CCCN1C(=O)NCc1ccc(cc1C)C(=O)N1Cc2cnn(C)c2Nc2ccccc12, CN1CCCN(CC1)C(=S)[C@@H]1CCCN1C(=O)NCc1ccc(cc1C)C(=O)N1Cc2cnn(C)c2Nc2ccccc12, CN1CCCN(CC1)C(=S)[C@@H]1CCCN1C(=O)NCc1ccc(cc1C)C(=O)N1Cc2cnn(C)c2Nc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCCN(CC1)C(=S)[C@@H]1CCCN1C(=O)NCc1ccc(cc1C)C(=O)N1Cc2cnn(C)c2Nc2ccccc12",600.29949352,43,4.272,121.07,0.00331361782009639,0.126,0.0646568089100482,0,0
"DRF053-(R)","CDK inhibitor","CSNK1A1","CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1",417.227708484,31,4.139,100.78,0.0251681166128616,0.104,0.0645840583064308,0,0
"oxiperomide","dopamine receptor antagonist","","O=c1[nH]c2ccccc2n1C1CCN(CCOc2ccccc2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O=c1[nH]c2ccccc2n1C1CCN(CCOc2ccccc2)CC1",337.179026976,25,2.725,50.26,0.0910371624795024,0.038,0.0645185812397512,0,0
"BI-224436","HIV integrase inhibitor","","Cc1nc2ccccc2c(-c2ccc3OCCc4ccnc2c34)c1[C@H](OC(C)(C)C)C(O)=O, Cc1nc2ccccc2c(-c2ccc3OCCc4ccnc2c34)c1[C@H](OC(C)(C)C)C(O)=O, Cc1nc2ccccc2c(-c2ccc3OCCc4ccnc2c34)c1[C@H](OC(C)(C)C)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1nc2ccccc2c(-c2ccc3OCCc4ccnc2c34)c1[C@H](OC(C)(C)C)C(O)=O",442.189257312,33,4.499,81.54,0.0370304118201346,0.092,0.0645152059100673,0,0
"pamapimod","p38 mapk inhibitor","MAPK10, MAPK11, MAPK14, MAPK8, MAPK9","O=C1C(OC2=CC=C(F)C=C2F)=CC3=CN=C(NC(CCO)CCO)N=C3N1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","rheumatology","rheumatoid arthritis","O=C1C(OC2=CC=C(F)C=C2F)=CC3=CN=C(NC(CCO)CCO)N=C3N1C",406.14526156,29,0.187,106.75,0.00696091736585258,0.122,0.0644804586829263,0,0
"BOS-172722","monopolar spindle 1 kinase inhibitor","","CCOc1cc(ccc1Nc1ncc2cc(C)nc(NCC(C)(C)C)c2n1)-c1nncn1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCOc1cc(ccc1Nc1ncc2cc(C)nc(NCC(C)(C)C)c2n1)-c1nncn1C",446.25425758,33,5.556,102.67,0.0269607895925058,0.102,0.0644803947962529,0,0
"PRIMA1","TP53 inhibitor","ACHE","OCC1(CO)N2CCC(CC2)C1=O, OCC1(CO)N2CCC(CC2)C1=O, OCC1(CO)N2CCC(CC2)C1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OCC1(CO)N2CCC(CC2)C1=O",185.10519334,13,-1.064,60.77,0.0689210113270949,0.06,0.0644605056635475,0,0
"CX-4945","casein kinase inhibitor","CSNK2A1, CSNK2A2, DAPK3, HIPK3","OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21, OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21, OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21, OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21, OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21",349.061804304,25,4.316,75.11,0.0589135219741822,0.07,0.0644567609870911,0,0
"IOX1","histone demethylase inhibitor","EGLN1, KDM3A, KDM4C, KDM6B","OC(=O)c1ccc(O)c2ncccc12, OC(=O)c1ccc(O)c2ncccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1ccc(O)c2ncccc12",189.042593084,14,1.334,70.42,0.108849649051643,0.02,0.0644248245258213,0,0
"lonafarnib","farnesyltransferase inhibitor","FNTA, HRAS, KRAS, NRAS","NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1, NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1, NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1, NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1, NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1, NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1, NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1",636.050228112,36,4.448,79.53,0.000770182784463145,0.128,0.0643850913922316,0,0
"BMS-599626","EGFR inhibitor, protein tyrosine kinase inhibitor","EGFR, ERBB2, ERBB4","Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12, Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12, Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12, Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12",530.219014944,39,3.983,119.63,0.00675935393261475,0.122,0.0643796769663074,0,0
"SC-10","protein kinase activator","PRKCA","CCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12, CCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12",339.105977624,22,5.816,54.55,0.0847382406113085,0.044,0.0643691203056542,0,0
"oxaceprol","anti-inflammatory agent","","CC(=O)N1C[C@H](O)C[C@H]1C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)N1C[C@H](O)C[C@H]1C(O)=O",173.068807832,12,-1.187,77.84,0.0487096890330117,0.08,0.0643548445165058,0,0
"NVP-ADW742","insulin growth factor receptor inhibitor","IGF1R","Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|",453.252860612,34,5.442,69.2,0.0586920566692657,0.07,0.0643460283346328,0,0
"GGTI-298","GGTase inhibitor","CDKN1A","COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12, COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12",479.224262916,34,5.876,132.25,0.00856755292177165,0.12,0.0642837764608858,0,0
"scabertopin","anticancer agent","","[H][C@]12C\C(C)=C/[C@@]3([H])OC(=O)C(=C)[C@]3([H])[C@H](CC(=C1)C(=O)O2)OC(=O)C(\C)=C/C |c:4,t:18|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@]12C\C(C)=C/[C@@]3([H])OC(=O)C(=C)[C@]3([H])[C@H](CC(=C1)C(=O)O2)OC(=O)C(\C)=C/C |c:4",358.141638424,29,2.194,78.9,0.0644827942749139,0.064,0.064241397137457,0,0
"TC-I-15","integrin inhibitor","ITGA2, ITGB1","CC1(C)SCN([C@@H]1C(=O)N[C@@H](CNC(=O)NCc1ccccc1)C(O)=O)S(=O)(=O)c1ccccc1, CC1(C)SCN([C@@H]1C(=O)N[C@@H](CNC(=O)NCc1ccccc1)C(O)=O)S(=O)(=O)c1ccccc1, CC1(C)SCN([C@@H]1C(=O)N[C@@H](CNC(=O)NCc1ccccc1)C(O)=O)S(=O)(=O)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC1(C)SCN([C@@H]1C(=O)N[C@@H](CNC(=O)NCc1ccccc1)C(O)=O)S(=O)(=O)c1ccccc1",520.145026616,35,-0.351,178.59,0.00030314637532134,0.128,0.0641515731876607,0,0
"hydrastine-(1R,9S)","tyrosine hydroxylase inhibitor","","COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3cc12, COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3cc12, COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3cc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3cc12",383.136887392,28,2.58,66.46,0.0423019442248272,0.086,0.0641509721124136,0,0
"N-[2-(piperidinylamino)ethyl]-4-iodobenzamide","sigma receptor ligand","","Ic1ccc(cc1)C(=O)NCCN1CCCCC1, Ic1ccc(cc1)C(=O)NCCN1CCCCC1, Ic1ccc(cc1)C(=O)NCCN1CCCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Ic1ccc(cc1)C(=O)NCCN1CCCCC1",358.054211228,18,3.212,32.34,0.0202654007441956,0.108,0.0641327003720978,0,0
"aurora-a-inhibitor-i","Aurora kinase inhibitor","AURKA","CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1",587.221179132,42,4.788,102.49,0.00626298955873821,0.122,0.0641314947793691,0,0
"KU-55933","ATM kinase inhibitor","ATM, PRKDC","O=c1cc(oc(c1)-c1cccc2Sc3ccccc3Sc12)N1CCOCC1, O=c1cc(oc(c1)-c1cccc2Sc3ccccc3Sc12)N1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=c1cc(oc(c1)-c1cccc2Sc3ccccc3Sc12)N1CCOCC1",395.064985404,27,6.068,93.28,0.0322494842558261,0.096,0.0641247421279131,0,0
"enciprazine","GABA receptor modulator","GABRA1","COc1ccccc1N1CCN(C[C@@H](O)COc2cc(OC)c(OC)c(OC)c2)CC1 |&1:13,r|, COc1ccccc1N1CCN(C[C@@H](O)COc2cc(OC)c(OC)c(OC)c2)CC1 |&1:13,r|, COc1ccccc1N1CCN(C[C@@H](O)COc2cc(OC)c(OC)c(OC)c2)CC1 |&1:13,r|",0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1ccccc1N1CCN(C[C@@H](O)COc2cc(OC)c(OC)c(OC)c2)CC1 |&1:13",432.226036744,31,2.441,72.86,0.0222140199600787,0.106,0.0641070099800393,0,0
"4-methylgenistein","protein tyrosine kinase inhibitor","CYP19A1, ESRRA, ESRRB, ESRRG, FASN","COc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O",284.068473484,21,3.652,79.9,0.0822116168979899,0.046,0.0641058084489949,0,0
"vincristine (sulfate)","","","CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|",824.399643992,60,3.561,171.17,0.000206912694950075,0.128,0.064103456347475,0,0
"OCO-1112","cholesterol inhibitor","","CC(C)c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(O)=O, CC(C)c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(O)=O, CC(C)c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(O)=O, CC(C)c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(O)=O, CC(C)c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(O)=O, CC(C)c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(O)=O",327.147058152,24,4.174,75.63,0.0741712921258703,0.054,0.0640856460629352,0,0
"MC1568","HDAC inhibitor","HDAC2","Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1, Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1, Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1, Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1",314.10667056,23,2.375,71.33,0.0581629459937448,0.07,0.0640814729968724,0,0
"AZD8055","mTOR inhibitor","MTOR","COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C",465.237604472,34,3.41,93.07,0.0160894581543927,0.112,0.0640447290771963,0,0
"flumatinib","Bcr-Abl kinase inhibitor","ABL1, PDGFRB","CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1",562.241642208,41,2.799,99.17,0.00599421694963333,0.122,0.0639971084748167,0,0
"CB-5083","valosin-containing protein inhibitor","VCP","Cc1cc2c(cccc2n1-c1nc2CCOCc2c(NCc2ccccc2)n1)C(N)=O, Cc1cc2c(cccc2n1-c1nc2CCOCc2c(NCc2ccccc2)n1)C(N)=O, Cc1cc2c(cccc2n1-c1nc2CCOCc2c(NCc2ccccc2)n1)C(N)=O, Cc1cc2c(cccc2n1-c1nc2CCOCc2c(NCc2ccccc2)n1)C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1cc2c(cccc2n1-c1nc2CCOCc2c(NCc2ccccc2)n1)C(N)=O",413.185174976,31,3.33,95.06,0.0259351537187047,0.102,0.0639675768593523,0,0
"GR-135531","melatonin receptor agonist","","COC(=O)Nc1ccc2[nH]cc(CCNC(C)=O)c2c1, COC(=O)Nc1ccc2[nH]cc(CCNC(C)=O)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)Nc1ccc2[nH]cc(CCNC(C)=O)c2c1",275.126991404,20,1.111,83.22,0.0419017890961659,0.086,0.0639508945480829,0,0
"vorasidenib","isocitrate dehydrogenase inhibitor","","C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(n1)-c1cccc(Cl)n1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(n1)-c1cccc(Cl)n1)C(F)(F)F",414.079441416,27,4.994,75.62,0.02388889720662,0.104,0.06394444860331,0,0
"CH5132799","PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG","CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1, CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1, CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1, CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1",377.127008468,26,0.53,135.81,0.00388200226267723,0.124,0.0639410011313386,0,0
"ACT-462206","orexin receptor antagonist","HCRTR1, HCRTR2","COc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1C(=O)Nc1cc(C)cc(C)c1, COc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1C(=O)Nc1cc(C)cc(C)c1, COc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1C(=O)Nc1cc(C)cc(C)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1C(=O)Nc1cc(C)cc(C)c1",388.145678248,27,3.246,84.09,0.023770701934247,0.104,0.0638853509671235,0,0
"fpa-124","apoptosis stimulant","","Cl[Cu]Cl.NC(=S)N\N=C\c1coc2ccccc2c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cl[Cu]Cl.NC(=S)N\N=C\c1coc2ccccc2c1=O",379.908850388,20,4.083,112.71,0.00372269350857687,0.124,0.0638613467542884,0,0
"GAL-021","calcium channel blocker","","CCCNc1nc(NCCC)nc(n1)N(C)OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCNc1nc(NCCC)nc(n1)N(C)OC",254.185509324,18,1.251,75.2,0.0536808263555579,0.074,0.063840413177779,0,0
"LB42708","farnesyltransferase inhibitor","","Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1",554.131738204,37,5.784,52.29,0.0176407527669763,0.11,0.0638203763834882,0,0
"3-MPPI","adrenergic receptor ligand","ADRA1A","COc1ccccc1N1CCN(CCn2c(=O)[nH]c3c4ccccc4[nH]c3c2=O)CC1, COc1ccccc1N1CCN(CCn2c(=O)[nH]c3c4ccccc4[nH]c3c2=O)CC1, COc1ccccc1N1CCN(CCn2c(=O)[nH]c3c4ccccc4[nH]c3c2=O)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"preclinical","","","COc1ccccc1N1CCN(CCn2c(=O)[nH]c3c4ccccc4[nH]c3c2=O)CC1",419.19573966,31,4.184,86.36,0.0336209903169832,0.094,0.0638104951584916,0,0
"tozadenant","adenosine receptor antagonist","ADORA2A","COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12, COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12, COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12, COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12",406.167476312,28,1.062,115.4,0.00561144285650979,0.122,0.0638057214282549,0,0
"AG-556","tyrosine kinase inhibitor","","Oc1ccc(\C=C(/C#N)C(=O)NCCCCc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)NCCCCc2ccccc2)cc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(\C=C(/C#N)C(=O)NCCCCc2ccccc2)cc1O",336.1473925,25,3.484,93.35,0.0435576958557734,0.084,0.0637788479278867,0,0
"ARRY-334543","EGFR inhibitor","ERBB2","C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 |c:34|, C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 |c:34|, C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 |c:34|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 |c:34|",466.097872528,32,3.687,121.79,0.00552631982656833,0.122,0.0637631599132842,0,0
"gemcitabine-elaidate","apoptosis inhibitor, DNA synthesis inhibitor","CMPK1, RRM1, TYMS","CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O, CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O, CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O, CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O, CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O",527.317077916,37,8.722,116.67,0.0155136199914877,0.112,0.0637568099957439,0,0
"vimirogant","ror antagonist","RORC","CCS(=O)(=O)c1ccc(CNC(=O)c2cnc3[C@H](C(C)C)N(C[C@@H]4CC[C@H](CC4)C(F)(F)F)Cc3c2)nc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","neurology/psychiatry","multiple sclerosis","CCS(=O)(=O)c1ccc(CNC(=O)c2cnc3[C@H](C(C)C)N(C[C@@H]4CC[C@H](CC4)C(F)(F)F)Cc3c2)nc1",552.23819664,38,4.421,100.64,0.00549022234256608,0.122,0.063745111171283,0,0
"h3b-6527","fgfr inhibitor","FGFR4","CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)c(NC(=O)C=C)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","hepatocellular carcinoma (hcc)","CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)c(NC(=O)C=C)c1",628.208006928,43,4.014,124.19,0.00148728641045626,0.126,0.0637436432052281,0,0
"dextrorotation-nimorazole-phosphate-ester","antiinfective drug","","Cc1ncc(n1C[C@@H](CN1CCOCC1)OP(O)(O)=O)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ncc(n1C[C@@H](CN1CCOCC1)OP(O)(O)=O)[N+]([O-])=O",350.099135578,23,-1.882,150,0.00148143874820708,0.126,0.0637407193741035,0,0
"oleanolic-acid","G protein-coupled receptor agonist","GPBAR1","CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O |c:10|, CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O |c:10|, CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O |c:10|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O |c:10|",456.360345396,33,9.052,57.53,0.127461126529718,0,0.0637305632648589,1,0
"BMS-587101","integrin antagonist","ITGAL, ITGB2","CN1C(=O)N(C(=O)[C@]11CN(Cc2cc(cs2)C(O)=O)C[C@H]1c1ccc(cc1)C#N)c1cc(Cl)cc(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN1C(=O)N(C(=O)[C@]11CN(Cc2cc(cs2)C(O)=O)C[C@H]1c1ccc(cc1)C#N)c1cc(Cl)cc(Cl)c1",554.05823148,37,2.975,133.19,0.00138237851701748,0.126,0.0636911892585087,0,0
"deltarasin","phosphodiesterase inhibitor","KRAS","C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1, C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1, C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1, C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1, C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1",603.299810804,46,8.952,56.9,0.0793581343785086,0.048,0.0636790671892543,0,0
"AR-A014418","glycogen synthase kinase inhibitor","GSK3B","COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1, COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1, COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1, COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1, COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1",308.057925864,21,1,134.63,0.00735036045299746,0.12,0.0636751802264987,0,0
"transcrocetinate","glutamate receptor antagonist","","C\C(\C=C\C=C(/C)C(O)=O)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C\C(\C=C\C=C(/C)C(O)=O)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O",328.167459248,24,4.472,74.6,0.0793121895018506,0.048,0.0636560947509253,0,0
"1-deoxymannojirimycin","alpha mannosidase inhibitor","MAN2A1","OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O",163.084457896,11,-0.929,92.95,0.0373030927007536,0.09,0.0636515463503768,0,0
"glpg0974","free fatty acid receptor antagonist","FFAR2","C[C@@]1(CCN1C(=O)c1csc2ccccc12)C(=O)N(CCCC(O)=O)Cc1cccc(Cl)c1 |a:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","gastroenterology","ulcerative colitis","C[C@@]1(CCN1C(=O)c1csc2ccccc12)C(=O)N(CCCC(O)=O)Cc1cccc(Cl)c1 |a:1|",484.12235596,33,4.167,106.16,0.00729591886505607,0.12,0.063647959432528,0,0
"foslinanib","anticancer agent","","COc1ccc2[nH]c(cc(=O)c2c1OP(O)(O)=O)-c1cccc(F)c1.[NaH].[NaH]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","oncology","neuroendocrine tumors of pancreatic origin (pnet)","COc1ccc2[nH]c(cc(=O)c2c1OP(O)(O)=O)-c1cccc(F)c1.[NaH].[NaH]",413.04164061,27,2.727,118.66,0.00527618577741307,0.122,0.0636380928887065,0,0
"GW-3965","LXR agonist","NR1H2, NR1H3","OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1",581.194456192,41,8.19,49.77,0.0432556798160127,0.084,0.0636278399080063,0,0
"efaproxiral","hemoglobin oxygen release stimulant","HBA1, HBB","Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(O)=O)cc2)c1, Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(O)=O)cc2)c1, Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(O)=O)cc2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(O)=O)cc2)c1",341.162708216,25,3.612,75.63,0.0591421015605418,0.068,0.0635710507802709,0,0
"TCS-21311","JAK inhibitor","JAK3","CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|, CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|, CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|, CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|, CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|",526.18278994,38,3.396,105.74,0.00706180329175558,0.12,0.0635309016458778,0,0
"ID-8","","","COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12, COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12, COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12, COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12, COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12, COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12, COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12",298.095356928,22,4.007,77.53,0.0850536712860644,0.042,0.0635268356430322,0,0
"CHC","monocarboxylate transporter inhibitor","SLC16A1","OC(=O)C(=C\c1ccc(O)cc1)\C#N, OC(=O)C(=C\c1ccc(O)cc1)\C#N",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)C(=C\c1ccc(O)cc1)\C#N",189.042593084,14,1.144,81.32,0.0830318142110803,0.044,0.0635159071055402,0,0
"2-(3-mercaptopropyl)pentanedioic-acid","glutamate carboxypeptidase inhibitor","FOLH1","OC(=O)CC[C@@H](CCCS)C(O)=O |&1:5,r|, OC(=O)CC[C@@H](CCCS)C(O)=O |&1:5,r|, OC(=O)CC[C@@H](CCCS)C(O)=O |&1:5,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC(=O)CC[C@@H](CCCS)C(O)=O |&1:5",206.061279928,13,0.906,113.4,0.0210144626071533,0.106,0.0635072313035766,0,0
"ML193","G protein-coupled receptor antagonist","GPR55","Cc1noc(NS(=O)(=O)c2ccc(NC(=O)c3cc(nc4c(C)cc(C)cc34)-c3ccccn3)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(NC(=O)c3cc(nc4c(C)cc(C)cc34)-c3ccccn3)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(NC(=O)c3cc(nc4c(C)cc(C)cc34)-c3ccccn3)cc2)c1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1noc(NS(=O)(=O)c2ccc(NC(=O)c3cc(nc4c(C)cc(C)cc34)-c3ccccn3)cc2)c1C",527.16272528,38,4.894,135.46,0.00501186789739387,0.122,0.0635059339486969,0,0
"ML161","protease-activated receptor inhibitor","","CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1, CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1",360.047339884,22,3.867,58.2,0.0309758524884703,0.096,0.0634879262442351,0,0
"dl-cystine","","","N[C@@H](CSSC[C@@H](N)C(O)=O)C(O)=O |&1:1,&2:6,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","N[C@@H](CSSC[C@@H](N)C(O)=O)C(O)=O |&1:1",240.023848864,14,-3.312,177.24,0.000969624420316971,0.126,0.0634848122101585,0,0
"ORE1001","angiotensin converting enzyme inhibitor","ACE2","CC(C)C[C@H](N[C@@H](Cc1cncn1Cc1cc(Cl)cc(Cl)c1)C(O)=O)C(O)=O, CC(C)C[C@H](N[C@@H](Cc1cncn1Cc1cc(Cl)cc(Cl)c1)C(O)=O)C(O)=O, CC(C)C[C@H](N[C@@H](Cc1cncn1Cc1cc(Cl)cc(Cl)c1)C(O)=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","CC(C)C[C@H](N[C@@H](Cc1cncn1Cc1cc(Cl)cc(Cl)c1)C(O)=O)C(O)=O",427.106561576,28,1.562,104.45,0.00495954903595093,0.122,0.0634797745179755,0,0
"hexamethylenebisacetamide","AKT inhibitor, differentiation inducer, NFKB pathway inhibitor","AKT1","CC(=O)NCCCCCCNC(C)=O, CC(=O)NCCCCCCNC(C)=O, CC(=O)NCCCCCCNC(C)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(=O)NCCCCCCNC(C)=O",200.15247788,14,0.642,58.2,0.0949496943414266,0.032,0.0634748471707133,0,0
"DAU-5884","acetylcholine receptor antagonist","CHRM3","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"preclinical","","","CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O",315.158291532,23,2.192,61.88,0.066885805393639,0.06,0.0634429026968195,0,0
"nTZDpa","PPAR receptor agonist","PPARG","OC(=O)c1c(Sc2ccccc2)c2cc(Cl)ccc2n1Cc1ccc(Cl)cc1, OC(=O)c1c(Sc2ccccc2)c2cc(Cl)ccc2n1Cc1ccc(Cl)cc1, OC(=O)c1c(Sc2ccccc2)c2cc(Cl)ccc2n1Cc1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1c(Sc2ccccc2)c2cc(Cl)ccc2n1Cc1ccc(Cl)cc1",427.02005508,28,7.211,67.53,0.0448849775602914,0.082,0.0634424887801457,0,0
"alk2-in-1","alk inihibitor","ALK","CCOC1(CCN(CC1)C(C)C)c1ccc(nc1)-c1cc2c(ccnn2c1)N1CCN(CC1)C(=O)O[C@@H]1CCOC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","glioma","CCOC1(CCN(CC1)C(C)C)c1ccc(nc1)-c1cc2c(ccnn2c1)N1CCN(CC1)C(=O)O[C@@H]1CCOC1",562.326753824,41,3.885,84.67,0.0108742583003559,0.116,0.063437129150178,0,0
"mifobate","PPAR receptor antagonist","PPARG","COP(=O)(OC)O[C@@H](c1ccc(Cl)cc1)P(=O)(OC)OC |&1:7,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COP(=O)(OC)O[C@@H](c1ccc(Cl)cc1)P(=O)(OC)OC |&1:7",358.013803824,21,0.898,99.91,0.00486800871494377,0.122,0.0634340043574719,0,0
"sr 202","ppar receptor antagonist","","COP(=O)(OC)OC(c1ccc(Cl)cc1)P(=O)(OC)OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COP(=O)(OC)OC(c1ccc(Cl)cc1)P(=O)(OC)OC",358.013803824,21,0.898,99.91,0.00486800871494378,0.122,0.0634340043574719,0,0
"ralinepag","IP1 prostacyclin receptor agonist","","OC(=O)COC[C@H]1CC[C@H](COC(=O)N(c2ccccc2)c2ccc(Cl)cc2)CC1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","OC(=O)COC[C@H]1CC[C@H](COC(=O)N(c2ccccc2)c2ccc(Cl)cc2)CC1 |r|",431.149950612,30,4.655,76.07,0.028732233500266,0.098,0.063366116750133,0,0
"S-3304","matrix metalloprotease inhibitor","","Cc1ccc(cc1)C#Cc1ccc(s1)S(=O)(=O)N[C@H](Cc1c[nH]c2ccccc12)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","Cc1ccc(cc1)C#Cc1ccc(s1)S(=O)(=O)N[C@H](Cc1c[nH]c2ccccc12)C(O)=O",464.08644912,32,1.89,135.88,0.00269927741241316,0.124,0.0633496387062066,0,0
"EPZ015666","protein arginine N-methyltransferase inhibitor","PRMT5","O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1, O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1",383.19573966,28,-0.0290000000000001,99.61,0.0106695333542875,0.116,0.0633347666771437,0,0
"senaparib","parp inhibitor","PARP1","Fc1ccc(CN2C(=O)NC(=O)c3c(F)cccc23)cc1C(=O)N4CCN(CC4)c5ncccn5",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","breast cancer","Fc1ccc(CN2C(=O)NC(=O)c3c(F)cccc23)cc1C(=O)N4CCN(CC4)c5ncccn5",478.15649494,35,2.568,98.74,0.010667610437806,0.116,0.063333805218903,0,0
"AZD5363","AKT inhibitor","AKT1, AKT2, AKT3","NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1, NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1, NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1",428.17275172,30,2.443,120.16,0.00659936642245441,0.12,0.0632996832112272,0,0
"AF38469","sortilin inhibitor","SORT1","Cc1cccc(NC(=O)c2ccc(cc2C(O)=O)C(F)(F)F)n1, Cc1cccc(NC(=O)c2ccc(cc2C(O)=O)C(F)(F)F)n1, Cc1cccc(NC(=O)c2ccc(cc2C(O)=O)C(F)(F)F)n1, Cc1cccc(NC(=O)c2ccc(cc2C(O)=O)C(F)(F)F)n1, Cc1cccc(NC(=O)c2ccc(cc2C(O)=O)C(F)(F)F)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cccc(NC(=O)c2ccc(cc2C(O)=O)C(F)(F)F)n1",324.072176872,23,3.324,79.29,0.0485867321418154,0.078,0.0632933660709077,0,0
"setipiprant","prostaglandin inhibitor","PTGDR2","OC(=O)Cn1c2CCN(Cc2c2cc(F)ccc12)C(=O)c1cccc2ccccc12, OC(=O)Cn1c2CCN(Cc2c2cc(F)ccc12)C(=O)c1cccc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","OC(=O)Cn1c2CCN(Cc2c2cc(F)ccc12)C(=O)c1cccc2ccccc12",402.137970688,30,4.632,62.54,0.0745453289910273,0.052,0.0632726644955137,0,0
"deazaguanine","DNA synthesis inhibitor","","Nc1cc2[nH]cnc2c(O)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1cc2[nH]cnc2c(O)n1",150.054160812,11,0.298,87.82,0.0745243569865925,0.052,0.0632621784932962,0,0
"estradiol-3-O-sulfamate","steryl sulfatase inhibitor","","C[C@]12CC[C@H]3[C@@H](CCc4cc(OS(N)(=O)=O)ccc34)[C@@H]1CC[C@@H]2O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@]12CC[C@H]3[C@@H](CCc4cc(OS(N)(=O)=O)ccc34)[C@@H]1CC[C@@H]2O",351.15042928,24,2.251,98,0.0164868009793402,0.11,0.0632434004896701,0,0
"RS-67506","serotonin receptor partial agonist","HTR4","COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1, COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1, COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1, COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1",417.148905056,27,1.606,110.11,0.00443295932257624,0.122,0.0632164796612881,0,0
"benzo[d]thiazole-2(3H)-thione","","","S=c1[nH]c2ccccc2s1, S=c1[nH]c2ccccc2s1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","S=c1[nH]c2ccccc2s1",166.98634116,10,2.115,76.12,0.0803568989982947,0.046,0.0631784494991473,0,0
"arcyriaflavin-a","CDK inhibitor","CCND1, CDK4","O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21",325.085126592,25,4.01,77.75,0.0883503211065506,0.038,0.0631751605532753,0,0
"HA-130","autotaxin inhibitor","ENPP2","OB(O)c1cccc(COc2ccc(\C=C3/SC(=O)N(Cc4ccc(F)cc4)C3=O)cc2)c1, OB(O)c1cccc(COc2ccc(\C=C3/SC(=O)N(Cc4ccc(F)cc4)C3=O)cc2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OB(O)c1cccc(COc2ccc(\C=C3/SC(=O)N(Cc4ccc(F)cc4)C3=O)cc2)c1",463.106102328,33,4.134,112.37,0.010326344683428,0.116,0.063163172341714,0,0
"tas4464","nedd activating enzyme inhibitor","NAE1","NC1=NC=NC2=C1C(C#CC3=C(F)C=CC=C3OCC)=CN2[C@@H]4O[C@H](CNS(=O)(N)=O)[C@@H](O)[C@H]4O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","hematologic malignancy","multiple myeloma","NC1=NC=NC2=C1C(C#CC3=C(F)C=CC=C3OCC)=CN2[C@@H]4O[C@H](CNS(=O)(N)=O)[C@@H](O)[C@H]4O",506.138381676,35,-1.052,193.47,0.000252709963464032,0.126,0.063126354981732,0,0
"LDN-209929","haspin kinase inhibitor","GSG2","COc1ccc2nc3ccc(Cl)cc3c(SCCCN)c2c1, COc1ccc2nc3ccc(Cl)cc3c(SCCCN)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc2nc3ccc(Cl)cc3c(SCCCN)c2c1",332.075011844,22,4.276,73.44,0.0462105261256064,0.08,0.0631052630628032,0,0
"Y-39983","rho associated kinase inhibitor","ROCK1, ROCK2","C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12, C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12, C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12, C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12, C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12, C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12, C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12",280.132411132,21,2.27,83.8,0.0602002496258293,0.066,0.0631001248129147,0,0
"AVL-292","Bruton's tyrosine kinase (BTK) inhibitor","BTK, YES1","COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1, COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1, COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1, COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1, COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1, COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1, COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1",423.170667784,31,3.041,97.4,0.0181676846786627,0.108,0.0630838423393313,0,0
"LY255283","leukotriene receptor antagonist","LTB4R, LTB4R2","CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1, CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1, CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1, CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1",360.216140756,26,5.043,100.99,0.0380940783292011,0.088,0.0630470391646006,0,0
"BRD4770","histone lysine methyltransferase inhibitor","EHMT2","COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1, COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1, COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1, COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1",413.173941596,31,5.246,73.22,0.0660334115618662,0.06,0.0630167057809331,0,0
"biib068","bruton's tyrosine kinase (btk) inhibitor","BTK","CC(C)OC1CN(C1)C(=O)NCc1ccc(cc1C)-c1ccnc(Nc2cnn(C)c2)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)OC1CN(C1)C(=O)NCc1ccc(cc1C)-c1ccnc(Nc2cnn(C)c2)n1",435.238273168,32,2.735,97.2,0.0160116248337287,0.11,0.0630058124168643,0,0
"tucidinostat","HDAC inhibitor","","Nc1cc(F)ccc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Nc1cc(F)ccc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1",390.149204068,29,2.472,97.11,0.0220106326575934,0.104,0.0630053163287967,0,0
"sincalide","cholecystokinin agonist","","CSCC[C@H](NC(=O)[C@H](Cc1ccc(OS(O)(=O)=O)cc1)NC(=O)[C@@H](N)CC(O)=O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CSCC[C@H](NC(=O)[C@H](Cc1ccc(OS(O)(=O)=O)cc1)NC(=O)[C@@H](N)CC(O)=O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O",1142.350738904,78,-1.659,485.78,1.23598487359873e-09,0.126,0.0630000006179924,0,0
"KW-2478","HSP inhibitor","","CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC, CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC, CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC, CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC",574.289030924,41,1.877,127.23,0.00187795326517508,0.124,0.0629389766325875,0,0
"radiprodil","acetylcholine receptor antagonist","","Fc1ccc(CC2CCN(CC2)C(=O)C(=O)Nc2ccc3[nH]c(=O)oc3c2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Fc1ccc(CC2CCN(CC2)C(=O)C(=O)Nc2ccc3[nH]c(=O)oc3c2)cc1",397.14378434,29,2.547,95.41,0.0197741897079986,0.106,0.0628870948539993,0,0
"trimetaphan camsilate","acetylcholine receptor antagonist","CHRNA10","CC1(C)C2CCC1(CS([O-])(=O)=O)C(=O)C2.O=C1N(Cc2ccccc2)C2C[S+]3CCCC3C2N1Cc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"withdrawn","cardiology","hypertension","CC1(C)C2CCC1(CS([O-])(=O)=O)C(=O)C2.O=C1N(Cc2ccccc2)C2C[S+]3CCCC3C2N1Cc1ccccc1",596.23786438,41,4.859,106.2,0.00375299528244293,0.122,0.0628764976412215,0,0
"benzoquinonium-dibromide","cholinergic receptor antagonist","CHRNA1","CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)Cc2ccccc2)=CC1=O)Cc1ccccc1 |c:30,t:9|, CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)Cc2ccccc2)=CC1=O)Cc1ccccc1 |c:30,t:9|, CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)Cc2ccccc2)=CC1=O)Cc1ccccc1 |c:30,t:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"preclinical","","","CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)Cc2ccccc2)=CC1=O)Cc1ccccc1 |c:30",546.392279680181,40,5.724,58.2,0.0357399318303039,0.09,0.0628699659151519,0,0
"dideoxyadenosine","nucleoside reverse transcriptase inhibitor","","Nc1ncnc2n(cnc12)[C@H]1CC[C@@H](CO)O1, Nc1ncnc2n(cnc12)[C@H]1CC[C@@H](CO)O1, Nc1ncnc2n(cnc12)[C@H]1CC[C@@H](CO)O1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Nc1ncnc2n(cnc12)[C@H]1CC[C@@H](CO)O1",235.106924656,17,-0.215,99.08,0.0277324037886662,0.098,0.0628662018943331,0,0
"azd5423","glucocorticoid receptor modulator","BGLAP, NR3C1","COc1cccc(c1)[C@@H](Oc1ccc2n(ncc2c1)-c1ccc(F)cc1)[C@H](C)NC(=O)C(F)(F)F |a:8,26|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","pulmonary","chronic obstructive pulmonary disease (copd)","COc1cccc(c1)[C@@H](Oc1ccc2n(ncc2c1)-c1ccc(F)cc1)[C@H](C)NC(=O)C(F)(F)F |a:8",487.151904412,35,5.982,65.38,0.0417252676484244,0.084,0.0628626338242122,0,0
"MK-1064","orexin receptor antagonist","","COc1ccc(CNC(=O)c2cc(cnc2-c2ccccn2)-c2cncc(Cl)c2)nc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1ccc(CNC(=O)c2cc(cnc2-c2ccccn2)-c2cncc(Cl)c2)nc1OC",461.12546718,33,3.188,99.12,0.0116560159908392,0.114,0.0628280079954196,0,0
"SB-228357","serotonin receptor antagonist","HTR2A, HTR2B, HTR2C","COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F, COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F, COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F, COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F",431.125689664,31,4.159,54.46,0.0516492675132272,0.074,0.0628246337566136,0,0
"PSB-603","adenosine receptor antagonist","ADORA1, ADORA2A, ADORA2B, ADORA3","CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(Cl)cc1, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(Cl)cc1, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(Cl)cc1, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(Cl)cc1",528.13465196,36,5.285,132.54,0.00364249223558051,0.122,0.0628212461177902,0,0
"PD-184352","MEK inhibitor","MAP2K1, MAP3K1, MAP3K2","Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F",477.975659808,25,5.975,50.36,0.00759555008874226,0.118,0.0627977750443711,0,0
"RGX-104","LXR agonist","","C[C@H](CCOc1cccc(CC(O)=O)c1)N(CC(c1ccccc1)c1ccccc1)Cc1cccc(c1Cl)C(F)(F)F, C[C@H](CCOc1cccc(CC(O)=O)c1)N(CC(c1ccccc1)c1ccccc1)Cc1cccc(c1Cl)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@H](CCOc1cccc(CC(O)=O)c1)N(CC(c1ccccc1)c1ccccc1)Cc1cccc(c1Cl)C(F)(F)F",595.210106256,42,8.65,49.77,0.043595047957158,0.082,0.062797523978579,0,0
"T-1095","sodium/glucose cotransporter inhibitor","","COC(=O)OC[C@H]1O[C@@H](Oc2cc(C)cc(O)c2C(=O)CCc2ccc3occc3c2)[C@H](O)[C@@H](O)[C@@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)OC[C@H]1O[C@@H](Oc2cc(C)cc(O)c2C(=O)CCc2ccc3occc3c2)[C@H](O)[C@@H](O)[C@@H]1O",516.163161716,37,2.87,165.12,0.00158992228410457,0.124,0.0627949611420523,0,0
"isosteviol","","","C[C@]12C[C@@]3(CC1=O)CC[C@H]1[C@@](C)(CCC[C@@]1(C)C(O)=O)[C@@H]3CC2 |a:1,3,9,10,15,&1:20|, C[C@]12C[C@@]3(CC1=O)CC[C@H]1[C@@](C)(CCC[C@@]1(C)C(O)=O)[C@@H]3CC2 |a:1,3,9,10,15,&1:20|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@]12C[C@@]3(CC1=O)CC[C@H]1[C@@](C)(CCC[C@@]1(C)C(O)=O)[C@@H]3CC2 |a:1",318.21949482,23,4.534,54.37,0.123454648513955,0.002,0.0627273242569777,1,0
"cinepazide","calcium channel activator","","COc1cc(\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2)cc(OC)c1OC, COc1cc(\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2)cc(OC)c1OC, COc1cc(\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2)cc(OC)c1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","COc1cc(\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2)cc(OC)c1OC",417.226371092,30,0.781,71.55,0.017408903657747,0.108,0.0627044518288735,0,0
"etomoxir","carnitine palmitoyltransferase inhibitor","CPT1A","CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1, CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1, CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1",326.128486896,22,4.076,48.06,0.0874056942727337,0.038,0.0627028471363668,0,0
"K145","sphingosine kinase inhibitor","SPHK2","CCCCOc1ccc(CC\C=C2/SC(=O)N(CCN)C2=O)cc1, CCCCOc1ccc(CC\C=C2/SC(=O)N(CCN)C2=O)cc1, CCCCOc1ccc(CC\C=C2/SC(=O)N(CCN)C2=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCOc1ccc(CC\C=C2/SC(=O)N(CCN)C2=O)cc1",348.150763628,24,2.627,97.93,0.0193981450803645,0.106,0.0626990725401822,0,0
"JNJ-26990990","anticonvulsant","","NS(=O)(=O)NCc1csc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NS(=O)(=O)NCc1csc2ccccc12",242.01836956,15,0.796,108.81,0.0153566218476316,0.11,0.0626783109238158,0,0
"Nampt-IN-1","","","CC(C)(O)CS(=O)(=O)Nc1ccc2CN(CCc2c1)C(=O)COc1cccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(O)CS(=O)(=O)Nc1ccc2CN(CCc2c1)C(=O)COc1cccnc1",419.1514919,29,1.327,117.21,0.0053023935516302,0.12,0.0626511967758151,0,0
"2-deoxy-2-([methyl(nitroso)carbamoyl]amino)hexose","","","CN([NH2+][O-])C(=O)N[C@@H](C=O)[C@@H](O)[C@@H](O)[C@@H](O)CO |&1:7,&2:10,&3:12,&4:14,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","oncology, endocrinology","pancreatic cancer, hypoglycemia","CN([NH2+][O-])C(=O)N[C@@H](C=O)[C@@H](O)[C@@H](O)[C@@H](O)CO |&1:7",267.106649884,18,-4.02,170,0.00126774657187492,0.124,0.0626338732859375,0,0
"WZ4003","AMPK inhibitor","NUAK1, NUAK2","CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1, CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1, CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1, CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1, CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1",496.198966468,35,3.894,91.85,0.0112485358766791,0.114,0.0626242679383396,0,0
"DMH4","VEGFR inhibitor","KDR","C(CN1CCOCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccccc1, C(CN1CCOCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccccc1, C(CN1CCOCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C(CN1CCOCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccccc1",400.189926008,30,3.705,51.89,0.0792337878339398,0.046,0.0626168939169699,0,0
"aticaprant","opioid receptor antagonist","","Cc1cc(C)cc(c1)[C@@H]1CCCN1Cc1ccc(Oc2ccc(cc2F)C(N)=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1cc(C)cc(c1)[C@@H]1CCCN1Cc1ccc(Oc2ccc(cc2F)C(N)=O)cc1",418.205656324,31,5.495,55.56,0.0911979080494261,0.034,0.0625989540247131,0,0
"oxidopamine","neurotoxin","","NCCc1cc(O)c(O)cc1O, NCCc1cc(O)c(O)cc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NCCc1cc(O)c(O)cc1O",169.073893212,12,0.245,86.71,0.0611818415201922,0.064,0.0625909207600961,0,0
"PT-2385","hypoxia inducible factor inhibitor","EPAS1","CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c2CC(F)(F)[C@@H](O)c12, CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c2CC(F)(F)[C@@H](O)c12, CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c2CC(F)(F)[C@@H](O)c12, CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c2CC(F)(F)[C@@H](O)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c2CC(F)(F)[C@@H](O)c12",383.043913524,26,2.927,95.77,0.0151761986759054,0.11,0.0625880993379527,0,0
"mk-0429","integrin antagonist","ITGAV","COc1ccc(cn1)[C@H](CC(=O)O)N2CCN(CCCc3ccc4CCCNc4n3)C2=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","nephrology","diabetic nephropathy","COc1ccc(cn1)[C@H](CC(=O)O)N2CCN(CCCc3ccc4CCCNc4n3)C2=O",439.221954408,32,1.809,107.89,0.00911630482120639,0.116,0.0625581524106032,0,0
"3-deazaadenosine","adenosylhomocysteinase inhibitor","AHCY","Nc1nccc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O |a:10,12,&1:15,&2:17|, Nc1nccc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O |a:10,12,&1:15,&2:17|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Nc1nccc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O |a:10",266.101504928,19,-1.104,126.65,0.00906289105605433,0.116,0.0625314455280272,0,0
"3-deazaadenosine (hydrochloride)","adenosylhomocysteinase inhibitor","AHCY","Nc1nccc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","immunology","rheumatoid arthritis","Nc1nccc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",266.101504928,19,-1.104,126.65,0.00906289105605433,0.116,0.0625314455280272,0,0
"GW-405833","cannabinoid receptor agonist","CNR2","COc1ccc2n(C(=O)c3cccc(Cl)c3Cl)c(C)c(CCN3CCOCC3)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc2n(C(=O)c3cccc(Cl)c3Cl)c(C)c(CCN3CCOCC3)c2c1",446.116397988,30,4.122,43.7,0.0370137354222459,0.088,0.0625068677111229,0,0
"SC-51089","prostanoid receptor antagonist","PTGER1","Clc1ccc2Oc3ccccc3CN(C(=O)NNC(=O)CCc3ccncc3)c2c1, Clc1ccc2Oc3ccccc3CN(C(=O)NNC(=O)CCc3ccncc3)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1ccc2Oc3ccccc3CN(C(=O)NNC(=O)CCc3ccncc3)c2c1",422.114568148,30,3.173,83.56,0.0210056387065806,0.104,0.0625028193532903,0,0
"AQ-RA741","acetylcholine receptor antagonist","CHRM2","CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1, CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1, CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"preclinical","","","CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1",463.294725424,34,3.656,68.78,0.0309646348232705,0.094,0.0624823174116353,0,0
"olodanrigan","angiotensin antagonist","","COc1ccc2CN([C@@H](Cc2c1OCc1ccccc1)C(O)=O)C(=O)C(c1ccccc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1ccc2CN([C@@H](Cc2c1OCc1ccccc1)C(O)=O)C(=O)C(c1ccccc1)c1ccccc1",507.204573028,38,5.361,76.07,0.0348132809513758,0.09,0.0624066404756879,0,0
"ursolic-acid","ATPase inhibitor, NFkB pathway inhibitor, STAT inhibitor","HSD11B1, PLA2G1B, PTPN1, PYGM","C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|",456.360345396,33,8.954,57.53,0.124811340054502,0,0.0624056700272512,1,0
"NU-2058","cyclin D inhibitor","CCNA2, CDK2","Nc1nc(OCC2CCCCC2)c2[nH]cnc2n1, Nc1nc(OCC2CCCCC2)c2[nH]cnc2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1nc(OCC2CCCCC2)c2[nH]cnc2n1",247.143310164,18,2.751,89.71,0.0647933893360665,0.06,0.0623966946680333,0,0
"BC-11","urokinase inhibitor","PLAU","NC(=N)SCc1ccc(cc1)B(O)O, NC(=N)SCc1ccc(cc1)B(O)O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC(=N)SCc1ccc(cc1)B(O)O",210.063428992,14,0.901,115.63,0.0227655338734875,0.102,0.0623827669367438,0,0
"CP-547632","kinase inhibitor","","NC(=O)c1c(NC(=O)NCCCCN2CCCC2)snc1OCc1c(F)cc(Br)cc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NC(=O)c1c(NC(=O)NCCCCN2CCCC2)snc1OCc1c(F)cc(Br)cc1F",531.075129168,32,3.265,137.82,0.000730206676781148,0.124,0.0623651033383906,0,0
"sulfamethoxypyridazine","bacterial antifolate","","COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1, COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1, COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1",280.063011244,19,1.187,115.58,0.0146343091001393,0.11,0.0623171545500697,0,0
"sdz-mks 492","phosphodiesterase inhibitor","PDE3A","COCCn1c(N[C@@H](CO)c2ccc(OC)c(OC)c2)nc2n(C)c(=O)n(C)c(=O)c12 |a:7|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","pulmonary","asthma","COCCn1c(N[C@@H](CO)c2ccc(OC)c(OC)c2)nc2n(C)c(=O)n(C)c(=O)c12 |a:7|",433.196133584,31,2.166,121.77,0.00663261106174807,0.118,0.062316305530874,0,0
"timofibrate","cholesterol inhibitor, lipase clearing factor inhibitor","LPL","CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|, CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|, CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|, CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|, CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|, CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17",329.048856672,21,2.397,92.14,0.0166299154011385,0.108,0.0623149577005693,0,0
"WYE-125132","mTOR inhibitor","MTOR","CNC(=O)Nc1ccc(cc1)-c1nc(N2C[C@@H]3CC[C@H](C2)O3)c2cnn(C3CCC4(CC3)OCCO4)c2n1 |&1:16,19|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CNC(=O)Nc1ccc(cc1)-c1nc(N2C[C@@H]3CC[C@H](C2)O3)c2cnn(C3CCC4(CC3)OCCO4)c2n1 |&1:16",519.259402536,38,3.385,115.66,0.00660630749666631,0.118,0.0623031537483332,0,0
"caffeic-acid","HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor","ALOX5, MIF","OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)\C=C\c1ccc(O)c(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)\C=C\c1ccc(O)c(O)c1",180.042258736,13,1.258,77.76,0.0905781185299607,0.034,0.0622890592649803,0,0
"abafungin","sterol methyltransferase inhibitor","","Cc1ccc(Oc2ccccc2-c2csc(NC3=NCCCN3)n2)c(C)c1 |t:18|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cc1ccc(Oc2ccccc2-c2csc(NC3=NCCCN3)n2)c(C)c1 |t:18|",378.151432324,27,4.776,86.78,0.0405697250154565,0.084,0.0622848625077282,0,0
"LH846","casein kinase inhibitor","CSNK1D","Cc1cc2sc(NC(=O)Cc3ccccc3)nc2cc1Cl, Cc1cc2sc(NC(=O)Cc3ccccc3)nc2cc1Cl, Cc1cc2sc(NC(=O)Cc3ccccc3)nc2cc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc2sc(NC(=O)Cc3ccccc3)nc2cc1Cl",316.043711716,21,3.562,70.23,0.0485634412883759,0.076,0.062281720644188,0,0
"CFTRinh-172","chloride channel blocker","CFTR","OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1, OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1, OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1, OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1, OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1",409.00541984,27,3.97,115,0.00855213868024357,0.116,0.0622760693401218,0,0
"sapacitabine","DNA synthesis inhibitor","","CCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N)c(=O)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N)c(=O)n1",490.315520444,35,6.5,137.47,0.0085447185622947,0.116,0.0622723592811474,0,0
"brivanib-alaninate","FGFR inhibitor, VEGFR inhibitor","FGFR3","C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N, C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N, C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N, C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N, C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N, C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N",441.181232468,32,4.152,116.76,0.0125395225718212,0.112,0.0622697612859106,0,0
"BW-373U86","opioid receptor agonist","OPRD1","CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(O)c1, CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(O)c1, CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(O)c1",435.288577424,32,4.513,47.02,0.0744666407944192,0.05,0.0622333203972096,0,0
"URB597","FAAH inhibitor","FAAH, FAAH2, TRPA1","NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1",338.163042564,25,4.102,81.42,0.0624353489623995,0.062,0.0622176744811997,0,0
"2-hydroxyflutamide","androgen receptor antagonist","AR","CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O",292.067091492,20,1.692,92.47,0.0264271744430111,0.098,0.0622135872215056,0,0
"JNJ-17203212","TRPV antagonist","TRPV1","FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1, FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1, FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1, FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1",419.11807942,29,3.791,61.36,0.034414106994735,0.09,0.0622070534973675,0,0
"imetit","histamine receptor agonist","HRH3, HRH4","NC(=N)SCCc1cnc[nH]1, NC(=N)SCCc1cnc[nH]1",0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC(=N)SCCc1cnc[nH]1",170.06261732,11,0.184,103.85,0.0323838451037179,0.092,0.0621919225518589,0,0
"naloxone-benzoylhydrazone","opioid receptor antagonist","OPRK1, OPRM1","Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1",445.200156344,33,2.582,94.39,0.0163276336260105,0.108,0.0621638168130053,0,0
"asp5878","fgfr inhibitor","FGFR3","OCCN1N=CC(NC2=NC=C(OCC3=C(F)C(OC)=CC(OC)=C3F)C=N2)=C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OCCN1N=CC(NC2=NC=C(OCC3=C(F)C(OC)=CC(OC)=C3F)C=N2)=C1",407.140510528,29,0.399,100.27,0.00830939874396647,0.116,0.0621546993719832,0,0
"GSK2879552","histone lysine demethylase inhibitor","KDM1A","OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1, OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1, OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1, OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1, OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1",364.215078136,27,3.663,52.57,0.0902950759113103,0.034,0.0621475379556551,0,0
"GS-9973","SYK inhibitor","SYK","C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1",411.180758292,31,5.157,83.37,0.0542301473549069,0.07,0.0621150736774535,0,0
"allopurinol-riboside","anti-leishmanial agent, phosphorylase inhibitor, anti-leishmanial agent, phosphorylase inhibitor","","OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ncc2c(O)ncnc12, OC[C@H]1O[C@H]([C@@H](O)[C@H]1O)n1ncc2c1[nH]cnc2=O |a:2,4,7,&1:5|, OC[C@H]1O[C@H](C(O)[C@H]1O)n1[nH]cc2c1ncnc2=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ncc2c(O)ncnc12",268.080769484,19,-0.673999999999999,133.75,0.00815526140511946,0.116,0.0620776307025597,0,0
"tomelukast","leukotriene receptor antagonist","CYSLTR1","CCCc1c(OCCCCc2nn[nH]n2)ccc(C(C)=O)c1O, CCCc1c(OCCCCc2nn[nH]n2)ccc(C(C)=O)c1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCCc1c(OCCCCc2nn[nH]n2)ccc(C(C)=O)c1O",318.169190564,23,4.191,100.99,0.0421343782519787,0.082,0.0620671891259894,0,0
"MBX-2982","glucose dependent insulinotropic receptor agonist","GPR119","CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1, CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1, CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1, CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1, CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1, CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1, CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1",448.179378388,32,3.628,122.98,0.00811157647393625,0.116,0.0620557882369681,0,0
"ly2922470","g protein-coupled receptor agonist","FFAR1","COc1cccc2CCCN(Cc3ccc(COc4ccc(cc4)[C@H](CC(O)=O)C#CC)s3)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","endocrinology","diabetes mellitus","COc1cccc2CCCN(Cc3ccc(COc4ccc(cc4)[C@H](CC(O)=O)C#CC)s3)c12",475.181729408,34,4.735,87.24,0.0200171846462813,0.104,0.0620085923231406,0,0
"liothyronine-(isomer)","","","N[C@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O",650.790051864,23,2.9,92.78,1.36299611949379e-05,0.124,0.0620068149805975,0,0
"SM-164","XIAP inhibitor","BIRC2, BIRC3, XIAP","CN[C@@H](C)C(=O)N[C@H]1CCCC[C@H]2CC[C@H](N2C1=O)C(=O)N[C@H](c1cn(CCCCc2ccc(CCCCn3cc(nn3)[C@@H](NC(=O)[C@@H]3CC[C@@H]4CCCC[C@H](NC(=O)[C@H](C)NC)C(=O)N34)c3ccccc3)cc2)nn1)c1ccccc1, CN[C@@H](C)C(=O)N[C@H]1CCCC[C@H]2CC[C@H](N2C1=O)C(=O)N[C@H](c1cn(CCCCc2ccc(CCCCn3cc(nn3)[C@@H](NC(=O)[C@@H]3CC[C@@H]4CCCC[C@H](NC(=O)[C@H](C)NC)C(=O)N34)c3ccccc3)cc2)nn1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN[C@@H](C)C(=O)N[C@H]1CCCC[C@H]2CC[C@H](N2C1=O)C(=O)N[C@H](c1cn(CCCCc2ccc(CCCCn3cc(nn3)[C@@H](NC(=O)[C@@H]3CC[C@@H]4CCCC[C@H](NC(=O)[C@H](C)NC)C(=O)N34)c3ccccc3)cc2)nn1)c1ccccc1",1120.669826408,82,6.856,242.5,1.18584325368435e-05,0.124,0.0620059292162684,0,0
"BGT226","PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CG","COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1",534.1991087,39,4.402,77.21,0.018003817566472,0.106,0.062001908783236,0,0
"3-carboxy-4-hydroxyphenylglycine-(R)","glutamate receptor antagonist","GRIN1, GRIN2A, GRIN2B, GRIN2C","N[C@@H](C(O)=O)c1ccc(O)c(c1)C(O)=O, N[C@@H](C(O)=O)c1ccc(O)c(c1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@@H](C(O)=O)c1ccc(O)c(c1)C(O)=O",211.048072388,15,-2.137,120.85,0.0119047101693409,0.112,0.0619523550846704,0,0
"3-carboxy-4-hydroxyphenylglycine-(S)","glutamate receptor antagonist","GRM1, GRM5","N[C@H](C(O)=O)c1ccc(O)c(c1)C(O)=O, N[C@H](C(O)=O)c1ccc(O)c(c1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@H](C(O)=O)c1ccc(O)c(c1)C(O)=O",211.048072388,15,-2.137,120.85,0.0119047101693409,0.112,0.0619523550846704,0,0
"cianidanol","fatty acid synthase inhibitor","PTGS1","O[C@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1ccc(O)c(O)c1, O[C@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1ccc(O)c(O)c1",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","O[C@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1ccc(O)c(O)c1",290.079038168,21,1.461,110.38,0.0218711042675784,0.102,0.0619355521337892,0,0
"GR-159897","tachykinin antagonist","TAC1, TACR2","COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1, COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1, COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1, COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1, COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1",414.177727324,29,3.007,64.54,0.0298232858293785,0.094,0.0619116429146893,0,0
"L-quisqualic-acid","glutamate receptor agonist","FOLH1, GRIA2, GRIK1, GRIK2, GRM1, GRM2, GRM3, GRM5, GRM7, GRM8","N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O, N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O, N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O, N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O, N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O",189.038570324,13,-4.386,131.32,0.00577796215580946,0.118,0.0618889810779047,0,0
"PF-06305591","sodium channel blocker","","C[C@H]([C@H](N)c1nc2cc(ccc2[nH]1)C(C)(C)C)C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@H]([C@H](N)c1nc2cc(ccc2[nH]1)C(C)(C)C)C(N)=O",274.179361324,20,1.474,97.79,0.0337092586720079,0.09,0.0618546293360039,0,0
"eprodisate","amyloid protein inhibitor, antiamyloidogenic agent","SAA1","OS(=O)(=O)CCCS(O)(=O)=O, OS(=O)(=O)CCCS(O)(=O)=O, OS(=O)(=O)CCCS(O)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","OS(=O)(=O)CCCS(O)(=O)=O",203.976229976,11,-1.656,125.5,0.0057013324993496,0.118,0.0618506662496748,0,0
"apararenone","mineralocorticoid receptor antagonist","","CC1(C)Oc2cc(NS(C)(=O)=O)ccc2N(C1=O)c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC1(C)Oc2cc(NS(C)(=O)=O)ccc2N(C1=O)c1ccc(F)cc1",364.089306244,25,2.398,84.09,0.02169027865238,0.102,0.06184513932619,0,0
"pimonidazole","","","O[C@@H](CN1CCCCC1)Cn1ccnc1[N+]([O-])=O |&1:1,r|, O[C@@H](CN1CCCCC1)Cn1ccnc1[N+]([O-])=O |&1:1,r|, O[C@@H](CN1CCCCC1)Cn1ccnc1[N+]([O-])=O |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","O[C@@H](CN1CCCCC1)Cn1ccnc1[N+]([O-])=O |&1:1",254.137890436,18,0.375,84.43,0.0356654494236723,0.088,0.0618327247118361,0,0
"rosiptor","SHIP1 phosphatase activator","","[H][C@@]12CCC(=C)[C@@]1(C)CC[C@@]([H])([C@H]2CN)[C@@]1(C)CC[C@H](O)C[C@@H]1CO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","[H][C@@]12CCC(=C)[C@@]1(C)CC[C@@]([H])([C@H]2CN)[C@@]1(C)CC[C@H](O)C[C@@H]1CO",321.26677936,25,3.55,66.48,0.109659967040688,0.014,0.061829983520344,0,0
"meclinertant","neurotensin receptor antagonist","NTSR1, NTSR2","COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O, COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O, COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O",586.198297772,42,3.721,115.57,0.00365740685322449,0.12,0.0618287034266122,0,0
"AZ505","histone lysine methyltransferase inhibitor","SMYD2","Oc1ccc(CCNCCN(C2CCCCC2)C(=O)CCNCCc2ccc(Cl)c(Cl)c2)c2OCC(=O)Nc12, Oc1ccc(CCNCCN(C2CCCCC2)C(=O)CCNCCc2ccc(Cl)c(Cl)c2)c2OCC(=O)Nc12, Oc1ccc(CCNCCN(C2CCCCC2)C(=O)CCNCCc2ccc(Cl)c(Cl)c2)c2OCC(=O)Nc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(CCNCCN(C2CCCCC2)C(=O)CCNCCc2ccc(Cl)c(Cl)c2)c2OCC(=O)Nc12",576.227011056,39,4.372,102.93,0.00365672760044875,0.12,0.0618283638002244,0,0
"piclamilast","phosphodiesterase inhibitor","PDE4A, PDE4B, PDE4C, PDE4D","COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl, COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl, COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl, COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl",380.069447796,25,3.806,60.45,0.0356533418548227,0.088,0.0618266709274113,0,0
"AMG-925","CDK inhibitor, FLT3 inhibitor","CDK4, CDK6, FLT3","C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12 |r|, C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12 |r|, C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12 |r|, C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12 |r|, C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12 |r|",471.238273168,35,3.208,109.06,0.0115820130289205,0.112,0.0617910065144602,0,0
"SNG-1153","selective estrogen receptor modulator (SERM)","ESR1","CC(C)=CCc1c(O)cc(O)c2c1oc(c(O)c2=O)-c1ccc(cc1)C(F)(F)F, CC(C)=CCc1c(O)cc(O)c2c1oc(c(O)c2=O)-c1ccc(cc1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)=CCc1c(O)cc(O)c2c1oc(c(O)c2=O)-c1ccc(cc1)C(F)(F)F",406.102808304,29,6.69,90.9,0.0475732435405325,0.076,0.0617866217702662,0,0
"BVD-523","MAP kinase inhibitor","","CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1, CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1, CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1",432.111981304,29,4.448,90.04,0.015540029803491,0.108,0.0617700149017455,0,0
"ZM-447439","Aurora kinase inhibitor","AURKA, AURKB","COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1",513.237604472,38,3.368,97.84,0.0114282868305268,0.112,0.0617141434152634,0,0
"cyt387","JAK inhibitor","JAK1, JAK2, JAK3","O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",414.180423944,31,2.525,103.17,0.0173755392188192,0.106,0.0616877696094096,0,0
"ANA-12","tropomyosin receptor kinase inhibitor","NTRK2","O=C(Nc1ccccc1C(=O)N[C@H]1CCCCNC1=O)c1cc2ccccc2s1 |&1:12,r|, O=C(Nc1ccccc1C(=O)N[C@H]1CCCCNC1=O)c1cc2ccccc2s1 |&1:12,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(Nc1ccccc1C(=O)N[C@H]1CCCCNC1=O)c1cc2ccccc2s1 |&1:12",407.130362532,29,3.795,115.54,0.0133511372165815,0.11,0.0616755686082908,0,0
"priralfinamide","sodium channel blocker","CACNA1B","C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O, C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O, C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O",302.143056068,22,2.5,64.35,0.0733390472872526,0.05,0.0616695236436263,0,0
"rosiglitazone","insulin sensitizer, PPAR receptor agonist, insulin sensitizer, ppar receptor agonist","FFAR1, PPARG, TRPC5, TRPM3","CN(CCOc1ccc(C[C@H]2SC(=O)NC2=O)cc1)c1ccccn1 |&1:10|, CN(CCOc1ccc(C[C@H]2SC(=O)NC2=O)cc1)c1ccccn1 |&1:10|, CN(CCOc1ccc(C[C@H]2SC(=O)NC2=O)cc1)c1ccccn1 |&1:10|, CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","insulin sensitizer","diabetes mellitus","CN(CCOc1ccc(C[C@H]2SC(=O)NC2=O)cc1)c1ccccn1 |&1:10|",357.114712468,25,2.443,96.83,0.0193312719961164,0.104,0.0616656359980582,0,0
"doramapimod","p38 MAPK inhibitor","MAPK11, MAPK12, MAPK13, MAPK14","Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C",527.289640044,39,5.114,80.65,0.0232282046144299,0.1,0.061614102307215,0,0
"upamostat","serine protease inhibitor","","CCOC(=O)N1CCN(CC1)C(=O)[C@H](Cc1cccc(c1)C(=N)NO)NS(=O)(=O)c1c(cc(cc1C(C)C)C(C)C)C(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCOC(=O)N1CCN(CC1)C(=O)[C@H](Cc1cccc(c1)C(=N)NO)NS(=O)(=O)c1c(cc(cc1C(C)C)C(C)C)C(C)C",629.324705224,44,5.716,160.51,0.00119303804906094,0.122,0.0615965190245305,0,0
"misonidazole","","","COC[C@@H](O)Cn1ccnc1[N+]([O-])=O |&1:3,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COC[C@@H](O)Cn1ccnc1[N+]([O-])=O |&1:3",201.074955832,14,-0.532,90.42,0.0351737031858286,0.088,0.0615868515929143,0,0
"dorsomorphin","AMPK inhibitor","ACVR1, BMPR1A, BMPR1B, EPHA2, FKBP1A, FLT1, FLT3, KDR, LCK, MKNK1, PRKAA1, RPS6KA1, SRC","C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1, C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1, C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1, C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1, C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1, C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1, C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1",399.20591042,30,3.717,55.55,0.0750780344124346,0.048,0.0615390172062173,0,0
"ravuconazole","sterol demethylase inhibitor","","C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@](O)(Cn1cncn1)c1ccc(F)cc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@](O)(Cn1cncn1)c1ccc(F)cc1F",437.112187604,31,3.206,115.86,0.0089190944069554,0.114,0.0614595472034777,0,0
"sertindole","dopamine receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, KCNH2","Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12, Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12, Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12, Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12, Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12",0,0,0,0,0,0,0,0,1,8,1,1,0,0,1,3,0,0,1,3,0,0,0,0,"withdrawn","","","Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12",440.177917352,31,4.14,40.51,0.0568962416779454,0.066,0.0614481208389727,0,0
"BI-409306","phosphodiesterase inhibitor","","Oc1nc(Cc2ccccn2)nc2n(ncc12)C1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Oc1nc(Cc2ccccn2)nc2n(ncc12)C1CCOCC1",311.138224784,23,1.744,85.95,0.0388906815405011,0.084,0.0614453407702506,0,0
"PF-4800567","casein kinase inhibitor","CSNK1D, CSNK1E","Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1",359.114902496,25,2.854,88.08,0.0248275102582393,0.098,0.0614137551291196,0,0
"quiflapon","leukotriene synthesis inhibitor","ALOX5, ALOX5AP","CC(C)(C)Sc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12, CC(C)(C)Sc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)(C)Sc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12",586.20569166,41,8.475,89.65,0.0167766066964281,0.106,0.061388303348214,0,0
"TCS-HDAC6-20b","HDAC inhibitor","HDAC6","CC(C)C(=O)SCCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)NC12CC3CC(CC(C3)C1)C2, CC(C)C(=O)SCCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)NC12CC3CC(CC(C3)C1)C2, CC(C)C(=O)SCCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)NC12CC3CC(CC(C3)C1)C2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)C(=O)SCCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)NC12CC3CC(CC(C3)C1)C2",480.302178888,33,5.738,109.8,0.0107634167060694,0.112,0.0613817083530347,0,0
"chlorazanil","","","Nc1ncnc(Nc2ccc(Cl)cc2)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1ncnc(Nc2ccc(Cl)cc2)n1",221.046822936,15,1.372,76.72,0.0587421659469943,0.064,0.0613710829734971,0,0
"salubrinal","eukaryotic translation initiation factor inhibitor","EIF2S1","ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|, ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|, ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|, ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|, ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|, ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|, ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4",478.018865204,30,5.293,98.14,0.00671704891634953,0.116,0.0613585244581748,0,0
"dimesna","tubulin polymerization inhibitor","","OS(=O)(=O)CCSSCCS(O)(=O)=O, OS(=O)(=O)CCSSCCS(O)(=O)=O, OS(=O)(=O)CCSSCCS(O)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","OS(=O)(=O)CCSSCCS(O)(=O)=O",281.93602204,14,-0.788,176.1,0.000679028829773379,0.122,0.0613395144148867,0,0
"SB-243213","serotonin receptor inverse agonist","HTR2A, HTR2B, HTR2C, HTR6","Cc1cc2CCN(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c2cc1C(F)(F)F, Cc1cc2CCN(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c2cc1C(F)(F)F, Cc1cc2CCN(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c2cc1C(F)(F)F, Cc1cc2CCN(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c2cc1C(F)(F)F",0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1cc2CCN(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c2cc1C(F)(F)F",428.146010508,31,3.852,67.35,0.038674131494418,0.084,0.061337065747209,0,0
"AZD7594","glucocorticoid receptor modulator","","C[C@H](NC(=O)C(C)(F)F)[C@H](Oc1ccc2n(ncc2c1)-c1cccc(c1)C(=O)N[C@@H]1CCOC1)c1ccc2OCCOc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@H](NC(=O)C(C)(F)F)[C@H](Oc1ccc2n(ncc2c1)-c1cccc(c1)C(=O)N[C@@H]1CCOC1)c1ccc2OCCOc2c1",606.228991184,44,4.537,112.94,0.00465919562913169,0.118,0.0613295978145658,0,0
"tyrphostin-AG-879","tyrosine kinase inhibitor","ERBB2, KDR, NTRK1","CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C",316.160934388,22,4.196,102.13,0.0345071704696257,0.088,0.0612535852348129,0,0
"iniparib","PARP inhibitor","PARP1","NC(=O)c1ccc(I)c(c1)[N+]([O-])=O, NC(=O)c1ccc(I)c(c1)[N+]([O-])=O, NC(=O)c1ccc(I)c(c1)[N+]([O-])=O, NC(=O)c1ccc(I)c(c1)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","NC(=O)c1ccc(I)c(c1)[N+]([O-])=O",291.93449002,13,1.869,86.23,0.00650644917184118,0.116,0.0612532245859206,0,0
"repotrectinib","receptor tyrosine protein kinase inhibitor","","C[C@H]1CNC(=O)c2cnn3ccc(N[C@H](C)c4cc(F)ccc4O1)nc23",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","C[C@H]1CNC(=O)c2cnn3ccc(N[C@H](C)c4cc(F)ccc4O1)nc23",355.144453036,26,3.081,80.55,0.0424914800184863,0.08,0.0612457400092431,0,0
"AMG-176","MCL1 inhibitor","","CO[C@H]1\C=C\C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)c2ccc3OC[C@]4(CCCc5cc(Cl)ccc45)CN(C[C@@H]4CC[C@@H]14)c3c2 |t:3|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CO[C@H]1\C=C\C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)c2ccc3OC[C@]4(CCCc5cc(Cl)ccc45)CN(C[C@@H]4CC[C@@H]14)c3c2 |t:3|",612.242471092,42,6.495,93.32,0.00647219861850831,0.116,0.0612360993092542,0,0
"lauric-diethanolamide","","","CCCCCCCCCCCC(=O)N(CCO)CCO, CCCCCCCCCCCC(=O)N(CCO)CCO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCCCCCC(=O)N(CCO)CCO",287.246043916,20,3.808,60.77,0.0964478414078384,0.026,0.0612239207039192,0,0
"mik665","mcl1 inhibitor","MCL1","COc1ccccc1-c1nccc(COc2ccccc2C[C@@H](Oc2ncnc3sc(c(-c4ccc(OCCN5CCN(C)CC5)c(Cl)c4C)c23)-c2ccc(F)cc2)C(O)=O)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","hematologic malignancy","multiple myeloma","COc1ccccc1-c1nccc(COc2ccccc2C[C@@H](Oc2ncnc3sc(c(-c4ccc(OCCN5CCN(C)CC5)c(Cl)c4C)c23)-c2ccc(F)cc2)C(O)=O)n1",874.271560028,62,7.797,160.5,0.000360351711514409,0.122,0.0611801758557572,0,0
"pumosetrag","serotonin receptor agonist","HTR3A, HTR4","O=C(N[C@H]1CN2CCC1CC2)c1c[nH]c2ccsc2c1=O",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O=C(N[C@H]1CN2CCC1CC2)c1c[nH]c2ccsc2c1=O",303.104147784,21,2.484,93.44,0.0302296538720888,0.092,0.0611148269360444,0,0
"resibufogenin","Na/K-ATPase inhibitor","","C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@]11O[C@@H]1C[C@@H]2c1ccc(=O)oc1, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@]11O[C@@H]1C[C@@H]2c1ccc(=O)oc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@]11O[C@@H]1C[C@@H]2c1ccc(=O)oc1",384.230059504,28,4.787,62.97,0.0742250335848897,0.048,0.0611125167924449,0,0
"AZD5582","XIAP inhibitor","BIRC2, BIRC3, XIAP","CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]1[C@@H](Cc2ccccc12)OCC#CC#CCO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC)C1CCCCC1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]1[C@@H](Cc2ccccc12)OCC#CC#CCO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC)C1CCCCC1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]1[C@@H](Cc2ccccc12)OCC#CC#CCO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC)C1CCCCC1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]1[C@@H](Cc2ccccc12)OCC#CC#CCO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC)C1CCCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]1[C@@H](Cc2ccccc12)OCC#CC#CCO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC)C1CCCCC1",1014.594261456,74,6.12,199.54,5.3577256770017e-05,0.122,0.061026788628385,0,0
"PF-06412562","dopamine receptor partial agonist","","Cc1cc(Oc2nccc3[nH]ncc23)ccc1-c1c(C)ncnc1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1cc(Oc2nccc3[nH]ncc23)ccc1-c1c(C)ncnc1C",331.143310164,25,3.819,76.58,0.0759614190469039,0.046,0.060980709523452,0,0
"CXD101","HDAC inhibitor","","Cc1nn(C)cc1CN1CCC(CC1)c1ccc(cc1)C(=O)Nc1ccccc1N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","Cc1nn(C)cc1CN1CCC(CC1)c1ccc(cc1)C(=O)Nc1ccccc1N",403.237210548,30,2.882,76.18,0.0358926867658456,0.086,0.0609463433829228,0,0
"streptozocin","dna alkylating drug","","CN([N+][O-])C(=O)NC1[C@@H](O)OC(CO)[C@@H](O)[C@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","oncology","pancreatic cancer","CN([N+][O-])C(=O)NC1[C@@H](O)OC(CO)[C@@H](O)[C@H]1O",265.09099982,18,-1.963,145.55,0.00387385095215358,0.118,0.0609369254760768,0,0
"MK-8033","c-Met inhibitor","MET","Cn1cc(cn1)-c1cnc2ccc3ccc(CS(=O)(=O)NCc4ccccn4)cc3c(=O)c2c1, Cn1cc(cn1)-c1cnc2ccc3ccc(CS(=O)(=O)NCc4ccccn4)cc3c(=O)c2c1, Cn1cc(cn1)-c1cnc2ccc3ccc(CS(=O)(=O)NCc4ccccn4)cc3c(=O)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cn1cc(cn1)-c1cnc2ccc3ccc(CS(=O)(=O)NCc4ccccn4)cc3c(=O)c2c1",471.136510532,34,3.109,115.22,0.00783136886655144,0.114,0.0609156844332757,0,0
"etripamil","calcium channel blocker","CACNA1C","COC(=O)c1cccc(CCN(C)CCC[C@](C#N)(C(C)C)c2ccc(OC)c(OC)c2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","cardiology","ventricular tachycardia (vt)","COC(=O)c1cccc(CCN(C)CCC[C@](C#N)(C(C)C)c2ccc(OC)c(OC)c2)c1",452.267507632,33,5.073,71.79,0.0417898751665032,0.08,0.0608949375832516,0,0
"VX-765","caspase inhibitor","CASP1","CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C",508.208862456,35,1.998,140.06,0.00175046349186846,0.12,0.0608752317459342,0,0
"vx-765","caspase inhibitor","","CCO[C@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCO[C@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C",508.208862456,35,1.998,140.06,0.00175046349186846,0.12,0.0608752317459342,0,0
"trovafloxacin","bacterial DNA gyrase inhibitor","TOP2A","N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F",416.109625,30,4.766,101.45,0.0236116436405431,0.098,0.0608058218202715,0,0
"AG-1024","insulin growth factor receptor inhibitor","IGF1R","CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O, CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O",304.021125136,18,3.656,67.81,0.0355777361048507,0.086,0.0607888680524253,0,0
"uki-1","urokinase inhibitor","","CCOC(=O)N1CCN(CC1)C(=O)[C@H](Cc1cccc(c1)C(N)=N)NS(=O)(=O)c1c(cc(cc1C(C)C)C(C)C)C(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)N1CCN(CC1)C(=O)[C@H](Cc1cccc(c1)C(N)=N)NS(=O)(=O)c1c(cc(cc1C(C)C)C(C)C)C(C)C",613.329790604,43,5.585,154.27,0.00155374065974444,0.12,0.0607768703298722,0,0
"PF-06651600","JAK inhibitor","","C[C@H]1CC[C@H](CN1C(=O)C=C)Nc1ncnc2[nH]ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","C[C@H]1CC[C@H](CN1C(=O)C=C)Nc1ncnc2[nH]ccc12",285.158960228,21,1.921,73.91,0.0615425052902786,0.06,0.0607712526451393,0,0
"LIMKi-3","LIM kinase inhibitor","LIMK1","CC(C)C(=O)Nc1ncc(s1)-c1cc(nn1-c1c(Cl)cccc1Cl)C(F)F, CC(C)C(=O)Nc1ncc(s1)-c1cc(nn1-c1c(Cl)cccc1Cl)C(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)C(=O)Nc1ncc(s1)-c1cc(nn1-c1c(Cl)cccc1Cl)C(F)F",430.023343868,27,3.915,88.05,0.0095252534110464,0.112,0.0607626267055232,0,0
"puromycin","protein synthesis inhibitor","NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1","COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)n2cnc3c(ncnc23)N(C)C)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)n2cnc3c(ncnc23)N(C)C)cc1",471.223017028,34,0.6,160.88,0.00147467539905212,0.12,0.0607373376995261,0,0
"puromycin dihydrochloride","ribosomal protein inhibitor","","COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)OC([C@@H]2O)n2cnc3c(ncnc23)N(C)C)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)OC([C@@H]2O)n2cnc3c(ncnc23)N(C)C)cc1",471.223017028,34,0.6,160.88,0.00147467539905212,0.12,0.0607373376995261,0,0
"MK-0893","glucagon receptor antagonist","GCGR","COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1, COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1, COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1, COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1, COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1",587.137861704,41,8.014,93.45,0.0134621128388359,0.108,0.060731056419418,0,0
"GW-788388","ALK tyrosine kinase receptor inhibitor","LCK, MAPK14, TGFBR1","O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1, O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1, O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1, O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1",425.185174976,32,3.88,92.79,0.0294602354884712,0.092,0.0607301177442356,0,0
"GSK2881078","androgen receptor modulator","","C[C@H](CS(C)(=O)=O)n1ccc2c(c(ccc12)C#N)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@H](CS(C)(=O)=O)n1ccc2c(c(ccc12)C#N)C(F)(F)F",330.064983316,22,3.402,71.24,0.0413848978081322,0.08,0.0606924489040661,0,0
"XL888","HSP inhibitor","","[H][C@]1(C[C@@H]2CC[C@H](C1)N2c1ccc(cn1)C(=O)C1CC1)NC(=O)c1cc(N[C@H](C)CC)c(cc1C)C(N)=O |TLB:9:8:4.5:1.2.7|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","[H][C@]1(C[C@@H]2CC[C@H](C1)N2c1ccc(cn1)C(=O)C1CC1)NC(=O)c1cc(N[C@H](C)CC)c(cc1C)C(N)=O |TLB:9:8:4.5:1.2.7|",503.289640044,38,4.89,117.42,0.0133490247280865,0.108,0.0606745123640432,0,0
"AV-608","tachykinin antagonist","TACR1","FC(F)(F)c1cc(cc(c1)C(F)(F)F)C(=O)N1CC[C@@H](C[C@H]1Cc1ccc(Cl)cc1)NC(=O)c1ccnc2ccccc12, FC(F)(F)c1cc(cc(c1)C(F)(F)F)C(=O)N1CC[C@@H](C[C@H]1Cc1ccc(Cl)cc1)NC(=O)c1ccnc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","FC(F)(F)c1cc(cc(c1)C(F)(F)F)C(=O)N1CC[C@@H](C[C@H]1Cc1ccc(Cl)cc1)NC(=O)c1ccnc2ccccc12",619.146124008,43,7.809,62.3,0.019323954515466,0.102,0.060661977257733,0,0
"apatinib","RET tyrosine kinase inhibitor","CSK, KDR, KIT, RET","O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1, O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1, O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1",397.190260356,30,4.262,90.7,0.0413214329809185,0.08,0.0606607164904592,0,0
"emricasan","caspase inhibitor","CASP1, CASP3, CASP7","C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COc1c(F)c(F)cc(F)c1F, C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COc1c(F)c(F)cc(F)c1F, C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COc1c(F)c(F)cc(F)c1F, C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COc1c(F)c(F)cc(F)c1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COc1c(F)c(F)cc(F)c1F",569.178513084,40,3.095,150.9,0.00131330143046923,0.12,0.0606566507152346,0,0
"aminopurvalanol-a","CDK inhibitor, tyrosine kinase inhibitor","CDK1, CDK2, CDK5","CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1",403.188736132,28,3.464,113.91,0.0111807193427405,0.11,0.0605903596713702,0,0
"SR-3306","JNK inhibitor","MAPK10, MAPK8, MAPK9","Cc1ccc(cn1)-c1ncn(n1)-c1ccc(Nc2nccc(n2)-c2cccc(c2)N2CCOCC2)cc1, Cc1ccc(cn1)-c1ncn(n1)-c1ccc(Nc2nccc(n2)-c2cccc(c2)N2CCOCC2)cc1, Cc1ccc(cn1)-c1ncn(n1)-c1ccc(Nc2nccc(n2)-c2cccc(c2)N2CCOCC2)cc1, Cc1ccc(cn1)-c1ncn(n1)-c1ccc(Nc2nccc(n2)-c2cccc(c2)N2CCOCC2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(cn1)-c1ncn(n1)-c1ccc(Nc2nccc(n2)-c2cccc(c2)N2CCOCC2)cc1",490.222957452,37,4.238,93.88,0.0211424135193872,0.1,0.0605712067596936,0,0
"remimazolam","benzodiazepine receptor agonist","GABBR1","COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc12 |t:7|, COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc12 |t:7|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc12 |t:7|",438.069137948,28,3.856,69.37,0.0149558243968804,0.106,0.0604779121984402,0,0
"INC-280","c-Met inhibitor","MET","CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1, CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1, CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1, CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1, CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1",412.144787384,31,3.28,85.07,0.0328732513946707,0.088,0.0604366256973353,0,0
"ketohexokinase-inhibitor-1","kinase inhibitor","","[H][C@@]12CN(C[C@]1([H])[C@H]2CC(O)=O)c1cc(nc(n1)N1CC[C@@H]1C)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@@]12CN(C[C@]1([H])[C@H]2CC(O)=O)c1cc(nc(n1)N1CC[C@@H]1C)C(F)(F)F",356.146010508,27,3.281,69.56,0.0688370736164722,0.052,0.0604185368082361,0,0
"PNU-177864","dopamine receptor antagonist","DRD3","CCCNCCc1ccc(NS(=O)(=O)c2ccc(OC(F)(F)F)cc2)cc1, CCCNCCc1ccc(NS(=O)(=O)c2ccc(OC(F)(F)F)cc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,"preclinical","","","CCCNCCc1ccc(NS(=O)(=O)c2ccc(OC(F)(F)F)cc2)cc1",402.122498192,27,4.333,75.81,0.0268355709893903,0.094,0.0604177854946951,0,0
"KP-1212","","","NC1=NC(=O)N(CN1)[C@H]1C[C@@H](O)[C@@H](CO)O1 |t:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NC1=NC(=O)N(CN1)[C@H]1C[C@@H](O)[C@@H](CO)O1 |t:1|",230.101504928,16,-1.668,120.41,0.0107853657939414,0.11,0.0603926828969707,0,0
"APD668","glucose dependent insulinotropic receptor agonist","GPR119","CC(C)OC(=O)N1CCC(CC1)Oc1ncnc2n(ncc12)-c1ccc(cc1F)S(C)(=O)=O, CC(C)OC(=O)N1CCC(CC1)Oc1ncnc2n(ncc12)-c1ccc(cc1F)S(C)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)OC(=O)N1CCC(CC1)Oc1ncnc2n(ncc12)-c1ccc(cc1F)S(C)(=O)=O",477.148218088,33,3.518,124.89,0.00477398715353238,0.116,0.0603869935767662,0,0
"roscovitine","CDK inhibitor","CDK2, CDK9","CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1",354.216809452,26,3.506,87.89,0.0407476021986184,0.08,0.0603738010993092,0,0
"benactyzine","butyrylcholinesterase inhibitor","","CCN(CC)CCOC(=O)C(O)(c1ccccc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN(CC)CCOC(=O)C(O)(c1ccccc1)c1ccccc1",327.18344366,24,3.445,49.77,0.108660094677776,0.012,0.060330047338888,0,0
"caricotamide","NADPH quinone oxidoreductase inhibitor","NQO2","NC(=O)CN1C=CCC(=C1)C(N)=O |c:5,8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NC(=O)CN1C=CCC(=C1)C(N)=O |c:5",181.085126592,13,-1.236,89.42,0.0386553357953446,0.082,0.0603276678976723,0,0
"chlormerodrin","sodium/potassium/chloride transporter inhibitor","ALDH5A1, SLC12A1","COC(CNC(=O)N)C[Hg]Cl",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","urology","urinary frequency","COC(CNC(=O)N)C[Hg]Cl",368.021548272,11,-0.556,64.35,0.000613198471151367,0.12,0.0603065992355757,0,0
"topilutamide","androgen receptor antagonist","","C[C@](O)(CNC(=O)C(F)(F)F)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@](O)(CNC(=O)C(F)(F)F)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O |&1:1",403.060289772,27,1.468,121.57,0.00460080006890863,0.116,0.0603004000344543,0,0
"schisandrol-B","lipid peroxidase inhibitor","","COc1cc2C[C@](C)(O)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC, COc1cc2C[C@](C)(O)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC, COc1cc2C[C@](C)(O)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1cc2C[C@](C)(O)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC",416.183503236,30,3.413,75.61,0.0305683989274506,0.09,0.0602841994637253,0,0
"LCQ908","diacylglycerol O acyltransferase inhibitor","DGAT1","OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|",455.182061668,33,5.748,75.11,0.0425544784388799,0.078,0.0602772392194399,0,0
"CPI-360","histone lysine methyltransferase inhibitor","EZH2","COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCOCC2)c2ccccc12, COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCOCC2)c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCOCC2)c2ccccc12",437.231456472,32,4.209,85.35,0.0284802362224297,0.092,0.0602401181112148,0,0
"capromorelin","growth hormone secretagogue receptor agonist","","CN1N=C2CCN(C[C@@]2(Cc2ccccc2)C1=O)C(=O)[C@@H](COCc1ccccc1)NC(=O)C(C)(C)N |t:2|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1N=C2CCN(C[C@@]2(Cc2ccccc2)C1=O)C(=O)[C@@H](COCc1ccccc1)NC(=O)C(C)(C)N |t:2|",505.2689046,37,1.454,117.33,0.00440131929848886,0.116,0.0602006596492444,0,0
"TC-G-1008","G protein-coupled receptor agonist","GPR39","CNc1nc(NCc2ccc(NS(C)(=O)=O)cc2Cl)cc(n1)-c1ccccn1, CNc1nc(NCc2ccc(NS(C)(=O)=O)cc2Cl)cc(n1)-c1ccccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CNc1nc(NCc2ccc(NS(C)(=O)=O)cc2Cl)cc(n1)-c1ccccn1",418.097872528,28,2.915,117.28,0.00635838285881155,0.114,0.0601791914294058,0,0
"pirbuterol","adrenergic receptor agonist","ADRB1, ADRB2","Oc1ccc(nc1CO)C(O)CNC(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,"withdrawn","pulmonary","bronchospasm","Oc1ccc(nc1CO)C(O)CNC(C)(C)C",240.1473925,17,0.366,85.61,0.0383185866288693,0.082,0.0601592933144346,0,0
"NAN-190","serotonin receptor agonist","ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1F","COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1, COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,1,3,0,0,0,0,"preclinical","","","COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1",393.205241724,29,3.549,53.09,0.0702843238628151,0.05,0.0601421619314076,0,0
"padsevonil","antiepileptic","","COCc1nn2c(CN3C[C@@H](CC(F)(F)Cl)CC3=O)c(nc2s1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COCc1nn2c(CN3C[C@@H](CC(F)(F)Cl)CC3=O)c(nc2s1)C(F)(F)F",432.044615468,27,2.367,87.97,0.00624039411932894,0.114,0.0601201970596645,0,0
"mrtx849","ras gtpase inhibitor","KRAS","CN1CCC[C@H]1COc2nc3CN(CCc3c(n2)N4CCN([C@@H](CC#N)C4)C(=O)C(=C)F)c5cccc6cccc(Cl)c56",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","oncology","gastric adenocarcinoma","CN1CCC[C@H]1COc2nc3CN(CCc3c(n2)N4CCN([C@@H](CC#N)C4)C(=O)C(=C)F)c5cccc6cccc(Cl)c56",603.25247926,43,5.215,88.83,0.00817670698227266,0.112,0.0600883534911363,0,0
"ebrotidine","histamine receptor antagonist","HRH2","NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1, NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1, NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1, NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1, NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1",475.975848884,26,2.693,195.24,0.00015714794559274,0.12,0.0600785739727964,0,0
"NG-nitro-arginine","nitric oxide synthase inhibitor","NOS1, NOS2, NOS3","N[C@@H](CCCNC(N)=N[N+]([O-])=O)C(O)=O, N[C@@H](CCCNC(N)=N[N+]([O-])=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","N[C@@H](CCCNC(N)=N[N+]([O-])=O)C(O)=O",219.096753896,15,-2.3,156.87,0.00412594103295474,0.116,0.0600629705164774,0,0
"protoporphyrin-IX","heme oxygenase inhibitor","HMOX1","Cc1c(C=C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C=C)c5C)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C, Cc1c(C=C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C=C)c5C)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1c(C=C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C=C)c5C)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C",562.258005568,42,5.046,131.96,0.0061212208219531,0.114,0.0600606104109766,0,0
"cenisertib","aurora kinase inhibitor","AURKB, KDR","[H][C@@]1([C@H]([C@H]2C(N)=O)NC3=NC(NC4=CC=C(C(C)=C4)N5CCN(CC5)C)=NC=C3F)C[C@]2(C=C1)[H]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","pancreatic cancer","[H][C@@]1([C@H]([C@H]2C(N)=O)NC3=NC(NC4=CC=C(C(C)=C4)N5CCN(CC5)C)=NC=C3F)C[C@]2(C=C1)[H]",451.2495868,35,0.434,98.35,0.0121174200033456,0.108,0.0600587100016728,0,0
"KG-5","RAF inhibitor","BRAF, FLT3, KIT, PDGFRB","CSc1nc(N)cc(Oc2ccc(cc2)-c2nnc(Nc3cccc(c3)C(F)(F)F)[nH]2)n1, CSc1nc(N)cc(Oc2ccc(cc2)-c2nnc(Nc3cccc(c3)C(F)(F)F)[nH]2)n1, CSc1nc(N)cc(Oc2ccc(cc2)-c2nnc(Nc3cccc(c3)C(F)(F)F)[nH]2)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CSc1nc(N)cc(Oc2ccc(cc2)-c2nnc(Nc3cccc(c3)C(F)(F)F)[nH]2)n1",459.108913792,32,6.289,139.93,0.00809944745573284,0.112,0.0600497237278664,0,0
"chlorfenson","other antifungal","","Clc1ccc(OS(=O)(=O)c2ccc(Cl)cc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Clc1ccc(OS(=O)(=O)c2ccc(Cl)cc2)cc1",301.957120476,18,3.394,51.75,0.0500964128063473,0.07,0.0600482064031737,0,0
"LY3214996","ERK inhibitor","","Cn1nccc1Nc1nccc(n1)-c1cc2C(=O)N(CCN3CCOCC3)C(C)(C)c2s1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cn1nccc1Nc1nccc(n1)-c1cc2C(=O)N(CCN3CCOCC3)C(C)(C)c2s1",453.194694104,32,0.694,116.65,0.00407327374600816,0.116,0.0600366368730041,0,0
"DMPS","chelating agent","","OS(=O)(=O)C[C@@H](S)CS |&1:5,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OS(=O)(=O)C[C@@H](S)CS |&1:5",187.963557116,9,0.316,140.35,0.00606055188268296,0.114,0.0600302759413415,0,0
"BIO-5192","integrin inhibitor","ITGA4, ITGB1","CC(C)C[C@H](N(C)C(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)NCC[C@H](NC(=O)[C@@H]1CCCN1S(=O)(=O)c1cc(Cl)cc(Cl)c1)C(O)=O, CC(C)C[C@H](N(C)C(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)NCC[C@H](NC(=O)[C@@H]1CCCN1S(=O)(=O)c1cc(Cl)cc(Cl)c1)C(O)=O, CC(C)C[C@H](N(C)C(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)NCC[C@H](NC(=O)[C@@H]1CCCN1S(=O)(=O)c1cc(Cl)cc(Cl)c1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)C[C@H](N(C)C(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)NCC[C@H](NC(=O)[C@@H]1CCCN1S(=O)(=O)c1cc(Cl)cc(Cl)c1)C(O)=O",816.247488792,55,2.802,202.7,3.17541477067149e-05,0.12,0.0600158770738534,0,0
"iodoxamic acid","radiopaque medium","","OC(=O)C1=C(I)C=C(I)C(NC(=O)CCOCCOCCOCCOCCC(=O)NC2=C(I)C=C(I)C(C(O)=O)=C2I)=C1I",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","radiology","contrast agent","OC(=O)C1=C(I)C=C(I)C(NC(=O)CCOCCOCCOCCOCCC(=O)NC2=C(I)C=C(I)C(C(O)=O)=C2I)=C1I",1287.585583032,44,4.684,169.72,1.09416368304968e-10,0.12,0.0600000000547082,0,0
"ethylnorepinephrine","bronchodilator","","CC[C@@H](N)[C@@H](O)c1ccc(O)c(O)c1 |&1:2,&2:4|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC[C@@H](N)[C@@H](O)c1ccc(O)c(O)c1 |&1:2",197.10519334,14,0.705,86.71,0.0558679917022,0.064,0.0599339958511,0,0
"laflunimus","prostagladin inhibitor","PTGS1, PTGS2","Cc1cc(NC(=O)[C@@H](C#N)C(=O)C2CC2)ccc1C(F)(F)F |&1:7,r|",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1cc(NC(=O)[C@@H](C#N)C(=O)C2CC2)ccc1C(F)(F)F |&1:7",310.092912316,22,2.769,69.96,0.0578317965099037,0.062,0.0599158982549518,0,0
"AS-1269574","glucose dependent insulinotropic receptor agonist","GPR119","Cc1cc(NCCO)nc(n1)-c1ccc(Br)cc1, Cc1cc(NCCO)nc(n1)-c1ccc(Br)cc1, Cc1cc(NCCO)nc(n1)-c1ccc(Br)cc1, Cc1cc(NCCO)nc(n1)-c1ccc(Br)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(NCCO)nc(n1)-c1ccc(Br)cc1",307.032024168,18,2.536,58.04,0.0316747019837768,0.088,0.0598373509918884,0,0
"ABT-639","calcium channel blocker","CACNA1G, CACNA1H, CACNA1I","Fc1ccccc1NS(=O)(=O)c1cc(C(=O)N2CCN3CCC[C@@H]3C2)c(Cl)cc1F, Fc1ccccc1NS(=O)(=O)c1cc(C(=O)N2CCN3CCC[C@@H]3C2)c(Cl)cc1F, Fc1ccccc1NS(=O)(=O)c1cc(C(=O)N2CCN3CCC[C@@H]3C2)c(Cl)cc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Fc1ccccc1NS(=O)(=O)c1cc(C(=O)N2CCN3CCC[C@@H]3C2)c(Cl)cc1F",455.08819662,30,3.392,78.1,0.0115456014810493,0.108,0.0597728007405246,0,0
"GSK163090","serotonin receptor antagonist","HTR1A, HTR1B, HTR1D","Cc1ccc2c(cccc2n1)N1CCN(CCc2cccc(c2)N2CCNC2=O)CC1, Cc1ccc2c(cccc2n1)N1CCN(CCc2cccc(c2)N2CCNC2=O)CC1, Cc1ccc2c(cccc2n1)N1CCN(CCc2cccc(c2)N2CCNC2=O)CC1",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1ccc2c(cccc2n1)N1CCN(CCc2cccc(c2)N2CCNC2=O)CC1",415.237210548,31,3.106,51.71,0.0615193525804512,0.058,0.0597596762902256,0,0
"H2L-5765834","lysophosphatidic acid receptor antagonist","LPAR1, LPAR3","OC(=O)c1ccc2C(=O)N(C(=O)c2c1)c1cccc(Oc2ccc(cc2)[N+]([O-])=O)c1, OC(=O)c1ccc2C(=O)N(C(=O)c2c1)c1cccc(Oc2ccc(cc2)[N+]([O-])=O)c1, OC(=O)c1ccc2C(=O)N(C(=O)c2c1)c1cccc(Oc2ccc(cc2)[N+]([O-])=O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1ccc2C(=O)N(C(=O)c2c1)c1cccc(Oc2ccc(cc2)[N+]([O-])=O)c1",404.064450724,30,3.688,127.05,0.0134923702780687,0.106,0.0597461851390344,0,0
"azd-7648","dna protein kinase inhibitor","PRKDC","Cc1cc2ncnn2cc1Nc1ncc2n(C)c(=O)n(C3CCOCC3)c2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","oncology","melanoma","Cc1cc2ncnn2cc1Nc1ncc2n(C)c(=O)n(C3CCOCC3)c2n1",380.17092188,28,0.399,104.16,0.0114550654710232,0.108,0.0597275327355116,0,0
"ML314","neurotensin agonist","NTSR1","COc1ccccc1N1CCN(CC1)c1nc(nc2cc(OC)c(OC)cc12)C1CC1, COc1ccccc1N1CCN(CC1)c1nc(nc2cc(OC)c(OC)cc12)C1CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccccc1N1CCN(CC1)c1nc(nc2cc(OC)c(OC)cc12)C1CC1",420.216140756,31,4.07,59.95,0.0574049408589958,0.062,0.0597024704294979,0,0
"CGP-57380","MAP kinase inhibitor","AURKB, LCK, MKNK1, MKNK2, SGK1","Nc1ncnc2n[nH]c(Nc3ccc(F)cc3)c12, Nc1ncnc2n[nH]c(Nc3ccc(F)cc3)c12, Nc1ncnc2n[nH]c(Nc3ccc(F)cc3)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1ncnc2n[nH]c(Nc3ccc(F)cc3)c12",244.087272508,18,2.032,92.51,0.0553162374518752,0.064,0.0596581187259376,0,0
"DMNB","DNA dependent protein kinase inhibitor","","COc1cc(C=O)c(cc1OC)[N+]([O-])=O, COc1cc(C=O)c(cc1OC)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(C=O)c(cc1OC)[N+]([O-])=O",211.048072388,15,1.172,78.67,0.0672791036515432,0.052,0.0596395518257716,0,0
"BMS-935177","Bruton's tyrosine kinase (BTK) inhibitor","","Cc1c(cccc1-n1cnc2ccccc2c1=O)-c1ccc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1c(cccc1-n1cnc2ccccc2c1=O)-c1ccc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O",502.200490692,38,5.979,114,0.0192576209663695,0.1,0.0596288104831847,0,0
"naringenin","aromatase inhibitor, TRPV antagonist","CYP19A1, CYP1B1, ESR2, GLO1, HSD17B1","Oc1ccc(cc1)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1, Oc1ccc(cc1)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Oc1ccc(cc1)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1",272.068473484,20,2.029,86.99,0.0512369877040106,0.068,0.0596184938520053,0,0
"isoliquiritigenin","guanylate cyclase activator","GABBR1","Oc1ccc(\C=C\C(=O)c2ccc(O)cc2O)cc1, Oc1ccc(\C=C\C(=O)c2ccc(O)cc2O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(\C=C\C(=O)c2ccc(O)cc2O)cc1",256.073558864,19,3.059,77.76,0.0911186663959569,0.028,0.0595593331979785,0,0
"PF-5274857","smoothened receptor antagonist","SMO","Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O, Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O, Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O, Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O, Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O, Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O",436.13358934,29,2.755,91.85,0.00899454040813958,0.11,0.0594972702040698,0,0
"dianhydrogalactitol","DNA alkylating agent","","O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1, O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1, O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1",146.0579088,10,-1.86,65.52,0.0649809339459269,0.054,0.0594904669729634,0,0
"GSK-J4","histone lysine demethylase inhibitor","KDM6A, KDM6B","CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1",417.216475104,31,4.453,80.24,0.042974925489311,0.076,0.0594874627446555,0,0
"mitoguazone","polyamine biosynthesis inhibitor","AMD1","C\C(=N/NC(=N)N)\C=N\NC(=N)N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","oncology","follicular lymphoma","C\C(=N/NC(=N)N)\C=N\NC(=N)N",184.118492384,13,1.199,148.52,0.0169738698555799,0.102,0.0594869349277899,0,0
"benzoylpas","","","OC(=O)c1ccc(NC(=O)c2ccccc2)cc1O, OC(=O)c1ccc(NC(=O)c2ccccc2)cc1O, OC(=O)c1ccc(NC(=O)c2ccccc2)cc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1ccc(NC(=O)c2ccccc2)cc1O",257.068807832,19,2.631,86.63,0.0669524123052729,0.052,0.0594762061526365,0,0
"D609","phospholipase inhibitor","","SC(=S)OC1CC2CC1C1CCCC21, SC(=S)OC1CC2CC1C1CCCC21, SC(=S)OC1CC2CC1C1CCCC21, SC(=S)OC1CC2CC1C1CCCC21",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","SC(=S)OC1CC2CC1C1CCCC21",228.064257132,14,3.613,80.12,0.06289235720504,0.056,0.05944617860252,0,0
"d609","phospholipase inhibitor","","SC(=S)O[C@@H]1C[C@@H]2C[C@H]1[C@H]1CCC[C@@H]21 |&1:4,&2:6,8,&3:9,13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","neurology","alzheimer's disease","SC(=S)O[C@@H]1C[C@@H]2C[C@H]1[C@H]1CCC[C@@H]21 |&1:4",228.064257132,14,3.613,80.12,0.06289235720504,0.056,0.05944617860252,0,0
"eleclazine","late sodium current inhibitor","","FC(F)(F)Oc1ccc(cc1)-c1ccc2OCCN(Cc3ncccn3)C(=O)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","FC(F)(F)Oc1ccc(cc1)-c1ccc2OCCN(Cc3ncccn3)C(=O)c2c1",415.114376032,30,3.887,64.55,0.0448519411329887,0.074,0.0594259705664943,0,0
"veralipride","dopamine receptor antagonist","","COc1cc(cc(C(=O)NC[C@@H]2CCCN2CC=C)c1OC)S(N)(=O)=O |&1:11,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(cc(C(=O)NC[C@@H]2CCCN2CC=C)c1OC)S(N)(=O)=O |&1:11",383.1514919,26,0.459,119.34,0.00483438892878313,0.114,0.0594171944643916,0,0
"arimoclomol","superoxide dismutase inhibitor","HSPA1A, SOD1","O[C@@H](CO\N=C(/Cl)\c1ccc[n+]([O-])c1)CN2CCCCC2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","neurology/psychiatry","amyotrophic lateral sclerosis (als)","O[C@@H](CO\N=C(/Cl)\c1ccc[n+]([O-])c1)CN2CCCCC2",313.11931918,21,2.491,72,0.0388306720450002,0.08,0.0594153360225001,0,0
"quinolinic-acid","glutamate receptor agonist","","OC(=O)c1cccnc1C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1cccnc1C(O)=O",167.02185764,12,0.089,87.49,0.0607646469564306,0.058,0.0593823234782153,0,0
"piroximone","phosphodiesterase inhibitor","PDE3A","CCc1[nH]c(=O)[nH]c1C(=O)c1ccncc1, CCc1[nH]c(=O)[nH]c1C(=O)c1ccncc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCc1[nH]c(=O)[nH]c1C(=O)c1ccncc1",217.085126592,16,0.649,78.61,0.0647629889206198,0.054,0.0593814944603099,0,0
"L-168049","glucagon receptor antagonist","GCGR","CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1, CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1, CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1, CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1",466.04475304,29,7.447,37.91,0.0467172103566132,0.072,0.0593586051783066,0,0
"WAY-207024","gonadotropin releasing factor hormone receptor antagonist","GNRHR, HRH2, TACR2","CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1, CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1, CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1, CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1, CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1",476.268845024,36,5.709,60.94,0.0686633423615498,0.05,0.0593316711807749,0,0
"LDC1267","protein tyrosine kinase inhibitor","AXL, MERTK, TYRO3","CCOc1cn(nc1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)c(F)c1)-c1ccc(F)cc1C, CCOc1cn(nc1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)c(F)c1)-c1ccc(F)cc1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOc1cn(nc1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)c(F)c1)-c1ccc(F)cc1C",560.187126372,41,5.409,96.73,0.0125550404787112,0.106,0.0592775202393556,0,0
"TC-N-1752","sodium channel blocker","SCN9A","CC(=O)Nc1cccc(Nc2ncnc(n2)N2CCC(CC2)OCc2ccc(OC(F)(F)F)cc2)c1C, CC(=O)Nc1cccc(Nc2ncnc(n2)N2CCC(CC2)OCc2ccc(OC(F)(F)F)cc2)c1C, CC(=O)Nc1cccc(Nc2ncnc(n2)N2CCC(CC2)OCc2ccc(OC(F)(F)F)cc2)c1C",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)Nc1cccc(Nc2ncnc(n2)N2CCC(CC2)OCc2ccc(OC(F)(F)F)cc2)c1C",516.209673384,37,4.606,101.5,0.0105311376978318,0.108,0.0592655688489159,0,0
"embelin","HCV inhibitor, XIAP inhibitor","XIAP","CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|",294.183109312,21,5.255,71.44,0.112530189115391,0.006,0.0592650945576955,0,0
"CFI-400945","serine/threonine kinase inhibitor","","COc1ccc2NC(=O)[C@@]3(C[C@H]3c3ccc4c(\C=C\c5ccc(CN6C[C@H](C)O[C@H](C)C6)cc5)[nH]nc4c3)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1ccc2NC(=O)[C@@]3(C[C@H]3c3ccc4c(\C=C\c5ccc(CN6C[C@H](C)O[C@H](C)C6)cc5)[nH]nc4c3)c2c1",534.263090948,40,5.596,79.48,0.0284757067075838,0.09,0.0592378533537919,0,0
"PNU-142633","serotonin receptor agonist","HTR1D","CNC(=O)c1ccc2[C@H](CCN3CCN(CC3)c3ccc(cc3)C(N)=O)OCCc2c1, CNC(=O)c1ccc2[C@H](CCN3CCN(CC3)c3ccc(cc3)C(N)=O)OCCc2c1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CNC(=O)c1ccc2[C@H](CCN3CCN(CC3)c3ccc(cc3)C(N)=O)OCCc2c1",422.23179082,31,2.113,87.9,0.018437903515872,0.1,0.059218951757936,0,0
"ITX5061","SR-BI inhibitor","","COc1c(NC(=O)C(=O)c2ccc(OCCN3CCOCC3)c3ccccc23)cc(cc1NS(C)(=O)=O)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1c(NC(=O)C(=O)c2ccc(OCCN3CCOCC3)c3ccccc23)cc(cc1NS(C)(=O)=O)C(C)(C)C",583.235221524,41,4.213,131.65,0.0024261449697878,0.116,0.0592130724848939,0,0
"ZK-93423","benzodiazepine receptor agonist","GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2","CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC",0,0,0,0,0,0,0,0,0,0,0,0,1,6,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC",390.157957184,29,4.06,73.44,0.0543776974578332,0.064,0.0591888487289166,0,0
"taselisib","PI3K inhibitor","PIK3CA","CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O",460.233522136,34,4.236,118.67,0.0123145786957993,0.106,0.0591572893478996,0,0
"SAR-245409","PI3K inhibitor","MTOR, PIK3CG","COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(NC(=O)c3ccc(C)c(OC)c3)cc2)cc(OC)c1, COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(NC(=O)c3ccc(C)c(OC)c3)cc2)cc(OC)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(NC(=O)c3ccc(C)c(OC)c3)cc2)cc(OC)c1",599.183854648,43,5.265,149.15,0.00226682513403154,0.116,0.0591334125670158,0,0
"islatravir","nucleoside reverse transcriptase inhibitor","","Nc1nc(F)nc2n(cnc12)[C@H]1C[C@H](O)[C@@](CO)(O1)C#C |a:11,13,15|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","infectious disease","human immunodeficiency virus (hiv-1)","Nc1nc(F)nc2n(cnc12)[C@H]1C[C@H](O)[C@@](CO)(O1)C#C |a:11",293.092417464,21,-0.545,119.31,0.0102351316038288,0.108,0.0591175658019144,0,0
"AZM-475271","SRC inhibitor","SRC","COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1, COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1, COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1, COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1",442.177168404,31,3.714,68.74,0.0262188763236109,0.092,0.0591094381618055,0,0
"vaniprevir","serine protease inhibitor","","CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@@H](NC(=O)OCC(C)(C)CCCCc1cccc3CN(Cc13)C(=O)O2)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1, CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@@H](NC(=O)OCC(C)(C)CCCCc1cccc3CN(Cc13)C(=O)O2)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@@H](NC(=O)OCC(C)(C)CCCCc1cccc3CN(Cc13)C(=O)O2)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1",757.37204934,53,4.717,188.9,0.000180260426849788,0.118,0.0590901302134249,0,0
"troglitazone","insulin sensitizer, PPAR receptor agonist","CYP2C8, PPARG, TRPM3","Cc1c(C)c2O[C@@](C)(COc3ccc(C[C@H]4SC(=O)NC4=O)cc3)CCc2c(C)c1O |&1:6,r|, Cc1c(C)c2O[C@@](C)(COc3ccc(C[C@H]4SC(=O)NC4=O)cc3)CCc2c(C)c1O |&1:6,r|, Cc1c(C)c2O[C@@](C)(COc3ccc(C[C@H]4SC(=O)NC4=O)cc3)CCc2c(C)c1O |&1:6,r|, Cc1c(C)c2O[C@@](C)(COc3ccc(C[C@H]4SC(=O)NC4=O)cc3)CCc2c(C)c1O |&1:6,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","Cc1c(C)c2O[C@@](C)(COc3ccc(C[C@H]4SC(=O)NC4=O)cc3)CCc2c(C)c1O |&1:6",441.160993964,31,3.603,110.16,0.0101721408263881,0.108,0.059086070413194,0,0
"avadomide","antitumor agent","","Cc1nc2cccc(N)c2c(=O)n1[C@H]1CCC(=O)NC1=O |&1:13,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1nc2cccc(N)c2c(=O)n1[C@H]1CCC(=O)NC1=O |&1:13",286.106590308,21,-0.0450000000000002,107.08,0.0180140278498112,0.1,0.0590070139249056,0,0
"BMS-779788","LXR agonist","","CC(C)(O)c1cn(c(n1)C(C)(C)c1ccccc1Cl)-c1ccc(cc1)-c1cccc(c1)S(C)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)(O)c1cn(c(n1)C(C)(C)c1ccccc1Cl)-c1ccc(cc1)-c1cccc(c1)S(C)(=O)=O",508.158741468,35,6.753,80.57,0.021895828820709,0.096,0.0589479144103545,0,0
"AZD4547","FGFR inhibitor","FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, KDR","COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)[nH]n2)cc(OC)c1, COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)[nH]n2)cc(OC)c1, COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)[nH]n2)cc(OC)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)[nH]n2)cc(OC)c1",463.258339916,34,5.046,91.51,0.02586766109949,0.092,0.058933830549745,0,0
"SUN-11602","fibroblast growth factor mimetic","FGFR1","CN(C1CCN(Cc2ccc(cc2)C(N)=O)CC1)C(=O)CNc1c(C)c(C)c(N)c(C)c1C, CN(C1CCN(Cc2ccc(cc2)C(N)=O)CC1)C(=O)CNc1c(C)c(C)c(N)c(C)c1C, CN(C1CCN(Cc2ccc(cc2)C(N)=O)CC1)C(=O)CNc1c(C)c(C)c(N)c(C)c1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C1CCN(Cc2ccc(cc2)C(N)=O)CC1)C(=O)CNc1c(C)c(C)c(N)c(C)c1C",451.294725424,33,2.062,104.69,0.00984885980340512,0.108,0.0589244299017026,0,0
"stattic","","","[O-][N+](=O)c1ccc2C=CS(=O)(=O)c2c1 |c:7|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[O-][N+](=O)c1ccc2C=CS(=O)(=O)c2c1 |c:7|",210.99392864,14,1.468,85.66,0.0498385702150203,0.068,0.0589192851075102,0,0
"4-iodo-6-phenylpyrimidine","macrophage migration inhibiting factor inhibitor","MIF","Ic1cc(ncn1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Ic1cc(ncn1)-c1ccccc1",281.965396224,13,2.915,25.78,0.0418037799800598,0.076,0.0589018899900299,0,0
"adipic-acid","solute carrier family member inhibitor","SLC22A6","OC(=O)CCCCC(O)=O",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)CCCCC(O)=O",146.0579088,10,0.00599999999999995,74.6,0.0817183155902683,0.036,0.0588591577951341,0,0
"AB-423","HBV capsid assembly inhibitor","","CC[C@@H](C)NS(=O)(=O)c1ccc(F)c(c1)C(=O)Nc1ccc(F)c(F)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC[C@@H](C)NS(=O)(=O)c1ccc(F)c(c1)C(=O)Nc1ccc(F)c(F)c1",386.091198064,26,3.566,83.65,0.0217135774015607,0.096,0.0588567887007803,0,0
"A-1120","retinoid receptor ligand","RBP4","OC(=O)c1ccccc1NC(=O)N1CCC(CC1)c1ccccc1C(F)(F)F, OC(=O)c1ccccc1NC(=O)N1CCC(CC1)c1ccccc1C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1ccccc1NC(=O)N1CCC(CC1)c1ccccc1C(F)(F)F",392.134777128,28,4.271,69.64,0.0477093347454189,0.07,0.0588546673727094,0,0
"GSK1059615","PI3K inhibitor","PIK3CG","O=C1NC(=O)\C(S1)=C\c1ccc2nccc(-c3ccncc3)c2c1, O=C1NC(=O)\C(S1)=C\c1ccc2nccc(-c3ccncc3)c2c1, O=C1NC(=O)\C(S1)=C\c1ccc2nccc(-c3ccncc3)c2c1, O=C1NC(=O)\C(S1)=C\c1ccc2nccc(-c3ccncc3)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","O=C1NC(=O)\C(S1)=C\c1ccc2nccc(-c3ccncc3)c2c1",333.057197592,24,2.262,97.25,0.0256838583172392,0.092,0.0588419291586196,0,0
"VX-11e","MAP kinase inhibitor","MAPK1","Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(c1)C(=O)N[C@H](CO)c1cccc(Cl)c1, Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(c1)C(=O)N[C@H](CO)c1cccc(Cl)c1, Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(c1)C(=O)N[C@H](CO)c1cccc(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(c1)C(=O)N[C@H](CO)c1cccc(Cl)c1",499.09780846,34,4.566,102.93,0.00763021621313156,0.11,0.0588151081065658,0,0
"apratastat","matrix metalloprotease inhibitor, tumor necrosis factor production inhibitor","ADAM17, MMP1, MMP13, MMP9","CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1, CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1, CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1, CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1",414.091928424,27,0.934,149.85,0.00161421324183768,0.116,0.0588071066209188,0,0
"aminolevulinic-acid-benzyl-ester","","","NCC(=O)CCC(=O)OCc1ccccc1, NCC(=O)CCC(=O)OCc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","NCC(=O)CCC(=O)OCc1ccccc1",221.10519334,16,0.482,69.39,0.0695640139980267,0.048,0.0587820069990133,0,0
"WR99210","dihydrofolate reductase inhibitor","TYMS","CC1(C)N=C(N)N=C(N)N1OCCCOc1cc(Cl)c(Cl)cc1Cl |t:3,6|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","infectious disease","malaria","CC1(C)N=C(N)N=C(N)N1OCCCOc1cc(Cl)c(Cl)cc1Cl |t:3",393.052607856,24,3.111,98.46,0.00746411289183911,0.11,0.0587320564459196,0,0
"GSK2190915","lipoxygenase inhibitor","ALOX5AP","CCOc1ccc(cn1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OCc4ccc(C)cn4)ccc23)cc1, CCOc1ccc(cn1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OCc4ccc(C)cn4)ccc23)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCOc1ccc(cn1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OCc4ccc(C)cn4)ccc23)cc1",637.297427856,46,8.478,111.77,0.00944934377385016,0.108,0.0587246718869251,0,0
"azd1940","cannabinoid receptor agonist","CNR1, CNR2","CCS(=O)(=O)Nc1ccc2n(CC3CCC(F)(F)CC3)c(nc2c1)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","neurology/psychiatry","acute pain","CCS(=O)(=O)Nc1ccc2n(CC3CCC(F)(F)CC3)c(nc2c1)C(C)(C)C",413.194854608,28,4.537,72.37,0.0294453914223905,0.088,0.0587226957111952,0,0
"3-MATIDA","glutamate receptor antagonist","GRM1","Cc1cc(sc1[C@@H](N)C(O)=O)C(O)=O |&1:6,r|, Cc1cc(sc1[C@@H](N)C(O)=O)C(O)=O |&1:6,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(sc1[C@@H](N)C(O)=O)C(O)=O |&1:6",215.025228768,14,-3.292,128.86,0.00541360429299304,0.112,0.0587068021464965,0,0
"diminazene-aceturate","angiotensin converting enzyme activator","AOC1, PRDX5, PRSS1","NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1",281.13889348,21,2.551,136.49,0.0193668718665693,0.098,0.0586834359332847,0,0
"AZD9056","purinergic receptor antagonist","","OCCCNCCCc1ccc(Cl)c(c1)C(=O)NCC12CC3CC(CC(C3)C1)C2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OCCCNCCCc1ccc(Cl)c(c1)C(=O)NCC12CC3CC(CC(C3)C1)C2",418.23870604,29,5.41,61.36,0.0513640950139974,0.066,0.0586820475069987,0,0
"VU0364439","glutamate receptor positive allosteric modulator","GRM4","Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl, Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl, Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl",421.005467636,27,3.767,96.54,0.00936146173189693,0.108,0.0586807308659485,0,0
"UNC3230","phosphatidyl-inositol activator","PIP5K1C","NC(=O)c1nc(Nc2ccccc2)sc1NC(=O)C1CCCCC1, NC(=O)c1nc(Nc2ccccc2)sc1NC(=O)C1CCCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC(=O)c1nc(Nc2ccccc2)sc1NC(=O)C1CCCCC1",344.13069688,24,2.605,125.35,0.0113408019996851,0.106,0.0586704009998426,0,0
"ipsapirone","serotonin receptor agonist","HTR1A","O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12, O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12",401.152160596,28,1.529,95.09,0.011295432858185,0.106,0.0586477164290925,0,0
"BW-B70C","lipoxygenase inhibitor","ALOX5","C[C@@H](\C=C\c1cccc(Oc2ccc(F)cc2)c1)N(O)C(N)=O |&1:1,r|, C[C@@H](\C=C\c1cccc(Oc2ccc(F)cc2)c1)N(O)C(N)=O |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](\C=C\c1cccc(Oc2ccc(F)cc2)c1)N(O)C(N)=O |&1:1",316.122320624,23,2.768,75.79,0.0552126605180747,0.062,0.0586063302590373,0,0
"AMG-319","PI3K inhibitor","PIK3CD","C[C@H](Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1, C[C@H](Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@H](Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1",385.145121732,29,3.492,92.27,0.0351650984007831,0.082,0.0585825492003915,0,0
"AMG319","PI3K inhibitor","PIK3CD","C[C@@H](Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1 |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@@H](Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1 |&1:1",385.145121732,29,3.492,92.27,0.0351650984007831,0.082,0.0585825492003915,0,0
"CNQX","glutamate receptor antagonist","GRIA1, GRIA2, GRIA3, GRIA4","[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N",232.023254608,17,1.527,132.65,0.0211607159009633,0.096,0.0585803579504817,0,0
"genz-123346","glucosylceramidase inhibitor","UGCG","CCCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1, CCCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1",418.283157696,30,4.229,71.03,0.0391433278267747,0.078,0.0585716639133874,0,0
"avitinib","EGFR inhibitor","","CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3cc[nH]c3n2)cc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3cc[nH]c3n2)cc1F",487.213201292,36,4.438,98.41,0.0171317458109526,0.1,0.0585658729054763,0,0
"O-acetyl-L-serine","","PTGS1","CC(=O)OC[C@H](N)C(O)=O",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)OC[C@H](N)C(O)=O",147.053157768,10,-3.216,89.62,0.027077016335093,0.09,0.0585385081675465,0,0
"YM-244769","sodium/calcium exchange inhibitor","","Nc1cccc(CNC(=O)c2ccc(Oc3ccc(OCc4cccc(F)c4)cc3)nc2)c1, Nc1cccc(CNC(=O)c2ccc(Oc3ccc(OCc4cccc(F)c4)cc3)nc2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1cccc(CNC(=O)c2ccc(Oc3ccc(OCc4cccc(F)c4)cc3)nc2)c1",443.164519784,33,5.063,86.47,0.0370569536042349,0.08,0.0585284768021175,0,0
"SHP099","protein tyrosine kinase inhibitor","PTPN11","CC1(N)CCN(CC1)c1cnc(c(N)n1)-c1cccc(Cl)c1Cl, CC1(N)CCN(CC1)c1cnc(c(N)n1)-c1cccc(Cl)c1Cl, CC1(N)CCN(CC1)c1cnc(c(N)n1)-c1cccc(Cl)c1Cl, CC1(N)CCN(CC1)c1cnc(c(N)n1)-c1cccc(Cl)c1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC1(N)CCN(CC1)c1cnc(c(N)n1)-c1cccc(Cl)c1Cl",351.101750968,23,3.943,81.06,0.0290271575525563,0.088,0.0585135787762782,0,0
"EVP4593","NFkB pathway inhibitor","","Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1",356.16371126,27,3.99,73.06,0.0749982619916565,0.042,0.0584991309958282,0,0
"resatorvid","toll-like receptor inhibitor","TLR4","CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl |t:5|, CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl |t:5|, CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl |t:5|, CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl |t:5|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl |t:5|",361.055084924,23,3.109,80.85,0.0189322889423385,0.098,0.0584661444711693,0,0
"tomivosertib","MAPK-interacting kinase inhibitor","","Cc1cc(Nc2cc(N)ncn2)c(=O)n2c1C(=O)NC21CCCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1cc(Nc2cc(N)ncn2)c(=O)n2c1C(=O)NC21CCCCC1",340.16477388,25,2.414,114.93,0.0189287966486667,0.098,0.0584643983243334,0,0
"AZ191","DYRK inhibitor","DYRK1B","COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1, COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1, COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1, COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1, COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1, COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1",429.227708484,32,2.708,71.34,0.0328723996054302,0.084,0.0584361998027151,0,0
"L-NAME","nitric oxide synthase inhibitor","NOS3","COC(=O)[C@@H](N)CCCNC(N)=N[N+]([O-])=O, COC(=O)[C@@H](N)CCCNC(N)=N[N+]([O-])=O, COC(=O)[C@@H](N)CCCNC(N)=N[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","COC(=O)[C@@H](N)CCCNC(N)=N[N+]([O-])=O",233.11240396,16,0.187,145.87,0.0087848687188073,0.108,0.0583924343594036,0,0
"SB-258585","serotonin receptor antagonist","HTR6","COc1ccc(NS(=O)(=O)c2ccc(I)cc2)cc1N1CCN(C)CC1, COc1ccc(NS(=O)(=O)c2ccc(I)cc2)cc1N1CCN(C)CC1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(NS(=O)(=O)c2ccc(I)cc2)cc1N1CCN(C)CC1",487.042660564,26,3.67,70.26,0.00277120304828444,0.114,0.0583856015241422,0,0
"AST-1306","EGFR inhibitor","EGFR, ERBB2","Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1, Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1, Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1, Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1",448.110231716,32,4.978,76.14,0.0326850623166074,0.084,0.0583425311583037,0,0
"LY3295668","Aurora kinase inhibitor","","C[C@@H]1C[C@@](Cc2nc(Nc3cc(C)[nH]n3)ccc2F)(CCN1Cc1cccc(Cl)c1F)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","C[C@@H]1C[C@@](Cc2nc(Nc3cc(C)[nH]n3)ccc2F)(CCN1Cc1cccc(Cl)c1F)C(O)=O",489.174309192,34,4.847,94.14,0.0126421429550863,0.104,0.0583210714775431,0,0
"bucladesine (sodium)","","","CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15",469.136249358,32,-0.0310000000000003,173.8,0.000621254207339442,0.116,0.0583106271036697,0,0
"TPCA-1","IKK inhibitor","IKBKB","NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1",279.04777578,19,0.787,126.45,0.0106078903708756,0.106,0.0583039451854378,0,0
"ASP-9521","aldo-keto reductase inhibitor","","COc1ccc2[nH]c(cc2c1)C(=O)N1CCC(CC(C)(C)O)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc2[nH]c(cc2c1)C(=O)N1CCC(CC(C)(C)O)CC1",330.194342692,24,2.914,65.56,0.0645969003003878,0.052,0.0582984501501939,0,0
"D-7193","","","CC(=O)N[C@@H](CSSC[C@H](NC(C)=O)C(O)=O)C(O)=O, CC(=O)N[C@@H](CSSC[C@H](NC(C)=O)C(O)=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(=O)N[C@@H](CSSC[C@H](NC(C)=O)C(O)=O)C(O)=O",324.044978232,20,-2.76,183.4,0.000514744752821389,0.116,0.0582573723764107,0,0
"genistein","tyrosine kinase inhibitor","CFTR, ESR1, ESR2, ESRRA, ESRRB, ESRRG, NCOA1, NCOA2, PPARG, PTK2B, TOP2A, TRPC5","Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O",270.05282342,20,3.331,90.9,0.0664990276968152,0.05,0.0582495138484076,0,0
"emeramide","antioxidant","","SCCNC(=O)c1cccc(c1)C(=O)NCCS",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","SCCNC(=O)c1cccc(c1)C(=O)NCCS",284.065319752,18,2.176,135.8,0.00847660997919699,0.108,0.0582383049895985,0,0
"trans-4-[8-(3-fluorophenyl)-1,7-naphthyridin-6-yl]cyclohexanecarboxylic-acid","","","OC(=O)C1CCC(CC1)c1cc2cccnc2c(n1)-c1cccc(F)c1, OC(=O)C1CCC(CC1)c1cc2cccnc2c(n1)-c1cccc(F)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)C1CCC(CC1)c1cc2cccnc2c(n1)-c1cccc(F)c1",350.143056068,26,3.71,63.08,0.0804580144902059,0.036,0.058229007245103,0,0
"Ro-3","purinergic receptor antagonist","P2RX3","COc1cc(Cc2cnc(N)nc2N)c(cc1OC)C(C)C, COc1cc(Cc2cnc(N)nc2N)c(cc1OC)C(C)C, COc1cc(Cc2cnc(N)nc2N)c(cc1OC)C(C)C, COc1cc(Cc2cnc(N)nc2N)c(cc1OC)C(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(Cc2cnc(N)nc2N)c(cc1OC)C(C)C",302.174275944,22,2.273,96.28,0.0344509983846175,0.082,0.0582254991923088,0,0
"canertinib","EGFR inhibitor","AKT1, EGFR, ERBB2, ERBB4","Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl",485.16299556,34,3.079,88.61,0.0102762380275101,0.106,0.0581381190137551,0,0
"apronal","cytochrome P450 modulator","","CC(C)[C@H](CC=C)C(=O)NC(N)=O |&1:3,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)[C@H](CC=C)C(=O)NC(N)=O |&1:3",184.121177752,13,1.677,72.19,0.102273945675149,0.014,0.0581369728375745,0,0
"BMS-582949","p38 MAPK inhibitor","","CCCNC(=O)c1cn2ncnc(Nc3cc(ccc3C)C(=O)NC3CC3)c2c1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCNC(=O)c1cn2ncnc(Nc3cc(ccc3C)C(=O)NC3CC3)c2c1C",406.211724072,30,3.458,100.42,0.0222601189228919,0.094,0.0581300594614459,0,0
"CGP-20712A","adrenergic receptor antagonist","ADRB1, ADRB3","CS(O)(=O)=O.Cn1cc(nc1-c1ccc(OC[C@H](O)CNCCOc2ccc(O)c(c2)C(N)=O)cc1)C(F)(F)F |&1:17,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,"preclinical","","","CS(O)(=O)=O.Cn1cc(nc1-c1ccc(OC[C@H](O)CNCCOc2ccc(O)c(c2)C(N)=O)cc1)C(F)(F)F |&1:17",590.165819548,40,2.554,194.61,0.000253030468732853,0.116,0.0581265152343664,0,0
"fosdagrocorat","glucocorticoid receptor agonist","NR3C1","FC(F)(F)[C@]1(OP(O)(O)=O)C[C@]2([H])[C@](C3=CC=C(C(NC(C=CC=N4)=C4C)=O)C=C3CC2)(CC1)CC5=CC=CC=C5",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","rheumatology","rheumatoid arthritis","FC(F)(F)[C@]1(OP(O)(O)=O)C[C@]2([H])[C@](C3=CC=C(C(NC(C=CC=N4)=C4C)=O)C=C3CC2)(CC1)CC5=CC=CC=C5",574.18444335,41,4.309,118.03,0.00422158081184475,0.112,0.0581107904059224,0,0
"AEG3482","HSP inducer","","NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1, NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1, NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1",280.008867496,18,0.811,126.97,0.00820246785537266,0.108,0.0581012339276863,0,0
"LPA2-antagonist-1","lysophosphatidic acid receptor antagonist","LPAR2","C[C@@H](CN1CCN(CC1)S(=O)(=O)c1ccc(Cl)c(Cl)c1)Nc1ncnc2c(C)csc12, C[C@@H](CN1CCN(CC1)S(=O)(=O)c1ccc(Cl)c(Cl)c1)Nc1ncnc2c(C)csc12, C[C@@H](CN1CCN(CC1)S(=O)(=O)c1ccc(Cl)c(Cl)c1)Nc1ncnc2c(C)csc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](CN1CCN(CC1)S(=O)(=O)c1ccc(Cl)c(Cl)c1)Nc1ncnc2c(C)csc12",499.067022336,31,3.395,115.05,0.00217877713284863,0.114,0.0580893885664243,0,0
"Se-methylselenocysteine","","","C[Se]C[C@H](N)C(O)=O, C[Se]C[C@H](N)C(O)=O, C[Se]C[C@H](N)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[Se]C[C@H](N)C(O)=O",182.979849828,8,-2.466,63.32,0.0161774777155614,0.1,0.0580887388577807,0,0
"MK-2894","prostaglandin inhibitor","PTGER4","Cc1sc(C)c(C(=O)NC2(CC2)c2ccc(cc2)C(O)=O)c1Cc1ccc(cc1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1sc(C)c(C(=O)NC2(CC2)c2ccc(cc2)C(O)=O)c1Cc1ccc(cc1)C(F)(F)F",473.127249224,33,4.74,94.64,0.0141667138768719,0.102,0.0580833569384359,0,0
"TC-E-5002","histone demethylase inhibitor","KDM2A, KDM4A, KDM4C, KDM5A, KDM6A, KDM7A, PHF8","ON(CCC(O)=O)C(=O)CCCCCCCCC1CC1, ON(CCC(O)=O)C(=O)CCCCCCCCC1CC1, ON(CCC(O)=O)C(=O)CCCCCCCCC1CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","ON(CCC(O)=O)C(=O)CCCCCCCCC1CC1",285.194008344,20,3.679,77.84,0.0681382730952324,0.048,0.0580691365476162,0,0
"sangivamycin","DNA inhibitor","","NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c12, NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c12, NC(=O)c1cn(C2OC(CO)[C@H](O)[C@@H]2O)c2ncnc(N)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c12",309.10731858,22,-1.754,169.74,0.0020460136021458,0.114,0.0580230068010729,0,0
"ARC-239","adrenergic receptor antagonist","ADRA2A, ADRA2B, ADRA2C","COc1ccccc1N1CCN(CCN2C(=O)c3ccccc3C(C)(C)C2=O)CC1, COc1ccccc1N1CCN(CCN2C(=O)c3ccccc3C(C)(C)C2=O)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,"preclinical","","","COc1ccccc1N1CCN(CCN2C(=O)c3ccccc3C(C)(C)C2=O)CC1",407.220891788,30,3.569,53.09,0.0640380952632462,0.052,0.0580190476316231,0,0
"BML-284","WNT agonist","","COc1cccc(c1)-c1cc(NCc2ccc3OCOc3c2)nc(N)n1, COc1cccc(c1)-c1cc(NCc2ccc3OCOc3c2)nc(N)n1, COc1cccc(c1)-c1cc(NCc2ccc3OCOc3c2)nc(N)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cccc(c1)-c1cc(NCc2ccc3OCOc3c2)nc(N)n1",350.137890436,26,3.157,91.52,0.0380157697840775,0.078,0.0580078848920388,0,0
"ceruletide","CCK receptor agonist","CCKAR","[H][C@](NC(=O)[C@H](Cc1ccc(OS(O)(=O)=O)cc1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@](NC(=O)[C@H](Cc1ccc(OS(O)(=O)=O)cc1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O",1351.448538356,95,-5.328,585.08,1.70387746356656e-11,0.116,0.0580000000085194,0,0
"NT157","IGF-1 inhibitor","IGF1R","Oc1cc(CNC(=S)\C=C\c2cc(O)c(O)c(Br)c2)cc(O)c1O, Oc1cc(CNC(=S)\C=C\c2cc(O)c(O)c(Br)c2)cc(O)c1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1cc(CNC(=S)\C=C\c2cc(O)c(O)c(Br)c2)cc(O)c1O",410.977605648,24,3.709,145.27,0.0019128505171595,0.114,0.0579564252585797,0,0
"MUT056399","FABI inhibitor","","CCc1cc(O)c(Oc2ccc(cc2F)C(N)=O)cc1F, CCc1cc(O)c(Oc2ccc(cc2F)C(N)=O)cc1F, CCc1cc(O)c(Oc2ccc(cc2F)C(N)=O)cc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCc1cc(O)c(Oc2ccc(cc2F)C(N)=O)cc1F",293.086349716,21,2.728,72.55,0.0638905652658001,0.052,0.0579452826329,0,0
"CGP-60474","CDK inhibitor","CDK1, CDK2","OCCCNc1cc(ccn1)-c1ccnc(Nc2cccc(Cl)c2)n1, OCCCNc1cc(ccn1)-c1ccnc(Nc2cccc(Cl)c2)n1, OCCCNc1cc(ccn1)-c1ccnc(Nc2cccc(Cl)c2)n1, OCCCNc1cc(ccn1)-c1ccnc(Nc2cccc(Cl)c2)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OCCCNc1cc(ccn1)-c1ccnc(Nc2cccc(Cl)c2)n1",355.119987876,25,3.52,82.96,0.0358097065866124,0.08,0.0579048532933062,0,0
"SAG","smoothened receptor agonist","SMO, TRPC6","CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|, CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|, CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|, CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|, CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|",489.164161196,34,5.854,73.47,0.025792647240866,0.09,0.057896323620433,0,0
"ML130","NOD1 inhibitor","","Cc1ccc(cc1)S(=O)(=O)n1c(N)nc2ccccc12, Cc1ccc(cc1)S(=O)(=O)n1c(N)nc2ccccc12, Cc1ccc(cc1)S(=O)(=O)n1c(N)nc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(cc1)S(=O)(=O)n1c(N)nc2ccccc12",287.072847656,20,3.638,86.36,0.053750901773737,0.062,0.0578754508868685,0,0
"zacopride","serotonin receptor antagonist","HTR3A, HTR3B, HTR4, HTR5A","COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CN2CCC1CC2 |&1:13,THB:12:13:16.17:19.20|, COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CN2CCC1CC2 |&1:13,THB:12:13:16.17:19.20|, COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CN2CCC1CC2 |&1:13,THB:12:13:16.17:19.20|",0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CN2CCC1CC2 |&1:13",309.12440456,21,1.565,67.59,0.0377480979504803,0.078,0.0578740489752401,0,0
"C188-9","STAT inhibitor","","COc1ccc(cc1)S(=O)(=O)Nc1cc(c(O)c2ccccc12)-c1c(O)ccc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1)S(=O)(=O)Nc1cc(c(O)c2ccccc12)-c1c(O)ccc2ccccc12",471.114043772,34,6.29,104.24,0.0217460226020552,0.094,0.0578730113010276,0,0
"sitravatinib","receptor tyrosine protein kinase inhibitor","","COCCNCc1ccc(nc1)-c1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)c2s1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COCCNCc1ccc(nc1)-c1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)c2s1",629.190831848,45,4.414,142.71,0.0016535919883763,0.114,0.0578267959941882,0,0
"purvalanol-B","tyrosine kinase inhibitor","CDK2, CDK4, CDK5, MAPK1, MAPK3, SRPK2","CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1",432.16766634,30,3.896,125.19,0.00761603317196086,0.108,0.0578080165859804,0,0
"SB-590885","RAF inhibitor","BRAF","CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2\C(CCc2c1)=N\O)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2\C(CCc2c1)=N\O)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2\C(CCc2c1)=N\O)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2\C(CCc2c1)=N\O)-c1ccncc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2\C(CCc2c1)=N\O)-c1ccncc1",453.216475104,34,4.444,86.63,0.0315845040311222,0.084,0.0577922520155611,0,0
"mericitabine","HCV inhibitor","","CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C, CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C, CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C, CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C, CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C, CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C",399.180563772,28,2.298,122.74,0.00756055174239543,0.108,0.0577802758711977,0,0
"PD-198306","MAP kinase inhibitor, MEK inhibitor","MAP2K1, MAP2K2","Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1, Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1, Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1, Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1, Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1, Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1, Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1",476.020860412,26,5.74,50.36,0.00944263489456495,0.106,0.0577213174472825,0,0
"OSI-420","EGFR inhibitor","EGFR","COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO",379.153206152,28,2.185,85.73,0.0274359315791282,0.088,0.0577179657895641,0,0
"2-fluorofucose","","","C[C@@H]1O[C@H](O)[C@@H](F)[C@H](O)[C@@H]1O |&1:3|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@@H]1O[C@H](O)[C@@H](F)[C@H](O)[C@@H]1O |&1:3|",166.064137052,11,-0.678,69.92,0.0614316652035358,0.054,0.0577158326017679,0,0
"traxoprodil","glutamate receptor antagonist","GRIN2B","C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(CC1)c1ccccc1, C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(CC1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(CC1)c1ccccc1",327.18344366,24,2.518,63.93,0.0653646699338599,0.05,0.05768233496693,0,0
"NVP-BGJ398","FGFR inhibitor","FGFR1, FGFR2, FGFR3, FGFR4, KDR","CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1",559.186543212,38,4.468,95.09,0.00535038395160119,0.11,0.0576751919758006,0,0
"RQ-00203078","transient receptor potential channel antagonist","TRPM8","OC(=O)c1ccc(cc1)S(=O)(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1ncc(cc1Cl)C(F)(F)F, OC(=O)c1ccc(cc1)S(=O)(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1ncc(cc1Cl)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1ccc(cc1)S(=O)(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1ncc(cc1Cl)C(F)(F)F",554.013789516,36,6.793,105.18,0.00534625274012766,0.11,0.0576731263700638,0,0
"azd8329","11-beta hydroxysteroid dehydrogenase inhibitor","HSD11B1","CC(C)(C)c1c(cnn1-c1ccc(cc1)C(O)=O)C(=O)NC1C2CC3CC(C2)CC1C3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","endocrinology","obesity","CC(C)(C)c1c(cnn1-c1ccc(cc1)C(O)=O)C(=O)NC1C2CC3CC(C2)CC1C3",421.236541852,31,4.842,84.22,0.0393098840730609,0.076,0.0576549420365305,0,0
"SB-297006","CC chemokine receptor antagonist","CCR3","CCOC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1ccccc1, CCOC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1ccccc1",342.121571676,25,3.416,98.54,0.0332791593123126,0.082,0.0576395796561563,0,0
"Y-27632","rho associated kinase inhibitor","PKIA, PKN2, PRKACA, PRKCE, ROCK1, ROCK2","C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1",247.168462292,18,0.862,68.01,0.0672020269013846,0.048,0.0576010134506923,0,0
"taranabant","cannabinoid receptor inverse agonist","CNR1","C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N, C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N, C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N, C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N, C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N",515.15873938,36,6.557,75.01,0.0251989562085442,0.09,0.0575994781042721,0,0
"ICI-215,001","adrenergic receptor agonist","ADRB3","O[C@@H](CNCCOc1ccc(OCC(O)=O)cc1)COc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"preclinical","","","O[C@@H](CNCCOc1ccc(OCC(O)=O)cc1)COc1ccccc1",361.152537456,26,1.903,97.25,0.0191744452937332,0.096,0.0575872226468666,0,0
"tavapadon","dopamine agonist","DRD1, DRD5","CN1C(=O)NC(=O)C(=C1c2ccc(Oc3ncccc3C(F)(F)F)cc2C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"phase 2","neurology/psychiatry","parkinson's disease","CN1C(=O)NC(=O)C(=C1c2ccc(Oc3ncccc3C(F)(F)F)cc2C)C",391.114376032,28,3.72,71.53,0.0411572537352021,0.074,0.057578626867601,0,0
"ZD-7114","adrenergic receptor agonist","ADRB3","COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1, COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1, COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1, COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"phase 1","","","COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1",418.21038668,30,1.503,98.28,0.010994481692794,0.104,0.057497240846397,0,0
"trabodenoson","adenosine receptor agonist","","O[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@H]([C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","O[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@H]([C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12",380.14443236,27,0.828,157.69,0.0029489311622069,0.112,0.0574744655811035,0,0
"AMPA-(RS)","glutamate receptor agonist","GRIN1","Cc1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:8|, Cc1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:8|",186.0640568,13,-3.438,109.32,0.0129425355814306,0.102,0.0574712677907153,0,0
"AMPA-(S)","glutamate receptor agonist","GRIA2, GRIN1","Cc1o[nH]c(=O)c1C[C@H](N)C(O)=O, Cc1o[nH]c(=O)c1C[C@H](N)C(O)=O, Cc1o[nH]c(=O)c1C[C@H](N)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1o[nH]c(=O)c1C[C@H](N)C(O)=O",186.0640568,13,-3.438,109.32,0.0129425355814306,0.102,0.0574712677907153,0,0
"BIRT-377","lymphocyte function-associated antigen negative modulator","ICAM1","CN1C(=O)N(C(=O)[C@@]1(C)Cc1ccc(Br)cc1)c1cc(Cl)cc(Cl)c1, CN1C(=O)N(C(=O)[C@@]1(C)Cc1ccc(Br)cc1)c1cc(Cl)cc(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1C(=O)N(C(=O)[C@@]1(C)Cc1ccc(Br)cc1)c1cc(Cl)cc(Cl)c1",439.96939518,25,4.655,40.62,0.0169259076956578,0.098,0.0574629538478289,0,0
"IKK-2-inhibitor","IKK inhibitor, SYK inhibitor","IKBKB","NC(=O)c1sc(cc1N)-c1ccsc1, NC(=O)c1sc(cc1N)-c1ccsc1, NC(=O)c1sc(cc1N)-c1ccsc1, NC(=O)c1sc(cc1N)-c1ccsc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC(=O)c1sc(cc1N)-c1ccsc1",224.007804876,14,0.828,125.59,0.0128471700284889,0.102,0.0574235850142445,0,0
"SB-200646","serotonin receptor antagonist","HTR2B, HTR2C","Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12",266.116761068,20,1.687,58.95,0.0988350284698434,0.016,0.0574175142349217,0,0
"tiplaxtinin","plasminogen activator inhibitor","SERPINE1","OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1, OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1, OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1, OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1, OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1",439.103142652,32,6.443,68.53,0.0668294958556574,0.048,0.0574147479278287,0,0
"EC-144","HSP inhibitor","HSP90AA1, HSP90AB1","COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)nc(N)nc23)c1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)nc(N)nc23)c1C",413.161852688,29,3.252,99.08,0.014795325930029,0.1,0.0573976629650145,0,0
"batefenterol","acetylcholine receptor antagonist, adrenergic receptor agonist","","COc1cc(NC(=O)CCN2CCC(CC2)OC(=O)Nc2ccccc2-c2ccccc2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2nc(O)ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1cc(NC(=O)CCN2CCC(CC2)OC(=O)Nc2ccccc2-c2ccccc2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2nc(O)ccc12",739.277276364,53,5.851,165.51,0.000630827373899679,0.114,0.0573154136869498,0,0
"nicodicosapent","sterol regulatory element binding protein (SREBP) inhibitor","","CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCNC(=O)c1cccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCNC(=O)c1cccnc1",449.304227488,33,7.77700000000001,71.09,0.084554524579285,0.03,0.0572772622896425,0,0
"E7820","angiogenesis inhibitor","","Cc1ccc(NS(=O)(=O)c2cccc(c2)C#N)c2[nH]cc(C#N)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1ccc(NS(=O)(=O)c2cccc(c2)C#N)c2[nH]cc(C#N)c12",336.068096624,24,2.669,117.92,0.0165087988297807,0.098,0.0572543994148903,0,0
"cyclopamine","hedgehog pathway inhibitor","","C[C@@H]1[C@@H]2NC[C@@H](C)C[C@H]2O[C@]11CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC2=C1C |c:32,t:18|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H]1[C@@H]2NC[C@@H](C)C[C@H]2O[C@]11CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC2=C1C |c:32",411.313729552,30,3.646,41.49,0.0764106360611303,0.038,0.0572053180305652,0,0
"xiliertinib","egfr inhibitor","EGFR, ERBB4","O=C(N1C[C@]2([H])N(C)CC[C@]2([H])C1)NC3=CC4=C(NC5=CC=CC(C#C)=C5)N=CN=C4C=C3OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","esophageal cancer","O=C(N1C[C@]2([H])N(C)CC[C@]2([H])C1)NC3=CC4=C(NC5=CC=CC(C#C)=C5)N=CN=C4C=C3OC",442.211724072,35,0.502,81.56,0.0223374551083055,0.092,0.0571687275541527,0,0
"MK-0608","antiviral","","C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1ccc2c(N)ncnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1ccc2c(N)ncnc12",280.117154992,20,-0.142,126.65,0.0103215361893333,0.104,0.0571607680946667,0,0
"CP-945,598","cannabinoid receptor antagonist","CNR1","CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O, CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O, CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O",509.14976378,35,4.863,101.96,0.00830518602605825,0.106,0.0571525930130291,0,0
"XBD173","benzodiazepine receptor ligand","TSPO","CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1, CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1, CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1",401.185174976,30,2.655,73.02,0.0382713160056184,0.076,0.0571356580028092,0,0
"ellagic-acid","glutathione transferase inhibitor, non-nucleoside reverse transcriptase inhibitor","CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CSNK2A1, GSK3B, PRKACA, PRKCA, PRKCB, SQLE, SYK","Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O, Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O, Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O, Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O, Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O",302.006267152,22,2.836,141.34,0.0142638945762897,0.1,0.0571319472881449,0,0
"rifamycin-sv","RNA synthesis inhibitor","","CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)cc(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:23,t:3,25|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)cc(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:23",697.309825944,50,3.966,201.31,0.000236792473065879,0.114,0.0571183962365329,0,0
"rifamycin sv na","rna synthesis inhibitor","","CO[C@H]1C=CO[C@@]2(C)Oc3c(C2=O)c2c(O)cc(NC(=O)\C(C)=C/C=C\[C@@H](C)[C@@H](O)[C@@H](C)[C@H](O)[C@H](C)[C@H]([C@H]1C)C(=O)OC)c(O)c2c(O)c3C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CO[C@H]1C=CO[C@@]2(C)Oc3c(C2=O)c2c(O)cc(NC(=O)\C(C)=C/C=C\[C@@H](C)[C@@H](O)[C@@H](C)[C@H](O)[C@H](C)[C@H]([C@H]1C)C(=O)OC)c(O)c2c(O)c3C",697.309825944,50,3.629,201.31,0.000218008366920121,0.114,0.0571090041834601,0,0
"PF-03814735","Aurora kinase inhibitor","AURKA, AURKB","CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21, CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21, CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21, CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21",474.1991087,34,2.981,99.25,0.0101895524677163,0.104,0.0570947762338582,0,0
"CHIR-99021","glycogen synthase kinase inhibitor","CDK1, GSK3A, GSK3B, MAPK1","Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl",464.103147936,32,4.476,115.2,0.00817333005216406,0.106,0.057086665026082,0,0
"CFI-402257","dual specificity protein kinase inhibitor","","Cc1cc(ccc1C(=O)NC1CC1)-c1cnn2c(NC[C@H]3C[C@@](C)(O)C3)cc(Oc3cccnc3)nc12 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","Cc1cc(ccc1C(=O)NC1CC1)-c1cnn2c(NC[C@H]3C[C@@](C)(O)C3)cc(Oc3cccnc3)nc12 |r|",498.23793882,37,4.596,113.67,0.0121558464484234,0.102,0.0570779232242117,0,0
"T-5224","AP inhibitor","JUN","OC(=O)CCc1cc(ccc1OCc1ccc2c(c1)o[nH]c2=O)C(=O)c1ccc(OC2CCCC2)cc1O, OC(=O)CCc1cc(ccc1OCc1ccc2c(c1)o[nH]c2=O)C(=O)c1ccc(OC2CCCC2)cc1O, OC(=O)CCc1cc(ccc1OCc1ccc2c(c1)o[nH]c2=O)C(=O)c1ccc(OC2CCCC2)cc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)CCc1cc(ccc1OCc1ccc2c(c1)o[nH]c2=O)C(=O)c1ccc(OC2CCCC2)cc1O",517.173666824,38,5.1,139.06,0.00615077790832613,0.108,0.0570753889541631,0,0
"LY2828360","cannabinoid receptor agonist","","CN1CCN(CC1)c1nc(C)nc2n(C3CCOCC3)c(nc12)-c1ccccc1Cl, CN1CCN(CC1)c1nc(C)nc2n(C3CCOCC3)c(nc12)-c1ccccc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN1CCN(CC1)c1nc(C)nc2n(C3CCOCC3)c(nc12)-c1ccccc1Cl",426.193487164,30,3.999,59.31,0.0401386411091507,0.074,0.0570693205545753,0,0
"eniporide","sodium/hydrogen antiport inhibitor","","Cc1cc(c(cc1C(=O)NC(N)=N)S(C)(=O)=O)-n1cccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(c(cc1C(=O)NC(N)=N)S(C)(=O)=O)-n1cccc1",320.094311372,22,1.767,126.42,0.0101057687171437,0.104,0.0570528843585719,0,0
"bisindolylmaleimide-IX","PKC inhibitor","AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1","Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|",457.157245976,33,4.304,131.2,0.00803985804699177,0.106,0.0570199290234959,0,0
"BMS-688521","ICAM1 antagonist, leukocyte function-associated antigen receptor antagonist","ICAM1","CN1C(=O)N(C(=O)[C@]11CN(C[C@H]1c1ccc(cc1)C#N)c1ccc(cn1)C(O)=O)c1cc(Cl)cc(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1C(=O)N(C(=O)[C@]11CN(C[C@H]1c1ccc(cc1)C#N)c1ccc(cn1)C(O)=O)c1cc(Cl)cc(Cl)c1",535.081409448,37,4.049,117.84,0.00403178643124116,0.11,0.0570158932156206,0,0
"UNC0321","histone lysine methyltransferase inhibitor","EHMT2","COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1",515.3583883,37,2.137,78.46,0.0100109726103839,0.104,0.057005486305192,0,0
"SDZ-205-557","serotonin receptor antagonist","HTR3A, HTR3B","CCN(CC)CCOC(=O)c1cc(Cl)c(N)cc1OC, CCN(CC)CCOC(=O)c1cc(Cl)c(N)cc1OC",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN(CC)CCOC(=O)c1cc(Cl)c(N)cc1OC",300.124070212,20,2.377,64.79,0.0479033380994456,0.066,0.0569516690497228,0,0
"GSK239512","histamine receptor antagonist","","O=C1CCCN1c1ccc(Oc2ccc3CCN(CCc3c2)C2CCC2)nc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C1CCCN1c1ccc(Oc2ccc3CCN(CCc3c2)C2CCC2)nc1",377.210327104,28,3.009,45.67,0.0838782918812888,0.03,0.0569391459406444,0,0
"L-kynurenine","aryl hydrocarbon receptor agonist","","N[C@@H](CC(=O)c1ccccc1N)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","N[C@@H](CC(=O)c1ccccc1N)C(O)=O",208.084792244,15,-2.116,106.41,0.0178440710054263,0.096,0.0569220355027132,0,0
"LY2608204","glucokinase activator","GCK","O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1",559.199705044,37,5.41,141.29,0.00184035971810142,0.112,0.0569201798590507,0,0
"resiquimod","toll-like receptor agonist","TLR7, TLR8","CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O",314.174275944,23,1.944,86.19,0.0378176561633927,0.076,0.0569088280816963,0,0
"CP-316819","glycogen phosphorylase inhibitor","PYGL","CON(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1, CON(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1, CON(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CON(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1",415.129883864,29,2.737,94.66,0.0137963348022981,0.1,0.056898167401149,0,0
"GANT-58","GLI antagonist","GLI1","c1cc(ccn1)-c1sc(c(c1-c1ccncc1)-c1ccncc1)-c1ccncc1, c1cc(ccn1)-c1sc(c(c1-c1ccncc1)-c1ccncc1)-c1ccncc1, c1cc(ccn1)-c1sc(c(c1-c1ccncc1)-c1ccncc1)-c1ccncc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","c1cc(ccn1)-c1sc(c(c1-c1ccncc1)-c1ccncc1)-c1ccncc1",392.109567512,29,3.297,79.8,0.0377907452385979,0.076,0.0568953726192989,0,0
"CHPG","glutamate receptor agonist","GRM5","N[C@@H](C(O)=O)c1cc(O)ccc1Cl |&1:1,r|, N[C@@H](C(O)=O)c1cc(O)ccc1Cl |&1:1,r|, N[C@@H](C(O)=O)c1cc(O)ccc1Cl |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@@H](C(O)=O)c1cc(O)ccc1Cl |&1:1",201.019270796,13,-1.559,83.55,0.025745118326323,0.088,0.0568725591631615,0,0
"CC4","nicotinic receptor agonist","CHRNB2","O=c1cccc2[C@@H]3C[C@@H](CN(CCN4C[C@@H]5C[C@H](C4)c4cccc(=O)n4C5)C3)Cn12, O=c1cccc2[C@@H]3C[C@@H](CN(CCN4C[C@@H]5C[C@H](C4)c4cccc(=O)n4C5)C3)Cn12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"preclinical","","","O=c1cccc2[C@@H]3C[C@@H](CN(CCN4C[C@@H]5C[C@H](C4)c4cccc(=O)n4C5)C3)Cn12",406.2368762,30,2.772,50.48,0.057672461169398,0.056,0.056836230584699,0,0
"pf 03716556","h+/k+-atpase inhibitor","ATP4A","CN(CCO)C(=O)c1cc(N[C@@H]2CCOc3cccc(C)c23)c2nc(C)cn2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","gastroenterology","gastroesophageal reflux disease (gerd)","CN(CCO)C(=O)c1cc(N[C@@H]2CCOc3cccc(C)c23)c2nc(C)cn2c1",394.200490692,29,3.42,79.1,0.0376603071816662,0.076,0.0568301535908331,0,0
"UNC0737","histone lysine methyltransferase inhibitor","EHMT1, EHMT2","COc1cc2c(nc(nc2cc1OCCCN1CCCC1)C1CCCCC1)N(C)C1CCN(CC1)C(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2c(nc(nc2cc1OCCCN1CCCC1)C1CCCCC1)N(C)C1CCN(CC1)C(C)C",523.388625808,38,5.807,53.96,0.0436340784462518,0.07,0.0568170392231259,0,0
"molnupiravir","antiviral","","CC(C)C(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=CC(=NC2=O)NO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","CC(C)C(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=CC(=NC2=O)NO",329.122299948,23,-1.205,140.92,0.00355753651054657,0.11,0.0567787682552733,0,0
"fluprazine","serotonin receptor agonist","HTR1A, HTR1B","NC(=O)NCCN1CCN(CC1)c1cccc(c1)C(F)(F)F, NC(=O)NCCN1CCN(CC1)c1cccc(c1)C(F)(F)F",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","NC(=O)NCCN1CCN(CC1)c1cccc(c1)C(F)(F)F",316.151095888,22,1.541,61.6,0.0455237661288511,0.068,0.0567618830644255,0,0
"oxymetholone","","","CC1(O)CCC2C3CCC4CC(=O)C(CC4(C)C3CCC12C)C=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CC1(O)CCC2C3CCC4CC(=O)C(CC4(C)C3CCC12C)C=O",332.235144884,24,4.491,54.37,0.111517273913106,0.002,0.0567586369565528,0,0
"naquotinib","EGFR inhibitor","","CCc1nc(C(N)=O)c(Nc2ccc(cc2)N2CCC(CC2)N2CCN(C)CC2)nc1O[C@@H]1CCN(C1)C(=O)C=C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCc1nc(C(N)=O)c(Nc2ccc(cc2)N2CCC(CC2)N2CCN(C)CC2)nc1O[C@@H]1CCN(C1)C(=O)C=C",562.337987204,41,2.561,120.16,0.00347650253195273,0.11,0.0567382512659764,0,0
"pacritinib","FLT3 inhibitor, JAK inhibitor","FLT3, JAK1, JAK2, JAK3","C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|",472.247440884,35,4.157,68.74,0.0354600363189115,0.078,0.0567300181594558,0,0
"2-[1-(4-piperonyl)piperazinyl]benzothiazole","serotonin receptor agonist","HTR4","C(N1CCN(CC1)c1nc2ccccc2s1)c1ccc2OCOc2c1, C(N1CCN(CC1)c1nc2ccccc2s1)c1ccc2OCOc2c1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C(N1CCN(CC1)c1nc2ccccc2s1)c1ccc2OCOc2c1",353.119797848,25,3.102,66.07,0.0494431758476919,0.064,0.0567215879238459,0,0
"GSK2126458","mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG","COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1, COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1, COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1, COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1, COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1, COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1, COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1",505.102016844,36,4.329,115.34,0.00741731632175027,0.106,0.0567086581608751,0,0
"BAY-85-8050","","","N[C@@H](C[C@@H](F)C(O)=O)C(O)=O |&1:1,&2:3,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","N[C@@H](C[C@@H](F)C(O)=O)C(O)=O |&1:1",165.043735956,11,-3.209,100.62,0.0173846649393747,0.096,0.0566923324696874,0,0
"ATPA","glutamate receptor agonist","GRIK1","CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11,r|, CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11,r|, CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11,r|, CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11,r|, CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11",228.111006992,16,-2.691,109.32,0.0113740580625541,0.102,0.0566870290312771,0,0
"methylbenactyzium-bromide","cholinergic receptor antagonist","","CC[N+](C)(CC)CCOC(=O)C(O)(c1ccccc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC[N+](C)(CC)CCOC(=O)C(O)(c1ccccc1)c1ccccc1",342.206370176091,25,3.254,46.53,0.0993024265480869,0.014,0.0566512132740434,0,0
"L-690330","inositol monophosphatase inhibitor","IMPA1","CC(Oc1ccc(O)cc1)(P(O)(O)=O)P(O)(O)=O, CC(Oc1ccc(O)cc1)(P(O)(O)=O)P(O)(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(Oc1ccc(O)cc1)(P(O)(O)=O)P(O)(O)=O",298.000740604,18,-1.785,164.14,0.00120050883168543,0.112,0.0566002544158427,0,0
"zeatin","","","C\C(CO)=C/CNc1ncnc2nc[nH]c12, C\C(CO)=C/CNc1ncnc2nc[nH]c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C\C(CO)=C/CNc1ncnc2nc[nH]c12",219.112010036,16,-0.132,86.72,0.0431844623257184,0.07,0.0565922311628592,0,0
"eterobarb","anticonvulsant","","CCC1(C(=O)N(COC)C(=O)N(COC)C1=O)c1ccccc1, CCC1(C(=O)N(COC)C(=O)N(COC)C1=O)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCC1(C(=O)N(COC)C(=O)N(COC)C1=O)c1ccccc1",320.13722174,23,1.495,76.15,0.0370979490931421,0.076,0.056548974546571,0,0
"A-674563","AKT inhibitor","AKT1, PKIA, PRKACA","Cc1[nH]nc2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1, Cc1[nH]nc2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1, Cc1[nH]nc2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1[nH]nc2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1",358.179361324,27,4.428,76.82,0.073084410089713,0.04,0.0565422050448565,0,0
"LY2795050","opioid receptor antagonist","","NC(=O)c1ccc(Oc2ccc(CN3CCC[C@H]3c3cccnc3)cc2)c(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC(=O)c1ccc(Oc2ccc(CN3CCC[C@H]3c3cccnc3)cc2)c(Cl)c1",407.140054624,29,3.83,68.45,0.0390652889056775,0.074,0.0565326444528388,0,0
"AC-261066","retinoid receptor agonist","RARB","CCCCOCCOc1nc(sc1C)-c1ccc(C(O)=O)c(F)c1, CCCCOCCOc1nc(sc1C)-c1ccc(C(O)=O)c(F)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCOCCOc1nc(sc1C)-c1ccc(C(O)=O)c(F)c1",353.10970734,24,3.352,96.89,0.021049624880052,0.092,0.056524812440026,0,0
"cinalukast","leukotriene receptor antagonist","CYSLTR1","CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O",412.182063756,29,4.02,107.53,0.0150293146964113,0.098,0.0565146573482057,0,0
"GM-1485","immunophilin ligand","FKBP1A","CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(O)=O",241.131408088,17,0.813,74.68,0.0529886854411395,0.06,0.0564943427205698,0,0
"voruciclib","CDK9 inhibitor","","CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccc(cc1Cl)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccc(cc1Cl)C(F)(F)F",469.090385048,32,4.876,94.14,0.012976419261932,0.1,0.056488209630966,0,0
"PPY-A","Abl kinase inhibitor","ABL1, BCR","COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C, COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C, COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C, COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C, COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C",372.15862588,28,3.659,71.11,0.062954545913266,0.05,0.056477272956633,0,0
"NVP-HSP990","HSP inhibitor","HSP90AA1, HSP90AB1","COc1cccc(n1)-c1cc(F)ccc1[C@H]1Cc2nc(N)nc(C)c2C(=O)N1, COc1cccc(n1)-c1cc(F)ccc1[C@H]1Cc2nc(N)nc(C)c2C(=O)N1, COc1cccc(n1)-c1cc(F)ccc1[C@H]1Cc2nc(N)nc(C)c2C(=O)N1, COc1cccc(n1)-c1cc(F)ccc1[C@H]1Cc2nc(N)nc(C)c2C(=O)N1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1cccc(n1)-c1cc(F)ccc1[C@H]1Cc2nc(N)nc(C)c2C(=O)N1",379.144453036,28,2.689,103.02,0.0209371533046606,0.092,0.0564685766523303,0,0
"2,4-dihydroxypyrimidine-5-carboxylic acid","","","O=C(N1)NC=C(C(O)=O)C1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(N1)NC=C(C(O)=O)C1=O",156.017106608,11,-0.055,95.5,0.0508640086402949,0.062,0.0564320043201474,0,0
"selumetinib","MEK inhibitor","MAP2K1","Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO",456.00000834,27,3.696,88.41,0.00483314526442914,0.108,0.0564165726322146,0,0
"troventol","","","CCC(CO)(C(=O)OC1C[C@@H]2CC[C@H](C1)[N+]2(C)C)c1ccccc1 |&1:2,&2:13,&3:10,TLB:7:8:11.12:15|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCC(CO)(C(=O)OC1C[C@@H]2CC[C@H](C1)[N+]2(C)C)c1ccccc1 |&1:2",332.222020240091,24,2.916,46.53,0.0928240576735834,0.02,0.0564120288367917,0,0
"CW-008","PKA activator","PRKACA","COc1ccn2ncc(-c3nc4n[nH]c(NC(=O)c5ccc(F)cc5)c4cc3F)c2c1, COc1ccn2ncc(-c3nc4n[nH]c(NC(=O)c5ccc(F)cc5)c4cc3F)c2c1, COc1ccn2ncc(-c3nc4n[nH]c(NC(=O)c5ccc(F)cc5)c4cc3F)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccn2ncc(-c3nc4n[nH]c(NC(=O)c5ccc(F)cc5)c4cc3F)c2c1",420.114630128,31,4.931,97.2,0.0308156170961555,0.082,0.0564078085480778,0,0
"olomoucine","CDK inhibitor","CDK1, CDK2, CDK5, MAPK1","Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc12, Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc12",298.154209196,22,1.805,87.89,0.0408031003909604,0.072,0.0564015501954802,0,0
"monepantel","mTOR inhibitor","","C[C@](COc1cc(ccc1C(F)(F)F)C#N)(NC(=O)c1ccc(SC(F)(F)F)cc1)C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@](COc1cc(ccc1C(F)(F)F)C#N)(NC(=O)c1ccc(SC(F)(F)F)cc1)C#N",473.063266976,32,5.252,111.21,0.00874881888570272,0.104,0.0563744094428514,0,0
"diiodothyropropionic-acid","thyroid hormone stimulant","","OC(=O)CCc1cc(I)c(Oc2ccc(O)cc2)c(I)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)CCc1cc(I)c(Oc2ccc(O)cc2)c(I)c1",509.882504864,21,4.829,66.76,0.000732315097542416,0.112,0.0563661575487712,0,0
"GDC-0980","mTOR inhibitor, PI3K inhibitor","FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK","C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1",498.21615782,35,-0.625,162.07,0.000701981805453273,0.112,0.0563509909027266,0,0
"SCH-51344","MTH1 inhibitor","NUDT1","COc1ccc2nc3n[nH]c(C)c3c(NCCOCCO)c2c1, COc1ccc2nc3n[nH]c(C)c3c(NCCOCCO)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc2nc3n[nH]c(C)c3c(NCCOCCO)c2c1",316.1535405,23,1.55,92.29,0.0286977011368205,0.084,0.0563488505684102,0,0
"pyridoxal-isonicotinoyl-hydrazone","apoptosis stimulant","","Cc1ncc(CO)c(\C=N\NC(=O)c2ccncc2)c1O, Cc1ncc(CO)c(\C=N\NC(=O)c2ccncc2)c1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1ncc(CO)c(\C=N\NC(=O)c2ccncc2)c1O",286.106590308,21,0.588,107.7,0.0206835025209699,0.092,0.0563417512604849,0,0
"LY215490","glutamate receptor antagonist","GRIA1, GRIA2, GRIA3, GRIA4, GRIK1","OC(=O)[C@@H]1C[C@H]2C[C@@H](CCc3nn[nH]n3)CC[C@H]2CN1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC(=O)[C@@H]1C[C@H]2C[C@@H](CCc3nn[nH]n3)CC[C@H]2CN1",279.169524912,20,2.387,103.79,0.032605111070646,0.08,0.056302555535323,0,0
"AMD-3465","CC chemokine receptor antagonist","CXCR4","C(NCc1ccccn1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(NCc1ccccn1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(NCc1ccccn1)c1ccc(CN2CCCNCCNCCCNCC2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C(NCc1ccccn1)c1ccc(CN2CCCNCCNCCCNCC2)cc1",410.315795216,30,1.18,64.25,0.0265746380767289,0.086,0.0562873190383645,0,0
"mhp","sphingosine kinase inhibitor","SPHK1","OC(C=C1)=CC=C1C[C@@H](C(OC)=O)NC(CCCCC)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","dermatology","sunburn","OC(C=C1)=CC=C1C[C@@H](C(OC)=O)NC(CCCCC)=O",293.162708216,21,2.012,75.63,0.0505254314720146,0.062,0.0562627157360073,0,0
"N6-methyladenosine","","","CNc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CNc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CNc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",281.11240396,20,-0.954,125.55,0.00848752158679721,0.104,0.0562437607933986,0,0
"JTE-013","lysophospholipid receptor antagonist","P2RY10, S1PR2","CC(C)c1cc(NNC(=O)Nc2cc(Cl)nc(Cl)c2)nc2n(C)nc(C)c12, CC(C)c1cc(NNC(=O)Nc2cc(Cl)nc(Cl)c2)nc2n(C)nc(C)c12, CC(C)c1cc(NNC(=O)Nc2cc(Cl)nc(Cl)c2)nc2n(C)nc(C)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)c1cc(NNC(=O)Nc2cc(Cl)nc(Cl)c2)nc2n(C)nc(C)c12",407.102813588,27,4.749,96.76,0.0164064312439461,0.096,0.0562032156219731,0,0
"val-tyr","angiotensin converting enzyme inhibitor","","CC(C)[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O",280.14230712,20,-1.432,112.65,0.0103985379379702,0.102,0.0561992689689851,0,0
"neuropathiazol","neural stem cell inducer","BMP2, LIF","CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1, CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1, CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1, CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1, CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1, CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1",338.108898816,24,4.784,70.67,0.0743450229841186,0.038,0.0561725114920593,0,0
"edelfosine","phospholipase inhibitor","","CCCCCCCCCCCCCCCCCCOC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC |a:20,&1:23|, CCCCCCCCCCCCCCCCCCOC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC |a:20,&1:23|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCCCCCCCCCCCCCCCCOC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC |a:20",524.407451658091,35,7.426,84.03,0.0162552764970092,0.096,0.0561276382485046,0,0
"snog","","","N[C@@H](CCC(=O)N[C@@H](CS[N+][O-])C(=O)NCC(O)=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","N[C@@H](CCC(=O)N[C@@H](CS[N+][O-])C(=O)NCC(O)=O)C(O)=O",336.073969852,22,-4.916,207.18,0.000207902839771901,0.112,0.056103951419886,0,0
"XL041","LXR agonist","","CC(C)(O)c1cn(c(n1)C(C)(C)c1c(Cl)cccc1Cl)-c1ccc(cc1F)-c1cc(F)c(CO)c(c1)S(C)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(O)c1cn(c(n1)C(C)(C)c1c(Cl)cccc1Cl)-c1ccc(cc1F)-c1cc(F)c(CO)c(c1)S(C)(=O)=O",608.111490176,40,6.886,100.8,0.00417959052360584,0.108,0.0560897952618029,0,0
"acesulfame-potassium","","","CC1=CC(=O)NS(=O)(=O)O1 |t:1|, CC1=CC(=O)NS(=O)(=O)O1 |t:1|, CC1=CC(=O)NS(=O)(=O)O1 |t:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC1=CC(=O)NS(=O)(=O)O1 |t:1|",162.99392864,10,-1.514,80.85,0.0341602958274936,0.078,0.0560801479137468,0,0
"(2s)-2-amino-5-({(1r)-2-[(carboxymethyl)amino]-1-[(nitrososulfanyl)methyl]-2-oxoethyl}amino)-5-oxopentanoic acid","nitric oxide stimulant","","N[C@@H](CCC(=O)N[C@@H](CS[NH2+][O-])C(=O)NCC(O)=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","N[C@@H](CCC(=O)N[C@@H](CS[NH2+][O-])C(=O)NCC(O)=O)C(O)=O",338.089619916,22,-4.916,223.79,0.000134811860438331,0.112,0.0560674059302192,0,0
"DCC-2618","KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","KIT, PDGFRA","Cn1cc(cn1)-c1cc(Oc2cc(F)c(NC(=O)C3(CC3)C(=O)Nc3ccccc3)cc2F)ccn1, Cn1cc(cn1)-c1cc(Oc2cc(F)c(NC(=O)C3(CC3)C(=O)Nc3ccccc3)cc2F)ccn1, Cn1cc(cn1)-c1cc(Oc2cc(F)c(NC(=O)C3(CC3)C(=O)Nc3ccccc3)cc2F)ccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cn1cc(cn1)-c1cc(Oc2cc(F)c(NC(=O)C3(CC3)C(=O)Nc3ccccc3)cc2F)ccn1",489.161245972,36,4.348,98.14,0.0161121474722106,0.096,0.0560560737361053,0,0
"alofanib","fgfr inhibitor","FGFR2","Cc1cc(c(NS(=O)(=O)c2cccc(c2)C(O)=O)cc1-c1cccnc1)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","ovarian cancer","Cc1cc(c(NS(=O)(=O)c2cccc(c2)C(O)=O)cc1-c1cccnc1)[N+]([O-])=O",413.0681562,29,4.205,147.88,0.00609697636379296,0.106,0.0560484881818965,0,0
"NTNCB","neuropeptide receptor antagonist","NPY5R","[O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14,17,&1:21|, [O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14,17,&1:21|, [O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14,17,&1:21|, [O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14,17,&1:21|, [O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14,17,&1:21|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14",471.219177536,33,4.578,109.72,0.0100876016814024,0.102,0.0560438008407012,0,0
"bleomycin (sulfate)","","","CC(O)C(NC(=O)C(C)C(O)C(C)NC(=O)C(NC(=O)c1nc(nc(N)c1C)C(CC(N)=O)NCC(N)C(N)=O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1c[nH]cn1)C(=O)NCCc1nc(cs1)-c1nc(cs1)C(=O)NCCC[S+](C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CC(O)C(NC(=O)C(C)C(O)C(C)NC(=O)C(NC(=O)c1nc(nc(N)c1C)C(CC(N)=O)NCC(N)C(N)=O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1c[nH]cn1)C(=O)NCCc1nc(cs1)-c1nc(cs1)C(=O)NCCC[S+](C)C",1414.51843212809,96,-8.766,683.55,2.08403375816223e-13,0.112,0.0560000000001042,0,0
"hetacillin","penicillin binding protein inhibitor, bacterial cell wall synthesis inhibitor","","CC1(C)S[C@@H]2[C@H](N3C(=O)[C@H](NC3(C)C)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2C(N3C(=O)[C@H](NC3(C)C)c3ccccc3)C(=O)N2[C@H]1C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","obstetrics/gynecology, infectious disease","mastitis, gram-positive bacterial infections","CC1(C)S[C@@H]2[C@H](N3C(=O)[C@H](NC3(C)C)c3ccccc3)C(=O)N2[C@H]1C(O)=O",389.140927216,27,1.77,115.25,0.00797450408577463,0.104,0.0559872520428873,0,0
"hetacillin potassium","bacterial cell wall synthesis inhibitor, penicillin binding protein inhibitor","","CC1(C)S[C@@H]2C(N3C(=O)[C@H](NC3(C)C)c3ccccc3)C(=O)N2[C@H]1C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","infectious disease, obstetrics/gynecology","gram-positive bacterial infections, mastitis","CC1(C)S[C@@H]2C(N3C(=O)[C@H](NC3(C)C)c3ccccc3)C(=O)N2[C@H]1C(O)=O",389.140927216,27,1.77,115.25,0.00797450408577461,0.104,0.0559872520428873,0,0
"SD-208","TGF beta receptor inhibitor","TGFBR1","Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1, Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1, Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1",352.06395022,25,2.38,76.48,0.0339139328219073,0.078,0.0559569664109536,0,0
"ICI-89406","adrenergic receptor antagonist","ADRB1, ADRB2","O[C@@H](CNCCNC(=O)Nc1ccccc1)COc1ccccc1C#N |&1:1,r|, O[C@@H](CNCCNC(=O)Nc1ccccc1)COc1ccccc1C#N |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,"phase 1","","","O[C@@H](CNCCNC(=O)Nc1ccccc1)COc1ccccc1C#N |&1:1",354.169190564,26,1.308,106.41,0.0158882639474738,0.096,0.0559441319737369,0,0
"fulacimstat","chymotrypsin inhibitor","CTRL","CN1C(=O)Oc2cc(ccc12)N3C=C(C(=O)O)C(=O)N([C@@H]4CCc5c4cccc5C(F)(F)F)C3=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","endocrinology","diabetes mellitus","CN1C(=O)Oc2cc(ccc12)N3C=C(C(=O)O)C(=O)N([C@@H]4CCc5c4cccc5C(F)(F)F)C3=O",487.099119892,35,2.99,107.46,0.00782735350964368,0.104,0.0559136767548218,0,0
"TC-G-1004","adenosine receptor antagonist","ADORA2A","COC1CCN(CC1)c1cccc(n1)-c1cc(NC(C)=O)nc(n1)-n1nc(C)cc1C, COC1CCN(CC1)c1cccc(n1)-c1cc(NC(C)=O)nc(n1)-n1nc(C)cc1C, COC1CCN(CC1)c1cccc(n1)-c1cc(NC(C)=O)nc(n1)-n1nc(C)cc1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC1CCN(CC1)c1cccc(n1)-c1cc(NC(C)=O)nc(n1)-n1nc(C)cc1C",421.222623104,31,3.273,98.06,0.0198094700061152,0.092,0.0559047350030576,0,0
"pyrazoloacridine","rna synthesis inhibitor, topoisomerase inhibitor","TOP1, TOP2A","COc1ccc2nc3c(ccc4n(CCCN(C)C)[nH]c(c34)c2c1)[N+]([O-])=O, COc1ccc2nc3c(ccc4n(CCCN(C)C)[nH]c(c34)c2c1)[N+]([O-])=O, COc1ccc2Nc3c(ccc4c3c(nn4CCCN(C)C)c2c1)[N+](=O)[O-]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","oncology","melanoma","COc1ccc2nc3c(ccc4n(CCCN(C)C)[nH]c(c34)c2c1)[N+]([O-])=O",367.164439532,27,2.633,89.22,0.0298032202329001,0.082,0.0559016101164501,0,0
"SYM-2081","kainate receptor antagonist","GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SLC1A2","C[C@H](C[C@H](N)C(O)=O)C(O)=O, C[C@H](C[C@H](N)C(O)=O)C(O)=O",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H](C[C@H](N)C(O)=O)C(O)=O",161.068807832,11,-3.056,100.62,0.019800370299472,0.092,0.055900185149736,0,0
"tienilic-acid","cytochrome P450 inhibitor, sodium/potassium/chloride transporter inhibitor","CYP2C9, SLC12A1","OC(=O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl, OC(=O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl, OC(=O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","OC(=O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl",329.952035096,20,3.179,91.84,0.0157811218836489,0.096,0.0558905609418244,0,0
"XD-14","bromodomain inhibitor","BRD2, BRD3, BRD4, BRDT","CCN(CC)S(=O)(=O)c1ccc(O)c(NC(=O)c2[nH]c(C)c(C(C)=O)c2CC)c1, CCN(CC)S(=O)(=O)c1ccc(O)c(NC(=O)c2[nH]c(C)c(C(C)=O)c2CC)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN(CC)S(=O)(=O)c1ccc(O)c(NC(=O)c2[nH]c(C)c(C(C)=O)c2CC)c1",421.167141964,29,2.865,127.95,0.00574208989677569,0.106,0.0558710449483878,0,0
"seocalcitol","vitamin D receptor agonist","VDR","CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C",454.344695332,33,7.025,60.69,0.0797386874973138,0.032,0.0558693437486569,0,0
"NU-6027","CDK inhibitor","CCNA2, CDK2","Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1, Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1, Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1",251.138224784,18,2.608,116.48,0.0316526006212566,0.08,0.0558263003106283,0,0
"tretazicar","DNA replication inhibitor","NQO2","NC(=O)c1cc(N2CC2)c(cc1[N+]([O-])=O)[N+]([O-])=O, NC(=O)c1cc(N2CC2)c(cc1[N+]([O-])=O)[N+]([O-])=O, NC(=O)c1cc(N2CC2)c(cc1[N+]([O-])=O)[N+]([O-])=O, NC(=O)c1cc(N2CC2)c(cc1[N+]([O-])=O)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NC(=O)c1cc(N2CC2)c(cc1[N+]([O-])=O)[N+]([O-])=O",252.049469356,18,0.692,132.38,0.0136377519209441,0.098,0.0558188759604721,0,0
"nibentan","potassium channel blocker","","CCN(CC)CCCC[C@@H](NC(=O)c1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:9,r|, CCN(CC)CCCC[C@@H](NC(=O)c1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:9,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCN(CC)CCCC[C@@H](NC(=O)c1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:9",383.220891788,28,4.905,75.48,0.0594979028218334,0.052,0.0557489514109167,0,0
"MM-11253","retinoid receptor antagonist","RARG","CC1(C)CCC(C)(C)c2cc(ccc12)C1(SCCS1)c1ccc2cc(ccc2c1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(SCCS1)c1ccc2cc(ccc2c1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(SCCS1)c1ccc2cc(ccc2c1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC1(C)CCC(C)(C)c2cc(ccc12)C1(SCCS1)c1ccc2cc(ccc2c1)C(O)=O",462.1687222,32,9.046,87.9,0.0474956009386155,0.064,0.0557478004693077,0,0
"elacytarabine","antineoplastic agent","DCK","CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@H]([C@@H](O)[C@@H]1O)n1ccc(N)nc1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@H]([C@@H](O)[C@@H]1O)n1ccc(N)nc1=O",507.33083616,36,7.598,136.9,0.00949272855154529,0.102,0.0557463642757726,0,0
"dalcetrapib","cholesteryl ester transfer protein inhibitor","CETP","CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C, CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C, CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C",389.23885036,27,6.852,71.47,0.0714766529429878,0.04,0.0557383264714939,0,0
"apafant","platelet activating factor receptor antagonist","PTAFR","Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl |c:6|, Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl |c:6|, Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl |c:6|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl |c:6|",455.118273624,31,3.762,100.85,0.00940782221379615,0.102,0.0557039111068981,0,0
"L-755507","adrenergic receptor agonist","ADRB1, ADRB2, ADRB3","CCCCCCNC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1, CCCCCCNC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1, CCCCCCNC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,"preclinical","","","CCCCCCNC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1",584.266856,41,4.416,157.4,0.00137098635076223,0.11,0.0556854931753811,0,0
"CB-839","glutaminase inhibitor","GLS","FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1, FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1, FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1, FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1, FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1",571.161343288,40,4.251,160.12,0.00134304019986173,0.11,0.0556715200999309,0,0
"nelotanserin","serotonin receptor inverse agonist","","COc1ccc(NC(=O)Nc2ccc(F)cc2F)cc1-c1c(Br)cnn1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1ccc(NC(=O)Nc2ccc(F)cc2F)cc1-c1c(Br)cnn1C",436.03464426,27,4,68.18,0.0133017070725077,0.098,0.0556508535362538,0,0
"AT-9283","Aurora kinase inhibitor, JAK inhibitor","AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A","O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1",381.191322976,28,1.071,110.96,0.0112619909696385,0.1,0.0556309954848192,0,0
"mdr-652","trpv agonist","TRPV1","O=C(NC1=CC=C(CO)C(F)=C1)NCC2=C(C3=CC=CC(Cl)=C3)N=C(C(C)(C)C)S2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","neurology/psychiatry","chronic pain","O=C(NC1=CC=C(CO)C(F)=C1)NCC2=C(C3=CC=CC(Cl)=C3)N=C(C(C)(C)C)S2",447.118353876,30,1.361,99.02,0.00525926867642362,0.106,0.0556296343382118,0,0
"NTRC-824","neurotensin receptor antagonist","NTSR2","CC(C)C[C@H](NC(=O)Cn1cc(C(=O)C(F)(F)F)c2cc(NS(=O)(=O)c3ccc(C)cc3)ccc12)C(O)=O, CC(C)C[C@H](NC(=O)Cn1cc(C(=O)C(F)(F)F)c2cc(NS(=O)(=O)c3ccc(C)cc3)ccc12)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)C[C@H](NC(=O)Cn1cc(C(=O)C(F)(F)F)c2cc(NS(=O)(=O)c3ccc(C)cc3)ccc12)C(O)=O",553.149441212,38,2.452,142.95,0.00124800989473477,0.11,0.0556240049473674,0,0
"AZD5153","bromodomain inhibitor","","[H][C@]1(C)N(CCOc2ccc(cc2)C2CCN(CC2)c2ccc3nnc(OC)n3n2)CCN(C)C1=O |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","[H][C@]1(C)N(CCOc2ccc(cc2)C2CCN(CC2)c2ccc3nnc(OC)n3n2)CCN(C)C1=O |r|",479.264487916,36,4.936,88.33,0.0292088949059266,0.082,0.0556044474529633,0,0
"ITE","aryl hydrocarbon receptor agonist","AHR","COC(=O)c1csc(n1)C(=O)c1c[nH]c2ccccc12, COC(=O)c1csc(n1)C(=O)c1c[nH]c2ccccc12, COC(=O)c1csc(n1)C(=O)c1c[nH]c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)c1csc(n1)C(=O)c1c[nH]c2ccccc12",286.04121318,20,2.541,100.29,0.0312035465365182,0.08,0.0556017732682591,0,0
"docebenone","lipoxygenase inhibitor","ALOX5","CC1=C(C)C(=O)C(CCCCC#CCCCC#CCO)=C(C)C1=O |c:1,t:19|, CC1=C(C)C(=O)C(CCCCC#CCCCC#CCO)=C(C)C1=O |c:1,t:19|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC1=C(C)C(=O)C(CCCCC#CCCCC#CCO)=C(C)C1=O |c:1",326.188194692,24,3.087,54.37,0.0932005805190352,0.018,0.0556002902595176,0,0
"tyrphostin-AG-99","tyrosine kinase inhibitor","EGFR","NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N, NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N, NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N",204.053492116,15,0.171,107.34,0.0331748379099171,0.078,0.0555874189549586,0,0
"orelabrutinib","","","NC(=O)c1ccc(nc1c2ccc(Oc3ccccc3)cc2)C4CCN(CC4)C(=O)C=C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","NC(=O)c1ccc(nc1c2ccc(Oc3ccccc3)cc2)C4CCN(CC4)C(=O)C=C",427.18959166,32,3.622,85.52,0.0311442337402584,0.08,0.0555721168701292,0,0
"A-1070722","glycogen synthase kinase inhibitor","GSK3A, GSK3B","COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1, COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1, COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1, COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1, COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1, COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1",362.099060316,26,2.99,76.14,0.0391129547146642,0.072,0.0555564773573321,0,0
"MDMS","DNA inhibitor","","CS(=O)(=O)OCOS(C)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CS(=O)(=O)OCOS(C)(=O)=O",203.976229976,11,-1.811,103.5,0.00910905722105573,0.102,0.0555545286105279,0,0
"LY2584702","ribosomal protein inhibitor","RPS6KB1","Cn1cc(nc1C1CCN(CC1)c1ncnc2n[nH]cc12)-c1ccc(F)c(c1)C(F)(F)F, Cn1cc(nc1C1CCN(CC1)c1ncnc2n[nH]cc12)-c1ccc(F)c(c1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cn1cc(nc1C1CCN(CC1)c1ncnc2n[nH]cc12)-c1ccc(F)c(c1)C(F)(F)F",445.163806488,32,5.161,75.52,0.0370443584839063,0.074,0.0555221792419531,0,0
"VU152100","acetylcholine receptor allosteric modulator","CHRM4","COc1ccc(CNC(=O)c2sc3nc(C)cc(C)c3c2N)cc1, COc1ccc(CNC(=O)c2sc3nc(C)cc(C)c3c2N)cc1, COc1ccc(CNC(=O)c2sc3nc(C)cc(C)c3c2N)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"preclinical","","","COc1ccc(CNC(=O)c2sc3nc(C)cc(C)c3c2N)cc1",341.119797848,24,2.978,105.48,0.020963108126217,0.09,0.0554815540631085,0,0
"WAY-100635","serotonin receptor antagonist","HTR1A","COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1, COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1, COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1",422.268176328,31,4.506,48.91,0.0769394780508258,0.034,0.0554697390254129,0,0
"PRT062070","JAK inhibitor, SYK inhibitor","SYK","CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1",445.189608724,31,1.826,141.93,0.00288125984062838,0.108,0.0554406299203142,0,0
"BAY-W-9798","antioxidant","","COC(=O)C1=C(C)N(C)C(C)=C(C1c1ccc(cc1)C(F)(F)F)C(=O)OC |c:4,10|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COC(=O)C1=C(C)N(C)C(C)=C(C1c1ccc(cc1)C(F)(F)F)C(=O)OC |c:4",383.13444278,27,3.784,55.84,0.0568650565505858,0.054,0.0554325282752929,0,0
"RS-23597-190","serotonin receptor antagonist","HTR4","COc1cc(N)c(Cl)cc1C(=O)OCCCN1CCCCC1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(N)c(Cl)cc1C(=O)OCCCN1CCCCC1",326.139720276,22,2.753,64.79,0.0448563796088523,0.066,0.0554281898044261,0,0
"IKK-16","IKK inhibitor","IKBKB","O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1",483.209281548,35,4.547,89.6,0.0188304435988001,0.092,0.0554152217994,0,0
"disodium-sebacate","","HBB","OC(=O)CCCCCCCCC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC(=O)CCCCCCCCC(O)=O",202.120509056,14,2.282,74.6,0.0928273284846176,0.018,0.0554136642423088,0,0
"mibampator","glutamate receptor modulator","GRIA1","CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1, CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1, CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1, CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1",438.16469944,29,3.438,109.1,0.00680664452952419,0.104,0.0554033222647621,0,0
"AZD8330","MEK inhibitor","MAP3K1","Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O",461.024782244,25,4.195,92.59,0.00277884066393122,0.108,0.0553894203319656,0,0
"CU-CPT-4a","toll-like receptor inhibitor","TLR3","OC(=O)[C@@H](Cc1ccccc1)NC(=O)c1sc2cc(F)ccc2c1Cl, OC(=O)[C@@H](Cc1ccccc1)NC(=O)c1sc2cc(F)ccc2c1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)[C@@H](Cc1ccccc1)NC(=O)c1sc2cc(F)ccc2c1Cl",377.028870176,25,1.752,94.64,0.0107568231839829,0.1,0.0553784115919914,0,0
"geldanamycin","HSP inhibitor","HSP90AA1","CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,t:13,19,21,32|, CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,t:13,19,21,32|, CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,t:13,19,21,32|, CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,t:13,19,21,32|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7",560.27338086,40,1.021,163.48,0.000730253338424226,0.11,0.0553651266692121,0,0
"NSC-663284","CDC inhibitor","CDC25A, CDC25B, CDC25C","ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|",321.088019052,22,0.707,71.53,0.0267068207755315,0.084,0.0553534103877658,0,0
"EHop-016","Ras GTPase inhibitor","RAC1, RAC3","CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12",430.24810958,32,4.09,67.24,0.0487057460306842,0.062,0.0553528730153421,0,0
"CCT196969","RAF inhibitor","","CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc4nc(O)cnc34)cc2F)n(n1)-c1ccccc1, CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc4nc(O)cnc34)cc2F)n(n1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc4nc(O)cnc34)cc2F)n(n1)-c1ccccc1",513.192465848,38,3.906,127.08,0.00665979956897376,0.104,0.0553298997844869,0,0
"thiazovivin","rho associated kinase inhibitor","","O=C(NCc1ccccc1)c1csc(Nc2ccncn2)n1, O=C(NCc1ccccc1)c1csc(Nc2ccncn2)n1, O=C(NCc1ccccc1)c1csc(Nc2ccncn2)n1, O=C(NCc1ccccc1)c1csc(Nc2ccncn2)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(NCc1ccccc1)c1csc(Nc2ccncn2)n1",311.084081036,22,1.68,108.04,0.0186278417599215,0.092,0.0553139208799607,0,0
"AMG900","Aurora kinase inhibitor","AURKA, AURKB, AURKC","Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12, Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12, Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12, Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12, Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12",503.152829292,37,5.022,139.97,0.00655832057432768,0.104,0.0552791602871638,0,0
"tabimorelin","growth hormone secretagogue receptor agonist","GHSR","CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)\C=C\CC(C)(C)N, CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)\C=C\CC(C)(C)N, CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)\C=C\CC(C)(C)N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)\C=C\CC(C)(C)N",528.31004114,39,4.082,95.74,0.0125392283562239,0.098,0.0552696141781119,0,0
"glutathione-monoisopropyl-ester","lipid peroxidase inhibitor","","CC(C)OC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O, CC(C)OC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)OC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O",349.130756456,23,-3.026,186.62,0.000490448295080436,0.11,0.0552452241475402,0,0
"reversine","Aurora kinase inhibitor","AURKB, INCENP, MAP2K1","C1CCC(CC1)Nc1nc(Nc2ccc(cc2)N2CCOCC2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Nc2ccc(cc2)N2CCOCC2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Nc2ccc(cc2)N2CCOCC2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Nc2ccc(cc2)N2CCOCC2)nc2nc[nH]c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C1CCC(CC1)Nc1nc(Nc2ccc(cc2)N2CCOCC2)nc2nc[nH]c12",393.227708484,29,3.823,90.99,0.0324744843951329,0.078,0.0552372421975664,0,0
"PP242","mTOR inhibitor","MTOR, PASK","CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12",308.138559132,23,2.8,105.64,0.0344550705655456,0.076,0.0552275352827728,0,0
"lomeguatrib","O6-alkylguanine-DNA alkyltransferase inhibitor","MGMT","Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1, Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1, Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1, Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1, Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1",324.963292976,18,1.831,117.95,0.00444896424126578,0.106,0.0552244821206329,0,0
"GNF-2","Bcr-Abl kinase inhibitor","ABL1, BCR","NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1, NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1, NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1, NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1",374.099060316,27,3.752,90.13,0.0324431439895572,0.078,0.0552215719947786,0,0
"GSK923295","centromere associated protein inhibitor","CENPE","CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1, CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1",591.261232376,42,5.807,108.2,0.00639503859112273,0.104,0.0551975192955614,0,0
"theaflavin","antiviral","","O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(=O)c2c(O)c(O)cc(cc12)[C@H]1Oc2cc(O)cc(O)c2C[C@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(=O)c2c(O)c(O)cc(cc12)[C@H]1Oc2cc(O)cc(O)c2C[C@H]1O",564.126776208,41,2.737,217.6,0.000364437522075067,0.11,0.0551822187610375,0,0
"gne-477","mtor inhibitor","MTOR, PIK3CA","NC1=NC=C(C2=NC(N3CCOCC3)=C4C(C(C)=C(CN5CCN(S(=O)(C)=O)CC5)S4)=N2)C=N1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","oncology","renal cell carcinoma (rcc)","NC1=NC=C(C2=NC(N3CCOCC3)=C4C(C(C)=C(CN5CCN(S(=O)(C)=O)CC5)S4)=N2)C=N1",504.172578756,34,-2.116,162.23,0.000334269047089609,0.11,0.0551671345235448,0,0
"madrasin","cell splicing inhibitor","","COc1ccc2c(C)nc(Nc3nc(=O)c(C)c(C)[nH]3)nc2c1, COc1ccc2c(C)nc(Nc3nc(=O)c(C)c(C)[nH]3)nc2c1, COc1ccc2c(C)nc(Nc3nc(=O)c(C)c(C)[nH]3)nc2c1, COc1ccc2c(C)nc(Nc3nc(=O)c(C)c(C)[nH]3)nc2c1, COc1ccc2c(C)nc(Nc3nc(=O)c(C)c(C)[nH]3)nc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc2c(C)nc(Nc3nc(=O)c(C)c(C)[nH]3)nc2c1",311.138224784,23,3.488,92.79,0.0503027048530385,0.06,0.0551513524265193,0,0
"SRC-kinase-inhibitor-I","SRC inhibitor","CSK, LCK, RIPK2","COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC, COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC, COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC, COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC",373.142641468,28,4.067,65.5,0.0763007458458445,0.034,0.0551503729229222,0,0
"CV-1808","adenosine receptor agonist","ADORA2A","Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",358.138953056,26,0.523,151.57,0.00423306049038399,0.106,0.055116530245192,0,0
"CP-91149","glycogen phosphorylase inhibitor","PYGL","CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1, CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1, CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1, CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1",399.134969244,28,2.828,85.43,0.0202100046639465,0.09,0.0551050023319732,0,0
"tozasertib","Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor","AURKA, AURKB, AURKC, LCK","CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1",464.210678516,33,3.556,127.37,0.00618993632767955,0.104,0.0550949681638398,0,0
"JNJ-64619178","protein arginine N-methyltransferase inhibitor","","Nc1nc2cc(CC[C@H]3C[C@H]([C@H](O)[C@@H]3O)n3ccc4c(N)ncnc34)ccc2cc1Br",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Nc1nc2cc(CC[C@H]3C[C@H]([C@H](O)[C@@H]3O)n3ccc4c(N)ncnc34)ccc2cc1Br",482.106586076,31,3.576,136.1,0.00209755306408963,0.108,0.0550487765320448,0,0
"LX1031","tryptophan hydroxylase inhibitor","TPH1","COc1cccc(c1)-c1ccc(cc1)[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F, COc1cccc(c1)-c1ccc(cc1)[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1cccc(c1)-c1ccc(cc1)[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F",538.18278994,39,4.004,133.58,0.00407536258598941,0.106,0.0550376812929947,0,0
"2-chloroadenosine","adenosine receptor agonist","ADORA1, ADORA2A, ADORA2B","Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O",301.057781544,20,-0.706,139.54,0.00406598586547776,0.106,0.0550329929327389,0,0
"EG00229","neuropilin receptor antagonist","NRP1","NC(=N)NCCC[C@H](NC(=O)c1sccc1NS(=O)(=O)c1cccc2nsnc12)C(O)=O, NC(=N)NCCC[C@H](NC(=O)c1sccc1NS(=O)(=O)c1cccc2nsnc12)C(O)=O, NC(=N)NCCC[C@H](NC(=O)c1sccc1NS(=O)(=O)c1cccc2nsnc12)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC(=N)NCCC[C@H](NC(=O)c1sccc1NS(=O)(=O)c1cccc2nsnc12)C(O)=O",497.060979708,32,-0.235,265.11,3.65163265045343e-05,0.11,0.0550182581632523,0,0
"rezafungin (acetate)","other antifungal","","[H][C@@]12C[C@@H](O)CN1C(=O)[C@@]([H])(NC(=O)[C@H](C[C@@H](O)[C@]([H])(NC(=O)[C@]1([H])[C@@H](O)[C@@H](C)CN1C(=O)[C@@]([H])(NC(=O)[C@@]([H])(NC2=O)[C@H](O)[C@@H](O)c1ccc(O)cc1)[C@@H](C)O)OCC[N+](C)(C)C)NC(=O)c1ccc(cc1)-c1ccc(cc1)-c1ccc(OCCCCC)cc1)[C@@H](C)O.CC(=O)O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","infectious disease","candidemia","[H][C@@]12C[C@@H](O)CN1C(=O)[C@@]([H])(NC(=O)[C@H](C[C@@H](O)[C@]([H])(NC(=O)[C@]1([H])[C@@H](O)[C@@H](C)CN1C(=O)[C@@]([H])(NC(=O)[C@@]([H])(NC2=O)[C@H](O)[C@@H](O)c1ccc(O)cc1)[C@@H](C)O)OCC[N+](C)(C)C)NC(=O)c1ccc(cc1)-c1ccc(cc1)-c1ccc(OCCCCC)cc1)[C@@H](C)O.CC(=O)O",1285.62384904809,98,5.184,403.72,1.44909559921074e-07,0.11,0.05500007245478,0,0
"PQ-401","IGF-1 inhibitor","IGF1R","COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12",341.093104432,24,3.437,63.25,0.0599990282969394,0.05,0.0549995141484697,0,0
"epigallocatechin-(-)","","","O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(O)c(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(O)c(O)c1",306.073952788,22,1.484,130.61,0.0119403225927239,0.098,0.0549701612963619,0,0
"AMZ30","protein phosphatase inhibitor","","[O-][N+](=O)c1cccc(c1)S(=O)(=O)n1cccc1\C=C(/C#N)S(=O)(=O)c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[O-][N+](=O)c1cccc(c1)S(=O)(=O)n1cccc1\C=C(/C#N)S(=O)(=O)c1ccc(F)cc1",461.015155324,31,3.16,156.9,0.00193668431102748,0.108,0.0549683421555137,0,0
"palifosfamide","DNA alkylating agent","","OP(=O)(NCCCl)NCCCl, OP(=O)(NCCCl)NCCCl, OP(=O)(NCCCl)NCCCl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","OP(=O)(NCCCl)NCCCl",219.993519582,11,-0.0710000000000002,71.17,0.0199188996817563,0.09,0.0549594498408782,0,0
"AS-703026","MEK inhibitor","MAP2K1, MAP2K2","OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F, OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F, OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F, OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F, OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F, OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F, OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F",431.01421756,23,1.664,94.48,0.00184954567789408,0.108,0.054924772838947,0,0
"apigenin","casein kinase inhibitor, cell proliferation inhibitor","AKR1B1, AR, CDK6, CFTR, CYP19A1, CYP1B1, HSD17B1","Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1, Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1, Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1, Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1, Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1",270.05282342,20,3.668,90.9,0.07181849845721,0.038,0.054909249228605,0,0
"nithiamide","bacterial DNA inhibitor","","CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)Nc1ncc(s1)[N+]([O-])=O",187.00516202,12,-0.265,113.37,0.0197883091449903,0.09,0.0548941545724952,0,0
"NS-1643","voltage-gated potassium channel activator","KCNH2, KCNH6, KCNMA1","Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F, Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F, Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F, Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F, Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F, Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F",380.0595615,26,4.378,81.59,0.0317776461549822,0.078,0.0548888230774911,0,0
"cordycepin","DNA inhibitor","","Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@H]1O",251.101839276,18,-1.245,119.31,0.0117662060091979,0.098,0.054883103004599,0,0
"GR-79236","adenosine receptor agonist","ADORA1, ADORA2A","OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@H]3CCC[C@@H]3O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@H]3CCC[C@@H]3O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@H]3CCC[C@@H]3O)ncnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@H]3CCC[C@@H]3O)ncnc12",351.154268772,25,-0.296,145.78,0.00371851226426087,0.106,0.0548592561321304,0,0
"tariquidar","P glycoprotein inhibitor","ABCB1","COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC",646.279134936,48,5.353,111.25,0.00570483013671039,0.104,0.0548524150683552,0,0
"castanospermine","glucosidase inhibitor","GAA, GBA","O[C@H]1CCN2C[C@H](O)[C@@H](O)[C@H](O)[C@@H]12, O[C@H]1CCN2C[C@H](O)[C@@H](O)[C@H](O)[C@@H]12, O[C@H]1CCN2C[C@H](O)[C@@H](O)[C@H](O)[C@@H]12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O[C@H]1CCN2C[C@H](O)[C@@H](O)[C@H](O)[C@@H]12",189.10010796,13,-1.792,84.16,0.0316842778795855,0.078,0.0548421389397928,0,0
"LP-533401","tryptophan hydroxylase inhibitor","","N[C@@H](Cc1ccc(cc1)-c1cc(O[C@@H](c2ccc(cc2)-c2cccc(F)c2)C(F)(F)F)nc(N)n1)C(O)=O |&1:13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@@H](Cc1ccc(cc1)-c1cc(O[C@@H](c2ccc(cc2)-c2cccc(F)c2)C(F)(F)F)nc(N)n1)C(O)=O |&1:13|",526.162803444,38,4.25,124.35,0.00566689688562437,0.104,0.0548334484428122,0,0
"dixanthogen","","","CCOC(=S)SSC(=S)OCC, CCOC(=S)SSC(=S)OCC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=S)SSC(=S)OCC",241.95636356,12,1.806,133.24,0.00565705683132882,0.104,0.0548285284156644,0,0
"AZD1981","CRTH receptor antagonist","PTGDR2","CC(=O)Nc1cccc2n(CC(O)=O)c(C)c(Sc3ccc(Cl)cc3)c12, CC(=O)Nc1cccc2n(CC(O)=O)c(C)c(Sc3ccc(Cl)cc3)c12, CC(=O)Nc1cccc2n(CC(O)=O)c(C)c(Sc3ccc(Cl)cc3)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(=O)Nc1cccc2n(CC(O)=O)c(C)c(Sc3ccc(Cl)cc3)c12",388.064841084,26,4.123,96.63,0.0176479128792834,0.092,0.0548239564396417,0,0
"ML10302","serotonin receptor partial agonist","HTR3A, HTR3B, HTR4","COc1cc(N)c(Cl)cc1C(=O)OCCN1CCCCC1, COc1cc(N)c(Cl)cc1C(=O)OCCN1CCCCC1, COc1cc(N)c(Cl)cc1C(=O)OCCN1CCCCC1",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(N)c(Cl)cc1C(=O)OCCN1CCCCC1",312.124070212,21,2.395,64.79,0.0455839473727095,0.064,0.0547919736863547,0,0
"CNX-774","Bruton's tyrosine kinase (BTK) inhibitor","BTK","CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1",499.176815784,37,3.039,130.16,0.00557208481783399,0.104,0.054786042408917,0,0
"maribavir","cytomegalovirus inhibitor, protein kinase inhibitor","PYGM","CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O, CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O, CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O",375.075261448,24,2.502,99.77,0.00956457294739353,0.1,0.0547822864736968,0,0
"H-89","PKA inhibitor","GSG2, PKIA, PRKACA","Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1",445.04595998,27,3.609,79.47,0.00754283308417393,0.102,0.054771416542087,0,0
"bergenin","interleukin inhibitor","IL1B, TNF","COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O, COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O, COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O",328.079432092,23,-0.937,145.91,0.00346998868287417,0.106,0.0547349943414371,0,0
"TWS-119","glycogen synthase kinase inhibitor","GSK3B, JUN, MYC","Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1",318.111675688,24,3.549,97.05,0.0493516667432893,0.06,0.0546758333716447,0,0
"SSR180711","acetylcholine receptor agonist","CHRNA7","Brc1ccc(OC(=O)N2CC[N@@]3CC[C@H]2CC3)cc1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"phase 2","","","Brc1ccc(OC(=O)N2CC[N@@]3CC[C@H]2CC3)cc1 |r|",324.047339884,19,2.573,32.78,0.0473461279063364,0.062,0.0546730639531682,0,0
"flurofamide","urease inhibitor","","NP(N)(=O)NC(=O)c1ccc(F)cc1, NP(N)(=O)NC(=O)c1ccc(F)cc1, NP(N)(=O)NC(=O)c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NP(N)(=O)NC(=O)c1ccc(F)cc1",217.041641378,14,-0.294000000000001,108.02,0.0172413656396405,0.092,0.0546206828198203,0,0
"rolapitant","neurokinin receptor antagonist","","[H][C@](C)(OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)c1ccccc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","[H][C@](C)(OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)c1ccccc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F",500.189847392,36,5.235,50.36,0.0452018678318198,0.064,0.0546009339159099,0,0
"SR-3576","JNK inhibitor","MAPK10","COc1cc(NC(=O)c2cccc(c2)-n2cc(NC(=O)Nc3cccc(C)c3)cn2)cc(OC)c1OC, COc1cc(NC(=O)c2cccc(c2)-n2cc(NC(=O)Nc3cccc(C)c3)cn2)cc(OC)c1OC, COc1cc(NC(=O)c2cccc(c2)-n2cc(NC(=O)Nc3cccc(C)c3)cn2)cc(OC)c1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(NC(=O)c2cccc(c2)-n2cc(NC(=O)Nc3cccc(C)c3)cn2)cc(OC)c1OC",501.201218964,37,3.833,115.74,0.00898006527204953,0.1,0.0544900326360248,0,0
"OP-0595","beta lactamase inhibitor","","NCCONC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NCCONC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O",324.073969852,21,-3.305,159.88,0.000977041103390589,0.108,0.0544885205516953,0,0
"ORG-25543","glycine transporter inhibitor","GLRB, SLC6A5","COc1cc(cc(OC)c1OCc1ccccc1)C(=O)NCC1(CCCC1)N(C)C, COc1cc(cc(OC)c1OCc1ccccc1)C(=O)NCC1(CCCC1)N(C)C",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(cc(OC)c1OCc1ccccc1)C(=O)NCC1(CCCC1)N(C)C",412.236207504,30,3.72,60.03,0.0508898331283787,0.058,0.0544449165641893,0,0
"7-hydroxystaurosporine","CDK inhibitor, CHK inhibitor, PKC inhibitor","CDK1, CHEK1, CHEK2, GSK3B, LCK, MAPK14, MARK1, MARK3, PDPK1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG","CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13, CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13, CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13",482.195405312,36,5.583,89.68,0.0308794464830328,0.078,0.0544397232415164,0,0
"pyronaridine","antimalarial agent","","COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1, COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1, COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1",517.224452944,37,4.902,73.75,0.0208127703412187,0.088,0.0544063851706094,0,0
"SB-683698","integrin antagonist","ITGA4, ITGAV, ITGB1, ITGB7","COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1, COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1, COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1, COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1, COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1",473.079678132,32,3.628,84.86,0.0107935576251774,0.098,0.0543967788125887,0,0
"GW-842166","cannabinoid receptor agonist","CNR2","FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1, FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1, FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1",448.068065804,29,3.88,76.14,0.0127766213234881,0.096,0.0543883106617441,0,0
"filibuvir","non-nucleoside reverse transcriptase inhibitor","","O=C(O1)C(CC2=NN(C(C)=C3)C(N=C3C)=N2)=C(O)C[C@@]1(C4CCCC4)CCC5=CC(CC)=NC(CC)=C5",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","infectious disease","hepatitis c","O=C(O1)C(CC2=NN(C(C)=C3)C(N=C3C)=N2)=C(O)C[C@@]1(C4CCCC4)CCC5=CC(CC)=NC(CC)=C5",503.289640044,37,3.197,99.21,0.0107030633749096,0.098,0.0543515316874548,0,0
"latrunculin-B","actin polymerization inhibitor","ACTA1, MKL1, SPIRE2","C[C@H]1CC[C@@H]2C[C@H](C[C@@](O)(O2)[C@@H]2CSC(=O)N2)OC(=O)\C=C(C)/CC\C=C/1 |c:27,t:22|, C[C@H]1CC[C@@H]2C[C@H](C[C@@](O)(O2)[C@@H]2CSC(=O)N2)OC(=O)\C=C(C)/CC\C=C/1 |c:27,t:22|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@H]1CC[C@@H]2C[C@H](C[C@@](O)(O2)[C@@H]2CSC(=O)N2)OC(=O)\C=C(C)/CC\C=C/1 |c:27",395.176644028,27,3.775,110.16,0.012642519339103,0.096,0.0543212596695515,0,0
"WAY-213613","glutamate inhibitor","SLC1A2","N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O, N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O, N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O, N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O",414.002675436,25,0.25,101.65,0.00263451548040837,0.106,0.0543172577402042,0,0
"salsolinol-1-carboxylic-acid","","","C[C@]1(NCCc2cc(O)c(O)cc12)C(O)=O |&1:1,r|, C[C@]1(NCCc2cc(O)c(O)cc12)C(O)=O |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@]1(NCCc2cc(O)c(O)cc12)C(O)=O |&1:1",223.084457896,16,0.49,89.79,0.0426271851730753,0.066,0.0543135925865377,0,0
"fucoxanthin","anticancer agent","","[H]C(=[C@@]=C1C(C)(C)C[C@@H](C[C@@]1(C)O)OC(C)=O)C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]12O[C@@]1(C)C[C@H](O)CC2(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","[H]C(=[C@@]=C1C(C)(C)C[C@@H](C[C@@]1(C)O)OC(C)=O)C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]12O[C@@]1(C)C[C@H](O)CC2(C)C",658.423339576,49,9.874,96.36,0.0226119286321986,0.086,0.0543059643160993,0,0
"AVN-492","serotonin receptor antagonist","","CNc1nn2c(C)c(N(C)C)c(C)nc2c1S(=O)(=O)c1ccccc1, CNc1nn2c(C)c(N(C)C)c(C)nc2c1S(=O)(=O)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CNc1nn2c(C)c(N(C)C)c(C)nc2c1S(=O)(=O)c1ccccc1",359.141595912,25,3.136,87.98,0.0266020534521011,0.082,0.0543010267260505,0,0
"MSX-122","CC chemokine receptor antagonist","CXCR4","C(Nc1ncccn1)c1ccc(CNc2ncccn2)cc1, C(Nc1ncccn1)c1ccc(CNc2ncccn2)cc1, C(Nc1ncccn1)c1ccc(CNc2ncccn2)cc1, C(Nc1ncccn1)c1ccc(CNc2ncccn2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C(Nc1ncccn1)c1ccc(CNc2ncccn2)cc1",292.143644512,22,1.604,75.62,0.058498387071028,0.05,0.054249193535514,0,0
"bexagliflozin","solute carrier family member inhibitor","","OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(OCCOC3CC3)cc2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(OCCOC3CC3)cc2)c1",464.160180948,32,2.867,108.61,0.00641957211038075,0.102,0.0542097860551904,0,0
"narlaprevir","HCV inhibitor","","CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1, CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1, CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1, CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1",707.429170292,49,5.967,179.23,0.000402367141866939,0.108,0.0542011835709335,0,0
"glutathione","antioxidant","ESD, GGT1, GLO1, GLRX, GLRX2, GPX1, GPX2, GPX3, GPX4, GPX5, GPX6, GPX7, GPX8, GSR, GSS, GSTA1, GSTA2, GSTA3, GSTA4, GSTA5, GSTK1, GSTM1, GSTM2, GSTM3, GSTM4, GSTM5, GSTO1, GSTO2, GSTP1, GSTT1, GSTZ1, HAGH, HPGDS, LTC4S, MGST1, MGST2, MGST3, TXNDC12","N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O, N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O",307.083806264,20,-4.23,197.62,0.000387251960748743,0.108,0.0541936259803744,0,0
"perifosine","AKT inhibitor","AKT1","CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|, CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|, CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|, CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|, CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|",462.370672226091,31,8.312,65.57,0.0523461128216992,0.056,0.0541730564108496,0,0
"GSK2830371","protein phosphatase inhibitor","PPM1D","Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1, Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1, Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1",460.169974848,31,3.629,111.36,0.00634433930037241,0.102,0.0541721696501862,0,0
"FIT","opioid receptor agonist","OPRD1","CCC(=O)N(C1CCN(CCc2ccc(cc2)N=C=S)CC1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCC(=O)N(C1CCN(CCc2ccc(cc2)N=C=S)CC1)c1ccccc1",393.187483484,28,5.372,68,0.0623386489262119,0.046,0.0541693244631059,0,0
"ZCL-278","CDC inhibitor","CDC42","Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1",582.975035868,34,4.305,162.78,0.00024231609654322,0.108,0.0541211580482716,0,0
"6-diazo-5-oxo-L-norleucine","glutamate receptor antagonist, glutaminase inhibitor","","N[C@@H](CCC(=O)C[N+]#N)C(O)=O, N[C@@H](CCC(=O)C[N+]#N)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@@H](CCC(=O)C[N+]#N)C(O)=O",172.071667600091,12,-4.166,108.54,0.0122416337795844,0.096,0.0541208168897922,0,0
"beta-amyloid-synthesis-inhibitor","beta amyloid synthesis inhibitor","APP","Oc1cccc(Nc2ccc(Nc3cccc(O)c3)nn2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1cccc(Nc2ccc(Nc3cccc(O)c3)nn2)c1",294.111675688,22,3.008,90.3,0.0561763373182434,0.052,0.0540881686591217,0,0
"ML9","myosin light chain kinase inhibitor","TRPC6","Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1, Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1, Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1, Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1",324.069926464,21,2.76,57.79,0.0441354673052225,0.064,0.0540677336526112,0,0
"JK-184","hedgehog pathway inhibitor","","CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1",350.120132196,25,4.634,79.69,0.0560177555043452,0.052,0.0540088777521726,0,0
"antagonist-g","neuropeptide receptor antagonist","MAPK8","CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCNC(N)=N)C(N)=O, CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCNC(N)=N)C(N)=O, CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCNC(N)=N)C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCNC(N)=N)C(N)=O",950.494898832,68,4.103,324.6,2.08983871694225e-06,0.108,0.0540010449193585,0,0
"NOV-002","","GSR","N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@@H](N)C(O)=O)C(=O)NCC(O)=O)C(=O)NCC(O)=O)C(O)=O, N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@@H](N)C(O)=O)C(=O)NCC(O)=O)C(=O)NCC(O)=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@@H](N)C(O)=O)C(=O)NCC(O)=O)C(=O)NCC(O)=O)C(O)=O",612.151962464,40,-6.622,368.24,2.81350429891288e-07,0.108,0.0540001406752149,0,0
"rezafungin","","","CCCCCOc1ccc(cc1)c2ccc(cc2)c3ccc(cc3)C(=O)N[C@H]4C[C@@H](O)[C@H](NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@@H](O)CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)[C@H](O)[C@@H](O)c7ccc(O)cc7)[C@@H](C)O)OCC[N+](C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCCCCOc1ccc(cc1)c2ccc(cc2)c3ccc(cc3)C(=O)N[C@H]4C[C@@H](O)[C@H](NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@@H](O)CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)[C@H](O)[C@@H](O)c7ccc(O)cc7)[C@@H](C)O)OCC[N+](C)(C)C",1225.60271968009,88,5.264,366.42,1.47103676456803e-07,0.108,0.0540000735518382,0,0
"GMX1778","NAMPT inhibitor","NAMPT","Clc1ccc(OCCCCCCN\C(NC#N)=N\c2ccncc2)cc1, Clc1ccc(OCCCCCCN\C(NC#N)=N\c2ccncc2)cc1, Clc1ccc(OCCCCCCN\C(NC#N)=N\c2ccncc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","Clc1ccc(OCCCCCCN\C(NC#N)=N\c2ccncc2)cc1",371.151288004,26,3.857,82.33,0.0339389970026379,0.074,0.053969498501319,0,0
"R112","SYK inhibitor","SYK","Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1, Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1, Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1, Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1, Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1",312.102253876,23,2.958,90.3,0.045938560101875,0.062,0.0539692800509375,0,0
"BTB1","mitotic kinesin inhibitor","KIF18A","[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)c1ccccc1, [O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)c1ccccc1, [O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)c1ccccc1",296.986256416,19,3.51,85.66,0.0338692395043665,0.074,0.0539346197521833,0,0
"DAPT","gamma secretase inhibitor","","C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1",432.186063752,31,3.837,84.5,0.0238691793240905,0.084,0.0539345896620453,0,0
"E-4031","potassium channel blocker","KCNH1, KCNH2","Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1, Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1, Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1, Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1",401.177312724,28,2.218,87.75,0.0157751748215173,0.092,0.0538875874107586,0,0
"NVP-231","ceramidase inhibitor","CERK","O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1, O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1, O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1, O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1, O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1",431.16674804,31,5.114,99.33,0.023725827073033,0.084,0.0538629135365165,0,0
"benfluralin","","CYP1A1, CYP1A2, CYP2B6, CYP3A4, ESR1, MMP1, SULT2A1, UGT1A1","CCCCN(CC)c1c(cc(cc1[N+]([O-])=O)C(F)(F)F)[N+]([O-])=O, CCCCN(CC)c1c(cc(cc1[N+]([O-])=O)C(F)(F)F)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCCCN(CC)c1c(cc(cc1[N+]([O-])=O)C(F)(F)F)[N+]([O-])=O",335.109290652,23,4.713,89.52,0.0416894592722959,0.066,0.053844729636148,0,0
"efletirizine","antihistamine","","OC(=O)COCCN1CCN(CC1)C(c1ccc(F)cc1)c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","OC(=O)COCCN1CCN(CC1)C(c1ccc(F)cc1)c1ccc(F)cc1",390.175499068,28,2.505,53.01,0.0476712831261489,0.06,0.0538356415630745,0,0
"AZD7545","pyruvate dehydrogenase kinase inhibitor","PDK1","CN(C)C(=O)c1ccc(cc1)S(=O)(=O)c1ccc(NC(=O)[C@@](C)(O)C(F)(F)F)c(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN(C)C(=O)c1ccc(cc1)S(=O)(=O)c1ccc(NC(=O)[C@@](C)(O)C(F)(F)F)c(Cl)c1",478.057705016,31,3.02,112.16,0.00350705109946117,0.104,0.0537535255497306,0,0
"amthamine","histamine receptor agonist","HRH2","Cc1nc(N)sc1CCN, Cc1nc(N)sc1CCN",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1nc(N)sc1CCN",157.067368352,10,-0.768,93.17,0.0354738257922034,0.072,0.0537369128961017,0,0
"MK-8745","Aurora kinase inhibitor","AURKA","Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1, Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1",431.098287128,29,3.054,89.6,0.0114732441892945,0.096,0.0537366220946472,0,0
"BLZ945","CSF1R inhibitor","","CNC(=O)c1cc(Oc2ccc3nc(N[C@@H]4CCCC[C@H]4O)sc3c2)ccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","CNC(=O)c1cc(Oc2ccc3nc(N[C@@H]4CCCC[C@H]4O)sc3c2)ccn1",398.141261564,28,2.316,124.61,0.00745558363217561,0.1,0.0537277918160878,0,0
"LY3009120","RAF inhibitor","BRAF, RAF1","CNc1ncc2cc(c(C)nc2n1)-c1cc(NC(=O)NCCC(C)(C)C)c(F)cc1C, CNc1ncc2cc(c(C)nc2n1)-c1cc(NC(=O)NCCC(C)(C)C)c(F)cc1C, CNc1ncc2cc(c(C)nc2n1)-c1cc(NC(=O)NCCC(C)(C)C)c(F)cc1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CNc1ncc2cc(c(C)nc2n1)-c1cc(NC(=O)NCCC(C)(C)C)c(F)cc1C",424.238687768,31,4.628,91.83,0.0294012344006193,0.078,0.0537006172003096,0,0
"OT-R-antagonist-1","oxytocin receptor antagonist","AVPR1A, OXTR","CO\N=C1\C[C@H](N(C1)C(=O)c1ccc(cc1)-c1ccccc1C)C(=O)NC[C@@H](O)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CO\N=C1\C[C@H](N(C1)C(=O)c1ccc(cc1)-c1ccccc1C)C(=O)NC[C@@H](O)c1ccccc1",471.215806408,35,4.43,91.23,0.0233622594297708,0.084,0.0536811297148854,0,0
"Mps-BAY-2a","monopolar spindle 1 kinase inhibitor","TTK","CC(C)CNc1nc(cn2c(cnc12)-c1ccc(cc1)C(=O)NC1CC1)-c1cccc2ncccc12, CC(C)CNc1nc(cn2c(cnc12)-c1ccc(cc1)C(=O)NC1CC1)-c1cccc2ncccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)CNc1nc(cn2c(cnc12)-c1ccc(cc1)C(=O)NC1CC1)-c1cccc2ncccc12",476.232459516,36,5.918,84.21,0.0433250179644646,0.064,0.0536625089822323,0,0
"pilaralisib","PI3K inhibitor","","COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1, COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1, COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1, COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1, COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1, COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1",540.13465196,37,3.646,156.71,0.00131801195522946,0.106,0.0536590059776147,0,0
"gedunin","HSP inhibitor","HSP90AA1","CC(=O)O[C@@H]1C[C@H]2C(C)(C)C(=O)C=C[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](OC(=O)[C@H]4O[C@@]34[C@]12C)c1ccoc1 |c:12|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)O[C@@H]1C[C@H]2C(C)(C)C(=O)C=C[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](OC(=O)[C@H]4O[C@@]34[C@]12C)c1ccoc1 |c:12|",482.230453428,35,3.557,95.34,0.0133106128832463,0.094,0.0536553064416232,0,0
"pexmetinib","MAP kinase inhibitor, TIE tyrosine kinase inhibitor","MAPK14, TEK","Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C",556.259817136,41,5.488,106.23,0.0112959061309518,0.096,0.0536479530654759,0,0
"capsazepine","TRPV agonist","TRPV1, TRPV4","Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1, Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1, Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1, Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1",376.101226592,25,4.561,87.82,0.0252824767521925,0.082,0.0536412383760963,0,0
"BMS-986195","Bruton's tyrosine kinase (BTK) inhibitor","","CC#CC(=O)N[C@H]1CCCN(C1)c1c(F)cc(C(N)=O)c2[nH]c(C)c(C)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC#CC(=O)N[C@H]1CCCN(C1)c1c(F)cc(C(N)=O)c2[nH]c(C)c(C)c12",370.180504196,27,3.315,91.22,0.0312477471300173,0.076,0.0536238735650087,0,0
"frentizole","immunosuppressant","","COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1, COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1, COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1, COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1",299.072847656,21,2.306,91.49,0.0332364994409241,0.074,0.053618249720462,0,0
"GSK189254","histamine receptor antagonist","","CNC(=O)c1ccc(Oc2ccc3CCN(CCc3c2)C2CCC2)nc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CNC(=O)c1ccc(Oc2ccc3CCN(CCc3c2)C2CCC2)nc1",351.19467704,26,3.04,54.46,0.0812259783571807,0.026,0.0536129891785903,0,0
"JNJ-678","RSV fusion inhibitor","","CS(=O)(=O)CCCn1c(Cn2c3cnccc3n(CC(F)(F)F)c2=O)cc2cc(Cl)ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CS(=O)(=O)CCCn1c(Cn2c3cnccc3n(CC(F)(F)F)c2=O)cc2cc(Cl)ccc12",500.08967384,33,3.889,87.27,0.00720915373033815,0.1,0.0536045768651691,0,0
"MRS-1334","adenosine receptor antagonist","ADORA3","CCOC(=O)C1=C(C)NC(=C([C@@H]1C#Cc1ccccc1)C(=O)OCc1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:11,r,c:5,9|, CCOC(=O)C1=C(C)NC(=C([C@@H]1C#Cc1ccccc1)C(=O)OCc1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:11,r,c:5,9|, CCOC(=O)C1=C(C)NC(=C([C@@H]1C#Cc1ccccc1)C(=O)OCc1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:11,r,c:5,9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)C1=C(C)NC(=C([C@@H]1C#Cc1ccccc1)C(=O)OCc1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:11",522.179086552,39,7.815,107.77,0.0270451049850478,0.08,0.0535225524925239,0,0
"ML141","GTPase inhibitor","CDC42","COc1ccc(cc1)[C@H]1CC(=NN1c1ccc(cc1)S(N)(=O)=O)c1ccccc1 |&1:8,r,c:11|, COc1ccc(cc1)[C@H]1CC(=NN1c1ccc(cc1)S(N)(=O)=O)c1ccccc1 |&1:8,r,c:11|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1)[C@H]1CC(=NN1c1ccc(cc1)S(N)(=O)=O)c1ccccc1 |&1:8",407.130362532,29,3.963,93.37,0.0230327960078433,0.084,0.0535163980039216,0,0
"CC-90003","MAP kinase inhibitor","","COc1cc(Nc2ncc(c(Nc3ccc(C)cc3NC(=O)C=C)n2)C(F)(F)F)c(C)cn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1cc(Nc2ncc(c(Nc3ccc(C)cc3NC(=O)C=C)n2)C(F)(F)F)c(C)cn1",458.167808572,33,4.134,101.06,0.0150323835560024,0.092,0.0535161917780012,0,0
"6-diazo-5-oxo-l-nor-leucine","glutaminase inhibitor","GGT1, GLS","N[C@@H](CCC(=O)C=[N+]=[N-])C(=O)O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","hematologic malignancy","burkitt's lymphoma","N[C@@H](CCC(=O)C=[N+]=[N-])C(=O)O",171.064391148,12,-3.344,80.39,0.0289652449804287,0.078,0.0534826224902143,0,0
"recilisib","free radical scavenger","","OC(=O)c1ccc(\C=C\S(=O)(=O)Cc2ccc(Cl)cc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC(=O)c1ccc(\C=C\S(=O)(=O)Cc2ccc(Cl)cc2)cc1",336.022307576,22,3.827,79.82,0.0329369862098895,0.074,0.0534684931049447,0,0
"autotaxin-modulator-1","autotaxin inhibitor","ENPP2","C[C@@H](N1[C@H]2CC[C@@H]1C[C@@H](C2)C(O)=O)c1ccc2ccc(O[C@H]3CC[C@H](CC3)C(F)(F)F)c(c2c1)C(F)(F)F |a:1,21,24,&1:3,&2:6,&3:8,wU:8.11,21.22,24.29,wD:1.0,3.2,6.6,(6.23,2.09,;5.61,1.02,;4.07,1.02,;3.25,-.38,;2.26,.16,;2.26,1.96,;3.29,2.4,;1.65,2.4,;.83,1.02,;1.62,-.38,;-.71,1.02,;-1.33,2.09,;-1.33,-.04,;6.38,-.31,;5.62,-1.65,;6.4,-2.98,;7.94,-2.98,;8.71,-4.31,;10.25,-4.31,;11.01,-2.97,;12.56,-2.97,;13.33,-4.31,;14.87,-4.31,;15.64,-5.64,;14.86,-6.98,;13.32,-6.97,;12.56,-5.64,;15.63,-8.31,;16.86,-8.31,;15.02,-9.38,;16.25,-9.38,;10.24,-1.64,;8.71,-1.65,;7.94,-.32,;11.01,-.31,;12.24,-.3,;10.39,.76,;11.62,.76,)|, C[C@@H](N1[C@H]2CC[C@@H]1C[C@@H](C2)C(O)=O)c1ccc2ccc(O[C@H]3CC[C@H](CC3)C(F)(F)F)c(c2c1)C(F)(F)F |a:1,21,24,&1:3,&2:6,&3:8,wU:8.11,21.22,24.29,wD:1.0,3.2,6.6,(6.23,2.09,;5.61,1.02,;4.07,1.02,;3.25,-.38,;2.26,.16,;2.26,1.96,;3.29,2.4,;1.65,2.4,;.83,1.02,;1.62,-.38,;-.71,1.02,;-1.33,2.09,;-1.33,-.04,;6.38,-.31,;5.62,-1.65,;6.4,-2.98,;7.94,-2.98,;8.71,-4.31,;10.25,-4.31,;11.01,-2.97,;12.56,-2.97,;13.33,-4.31,;14.87,-4.31,;15.64,-5.64,;14.86,-6.98,;13.32,-6.97,;12.56,-5.64,;15.63,-8.31,;16.86,-8.31,;15.02,-9.38,;16.25,-9.38,;10.24,-1.64,;8.71,-1.65,;7.94,-.32,;11.01,-.31,;12.24,-.3,;10.39,.76,;11.62,.76,)|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](N1[C@H]2CC[C@@H]1C[C@@H](C2)C(O)=O)c1ccc2ccc(O[C@H]3CC[C@H](CC3)C(F)(F)F)c(c2c1)C(F)(F)F |a:1",543.220813172,38,7.817,49.77,0.048740188403385,0.058,0.0533700942016925,0,0
"RS-102221","serotonin receptor antagonist","HTR2A, HTR2B, HTR2C","COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O, COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O, COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O, COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O, COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O",0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O",612.186554992,42,2.943,151.52,0.000707546421597731,0.106,0.0533537732107989,0,0
"salazodine","","","COc1ccc(NS(=O)(=O)c2ccc(cc2)\N=N\c2ccc(O)c(c2)C(O)=O)nn1, COc1ccc(NS(=O)(=O)c2ccc(cc2)N=Nc2ccc(O)c(c2)C(O)=O)nn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","null","ulcerative colitis","COc1ccc(NS(=O)(=O)c2ccc(cc2)\N=N\c2ccc(O)c(c2)C(O)=O)nn1",429.0743042,30,3.76,171.81,0.0027047316289088,0.104,0.0533523658144544,0,0
"FLT3-IN-1","FLT3 inhibitor","","CCCNc1nc(Nc2ccc(cc2)C#N)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)\C=C\CN(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCNc1nc(Nc2ccc(cc2)C#N)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)\C=C\CN(C)C",530.311772456,39,3.091,126.28,0.00465453989171997,0.102,0.05332726994586,0,0
"HPPH","photosensitizing agent","","CCCCCCO[C@H](C)c1c(C)c2cc3nc([C@@H](CCC(O)=O)[C@@H]3C)c3CC(=O)c4c(C)c(cc5nc(cc1[nH]2)c(C)c5CC)[nH]c34 |&1:7|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCCCCO[C@H](C)c1c(C)c2cc3nc([C@@H](CCC(O)=O)[C@@H]3C)c3CC(=O)c4c(C)c(cc5nc(cc1[nH]2)c(C)c5CC)[nH]c34 |&1:7|",636.367556016,47,6.872,120.96,0.0066487333576996,0.1,0.0533243666788498,0,0
"t-025","clk inhibitor","","CNc1nc(NCc2ncccn2)c2c(c[nH]c2n1)-c1ccc2ncccc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CNc1nc(NCc2ncccn2)c2c(c[nH]c2n1)-c1ccc2ncccc2c1",382.165442576,29,2.825,104.3,0.0245264414020201,0.082,0.0532632207010101,0,0
"CU-T12-9","toll-like receptor agonist","TLR1, TLR2","CNc1ccc(cc1-n1cnc(c1)-c1ccc(cc1)C(F)(F)F)[N+]([O-])=O, CNc1ccc(cc1-n1cnc(c1)-c1ccc(cc1)C(F)(F)F)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CNc1ccc(cc1-n1cnc(c1)-c1ccc(cc1)C(F)(F)F)[N+]([O-])=O",362.099060316,26,4.559,72.99,0.0604556266716458,0.046,0.0532278133358229,0,0
"KHS-101","neural stem cell inducer","TACC3","CC(C)CNc1ccnc(NCc2csc(n2)-c2ccccc2)n1, CC(C)CNc1ccnc(NCc2csc(n2)-c2ccccc2)n1, CC(C)CNc1ccnc(NCc2csc(n2)-c2ccccc2)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)CNc1ccnc(NCc2csc(n2)-c2ccccc2)n1",339.151766672,24,3.734,90.97,0.0364420292366821,0.07,0.0532210146183411,0,0
"PD-318088","MEK inhibitor","","OC[C@@H](O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F |&1:2,r|, OC[C@@H](O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F |&1:2,r|, OC[C@@H](O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F |&1:2,r|, OC[C@@H](O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F |&1:2,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC[C@@H](O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F |&1:2",559.905551656,27,4.193,90.82,0.000432384130687211,0.106,0.0532161920653436,0,0
"dodecyl-sulfate","","LYZ","CCCCCCCCCCCCOS(O)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCCCCCCOS(O)(=O)=O",266.155180312,17,4.106,71.98,0.068423919905584,0.038,0.053211959952792,0,0
"Ro-61-8048","kynurenine 3-monooxygenase inhibitor","KMO","COc1ccc(cc1OC)S(=O)(=O)Nc1nc(cs1)-c1cccc(c1)[N+]([O-])=O, COc1ccc(cc1OC)S(=O)(=O)Nc1nc(cs1)-c1cccc(c1)[N+]([O-])=O, COc1ccc(cc1OC)S(=O)(=O)Nc1nc(cs1)-c1cccc(c1)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1OC)S(=O)(=O)Nc1nc(cs1)-c1cccc(c1)[N+]([O-])=O",421.0402272,28,3.005,157.28,0.00240644376664134,0.104,0.0532032218833207,0,0
"melphalan-n-oxide","hypoxia inducible factor inhibitor","HIF1A","N[C@@H](Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","N[C@@H](Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O",320.069447796,20,-0.923,86.38,0.00835568727881663,0.098,0.0531778436394083,0,0
"PX-478","hypoxia inducible factor inhibitor","","N[C@@H](Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O |&1:1|, N[C@@H](Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O |&1:1|, N[C@@H](Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O |&1:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","N[C@@H](Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O |&1:1|",320.069447796,20,-0.923,86.38,0.00835568727881663,0.098,0.0531778436394083,0,0
"ZM-306416","Abl kinase inhibitor, SRC inhibitor, VEGFR inhibitor","EGFR, FLT1, FLT4, KDR","COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC",333.068032556,23,3.369,56.27,0.0662991290135675,0.04,0.0531495645067838,0,0
"I-CBP-112","bromodomain inhibitor","CREBBP, EP300","CCC(=O)N1CCOc2c(C1)cc(cc2OC[C@H]1CCCN(C)C1)-c1ccc(OC)c(OC)c1, CCC(=O)N1CCOc2c(C1)cc(cc2OC[C@H]1CCCN(C)C1)-c1ccc(OC)c(OC)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCC(=O)N1CCOc2c(C1)cc(cc2OC[C@H]1CCCN(C)C1)-c1ccc(OC)c(OC)c1",468.262422252,34,3.528,60.47,0.0322647588567328,0.074,0.0531323794283664,0,0
"D-3263","transient receptor potential channel agonist","","COc1ccc2n(C(=O)[C@@H]3C[C@H](C)CC[C@H]3C(C)C)c(=O)n(CCN)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1ccc2n(C(=O)[C@@H]3C[C@H](C)CC[C@H]3C(C)C)c(=O)n(CCN)c2c1",373.236541852,27,3.759,79.25,0.042260858186865,0.064,0.0531304290934325,0,0
"THZ2","CDK inhibitor","CDK7","CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1",565.199300816,41,4.746,115.04,0.00623104124429415,0.1,0.0531155206221471,0,0
"PMPA","glutamate receptor antagonist","FOLH1","OC(=O)CC[C@@H](CP(O)(O)=O)C(O)=O |&1:5,r|, OC(=O)CC[C@@H](CP(O)(O)=O)C(O)=O |&1:5,r|, OC(=O)CC[C@@H](CP(O)(O)=O)C(O)=O |&1:5,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)CC[C@@H](CP(O)(O)=O)C(O)=O |&1:5",226.024239322,14,-2.009,141.94,0.00421492067478792,0.102,0.053107460337394,0,0
"t-1101 (tosylate)","hec1 inhibitor","NDC80, NEK2","COCCOc1cnc(Sc2cc(C)c(-c3csc(NC(=O)c4ccncc4)n3)c(C)c2)cn1.Cc1ccc(cc1)S(=O)(=O)O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","prostate cancer","COCCOc1cnc(Sc2cc(C)c(-c3csc(NC(=O)c4ccncc4)n3)c(C)c2)cn1.Cc1ccc(cc1)S(=O)(=O)O",665.143646712,45,4.737,215.41,0.000140669666800892,0.106,0.0530703348334004,0,0
"bafetinib","Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor","ABL1, BCR, LYN","CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1, CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1, CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1, CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1, CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1, CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1",576.257292272,42,3.316,99.17,0.00612766253403923,0.1,0.0530638312670196,0,0
"UNC2250","MER tyrosine kinase inhibitor","MERTK","CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CN2CCOCC2)cn1 |r|, CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CN2CCOCC2)cn1 |r|, CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CN2CCOCC2)cn1 |r|, CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CN2CCOCC2)cn1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CN2CCOCC2)cn1 |r|",440.289974392,32,2.542,95.43,0.0141275938545306,0.092,0.0530637969272653,0,0
"ibutamoren","growth hormone secretagogue receptor agonist","GHR, GHSR","CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1, CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1, CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1",528.240641252,37,1.914,130.42,0.00210502533735893,0.104,0.0530525126686795,0,0
"sorivudine","dna polymerase inhibitor","DPYD","OC[C@H]1O[C@H]([C@@H](O)[C@@H]1O)N2C=C(\C=C\Br)C(=O)NC2=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","infectious disease","virus herpes simplex (hsv)","OC[C@H]1O[C@H]([C@@H](O)[C@@H]1O)N2C=C(\C=C\Br)C(=O)NC2=O",347.995698236,20,-0.799,119.33,0.0020710961705126,0.104,0.0530355480852563,0,0
"A-317491","purinergic receptor antagonist","P2RX3","OC(=O)c1cc(C(O)=O)c(cc1C(O)=O)C(=O)N(Cc1cccc(Oc2ccccc2)c1)[C@H]1CCCc2ccccc12, OC(=O)c1cc(C(O)=O)c(cc1C(O)=O)C(=O)N(Cc1cccc(Oc2ccccc2)c1)[C@H]1CCCc2ccccc12, OC(=O)c1cc(C(O)=O)c(cc1C(O)=O)C(=O)N(Cc1cccc(Oc2ccccc2)c1)[C@H]1CCCc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1cc(C(O)=O)c(cc1C(O)=O)C(=O)N(Cc1cccc(Oc2ccccc2)c1)[C@H]1CCCc2ccccc12",565.173666824,42,6.191,141.44,0.00606907002006201,0.1,0.053034535010031,0,0
"STF-083010","serine/threonine kinase inhibitor","ERN1","Oc1ccc2ccccc2c1\C=N\S(=O)(=O)c1cccs1, Oc1ccc2ccccc2c1\C=N\S(=O)(=O)c1cccs1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc2ccccc2c1\C=N\S(=O)(=O)c1cccs1",317.018035212,21,3.061,103.35,0.020053019353776,0.086,0.053026509676888,0,0
"Ro-3306","CDK inhibitor","CDK1","O=C1N=C(NCc2cccs2)S\C1=C/c1ccc2ncccc2c1 |t:2|, O=C1N=C(NCc2cccs2)S\C1=C/c1ccc2ncccc2c1 |t:2|, O=C1N=C(NCc2cccs2)S\C1=C/c1ccc2ncccc2c1 |t:2|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C1N=C(NCc2cccs2)S\C1=C/c1ccc2ncccc2c1 |t:2|",351.050004036,24,3.053,107.89,0.0160051393320478,0.09,0.0530025696660239,0,0
"tpps4","","","OS(=O)(=O)c1ccc(cc1)-c1c2ccc(n2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc([nH]2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc([nH]2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc1n2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OS(=O)(=O)c1ccc(cc1)-c1c2ccc(n2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc([nH]2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc([nH]2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc1n2",934.0743064,64,6.068,308.36,2.90506549977632e-06,0.106,0.0530014525327499,0,0
"FERb-033","EGFR inhibitor","ERBB2","O\N=C\c1ccc(c(Cl)c1O)-c1ccc(O)c(F)c1, O\N=C\c1ccc(c(Cl)c1O)-c1ccc(O)c(F)c1, O\N=C\c1ccc(c(Cl)c1O)-c1ccc(O)c(F)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O\N=C\c1ccc(c(Cl)c1O)-c1ccc(O)c(F)c1",281.025499048,19,3.872,73.05,0.0699128997517565,0.036,0.0529564498758783,0,0
"dinaciclib","CDK inhibitor","CDK1, CDK2, CDK5, CDK9","CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO, CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO, CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO, CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO, CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO, CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO, CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO",396.227374136,29,4.188,92.63,0.0318456245714256,0.074,0.0529228122857128,0,0
"4,5,6,7-tetrabromobenzotriazole","casein kinase inhibitor","AKT1, CHEK1, CSNK2A1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SGK1","Brc1c(Br)c(Br)c2n[nH]nc2c1Br, Brc1c(Br)c(Br)c2n[nH]nc2c1Br, Brc1c(Br)c(Br)c2n[nH]nc2c1Br, Brc1c(Br)c(Br)c2n[nH]nc2c1Br",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Brc1c(Br)c(Br)c2n[nH]nc2c1Br",430.690395432,13,6.017,41.57,0.00184539851291692,0.104,0.0529226992564585,0,0
"nexturastat-A","HDAC inhibitor","HDAC1, HDAC6","CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1, CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1, CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1, CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1, CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1",341.173941596,25,3.085,81.67,0.04580734266124,0.06,0.05290367133062,0,0
"rebastinib","Bcr-Abl kinase inhibitor, TIE tyrosine kinase inhibitor, VEGFR inhibitor","ABL1, BCR, FGR, FLT3, HCK, LYN, SRC","CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1",553.223765976,41,4.03,123.06,0.00578207572304311,0.1,0.0528910378615216,0,0
"ACDPP","glutamate receptor antagonist","GRM5","CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1, CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1, CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1",292.083936716,20,1.314,97.03,0.0217654815940783,0.084,0.0528827407970391,0,0
"LMK-235","HDAC inhibitor","HDAC4, HDAC5","Cc1cc(C)cc(c1)C(=O)NOCCCCCC(=O)NO, Cc1cc(C)cc(c1)C(=O)NOCCCCCC(=O)NO, Cc1cc(C)cc(c1)C(=O)NOCCCCCC(=O)NO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(C)cc(c1)C(=O)NOCCCCCC(=O)NO",294.157957184,21,2.424,87.66,0.04168432758625,0.064,0.052842163793125,0,0
"GSK2330672","bile acid transporter inhibitor","SLC10A2","CCCC[C@]1(CC)CS(=O)(=O)c2cc(CNC(CC(O)=O)CC(O)=O)c(OC)cc2[C@H](N1)c1ccccc1, CCCC[C@]1(CC)CS(=O)(=O)c2cc(CNC(CC(O)=O)CC(O)=O)c(OC)cc2[C@H](N1)c1ccccc1",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCC[C@]1(CC)CS(=O)(=O)c2cc(CNC(CC(O)=O)CC(O)=O)c(OC)cc2[C@H](N1)c1ccccc1",546.239972556,38,3.63,150.41,0.00165265263810213,0.104,0.0528263263190511,0,0
"ZAPA","","","NC(=N)S\C=C/C(O)=O, NC(=N)S\C=C/C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC(=N)S\C=C/C(O)=O",146.014998432,9,0.161,112.47,0.02963949036253,0.076,0.052819745181265,0,0
"RS-39604","serotonin receptor antagonist","HTR4","COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1, COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1, COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1, COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1",553.201334552,37,3.146,128.57,0.00163737133023982,0.104,0.0528186856651199,0,0
"A66","PI3K inhibitor","PIK3CA","Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C",393.129316976,26,0.51,157.69,0.00159023456316219,0.104,0.0527951172815811,0,0
"SHA-68","neuropeptide receptor antagonist","NPSR1","Fc1ccc(CNC(=O)N2CCN3[C@@H](C2)C(OC3=O)(c2ccccc2)c2ccccc2)cc1 |&1:13,r|, Fc1ccc(CNC(=O)N2CCN3[C@@H](C2)C(OC3=O)(c2ccccc2)c2ccccc2)cc1 |&1:13,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1ccc(CNC(=O)N2CCN3[C@@H](C2)C(OC3=O)(c2ccccc2)c2ccccc2)cc1 |&1:13",445.180169848,33,4.169,61.88,0.0495021172132957,0.056,0.0527510586066478,0,0
"JNJ-1661010","FAAH inhibitor","FAAH","O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1, O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1, O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1, O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1",365.131031228,26,3.366,89.6,0.0294918920500164,0.076,0.0527459460250082,0,0
"CYC116","Aurora kinase inhibitor","AURKA, AURKB, KDR","Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1",368.14193026,26,1.557,117.43,0.00942758062459278,0.096,0.0527137903122964,0,0
"KB-R7943","sodium/calcium exchange inhibitor","SLC8A1, TRPC3, TRPC5, TRPC6","NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1, NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1, NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1",331.099062404,23,3.751,127.54,0.0154216164406325,0.09,0.0527108082203162,0,0
"CITCO","constitutive androstane receptor (CAR) agonist","NR1I3","Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1, Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1, Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1, Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1",434.976666044,27,7.376,67.13,0.0314114665563371,0.074,0.0527057332781685,0,0
"2-chloro-N6-cyclopentyladenosine","adenosine receptor agonist","ADORA1, ADORA2A, ADORA2B, ADORA3","OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12",369.1203818,25,1.016,125.55,0.00532798141346294,0.1,0.0526639907067315,0,0
"ZLN024","AMPK activator","PRKAA1, PRKAB1, PRKAG1","Cc1ccc(OCCSc2ncccn2)c(Br)c1, Cc1ccc(OCCSc2ncccn2)c(Br)c1, Cc1ccc(OCCSc2ncccn2)c(Br)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(OCCSc2ncccn2)c(Br)c1",323.993196136,18,3.457,60.31,0.0252762451484282,0.08,0.0526381225742141,0,0
"AS-1892802","rho associated kinase inhibitor","ROCK1","OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1, OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1, OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1, OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1, OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1",333.147726848,25,2.708,74.25,0.0592463439983154,0.046,0.0526231719991577,0,0
"MSDC-0160","insulin sensitizer","","CCc1ccc(nc1)C(=O)COc1ccc(C[C@@H]2SC(=O)NC2=O)cc1 |&1:17,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCc1ccc(nc1)C(=O)COc1ccc(C[C@@H]2SC(=O)NC2=O)cc1 |&1:17",370.098728056,26,1.834,110.66,0.0112449085324097,0.094,0.0526224542662048,0,0
"SKI-II","sphingosine kinase inhibitor","SPHK1","Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1",302.028061652,20,4.286,73.39,0.059184744277203,0.046,0.0525923721386015,0,0
"palmitoylcarnitine","protein kinase inhibitor","","CCCCCCCCCCCCCCCC(=O)O[C@@H](CC(O)=O)C[N+](C)(C)C |&1:18|, CCCCCCCCCCCCCCCC(=O)O[C@@H](CC(O)=O)C[N+](C)(C)C |&1:18|, CCCCCCCCCCCCCCCC(=O)O[C@@H](CC(O)=O)C[N+](C)(C)C |&1:18|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCCCCCCCCCC(=O)O[C@@H](CC(O)=O)C[N+](C)(C)C |&1:18|",400.342135372091,28,7.13,63.6,0.0871758330146501,0.018,0.052587916507325,0,0
"etifenin","renal function diagnostic agent","","CCc1cccc(CC)c1NC(=O)CN(CC(O)=O)CC(O)=O, CCc1cccc(CC)c1NC(=O)CN(CC(O)=O)CC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCc1cccc(CC)c1NC(=O)CN(CC(O)=O)CC(O)=O",322.152871804,23,-1.221,106.94,0.00915144149765299,0.096,0.0525757207488265,0,0
"limonin","HIV protease inhibitor","","CC1(C)O[C@H]2CC(=O)OC[C@@]22[C@H]1CC(=O)[C@]1(C)[C@@H]2CC[C@@]2(C)[C@@H](OC(=O)[C@H]3O[C@@]123)c1ccoc1, CC1(C)O[C@H]2CC(=O)OC[C@@]22[C@H]1CC(=O)[C@]1(C)[C@@H]2CC[C@@]2(C)[C@@H](OC(=O)[C@H]3O[C@@]123)c1ccoc1, CC1(C)O[C@H]2CC(=O)OC[C@@]22[C@H]1CC(=O)[C@]1(C)[C@@H]2CC[C@@]2(C)[C@@H](OC(=O)[C@H]3O[C@@]123)c1ccoc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC1(C)O[C@H]2CC(=O)OC[C@@]22[C@H]1CC(=O)[C@]1(C)[C@@H]2CC[C@@]2(C)[C@@H](OC(=O)[C@H]3O[C@@]123)c1ccoc1",470.19406792,34,1.565,104.57,0.00702603642466369,0.098,0.0525130182123318,0,0
"SB-408124","orexin receptor antagonist","HCRTR1, HCRTR2","CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1, CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1, CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1, CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1, CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1",356.144867636,26,3.431,57.26,0.0749406740104741,0.03,0.052470337005237,0,0
"BMS-536924","IGF-1 inhibitor","AKT1, CCNE1, CDK2, CYP3A4, ERBB2, IGF1R, KDR, LCK, MAPK1, MET, PDGFRA, PDGFRB","Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1, Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1, Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1, Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1, Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1",479.172417372,34,3.591,106.27,0.00894062827329555,0.096,0.0524703141366478,0,0
"GNF-5","Bcr-Abl kinase inhibitor","ABL1, BCR","OCCNC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1, OCCNC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1, OCCNC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OCCNC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1",418.125275064,30,3.561,96.37,0.0189253923978997,0.086,0.0524626961989499,0,0
"galidesivir","antiviral","","Nc1ncnc2c(c[nH]c12)[C@@H]1N[C@H](CO)[C@@H](O)[C@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Nc1ncnc2c(c[nH]c12)[C@@H]1N[C@H](CO)[C@@H](O)[C@H]1O",265.11748934,19,-1.058,140.31,0.00685206113787445,0.098,0.0524260305689372,0,0
"RU-58841","androgen receptor antagonist","AR","CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F, CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F",369.130026096,26,1.823,84.64,0.0207783439772388,0.084,0.0523891719886194,0,0
"UNC0638","histone lysine methyltransferase inhibitor","EHMT1, EHMT2","COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1",509.372975744,37,5.244,62.75,0.0347396145898715,0.07,0.0523698072949358,0,0
"linsitinib","IGF-1 inhibitor","IGF1R, INSR, INSRR","C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|",421.190260356,32,4.93,89.33,0.0447234323302904,0.06,0.0523617161651452,0,0
"homoquinolinic-acid","glutamate receptor agonist","GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D","OC(=O)Cc1cccnc1C(O)=O, OC(=O)Cc1cccnc1C(O)=O, OC(=O)Cc1cccnc1C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)Cc1cccnc1C(O)=O",181.037507704,13,-0.099,87.49,0.0527075571381777,0.052,0.0523537785690888,0,0
"VX-702","p38 MAPK inhibitor","IL1B, IL6, MAPK11, MAPK12, MAPK14, TNF","NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F",404.089638504,29,3.142,102.31,0.0165694715470459,0.088,0.052284735773523,0,0
"APTO-253","kr√ºppel-like factor expression enhancer","KLF4","Cc1[nH]c2ccc(F)cc2c1-c1nc2c([nH]1)c1cccnc1c1ncccc21, Cc1[nH]c2ccc(F)cc2c1-c1nc2c([nH]1)c1cccnc1c1ncccc21, Cc1[nH]c2ccc(F)cc2c1-c1nc2c([nH]1)c1cccnc1c1ncccc21, Cc1[nH]c2ccc(F)cc2c1-c1nc2c([nH]1)c1cccnc1c1ncccc21, Cc1[nH]c2ccc(F)cc2c1-c1nc2c([nH]1)c1cccnc1c1ncccc21",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1[nH]c2ccc(F)cc2c1-c1nc2c([nH]1)c1cccnc1c1ncccc21",367.123323668,28,3.944,70.25,0.0765570221026468,0.028,0.0522785110513234,0,0
"SB-328437","CCR antagonist","","COC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1cccc2ccccc12, COC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1cccc2ccccc12, COC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1cccc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1cccc2ccccc12",378.121571676,28,4.259,98.54,0.0345023270566037,0.07,0.0522511635283019,0,0
"ercalcitriol","vitamin D receptor agonist","VDR","C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C",428.329045268,31,6.518,60.69,0.0824795965934315,0.022,0.0522397982967157,0,0
"foscenvivint","wnt signaling inhibitor","CCND1, CTNNB1","[H][C@]12[C@H](C)N(Cc3cccc4cccnc34)C(=O)[C@H](Cc3ccc(OP(O)(O)=O)cc3)N1C(=O)CN(C)N2C(=O)NCc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","oncology","hepatocellular carcinoma (hcc)","[H][C@]12[C@H](C)N(Cc3cccc4cccnc34)C(=O)[C@H](Cc3ccc(OP(O)(O)=O)cc3)N1C(=O)CN(C)N2C(=O)NCc1ccccc1",658.23048409,48,1.528,165.66,0.000477639711216577,0.104,0.0522388198556083,0,0
"carnosine","antiglycating agent","","NCCC(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O |&1:6,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NCCC(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O |&1:6",226.106590308,16,-4.099,121.1,0.00646062988626887,0.098,0.0522303149431344,0,0
"BIIB021","HSP inhibitor","HSP90AA1","COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C",318.09958678,22,1.592,91.74,0.0224065385662397,0.082,0.0522032692831199,0,0
"methylatropine-nitrate","acetylcholine receptor antagonist","CHRM1","C[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |&1:3,6,8,&2:13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"preclinical","","","C[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |&1:3",304.190720112091,22,1.637,46.53,0.0843981268543063,0.02,0.0521990634271532,0,0
"altanserin","serotonin receptor antagonist","HTR2A","Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1",411.141676164,29,4.614,90.19,0.0263386404632741,0.078,0.052169320231637,0,0
"LTB4","leukocyte activator","LTB4R, LTB4R2","CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O",336.230059504,24,4.499,77.76,0.0623190771271394,0.042,0.0521595385635697,0,0
"SSR128129E","","","COc1c(C)c(C(=O)c2ccc(N)c(c2)C(O)=O)n2ccccc12, COc1c(C)c(C(=O)c2ccc(N)c(c2)C(O)=O)n2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1c(C)c(C(=O)c2ccc(N)c(c2)C(O)=O)n2ccccc12",324.111006992,24,3.757,94.03,0.0483109269651844,0.056,0.0521554634825922,0,0
"SNAP-5089","adrenergic receptor antagonist","ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CACNA1C, CACNA1D","COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccc(cc1)[N+]([O-])=O)C(=O)NCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |&1:11,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccc(cc1)[N+]([O-])=O)C(=O)NCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |&1:11,c:4,9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,6,0,0,0,0,"preclinical","","","COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccc(cc1)[N+]([O-])=O)C(=O)NCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |&1:11",608.29987038,45,7.136,113.81,0.0102932303455344,0.094,0.0521466151727672,0,0
"EPZ004777","histone lysine methyltransferase inhibitor","DOT1L","CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12",539.322002792,39,3.338,150.79,0.00226411166781197,0.102,0.052132055833906,0,0
"NVP-BHG712","ephrin inhibitor","EPHB4","Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F",503.16814292,37,5.227,97.62,0.0181865444063091,0.086,0.0520932722031546,0,0
"CGP-74514","CDK inhibitor","CDK1","CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc12, CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc12, CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc12, CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc12",385.178171448,27,3.935,93.68,0.0241836815907703,0.08,0.0520918407953851,0,0
"tolcapone","catechol O methyltransferase inhibitor","COMT","Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O",273.063722452,20,4.112,100.67,0.0601625783226007,0.044,0.0520812891613003,0,0
"semapimod","cytokine production inhibitor, p38 MAPK inhibitor","MAPK14","CC(=NNC(N)=N)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(cc(c2)C(C)=NNC(N)=N)C(C)=NNC(N)=N)cc(c1)C(C)=NNC(N)=N, CC(=NNC(N)=N)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(cc(c2)C(C)=NNC(N)=N)C(C)=NNC(N)=N)cc(c1)C(C)=NNC(N)=N, CC(=NNC(N)=N)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(cc(c2)C(C)=NNC(N)=N)C(C)=NNC(N)=N)cc(c1)C(C)=NNC(N)=N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(=NNC(N)=N)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(cc(c2)C(C)=NNC(N)=N)C(C)=NNC(N)=N)cc(c1)C(C)=NNC(N)=N",744.452062904,54,7.59,355.24,1.32295315638561e-05,0.104,0.0520066147657819,0,0
"EDTMP","chelating agent","","OP(O)(=O)CN(CCN(CP(O)(O)=O)CP(O)(O)=O)CP(O)(O)=O, OP(O)(=O)CN(CCN(CP(O)(O)=O)CP(O)(O)=O)CP(O)(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OP(O)(=O)CN(CCN(CP(O)(O)=O)CP(O)(O)=O)CP(O)(O)=O",435.9966706,24,-7.624,275.84,3.16752981213645e-06,0.104,0.0520015837649061,0,0
"TPPS4","","","OS(=O)(=O)c1ccc(cc1)-c1c2ccc(n2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc([nH]2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc(n2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc1[nH]2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OS(=O)(=O)c1ccc(cc1)-c1c2ccc(n2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc([nH]2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc(n2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc1[nH]2",934.0743064,64,6.068,308.36,2.90506549977633e-06,0.104,0.0520014525327499,0,0
"oxaloacetate","glutamate release inhibitor","","OC(=O)C=C(O)C(O)=O, OC(=O)C=C(O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","OC(=O)C=C(O)C(O)=O",132.005873228,9,-0.497,94.83,0.0518545225628047,0.052,0.0519272612814023,0,0
"sesamin","NFkB pathway inhibitor","","C1Oc2ccc(cc2O1)[C@H]1OC[C@H]2[C@@H]1CO[C@@H]2c1ccc2OCOc2c1, C1Oc2ccc(cc2O1)[C@H]1OC[C@H]2[C@@H]1CO[C@@H]2c1ccc2OCOc2c1, C1Oc2ccc(cc2O1)[C@H]1OC[C@H]2[C@@H]1CO[C@@H]2c1ccc2OCOc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C1Oc2ccc(cc2O1)[C@H]1OC[C@H]2[C@@H]1CO[C@@H]2c1ccc2OCOc2c1",354.110338296,26,2.746,55.38,0.069851773109297,0.034,0.0519258865546485,0,0
"bevenopran","opioid receptor antagonist","","COc1cc(CNCCC2CCOCC2)ccc1Oc1cnc(cn1)C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1cc(CNCCC2CCOCC2)ccc1Oc1cnc(cn1)C(N)=O",386.195405312,28,0.768,108.59,0.00981451691684269,0.094,0.0519072584584213,0,0
"CP-724714","EGFR inhibitor, protein tyrosine kinase inhibitor","ERBB2","COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1, COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1, COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1, COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1, COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1",469.211389724,35,3.276,98.26,0.015810689160424,0.088,0.051905344580212,0,0
"L-670596","prostanoid receptor antagonist","","CS(=O)(=O)c1ccc(Cn2c3[C@@H](CC(O)=O)CCCc3c3cc(F)cc(F)c23)cc1 |&1:11,r|, CS(=O)(=O)c1ccc(Cn2c3[C@@H](CC(O)=O)CCCc3c3cc(F)cc(F)c23)cc1 |&1:11,r|, CS(=O)(=O)c1ccc(Cn2c3[C@@H](CC(O)=O)CCCc3c3cc(F)cc(F)c23)cc1 |&1:11,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CS(=O)(=O)c1ccc(Cn2c3[C@@H](CC(O)=O)CCCc3c3cc(F)cc(F)c23)cc1 |&1:11",433.115935592,30,4.512,84.75,0.0217980168815239,0.082,0.051899008440762,0,0
"usl311","cc chemokine receptor antagonist","CXCR4","CC(C)N1CCC(CC1)N1CCCN(CC1)c1cccc(n1)C(=O)Nc1ccncc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","oncology","glioblastoma","CC(C)N1CCC(CC1)N1CCCN(CC1)c1cccc(n1)C(=O)Nc1ccncc1",422.279409708,31,2.915,64.6,0.0377251416280131,0.066,0.0518625708140065,0,0
"MK-5046","bombesin receptor agonist","BRS3, GRPR, NMBR","O[C@@](Cc1ncc(CC2(CC2)C(F)(F)F)[nH]1)(c1ccc(cc1)-n1cccn1)C(F)(F)F, O[C@@](Cc1ncc(CC2(CC2)C(F)(F)F)[nH]1)(c1ccc(cc1)-n1cccn1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O[C@@](Cc1ncc(CC2(CC2)C(F)(F)F)[nH]1)(c1ccc(cc1)-n1cccn1)C(F)(F)F",444.138480516,31,5.015,66.73,0.0357136208600722,0.068,0.0518568104300361,0,0
"GKA-50","glucokinase activator","GCK","COC[C@H](C)Oc1cc(O[C@@H](C)Cc2ccccc2)cc(c1)C(=O)Nc1ccc(cn1)C(O)=O, COC[C@H](C)Oc1cc(O[C@@H](C)Cc2ccccc2)cc(c1)C(=O)Nc1ccc(cn1)C(O)=O, COC[C@H](C)Oc1cc(O[C@@H](C)Cc2ccccc2)cc(c1)C(=O)Nc1ccc(cn1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC[C@H](C)Oc1cc(O[C@@H](C)Cc2ccccc2)cc(c1)C(=O)Nc1ccc(cn1)C(O)=O",464.194736616,34,4.512,106.98,0.0156643553797523,0.088,0.0518321776898762,0,0
"JNJ-47965567","purinergic receptor antagonist","P2RX7","O=C(NCC1(CCOCC1)N1CCN(CC1)c1ccccc1)c1cccnc1Sc1ccccc1, O=C(NCC1(CCOCC1)N1CCN(CC1)c1ccccc1)c1cccnc1Sc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(NCC1(CCOCC1)N1CCN(CC1)c1ccccc1)c1cccnc1Sc1ccccc1",488.224597264,35,4.59,83,0.0196538699719046,0.084,0.0518269349859523,0,0
"salicin","anti-inflammatory agent","","OC[C@H]1O[C@@H](Oc2ccccc2CO)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2ccccc2CO)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2ccccc2CO)[C@H](O)[C@@H](O)[C@@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC[C@H]1O[C@@H](Oc2ccccc2CO)[C@H](O)[C@@H](O)[C@@H]1O",286.105252916,20,-0.501,119.61,0.00964922075250145,0.094,0.0518246103762507,0,0
"nicotinamide riboside","sirt activator","SIRT1","NC(=O)c1ccc[n+](c1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","cardiology","cardiomyopathy","NC(=O)c1ccc[n+](c1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O",255.097548000091,18,-0.485,116.89,0.0136040882837123,0.09,0.0518020441418561,0,0
"UNC1215","L3MBTL antagonist","L3MBTL3","O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1",529.341675616,39,4.561,59.13,0.0315321064127612,0.072,0.0517660532063806,0,0
"pyrazinoylguanidine","diuretic","","NC(=N)NC(=O)c1cnccn1, NC(=N)NC(=O)c1cnccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","NC(=N)NC(=O)c1cnccn1",165.065059844,12,-1.273,104.75,0.0315073223463259,0.072,0.0517536611731629,0,0
"NSC-95397","CDC inhibitor","CDC25A, CDC25B","OCCSC1=C(SCCO)C(=O)c2ccccc2C1=O |c:4|, OCCSC1=C(SCCO)C(=O)c2ccccc2C1=O |c:4|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OCCSC1=C(SCCO)C(=O)c2ccccc2C1=O |c:4|",310.033350928,20,1.286,125.2,0.0074317769865563,0.096,0.0517158884932781,0,0
"atr inhibitor 2","atr kinase inhibitor","ATR","Nc1nn2cc(F)cnc2c1C(=O)Nc1cncc(F)c1N1CCC(CC1)C(=O)N1CCN(CC1)C1COC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","oncology","ovarian cancer","Nc1nn2cc(F)cnc2c1C(=O)Nc1cncc(F)c1N1CCC(CC1)C(=O)N1CCN(CC1)C1COC1",541.236142228,39,-0.108,134.22,0.00136495250320668,0.102,0.0516824762516033,0,0
"2'-MeCCPA","adenosine receptor agonist","ADORA1","C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12",383.136031864,26,1.433,125.55,0.00531539093839677,0.098,0.0516576954691984,0,0
"MGCD-265","VEGFR inhibitor","AXL, MET","Cn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)c2s1, Cn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)c2s1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)c2s1",517.1042451,36,4.644,141.4,0.00330060305809624,0.1,0.0516503015290481,0,0
"eact","calcium-activated chloride channel inhibitor","ANO1","COCCN(C(=O)c1cc(OC)c(OC)c(OC)c1)c1nc(cs1)-c1ccccc1, COCCN(C(=O)c1cc(OC)c(OC)c(OC)c1)c1nc(cs1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COCCN(C(=O)c1cc(OC)c(OC)c(OC)c1)c1nc(cs1)-c1ccccc1",428.140592868,30,3.258,98.36,0.0132806844242546,0.09,0.0516403422121273,0,0
"S26948","PPAR receptor agonist","PPARG","COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC, COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC, COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC",519.13517314,37,4.626,129.14,0.00522712825366902,0.098,0.0516135641268345,0,0
"RS-56812","serotonin receptor partial agonist","HTR3A","Cn1cc(C(=O)C(=O)N[C@H]2C[N@@]3CC[C@H]2CC3)c2ccccc12",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cn1cc(C(=O)C(=O)N[C@H]2C[N@@]3CC[C@H]2CC3)c2ccccc12",311.163376912,23,1.834,54.34,0.0792162997934557,0.024,0.0516081498967279,0,0
"DDR1-IN-1","discoidin domain receptor inhibitor","DDR1, DDR2","CCN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Oc3ccc4NC(=O)Cc4c3)c2)CC1, CCN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Oc3ccc4NC(=O)Cc4c3)c2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Oc3ccc4NC(=O)Cc4c3)c2)CC1",552.234825512,40,4.203,73.91,0.0151855381250664,0.088,0.0515927690625332,0,0
"tangeritin","cell cycle inhibitor","","COc1ccc(cc1)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1, COc1ccc(cc1)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1",372.12090298,27,4.193,76.36,0.0511457559192969,0.052,0.0515728779596485,0,0
"2-amino-2-(4-hydroxyphenyl)acetic acid","","","N[C@@H](C(O)=O)c1ccc(O)cc1 |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","N[C@@H](C(O)=O)c1ccc(O)cc1 |&1:1",167.058243148,12,-2.181,83.55,0.0389989552998505,0.064,0.0514994776499252,0,0
"oxfenicine","carnitine palmitoyltransferase inhibitor","CPT1A, CPT1B","N[C@@H](C(O)=O)c1ccc(O)cc1, N[C@@H](C(O)=O)c1ccc(O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","N[C@@H](C(O)=O)c1ccc(O)cc1",167.058243148,12,-2.181,83.55,0.0389989552998504,0.064,0.0514994776499252,0,0
"BAY-1436032","isocitrate dehydrogenase inhibitor","","C[C@H]1C[C@H](CC(C)(C)C1)n1c(Nc2ccc(OC(F)(F)F)cc2)nc2cc(CCC(O)=O)ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@H]1C[C@H](CC(C)(C)C1)n1c(Nc2ccc(OC(F)(F)F)cc2)nc2cc(CCC(O)=O)ccc12",489.22392648,35,7.538,76.38,0.0449213528099319,0.058,0.0514606764049659,0,0
"JNJ-7706621","CDK inhibitor","AURKA, AURKB, CDK1, CDK2","Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F",394.065965684,27,1.799,154.37,0.00289733639085575,0.1,0.0514486681954279,0,0
"tetramethylthiuram-monosulfide","","","CN(C)C(=S)SC(=S)N(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)C(=S)SC(=S)N(C)C",208.016261384,11,1.293,95.96,0.0208426442572697,0.082,0.0514213221286349,0,0
"broxuridine","antimetabolite","","OC[C@H]1O[C@H](C[C@@H]1O)n1cc(Br)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(Br)c(=O)[nH]c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC[C@H]1O[C@H](C[C@@H]1O)n1cc(Br)c(=O)[nH]c1=O",305.985133552,17,-0.0220000000000001,104.55,0.00481493894617668,0.098,0.0514074694730883,0,0
"tetomilast","phosphodiesterase inhibitor","PDE4D","CCOc1ccc(cc1OCC)-c1nc(cs1)-c1cccc(n1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCOc1ccc(cc1OCC)-c1nc(cs1)-c1cccc(n1)C(O)=O",370.098728056,26,3.38,109.78,0.0166774289249981,0.086,0.051338714462499,0,0
"L-mimosine","dopamine beta hydroxylase inhibitor, eukaryotic translation initiation factor inhibitor","DBH, EIF5A","N[C@@H](CN1CC(=O)C(=O)C=C1)C(O)=O |c:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@@H](CN1CC(=O)C(=O)C=C1)C(O)=O |c:9|",198.0640568,14,-3.509,100.7,0.0146541798360226,0.088,0.0513270899180113,0,0
"KRCA-0008","ALK inihibitor","ALK","COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccc(cc2OC)N2CCN(CC2)C(C)=O)n1)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccc(cc2OC)N2CCN(CC2)C(C)=O)n1)N1CCN(CC1)C(C)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccc(cc2OC)N2CCN(CC2)C(C)=O)n1)N1CCN(CC1)C(C)=O",608.262629344,43,3.583,115.4,0.00263991128350879,0.1,0.0513199556417544,0,0
"DG051","leukotriene synthesis inhibitor","","OC(=O)CCCN1CCC[C@H]1COc1ccc(Oc2ccc(Cl)cc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)CCCN1CCC[C@H]1COc1ccc(Oc2ccc(Cl)cc2)cc1",389.139385928,27,4.334,59,0.0526279146778774,0.05,0.0513139573389387,0,0
"E3330","NFkB pathway inhibitor","","CCCCCCCCC\C(=C/C1=C(C)C(=O)C(OC)=C(OC)C1=O)C(O)=O |c:11,t:18|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCCC\C(=C/C1=C(C)C(=O)C(OC)=C(OC)C1=O)C(O)=O |c:11",378.20423868,27,4.866,89.9,0.0386113251341958,0.064,0.0513056625670979,0,0
"MK-6096","orexin receptor antagonist","HCRTR1, HCRTR2","C[C@@H]1CC[C@@H](COc2ccc(F)cn2)CN1C(=O)c1cc(C)ccc1-c1ncccn1, C[C@@H]1CC[C@@H](COc2ccc(F)cn2)CN1C(=O)c1cc(C)ccc1-c1ncccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@@H]1CC[C@@H](COc2ccc(F)cn2)CN1C(=O)c1cc(C)ccc1-c1ncccn1",420.19615426,31,4.304,68.21,0.050588532189685,0.052,0.0512942660948425,0,0
"3'-fluorobenzylspiperone","dopamine receptor ligand","DRD2","Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,"preclinical","","","Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1",503.238433672,37,5.65,43.86,0.0665883287660649,0.036,0.0512941643830325,0,0
"RN-1747","TRPV agonist","TRPV4","[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1, [O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1, [O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1, [O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1",395.070654736,26,2.977,92.14,0.0125689635222767,0.09,0.0512844817611384,0,0
"carboxypyridine-disulfide","","","OC(=O)c1ccc(SSc2ccc(cn2)C(O)=O)nc1, OC(=O)c1ccc(SSc2ccc(cn2)C(O)=O)nc1, OC(=O)c1ccc(SSc2ccc(cn2)C(O)=O)nc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)c1ccc(SSc2ccc(cn2)C(O)=O)nc1",307.992548736,20,1.376,150.98,0.00440187067918859,0.098,0.0512009353395943,0,0
"GR-103691","dopamine receptor antagonist","DRD3","COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(cc2)-c2ccc(cc2)C(C)=O)CC1, COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(cc2)-c2ccc(cc2)C(C)=O)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(cc2)-c2ccc(cc2)C(C)=O)CC1",485.26784198,36,5.659,61.88,0.054339595490175,0.048,0.0511697977450875,0,0
"(4s,4ar,5s,5ar,6s,12as)-4-(dimethylamino)-5,6,10,12a-tetrahydroxy-6-methyl-1,3,11,12-tetraoxo-1,2,3,4,4a,5,5a,6,11,11a,12,12a-dodecahydro-2-naphthacenecarboxamide hydrate","","","CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O",460.148180348,33,-2.699,195.53,0.000304647063574127,0.102,0.0511523235317871,0,0
"oxytetracycline dihydrate","","","CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O",460.148180348,33,-2.699,195.53,0.000304647063574127,0.102,0.0511523235317871,0,0
"procyanidin-B-2","","","O[C@H]1Cc2c(O)cc(O)c([C@@H]3[C@@H](O)[C@H](Oc4cc(O)cc(O)c34)c3ccc(O)c(O)c3)c2O[C@@H]1c1ccc(O)c(O)c1, O[C@H]1Cc2c(O)cc(O)c([C@@H]3[C@@H](O)[C@H](Oc4cc(O)cc(O)c34)c3ccc(O)c(O)c3)c2O[C@@H]1c1ccc(O)c(O)c1, O[C@H]1Cc2c(O)cc(O)c([C@@H]3[C@@H](O)[C@H](Oc4cc(O)cc(O)c34)c3ccc(O)c(O)c3)c2O[C@@H]1c1ccc(O)c(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O[C@H]1Cc2c(O)cc(O)c([C@@H]3[C@@H](O)[C@H](Oc4cc(O)cc(O)c34)c3ccc(O)c(O)c3)c2O[C@@H]1c1ccc(O)c(O)c1",578.142426272,42,2.658,220.76,0.000299199296031163,0.102,0.0511495996480156,0,0
"zaltidine","histamine receptor antagonist","HRH2","Cc1nc(c[nH]1)-c1csc(NC(N)=N)n1, Cc1nc(c[nH]1)-c1csc(NC(N)=N)n1, Cc1nc(c[nH]1)-c1csc(NC(N)=N)n1",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cc1nc(c[nH]1)-c1csc(NC(N)=N)n1",222.06876532,15,0.719,131.71,0.0142940679914991,0.088,0.0511470339957495,0,0
"PF-573228","focal adhesion kinase inhibitor","CDK1, CDK2, CDK7, GSK3B, IKBKB","CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1",491.12389516,34,3.129,121.46,0.00423801595638379,0.098,0.0511190079781919,0,0
"SB-452533","TRPV antagonist","TRPV1","CCN(CCNC(=O)Nc1ccccc1Br)c1cccc(C)c1, CCN(CCNC(=O)Nc1ccccc1Br)c1cccc(C)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN(CCNC(=O)Nc1ccccc1Br)c1cccc(C)c1",375.094624424,23,4.595,44.37,0.0442257435888506,0.058,0.0511128717944253,0,0
"fedovapagon","vasopressin receptor agonist","AVPR2","CN(C)C(=O)[C@@H]1CCCN1C(=O)NCc2ccc(cc2C)C(=O)N3CCCCc4ccccc34",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","urology","benign prostatic hyperplasia (bph)","CN(C)C(=O)[C@@H]1CCCN1C(=O)NCc2ccc(cc2C)C(=O)N3CCCCc4ccccc34",462.263090948,34,3.237,72.96,0.0261227537433746,0.076,0.0510613768716873,0,0
"SN-6","sodium/calcium exchange inhibitor","","CCOC(=O)[C@H]1CS[C@H](Cc2ccc(OCc3ccc(cc3)[N+]([O-])=O)cc2)N1 |&1:5,&2:8,r|, CCOC(=O)[C@H]1CS[C@H](Cc2ccc(OCc3ccc(cc3)[N+]([O-])=O)cc2)N1 |&1:5,&2:8,r|, CCOC(=O)[C@H]1CS[C@H](Cc2ccc(OCc3ccc(cc3)[N+]([O-])=O)cc2)N1 |&1:5,&2:8,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)[C@H]1CS[C@H](Cc2ccc(OCc3ccc(cc3)[N+]([O-])=O)cc2)N1 |&1:5",402.124942804,28,3.878,116,0.0120832361875685,0.09,0.0510416180937842,0,0
"iopanic-acid","thyroid hormone inhibitor","","CC[C@@H](Cc1c(I)cc(I)c(N)c1I)C(O)=O |&1:2,r|, CC[C@@H](Cc1c(I)cc(I)c(N)c1I)C(O)=O |&1:2,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CC[C@@H](Cc1c(I)cc(I)c(N)c1I)C(O)=O |&1:2",570.800222624,17,4.867,63.32,7.42629945118675e-05,0.102,0.0510371314972559,0,0
"SDZ-21009","adrenergic receptor antagonist, serotonin receptor antagonist","HTR1A, HTR1B","CC(C)OC(=O)c1cc2c(OC[C@@H](O)CNC(C)(C)C)cccc2[nH]1 |&1:12,r|, CC(C)OC(=O)c1cc2c(OC[C@@H](O)CNC(C)(C)C)cccc2[nH]1 |&1:12,r|, CC(C)OC(=O)c1cc2c(OC[C@@H](O)CNC(C)(C)C)cccc2[nH]1 |&1:12,r|",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)OC(=O)c1cc2c(OC[C@@H](O)CNC(C)(C)C)cccc2[nH]1 |&1:12",348.204907376,25,3.164,83.58,0.0380730159891769,0.064,0.0510365079945884,0,0
"PF-06273340","tyrosine kinase receptor inhibitor","","CC(C)(CO)n1cc(C(=O)c2cncc(NC(=O)Cc3ccc(Cl)cn3)c2)c2cnc(N)nc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)(CO)n1cc(C(=O)c2cncc(NC(=O)Cc3ccc(Cl)cn3)c2)c2cnc(N)nc12",479.147265244,34,1.455,148.91,0.00198515442669578,0.1,0.0509925772133479,0,0
"N6-cyclopentyladenosine","adenosine receptor agonist","ADORA1, ADORA2A, ADORA2B, ADORA3, SLC29A1","OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12",335.159354152,24,0.304999999999999,125.55,0.0079841092094911,0.094,0.0509920546047455,0,0
"adriforant (hydrochloride)","histamine receptor antagonist","HRH4","NC1=NC(N2C[C@H](NC)CC2)=CC(NCC3CC3)=N1.[H]Cl.[H]Cl.[H]Cl",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","dermatology","dermatitis","NC1=NC(N2C[C@H](NC)CC2)=CC(NCC3CC3)=N1.[H]Cl.[H]Cl.[H]Cl",370.12062784,25,1.624,78.04,0.0179370861877405,0.084,0.0509685430938703,0,0
"D-4476","TGF beta receptor inhibitor","CSNK1A1, CSNK1D, TGFB1","NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCCOc2c1)-c1ccccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCCOc2c1)-c1ccccn1",398.137890436,30,3.208,103.12,0.0238153412594808,0.078,0.0509076706297404,0,0
"desoxycortone","mineralocorticoid receptor agonist","NR3C1, NR3C2","C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:8|",330.21949482,24,3.789,54.37,0.0998089841355841,0.002,0.050904492067792,0,0
"CYC065","CDK inhibitor","","CC[C@H](Nc1nc(NCc2cnc(C)cc2C)c2ncn(C(C)C)c2n1)[C@@H](C)O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC[C@H](Nc1nc(NCc2cnc(C)cc2C)c2ncn(C(C)C)c2n1)[C@@H](C)O",397.259008612,29,3.466,100.78,0.0217699737055259,0.08,0.050884986852763,0,0
"GS-9620","toll-like receptor agonist","TLR7","CCCCOc1nc(N)c2NC(=O)CN(Cc3cccc(CN4CCCC4)c3)c2n1, CCCCOc1nc(N)c2NC(=O)CN(Cc3cccc(CN4CCCC4)c3)c2n1, CCCCOc1nc(N)c2NC(=O)CN(Cc3cccc(CN4CCCC4)c3)c2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCCOc1nc(N)c2NC(=O)CN(Cc3cccc(CN4CCCC4)c3)c2n1",410.2430242,30,3.373,96.61,0.021639449729115,0.08,0.0508197248645575,0,0
"CPI-1205","EZH2 inhibitor","","COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCN(CC(F)(F)F)CC2)c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCN(CC(F)(F)F)CC2)c2ccccc12",518.250475576,37,5.677,79.36,0.0215492433930217,0.08,0.0507746216965109,0,0
"SU3327","JNK inhibitor","MAPK8","Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1",260.944887336,15,0.776,189.61,0.00151418941517394,0.1,0.050757094707587,0,0
"AT13148","protein kinase inhibitor","AKT1, AKT2, AKT3, ROCK1, ROCK2, SGK3","NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1, NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1, NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1, NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1, NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1, NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1",313.098189812,22,3.351,74.93,0.055464465452138,0.046,0.050732232726069,0,0
"poziotinib","EGFR inhibitor","EGFR, ERBB2, ERBB4","COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C",490.097474112,33,4.468,76.58,0.0134346445921216,0.088,0.0507173222960608,0,0
"sar125844","c-met inhibitor","MET","Fc1ccc(cc1)c2ccc3nnc(Sc4ccc5nc(NC(=O)NCCN6CCOCC6)sc5c4)n3n2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","oncology","gastric adenocarcinoma","Fc1ccc(cc1)c2ccc3nnc(Sc4ccc5nc(NC(=O)NCCN6CCOCC6)sc5c4)n3n2",550.136942196,38,4.596,163.11,0.00142188182047258,0.1,0.0507109409102363,0,0
"necrostatin-1","RIPK inhibitor","RIPK1","CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|, CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|, CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|, CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|, CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|",259.077933036,18,1.845,80.22,0.0493988654240552,0.052,0.0506994327120276,0,0
"GW-583340","EGFR inhibitor","EGFR, ERBB2","CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1",597.10713756,40,5.228,142.72,0.00137381072971406,0.1,0.050686905364857,0,0
"SKLB1002","VEGFR inhibitor","KDR","COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC, COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC, COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC",320.040167624,21,2.073,123.56,0.00926436284009771,0.092,0.0506321814200489,0,0
"sulmazole","adenosine receptor antagonist","","COc1cc(ccc1-c1nc2ncccc2[nH]1)[S@@](C)=O |r|, COc1cc(ccc1-c1nc2ncccc2[nH]1)[S@@](C)=O |r|, COc1cc(ccc1-c1nc2ncccc2[nH]1)[S@@](C)=O |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1cc(ccc1-c1nc2ncccc2[nH]1)[S@@](C)=O |r|",287.072847656,20,1.374,87.08,0.0310618940250959,0.07,0.050530947012548,0,0
"thymol-iodide","","","CC(C)c1cc(c(C)cc1OI)-c1cc(C(C)C)c(OI)cc1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)c1cc(c(C)cc1OI)-c1cc(C(C)C)c(OI)cc1C",549.986576008,24,9.218,18.46,0.0050178280060462,0.096,0.0505089140030231,0,0
"filgotinib","JAK inhibitor","JAK1, JAK2, JAK3, TYK2","O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1, O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1, O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1, O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1, O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1",425.152160596,30,1.986,105.05,0.00897987007727597,0.092,0.050489935038638,0,0
"chs-828","nampt inhibitor","A1BG, NAMPT","Clc1ccc(OCCCCCC\N=C(\NC#N)Nc2ccncc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","lung cancer","Clc1ccc(OCCCCCC\N=C(\NC#N)Nc2ccncc2)cc1",371.151288004,26,3.973,82.33,0.0348844616588622,0.066,0.0504422308294311,0,0
"parsaclisib","PI3K inhibitor","","CCOc1c(cc(Cl)c(F)c1[C@@H]1CNC(=O)C1)[C@H](C)n1nc(C)c2c(N)ncnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCOc1c(cc(Cl)c(F)c1[C@@H]1CNC(=O)C1)[C@H](C)n1nc(C)c2c(N)ncnc12",432.147679844,30,2.883,107.95,0.00885217021581055,0.092,0.0504260851079053,0,0
"TG-101209","JAK inhibitor","JAK2, JAK3","CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1",509.25729436,36,3.956,110.87,0.00680196119291528,0.094,0.0504009805964576,0,0
"rofecoxib","cyclooxygenase inhibitor","ELN, PTGS2","CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|",314.061279928,22,3.252,68.82,0.0606188106396189,0.04,0.0503094053198095,0,0
"phenylacetylglutamine","DNA methylase inhibitor, protein synthesis inhibitor","","NC(=O)CC[C@H](NC(=O)Cc1ccccc1)C(O)=O, NC(=O)CC[C@H](NC(=O)Cc1ccccc1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NC(=O)CC[C@H](NC(=O)Cc1ccccc1)C(O)=O",264.111006992,19,-2.272,109.49,0.0106070580666674,0.09,0.0503035290333337,0,0
"IB-MECA","adenosine receptor agonist","ADORA1, ADORA2A, ADORA2B, ADORA3","CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)ncnc12, CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)ncnc12, CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)ncnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)ncnc12",510.051251088,29,2.2,134.42,0.000503948590057101,0.1,0.0502519742950286,0,0
"caracemide","ribonucleotide reductase inhibitor","RRM1","CNC(=O)ON(C(C)=O)C(=O)NC, CNC(=O)ON(C(C)=O)C(=O)NC, CNC(=O)ON(C(C)=O)C(=O)NC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CNC(=O)ON(C(C)=O)C(=O)NC",189.074955832,13,-0.639,87.74,0.0384462662667856,0.062,0.0502231331333928,0,0
"tetrahydropapaverine","","","COc1ccc(C[C@H]2NCCc3cc(OC)c(OC)cc23)cc1OC |&1:7|, COc1ccc(C[C@H]2NCCc3cc(OC)c(OC)cc23)cc1OC |&1:7|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(C[C@H]2NCCc3cc(OC)c(OC)cc23)cc1OC |&1:7|",343.17835828,25,2.743,48.95,0.0824362995303126,0.018,0.0502181497651563,0,0
"BTB06584","ATPase inhibitor","ATP5F1","[O-][N+](=O)c1ccc(cc1OC(=O)c1ccc(Cl)cc1)S(=O)(=O)c1ccccc1, [O-][N+](=O)c1ccc(cc1OC(=O)c1ccc(Cl)cc1)S(=O)(=O)c1ccccc1, [O-][N+](=O)c1ccc(cc1OC(=O)c1ccc(Cl)cc1)S(=O)(=O)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[O-][N+](=O)c1ccc(cc1OC(=O)c1ccc(Cl)cc1)S(=O)(=O)c1ccccc1",417.007385784,28,5.012,111.96,0.0122757190849147,0.088,0.0501378595424573,0,0
"VU0364739","phospholipase inhibitor","PLD2","Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc3ccccc3c2)CC1, Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc3ccccc3c2)CC1, Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc3ccccc3c2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc3ccccc3c2)CC1",446.211804324,33,4.243,64.68,0.0462475155375364,0.054,0.0501237577687682,0,0
"omega-(4-iodophenyl)pentadecanoic-acid","","","OC(=O)CCCCCCCCCCCCCCc1ccc(I)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)CCCCCCCCCCCCCCc1ccc(I)cc1",444.152528296,24,9.514,37.3,0.042153350955902,0.058,0.050076675477951,0,0
"NSC-5844","CC chemokine receptor agonist","CCR1","Clc1ccc2c(NCCNc3ccnc4cc(Cl)ccc34)ccnc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1ccc2c(NCCNc3ccnc4cc(Cl)ccc34)ccnc2c1",382.075201872,26,4.576,49.84,0.0641481415978442,0.036,0.0500740707989221,0,0
"CGH2466","adenosine receptor antagonist","ADORA1, ADORA2B, ADORA3","Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1, Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1, Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1, Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1, Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1",320.989423648,20,3.598,80.04,0.0281298104532365,0.072,0.0500649052266182,0,0
"asunaprevir","HCV inhibitor","","COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12, COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12, COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12, COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12, COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12, COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12",747.270476732,51,4.41,190.71,0.000128743960429933,0.1,0.050064371980215,0,0
"SR-1078","retinoid receptor agonist","RORA, RORC","OC(c1ccc(NC(=O)c2ccc(cc2)C(F)(F)F)cc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(NC(=O)c2ccc(cc2)C(F)(F)F)cc1)(C(F)(F)F)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(c1ccc(NC(=O)c2ccc(cc2)C(F)(F)F)cc1)(C(F)(F)F)C(F)(F)F",431.05678254,29,5.747,49.33,0.0541151150139959,0.046,0.050057557506998,0,0
"GSK-J5","histone demethylase control","","CCOC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1",417.216475104,31,4.364,80.24,0.0420858990903594,0.058,0.0500429495451797,0,0
"PF-05212384","mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA","CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1",615.328150792,45,2.645,128.29,0.00208407015729409,0.098,0.050042035078647,0,0
"AGI-6780","isocitrate dehydrogenase inhibitor","IDH2","FC(F)(F)c1cccc(NC(=O)Nc2cc(ccc2-c2ccsc2)S(=O)(=O)NC2CC2)c1, FC(F)(F)c1cccc(NC(=O)Nc2cc(ccc2-c2ccsc2)S(=O)(=O)NC2CC2)c1, FC(F)(F)c1cccc(NC(=O)Nc2cc(ccc2-c2ccsc2)S(=O)(=O)NC2CC2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)c1cccc(NC(=O)Nc2cc(ccc2-c2ccsc2)S(=O)(=O)NC2CC2)c1",481.074168096,32,4.094,123.92,0.00406885768533142,0.096,0.0500344288426657,0,0
"gsk-626616","dual specificity protein kinase inhibitor","DYRK3","Clc1cccc(Cl)c1\N=C/2\NC(=O)\C(=C\c3ccc4nccnc4c3)\S2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","hematology","anemia","Clc1cccc(Cl)c1\N=C/2\NC(=O)\C(=C\c3ccc4nccnc4c3)\S2",399.9952373,26,3.313,92.54,0.0120273389594163,0.088,0.0500136694797081,0,0
"Lu-AA-47070","adenosine receptor antagonist","ADORA2A","CC(C)(C)CC(=O)Nc1c(F)cc(cc1F)C(=O)\N=c1/sccn1COP(O)(O)=O, CC(C)(C)CC(=O)Nc1c(F)cc(cc1F)C(=O)\N=c1/sccn1COP(O)(O)=O, CC(C)(C)CC(=O)Nc1c(F)cc(cc1F)C(=O)\N=c1/sccn1COP(O)(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)(C)CC(=O)Nc1c(F)cc(cc1F)C(=O)\N=c1/sccn1COP(O)(O)=O",463.07784943,30,2.885,140.03,0.00202336918273358,0.098,0.0500116845913668,0,0
"Ro-15-4513","GABA benzodiazepine site receptor inverse agonist","GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB2, GABRG2","CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(ccc-21)N=[N+]=[N-], CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(ccc-21)N=[N+]=[N-]",0,0,0,0,0,0,0,0,0,0,0,0,1,8,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(ccc-21)N=[N+]=[N-]",326.112738308,24,2.802,76.79,0.0540112231923079,0.046,0.0500056115961539,0,0
"SB-2343","mTOR inhibitor, PI3K inhibitor","MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG","CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1, CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1, CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1, CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1, CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1",354.191657324,26,1.479,107.87,0.016006962339137,0.084,0.0500034811695685,0,0
"YM-58483","calcium channel blocker","TRPC3, TRPC5, TRPM4","Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F",421.043200228,28,3.513,100.94,0.00998614228120716,0.09,0.0499930711406036,0,0
"fexinidazole","","","CSc1ccc(OCc2ncc(n2C)[N+]([O-])=O)cc1, CSc1ccc(OCc2ncc(n2C)[N+]([O-])=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CSc1ccc(OCc2ncc(n2C)[N+]([O-])=O)cc1",279.067762276,19,2.707,95.49,0.033985976157679,0.066,0.0499929880788395,0,0
"evobrutinib","Bruton's tyrosine kinase (BTK) inhibitor","","Nc1ncnc(NCC2CCN(CC2)C(=O)C=C)c1-c1ccc(Oc2ccccc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Nc1ncnc(NCC2CCN(CC2)C(=O)C=C)c1-c1ccc(Oc2ccccc2)cc1",429.216475104,32,4.107,93.37,0.0279507948445973,0.072,0.0499753974222987,0,0
"TRV130","opioid receptor agonist","OPRM1","COc1ccsc1CNCC[C@]1(CCOC2(CCCC2)C1)c1ccccn1, COc1ccsc1CNCC[C@]1(CCOC2(CCCC2)C1)c1ccccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1ccsc1CNCC[C@]1(CCOC2(CCCC2)C1)c1ccccn1",386.2027992,27,3.116,71.62,0.0319352767172672,0.068,0.0499676383586336,0,0
"SNS-314","Aurora kinase inhibitor","AURKA, AURKB, AURKC","Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1, Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1, Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1, Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1, Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1",430.04372878,28,2.114,148.31,0.00192079974731433,0.098,0.0499603998736572,0,0
"SBHA","HDAC inhibitor","HDAC1, HDAC3","ONC(=O)CCCCCCC(=O)NO, ONC(=O)CCCCCCC(=O)NO, ONC(=O)CCCCCCC(=O)NO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","ONC(=O)CCCCCCC(=O)NO",204.111006992,14,-0.152,98.66,0.0298272490895843,0.07,0.0499136245447922,0,0
"lonapalene","lipoxygenase inhibitor","ALOX5","COc1c(OC)c(OC(=O)C)c2cc(Cl)ccc2c1OC(=O)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","dermatology","psoriasis","COc1c(OC)c(OC(=O)C)c2cc(Cl)ccc2c1OC(=O)C",338.05571588,23,3.042,71.06,0.0396453761509593,0.06,0.0498226880754797,0,0
"GW-1100","G protein-coupled receptor agonist","FFAR1","CCOC(=O)c1ccc(cc1)-n1cc(Cc2cnc(OCC)nc2)c(=O)nc1SCc1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)c1ccc(cc1)-n1cc(Cc2cnc(OCC)nc2)c(=O)nc1SCc1ccc(F)cc1",520.1580545,37,6.506,121.5,0.00961462302302464,0.09,0.0498073115115123,0,0
"licostinel","NMDA receptor antagonist ","","[O-][N+](=O)c1c(Cl)c(Cl)cc2[nH]c(=O)c(=O)[nH]c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","[O-][N+](=O)c1c(Cl)c(Cl)cc2[nH]c(=O)c(=O)[nH]c12",274.950060936,17,3.906,108.86,0.0235340254483579,0.076,0.049767012724179,0,0
"DMSO","control vehicle","","CS(C)=O.CS(C)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CS(C)=O.CS(C)=O",156.027871624,8,-1.436,72.56,0.0315250344491118,0.068,0.0497625172245559,0,0
"PI3Kd-IN-2","PI3K inhibitor","","COc1ncc(cc1NS(C)(=O)=O)-c1nc(nc2c(CN3CCC(CC3)C(C)(C)O)cc(F)cc12)N1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ncc(cc1NS(C)(=O)=O)-c1nc(nc2c(CN3CCC(CC3)C(C)(C)O)cc(F)cc12)N1CCOCC1",588.253017504,41,3.219,138.39,0.00144371576166176,0.098,0.0497218578808309,0,0
"MMV-390048","PI4K inhibitor","","CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(c1)-c1ccc(nc1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(c1)-c1ccc(nc1)C(F)(F)F",393.075882348,27,3.844,94.32,0.0193866763409361,0.08,0.0496933381704681,0,0
"AZD1390","ATM kinase inhibitor","","CC(C)n1c2c(cnc3cc(F)c(cc23)-c2ccc(OCCCN3CCCCC3)nc2)n(C)c1=O, CC(C)n1c2c(cnc3cc(F)c(cc23)-c2ccc(OCCCN3CCCCC3)nc2)n(C)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)n1c2c(cnc3cc(F)c(cc23)-c2ccc(OCCCN3CCCCC3)nc2)n(C)c1=O",477.254003484,35,4.297,65.18,0.0353632694563514,0.064,0.0496816347281757,0,0
"BTT-3033","integrin inhibitor","ITGA2, ITGB1","CN(c1ccc(NC(=O)Nc2ccccc2)cc1)S(=O)(=O)c1cnn(c1)-c1ccc(F)cc1, CN(c1ccc(NC(=O)Nc2ccccc2)cc1)S(=O)(=O)c1cnn(c1)-c1ccc(F)cc1, CN(c1ccc(NC(=O)Nc2ccccc2)cc1)S(=O)(=O)c1cnn(c1)-c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(c1ccc(NC(=O)Nc2ccccc2)cc1)S(=O)(=O)c1cnn(c1)-c1ccc(F)cc1",465.12708872,33,3.995,104.71,0.0113455925801748,0.088,0.0496727962900874,0,0
"florifenine","anti-inflammatory agent","","FC(F)(F)c1ccc2c(Nc3ccccc3C(=O)OCCN3CCCC3)ccnc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)c1ccc2c(Nc3ccccc3C(=O)OCCN3CCCC3)ccnc2c1",429.166411604,31,4.986,54.46,0.0653429342051706,0.034,0.0496714671025853,0,0
"PFI-1","bromodomain inhibitor","BRD4","COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1",347.093977024,24,1.354,96.12,0.0152465276904445,0.084,0.0496232638452222,0,0
"ezatiostat","glutathione transferase inhibitor","GSTP1","CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1, CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1, CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1, CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1, CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1",529.22465684,37,2.808,162.12,0.00122885630778645,0.098,0.0496144281538932,0,0
"SJG-136","DNA intercalating agent","","COc1cc2c(cc1OCCCOc1cc3N=C[C@@H]4CC(=C)CN4C(=O)c3cc1OC)N=C[C@@H]1CC(=C)CN1C2=O |c:17,35|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1cc2c(cc1OCCCOc1cc3N=C[C@@H]4CC(=C)CN4C(=O)c3cc1OC)N=C[C@@H]1CC(=C)CN1C2=O |c:17",556.232184744,41,1.92,102.26,0.00519668767542933,0.094,0.0495983438377147,0,0
"cabotegravir","HIV integrase inhibitor","","C[C@H]1CO[C@@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12, C[C@H]1CO[C@@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C[C@H]1CO[C@@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12",405.113627084,29,3.716,100.87,0.0191939919024755,0.08,0.0495969959512377,0,0
"pco371","","PTH1R","Cc1cc(cc(C)c1CCS(=O)(=O)N1CCC2(CC1)NC(=NC2=O)c1ccc(OC(F)(F)F)cc1)N1C(=O)NC(=O)C1(C)C |c:22|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","endocrinology","hypoparathyroidism","Cc1cc(cc(C)c1CCS(=O)(=O)N1CCC2(CC1)NC(=NC2=O)c1ccc(OC(F)(F)F)cc1)N1C(=O)NC(=O)C1(C)C |c:22|",635.202539404,44,4.489,145.86,0.00107757582235999,0.098,0.04953878791118,0,0
"milademetan","MDM inhibitor","","CC1(C)CCC2(CC1)N[C@H]([C@H](c1ccnc(Cl)c1F)[C@]21C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@@H]1CC[C@H](OC1)C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC1(C)CCC2(CC1)N[C@H]([C@H](c1ccnc(Cl)c1F)[C@]21C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@@H]1CC[C@H](OC1)C(N)=O",617.197188148,42,3.566,135.44,0.00106130491853311,0.098,0.0495306524592666,0,0
"coumophos","cholinesterase inhibitor","","CCOP(=S)(OCC)Oc1ccc2c(C)c(Cl)c(=O)oc2c1, CCOP(=S)(OCC)Oc1ccc2c(C)c(Cl)c(=O)oc2c1, CCOP(=S)(OCC)Oc1ccc2c(C)c(Cl)c(=O)oc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOP(=S)(OCC)Oc1ccc2c(C)c(Cl)c(=O)oc2c1",362.014458922,22,5.5,99.8,0.0170579066749326,0.082,0.0495289533374663,0,0
"cis-aconitic-acid","","ACO2","OC(=O)C\C(=C\C(O)=O)C(O)=O, OC(=O)C\C(=C\C(O)=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)C\C(=C\C(O)=O)C(O)=O",174.016437912,12,-1.034,111.9,0.0230520406654931,0.076,0.0495260203327466,0,0
"nitroflurbiprofen","cyclooxygenase inhibitor","","C[C@@H](C(=O)OCCCCO[N+]([O-])=O)c1ccc(c(F)c1)-c1ccccc1 |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](C(=O)OCCCCO[N+]([O-])=O)c1ccc(c(F)c1)-c1ccccc1 |&1:1",361.13255096,26,5.044,78.67,0.0610493729852811,0.038,0.0495246864926406,0,0
"PF-06650833","kinase inhibitor","","CC[C@H]1[C@@H](COc2nccc3cc(C(N)=O)c(OC)cc23)NC(=O)[C@H]1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC[C@H]1[C@@H](COc2nccc3cc(C(N)=O)c(OC)cc23)NC(=O)[C@H]1F",361.14378434,26,2.002,103.54,0.0170209620145618,0.082,0.0495104810072809,0,0
"pimodivir","antiviral","","OC(=O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(ncc1F)-c1c[nH]c2ncc(F)cc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","OC(=O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(ncc1F)-c1c[nH]c2ncc(F)cc12",399.150681288,29,3.775,103.79,0.0209504246985749,0.078,0.0494752123492875,0,0
"5-iodo-A-85380","acetylcholine receptor agonist","","Ic1cncc(OC[C@@H]2CCN2)c1, Ic1cncc(OC[C@@H]2CCN2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Ic1cncc(OC[C@@H]2CCN2)c1",289.991610972,13,1.552,34.15,0.0207879859353111,0.078,0.0493939929676555,0,0
"barasertib-HQPA","Aurora kinase inhibitor","AURKB","CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1",507.23941604,37,3.025,128.29,0.00478601991362157,0.094,0.0493930099568108,0,0
"teglicar","carnitine palmitoyltransferase inhibitor","CPT1A","CCCCCCCCCCCCCCNC(=O)N[C@H](CC(O)=O)C[N+](C)(C)C |a:18|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","endocrinology","diabetes mellitus","CCCCCCCCCCCCCCNC(=O)N[C@H](CC(O)=O)C[N+](C)(C)C |a:18|",400.353368752091,28,5.629,78.43,0.0447492774649131,0.054,0.0493746387324566,0,0
"P276-00","CDK inhibitor","CDK1, CDK4, CDK9","CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl",401.10300042,28,3.951,94.14,0.0207415417221123,0.078,0.0493707708610562,0,0
"cinaciguat","guanylate cyclase activator","GUCY1A3, GUCY1B3","OC(=O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(cc1)C(O)=O, OC(=O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(cc1)C(O)=O, OC(=O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(cc1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(cc1)C(O)=O",565.282823348,42,7.483,87.07,0.028646106531761,0.07,0.0493230532658805,0,0
"epicatechin-gallate-(-)","bacterial DNA gyrase inhibitor","BACE1, FASN","Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1ccc(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1ccc(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1ccc(O)c(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1ccc(O)c(O)c1",442.089996776,32,3.558,177.14,0.00264224131722272,0.096,0.0493211206586114,0,0
"NN-DNJ","glucosidase inhibitor","GBA","CCCCCCCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO",289.225308472,20,2.647,84.16,0.0426267746530566,0.056,0.0493133873265283,0,0
"DSPC","","","CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC |&1:21,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC |&1:21",790.632031858091,54,16.128,118.17,0.00860498368067904,0.09,0.0493024918403395,0,0
"OTS167","maternal embryonic leucine zipper kinase inhibitor","MELK","CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|, CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|, CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|, CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|, CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|, CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|",486.158931496,33,5.125,78.35,0.0165922716380636,0.082,0.0492961358190318,0,0
"CRT0044876","","","OC(=O)c1cc2cccc([N+]([O-])=O)c2[nH]1, OC(=O)c1cc2cccc([N+]([O-])=O)c2[nH]1, OC(=O)c1cc2cccc([N+]([O-])=O)c2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1cc2cccc([N+]([O-])=O)c2[nH]1",206.032756672,15,2.553,96.23,0.0705901444556043,0.028,0.0492950722278021,0,0
"VU0155069","phospholipase inhibitor","PLD1","C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1, C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1, C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1, C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1",462.182253784,33,4.563,70.13,0.0305874469927898,0.068,0.0492937234963949,0,0
"BAY-8002","monocarboxylate transporter inhibitor","","OC(=O)c1ccccc1NC(=O)c1cc(ccc1Cl)S(=O)(=O)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1ccccc1NC(=O)c1cc(ccc1Cl)S(=O)(=O)c1ccccc1",415.028121228,28,4.633,108.92,0.0125804373186748,0.086,0.0492902186593374,0,0
"acetylsalicylsalicylic-acid","cyclooxygenase inhibitor","","CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O",300.063388104,22,2.924,89.9,0.048564318795017,0.05,0.0492821593975085,0,0
"UNC0642","histone lysine methyltransferase inhibitor","EHMT1, EHMT2","COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1",546.349381088,39,5.46,65.99,0.0225355541601317,0.076,0.0492677770800658,0,0
"pritelivir","helicase primase inhibitor","","CN(C(=O)Cc1ccc(cc1)-c1ccccn1)c1nc(C)c(s1)S(N)(=O)=O, CN(C(=O)Cc1ccc(cc1)-c1ccccn1)c1nc(C)c(s1)S(N)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN(C(=O)Cc1ccc(cc1)-c1ccccn1)c1nc(C)c(s1)S(N)(=O)=O",402.082032436,27,0.93,142.87,0.00252421555098005,0.096,0.04926210777549,0,0
"GSK-J1","histone demethylase inhibitor","KDM6B","OC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, OC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, OC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, OC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1",389.185174976,29,3.709,91.24,0.0345098687899456,0.064,0.0492549343949728,0,0
"RS-100329","adrenergic receptor antagonist","ADRA1A, ADRA1D","Cc1c[nH]c(=O)n(CCCN2CCN(CC2)c2ccccc2OCC(F)(F)F)c1=O, Cc1c[nH]c(=O)n(CCCN2CCN(CC2)c2ccccc2OCC(F)(F)F)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,"preclinical","","","Cc1c[nH]c(=O)n(CCCN2CCN(CC2)c2ccccc2OCC(F)(F)F)c1=O",426.18787532,30,4.166,70.57,0.0324712913108009,0.066,0.0492356456554004,0,0
"nimustine","DNA alkylating agent, dna damage inducer","","Cc1ncc(CNC(=O)N(CCCl)N=O)c(N)n1, Cc1ncc(CNC(=O)N(CCCl)[NH2+][O-])c(N)n1, Cc1ncc(CNC(=O)N(CCCl)[NH2+][O-])c(N)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","oncology","brain tumors","Cc1ncc(CNC(=O)N(CCCl)N=O)c(N)n1",272.078851336,18,-0.236,113.57,0.0104395067030334,0.088,0.0492197533515167,0,0
"barasertib","Aurora kinase inhibitor","AURKA, AURKB","CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1)CCOP(O)(O)=O, CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1)CCOP(O)(O)=O, CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1)CCOP(O)(O)=O, CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1)CCOP(O)(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1)CCOP(O)(O)=O",587.205746562,41,1.796,184.63,0.000357825626914743,0.098,0.0491789128134574,0,0
"CF102","adenosine receptor agonist","ADORA1, ADORA2A, ADORA2B, ADORA3","CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12, CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12, CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12, CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12",544.012278736,30,2.911,134.42,0.000335455102028583,0.098,0.0491677275510143,0,0
"THK5351","PET radiotracer ","","CNc1ccc(cn1)-c1ccc2cc(OC[C@H](O)CF)ccc2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CNc1ccc(cn1)-c1ccc2cc(OC[C@H](O)CF)ccc2n1",327.138305036,24,3.147,67.27,0.0702910938432597,0.028,0.0491455469216299,0,0
"UNC2025","FLT3 inhibitor, MER tyrosine kinase inhibitor","FLT3, MERTK","CCCCNc1ncc2c(cn([C@H]3CC[C@H](O)CC3)c2n1)-c1ccc(CN2CCN(C)CC2)cc1 |r|, CCCCNc1ncc2c(cn([C@H]3CC[C@H](O)CC3)c2n1)-c1ccc(CN2CCN(C)CC2)cc1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCNc1ncc2c(cn([C@H]3CC[C@H](O)CC3)c2n1)-c1ccc(CN2CCN(C)CC2)cc1 |r|",476.3263599,35,4.477,69.45,0.0342660506703699,0.064,0.0491330253351849,0,0
"2-oxoglutaric-acid","","OXGR1","OC(=O)CCC(=O)C(O)=O, OC(=O)CCC(=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)CCC(=O)C(O)=O",146.021523292,10,-1.056,91.67,0.044166858350508,0.054,0.049083429175254,0,0
"danoprevir","HCV inhibitor","","CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1Cc2cccc(F)c2C1)C(=O)NS(=O)(=O)C1CC1 |c:14|, CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1Cc2cccc(F)c2C1)C(=O)NS(=O)(=O)C1CC1 |c:14|, CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1Cc2cccc(F)c2C1)C(=O)NS(=O)(=O)C1CC1 |c:14|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1Cc2cccc(F)c2C1)C(=O)NS(=O)(=O)C1CC1 |c:14|",731.300027272,51,3.73,188.9,0.00016646655296458,0.098,0.0490832332764823,0,0
"foretinib","VEGFR inhibitor","FLT1, FLT4, KDR, MET","COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1",632.244641248,46,4.554,111.25,0.00414357585865125,0.094,0.0490717879293256,0,0
"SF-11","neuropeptide receptor antagonist","MCOLN3, NPY2R","CCOc1ccc(NC(=S)N2CCC(CC2)C(O)(c2ccccc2)c2ccccc2)cc1, CCOc1ccc(NC(=S)N2CCC(CC2)C(O)(c2ccccc2)c2ccccc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOc1ccc(NC(=S)N2CCC(CC2)C(O)(c2ccccc2)c2ccccc2)cc1",446.2027992,32,6.117,76.82,0.0440089598101711,0.054,0.0490044799050855,0,0
"broxaldine","","","Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1, Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1, Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1",418.915652792,22,5.538,39.19,0.0179860092626495,0.08,0.0489930046313247,0,0
"SDZ-WAG-994","adenosine receptor agonist","ADORA1","CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12, CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12, CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12, CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12",363.19065428,26,0.964,114.55,0.00980548494629917,0.088,0.0489027424731496,0,0
"MRX-2843","MER tyrosine kinase inhibitor","","CN1CCN(Cc2ccc(cc2)-c2cn([C@H]3CC[C@H](O)CC3)c3nc(NCCC4CC4)ncc23)CC1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN1CCN(Cc2ccc(cc2)-c2cn([C@H]3CC[C@H](O)CC3)c3nc(NCCC4CC4)ncc23)CC1 |r|",488.3263599,36,4.645,69.45,0.0337644396036257,0.064,0.0488822198018128,0,0
"PI4KIII-beta-inhibitor-1","PI4K inhibitor","PI4K2B","COc1ccc(cc1S(=O)(=O)Nc1ccc(O)cc1)-c1sc(NC(=O)C(C)(C)C)nc1C, COc1ccc(cc1S(=O)(=O)Nc1ccc(O)cc1)-c1sc(NC(=O)C(C)(C)C)nc1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1S(=O)(=O)Nc1ccc(O)cc1)-c1sc(NC(=O)C(C)(C)C)nc1C",475.1235629,32,2.912,154.24,0.00174213521714601,0.096,0.048871067608573,0,0
"NVP-DPP728","dipeptidyl peptidase inhibitor","DPP4","O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N, O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N, O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N, O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N, O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N, O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N",298.154209196,22,-0.103,104.84,0.0176651025247769,0.08,0.0488325512623885,0,0
"succinylsulfathiazole","dihydrofolate reductase inhibitor","DHFR","OC(=O)CCC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1, OC(=O)CCC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)CCC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1",355.029662516,23,-0.089,162.08,0.00154473296986289,0.096,0.0487723664849314,0,0
"epigallocatechin-gallate-(-)","bacterial DNA gyrase inhibitor","ELANE, EP300, FASN, KAT2B, MMP14, MMP2","Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1",458.084911396,33,3.581,197.37,0.00142974437508672,0.096,0.0487148721875434,0,0
"SANT-2","smoothened receptor antagonist","SHH, SMO","CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1, CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1, CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1, CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1, CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1, CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1",479.161183992,34,5.609,85.47,0.023415604134106,0.074,0.048707802067053,0,0
"NNC-55-0396","T-type calcium channel blocker","CATSPER1, CATSPER2, CATSPER3, CATSPER4","CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1",491.294805676,36,5.823,58.22,0.0533702012473685,0.044,0.0486851006236842,0,0
"manitimus","dehydrogenase inhibitor","","FC(F)(F)c1ccc(NC(=O)[C@H](C#N)C(=O)CCC#C)cc1 |&1:11,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)c1ccc(NC(=O)[C@H](C#N)C(=O)CCC#C)cc1 |&1:11",308.077262252,22,2.382,69.96,0.0553370508537766,0.042,0.0486685254268883,0,0
"NGD-94-1","dopamine receptor antagonist","DRD4","C(N1CCN(CC1)c1ncccn1)c1cnc([nH]1)-c1ccccc1, C(N1CCN(CC1)c1ncccn1)c1cnc([nH]1)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,"phase 1","","","C(N1CCN(CC1)c1ncccn1)c1cnc([nH]1)-c1ccccc1",320.17494464,24,2.042,60.94,0.0730977445862264,0.024,0.0485488722931132,0,0
"pevonedistat","nedd activating enzyme inhibitor","NAE1, UBA3","NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12",443.16272528,31,1.696,140.74,0.0030109574805152,0.094,0.0485054787402576,0,0
"pamicogrel","cyclooxygenase inhibitor","PTGS2","O=C(OCC)CN1C(C2=NC(C3=CC=C(OC)C=C3)=C(C4=CC=C(OC)C=C4)S2)=CC=C1",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","hematology","thrombosis","O=C(OCC)CN1C(C2=NC(C3=CC=C(OC)C=C3)=C(C4=CC=C(OC)C=C4)S2)=CC=C1",448.145678248,32,3.14,85.66,0.0169559491522889,0.08,0.0484779745761444,0,0
"ABT-702","adenosine kinase inhibitor","ADK","Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1, Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1",462.080371328,30,4.126,90.05,0.00888909600580808,0.088,0.048444548002904,0,0
"ABT-751","tubulin polymerization inhibitor","TUBB","COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1",371.093977024,26,2.912,108.93,0.0148356256310807,0.082,0.0484178128155404,0,0
"STAT3-inhibitor-VI","STAT inhibitor","STAT3","Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1, Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1, Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1, Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1, Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1, Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1",365.05692282,25,1.397,138.38,0.00479079251824405,0.092,0.048395396259122,0,0
"GS-39783","GABA receptor modulator","GABBR1","CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O, CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O, CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O",337.157245976,23,5.434,118.28,0.0247525085049953,0.072,0.0483762542524976,0,0
"WAY-316606","secreted frizzled related protein inhibitor","SFRP1","FC(F)(F)c1ccc(cc1S(=O)(=O)NC1CCNCC1)S(=O)(=O)c1ccccc1, FC(F)(F)c1ccc(cc1S(=O)(=O)NC1CCNCC1)S(=O)(=O)c1ccccc1, FC(F)(F)c1ccc(cc1S(=O)(=O)NC1CCNCC1)S(=O)(=O)c1ccccc1, FC(F)(F)c1ccc(cc1S(=O)(=O)NC1CCNCC1)S(=O)(=O)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)c1ccc(cc1S(=O)(=O)NC1CCNCC1)S(=O)(=O)c1ccccc1",448.073833748,29,2.927,109.1,0.00474782967813176,0.092,0.0483739148390659,0,0
"alvocidib","CDK inhibitor","CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM","CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl",401.10300042,28,3.951,94.14,0.0207415417221123,0.076,0.0483707708610562,0,0
"BAY-1251152","CDK9 inhibitor","","COc1cc(F)ccc1-c1cc(Nc2cc(C[S@](C)(=N)=O)ccn2)ncc1F |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1cc(F)ccc1-c1cc(Nc2cc(C[S@](C)(=N)=O)ccn2)ncc1F |r|",404.111853256,28,4.443,96.34,0.0206958456413873,0.076,0.0483479228206936,0,0
"estetrol","selective estrogen receptor modulator (SERM)","ESR1","C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O",304.167459248,22,2.819,80.92,0.052610905926261,0.044,0.0483054529631305,0,0
"2,4-dinitrochlorobenzene","thioredoxin inhibitor","TXN","[O-][N+](=O)c1ccc(Cl)c(c1)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","[O-][N+](=O)c1ccc(Cl)c(c1)[N+]([O-])=O",201.978134256,13,2.428,86.28,0.0605631966853731,0.036,0.0482815983426866,0,0
"LM-22A4","tropomyosin receptor kinase inhibitor","NTRK2","OCCNC(=O)c1cc(cc(c1)C(=O)NCCO)C(=O)NCCO, OCCNC(=O)c1cc(cc(c1)C(=O)NCCO)C(=O)NCCO, OCCNC(=O)c1cc(cc(c1)C(=O)NCCO)C(=O)NCCO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OCCNC(=O)c1cc(cc(c1)C(=O)NCCO)C(=O)NCCO",339.143035392,24,-1.89,147.99,0.00253198173486952,0.094,0.0482659908674348,0,0
"MLN2480","RAF inhibitor","","C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(s1)C(=O)Nc1cc(c(Cl)cn1)C(F)(F)F, C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(s1)C(=O)Nc1cc(c(Cl)cn1)C(F)(F)F, C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(s1)C(=O)Nc1cc(c(Cl)cn1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(s1)C(=O)Nc1cc(c(Cl)cn1)C(F)(F)F",505.010233644,32,1.816,164.02,0.000520040003604258,0.096,0.0482600200018021,0,0
"las101057","adenosine receptor antagonist","ADORA2B","Fc1cnccc1-c1ncc(NC(=O)C2CC2)nc1-c1cccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","pulmonary","asthma","Fc1cnccc1-c1ncc(NC(=O)C2CC2)nc1-c1cccnc1",335.118238288,25,1.421,80.66,0.0363894149052975,0.06,0.0481947074526487,0,0
"AZD8186","PI3K inhibitor","PIK3CB, PIK3CD","C[C@@H](Nc1cc(F)cc(F)c1)c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C, C[C@@H](Nc1cc(F)cc(F)c1)c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C, C[C@@H](Nc1cc(F)cc(F)c1)c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C, C[C@@H](Nc1cc(F)cc(F)c1)c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@@H](Nc1cc(F)cc(F)c1)c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C",457.18131272,33,4.777,75.02,0.0323769557328246,0.064,0.0481884778664123,0,0
"CC-223","mTOR inhibitor","MTOR","CO[C@H]1CC[C@@H](CC1)N1C(=O)CNc2ncc(nc12)-c1ccc(nc1)C(C)(C)O |r|, CO[C@H]1CC[C@@H](CC1)N1C(=O)CNc2ncc(nc12)-c1ccc(nc1)C(C)(C)O |r|, CO[C@H]1CC[C@@H](CC1)N1C(=O)CNc2ncc(nc12)-c1ccc(nc1)C(C)(C)O |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CO[C@H]1CC[C@@H](CC1)N1C(=O)CNc2ncc(nc12)-c1ccc(nc1)C(C)(C)O |r|",397.211389724,29,1.704,100.47,0.0143560453323666,0.082,0.0481780226661833,0,0
"SD-2590","matrix metalloprotease inhibitor","MMP1, MMP13, MMP2","COCCN1CCC(CC1)(C(=O)NO)S(=O)(=O)c1ccc(Oc2ccc(OC(F)(F)F)cc2)cc1, COCCN1CCC(CC1)(C(=O)NO)S(=O)(=O)c1ccc(Oc2ccc(OC(F)(F)F)cc2)cc1, COCCN1CCC(CC1)(C(=O)NO)S(=O)(=O)c1ccc(Oc2ccc(OC(F)(F)F)cc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COCCN1CCC(CC1)(C(=O)NO)S(=O)(=O)c1ccc(Oc2ccc(OC(F)(F)F)cc2)cc1",518.1334568,35,2.477,122.78,0.00231664471018145,0.094,0.0481583223550907,0,0
"LXS196","PKC inhibitor","","CC1(N)CCN(CC1)c1cccnc1NC(=O)c1nc(cnc1N)-c1ncccc1C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC1(N)CCN(CC1)c1cccnc1NC(=O)c1nc(cnc1N)-c1ncccc1C(F)(F)F",472.194692016,34,2.698,135.94,0.00428546838687619,0.092,0.0481427341934381,0,0
"WDR5-0103","histone lysine methyltransferase inhibitor","WDR5","COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1, COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1, COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1, COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1",383.18450628,28,2.816,71.11,0.0402815751083621,0.056,0.0481407875541811,0,0
"rigosertib","cell cycle inhibitor, PLK inhibitor","PLK1","COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1",451.13008776,31,0.112000000000001,128.77,0.00222881620313492,0.094,0.0481144081015675,0,0
"L-152804","neuropeptide receptor antagonist","NPY5R","CC1(C)CC(=O)C([C@@H]2C3=C(CC(C)(C)CC3=O)Oc3ccccc23)C(=O)C1 |&1:7,r,t:8|, CC1(C)CC(=O)C([C@@H]2C3=C(CC(C)(C)CC3=O)Oc3ccccc23)C(=O)C1 |&1:7,r,t:8|, CC1(C)CC(=O)C([C@@H]2C3=C(CC(C)(C)CC3=O)Oc3ccccc23)C(=O)C1 |&1:7,r,t:8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC1(C)CC(=O)C([C@@H]2C3=C(CC(C)(C)CC3=O)Oc3ccccc23)C(=O)C1 |&1:7",366.183109312,27,2.815,60.44,0.0602242491841851,0.036,0.0481121245920925,0,0
"ethacridine-lactate-monohydrate","DNA intercalating agent","","CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOc1ccc2nc3cc(N)ccc3c(N)c2c1",253.1215121,19,2.184,74.16,0.0862225395271012,0.01,0.0481112697635506,0,0
"BMS-690514","EGFR inhibitor, VEGFR inhibitor","EGFR, ERBB2, FLT3, KDR","COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1",368.196074008,27,1.786,100.94,0.0182167142076088,0.078,0.0481083571038044,0,0
"PG-9","acetylcholine receptor agonist","","C[C@@H](C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C)c1ccc(Br)cc1 |&1:5,7,10,&2:1,r,TLB:13:12:8.9:5.6.11|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C)c1ccc(Br)cc1 |&1:5",351.083391044,21,3.758,29.54,0.0561727990502862,0.04,0.0480863995251431,0,0
"pg-9 maleate","cholinergic receptor modulator","","CC(C(=O)OC1CC2CCC(C1)N2C)c1ccc(Br)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C(=O)OC1CC2CCC(C1)N2C)c1ccc(Br)cc1",351.083391044,21,3.758,29.54,0.0561727990502862,0.04,0.0480863995251431,0,0
"MSDC-0602K","mitochondrial pyruvate carrier modulator","","COc1cccc(c1)C(=O)COc1ccc(Cc2sc(O)nc2O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1cccc(c1)C(=O)COc1ccc(Cc2sc(O)nc2O)cc1",371.082743644,26,2.836,117.12,0.0120803568619873,0.084,0.0480401784309937,0,0
"SEN-1269","beta amyloid inhibitor","APP","CN(C)c1cccc(Oc2cnc(Nc3cccc(O)c3)nc2)c1, CN(C)c1cccc(Oc2cnc(Nc3cccc(O)c3)nc2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)c1cccc(Oc2cnc(Nc3cccc(O)c3)nc2)c1",322.142975816,24,2.953,70.51,0.0700781006682639,0.026,0.0480390503341319,0,0
"acetylspiramycin","other antibiotic","","[H][C@@]1(C[C@@](C)(O)[C@@H](O)[C@H](C)O1)O[C@@H]1[C@@H](C)O[C@@]([H])(O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](O[C@@]3([H])CC[C@@H]([C@@H](C)O3)N(C)C)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@]([H])(OC(C)=O)[C@@H]2OC)[C@H](O)[C@H]1N(C)C |t:42,44|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@@]1(C[C@@](C)(O)[C@@H](O)[C@H](C)O1)O[C@@H]1[C@@H](C)O[C@@]([H])(O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](O[C@@]3([H])CC[C@@H]([C@@H](C)O3)N(C)C)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@]([H])(OC(C)=O)[C@@H]2OC)[C@H](O)[C@H]1N(C)C |t:42",884.524569732,66,2.669,201.45,7.79988585593501e-05,0.096,0.0480389994292797,0,0
"SKLB-1028","Abl kinase inhibitor, EGFR inhibitor, FLT3 inhibitor","","CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc12",443.254591928,33,3.303,87.03,0.0240231734020356,0.072,0.0480115867010178,0,0
"PD-173212","calcium channel blocker","CACNA1B","CC(C)C[C@H](N(C)Cc1ccc(cc1)C(C)(C)C)C(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)NC(C)(C)C, CC(C)C[C@H](N(C)Cc1ccc(cc1)C(C)(C)C)C(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)NC(C)(C)C, CC(C)C[C@H](N(C)Cc1ccc(cc1)C(C)(C)C)C(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)NC(C)(C)C, CC(C)C[C@H](N(C)Cc1ccc(cc1)C(C)(C)C)C(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)NC(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)C[C@H](N(C)Cc1ccc(cc1)C(C)(C)C)C(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)NC(C)(C)C",599.408692556,44,8.791,70.67,0.0400145567592962,0.056,0.0480072783796481,0,0
"NO-ASA","cyclooxygenase inhibitor","PTGS2","CC(=O)Oc1ccccc1C(=O)Oc1cccc(CO[N+]([O-])=O)c1, CC(=O)Oc1ccccc1C(=O)Oc1cccc(CO[N+]([O-])=O)c1",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(=O)Oc1ccccc1C(=O)Oc1cccc(CO[N+]([O-])=O)c1",331.069201756,24,3.45,104.97,0.0300062441124122,0.066,0.0480031220562061,0,0
"GSK2256294A","epoxide hydolase inhibitor","EPHX2","CNc1nc(C)nc(N[C@H]2CCC[C@H](C2)C(=O)NCc2ccc(cc2C(F)(F)F)C#N)n1, CNc1nc(C)nc(N[C@H]2CCC[C@H](C2)C(=O)NCc2ccc(cc2C(F)(F)F)C#N)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CNc1nc(C)nc(N[C@H]2CCC[C@H](C2)C(=O)NCc2ccc(cc2C(F)(F)F)C#N)n1",447.199443048,32,2.779,115.62,0.00799803317473553,0.088,0.0479990165873678,0,0
"NSC-23766","Ras GTPase inhibitor","","CCN(CC)CCC[C@@H](C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1 |&1:8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN(CC)CCC[C@@H](C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1 |&1:8|",421.29539412,31,3.834,91.99,0.0259576792264326,0.07,0.0479788396132163,0,0
"leucylleucine-methyl-ester","","","COC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C",258.194342692,18,2.231,81.42,0.0536988013527816,0.042,0.0478494006763908,0,0
"AM211","prostaglandin inhibitor","","CCN(Cc1cc(ccc1-c1cc(CC(O)=O)ccc1OC)C(F)(F)F)C(=O)NCc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN(Cc1cc(ccc1-c1cc(CC(O)=O)ccc1OC)C(F)(F)F)C(=O)NCc1ccccc1",500.192292004,36,5.542,78.87,0.0256792699021741,0.07,0.047839634951087,0,0
"SB-756050","G protein-coupled receptor agonist","GPBAR1","COc1ccc(cc1OC)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)c1ccc(OC)c(OC)c1, COc1ccc(cc1OC)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)c1ccc(OC)c(OC)c1, COc1ccc(cc1OC)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)c1ccc(OC)c(OC)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1ccc(cc1OC)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)c1ccc(OC)c(OC)c1",500.128707856,33,1.55,128.44,0.00157122859351156,0.094,0.0477856142967558,0,0
"bay-85-8501","elastase inhibitor","ELANE","CN1[C@@H](C(C#N)=C(C)N(C1=O)c1cccc(c1)C(F)(F)F)c1ccc(cc1S(C)(=O)=O)C#N |a:2,t:5|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN1[C@@H](C(C#N)=C(C)N(C1=O)c1cccc(c1)C(F)(F)F)c1ccc(cc1S(C)(=O)=O)C#N |a:2",474.097346064,33,2.756,113.65,0.00552357714741189,0.09,0.0477617885737059,0,0
"phytosphingosine","","","CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO",317.292994108,22,5.027,86.71,0.0574753901700527,0.038,0.0477376950850264,0,0
"clamikalant","ATP-sensitive potassium channel antagonist","","CNC(=S)NS(=O)(=O)c1cc(CCNC(=O)c2cc(Cl)ccc2OC)ccc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CNC(=S)NS(=O)(=O)c1cc(CCNC(=O)c2cc(Cl)ccc2OC)ccc1OC",471.068940484,30,2.897,146.23,0.0014527765198051,0.094,0.0477263882599025,0,0
"UNC669","L3MBTL antagonist","L3MBTL1","Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1, Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1, Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1",337.07897436,20,2.017,36.44,0.0354289754703611,0.06,0.0477144877351805,0,0
"rislenemdaz","ionotropic glutamate receptor antagonist","","Cc1ccc(COC(=O)N2CC[C@H](CNc3ncccn3)[C@H](F)C2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(COC(=O)N2CC[C@H](CNc3ncccn3)[C@H](F)C2)cc1",358.180504196,26,2.945,67.35,0.051418465866449,0.044,0.0477092329332245,0,0
"KD025","rho associated kinase inhibitor","ROCK2","CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1, CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1, CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1, CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1, CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1, CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1",452.196074008,34,5.461,104.82,0.0273631184989663,0.068,0.0476815592494832,0,0
"CEP-40783","AXL kinase inhibitor","","COc1cc2nccc(Oc3ccc(NC(=O)c4cn(C(C)C)c(=O)n(-c5ccc(F)cc5)c4=O)cc3F)c2cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2nccc(Oc3ccc(NC(=O)c4cn(C(C)C)c(=O)n(-c5ccc(F)cc5)c4=O)cc3F)c2cc1OC",588.182040992,43,5.65,113.68,0.00733813098440224,0.088,0.0476690654922011,0,0
"vx-984","dna repair enzyme inhibitor","","[2H]c1nc(C)nc([2H])c1-c1cc(NC[C@@H](C)c2cccc3c(ccnc23)C(=O)NC)ncn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","breast cancer","[2H]c1nc(C)nc([2H])c1-c1cc(NC[C@@H](C)c2cccc3c(ccnc23)C(=O)NC)ncn1",415.208961848,33,1.823,105.58,0.0213119034351464,0.074,0.0476559517175732,0,0
"RU-SKI-43","hedgehog pathway inhibitor","HHAT","CC[C@@H](C)CNCC(=O)N1CCc2sccc2[C@@H]1COc1cccc(C)c1 |&1:2,&2:17|, CC[C@@H](C)CNCC(=O)N1CCc2sccc2[C@@H]1COc1cccc(C)c1 |&1:2,&2:17|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC[C@@H](C)CNCC(=O)N1CCc2sccc2[C@@H]1COc1cccc(C)c1 |&1:2",386.2027992,27,3.821,69.81,0.0392907393661903,0.056,0.0476453696830951,0,0
"taletrectinib","proto-oncogene tyrosine protein kinase inhibitor","ROS1","C[C@@H](N)COc1ccc(cc1)-c1cnc2ccc(N[C@H](C)c3cccc(F)c3)nn12.OC(=O)CCCCC(=O)O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","oncology","non-small cell lung cancer (nsclc)","C[C@@H](N)COc1ccc(cc1)-c1cnc2ccc(N[C@H](C)c3cccc(F)c3)nn12.OC(=O)CCCCC(=O)O",551.254397408,40,5.184,152.07,0.00326898980131325,0.092,0.0476344949006566,0,0
"XL147","PI3K inhibitor","PIK3CA, PIK3CD, PIK3CG","Cc1ccc(cc1)S(=O)(=O)Nc1nc2ccccc2nc1Nc1ccc2nsnc2c1, Cc1ccc(cc1)S(=O)(=O)Nc1nc2ccccc2nc1Nc1ccc2nsnc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1ccc(cc1)S(=O)(=O)Nc1nc2ccccc2nc1Nc1ccc2nsnc2c1",448.077615752,31,4.947,146.38,0.00520329276107787,0.09,0.0476016463805389,0,0
"azaserine","purine antagonist","","N[C@@H](COC(=O)C[N+]#N)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@@H](COC(=O)C[N+]#N)C(O)=O",174.050932156091,12,-4.298,117.77,0.00915480264812273,0.086,0.0475774013240614,0,0
"DSR-6434","toll-like receptor agonist","TLR7","CCCCNc1nc(N)c2[nH]c(=O)n(Cc3ccc(OCCN(C)C)nc3)c2n1, CCCCNc1nc(N)c2[nH]c(=O)n(Cc3ccc(OCCN(C)C)nc3)c2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCNc1nc(N)c2[nH]c(=O)n(Cc3ccc(OCCN(C)C)nc3)c2n1",400.233522136,29,1.626,126.98,0.00713842813896156,0.088,0.0475692140694808,0,0
"esaxerenone","mineralocorticoid receptor antagonist","","Cc1c(cn(CCO)c1-c1ccccc1C(F)(F)F)C(=O)Nc1ccc(cc1)S(C)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1c(cn(CCO)c1-c1ccccc1C(F)(F)F)C(=O)Nc1ccc(cc1)S(C)(=O)=O",466.117412812,32,3.382,96.78,0.00911956266847408,0.086,0.047559781334237,0,0
"hematoporphyrin (dihydrochloride)","","","CC(O)c1c(C)c2cc3[nH]c(cc4nc(cc5[nH]c(cc1n2)c(C)c5CCC(O)=O)c(CCC(O)=O)c4C)c(C)c3C(C)O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CC(O)c1c(C)c2cc3[nH]c(cc4nc(cc5[nH]c(cc1n2)c(C)c5CCC(O)=O)c(CCC(O)=O)c4C)c(C)c3C(C)O",598.279134936,44,3.527,172.42,0.00111159566695709,0.094,0.0475557978334785,0,0
"shikimic-acid","","","O[C@@H]1CC(=C[C@@H](O)[C@@H]1O)C(O)=O |a:1,&1:5,&2:7,c:3|, O[C@@H]1CC(=C[C@@H](O)[C@@H]1O)C(O)=O |a:1,&1:5,&2:7,c:3|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O[C@@H]1CC(=C[C@@H](O)[C@@H]1O)C(O)=O |a:1",174.05282342,12,-1.094,97.99,0.0310747324505417,0.064,0.0475373662252709,0,0
"kainic-acid","kainate receptor agonist","GRIA1, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5","CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O, CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O",213.10010796,15,-0.213,86.63,0.0390675601796427,0.056,0.0475337800898214,0,0
"BMS-191095","KATP activator, potassium channel agonist","","CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N(Cc1ncc[nH]1)c1ccc(Cl)cc1)C#N, CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N(Cc1ncc[nH]1)c1ccc(Cl)cc1)C#N, CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N(Cc1ncc[nH]1)c1ccc(Cl)cc1)C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N(Cc1ncc[nH]1)c1ccc(Cl)cc1)C#N",408.135303592,29,3.959,85.17,0.0270553321451804,0.068,0.0475276660725902,0,0
"GSK2193874","transient receptor potential channel antagonist","TRPV4","FC(F)(F)c1cccc(c1)-c1nc2cc(Br)ccc2c(C(=O)NC2(CC2)c2ccccc2)c1CN1CCC(CC1)N1CCCCC1, FC(F)(F)c1cccc(c1)-c1nc2cc(Br)ccc2c(C(=O)NC2(CC2)c2ccccc2)c1CN1CCC(CC1)N1CCCCC1, FC(F)(F)c1cccc(c1)-c1nc2cc(Br)ccc2c(C(=O)NC2(CC2)c2ccccc2)c1CN1CCC(CC1)N1CCCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)c1cccc(c1)-c1nc2cc(Br)ccc2c(C(=O)NC2(CC2)c2ccccc2)c1CN1CCC(CC1)N1CCCCC1",690.218108596,46,8.299,48.47,0.0110513915018993,0.084,0.0475256957509497,0,0
"A-485","histone acetyltransferase inhibitor","","CNC(=O)Nc1ccc2c(CC[C@@]22OC(=O)N(CC(=O)N(Cc3ccc(F)cc3)[C@@H](C)C(F)(F)F)C2=O)c1, CNC(=O)Nc1ccc2c(CC[C@@]22OC(=O)N(CC(=O)N(Cc3ccc(F)cc3)[C@@H](C)C(F)(F)F)C2=O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CNC(=O)Nc1ccc2c(CC[C@@]22OC(=O)N(CC(=O)N(Cc3ccc(F)cc3)[C@@H](C)C(F)(F)F)C2=O)c1",536.168282748,38,3.189,108.05,0.00502118933664257,0.09,0.0475105946683213,0,0
"UBP-310","glutamate receptor antagonist","GRIK1, GRIK5","Cc1cn(C[C@H](N)C(O)=O)c(=O)n(Cc2ccsc2C(O)=O)c1=O, Cc1cn(C[C@H](N)C(O)=O)c(=O)n(Cc2ccsc2C(O)=O)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cn(C[C@H](N)C(O)=O)c(=O)n(Cc2ccsc2C(O)=O)c1=O",353.0681562,24,-1.994,172.86,0.00099552666479881,0.094,0.0474977633323994,0,0
"besifovir","antiviral","GPT","Nc1ncc2ncn(CC3(CC3)OCP(O)(O)=O)c2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","infectious disease","hepatitis b","Nc1ncc2ncn(CC3(CC3)OCP(O)(O)=O)c2n1",299.078340558,20,-1.571,146.19,0.00295865952679888,0.092,0.0474793297633994,0,0
"PCA-4248","platelet activating factor receptor antagonist","PTAFR","COC(=O)C1=C(C)NC(C)=C([C@@H]1C)C(=O)OCCSc1ccccc1 |&1:11,r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1C)C(=O)OCCSc1ccccc1 |&1:11,r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1C)C(=O)OCCSc1ccccc1 |&1:11,r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1C)C(=O)OCCSc1ccccc1 |&1:11,r,c:4,9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COC(=O)C1=C(C)NC(C)=C([C@@H]1C)C(=O)OCCSc1ccccc1 |&1:11",361.134779216,25,4.66,89.93,0.0349312896781637,0.06,0.0474656448390818,0,0
"ONO-4059","Bruton's tyrosine kinase (BTK) inhibitor","BTK","CC#CC(=O)N1CC[C@H](C1)n1c2ncnc(N)c2n(-c2ccc(Oc3ccccc3)cc2)c1=O, CC#CC(=O)N1CC[C@H](C1)n1c2ncnc(N)c2n(-c2ccc(Oc3ccccc3)cc2)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC#CC(=O)N1CC[C@H](C1)n1c2ncnc(N)c2n(-c2ccc(Oc3ccccc3)cc2)c1=O",454.175338564,34,2.838,108.27,0.012848852759279,0.082,0.0474244263796395,0,0
"KX2-391","SRC inhibitor, tubulin polymerization inhibitor","SRC","O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1, O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1, O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1, O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1",431.220891788,32,3.094,63.69,0.0408040135395645,0.054,0.0474020067697823,0,0
"XL019","JAK inhibitor","JAK1, JAK2, JAK3","O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1, O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1, O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1, O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1, O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1, O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1",444.227374136,33,2.776,91.41,0.0187340812133516,0.076,0.0473670406066758,0,0
"PF-8380","autotaxin inhibitor","ENPP2","Clc1cc(Cl)cc(COC(=O)N2CCN(CCC(=O)c3ccc4[nH]c(=O)oc4c3)CC2)c1, Clc1cc(Cl)cc(COC(=O)N2CCN(CCC(=O)c3ccc4[nH]c(=O)oc4c3)CC2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1cc(Cl)cc(COC(=O)N2CCN(CCC(=O)c3ccc4[nH]c(=O)oc4c3)CC2)c1",477.085826132,32,3.108,95.85,0.00671893921097252,0.088,0.0473594696054863,0,0
"SR-33805","calcium channel blocker","","COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC, COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC, COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC, COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC, COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC",564.26579338,40,6.168,78.38,0.0166040373892597,0.078,0.0473020186946298,0,0
"tesaglitazar","insulin sensitizer, PPAR receptor agonist","PPARA, PPARG","CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(O)=O, CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(O)=O, CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(O)=O",408.124274108,28,2.254,107.51,0.00858782953588368,0.086,0.0472939147679418,0,0
"mimosine","DNA replication inhibitor","CCL2, SHMT1, SHMT2, TYR","N[C@@H](Cn1ccc(=O)c(O)c1)C(O)=O, N[C@@H](Cn1ccc(=O)c(O)c1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@@H](Cn1ccc(=O)c(O)c1)C(O)=O",198.0640568,14,-1.267,105.55,0.0225167973644897,0.072,0.0472583986822449,0,0
"AZD8931","EGFR inhibitor","EGFR, ERBB2, ERBB3","CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC, CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC, CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC, CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC, CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC, CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC",473.16299556,33,2.937,88.61,0.0104987234868474,0.084,0.0472493617434237,0,0
"JW-642","monoacylglycerol lipase inhibitor","MGLL","FC(F)(F)C(OC(=O)N1CCN(Cc2cccc(Oc3ccccc3)c2)CC1)C(F)(F)F, FC(F)(F)C(OC(=O)N1CCN(Cc2cccc(Oc3ccccc3)c2)CC1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)C(OC(=O)N1CCN(Cc2cccc(Oc3ccccc3)c2)CC1)C(F)(F)F",462.13781182,32,5.744,42.01,0.0604340522806557,0.034,0.0472170261403279,0,0
"BCX-1470","complement inhibitor, serine protease inhibitor","CFD","NC(=N)c1cc2ccc(OC(=O)c3cccs3)cc2s1, NC(=N)c1cc2ccc(OC(=O)c3cccs3)cc2s1, NC(=N)c1cc2ccc(OC(=O)c3cccs3)cc2s1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","NC(=N)c1cc2ccc(OC(=O)c3cccs3)cc2s1",302.01836956,20,2.596,132.65,0.0104128385492662,0.084,0.0472064192746331,0,0
"SC-12267","dihydroorotate dehydrogenase inhibitor","IL17A","COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|, COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|, COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|, COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|, COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|, COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|",355.121986276,26,3.337,75.63,0.0503242162714803,0.044,0.0471621081357402,0,0
"crolibulin","tubulin polymerization inhibitor","","COc1cc(cc(Br)c1OC)[C@H]1C(C#N)=C(N)Oc2c(N)c(N)ccc12 |t:15|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","COc1cc(cc(Br)c1OC)[C@H]1C(C#N)=C(N)Oc2c(N)c(N)ccc12 |t:15|",416.048402504,26,1.626,129.54,0.0023198859936001,0.092,0.0471599429968,0,0
"PF-06928215","cyclic GMP-AMP synthase inhibitor","","OC(=O)[C@@H]1CCCC[C@@H]1NC(=O)c1cnn2c(O)cc(nc12)-c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)[C@@H]1CCCC[C@@H]1NC(=O)c1cnn2c(O)cc(nc12)-c1ccccc1",380.14845512,28,3.522,116.82,0.018259199034275,0.076,0.0471295995171375,0,0
"FN-1501","tyrosine kinase inhibitor","","CN1CCN(Cc2ccc(NC(=O)c3[nH]ncc3Nc3ncnc4[nH]ccc34)cc2)CC1, CN1CCN(Cc2ccc(NC(=O)c3[nH]ncc3Nc3ncnc4[nH]ccc34)cc2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN1CCN(Cc2ccc(NC(=O)c3[nH]ncc3Nc3ncnc4[nH]ccc34)cc2)CC1",431.21820642,32,2.452,117.86,0.0102460750761588,0.084,0.0471230375380794,0,0
"pf-06952229","antineoplastic agent","TGFBR1","CC(C)c1cnc(cc1Nc1ccncc1C(=O)NC(CO)CO)-c1cc(Cl)ccc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","breast cancer","CC(C)c1cnc(cc1Nc1ccncc1C(=O)NC(CO)CO)-c1cc(Cl)ccc1F",458.152096528,32,3.189,107.37,0.00823925027085431,0.086,0.0471196251354272,0,0
"THZ1","CDK inhibitor","CDK7","CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1",565.199300816,41,4.746,115.04,0.00623104124429415,0.088,0.0471155206221471,0,0
"5'-chloro-5'-deoxy-ENBA-(+/-)","adenosine receptor agonist","ADORA1","O[C@@H]1[C@@H](CCl)O[C@H]([C@@H]1O)n1cnc2c(N[C@H]3C[C@@H]4CC[C@H]3C4)ncnc12 |a:1,2,6,7,&1:17,20,&2:15|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O[C@@H]1[C@@H](CCl)O[C@H]([C@@H]1O)n1cnc2c(N[C@H]3C[C@@H]4CC[C@H]3C4)ncnc12 |a:1",379.141117244,26,1.815,105.32,0.0102153081965264,0.084,0.0471076540982632,0,0
"linifanib","PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK","Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1, Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1, Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1, Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1, Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1, Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1",375.149538416,28,5.133,95.83,0.048184752221873,0.046,0.0470923761109365,0,0
"ibiglustat","glucosylceramidase inhibitor","","CC(C)(NC(=O)O[C@@H]1CN2CCC1CC2)c1csc(n1)-c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(NC(=O)O[C@@H]1CN2CCC1CC2)c1csc(n1)-c1ccc(F)cc1",389.157326228,27,3.275,82.7,0.0241248076353369,0.07,0.0470624038176684,0,0
"PFI-4","bromodomain inhibitor","BRPF1","COc1ccccc1C(=O)Nc1cc2n(C)c(=O)n(C)c2cc1N1CCCC1, COc1ccccc1C(=O)Nc1cc2n(C)c(=O)n(C)c2cc1N1CCCC1, COc1ccccc1C(=O)Nc1cc2n(C)c(=O)n(C)c2cc1N1CCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccccc1C(=O)Nc1cc2n(C)c(=O)n(C)c2cc1N1CCCC1",380.184840628,28,2.465,68.5,0.0421030713432324,0.052,0.0470515356716162,0,0
"antimony-potassium","","","[H][C@]12O[SbH]3(OC1=O)OC(=O)[C@]([H])(O3)[C@@]1([H])O[SbH]3(OC(=O)[C@]2([H])O3)OC1=O |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","[H][C@]12O[SbH]3(OC1=O)OC(=O)[C@]([H])(O3)[C@@]1([H])O[SbH]3(OC(=O)[C@]2([H])O3)OC1=O |r|",535.793557032,26,-0.86,142.12,5.3889357389086e-05,0.094,0.0470269446786945,0,0
"tno155","tyrosine phosphatase inhibitor","PTPN11","C[C@@H]1OCC2(CCN(CC2)c2cnc(Sc3ccnc(N)c3Cl)c(N)n2)[C@@H]1N |a:1,26|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","oncology","colorectal cancer","C[C@@H]1OCC2(CCN(CC2)c2cnc(Sc3ccnc(N)c3Cl)c(N)n2)[C@@H]1N |a:1",421.145157068,28,2.082,154.5,0.00204221246526367,0.092,0.0470211062326318,0,0
"capreomycin (sulfate)","","","CC1NC(=O)C(N)CNC(=O)C(NC(=O)\C(NC(=O)C(CNC(=O)CC(N)CCCN)NC1=O)=C/NC(N)=O)C1CCNC(=N)N1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CC1NC(=O)C(N)CNC(=O)C(NC(=O)\C(NC(=O)C(CNC(=O)CC(N)CCCN)NC1=O)=C/NC(N)=O)C1CCNC(=N)N1",652.351739748,46,-3.148,355.69,1.34511139760506e-06,0.094,0.0470006725556988,0,0
"CVT-10216","aldehyde dehydrogenase inhibitor","ALDH2","CS(=O)(=O)Nc1ccc(cc1)-c1coc2cc(OCc3cccc(c3)C(O)=O)ccc2c1=O, CS(=O)(=O)Nc1ccc(cc1)-c1coc2cc(OCc3cccc(c3)C(O)=O)ccc2c1=O, CS(=O)(=O)Nc1ccc(cc1)-c1coc2cc(OCc3cccc(c3)C(O)=O)ccc2c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CS(=O)(=O)Nc1ccc(cc1)-c1coc2cc(OCc3cccc(c3)C(O)=O)ccc2c1=O",465.088222948,33,5.029,131.29,0.00793001118601636,0.086,0.0469650055930082,0,0
"sodium-danshensu","","","O[C@@H](Cc1ccc(O)c(O)c1)C(O)=O |&1:1|, O[C@@H](Cc1ccc(O)c(O)c1)C(O)=O |&1:1|, O[C@@H](Cc1ccc(O)c(O)c1)C(O)=O |&1:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O[C@@H](Cc1ccc(O)c(O)c1)C(O)=O |&1:1|",198.05282342,14,0.203,97.99,0.0378848822308575,0.056,0.0469424411154287,0,0
"AZD3463","ALK tyrosine kinase receptor inhibitor, insulin growth factor receptor inhibitor","ALK, IGF1R","COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1",448.1778371,32,4.402,92.09,0.0198346776457,0.074,0.04691733882285,0,0
"PD-0325901","MEK inhibitor","MAP2K1","OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F, OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F, OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F",481.995039588,26,3.395,90.82,0.00181634419586314,0.092,0.0469081720979316,0,0
"PF-04620110","diacylglycerol O acyltransferase inhibitor","DGAT1","Nc1ncnc2OCCN(c3ccc(cc3)[C@H]3CC[C@H](CC(O)=O)CC3)C(=O)c12 |r|, Nc1ncnc2OCCN(c3ccc(cc3)[C@H]3CC[C@H](CC(O)=O)CC3)C(=O)c12 |r|, Nc1ncnc2OCCN(c3ccc(cc3)[C@H]3CC[C@H](CC(O)=O)CC3)C(=O)c12 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Nc1ncnc2OCCN(c3ccc(cc3)[C@H]3CC[C@H](CC(O)=O)CC3)C(=O)c12 |r|",396.179755248,29,3.161,118.64,0.0138124585522367,0.08,0.0469062292761184,0,0
"PF-915275","11-beta hydroxysteroid dehydrogenase inhibitor","HSD11B1","Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1, Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1, Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1, Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1",350.083746688,25,3.765,117.25,0.0196950635361682,0.074,0.0468475317680841,0,0
"XL647","EGFR inhibitor, VEGFR inhibitor","EGFR, EPHB4, ERBB2, FLT4, KDR","COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1, COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1, COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1, COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1, COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1",490.13385962,33,4.836,59.51,0.0216416719585616,0.072,0.0468208359792808,0,0
"KI-20227","c-Fms inhibitor","CSF1R, KDR, KIT, PDGFRB","COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)N[C@@H](C)c1nccs1 |&1:27,r|, COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)N[C@@H](C)c1nccs1 |&1:27,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)N[C@@H](C)c1nccs1 |&1:27",480.146740868,34,2.418,132.07,0.00362115603421005,0.09,0.046810578017105,0,0
"AZD5438","CDK inhibitor","KCNH2","CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1",371.141595912,26,2.094,98.15,0.0155554467924847,0.078,0.0467777233962424,0,0
"PF-04457845","FAAH inhibitor","FAAH","FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1",455.15690954,33,3.738,80.24,0.023548014827873,0.07,0.0467740074139365,0,0
"GDC-0941","PI3K inhibitor","PIK3CA, PIK3CB, PIK3CD, PIK3CG","CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1",513.161679724,35,2.33,144.17,0.00153393400965424,0.092,0.0467669670048271,0,0
"CR8-(R)","CDK inhibitor","CCNA2","CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1",431.243358548,32,4.283,100.78,0.0235215602553939,0.07,0.0467607801276969,0,0
"CCT129202","Aurora kinase inhibitor","AURKA, AURKB, AURKC","CN(C)c1ccc(cc1)-c1nc2ncc(Cl)c(N3CCN(CC(=O)Nc4nccs4)CC3)c2[nH]1, CN(C)c1ccc(cc1)-c1nc2ncc(Cl)c(N3CCN(CC(=O)Nc4nccs4)CC3)c2[nH]1, CN(C)c1ccc(cc1)-c1nc2ncc(Cl)c(N3CCN(CC(=O)Nc4nccs4)CC3)c2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)c1ccc(cc1)-c1nc2ncc(Cl)c(N3CCN(CC(=O)Nc4nccs4)CC3)c2[nH]1",496.1560561,34,2.859,121.52,0.00351442929793088,0.09,0.0467572146489654,0,0
"BAY-61-3606","SYK inhibitor","SYK","COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1, COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1, COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1, COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1, COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1",390.144038436,29,3.355,116.66,0.0174558895053507,0.076,0.0467279447526754,0,0
"NVP-TAE684","ALK tyrosine kinase receptor inhibitor","ALK, INSR","COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1",613.26018682,42,5.548,111.31,0.0033101364643107,0.09,0.0466550682321553,0,0
"BIBU-1361","EGFR inhibitor","EGFR","CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1",443.200049764,31,4.097,70.07,0.0272242929950252,0.066,0.0466121464975126,0,0
"LX7101","LIM kinase inhibitor, rho associated kinase inhibitor","LIMK2, ROCK1, ROCK2","CN(C)C(=O)Oc1cccc(NC(=O)C2(CN)CCN(CC2)c2ncnc3[nH]cc(C)c23)c1, CN(C)C(=O)Oc1cccc(NC(=O)C2(CN)CCN(CC2)c2ncnc3[nH]cc(C)c23)c1, CN(C)C(=O)Oc1cccc(NC(=O)C2(CN)CCN(CC2)c2ncnc3[nH]cc(C)c23)c1, CN(C)C(=O)Oc1cccc(NC(=O)C2(CN)CCN(CC2)c2ncnc3[nH]cc(C)c23)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","CN(C)C(=O)Oc1cccc(NC(=O)C2(CN)CCN(CC2)c2ncnc3[nH]cc(C)c23)c1",451.233187788,33,1.689,129.47,0.0050918696275414,0.088,0.0465459348137707,0,0
"CUDC-907","PI3K inhibitor","HDAC2, PIK3R1","COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1, COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1, COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1, COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1, COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1",508.164122248,36,1.616,166.96,0.00107760112890755,0.092,0.0465388005644538,0,0
"nicaraven","free radical scavenger","","C[C@@H](CNC(=O)c1cccnc1)NC(=O)c1cccnc1 |&1:1,r|, C[C@@H](CNC(=O)c1cccnc1)NC(=O)c1cccnc1 |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C[C@@H](CNC(=O)c1cccnc1)NC(=O)c1cccnc1 |&1:1",284.127325752,21,0.6,83.98,0.0370636719861727,0.056,0.0465318359930863,0,0
"CHIR-98014","glycogen synthase kinase inhibitor","GSK3A, GSK3B","Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O, Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O, Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O, Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O",485.088226144,33,4.781,149.71,0.00303286549290518,0.09,0.0465164327464526,0,0
"orotic-acid","","DHODH","OC(=O)c1cc(=O)[nH]c(=O)[nH]1, OC(=O)c1cc(=O)[nH]c(=O)[nH]1, OC(=O)c1cc(=O)[nH]c(=O)[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)c1cc(=O)[nH]c(=O)[nH]1",156.017106608,11,-0.475,103.02,0.039024371299813,0.054,0.0465121856499065,0,0
"iofendylate","radiopaque medium","","CCOC(=O)CCCCCCCCC(C)C1=CC=C(C=C1)I",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","radiology","mri contrast agent","CCOC(=O)CCCCCCCCC(C)C1=CC=C(C=C1)I",416.121228168,22,6.832,26.3,0.034994715264237,0.058,0.0464973576321185,0,0
"talabostat","dipeptidyl peptidase inhibitor, fibroblast activation protein inhibitor","DPP4","CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O, CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O, CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O",214.148872868,15,-0.567,86.79,0.0349508313593418,0.058,0.0464754156796709,0,0
"icaritin","PPAR receptor antagonist","PDE5A","COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O",368.12598836,27,5.68,100.13,0.0469161893893372,0.046,0.0464580946946686,0,0
"Ro-19-4605","GABA benzodiazepine site receptor inverse agonist","GABRA1, GABRA2, GABRA3, GABRA5","CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C, CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C, CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C, CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C",319.099062404,22,2.844,92.67,0.0289145148803491,0.064,0.0464572574401745,0,0
"donitriptan","serotonin receptor agonist","HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR5A, HTR6","NCCc1c[nH]c2ccc(OCC(=O)N3CCN(CC3)c3ccc(cc3)C#N)cc12, NCCc1c[nH]c2ccc(OCC(=O)N3CCN(CC3)c3ccc(cc3)C#N)cc12, NCCc1c[nH]c2ccc(OCC(=O)N3CCN(CC3)c3ccc(cc3)C#N)cc12, NCCc1c[nH]c2ccc(OCC(=O)N3CCN(CC3)c3ccc(cc3)C#N)cc12",0,0,0,0,0,0,0,0,1,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NCCc1c[nH]c2ccc(OCC(=O)N3CCN(CC3)c3ccc(cc3)C#N)cc12",403.20082504,30,2.293,98.38,0.0189104561257406,0.074,0.0464552280628703,0,0
"IMREG-1","","","N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(O)=O, N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(O)=O",295.116820644,21,-3.441,141.75,0.00286965739448727,0.09,0.0464348286972436,0,0
"SX-011","MAP kinase inhibitor","MAPK14","CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(cc12)C(=O)N1CCC(Cc2ccc(F)cc2)CC1, CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(cc12)C(=O)N1CCC(Cc2ccc(F)cc2)CC1, CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(cc12)C(=O)N1CCC(Cc2ccc(F)cc2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(cc12)C(=O)N1CCC(Cc2ccc(F)cc2)CC1",483.172497624,34,4.705,62.62,0.0287876433395896,0.064,0.0463938216697948,0,0
"cariporide","sodium/hydrogen exchanger inhibitor","SLC9A1","CC(C)c1ccc(cc1S(C)(=O)=O)C(=O)N=C(N)N",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(C)c1ccc(cc1S(C)(=O)=O)C(=O)N=C(N)N",283.099062404,19,1.695,123.99,0.012709833762923,0.08,0.0463549168814615,0,0
"KN-62","calcium/calmodulin dependent protein kinase inhibitor, purinergic receptor antagonist","AKT1, CAMK2A, CHEK1, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, P2RX7, PRKCA, ROCK1, RPS6KB1, SGK1","CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(CC1)c1ccccc1)S(=O)(=O)c1cccc2cnccc12 |&1:2,r|, CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(CC1)c1ccccc1)S(=O)(=O)c1cccc2cnccc12 |&1:2,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(CC1)c1ccccc1)S(=O)(=O)c1cccc2cnccc12 |&1:2",721.20287584,51,4.482,146.84,0.000675368844669668,0.092,0.0463376844223348,0,0
"PU-H71","HSP inhibitor","HSP90AA1","CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12, CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12, CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12, CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12",512.049142912,28,3.584,125.41,0.000660166406684853,0.092,0.0463300832033424,0,0
"C-021","CC chemokine receptor antagonist","CCR4","COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1, COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1, COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1, COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1, COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1, COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1",467.326025552,34,5.734,62.75,0.05263530971771,0.04,0.046317654858855,0,0
"CGS-21680","adenosine receptor agonist","ADORA1, ADORA2A, ADORA2B, ADORA3","CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)nc(NCCc3ccc(CCC(O)=O)cc3)nc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)nc(NCCc3ccc(CCC(O)=O)cc3)nc12",499.217931648,36,1.22,197.74,0.000593577163500348,0.092,0.0462967885817502,0,0
"5-[({[1-(2-chloroethyl)-2-oxohydrazino]carbonyl}amino)methyl]-2-methyl-4-pyrimidinamine hydrochloride","","","Cc1ncc(CNC(=O)N(CCCl)[N+][O-])c(N)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","Cc1ncc(CNC(=O)N(CCCl)[N+][O-])c(N)n1",272.078851336,18,-0.786,107.2,0.0105720994807644,0.082,0.0462860497403822,0,0
"peposertib","DNA dependent protein kinase inhibitor","","COc1ccc(nn1)[C@@H](O)c1cc(c(F)cc1Cl)-c1ncnc2cc(ccc12)N1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","COc1ccc(nn1)[C@@H](O)c1cc(c(F)cc1Cl)-c1ncnc2cc(ccc12)N1CCOCC1",481.131695432,34,3.239,93.49,0.0105076766319777,0.082,0.0462538383159889,0,0
"LB-100","protein phosphatase inhibitor","","CN1CCN(CC1)C(=O)[C@@H]1[C@H]2CC[C@H](O2)[C@@H]1C(O)=O |&1:10,13,&2:15,&3:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN1CCN(CC1)C(=O)[C@@H]1[C@H]2CC[C@H](O2)[C@@H]1C(O)=O |&1:10",268.14230712,19,-1.215,70.08,0.0305007859148818,0.062,0.0462503929574409,0,0
"lb-100","protein phosphatase inhibitor","PPP5C","CN1CCN(CC1)C(=O)C1C2CCC(O2)C1C(O)=O, CN1CCN(CC1)C(=O)[C@H]1[C@H]2CC[C@H](O2)[C@@H]1C(O)=O |&1:15,&2:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"phase 2","neurology","depression","CN1CCN(CC1)C(=O)C1C2CCC(O2)C1C(O)=O",268.14230712,19,-1.215,70.08,0.0305007859148818,0.062,0.0462503929574409,0,0
"sulfanilate-zinc","","","Nc1ccc(cc1)S(=O)(=O)O[Zn]OS(=O)(=O)c1ccc(N)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1ccc(cc1)S(=O)(=O)O[Zn]OS(=O)(=O)c1ccc(N)cc1",407.942820304,23,-0.402,155.54,0.000470292157228127,0.092,0.0462351460786141,0,0
"BX-795","IKK inhibitor","CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1","Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1, Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1, Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1, Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1",591.091342072,34,3.29,139.52,0.000266774246745378,0.092,0.0461333871233727,0,0
"S-trityl-L-cysteine","mitotic kinesin inhibitor","","N[C@H](CSC(c1ccccc1)(c1ccccc1)c1ccccc1)C(O)=O, N[C@H](CSC(c1ccccc1)(c1ccccc1)c1ccccc1)C(O)=O, N[C@H](CSC(c1ccccc1)(c1ccccc1)c1ccccc1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@H](CSC(c1ccccc1)(c1ccccc1)c1ccccc1)C(O)=O",363.129299912,26,2.887,88.62,0.0281781182481988,0.064,0.0460890591240994,0,0
"T-0901317","LXR agonist","NCOA1, NCOA2, NR1H2, NR1H3, NR1I2, RXRB","OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F",481.039418224,31,6.532,65.99,0.0221206856877894,0.07,0.0460603428438947,0,0
"saracatinib","SRC inhibitor","ABL1, LCK, SRC, YES1","CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1",541.209196804,38,2.814,90.44,0.00610015219561997,0.086,0.04605007609781,0,0
"neohesperidin","","","[H][C@@]1(O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(OC)c(O)c2)O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@@]1(O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(OC)c(O)c2)O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O",610.189770388,44,-0.464,234.29,7.49215003315743e-05,0.092,0.0460374607501658,0,0
"fisogatinib","fibroblast growth factor inhibitor","","COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(N[C@@H]3COCC[C@@H]3NC(=O)C=C)ncc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(N[C@@H]3COCC[C@@H]3NC(=O)C=C)ncc2c1",502.117460608,34,4.296,94.6,0.00805560043456144,0.084,0.0460278002172807,0,0
"UBP-296","glutamate receptor antagonist","GRIK1","N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O |&1:1,r|, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O |&1:1,r|, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O |&1:1",333.0960852,24,-1.237,144.62,0.00370884081835078,0.088,0.0458544204091754,0,0
"UBP-302","glutamate receptor antagonist","GRIK1","N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O",333.0960852,24,-1.237,144.62,0.00370884081835078,0.088,0.0458544204091754,0,0
"sphingosylphosphorylcholine","gene expression stimulant","GPR12","CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(=O)OCC[N+](C)(C)C |a:15,17,&1:21|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(=O)OCC[N+](C)(C)C |a:15",465.345185750091,31,4.97,111.82,0.00769643831556877,0.084,0.0458482191577844,0,0
"anamorelin","growth hormone secretagogue receptor agonist","GHSR","CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C1)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)C(C)(C)N, CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C1)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)C(C)(C)N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C1)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)C(C)(C)N",546.331839204,40,1.662,114.77,0.00367852748501897,0.088,0.0458392637425095,0,0
"PSB-1115","adenosine receptor antagonist","ADORA1, ADORA2B, ADORA3","CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O",350.068490548,24,2.238,146.29,0.00556655613941034,0.086,0.0457832780697052,0,0
"M-344","HDAC inhibitor","HDAC8","CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO",307.18959166,22,2.171,81.67,0.0415112149930579,0.05,0.0457556074965289,0,0
"NSC-636819","histone demethylase inhibitor","KDM4A, KDM4B","[O-][N+](=O)c1cc(c(\C=C\c2ccc(Cl)c(Cl)c2)cc1\C=C\c1ccc(Cl)c(Cl)c1)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[O-][N+](=O)c1cc(c(\C=C\c2ccc(Cl)c(Cl)c2)cc1\C=C\c1ccc(Cl)c(Cl)c1)[N+]([O-])=O",507.955117584,32,9.14,86.28,0.0174193221909673,0.074,0.0457096610954836,0,0
"GDC-0084","mTOR inhibitor, PI3K inhibitor","","CC1(C)OCCn2c1nc1c(nc(nc21)-c1cnc(N)nc1)N1CCOCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC1(C)OCCn2c1nc1c(nc(nc21)-c1cnc(N)nc1)N1CCOCC1",382.186571944,28,1.011,117.1,0.00941627688963541,0.082,0.0457081384448177,0,0
"taxifolin","opioid receptor antagonist","ADIPOR2","O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1",304.058302724,22,1.449,127.45,0.0133479439824994,0.078,0.0456739719912497,0,0
"DVD-111","","","CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)Cc1ccccc1, CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)Cc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)Cc1ccccc1",318.157957184,23,1.288,75.71,0.0373396775869346,0.054,0.0456698387934673,0,0
"elafibranor","PPAR receptor agonist","PPARA, PPARD, PPARG","CSc1ccc(cc1)C(=O)\C=C\c1cc(C)c(OC(C)(C)C(O)=O)c(C)c1, CSc1ccc(cc1)C(=O)\C=C\c1cc(C)c(OC(C)(C)C(O)=O)c(C)c1, CSc1ccc(cc1)C(=O)\C=C\c1cc(C)c(OC(C)(C)C(O)=O)c(C)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CSc1ccc(cc1)C(=O)\C=C\c1cc(C)c(OC(C)(C)C(O)=O)c(C)c1",384.139530248,27,4.975,88.9,0.0353377859373334,0.056,0.0456688929686667,0,0
"TCV-309","platelet activating factor receptor antagonist","","CCC[n+]1cc(Br)cc(c1)C(=O)N(CCC(=O)NCCOC(=O)N1CCc2ccccc2C1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCC[n+]1cc(Br)cc(c1)C(=O)N(CCC(=O)NCCOC(=O)N1CCc2ccccc2C1)c1ccccc1",593.175794088091,39,5.632,82.83,0.00528437253319153,0.086,0.0456421862665958,0,0
"celgosivir","glucosidase inhibitor","","[H][C@]12[C@@H](O)CCN1C[C@H](OC(=O)CCC)[C@@H](O)[C@@H]2O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","[H][C@]12[C@@H](O)CCN1C[C@H](OC(=O)CCC)[C@@H](O)[C@@H]2O",259.141972772,19,-0.659,90.23,0.0272632893978983,0.064,0.0456316446989492,0,0
"GSK2334470","phosphoinositide dependent kinase inhibitor","AURKA, AURKB, PDPK1","CNc1nc(cc(n1)-c1ccc2c(N)[nH]nc2c1)N1C[C@H](CC[C@H]1C)C(=O)NC1CCCCC1, CNc1nc(cc(n1)-c1ccc2c(N)[nH]nc2c1)N1C[C@H](CC[C@H]1C)C(=O)NC1CCCCC1, CNc1nc(cc(n1)-c1ccc2c(N)[nH]nc2c1)N1C[C@H](CC[C@H]1C)C(=O)NC1CCCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CNc1nc(cc(n1)-c1ccc2c(N)[nH]nc2c1)N1C[C@H](CC[C@H]1C)C(=O)NC1CCCCC1",462.285557708,34,5.296,124.85,0.0131657002461684,0.078,0.0455828501230842,0,0
"CDK9-IN-6","CDK inhibitor","CDK9","COC[C@H](C)N[C@H]1CC[C@@H](CC1)Nc1cc(c(Cl)cn1)-c1cccc(NCC2(CCOCC2)C#N)n1, COC[C@H](C)N[C@H]1CC[C@@H](CC1)Nc1cc(c(Cl)cn1)-c1cccc(NCC2(CCOCC2)C#N)n1, COC[C@H](C)N[C@H]1CC[C@@H](CC1)Nc1cc(c(Cl)cn1)-c1cccc(NCC2(CCOCC2)C#N)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC[C@H](C)N[C@H]1CC[C@@H](CC1)Nc1cc(c(Cl)cn1)-c1cccc(NCC2(CCOCC2)C#N)n1",512.266652104,36,3.712,104.12,0.00697070442502021,0.084,0.0454853522125101,0,0
"riodipine","calcium channel blocker","","COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1OC(F)F)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1OC(F)F)C(=O)OC |c:4,9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1OC(F)F)C(=O)OC |c:4",367.123129148,26,4.042,73.86,0.0469490154757661,0.044,0.045474507737883,0,0
"ASC-J9","androgen receptor enhancer","AR","COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC, COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC, COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC, COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC, COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC",396.157288488,29,3.703,74.22,0.042901787156419,0.048,0.0454508935782095,0,0
"BX-912","pyruvate dehydrogenase kinase inhibitor","CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1","Brc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCc1cnc[nH]1, Brc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCc1cnc[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Brc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCc1cnc[nH]1",470.117819456,30,2.201,110.86,0.00284076450986274,0.088,0.0454203822549314,0,0
"TG-100801","SRC inhibitor, VEGFR inhibitor","CSK, FGFR1, FLT1, FLT4, KDR, SRC","Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl",579.2037175,42,6.847,89.47,0.0168207119248141,0.074,0.045410355962407,0,0
"FLI-06","notch signaling inhibitor","","CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|, CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|, CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|, CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|, CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|, CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|, CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|, CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5",438.21547206,32,3.849,98.87,0.0187999039448183,0.072,0.0453999519724092,0,0
"lotamilast","phosphodiesterase inhibitor","","CNc1nc(-c2cccc(NC(=O)c3ccc(cc3)C(=O)OC)c2)c2cc(OC)c(OC)cc2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CNc1nc(-c2cccc(NC(=O)c3ccc(cc3)C(=O)OC)c2)c2cc(OC)c(OC)cc2n1",472.174669868,35,3.956,111.67,0.0127920416137758,0.078,0.0453960208068879,0,0
"Neu2000","ionotropic glutamate receptor antagonist","","OC(=O)c1cc(NCc2c(F)c(F)c(c(F)c2F)C(F)(F)F)ccc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)c1cc(NCc2c(F)c(F)c(c(F)c2F)C(F)(F)F)ccc1O",383.039240656,26,4.585,69.56,0.0407665369283851,0.05,0.0453832684641926,0,0
"delanzomib","proteasome inhibitor","CMA1, CTSG, CYP3A4, ELANE","CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O",413.212201396,30,2.175,131.78,0.00674905792112086,0.084,0.0453745289605604,0,0
"iberdomide","cereblon modulator","","O=C1N(Cc2c1cccc2OCc1ccc(CN2CCOCC2)cc1)[C@H]1CCC(=O)NC1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C1N(Cc2c1cccc2OCc1ccc(CN2CCOCC2)cc1)[C@H]1CCC(=O)NC1=O",449.195070964,33,1.356,88.18,0.0127330849780138,0.078,0.0453665424890069,0,0
"NS-19504","calcium-activated potassium channel activator","KCNMA1","Nc1ncc(Cc2ccc(Br)cc2)s1, Nc1ncc(Cc2ccc(Br)cc2)s1, Nc1ncc(Cc2ccc(Br)cc2)s1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1ncc(Cc2ccc(Br)cc2)s1",267.966981388,14,1.955,67.15,0.0227207239062525,0.068,0.0453603619531262,0,0
"CP-775146","PPAR receptor agonist","PPARA","CC(C)c1ccc(CC(=O)N2CCC[C@H](C2)c2cccc(OC(C)(C)C(O)=O)c2)cc1, CC(C)c1ccc(CC(=O)N2CCC[C@H](C2)c2cccc(OC(C)(C)C(O)=O)c2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)c1ccc(CC(=O)N2CCC[C@H](C2)c2cccc(OC(C)(C)C(O)=O)c2)cc1",423.240958536,31,4.963,66.84,0.0567059350711623,0.034,0.0453529675355812,0,0
"ICI-185,282","thromboxane receptor antagonist","","OC(=O)CCC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)C(F)(F)F, OC(=O)CCC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)C(F)(F)F, OC(=O)CCC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC(=O)CCC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)C(F)(F)F",374.134108432,26,4.305,75.99,0.0405780743345934,0.05,0.0452890371672967,0,0
"tenovin-1","SIRT inhibitor, TP53 activator","SIRT1","CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1",369.151097976,26,4.516,102.32,0.0265296127073284,0.064,0.0452648063536642,0,0
"entinostat","HDAC inhibitor","HDAC1, HDAC2, HDAC3, HDAC9","Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1",376.1535405,28,2.203,106.34,0.0185284524895268,0.072,0.0452642262447634,0,0
"IPA-3","p21 activated kinase inhibitor","PAK1","Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12",350.043521688,24,6.192,91.06,0.050476705481848,0.04,0.045238352740924,0,0
"cediranib","KIT inhibitor, VEGFR inhibitor","CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB","COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1",450.206718944,33,4.122,72.5,0.034459979881645,0.056,0.0452299899408225,0,0
"BIMU-8","serotonin receptor agonist","HTR4","CC(C)n1c2ccccc2n(C(=O)N[C@@H]2C[C@@H]3CC[C@H](C2)N3C)c1=O |&1:14,16,19|",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)n1c2ccccc2n(C(=O)N[C@@H]2C[C@@H]3CC[C@H](C2)N3C)c1=O |&1:14",342.205576072,25,2.113,59.27,0.0584018863522749,0.032,0.0452009431761375,0,0
"VTP-27999","renin inhibitor","REN","CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1, CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1",524.276548092,36,2.703,101.16,0.00438531594262318,0.086,0.0451926579713116,0,0
"SAM-315","serotonin receptor antagonist","","O=S(=O)(c1n[nH]c2ccc(cc12)N1CCNCC1)c1cccc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=S(=O)(c1n[nH]c2ccc(cc12)N1CCNCC1)c1cccc2ccccc12",392.13069688,28,4.934,86.47,0.0383766124016235,0.052,0.0451883062008118,0,0
"ce-245677","tie tyrosine kinase inhibitor","NTRK1, NTRK2, TEK","O=C(NC1=CC=C(Cl)C=C1Cl)NC2=CC(C(C3=CN(C(C)C)C4=NC=NC(N)=C43)=O)=CC=C2OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","breast cancer","O=C(NC1=CC=C(Cl)C=C1Cl)NC2=CC(C(C3=CN(C(C)C)C4=NC=NC(N)=C43)=O)=CC=C2OC",512.113043924,35,1.833,121.41,0.00235798768423134,0.088,0.0451789938421157,0,0
"prinomastat","matrix metalloprotease inhibitor","","CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(Oc2ccncc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(Oc2ccncc2)cc1",423.092262772,28,1.629,142.51,0.00230263846330338,0.088,0.0451513192316517,0,0
"M8-B","transient receptor potential channel antagonist","TRPM8","COc1cc(CN(CCN)C(=O)c2cccs2)ccc1OCc1ccccc1, COc1cc(CN(CCN)C(=O)c2cccs2)ccc1OCc1ccccc1, COc1cc(CN(CCN)C(=O)c2cccs2)ccc1OCc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(CN(CCN)C(=O)c2cccs2)ccc1OCc1ccccc1",396.150763628,28,2.837,93.03,0.0182747621571183,0.072,0.0451373810785592,0,0
"beta-glycerophosphoric-acid","","","OCC(CO)OP(O)(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OCC(CO)OP(O)(O)=O",172.013674638,10,-3.109,117.03,0.00826335425128503,0.082,0.0451316771256425,0,0
"methotrexate(+/-)","","","CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)NC(CCC(O)=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)NC(CCC(O)=O)C(O)=O",454.171315804,33,-2.668,210.54,0.000250070899894163,0.09,0.0451250354499471,0,0
"S-111","PARP inhibitor","PARP1","CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C",460.391645524,33,7.963,60.69,0.0862438014692415,0.004,0.0451219007346207,0,0
"aminopterin","dihydrofolate reductase inhibitor","DHFR, SLC46A1","Nc1nc(N)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1, Nc1nc(N)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1, Nc1nc(N)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Nc1nc(N)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1",440.15566574,32,-3.231,219.33,0.000197271746603836,0.09,0.0450986358733019,0,0
"tenatoprazole","ATPase inhibitor","IDO1","COc1ccc2[nH]c(nc2n1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|, COc1ccc2[nH]c(nc2n1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1ccc2[nH]c(nc2n1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|",346.109961436,24,0.808,109.2,0.0101338928499879,0.08,0.0450669464249939,0,0
"proglumide","CCK receptor antagonist","CCKAR, CCKBR","CCCN(CCC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccccc1 |&1:9|, CCCN(CCC)C(=O)C(CCC(O)=O)NC(=O)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CCCN(CCC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccccc1 |&1:9|",334.189257312,24,2.304,86.71,0.0320374069181433,0.058,0.0450187034590717,0,0
"VLX1570","deubiquitinase inhibitor","","[O-][N+](=O)c1cc(\C=C2/CCN(C\C(=C/c3ccc(F)c(c3)[N+]([O-])=O)C2=O)C(=O)C=C)ccc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","[O-][N+](=O)c1cc(\C=C2/CCN(C\C(=C/c3ccc(F)c(c3)[N+]([O-])=O)C2=O)C(=O)C=C)ccc1F",469.108541704,34,3.814,123.66,0.00803414990687857,0.082,0.0450170749534393,0,0
"fapi-4","fibroblast activation protein inhibitor","FAP","O=C(NCC(N1CC(F)(F)C[C@]1(C#N)[H])=O)C2=CC=NC3=CC=C(OCCCN4CCN(C(CN5CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC5)=O)CC4)C=C32",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","oncology","breast cancer","O=C(NCC(N1CC(F)(F)C[C@]1(C#N)[H])=O)C2=CC=NC3=CC=C(OCCCN4CCN(C(CN5CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC5)=O)CC4)C=C32",872.399244368,63,-5.338,243.2,2.78227936292775e-06,0.09,0.0450013911396815,0,0
"ml355","lipoxygenase inhibitor","ALOX12","COc1cccc(CNc2ccc(cc2)S(=O)(=O)Nc3nc4ccccc4s3)c1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","hematology","thrombosis","COc1cccc(CNc2ccc(cc2)S(=O)(=O)Nc3nc4ccccc4s3)c1O",441.081698088,30,3.221,137.17,0.00396488080680152,0.086,0.0449824404034008,0,0
"S-17092","prolyl endopeptidase inhibitor","","O=C([C@@H]1C[C@H]1c1ccccc1)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N1CCSC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C([C@@H]1C[C@H]1c1ccccc1)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N1CCSC1",384.187149136,27,3.108,65.92,0.0379348236845532,0.052,0.0449674118422766,0,0
"cyclopiazonic-acid","ATPase inhibitor","ATP2A1","CC(=O)C1=C(O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O |a:6,7,8,&1:3,c:3|, CC(=O)C1=C(O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O |a:6,7,8,&1:3,c:3|, CC(=O)C1=C(O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O |a:6,7,8,&1:3,c:3|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)C1=C(O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O |a:6",336.1473925,25,2.669,73.4,0.0559056159321564,0.034,0.0449528079660782,0,0
"indeglitazar","PPAR receptor agonist","NCOA1, PPARA, PPARD, PPARG","COc1ccc(cc1)S(=O)(=O)n1cc(CCC(O)=O)c2cc(OC)ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1ccc(cc1)S(=O)(=O)n1cc(CCC(O)=O)c2cc(OC)ccc12",389.093308328,27,2.907,103.21,0.0138664398397512,0.076,0.0449332199198756,0,0
"ML786","RAF inhibitor","BRAF, RAF1","CC(C)(N)c1cc(cc(c1)C(F)(F)F)C(=O)N[C@@H]1CCc2ccc(Oc3ccnc4NC(=O)CCc34)cc2C1, CC(C)(N)c1cc(cc(c1)C(F)(F)F)C(=O)N[C@@H]1CCc2ccc(Oc3ccnc4NC(=O)CCc34)cc2C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(N)c1cc(cc(c1)C(F)(F)F)C(=O)N[C@@H]1CCc2ccc(Oc3ccnc4NC(=O)CCc34)cc2C1",538.219175448,39,4.106,106.34,0.00782127293680954,0.082,0.0449106364684048,0,0
"GSK3326595","protein arginine N-methyltransferase inhibitor","","CC(=O)N1CCC(CC1)Nc1cc(ncn1)C(=O)NC[C@H](O)CN1CCc2ccccc2C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","CC(=O)N1CCC(CC1)Nc1cc(ncn1)C(=O)NC[C@H](O)CN1CCc2ccccc2C1",452.253588884,33,0.519,110.69,0.00576000860784926,0.084,0.0448800043039246,0,0
"NVP-BEZ235","mTOR inhibitor, PI3K inhibitor","ATR, MTOR, PIK3CA, PIK3CD, PIK3CG","Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1",469.190260356,36,4.918,76.5,0.0477466355633074,0.042,0.0448733177816537,0,0
"CCMQ","homoquinolinic acid binding inhibitor","","OC(=O)Cc1cc2ccccc2nc1C(O)=O, OC(=O)Cc1cc2ccccc2nc1C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)Cc1cc2ccccc2nc1C(O)=O",231.053157768,17,1.256,87.49,0.0556948539211964,0.034,0.0448474269605982,0,0
"lestaurtinib","FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor","FLT3, NTRK1, NTRK2, NTRK3","C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|, C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","oncology","acute myeloid leukemia (aml)","C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1",439.153206152,33,5.167,88.65,0.0396710671583282,0.05,0.0448355335791641,0,0
"dofequidar","MRP inhibitor, P glycoprotein inhibitor","ABCB1","OC(COc1cccc2ncccc12)CN1CCN(CC1)C(=O)C(c1ccccc1)c1ccccc1, OC(COc1cccc2ncccc12)CN1CCN(CC1)C(=O)C(c1ccccc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","OC(COc1cccc2ncccc12)CN1CCN(CC1)C(=O)C(c1ccccc1)c1ccccc1",481.236541852,36,3.849,65.9,0.0356588439433113,0.054,0.0448294219716556,0,0
"dofequidar fumarate","mrp inhibitor","ABCB1, ABCC1","O[C@@H](COc1cccc2ncccc12)CN1CCN(CC1)C(=O)C(c1ccccc1)c1ccccc1 |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","O[C@@H](COc1cccc2ncccc12)CN1CCN(CC1)C(=O)C(c1ccccc1)c1ccccc1 |&1:1",481.236541852,36,3.849,65.9,0.0356588439433113,0.054,0.0448294219716556,0,0
"azd-4017","11-beta hydroxysteroid dehydrogenase inhibitor","GGT1, HSD11B1","CCCSc1nc(ccc1C(=O)NC1CCCCC1)N1CCC[C@@H](CC(O)=O)C1 |a:23|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","endocrinology","obesity","CCCSc1nc(ccc1C(=O)NC1CCCCC1)N1CCC[C@@H](CC(O)=O)C1 |a:23|",419.224262916,29,4.885,107.83,0.0155848075372555,0.074,0.0447924037686277,0,0
"4SC-202","HDAC inhibitor","HDAC1","Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1",447.136510532,32,2.947,120.39,0.00747717153929494,0.082,0.0447385857696475,0,0
"salvinorin-A","opioid receptor agonist","OPRD1, OPRK1, OPRM1","COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1, COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1, COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1",432.178417856,31,2.297,109.11,0.00938571699766708,0.08,0.0446928584988335,0,0
"amiprilose","CD antagonist","","CN(C)CCCO[C@H]1[C@H](O[C@@H]2OC(C)(C)O[C@H]12)[C@H](O)CO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CN(C)CCCO[C@H]1[C@H](O[C@@H]2OC(C)(C)O[C@H]12)[C@H](O)CO",305.183837584,21,-0.841,80.62,0.0173542445405296,0.072,0.0446771222702648,0,0
"JNJ-10397049","orexin receptor antagonist","HCRTR1, HCRTR2","CC1(C)OC[C@H](NC(=O)Nc2ccc(Br)cc2Br)[C@@H](O1)c1ccccc1, CC1(C)OC[C@H](NC(=O)Nc2ccc(Br)cc2Br)[C@@H](O1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC1(C)OC[C@H](NC(=O)Nc2ccc(Br)cc2Br)[C@@H](O1)c1ccccc1",481.9840667,26,4.786,59.59,0.0052533685212835,0.084,0.0446266842606418,0,0
"lucitanib","FGFR inhibitor, VEGFR inhibitor","FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET","CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12",443.18450628,33,3.6,95.7,0.0212299563029855,0.068,0.0446149781514927,0,0
"DPI-201106","sodium channel activator","ADRB2","O[C@@H](COc1cccc2[nH]c(cc12)C#N)CN1CCN(CC1)C(c1ccccc1)c1ccccc1 |&1:1,r|, O[C@@H](COc1cccc2[nH]c(cc12)C#N)CN1CCN(CC1)C(c1ccccc1)c1ccccc1 |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"phase 2","","","O[C@@H](COc1cccc2[nH]c(cc12)C#N)CN1CCN(CC1)C(c1ccccc1)c1ccccc1 |&1:1",466.2368762,35,3.935,75.52,0.0332087006440408,0.056,0.0446043503220204,0,0
"AMG-517","TRPV antagonist","TRPV1","CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1, CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1, CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1, CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1",430.071131316,30,4.055,105.24,0.0131483783684495,0.076,0.0445741891842248,0,0
"ZD-2079","adrenergic receptor agonist","ADRB3","O[C@@H](CNCCOc1ccc(CC(O)=O)cc1)c1ccccc1, O[C@@H](CNCCOc1ccc(CC(O)=O)cc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"phase 2","","","O[C@@H](CNCCOc1ccc(CC(O)=O)cc1)c1ccccc1",315.147058152,23,2.082,78.79,0.045033032776405,0.044,0.0445165163882025,0,0
"AZD0156","ATM kinase inhibitor","","CN(C)CCCOc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(C4CCOCC4)c3c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN(C)CCCOc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(C4CCOCC4)c3c2c1",461.242689852,34,2.742,74.41,0.0229970362750128,0.066,0.0444985181375064,0,0
"BEBT-908","PI3K inhibitor","","CNc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CNc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1",507.18010666,36,1.347,169.76,0.000967997635779355,0.088,0.0444839988178897,0,0
"Gue-1654","oxoeicosanoid receptor modulator","OXER1","CSc1nc2ccc3nc(NC(=O)C(c4ccccc4)c4ccccc4)sc3c2s1, CSc1nc2ccc3nc(NC(=O)C(c4ccccc4)c4ccccc4)sc3c2s1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CSc1nc2ccc3nc(NC(=O)C(c4ccccc4)c4ccccc4)sc3c2s1",447.053375164,30,4.665,136.66,0.00495180217666576,0.084,0.0444759010883329,0,0
"PF-3845","FAAH inhibitor","FAAH","FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1",456.177310636,33,4.505,67.35,0.036887386201477,0.052,0.0444436931007385,0,0
"m-chlorophenylbiguanide","serotonin receptor agonist","HTR3A, HTR3B","NC(N)=NC(=N)Nc1cccc(Cl)c1, NC(N)=NC(=N)Nc1cccc(Cl)c1",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC(N)=NC(=N)Nc1cccc(Cl)c1",211.062473,14,1.086,100.28,0.0328587922729925,0.056,0.0444293961364962,0,0
"loxistatin-acid","cysteine peptidase inhibitor","CTSB","CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O, CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O, CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O",314.184171932,22,1.561,108.03,0.0168339860349853,0.072,0.0444169930174926,0,0
"NAV-26","voltage-gated sodium channel blocker","SCN9A","FC(F)(F)Oc1ccc(CNC(=O)[C@H]2N(C3CCOCC3)C(=O)c3ccccc23)cc1 |&1:13,r|, FC(F)(F)Oc1ccc(CNC(=O)[C@H]2N(C3CCOCC3)C(=O)c3ccccc23)cc1 |&1:13,r|, FC(F)(F)Oc1ccc(CNC(=O)[C@H]2N(C3CCOCC3)C(=O)c3ccccc23)cc1 |&1:13,r|",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)Oc1ccc(CNC(=O)[C@H]2N(C3CCOCC3)C(=O)c3ccccc23)cc1 |&1:13",434.145341812,31,3.524,67.87,0.0307955812483232,0.058,0.0443977906241616,0,0
"darapladib","phospholipase inhibitor","PLA2G7","CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1",666.265160336,47,8.96,83.74,0.0127872494761793,0.076,0.0443936247380896,0,0
"tolrestat","aldose reductase inhibitor","AKR1A1, AKR1B1, AKR1B10","COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O, COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O, COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O, COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O, COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O, COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O",357.064648968,24,1.825,81.86,0.0187008255109238,0.07,0.0443504127554619,0,0
"LRRK2-IN-1","leucine rich repeat kinase inhibitor","LRRK2","COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1",570.306687076,42,2.884,97.38,0.00662017146859468,0.082,0.0443100857342973,0,0
"taltobulin","tubulin polymerization inhibitor","","CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1, CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1, CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1, CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1, CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1, CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1",473.325356856,34,3.7,98.74,0.0125295367817257,0.076,0.0442647683908628,0,0
"CPI-169","histone lysine methyltransferase inhibitor","EZH2","CCS(=O)(=O)N1CCC(CC1)[C@@H](C)n1c(C)c(C(=O)NCc2c(OC)cc(C)[nH]c2=O)c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCS(=O)(=O)N1CCC(CC1)[C@@H](C)n1c(C)c(C(=O)NCc2c(OC)cc(C)[nH]c2=O)c2ccccc12",528.240641252,37,4.204,121.88,0.00448921520288043,0.084,0.0442446076014402,0,0
"LGK-974","porcupine inhibitor","PORCN","Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C, Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C, Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C, Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C, Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C, Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C",396.16985926,30,1.872,93.55,0.0224855786339152,0.066,0.0442427893169576,0,0
"GSK2801","bromodomain inhibitor","BAZ2A, BAZ2B","CCCOc1ccn2c(cc(-c3ccccc3S(C)(=O)=O)c2c1)C(C)=O, CCCOc1ccn2c(cc(-c3ccccc3S(C)(=O)=O)c2c1)C(C)=O, CCCOc1ccn2c(cc(-c3ccccc3S(C)(=O)=O)c2c1)C(C)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCOc1ccn2c(cc(-c3ccccc3S(C)(=O)=O)c2c1)C(C)=O",371.119129152,26,4.507,73.23,0.04845383223776,0.04,0.04422691611888,0,0
"Mps1-IN-1","monopolar spindle 1 kinase inhibitor","TTK","COc1cc(ccc1Nc1cc(Nc2ccccc2S(=O)(=O)C(C)C)c2cc[nH]c2n1)N1CCC(O)CC1, COc1cc(ccc1Nc1cc(Nc2ccccc2S(=O)(=O)C(C)C)c2cc[nH]c2n1)N1CCC(O)CC1, COc1cc(ccc1Nc1cc(Nc2ccccc2S(=O)(=O)C(C)C)c2cc[nH]c2n1)N1CCC(O)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(ccc1Nc1cc(Nc2ccccc2S(=O)(=O)C(C)C)c2cc[nH]c2n1)N1CCC(O)CC1",535.225325536,38,5.915,127.96,0.00630951836134522,0.082,0.0441547591806726,0,0
"COH29","ribonucleotide reductase inhibitor","","Oc1ccc(cc1O)C(=O)Nc1nc(c(s1)-c1ccccc1)-c1ccc(O)c(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Oc1ccc(cc1O)C(=O)Nc1nc(c(s1)-c1ccccc1)-c1ccc(O)c(O)c1",420.077992612,30,4.36,151.15,0.00625068083228792,0.082,0.044125340416144,0,0
"BIBX-1382","EGFR inhibitor","EGFR, ERBB2","CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1",387.137449508,27,2.373,78.86,0.0222253562446768,0.066,0.0441126781223384,0,0
"AZ-7371","antibacterial ","","COc1ncnc(Cn2cc(C(=O)NCCO)c3ncc(C)cc23)c1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ncnc(Cn2cc(C(=O)NCCO)c3ncc(C)cc23)c1C",355.164439532,26,0.531,102.16,0.0141745180836642,0.074,0.0440872590418321,0,0
"BI-D1870","ribosomal protein inhibitor","RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6","CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6",391.181981416,28,3.884,81.59,0.0341273371723327,0.054,0.0440636685861663,0,0
"3-bromopyruvate","hexokinase inhibitor","HK2","OC(=O)C(O)=CBr, OC(=O)C(O)=CBr, OC(=O)C(O)=CBr, OC(=O)C(O)=CBr",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)C(O)=CBr",165.926556056,7,1.016,57.53,0.0501101065295509,0.038,0.0440550532647755,0,0
"actinoquinol","","","CCOc1ccc(c2cccnc12)S(O)(=O)=O, CCOc1ccc(c2cccnc12)S(O)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOc1ccc(c2cccnc12)S(O)(=O)=O",253.040878832,17,1.057,84.87,0.0340800445552183,0.054,0.0440400222776091,0,0
"salvianolic-acid-A","matrix metalloprotease inhibitor","","OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1\C=C\c1ccc(O)c(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1\C=C\c1ccc(O)c(O)c1",494.121296904,36,4.589,184.98,0.00205663761756542,0.086,0.0440283188087827,0,0
"tavilermide","tyrosine kinase partial agonist","","NCCCC[C@@H]1NC(=O)[C@H](CCC(O)=O)NC(=O)c2cc(ccc2OCC[C@H](NC1=O)C(=O)NCC(O)=O)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","NCCCC[C@@H]1NC(=O)[C@H](CCC(O)=O)NC(=O)c2cc(ccc2OCC[C@H](NC1=O)C(=O)NCC(O)=O)[N+]([O-])=O",580.212905844,41,-2.523,269.39,2.05549169428626e-05,0.088,0.0440102774584714,0,0
"DOTMP","","","OP(O)(=O)CN1CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OP(O)(=O)CN1CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CC1",548.096718984,32,-8.128,282.32,1.04321911757924e-06,0.088,0.0440005216095588,0,0
"MK-8617","hypoxia inducible factor prolyl hydroxylase inhibitor","","COc1ccc(cc1)C(NC(=O)c1cnc(nc1O)-c1cccnn1)c1ccc(OC)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1)C(NC(=O)c1cnc(nc1O)-c1cccnn1)c1ccc(OC)cc1",443.159354152,33,3.465,119.35,0.0119893304456651,0.076,0.0439946652228326,0,0
"cilomilast","phosphodiesterase inhibitor","PDE4A, PDE4B, PDE4D","COc1ccc(cc1OC1CCCC1)C1(CCC(CC1)C(O)=O)C#N, COc1ccc(cc1OC1CCCC1)[C@]1(CC[C@@H](CC1)C(O)=O)C#N |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1ccc(cc1OC1CCCC1)C1(CCC(CC1)C(O)=O)C#N",343.17835828,25,3.091,79.55,0.0459252317527796,0.042,0.0439626158763898,0,0
"almorexant","orexin receptor antagonist","HCRTR1, HCRTR2","CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1, CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1",512.228677512,37,5.182,50.8,0.0418476892142614,0.046,0.0439238446071307,0,0
"ridinilazole","antibacterial","","c1cc(ccn1)-c1nc2ccc(cc2[nH]1)-c1ccc2nc([nH]c2c1)-c1ccncc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","c1cc(ccn1)-c1nc2ccc(cc2[nH]1)-c1ccc2nc([nH]c2c1)-c1ccncc1",388.143644512,30,3.954,83.14,0.0558212649320463,0.032,0.0439106324660231,0,0
"CK-636","actin related protein inhibitor","ACTR2, ACTR3, ARPC1B, ARPC2, ARPC3, ARPC4, ARPC5","Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1, Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1, Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1",284.098334132,20,2.701,73.13,0.0617936702237954,0.026,0.0438968351118977,0,0
"cb-1158","arginase inhibitor","ARG1, ARG2, IFNLR1","C[C@H](N)C(=O)N1C[C@H](CCCB(O)O)[C@@](N)(C1)C(=O)O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","bladder cancer","C[C@H](N)C(=O)N1C[C@H](CCCB(O)O)[C@@](N)(C1)C(=O)O",287.165251204,20,-4.439,150.11,0.00177950621376611,0.086,0.0438897531068831,0,0
"UNC0631","histone lysine methyltransferase inhibitor","EHMT2","COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C",635.488674192,46,6.877,69.23,0.0177126373246194,0.07,0.0438563186623097,0,0
"camicinal","motilin receptor agonist","MLNR","C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(CC3)Nc3cccc(F)c3)cc2)CCN1, C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(CC3)Nc3cccc(F)c3)cc2)CCN1, C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(CC3)Nc3cccc(F)c3)cc2)CCN1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(CC3)Nc3cccc(F)c3)cc2)CCN1",424.263839896,31,3.158,47.61,0.0555703026476345,0.032,0.0437851513238173,0,0
"PIK-93","PI3K inhibitor","PI4KB, PIK3C3, PIK3CG","CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO, CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO, CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO, CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO, CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO",389.027075672,24,0.725,145.01,0.00156487593992318,0.086,0.0437824379699616,0,0
"WZ8040","EGFR inhibitor","EGFR","CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1",480.1499081,33,4.093,98.69,0.009348826103655,0.078,0.0436744130518275,0,0
"AK-7","SIRT inhibitor","SIRT2","Brc1cccc(NC(=O)c2cccc(c2)S(=O)(=O)N2CCCCCC2)c1, Brc1cccc(NC(=O)c2cccc(c2)S(=O)(=O)N2CCCCCC2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Brc1cccc(NC(=O)c2cccc(c2)S(=O)(=O)N2CCCCCC2)c1",436.045625632,26,4.101,74.86,0.00931044620883747,0.078,0.0436552231044187,0,0
"MK-3697","orexin receptor antagonist","HCRTR2","COc1ccc(CNC(=O)c2cc(ncc2-c2nccs2)-c2cncc(C)c2)nc1OC, COc1ccc(CNC(=O)c2cc(ncc2-c2nccs2)-c2cncc(C)c2)nc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1ccc(CNC(=O)c2cc(ncc2-c2nccs2)-c2cncc(C)c2)nc1OC",447.136510532,32,2.16,127.36,0.00525639425805718,0.082,0.0436281971290286,0,0
"MK-5108","Aurora kinase inhibitor","AURKA, AURKB, AURKC","OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|, OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|, OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|, OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|, OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|, OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|, OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|",461.097618432,31,4.384,112.58,0.00725284589976853,0.08,0.0436264229498843,0,0
"altiratinib","MET inhibitor, VEGFR inhibitor","KDR, MET, TEK","Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1, Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1",510.151489812,37,4.175,109.42,0.00912728744889976,0.078,0.0435636437244499,0,0
"BFH772","VEGFR inhibitor","","OCc1cc(Oc2ccc3c(cccc3c2)C(=O)Nc2cccc(c2)C(F)(F)F)ncn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OCc1cc(Oc2ccc3c(cccc3c2)C(=O)Nc2cccc(c2)C(F)(F)F)ncn1",439.114376032,32,4.378,84.34,0.0290346748228228,0.058,0.0435173374114114,0,0
"barium-6-O-phosphonato-D-glucose","","","O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H](O)C=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H](O)C=O",260.029718626,16,-4.554,174.56,0.000747795825489654,0.086,0.0433738979127448,0,0
"GSK429286A","rho associated kinase inhibitor","ROCK1","CC1=C([C@@H](CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2c[nH]nc2cc1F |&1:3,r,t:1|, CC1=C([C@@H](CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2c[nH]nc2cc1F |&1:3,r,t:1|, CC1=C([C@@H](CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2c[nH]nc2cc1F |&1:3,r,t:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC1=C([C@@H](CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2c[nH]nc2cc1F |&1:3",432.120938632,31,4.201,86.88,0.0247146464352378,0.062,0.0433573232176189,0,0
"KS-176","BCRP inhibitor","ABCG2","OCCc1ccc(NC(=O)c2ccccc2NC(=O)c2ccc(cc2)[N+]([O-])=O)cc1, OCCc1ccc(NC(=O)c2ccccc2NC(=O)c2ccc(cc2)[N+]([O-])=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OCCc1ccc(NC(=O)c2ccccc2NC(=O)c2ccc(cc2)[N+]([O-])=O)cc1",405.132470708,30,3.632,121.57,0.0147118930057925,0.072,0.0433559465028962,0,0
"tomeglovir","antiviral","","CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1ccc(NC(=O)C(C)(C)CO)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1ccc(NC(=O)C(C)(C)CO)cc1",441.172227344,31,3.488,107.12,0.0106038113849792,0.076,0.0433019056924896,0,0
"phortress","aryl hydrocarbon receptor ligand","AHR","Cc1cc(ccc1NC(=O)[C@@H](N)CCCCN)-c1nc2cc(F)ccc2s1, Cc1cc(ccc1NC(=O)[C@@H](N)CCCCN)-c1nc2cc(F)ccc2s1, Cc1cc(ccc1NC(=O)[C@@H](N)CCCCN)-c1nc2cc(F)ccc2s1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1cc(ccc1NC(=O)[C@@H](N)CCCCN)-c1nc2cc(F)ccc2s1",386.157660576,27,2.442,122.27,0.00857693150060924,0.078,0.0432884657503046,0,0
"tbaj-587","atp synthase inhibitor","","COc1cc(cc(OC)n1)[C@](O)(CCN(C)C)[C@H](c1cccc(OC)c1F)c1cc2cc(Br)ccc2nc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","infectious disease","tuberculosis","COc1cc(cc(OC)n1)[C@](O)(CCN(C)C)[C@H](c1cccc(OC)c1F)c1cc2cc(Br)ccc2nc1OC",613.158761476,40,6.224,86.17,0.0044196602578278,0.082,0.0432098301289139,0,0
"tetraethylenepentamine","superoxide dismutase inhibitor","SOD1, SOD2","NCCNCCNCCNCCN, NCCNCCNCCNCCN, NCCNCCNCCNCCN, NCCNCCNCCNCCN, NCCNCCNCCNCCN",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","NCCNCCNCCNCCN",189.195345736,13,-2.5,88.13,0.0244175953942793,0.062,0.0432087976971396,0,0
"GW-2580","cFMS kinase inhibitor","CSF1R","COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1, COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1, COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1",366.169190564,27,2.493,105.51,0.0204105827587558,0.066,0.0432052913793779,0,0
"K-Ras(G12C)-inhibitor-12","K-Ras inhibitor","KRAS","Oc1cc(Cl)c(I)cc1NCC(=O)N1CCN(CC1)C(=O)C=C, Oc1cc(Cl)c(I)cc1NCC(=O)N1CCN(CC1)C(=O)C=C, Oc1cc(Cl)c(I)cc1NCC(=O)N1CCN(CC1)C(=O)C=C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1cc(Cl)c(I)cc1NCC(=O)N1CCN(CC1)C(=O)C=C",449.000317084,23,2.419,72.88,0.00238765446078576,0.084,0.0431938272303929,0,0
"dacinostat","HDAC inhibitor","HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9","OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1",379.18959166,28,2.279,88.59,0.02628304547419,0.06,0.043141522737095,0,0
"SB-705498","TRPV antagonist","TRPV1","FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br, FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br, FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br, FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br, FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br",428.045957892,26,4.441,57.26,0.0182608713468669,0.068,0.0431304356734334,0,0
"UNC0224","histone lysine methyltransferase inhibitor","EHMT1, EHMT2","COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1",485.347823616,35,2.685,69.23,0.0181827255982474,0.068,0.0430913627991237,0,0
"vecabrutinib","Bruton's tyrosine kinase (BTK) inhibitor","","NC(=O)[C@H]1CCN(C[C@@H]1N1CCC[C@@H](Nc2cc(Cl)cc(c2)C(F)(F)F)C1=O)c1ncnc(N)c1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","NC(=O)[C@H]1CCN(C[C@@H]1N1CCC[C@@H](Nc2cc(Cl)cc(c2)C(F)(F)F)C1=O)c1ncnc(N)c1F",529.161613568,36,3.082,130.47,0.00217527628365273,0.084,0.0430876381418264,0,0
"INCB-003284","CC chemokine receptor antagonist","","COc1ccc(cn1)C1(O)CCC(CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F, COc1ccc(cn1)C1(O)CCC(CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1ccc(cn1)C1(O)CCC(CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F",520.229740132,37,3.003,103.79,0.00614914985257183,0.08,0.0430745749262859,0,0
"INCB-3284","CC chemokine receptor antagonist","CCR2","COc1ccc(cn1)[C@]1(O)CC[C@@H](CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F, COc1ccc(cn1)[C@]1(O)CC[C@@H](CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1ccc(cn1)[C@]1(O)CC[C@@H](CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F",520.229740132,37,3.003,103.79,0.00614914985257183,0.08,0.0430745749262859,0,0
"metrifonate","acetylcholinesterase inhibitor","ACHE","COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6,r|, COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6,r|, COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6,r|, COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6,r|, COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6",255.922578406,12,0.527,65.57,0.0140903810282635,0.072,0.0430451905141318,0,0
"EDO-S101","HDAC inhibitor","","Cn1c(CCCCCCC(=O)NO)nc2cc(ccc12)N(CCCl)CCCl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","Cn1c(CCCCCCC(=O)NO)nc2cc(ccc12)N(CCCl)CCCl",414.158931496,27,4.172,70.39,0.0220432057086532,0.064,0.0430216028543266,0,0
"dihydrostreptomycin [5mm]","bacterial 30s ribosomal subunit inhibitor","","CN[C@H]1C(O)C(O)C(CO)OC1OC1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)OC(C)[C@]1(O)CO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","infectious disease","tuberculosis","CN[C@H]1C(O)C(O)C(CO)OC1OC1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)OC(C)[C@]1(O)CO",583.281319752,40,-3.775,334.59,2.46120253631013e-06,0.086,0.0430012306012682,0,0
"radotinib","Bcr-Abl kinase inhibitor","","Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cnccn3)c2)cc(c1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cnccn3)c2)cc(c1)C(F)(F)F",530.179041952,39,3.765,110.51,0.00791429621556521,0.078,0.0429571481077826,0,0
"nebivolol hydrochloride","adrenergic receptor antagonist","","O[C@@H](CNC[C@@H](O)[C@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1 |&1:1,&2:5,&3:7,&4:18|, O[C@H](CNC[C@@H](O)[C@@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","cardiology","hypertension","O[C@@H](CNC[C@@H](O)[C@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1 |&1:1",405.17516472,29,2.738,70.95,0.0298424315662213,0.056,0.0429212157831107,0,0
"mibefradil","T-type calcium channel blocker","ANO1, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CATSPER1, CATSPER2, CATSPER3, CATSPER4","COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C",495.289720296,36,5.099,67.45,0.0334798652419283,0.052,0.0427399326209642,0,0
"omecamtiv-mecarbil","cardiac myosin activator","MYBPC3","COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1, COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1, COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1",401.186317848,29,1.06,86.8,0.0152887139979193,0.07,0.0426443569989597,0,0
"darusentan","endothelin receptor antagonist","EDNRA","COc1cc(OC)nc(O[C@H](C(O)=O)C(OC)(c2ccccc2)c2ccccc2)n1, COc1cc(OC)nc(O[C@H](C(O)=O)C(OC)(c2ccccc2)c2ccccc2)n1, COc1cc(OC)nc(O[C@H](C(O)=O)C(OC)(c2ccccc2)c2ccccc2)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1cc(OC)nc(O[C@H](C(O)=O)C(OC)(c2ccccc2)c2ccccc2)n1",410.147786424,30,4.329,100,0.0252548695778977,0.06,0.0426274347889488,0,0
"pyroxamide","HDAC inhibitor","HDAC1","ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","ONC(=O)CCCCCCC(=O)Nc1cccnc1",265.142641468,19,0.6,91.32,0.0312352805239168,0.054,0.0426176402619584,0,0
"R547","CDK inhibitor","CDK1, CDK2, CDK4, CDK7","COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N, COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N, COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N, COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N",441.128231592,30,2.224,135.89,0.00319706725116402,0.082,0.042598533625582,0,0
"delgocitinib","JAK inhibitor","","C[C@H]1CN(C(=O)CC#N)[C@]11CCN(C1)c1ncnc2[nH]ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@H]1CN(C(=O)CC#N)[C@]11CCN(C1)c1ncnc2[nH]ccc12",310.154209196,23,1.245,88.91,0.0330911997902572,0.052,0.0425455998951286,0,0
"glesatinib","tyrosine kinase inhibitor","","COCCNCc1ccc(nc1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccc(F)cc4)cc3F)c2s1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COCCNCc1ccc(nc1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccc(F)cc4)cc3F)c2s1",619.152338164,43,4.396,157.73,0.000932564051558027,0.084,0.042466282025779,0,0
"UNC0646","histone lysine methyltransferase inhibitor","EHMT2","COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C",621.473024128,45,6.26,69.23,0.01691842241113,0.068,0.042459211205565,0,0
"DBPR108","dipeptidyl peptidase inhibitor","DPP4","CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N, CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N, CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N, CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N",324.19615426,23,0.239,76.44,0.0248854379390192,0.06,0.0424427189695096,0,0
"sinomenine","angiogenesis inhibitor","","COC1=C[C@@H]2[C@@H]3Cc4ccc(OC)c(O)c4[C@]2(CCN3C)CC1=O |t:2|, COC1=C[C@@H]2[C@@H]3Cc4ccc(OC)c(O)c4[C@]2(CCN3C)CC1=O |t:2|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC1=C[C@@H]2[C@@H]3Cc4ccc(OC)c(O)c4[C@]2(CCN3C)CC1=O |t:2|",329.162708216,24,0.988,59,0.0488679442734179,0.036,0.0424339721367089,0,0
"ML298","phospholipase inhibitor","PLD2","Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc(F)c(F)c2)CC1, Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc(F)c(F)c2)CC1, Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc(F)c(F)c2)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc(F)c(F)c2)CC1",432.177310636,31,3.299,64.68,0.032821812734108,0.052,0.042410906367054,0,0
"6,7-dehydro-17-acetoxy-progesterone","steroidal progestin","","CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |c:9,t:11|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |c:9,t:11|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |c:9,t:11|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |c:9",370.21440944,27,3.657,60.44,0.0667695982049251,0.018,0.0423847991024626,0,0
"CQS","","","Nc1ccc(cc1)S(=O)(=O)Nc1cnc2c(Cl)cccc2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1ccc(cc1)S(=O)(=O)Nc1cnc2c(Cl)cccc2n1",334.029124272,22,2.188,106.35,0.0127534558026241,0.072,0.042376727901312,0,0
"UNC2327","protein arginine N-methyltransferase inhibitor","PRMT3","O=C(NCC(=O)N1CCCCC1)Nc1ccc2nnsc2c1, O=C(NCC(=O)N1CCCCC1)Nc1ccc2nnsc2c1, O=C(NCC(=O)N1CCCCC1)Nc1ccc2nnsc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(NCC(=O)N1CCCCC1)Nc1ccc2nnsc2c1",319.110295784,22,0.82,115.46,0.0105691884362843,0.074,0.0422845942181422,0,0
"KBG","neprilysin inhibitor","MME","O[C@H]1O[C@@H]2CO[C@@H](O[C@H]2[C@H](O)[C@H]1O)c1ccccc1 |a:3,8,9,11,&1:1,&2:6|, O[C@H]1O[C@@H]2CO[C@@H](O[C@H]2[C@H](O)[C@H]1O)c1ccccc1 |a:3,8,9,11,&1:1,&2:6|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O[C@H]1O[C@@H]2CO[C@@H](O[C@H]2[C@H](O)[C@H]1O)c1ccccc1 |a:3",268.094688232,19,0.223,88.38,0.0284877039800871,0.056,0.0422438519900436,0,0
"fantofarone","calcium channel blocker","","COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(cn3ccccc23)C(C)C)cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(cn3ccccc23)C(C)C)cc1OC",550.250143316,39,6.564,77.86,0.0204823790721288,0.064,0.0422411895360644,0,0
"Mps1-IN-5","protein kinase inhibitor","","COc1cc(ccc1Nc1nc2ccc(cn2n1)-c1ccc(NC(=O)[C@H](C)c2ccc(F)cc2)cc1)S(C)(=O)=O, COc1cc(ccc1Nc1nc2ccc(cn2n1)-c1ccc(NC(=O)[C@H](C)c2ccc(F)cc2)cc1)S(C)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1cc(ccc1Nc1nc2ccc(cn2n1)-c1ccc(NC(=O)[C@H](C)c2ccc(F)cc2)cc1)S(C)(=O)=O",559.168953532,40,4.451,123.07,0.00442194379723662,0.08,0.0422109718986183,0,0
"ethyl-2-(carbamoyloxy)benzoate","","","CCOC(=O)c1ccccc1OC(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCOC(=O)c1ccccc1OC(N)=O",209.068807832,15,1.288,78.62,0.0722710037650839,0.012,0.0421355018825419,0,0
"balicatib","cathepsin inhibitor","CTSK","CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N, CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N, CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N, CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N, CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N",411.263425296,30,2.426,88.47,0.0202457414157498,0.064,0.0421228707078749,0,0
"FR-122047","cyclooxygenase inhibitor","","COc1ccc(cc1)-c1nc(sc1-c1ccc(OC)cc1)C(=O)N1CCN(C)CC1, COc1ccc(cc1)-c1nc(sc1-c1ccc(OC)cc1)C(=O)N1CCN(C)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1)-c1nc(sc1-c1ccc(OC)cc1)C(=O)N1CCN(C)CC1",423.16166266,30,3.076,83.14,0.0202165620699867,0.064,0.0421082810349933,0,0
"PI3K-IN-2","PI3K inhibitor","","Nc1cc(c(cn1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Nc1cc(c(cn1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F",411.16305754,29,1.826,102.52,0.0101477062398009,0.074,0.0420738531199004,0,0
"dl-tboa","excitatory amino acid transporter inhibitor","EAAT1, EAAT2, EAAT3","N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O |&1:1,2|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O |&1:1",239.079372516,17,-2.242,109.85,0.0121411968662875,0.072,0.0420705984331437,0,0
"evogliptin","dipeptidyl peptidase inhibitor","DPP4","CC(C)(C)OC[C@H]1N(CCNC1=O)C(=O)C[C@H](N)Cc2cc(F)c(F)cc2F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","endocrinology","diabetes mellitus","CC(C)(C)OC[C@H]1N(CCNC1=O)C(=O)C[C@H](N)Cc2cc(F)c(F)cc2F",401.192626352,28,1.469,84.66,0.0141208021937339,0.07,0.0420604010968669,0,0
"emodepside","nematocide","","[H][C@]1(C)OC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](Cc2ccc(cc2)N2CCOCC2)OC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)OC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](Cc2ccc(cc2)N2CCOCC2)OC(=O)[C@H](CC(C)C)N(C)C1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","[H][C@]1(C)OC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](Cc2ccc(cc2)N2CCOCC2)OC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)OC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](Cc2ccc(cc2)N2CCOCC2)OC(=O)[C@H](CC(C)C)N(C)C1=O",1118.65150156,81,8.764,211.38,3.24707294917656e-05,0.084,0.0420162353647459,0,0
"terutroban","prostanoid receptor antagonist","TBXA2R","Cc1ccc2C[C@@H](CCc2c1CCC(O)=O)NS(=O)(=O)c1ccc(Cl)cc1, Cc1ccc2C[C@@H](CCc2c1CCC(O)=O)NS(=O)(=O)c1ccc(Cl)cc1, Cc1ccc2C[C@@H](CCc2c1CCC(O)=O)NS(=O)(=O)c1ccc(Cl)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cc1ccc2C[C@@H](CCc2c1CCC(O)=O)NS(=O)(=O)c1ccc(Cl)cc1",407.095806864,27,3.635,91.85,0.0140245964617254,0.07,0.0420122982308627,0,0
"sipatrigine","voltage-gated sodium channel blocker","CACNA1D, SCN10A, SCN1A, SCN3A, SCN4A, SCN5A, SCN9A","CN1CCN(CC1)c1ncc(c(N)n1)-c1cc(Cl)cc(Cl)c1Cl, CN1CCN(CC1)c1ncc(c(N)n1)-c1cc(Cl)cc(Cl)c1Cl, CN1CCN(CC1)c1ncc(c(N)n1)-c1cc(Cl)cc(Cl)c1Cl",0,0,1,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN1CCN(CC1)c1ncc(c(N)n1)-c1cc(Cl)cc(Cl)c1Cl",371.047128552,23,4.146,58.28,0.0320135824893673,0.052,0.0420067912446837,0,0
"CEP-33779","JAK inhibitor","JAK2","CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1",462.183795072,33,3.851,91.22,0.0159891411289219,0.068,0.0419945705644609,0,0
"daprodustat","hypoxia inducible factor inhibitor","EGLN1","OC(=O)CNC(=O)c1c(O)n(C2CCCCC2)c(=O)n(C2CCCCC2)c1=O, OC(=O)CNC(=O)c1c(O)n(C2CCCCC2)c(=O)n(C2CCCCC2)c1=O, OC(=O)CNC(=O)c1c(O)n(C2CCCCC2)c(=O)n(C2CCCCC2)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","OC(=O)CNC(=O)c1c(O)n(C2CCCCC2)c(=O)n(C2CCCCC2)c1=O",393.189985584,28,2.655,130.63,0.00792855647242297,0.076,0.0419642782362115,0,0
"SB-742457","serotonin receptor antagonist","HTR6","O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1, O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1, O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1",353.119797848,25,2.832,70.68,0.041913459081703,0.042,0.0419567295408515,0,0
"arbutin","melanin inhibitor","TYR","OC[C@H]1O[C@@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","OC[C@H]1O[C@@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O",272.089602852,19,-0.0959999999999999,119.61,0.0118073120694246,0.072,0.0419036560347123,0,0
"AUT-1","potassium channel activator","","CC[C@H]1NC(=O)N(C1=O)c1ccc(Oc2ccc(C)c(OC)c2)nc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC[C@H]1NC(=O)N(C1=O)c1ccc(Oc2ccc(C)c(OC)c2)nc1",341.137556088,25,2.801,80.76,0.0437669480187012,0.04,0.0418834740093506,0,0
"gemilukast","leukotriene receptor antagonist","CYSLTR1, CYSLTR2","O=C(O)CCCN1C(C)=C(CCCC(O)=O)C2=C1C(C#CC3=CC=C(OCCCCC4=CC=CC(F)=C4C)C=C3)=CC=C2F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","pulmonary","asthma","O=C(O)CCCN1C(C)=C(CCCC(O)=O)C2=C1C(C#CC3=CC=C(OCCCCC4=CC=CC(F)=C4C)C=C3)=CC=C2F",601.263979724,44,5.408,87.07,0.0117495697231365,0.072,0.0418747848615683,0,0
"etilevodopa","dopamine receptor agonist","DRD3","CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1, CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1, CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1, CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,"phase 3","","","CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1",225.10010796,16,0.88,92.78,0.0417447126911148,0.042,0.0418723563455574,0,0
"GPR120-modulator-1","G protein-coupled receptor modulator","FFAR4","Cc1cc(OCc2nc(cs2)-c2ccccc2Cl)ccc1OCC(O)=O, Cc1cc(OCc2nc(cs2)-c2ccccc2Cl)ccc1OCC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(OCc2nc(cs2)-c2ccccc2Cl)ccc1OCC(O)=O",389.048856672,26,4.261,96.89,0.0177225662180886,0.066,0.0418612831090443,0,0
"brefeldin-A","protein synthesis inhibitor","ARF1, CYTH2","C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5",280.167459248,20,2.363,66.76,0.071662996319063,0.012,0.0418314981595315,0,0
"tribomsalan","","","Oc1c(Br)cc(Br)cc1C(=O)Nc1ccc(Br)cc1, Oc1c(Br)cc(Br)cc1C(=O)Nc1ccc(Br)cc1, Oc1c(Br)cc(Br)cc1C(=O)Nc1ccc(Br)cc1, Oc1c(Br)cc(Br)cc1C(=O)Nc1ccc(Br)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1c(Br)cc(Br)cc1C(=O)Nc1ccc(Br)cc1",446.810514796,19,5.41,49.33,0.0035943603969824,0.08,0.0417971801984912,0,0
"PD-160170","neuropeptide receptor antagonist","NPY1R","CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O, CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O, CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O",371.093977024,26,3.368,124.57,0.0115837862901161,0.072,0.041791893145058,0,0
"PGL5001","JNK inhibitor","MAPK10, MAPK8, MAPK9","N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2",457.157245976,33,2.269,112.4,0.00754993807374207,0.076,0.041774969036871,0,0
"PD-158780","EGFR inhibitor","EGFR","CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1, CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1, CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1, CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1, CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1",329.027607484,20,2.944,62.73,0.0294913857901809,0.054,0.0417456928950904,0,0
"amg 333","transient receptor potential channel antagonist","TRPM8","OC(=O)c1ccc(nc1)C(=O)N[C@@H](c1ccc(OC(F)(F)F)c(F)c1)c1ncccc1F |a:12|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","neurology/psychiatry","migraine headache","OC(=O)c1ccc(nc1)C(=O)N[C@@H](c1ccc(OC(F)(F)F)c(F)c1)c1ncccc1F |a:12|",453.074796964,32,3.49,101.41,0.0114622860544186,0.072,0.0417311430272093,0,0
"4-phenolsulfonic-acid","","","Oc1ccc(cc1)S(O)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(cc1)S(O)(=O)=O",173.998679672,11,0.21,82.98,0.0473770657083495,0.036,0.0416885328541748,0,0
"MM77","serotonin receptor antagonist","HTR1A","COc1ccccc1N1CCN(CCCCN2C(=O)CCC2=O)CC1, COc1ccccc1N1CCN(CCCCN2C(=O)CCC2=O)CC1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccccc1N1CCN(CCCCN2C(=O)CCC2=O)CC1",345.205241724,25,1.587,53.09,0.0553198234747929,0.028,0.0416599117373965,0,0
"m-THP","","","Oc1cccc(c1)-c1c2ccc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc1n2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Oc1cccc(c1)-c1c2ccc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc1n2",678.22670544,52,10.068,138.28,0.0112862792522503,0.072,0.0416431396261251,0,0
"CEP-37440","ALK tyrosine kinase receptor inhibitor","ALK","CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl",579.272465756,41,3.422,114.88,0.00323807110958615,0.08,0.0416190355547931,0,0
"moracizine","sodium channel blocker","SCN5A","CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN3CCOCC3)c2c1, CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN3CCOCC3)c2c1, CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN3CCOCC3)c2c1",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","cardiology","ventricular arrhythmias","CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN3CCOCC3)c2c1",427.15657728,30,2.288,96.41,0.0112364659028603,0.072,0.0416182329514302,0,0
"RN-1734","TRPV antagonist","TRPV4","CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl",352.077904304,21,3.734,57.79,0.0291392784163906,0.054,0.0415696392081953,0,0
"halopemide","phospholipase inhibitor","PLD1, PLD2","Fc1ccc(cc1)C(=O)NCCN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O, Fc1ccc(cc1)C(=O)NCCN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O, Fc1ccc(cc1)C(=O)NCCN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O, Fc1ccc(cc1)C(=O)NCCN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O, Fc1ccc(cc1)C(=O)NCCN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Fc1ccc(cc1)C(=O)NCCN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O",416.141531844,29,2.998,70.13,0.0250638780048736,0.058,0.0415319390024368,0,0
"SGC-707","protein arginine N-methyltransferase inhibitor","PRMT3","O=C(NCC(=O)N1CCCC1)Nc1ccc2cnccc2c1, O=C(NCC(=O)N1CCCC1)Nc1ccc2cnccc2c1, O=C(NCC(=O)N1CCCC1)Nc1ccc2cnccc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(NCC(=O)N1CCCC1)Nc1ccc2cnccc2c1",298.142975816,22,0.75,74.33,0.0430449884818571,0.04,0.0415224942409286,0,0
"CJ-13610","lipoxygenase inhibitor","","Cc1nccn1-c1ccc(Sc2cccc(c2)C2(CCOCC2)C(N)=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1nccn1-c1ccc(Sc2cccc(c2)C2(CCOCC2)C(N)=O)cc1",393.151097976,28,3.356,95.44,0.0210285164363081,0.062,0.041514258218154,0,0
"mitapivat","pyruvate kinase isozyme activator","","O=C(N1CCN(CC2CC2)CC1)c1ccc(NS(=O)(=O)c2cccc3cccnc23)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(N1CCN(CC2CC2)CC1)c1ccc(NS(=O)(=O)c2cccc3cccnc23)cc1",450.172561692,32,2.746,90.99,0.0130129012853218,0.07,0.0415064506426609,0,0
"guanidinoethyldisulfide-bicarbonate","nitric oxide synthase inhibitor","NOS2","NC(=N)NCCSSCCNC(N)=N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NC(=N)NCCSSCCNC(N)=N",236.087786512,14,0.65,174.4,0.00300112635243823,0.08,0.0415005631762191,0,0
"TG-100572","SRC inhibitor, VEGFR inhibitor","KDR, SRC","Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl",475.177502752,34,4.939,83.4,0.0229375117388119,0.06,0.0414687558694059,0,0
"2-fluoro-2-deoxy-D-galactose","","LCT","OC[C@H]1O[C@@H](O)[C@@H](F)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:6,&4:8,&5:10,r|, OC[C@H]1O[C@@H](O)[C@@H](F)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:6,&4:8,&5:10,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC[C@H]1O[C@@H](O)[C@@H](F)[C@@H](O)[C@@H]1O |&1:2",182.059051672,12,-1.381,90.15,0.0287520665410656,0.054,0.0413760332705328,0,0
"AZ3146","monopolar spindle 1 kinase inhibitor","","COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1",452.253588884,33,2.604,86.44,0.0166692283291331,0.066,0.0413346141645666,0,0
"FG-4592","hypoxia inducible factor prolyl hydroxylase inhibitor","EGLN1, EGLN2, EGLN3","Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12",352.105921612,26,0.993999999999999,108.75,0.0146565760967419,0.068,0.041328288048371,0,0
"CK-101","EGFR inhibitor","","OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F, OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F",530.224180576,39,4.095,93.62,0.0126208335255338,0.07,0.0413104167627669,0,0
"ICI-192605","thromboxane receptor antagonist","TBXA2R","OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl, OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl, OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl",402.123401516,28,4.709,75.99,0.0365324100252327,0.046,0.0412662050126164,0,0
"daltroban","thromboxane receptor antagonist","TBXA2R","OC(=O)Cc1ccc(CCNS(=O)(=O)c2ccc(Cl)cc2)cc1, OC(=O)Cc1ccc(CCNS(=O)(=O)c2ccc(Cl)cc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","OC(=O)Cc1ccc(CCNS(=O)(=O)c2ccc(Cl)cc2)cc1",353.048856672,23,2.788,91.85,0.0164620319291135,0.066,0.0412310159645567,0,0
"genipin","choleretic agent","","COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO |c:13,t:4|, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO |c:13,t:4|, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO |c:13,t:4|, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO |c:13,t:4|, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO |c:13,t:4|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO |c:13",226.084123548,16,-0.746,75.99,0.0404382234360305,0.042,0.0412191117180152,0,0
"JW-67","WNT pathway inhibitor","APC, AXIN1, GSK3B","O=C1Nc2ccccc2C11OCC2(CO1)COC1(OC2)C(=O)Nc2ccccc12, O=C1Nc2ccccc2C11OCC2(CO1)COC1(OC2)C(=O)Nc2ccccc12, O=C1Nc2ccccc2C11OCC2(CO1)COC1(OC2)C(=O)Nc2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C1Nc2ccccc2C11OCC2(CO1)COC1(OC2)C(=O)Nc2ccccc12",394.116486296,29,0.272,95.12,0.0123413788476836,0.07,0.0411706894238418,0,0
"RKI-1447","rho associated kinase inhibitor","CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2","Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1, Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1, Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1, Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1",326.083746688,23,1.804,115.38,0.0143120241736157,0.068,0.0411560120868079,0,0
"EPZ-5676","histone lysine methyltransferase inhibitor","DOT1L","CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1",562.337987204,41,3.722,151.23,0.0022518783643852,0.08,0.0411259391821926,0,0
"fostemsavir","antiviral","","COc1cnc(-n2cnc(C)n2)c2n(COP(O)(O)=O)cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1cnc(-n2cnc(C)n2)c2n(COP(O)(O)=O)cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12",583.158047422,41,0.131,192.02,0.000220787503401218,0.082,0.0411103937517006,0,0
"nitrocaramiphen","cholinergic receptor antagonist","CHRM1","CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O, CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"preclinical","","","CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O",334.189257312,24,4.083,72.68,0.0661972912939929,0.016,0.0410986456469964,0,0
"elubrixin","cc chemokine receptor antagonist","CXCR2","Oc1c(NC(=O)Nc2cccc(F)c2Cl)ccc(Cl)c1S(=O)(=O)N1CCNCC1.Cc1ccc(cc1)S(=O)(=O)O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","pulmonary","cystic fibrosis","Oc1c(NC(=O)Nc2cccc(F)c2Cl)ccc(Cl)c1S(=O)(=O)N1CCNCC1.Cc1ccc(cc1)S(=O)(=O)O",634.05257472,40,4.313,181.9,0.000183166590300153,0.082,0.0410915832951501,0,0
"ciluprevir","serine protease inhibitor","","COc1ccc2c(O[C@@H]3C[C@@H]4N(C3)C(=O)[C@H](CCCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(O)=O)NC(=O)OC3CCCC3)cc(nc2c1)-c1csc(NC(C)C)n1 |c:22|, COc1ccc2c(O[C@@H]3C[C@@H]4N(C3)C(=O)[C@H](CCCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(O)=O)NC(=O)OC3CCCC3)cc(nc2c1)-c1csc(NC(C)C)n1 |c:22|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc2c(O[C@@H]3C[C@@H]4N(C3)C(=O)[C@H](CCCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(O)=O)NC(=O)OC3CCCC3)cc(nc2c1)-c1csc(NC(C)C)n1 |c:22|",774.34108356,55,5.817,209.55,0.000154577536169997,0.082,0.041077288768085,0,0
"omeprazole-sulfide","ATPase inhibitor","","COc1ccc2nc(SCc3ncc(C)c(OC)c3C)[nH]c2c1, COc1ccc2nc(SCc3ncc(C)c(OC)c3C)[nH]c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1ccc2nc(SCc3ncc(C)c(OC)c3C)[nH]c2c1",329.119797848,23,2.633,85.33,0.0321451087455058,0.05,0.0410725543727529,0,0
"TG-100713","PI3K inhibitor","","Nc1nc(N)c2nc(cnc2n1)-c1cccc(O)c1, Nc1nc(N)c2nc(cnc2n1)-c1cccc(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1nc(N)c2nc(cnc2n1)-c1cccc(O)c1",254.09160894,19,0.325,123.83,0.0181390907773547,0.064,0.0410695453886774,0,0
"tributyrin","HDAC inhibitor","","CCCC(=O)OCC(COC(=O)CCC)OC(=O)CCC, CCCC(=O)OCC(COC(=O)CCC)OC(=O)CCC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCCC(=O)OCC(COC(=O)CCC)OC(=O)CCC",302.172938552,21,2.806,78.9,0.0460932122336824,0.036,0.0410466061168412,0,0
"exherin","cadherin antagonist","CDH2","CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O, CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O, CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O, CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O, CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O",570.204272808,38,-0.382,267.87,2.29088093622444e-05,0.082,0.0410114544046811,0,0
"PRT062607","SYK inhibitor","FGR, MAP3K9, SYK","N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1",393.202556356,29,2.385,149.66,0.00602025786159809,0.076,0.041010128930799,0,0
"antimony potassium tartrate trihydrate","","","OC(=O)C1O[Sb]2OC(C(O[Sb]3OC1C(=O)O3)C(O)=O)C(=O)O2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)C1O[Sb]2OC(C(O[Sb]3OC1C(=O)O3)C(O)=O)C(=O)O2",535.793557032,22,-1.566,164.12,1.08263918365568e-05,0.082,0.0410054131959183,0,0
"heparin (sodium salt)","thrombin inhibitor","","CC(=O)NC1C(O)OC(COS(O)(=O)=O)C(OC2OC(C(OC3OC(CO)C(OC4OC(C(O)C(O)C4OS(O)(=O)=O)C(O)=O)C(OS(O)(=O)=O)C3NS(O)(=O)=O)C(O)C2OS(O)(=O)=O)C(O)=O)C1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CC(=O)NC1C(O)OC(COS(O)(=O)=O)C(OC2OC(C(OC3OC(CO)C(OC4OC(C(O)C(O)C4OS(O)(=O)=O)C(O)=O)C(OS(O)(=O)=O)C3NS(O)(=O)=O)C(O)C2OS(O)(=O)=O)C(O)=O)C1O",1134.006995284,70,-13.27,652.39,2.90766120760442e-13,0.082,0.0410000000001454,0,0
"velaresol","","","OC(=O)CCCCOc1cccc(O)c1C=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)CCCCOc1cccc(O)c1C=O",238.084123548,17,1.912,83.83,0.0599230706703721,0.022,0.0409615353351861,0,0
"tandutinib","FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","CSF1R, FLT3, KIT, PDGFD, PDGFRB","COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1",562.326753824,41,4.214,92.29,0.00988923142327718,0.072,0.0409446157116386,0,0
"VU0240551","potassium/chloride cotransporter inhibitor","SLC12A5","Cc1csc(NC(=O)CSc2ccc(nn2)-c2ccccc2)n1",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1csc(NC(=O)CSc2ccc(nn2)-c2ccccc2)n1",342.060903068,23,2.395,121.31,0.00988548452472791,0.072,0.0409427422623639,0,0
"yoda-1","piezo channel activator","PIEZO1","Clc1cccc(Cl)c1CSc1nnc(s1)-c1cnccn1, Clc1cccc(Cl)c1CSc1nnc(s1)-c1cnccn1, Clc1cccc(Cl)c1CSc1nnc(s1)-c1cnccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1cccc(Cl)c1CSc1nnc(s1)-c1cnccn1",353.956743616,21,3.895,105.1,0.0098702473681807,0.072,0.0409351236840904,0,0
"deoxycorticosterone-acetate","progestogen hormone","NR3C2","CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|",372.230059504,27,4.529,60.44,0.077866909284668,0.004,0.040933454642334,0,0
"DUP-697","cyclooxygenase inhibitor","PTGS2","CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1, CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1, CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1",409.944611944,23,4.987,70.76,0.0118662368673375,0.07,0.0409331184336688,0,0
"THZ1-R","CDK inhibitor","CDK7","CN(C)CCCC(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1, CN(C)CCCC(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)CCCC(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1",567.21495088,41,4.657,115.04,0.00581207610403215,0.076,0.0409060380520161,0,0
"ono-4059","bruton's tyrosine kinase (btk) inhibitor","","Nc1ncnc2n(C3CCCN(C3)C(=O)C=C)c(=O)n(-c3ccc(Oc4ccccc4)cc3)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Nc1ncnc2n(C3CCCN(C3)C(=O)C=C)c(=O)n(-c3ccc(Oc4ccccc4)cc3)c12",456.190988628,34,2.614,108.27,0.0116042404003011,0.07,0.0408021202001505,0,0
"CKI-7","casein kinase inhibitor","CSNK1G2","NCCNS(=O)(=O)c1ccc(Cl)c2ccncc12, NCCNS(=O)(=O)c1ccc(Cl)c2ccncc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NCCNS(=O)(=O)c1ccc(Cl)c2ccncc12",285.033875304,18,0.731,93.46,0.0153980597490215,0.066,0.0406990298745107,0,0
"BMS-CCR2-22","CC chemokine receptor antagonist","CCR2","CSc1ccc(cc1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)c1cc(ccc1NC(=O)NC(C)C)C(F)(F)F, CSc1ccc(cc1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)c1cc(ccc1NC(=O)NC(C)C)C(F)(F)F, CSc1ccc(cc1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)c1cc(ccc1NC(=O)NC(C)C)C(F)(F)F, CSc1ccc(cc1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)c1cc(ccc1NC(=O)NC(C)C)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CSc1ccc(cc1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)c1cc(ccc1NC(=O)NC(C)C)C(F)(F)F",593.228360228,41,4.985,153.73,0.00138528787630364,0.08,0.0406926439381518,0,0
"LY450108","glutamate receptor modulator","","CC(C)S(=O)(=O)NC[C@H](C)c1ccc(NC(=O)c2cc(F)cc(F)c2)cc1, CC(C)S(=O)(=O)NC[C@H](C)c1ccc(NC(=O)c2cc(F)cc(F)c2)cc1, CC(C)S(=O)(=O)NC[C@H](C)c1ccc(NC(=O)c2cc(F)cc(F)c2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)S(=O)(=O)NC[C@H](C)c1ccc(NC(=O)c2cc(F)cc(F)c2)cc1",396.131920004,27,3.527,83.65,0.0213094798217468,0.06,0.0406547399108734,0,0
"dihydromyricetin","","","O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1",320.053217344,23,1.472,147.68,0.00725846529537924,0.074,0.0406292326476896,0,0
"sb-431542","activin receptor inhibitor","A1BG, ACVR1B, ACVR1C, TGFBR1","NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","oncology","brain tumors","NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1",384.122240372,29,3.345,103.12,0.027250849675158,0.054,0.040625424837579,0,0
"SB-431542","TGF beta receptor inhibitor","ACVR1C, TGFBR1","NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1",384.122240372,29,3.345,103.12,0.027250849675158,0.054,0.040625424837579,0,0
"scriptaid","HDAC inhibitor","HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9","ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23, ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23, ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23",326.126657056,24,2.366,86.71,0.0391543623763721,0.042,0.040577181188186,0,0
"K02288","bone morphogenic protein inhibitor","BMP1","COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1",352.14230712,26,3.632,86.83,0.0450591846897973,0.036,0.0405295923448987,0,0
"aloxistatin","protease inhibitor","CTSG","CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C",342.21547206,24,2.305,97.03,0.0210578239954177,0.06,0.0405289119977088,0,0
"PF-05190457","growth hormone secretagogue receptor inverse agonist","GHSR","Cc1cn2cc(CC(=O)N3CCC4(CN(C4)[C@@H]4CCc5cc(ccc45)-c4cc(C)ncn4)CC3)nc2s1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1cn2cc(CC(=O)N3CCC4(CN(C4)[C@@H]4CCc5cc(ccc45)-c4cc(C)ncn4)CC3)nc2s1",512.235830644,37,2.944,94.87,0.00899706808709559,0.072,0.0404985340435478,0,0
"GSK2837808A","lactate dehydrogenase inhibitor","LDHA","COc1ncc(-c2ccc3c(Nc4cc(Oc5cc(F)cc(F)c5)cc(c4)C(O)=O)c(cnc3c2)S(=O)(=O)NC2CC2)c(OC)n1, COc1ncc(-c2ccc3c(Nc4cc(Oc5cc(F)cc(F)c5)cc(c4)C(O)=O)c(cnc3c2)S(=O)(=O)NC2CC2)c(OC)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ncc(-c2ccc3c(Nc4cc(Oc5cc(F)cc(F)c5)cc(c4)C(O)=O)c(cnc3c2)S(=O)(=O)NC2CC2)c(OC)n1",649.14427558,46,5.938,170.24,0.000992617730692203,0.08,0.0404963088653461,0,0
"TAK-960","PLK inhibitor","PLK1","COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1, COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1, COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1, COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1, COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1",561.267522608,40,3.203,102.93,0.00493643609557978,0.076,0.0404682180477899,0,0
"MC-1","","AADAT, ABAT, AGXT, AGXT2, ALAS1, AZIN2, BCAT1, BCAT2, CBS, CCBL1, CCBL2, CSAD, CTH, DDC, FTCD, GAD1, GAD2, GADL1, GCAT, GLDC, GOT1, GOT2, GPT, GPT2, HDC, IGSF10, KYNU, MOCOS, NFS1, OAT, ODC1, PDXDC1, PDXP, PHYKPL, PNPO, PROSC, PSAT1, PYGB, PYGL, PYGM, SCLY, SDS, SDSL, SEPSECS, SGPL1, SHMT1, SHMT2, SPTLC1, SPTLC2, SPTLC3, SRR, TAT, THNSL1","Cc1ncc(COP(O)(O)=O)c(C=O)c1O, Cc1ncc(COP(O)(O)=O)c(C=O)c1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cc1ncc(COP(O)(O)=O)c(C=O)c1O",247.02457367,16,-1.236,126.76,0.00693240103537049,0.074,0.0404662005176852,0,0
"batabulin","tubulin polymerisation inhibitor","TUBB","O=S(C1=C(F)C(F)=C(F)C(F)=C1F)(NC2=CC=C(OC)C(F)=C2)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","breast cancer","O=S(C1=C(F)C(F)=C(F)C(F)=C1F)(NC2=CC=C(OC)C(F)=C2)=O",371.005083404,24,1.519,63.78,0.0188994070659998,0.062,0.0404497035329999,0,0
"ar-9281","epoxide hydolase inhibitor","EPHX2","CC(=O)N1CCC(CC1)NC(=O)NC23CC4CC(CC(C4)C2)C3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","cardiology","hypertension","CC(=O)N1CCC(CC1)NC(=O)NC23CC4CC(CC(C4)C2)C3",319.225977168,23,2.413,61.44,0.0648648102519686,0.016,0.0404324051259843,0,0
"astilbin","nuclear factor erythroid derived, like (NRF2) activator","","C[C@@H]1O[C@@H](O[C@@H]2[C@H](Oc3cc(O)cc(O)c3C2=O)c2ccc(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H]1O[C@@H](O[C@@H]2[C@H](Oc3cc(O)cc(O)c3C2=O)c2ccc(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O",450.116211524,32,0.615,186.37,0.000856913522174429,0.08,0.0404284567610872,0,0
"pf 04531083","voltage-gated sodium channel modulator","SCN10A","ClC1=CC=C(OC)C=C1C2=C(N=C(NC(C3=CC=NN3C)=O)C=C2)N",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","neurology/psychiatry","chronic pain","ClC1=CC=C(OC)C=C1C2=C(N=C(NC(C3=CC=NN3C)=O)C=C2)N",357.099252432,25,0.896,92.31,0.0147616870013893,0.066,0.0403808435006946,0,0
"teroxirone","DNA inhibitor","","O=c1n(C[C@H]2CO2)c(=O)n(C[C@H]2CO2)c(=O)n1C[C@H]1CO1 |&1:4,&2:11,&3:18,r|, O=c1n(C[C@H]2CO2)c(=O)n(C[C@H]2CO2)c(=O)n1C[C@H]1CO1 |&1:4,&2:11,&3:18,r|, O=c1n(C[C@H]2CO2)c(=O)n(C[C@H]2CO2)c(=O)n1C[C@H]1CO1 |&1:4,&2:11,&3:18,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","O=c1n(C[C@H]2CO2)c(=O)n(C[C@H]2CO2)c(=O)n1C[C@H]1CO1 |&1:4",297.0960852,21,-0.141,103.59,0.0147184147274646,0.066,0.0403592073637323,0,0
"resminostat","HDAC inhibitor","HDAC1, HDAC3, HDAC6, HDAC8","CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1",349.109627088,24,1.078,100.02,0.0124395937500614,0.068,0.0402197968750307,0,0
"RS-79948","adrenergic receptor antagonist","ADRA2A","CCS(=O)(=O)N1CCC[C@@H]2CN3CCc4cc(OC)ccc4[C@@H]3C[C@H]12, CCS(=O)(=O)N1CCC[C@@H]2CN3CCc4cc(OC)ccc4[C@@H]3C[C@H]12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"preclinical","","","CCS(=O)(=O)N1CCC[C@@H]2CN3CCc4cc(OC)ccc4[C@@H]3C[C@H]12",364.182063756,25,2.365,58.23,0.0384287264251226,0.042,0.0402143632125613,0,0
"N-acetyl-D-glucosamine","","B4GALT1, B4GALT2, B4GALT3, B4GALT4, NAGK, NAGLU, NAGPA, RENBP","CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO, CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO",221.0899372,15,-3.116,127.09,0.00640807348753876,0.074,0.0402040367437694,0,0
"sstr5 antagonist 1","","SSTR5","CCOc1cc(CN2CC3(C2)CC(=NO3)N2CCC(CC2)C(O)=O)cc(OCC)c1-c1ccc(F)cc1 |c:13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","endocrinology","diabetes mellitus","CCOc1cc(CN2CC3(C2)CC(=NO3)N2CCC(CC2)C(O)=O)cc(OCC)c1-c1ccc(F)cc1 |c:13|",511.248249408,37,5.19,83.83,0.0204061998217698,0.06,0.0402030999108849,0,0
"oprozomib","proteasome inhibitor","","COC[C@H](NC(=O)[C@H](COC)NC(=O)c1cnc(C)s1)C(=O)N[C@@H](Cc1ccccc1)C(=O)[C@@]1(C)CO1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","COC[C@H](NC(=O)[C@H](COC)NC(=O)c1cnc(C)s1)C(=O)N[C@@H](Cc1ccccc1)C(=O)[C@@]1(C)CO1",532.199170364,37,-1.244,176.49,0.000303842169067615,0.08,0.0401519210845338,0,0
"oprozomib (onx 0912)","proteasome inhibitor","","COC[C@H](NC(=O)[C@H](COC)NC(=O)c1cnc(C)s1)C(=O)N[C@@H](Cc1ccccc1)C(=O)C1(C)CO1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","COC[C@H](NC(=O)[C@H](COC)NC(=O)c1cnc(C)s1)C(=O)N[C@@H](Cc1ccccc1)C(=O)C1(C)CO1",532.199170364,37,-1.244,176.49,0.000303842169067615,0.08,0.0401519210845338,0,0
"VE-821","ATR kinase inhibitor","ATR","CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1, CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1, CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1, CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1",368.094311372,26,2.468,123.42,0.0102630052174365,0.07,0.0401315026087183,0,0
"morphothiadin","antiinfective drug","","CCOC(=O)C1=C(CN2CCOCC2)NC(=N[C@@H]1c1ccc(F)cc1Br)c1nccs1 |&1:17,r,c:5,16|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)C1=C(CN2CCOCC2)NC(=N[C@@H]1c1ccc(F)cc1Br)c1nccs1 |&1:17",508.058001884,31,3.183,104.29,0.00214099129021418,0.078,0.0400704956451071,0,0
"kaempferol","bone resorption inhibitor, estrogen-related receptor inverse agonist","AKR1B1, ALOX15B, ALOX5, AR, CYP1B1, GLO1, HSD17B1, UGT3A1","Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O",286.04773804,21,3.691,111.13,0.040139308010799,0.04,0.0400696540053995,0,0
"N-acetylglycyl-D-glutamic-acid","glutamate receptor agonist","","CC(=O)NCC(=O)N[C@H](CCC(O)=O)C(O)=O, CC(=O)NCC(=O)N[C@H](CCC(O)=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)NCC(=O)N[C@H](CCC(O)=O)C(O)=O",246.085186168,17,-3.901,132.8,0.00404804829694997,0.076,0.040024024148475,0,0
"sacubitrilat","neprilysin inhibitor","","[H]N([C@@H](C[C@@H](C)C(O)=O)Cc1ccc(cc1)-c1ccccc1)C(=O)CCC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H]N([C@@H](C[C@@H](C)C(O)=O)Cc1ccc(cc1)-c1ccccc1)C(=O)CCC(O)=O",383.1732729,29,3.116,103.7,0.0260339832852944,0.054,0.0400169916426472,0,0
"iRGD-peptide","integrin signaling activator","","[H][C@@]12CCCN1C(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@]([H])(CC(O)=O)NC(=O)CNC(=O)[C@]([H])(CCCNC(N)=N)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC2=O)C(O)=O, [H][C@@]12CCCN1C(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@]([H])(CC(O)=O)NC(=O)CNC(=O)[C@]([H])(CCCNC(N)=N)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC2=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@@]12CCCN1C(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@]([H])(CC(O)=O)NC(=O)CNC(=O)[C@]([H])(CCCNC(N)=N)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC2=O)C(O)=O",947.358935504,67,-1.861,500.45,7.02606433713294e-09,0.08,0.0400000035130322,0,0
"nobiletin","MEK inhibitor","MAP2K1","COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1, COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1",402.131467664,29,4.108,85.59,0.0319201823761326,0.048,0.0399600911880663,0,0
"triapine","ribonucleotide reductase inhibitor","RRM1, RRM2","NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NC(=S)N\N=C\c1ncccc1N",195.057866288,13,0.355,121.41,0.0198583219763332,0.06,0.0399291609881666,0,0
"SB-203580","p38 MAPK inhibitor","AKT1, ALOX5, CHEK1, CYP2D6, CYP3A4, GAK, GSK3B, LCK, MAPK1, MAPK10, MAPK11, MAPK12, MAPK14, MAPK8, MAPK9, PRKCA, RAF1, RIPK2, ROCK1, RPS6KB1, SGK1, SRC, TNF","C[S@@](=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1 |&1:1|, C[S@@](=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1 |&1:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[S@@](=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1 |&1:1|",377.099811352,27,3.754,77.85,0.0398542546467293,0.04,0.0399271273233647,0,0
"fosbretabulin","tubulin polymerization inhibitor, ve-cadherin antagonist, tubulin polymerization inhibitor, VE-cadherin antagonist","CDH5","COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O",396.097404262,27,2.215,113.49,0.00784607474016031,0.072,0.0399230373700802,0,0
"GSK-J2","histone demethylase inhibitor","","OC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1, OC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1, OC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1",389.185174976,29,3.62,91.24,0.0337897769412083,0.046,0.0398948884706042,0,0
"MRS-3777","adenosine receptor antagonist","ADORA1, ADORA2A, ADORA2B, ADORA3","C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12.C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12.C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12.C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12.C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12",618.317920456,46,8.326,151.44,0.00573470161382004,0.074,0.03986735080691,0,0
"GR-144053","integrin antagonist","ITGA2B, ITGB3","NC(=N)c1ccc(cc1)N1CCN(CC1)C1CCN(CC(O)=O)CC1, NC(=N)c1ccc(cc1)N1CCN(CC1)C1CCN(CC(O)=O)CC1, NC(=N)c1ccc(cc1)N1CCN(CC1)C1CCN(CC(O)=O)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC(=N)c1ccc(cc1)N1CCN(CC1)C1CCN(CC(O)=O)CC1",345.216475104,25,-0.784,96.89,0.01171584501759,0.068,0.039857922508795,0,0
"gastrodin","","","OC[C@H]1O[C@@H](Oc2ccc(CO)cc2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@@H]1O[C@@H](Oc2ccc(CO)cc2)[C@H](O)[C@@H](O)[C@@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC[C@H]1O[C@@H](Oc2ccc(CO)cc2)[C@H](O)[C@@H](O)[C@@H]1O",286.105252916,20,-0.501,119.61,0.00964922075250145,0.07,0.0398246103762507,0,0
"PAOPA","dopamine receptor modulator","DRD2","NC(=O)CN1CC[C@@H](NC(=O)[C@@H]2CCCN2)C1=O, NC(=O)CN1CC[C@@H](NC(=O)[C@@H]2CCCN2)C1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,"preclinical","","","NC(=O)CN1CC[C@@H](NC(=O)[C@@H]2CCCN2)C1=O",254.137890436,18,-1.747,104.53,0.0136028266461383,0.066,0.0398014133230691,0,0
"e-64","","","CC(C)C[C@H](NC(=O)[C@@H]1O[C@H]1C(O)=O)C(=O)NCCCCN=C(N)N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CC(C)C[C@H](NC(=O)[C@@H]1O[C@H]1C(O)=O)C(=O)NCCCCN=C(N)N",357.201218964,25,-0.635,172.43,0.00159979903191485,0.078,0.0397998995159574,0,0
"TG100-115","PI3K inhibitor","PIK3CA, PIK3CB, PIK3CD, PIK3CG","Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1, Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1",346.117823688,26,1.948,144.06,0.00947583015792912,0.07,0.0397379150789646,0,0
"beclabuvir","antiviral","","COc1ccc2-c3c(C4CCCCC4)c4ccc(cc4n3C[C@]3(C[C@H]3c2c1)C(=O)N1[C@H]2CC[C@@H]1CN(C)C2)C(=O)NS(=O)(=O)N(C)C |THB:27:29:31.32:34.35.37|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1ccc2-c3c(C4CCCCC4)c4ccc(cc4n3C[C@]3(C[C@H]3c2c1)C(=O)N1[C@H]2CC[C@@H]1CN(C)C2)C(=O)NS(=O)(=O)N(C)C |THB:27:29:31.32:34.35.37|",659.31414054,47,5.657,112.57,0.0034743721332789,0.076,0.0397371860666394,0,0
"JI-101","kinase inhibitor","","COc1ccc(Br)cc1NC(=O)Nc1cccc2n(Cc3ccnc(N)c3)ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","COc1ccc(Br)cc1NC(=O)Nc1cccc2n(Cc3ccnc(N)c3)ccc12",465.08003698,30,4.021,94.2,0.00733533017714224,0.072,0.0396676650885711,0,0
"tyroserleutide","antitumor agent","PIK3CA","CC(C)C[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","oncology","hepatocellular carcinoma (hcc)","CC(C)C[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O",381.189985584,27,-2.086,161.98,0.00127612932640486,0.078,0.0396380646632024,0,0
"melengestrol-acetate","progesterone receptor agonist","","CC(=O)O[C@]1(C(C)=O)C(=C)C[C@H]2[C@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@@H]3CC[C@]12C |a:4,22,27,&1:11,&2:12,&3:24,t:13,16|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)O[C@]1(C(C)=O)C(=C)C[C@H]2[C@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@@H]3CC[C@]12C |a:4",396.230059504,29,3.795,60.44,0.0592616559884743,0.02,0.0396308279942372,0,0
"2-aminobenzenesulfonamide","carbonic anhydrase inhibitor","CA12, CA14, CA2, CA6, CA9","Nc1ccccc1S(N)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1ccccc1S(N)(=O)=O",172.030648496,11,0.522,94.56,0.041251270828821,0.038,0.0396256354144105,0,0
"apyramide","cyclooxygenase inhibitor","","COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)Oc3ccc(NC(C)=O)cc3)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)Oc3ccc(NC(C)=O)cc3)c2c1",490.129549516,35,4.559,86.63,0.0171756458321648,0.062,0.0395878229160824,0,0
"verinurad","urate transporter inhibitor","SLC22A12","CC(C)(Sc1ccncc1-c1ccc(C#N)c2ccccc12)C(O)=O, CC(C)(Sc1ccncc1-c1ccc(C#N)c2ccccc12)C(O)=O",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)(Sc1ccncc1-c1ccc(C#N)c2ccccc12)C(O)=O",348.093248752,25,4.052,99.28,0.0331532112108396,0.046,0.0395766056054198,0,0
"MM-206","STAT inhibitor","","Oc1c(Sc2ccccc2)cc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1c(Sc2ccccc2)cc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)c2ccccc12",497.017876344,33,6.575,100.08,0.0110984141201223,0.068,0.0395492070600612,0,0
"CL316243","adrenergic receptor agonist","ADRB3, UCP1, UCP2, UCP3","C[C@H](Cc1ccc2OC(Oc2c1)(C(O)=O)C(O)=O)NC[C@H](O)c1cccc(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"phase 2","","","C[C@H](Cc1ccc2OC(Oc2c1)(C(O)=O)C(O)=O)NC[C@H](O)c1cccc(Cl)c1",421.09282966,29,2.087,125.32,0.00505516643330033,0.074,0.0395275832166502,0,0
"FK-3311","cyclooxygenase inhibitor","PTGS2","CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1, CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1, CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1",341.053335336,23,2.942,80.85,0.0290151089785868,0.05,0.0395075544892934,0,0
"OSI-027","mTOR inhibitor","MTOR","COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12 |r|, COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12 |r|, COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12 |r|",406.175338564,30,2.641,131.42,0.0090073381538494,0.07,0.0395036690769247,0,0
"ASP3026","ALK tyrosine kinase receptor inhibitor","ALK","COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1",580.29440814,41,4.096,124.2,0.0030043194374516,0.076,0.0395021597187258,0,0
"artelinic acid","antimalarial agent","","C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](OCc3ccc(cc3)C(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4 |a:1,4,5,7,20,22,26,27|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","infectious disease","malaria","C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](OCc3ccc(cc3)C(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4 |a:1",418.1991533,30,4.659,83.45,0.0328934222707617,0.046,0.0394467111353809,0,0
"ML277","potassium channel activator","KCNQ1","COc1ccc(cc1)-c1csc(NC(=O)[C@H]2CCCCN2S(=O)(=O)c2ccc(C)cc2)n1, COc1ccc(cc1)-c1csc(NC(=O)[C@H]2CCCCN2S(=O)(=O)c2ccc(C)cc2)n1, COc1ccc(cc1)-c1csc(NC(=O)[C@H]2CCCCN2S(=O)(=O)c2ccc(C)cc2)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1)-c1csc(NC(=O)[C@H]2CCCCN2S(=O)(=O)c2ccc(C)cc2)n1",471.12864828,32,4.003,125.22,0.00489332517966182,0.074,0.0394466625898309,0,0
"ar-13324 m1 metabolite","protein kinase c inhibitor","PRKCA, ROCK1","NC[C@@H](C(=O)Nc1ccc2cnccc2c1)c1ccc(CO)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","ophthalmology","macular degeneration","NC[C@@H](C(=O)Nc1ccc2cnccc2c1)c1ccc(CO)cc1",321.147726848,24,1.023,88.24,0.0308831001229835,0.048,0.0394415500614917,0,0
"remoxipride","dopamine receptor antagonist","DRD2, DRD3, DRD4, HTR2A, SIGMAR1","CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC",0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,3,0,0,0,0,0,0,0,0,"withdrawn","","","CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC",370.089204696,22,2.874,50.8,0.0228604079395431,0.056,0.0394302039697716,0,0
"CUDC-101","EGFR inhibitor","EGFR, ERBB2","COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO, COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO, COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO",434.195405312,32,3.619,105.6,0.0167700754913762,0.062,0.0393850377456881,0,0
"calpeptin","calpain inhibitor","","CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O",362.22055744,26,4.542,84.5,0.0466461052228076,0.032,0.0393230526114038,0,0
"L-732,138","tachykinin antagonist","TACR1, TACR2","CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F, CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F, CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F, CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F",472.122161756,33,5.052,71.19,0.0266388941571339,0.052,0.039319447078567,0,0
"vericiguat","guanylate cyclase stimulant","","COC(=O)Nc1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncc(F)cc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COC(=O)Nc1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncc(F)cc12",426.136428192,31,2.362,146.86,0.00461469818740187,0.074,0.0393073490937009,0,0
"chloralose","","","OC[C@@H](O)[C@H]1O[C@@H]2O[C@@H](O[C@@H]2[C@H]1O)C(Cl)(Cl)Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC[C@@H](O)[C@H]1O[C@@H]2O[C@@H](O[C@@H]2[C@H]1O)C(Cl)(Cl)Cl",307.962121112,17,-0.146,88.38,0.00647040501622265,0.072,0.0392352025081113,0,0
"eglumetad","glutamate receptor agonist","GRM2, GRM3, GRM6, GRM8","N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O",185.068807832,13,-3.39,100.62,0.0163515529062922,0.062,0.0391757764531461,0,0
"PRX-07034","serotonin receptor antagonist","","COc1cc(Cl)cc([C@H](C)Nc2cc(ccc2S(C)(=O)=O)N2CCNCC2)c1OC |&1:8,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1cc(Cl)cc([C@H](C)Nc2cc(ccc2S(C)(=O)=O)N2CCNCC2)c1OC |&1:8",453.148905056,30,3.699,88.28,0.0103111809974869,0.068,0.0391555904987435,0,0
"nitecapone","catechol O methyltransferase inhibitor","COMT","CC(=O)C(=Cc1cc(O)c(O)c(c1)[N+]([O-])=O)C(C)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(=O)C(=Cc1cc(O)c(O)c(c1)[N+]([O-])=O)C(C)=O",265.058637072,19,2.645,117.74,0.0281049987166065,0.05,0.0390524993583032,0,0
"kifunensine","mannosidase inhibitor","MAN1B1, MAN2A1","OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12, OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12, OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12, OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12",232.069536104,16,-1.755,130.33,0.00802533474752724,0.07,0.0390126673737636,0,0
"antimonyl","","","O=C1O[SbH]23OC1C1O[SbH]4(OC(C(O2)C(=O)O3)C(=O)O4)OC1=O, O=C1O[SbH]23OC1C1O[SbH]4(OC(C(O2)C(=O)O3)C(=O)O4)OC1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","O=C1O[SbH]23OC1C1O[SbH]4(OC(C(O2)C(=O)O3)C(=O)O4)OC1=O",535.793557032,22,-0.86,142.12,2.14385471313577e-05,0.078,0.0390107192735657,0,0
"dihydrostreptomycin","bacterial 30S ribosomal subunit inhibitor","","CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]2NC(N)=N)O[C@@H](C)[C@]1(O)CO.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]2NC(N)=N)O[C@@H](C)[C@]1(O)CO, CN[C@H]1C(O)C(O)C(CO)OC1OC1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)OC(C)[C@]1(O)CO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]2NC(N)=N)O[C@@H](C)[C@]1(O)CO.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]2NC(N)=N)O[C@@H](C)[C@]1(O)CO",1166.562639504,80,-7.55,669.18,3.68666111735656e-12,0.078,0.0390000000018433,0,0
"PKI-179","mTOR inhibitor, PI3K inhibitor","MTOR","O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1[C@H]2CC[C@@H]1COC2 |&1:29,&2:32|, O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1[C@H]2CC[C@@H]1COC2 |&1:29,&2:32|, O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1[C@H]2CC[C@@H]1COC2 |&1:29,&2:32|, O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1[C@H]2CC[C@@H]1COC2 |&1:29,&2:32|, O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1[C@H]2CC[C@@H]1COC2 |&1:29,&2:32|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1[C@H]2CC[C@@H]1COC2 |&1:29",488.228436756,36,2.03,117.63,0.00599927350217467,0.072,0.0389996367510873,0,0
"tie2-kinase-inhibitor","TIE tyrosine kinase inhibitor","KDR, MAPK14","COc1ccc2cc(ccc2c1)-c1[nH]c(nc1-c1ccncc1)-c1ccc(cc1)[S@@](C)=O |r|, COc1ccc2cc(ccc2c1)-c1[nH]c(nc1-c1ccncc1)-c1ccc(cc1)[S@@](C)=O |r|, COc1ccc2cc(ccc2c1)-c1[nH]c(nc1-c1ccncc1)-c1ccc(cc1)[S@@](C)=O |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc2cc(ccc2c1)-c1[nH]c(nc1-c1ccncc1)-c1ccc(cc1)[S@@](C)=O |r|",439.135447912,32,4.774,87.08,0.0299830188028478,0.048,0.0389915094014239,0,0
"A-922500","diacylglycerol O acyltransferase inhibitor","DGAT1","OC(=O)[C@@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1, OC(=O)[C@@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1, OC(=O)[C@@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)[C@@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1",428.173607248,32,4.484,95.5,0.0298599152532217,0.048,0.0389299576266109,0,0
"A922500","diacylglycerol O acyltransferase inhibitor","DGAT1","OC(=O)[C@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)[C@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1",428.173607248,32,4.484,95.5,0.0298599152532217,0.048,0.0389299576266109,0,0
"SR-1664","PPAR receptor ligand","PPARG","C[C@H](NC(=O)c1ccc2n(Cc3ccc(cc3)-c3ccccc3C(O)=O)c(C)c(C)c2c1)c1ccc(cc1)[N+]([O-])=O, C[C@H](NC(=O)c1ccc2n(Cc3ccc(cc3)-c3ccccc3C(O)=O)c(C)c(C)c2c1)c1ccc(cc1)[N+]([O-])=O, C[C@H](NC(=O)c1ccc2n(Cc3ccc(cc3)-c3ccccc3C(O)=O)c(C)c(C)c2c1)c1ccc(cc1)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H](NC(=O)c1ccc2n(Cc3ccc(cc3)-c3ccccc3C(O)=O)c(C)c(C)c2c1)c1ccc(cc1)[N+]([O-])=O",547.210721028,41,7.694,114.47,0.0197343420061081,0.058,0.038867171003054,0,0
"vicagrel","platelet aggregation inhibitor","P2RY12","COC(=O)[C@@H](N1CCc2sc(OC(=O)C)cc2C1)c3ccccc3Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","cardiology","coronary artery disease (cad)","COC(=O)[C@@H](N1CCc2sc(OC(=O)C)cc2C1)c3ccccc3Cl",379.064506736,25,2.509,84.08,0.0156800709992444,0.062,0.0388400354996222,0,0
"BMY-7378","adrenergic receptor antagonist, serotonin receptor antagonist","ADRA1A, ADRA1B, ADRA1D, HTR1A","COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1, COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1, COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1, COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,3,0,0,0,0,"preclinical","","","COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1",385.236541852,28,3.141,53.09,0.0616686589929572,0.016,0.0388343294964786,0,0
"BLU9931","FGFR inhibitor","FGFR4","COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(Nc3c(C)cccc3NC(=O)C=C)ncc2c1, COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(Nc3c(C)cccc3NC(=O)C=C)ncc2c1, COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(Nc3c(C)cccc3NC(=O)C=C)ncc2c1, COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(Nc3c(C)cccc3NC(=O)C=C)ncc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(Nc3c(C)cccc3NC(=O)C=C)ncc2c1",508.106895924,35,5.81,85.37,0.0156627084045418,0.062,0.0388313542022709,0,0
"1-phenylbiguanide","serotonin receptor agonist","HTR3A, HTR3B","NC(N)=NC(=N)Nc1ccccc1, NC(N)=NC(=N)Nc1ccccc1",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NC(N)=NC(=N)Nc1ccccc1",177.101445352,13,0.464,100.28,0.049588416645289,0.028,0.0387942083226445,0,0
"endo-IWR-1","PARP inhibitor","TNKS, TNKS2","O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|",409.142641468,31,2.779,79.37,0.0355490417694305,0.042,0.0387745208847152,0,0
"exo-IWR-1","WNT signaling inhibitor negative control","TNKS","O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@H]3C[C@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@H]3C[C@H](C=C3)[C@H]2C1=O |c:29|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@H]3C[C@H](C=C3)[C@H]2C1=O |c:29|",409.142641468,31,2.779,79.37,0.0355490417694305,0.042,0.0387745208847152,0,0
"dofetilide","potassium channel blocker","KCNH1, KCNH2, KCNJ12, KCNK2","CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1",441.139212964,29,2.138,121.57,0.00346303141747835,0.074,0.0387315157087392,0,0
"clioquinol","chelating agent","OPRK1","Oc1c(I)cc(Cl)c2cccnc12, Oc1c(I)cc(Cl)c2cccnc12, Oc1c(I)cc(Cl)c2cccnc12, Oc1c(I)cc(Cl)c2cccnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","Oc1c(I)cc(Cl)c2cccnc12",304.91043946,13,3.409,33.12,0.0234383220164431,0.054,0.0387191610082215,0,0
"nelociguat","guanylate cyclase stimulant","","COC(=O)Nc1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)Nc1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12",408.145850004,30,2.201,146.86,0.00541224504984568,0.072,0.0387061225249228,0,0
"JNJ-42165279","FAAH inhibitor","FAAH","FC1(F)Oc2ccc(CN3CCN(CC3)C(=O)Nc3cnccc3Cl)cc2O1, FC1(F)Oc2ccc(CN3CCN(CC3)C(=O)Nc3cnccc3Cl)cc2O1, FC1(F)Oc2ccc(CN3CCN(CC3)C(=O)Nc3cnccc3Cl)cc2O1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","FC1(F)Oc2ccc(CN3CCN(CC3)C(=O)Nc3cnccc3Cl)cc2O1",410.095724524,28,1.978,66.93,0.0194005551487377,0.058,0.0387002775743689,0,0
"PF-04418948","prostaglandin inhibitor","PTGER2","COc1ccc2cc(OCC3(CN(C3)C(=O)c3ccc(F)cc3)C(O)=O)ccc2c1, COc1ccc2cc(OCC3(CN(C3)C(=O)c3ccc(F)cc3)C(O)=O)ccc2c1, COc1ccc2cc(OCC3(CN(C3)C(=O)c3ccc(F)cc3)C(O)=O)ccc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1ccc2cc(OCC3(CN(C3)C(=O)c3ccc(F)cc3)C(O)=O)ccc2c1",409.13255096,30,3.616,76.07,0.0373621195310466,0.04,0.0386810597655233,0,0
"BIX-01294","histone lysine methyltransferase inhibitor","EHMT1, EHMT2","COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1",490.305624456,36,4.184,65.99,0.0312435939022908,0.046,0.0386217969511454,0,0
"CC-930","JNK inhibitor","","O[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1, O[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1, O[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1, O[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1, O[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1",448.183458636,32,3.199,97.12,0.013227491899164,0.064,0.038613745949582,0,0
"SGI-1027","DNA methyltransferase inhibitor","DNMT1, DNMT3A, DNMT3B","Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1, Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1, Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1, Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1",461.196408356,35,4.181,117.85,0.0151925422473019,0.062,0.0385962711236509,0,0
"atuveciclib","CDK9 inhibitor","","COc1cc(F)ccc1-c1ncnc(Nc2cccc(C[S@](C)(=N)=O)c2)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1cc(F)ccc1-c1ncnc(Nc2cccc(C[S@](C)(=N)=O)c2)n1",387.116524036,27,3.024,109.23,0.0130231853001036,0.064,0.0385115926500518,0,0
"decernotinib","protein tyrosine kinase inhibitor, JAK inhibitor","JAK2, JAK3","CC[C@@](C)(Nc1ccnc(n1)-c1c[nH]c2ncccc12)C(=O)NCC(F)(F)F |&1:2,r|, CC[C@@](C)(Nc1ccnc(n1)-c1c[nH]c2ncccc12)C(=O)NCC(F)(F)F |&1:2,r|, CC[C@@](C)(Nc1ccnc(n1)-c1c[nH]c2ncccc12)C(=O)NCC(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","immunology","rheumatoid arthritis","CC[C@@](C)(Nc1ccnc(n1)-c1c[nH]c2ncccc12)C(=O)NCC(F)(F)F |&1:2",392.157243888,28,3.27,95.59,0.0210118297163472,0.056,0.0385059148581736,0,0
"carebastine","histamine receptor antagonist","HRH1","CC(C)(C(O)=O)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CC(C)(C(O)=O)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)(C(O)=O)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1",499.272258664,37,5.929,66.84,0.0469856177715564,0.03,0.0384928088857782,0,0
"KRN-633","VEGFR inhibitor","FLT1, FLT4, KDR","CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl, CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl, CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl",416.125132832,29,3.152,94.6,0.0149193883801219,0.062,0.0384596941900609,0,0
"SirReal-2","SIRT inhibitor","SIRT2","Cc1cc(C)nc(SCC(=O)Nc2ncc(Cc3cccc4ccccc34)s2)n1, Cc1cc(C)nc(SCC(=O)Nc2ncc(Cc3cccc4ccccc34)s2)n1, Cc1cc(C)nc(SCC(=O)Nc2ncc(Cc3cccc4ccccc34)s2)n1, Cc1cc(C)nc(SCC(=O)Nc2ncc(Cc3cccc4ccccc34)s2)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(C)nc(SCC(=O)Nc2ncc(Cc3cccc4ccccc34)s2)n1",420.10785326,29,2.881,121.31,0.00688852656674455,0.07,0.0384442632833723,0,0
"MK-3207","calcitonin antagonist","CALCA","Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31, Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31, Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31",557.223846228,41,3.271,103.43,0.00686831338175314,0.07,0.0384341566908766,0,0
"suprofen","cyclooxygenase inhibitor","PTGS1, PTGS2","C[C@@H](C(O)=O)c1ccc(cc1)C(=O)c1cccs1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)C(=O)c1cccs1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)C(=O)c1cccs1 |&1:1,r|",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","C[C@@H](C(O)=O)c1ccc(cc1)C(=O)c1cccs1 |&1:1",260.050715244,18,2.279,82.61,0.0507206847662545,0.026,0.0383603423831272,0,0
"S4","carbonic anhydrase inhibitor","CA12, CA9","Cc1cc(C)cc(NC(=O)Nc2ccc(OS(N)(=O)=O)cc2)c1, Cc1cc(C)cc(NC(=O)Nc2ccc(OS(N)(=O)=O)cc2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1cc(C)cc(NC(=O)Nc2ccc(OS(N)(=O)=O)cc2)c1",335.093977024,23,0.969,118.9,0.00871364007618887,0.068,0.0383568200380944,0,0
"talmapimod","p38 MAPK inhibitor","IL1B, MAPK11, MAPK14, MT-CO2, TNF","C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C",512.19904672,36,4.161,65.86,0.0187009571377582,0.058,0.0383504785688791,0,0
"PF-04136309","CC chemokine receptor antagonist","","O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1, O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1, O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1, O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1, O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1",568.240973512,41,2.088,120.34,0.00267909940395844,0.074,0.0383395497019792,0,0
"indisulam","CDK inhibitor","CA1, CA12, CA14, CA2, CA6, CA7, CA9","NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12, NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12, NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12, NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12",384.995775544,24,1.904,138.88,0.00264968461275055,0.074,0.0383248423063753,0,0
"SA-47","FAAH inhibitor","FAAH","CNC(=O)COC(=O)NCCC1CCN(CC1)c1cccc(C)n1, CNC(=O)COC(=O)NCCC1CCN(CC1)c1cccc(C)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CNC(=O)COC(=O)NCCC1CCN(CC1)c1cccc(C)n1",334.200490692,24,2.081,83.56,0.0326020239990539,0.044,0.038301011999527,0,0
"TAK-220","CC chemokine receptor antagonist","CCR5","CC(=O)N1CCC(CC1)C(=O)N(CCCN1CCC(Cc2ccc(cc2)C(N)=O)CC1)c1ccc(C)c(Cl)c1, CC(=O)N1CCC(CC1)C(=O)N(CCCN1CCC(Cc2ccc(cc2)C(N)=O)CC1)c1ccc(C)c(Cl)c1, CC(=O)N1CCC(CC1)C(=O)N(CCCN1CCC(Cc2ccc(cc2)C(N)=O)CC1)c1ccc(C)c(Cl)c1, CC(=O)N1CCC(CC1)C(=O)N(CCCN1CCC(Cc2ccc(cc2)C(N)=O)CC1)c1ccc(C)c(Cl)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(=O)N1CCC(CC1)C(=O)N(CCCN1CCC(Cc2ccc(cc2)C(N)=O)CC1)c1ccc(C)c(Cl)c1",552.286718852,39,4.029,86.95,0.00858783080106718,0.068,0.0382939154005336,0,0
"BI-2536","PLK inhibitor","BRD4, PLK1, PLK2, PLK3","CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O",521.311438108,38,3.443,102.93,0.00855354255508073,0.068,0.0382767712775404,0,0
"C34","toll-like receptor inhibitor","TLR4","CC(C)O[C@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1NC(C)=O, CC(C)O[C@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1NC(C)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)O[C@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1NC(C)=O",389.168581444,27,0.418,126.46,0.00442653932584699,0.072,0.0382132696629235,0,0
"BTK-IN-1","Bruton's tyrosine kinase (BTK) inhibitor","","Clc1cccc(NCC(=O)N[C@@H]2CCCN(C2)c2ncnc3[nH]ccc23)c1 |&1:11,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1cccc(NCC(=O)N[C@@H]2CCCN(C2)c2ncnc3[nH]ccc23)c1 |&1:11",384.146536972,27,3.462,85.94,0.0263515013400346,0.05,0.0381757506700173,0,0
"tenovin-6","SIRT inhibitor","SIRT1, SIRT2, SIRT3","CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1",454.240247328,32,4.915,105.56,0.0143200173033878,0.062,0.0381600086516939,0,0
"tenylidone","","","O=C1\C(CCC\C1=C/c1cccs1)=C\c1cccs1, O=C1\C(CCC\C1=C/c1cccs1)=C\c1cccs1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C1\C(CCC\C1=C/c1cccs1)=C\c1cccs1",286.048607068,19,2.625,73.55,0.046281579590073,0.03,0.0381407897950365,0,0
"acetriazoic-acid","","","CC(=O)Nc1c(I)cc(I)c(C(O)=O)c1I, CC(=O)Nc1c(I)cc(I)c(C(O)=O)c1I, CC(=O)Nc1c(I)cc(I)c(C(O)=O)c1I",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)Nc1c(I)cc(I)c(C(O)=O)c1I",556.748187052,16,4.095,66.4,6.35853668443811e-05,0.076,0.0380317926834222,0,0
"salvianolic-acid-B","EGFR inhibitor, metalloproteinase inhibitor","MMP9","OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@H](C(=O)O[C@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1, OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@H](C(=O)O[C@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@H](C(=O)O[C@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1",718.15338488,52,4.17,278.04,4.04921583092873e-05,0.076,0.0380202460791546,0,0
"felypressin","vasopressin receptor agonist","","[H][C@@]1(Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)NCC(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@@]1(Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)NCC(N)=O",1039.4367919,73,-1.458,455.92,9.60121911395818e-09,0.076,0.0380000048006096,0,0
"FIPI","phospholipase inhibitor","PLD1, PLD2","Fc1ccc2[nH]c(cc2c1)C(=O)NCCN1CCC(CC1)n1c2ccccc2[nH]c1=O, Fc1ccc2[nH]c(cc2c1)C(=O)NCCN1CCC(CC1)n1c2ccccc2[nH]c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Fc1ccc2[nH]c(cc2c1)C(=O)NCCN1CCC(CC1)n1c2ccccc2[nH]c1=O",421.191403228,31,2.542,85.92,0.02190866908567,0.054,0.037954334542835,0,0
"semagacestat (ly450139)","gamma secretase inhibitor","","CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@@H]1c2ccccc2CCN(C)C1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@@H]1c2ccccc2CCN(C)C1=O",361.200156344,26,0.716,98.74,0.0139025849661987,0.062,0.0379512924830994,0,0
"semagacestat","gamma secretase inhibitor","PSEN1","CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@H]1c2ccccc2CCN(C)C1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@H]1c2ccccc2CCN(C)C1=O",361.200156344,26,0.716,98.74,0.0139025849661987,0.062,0.0379512924830993,0,0
"Ko143","BCRP inhibitor","ABCB1, ABCC1","COc1ccc2c3C[C@@H]4N([C@@H](CC(C)C)c3[nH]c2c1)C(=O)[C@H](CCC(=O)OC(C)(C)C)NC4=O, COc1ccc2c3C[C@@H]4N([C@@H](CC(C)C)c3[nH]c2c1)C(=O)[C@H](CCC(=O)OC(C)(C)C)NC4=O, COc1ccc2c3C[C@@H]4N([C@@H](CC(C)C)c3[nH]c2c1)C(=O)[C@H](CCC(=O)OC(C)(C)C)NC4=O, COc1ccc2c3C[C@@H]4N([C@@H](CC(C)C)c3[nH]c2c1)C(=O)[C@H](CCC(=O)OC(C)(C)C)NC4=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc2c3C[C@@H]4N([C@@H](CC(C)C)c3[nH]c2c1)C(=O)[C@H](CCC(=O)OC(C)(C)C)NC4=O",469.25767122,34,4.466,100.73,0.0158591028360744,0.06,0.0379295514180372,0,0
"KHK-IN-1","hexokinase inhibitor","KHK","CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1, CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1, CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1, CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1, CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1",422.200113832,30,3.135,116.19,0.00985802298167222,0.066,0.0379290114908361,0,0
"P7C3","NAMPT inhibitor","NAMPT","O[C@@H](CNc1ccccc1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:1,r|, O[C@@H](CNc1ccccc1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O[C@@H](CNc1ccccc1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:1",471.978587396,26,6.217,37.19,0.0157653687624554,0.06,0.0378826843812277,0,0
"N-acetylmannosamine","","","CC(=O)N[C@H]1[C@@H](O)O[C@@H](CO)[C@@H](O)[C@H]1O |a:5,11,13,&1:4,&2:8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(=O)N[C@H]1[C@@H](O)O[C@@H](CO)[C@@H](O)[C@H]1O |a:5",221.0899372,15,-1.488,119.25,0.0114003124253966,0.064,0.0377001562126983,0,0
"GW-311616","elastase inhibitor, leukocyte elastase inhibitor","ELANE","CC(C)[C@H]1[C@H]2[C@@H](CCN2C(=O)\C=C\CN2CCCCC2)N(C1=O)S(C)(=O)=O, CC(C)[C@H]1[C@H]2[C@@H](CCN2C(=O)\C=C\CN2CCCCC2)N(C1=O)S(C)(=O)=O, CC(C)[C@H]1[C@H]2[C@@H](CCN2C(=O)\C=C\CN2CCCCC2)N(C1=O)S(C)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)[C@H]1[C@H]2[C@@H](CCN2C(=O)\C=C\CN2CCCCC2)N(C1=O)S(C)(=O)=O",397.203527472,27,1.294,86.38,0.0113878796641986,0.064,0.0376939398320993,0,0
"bitopertin","glycine transporter inhibitor","SLC6A5, SLC6A9","C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F, C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F",1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F",543.10627466,36,5.383,88.19,0.00726636235871306,0.068,0.0376331811793565,0,0
"A740003","purinergic receptor antagonist","P2RX7","COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10",474.23793882,35,3.669,120.66,0.00924660210860313,0.066,0.0376233010543016,0,0
"STF-31","NAMPT inhibitor","NAMPT, SLC2A1","CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1",423.16166266,30,4.117,96.54,0.0191500606331734,0.056,0.0375750303165867,0,0
"citarinostat","HDAC inhibitor","","ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1Cl",467.172417372,33,4.36,107.45,0.0110917184104557,0.064,0.0375458592052279,0,0
"LY2857785","CDK inhibitor","CDK9","CC(C)c1n(C)nc2ccc(cc12)-c1ccnc(N[C@H]2CC[C@@H](CC2)NC2CCOCC2)n1 |r|, CC(C)c1n(C)nc2ccc(cc12)-c1ccnc(N[C@H]2CC[C@@H](CC2)NC2CCOCC2)n1 |r|, CC(C)c1n(C)nc2ccc(cc12)-c1ccnc(N[C@H]2CC[C@@H](CC2)NC2CCOCC2)n1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)c1n(C)nc2ccc(cc12)-c1ccnc(N[C@H]2CC[C@@H](CC2)NC2CCOCC2)n1 |r|",448.295059772,33,4.42,76.89,0.0350313678310064,0.04,0.0375156839155032,0,0
"GSK256066","phosphodiesterase inhibitor","PDE4A","COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1, COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1, COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1",518.162390932,37,3.315,140.07,0.00301725994576455,0.072,0.0375086299728823,0,0
"leptomycin b","exportin antagonist","XPO1","CC\C(\C=C\[C@@H]1OC(=O)C=C[C@@H]1C)=C\[C@H](C)C\C=C\C(\C)=C\[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C\C(O)=O |c:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","anticancer antibiotic","CC\C(\C=C\[C@@H]1OC(=O)C=C[C@@H]1C)=C\[C@H](C)C\C=C\C(\C)=C\[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C\C(O)=O |c:9|",540.345089256,39,6.472,100.9,0.0149590302131927,0.06,0.0374795151065964,0,0
"briciclib","cyclin D inhibitor","CCND1","COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(OP(O)(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(OP(O)(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(OP(O)(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(OP(O)(O)=O)c2)c(OC)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(OP(O)(O)=O)c2)c(OC)c1",474.074954566,31,1.149,156.01,0.000884337713912992,0.074,0.0374421688569565,0,0
"AZD7687","diacylglycerol O acyltransferase inhibitor","DGAT1","Cc1nc(C)c(nc1C(N)=O)-c1ccc(cc1)[C@H]1CC[C@H](CC(O)=O)CC1 |r|, Cc1nc(C)c(nc1C(N)=O)-c1ccc(cc1)[C@H]1CC[C@H](CC(O)=O)CC1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1nc(C)c(nc1C(N)=O)-c1ccc(cc1)[C@H]1CC[C@H](CC(O)=O)CC1 |r|",367.18959166,27,3.128,106.17,0.0228652364184648,0.052,0.0374326182092324,0,0
"AT13387","HSP inhibitor","HSP90AA1","CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O",409.236541852,30,3.172,67.25,0.0408574638520881,0.034,0.037428731926044,0,0
"palosuran","urotensin receptor antagonist","UTS2R","Cc1cc(NC(=O)NCCN2CCC(O)(Cc3ccccc3)CC2)c2ccccc2n1, Cc1cc(NC(=O)NCCN2CCC(O)(Cc3ccccc3)CC2)c2ccccc2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1cc(NC(=O)NCCN2CCC(O)(Cc3ccccc3)CC2)c2ccccc2n1",418.2368762,31,2.883,77.49,0.0307988682539105,0.044,0.0373994341269552,0,0
"ATB-346","cyclooxygenase inhibitor","PTGER2","COc1ccc2cc(ccc2c1)[C@@H](C)C(=O)Oc1ccc(cc1)C(N)=S |&1:12,r|, COc1ccc2cc(ccc2c1)[C@@H](C)C(=O)Oc1ccc(cc1)C(N)=S |&1:12,r|, COc1ccc2cc(ccc2c1)[C@@H](C)C(=O)Oc1ccc(cc1)C(N)=S |&1:12,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1ccc2cc(ccc2c1)[C@@H](C)C(=O)Oc1ccc(cc1)C(N)=S |&1:12",365.108564468,26,4.186,93.64,0.0327462556935355,0.042,0.0373731278467677,0,0
"volasertib","PLK inhibitor","PLK1","CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O",618.40058746,45,4.201,106.17,0.00472430678533694,0.07,0.0373621533926685,0,0
"tanespimycin","HSP inhibitor","HSP90AA1","CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7",585.305015336,42,1.796,166.28,0.000721246039836208,0.074,0.0373606230199181,0,0
"A-7","calmodulin antagonist","","NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12, NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12, NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12, NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12, NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12, NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12",396.163826848,26,5.691,80.57,0.0305899639027867,0.044,0.0372949819513934,0,0
"iododexetimide","acetylcholine receptor antagonist","","Ic1ccc(CN2CCC(CC2)[C@]2(CCC(=O)NC2=O)c2ccccc2)cc1 |&1:12,r|, Ic1ccc(CN2CCC(CC2)[C@]2(CCC(=O)NC2=O)c2ccccc2)cc1 |&1:12,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Ic1ccc(CN2CCC(CC2)[C@]2(CCC(=O)NC2=O)c2ccccc2)cc1 |&1:12",488.09607604,28,4.534,49.41,0.00853773032424155,0.066,0.0372688651621208,0,0
"acrizanib","vegfr inhibitor","","CNCc1cc(Oc2ccc3n(ccc3c2)C(=O)Nc2cc(n(C)n2)C(F)(F)F)ncn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","ophthalmology","macular degeneration","CNCc1cc(Oc2ccc3n(ccc3c2)C(=O)Nc2cc(n(C)n2)C(F)(F)F)ncn1",445.147407476,32,2.104,98.89,0.0104650086132006,0.064,0.0372325043066003,0,0
"L-NIL","nitric oxide synthase inhibitor","NOS1, NOS2, NOS3","CC(=N)NCCCC[C@H](N)C(O)=O, CC(=N)NCCCC[C@H](N)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=N)NCCCC[C@H](N)C(O)=O",187.132076784,13,-2.005,99.2,0.0224533838343349,0.052,0.0372266919171675,0,0
"alvespimycin","HSP inhibitor","HSP90AA1","CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7",616.347214496,44,1.034,169.52,0.000419015111441039,0.074,0.0372095075557205,0,0
"metazosin","adrenergic receptor antagonist","ADRA1A","CO[C@@H](C)C(=O)N1CCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1 |&1:2,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"phase 2","","","CO[C@@H](C)C(=O)N1CCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1 |&1:2",375.19065428,27,1.054,103.04,0.0123396184852779,0.062,0.0371698092426389,0,0
"mesulergine","dopamine receptor agonist","HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR6, HTR7","CN(C)S(=O)(=O)N[C@H]1C[C@H]2[C@@H](Cc3cn(C)c4cccc2c34)N(C)C1, CN(C)S(=O)(=O)N[C@H]1C[C@H]2[C@@H](Cc3cn(C)c4cccc2c34)N(C)C1",0,0,0,0,0,0,0,0,1,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN(C)S(=O)(=O)N[C@H]1C[C@H]2[C@@H](Cc3cn(C)c4cccc2c34)N(C)C1",362.177647072,25,1.302,65.96,0.0262930328780883,0.048,0.0371465164390442,0,0
"CGK-733","ATM kinase inhibitor, ATR kinase inhibitor","ATM, ATR","[O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|, [O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|, [O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|, [O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|, [O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|, [O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10",554.014922696,35,6.45,128.39,0.00228594359349339,0.072,0.0371429717967467,0,0
"lanraplenib","protein tyrosine kinase inhibitor","A1BG, LAT, TNK1","Nc1cncc(n1)c2cn3ccnc3c(Nc4ccc(cc4)N5CCN(CC5)C6COC6)n2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","rheumatology","lupus","Nc1cncc(n1)c2cn3ccnc3c(Nc4ccc(cc4)N5CCN(CC5)C6COC6)n2",443.21820642,33,1.895,109.73,0.0101991440750769,0.064,0.0370995720375384,0,0
"emamectin","GABA receptor agonist","","[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@]([H])(O[C@H]4C[C@H](OC)[C@@]([H])(O[C@H]5C[C@@H](OC)[C@H](NC)[C@@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@@H]4C[C@@H](C[C@]5(O4)O[C@H](C(C)C)[C@@H](C)C=C5)OC(=O)[C@H](C=C(C)[C@H]1O)[C@@]23O |c:4,55,t:6,38,62|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@]([H])(O[C@H]4C[C@H](OC)[C@@]([H])(O[C@H]5C[C@@H](OC)[C@H](NC)[C@@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@@H]4C[C@@H](C[C@]5(O4)O[C@H](C(C)C)[C@@H](C)C=C5)OC(=O)[C@H](C=C(C)[C@H]1O)[C@@]23O |c:4",871.508191396,65,2.032,161.86,0.000181077072520787,0.074,0.0370905385362604,0,0
"sx-682","antitumor agent","CXCL11, CXCR1, CXCR2","OB(O)c1ccc(OC(F)(F)F)cc1CSc1ncc(cn1)C(=O)Nc1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","hematologic malignancy","myeloproliferative neoplasms","OB(O)c1ccc(OC(F)(F)F)cc1CSc1ncc(cn1)C(=O)Nc1ccc(F)cc1",467.073420208,32,3.329,129.87,0.00410614329642009,0.07,0.03705307164821,0,0
"ccr1 antagonist 9","ccr antagonist","CCR1","O=C(C1=CN=CC2=C1C=NN2C3=CC=C(F)C=C3)NCC4=CC(S(=O)(C)=O)=NC=C4",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","rheumatology","rheumatoid arthritis","O=C(C1=CN=CC2=C1C=NN2C3=CC=C(F)C=C3)NCC4=CC(S(=O)(C)=O)=NC=C4",425.095788592,30,-0.665,111.94,0.00401998495844282,0.07,0.0370099924792214,0,0
"esculin","antioxidant","","OC[C@H]1O[C@@H](Oc2cc3ccc(=O)oc3cc2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2cc3ccc(=O)oc3cc2O)[C@@H](O)[C@@H](O)[C@@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC[C@H]1O[C@@H](Oc2cc3ccc(=O)oc3cc2O)[C@H](O)[C@@H](O)[C@@H]1O",340.079432092,24,0.264,149.82,0.00401924303044198,0.07,0.037009621515221,0,0
"adaptavir","CC chemokine receptor antagonist","CCR5","C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O, C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O, C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O, C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O",856.392661092,60,-7.892,437.28,1.21404588203112e-08,0.074,0.0370000060702294,0,0
"GW-501516","PPAR receptor agonist","PPARA, PPARD","Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F",453.068020096,30,4.977,112.96,0.00799527221183607,0.066,0.036997636105918,0,0
"gallic-acid","beta amyloid protein neurotoxicity inhibitor, PPAR receptor agonist","CA1, CA12, CA14, CA2, CA4, CA6, CA9, SELP","OC(=O)c1cc(O)c(O)c(O)c1, OC(=O)c1cc(O)c(O)c(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1cc(O)c(O)c(O)c1",170.021523292,12,1.009,97.99,0.0558552209524116,0.018,0.0369276104762058,0,0
"ecabapide","","","CNC(=O)c1cccc(NCC(=O)NCCc2ccc(OC)c(OC)c2)c1, CNC(=O)c1cccc(NCC(=O)NCCc2ccc(OC)c(OC)c2)c1, CNC(=O)c1cccc(NCC(=O)NCCc2ccc(OC)c(OC)c2)c1, CNC(=O)c1cccc(NCC(=O)NCCc2ccc(OC)c(OC)c2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CNC(=O)c1cccc(NCC(=O)NCCc2ccc(OC)c(OC)c2)c1",371.18450628,27,1.675,88.69,0.0218444266987113,0.052,0.0369222133493557,0,0
"methiazole","anthelmintic agent","","COC(=O)Nc1nc2ccc(SC(C)C)cc2[nH]1, COC(=O)Nc1nc2ccc(SC(C)C)cc2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)Nc1nc2ccc(SC(C)C)cc2[nH]1",265.08849772,18,3.06,92.31,0.0438092989353008,0.03,0.0369046494676504,0,0
"vamorolone","glucocorticoid receptor agonist","DMD, NFKB1, NR3C1","[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)CC=C1[C@@]2([H])CCC2=CC(=O)C=C[C@]12C |c:15,26,t:22|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","genetics","duchenne muscular dystrophy (dmd)","[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)CC=C1[C@@]2([H])CCC2=CC(=O)C=C[C@]12C |c:15",356.198759376,28,2.487,74.6,0.0637372110629908,0.01,0.0368686055314954,0,0
"fisetin","Aurora kinase inhibitor","CDK6, FASN","Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O",286.04773804,21,3.852,111.13,0.0416889162504876,0.032,0.0368444581252438,0,0
"thaliblastine","DNA inhibitor","","COc1cc(C[C@@H]2N(C)CCc3cc(OC)c(OC)cc23)c(Oc2cc3C[C@@H]4N(C)CCc5cc(OC)c(OC)c(-c3cc2OC)c45)cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1cc(C[C@@H]2N(C)CCc3cc(OC)c(OC)cc23)c(Oc2cc3C[C@@H]4N(C)CCc5cc(OC)c(OC)c(-c3cc2OC)c45)cc1OC",696.341066496,51,5.694,80.32,0.00764765883939369,0.066,0.0368238294196968,0,0
"rauwolscine","adrenergic receptor antagonist","ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR1E, HTR2B","COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12",0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,1,3,0,0,0,0,"preclinical","","","COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12",354.194342692,26,2.722,65.56,0.0555737206181995,0.018,0.0367868603090998,0,0
"TP-0903","AXL kinase inhibitor","AXL","CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl, CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl, CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl, CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl, CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl",515.18702188,35,3.571,102.08,0.0052377613766849,0.068,0.0366188806883425,0,0
"LY311727","phospholipase inhibitor","","CCc1c(CC(N)=O)c2cc(OCCCP(O)(O)=O)ccc2n1Cc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCc1c(CC(N)=O)c2cc(OCCCP(O)(O)=O)ccc2n1Cc1ccccc1",430.165758594,30,2.078,124.59,0.00519912500373033,0.068,0.0365995625018652,0,0
"secoisolariciresinol-(-)","","","COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc(O)c(OC)c2)ccc1O, COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc(O)c(OC)c2)ccc1O, COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc(O)c(OC)c2)ccc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc(O)c(OC)c2)ccc1O",362.172938552,26,1.742,99.38,0.0171562298942517,0.056,0.0365781149471259,0,0
"JDTic","opioid receptor antagonist","OPRK1","CC(C)[C@@H](CN1CC[C@](C)([C@@H](C)C1)c1cccc(O)c1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1, CC(C)[C@@H](CN1CC[C@](C)([C@@H](C)C1)c1cccc(O)c1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)[C@@H](CN1CC[C@](C)([C@@H](C)C1)c1cccc(O)c1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1",465.299142108,34,3.764,84.83,0.0211037562826913,0.052,0.0365518781413457,0,0
"VL285","PROTAC","","CC(C)[C@H](N1Cc2ccccc2C1=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)NCc1ccc(cc1)-c1scnc1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)[C@H](N1Cc2ccccc2C1=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)NCc1ccc(cc1)-c1scnc1C",532.214426504,38,2.908,131.08,0.00302639147330085,0.07,0.0365131957366504,0,0
"pf-00446687","melanocortin receptor agonist","MC4R","O=C([C@H]1[C@H](C2=C(C=C(F)C=C2)F)CN(C(C)(C)C)C1)N3C[C@H]([C@](O)(C4=CC=CC=C4)[C@@H](C)C3)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","neurology/psychiatry","hypoactive sexual desire disorder","O=C([C@H]1[C@H](C2=C(C=C(F)C=C2)F)CN(C(C)(C)C)C1)N3C[C@H]([C@](O)(C4=CC=CC=C4)[C@@H](C)C3)C",470.274484832,34,2.487,43.78,0.0349744929285384,0.038,0.0364872464642692,0,0
"DMP-777","elastase inhibitor","MPO","CCC[C@@H](NC(=O)N1[C@@H](Oc2ccc(cc2)C(=O)N2CCN(C)CC2)C(CC)(CC)C1=O)c1ccc2OCOc2c1, CCC[C@@H](NC(=O)N1[C@@H](Oc2ccc(cc2)C(=O)N2CCN(C)CC2)C(CC)(CC)C1=O)c1ccc2OCOc2c1, CCC[C@@H](NC(=O)N1[C@@H](Oc2ccc(cc2)C(=O)N2CCN(C)CC2)C(CC)(CC)C1=O)c1ccc2OCOc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCC[C@@H](NC(=O)N1[C@@H](Oc2ccc(cc2)C(=O)N2CCN(C)CC2)C(CC)(CC)C1=O)c1ccc2OCOc2c1",564.294785,41,4.786,100.65,0.00895170962836905,0.064,0.0364758548141845,0,0
"AZD3759","EGFR inhibitor","EGFR","COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C, COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C",459.147345496,32,3.124,79.82,0.0148964586546061,0.058,0.036448229327303,0,0
"anisodamine","lipid peroxidase inhibitor","ADRA1A","CN1[C@H]2C[C@H](O)[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c1ccccc1 |a:4,6,8,13,&1:2,THB:5:4:1:7.8.9|, CN1[C@H]2C[C@H](O)[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c1ccccc1 |a:4,6,8,13,&1:2,THB:5:4:1:7.8.9|, CN1[C@H]2C[C@H](O)[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c1ccccc1 |a:4,6,8,13,&1:2,THB:5:4:1:7.8.9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"phase 3","","","CN1[C@H]2C[C@H](O)[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c1ccccc1 |a:4",305.162708216,22,0.798,70,0.0408086558808792,0.032,0.0364043279404396,0,0
"XL388","mTOR inhibitor","MTOR","Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O, Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O",455.131505404,32,3.491,110.97,0.00876900014402589,0.064,0.0363845000720129,0,0
"3-bromo-7-nitroindazole","nitric oxide synthase inhibitor","NOS1, NOS2, NOS3","[O-][N+](=O)c1cccc2c(Br)[nH]nc12, [O-][N+](=O)c1cccc2c(Br)[nH]nc12, [O-][N+](=O)c1cccc2c(Br)[nH]nc12, [O-][N+](=O)c1cccc2c(Br)[nH]nc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[O-][N+](=O)c1cccc2c(Br)[nH]nc12",240.948688468,13,3.16,71.82,0.0407540285662484,0.032,0.0363770142831242,0,0
"symclosene","","","Cln1c(=O)n(Cl)c(=O)n(Cl)c1=O, Cln1c(=O)n(Cl)c(=O)n(Cl)c1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cln1c(=O)n(Cl)c(=O)n(Cl)c1=O",230.9005239,12,1.095,66,0.0287366747516253,0.044,0.0363683373758127,0,0
"atropine-oxide","acetylcholine receptor antagonist","CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","C[N@@+]1([O-])[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1 |&1:3,6,8,&2:1,&3:13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,5,0,0,0,0,0,0,"preclinical","","","C[N@@+]1([O-])[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1 |&1:3",305.162708216,22,1.147,69.59,0.044698879586102,0.028,0.036349439793051,0,0
"fevipiprant","prostaglandin inhibitor","","Cc1c(CC(O)=O)c2cccnc2n1Cc1ccc(cc1C(F)(F)F)S(C)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1c(CC(O)=O)c2cccnc2n1Cc1ccc(cc1C(F)(F)F)S(C)(=O)=O",426.086112684,29,3.729,97.64,0.0126525534251625,0.06,0.0363262767125813,0,0
"etebenecid","uricosuric blocker","","CCN(CC)S(=O)(=O)c1ccc(cc1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN(CC)S(=O)(=O)c1ccc(cc1)C(O)=O",257.07217896,17,1.571,83.06,0.0365194431975393,0.036,0.0362597215987696,0,0
"AI-10-49","core binding factor inhibitor","CBFB","FC(F)(F)Oc1ccc2nc([nH]c2c1)-c1ccc(OCCOCCOc2ccc(nc2)-c2nc3ccc(OC(F)(F)F)cc3[nH]2)cn1, FC(F)(F)Oc1ccc2nc([nH]c2c1)-c1ccc(OCCOCCOc2ccc(nc2)-c2nc3ccc(OC(F)(F)F)cc3[nH]2)cn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","FC(F)(F)Oc1ccc2nc([nH]c2c1)-c1ccc(OCCOCCOc2ccc(nc2)-c2nc3ccc(OC(F)(F)F)cc3[nH]2)cn1",660.155587124,47,5.978,129.29,0.00250276045312997,0.07,0.036251380226565,0,0
"YM-298198","glutamate receptor antagonist","GRM1","CN(C1CCCCC1)C(=O)c1sc2nc3ccc(N)cc3n2c1C, CN(C1CCCCC1)C(=O)c1sc2nc3ccc(N)cc3n2c1C, CN(C1CCCCC1)C(=O)c1sc2nc3ccc(N)cc3n2c1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C1CCCCC1)C(=O)c1sc2nc3ccc(N)cc3n2c1C",342.151432324,24,2.763,91.87,0.0264499989531829,0.046,0.0362249994765915,0,0
"fenoterol","adrenergic receptor agonist","ADRB2","C[C@@H](Cc1ccc(O)cc1)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:1,12,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"withdrawn","","","C[C@@H](Cc1ccc(O)cc1)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:1",303.147058152,22,2.038,92.95,0.0343278705049998,0.038,0.0361639352524999,0,0
"fenoterol hydrobromide","adrenergic receptor agonist","","C[C@@H](Cc1ccc(O)cc1)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:1,&2:12|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","C[C@@H](Cc1ccc(O)cc1)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:1",303.147058152,22,2.038,92.95,0.0343278705049998,0.038,0.0361639352524999,0,0
"tefinostat","hdac inhibitor","HDAC1","ONC(=O)CCCCCCC(=O)Nc1ccc(CN[C@H](C(=O)OC2CCCC2)c2ccccc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","oncology","hepatocellular carcinoma (hcc)","ONC(=O)CCCCCCC(=O)Nc1ccc(CN[C@H](C(=O)OC2CCCC2)c2ccccc2)cc1",495.273321284,36,3.901,116.76,0.00816743209132252,0.064,0.0360837160456613,0,0
"gly-gln","","","NCC(=O)N[C@@H](CCC(N)=O)C(O)=O, NCC(=O)N[C@@H](CCC(N)=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NCC(=O)N[C@@H](CCC(N)=O)C(O)=O",203.090605896,14,-4.905,135.51,0.00416069057836552,0.068,0.0360803452891828,0,0
"mk-0941","glucokinase activator","GCK","CS(=O)(O)=O.O=C(NC1=NN(C)C=C1)C2=CC(O[C@@H](C)CO)=CC(OC3=CC=C(S(=O)(CC)=O)N=C3)=C2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","endocrinology","diabetes mellitus","CS(=O)(O)=O.O=C(NC1=NN(C)C=C1)C2=CC(O[C@@H](C)CO)=CC(OC3=CC=C(S(=O)(CC)=O)N=C3)=C2",556.129770476,37,0.0299999999999997,201.02,0.000132733238556575,0.072,0.0360663666192783,0,0
"efatutazone","PPAR receptor agonist","PPARG","Cc1cc(Oc2ccc3nc(COc4ccc(C[C@H]5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N |r|, Cc1cc(Oc2ccc3nc(COc4ccc(C[C@H]5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N |r|, Cc1cc(Oc2ccc3nc(COc4ccc(C[C@H]5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cc1cc(Oc2ccc3nc(COc4ccc(C[C@H]5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N |r|",502.167476312,36,3.381,133.77,0.00412669261291173,0.068,0.0360633463064559,0,0
"ha14-1","bcl inhibitor","BCL2","CCOC(=O)C(C#N)C1c2cc(Br)ccc2OC(N)=C1C(=O)OCC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","oncology","acute myeloid leukemia (aml)","CCOC(=O)C(C#N)C1c2cc(Br)ccc2OC(N)=C1C(=O)OCC",408.032083744,25,2.444,111.64,0.00412297820242374,0.068,0.0360614891012119,0,0
"HA14-1","BCL inhibitor","BCL2","CCOC(=O)[C@@H](C#N)[C@H]1C(C(=O)OCC)=C(N)Oc2ccc(Br)cc12 |&1:5,8,r,t:14|, CCOC(=O)[C@@H](C#N)[C@H]1C(C(=O)OCC)=C(N)Oc2ccc(Br)cc12 |&1:5,8,r,t:14|, CCOC(=O)[C@@H](C#N)[C@H]1C(C(=O)OCC)=C(N)Oc2ccc(Br)cc12 |&1:5,8,r,t:14|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)[C@@H](C#N)[C@H]1C(C(=O)OCC)=C(N)Oc2ccc(Br)cc12 |&1:5",408.032083744,25,2.444,111.64,0.00412297820242374,0.068,0.0360614891012119,0,0
"AZD2858","glycogen synthase kinase inhibitor","GSK3B","CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1, CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1, CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1, CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1, CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1",453.158308596,32,0.426,142.79,0.00208665786616229,0.07,0.0360433289330811,0,0
"alpha-glucosyl-hesperidin","antioxidant","","COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O)cc2O1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O)cc2O1",772.242593808,54,-2.001,313.44,1.7061977013597e-06,0.072,0.0360008530988507,0,0
"MK-0773","androgen receptor modulator","AR","CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6ncccc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O |t:35|, CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6ncccc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O |t:35|, CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6ncccc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O |t:35|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6ncccc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O |t:35|",479.269653548,35,4.099,90.98,0.0179691803912461,0.054,0.0359845901956231,0,0
"L-165041","PPAR receptor agonist","PPARD","CCCc1c(O)c(ccc1OCCCOc1ccc(OCC(O)=O)cc1)C(C)=O, CCCc1c(O)c(ccc1OCCCOc1ccc(OCC(O)=O)cc1)C(C)=O, CCCc1c(O)c(ccc1OCCCOc1ccc(OCC(O)=O)cc1)C(C)=O, CCCc1c(O)c(ccc1OCCCOc1ccc(OCC(O)=O)cc1)C(C)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCc1c(O)c(ccc1OCCCOc1ccc(OCC(O)=O)cc1)C(C)=O",402.167853172,29,4.478,102.29,0.0239081551889086,0.048,0.0359540775944543,0,0
"rimeporide","sodium/hydrogen exchanger inhibitor","","Cc1cc(c(cc1C(=O)NC(N)=N)S(C)(=O)=O)S(C)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1cc(c(cc1C(=O)NC(N)=N)S(C)(=O)=O)S(C)(=O)=O",333.04531258,21,0.621,164.01,0.00187518813651026,0.07,0.0359375940682551,0,0
"luteolin","glucosidase inhibitor","TOP1","Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccc(O)c(O)c1, Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccc(O)c(O)c1, Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccc(O)c(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccc(O)c(O)c1",286.04773804,21,3.423,111.13,0.0376815394363334,0.034,0.0358407697181667,0,0
"RAF265","RAF inhibitor, VEGFR inhibitor","BRAF","Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12, Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12, Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12, Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12",518.128978452,37,5.396,80.65,0.0196166902312896,0.052,0.0358083451156448,0,0
"TFC-007","prostaglandin inhibitor","HPGDS","O=C(Nc1ccc(cc1)N1CCC(CC1)C(=O)N1CCOCC1)c1cnc(Oc2ccccc2)nc1, O=C(Nc1ccc(cc1)N1CCC(CC1)C(=O)N1CCOCC1)c1cnc(Oc2ccccc2)nc1, O=C(Nc1ccc(cc1)N1CCC(CC1)C(=O)N1CCOCC1)c1cnc(Oc2ccccc2)nc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(Nc1ccc(cc1)N1CCC(CC1)C(=O)N1CCOCC1)c1cnc(Oc2ccccc2)nc1",487.221954408,36,2.686,96.89,0.0116090183680238,0.06,0.0358045091840119,0,0
"RG108","DNA methyltransferase inhibitor","DNMT1, DNMT3B","OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O, OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O, OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O, OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O",334.095356928,25,0.429,90.47,0.023597720328478,0.048,0.035798860164239,0,0
"PD-153035","EGFR inhibitor","EGFR, KDR","COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC",359.026938788,22,3.384,56.27,0.0295285269663854,0.042,0.0357642634831927,0,0
"HTMT","histamine receptor agonist","HRH4","C[C@@H](CCCCC(=O)Nc1ccc(cc1)C(F)(F)F)NCCc1cnc[nH]1 |&1:1|, C[C@@H](CCCCC(=O)Nc1ccc(cc1)C(F)(F)F)NCCc1cnc[nH]1 |&1:1|",0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](CCCCC(=O)Nc1ccc(cc1)C(F)(F)F)NCCc1cnc[nH]1 |&1:1|",382.19804608,27,2.997,69.81,0.0354662227007004,0.036,0.0357331113503502,0,0
"PD-161570","FGFR inhibitor","FGFR1","CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl",531.2280141,36,5.938,95.07,0.00940981847801473,0.062,0.0357049092390074,0,0
"GDC-0575","CHK inhibitor","","N[C@@H]1CCCN(C1)c1c(Br)cnc2[nH]cc(NC(=O)C3CC3)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","N[C@@H]1CCCN(C1)c1c(Br)cnc2[nH]cc(NC(=O)C3CC3)c12",377.08512236,23,2.33,87.04,0.00932532331322078,0.062,0.0356626616566104,0,0
"cyproterone","","","CC(=O)[C@@]1(O)CCC2C3C=C(Cl)C4=CC(=O)[C@@H]5CC5[C@]4(C)C3CC[C@]12C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CC(=O)[C@@]1(O)CCC2C3C=C(Cl)C4=CC(=O)[C@@H]5CC5[C@]4(C)C3CC[C@]12C",374.164872404,26,2.542,54.37,0.0433096558820442,0.028,0.0356548279410221,0,0
"TU-2100","","","CCOC(=O)c1ccccc1OC(=O)CCCCCCCC(=O)Oc1ccccc1C(=O)OCC, CCOC(=O)c1ccccc1OC(=O)CCCCCCCC(=O)Oc1ccccc1C(=O)OCC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCOC(=O)c1ccccc1OC(=O)CCCCCCCC(=O)Oc1ccccc1C(=O)OCC",484.209717984,35,6.205,105.2,0.0192251899540011,0.052,0.0356125949770006,0,0
"YM-298198-desmethyl","glutamate receptor antagonist","GRM1","Cc1c(sc2nc3ccc(N)cc3n12)C(=O)NC1CCCCC1, Cc1c(sc2nc3ccc(N)cc3n12)C(=O)NC1CCCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1c(sc2nc3ccc(N)cc3n12)C(=O)NC1CCCCC1",328.13578226,23,2.621,100.66,0.0232112653859522,0.048,0.0356056326929761,0,0
"tolebrutinib","bruton's tyrosine kinase (btk) inhibitor","BTK","Nc1nccc2n([C@@H]3CCCN(C3)C(=O)C=C)c(=O)n(-c3ccc(Oc4ccccc4)cc3)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","neurology/psychiatry","multiple sclerosis","Nc1nccc2n([C@@H]3CCCN(C3)C(=O)C=C)c(=O)n(-c3ccc(Oc4ccccc4)cc3)c12",455.19573966,34,2.927,95.38,0.0172032259804234,0.054,0.0356016129902117,0,0
"methacycline","protein synthesis inhibitor","","[H][C@]12[C@H](O)[C@@]3([H])[C@H](N(C)C)C(=O)[C@H](C(N)=O)C(=O)[C@@]3(O)C(=O)[C@H]1C(=O)c1c(O)cccc1C2=C |&1:22,&2:12|, [H][C@]12[C@H](O)[C@@]3([H])[C@H](N(C)C)C(=O)[C@H](C(N)=O)C(=O)[C@@]3(O)C(=O)[C@H]1C(=O)c1c(O)cccc1C2=C |&1:22,&2:12|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","pulmonary","bronchitis","[H][C@]12[C@H](O)[C@@]3([H])[C@H](N(C)C)C(=O)[C@H](C(N)=O)C(=O)[C@@]3(O)C(=O)[C@H]1C(=O)c1c(O)cccc1C2=C |&1:22",442.137615664,34,-1.726,175.3,0.00119633635885295,0.07,0.0355981681794265,0,0
"C-1","protein kinase inhibitor","PRKCA","O=S(=O)(N1CCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCNCC1)c1cccc2cnccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=S(=O)(N1CCNCC1)c1cccc2cnccc12",277.08849772,19,0.528,70.68,0.0369953285713632,0.034,0.0354976642856816,0,0
"ammonium-perfluorocaprylate","Pim kinase inhibitor","PIM1","OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F, OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F",413.973702572,25,5.905,37.3,0.0449302642190178,0.026,0.0354651321095089,0,0
"A205804","ICAM1 expression inhibitor","ICAM1, SELE","Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1",300.039105004,20,2.689,109.52,0.0189301514201328,0.052,0.0354650757100664,0,0
"methyllycaconitine","acetylcholine receptor antagonist","CHRNA7","CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14, CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14, CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14, CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"preclinical","","","CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14",682.3465458,49,1.249,144.3,0.000517696009080233,0.07,0.0352588480045401,0,0
"adavivint","WNT pathway inhibitor","","CC(C)CC(=O)Nc1cncc(c1)-c1ccc2[nH]nc(-c3nc4cncc(-c5cccc(F)c5)c4[nH]3)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)CC(=O)Nc1cncc(c1)-c1ccc2[nH]nc(-c3nc4cncc(-c5cccc(F)c5)c4[nH]3)c2c1",505.202636608,38,5.435,112.24,0.0163855954266495,0.054,0.0351927977133248,0,0
"Rec-15/2615","adrenergic receptor antagonist","ADRA1A","COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)COc1c(OC)cccc1C(C)C, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)COc1c(OC)cccc1C(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"phase 2","","","COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)COc1c(OC)cccc1C(C)C",495.248169156,36,3.554,112.27,0.00832750211675802,0.062,0.035163751058379,0,0
"butein","EGFR inhibitor, SRC inhibitor","ACE","Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1, Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1, Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1, Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1",272.068473484,20,2.814,97.99,0.0482851330211723,0.022,0.0351425665105862,0,0
"gsk2245035","toll-like receptor agonist","TLR7","O=C1NC2=C(N=C(N=C2N1CCCCCN3CCCCC3)O[C@H](CCC)C)N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","pulmonary","asthma","O=C1NC2=C(N=C(N=C2N1CCCCCN3CCCCC3)O[C@H](CCC)C)N",390.274324328,28,1.997,95.55,0.0161784356200764,0.054,0.0350892178100382,0,0
"naringin","cytochrome P450 inhibitor","SLCO1A2","C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(O)cc2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(O)cc2)[C@H](O)[C@H](O)[C@H]1O",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(O)cc2)[C@H](O)[C@H](O)[C@H]1O",580.179205704,41,-0.111,225.06,0.000103877432243371,0.07,0.0350519387161217,0,0
"MRS-1845","calcium channel blocker","","CCOC(=O)C1=C(C)N(CC#C)C(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |&1:15,r,c:5,13|, CCOC(=O)C1=C(C)N(CC#C)C(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |&1:15,r,c:5,13|, CCOC(=O)C1=C(C)N(CC#C)C(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |&1:15,r,c:5,13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)C1=C(C)N(CC#C)C(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |&1:15",398.147786424,29,3.442,98.98,0.0220828841631829,0.048,0.0350414420815914,0,0
"KM-0118","anticancer agent","","CN(C)CCNC(=O)COc1c2Cc3cccc(Cc4cccc(Cc5cccc(Cc1ccc2)c5OCC(=O)NCCN(C)C)c4OCC(=O)NCCN(C)C)c3OCC(=O)NCCN(C)C, CN(C)CCNC(=O)COc1c2Cc3cccc(Cc4cccc(Cc5cccc(Cc1ccc2)c5OCC(=O)NCCN(C)C)c4OCC(=O)NCCN(C)C)c3OCC(=O)NCCN(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN(C)CCNC(=O)COc1c2Cc3cccc(Cc4cccc(Cc5cccc(Cc1ccc2)c5OCC(=O)NCCN(C)C)c4OCC(=O)NCCN(C)C)c3OCC(=O)NCCN(C)C",936.547311264,68,2.78,166.28,8.27876720926534e-05,0.07,0.0350413938360463,0,0
"bimosiamose","p selectin inhibitor","ICAM1, SELE, SELP","OC[C@H]1O[C@H](Oc2ccc(CCCCCCc3ccc(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)c(c3)-c3cccc(CC(O)=O)c3)cc2-c2cccc(CC(O)=O)c2)[C@@H](O)[C@@H](O)[C@@H]1O |a:2,4,21,23,26,28,30,56,58,60|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","pulmonary","chronic obstructive pulmonary disease (copd)","OC[C@H]1O[C@H](Oc2ccc(CCCCCCc3ccc(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)c(c3)-c3cccc(CC(O)=O)c3)cc2-c2cccc(CC(O)=O)c2)[C@@H](O)[C@@H](O)[C@@H]1O |a:2",862.341185648,62,5.954,273.36,2.22900147490006e-05,0.07,0.0350111450073745,0,0
"E-64","calpain inhibitor, cysteine protease inhibitor","CTSS","CC(C)C[C@H](NC(=O)[C@H]1O[C@@H]1C(O)=O)C(=O)NCCCCNC(N)=N, CC(C)C[C@H](NC(=O)[C@H]1O[C@@H]1C(O)=O)C(=O)NCCCCNC(N)=N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)C[C@H](NC(=O)[C@H]1O[C@@H]1C(O)=O)C(=O)NCCCCNC(N)=N",357.201218964,25,0.0259999999999998,169.93,0.00199290135529279,0.068,0.0349964506776464,0,0
"zatebradine","HCN channel blocker","HCN1, HCN2, HCN3, HCN4","COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC, COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC, COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC, COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC",456.262422252,33,2.698,60.47,0.0279738660963566,0.042,0.0349869330481783,0,0
"TCS-OX2-29","orexin receptor antagonist","HCRTR2","COc1cc2CCN(Cc2cc1OC)C(=O)[C@@H](NCc1ccncc1)C(C)(C)C, COc1cc2CCN(Cc2cc1OC)C(=O)[C@@H](NCc1ccncc1)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2CCN(Cc2cc1OC)C(=O)[C@@H](NCc1ccncc1)C(C)(C)C",397.236541852,29,2.29,63.69,0.0379314944335731,0.032,0.0349657472167866,0,0
"TAK-901","Aurora kinase inhibitor","AURKB","CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12, CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12, CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12",504.219511884,36,5.079,103.54,0.0119164135700445,0.058,0.0349582067850222,0,0
"piricapiron","dopamine receptor antagonist, serotonin receptor antagonist, dopamine receptor antagonist, serotonin receptor antagonist","HTR2A","CC1(C)C2CCC1(C)C(=O)N(CCCCN1CCN(CC1)c1ccccn1)C2=O, CC1(C)[C@@H]2CC[C@@]1(C)C(=O)N(CCCCN1CCN(CC1)c1ccccn1)C2=O |&1:3,6|",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC1(C)C2CCC1(C)C(=O)N(CCCCN1CCN(CC1)c1ccccn1)C2=O",398.268176328,29,3.067,56.75,0.0518344199398576,0.018,0.0349172099699288,0,0
"trimetrexate","dihydrofolate reductase inhibitor","DHFR","COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC",369.180089596,27,2.176,117.54,0.0133905429498838,0.056,0.0346952714749419,0,0
"SDZ-NKT-343","tachykinin antagonist","TACR1","CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O",579.248169156,43,5.85,124.89,0.00735849073439665,0.062,0.0346792453671983,0,0
"PR-619","DUB inhibitor","","Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1nc(N)c(SC#N)cc1SC#N",222.99863716,14,0.548,163.11,0.00518862694093655,0.064,0.0345943134704683,0,0
"sigma-2 receptor antagonist 1","sigma receptor antagonist","PGRMC1, TMEM97","CC(C)(C)Oc1cc(CCC(C)(C)N2Cc3ccc(cc3C2)S(=O)(=O)C)ccc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","neurology/psychiatry","alzheimer's disease","CC(C)(C)Oc1cc(CCC(C)(C)N2Cc3ccc(cc3C2)S(=O)(=O)C)ccc1O",431.213029536,30,4.626,75.22,0.0290431529369067,0.04,0.0345215764684534,0,0
"hyodeoxycholic-acid","atherosclerosis formation inhibitor","","C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C",392.29265976,28,6.389,77.76,0.064997677504942,0.004,0.034498838752471,0,0
"CZC24832","PI3K inhibitor","PIK3CG","CC(C)(C)NS(=O)(=O)c1cncc(c1)-c1cc(F)c2nc(N)nn2c1, CC(C)(C)NS(=O)(=O)c1cncc(c1)-c1cc(F)c2nc(N)nn2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)NS(=O)(=O)c1cncc(c1)-c1cc(F)c2nc(N)nn2c1",364.111773004,25,1.387,123.65,0.00686366577424615,0.062,0.0344318328871231,0,0
"GW-0742","PPAR receptor agonist","PPARD","Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F",471.058598284,31,5.138,112.96,0.00681970115184763,0.062,0.0344098505759238,0,0
"ONO-4817","matrix metalloprotease inhibitor","MMP8","CCOCOC[C@H](C[C@H](C)C(=O)NO)NC(=O)c1ccc(Oc2ccccc2)cc1, CCOCOC[C@H](C[C@H](C)C(=O)NO)NC(=O)c1ccc(Oc2ccccc2)cc1, CCOCOC[C@H](C[C@H](C)C(=O)NO)NC(=O)c1ccc(Oc2ccccc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCOCOC[C@H](C[C@H](C)C(=O)NO)NC(=O)c1ccc(Oc2ccccc2)cc1",416.194736616,30,2.668,106.12,0.0127791313230427,0.056,0.0343895656615213,0,0
"methacycline hcl","protein synthesis inhibitor","","CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","pulmonary","bronchitis","CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O",442.137615664,32,-1.726,175.3,0.000754891147107461,0.068,0.0343774455735537,0,0
"LY223982","leukotriene receptor antagonist","LTB4R","COc1ccc(\C=C\CCCCOc2ccc(cc2CCC(O)=O)C(=O)c2cccc(c2)C(O)=O)cc1, COc1ccc(\C=C\CCCCOc2ccc(cc2CCC(O)=O)C(=O)c2cccc(c2)C(O)=O)cc1, COc1ccc(\C=C\CCCCOc2ccc(cc2CCC(O)=O)C(=O)c2cccc(c2)C(O)=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1ccc(\C=C\CCCCOc2ccc(cc2CCC(O)=O)C(=O)c2cccc(c2)C(O)=O)cc1",502.1991533,37,6.436,110.13,0.0187250609141079,0.05,0.0343625304570539,0,0
"RG2833","HDAC inhibitor","HDAC1, HDAC3","Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N",339.19467704,25,3.017,84.22,0.0445787810722107,0.024,0.0342893905361054,0,0
"emetine","protein synthesis inhibitor","RPS2","CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12",480.29880776,35,4.349,52.19,0.0445752737920335,0.024,0.0342876368960167,0,0
"MK-4074","acetyl-CoA carboxylase inhibitor","","COc1cc(cc2n(cc(C)c12)C1CC1)C(=O)N1CCC2(CC1)CC(=O)c1cc(ccc1O2)-c1cncc(c1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1cc(cc2n(cc(C)c12)C1CC1)C(=O)N1CCC2(CC1)CC(=O)c1cc(ccc1O2)-c1cncc(c1)C(O)=O",565.221285712,42,4.729,110.96,0.00856366099437192,0.06,0.034281830497186,0,0
"glycerol-phenylbutyrate","sigma receptor ligand","","O=C(CCCc1ccccc1)OCC(COC(=O)CCCc1ccccc1)OC(=O)CCCc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","O=C(CCCc1ccccc1)OCC(COC(=O)CCCc1ccccc1)OC(=O)CCCc1ccccc1",530.266838936,39,7.141,78.9,0.0365352773271862,0.032,0.0342676386635931,0,0
"KI-8751","KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","KDR","COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC",469.124940716,34,4.111,81.71,0.0225106990390876,0.046,0.0342553495195438,0,0
"ribitol","","","OC[C@H](O)[C@H](O)[C@H](O)CO, OC[C@H](O)[C@H](O)[C@H](O)CO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC[C@H](O)[C@H](O)[C@H](O)CO",152.068473484,10,-3.224,101.15,0.0185093059685072,0.05,0.0342546529842536,0,0
"PD-166793","collagenase inhibitor, metalloproteinase inhibitor","MMP13, MMP2, MMP3","CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O, CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O, CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O, CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O",411.013991156,24,2.006,91.85,0.00433174229461989,0.064,0.0341658711473099,0,0
"(d-ala2,d-leu5)-enkephalin","opioid receptor agonist","","CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O",569.284948588,41,-0.638999999999999,199.95,0.000211915582145138,0.068,0.0341059577910726,0,0
"BW-180C","opioid receptor agonist","OPRD1, OPRM1","CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O",569.284948588,41,-0.638999999999999,199.95,0.000211915582145138,0.068,0.0341059577910726,0,0
"adrenosterone","11-beta hydroxysteroid dehydrogenase inhibitor","HSD11B1, HSD11B2","C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O |t:9|, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O |t:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O |t:9|",300.172544628,22,0.741,51.21,0.0680995585923792,0,0.0340497792961896,0,0
"adatanserin","serotonin receptor agonist, serotonin receptor antagonist","HTR1A, HTR2A","O=C(NCCN1CCN(CC1)c1ncccn1)C12CC3CC(CC(C3)C1)C2, O=C(NCCN1CCN(CC1)c1ncccn1)C12CC3CC(CC(C3)C1)C2, O=C(NCCN1CCN(CC1)c1ncccn1)C12CC3CC(CC(C3)C1)C2, O=C(NCCN1CCN(CC1)c1ncccn1)C12CC3CC(CC(C3)C1)C2",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O=C(NCCN1CCN(CC1)c1ncccn1)C12CC3CC(CC(C3)C1)C2",369.252860612,27,2.887,61.36,0.0560076123075698,0.012,0.0340038061537849,0,0
"arbutamine","adrenergic receptor agonist","ADRB1, ADRB2, ADRB3","Oc1ccc(cc1O)[C@@H](O)CNCCCCc2ccc(O)cc2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,3,0,0,0,0,"withdrawn","cardiology","coronary artery disease (cad)","Oc1ccc(cc1O)[C@@H](O)CNCCCCc2ccc(O)cc2",317.162708216,23,2.666,92.95,0.0360030343265915,0.032,0.0340015171632957,0,0
"GW-7647","PPAR receptor agonist","PPARA","CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O, CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O, CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O",502.322914332,35,7.904,94.94,0.0238793523803304,0.044,0.0339396761901652,0,0
"cromakalim","","KCNJ8","CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N.CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N1CCCC1=O)C#N, CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N.CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N1CCCC1=O)C#N, CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N.CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N1CCCC1=O)C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N.CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N1CCCC1=O)C#N",572.263484872,42,2.552,147.12,0.00184700090458122,0.066,0.0339235004522906,0,0
"GDC-0623","MEK inhibitor","","OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F, OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F, OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F, OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F, OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F",456.009466528,25,4.524,87.89,0.00378335054289298,0.064,0.0338916752714465,0,0
"ICG-001","beta-catenin inhibitor","CTNNB1","Oc1ccc(C[C@@H]2N3[C@H](CN(Cc4cccc5ccccc45)C2=O)N(CCC3=O)C(=O)NCc2ccccc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(C[C@@H]2N3[C@H](CN(Cc4cccc5ccccc45)C2=O)N(CCC3=O)C(=O)NCc2ccccc2)cc1",548.242355504,41,4.283,93.19,0.013740817767009,0.054,0.0338704088835045,0,0
"RHC-80267","triacylglycerol lipase inhibitor","DAGLA, DAGLB","O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1, O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1, O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1",394.258005568,28,3.758,101.38,0.0197204486152279,0.048,0.033860224307614,0,0
"NXY-059","free radical scavenger","","CC(C)(C)[N+](\[O-])=C\c1ccc(cc1S(O)(=O)=O)S(O)(=O)=O, CC(C)(C)[N+](\[O-])=C\c1ccc(cc1S(O)(=O)=O)S(O)(=O)=O, CC(C)(C)[N+](\[O-])=C\c1ccc(cc1S(O)(=O)=O)S(O)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(C)(C)[N+](\[O-])=C\c1ccc(cc1S(O)(=O)=O)S(O)(=O)=O",337.02899382,21,-0.595,151.57,0.00168833865076077,0.066,0.0338441693253804,0,0
"PD-168393","EGFR inhibitor","EGFR, ERBB2, SRC","Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1, Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1, Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1, Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1",368.027273136,23,3.368,66.91,0.023481683861816,0.044,0.033740841930908,0,0
"belizatinib","receptor tyrosine protein kinase inhibitor","","CC(C)NC(=O)[C@H]1CC[C@H](CC1)n1c(NC(=O)c2ccc(F)cc2)nc2ccc(CN3CCC(CC3)C(C)(C)O)cc12 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)NC(=O)[C@H]1CC[C@H](CC1)n1c(NC(=O)c2ccc(F)cc2)nc2ccc(CN3CCC(CC3)C(C)(C)O)cc12 |r|",577.342818488,42,5.244,99.49,0.00947844426971242,0.058,0.0337392221348562,0,0
"carcainium chloride","antitussive","","O=C(NC1=CC=CC=C1)C[N+](C)(C)CC(NC2=CC=CC=C2)=O.[Cl-]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","infectious disease","pneumonia","O=C(NC1=CC=CC=C1)C[N+](C)(C)CC(NC2=CC=CC=C2)=O.[Cl-]",347.140054624,24,0.52,58.2,0.0294653732255163,0.038,0.0337326866127582,0,0
"dihydroxyphenylglycine","glutamate receptor agonist","GRM1, GRM5","N[C@@H](C(O)=O)c1cc(O)cc(O)c1 |&1:1,r|, N[C@@H](C(O)=O)c1cc(O)cc(O)c1 |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@@H](C(O)=O)c1cc(O)cc(O)c1 |&1:1",183.053157768,13,-2.587,103.78,0.0193594471235191,0.048,0.0336797235617596,0,0
"3,5-DHPG-(S)","glutamate receptor agonist","GRM1","N[C@H](C(O)=O)c1cc(O)cc(O)c1, N[C@H](C(O)=O)c1cc(O)cc(O)c1, N[C@H](C(O)=O)c1cc(O)cc(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@H](C(O)=O)c1cc(O)cc(O)c1",183.053157768,13,-2.587,103.78,0.0193594471235191,0.048,0.0336797235617596,0,0
"IPAG","","","Ic1ccc(NC(=N)NC2C3CC4CC(C3)CC2C4)cc1, Ic1ccc(NC(=N)NC2C3CC4CC(C3)CC2C4)cc1, Ic1ccc(NC(=N)NC2C3CC4CC(C3)CC2C4)cc1, Ic1ccc(NC(=N)NC2C3CC4CC(C3)CC2C4)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Ic1ccc(NC(=N)NC2C3CC4CC(C3)CC2C4)cc1",395.085845704,21,5.672,47.91,0.0212490618429339,0.046,0.0336245309214669,0,0
"editol","","","C[C@@H](O)CN(CCN(C[C@@H](C)O)C[C@@H](C)O)C[C@@H](C)O |&1:1,&2:9,&3:13,&4:17,r|, C[C@@H](O)CN(CCN(C[C@@H](C)O)C[C@@H](C)O)C[C@@H](C)O |&1:1,&2:9,&3:13,&4:17,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](O)CN(CCN(C[C@@H](C)O)C[C@@H](C)O)C[C@@H](C)O |&1:1",292.236207504,20,-1.08,87.4,0.0151709602754291,0.052,0.0335854801377145,0,0
"harringtonine","protein synthesis inhibitor","","[H][C@@]12[C@H](OC(=O)[C@@](O)(CCC(C)(C)O)CC(=O)OC)C(OC)=C[C@@]11CCCN1CCc1cc3OCOc3cc21 |c:21|, [H][C@@]12[C@H](OC(=O)[C@@](O)(CCC(C)(C)O)CC(=O)OC)C(OC)=C[C@@]11CCCN1CCc1cc3OCOc3cc21 |c:21|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","[H][C@@]12[C@H](OC(=O)[C@@](O)(CCC(C)(C)O)CC(=O)OC)C(OC)=C[C@@]11CCCN1CCc1cc3OCOc3cc21 |c:21|",531.246831764,39,1.361,123.99,0.0031446550220093,0.064,0.0335723275110046,0,0
"DNQX","glutamate receptor antagonist","GRIA1, GRIA2, GRIK1, GRIN1, GRIN2A, GRIN2B","[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O",252.013083848,18,1.696,152,0.0111085370554436,0.056,0.0335542685277218,0,0
"epi-001","ppar receptor modulator","AR","OCC(O)COC1=CC=C(C(C)(C2=CC=C(OCC(O)CCl)C=C2)C)C=C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","oncology","prostate cancer","OCC(O)COC1=CC=C(C(C)(C2=CC=C(OCC(O)CCl)C=C2)C)C=C1",394.154701644,27,2.446,79.15,0.0190651402154071,0.048,0.0335325701077035,0,0
"NPC-01","steroid","","C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O |t:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O |t:9|",302.188194692,22,1.154,54.37,0.0668325158354657,0,0.0334162579177328,0,0
"Ro-28-1675","glucokinase activator","GCK","CS(=O)(=O)c1ccc(cc1)[C@@H](CC1CCCC1)C(=O)Nc1nccs1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CS(=O)(=O)c1ccc(cc1)[C@@H](CC1CCCC1)C(=O)Nc1nccs1",378.107184564,25,3.556,112.75,0.010724021592358,0.056,0.033362010796179,0,0
"lanifibranor","PPAR receptor agonist","","OC(=O)CCCc1cc2cc(Cl)ccc2n1S(=O)(=O)c1ccc2ncsc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)CCCc1cc2cc(Cl)ccc2n1S(=O)(=O)c1ccc2ncsc2c1",434.01617664,28,4.029,125.88,0.00468678745775438,0.062,0.0333433937288772,0,0
"ON-01500","apoptosis stimulant","","COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(N)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(N)c2)c(OC)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(N)c2)c(OC)c1",393.124608456,27,2.433,105.46,0.0106746870606413,0.056,0.0333373435303207,0,0
"clomesone","DNA inhibitor","","CS(=O)(=O)CS(=O)(=O)OCCCl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CS(=O)(=O)CS(=O)(=O)OCCCl",235.957993068,12,-0.712,94.27,0.00866288995120311,0.058,0.0333314449756016,0,0
"pibenzimol","DNA inhibitor","","CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1ccc2nc([nH]c2c1)-c1ccc(O)cc1, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1ccc2nc([nH]c2c1)-c1ccc(O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1ccc2nc([nH]c2c1)-c1ccc(O)cc1",424.201159388,32,4.084,84.07,0.0384538330742542,0.028,0.0332269165371271,0,0
"GR-113808","serotonin receptor antagonist","HTR4","Cn1cc(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)c2ccccc12, Cn1cc(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)c2ccccc12",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cn1cc(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)c2ccccc12",393.172227344,27,2.132,89.02,0.014443005620445,0.052,0.0332215028102225,0,0
"ZM-226600","Kir6 channel (KATP) activator","","C[C@@](O)(C(=O)Nc1ccc(cc1)S(=O)(=O)c1ccccc1)C(F)(F)F |&1:1|, C[C@@](O)(C(=O)Nc1ccc(cc1)S(=O)(=O)c1ccccc1)C(F)(F)F |&1:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@](O)(C(=O)Nc1ccc(cc1)S(=O)(=O)c1ccccc1)C(F)(F)F |&1:1|",373.059563588,25,2.851,91.85,0.0164277848364944,0.05,0.0332138924182472,0,0
"gefapixant","purinergic receptor antagonist","","COc1cc(C(C)C)c(Oc2cnc(N)nc2N)cc1S(N)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1cc(C(C)C)c(Oc2cnc(N)nc2N)cc1S(N)(=O)=O",353.115775088,24,0.6,164.82,0.00226106438567716,0.064,0.0331305321928386,0,0
"ddd107498 (succinate)","antimalarial agent","","Fc1ccc2nc(cc(C(=O)NCCN3CCCC3)c2c1)-c1ccc(CN2CCOCC2)cc1.OC(=O)CCC(=O)O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","infectious disease","malaria","Fc1ccc2nc(cc(C(=O)NCCN3CCCC3)c2c1)-c1ccc(CN2CCOCC2)cc1.OC(=O)CCC(=O)O",580.269713124,42,2.72,132.3,0.0022401052021618,0.064,0.0331200526010809,0,0
"UK-356618","metalloproteinase inhibitor","MMP13, MMP14, MMP2, MMP3, MMP9","C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1, C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1, C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1, C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1, C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1",557.325356856,41,6.669,107.53,0.0142329729059457,0.052,0.0331164864529728,0,0
"ICA-121431","sodium channel blocker","SCN1A, SCN3A","O=C(Nc1ccc(cc1)S(=O)(=O)Nc1nccs1)C(c1ccccc1)c1ccccc1, O=C(Nc1ccc(cc1)S(=O)(=O)Nc1nccs1)C(c1ccccc1)c1ccccc1, O=C(Nc1ccc(cc1)S(=O)(=O)Nc1nccs1)C(c1ccccc1)c1ccccc1, O=C(Nc1ccc(cc1)S(=O)(=O)Nc1nccs1)C(c1ccccc1)c1ccccc1",0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O=C(Nc1ccc(cc1)S(=O)(=O)Nc1nccs1)C(c1ccccc1)c1ccccc1",449.086783468,31,3.737,124.78,0.00622183648018204,0.06,0.033110918240091,0,0
"LY2365109","glycine transporter inhibitor","SLC6A9","CN(CCOc1ccc(cc1C(C)(C)C)-c1ccc2OCOc2c1)CC(O)=O, CN(CCOc1ccc(cc1C(C)(C)C)-c1ccc2OCOc2c1)CC(O)=O",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(CCOc1ccc(cc1C(C)(C)C)-c1ccc2OCOc2c1)CC(O)=O",385.188922964,28,2.041,68.23,0.0341574550856792,0.032,0.0330787275428396,0,0
"cilengitide","integrin antagonist","ITGAV, ITGB3","CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O, CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O, CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O, CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O",588.30199562,42,1.368,235.91,0.000120385582458264,0.066,0.0330601927912291,0,0
"INT-747","FXR agonist","","CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12, CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12, CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12",420.323959888,30,7.044,77.76,0.0621018815553475,0.004,0.0330509407776737,0,0
"SR-2211","retinoid receptor inverse agonist","RORC","OC(c1ccc(c(F)c1)-c1ccc(CN2CCN(Cc3ccncc3)CC2)cc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(c(F)c1)-c1ccc(CN2CCN(Cc3ccncc3)CC2)cc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(c(F)c1)-c1ccc(CN2CCN(Cc3ccncc3)CC2)cc1)(C(F)(F)F)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(c1ccc(c(F)c1)-c1ccc(CN2CCN(Cc3ccncc3)CC2)cc1)(C(F)(F)F)C(F)(F)F",527.180759928,37,5.804,39.6,0.0440978384118101,0.022,0.033048919205905,0,0
"polydatin","ICAM1 expression inhibitor","ICAM1","OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O",390.131467664,28,2.132,139.84,0.00607181849574818,0.06,0.0330359092478741,0,0
"BMS-813160","CC chemokine receptor antagonist","","CC(=O)N[C@@H]1C[C@@H](CC[C@@H]1N1CC[C@H](Nc2ncnc3cc(nn23)C(C)(C)C)C1=O)NC(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(=O)N[C@@H]1C[C@@H](CC[C@@H]1N1CC[C@H](Nc2ncnc3cc(nn23)C(C)(C)C)C1=O)NC(C)(C)C",484.32742252,35,2.394,116.55,0.00586460117141966,0.06,0.0329323005857098,0,0
"GW-627368","prostanoid receptor antagonist","PTGER4","CCOc1c2CN(C(=O)c2c(OCC)c2ccccc12)c1ccc(CC(=O)NS(=O)(=O)c2ccccc2)cc1, CCOc1c2CN(C(=O)c2c(OCC)c2ccccc12)c1ccc(CC(=O)NS(=O)(=O)c2ccccc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOc1c2CN(C(=O)c2c(OCC)c2ccccc12)c1ccc(CC(=O)NS(=O)(=O)c2ccccc2)cc1",544.166807616,39,5.029,110.39,0.00774652098618082,0.058,0.0328732604930904,0,0
"emiglitate","alpha glucoside inhibitor","","CCOC(=O)c1ccc(OCCN2C[C@H](O)[C@@H](O)[C@H](O)[C@H]2CO)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)c1ccc(OCCN2C[C@H](O)[C@@H](O)[C@H](O)[C@H]2CO)cc1",355.16310214,25,0.538,119.69,0.00756127342876628,0.058,0.0327806367143831,0,0
"decamethoxine","antiseptic","","CC(C)[C@H]1CC[C@H](C)C[C@@H]1OC(=O)C[N+](C)(C)CCCCCCCCCC[N+](C)(C)CC(=O)O[C@H]1C[C@H](C)CC[C@@H]1C(C)C |&1:40,&2:36,&3:34,&4:9,&5:6,&6:3|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)[C@H]1CC[C@H](C)C[C@@H]1OC(=O)C[N+](C)(C)CCCCCCCCCC[N+](C)(C)CC(=O)O[C@H]1C[C@H](C)CC[C@@H]1C(C)C |&1:40",622.563761688181,44,10.068,52.6,0.0474647796166775,0.018,0.0327323898083388,0,0
"tosedostat","peptidase inhibitor","ANPEP, LAP3, NPEPPS","CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1",406.21038668,29,2.144,124.96,0.00736147474274142,0.058,0.0326807373713707,0,0
"rosamicin","protein synthesis inhibitor","","CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\[C@]2(C)O[C@H]2[C@@H]1C |t:34|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\[C@]2(C)O[C@H]2[C@@H]1C |t:34|",581.356382212,41,1.74,135.13,0.00127768415172396,0.064,0.032638842075862,0,0
"3-ethyl-7-hydroxy-2,8,12,16-tetramethyl-5,13-dioxo-10-(2-oxoethyl)-4,17-dioxabicyclo[14.1.0]heptadec-14-en-9-yl 3,4,6-trideoxy-3-(dimethylamino)hexopyranoside","","","CC[C@H]1OC(=O)C[C@@H](O)[C@@H](C)[C@@H](O[C@H]2O[C@@H](C)C[C@@H]([C@@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\[C@@]2(C)O[C@@H]2[C@@H]1C |&1:2,&2:7,&3:9,&4:11,&5:13,&6:15,&7:18,&8:19,&9:24,&11:35,&12:38,&13:39,r,t:34|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CC[C@H]1OC(=O)C[C@@H](O)[C@@H](C)[C@@H](O[C@H]2O[C@@H](C)C[C@@H]([C@@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\[C@@]2(C)O[C@@H]2[C@@H]1C |&1:2",581.356382212,41,1.74,135.13,0.00127768415172396,0.064,0.032638842075862,0,0
"dichlorisone-acetate","","","CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C |c:19,t:15|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C |c:19",454.131379356,30,2.6,80.67,0.00918618366210803,0.056,0.032593091831054,0,0
"ONX-0914","proteasome inhibitor","","COc1ccc(C[C@H](NC(=O)[C@H](C)NC(=O)CN2CCOCC2)C(=O)N[C@@H](Cc2ccccc2)C(=O)[C@@]2(C)CO2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(C[C@H](NC(=O)[C@H](C)NC(=O)CN2CCOCC2)C(=O)N[C@@H](Cc2ccccc2)C(=O)[C@@]2(C)CO2)cc1",580.28969962,42,0.694,138.6,0.00117828244175289,0.064,0.0325891412208764,0,0
"atm-3507","tropomyosin receptor kinase inhibitor","TPM3","CN1CCN(CCCn2c(C)c(C)c3cc(Oc4cccc(c4)C(=O)N5CCN(CCc6ccc(F)cc6)CC5)ccc23)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","oncology","ovarian cancer","CN1CCN(CCCn2c(C)c(C)c3cc(Oc4cccc(c4)C(=O)N5CCN(CCc6ccc(F)cc6)CC5)ccc23)CC1",611.363553932,45,5.45,44.19,0.0311055561295441,0.034,0.0325527780647721,0,0
"MRS-2578","purinergic receptor antagonist","P2RY6","S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1, S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1, S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1, S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1",472.06322864,30,6.762,201.2,0.0010241744952744,0.064,0.0325120872476372,0,0
"CP-471474","matrix metalloprotease inhibitor","MMP1, MMP13, MMP2, MMP3, MMP9","CC(C)(NS(=O)(=O)c1ccc(Oc2ccc(F)cc2)cc1)C(=O)NO, CC(C)(NS(=O)(=O)c1ccc(Oc2ccc(F)cc2)cc1)C(=O)NO, CC(C)(NS(=O)(=O)c1ccc(Oc2ccc(F)cc2)cc1)C(=O)NO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(NS(=O)(=O)c1ccc(Oc2ccc(F)cc2)cc1)C(=O)NO",368.084220864,25,1.883,113.11,0.0089813260185851,0.056,0.0324906630092926,0,0
"bithionol","autotaxin inhibitor","ESR1, ESR2, MCL1","Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O",353.884261152,19,5.893,65.76,0.0249572293055367,0.04,0.0324786146527684,0,0
"cc-92480","ubiquitin ligase inhibitor","CRBN","Fc1cc(ccc1N2CCN(Cc3ccc(COc4cccc5C(=O)N(Cc45)[C@H]6CCC(=O)NC6=O)cc3)CC2)C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","hematologic malignancy","multiple myeloma","Fc1cc(ccc1N2CCN(Cc3ccc(COc4cccc5C(=O)N(Cc45)[C@H]6CCC(=O)NC6=O)cc3)CC2)C#N",567.22818266,42,3.571,105.98,0.0069074047326039,0.058,0.0324537023663019,0,0
"MK-0812","CC chemokine receptor antagonist","CCR2","CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F, CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F, CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F",469.255226608,33,2.505,63.69,0.0183291011691846,0.046,0.0321645505845923,0,0
"nanchangmycin","other antibiotic","","CO[C@H]1CC[C@@H](O[C@H]2C[C@@H](O[C@]3(O[C@H](C[C@@H]3C)[C@H]3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C |a:2,7,11,13,15,19,23,26,28,30,34,36,38,40,42,49,52,59,&1:5,&2:9,&3:17|, CO[C@H]1CC[C@@H](O[C@H]2C[C@@H](O[C@]3(O[C@H](C[C@@H]3C)[C@H]3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C |a:2,7,11,13,15,19,23,26,28,30,34,36,38,40,42,49,52,59,&1:5,&2:9,&3:17|, CO[C@H]1CC[C@@H](O[C@H]2C[C@@H](O[C@]3(O[C@H](C[C@@H]3C)[C@H]3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C |a:2,7,11,13,15,19,23,26,28,30,34,36,38,40,42,49,52,59,&1:5,&2:9,&3:17|, CO[C@H]1CC[C@@H](O[C@H]2C[C@@H](O[C@]3(O[C@H](C[C@@H]3C)[C@H]3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C |a:2,7,11,13,15,19,23,26,28,30,34,36,38,40,42,49,52,59,&1:5,&2:9,&3:17|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CO[C@H]1CC[C@@H](O[C@H]2C[C@@H](O[C@]3(O[C@H](C[C@@H]3C)[C@H]3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C |a:2",866.539157176,61,4.488,188.9,7.91760471844684e-05,0.064,0.0320395880235922,0,0
"cephalomannine","DNA polymerase inhibitor","","C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1 |t:47|, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1 |t:47|, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1 |t:47|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1 |t:47|",831.346605376,60,2.242,221.29,3.9680763346725e-05,0.064,0.0320198403816734,0,0
"sultopride","dopamine receptor antagonist","","CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(=O)(=O)CC |&1:6,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(=O)(=O)CC |&1:6",354.161328312,24,2.04,84.09,0.0200387088146811,0.044,0.0320193544073405,0,0
"tipelukast","leukotriene receptor antagonist","","CCCc1c(O)c(ccc1SCCCOc1ccc(C(C)=O)c(OCCCC(O)=O)c1CCC)C(C)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCc1c(O)c(ccc1SCCCOc1ccc(C(C)=O)c(OCCCC(O)=O)c1CCC)C(C)=O",530.233824556,37,6.892,135.43,0.00603592755799601,0.058,0.032017963778998,0,0
"polymyxin b nonapeptide (tfa)","bacterial permeability inducer","","FC(F)(F)C(O)=O.FC(F)(F)C(O)=O.FC(F)(F)C(O)=O.FC(F)(F)C(O)=O.O=C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@]1([H])[C@H](O)C)=O)CCN)=O)CCN)=O)CC(C)C)[C@H](NC([C@@H](NC([C@H](CCNC1=O)NC([C@H](CCN)NC([C@@H](N)[C@H](O)C)=O)=O)=O)CCN)=O)CC2=CC=CC=C2.FC(F)(F)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","infectious disease","gram-negative bacterial infections","FC(F)(F)C(O)=O.FC(F)(F)C(O)=O.FC(F)(F)C(O)=O.FC(F)(F)C(O)=O.O=C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@]1([H])[C@H](O)C)=O)CCN)=O)CCN)=O)CC(C)C)[C@H](NC([C@@H](NC([C@H](CCNC1=O)NC([C@H](CCN)NC([C@@H](N)[C@H](O)C)=O)=O)=O)CCN)=O)CC2=CC=CC=C2.FC(F)(F)C(O)=O",1532.530468848,104,1.373,618.96,4.21297456897959e-12,0.064,0.0320000000021065,0,0
"ISRIB","eukaryotic translation initiation factor inhibitor, PERK inhibitor","EIF2A, EIF2AK3","Clc1ccc(OCC(=O)N[C@H]2CC[C@@H](CC2)NC(=O)COc2ccc(Cl)cc2)cc1 |r|, Clc1ccc(OCC(=O)N[C@H]2CC[C@@H](CC2)NC(=O)COc2ccc(Cl)cc2)cc1 |r|, Clc1ccc(OCC(=O)N[C@H]2CC[C@@H](CC2)NC(=O)COc2ccc(Cl)cc2)cc1 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Clc1ccc(OCC(=O)N[C@H]2CC[C@@H](CC2)NC(=O)COc2ccc(Cl)cc2)cc1 |r|",450.111312608,30,4.548,76.66,0.0177427192123009,0.046,0.0318713596061505,0,0
"remetinostat","HDAC inhibitor","","COC(=O)c1ccc(OC(=O)CCCCCCC(=O)NO)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COC(=O)c1ccc(OC(=O)CCCCCCC(=O)NO)cc1",323.136887392,23,2.319,101.93,0.0235767696693304,0.04,0.0317883848346652,0,0
"alexidine","phosphatidylglycerophosphatase inhibitor","PTPMT1","CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|, CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|, CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|, CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|, CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|, CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|, CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29",508.468941792,36,6.652,172.58,0.00322325444111845,0.06,0.0316116272205592,0,0
"IRL-2500","endothelin receptor antagonist","EDNRB","CN([C@H](Cc1ccc(cc1)-c1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O)C(=O)c1cc(C)cc(C)c1, CN([C@H](Cc1ccc(cc1)-c1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O)C(=O)c1cc(C)cc(C)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN([C@H](Cc1ccc(cc1)-c1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O)C(=O)c1cc(C)cc(C)c1",573.2627566,43,4.821,102.5,0.0110440318262529,0.052,0.0315220159131264,0,0
"kakonein","GABA receptor antagonist, serotonin receptor antagonist","","OC[C@H]1O[C@@H]([C@@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O |&1:2,&2:4,&3:5,&4:7,&5:9,r|, OC[C@H]1O[C@@H]([C@@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O |&1:2,&2:4,&3:5,&4:7,&5:9,r|, OC[C@H]1O[C@@H]([C@@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O |&1:2,&2:4,&3:5,&4:7,&5:9,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC[C@H]1O[C@@H]([C@@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O |&1:2",416.11073222,30,1.937,160.82,0.00304106378461789,0.06,0.0315205318923089,0,0
"puerarin","serotonin receptor antagonist","","OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O",416.11073222,30,1.937,160.82,0.00304106378461789,0.06,0.0315205318923089,0,0
"taprenepag","prostaglandin receptor agonist","PTGER2","OC(=O)COc1cccc(CN(Cc2ccc(cc2)-n2cccn2)S(=O)(=O)c2cccnc2)c1, OC(=O)COc1cccc(CN(Cc2ccc(cc2)-n2cccn2)S(=O)(=O)c2cccnc2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)COc1cccc(CN(Cc2ccc(cc2)-n2cccn2)S(=O)(=O)c2cccnc2)c1",478.131090804,34,2.716,123,0.00503763730875191,0.058,0.031518818654376,0,0
"mocetinostat","HDAC inhibitor","HDAC1, HDAC11, HDAC2, HDAC3","Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1",396.16985926,30,2.744,105.82,0.0209861371331185,0.042,0.0314930685665592,0,0
"aranidipine","l-type calcium channel blocker","CACNA1C","COC(=O)C1=C(C)NC(=C(C1c2ccccc2[N+](=O)[O-])C(=O)OCC(=O)C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","cardiology","hypertension","COC(=O)C1=C(C)NC(=C(C1c2ccccc2[N+](=O)[O-])C(=O)OCC(=O)C)C",388.12705098,28,2.952,124.84,0.010974105838365,0.052,0.0314870529191825,0,0
"ACY-1215","HDAC inhibitor","HDAC1, HDAC2, HDAC3, HDAC6, HDAC8","ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1, ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1, ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1, ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1, ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1, ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1",433.211389724,32,3.738,107.45,0.0169329556478545,0.046,0.0314664778239273,0,0
"cinobufotalin","anticancer agent","","[H][C@@]12CC[C@]3(O)C[C@@H](O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@H]([C@@H](OC(C)=O)[C@H]3O[C@@]213)c1ccc(=O)oc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","[H][C@@]12CC[C@]3(O)C[C@@H](O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@H]([C@@H](OC(C)=O)[C@H]3O[C@@]213)c1ccc(=O)oc1",458.230453428,35,2.954,109.5,0.0146559786357476,0.048,0.0313279893178738,0,0
"HBED","chelating agent","","OC(=O)CN(CCN(CC(O)=O)Cc1ccccc1O)Cc1ccccc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","OC(=O)CN(CCN(CC(O)=O)Cc1ccccc1O)Cc1ccccc1O",388.163436488,28,-0.878,121.54,0.0046552877227774,0.058,0.0313276438613887,0,0
"AZ-10606120","purinergic receptor antagonist","P2RX7","OCCNCCNc1ccc2c(NC(=O)CC34CC5CC(CC(C5)C3)C4)cccc2n1, OCCNCCNc1ccc2c(NC(=O)CC34CC5CC(CC(C5)C3)C4)cccc2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OCCNCCNc1ccc2c(NC(=O)CC34CC5CC(CC(C5)C3)C4)cccc2n1",422.268176328,31,4.805,86.28,0.0363450295410692,0.026,0.0311725147705346,0,0
"imidurea","other antibiotic","","OCN1[C@@H](NC(=O)NCNC(=O)N[C@@H]2N(CO)C(=O)NC2=O)C(=O)NC1=O |&1:3,&2:13,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OCN1[C@@H](NC(=O)NCNC(=O)N[C@@H]2N(CO)C(=O)NC2=O)C(=O)NC1=O |&1:3",388.109109472,27,-1.377,221.54,0.000323839855366615,0.062,0.0311619199276833,0,0
"amygdalin","caspase activator","CASP3","OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O",457.158410684,32,-2.076,202.32,0.000258697071646731,0.062,0.0311293485358234,0,0
"RRx-001","glucose 6-phosphate dehydrogenase inhibitor","G6PD","[O-][N+](=O)C1(CN(C1)C(=O)CBr)[N+]([O-])=O, [O-][N+](=O)C1(CN(C1)C(=O)CBr)[N+]([O-])=O, [O-][N+](=O)C1(CN(C1)C(=O)CBr)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","[O-][N+](=O)C1(CN(C1)C(=O)CBr)[N+]([O-])=O",266.949082392,14,0.254,106.59,0.00625085991230898,0.056,0.0311254299561545,0,0
"capobenic-acid","","","COc1cc(cc(OC)c1OC)C(=O)NCCCCCC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(cc(OC)c1OC)C(=O)NCCCCCC(O)=O",325.152537456,23,1.518,94.09,0.022170613262901,0.04,0.0310853066314505,0,0
"hydroxysafflor-yellow-A","antitumor agent","","[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@]1(O)C(=O)[C@@H]([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C(=O)[C@H](C(=O)\C=C\c2ccc(O)cc2)C1=O |&1:12,&2:30,&3:16|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@]1(O)C(=O)[C@@H]([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C(=O)[C@H](C(=O)\C=C\c2ccc(O)cc2)C1=O |&1:12",612.169034944,44,-4.197,289.04,8.03794218458644e-06,0.062,0.0310040189710923,0,0
"CTS21166","beta-secretase inhibitor","BACE1","CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(O)=O, CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(O)=O",892.454198728,63,-3.691,375.84,1.19169471231988e-07,0.062,0.0310000595847356,0,0
"trimethylolpropane-triacrylate","","","CCC(COC(=O)C=C)(COC(=O)C=C)COC(=O)C=C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCC(COC(=O)C=C)(COC(=O)C=C)COC(=O)C=C",296.12598836,21,2.375,78.9,0.0478320610913411,0.014,0.0309160305456705,0,0
"firategrast","integrin antagonist","ITGA4","CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1",499.180644024,36,2.837,94.09,0.00967702869474686,0.052,0.0308385143473734,0,0
"protokylol","adrenergic receptor agonist","ADRB2","O1c2ccc(cc2OC1)CC(NCC(O)c3ccc(O)c(O)c3)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"withdrawn","infectious disease","respiratory tract infections","O1c2ccc(cc2OC1)CC(NCC(O)c3ccc(O)c(O)c3)C",331.141972772,24,2.362,91.18,0.0315284710242225,0.03,0.0307642355121112,0,0
"SB-269970","serotonin receptor antagonist","HTR7","CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1, CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1, CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1, CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1, CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1",352.182063756,24,2.83,69.23,0.0354264024419955,0.026,0.0307132012209978,0,0
"camobucol","anti-inflammatory agent","","CC(C)(C)c1cc(SC(C)(C)Sc2cc(c(OCC(O)=O)c(c2)C(C)(C)C)C(C)(C)C)cc(c1O)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)c1cc(SC(C)(C)Sc2cc(c(OCC(O)=O)c(c2)C(C)(C)C)C(C)(C)C)cc(c1O)C(C)(C)C",574.31505208,39,10.837,117.36,0.013250128971219,0.048,0.0306250644856095,0,0
"diroximel-fumarate","anti-inflammatory agent","","COC(=O)\C=C\C(=O)OCCN1C(=O)CCC1=O, COC(=O)\C=C\C(=O)OCCN1C(=O)CCC1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COC(=O)\C=C\C(=O)OCCN1C(=O)CCC1=O",255.074287136,18,-0.812,89.98,0.0232144153357617,0.038,0.0306072076678808,0,0
"adaprev","TGF beta receptor inhibitor","AKR1B1, GPI, HK1, M6PR, PYGM","O[C@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O |a:3,10,12,14,&1:1|, O[C@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O |a:3,10,12,14,&1:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","O[C@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O |a:3",260.029718626,16,-3.355,166.72,0.00120297815472653,0.06,0.0306014890773633,0,0
"alicapistat","calpain inhibitor","CAPN1, CAPN2","O=C(N[C@H](Cc1ccccc1)C(=O)C(=O)NC1CC1)[C@H]1CCC(=O)N1Cc1ccccc1 |&1:3|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","neurology/psychiatry","alzheimer's disease","O=C(N[C@H](Cc1ccccc1)C(=O)C(=O)NC1CC1)[C@H]1CCC(=O)N1Cc1ccccc1 |&1:3|",433.200156344,32,2.155,95.58,0.0151529558625223,0.046,0.0305764779312612,0,0
"carzenide","","CA1, CA12, CA14, CA2, CA6, CA9","NS(=O)(=O)c1ccc(cc1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NS(=O)(=O)c1ccc(cc1)C(O)=O",201.009578704,13,0.096,105.84,0.0231134295214349,0.038,0.0305567147607174,0,0
"gallium-triquinolin-8-olate","","","O([Ga](Oc1cccc2cccnc12)Oc1cccc2cccnc12)c1cccc2cccnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","O([Ga](Oc1cccc2cccnc12)Oc1cccc2cccnc12)c1cccc2cccnc12",501.060390036,34,6.216,66.36,0.0250297378487205,0.036,0.0305148689243603,0,0
"lometrexol","glycinamide ribonucleotide formyltransferase inhibitor","GART","Nc1nc(=O)c2C[C@@H](CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Nc1nc(=O)c2C[C@@H](CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1",443.18048352,32,0.409,187.5,0.000936698013803603,0.06,0.0304683490069018,0,0
"asymmetrical-dimethylarginine","nitric oxide synthase inhibitor","NOS2, NOS3","CN(C)C(=N)NCCC[C@H](N)C(O)=O, CN(C)C(=N)NCCC[C@H](N)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN(C)C(=N)NCCC[C@H](N)C(O)=O",202.142975816,14,-1.898,102.44,0.0188735719075921,0.042,0.030436785953796,0,0
"CT-7758","integrin antagonist","ITGA4","OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|, OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|, OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|, OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|, OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|, OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|",520.11100276,34,2.639,104.21,0.00280709211199094,0.058,0.0304035460559955,0,0
"oligomycin-A","ATP synthase inhibitor, ATPase inhibitor","ATP5A1","[H][C@]12CC[C@@H](CC)\C=C\C=C\C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)\C=C\C(=O)O[C@]([H])([C@@H]1C)[C@H](C)[C@@]1(CC[C@H](C)[C@H](C[C@@H](C)O)O1)O2 |t:7,9,35|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@]12CC[C@@H](CC)\C=C\C=C\C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)\C=C\C(=O)O[C@]([H])([C@@H]1C)[C@H](C)[C@@]1(CC[C@H](C)[C@H](C[C@@H](C)O)O1)O2 |t:7",790.523113188,58,6.052,180.05,0.000439822972358939,0.06,0.0302199114861795,0,0
"arctigenin","MEK inhibitor","CHUK, MAP2K1","COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc2ccc(O)c(OC)c2)cc1OC, COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc2ccc(O)c(OC)c2)cc1OC, COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc2ccc(O)c(OC)c2)cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc2ccc(O)c(OC)c2)cc1OC",372.157288488,27,2.77,74.22,0.0383863735654006,0.022,0.0301931867827003,0,0
"wiskostatin","actin related protein inhibitor, neural Wiskott-Aldrich syndrome protein inhibitor","WASL","CN(C)C[C@@H](O)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:4,r|, CN(C)C[C@@H](O)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:4,r|, CN(C)C[C@@H](O)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:4,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN(C)C[C@@H](O)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:4",423.978587396,22,4.612,28.4,0.0163333235247413,0.044,0.0301666617623707,0,0
"mevastatin","HMGCR inhibitor","HMGCR","CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12",390.240624188,28,4.07,72.83,0.0442891906017423,0.016,0.0301445953008711,0,0
"sinefungin","DNA methyltransferase inhibitor, RNA synthesis inhibitor","CARM1","N[C@@H](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12, N[C@@H](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@@H](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12",381.176066836,27,-4.259,208.65,0.000254152441139916,0.06,0.03012707622057,0,0
"im156","ampk activator","NDUFS1, PRKAA2","NC(Nc1ccc(OC(F)(F)F)cc1)=NC(=N)N1CCCC1.CC(=O)O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","breast cancer","NC(Nc1ccc(OC(F)(F)F)cc1)=NC(=N)N1CCCC1.CC(=O)O",375.15182416,26,3.203,124.03,0.0102367799629354,0.05,0.0301183899814677,0,0
"kasugamycin","bacterial 30S ribosomal subunit inhibitor","","C[C@H]1O[C@H](O[C@@H]2[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@H]2O)[C@@H](N)C[C@@H]1NC(=N)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H]1O[C@H](O[C@@H]2[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@H]2O)[C@@H](N)C[C@@H]1NC(=N)C(O)=O",379.15907938,26,-4.513,218.81,0.000157270326944086,0.06,0.030078635163472,0,0
"2,4-dinitrophenol","ATP synthase inhibitor","APP","Oc1ccc(cc1[N+]([O-])=O)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(cc1[N+]([O-])=O)[N+]([O-])=O",184.012021228,13,2.258,106.51,0.0561089859684154,0.004,0.0300544929842077,0,0
"DU-728","structural glycoprotein antagonist","ITGA2B, ITGB3","N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O, N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O",433.192110824,30,-6.371,270.05,2.09944240788926e-05,0.06,0.0300104972120394,0,0
"epitalon (tfa)","","TERT","C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O.OC(=O)C(F)(F)F |a:1,6,15|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","ophthalmology","retinitis pigmentosa (rp)","C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O.OC(=O)C(F)(F)F |a:1",504.131542216,34,-5.045,262.52,1.5954039602104e-05,0.06,0.0300079770198011,0,0
"hygromycin-B","polypeptide synthesis inhibitor","","CN[C@H]1C[C@@H](N)[C@H](O)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@@H]3O[C@@]4(O[C@H]23)O[C@H]([C@@H](N)CO)[C@H](O)[C@H](O)[C@H]4O)[C@@H]1O |a:2,4,6,8,10,12,15,17,21,23,24,28,30,32,34,&1:19|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN[C@H]1C[C@@H](N)[C@H](O)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@@H]3O[C@@]4(O[C@H]23)O[C@H]([C@@H](N)CO)[C@H](O)[C@H](O)[C@H]4O)[C@@H]1O |a:2",527.232638244,36,-5.261,272.06,1.10684729430639e-05,0.06,0.0300055342364715,0,0
"safflower-yellow","anti-inflammatory agent","","OC[C@H]1O[C@@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@]1(O)C(=O)[C@@H](\C=C2/C(=O)C(=C(O)\C=C\c3ccc(O)cc3)C(=O)[C@@](O)([C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C2=O)C(=O)C(=C(O)\C=C\c2ccc(O)cc2)C1=O |a:2,5,7,9,11,34,38,41,43,45,&1:4,&2:15,&3:20,&4:36,&5:51|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC[C@H]1O[C@@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@]1(O)C(=O)[C@@H](\C=C2/C(=O)C(=C(O)\C=C\c3ccc(O)cc3)C(=O)[C@@](O)([C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C2=O)C(=O)C(=C(O)\C=C\c2ccc(O)cc2)C1=O |a:2",910.216772984,65,-0.586999999999997,404.1,1.37416872312928e-07,0.06,0.0300000687084362,0,0
"setmelanotide","melanocortin receptor agonist","","[H][C@]1(Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@@H](C)NC(=O)[C@]([H])(CSSC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O, [H][C@]1(Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@@H](C)NC(=O)[C@]([H])(CSSC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","[H][C@]1(Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@@H](C)NC(=O)[C@]([H])(CSSC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O",1116.485807756,80,1.713,494.76,6.75438871335882e-09,0.06,0.0300000033771944,0,0
"hexasodium-phytate","","","OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O, OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O",659.861371236,36,-11.406,459.42,1.33602620057262e-09,0.06,0.0300000006680131,0,0
"12-O-tetradecanoylphorbol-13-acetate","PKC activator","KCNT2, TRPV4","CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|, CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|, CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|, CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|, CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|, CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|, CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33",616.397518752,44,6.511,130.36,0.00396222627743941,0.056,0.0299811131387197,0,0
"D-157495","decapping scavenger enzyme inhibitor","","Nc1nc(N)c2c(OCC3CCN(Cc4c(Cl)cccc4Cl)CC3)cccc2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1nc(N)c2c(OCC3CCN(Cc4c(Cl)cccc4Cl)CC3)cccc2n1",431.127965716,29,4.366,90.29,0.0155036126043726,0.044,0.0297518063021863,0,0
"salidroside","beta amyloid protein neurotoxicity inhibitor","APP","OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O",300.12090298,21,-0.145,119.61,0.00948489586939592,0.05,0.029742447934698,0,0
"LCL-161","XIAP inhibitor","BIRC2, XIAP","CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1",500.225740136,35,3.947,119.64,0.00546593390800486,0.054,0.0297329669540024,0,0
"TC-H-106","HDAC inhibitor","HDAC1, HDAC2, HDAC3, HDAC8","Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1, Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1, Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1, Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1, Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1, Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1",339.19467704,25,2.907,84.22,0.0434435079278537,0.016,0.0297217539639268,0,0
"nastorazepide","CCK receptor antagonist","CCKBR","CC(C)(C)C(=O)CN1c2ccccc2N(C[C@@H](NC(=O)Nc2cccc(c2)C(O)=O)C1=O)C1CCCCC1, CC(C)(C)C(=O)CN1c2ccccc2N(C[C@@H](NC(=O)Nc2cccc(c2)C(O)=O)C1=O)C1CCCCC1, CC(C)(C)C(=O)CN1c2ccccc2N(C[C@@H](NC(=O)Nc2cccc(c2)C(O)=O)C1=O)C1CCCCC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)(C)C(=O)CN1c2ccccc2N(C[C@@H](NC(=O)Nc2cccc(c2)C(O)=O)C1=O)C1CCCCC1",520.268570252,38,4.284,119.05,0.00742619196574817,0.052,0.0297130959828741,0,0
"sulfatinib","tyrosine kinase inhibitor","","CN(C)CCNS(=O)(=O)Cc1cccc(Nc2nccc(Oc3ccc4[nH]c(C)cc4c3)n2)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN(C)CCNS(=O)(=O)Cc1cccc(Nc2nccc(Oc3ccc4[nH]c(C)cc4c3)n2)c1",480.194359756,34,2.961,120.62,0.00537918659935833,0.054,0.0296895932996792,0,0
"cepharanthine","NFkB pathway inhibitor","","COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34",606.272986936,45,5.417,61.86,0.0233212836155911,0.036,0.0296606418077955,0,0
"corosolic-acid","PKC inhibitor, protein tyrosine kinase inhibitor","HSD11B1, PTPN1","C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|",472.355260016,34,8.142,77.76,0.0590882740675236,0,0.0295441370337618,0,0
"odanacatib","cathepsin inhibitor","CTSK","CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N",525.170925604,36,5.265,107.44,0.00693931785605231,0.052,0.0294696589280262,0,0
"ambazone","DNA damage inducer","","NC(=S)NNc1ccc(cc1)N=NC(N)=N, NC(=S)NNc1ccc(cc1)N=NC(N)=N, NC(=S)NNc1ccc(cc1)N=NC(N)=N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","NC(=S)NNc1ccc(cc1)N=NC(N)=N",237.079664352,16,1.657,156.76,0.0089013102793079,0.05,0.029450655139654,0,0
"PD-173074","FGFR inhibitor, VEGFR inhibitor","FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB","CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1",523.327088172,38,4.524,113.53,0.00831311183205152,0.05,0.0291565559160258,0,0
"fosfructose","fructose diphosphate stimulant","","O[C@@H]1[C@@H](COP(O)(O)=O)OC(O)(COP(O)(O)=O)[C@H]1O, O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)C(=O)COP(O)(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","O[C@@H]1[C@@H](COP(O)(O)=O)OC(O)(COP(O)(O)=O)[C@H]1O",339.996049148,20,-5.056,223.06,7.98416140482135e-05,0.058,0.0290399208070241,0,0
"Ro-90-7501","beta amyloid protein neurotoxicity inhibitor","APP","Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1, Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1, Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1, Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1",340.143644512,26,2.884,109.4,0.0300753011677085,0.028,0.0290376505838543,0,0
"BAX-channel-blocker","cytochrome C release inhibitor","BAX","O[C@@H](CN1CCNCC1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:1|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O[C@@H](CN1CCNCC1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:1|",465.005136492,25,4.016,40.43,0.00805962404633537,0.05,0.0290298120231677,0,0
"7-((r)-2-amino-2-phenylacetamido)-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate","","","N[C@@H](C(=O)NC1C2CCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","N[C@@H](C(=O)NC1C2CCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1",349.082933672,24,0.473,112.73,0.00802781113223774,0.05,0.0290139055661189,0,0
"PCI-27483","ERK1 and ERK2 phosphorylation inhibitor","","NC(=N)c1ccc2nc([nH]c2c1)-c1cc(CC(=O)N[C@@H](CC(O)=O)C(O)=O)cc(c1O)-c1cc(ccc1O)S(N)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NC(=N)c1ccc2nc([nH]c2c1)-c1cc(CC(=O)N[C@@H](CC(O)=O)C(O)=O)cc(c1O)-c1cc(ccc1O)S(N)(=O)=O",596.132547348,42,-1.457,291.25,1.38409265943986e-05,0.058,0.0290069204632972,0,0
"2-hydroxy-4-((E)-3-(4-hydroxyphenyl)acryloyl)-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-6-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)cyclohexane-1,3,5-trione","","","OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1C(=O)C(=C(O)\C=C\c2ccc(O)cc2)C(=O)[C@@](O)([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C1=O |a:2,4,5,7,9,30,32,35,37,39,&1:11,&2:14,&3:28|, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1C(=O)C(=C(O)\C=C\c2ccc(O)cc2)C(=O)[C@@](O)([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C1=O |a:2,4,5,7,9,30,32,35,37,39,&1:11,&2:14,&3:28|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1C(=O)C(=C(O)\C=C\c2ccc(O)cc2)C(=O)[C@@](O)([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C1=O |a:2",612.169034944,43,-2.423,292.2,9.16736544853234e-06,0.058,0.0290045836827243,0,0
"ornipressin","vasoconstrictor","","[H][C@@]1(Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@@]1(Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O",1041.416056456,73,-2.222,476.15,4.7500592536394e-09,0.058,0.0290000023750296,0,0
"delcasertib","PKC inhibitor","","CC(C)C[C@H](NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)C[C@H](NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(O)=O",2878.466750448,201,-11.948,1436.41,2.22044604925031e-16,0.058,0.0290000000000001,0,0
"vilanterol trifenatate","adrenergic receptor agonist","ADRB2","OC(=O)C(c1ccccc1)(c1ccccc1)c1ccccc1.OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCOCc1c(Cl)cccc1Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"phase 3","lung diseases","chronic obstructive pulmonary disease (copd)","OC(=O)C(c1ccccc1)(c1ccccc1)c1ccccc1.OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCOCc1c(Cl)cccc1Cl",773.288608268,54,9.425,128.48,0.00199439796321183,0.056,0.0289971989816059,0,0
"FK-888","tachykinin antagonist","TACR1, TACR2","CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12",588.273655632,44,4.956,94.88,0.0119682459007776,0.046,0.0289841229503888,0,0
"cyclopiazonic acid","endoplasmic reticulum calcium atpase inhibitor","","CC(=O)[C@H]1C(=O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O |&1:3|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)[C@H]1C(=O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O |&1:3|",336.1473925,25,1.324,70.24,0.0438036966737842,0.014,0.0289018483368921,0,0
"omtriptolide","ERK1 and ERK2 phosphorylation inhibitor","","[H][C@@]12C[C@@H]3O[C@@]33[C@H](OC(=O)CCC(O)=O)[C@]4(O[C@H]4[C@@H]4O[C@]34[C@@]1(C)CCC1=C2COC1=O)C(C)C |c:30|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@@]12C[C@@H]3O[C@@]33[C@H](OC(=O)CCC(O)=O)[C@]4(O[C@H]4[C@@H]4O[C@]34[C@@]1(C)CCC1=C2COC1=O)C(C)C |c:30|",460.173332476,34,0.103,127.49,0.00367880661965807,0.054,0.028839403309829,0,0
"BMS-626529","HIV attachment inhibitor","","COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12, COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12",473.181152216,35,2.057,126.31,0.00562236263458776,0.052,0.0288111813172939,0,0
"GR125487","serotonin receptor antagonist","HTR4","COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1, COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1, COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1, COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1",0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1",427.157720152,29,2.825,109.11,0.00761150127518783,0.05,0.0288057506375939,0,0
"cycloheximide","protein synthesis inhibitor","RPL3","C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1, C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1, C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1, C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1",281.162708216,20,0.758,83.47,0.0333645677988324,0.024,0.0286822838994162,0,0
"zaurategrast ethyl ester","integrin antagonist","ITGA4, ITGB7","O=C(OCC)[C@H](CC1=CC=C(NC2=NC=CC3=C2C=NC=C3)C=C1)NC4=C(Br)C(C45CCCCC5)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","neurology/psychiatry","multiple sclerosis","O=C(OCC)[C@H](CC1=CC=C(NC2=NC=CC3=C2C=NC=C3)C=C1)NC4=C(Br)C(C45CCCCC5)=O",548.142302888,36,2.836,92.15,0.00315933947600099,0.054,0.0285796697380005,0,0
"6-iodo-nordihydrocapsaicin","TRPV antagonist","TRPV1","CCCCCCCCC(=O)NCc1cc(OC)c(O)cc1I, CCCCCCCCC(=O)NCc1cc(OC)c(O)cc1I",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCCC(=O)NCc1cc(OC)c(O)cc1I",419.095741692,22,5.396,58.56,0.0111158452403099,0.046,0.0285579226201549,0,0
"telcagepant","calcitonin antagonist","CALCRL, RAMP1","Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F, Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F, Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F, Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F",566.206479824,40,3.74,103.33,0.00495793343398506,0.052,0.0284789667169925,0,0
"GPI-1046","FKBP inhibitor","FKBP1A","CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)OCCCc1cccnc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)OCCCc1cccnc1",360.204907376,26,2.108,76.57,0.0328486071983117,0.024,0.0284243035991559,0,0
"monocrotaline","antitumor agent","","C[C@H]1C(=O)O[C@@H]2CCN3CC=C(COC(=O)[C@](C)(O)[C@]1(C)O)[C@H]23 |t:10|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H]1C(=O)O[C@@H]2CCN3CC=C(COC(=O)[C@](C)(O)[C@]1(C)O)[C@H]23 |t:10|",325.152537456,23,0.0180000000000001,96.3,0.0146903250665648,0.042,0.0283451625332824,0,0
"WHI-P154","JAK inhibitor","EGFR, JAK1, JAK2, JAK3","COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC",375.021853408,23,2.978,76.5,0.0145858515884546,0.042,0.0282929257942273,0,0
"arsanilic-acid","","LYZ","Nc1ccc(cc1)[As](O)(O)=O, Nc1ccc(cc1)[As](O)(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Nc1ccc(cc1)[As](O)(O)=O",216.972014616,11,0.929,83.55,0.0205241185858096,0.036,0.0282620592929048,0,0
"velneperit","neuropeptide receptor antagonist","NPY5R","CC(C)(C)S(=O)(=O)N[C@H]1CC[C@@H](CC1)C(=O)Nc1ccc(cn1)C(F)(F)F |r|, CC(C)(C)S(=O)(=O)N[C@H]1CC[C@@H](CC1)C(=O)Nc1ccc(cn1)C(F)(F)F |r|, CC(C)(C)S(=O)(=O)N[C@H]1CC[C@@H](CC1)C(=O)Nc1ccc(cn1)C(F)(F)F |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)(C)S(=O)(=O)N[C@H]1CC[C@@H](CC1)C(=O)Nc1ccc(cn1)C(F)(F)F |r|",407.149047288,27,2.894,96.54,0.0105127864055862,0.046,0.0282563932027931,0,0
"G-749","tyrosine kinase inhibitor","","CN1CCC(CC1)Nc1nc(Nc2ccc(Oc3ccccc3)cc2)c2c(O)ncc(Br)c2n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CN1CCC(CC1)Nc1nc(Nc2ccc(Oc3ccccc3)cc2)c2c(O)ncc(Br)c2n1",520.12223614,34,5.143,95.43,0.00633531045065203,0.05,0.028167655225326,0,0
"JZL-195","FAAH inhibitor, monoacylglycerol lipase inhibitor","FAAH, MGLL","[O-][N+](=O)c1ccc(OC(=O)N2CCN(Cc3cccc(Oc4ccccc4)c3)CC2)cc1, [O-][N+](=O)c1ccc(OC(=O)N2CCN(Cc3cccc(Oc4ccccc4)c3)CC2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[O-][N+](=O)c1ccc(OC(=O)N2CCN(Cc3cccc(Oc4ccccc4)c3)CC2)cc1",433.163770836,32,4.315,85.15,0.0322407321741611,0.024,0.0281203660870806,0,0
"LFM-A13","Bruton's tyrosine kinase (BTK) inhibitor","BTK","CC(=O)[C@@H](C#N)C(=O)Nc1cc(Br)ccc1Br |&1:3,r|, CC(=O)[C@@H](C#N)C(=O)Nc1cc(Br)ccc1Br |&1:3,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)[C@@H](C#N)C(=O)Nc1cc(Br)ccc1Br |&1:3",357.895251696,17,2.797,69.96,0.00618787224736167,0.05,0.0280939361236808,0,0
"BMS-470539","melanocortin receptor agonist","MC1R","CCCC(=O)C1(CCN(CC1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)[C@@H](N)Cc1cncn1C)c1ccccc1, CCCC(=O)C1(CCN(CC1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)[C@@H](N)Cc1cncn1C)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCC(=O)C1(CCN(CC1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)[C@@H](N)Cc1cncn1C)c1ccccc1",559.315854792,41,2.941,119.55,0.00415770008388156,0.052,0.0280788500419408,0,0
"BIO-1211","integrin antagonist","ITGA4, ITGB1","CC(C)C[C@H](NC(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(O)=O, CC(C)C[C@H](NC(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(O)=O, CC(C)C[C@H](NC(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)C[C@H](NC(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(O)=O",708.348277116,51,2.359,223.34,9.26572013768493e-05,0.056,0.0280463286006884,0,0
"icariin","phosphodiesterase inhibitor","PDE5A","COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O",676.23672058,48,3.342,238.2,9.01983641415789e-05,0.056,0.0280450991820708,0,0
"lappaconite","sodium channel blocker","","CCN1C[C@@]2(CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@]5(O)[C@](O)(C[C@@H]6OC)[C@@H](C[C@H]23)[C@@H]14)OC(=O)c1ccccc1NC(C)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCN1C[C@@]2(CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@]5(O)[C@](O)(C[C@@H]6OC)[C@@H](C[C@H]23)[C@@H]14)OC(=O)c1ccccc1NC(C)=O",584.309766368,42,2.261,126.79,0.00206522806592391,0.054,0.028032614032962,0,0
"lappaconite hbr","sodium channel blocker","","CCN1C[C@@]2(CC[C@@H](OC)[C@@]34[C@H]5C[C@H]6[C@H](OC)[C@]5(O)[C@](O)(C[C@@H]6OC)[C@H](C[C@H]23)C14)OC(=O)c1ccccc1NC(C)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCN1C[C@@]2(CC[C@@H](OC)[C@@]34[C@H]5C[C@H]6[C@H](OC)[C@]5(O)[C@](O)(C[C@@H]6OC)[C@H](C[C@H]23)C14)OC(=O)c1ccccc1NC(C)=O",584.309766368,42,2.261,126.79,0.00206522806592391,0.054,0.028032614032962,0,0
"ATN-161","integrin antagonist","ITGA5, ITGAV, ITGB1, ITGB3","CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O, CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O, CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O, CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O, CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O, CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O",597.23293008,41,-5.192,310.6,2.73481440788908e-06,0.056,0.0280013674072039,0,0
"PTC-209","BMI-1 inhibitor","","COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1",492.920755236,26,4.766,92.58,0.001879573169469,0.054,0.0279397865847345,0,0
"varespladib","secretory phospholipase inhibitor","PLA2G2A","CCc1c(C(=O)C(N)=O)c2c(OCC(O)=O)cccc2n1Cc1ccccc1, CCc1c(C(=O)C(N)=O)c2c(OCC(O)=O)cccc2n1Cc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCc1c(C(=O)C(N)=O)c2c(OCC(O)=O)cccc2n1Cc1ccccc1",380.13722174,28,2.394,111.62,0.015664837576838,0.04,0.027832418788419,0,0
"digitoxigenin","ATPase inhibitor","ATP1A1","C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|",374.245709568,27,3.685,66.76,0.0534821918479008,0.002,0.0277410959239504,0,0
"phthalylsulfacetamide","","","CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1, CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1, CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1, CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1",362.057257168,25,1.343,138.02,0.00512016403126052,0.05,0.0275600820156303,0,0
"targinine","nitric oxide synthase inhibitor","NOS3","CNC(=N)NCCC[C@H](N)C(O)=O, CNC(=N)NCCC[C@H](N)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CNC(=N)NCCC[C@H](N)C(O)=O",188.127325752,13,-2.461,111.23,0.014947457235468,0.04,0.027473728617734,0,0
"indium-tri(2-propanolate)","","","CC(C)O[In](OC(C)C)OC(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)O[In](OC(C)C)OC(C)C",292.052947532,13,2.805,27.69,0.0309325728843553,0.024,0.0274662864421777,0,0
"2-TEDC","lipoxygenase inhibitor","ALOX12","Oc1ccc(\C=C(/C#N)C(=O)OCCc2cccs2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)OCCc2cccs2)cc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1ccc(\C=C(/C#N)C(=O)OCCc2cccs2)cc1O",315.056528896,22,2.15,118.79,0.0148733729197164,0.04,0.0274366864598582,0,0
"TCS-2314","integrin inhibitor","ITGA4, ITGB1","Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N2CCOC[C@H]2C(=O)N2CCC(CC(O)=O)CC2)cc1, Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N2CCOC[C@H]2C(=O)N2CCC(CC(O)=O)CC2)cc1, Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N2CCOC[C@H]2C(=O)N2CCC(CC(O)=O)CC2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N2CCOC[C@H]2C(=O)N2CCC(CC(O)=O)CC2)cc1",522.247834808,38,1.362,128.28,0.0028054348521804,0.052,0.0274027174260902,0,0
"L-monomethylarginine","nitric oxide synthase inhibitor","NOS1, NOS2","CN[C@@H](CCCNC(N)=N)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CN[C@@H](CCCNC(N)=N)C(O)=O",188.127325752,13,-2.534,111.23,0.0146860622635879,0.04,0.0273430311317939,0,0
"sorbitan-monostearate","","","CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O |a:23,26,28,&1:21|, CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O |a:23,26,28,&1:21|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O |a:23",430.329439192,30,7.508,96.22,0.0366772568343875,0.018,0.0273386284171938,0,0
"BT-11","cAMP stimulant","","O=C(N1CCN(CC1)C(=O)c1cccc(n1)-c1nc2ccccc2[nH]1)c1cccc(n1)-c1nc2ccccc2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","O=C(N1CCN(CC1)C(=O)c1cccc(n1)-c1nc2ccccc2[nH]1)c1cccc(n1)-c1nc2ccccc2[nH]1",528.202222008,40,3.066,123.76,0.00648295346528395,0.048,0.027241476732642,0,0
"tetroquinone","","","OC1C(=O)C(=O)C(O)C(=O)C1=O, OC1C(=O)C(=O)C(O)C(=O)C1=O, OC1C(=O)C(=O)C(O)C(=O)C1=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC1C(=O)C(=O)C(O)C(=O)C1=O",172.000787848,12,-2.032,108.74,0.0204312724801789,0.034,0.0272156362400895,0,0
"otamixaban","coagulation factor inhibitor","F10","COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1, COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1, COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1, COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1",446.195405312,33,4.349,132.21,0.0102970446590673,0.044,0.0271485223295336,0,0
"istaroxime","ATPase inhibitor","ATP1A1","C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O",360.241292884,26,1.666,81.75,0.0262924157960548,0.028,0.0271462078980274,0,0
"vicriviroc","CC chemokine receptor antagonist","CCR5","COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)c1c(C)ncnc1C)c1ccc(cc1)C(F)(F)F, COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)c1c(C)ncnc1C)c1ccc(cc1)C(F)(F)F, COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)c1c(C)ncnc1C)c1ccc(cc1)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)c1c(C)ncnc1C)c1ccc(cc1)C(F)(F)F",533.297760116,38,3.37,61.8,0.0162415734796243,0.038,0.0271207867398122,0,0
"1,2,3,4,5,6-hexabromocyclohexane","JAK inhibitor","JAK2","BrC1C(Br)C(Br)C(Br)C(Br)C1Br, BrC1C(Br)C(Br)C(Br)C(Br)C1Br, BrC1C(Br)C(Br)C(Br)C(Br)C1Br",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","BrC1C(Br)C(Br)C(Br)C(Br)C1Br",551.556972792,12,5.862,0,0.00020590220885085,0.054,0.0271029511044254,0,0
"RU-28318","cytochrome P450 inhibitor","NR3C2","CCC[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)CCC(O)=O)[C@H]12 |t:5|, CCC[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)CCC(O)=O)[C@H]12 |t:5|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCC[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)CCC(O)=O)[C@H]12 |t:5|",402.277009696,29,5.173,74.6,0.0521772990668894,0.002,0.0270886495334447,0,0
"verbascoside","NFkB pathway inhibitor, PKC inhibitor","","C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)\C=C\c2ccc(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)\C=C\c2ccc(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)\C=C\c2ccc(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)\C=C\c2ccc(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O",624.205420452,44,0.264,245.29,4.96462357955214e-05,0.054,0.0270248231178978,0,0
"gentiopicrin","glutamate receptor downregulator","GRIN2B","OC[C@H]1O[C@@H](O[C@@H]2OC=C3C(=O)OCC=C3[C@H]2C=C)[C@H](O)[C@@H](O)[C@@H]1O |c:14,t:8|, OC[C@H]1O[C@@H](O[C@@H]2OC=C3C(=O)OCC=C3[C@H]2C=C)[C@H](O)[C@@H](O)[C@@H]1O |c:14,t:8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","OC[C@H]1O[C@@H](O[C@@H]2OC=C3C(=O)OCC=C3[C@H]2C=C)[C@H](O)[C@@H](O)[C@@H]1O |c:14",356.11073222,25,-0.511,134.91,0.00402996803054726,0.05,0.0270149840152736,0,0
"spr741 (acetate)","other antibiotic","","[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@@H](CO)NC(=O)[C@@H](NC(C)=O)[C@@H](C)O)[C@@H](C)O.CC(=O)O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","infectious disease","gram-negative bacterial infections","[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@@H](CO)NC(=O)[C@@H](NC(C)=O)[C@@H](C)O)[C@@H](C)O.CC(=O)O",1051.566208764,75,-1.192,467.05,9.39320985272229e-09,0.054,0.0270000046966049,0,0
"glafenine","cystic fibrosis transmembrane conductance regulator inhibitor, DeltaF508-CFTR Correctors, deltaf508-cftr correctors, cystic fibrosis transmembrane conductance regulator inhibitor","CFTR","OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12 |&1:2|, OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12 |&1:2|, OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12 |r|, OCC(O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"withdrawn","pulmonology","pain relief","OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12 |&1:2|",372.087684704,26,2.943,91.68,0.0216253628156397,0.032,0.0268126814078199,0,0
"liquiritin","antioxidant","","OC[C@H]1O[C@@H](Oc2ccc(cc2)[C@@H]2CC(=O)c3ccc(O)cc3O2)[C@H](O)[C@@H](O)[C@@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC[C@H]1O[C@@H](Oc2ccc(cc2)[C@@H]2CC(=O)c3ccc(O)cc3O2)[C@H](O)[C@@H](O)[C@@H]1O",418.126382284,30,1.129,145.91,0.00335732091662851,0.05,0.0266786604583143,0,0
"broxyquinoline","antiprotozoal agent","","Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Oc1c(Br)cc(Br)c2cccnc12",300.87378798,13,3.315,33.12,0.0251798808334341,0.028,0.0265899404167171,0,0
"eldecalcitol","bone formation stimulant","VDR","[H][C@@]12CC[C@H]([C@H](C)CCCC(C)(C)O)[C@@]1(C)CCC\C2=C/C=C1/C[C@@H](O)[C@@H](OCCCO)[C@H](O)C1=C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","[H][C@@]12CC[C@H]([C@H](C)CCCC(C)(C)O)[C@@]1(C)CCC\C2=C/C=C1/C[C@@H](O)[C@@H](OCCCO)[C@H](O)C1=C",490.3658247,36,5.883,90.15,0.0271472414611427,0.026,0.0265736207305714,0,0
"FR-139317","endothelin receptor antagonist","EDNRA","CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O, CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O, CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O, CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O",604.337318508,44,1.426,145.66,0.0010681925336413,0.052,0.0265340962668206,0,0
"usniacin-(+)","MAP kinase activator","PTPN1","CC(O)=C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@]2(C)C1=O |a:21,&1:3,t:6|, CC(O)=C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O |a:21,&1:3,t:6|, CC(O)=C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O |a:21,&1:3,t:6|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(O)=C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@]2(C)C1=O |a:21",344.089602852,25,2.42,121.13,0.015007757138849,0.038,0.0265038785694245,0,0
"sancycline","antitumor agent","","[H][C@@]12Cc3cccc(O)c3C(=O)[C@@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2 |&1:19,&2:12|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@@]12Cc3cccc(O)c3C(=O)[C@@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2 |&1:19",414.142701044,32,-0.804000000000001,155.07,0.00294807236588764,0.05,0.0264740361829438,0,0
"oglufanide","VEGF antagonist","","N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O",333.132470708,24,-2.098,145.51,0.00294107447949699,0.05,0.0264705372397485,0,0
"bromisoval","anti-inflammatory agent","","CC(C)[C@@H](Br)C(=O)NC(N)=O |&1:3,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)[C@@H](Br)C(=O)NC(N)=O |&1:3",222.000389692,11,0.805,72.19,0.0229167000635789,0.03,0.0264583500317894,0,0
"NKP-1339","HSP inhibitor","","Cl[Ru+3](Cl)(Cl)(Cl)([n+]1cc2ccccc2[nH]1)[n+]1cc2ccccc2[nH]1, Cl[Ru+3](Cl)(Cl)(Cl)([n+]1cc2ccccc2[nH]1)[n+]1cc2ccccc2[nH]1, Cl[Ru+3](Cl)(Cl)(Cl)([n+]1cc2ccccc2[nH]1)[n+]1cc2ccccc2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cl[Ru+3](Cl)(Cl)(Cl)([n+]1cc2ccccc2[nH]1)[n+]1cc2ccccc2[nH]1",477.883213504454,23,6.414,39.34,0.00690844883159903,0.046,0.0264542244157995,0,0
"nkp-1339","hsp inhibitor","","Cl[Ru](Cl)(Cl)(Cl)([n+]1cc2ccccc2[nH]1)[n+]1cc2ccccc2[nH]1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","Cl[Ru](Cl)(Cl)(Cl)([n+]1cc2ccccc2[nH]1)[n+]1cc2ccccc2[nH]1",477.884859244181,23,6.414,39.34,0.00690817886803426,0.046,0.0264540894340171,0,0
"golvatinib","VEGFR inhibitor","KDR, MET","CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1, CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1, CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1, CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1",633.287509104,46,3.629,119.14,0.00268655740352469,0.05,0.0263432787017623,0,0
"DPC-681","HIV protease inhibitor","","CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNCc1cccc(F)c1)C(C)(C)C)S(=O)(=O)c1cccc(N)c1, CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNCc1cccc(F)c1)C(C)(C)C)S(=O)(=O)c1cccc(N)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNCc1cccc(F)c1)C(C)(C)C)S(=O)(=O)c1cccc(N)c1",669.336018856,47,4.009,162.24,0.000578637722028895,0.052,0.0262893188610144,0,0
"NBQX","glutamate receptor antagonist","GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIN1, GRIN2A, GRIN2B","NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O",336.016454976,23,1.529,177.4,0.00253505669001013,0.05,0.0262675283450051,0,0
"bafilomycin-a1","ATPase inhibitor","","[H][C@@]1(OC(=O)\C(OC)=C\C(\C)=C/[C@@H](C)[C@@H](O)[C@@H](C)C\C(C)=C\C=C\[C@@H]1OC)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O)[C@H](C)[C@H](O1)C(C)C |c:10,t:7,20,22|, [H][C@@]1(OC(=O)\C(OC)=C\C(\C)=C/[C@@H](C)[C@@H](O)[C@@H](C)C\C(C)=C\C=C\[C@@H]1OC)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O)[C@H](C)[C@H](O1)C(C)C |c:10,t:7,20,22|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@@]1(OC(=O)\C(OC)=C\C(\C)=C/[C@@H](C)[C@@H](O)[C@@H](C)C\C(C)=C\C=C\[C@@H]1OC)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O)[C@H](C)[C@H](O1)C(C)C |c:10",622.408083436,45,4.692,134.91,0.00249255730424258,0.05,0.0262462786521213,0,0
"AM-24","lipoxygenase inhibitor","ALOX5","Oc1c(I)cc(I)cc1I, Oc1c(I)cc(I)cc1I, Oc1c(I)cc(I)cc1I",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Oc1c(I)cc(I)cc1I",471.731808716,10,4.82,20.23,0.000424250379645772,0.052,0.0262121251898229,0,0
"succinobucol","antioxidant","VCAM1","CC(C)(C)c1cc(SC(C)(C)Sc2cc(c(OC(=O)CCC(O)=O)c(c2)C(C)(C)C)C(C)(C)C)cc(c1O)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","CC(C)(C)c1cc(SC(C)(C)Sc2cc(c(OC(=O)CCC(O)=O)c(c2)C(C)(C)C)C(C)(C)C)cc(c1O)C(C)(C)C",616.325616764,42,10.695,134.43,0.0063424648106154,0.046,0.0261712324053077,0,0
"dolastatin-10","tubulin polymerization inhibitor","TUBB","CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C, CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C, CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C, CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C, CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C, CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C, CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C",784.492104896,55,3.813,161.65,0.000225152068708968,0.052,0.0261125760343545,0,0
"pf-06380101","tubulin inhibitor","TUBB","CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)C(C)(C)N)C(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","oncology","breast cancer","CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)C(C)(C)N)C(C)C",742.445154704,52,2.639,184.43,0.000136289484061801,0.052,0.0260681447420309,0,0
"mmaf (hydrochloride)","tubulin polymerisation inhibitor","TPPP","CC(C)[C@H](NC)C(N[C@H](C(N([C@@H]([C@@H](C)CC)[C@H](OC)CC(N1CCC[C@@]1([H])[C@H](OC)[C@@H](C)C(N[C@H](C(O)=O)CC2=CC=CC=C2)=O)=O)C)=O)C(C)C)=O.Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","oncology","breast cancer","CC(C)[C@H](NC)C(N[C@H](C(N([C@@H]([C@@H](C)CC)[C@H](OC)CC(N1CCC[C@@]1([H])[C@H](OC)[C@@H](C)C(N[C@H](C(O)=O)CC2=CC=CC=C2)=O)=O)C)=O)C(C)C)=O.Cl",767.459991752,54,1.191,166.61,0.000125899240906048,0.052,0.026062949620453,0,0
"epitalon","","","C[C@H](N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","C[C@H](N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O",390.138678284,27,-5.664,225.22,9.89870925520553e-05,0.052,0.026049493546276,0,0
"scopolamine-N-oxide","acetylcholine receptor antagonist","CHRM1, CHRM2, CHRM3, CHRM4","C[N@@+]1([O-])[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:3,5,7,8,10,14,&1:1,TLB:0:1:4.5.6:8.10,THB:2:1:4.5.6:8.10,9:8:1:4.5.6,9:10:1:4.5.6,11:5:1:8.10|, C[N@@+]1([O-])[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:3,5,7,8,10,14,&1:1,TLB:0:1:4.5.6:8.10,THB:2:1:4.5.6:8.10,9:8:1:4.5.6,9:10:1:4.5.6,11:5:1:8.10|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,"preclinical","","","C[N@@+]1([O-])[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:3",319.141972772,23,0.105,82.12,0.0238466329701991,0.028,0.0259233164850996,0,0
"trofinetide","anti-inflammatory agent, cytokine production inhibitor","ATF3, IFNG, IL6, TNF","NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O, C[C@]1(CCCN1C(=O)CN)C(=O)N[C@@H](CCC(O)=O)C(O)=O |a:1,13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O",301.127385328,21,-4.254,150.03,0.00168249339620646,0.05,0.0258412466981032,0,0
"evatanepag","prostaglandin inhibitor","PTGER2, PTGER4","CC(C)(C)c1ccc(CN(Cc2cccc(OCC(O)=O)c2)S(=O)(=O)c2cccnc2)cc1, CC(C)(C)c1ccc(CN(Cc2cccc(OCC(O)=O)c2)S(=O)(=O)c2cccnc2)cc1, CC(C)(C)c1ccc(CN(Cc2cccc(OCC(O)=O)c2)S(=O)(=O)c2cccnc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)(C)c1ccc(CN(Cc2cccc(OCC(O)=O)c2)S(=O)(=O)c2cccnc2)cc1",468.171892996,33,4.392,105.18,0.0115001865249328,0.04,0.0257500932624664,0,0
"leonurine","anti-inflammatory agent","","COc1cc(cc(OC)c1O)C(=O)OCCCCNC(N)=N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(cc(OC)c1O)C(=O)OCCCCNC(N)=N",311.148120772,22,1.437,126.89,0.0114027206672354,0.04,0.0257013603336177,0,0
"sulfacarbamide","","","NC(=O)NS(=O)(=O)c1ccc(N)cc1, NC(=O)NS(=O)(=O)c1ccc(N)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","NC(=O)NS(=O)(=O)c1ccc(N)cc1",215.036462148,14,-0.938,123.66,0.0108179746641378,0.04,0.0254089873320689,0,0
"KML29","monoacylglucerol lipase inhibitor","MGLL","OC(C1CCN(CC1)C(=O)OC(C(F)(F)F)C(F)(F)F)(c1ccc2OCOc2c1)c1ccc2OCOc2c1, OC(C1CCN(CC1)C(=O)OC(C(F)(F)F)C(F)(F)F)(c1ccc2OCOc2c1)c1ccc2OCOc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(C1CCN(CC1)C(=O)OC(C(F)(F)F)C(F)(F)F)(c1ccc2OCOc2c1)c1ccc2OCOc2c1",549.122221332,38,5.561,86.69,0.010753398684072,0.04,0.025376699342036,0,0
"incyclinide","matrix metalloprotease inhibitor","","[H][C@@]12Cc3cccc(O)c3C(=O)[C@@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)C[C@]1([H])C2 |&1:19,&2:12|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","[H][C@@]12Cc3cccc(O)c3C(=O)[C@@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)C[C@]1([H])C2 |&1:19",371.100501884,29,-0.602,151.83,0.00467346124217687,0.046,0.0253367306210884,0,0
"sndx-5613","","KMT2A, MEN1","CCN(C(C)C)C(=O)c1cc(F)ccc1Oc2cncnc2N3CC4(CCN(C[C@@H]5CC[C@H](CC5)NS(=O)(=O)CC)CC4)C3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","hematologic malignancy","acute myeloid leukemia (aml)","CCN(C(C)C)C(=O)c1cc(F)ccc1Oc2cncnc2N3CC4(CCN(C[C@@H]5CC[C@H](CC5)NS(=O)(=O)CC)CC4)C3",630.336353204,44,4.691,116.35,0.00251759702458237,0.048,0.0252587985122912,0,0
"rapastinel","glutamate receptor agonist","","C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(N)=O, C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(N)=O",413.227433712,29,-3.186,179.29,0.000481117223843774,0.05,0.0252405586119219,0,0
"cytochalasin-B","microtubule inhibitor","ACTB","C[C@H]1[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]22OC(=O)\C=C\[C@H](O)CCC[C@@H](C)C\C=C\[C@H]2[C@H](O)C1=C |t:20,30|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@H]1[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]22OC(=O)\C=C\[C@H](O)CCC[C@@H](C)C\C=C\[C@H]2[C@H](O)C1=C |t:20",479.267173284,35,4.145,95.86,0.0162583935139114,0.034,0.0251291967569557,0,0
"acetyl-11-keto-beta-boswellic-acid","lipoxygenase inhibitor","HSD11B1, HSD11B2","C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |a:1,4,8,15,19,24,29,34,35,&1:14,&2:26,c:10|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |a:1",512.350174636,37,8.442,80.67,0.0462367653953229,0.004,0.0251183826976614,0,0
"AKBA","lipoxygenase inhibitor","ALOX5","C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |c:10|, C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |c:10|, C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |c:10|, C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |c:10|, C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |c:10|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |c:10|",512.350174636,37,8.442,80.67,0.0462367653953229,0.004,0.0251183826976614,0,0
"L-(+)-rhamnose-monohydrate","","","C[C@@H]1O[C@@H](O)[C@H](O)[C@H](O)[C@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H]1O[C@@H](O)[C@H](O)[C@H](O)[C@H]1O",164.068473484,11,-0.994,90.15,0.0382274856072845,0.012,0.0251137428036422,0,0
"dexniguldipine","calmodulin antagonist","ADORA3","COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4",609.283885968,45,7.667,111.01,0.0121971800872775,0.038,0.0250985900436388,0,0
"niguldipine-(S)-(+)","adrenergic receptor antagonist","ADRA1A","COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,"preclinical","","","COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4",609.283885968,45,7.667,111.01,0.0121971800872775,0.038,0.0250985900436387,0,0
"pentetic-acid","chelating agent","","OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CCN(CC(O)=O)CC(O)=O, OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CCN(CC(O)=O)CC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CCN(CC(O)=O)CC(O)=O",393.138343936,27,-5.487,196.22,0.000188463371332693,0.05,0.0250942316856663,0,0
"netilmicin (sulfate)","","","CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1OC1OC[C@](C)(O)[C@H](NC)[C@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1OC1OC[C@](C)(O)[C@H](NC)[C@H]1O",475.300598652,33,-2.815,199.73,0.000187007795767557,0.05,0.0250935038978838,0,0
"bromfenac","cyclooxygenase inhibitor","PTGS1, PTGS2","Nc1c(CC(O)=O)cccc1C(=O)c1ccc(Br)cc1, Nc1c(CC(O)=O)cccc1C(=O)c1ccc(Br)cc1",0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","Nc1c(CC(O)=O)cccc1C(=O)c1ccc(Br)cc1",333.000055344,20,3.413,80.39,0.0201723279490942,0.03,0.0250861639745471,0,0
"gamithromycin","antibacterial ","","[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)N(CCC)C[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)N(CCC)C[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C",776.539825872,56,2.669,180.08,0.000168935910616627,0.05,0.0250844679553083,0,0
"bromebric-acid","DNA synthesis inhibitor, purine antagonist","","COc1ccc(cc1)C(=O)C(\Br)=C\C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1)C(=O)C(\Br)=C\C(O)=O",283.968420868,16,2.191,63.6,0.0281128776976647,0.022,0.0250564388488324,0,0
"neohesperidin-dihydrochalcone","","","COc1ccc(CCC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)cc2O)cc1O, COc1ccc(CCC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)cc2O)cc1O, COc1ccc(CCC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)cc2O)cc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(CCC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)cc2O)cc1O",612.205420452,43,0.338,245.29,5.34929535833916e-05,0.05,0.0250267464767917,0,0
"burixafor","cc chemokine receptor antagonist","CXCR4","Nc1cc(nc(NC[C@H]2CC[C@H](CNCCCNC3CCCCC3)CC2)n1)N1CCN(CCP(O)(O)=O)CC1.Br.Br |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","hematologic malignancy","multiple myeloma","Nc1cc(nc(NC[C@H]2CC[C@H](CNCCCNC3CCCCC3)CC2)n1)N1CCN(CCP(O)(O)=O)CC1.Br.Br |r|",726.234498386,41,3.987,161.71,3.75244824611699e-05,0.05,0.0250187622412306,0,0
"phenylmercuric-acetate","other antifungal","","CC(=O)O[Hg]c1ccccc1, CC(=O)O[Hg]c1ccccc1, CC(=O)O[Hg]c1ccccc1, CC(=O)O[Hg]c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)O[Hg]c1ccccc1",338.023072496,11,2.254,26.3,0.00601475550941728,0.044,0.0250073777547086,0,0
"voclosporin","calcineurin inhibitor","","[H][C@@]1(CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@]([H])(NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@]([H])([C@H](O)[C@H](C)C\C=C\C=C)N(C)C(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C1=O)C(C)C, [H][C@@]1(CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@]([H])(NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@]([H])([C@H](O)[C@H](C)C\C=C\C=C)N(C)C(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C1=O)C(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","[H][C@@]1(CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@]([H])(NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@]([H])([C@H](O)[C@H](C)C\C=C\C=C)N(C)C(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C1=O)C(C)C",1213.841367992,90,8.577,278.8,5.30943223510153e-06,0.05,0.0250026547161176,0,0
"orphanin-fq","opioid receptor agonist","OPRL1, OPRM1","CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O, CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O",1807.980548768,128,-10.027,831.4,2.22044604925031e-16,0.05,0.0250000000000001,0,0
"4-carboxy-3-hydroxyphenylglycine-(RS)","glutamate receptor agonist, glutamate receptor antagonist","GRM1","N[C@@H](C(O)=O)c1ccc(C(O)=O)c(O)c1 |&1:1,r|, N[C@@H](C(O)=O)c1ccc(C(O)=O)c(O)c1 |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@@H](C(O)=O)c1ccc(C(O)=O)c(O)c1 |&1:1",211.048072388,15,-2.137,120.85,0.0119047101693409,0.038,0.0249523550846704,0,0
"4-carboxy-3-hydroxyphenylglycine-(S)","glutamate receptor agonist, glutamate receptor antagonist","GRM1, GRM2","N[C@H](C(O)=O)c1ccc(C(O)=O)c(O)c1, N[C@H](C(O)=O)c1ccc(C(O)=O)c(O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@H](C(O)=O)c1ccc(C(O)=O)c(O)c1",211.048072388,15,-2.137,120.85,0.0119047101693409,0.038,0.0249523550846704,0,0
"MG-132","proteasome inhibitor","PSMB1","CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O",475.304621412,34,5.614,113.6,0.013528203606057,0.036,0.0247641018030285,0,0
"YS-201","calcium receptor antagonist","","CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCCCC1 |&1:12,r,c:5,10|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCCCC1 |&1:12",457.221285712,33,4.445,111.01,0.0132013139570717,0.036,0.0246006569785358,0,0
"pregnenolone-succinate","GABA receptor negative allosteric modulator","CYP17A1","CC(=O)[C@H]1CC[C@H]2[C@H]3CC=C4C[C@H](CC[C@]4(C)[C@@H]3CC[C@]12C)OC(=O)CCC(O)=O |a:3,12,15,20,&1:6,&2:7,&3:17,t:9|, CC(=O)[C@H]1CC[C@H]2[C@H]3CC=C4C[C@H](CC[C@]4(C)[C@@H]3CC[C@]12C)OC(=O)CCC(O)=O |a:3,12,15,20,&1:6,&2:7,&3:17,t:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)[C@H]1CC[C@H]2[C@H]3CC=C4C[C@H](CC[C@]4(C)[C@@H]3CC[C@]12C)OC(=O)CCC(O)=O |a:3",416.256274252,30,4.943,80.67,0.0391482380623513,0.01,0.0245741190311757,0,0
"TC-SP-14","sphingosine 1-phosphate receptor agonist","S1PR1","OC(=O)C1CN(Cc2ccc(-c3nc4cc(Cc5ccccc5F)ccc4s3)c(F)c2)C1, OC(=O)C1CN(Cc2ccc(-c3nc4cc(Cc5ccccc5F)ccc4s3)c(F)c2)C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)C1CN(Cc2ccc(-c3nc4cc(Cc5ccccc5F)ccc4s3)c(F)c2)C1",450.12135532,32,4.532,81.67,0.0247636650385484,0.024,0.0243818325192742,0,0
"frakefamide","opioid receptor agonist","OPRD1","C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)N[C@@H](Cc3ccccc3)C(=O)N, C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O.OC(=O)C(F)(F)F |a:1,5,18,30|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"phase 2","neurology/psychiatry","depression","C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)N[C@@H](Cc3ccccc3)C(=O)N",563.254397408,41,1.798,176.64,0.000763599271136117,0.048,0.0243817996355681,0,0
"marimastat","matrix metalloprotease inhibitor","MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP2, MMP20, MMP21, MMP23A, MMP24, MMP25, MMP26, MMP27, MMP28, MMP3, MMP7, MMP8, MMP9","CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C, CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C, CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C, CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C, CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C, CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C",331.210721028,23,0.355,127.76,0.00671091767952568,0.042,0.0243554588397628,0,0
"oleuropein","estrogen receptor agonist, antioxidant","GPER1","COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)\C(=C\C)[C@@H]1CC(=O)OCCc1ccc(O)c(O)c1 |t:4|, COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@@H](O)[C@@H](O)[C@@H]2O)\C(=C/C)[C@@H]1CC(=O)OCCc1ccc(O)c(O)c1 |&1:7,&2:9,&3:11,&4:14,&5:16,&6:18,&7:23,r,t:4|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","null","fungal infection","COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)\C(=C\C)[C@@H]1CC(=O)OCCc1ccc(O)c(O)c1 |t:4|",540.184291084,38,0.261,201.67,0.000255065273825234,0.048,0.0241275326369126,0,0
"aphidicolin","RNA synthesis inhibitor","","C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO, C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO, C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO",338.245709568,24,3.315,80.92,0.0421667429981706,0.006,0.0240833714990853,0,0
"TBOA-(DL)","excitatory amino acid transporter inhibitor","SLC1A1, SLC1A2, SLC1A3, SLC1A6, SLC1A7","N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O, N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O, N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O, N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O, N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O",1,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O",478.158745032,34,-2.318,219.7,0.000156372490223962,0.048,0.024078186245112,0,0
"gemcabene","ppar receptor agonist","APOB, LPA, PCSK9, PPARA, PPARG","CC(C)(CCCCOCCCCC(C)(C)C(O)=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","endocrinology","hypercholesterolemia","CC(C)(CCCCOCCCCC(C)(C)C(O)=O)C(O)=O",302.20932406,21,2.236,83.83,0.0360932389269163,0.012,0.0240466194634582,0,0
"dalargin","opioid receptor agonist","OPRM1","CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=N)C(O)=O |a:23,41,&1:4,&2:8,&3:28|, CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=N)C(O)=O |a:23,41,&1:4,&2:8,&3:28|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=N)C(O)=O |a:23",725.386059592,52,-1.041,290.95,7.03293989871037e-06,0.048,0.0240035164699494,0,0
"andrographolide","tumor necrosis factor production inhibitor","IL1B, IL6, NFKB1, NFKB2, TNF","C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H](C\C=C3/[C@H](O)COC3=O)C(=C)CC[C@H]12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H](C\C=C3/[C@H](O)COC3=O)C(=C)CC[C@H]12",350.20932406,25,2.913,86.99,0.0317380786769376,0.016,0.0238690393384688,0,0
"nocodazole","tubulin polymerization inhibitor","HPGDS","COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1",301.052112212,21,2.279,112.32,0.0197016501224244,0.028,0.0238508250612122,0,0
"JNJ-26481585","HDAC inhibitor","HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, MDM2","Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12, Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12, Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12, Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12, Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12",394.211724072,29,2.227,95.31,0.0196567827869202,0.028,0.0238283913934601,0,0
"phlorizin","sodium/glucose cotransporter inhibitor","SLC5A1, SLC5A11, SLC5A2, SLC5A3","OC[C@H]1O[C@@H](Oc2cc(O)cc(O)c2C(=O)CCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O",1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC[C@H]1O[C@@H](Oc2cc(O)cc(O)c2C(=O)CCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O",436.136946968,31,1.096,177.14,0.00132430741514776,0.046,0.0236621537075739,0,0
"benzquinamide","dopamine receptor agonist","DRD2, PTGS2","CCN(CC)C(=O)C1CN2CCc3cc(OC)c(OC)cc3C2CC1OC(=O)C",0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,"withdrawn","gastroenterology","nausea","CCN(CC)C(=O)C1CN2CCc3cc(OC)c(OC)cc3C2CC1OC(=O)C",404.231122124,29,1.688,68.31,0.0252014956705297,0.022,0.0236007478352649,0,0
"picrotoxinin","GABA receptor antagonist","GLRA1, GLRA2, GLRA3, GLRB, HTR3A, HTR3B","CC(=C)[C@@H]1[C@H]2OC(=O)[C@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C, CC(=C)[C@@H]1[C@H]2OC(=O)[C@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=C)[C@@H]1[C@H]2OC(=O)[C@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C",292.094688232,21,-0.472,85.36,0.0231392058146323,0.024,0.0235696029073161,0,0
"pirozadil","hypolipidemic","","COc1cc(cc(OC)c1OC)C(=O)OCc1cccc(COC(=O)c2cc(OC)c(OC)c(OC)c2)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1cc(cc(OC)c1OC)C(=O)OCc1cccc(COC(=O)c2cc(OC)c(OC)c(OC)c2)n1",527.179146128,38,3.462,120.87,0.0049453052777797,0.042,0.0234726526388899,0,0
"WIN-18446","aldehyde dehydrogenase inhibitor","ALDH1A2","ClC(Cl)C(=O)NCCCCCCCCNC(=O)C(Cl)Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","ClC(Cl)C(=O)NCCCCCCCCNC(=O)C(Cl)Cl",364.0278886,20,3.082,58.2,0.0148951424309898,0.032,0.0234475712154949,0,0
"citric-acid","coagulation factor inhibitor","AKR1B1, ANG, APRT, BHMT, C8G, CA4, CPB1, CS, CTDSP1, GNMT, HGS, HS3ST3A1, IL4I1, ITPA, LSM6, MDH2, MIF, PDE5A, PKD2L1, PLEKHA1, RNASE1, RNASE3, SRC, TNFSF13B, UCK2","OC(=O)CC(O)(CC(O)=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)CC(O)(CC(O)=O)C(O)=O",192.027002596,13,-2.247,132.13,0.00889418520082025,0.038,0.0234470926004101,0,0
"BMS-806","HIV attachment inhibitor","","COc1ccnc2[nH]cc(C(=O)C(=O)N3CCN(C[C@H]3C)C(=O)c3ccccc3)c12, COc1ccnc2[nH]cc(C(=O)C(=O)N3CCN(C[C@H]3C)C(=O)c3ccccc3)c12, COc1ccnc2[nH]cc(C(=O)C(=O)N3CCN(C[C@H]3C)C(=O)c3ccccc3)c12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1ccnc2[nH]cc(C(=O)C(=O)N3CCN(C[C@H]3C)C(=O)c3ccccc3)c12",406.164105184,30,2.683,95.6,0.0206397306078696,0.026,0.0233198653039348,0,0
"tetrandrine","calcium channel blocker","SLC6A3","COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34, COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34, COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34, COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34, COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34",622.304287064,46,5.49,61.86,0.02043717062337,0.026,0.023218585311685,0,0
"HA-1004","calcium channel blocker","","NC(=N)NCCNS(=O)(=O)c1cccc2cnccc12, NC(=N)NCCNS(=O)(=O)c1cccc2cnccc12, NC(=N)NCCNS(=O)(=O)c1cccc2cnccc12, NC(=N)NCCNS(=O)(=O)c1cccc2cnccc12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NC(=N)NCCNS(=O)(=O)c1cccc2cnccc12",293.09464572,20,0.492,129.34,0.00832380508817257,0.038,0.0231619025440863,0,0
"naringin-dihydrochalcone","cytochrome P450 inhibitor","","C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c(C(=O)CCc3ccc(O)cc3)c(O)c2)[C@H](O)[C@H](O)[C@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c(C(=O)CCc3ccc(O)cc3)c(O)c2)[C@H](O)[C@H](O)[C@H]1O",582.194855768,41,0.691,236.06,9.33871247643924e-05,0.046,0.0230466935623822,0,0
"ardeparin","thrombin inhibitor","SERPIND1","CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](OC)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](OC)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O",623.0132052,38,-7.359,342.65,2.06743400770608e-07,0.046,0.0230001033717004,0,0
"vipivotide tetraxetan","glutamate carboxypeptidase inhibitor","FOLH1","O=C(O)[C@H](CCCCNC([C@H](CC1=CC=C2C=CC=CC2=C1)NC([C@H]3CC[C@H](CNC(CN4CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC4)=O)CC3)=O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","oncology","prostate cancer","O=C(O)[C@H](CCCCNC([C@H](CC1=CC=C2C=CC=CC2=C1)NC([C@H]3CC[C@H](CNC(CN4CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC4)=O)CC3)=O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O",1041.501877192,74,-3.611,365.19,5.5600731353767e-08,0.046,0.0230000278003657,0,0
"2-deoxyglucose","glycolysis inhibitor","SLC2A1, SLC2A2, SLC2A3, SLC2A4","OC[C@H]1O[C@H](O)C[C@@H](O)[C@@H]1O, OC[C@H]1O[C@H](O)C[C@@H](O)[C@@H]1O, OC[C@H]1O[C@H](O)C[C@@H](O)[C@@H]1O",1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC[C@H]1O[C@H](O)C[C@@H](O)[C@@H]1O",164.068473484,11,-1.525,90.15,0.0337160818028816,0.012,0.0228580409014408,0,0
"[(2s,3s,5s,8r,9s,10s,13s,14s,16s,17r)-17-acetoxy-2,16-bis(4,4-dimethylpiperazin-4-ium-1-yl)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl] acetate","","","[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1",602.476009304182,47,4.144,59.08,0.0313421243592499,0.014,0.0226710621796249,0,0
"geniposide","GLP receptor agonist","GLP1R","COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO |c:25,t:4|, COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO |c:25,t:4|, COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO |c:25,t:4|, COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO |c:25,t:4|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO |c:25",388.136946968,27,-1.854,155.14,0.0013406404047306,0.044,0.0226703202023653,0,0
"hepsulfam","DNA cross-linking","","NS(=O)(=O)OCCCCCCCOS(N)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","NS(=O)(=O)OCCCCCCCOS(N)(=O)=O",290.060628296,17,-2.071,155.54,0.00131160933755042,0.044,0.0226558046687752,0,0
"ec5026","epoxide hydolase inhibitor","EPHX2","CC[C@H](C)C(=O)N1CCC(CC1)NC(=O)Nc1ccc(OC(F)(F)F)c(F)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"phase 1","neurology/psychiatry","pain relief","CC[C@H](C)C(=O)N1CCC(CC1)NC(=O)Nc1ccc(OC(F)(F)F)c(F)c1",405.167554476,28,3.544,70.67,0.0290973831967937,0.016,0.0225486915983968,0,0
"geniposidic-acid","cyclooxygenase inhibitor","","OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |c:8,t:12|, OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |c:8,t:12|, OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |c:8,t:12|, OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |c:8,t:12|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |c:8",374.121296904,26,-2.175,166.14,0.00106645224638689,0.044,0.0225332261231934,0,0
"SB-225002","CC chemokine receptor antagonist","CXCR2","Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O",350.9854679,21,3.195,104.5,0.00905739932179351,0.036,0.0225286996608968,0,0
"U-104","carbonic anhydrase inhibitor","CA1, CA12, CA2, CA9","NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1, NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1, NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1, NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1, NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1",309.058340464,21,1.102,109.67,0.0130493750147435,0.032,0.0225246875073718,0,0
"ganoderic-acid-a","JAK inhibitor","","[H][C@@]12C[C@H](O)C3=C(C(=O)C[C@]4(C)[C@H](C[C@H](O)[C@@]34C)[C@H](C)CC(=O)C[C@@H](C)C(O)=O)[C@@]1(C)CCC(=O)C2(C)C |t:5|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@@]12C[C@H](O)C3=C(C(=O)C[C@]4(C)[C@H](C[C@H](O)[C@@]34C)[C@H](C)CC(=O)C[C@@H](C)C(O)=O)[C@@]1(C)CCC(=O)C2(C)C |t:5|",516.308703748,38,1.055,128.97,0.0029509048678072,0.042,0.0224754524339036,0,0
"compound-w","beta-secretase inhibitor","BACE1","OC(=O)c1cc(Oc2ccc(cc2)[N+]([O-])=O)cc(Oc2ccc(cc2)[N+]([O-])=O)c1, OC(=O)c1cc(Oc2ccc(cc2)[N+]([O-])=O)cc(Oc2ccc(cc2)[N+]([O-])=O)c1, OC(=O)c1cc(Oc2ccc(cc2)[N+]([O-])=O)cc(Oc2ccc(cc2)[N+]([O-])=O)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)c1cc(Oc2ccc(cc2)[N+]([O-])=O)cc(Oc2ccc(cc2)[N+]([O-])=O)c1",396.059365344,29,4.383,142.04,0.0108991672759196,0.034,0.0224495836379598,0,0
"d-fructose","","","OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO",180.063388104,12,-3.839,118.22,0.00878510595856269,0.036,0.0223925529792813,0,0
"TAME","","","COC(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1ccc(C)cc1, COC(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1ccc(C)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1ccc(C)cc1",342.136176184,23,1.437,142.75,0.0047701169940042,0.04,0.0223850584970021,0,0
"bardoxolone-methyl","nuclear factor erythroid derived, like (NRF2) activator","PPARG, STAT3","COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:16,20|, COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:16,20|, COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:16,20|, COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:16,20|, COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:16,20|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:16",505.319208856,37,6.622,84.23,0.0326876479575967,0.012,0.0223438239787983,0,0
"gossypol","BCL inhibitor, MCL1 inhibitor","BCL2","CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O",518.19406792,38,8.16,155.52,0.00865995419967431,0.036,0.0223299770998372,0,0
"1,5-dicaffeoylquinic-acid","","","O[C@@H]1C[C@@](C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)\C=C\c1ccc(O)c(O)c1)C(O)=O, O[C@@H]1C[C@@](C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)\C=C\c1ccc(O)c(O)c1)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","O[C@@H]1C[C@@](C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)\C=C\c1ccc(O)c(O)c1)C(O)=O",516.126776208,37,2.016,211.28,0.00044311858797434,0.044,0.0222215592939872,0,0
"FPL-55712","leukotriene receptor antagonist","","CCCc1c(OC[C@@H](O)COc2ccc3c(oc(cc3=O)C(O)=O)c2CCC)ccc(C(C)=O)c1O |&1:7,r|, CCCc1c(OC[C@@H](O)COc2ccc3c(oc(cc3=O)C(O)=O)c2CCC)ccc(C(C)=O)c1O |&1:7,r|, CCCc1c(OC[C@@H](O)COc2ccc3c(oc(cc3=O)C(O)=O)c2CCC)ccc(C(C)=O)c1O |&1:7,r|, CCCc1c(OC[C@@H](O)COc2ccc3c(oc(cc3=O)C(O)=O)c2CCC)ccc(C(C)=O)c1O |&1:7,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCCc1c(OC[C@@H](O)COc2ccc3c(oc(cc3=O)C(O)=O)c2CCC)ccc(C(C)=O)c1O |&1:7",498.18898254,36,5.653,143.5,0.00631028954775219,0.038,0.0221551447738761,0,0
"ilomastat","matrix metalloprotease inhibitor","ACAN, ADAM28, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP8, MMP9","CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO",388.211055376,28,1.622,123.32,0.00820954185710623,0.036,0.0221047709285531,0,0
"talc","","","O=[Mg].O=[Mg].O=[Mg].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","O=[Mg].O=[Mg].O=[Mg].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O",359.80689204,18,-4.389,187.77,8.36985802857358e-05,0.044,0.0220418492901429,0,0
"4,6-diamino-3-hydroxy-2-(pentofuranosyloxy)cyclohexyl 2,6-diamino-2,6-dideoxyhexopyranoside","","","NCC1OC(OC2C(N)CC(N)C(O)C2OC2OC(CO)C(O)C2O)C(N)C(O)C1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","NCC1OC(OC2C(N)CC(N)C(O)C2OC2OC(CO)C(O)C2O)C(N)C(O)C1O",454.227493288,31,-4.814,262.38,2.79801462698293e-05,0.044,0.0220139900731349,0,0
"deforolimus","mTOR inhibitor","MTOR","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O |c:14,33,t:29,31|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O |c:14",989.562942998,69,5.082,211.31,1.81732193331524e-05,0.044,0.0220090866096666,0,0
"colistin (sulfate)","","","CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O",1154.749927196,81,0.634,490.66,2.87512307969083e-09,0.044,0.0220000014375615,0,0
"colistin-b-sulfate","","","CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)C(CCN)NC1=O)C(C)O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)C(CCN)NC1=O)C(C)O",1154.749927196,81,0.634,490.66,2.87512307969083e-09,0.044,0.0220000014375615,0,0
"colistin sulfate","","","CCC(C)C1NC(=O)C(NC(=O)C(CCN)NC(=O)C(CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC1=O)C(C)O)NC(=O)C(CCN)NC(=O)C(NC(=O)C(CCN)NC(=O)CCCCC(C)C)C(C)O)C(C)CC, CC(C)CCCCC(=O)N[C@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](CCN)C(=O)N[C@@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@@H](CNC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)C(C)C)[C@@H](C)O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CCC(C)C1NC(=O)C(NC(=O)C(CCN)NC(=O)C(CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC1=O)C(C)O)NC(=O)C(CCN)NC(=O)C(NC(=O)C(CCN)NC(=O)CCCCC(C)C)C(C)O)C(C)CC",1154.749927196,81,0.211999999999999,490.66,2.59237559489477e-09,0.044,0.0220000012961878,0,0
"dixyrazine","antipsychotic","","C[C@H](CN1CCN(CCOCCO)CC1)CN1c2ccccc2Sc2ccccc12 |&1:1,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H](CN1CCN(CCOCCO)CC1)CN1c2ccccc2Sc2ccccc12 |&1:1",427.229348296,30,3.342,64.48,0.0298796750288982,0.014,0.0219398375144491,0,0
"C106","","","CN1CCC[C@@H]1c1cccnc1.Cc1ccc(cc1)C(=O)O[C@@H]([C@@H](OC(=O)c1ccc(C)cc1)C(O)=O)C(O)=O |&1:5,&2:22,&3:23,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CN1CCC[C@@H]1c1cccnc1.Cc1ccc(cc1)C(=O)O[C@@H]([C@@H](OC(=O)c1ccc(C)cc1)C(O)=O)C(O)=O |&1:5",548.215865984,40,4.68,143.33,0.00380220318835005,0.04,0.021901101594175,0,0
"hypoestoxide","IKK inhibitor","IKBKB, IL1B, TNF","CC(=O)O[C@@H]1C[C@]2(C)O[C@H]2CC[C@]2(C)O[C@H]2C[C@@H]2CC(=O)C(=C)[C@@H]1C2(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(=O)O[C@@H]1C[C@]2(C)O[C@H]2CC[C@]2(C)O[C@H]2C[C@@H]2CC(=O)C(=C)[C@@H]1C2(C)C",376.224974124,27,3.151,68.43,0.0435017957064592,0,0.0217508978532296,0,0
"L-ascorbyl-6-palmitate","","","CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:19,21,&1:27|, CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:19,21,&1:27|, CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:19,21,&1:27|, CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:19,21,&1:27|, CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:19,21,&1:27|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:19",414.261753556,29,6.655,110.13,0.0254262286866778,0.018,0.0217131143433389,0,0
"actinonin","","","CCCCC[C@H](CC(=O)NO)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1CO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","infectious disease","gram-negative bacterial infections","CCCCC[C@H](CC(=O)NO)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1CO",385.25767122,27,1.33,118.97,0.00721159710148234,0.036,0.0216057985507412,0,0
"CUR-61414","smoothened receptor antagonist","DHH, IHH, SMO","COc1cccc(CN([C@H]2C[C@H](N(Cc3ccc4OCOc4c3)C2)C(=O)N2CCNCC2)C(=O)CC(C)(C)C)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","COc1cccc(CN([C@H]2C[C@H](N(Cc3ccc4OCOc4c3)C2)C(=O)N2CCNCC2)C(=O)CC(C)(C)C)c1",550.315520444,40,3.471,83.58,0.0106660608282596,0.032,0.0213330304141298,0,0
"vedotin","antimitotic agent","TNFRSF10B, TPPP","[H][C@]1(CCCN1C(=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@@H](NC)C(C)C)C(C)C)[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","hematologic malignancy","acute lymphoblastic leukemia (all)","[H][C@]1(CCCN1C(=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@@H](NC)C(C)C)C(C)C)[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1",717.504049484,52,3.252,149.54,0.000645384941241747,0.042,0.0213226924706209,0,0
"pamufetinib","","","CNC(=O)c1cc2c(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)ccnc2cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CNC(=O)c1cc2c(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)ccnc2cc1OC",518.142404436,37,4.322,133.67,0.00447613894497059,0.038,0.0212380694724853,0,0
"daidzin","antioxidant","ALDH2","OC[C@H]1O[C@@H](Oc2ccc3c(c2)occ(-c2ccc(O)cc2)c3=O)[C@H](O)[C@@H](O)[C@@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","OC[C@H]1O[C@@H](Oc2ccc3c(c2)occ(-c2ccc(O)cc2)c3=O)[C@H](O)[C@@H](O)[C@@H]1O",416.11073222,30,2.431,149.82,0.00442387173777264,0.038,0.0212119358688863,0,0
"GSK3117391","HDAC inhibitor","","ONC(=O)CCc1ccc(CN[C@@H](C2CCCCC2)C(=O)OC2CCCC2)cn1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","ONC(=O)CCc1ccc(CN[C@@H](C2CCCCC2)C(=O)OC2CCCC2)cn1",403.247106536,29,2.829,100.55,0.0163134085216702,0.026,0.0211567042608351,0,0
"beta-funaltrexamine","opioid receptor antagonist","OPRD1, OPRK1, OPRM1","COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45, COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45, COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45, COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45, COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45",454.21038668,33,0.766,108.33,0.00616597697484487,0.036,0.0210829884874224,0,0
"PD-156707","endothelin receptor antagonist","EDNRA, EDNRB","COc1ccc(cc1)C(=O)C(\Cc1cc(OC)c(OC)c(OC)c1)=C(/C(O)=O)c1ccc2OCOc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc(cc1)C(=O)C(\Cc1cc(OC)c(OC)c(OC)c1)=C(/C(O)=O)c1ccc2OCOc2c1",506.157682412,37,4.24,109.75,0.0101153918420597,0.032,0.0210576959210299,0,0
"ginsenoside rg1","solute carrier family member inhibitor","SLCO1B3","[H][C@]12C(C)(C)[C@@H](O)CC[C@]1(C)[C@]3([H])[C@@]([C@@](CC[C@]4([H])[C@@](CC/C=C(C)/C)(C)O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)(C)[C@]4([H])[C@H](O)C3)(C)C[C@@H]2O[C@]6([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","neurology/psychiatry","alzheimer's disease","[H][C@]12C(C)(C)[C@@H](O)CC[C@]1(C)[C@]3([H])[C@@]([C@@](CC[C@]4([H])[C@@](CC/C=C(C)/C)(C)O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)(C)[C@]4([H])[C@H](O)C3)(C)C[C@@H]2O[C@]6([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O",800.492206984,61,3.873,239.22,0.000102864299888469,0.042,0.0210514321499442,0,0
"birinapant","XIAP inhibitor","BIRC2, XIAP","CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC",806.429087952,58,2.684,194.92,9.32673018789826e-05,0.042,0.0210466336509395,0,0
"elamipretide","","CRLS1","Cc1cc(O)cc(C)c1C[C@H](NC(=O)[C@H](N)CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc2ccccc2)C(=O)N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","ophthalmology","macular degeneration","Cc1cc(O)cc(C)c1C[C@H](NC(=O)[C@H](N)CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc2ccccc2)C(=O)N",639.385665668,46,0.841,264.56,4.03529706265472e-05,0.042,0.0210201764853133,0,0
"elx-02","","","C[C@H](N)[C@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](N)C[C@H](N)[C@H]2O[C@H]3O[C@H]([C@@H](C)O)[C@@H](O)[C@H](O)[C@H]3N)[C@H](O)[C@@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@H](N)[C@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](N)C[C@H](N)[C@H]2O[C@H]3O[C@H]([C@@H](C)O)[C@@H](O)[C@H](O)[C@H]3N)[C@H](O)[C@@H]1O",482.258793416,33,-3.894,262.38,2.84410724819193e-05,0.042,0.021014220536241,0,0
"gepon","","","CC(C)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](N)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O |a:3,11,20,51,69,80,100,118,&1:7,&2:31,&3:42,&4:60,&5:71,&6:74,&7:89,&8:109|, CC(C)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](N)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O |a:3,11,20,51,69,80,100,118,&1:7,&2:31,&3:42,&4:60,&5:71,&6:74,&7:89,&8:109|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](N)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O |a:3",1816.975522964,127,-10.739,932.34,2.22044604925031e-16,0.042,0.0210000000000001,0,0
"daucosterol","apoptosis stimulant","","CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(C)C |t:13|, CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(C)C |t:13|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(C)C |t:13|",576.43898964,41,10.487,99.38,0.0274025522482555,0.014,0.0207012761241278,0,0
"prolylleucylglycinamide","melanocyte-stimulating hormone release inhibitor","","CC(C)C[C@@H](NC(=O)[C@H]1CCCN1)C(=O)NCC(N)=O |&1:4,&2:8,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)C[C@@H](NC(=O)[C@H]1CCCN1)C(=O)NCC(N)=O |&1:4",284.184840628,20,-0.608,113.32,0.0113660656570662,0.03,0.0206830328285331,0,0
"SSR240612","bradykinin receptor antagonist","","COc1ccc2cc(ccc2c1)S(=O)(=O)N[C@H](CC(=O)N[C@H](Cc1ccc(CN2[C@@H](C)CCC[C@H]2C)cc1)C(=O)N(C)C(C)C)c1ccc2OCOc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc2cc(ccc2c1)S(=O)(=O)N[C@H](CC(=O)N[C@H](Cc1ccc(CN2[C@@H](C)CCC[C@H]2C)cc1)C(=O)N(C)C(C)C)c1ccc2OCOc2c1",756.355671004,54,6.387,134.89,0.00122400542483427,0.04,0.0206120027124171,0,0
"cortodoxone","androgen receptor antagonist","AR","C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:8|",346.21440944,25,2.427,74.6,0.0409162957638486,0,0.0204581478819243,0,0
"2-iodomelatonin","melatonin receptor agonist","MTNR1A, MTNR1B, NQO2","COc1ccc2[nH]c(I)c(CCNC(C)=O)c2c1, COc1ccc2[nH]c(I)c(CCNC(C)=O)c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COc1ccc2[nH]c(I)c(CCNC(C)=O)c2c1",358.01782572,18,2.679,54.12,0.0108447290373658,0.03,0.0204223645186829,0,0
"tas-115 mesylate","protein tyrosine kinase inhibitor","HGF, PDGFRA, TNK1","CNC(=O)c1cc2c(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)ccnc2cc1OC.CS(=O)(=O)O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","osteosarcoma","CNC(=O)c1cc2c(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)ccnc2cc1OC.CS(=O)(=O)O",614.130519424,42,3.485,196.42,0.000272544057621693,0.04,0.0201362720288108,0,0
"h-ile-pro-pro-oh (hydrochloride)","angiotensin converting enzyme inhibitor","ACE","O=C(N1[C@@H](CCC1)C(N2[C@@H](CCC2)C(O)=O)=O)[C@H]([C@@H](C)CC)N.Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","cardiology","hypertension","O=C(N1[C@@H](CCC1)C(N2[C@@H](CCC2)C(O)=O)=O)[C@H]([C@@H](C)CC)N.Cl",361.176834056,24,0.924,103.94,0.00823137173233321,0.032,0.0201156858661666,0,0
"h-val-pro-pro-oh (tfa)","angiotensin converting enzyme inhibitor","ACE","N[C@@H](C(C)C)C(N1CCC[C@H]1C(N2CCC[C@H]2C(O)=O)=O)=O.OC(C(F)(F)F)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","cardiology","hypertension","N[C@@H](C(C)C)C(N1CCC[C@H]1C(N2CCC[C@H]2C(O)=O)=O)=O.OC(C(F)(F)F)=O",425.177370212,29,0.462,141.24,0.00213395864238538,0.038,0.0200669793211927,0,0
"dirithromycin","bacterial 50S ribosomal subunit inhibitor","","CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H](C2C)C1(C)O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","pulmonary","bronchitis","CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O",834.545305176,58,1.555,196.33,3.49396233878413e-05,0.04,0.0200174698116939,0,0
"BIBN4096","calcitonin antagonist","CALCA, CALCRL, RAMP1","NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1, NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1, NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1, NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1, NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1",867.206689804,54,3.298,176.47,1.54702091766633e-05,0.04,0.0200077351045883,0,0
"fumonisin-B1","","CERS1","CCCC[C@@H](C)[C@@H](OC(=O)C[C@@H](CC(O)=O)C(O)=O)[C@H](C[C@@H](C)C[C@H](O)CCCC[C@@H](O)C[C@H](O)[C@H](C)N)OC(=O)C[C@@H](CC(O)=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCC[C@@H](C)[C@@H](OC(=O)C[C@@H](CC(O)=O)C(O)=O)[C@H](C[C@@H](C)C[C@H](O)CCCC[C@@H](O)C[C@H](O)[C@H](C)N)OC(=O)C[C@@H](CC(O)=O)C(O)=O",721.388470188,50,1.731,288.51,1.01946487873216e-05,0.04,0.0200050973243937,0,0
"larazotide-acetate","tight junction regulator","","CC(C)C[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN)C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)C[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN)C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O",725.40718896,51,-4.799,301.32,1.74608964897219e-06,0.04,0.0200008730448245,0,0
"bismuth(III)-trifluoromethanesulfonate","direct substitution catalyst","","[Bi].OS(=O)(=O)C(F)(F)F.OS(=O)(=O)C(F)(F)F.OS(=O)(=O)C(F)(F)F",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[Bi].OS(=O)(=O)C(F)(F)F.OS(=O)(=O)C(F)(F)F.OS(=O)(=O)C(F)(F)F",658.859947356,25,0.495,188.25,1.08000809057469e-06,0.04,0.0200005400040453,0,0
"caspofungin (acetate)","","","CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@@H](O)[C@H](O)c1ccc(O)cc1)[C@H](O)CCN",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@@H](O)[C@H](O)c1ccc(O)cc1)[C@H](O)CCN",1092.643062116,77,4.018,412.03,7.16872168683719e-08,0.04,0.0200000358436084,0,0
"caspofungin acetate","","","CC[C@@H](C)C[C@@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)cc1)[C@H](O)CCN",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CC[C@@H](C)C[C@@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)cc1)[C@H](O)CCN",1092.643062116,77,4.018,412.03,7.16872168683719e-08,0.04,0.0200000358436084,0,0
"soblidotin","microtubule inhibitor","","[H][C@]1(CCCN1C(=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C)[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","[H][C@]1(CCCN1C(=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C)[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1",701.509134864,51,3.795,120.52,0.00168039034600573,0.038,0.0198401951730029,0,0
"oridonin","BCL inhibitor","BCL2","[H][C@@]1(O)[C@@]2([H])CC[C@]3([H])[C@@]1(C(=O)C2=C)[C@]1(O)OC[C@]32[C@@H](O)CCC(C)(C)[C@@]2([H])[C@@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@@]1(O)[C@@]2([H])CC[C@]3([H])[C@@]1(C(=O)C2=C)[C@]1(O)OC[C@]32[C@@H](O)CCC(C)(C)[C@@]2([H])[C@@H]1O",364.188588616,30,0.248,107.22,0.02359699381944,0.016,0.01979849690972,0,0
"oleandrin","Na/K-ATPase inhibitor","","CO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H]([C@H](C[C@]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[C@@H](C)[C@@H]1O |t:32|, CO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H]([C@H](C[C@]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[C@@H](C)[C@@H]1O |t:32|, CO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H]([C@H](C[C@]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[C@@H](C)[C@@H]1O |t:32|, CO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H]([C@H](C[C@]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[C@@H](C)[C@@H]1O |t:32|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H]([C@H](C[C@]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[C@@H](C)[C@@H]1O |t:32|",576.329833116,41,3.681,120.75,0.00323101052294711,0.036,0.0196155052614736,0,0
"tauroglycocholate","membrane permeability enhancer","","[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C)[C@H](C)CCC(=O)NCC(=O)NCCS(O)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C)[C@H](C)CCC(=O)NCC(=O)NCCS(O)(=O)=O",572.313137496,44,1.943,181.64,0.0011323657059541,0.038,0.019566182852977,0,0
"indium(III)-isopropoxide","","","[In].CC(C)O.CC(C)O.CC(C)O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[In].CC(C)O.CC(C)O.CC(C)O",295.076422628,13,1.152,60.69,0.00912697706463884,0.03,0.0195634885323194,0,0
"aceneuramic-acid","","CES1, SELE, SELP","CC(=O)N[C@@H]1[C@@H](O)C[C@](O)(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(=O)N[C@@H]1[C@@H](O)C[C@](O)(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O",309.105981188,21,-3.525,176.78,0.000894922843851612,0.038,0.0194474614219258,0,0
"atrasentan","endothelin receptor antagonist","EDNRA","CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1, CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1, CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1, CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1, CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1",510.272986936,37,4.232,88.54,0.0148883006573147,0.024,0.0194441503286573,0,0
"hexonic-acid","","","OC[C@@H](O)[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O |&1:2,&2:4,&3:6,&4:8,r|, OC[C@@H](O)[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O |&1:2,&2:4,&3:6,&4:8,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC[C@@H](O)[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O |&1:2",196.058302724,13,-3.739,138.45,0.00485764740469327,0.034,0.0194288237023466,0,0
"dinoprostone","prostanoid receptor agonist","CATSPER1, CATSPER2, CATSPER3, CATSPER4, PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, TBXA2R","CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O",352.224974124,25,2.79,94.83,0.0246478803753948,0.014,0.0193239401876974,0,0
"butaprost","prostaglandin receptor agonist","","CCCC1(CCC1)[C@H](O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCC1(CCC1)[C@H](O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC",408.28757438,29,4.071,83.83,0.0285385989016624,0.01,0.0192692994508312,0,0
"bardoxolone","nuclear factor erythroid derived, like (NRF2) activator","NOS2, PPARG","CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|, CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|, CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|, CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|, CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|, CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17",491.303558792,36,6.301,95.23,0.0261703669117327,0.012,0.0190851834558663,0,0
"TXA127","angiotensin receptor agonist","","CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(O)=O",898.466100804,64,-0.915,377.24,2.48581050857435e-07,0.038,0.0190001242905254,0,0
"16,16-dimethylprostaglandin-e2","prostanoid receptor agonist","HPGD","CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O, CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O, CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O",380.256274252,27,3.482,94.83,0.0237137972575528,0.014,0.0188568986287764,0,0
"dicloralurea","","","O[C@@H](NC(=O)N[C@@H](O)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl |&1:1,&2:6,r|, O[C@@H](NC(=O)N[C@@H](O)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl |&1:1,&2:6,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O[C@@H](NC(=O)N[C@@H](O)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl |&1:1",351.850958132,16,1.952,81.59,0.00353399696214901,0.034,0.0187669984810745,0,0
"OR-486","catechol O methyltransferase inhibitor","COMT","Oc1cc(cc(c1O)[N+]([O-])=O)[N+]([O-])=O, Oc1cc(cc(c1O)[N+]([O-])=O)[N+]([O-])=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1cc(cc(c1O)[N+]([O-])=O)[N+]([O-])=O",200.006935848,14,2.013,126.74,0.0292041706909336,0.008,0.0186020853454668,0,0
"RTA-408","nitric oxide production inhibitor","NFE2L2","CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:19,23|, CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:19,23|, CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:19,23|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:19",554.331999708,40,6.589,87.03,0.0190565383618202,0.018,0.0185282691809101,0,0
"D-(+)-maltose","","MGAM","OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O",342.116211524,23,-3.663,189.53,0.000463747670379552,0.036,0.0182318738351898,0,0
"CGP-71683","neuropeptide receptor antagonist","NPY5R","Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12 |r|, Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12 |r|, Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12 |r|, Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12 |r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12 |r|",475.204196168,34,4.982,118.38,0.0104276966703708,0.026,0.0182138483351854,0,0
"dtp3","dual specificity protein kinase inhibitor","MAP2K7","CC(=O)N[C@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](Cc2ccccc2)C(=O)N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","hematologic malignancy","multiple myeloma","CC(=O)N[C@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](Cc2ccccc2)C(=O)N",525.26996722,38,0.67,212.52,0.000313206204169021,0.036,0.0181566031020845,0,0
"ursodeoxycholyltaurine","cholesterol inhibitor","","C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C",499.29675916,34,4.856,132.31,0.00414081788405283,0.032,0.0180704089420264,0,0
"ascomycin","calcineurin inhibitor","FKBP1A","CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@@H](O)[C@@H](C1)OC |c:3|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@@H](O)[C@@H](C1)OC |c:3|",791.481976648,56,3.106,178.36,0.000136914591813527,0.036,0.0180684572959068,0,0
"dusquetide (tfa)","immunostimulant","SQSTM1","C[C@@H](C(N)=O)NC([C@H]1N(C([C@H](C(C)C)NC([C@H]([C@@H](C)CC)NC([C@H](CCCNC(N)=N)N)=O)=O)=O)CCC1)=O.OC(C(F)(F)F)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","dental","mucositis","C[C@@H](C(N)=O)NC([C@H]1N(C([C@H](C(C)C)NC([C@H]([C@@H](C)CC)NC([C@H](CCCNC(N)=N)N)=O)=O)=O)CCC1)=O.OC(C(F)(F)F)=O",667.362879536,46,0.0289999999999999,275.92,1.30162970975826e-05,0.036,0.0180065081485488,0,0
"NIM811","mitochondrial permeability transition inhibitor","","[H][C@]1(NC(=O)[C@]([H])([C@@H](C)CC)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@]([H])([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@]([H])(CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C1=O)C(C)C, [H][C@]1(NC(=O)[C@]([H])([C@@H](C)CC)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@]([H])([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@]([H])(CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C1=O)C(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","[H][C@]1(NC(=O)[C@]([H])([C@@H](C)CC)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@]([H])([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@]([H])(CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C1=O)C(C)C",1201.841367992,90,8.196,278.8,6.44266752227915e-06,0.036,0.0180032213337611,0,0
"alisporivir","cyclophilin inhibitor","","[H][C@]1(C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(CC)C(=O)[C@@H](C)N(C)C(=O)[C@H](CC)NC(=O)[C@]([H])([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@]([H])(CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C1=O)C(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","[H][C@]1(C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(CC)C(=O)[C@@H](C)N(C)C(=O)[C@H](CC)NC(=O)[C@]([H])([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@]([H])(CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C1=O)C(C)C",1215.857018056,89,8.576,278.8,4.01727028119544e-06,0.036,0.0180020086351406,0,0
"ALX-40-4C","CC chemokine receptor antagonist","","CC(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(N)=O",1463.947112816,103,-4.426,862.09,2.22044604925031e-16,0.036,0.0180000000000001,0,0
"d-pinitol","","","CO[C@@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CO[C@@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@H]1O",194.079038168,13,-1.797,110.38,0.0155523516898944,0.02,0.0177761758449472,0,0
"pinitol","gamma secretase inhibitor","","COC1C(O)[C@@H](O)C(O)C(O)[C@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COC1C(O)[C@@H](O)C(O)C(O)[C@H]1O",194.079038168,13,-1.797,110.38,0.0155523516898944,0.02,0.0177761758449472,0,0
"myricetin","androgen receptor agonist, cytochrome P450 inhibitor","PIK3CG","Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O",318.03756728,23,3.469,151.59,0.0113080402730381,0.024,0.017654020136519,0,0
"glucaric-acid","","","O[C@@H]([C@H](O)[C@@H](O)C(O)=O)[C@H](O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","O[C@@H]([C@H](O)[C@@H](O)C(O)=O)[C@H](O)C(O)=O",210.03756728,14,-3.582,155.52,0.00306892555456688,0.032,0.0175344627772834,0,0
"AGM-1470","cell cycle inhibitor","METAP2","CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl |a:2,3,6,10,13,&1:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl |a:2",401.160515296,27,2.482,89.69,0.012822200322506,0.022,0.017411100161253,0,0
"TNP-470","methionine aminopeptidase inhibitor","METAP2","CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl, CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl, CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl, CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl",401.160515296,27,2.482,89.69,0.012822200322506,0.022,0.017411100161253,0,0
"corticosterone","mineralocorticoid receptor agonist","HSD11B1, NCOA1, NR3C2","C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:9|",346.21440944,25,1.704,74.6,0.0344959272258244,0,0.0172479636129122,0,0
"miridesap","amyloid protein inhibitor","","OC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1CCC[C@@H]1C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1CCC[C@@H]1C(O)=O",340.163436488,24,-0.148,115.22,0.00805336243063192,0.026,0.017026681215316,0,0
"tuftsin","macrophage activator","","C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O",500.307081,35,-4.402,249.98,3.44679402371713e-05,0.034,0.0170172339701186,0,0
"secoisolariciresinol-diglucoside","antioxidant","","COc1cc(C[C@@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)Cc2ccc(O)c(OC)c2)ccc1O, COc1cc(C[C@@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)Cc2ccc(O)c(OC)c2)ccc1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COc1cc(C[C@@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)Cc2ccc(O)c(OC)c2)ccc1O",686.278585392,48,-0.473999999999999,257.68,1.77125575816533e-05,0.034,0.0170088562787908,0,0
"AP1903","","MTOR","CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc(c2)[C@@H](CCc2ccc(OC)c(OC)c2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)c2cc(OC)c(OC)c(OC)c2)c1)c1cc(OC)c(OC)c(OC)c1, CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc(c2)[C@@H](CCc2ccc(OC)c(OC)c2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)c2cc(OC)c(OC)c(OC)c2)c1)c1cc(OC)c(OC)c(OC)c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1/phase 2","","","CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc(c2)[C@@H](CCc2ccc(OC)c(OC)c2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)c2cc(OC)c(OC)c(OC)c2)c1)c1cc(OC)c(OC)c(OC)c1",1410.677441536,102,10.592,262.18,1.83681022516349e-06,0.034,0.0170009184051126,0,0
"exifone","nootropic agent","TYR","Oc1ccc(C(=O)c2cc(O)c(O)c(O)c2)c(O)c1O, Oc1ccc(C(=O)c2cc(O)c(O)c(O)c2)c(O)c1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","","","Oc1ccc(C(=O)c2cc(O)c(O)c(O)c2)c(O)c1O",278.04265266,20,3.017,138.45,0.0177724985315056,0.016,0.0168862492657528,0,0
"AT-406","IAP antagonist ","","CN[C@@H](C)C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C(=O)NC(c1ccccc1)c1ccccc1)C(=O)CC(C)C, CN[C@@H](C)C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C(=O)NC(c1ccccc1)c1ccccc1)C(=O)CC(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CN[C@@H](C)C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C(=O)NC(c1ccccc1)c1ccccc1)C(=O)CC(C)C",561.331504856,41,3.591,110.85,0.00567678088918693,0.028,0.0168383904445935,0,0
"dauricine","nfkb pathway inhibitor","GORASP1, PTGR1","COc1cc2CCN(C)[C@H](Cc3ccc(Oc4cc(C[C@H]5N(C)CCc6cc(OC)c(OC)cc56)ccc4O)cc3)c2cc1OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","oncology","colorectal cancer","COc1cc2CCN(C)[C@H](Cc3ccc(Oc4cc(C[C@H]5N(C)CCc6cc(OC)c(OC)cc56)ccc4O)cc3)c2cc1OC",624.319937128,46,5.625,72.86,0.0156757338962955,0.018,0.0168378669481477,0,0
"JZL-184","monoacylglucerol lipase inhibitor","MGLL","OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1, OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1, OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1",520.148180348,38,4.132,129.83,0.00559868431641377,0.028,0.0167993421582069,0,0
"taurocholate","G protein-coupled receptor agonist","CEL, FABP6, SLCO1C1","C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C, C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C",515.29167378,35,2.771,152.54,0.00133809034086152,0.032,0.0166690451704308,0,0
"perindoprilat","angiotensin converting enzyme inhibitor","ACE","CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(O)=O",340.199821996,24,-0.331999999999999,106.94,0.00930705816538832,0.024,0.0166535290826942,0,0
"alfadolone-acetate","benzodiazepine receptor agonist","","CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C",390.240624188,28,3.303,80.67,0.031019693325193,0.002,0.0165098466625965,0,0
"irganox-1010","antioxidant","","CC(C)(C)c1cc(CCC(=O)OCC(COC(=O)CCc2cc(c(O)c(c2)C(C)(C)C)C(C)(C)C)(COC(=O)CCc2cc(c(O)c(c2)C(C)(C)C)C(C)(C)C)COC(=O)CCc2cc(c(O)c(c2)C(C)(C)C)C(C)(C)C)cc(c1O)C(C)(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)c1cc(CCC(=O)OCC(COC(=O)CCc2cc(c(O)c(c2)C(C)(C)C)C(C)(C)C)(COC(=O)CCc2cc(c(O)c(c2)C(C)(C)C)C(C)(C)C)COC(=O)CCc2cc(c(O)c(c2)C(C)(C)C)C(C)(C)C)cc(c1O)C(C)(C)C",1176.784078896,85,18.554,186.12,0.000403013642041582,0.032,0.0162015068210208,0,0
"gprp (acetate)","","FGB, ITGA2B","O=C(O)[C@H]1N(C([C@H](CCCNC(N)=N)NC([C@H]2N(C(CN)=O)CCC2)=O)=O)CCC1.OC(C)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","hematology","thrombosis","O=C(O)[C@H]1N(C([C@H](CCCNC(N)=N)NC([C@H]2N(C(CN)=O)CCC2)=O)=O)CCC1.OC(C)=O",485.25979646,34,-1.82,232.24,0.000111491496342589,0.032,0.0160557457481713,0,0
"pepstatin","aspartic protease inhibitor","CTSB, CTSD, CTSL, REN","CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O, CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O",685.462578596,48,2.76,223.26,8.86773307241521e-05,0.032,0.0160443386653621,0,0
"4-galactosyllactose","","","OC[C@H]1O[C@@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)O[C@@H]3CO)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O |a:2,4,6,7,9,11,13,14,16,21,25,28,30,32,&1:18|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC[C@H]1O[C@@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)O[C@@H]3CO)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O |a:2",504.169034944,34,-5.629,268.68,1.19741650996332e-05,0.032,0.0160059870825498,0,0
"ginsenoside-RE","anti-inflammatory agent","","[H][C@@]1(CC[C@]2(C)[C@]1([H])[C@H](O)C[C@]1([H])[C@@]3(C)CC[C@H](O)C(C)(C)[C@]3([H])[C@H](C[C@@]21C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O)[C@](C)(CCC=C(C)C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","[H][C@@]1(CC[C@]2(C)[C@]1([H])[C@H](O)C[C@]1([H])[C@@]3(C)CC[C@H](O)C(C)(C)[C@]3([H])[C@H](C[C@@]21C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O)[C@](C)(CCC=C(C)C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O",946.550115784,70,3.039,298.14,5.17947357928698e-06,0.032,0.0160025897367896,0,0
"LY2510924","CC chemokine receptor antagonist","","[H][C@]1(CCCN=C(N)N)NC(=O)[C@H](CCCCNC(C)C)NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)CC[C@@H](NC(=O)CNC(=O)[C@H](Cc2ccc3ccccc3c2)NC1=O)C(=O)N[C@@H](CCCCNC(C)C)C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","[H][C@]1(CCCN=C(N)N)NC(=O)[C@H](CCCCNC(C)C)NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)CC[C@@H](NC(=O)CNC(=O)[C@H](Cc2ccc3ccccc3c2)NC1=O)C(=O)N[C@@H](CCCCNC(C)C)C(N)=O",1188.680785016,87,5.109,384.58,1.7848017866851e-07,0.032,0.0160000892400893,0,0
"saralasin","angiotensin receptor antagonist","AGTR1","C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","cardiology","hypertension","C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC",911.49773528,65,-4.792,353.26,1.54390519055999e-07,0.032,0.0160000771952595,0,0
"sulfuric acid compound with (2r,3r,4r,5r)-2-((1s,2s,3r,4s,6r)-4,6-diamino-3-((2r,3r,6s)-3-amino-6-((r)-1-(met hylamino)ethyl)tetrahydro-2h-pyran-2-yloxy)-2-h","","","CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O.CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@@H](CC[C@H]3N)[C@@H](C)N)[C@@H]2O)OC[C@]1(C)O.CN[C@H](C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O.CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@@H](CC[C@H]3N)[C@@H](C)N)[C@@H]2O)OC[C@]1(C)O.CN[C@H](C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1",1389.901795956,96,-9.88000000000001,627.17,1.05557857157179e-12,0.032,0.0160000000005278,0,0
"spirobromin","","","BrCCC(=O)N1CC[N+]2(CC1)CC[N+]1(CCN(CC1)C(=O)CCBr)CC2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","BrCCC(=O)N1CC[N+]2(CC1)CC[N+]1(CCN(CC1)C(=O)CCBr)CC2",494.088103304181,26,0.0539999999999997,40.62,0.00191895476799781,0.03,0.0159594773839989,0,0
"squalamine","antiviral","","[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)NCCCNCCCCN)[C@H](C)CC[C@@H](OS(O)(=O)=O)C(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)NCCCNCCCCN)[C@H](C)CC[C@@H](OS(O)(=O)=O)C(C)C",627.46449318,48,6.34,142.29,0.00555029549400172,0.026,0.0157751477470009,0,0
"BQ-123","endothelin receptor antagonist","EDNRA","[H][C@@]12CCCN1C(=O)[C@@]([H])(CC(O)=O)NC(=O)[C@@H](Cc1c[nH]c3ccccc13)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC2=O)C(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","[H][C@@]12CCCN1C(=O)[C@@]([H])(CC(O)=O)NC(=O)[C@@H](Cc1c[nH]c3ccccc13)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC2=O)C(C)C",610.311497684,46,3.62,189.8,0.000904014073655856,0.03,0.0154520070368279,0,0
"cipemastat","metalloproteinase inhibitor","ADAM17, MMP1, MMP13, MMP2, MMP3, MMP8, MMP9","CN1C(=O)N(C[C@@H]([C@@H](CC2CCCC2)C(=O)N2CCCCC2)C(=O)NO)C(=O)C1(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CN1C(=O)N(C[C@@H]([C@@H](CC2CCCC2)C(=O)N2CCCCC2)C(=O)NO)C(=O)C1(C)C",436.268570252,31,1.437,110.26,0.00672911757946942,0.024,0.0153645587897347,0,0
"dioscin","apoptosis stimulant","CXCR3","C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@H](CC[C@]5(C)[C@H]4CC[C@]23C)O[C@@H]2O[C@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)O[C@]11CC[C@@H](C)CO1 |t:8|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@H](CC[C@]5(C)[C@H]4CC[C@]23C)O[C@@H]2O[C@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)O[C@]11CC[C@@H](C)CO1 |t:8|",868.482036224,61,2.836,235.68,1.70394227740268e-05,0.03,0.015008519711387,0,0
"abarelix","gonadotropin releasing factor hormone receptor antagonist","GNRHR","CC(C)C[C@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(C)C[C@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O",1414.6840714,101,2.389,424.98,4.06770224660381e-09,0.03,0.0150000020338511,0,0
"CDBA","","","OC[C@H]1O[C@H]2O[C@H]3[C@@H](CO)O[C@@H](O[C@H]4[C@@H](CO)O[C@@H](O[C@H]5[C@@H](CO)O[C@@H](O[C@H]6[C@@H](CO)O[C@@H](O[C@H]7[C@@H](CO)O[C@@H](O[C@H]8[C@@H](CO)O[C@@H](O[C@@H]1[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H]7O)[C@@H](O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)[C@@H](O)[C@@H]3O |&1:2,&2:4,&3:6,&4:7,&5:11,&6:13,&7:14,&8:18,&9:20,&10:21,&11:25,&12:27,&13:28,&14:32,&15:34,&16:35,&17:39,&18:41,&19:42,&20:46,&21:48,&22:49,&23:51,&24:53,&25:55,&26:57,&27:59,&28:61,&29:63,&30:65,&31:67,&32:69,&33:71,&34:73,&35:75,r|, OC[C@H]1O[C@H]2O[C@H]3[C@@H](CO)O[C@@H](O[C@H]4[C@@H](CO)O[C@@H](O[C@H]5[C@@H](CO)O[C@@H](O[C@H]6[C@@H](CO)O[C@@H](O[C@H]7[C@@H](CO)O[C@@H](O[C@H]8[C@@H](CO)O[C@@H](O[C@@H]1[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H]7O)[C@@H](O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)[C@@H](O)[C@@H]3O |&1:2,&2:4,&3:6,&4:7,&5:11,&6:13,&7:14,&8:18,&9:20,&10:21,&11:25,&12:27,&13:28,&14:32,&15:34,&16:35,&17:39,&18:41,&19:42,&20:46,&21:48,&22:49,&23:51,&24:53,&25:55,&26:57,&27:59,&28:61,&29:63,&30:65,&31:67,&32:69,&33:71,&34:73,&35:75,r|, OC[C@H]1O[C@H]2O[C@H]3[C@@H](CO)O[C@@H](O[C@H]4[C@@H](CO)O[C@@H](O[C@H]5[C@@H](CO)O[C@@H](O[C@H]6[C@@H](CO)O[C@@H](O[C@H]7[C@@H](CO)O[C@@H](O[C@H]8[C@@H](CO)O[C@@H](O[C@@H]1[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H]7O)[C@@H](O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)[C@@H](O)[C@@H]3O |&1:2,&2:4,&3:6,&4:7,&5:11,&6:13,&7:14,&8:18,&9:20,&10:21,&11:25,&12:27,&13:28,&14:32,&15:34,&16:35,&17:39,&18:41,&19:42,&20:46,&21:48,&22:49,&23:51,&24:53,&25:55,&26:57,&27:59,&28:61,&29:63,&30:65,&31:67,&32:69,&33:71,&34:73,&35:75,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","OC[C@H]1O[C@H]2O[C@H]3[C@@H](CO)O[C@@H](O[C@H]4[C@@H](CO)O[C@@H](O[C@H]5[C@@H](CO)O[C@@H](O[C@H]6[C@@H](CO)O[C@@H](O[C@H]7[C@@H](CO)O[C@@H](O[C@H]8[C@@H](CO)O[C@@H](O[C@@H]1[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H]7O)[C@@H](O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)[C@@H](O)[C@@H]3O |&1:2",1134.36976394,77,-13.762,554.05,1.25324040341867e-11,0.03,0.0150000000062662,0,0
"melanotan i","","","CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O",1645.836510332,118,-2.466,642.98,1.57872042512715e-12,0.03,0.0150000000007894,0,0
"hydroxypropyl-beta-cyclodextrin","","","C[C@@H](O)COC[C@H]1O[C@@H]2O[C@@H]3[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]4[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]5[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]6[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]7[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]8[C@@H](COC[C@@H](C)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O |a:6,8,10,11,19,21,22,30,32,33,41,43,44,52,54,55,63,65,66,74,76,77,79,81,83,85,87,89,91,93,95,97,99,101,103,&1:1,&2:15,&3:26,&4:37,&5:48,&6:59,&7:70|, C[C@@H](O)COC[C@H]1O[C@@H]2O[C@@H]3[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]4[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]5[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]6[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]7[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]8[C@@H](COC[C@@H](C)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O |a:6,8,10,11,19,21,22,30,32,33,41,43,44,52,54,55,63,65,66,74,76,77,79,81,83,85,87,89,91,93,95,97,99,101,103,&1:1,&2:15,&3:26,&4:37,&5:48,&6:59,&7:70|, C[C@@H](O)COC[C@H]1O[C@@H]2O[C@@H]3[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]4[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]5[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]6[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]7[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]8[C@@H](COC[C@@H](C)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O |a:6,8,10,11,19,21,22,30,32,33,41,43,44,52,54,55,63,65,66,74,76,77,79,81,83,85,87,89,91,93,95,97,99,101,103,&1:1,&2:15,&3:26,&4:37,&5:48,&6:59,&7:70|, C[C@@H](O)COC[C@H]1O[C@@H]2O[C@@H]3[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]4[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]5[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]6[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]7[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]8[C@@H](COC[C@@H](C)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O |a:6,8,10,11,19,21,22,30,32,33,41,43,44,52,54,55,63,65,66,74,76,77,79,81,83,85,87,89,91,93,95,97,99,101,103,&1:1,&2:15,&3:26,&4:37,&5:48,&6:59,&7:70|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","C[C@@H](O)COC[C@H]1O[C@@H]2O[C@@H]3[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]4[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]5[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]6[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]7[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]8[C@@H](COC[C@@H](C)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O |a:6",1540.662817624,105,-11.872,618.66,1.70672476528469e-13,0.03,0.0150000000000853,0,0
"R306465","HDAC inhibitor","","ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1, ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1, ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1, ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1",413.115775088,29,1.709,124.11,0.005730419810353,0.024,0.0148652099051765,0,0
"alpha-D-glucopyranose","","","OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O",180.063388104,12,-1.697,110.38,0.0176594834505969,0.012,0.0148297417252984,0,0
"fructose","","","OC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","OC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O",180.063388104,12,-1.74,110.38,0.0174774229737502,0.012,0.0147387114868751,0,0
"CB-03-01","androgen receptor antagonist","AR","CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|",402.240624188,29,2.991,80.67,0.0272615752316774,0.002,0.0146307876158387,0,0
"clascoterone","androgen receptor antagonist","AR","CCC(=O)OC1(CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C)C(=O)CO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","dermatology","acne vulgaris (av)","CCC(=O)OC1(CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C)C(=O)CO",402.240624188,29,2.991,80.67,0.0272615752316774,0.002,0.0146307876158387,0,0
"aramchol","stearoyl-CoA desaturase inhibitor","","CCCCCCCCCCCCCCCCCCCC(=O)N[C@H]1CC[C@@]2(C)[C@H](C[C@@H](O)[C@H]3[C@@H]4CC[C@H]([C@H](C)CCC(O)=O)[C@@]4(C)[C@@H](O)C[C@H]23)C1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","CCCCCCCCCCCCCCCCCCCC(=O)N[C@H]1CC[C@@]2(C)[C@H](C[C@@H](O)[C@H]3[C@@H]4CC[C@H]([C@H](C)CCC(O)=O)[C@@]4(C)[C@@H](O)C[C@H]23)C1",701.595824628,50,14.228,106.86,0.0231222674433501,0.006,0.0145611337216751,0,0
"tribromoethanol","analgesic agent","","OCC(Br)(Br)Br, OCC(Br)(Br)Br",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OCC(Br)(Br)Br",279.773401016,6,2.351,20.23,0.00899143957594504,0.02,0.0144957197879725,0,0
"betamethasone sodium phosphate","","","C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","","","C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O",472.16623277,32,-0.519999999999999,151.17,0.000865859234163289,0.028,0.0144329296170816,0,0
"dexamethasone sodium phosphate","glucocorticoid receptor agonist","","C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O |c:11,t:7|, C[C@@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","lung diseases","acute respiratory distress syndrome","C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O |c:11",472.16623277,32,-0.519999999999999,151.17,0.000865859234163289,0.028,0.0144329296170816,0,0
"BQ-788","endothelin receptor antagonist","EDNRB","CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N1[C@@H](C)CCC[C@H]1C)C(O)=O, CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N1[C@@H](C)CCC[C@H]1C)C(O)=O, CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N1[C@@H](C)CCC[C@H]1C)C(O)=O, CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N1[C@@H](C)CCC[C@H]1C)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N1[C@@H](C)CCC[C@H]1C)C(O)=O",641.378848972,46,3.046,159.07,0.000761862903958572,0.028,0.0143809314519793,0,0
"trodusquemine","tyrosine phosphatase inhibitor","","[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)NCCCNCCCCNCCCN)[C@H](C)CC[C@@H](OS(O)(=O)=O)C(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)NCCCNCCCCNCCCN)[C@H](C)CC[C@@H](OS(O)(=O)=O)C(C)C",684.522342404,52,6.312,154.32,0.00268714287520791,0.026,0.014343571437604,0,0
"amxt-1501 tetrahydrochloride","ornithine decarboxylase inhibitor","ODC1, TPO","CCCCCCCCCCCCCCCC(=O)NCCCC[C@@H](N)C(=O)NCCCNCCCCNCCCN.Cl.Cl.Cl.Cl",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","oncology","neuroblastoma","CCCCCCCCCCCCCCCC(=O)NCCCC[C@@H](N)C(=O)NCCCNCCCCNCCCN.Cl.Cl.Cl.Cl",712.447086264,44,8.865,134.3,0.000650303093310238,0.028,0.0143251515466551,0,0
"bevirimat-dimeglumine","HIV capsid assembly inhibitor","","CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O",584.407689512,42,10.011,100.9,0.0245681595814259,0.004,0.0142840797907129,0,0
"prednisolone tebutate","glucocorticoid receptor agonist","NR3C1","[H][C@@]12CC[C@](O)(C(=O)COC(=O)CC(C)(C)C)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C |c:34,t:30|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","general surgery","hemorrhoids","[H][C@@]12CC[C@](O)(C(=O)COC(=O)CC(C)(C)C)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C |c:34",458.266838936,36,3.268,100.9,0.0240760330226196,0.004,0.0140380165113098,0,0
"threo-2-methylisocitrate-(DL)","isocitrate lyase substrate","","[NaH].[NaH].[NaH].[NaH].[NaH].[NaH].CC(O)([C@@H](CC(O)=O)C(O)=O)C(O)=O.CC(O)([C@H](CC(O)=O)C(O)=O)C(O)=O |a:9,23,&1:7,&2:21|, [NaH].[NaH].[NaH].[NaH].[NaH].[NaH].CC(O)([C@@H](CC(O)=O)C(O)=O)C(O)=O.CC(O)([C@H](CC(O)=O)C(O)=O)C(O)=O |a:9,23,&1:7,&2:21|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[NaH].[NaH].[NaH].[NaH].[NaH].[NaH].CC(O)([C@@H](CC(O)=O)C(O)=O)C(O)=O.CC(O)([C@H](CC(O)=O)C(O)=O)C(O)=O |a:9",556.070871192,34,-3.908,264.26,5.84989225263656e-06,0.028,0.0140029249461263,0,0
"deslorelin","gonadotropin releasing factor hormone receptor agonist","","CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1",1281.640711096,93,0.591,447.33,5.93822627973563e-09,0.028,0.0140000029691131,0,0
"hypericin","tyrosine kinase inhibitor","","Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O, Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O, Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O, Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O",504.084517472,38,6.42,155.52,0.00792461122076708,0.02,0.0139623056103835,0,0
"anguidine","protein synthesis inhibitor, apoptosis stimulant","SLC5A1","CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@]11CO1 |c:9|, CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1 |c:9|, CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1 |c:9|, CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1 |c:9|, CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1 |c:9|",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","endocrinology","diabetes mellitus","CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@]11CO1 |c:9|",366.167853172,26,0.808,94.59,0.0139025769589136,0.014,0.0139512884794568,0,0
"asiatic-acid","apoptosis stimulant","PYGM","C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|",488.350174636,35,7.439,97.99,0.0276185983868209,0,0.0138092991934105,0,0
"oridonin (isodonol)","bcl inhibitor","","O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O[C@@H]1[C@H]2CC[C@@H]3[C@@]45CO[C@](O)(C[C@@H]4C(C)(C)CC[C@@H]5O)[C@@]13C(=O)C2=C",348.193673996,25,1.06,86.99,0.0213661366966063,0.006,0.0136830683483031,0,0
"ginkgolide-A","GABA receptor antagonist","GLRA1, GLRB","C[C@@H]1C(=O)O[C@H]2C[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H]1C(=O)O[C@H]2C[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O",408.142032348,29,1.176,128.59,0.00510759207490959,0.022,0.0135537960374548,0,0
"picrotin","GABA receptor antagonist","GABRA1, GABRR1, GLRA1, GLRA2, GLRA3, GLRB","CC(C)(O)[C@H]1[C@H]2OC(=O)[C@@H]1[C@@]1(O)C[C@H]3O[C@]33C(=O)O[C@@H]2[C@@]13C |&1:4,&2:5,&3:9,&4:10,&5:13,&6:15,&7:19,&8:20,r|, CC(C)(O)[C@H]1[C@H]2OC(=O)[C@@H]1[C@@]1(O)C[C@H]3O[C@]33C(=O)O[C@@H]2[C@@]13C |&1:4,&2:5,&3:9,&4:10,&5:13,&6:15,&7:19,&8:20,r|, CC(C)(O)[C@H]1[C@H]2OC(=O)[C@@H]1[C@@]1(O)C[C@H]3O[C@]33C(=O)O[C@@H]2[C@@]13C |&1:4,&2:5,&3:9,&4:10,&5:13,&6:15,&7:19,&8:20,r|, CC(C)(O)[C@H]1[C@H]2OC(=O)[C@@H]1[C@@]1(O)C[C@H]3O[C@]33C(=O)O[C@@H]2[C@@]13C |&1:4,&2:5,&3:9,&4:10,&5:13,&6:15,&7:19,&8:20,r|",0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,"phase 2","pulmonology","respiratory distress syndrome (rds)","CC(C)(O)[C@H]1[C@H]2OC(=O)[C@@H]1[C@@]1(O)C[C@H]3O[C@]33C(=O)O[C@@H]2[C@@]13C |&1:4",310.105252916,22,-0.988,105.59,0.0105755444628548,0.016,0.0132877722314274,0,0
"picrotoxin","","","CC(C)(O)[C@@H]1[C@H]2OC(=O)[C@@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(O)[C@@H]1[C@H]2OC(=O)[C@@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C",310.105252916,22,-0.988,105.59,0.0105755444628548,0.016,0.0132877722314274,0,0
"thiophanate","","","COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC, COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC, COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC, COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC",342.045646928,22,1.776,164.9,0.00247453561115814,0.024,0.0132372678055791,0,0
"dusquetide","","","CC[C@H](C)[C@H](NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC[C@H](C)[C@H](NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N",553.370015604,39,-0.59,238.62,8.07610572591684e-05,0.026,0.0130403805286296,0,0
"NCX-1015","interleukin sythesis stimulator","","C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)c1ccc(CO[N+]([O-])=O)cc1 |c:13,t:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)c1ccc(CO[N+]([O-])=O)cc1 |c:13",539.215531636,39,3.19,153.27,0.00206705739474285,0.024,0.0130335286973714,0,0
"gynostemma-extract","calcium channel modulator","","CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C",916.5395511,64,4.453,277.91,6.02223090434201e-06,0.026,0.0130030111154522,0,0
"ginsenoside rd","apoptosis stimulant","","CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","immunology","immunostimulant","CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C",946.550115784,66,4.21,298.14,2.74611985254261e-06,0.026,0.0130013730599263,0,0
"ginsenoside-RD","calcium channel blocker","","CC(C)=CCC[C@@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C |a:9,11,14,16,18,20,23,25,26,29,30,34,36,38,41,43,45,47,49,52,54,56,61,64,&1:6|, CC(C)=CCC[C@@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C |a:9,11,14,16,18,20,23,25,26,29,30,34,36,38,41,43,45,47,49,52,54,56,61,64,&1:6|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(C)=CCC[C@@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C |a:9",946.550115784,66,4.21,298.14,2.74611985254261e-06,0.026,0.0130013730599263,0,0
"sennoside a","antiviral","","OC[C@H]1O[C@@H](Oc2cccc3c(-c4c5cccc(O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)c5c(O)c5c(O)cc(cc45)C(O)=O)c4cc(cc(O)c4c(O)c23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","infectious disease","human immunodeficiency virus (hiv-1)","OC[C@H]1O[C@@H](Oc2cccc3c(-c4c5cccc(O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)c5c(O)c5c(O)cc(cc45)C(O)=O)c4cc(cc(O)c4c(O)c23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O",862.195643616,62,3.208,354.28,1.74726477929405e-06,0.026,0.0130008736323896,0,0
"sennoside-protonated","","","OC[C@H]1O[C@@H](Oc2cccc3c(-c4c5cccc(O[C@H]6O[C@@H](CO)[C@@H](O)[C@@H](O)[C@@H]6O)c5c(O)c5c(O)cc(cc45)C(O)=O)c4cc(cc(O)c4c(O)c23)C(O)=O)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:19,&4:21,&5:24,&6:26,&7:28,&8:56,&9:58,&10:60,r|, OC[C@H]1O[C@@H](Oc2cccc3c(-c4c5cccc(O[C@H]6O[C@@H](CO)[C@@H](O)[C@@H](O)[C@@H]6O)c5c(O)c5c(O)cc(cc45)C(O)=O)c4cc(cc(O)c4c(O)c23)C(O)=O)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:19,&4:21,&5:24,&6:26,&7:28,&8:56,&9:58,&10:60,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC[C@H]1O[C@@H](Oc2cccc3c(-c4c5cccc(O[C@H]6O[C@@H](CO)[C@@H](O)[C@@H](O)[C@@H]6O)c5c(O)c5c(O)cc(cc45)C(O)=O)c4cc(cc(O)c4c(O)c23)C(O)=O)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2",862.195643616,62,3.208,354.28,1.74726477929405e-06,0.026,0.0130008736323896,0,0
"bismuth-oxalate","","","[Bi].[Bi].OC(=O)C(O)=O.OC(=O)C(O)=O.OC(=O)C(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[Bi].[Bi].OC(=O)C(O)=O.OC(=O)C(O)=O.OC(=O)C(O)=O",687.946723032,20,-2.064,223.8,3.98504433123611e-08,0.026,0.0130000199252217,0,0
"INT-767","FXR agonist","GPBAR1","CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOS(O)(=O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12, CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOS(O)(=O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12, CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOS(O)(=O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOS(O)(=O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12",472.285860128,32,5.287,112.44,0.0087371945461056,0.016,0.0123685972730528,0,0
"bq-123","endothelin receptor antagonist","","CC(C)CC1NC(=O)C(NC(=O)C2CCCN2C(=O)C(CC(O)=O)NC(=O)C(Cc2c[nH]c3ccccc23)NC1=O)C(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)CC1NC(=O)C(NC(=O)C2CCCN2C(=O)C(CC(O)=O)NC(=O)C(Cc2c[nH]c3ccccc23)NC1=O)C(C)C",610.311497684,44,3.62,189.8,0.000570373477678854,0.024,0.0122851867388394,0,0
"ginkgolide-B","platelet activating factor receptor antagonist","GLRA1, GLRA2, GLRA3, GLRB, HTR3A, HTR3B","C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O",424.136946968,30,0.146,148.82,0.00213838278352793,0.022,0.012069191391764,0,0
"ginsenoside rg3","","","CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C",784.497292364,55,5.318,218.99,8.62000351260815e-05,0.024,0.012043100017563,0,0
"sucrose-octaacetate","","","CC(=O)OC[C@H]1O[C@@](COC(C)=O)(O[C@H]2O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]2OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)OC[C@H]1O[C@@](COC(C)=O)(O[C@H]2O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]2OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O",678.200728996,47,0.0690000000000002,238.09,3.07016952258663e-05,0.024,0.0120153508476129,0,0
"azalomycin-B","bacterial 50S ribosomal subunit inhibitor","","CC[C@@H]1[C@@H](C)O[C@](O)(C[C@H]1O[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1)[C@@H](C)[C@H](O)[C@H](C)[C@H]1OC(=O)\C=C\C=C\[C@H](C)[C@H](OC(=O)\C=C\C=C\[C@@H]1C)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O[C@H]2C[C@H](O)[C@H](O)[C@H](C)O2)[C@H](CC)[C@@H](C)O1 |t:32,34,42,44|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC[C@@H]1[C@@H](C)O[C@](O)(C[C@H]1O[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1)[C@@H](C)[C@H](O)[C@H](C)[C@H]1OC(=O)\C=C\C=C\[C@H](C)[C@H](OC(=O)\C=C\C=C\[C@@H]1C)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O[C@H]2C[C@H](O)[C@H](O)[C@H](C)O2)[C@H](CC)[C@@H](C)O1 |t:32",1024.597065976,72,5.942,269.82,4.99357596593022e-06,0.024,0.012002496787983,0,0
"LTX-315","anticancer agent","","NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](C(c1ccccc1)c1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](C(c1ccccc1)c1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O",1438.839016972,105,3.167,479.38,1.96796815769142e-09,0.024,0.0120000009839841,0,0
"digoxigenin","steroid","","C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1 |t:26|, C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1 |t:26|, C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1 |t:26|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1 |t:26|",390.240624188,28,2.444,86.99,0.0219056894336328,0.002,0.0119528447168164,0,0
"reynoutrin","antioxidant","","O[C@@H]1CO[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@H](O)[C@H]1O, O[C@@H]1CO[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@H](O)[C@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","O[C@@H]1CO[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@H](O)[C@H]1O",434.084911396,31,1.954,190.28,0.00126600231376321,0.022,0.0116330011568816,0,0
"dexamethasone palmitate","glucocorticoid receptor agonist","NR3C1","CCCCCCCCCCCCCCCC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","rheumatology","rheumatoid arthritis","CCCCCCCCCCCCCCCC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C",630.429567828,45,9.099,100.9,0.0132005113327616,0.01,0.0116002556663808,0,0
"dehydrocholate","","","C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@H]3[C@@H](CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@@H]1CC3=O |a:1,7,16,18,&1:10,&2:11,&3:12,&4:25|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@H]3[C@@H](CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@@H]1CC3=O |a:1",402.240624188,29,2.664,88.51,0.0211113330900277,0.002,0.0115556665450138,0,0
"dehydrocholate-acid","","","C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@H]3[C@H](CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@H]1CC3=O, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@H]3[C@H](CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@H]1CC3=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@H]3[C@H](CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@H]1CC3=O",402.240624188,29,2.664,88.51,0.0211113330900277,0.002,0.0115556665450138,0,0
"triptolide","RNA polymerase inhibitor","RELA","CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|",360.157288488,26,-0.00699999999999995,84.12,0.0167055239930428,0.006,0.0113527619965214,0,0
"AMI-1","protein arginine N-methyltransferase inhibitor","PRMT1","Oc1cc(cc2cc(NC(=O)Nc3ccc4c(O)cc(cc4c3)S(O)(=O)=O)ccc12)S(O)(=O)=O, Oc1cc(cc2cc(NC(=O)Nc3ccc4c(O)cc(cc4c3)S(O)(=O)=O)ccc12)S(O)(=O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","Oc1cc(cc2cc(NC(=O)Nc3ccc4c(O)cc(cc4c3)S(O)(=O)=O)ccc12)S(O)(=O)=O",504.029722092,34,1.39,207.09,0.000280194623463409,0.022,0.0111400973117317,0,0
"madecassoside","anti-inflammatory agent","","[H][C@]12CC=C3[C@]4([H])[C@@H](C)[C@H](C)CC[C@@]4(CC[C@@]3(C)[C@]1(C)C[C@@H](O)[C@@]1([H])[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]21C)C(=O)O[C@@H]1O[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O |t:3|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[H][C@]12CC=C3[C@]4([H])[C@@H](C)[C@H](C)CC[C@@]4(CC[C@@]3(C)[C@]1(C)C[C@@H](O)[C@@]1([H])[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]21C)C(=O)O[C@@H]1O[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O |t:3|",974.508644896,71,1.67,335.44,1.00612250449713e-06,0.022,0.0110005030612522,0,0
"VU591","potassium channel blocker","KCNJ1","[O-][N+](=O)c1ccc2nc(COCc3nc4ccc(cc4[nH]3)[N+]([O-])=O)[nH]c2c1, [O-][N+](=O)c1ccc2nc(COCc3nc4ccc(cc4[nH]3)[N+]([O-])=O)[nH]c2c1, [O-][N+](=O)c1ccc2nc(COCc3nc4ccc(cc4[nH]3)[N+]([O-])=O)[nH]c2c1, [O-][N+](=O)c1ccc2nc(COCc3nc4ccc(cc4[nH]3)[N+]([O-])=O)[nH]c2c1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","[O-][N+](=O)c1ccc2nc(COCc3nc4ccc(cc4[nH]3)[N+]([O-])=O)[nH]c2c1",368.086917484,27,1.834,152.87,0.00561580762320742,0.016,0.0108079038116037,0,0
"paeoniflorin","anticonvulsant","","C[C@@]12C[C@@]3(O)O[C@@H](O1)[C@]1(COC(=O)c4ccccc4)[C@H]3C[C@]21O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O, C[C@@]12C[C@@]3(O)O[C@@H](O1)[C@]1(COC(=O)c4ccccc4)[C@H]3C[C@]21O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O, C[C@@]12C[C@@]3(O)O[C@@H](O1)[C@]1(COC(=O)c4ccccc4)[C@H]3C[C@]21O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@]12C[C@@]3(O)O[C@@H](O1)[C@]1(COC(=O)c4ccccc4)[C@H]3C[C@]21O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O",480.163161716,34,0.191,164.37,0.000993936968056876,0.02,0.0104969684840284,0,0
"betamethasone","glucocorticoid receptor agonist","NR3C1","C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]2(C)[C@]1(O)C(=O)CO, C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"","dermatology","corticosteroid-responsive dermatoses","C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]2(C)[C@]1(O)C(=O)CO",392.199902248,28,1.138,94.83,0.0127696045723656,0.008,0.0103848022861828,0,0
"U-75799E","growth hormone releasing factor agonist","GHSR","C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O, C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O, C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O",872.444577512,64,0.925000000000001,300.89,4.26985239742994e-06,0.02,0.0100021349261987,0,0
"lanatoside-C","cardiac glycoside","","C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](OC(C)=O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@@H](CC[C@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |a:1,3,5,7,9,11,13,15,17,22,24,26,29,31,33,35,38,42,45,53,55,57,60,&1:47,&2:50,&3:51,t:69|, C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](OC(C)=O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@@H](CC[C@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |a:1,3,5,7,9,11,13,15,17,22,24,26,29,31,33,35,38,42,45,53,55,57,60,&1:47,&2:50,&3:51,t:69|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](OC(C)=O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@@H](CC[C@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |a:1",984.492994832,69,1.377,288.28,1.38808058765228e-06,0.02,0.0100006940402938,0,0
"colforsin","adenylyl cyclase activator","ADCY2, ADCY5","CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C |a:4,5,13,15,17,22,25,&1:7|, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C |a:4,5,13,15,17,22,25,&1:7|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C |a:4",410.230453428,29,1.43,113.29,0.00735616829876905,0.012,0.00967808414938452,0,0
"fluprednisolone","glucocorticoid receptor agonist","NR3C1","C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)C[C@@H](C4=CC(=O)C=C[C@]34C)F)O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"withdrawn","ophthalmology","contact dermatitis","C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)C[C@@H](C4=CC(=O)C=C[C@]34C)F)O",378.184252184,27,0.739,94.83,0.0128555390598668,0.006,0.00942776952993339,0,0
"myricitrin","PKC inhibitor","NOS1, PRKCA","C[C@@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2cc(O)c(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2cc(O)c(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O",464.09547608,33,2.437,210.51,0.000690225750011788,0.018,0.00934511287500589,0,0
"hyperin","aldose reductase inhibitor","ACE, AKR1B1","OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:27,&4:29,&5:31,r|, OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:27,&4:29,&5:31,r|, OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:27,&4:29,&5:31,r|, OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:27,&4:29,&5:31,r|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2",464.09547608,33,1.711,210.51,0.000577689358474687,0.018,0.00928884467923734,0,0
"isoquercitrin","antioxidant","","OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O",464.09547608,33,1.711,210.51,0.000577689358474687,0.018,0.00928884467923734,0,0
"MM-102","WDR5/MLL interaction inhibitor","","CCC(CC)(NC(=O)C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC1(CCCC1)C(=O)NC(c1ccc(F)cc1)c1ccc(F)cc1, CCC(CC)(NC(=O)C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC1(CCCC1)C(=O)NC(c1ccc(F)cc1)c1ccc(F)cc1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCC(CC)(NC(=O)C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC1(CCCC1)C(=O)NC(c1ccc(F)cc1)c1ccc(F)cc1",669.381409488,48,4.169,178.3,0.000521663633799864,0.018,0.00926083181689993,0,0
"examorelin","growth hormone releasing factor agonist","GHRHR, GHSR","C[C@H](NC(=O)[C@@H](Cc1c(C)[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@H](NC(=O)[C@@H](Cc1c(C)[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O",886.460227576,65,1.161,300.89,4.07471093827194e-06,0.018,0.00900203735546914,0,0
"HP-228","nitric oxide synthase inhibitor","","CCCC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)NCC(N)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CCCC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)NCC(N)=O",983.50896866,71,-0.598000000000001,396.25,1.1358380182295e-07,0.018,0.00900005679190091,0,0
"epothilone-D","microtubule stabilizing agent, tubulin polymerization inhibitor","TUBB","C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1 |c:6|, C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1 |c:6|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1 |c:6|",491.270544412,34,2.942,124.96,0.00372137838468604,0.014,0.00886068919234302,0,0
"10-deacetylbaccatin","antitumor agent","","CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C |t:33|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C |t:33|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C |t:33|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C |t:33|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C |t:33|",544.230847352,39,-0.185,159.82,0.000689229529301361,0.016,0.00834461476465068,0,0
"rapacuronium bromide","acetylcholine receptor antagonist","CHRM2","[Br-].O=C(O[C@H]6[C@@H]([N+]1(C\C=C)CCCCC1)C[C@@H]5[C@]6(C)CC[C@H]3[C@H]5CC[C@H]4C[C@H](OC(=O)C)[C@@H](N2CCCCC2)C[C@]34C)CC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,"withdrawn","neurology/psychiatry","general anaesthetic","[Br-].O=C(O[C@H]6[C@@H]([N+]1(C\C=C)CCCCC1)C[C@@H]5[C@]6(C)CC[C@H]3[C@H]5CC[C@H]4C[C@H](OC(=O)C)[C@@H](N2CCCCC2)C[C@]34C)CC",676.381470532,44,8.495,55.84,0.00860376036017469,0.008,0.00830188018008734,0,0
"isoflupredone-acetate","","NR3C1","CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:19,t:15|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:19",420.194816868,30,1.152,100.9,0.00907066462742347,0.006,0.00753533231371174,0,0
"bruceantin","protein synthesis inhibitor","","COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1[C@@H](C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O |a:4,7,8,9,22,24,32,34,35,37,&1:25|, COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1[C@@H](C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O |a:4,7,8,9,22,24,32,34,35,37,&1:25|, COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1[C@@H](C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O |a:4,7,8,9,22,24,32,34,35,37,&1:25|, COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1[C@@H](C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O |a:4,7,8,9,22,24,32,34,35,37,&1:25|, COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1[C@@H](C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O |a:4,7,8,9,22,24,32,34,35,37,&1:25|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1[C@@H](C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O |a:4",548.225761972,39,1.372,162.73,0.000857800664645433,0.014,0.00742890033232272,0,0
"amyloid p-in-1","beta amyloid inhibitor","APP","O=C(CCCCC(=O)N1CCC[C@@H]1C(=O)OCOC(=O)OC2CCOCC2)N3CCC[C@@H]3C(=O)OCOC(=O)OC4CCOCC4",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","neurology/psychiatry","alzheimer's disease","O=C(CCCCC(=O)N1CCC[C@@H]1C(=O)OCOC(=O)OC2CCOCC2)N3CCC[C@@H]3C(=O)OCOC(=O)OC4CCOCC4",656.279254088,46,1.878,182.74,0.000231542379804722,0.014,0.00711577118990236,0,0
"MD-920","NFkB pathway inhibitor","AADACL2","C[C@@]12[C@H]3[C@H](C(O)=O)[C@@]45CC(=C)[C@@](O)(C4)CC[C@H]5[C@]3(OC1=O)C=C[C@@H]2O |c:25|, C[C@@]12[C@H]3[C@H](C(O)=O)[C@@]45CC(=C)[C@@](O)(C4)CC[C@H]5[C@]3(OC1=O)C=C[C@@H]2O |c:25|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","C[C@@]12[C@H]3[C@H](C(O)=O)[C@@]45CC(=C)[C@@](O)(C4)CC[C@H]5[C@]3(OC1=O)C=C[C@@H]2O |c:25|",346.141638424,25,-0.595,104.06,0.0101809156450072,0.004,0.0070904578225036,0,0
"valspodar","P glycoprotein inhibitor","ABCB1","C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C, C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C, C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C, C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C",1213.841367992,86,7.824,275.64,1.88938849766496e-06,0.014,0.00700094469424883,0,0
"strophanthidin acetate","atpase inhibitor","","C[C@]12CCC3C(CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CCC2C1=CC(=O)OC1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@]12CCC3C(CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CCC2C1=CC(=O)OC1",404.219888744,29,1.546,104.06,0.010785758794359,0.002,0.00639287939717952,0,0
"K-strophanthidin","ATPase inhibitor","ATP1A1","C[C@]12CC[C@H]3[C@@H](CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:27|, C[C@]12CC[C@H]3[C@@H](CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:27|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","C[C@]12CC[C@H]3[C@@H](CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:27|",404.219888744,29,1.546,104.06,0.010785758794359,0.002,0.00639287939717951,0,0
"cabaletta","pharmacological chaperone","","OC[C@H]1O[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","OC[C@H]1O[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O",342.116211524,23,-3.234,189.53,0.000515185540071626,0.012,0.00625759277003581,0,0
"bilobalide","GABA receptor modulator","GLRA1, GLRA2, GLRB, HTR3A, HTR3B","CC(C)(C)[C@]1(O)C[C@@H]2OC(=O)C[C@@]22C(=O)O[C@@H]3OC(=O)[C@H](O)[C@]123",0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(C)[C@]1(O)C[C@@H]2OC(=O)C[C@@]22C(=O)O[C@@H]3OC(=O)[C@H](O)[C@]123",326.100167536,23,-0.166,119.36,0.00809676189603064,0.004,0.00604838094801532,0,0
"epothilone-A","microtubule stabilizing agent","","C[C@H]1CCC[C@H]2O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1, C[C@H]1CCC[C@H]2O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@H]1CCC[C@H]2O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1",493.249808968,34,1.721,137.49,0.00197095623206385,0.01,0.00598547811603193,0,0
"epothilone b (epo906, patupilone)","microtubule stabilizing agent, tubulin polymerization inhibitor","","C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@@H](OC(=O)C[C@@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@@H](OC(=O)C[C@@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1",507.265459032,35,2.138,137.49,0.00196628301222374,0.01,0.00598314150611187,0,0
"epothilone-B","microtubule stabilizing agent, tubulin polymerization inhibitor","TUBB","C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 3","","","C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1",507.265459032,35,2.138,137.49,0.00196628301222374,0.01,0.00598314150611187,0,0
"ginsenoside-C-K","NFkB pathway inhibitor, nitric oxide synthase inhibitor","PTGS2","CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C",0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C",622.444468944,44,6.855,139.84,0.00299757163866124,0.008,0.00549878581933062,0,0
"astragaloside-a","anti-inflammatory agent","","CC(C)(O)[C@H]1CC[C@](C)(O1)[C@H]1[C@@H](O)C[C@@]2(C)[C@@H]3C[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O)C4(C)C, CC(C)(O)[C@H]1CC[C@](C)(O1)[C@H]1[C@@H](O)C[C@@]2(C)[C@@H]3C[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O)C4(C)C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","CC(C)(O)[C@H]1CC[C@](C)(O1)[C@H]1[C@@H](O)C[C@@]2(C)[C@@H]3C[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O)C4(C)C",784.460906856,55,3.326,228.22,4.27319842630482e-05,0.006,0.00302136599213152,0,0
"peruvoside","cardiac glycoside","","CO[C@H]1[C@@H](O)[C@@H](C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)[C@@H]1O |a:2,3,8,10,13,16,19,20,23,25,28,&1:5,&2:37,t:33|, CO[C@H]1[C@@H](O)[C@@H](C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)[C@@H]1O |a:2,3,8,10,13,16,19,20,23,25,28,&1:5,&2:37,t:33|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 1","","","CO[C@H]1[C@@H](O)[C@@H](C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)[C@@H]1O |a:2",548.298532988,39,1.494,131.75,0.00180771166071317,0.004,0.00290385583035659,0,0
"convallatoxin","cardiac glycoside","","C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C=O)[C@H]4CC[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:31|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C=O)[C@H]4CC[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:31|",550.277797544,39,1.141,162.98,0.000767344164814597,0.004,0.0023836720824073,0,0
"20-hydroxyecdysone","ecdysone receptor modulator","","CC(C)(O)CC[C@@H](O)[C@](C)(O)[C@@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@@H]3CC[C@]12C |t:16|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2","","","CC(C)(O)CC[C@@H](O)[C@](C)(O)[C@@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@@H]3CC[C@]12C |t:16|",480.308703748,34,1.049,138.45,0.00222683749799066,0.002,0.00211341874899533,0,0
"prednisolone-hemisuccinate","glucocorticoid receptor agonist","NR3C1","C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"preclinical","","","C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O |a:1",460.209717984,33,0.702000000000001,138.2,0.0026404973716808,0,0.0013202486858404,0,0
"hydrocortisone-hemisuccinate","","","C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O |t:9|",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O |t:9|",462.225368048,33,0.234000000000001,138.2,0.0022442355080517,0,0.00112211775402585,0,0
"hydrocortisone hemisuccinate","","","C[C@]12C[C@H](O)C3C(CCC4=CC(=O)CC[C@]34C)C1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"phase 2/phase 3","","","C[C@]12C[C@H](O)C3C(CCC4=CC(=O)CC[C@]34C)C1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O",462.225368048,33,0.234000000000001,138.2,0.00224423550805169,0,0.00112211775402585,0,0
